PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	JOYCE, BM; ROCKWOOD, KJ; MATEKOLE, CC				JOYCE, BM; ROCKWOOD, KJ; MATEKOLE, CC			USE OF GOAL ATTAINMENT SCALING IN BRAIN INJURY IN A REHABILITATION-HOSPITAL	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						BRAIN INJURY; FUNCTIONAL OUTCOME; REHABILITATION; GOAL ATTAINMENT SCALING		We report a study of the measurement properties of goal attainment (GA) scaling when used in the rehabilitation of brain injury patients. GA scaling is an individualized measurement technique with mathematical properties allowing for calculation of summary scores with a normal distribution. The present study examined 16 inpatients, 13 of whom had suffered a traumatic brain injury. In addition to GA scaling, standardized measures were employed to address issues such as content validity and construct validity. GA scaling change scores correlated highly (r = 0.81) with clinical judgment of efficacy and modestly with standard performance measures. A high level of inter-rater reliability was found between admission (r = 0.92) and discharge (r = 0.94) scores. GA scaling seems to be a feasible method of evaluating rehabilitation in brain injury patients, with promising measurement properties. The goals set are extremely meaningful to the patient and rehabilitation team, providing valuable feedback throughout the rehabilitation course.	DALHOUSIE UNIV, DIV PHYS MED & REHABIL, HALIFAX B3H 4H2, NS, CANADA; DALHOUSIE UNIV, DIV GERIATR MED, HALIFAX B3H 4H2, NS, CANADA; DALHOUSIE UNIV, DEPT PSYCHOL, HALIFAX B3H 4H2, NS, CANADA; DALHOUSIE UNIV, DEPT PSYCHIAT, HALIFAX B3H 4H2, NS, CANADA			Rockwood, Kenneth/AAD-8951-2019				HAFFEY WJ, 1989, REHABIL PSYCHOL, V34, P147, DOI 10.1037//0090-5550.34.2.147; Jennings B., 1983, ETHICS SOCIAL SCI PO, P3; JOHNSTON MV, 1991, AM J PHYS MED REHAB, V70, P40, DOI 10.1097/00002060-199102000-00008; Kirusek T. J., 1968, COMMUNITY MENTAL HLT, V4, P443; KLEIN RM, 1982, ARCH PHYS MED REHAB, V63, P335; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; Leonardelli C. A., 1988, MILWAUKEE EVALUATION; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MCGOURTY LK, 1988, MENTAL HLTH ASSESSME; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spector WD., 1990, QUALITY LIFE ASSESSM, P115; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; STOLEE P, 1992, J AM GERIATR SOC, P40; Streiner DL, 1989, HLTH MEASUREMENT SCA	16	58	58	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	1994	73	1					10	14		10.1097/00002060-199473010-00003			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	MX590	WOS:A1994MX59000003	8305175				2021-06-18	
J	SHAPIRA, Y; ARTRU, AA; LAM, AM				SHAPIRA, Y; ARTRU, AA; LAM, AM			KETAMINE DECREASES CEREBRAL INFARCT VOLUME AND IMPROVES NEUROLOGICAL OUTCOME FOLLOWING EXPERIMENTAL HEAD TRAUMA IN RATS	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						INTRAVENOUS ANESTHETICS; KETAMINE; BRAIN EDEMA; HEMORRHAGIC NECROSIS; NEUROLOGIC OUTCOME; EXCITATORY AMINO ACIDS; GLUTAMATE; N-METHYL-D-ASPARTATE RECEPTORS	METHYL-D-ASPARTATE; NMDA RECEPTOR ANTAGONIST; PROTECTS HIPPOCAMPAL-NEURONS; CULTURED CORTICAL-NEURONS; EXCITATORY AMINO-ACIDS; ISCHEMIC DAMAGE; GLUTAMATE ANTAGONIST; ARACHIDONIC-ACID; ARTERY OCCLUSION; BRAIN INJURY	In brain injury, concentrations of extracellular excitatory amino acids are increased and stimulate glutamate receptors in general and the N-methyl-D-aspartate (NMDA)-preferring subtype in particular. That stimulation causes substantial calcium influx, which appears to initiate a cascade of events leading to neuronal death. Blockage of NMDA receptors with specific antagonists or noncompetitive ion channel blockers provides protection against excitatory amino acid-induced neurotoxicity. We previously reported that the NMDA receptor antagonist dizocilpine maleate improved the neurological severity score (NSS) after head trauma in rats. The present study was designed to determine whether ketamine, a NMDA receptor antagonist like dizocilpine maleate, improves neurological outcome following head trauma in rats. Thirty-two male Sprague-Dawley rats (235-250 g) were divided into four groups. Groups A and B were surgically prepared only. Groups C and D were surgically prepared and then a nonpenetrating impact was delivered to the cranium over the left hemisphere. Groups A and C received no treatment. Groups B and D were treated with ketamine, 180 mg/kg i.p., 1 h after head trauma. The NSS was determined at 1, 2, 4, 10, 24, and 48 h following head trauma. After killing at 48 h, cortical slices were taken adjacent to the lesion on the traumatized hemisphere and from comparable sites on the nontraumatized hemisphere to measure the tissue specific gravity and water content. Brains were then placed in 4% formaldehyde and the volume of hemorrhagic necrosis measured 4 days later. Head trauma increased the NSS and, in the traumatized hemisphere, decreased the specific gravity, increased the water content, and caused cerebral infarction. With ketamine, the NSS at 24 and 48 h following head trauma was 7.4 +/- 2.6 and 6.7 +/- 2.6 (mean +/- SEM), respectively, significantly improved compared to the NSS in the untreated group of 12.6 +/- 2.6 and 11.3 +/- 2.6, respectively (p < 0.02, Mann-Whitney U test). With ketamine, the volume of hemorrhagic necrosis was 88.0 +/- 23.1 mm3, significantly less than that in the untreated group (147.4 +/- 22.4 mm3; p < 0.05, unpaired t test). The brain tissue specific gravity and water content at 48 h and the rectal temperature at 4 and 48 h after head trauma were not significantly different between treated and untreated groups. It is concluded that in this model of closed cranial impact, ketamine improves neurological outcome and decreases the volume of hemorrhagic necrosis without altering brain edema.	UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,RN-10,SEATTLE,WA 98195							ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; Artru A A, 1989, J Neurosurg Anesthesiol, V1, P8, DOI 10.1097/00008506-198903000-00003; ARTRU AA, 1989, STATUS KETAMINE ANES, P119; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BARTH TM, 1990, STROKE, V21, P153; BAUGHMAN VL, 1990, J NEUROSURG ANESTH, V2, P290, DOI 10.1097/00008506-199012000-00007; BELOPAVLOVIC M, 1982, ACTA ANAESTH SCAND, V26, P458, DOI 10.1111/j.1399-6576.1982.tb01799.x; BENEVISTE H, 1984, J NEUROCHEM, V43, P1369; BUCHAN A, 1990, J NEUROSCI, V10, P311; BULLOCK R, 1990, J CEREBR BLOOD F MET, V10, P668, DOI 10.1038/jcbfm.1990.120; BULLOCK R, 1990, STROKE, V21, P32; CABARROCAS F, 1973, NEURORADIOLOGY, V5, P59; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CHAN PH, 1989, BRAIN RES, V487, P380, DOI 10.1016/0006-8993(89)90845-7; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHURCH J, 1988, SIGMA PHENCYCLIDINE, P747; COLE DJ, 1990, STROKE, V21, P1333, DOI 10.1161/01.STR.21.9.1333; COLE DJ, 1990, CAN J NEUROL SCI, V17, P372, DOI 10.1017/S0317167100030900; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; CROSBY G, 1982, ANESTHESIOLOGY, V56, P437, DOI 10.1097/00000542-198206000-00005; DAVIS DW, 1988, ANESTHESIOLOGY, V69, P199, DOI 10.1097/00000542-198808000-00008; DAWSON B, 1971, ANESTH ANAL CURR RES, V50, P443; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DIEMER NH, 1990, STROKE, V21, P39; Domino EF, 1990, STATUS KETAMINE ANES; DRUMMOND JC, 1989, STROKE, V20, P1538, DOI 10.1161/01.STR.20.11.1538; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FENSKE A, 1978, J NEUROL, V219, P241, DOI 10.1007/BF00312977; FORD LM, 1989, ARCH NEUROL-CHICAGO, V46, P1090, DOI 10.1001/archneur.1989.00520460072016; FUKUDA S, 1983, ANESTH ANALG, V62, P553; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; GOLDBERG MP, 1990, STROKE, V21, P75; KIM JP, 1987, BRAIN RES, V437, P103, DOI 10.1016/0006-8993(87)91531-9; KOHMURA E, 1990, J CEREBR BLOOD F MET, V10, P877, DOI 10.1038/jcbfm.1990.144; LEES GJ, 1987, NEUROSCI LETT, V78, P180, DOI 10.1016/0304-3940(87)90630-6; LEES GJ, 1989, BRAIN RES, V502, P280, DOI 10.1016/0006-8993(89)90623-9; LEVY DI, 1990, NEUROLOGY, V40, P852, DOI 10.1212/WNL.40.5.852; LODGE D, 1986, J PHYSIOL-LONDON, V377, pP28; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MARCOUX FW, 1988, SIGMA PHENCYCLIDINE, P735; MARMAROU A, 1978, J NEUROSURG, V49, P503; MCINTOSH TK, 1988, 7TH INT S INTR PRESS, P199; MELDRUM BS, 1987, MED BIOL, V65, P153; MEYER FB, 1989, BRAIN RES REV, V14, P227, DOI 10.1016/0165-0173(89)90002-7; MEYER FB, 1990, J CEREBR BLOOD F MET, V10, P895, DOI 10.1038/jcbfm.1990.146; MICHENFELDER JD, 1989, BRAIN RES, V481, P228, DOI 10.1016/0006-8993(89)90798-1; NABESHIMA T, 1990, NEUROSCI LETT, V108, P321, DOI 10.1016/0304-3940(90)90661-R; NUSSMEIER NA, 1986, ANESTHESIOLOGY, V64, P165, DOI 10.1097/00000542-198602000-00006; OLNEY JW, 1986, NEUROSCI LETT, V68, P29, DOI 10.1016/0304-3940(86)90224-7; OZYURT E, 1988, J CEREBR BLOOD F MET, V8, P138, DOI 10.1038/jcbfm.1988.18; PATEL PM, 1991, ACTA NEUROPATHOL, V81, P339, DOI 10.1007/BF00305878; PFENNINGER E, 1989, STATUS KETAMINE ANES, P109; ROMAN R, 1989, NEUROSCI LETT, V104, P19, DOI 10.1016/0304-3940(89)90322-4; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; ROTHMAN SM, 1987, NEUROSCIENCE, V21, P673, DOI 10.1016/0306-4522(87)90028-5; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1990, J NEUROTRAUMA, V3, P131; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; SHINOJI K, 1987, BRAIN RES, V408, P385; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMON R, 1990, ANN NEUROL, V27, P606, DOI 10.1002/ana.410270604; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SKAPER SD, 1989, EXP NEUROL, V106, P297, DOI 10.1016/0014-4886(89)90163-5; STEINBERG GK, 1989, STROKE, V20, P1247, DOI 10.1161/01.STR.20.9.1247; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; TROP D, 1978, 5TH EUR C AN AMST, P221; VANRIJEN PC, 1991, STROKE, V22, P343, DOI 10.1161/01.STR.22.3.343; WEISS J, 1986, BRAIN RES, V380, P186, DOI 10.1016/0006-8993(86)91447-2; WIELOCH T, 1982, J CEREBR BLOOD F MET, V2, pS5; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WROBLEWSKI JT, 1987, P NATL ACAD SCI USA, V84, P5068, DOI 10.1073/pnas.84.14.5068; YU ACH, 1986, J NEUROCHEM, V47, P1181; YU ACH, 1987, J NEUROSCI RES, V17, P424, DOI 10.1002/jnr.490170414; ZAIDAN JR, 1991, ANESTHESIOLOGY, V74, P406, DOI 10.1097/00000542-199103000-00003	84	58	59	2	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	1992	4	4					231	240		10.1097/00008506-199210000-00001			10	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	JQ572	WOS:A1992JQ57200001	15815471				2021-06-18	
J	HAUG, HZ; SAVAGE, JD; LIKAVEC, MJ; CONFORTI, PJ				HAUG, HZ; SAVAGE, JD; LIKAVEC, MJ; CONFORTI, PJ			A REVIEW OF 100 CLOSED HEAD-INJURIES ASSOCIATED WITH FACIAL FRACTURES	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article									CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; HOSP ST RAPHAEL, DEPT ORAL & MAXILLOFACIAL SURG, NEW HAVEN, CT 06511 USA; METROHLTH MED CTR, NEUROSURG, CLEVELAND, OH USA	HAUG, HZ (corresponding author), METROHLTH MED CTR, DIV ORAL & MAXILLOFACIAL SURG, 3395 SCRANTON RD, CLEVELAND, OH 44109 USA.						ADEKEYE EO, 1980, ORAL SURG ORAL MED O, V49, P491, DOI 10.1016/0030-4220(80)90068-7; BECKER DP, 1986, NEUROLOGICAL SURGERY, P2016; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; HEIMGARTNERCANDINAS B, 1978, J MAXILLOFAC SURG, V6, P293, DOI 10.1016/S0301-0503(78)80109-X; KAUFMAN MS, 1984, J ORAL MAXIL SURG, V42, P250, DOI 10.1016/0278-2391(84)90457-9; LEE KF, 1987, J NEUROSURG, V66, P542, DOI 10.3171/jns.1987.66.4.0542; MORGAN B D G, 1972, British Journal of Plastic Surgery, V25, P147, DOI 10.1016/S0007-1226(72)80037-7; Murray J F, 1975, Clin Plast Surg, V2, P131; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; STEIDLER NE, 1980, J ORAL SURG, V9, P259; TEASDALE G, 1974, LANCET, V2, P81; TURVEY TA, 1977, J ORAL SURG, V35, P887; WAGNER WF, 1979, J ORAL SURG, V37, P97; ZALLEN RD, 1975, J ORAL SURG, V33, P431	15	58	61	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	MAR	1992	50	3					218	222		10.1016/0278-2391(92)90315-Q			5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	HF680	WOS:A1992HF68000003	1542064				2021-06-18	
J	MONTGOMERY, EA; FENTON, GW; MCCLELLAND, RJ; MACFLYNN, G; RUTHERFORD, WH				MONTGOMERY, EA; FENTON, GW; MCCLELLAND, RJ; MACFLYNN, G; RUTHERFORD, WH			THE PSYCHOBIOLOGY OF MINOR HEAD-INJURY	PSYCHOLOGICAL MEDICINE			English	Article							AUDITORY EVOKED-RESPONSES; CONCUSSION; SEQUELAE; COMPENSATION; POTENTIALS; NEUROSIS; MILD	Twenty-six consecutive admissions to an accident and emergency unit with minor head injury were examined. This was defined as a head injury warranting brief in-patient overnight stay but with a post-traumatic amnesia of less than 12 hours. Each patient had a neurological examination, a post-traumatic symptom check list completed, EEG power spectra analysis and auditory brain stem-evoked potential recordings, and a four-choice reaction-time measurement. These assessments were repeated six weeks later. Six months after the head injury a symptom check list was completed and four-choice reaction time measured again. Post-traumatic symptoms are persistent in half of all patients at six weeks and six months follow-up. The EEG power spectra showed a significant change in theta power between the first recording and the second one at six weeks, with relative reduction being noted. Approximately half of all the patients had significant delays in brain stem conduction time at day 0. There was a trend towards a decrease in brain stem conduction time at six weeks, though in almost half the brain stem conduction time still remained abnormal at six weeks. Head-injured patients had prolonged choice reaction times at day 0 with serial improvement between then and six months, though the values at six weeks were still significantly longer than health controls. It is suggested that these findings reflect both cortical and brain stem damage following minor head injury, the brain stem damage being more persistent. There appear to be three patterns of recovery, half recovering within six weeks, a minority persisting over six months with persisting brain stem dysfunction and less than a third showing an exacerbation of symptoms with no evidence of brain stem dysfunction, the exacerbation being possibly a consequence of psychological and social factors.	UNIV DUNDEE,DEPT PSYCHIAT,DUNDEE DD1 4HN,SCOTLAND; QUEENS UNIV BELFAST,DEPT MENTAL HLTH,BELFAST BT7 1NN,ANTRIM,NORTH IRELAND; HOLYWELL HOSP,ANTRIM,NORTH IRELAND; MATER INFIRMORIUM HOSP,BELFAST,NORTH IRELAND; ROYAL VICTORIA HOSP,BELFAST BT12 6BA,NORTH IRELAND							ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Brown GW., 1978, SOCIAL ORIGINS DEPRE; BROWN RH, 1981, ELECTROEN CLIN NEURO, V51, pP38; CARTLIDGE NEF, 1981, HEAD INJURY, P203; CHIAPPA KH, 1983, EVOKED POTENTIALS CL; COBB WA, 1963, ELECTROENCEPHALOGRAP, P232; COOPER R, 1965, ELECTROEN CLIN NEURO, V18, P217, DOI 10.1016/0013-4694(65)90088-X; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; ERICKSEN JD, 1866, CONCUSSION SPINE NER; GRONWALL D, 1974, LANCET, V2, P605; HARRISON MS, 1956, BRAIN, V79, P474, DOI 10.1093/brain/79.3.474; HENDERSON S, 1981, NEUROSIS SOCIAL ENV, P279; HOUSTON HG, 1985, BIOL PSYCHIAT, V20, P419, DOI 10.1016/0006-3223(85)90044-7; JOHNSON LC, 1975, BEHAVIOR BRAIN ELECT, P1; KAY DWK, 1971, LANCET, V2, P1052; KUNKEL H, 1977, EEG INFORMATICS DIDA, P9; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; NOSEWORTHY JH, 1981, ARCH NEUROL-CHICAGO, V38, P275, DOI 10.1001/archneur.1981.00510050041004; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; Ruff R.M., 1989, MILD HEAD INJURY, P176; RUTHERFORD WH, 1977, LANCET, V1, P1; Schoenhuber R, 1983, J Neurosurg Sci, V27, P157; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; TARSH MJ, 1985, BRIT J PSYCHIAT, V146, P18, DOI 10.1192/bjp.146.1.18; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67; Trimble MR, 1981, POSTTRAUMATIC NEUROS; WEIGHILL VE, 1983, J PSYCHOSOM RES, V27, P97, DOI 10.1016/0022-3999(83)90085-5; WEINER RD, 1983, EEG EVOKED POTENTIAL, P1; WILKINSON RT, 1975, BEHAV RES METH INSTR, V7, P441, DOI 10.3758/BF03201557; Wing JK, 1974, MEASUREMENT CLASSIFI, P233	40	58	58	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0033-2917			PSYCHOL MED	Psychol. Med.	MAY	1991	21	2					375	384		10.1017/S0033291700020481			10	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	FR873	WOS:A1991FR87300013	1876643				2021-06-18	
J	MATEER, CA; WILLIAMS, D				MATEER, CA; WILLIAMS, D			EFFECTS OF FRONTAL-LOBE INJURY IN CHILDHOOD	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article								The impact of frontal lobe damage may be viewed in terms of compromise to three general areas of ability: self-regulation, the allocation of attentional resources, and the ability to act on knowledge. These cognitive and behavioral functions are associated with major inputs to frontal structures from specific cortical and subcortical brain regions. Case studies of four children who sustained traumatic frontal lobe injury showed persistent patterns of cognitive and behavioral change marked by impaired attention, academic production deficits, irritability, distractibility, and social problems in the absence of apparent intellectual, linguistic, or perceptual compromise. Persisting deficits, interacting with growth and changes in environmental demands, compromise adaptation in home, school, and other social contexts.		MATEER, CA (corresponding author), GOOD SAMARITAN NEUROPSYCHOL SERV, 1322 3RD ST SE, SUITE 250, PUYALLUP, WA 98372 USA.						BRICKENKAMP R, 1975, TEST D2 CONCENTRATIO; BRODY EB, 1952, PSYCHOSOM MED, V14, P406, DOI 10.1097/00006842-195209000-00007; CHELUNE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P219, DOI 10.1080/01688638608401314; DAMASIO AR, 1985, CLIN NEUROPSYCHOLOGY, P360; Fuster J, 1989, PREFRONTAL CORTEX; Golden C., 1978, STROOP COLOR WORD TE; HAAS DC, 1975, ARCH NEUROL-CHICAGO, V32, P727, DOI 10.1001/archneur.1975.00490530049003; HAMMILL DD, 1985, DETROIT TESTS APTITU, V2; Kaufman A. S., 1983, KAUFMAN ASSESSMENT B; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Luria A. R, 1973, WORKING BRAIN; MESULAM MM, 1985, PRINCIPLES BEHAVIORA; MEYER D R, 1972, Acta Neurobiologiae Experimentalis (Warsaw), V32, P235; MILLER MH, 1976, PHYSIOL BEHAV, V17, P209, DOI 10.1016/0031-9384(76)90065-2; MILLNER B, 1971, BRIT MED J, V27, P272; MISHKIN M, 1969, NEUROPSYCHOLOGIA, V7, P537; Monroe M., 1966, GROUP DIAGNOSTIC REA; MORGAN D, 1988, TEACHING BEHAVIORALL; REITAN RM, 1964, MANUAL ADM SCORING R; Rey A, 1964, EXAMEN CLIN PSYCHOL; SANTOSTEFANO S, 1987, COGNITIVE CONTROL BA; Schaefer CE, 1989, HDB PARENT TRAINING; SINGH SD, 1976, J PSYCHOL, V51, P144; SLOSSON RL, 1981, SLOSSON INTELLIGENCE; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1987, BNI Q, V3, P28; WEBSTER R, 1981, LEARNING EFFICIENCY; Wechsler D., 1974, MANUAL WECHSLER INTE	29	58	60	0	19	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		1991	7	3					359	376		10.1080/87565649109540498			18	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	GH705	WOS:A1991GH70500006					2021-06-18	
J	STOKX, LC; GAILLARD, AWK				STOKX, LC; GAILLARD, AWK			TASK AND DRIVING PERFORMANCE OF PATIENTS WITH A SEVERE CONCUSSION OF THE BRAIN	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article										STOKX, LC (corresponding author), TNO SOESTERBERG,INST PERCEPT,POB 23,3769 ZG SOESTERBERG,NETHERLANDS.						Frowein H.W., 1981, SELECTIVE DRUG EFFEC; HOUTMANS MJM, 1981, ACTA PSYCHOL, V55, P143; JENNETT B, 1984, CLOSED HEAD INJURY P, P37; MORAAL J, 1982, 26TH P ANN M HUM FAC; Sanders A. F., 1977, ATTENTION PERFORM, P3; SANDERS AF, 1980, TUTORIALS MOTOR BEHA, P331, DOI DOI 10.1016/S0166-4115(08)61955-X; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1984, PSYCHOL SOCIAL FAMIL, P74; VELING IH, 1981, IZF1981M26 I PERC TN; WELFORD AT, 1980, HUMAN FACTORS, V23, P97	13	58	58	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1986	8	4					421	436		10.1080/01688638608401332			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	D6021	WOS:A1986D602100009	3745415				2021-06-18	
J	ROSENBLUM, WI; GREENBERG, RP; SEELIG, JM; BECKER, DP				ROSENBLUM, WI; GREENBERG, RP; SEELIG, JM; BECKER, DP			MIDBRAIN LESIONS - FREQUENT AND SIGNIFICANT PROGNOSTIC FEATURE IN CLOSED HEAD-INJURY	NEUROSURGERY			English	Article									VIRGINIA COMMONWEALTH UNIV, DEPT SURG NEUROSURG, RICHMOND, VA 23298 USA	ROSENBLUM, WI (corresponding author), VIRGINIA COMMONWEALTH UNIV, DEPT PATHOL NEUROPATHOL, RICHMOND, VA 23298 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K07-NS346-03] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [124587] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1975, HDB CLINICAL NEUROLO, V23, P35; BUDZILOVICH GN, 1976, HEAD INJURIES 2ND CH, P39; GREENBERG RP, 1977, J NEUROSURG, V47, P150, DOI 10.3171/jns.1977.47.2.0150; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; GREENBERG RP, 1964, CLIN NEUROSURG, V12, P129; MITCHELL DE, 1973, LANCET, V2, P215; NARAYAN RK, J NEUROSURG; NAUMENKO J, 1963, ACTA NEUROPATHOL BER, V2, P402; NEWLON P, REHABILITATION TRAUM; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; STRICH SJ, GREENFIELDS NEUROPAT, P327; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154	13	58	58	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery		1981	9	6					613	620		10.1227/00006123-198112000-00001			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	MT893	WOS:A1981MT89300001	7322325				2021-06-18	
J	RELANDER, M; TROUPP, H; BJORKEST.G				RELANDER, M; TROUPP, H; BJORKEST.G			CONTROLLED TRIAL OF TREATMENT FOR CEREBRAL CONCUSSION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									HELSINKI UNIV, CENT HOSP, NEUROSURG CLIN, HELSINKI, FINLAND							CAIRNS H, 1941, P ROY SOC MED, V35, P299; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Guttmann E, 1943, BRIT MED J, V1943, P94; HILTON J, CITED INDIRECTLY; MULLER R, 1956, ARCH NEURO PSYCHIATR, V76, P597; OLESEN S, 1963, UGESKRIFT LAEGER, V64, P123; RELANDER M, 1971, AKTIV BEHANDLING LAT; Russell WR, 1942, BMJ-BRIT MED J, V1942, P521, DOI 10.1136/bmj.2.4269.521; SILFVERSKIOLD BP, 1951, ACTA PSYCHIATRIC S74, P264; SYMONDS C, 1962, LANCET, V1, P1	10	58	58	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal		1972	4	5843					777	779		10.1136/bmj.4.5843.777			3	Medicine, General & Internal	General & Internal Medicine	O3691	WOS:A1972O369100018	4646510	Green Published			2021-06-18	
J	Hawryluk, GWJ; Aguilera, S; Buki, A; Bulger, E; Citerio, G; Cooper, DJ; Arrastia, RD; Diringer, M; Figaji, A; Gao, GY; Geocadin, R; Ghajar, J; Harris, O; Hoffer, A; Hutchinson, P; Joseph, M; Kitagawa, R; Manley, G; Mayer, S; Menon, DK; Meyfroidt, G; Michael, DB; Oddo, M; Okonkwo, D; Patel, M; Robertson, C; Rosenfeld, JV; Rubiano, AM; Sahuquillo, J; Servadei, F; Shutter, L; Stein, D; Stocchetti, N; Taccone, FS; Timmons, S; Tsai, E; Ullman, JS; Vespa, P; Videtta, W; Wright, DW; Zammit, C; Chesnut, RM				Hawryluk, Gregory W. J.; Aguilera, Sergio; Buki, Andras; Bulger, Eileen; Citerio, Giuseppe; Cooper, D. Jamie; Arrastia, Ramon Diaz; Diringer, Michael; Figaji, Anthony; Gao, Guoyi; Geocadin, Romergryko; Ghajar, Jamshid; Harris, Odette; Hoffer, Alan; Hutchinson, Peter; Joseph, Mathew; Kitagawa, Ryan; Manley, Geoffrey; Mayer, Stephan; Menon, David K.; Meyfroidt, Geert; Michael, Daniel B.; Oddo, Mauro; Okonkwo, David; Patel, Mayur; Robertson, Claudia; Rosenfeld, Jeffrey V.; Rubiano, Andres M.; Sahuquillo, Juan; Servadei, Franco; Shutter, Lori; Stein, Deborah; Stocchetti, Nino; Taccone, Fabio Silvio; Timmons, Shelly; Tsai, Eve; Ullman, Jamie S.; Vespa, Paul; Videtta, Walter; Wright, David W.; Zammit, Christopher; Chesnut, Randall M.			A management algorithm for patients with intracranial pressure monitoring: the Seattle International Severe Traumatic Brain Injury Consensus Conference (SIBICC)	INTENSIVE CARE MEDICINE			English	Article						Brain injury; Head trauma; Algorithm; Protocol; Consensus; Intracranial pressure; Tiers; Seattle; SIBICC	DECOMPRESSIVE CRANIECTOMY; AUTOREGULATION; TRIAL	Background Management algorithms for adult severe traumatic brain injury (sTBI) were omitted in later editions of the Brain Trauma Foundation's sTBI Management Guidelines, as they were not evidence-based. Methods We used a Delphi-method-based consensus approach to address management of sTBI patients undergoing intracranial pressure (ICP) monitoring. Forty-two experienced, clinically active sTBI specialists from six continents comprised the panel. Eight surveys iterated queries and comments. An in-person meeting included whole- and small-group discussions and blinded voting. Consensus required 80% agreement. We developed heatmaps based on a traffic-light model where panelists' decision tendencies were the focus of recommendations. Results We provide comprehensive algorithms for ICP-monitor-based adult sTBI management. Consensus established 18 interventions as fundamental and ten treatments not to be used. We provide a three-tier algorithm for treating elevated ICP. Treatments within a tier are considered empirically equivalent. Higher tiers involve higher risk therapies. Tiers 1, 2, and 3 include 10, 4, and 3 interventions, respectively. We include inter-tier considerations, and recommendations for critical neuroworsening to assist the recognition and treatment of declining patients. Novel elements include guidance for autoregulation-based ICP treatment based on MAP Challenge results, and two heatmaps to guide (1) ICP-monitor removal and (2) consideration of sedation holidays for neurological examination. Conclusions Our modern and comprehensive sTBI-management protocol is designed to assist clinicians managing sTBI patients monitored with ICP-monitors alone. Consensus-based (class III evidence), it provides management recommendations based on combined expert opinion. It reflects neither a standard-of-care nor a substitute for thoughtful individualized management.	[Hawryluk, Gregory W. J.] Univ Manitoba, Sect Neurosurg, GB1,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada; [Aguilera, Sergio] Valparaiso Univ, Almirante Nef Naval Hosp, Vina Del Mar, Chile; [Aguilera, Sergio] Univ Valparaiso, Valparaiso, Chile; [Buki, Andras] Med Sch, Dept Neurosurg, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Buki, Andras] Szentagothai Res Ctr, Ifjusag Utja 20, H-7624 Pecs, Hungary; [Buki, Andras] Univ Pecs, Pecs, Hungary; [Bulger, Eileen] Univ Washington, Harborview Med Ctr, Dept Surg, 325 Ninth Ave, Seattle, WA 98104 USA; [Citerio, Giuseppe] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy; [Citerio, Giuseppe] ASST Monza, Anaesthesia & Intens Care, San Gerardo & Desio Hosp, Monza, Italy; [Cooper, D. Jamie] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Intens Care Med, Melbourne, Vic, Australia; [Cooper, D. Jamie] Alfred Hosp, Dept Intens Care & Hyperbar Med, Melbourne, Vic, Australia; [Arrastia, Ramon Diaz] Univ Penn, Perelman Sch Med, Penn Presbyterian Med Ctr, Dept Neurol, 51 North 39th St, Philadelphia, PA 19104 USA; [Diringer, Michael] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Diringer, Michael] Barnes Jewish Hosp, Dept Neurol, 1 Barnes Jewish Hosp Plaza Suite 10400, St Louis, MO 63110 USA; [Figaji, Anthony] Univ Cape Town, Groote Schuur Hosp, Div Neurosurg, H53 Old Main Bldg,Main Rd, ZA-7925 Observatory, South Africa; [Figaji, Anthony] Univ Cape Town, Groote Schuur Hosp, Neurosci Inst, H53 Old Main Bldg,Main Rd, ZA-7925 Observatory, South Africa; [Gao, Guoyi] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Head Trauma, Dept Neurosurg,Renji Hosp, 1630 Dongfang Rd, Shanghai 200127, Peoples R China; [Geocadin, Romergryko] Johns Hopkins Univ, Sch Med, Dept Neurol, 600 N Wolfe St,Phipps 455, Baltimore, MD 21287 USA; [Ghajar, Jamshid] Stanford Neurosci Hlth Ctr, Dept Neurosurg, 213 Quarry Rd 4th Fl,MC 5958, Palo Alto, CA 94304 USA; [Harris, Odette] Dept Neurosurg, 300 Pasteur Dr,Room R205,Edwards Bldg,MC 5327, Stanford, CA 94305 USA; [Hoffer, Alan] Case Western Reserve Univ, Sch Med, Dept Neurol Surg, 11100 Euclid Ave,5042, Cleveland, OH 44106 USA; [Hutchinson, Peter] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB20QQ, England; [Hutchinson, Peter] Cambridge Biomed Campus, Cambridge CB20QQ, England; [Joseph, Mathew] Christian Med Coll & Hosp, Dept Neurol Sci, Ida Scudder Rd, Vellore, Tamil Nadu, India; [Kitagawa, Ryan] UTHealth, McGovern Med Sch, Vivian L Smith Dept Neurosurg, 6400 Fannin St,Suite 2800, Houston, TX 77030 USA; [Manley, Geoffrey] San Francisco Gen Hosp, Dept Neurosurg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Manley, Geoffrey] Univ Calif San Francisco, Ctr Trauma, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Mayer, Stephan] Henry Ford Hosp, Dept Neurol, Neurol, 2799 W Grand Blvd,K-11, Detroit, MI 48202 USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Hills Rd,Box 93, Cambridge CB2 0QQ, England; [Menon, David K.] Addenbrookes Hosp, Hills Rd,Box 93, Cambridge CB2 0QQ, England; [Meyfroidt, Geert] Univ Hosp Leuven, Dept & Lab Intens Care Med, Herestr 49,Box 7003 63, B-3000 Leuven, Belgium; [Meyfroidt, Geert] Katholieke Univ Leuven, Herestr 49,Box 7003 63, B-3000 Leuven, Belgium; [Michael, Daniel B.] Oakland Univ, William Beaumont Sch Med, Michigan Head & Spine Inst, Dept Neurosurg,Beaumont Hlth, Southfield, MI USA; [Oddo, Mauro] Univ Lausanne, CHUV Lausanne Univ Hosp, Fac Biol & Med, Dept Intens Care Med, Lausanne, Switzerland; [Okonkwo, David] Univ Pittsburgh, Presbyterian Med Ctr, Dept Neurosurg, Suite B-400 200 Lothrop St, Pittsburgh, PA 15213 USA; [Patel, Mayur] Vanderbilt Univ, Med Ctr, Dept Surg, 1211 21st Ave South,404 MAB, Nashville, TN 37212 USA; [Robertson, Claudia] Baylor Coll Med, Dept Neurosurg, One Baylor Plaza, Houston, TX 77030 USA; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] El Bosque Univ, Neurosci Inst, INUB MEDITECH Res Grp, Bogota, Colombia; [Rubiano, Andres M.] MEDITECH Fdn, Clin Res, Calle 7-A 44-95, Cali 760036, Colombia; [Sahuquillo, Juan] Univ Hosp Vall dHebron, Dept Neurosurg, Barcelona, Spain; [Servadei, Franco] Humanitas Univ & Res Hosp, Dept Neurosurg, Milan, Italy; [Shutter, Lori] Univ Pittsburgh, Med Ctr, Dept Crit Care Med Neurol & Neurosurg, 3550 Terrace St,Room 646, Pittsburgh, PA 15261 USA; [Stein, Deborah] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Surg, 1001 Potrero Ave,Ward 3A, San Francisco, CA 94110 USA; [Stein, Deborah] Univ Calif San Francisco, Ctr Trauma, 1001 Potrero Ave,Ward 3A, San Francisco, CA 94110 USA; [Stocchetti, Nino] Milan Univ, Dept Physiopathol & Transplantat, Milan, Italy; [Stocchetti, Nino] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurosci Intens Care Unit, Milan, Italy; [Taccone, Fabio Silvio] ULB, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Timmons, Shelly] Dept Neurol Surg, GH 5100 SNEU, Indianapolis, IN 46202 USA; [Tsai, Eve] Univ Ottawa, Suruchi Bhargava Chair Spinal Cord & Brain Regene, Ottawa Hosp, Dept Surg,Div Neurosurg, Civ Campus,1053 Carling Ave, Ottawa, ON K1Y 4E9, Canada; [Ullman, Jamie S.] North Shore Univ Hosp, Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Neurosurg, 300 Community Dr,9 Tower, Manhasset, NY USA; [Vespa, Paul] Univ Calif Los Angeles, Sch Med, Gary L Brinderson Family Chair Neurocrit Care, Los Angeles, CA USA; [Vespa, Paul] Univ Calif Los Angeles, Sch Med, Crit Care Med Res, Santa Monica, CA USA; [Vespa, Paul] Univ Calif Los Angeles, Sch Med, Neurosurg & Neurol, Santa Monica, CA USA; [Vespa, Paul] Ronald Reagan UCLA Med Ctr, Neurocrit Care, Santa Monica, CA USA; [Videtta, Walter] Posadas Hosp, Intens Care, Buenos Aires, DF, Argentina; [Wright, David W.] Emory Univ, Sch Med, Dept Emergency Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA; [Zammit, Christopher] Univ Rochester, Med Ctr, Dept Emergency Med, 265 Crittenden Blvd,Suite 2100,Box 655C, Rochester, NY 14642 USA; [Chesnut, Randall M.] Univ Washington, Dept Neurol Surg, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA; [Chesnut, Randall M.] Univ Washington, Dept Orthopaed Surg, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA; [Chesnut, Randall M.] Univ Washington, Sch Global Hlth, Mailstop 359766,325 Ninth Ave, Seattle, WA 98104 USA; [Chesnut, Randall M.] Univ Washington, Harborview Med Ctr, 325 Ninth Ave,Mailstop 359766, Seattle, WA 98104 USA	Chesnut, RM (corresponding author), Univ Washington, Harborview Med Ctr, 325 Ninth Ave,Mailstop 359766, Seattle, WA 98104 USA.	ghawryluk@hsc.mb.ca; chesnutr@uw.edu	RUBIANO, ANDRES M/K-6704-2012; Ullman, Jamie/AAP-5983-2020; Cooper, D. James/G-7961-2013; Sahuquillo, Juan/B-3577-2008; Tsai, Eve/D-7007-2014	RUBIANO, ANDRES M/0000-0001-8931-3254; Cooper, D. James/0000-0002-5872-9051; Sahuquillo, Juan/0000-0003-0713-5875; Chesnut, Randall/0000-0001-6377-3666; Hawryluk, Gregory/0000-0002-5604-7057; Figaji, Anthony/0000-0002-3357-6490; Shutter, Lori/0000-0002-1390-0628; Tsai, Eve/0000-0002-8152-349X	NIHRNational Institute for Health Research (NIHR); American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Neurotrauma and Critical Care, Bard; Brain Trauma Foundation; DePuy; Hemedex; Integra; Neurointensive Care Section of the European Society of Intensive Care Medicine; Neurosurgical Society of Australasia; MedtronicMedtronic; Moberg Research; NatusNational University of Singapore; Neuroptics; Raumedic; Sophysa; Stryker; Zoll; NIHR (Cambridge BRC); NIHR (Global Health Research Group on Neurotrauma)	We thank our moderators Kevin Dunne and Theodore Michalke, Jone Howard for our audience response system, Kelley Chaddock for extensive administrative support, Peter Hendrickson, PhD for managing our web-based surveys, PJH is supported by the NIHR (Research Professorship, Cambridge BRC and Global Health Research Group on Neurotrauma), and DKM is an Emeritus Senior Investigator of the National Institute of Health Research (UK). We thank our financial supporters who include Adler/Geirsch Attorney at Law, the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Neurotrauma and Critical Care, Bard, the Brain Trauma Foundation, DePuy, Hemedex, Integra, the Neurointensive Care Section of the European Society of Intensive Care Medicine, Neurosurgical Society of Australasia, Medtronic, Moberg Research, Natus, Neuroptics, Raumedic, Sophysa, Stryker, and Zoll.	[Anonymous], 2007, J NEUROTRAUM, V24, pS1, DOI 10.1089/neu.2007.9997; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2018, JAMA-J AM MED ASSOC, V320, P2211, DOI 10.1001/jama.2018.17075; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; Hendrickson P, 2018, WORLD NEUROSURG, V110, pE952, DOI 10.1016/j.wneu.2017.11.142; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Lang EW, 2000, BRIT J NEUROSURG, V14, P117; Lubillo S, 1999, J NEUROSURG, V91, P581, DOI 10.3171/jns.1999.91.4.0581; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; TEASDALE G, 1974, LANCET, V2, P81; Trauma ACoSCo, 2015, BOOK BEST PRACT MAN	20	57	57	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	DEC	2019	45	12								10.1007/s00134-019-05805-9		OCT 2019	12	Critical Care Medicine	General & Internal Medicine	JW5BG	WOS:000492941700002	31659383	Green Published, Other Gold	Y	N	2021-06-18	
J	Zyryanova, AF; Weis, F; Faille, A; Alard, AA; Crespillo-Casado, A; Sekine, Y; Harding, HP; Allen, F; Parts, L; Fromont, C; Fischer, PM; Warren, AJ; Ron, D				Zyryanova, Alisa F.; Weis, Felix; Faille, Alexandre; Alard, Akeel Abo; Crespillo-Casado, Ana; Sekine, Yusuke; Harding, Heather P.; Allen, Felicity; Parts, Leopold; Fromont, Christophe; Fischer, Peter M.; Warren, Alan J.; Ron, David			Binding of ISRIB reveals a regulatory site in the nucleotide exchange factor eIF2B	SCIENCE			English	Article							PHOSPHORYLATION; MUTATIONS	The integrated stress response (ISR) is a conserved translational and transcriptional program affecting metabolism, memory, and immunity. The ISR is mediated by stress-induced phosphorylation of eukaryotic translation initiation factor 2a (eIF2a) that attenuates the guanine nucleotide exchange factor eIF2B. A chemical inhibitor of the ISR, ISRIB, reverses the attenuation of eIF2B by phosphorylated eIF2a, protecting mice from neurodegeneration and traumatic brain injury. We describe a 4.1-angstrom-resolution cryo-electron microscopy structure of human eIF2B with an ISRIB molecule bound at the interface between the b and d regulatory subunits. Mutagenesis of residues lining this pocket altered the hierarchical cellular response to ISRIB analogs in vivo and ISRIB binding in vitro. Our findings point to a site in eIF2B that can be exploited by ISRIB to regulate translation.	[Zyryanova, Alisa F.; Weis, Felix; Faille, Alexandre; Crespillo-Casado, Ana; Sekine, Yusuke; Harding, Heather P.; Warren, Alan J.; Ron, David] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Weis, Felix; Faille, Alexandre; Warren, Alan J.] Univ Cambridge, Dept Haematol, Cambridge, England; [Weis, Felix; Faille, Alexandre; Warren, Alan J.] Univ Cambridge, Wellcome Trust Med Res Council Stem Cell Inst, Cambridge, England; [Weis, Felix; Warren, Alan J.] MRC, Mol Biol Lab, Francis Crick Ave, Cambridge CB2 0QH, England; [Alard, Akeel Abo; Fromont, Christophe; Fischer, Peter M.] Univ Nottingham, Sch Pharm, Div Biomol Sci & Med Chem, Nottingham NG7 2RD, England; [Allen, Felicity; Parts, Leopold] Wellcome Trust Sanger Inst, Wellcome Genome Campus, Hinxton CB10 1SA, Cambs, England	Zyryanova, AF; Warren, AJ; Ron, D (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England.; Warren, AJ (corresponding author), Univ Cambridge, Dept Haematol, Cambridge, England.; Warren, AJ (corresponding author), Univ Cambridge, Wellcome Trust Med Res Council Stem Cell Inst, Cambridge, England.; Warren, AJ (corresponding author), MRC, Mol Biol Lab, Francis Crick Ave, Cambridge CB2 0QH, England.	az310@cam.ac.uk; ajw1000@cam.ac.uk; dr360@medschl.cam.ac.uk	Allen, Felicity/K-8688-2016	Allen, Felicity/0000-0002-8694-3936; Fromont, Christophe/0000-0002-7295-6023; Harding, Heather/0000-0002-7359-7974; Ron, David/0000-0002-3014-5636; Weis, Felix/0000-0002-8137-3532; Parts, Leopold/0000-0002-2618-670X	Wellcome TrustWellcome TrustEuropean Commission [200848/Z/16/Z, 100140]; Specialist Programme from Bloodwise [12048]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_U105161083]; Higher Committee for Education Development, Iraq [4241047]; Royal Commission for the Exhibition of 1851	We acknowledge funding by a Wellcome Trust Principal Research Fellowship (Wellcome 200848/Z/16/Z) to D.R.; a Specialist Programme from Bloodwise (12048), the UK Medical Research Council (MC_U105161083), and core support from the Wellcome Trust Medical Research Council Cambridge Stem Cell Institute to A.J.W.; and a Wellcome Trust Strategic Award to the Cambridge Institute for Medical Research (Wellcome 100140). Support from A Higher Committee for Education Development, Iraq, Scholarship (4241047) to A. A. A. and a Research Fellowship from Royal Commission for the Exhibition of 1851 to F.A. is greatly appreciated.	Bogorad AM, 2017, NUCLEIC ACIDS RES, V45, P11962, DOI 10.1093/nar/gkx845; Chou A, 2017, P NATL ACAD SCI USA, V114, pE6420, DOI 10.1073/pnas.1707661114; CLEMENS MJ, 1982, NATURE, V296, P93, DOI 10.1038/296093a0; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; Halliday M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.49; Hearn BR, 2016, CHEMMEDCHEM, V11, P870, DOI 10.1002/cmdc.201500483; Kashiwagi K, 2016, NATURE, V531, P122, DOI 10.1038/nature16991; Pakos-Zebrucka K, 2016, EMBO REP, V17, P1374, DOI 10.15252/embr.201642195; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Sekine Y, 2015, SCIENCE, V348, P1027, DOI 10.1126/science.aaa6986; Sidrauski C, 2015, ELIFE, V4, DOI 10.7554/eLife.07314; Sidrauski C, 2013, ELIFE, V2, DOI 10.7554/eLife.00498; SIEKIERKA J, 1981, P NATL ACAD SCI-BIOL, V78, P220, DOI 10.1073/pnas.78.1.220; Tsai JC, 2018, SCIENCE, V359, P1483, DOI 10.1126/science.aaq0939	15	57	58	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 30	2018	359	6383					1533	1536		10.1126/science.aar5129			4	Multidisciplinary Sciences	Science & Technology - Other Topics	GA9JI	WOS:000428657000048	29599245	Green Accepted, Bronze			2021-06-18	
J	Darby, RR; Horn, A; Cushman, F; Fox, MD				Darby, R. Ryan; Horn, Andreas; Cushman, Fiery; Fox, Michael D.			Lesion network localization of criminal behavior	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						morality; functional connectivity; criminality; sociopathy; lesion	TRAUMATIC BRAIN-INJURY; MORAL JUDGMENT; FRONTOTEMPORAL DEMENTIA; PREFRONTAL CORTEX; DECISION-MAKING; ACQUIRED SOCIOPATHY; ULTIMATUM GAME; CONNECTIVITY; DAMAGE; PSYCHOPATHY	Following brain lesions, previously normal patients sometimes exhibit criminal behavior. Although rare, these cases can lend unique insight into the neurobiological substrate of criminality. Here we present a systematic mapping of lesions with known temporal association to criminal behavior, identifying 17 lesion cases. The lesion sites were spatially heterogeneous, including the medial prefrontal cortex, orbitofrontal cortex, and different locations within the bilateral temporal lobes. No single brain region was damaged in all cases. Because lesion-induced symptoms can come from sites connected to the lesion location and not just the lesion location itself, we also identified brain regions functionally connected to each lesion location. This technique, termed lesion network mapping, has recently identified regions involved in symptom generation across a variety of lesion-induced disorders. All lesions were functionally connected to the same network of brain regions. This criminality-associated connectivity pattern was unique compared with lesions causing four other neuropsychiatric syndromes. This network includes regions involved in morality, value-based decision making, and theory of mind, but not regions involved in cognitive control or empathy. Finally, we replicated our results in a separate cohort of 23 cases in which a temporal relationship between brain lesions and criminal behavior was implied but not definitive. Our results suggest that lesions in criminals occur in different brain locations but localize to a unique resting state network, providing insight into the neurobiology of criminal behavior.	[Darby, R. Ryan] Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN 37232 USA; [Darby, R. Ryan; Horn, Andreas; Fox, Michael D.] Harvard Med Sch, Dept Neurol, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA; [Darby, R. Ryan; Horn, Andreas; Fox, Michael D.] Harvard Med Sch, Dept Neurol, Beth Israel Deaconess Med Ctr, Div Cognit Neurol, Boston, MA 02115 USA; [Darby, R. Ryan; Fox, Michael D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Darby, R. Ryan] Harvard Med Sch, McLean Psychiat Hosp, Dept Neurol, Belmont, MA 02478 USA; [Horn, Andreas] Charite, Dept Neurol, Movement Disorder & Neuromodulat Unit, D-10117 Berlin, Germany; [Cushman, Fiery] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA; [Fox, Michael D.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA	Darby, RR (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN 37232 USA.; Darby, RR; Fox, MD (corresponding author), Harvard Med Sch, Dept Neurol, Beth Israel Deaconess Med Ctr, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA.; Darby, RR; Fox, MD (corresponding author), Harvard Med Sch, Dept Neurol, Beth Israel Deaconess Med Ctr, Div Cognit Neurol, Boston, MA 02115 USA.; Darby, RR; Fox, MD (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.; Darby, RR (corresponding author), Harvard Med Sch, McLean Psychiat Hosp, Dept Neurol, Belmont, MA 02478 USA.; Fox, MD (corresponding author), Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.	darby.ryan@gmail.com; foxmdphd@gmail.com	Horn, Andreas/R-6528-2017; Fox, Michael D./AAZ-3928-2020; Horn, Andreas GR/B-8988-2017	Fox, Michael D./0000-0001-8848-6399; Horn, Andreas GR/0000-0002-0695-6025; Cushman, Fiery/0000-0002-6929-9982	Sidney R. Baer, Jr. Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS083741]; Dystonia Foundation; Nancy Lurie Marks Foundation; Alzheimer's AssociationAlzheimer's Association; BrightFocus FoundationBrightFocus Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS083741] Funding Source: NIH RePORTER	We thank Joshua Greene and Danilo Bzdok for sharing data. This work was supported by funding from the Sidney R. Baer, Jr. Foundation (R.R.D. and M.D.F.), the National Institutes of Health Grant K23NS083741 (to M.D.F.), the Dystonia Foundation (M.D.F.), the Nancy Lurie Marks Foundation (M.D.F.), the Alzheimer's Association (R.R.D.), and the BrightFocus Foundation (R.R.D.).	Adolphs R, 2016, NEURON, V90, P1151, DOI 10.1016/j.neuron.2016.05.014; Anderson DA, 1999, J LAW ECON, V42, P611, DOI 10.1086/467436; Anderson NE, 2012, TRENDS COGN SCI, V16, P52, DOI 10.1016/j.tics.2011.11.008; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; ANDERSON SW, 1990, ARCH NEUROL-CHICAGO, V47, P397, DOI 10.1001/archneur.1990.00530040039017; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Baron-Cohen S, 2013, SCI EVIL EMPATHY ORI; Batts S, 2009, BEHAV SCI LAW, V27, P261, DOI 10.1002/bsl.857; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; Boes AD, 2015, BRAIN, V138, P3061, DOI 10.1093/brain/awv228; Braun Claude M J, 2008, Cogn Neuropsychiatry, V13, P296, DOI 10.1080/13546800802088580; Buckholtz JW, 2015, CURR OPIN BEHAV SCI, V3, P122, DOI 10.1016/j.cobeha.2015.03.004; Bufkin JL, 2005, TRAUMA VIOLENCE ABUS, V6, P176, DOI 10.1177/1524838005275089; Bzdok D, 2012, BRAIN STRUCT FUNCT, V217, P783, DOI 10.1007/s00429-012-0380-y; Cushman F, 2013, PERS SOC PSYCHOL REV, V17, P273, DOI 10.1177/1088868313495594; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Darby RR, 2017, BRAIN, V140, DOI 10.1093/brain/awx125; Darby RR, 2017, BRAIN, V140, P497, DOI 10.1093/brain/aww288; Darby RR, 2016, AJOB NEUROSCIENCE, V7, P193; de Oliveira-Souza R, 2008, NEUROIMAGE, V40, P1202, DOI 10.1016/j.neuroimage.2007.12.054; Denno D.W, 2015, BOSTON COLL LAW REV, V56, P493; Diehl-Schmid J, 2013, COGN BEHAV NEUROL, V26, P73, DOI 10.1097/WNN.0b013e31829cff11; Eickhoff SB, 2009, HUM BRAIN MAPP, V30, P2907, DOI 10.1002/hbm.20718; Ermer E, 2012, J ABNORM PSYCHOL, V121, P649, DOI 10.1037/a0026371; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Feng CL, 2015, HUM BRAIN MAPP, V36, P591, DOI 10.1002/hbm.22649; Fischer DB, 2016, NEUROLOGY, V87, P2427, DOI 10.1212/WNL.0000000000003404; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Fumagalli M, 2012, BRAIN, V135, P2006, DOI 10.1093/brain/awr334; Glenn AL, 2014, NAT REV NEUROSCI, V15, P54, DOI 10.1038/nrn3640; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greene JD, 2004, NEURON, V44, P389, DOI 10.1016/j.neuron.2004.09.027; Greene JD, 2001, SCIENCE, V293, P2105, DOI 10.1126/science.1062872; Grefkes C, 2014, LANCET NEUROL, V13, P206, DOI 10.1016/S1474-4422(13)70264-3; Horn A, 2017, ANN NEUROL, V82, P67, DOI 10.1002/ana.24974; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Koenigs M, 2007, J NEUROSCI, V27, P951, DOI 10.1523/JNEUROSCI.4606-06.2007; Koenigs M, 2012, SOC COGN AFFECT NEUR, V7, P708, DOI 10.1093/scan/nsr048; Koenigs M, 2010, NEUROPSYCHOLOGIA, V48, P2198, DOI 10.1016/j.neuropsychologia.2010.04.012; Laganiere S, 2016, NEUROLOGY, V86, P2187, DOI 10.1212/WNL.0000000000002741; Liljegren M, 2015, JAMA NEUROL, V72, P295, DOI 10.1001/jamaneurol.2014.3781; Mendez MF, 2009, CNS SPECTRUMS, V14, P608, DOI 10.1017/S1092852900023853; Mendez MF, 2005, COGN BEHAV NEUROL, V18, P193, DOI 10.1097/01.wnn.0000191292.17964.bb; Mendez MF, 2005, DEMENT GERIATR COGN, V20, P99, DOI 10.1159/000086474; Monakow C., 1914, LOKALISATION GROSSHI; Motzkin JC, 2011, J NEUROSCI, V31, P17348, DOI 10.1523/JNEUROSCI.4215-11.2011; O'Callaghan C, 2016, BRAIN, V139, P204, DOI 10.1093/brain/awv315; Pardini M, 2011, NEUROLOGY, V76, P1038, DOI 10.1212/WNL.0b013e318211c33e; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; Sutterer MJ, 2016, CORTEX, V78, P31, DOI 10.1016/j.cortex.2016.02.002; Taber-Thomas BC, 2014, BRAIN, V137, P1254, DOI 10.1093/brain/awt377; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Yarkoni T, 2011, NAT METHODS, V8, P665, DOI [10.1038/NMETH.1635, 10.1038/nmeth.1635]; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011; Young L, 2007, P NATL ACAD SCI USA, V104, P8235, DOI 10.1073/pnas.0701408104	56	57	57	3	40	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 16	2018	115	3					601	606		10.1073/pnas.1706587115			6	Multidisciplinary Sciences	Science & Technology - Other Topics	FT3ZS	WOS:000423091400059	29255017	Green Published, Other Gold			2021-06-18	
J	Kessler, RC; Stein, MB; Petukhova, MV; Bliese, P; Bossarte, RM; Bromet, EJ; Fullerton, CS; Gilman, SE; Ivany, C; Lewandowski-Romps, L; Bell, AM; Naifeh, JA; Nock, MK; Reis, BY; Rosellini, AJ; Sampson, NA; Zaslavsky, AM; Ursano, RJ				Kessler, R. C.; Stein, M. B.; Petukhova, M. V.; Bliese, P.; Bossarte, R. M.; Bromet, E. J.; Fullerton, C. S.; Gilman, S. E.; Ivany, C.; Lewandowski-Romps, L.; Bell, A. Millikan; Naifeh, J. A.; Nock, M. K.; Reis, B. Y.; Rosellini, A. J.; Sampson, N. A.; Zaslavsky, A. M.; Ursano, R. J.		Army STARRS Collaborators	Predicting suicides after outpatient mental health visits in the Army Study to Assess Risk and Resilience in Servicemembers (Army STARRS)	MOLECULAR PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; US ARMY; MILITARY; SOLDIERS; CARE; PREVENTION; DEATH; DEPLOYMENT; SYSTEM	The 2013 US Veterans Administration/Department of Defense Clinical Practice Guidelines (VA/DoD CPG) require comprehensive suicide risk assessments for VA/DoD patients with mental disorders but provide minimal guidance on how to carry out these assessments. Given that clinician-based assessments are not known to be strong predictors of suicide, we investigated whether a precision medicine model using administrative data after outpatient mental health specialty visits could be developed to predict suicides among outpatients. We focused on male nondeployed Regular US Army soldiers because they account for the vast majority of such suicides. Four machine learning classifiers (naive Bayes, random forests, support vector regression and elastic net penalized regression) were explored. Of the Army suicides in 2004-2009, 41.5% occurred among 12.0% of soldiers seen as outpatient by mental health specialists, with risk especially high within 26 weeks of visits. An elastic net classifier with 10-14 predictors optimized sensitivity (45.6% of suicide deaths occurring after the 15% of visits with highest predicted risk). Good model stability was found for a model using 2004-2007 data to predict 2008-2009 suicides, although stability decreased in a model using 2008-2009 data to predict 2010-2012 suicides. The 5% of visits with highest risk included only 0.1% of soldiers (1047.1 suicides/100 000 person-years in the 5 weeks after the visit). This is a high enough concentration of risk to have implications for targeting preventive interventions. An even better model might be developed in the future by including the enriched information on clinician-evaluated suicide risk mandated by the VA/DoD CPG to be recorded.	[Kessler, R. C.; Petukhova, M. V.; Rosellini, A. J.; Sampson, N. A.; Zaslavsky, A. M.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA; [Stein, M. B.] Univ Calif San Diego, Dept Psychiat & Family & Prevent Med, La Jolla, CA USA; [Stein, M. B.] VA San Diego Healthcare Syst, San Diego, CA USA; [Bliese, P.] Univ South Carolina, Darla Moore Sch Business, Columbia, SC USA; [Bossarte, R. M.] Post Deployment Hlth Serv, Dept Vet Affairs, Washington, DC USA; [Bromet, E. J.] Stony Brook Sch Med, Dept Psychiat & Behav Sci, Stony Brook, NY USA; [Fullerton, C. S.; Naifeh, J. A.; Ursano, R. J.] Uniformed Serv Univ Hlth Sci, Sch Med, Ctr Study Traumat Stress, Dept Psychiat, Bethesda, MD USA; [Gilman, S. E.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, Hlth Behav Branch, Bethesda, MD USA; [Gilman, S. E.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol & Social & Behav Sci, Boston, MA USA; [Ivany, C.] US Army Med Command, Behav Hlth Serv Line, Bethesda, MD USA; [Lewandowski-Romps, L.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Bell, A. Millikan] US Army Publ Hlth Command, Aberdeen Proving Ground, MD USA; [Nock, M. K.] Harvard Univ, Dept Psychol, Cambridge, MA USA; [Reis, B. Y.] Childrens Hosp Boston, Harvard Med Sch, Boston, MA USA	Kessler, RC (corresponding author), Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA.	Kessler@hcp.med.harvard.edu	Ursano, Robert/ABE-6533-2020; Nock, Matthew/AAE-8330-2019; Gilman, Stephen E./E-7632-2010; Bossarte, Robert/AAF-8571-2019	Gilman, Stephen E./0000-0002-8331-6419; Ursano, Robert/0000-0002-1861-9173; Naifeh, James/0000-0001-7248-3054; Bliese, paul/0000-0002-5384-8879	Department of the Army; US Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH) [U01MH087981]; Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [ZIAHD008960] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH087981] Funding Source: NIH RePORTER	Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement number U01MH087981 with the US Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH). Dr Gilman's participation in this work was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development. We thank Kenneth L Cox for helpful comments on an earlier version of this paper. Although a draft of this manuscript was submitted to the Army and NIMH for review and comment before submission, this was with the understanding that comments would be no more than advisory.	Ahmedani BK, 2014, J GEN INTERN MED, V29, P870, DOI 10.1007/s11606-014-2767-3; Armed Forces Health Surveillance Center (AFHSC), 2012, MSMR, V19, P7; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Bell NS, 2010, SUICIDE LIFE-THREAT, V40, P407, DOI 10.1521/suli.2010.40.4.407; Berrouiguet S, 2014, PSYCHIAT RES, V217, P154, DOI 10.1016/j.psychres.2014.02.034; Black SA, 2011, MIL PSYCHOL, V23, P433, DOI 10.1080/08995605.2011.590409; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Brugnoli R, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-83; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; ERDMAN HP, 1987, J CLIN PSYCHIAT, V48, P464; FDB Health. FDB First Databank, 2015, FDB 1 DAT; Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01; Gilman SE, 2014, PSYCHOL MED, V44, P2579, DOI 10.1017/S003329171400018X; Grove WM, 2000, PSYCHOL ASSESSMENT, V12, P19, DOI 10.1037/1040-3590.12.1.19; GUSTAFSON DH, 1977, COMPUT BIOMED RES, V10, P83, DOI 10.1016/0010-4809(77)90026-X; GUSTAFSON DH, 1981, COMPUT BIOMED RES, V14, P144, DOI 10.1016/0010-4809(81)90032-X; Hyman J, 2012, AM J PUBLIC HEALTH, V102, pS138, DOI 10.2105/AJPH.2011.300484; Ireland RR, 2012, MIL MED, V177, P1149, DOI 10.7205/MILMED-D-12-00051; Kessler RC, 2015, JAMA PSYCHIAT, V72, P49, DOI 10.1001/jamapsychiatry.2014.1754; Kessler RC, 2013, INT J METH PSYCH RES, V22, P267, DOI 10.1002/mpr.1401; Large MM, 2014, AUSTRALAS PSYCHIATRY, V22, P390, DOI 10.1177/1039856214537128; Leadholm AKK, 2014, J AFFECT DISORDERS, V156, P119, DOI 10.1016/j.jad.2013.12.003; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Liaw A., 2002, R NEWS, V2, P18, DOI DOI 10.1177/154405910408300516; McCarthy JF, 2015, AM J PUBLIC HEALTH, V105, P1935, DOI 10.2105/AJPH.2015.302737; Meyer D, 2015, PACKAGE E1071 MISC F, P5; Nock MK, 2013, PSYCHIATRY, V76, P97, DOI 10.1521/psyc.2013.76.2.97; Nowrangi MA, 2014, PSYCHOSOMATICS, V55, P430, DOI 10.1016/j.psym.2013.11.006; O'Connor E, 2013, ANN INTERN MED, V158, P741, DOI 10.7326/0003-4819-158-10-201305210-00642; Reger MA, 2015, JAMA PSYCHIAT, V72, P561, DOI 10.1001/jamapsychiatry.2014.3195; Rish I., 2001, EMPIRICAL STUDY NAIV; SAS Institute Inc, SAS STAT SOFTW 9 3 U; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES; Schoenbaum M, 2014, JAMA PSYCHIAT, V71, P493, DOI 10.1001/jamapsychiatry.2013.4417; Simon GE, 2006, AM J PSYCHIAT, V163, P41, DOI 10.1176/appi.ajp.163.1.41; Simon GE, 2007, BIPOLAR DISORD, V9, P526, DOI 10.1111/j.1399-5618.2007.00408.x; Simon GE, 2013, PSYCHIAT SERV, V64, P1195, DOI 10.1176/appi.ps.201200587; Smola AJ, 2004, STAT COMPUT, V14, P199, DOI 10.1023/B:STCO.0000035301.49549.88; Smolenski DJ, 2013, DEP DEFENSE SUICIDE; Street AE, 2015, PSYCHOL MED, V45, P717, DOI 10.1017/S003329171400258X; Ursano RJ, 2014, PSYCHIATRY, V77, P107, DOI 10.1521/psyc.2014.77.2.107; Valenstein M, 2009, J AFFECT DISORDERS, V112, P50, DOI 10.1016/j.jad.2008.08.020; Veterans Affairs/ Dept of Defense, 2013, ASS MAN PAT RISK SUI; While D, 2012, LANCET, V379, P1005, DOI 10.1016/S0140-6736(11)61712-1; Zamorski MA, 2011, INT REV PSYCHIATR, V23, P173, DOI 10.3109/09540261.2011.562186; Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x	48	57	57	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	APR	2017	22	4					544	551		10.1038/mp.2016.110			8	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	EP0TP	WOS:000397099900008	27431294	Green Accepted			2021-06-18	
J	Oliver, JM; Jones, MT; Kirk, KM; Gable, DA; Repshas, JT; Johnson, TA; Andreasson, U; Norgren, N; Blennow, K; Zetterberg, H				Oliver, Jonathan M.; Jones, Margaret T.; Kirk, K. Michele; Gable, David A.; Repshas, Justin T.; Johnson, Torie A.; Andreasson, Ulf; Norgren, Niklas; Blennow, Kaj; Zetterberg, Henrik			Serum Neurofilament Light in American Football Athletes over the Course of a Season	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; biomarkers; head trauma; traumatic brain injury	TRAUMATIC BRAIN-INJURY; HEAD IMPACT EXPOSURE; DIFFUSE AXONAL INJURY; HIGH-SCHOOL FOOTBALL; CEREBROSPINAL-FLUID; SPORTS-MEDICINE; YOUTH FOOTBALL; IN-VIVO; CONCUSSION; PLAYERS	Despite being underreported, American football boasts the highest incidence of concussion among all team sports, likely due to exposure to head impacts that vary in number and magnitude over the season. This study compared a biological marker of head trauma in American football athletes with non-contact sport athletes and examined changes over the course of a season. Baseline serum neurofilament light polypeptide (NFL) was measured after 9 weeks of no contact and compared with a non-contact sport. Serum NFL was then measured over the course of the entire season at eight time-points coincident with expected changes in likelihood of increased head impacts. Data were compared between starters (n = 11) and non-starters (n = 9). Compared with non-starters (mean +/- standard deviation) (7.30 +/- 3.57 pg . mL(-1)) and controls (6.75 +/- 1.68 pg . mL(-1)), serum NFL in starters (8.45 +/- 5.90 pg . mL(-1)) was higher at baseline (mean difference; +/-90% confidence interval) (1.69; +/-1.96 pg . mL(-1) and 1.15; +/-1.4 pg . mL(-1), respectively). Over the course of the season, an increase (effect size [ES] = 1.8; p < 0.001) was observed post-camp relative to baseline (1.52 +/- 1.18 pg . mL(-1)), which remained elevated until conference play, when a second increase was observed (ES = 2.6; p = 0.008) over baseline (4.82 +/- 2.64 pg . mL(-1)). A lack of change in non-starters resulted in substantial differences between starters and non-starters over the course of the season. These data suggest that a season of collegiate American football is associated with elevations in serum NFL, which is indicative of axonal injury, as a result of head impacts.	[Oliver, Jonathan M.; Kirk, K. Michele; Gable, David A.; Repshas, Justin T.; Johnson, Torie A.] Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, TCU Box 297730, Ft Worth, TX 76129 USA; [Kirk, K. Michele; Gable, David A.] Texas Christian Univ, Dept Sport Med, Ft Worth, TX 76129 USA; [Jones, Margaret T.] George Mason Univ, Div Hlth & Human Performance, Manassas, VA USA; [Kirk, K. Michele] John Peter Smith Hosp, Dept Sport Med, Ft Worth, TX 76104 USA; [Norgren, Niklas] UmanDiagnostics, Umea, Sweden; [Andreasson, Ulf; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England	Oliver, JM (corresponding author), Texas Christian Univ, Dept Kinesiol, Sports Concuss Res Grp, TCU Box 297730, Ft Worth, TX 76129 USA.	jonathan.oliver@tcu.edu					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Andreasson Ulf, 2016, Alzheimers Dement (Amst), V3, P98, DOI 10.1016/j.dadm.2016.05.005; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Farrell JAD, 2007, J MAGN RESON IMAGING, V26, P756, DOI 10.1002/jmri.21053; Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Johan Ljungqvist, J NEUROTRAUMA; Khademi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063172; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Millecamps S, 2007, J NEUROSCI, V27, P4947, DOI 10.1523/JNEUROSCI.5299-06.2007; Mukherjee P, 2008, AM J NEURORADIOL, V29, P843, DOI 10.3174/ajnr.A1052; Neselius S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099870; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Oliver JM, 2012, J ATHL TRAINING, V47, P257, DOI 10.4085/1062-6050-47.3.12; Oliver Jonathan M., 2016, J NEUROTRAUM, V33, P1784; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Rowlands DS, 2015, MED SCI SPORT EXER, V47, P547, DOI 10.1249/MSS.0000000000000447; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Tortelli R, 2012, EUR J NEUROL, V19, P1561, DOI 10.1111/j.1468-1331.2012.03777.x; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Yamamoto Joelle B, 2008, Res Sports Med, V16, P111, DOI 10.1080/15438620802103320; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	50	57	57	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2016	33	19					1784	+		10.1089/neu.2015.4295			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DY8KP	WOS:000385379100007					2021-06-18	
J	Trepanier, MO; Hopperton, KE; Orr, SK; Bazinet, RP				Trepanier, Marc-Olivier; Hopperton, Kathryn E.; Orr, Sarah K.; Bazinet, Richard P.			N-3 polyunsaturated fatty acids in animal models with neuroinflammation: An update	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Neuroinflammation; Omega-3 polyunsaturated fatty acids; Brain; Cytokines; Microglia; Docosahexaenoic acid	SPINAL-CORD-INJURY; OLFACTORY BULBECTOMIZED RAT; GROWTH-FACTOR EXPRESSION; DOCOSAHEXAENOIC ACID; EICOSAPENTAENOIC ACID; ETHYL-EICOSAPENTAENOATE; INFLAMMATORY RESPONSE; ALZHEIMERS-DISEASE; DOUBLE-BLIND; LIPID MEDIATORS	Neuroinflammation is a characteristic of a multitude of neurological and psychiatric disorders. Modulating inflammatory pathways offers a potential therapeutic target in these disorders. Omega-3 polyunsaturated fatty acids have anti-inflammatory and pro-resolving properties in the periphery, however, their effect on neuroinflammation is less studied. This review summarizes 61 animal studies that tested the effect of omega-3 polyunsaturated fatty acids on neuroinflammatory outcomes in vivo in various models including stroke, spinal cord injury, aging, Alzheimer's disease, Parkinson's disease, lipopolysaccharide and IL-113 injections, diabetes, neuropathic pain, traumatic brain injury, depression, surgically induced cognitive decline, whole body irradiation, amyotrophic lateral sclerosis, N-methyl-D-aspartate-induced excitotoxicity and lupus. The evidence presented in this review suggests anti-neuroinflammatory properties of omega-3 polyunsaturated fatty acids, however, it is not clear by which mechanism omega-3 polyunsaturated fatty acids exert their effect. Future research should aim to isolate the effect of omega-3 polyunsaturated fatty acids on neuroinflammatory signaling in vivo and elucidate the mechanisms underlying these effects. (C) 2016 Published by Elsevier B.V.	[Trepanier, Marc-Olivier; Hopperton, Kathryn E.; Orr, Sarah K.; Bazinet, Richard P.] Univ Toronto, Fac Med, Dept Nutr Sci, FitzGerald Bldg,150 Coll St,Room 306, Toronto, ON M5S 3E2, Canada	Bazinet, RP (corresponding author), Univ Toronto, Fac Med, Dept Nutr Sci, FitzGerald Bldg,150 Coll St,Room 306, Toronto, ON M5S 3E2, Canada.	richard.bazinet@utoronto.ca		Hopperton, Kathryn/0000-0003-0146-2744	Natural Sciences and Engineering Research Council of Canada, CanadaNatural Sciences and Engineering Research Council of Canada (NSERC); Canadian Institutes of Health Research, CanadaCanadian Institutes of Health Research (CIHR)	This work was supported by grants from the Natural Sciences and Engineering Research Council of Canada, Canada and the Canadian Institutes of Health Research, Canada to RPB. MOT received a studentship from the Natural Sciences and Engineering Research Council of Canada and RPB holds a Canada Research Chair in Brain Lipid Metabolism.	Alvarez-Nolting R, 2012, NEUROCHEM RES, V37, P105, DOI 10.1007/s11064-011-0588-x; Amminger GP, 2010, ARCH GEN PSYCHIAT, V67, P146, DOI 10.1001/archgenpsychiatry.2009.192; Ballesteros-Zebadua P, 2012, CNS NEUROL DISORD-DR, V11, P937, DOI 10.2174/1871527311201070937; Banks WA, 2015, BRAIN BEHAV IMMUN, V44, P1, DOI 10.1016/j.bbi.2014.08.007; Barden A, 2014, J LIPID RES, V55, P2401, DOI 10.1194/jlr.M045583; Baron Ralf, 2009, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-540-79090-7_1; Bazan NG, 2012, EXP NEUROL, V236, P122, DOI 10.1016/j.expneurol.2012.04.007; Bazinet R.P., 2014, NAT REV NEUROSCI; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; BLACK KL, 1984, PROSTAG OTH LIPID M, V28, P545, DOI 10.1016/0090-6980(84)90243-0; Bousquet M, 2011, AGEING RES REV, V10, P453, DOI 10.1016/j.arr.2011.03.001; Bousquet M, 2011, J LIPID RES, V52, P263, DOI 10.1194/jlr.M011692; Breitner J, 2013, ALZHEIMERS DEMENT, V9, P714, DOI 10.1016/j.jalz.2012.11.012; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cai DS, 2013, TRENDS ENDOCRIN MET, V24, P40, DOI 10.1016/j.tem.2012.11.003; Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S; Carson MJ, 2006, CLIN NEUROSCI RES, V6, P237, DOI 10.1016/j.cnr.2006.09.004; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Chang CY, 2013, J NUTR BIOCHEM, V24, P2127, DOI 10.1016/j.jnutbio.2013.08.004; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Choi SH, 2009, TRENDS PHARMACOL SCI, V30, P174, DOI 10.1016/j.tips.2009.01.002; COHEN SP, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.f7656, DOI 10.1136/BMJ.F7656]; Colas RA, 2014, AM J PHYSIOL-CELL PH, V307, pC39, DOI 10.1152/ajpcell.00024.2014; Crupi R, 2012, PREV MED, V54, pS103, DOI 10.1016/j.ypmed.2011.12.019; Crupi R, 2010, BIOL PSYCHIAT, V67, P558, DOI 10.1016/j.biopsych.2009.12.008; Dawczynski C, 2013, CLIN NUTR, V32, P686, DOI 10.1016/j.clnu.2012.12.010; Delpech J. C, 2014, NEUROPSYCHOPHARMACOL; DeMar JC, 2006, BBA-MOL CELL BIOL L, V1761, P1050, DOI 10.1016/j.bbalip.2006.06.006; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Eady TN, 2014, NEUROBIOL DIS, V62, P1, DOI 10.1016/j.nbd.2013.09.008; Eady Tiffany N, 2012, Exp Transl Stroke Med, V4, P19, DOI 10.1186/2040-7378-4-19; Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151; Figueroa JD, 2012, J NEUROTRAUM, V29, P551, DOI 10.1089/neu.2011.2141; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Green JT, 2008, J LIPID RES, V49, P939, DOI 10.1194/jlr.R700017-JLR200; Hall JCE, 2012, J NEUROCHEM, V121, P738, DOI 10.1111/j.1471-4159.2012.07726.x; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harrison J. L., 2015, BRAIN BEHAV IMMUN; Hashimoto M, 2014, J PHARMACOL SCI, V124, P294, DOI 10.1254/jphs.13R14CP; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hjorth E, 2013, J ALZHEIMERS DIS, V35, P697, DOI 10.3233/JAD-130131; Hjorth E, 2012, CURR OPIN CLIN NUTR, V15, P134, DOI 10.1097/MCO.0b013e32835017cc; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Hooijmans CR, 2012, J ALZHEIMERS DIS, V28, P191, DOI 10.3233/JAD-2011-111217; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Igarashi M, 2007, J LIPID RES, V48, P1150, DOI 10.1194/jlr.M600549-JLR200; Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362; Jaturapatporn D, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006378.pub2; Ji AL, 2012, NEUROTOXICOLOGY, V33, P780, DOI 10.1016/j.neuro.2012.02.018; Jia D, 2014, NEUROSCIENCE, V258, P228, DOI 10.1016/j.neuroscience.2013.11.016; Kavanagh T, 2004, PROSTAG LEUKOTR ESS, V70, P391, DOI 10.1016/j.plefa.2003.12.014; Keleshian VL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095318; Kelly JP, 1997, PHARMACOL THERAPEUT, V74, P299, DOI 10.1016/S0163-7258(97)00004-1; Kelly L, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.04.001; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Kyrkanides S, 1999, J NEUROIMMUNOL, V95, P95, DOI 10.1016/S0165-5728(98)00270-7; Labrousse VF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036861; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lalancette-Hebert M, 2011, STROKE, V42, P2903, DOI 10.1161/STROKEAHA.111.620856; Lang-Lazdunski L, 2003, J VASC SURG, V38, P564, DOI 10.1016/S0741-5214(03)00473-7; Lebbadi M, 2011, J ALZHEIMERS DIS, V27, P853, DOI 10.3233/JAD-2011-111010; Leonard BE, 2002, INT J NEUROPSYCHOPH, V5, P345, DOI 10.1017/S1461145702003140; Lim SN, 2013, NEUROBIOL DIS, V51, P104, DOI 10.1016/j.nbd.2012.10.021; Lim SN, 2013, EXP NEUROL, V239, P13, DOI 10.1016/j.expneurol.2012.09.015; Lim SN, 2010, PROSTAG LEUKOTR ESS, V83, P193, DOI 10.1016/j.plefa.2010.08.003; Liu J.J, 2014, BRAIN RES; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; Luchtman DW, 2012, BEHAV BRAIN RES, V226, P386, DOI 10.1016/j.bbr.2011.09.033; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Luo C., 2014, J LIPID RES; Lynch AM, 2007, NEUROBIOL AGING, V28, P845, DOI 10.1016/j.neurobiolaging.2006.04.006; Lynch AM, 2003, J BIOL CHEM, V278, P51075, DOI 10.1074/jbc.M307970200; Maher FO, 2004, NEUROBIOL AGING, V25, P795, DOI 10.1016/j.neurobiolaging.2003.08.007; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Martin DSD, 2002, J BIOL CHEM, V277, P34239, DOI 10.1074/jbc.M205289200; Mashour G.A., 2014, BR J ANAESTHESIA; Matsumoto H, 2007, J NEUROSCI RES, V85, P994, DOI 10.1002/jnr.21198; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; Meng QJ, 2010, EUR J PHARMACOL, V649, P127, DOI 10.1016/j.ejphar.2010.09.046; Michaud JP, 2013, P NATL ACAD SCI USA, V110, P1941, DOI 10.1073/pnas.1215165110; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Mingam R, 2008, EUR J NEUROSCI, V28, P1877, DOI 10.1111/j.1460-9568.2008.06470.x; Minogue AM, 2007, J NEUROCHEM, V103, P914, DOI 10.1111/j.1471-4159.2007.04848.x; Mischoulon D, 2015, J CLIN PSYCHIAT, V76, P54, DOI 10.4088/JCP.14m08986; Moranis A, 2012, BRAIN BEHAV IMMUN, V26, P721, DOI 10.1016/j.bbi.2011.11.001; Mosher KI, 2014, BIOCHEM PHARMACOL, V88, P594, DOI 10.1016/j.bcp.2014.01.008; Muntane G, 2010, NEUROCHEM INT, V56, P318, DOI 10.1016/j.neuint.2009.10.015; Myint AM, 2007, NEUROIMMUNOMODULAT, V14, P65, DOI 10.1159/000107420; Najjar S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-43; Okabe N, 2011, J STROKE CEREBROVASC, V20, P188, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.016; Orr SK, 2013, J NEUROCHEM, V127, P378, DOI 10.1111/jnc.12392; Orr SK, 2013, PROSTAG LEUKOTR ESS, V88, P97, DOI 10.1016/j.plefa.2012.05.008; Orr SK, 2010, NEUROCHEM RES, V35, P811, DOI 10.1007/s11064-010-0139-x; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Parrott MD, 2015, NEUROBIOL AGING, V36, P90, DOI 10.1016/j.neurobiolaging.2014.08.013; Paterniti I, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-6; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Rao JS, 2007, MOL PSYCHIATR, V12, P36, DOI 10.1038/sj.mp.4001888; Rees K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008454.pub2; Saijo K, 2009, CELL, V137, P47, DOI 10.1016/j.cell.2009.01.038; Salminen A, 2011, EUR J NEUROSCI, V34, P3, DOI 10.1111/j.1460-9568.2011.07738.x; Schomberg D, 2012, EXP NEUROL, V234, P262, DOI 10.1016/j.expneurol.2011.12.021; Schwartz M, 2014, EMBO J, V33, P7, DOI 10.1002/embj.201386609; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Serhan CN, 2013, CURR OPIN PHARMACOL, V13, P632, DOI 10.1016/j.coph.2013.05.012; Song C, 2004, J LIPID RES, V45, P1112, DOI 10.1194/jlr.M300526-JLr200; Song C, 2008, J NUTR, V138, P954; Song C, 2009, J NEUROSCI, V29, P14, DOI 10.1523/JNEUROSCI.3569-08.2009; Suridjan I., 2015, MOL PSYCHIAT; Taepavarapruk P, 2010, J NEUROCHEM, V112, P1054, DOI 10.1111/j.1471-4159.2009.06524.x; Tansey MG, 2010, NEUROBIOL DIS, V37, P510, DOI 10.1016/j.nbd.2009.11.004; Terrando N, 2013, FASEB J, V27, P3564, DOI 10.1096/fj.13-230276; Thal LJ, 2005, NEUROPSYCHOPHARMACOL, V30, P1204, DOI 10.1038/sj.npp.1300690; Tian YG, 2015, BIOCHEM BIOPH RES CO, V460, P799, DOI 10.1016/j.bbrc.2015.03.109; Torkildsen O, 2012, ARCH NEUROL-CHICAGO, V69, P1044, DOI 10.1001/archneurol.2012.283; Trepanier MO, 2012, EPILEPSY RES, V99, P225, DOI 10.1016/j.eplepsyres.2011.12.001; Wang DM, 2014, EUR J PHARMACOL, V728, P59, DOI 10.1016/j.ejphar.2014.01.057; Wang J., 2014, J ALZHEIMERS DIS JAD; Wang X., 2014, ALZHEIMERS DEMENT J; Wang Y., 2014, INT J DISTRIB SENS N, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0110024; Wang Y, 2014, J CHROMATOGR A, V1359, P60, DOI 10.1016/j.chroma.2014.07.006; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xu ZZ, 2013, ANN NEUROL, V74, P490, DOI 10.1002/ana.23928; Xu ZZ, 2013, J NEUROIMMUNE PHARM, V8, P37, DOI 10.1007/s11481-012-9394-8; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Yang DY, 2007, NEUROTOXICOLOGY, V28, P1220, DOI 10.1016/j.neuro.2007.08.003; Yates CM, 2014, PHARMACOL THERAPEUT, V141, P272, DOI 10.1016/j.pharmthera.2013.10.010; Yip PK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061626; Zendedel A, 2015, J NEUROIMMUNOL, V278, P200, DOI 10.1016/j.jneuroim.2014.11.007; Zhang WT, 2010, STROKE, V41, P2341, DOI 10.1161/STROKEAHA.110.586081; Zhao YG, 2011, ABSTR APPL ANAL, DOI 10.1155/2011/390543	137	57	59	0	25	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 15	2016	785						187	206		10.1016/j.ejphar.2015.05.045			20	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DS4LP	WOS:000380752900021	26036964				2021-06-18	
J	Liu, SJ; Zheng, P; Wright, DK; Dezsi, G; Braine, E; Nguyen, T; Corcoran, NM; Johnston, LA; Hovens, CM; Mayo, JN; Hudson, M; Shultz, SR; Jones, NC; O'Brien, TJ				Liu, Shi-jie; Zheng, Ping; Wright, David K.; Dezsi, Gabi; Braine, Emma; Thanh Nguyen; Corcoran, Niall M.; Johnston, Leigh A.; Hovens, Christopher M.; Mayo, Jamie N.; Hudson, Matthew; Shultz, Sandy R.; Jones, Nigel C.; O'Brien, Terence J.			Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau	BRAIN			English	Article						epilepsy; animal model; MRI; traumatic brain injury; PR55	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; STATUS EPILEPTICUS; SEIZURES; HIPPOCAMPUS; PATHOLOGY; NEURODEGENERATION; PHOSPHORYLATION; HOLOENZYME; EXPRESSION	Hyperphosphorylation of tau may contribute to epileptogenesis. Liu et al. reveal a reduction in the activity of protein phosphatase 2A (PP2A), with concomitant hyperphosphorylation of tau, in animal models of kindling, post-status epilepticus and post-traumatic epilepsy. Sodium selenate, a PP2A activator, prevents epileptogenesis in all three models.Hyperphosphorylation of tau may contribute to epileptogenesis. Liu et al. reveal a reduction in the activity of protein phosphatase 2A (PP2A), with concomitant hyperphosphorylation of tau, in animal models of kindling, post-status epilepticus and post-traumatic epilepsy. Sodium selenate, a PP2A activator, prevents epileptogenesis in all three models.There are no treatments in clinical practice known to mitigate the neurobiological processes that convert a healthy brain into an epileptic one, a phenomenon known as epileptogenesis. Downregulation of protein phosphatase 2A, a protein that causes the hyperphosphorylation of tau, is implicated in neurodegenerative diseases commonly associated with epilepsy, such as Alzheimer's disease and traumatic brain injury. Here we used the protein phosphatase 2A activator sodium selenate to investigate the role of protein phosphatase 2A in three different rat models of epileptogenesis: amygdala kindling, post-kainic acid status epilepticus, and post-traumatic epilepsy. Protein phosphatase 2A activity was decreased, and tau phosphorylation increased, in epileptogenic brain regions in all three models. Continuous sodium selenate treatment mitigated epileptogenesis and prevented the biochemical abnormalities, effects which persisted after drug withdrawal. Our studies indicate that limbic epileptogenesis is associated with downregulation of protein phosphatase 2A and the hyperphosphorylation of tau, and that targeting this mechanism with sodium selenate is a potential anti-epileptogenic therapy.	[Liu, Shi-jie; Zheng, Ping; Dezsi, Gabi; Braine, Emma; Mayo, Jamie N.; Hudson, Matthew; Shultz, Sandy R.; Jones, Nigel C.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Melbourne Brain Ctr, Dept Med, Parkville, Vic 3052, Australia; [Wright, David K.; Johnston, Leigh A.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Wright, David K.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia; [Thanh Nguyen; Corcoran, Niall M.; Hovens, Christopher M.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Neurol, Melbourne Brain Ctr, Parkville, Vic, Australia; [Johnston, Leigh A.] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic, Australia	Shultz, SR; Jones, NC (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Melbourne Brain Ctr, Dept Med, Parkville, Vic 3052, Australia.; O'Brien, TJ (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Level 4,Clin Sci Bldg, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au; ncjones@unimelb.edu.au; obrientj@unimelb.edu.au	Johnston, Leigh A/D-7102-2014; Hudson, Matthew/AAH-9168-2020	Johnston, Leigh A/0000-0002-5032-4674; Hovens, Christopher/0000-0002-0610-1289; Hudson, Matthew/0000-0001-5016-735X; Wright, David/0000-0002-7535-8651; O'Brien, Terence/0000-0002-7198-8621; Jones, Nigel/0000-0002-1080-8439	Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1006077, 1062653]; Victorian Neurotrauma Initiative Grant from Victorian Government Transport Accident Commission (VNI) [DNP13]; Royal Melbourne Hospital Neuroscience Foundation	This study was funded by grants from the Australian National Health and Medical Research Council (NHMRC Project Grants #1006077 and #1062653), a Victorian Neurotrauma Initiative Grant from the Victorian Government Transport Accident Commission (VNI Project Grant #DNP13) and the Royal Melbourne Hospital Neuroscience Foundation.	Abr`amoff M.D., 2005, BIOPHOTONICS INT, V11, P36, DOI [10.1117/1.3589100, DOI 10.1117/1.3589100]; Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Arias C, 2002, EXP NEUROL, V177, P284, DOI 10.1006/exnr.2002.7988; Aroniadou-Anderjaska V, 2008, EPILEPSY RES, V78, P102, DOI 10.1016/j.eplepsyres.2007.11.011; Ashford JW, 2011, J ALZHEIMERS DIS, V26, P331, DOI 10.3233/JAD-2011-0021; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Bolognin S, 2012, ACTA NEUROPATHOL, V123, P133, DOI 10.1007/s00401-011-0908-x; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Briellmann RS, 2002, NEUROLOGY, V58, P265, DOI 10.1212/WNL.58.2.265; Casillas-Espinosa PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130012; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; Desikan RS, 2011, ANN NEUROL, V70, P657, DOI 10.1002/ana.22509; Dudek FE, 2011, NEUROSCI LETT, V497, P240, DOI 10.1016/j.neulet.2011.03.071; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Franko E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071354; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Gunbey HP, 2011, NEURORADIOL J, V24, P316; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HIGUCHI N, 1992, MAGNET RESON MED, V27, P107, DOI 10.1002/mrm.1910270111; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Jones NC, 2012, NEUROBIOL DIS, V45, P897, DOI 10.1016/j.nbd.2011.12.005; Jupp B, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00368.x; Jupp B, 2012, EPILEPSIA, V53, P1233, DOI 10.1111/j.1528-1167.2012.03525.x; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Machnes ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076299; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; Morales I, 2013, J ALZHEIMERS DIS, V37, P849, DOI 10.3233/JAD-131843; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Powell KL, 2008, EPILEPSIA, V49, P1686, DOI 10.1111/j.1528-1167.2008.01593.x; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Qian W, 2010, J ALZHEIMERS DIS, V19, P1221, DOI [10.3233/JAD-2009-1317, 10.3233/JAD-2010-1317]; Ramirez-Munguia N, 2003, NEUROCHEM RES, V28, P1517, DOI 10.1023/A:1025670308663; Sen A, 2007, EPILEPSIA, V48, P1447, DOI 10.1111/j.1528-1167.2007.01107.x; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Simonato M, 2014, LANCET NEUROL, V13, P949, DOI 10.1016/S1474-4422(14)70076-6; Sontag JM, 2008, J NEUROSCI, V28, P11477, DOI 10.1523/JNEUROSCI.2816-08.2008; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Tringham E, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003120; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Vespa P, 2016, ANN NEUROL, V79, P579, DOI 10.1002/ana.24606; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Zilka N, 2009, J NEUROIMMUNOL, V209, P16, DOI 10.1016/j.jneuroim.2009.01.013	55	57	58	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2016	139		7				1919	1938		10.1093/brain/aww116			20	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DR2VW	WOS:000379763000015	27289302	Bronze			2021-06-18	
J	Louw, AM; Kolar, MK; Novikova, LN; Kingham, PJ; Wiberg, M; Kjems, J; Novikov, LN				Louw, Andrew M.; Kolar, Mallappa K.; Novikova, Liudmila N.; Kingham, Paul J.; Wiberg, Mikael; Kjems, Jorgen; Novikov, Lev N.			Chitosan polyplex mediated delivery of miRNA-124 reduces activation of microglial cells in vitro and in rat models of spinal cord injury	NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE			English	Article						Chitosan polyplex system; miRNA-124; Microglia/macrophage; Inflammation; Spinal cord injury	TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; SUBSTANTIA-NIGRA; GLIAL SCAR; MACROPHAGE; NANOPARTICLES; ALPHA; CNS; DIFFERENTIATION	Traumatic injury to the central nervous system (CNS) is further complicated by an increase in secondary neuronal damage imposed by activated microglia/macrophages. MicroRNA-124 (miR-124) is responsible for mouse monocyte quiescence and reduction of their inflammatory cytokine production. We describe the formulation and ex vivo transfection of chitosan/miR-124 polyplex particles into rat microglia and the resulting reduction of reactive oxygen species (ROS) and TNF-alpha and lower expression of MHC-II. Upon microinjection into uninjured rat spinal cords, particles formed with Cy3-labeled control sequence RNA, were specifically internalized by OX42 positive macrophages and microglia cells. Alternatively particles injected in the peritoneum were transported by macrophages to the site of spinal cord injury 72h post injection. Microinjections of chitosan/miR-124 particles significantly reduced the number of ED-1 positive macrophages in the injured spinal cord. Taken together, these data present a potential treatment technique to reduce inflammation for a multitude of CNS neurodegenerative conditions. (C) 2015 The Authors. Published by Elsevier Inc.	[Louw, Andrew M.; Kjems, Jorgen] Aarhus Univ, Interdisciplinary Nanosci Ctr, Aarhus C, Denmark; [Kolar, Mallappa K.; Novikova, Liudmila N.; Kingham, Paul J.; Wiberg, Mikael; Novikov, Lev N.] Umea Univ, Dept Integrat Med Biol, Umea, Sweden	Kjems, J (corresponding author), Aarhus Univ, Interdisciplinary Nanosci Ctr, Aarhus C, Denmark.; Novikov, LN (corresponding author), Umea Univ, Dept Integrat Med Biol, Umea, Sweden.	jk@mbg.au.dk; lev.novikov@umu.se	Kjems, Jorgen/I-3490-2016	Kjems, Jorgen/0000-0003-4128-9317; Novikov, Lev/0000-0001-5520-3890; Kingham, Paul/0000-0003-2596-5936	Swedish Research CouncilSwedish Research CouncilEuropean Commission [2014-2306]; Lundbeck Foundation Nanomedicine Centre for Individualized Management of Tissue Damage and Regeneration (LUNA); ERA-Net European transnational collaborative project: "Nano-Functionalised Implants for the Regenerative Treatment of Spinal Cord and Nerve Lesions" (Nano4Neuro)	The authors would like to acknowledge The Lundbeck Foundation Nanomedicine Centre for Individualized Management of Tissue Damage and Regeneration (LUNA), ERA-Net European transnational collaborative project: "Nano-Functionalised Implants for the Regenerative Treatment of Spinal Cord and Nerve Lesions" (Nano4Neuro) and the Swedish Research Council (grant 2014-2306, Medicine and Health) for their support of this research.	Akiyama H, 1994, Nihon Rinsho, V52, P2990; Andersen MO, 2008, BIOMATERIALS, V29, P506, DOI 10.1016/j.biomaterials.2007.10.003; Ballarin-Gonzalez B, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.2; Banerjee S, 2013, J IMMUNOL, V190, P6542, DOI 10.4049/jimmunol.1202496; Bao F, 2009, EXP NEUROL, V215, P308, DOI 10.1016/j.expneurol.2008.10.022; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Behr JP, 1997, CHIMIA, V51, P34; Cai DH, 2008, ONCOGENE, V27, P2772, DOI 10.1038/sj.onc.1210940; Center NSCIS, 2013, ANN STAT REP SPIN CO; Chung MJ, 2012, INT IMMUNOPHARMACOL, V12, P453, DOI 10.1016/j.intimp.2011.12.027; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Davis MJ, 2013, MBIO, V4, DOI 10.1128/mBio.00264-13; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Feng R, 2008, P NATL ACAD SCI USA, V105, P6057, DOI 10.1073/pnas.0711961105; Frank MG, 2006, J NEUROSCI METH, V151, P121, DOI 10.1016/j.jneumeth.2005.06.026; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Havenith CEG, 1998, GLIA, V22, P348, DOI 10.1002/(SICI)1098-1136(199804)22:4<348::AID-GLIA4>3.3.CO;2-X; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Howard KA, 2006, MOL THER, V14, P476, DOI 10.1016/j.ymthe.2006.04.010; Howard KA, 2009, MOL THER, V17, P162, DOI 10.1038/mt.2008.220; Howell OW, 2010, J NEUROPATH EXP NEUR, V69, P1017, DOI 10.1097/NEN.0b013e3181f3a5b1; Huh Y, 2003, NEUROSCI LETT, V349, P63, DOI 10.1016/S0304-3940(03)00743-2; Kaushal V, 2007, J NEUROSCI, V27, P234, DOI 10.1523/JNEUROSCI.3593-06.2007; Kierdorf K, 2013, NAT NEUROSCI, V16, P273, DOI 10.1038/nn.3318; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Klyachko NL, 2014, NANOMEDICINE-UK, V9, P1403, DOI [10.2217/nnm.13.115, 10.2217/NNM.13.115]; Kook SY, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.23993; Kurkowska-Jastrzebska I, 1999, ACTA NEUROBIOL EXP, V59, P1; LARRICK JW, 1990, FASEB J, V4, P3215; Lee H, 2014, FRONT BIOSCI-LANDMRK, V19, P272, DOI 10.2741/4206; Liu XD, 2007, BIOMATERIALS, V28, P1280, DOI 10.1016/j.biomaterials.2006.11.004; Ma ZW, 2015, J ORAL PATHOL MED, V44, P538, DOI 10.1111/jop.12269; Makeyev EV, 2007, MOL CELL, V27, P435, DOI 10.1016/j.molcel.2007.07.015; Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8; McGeer PL, 2003, ANN NEUROL, V54, P599, DOI 10.1002/ana.10728; Minagar A, 2003, MULT SCLER J, V9, P540, DOI 10.1191/1352458503ms965oa; Mishima T, 2007, BRAIN RES, V1131, P37, DOI 10.1016/j.brainres.2006.11.035; Mittnacht U, 2010, NANO LETT, V10, P3933, DOI 10.1021/nl1016909; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Nawroth I, 2013, ACTA ONCOL, V52, P1730, DOI 10.3109/0284186X.2012.726373; Nawroth I, 2010, RADIOTHER ONCOL, V97, P143, DOI 10.1016/j.radonc.2010.09.010; Noble LJ, 2002, J NEUROSCI, V22, P7526; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Qi L, 2010, INT J CLIN EXP MED, V3, P283; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sun Y, 2013, CELL RES, V23, P1270, DOI 10.1038/cr.2013.116; Traynor D, 2007, J CELL SCI, V120, P2318, DOI 10.1242/jcs.007732; Walton M, 1998, MOL BRAIN RES, V61, P11, DOI 10.1016/S0169-328X(98)00169-7; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Yang CX, 2015, THERANOSTICS, V5, P110, DOI 10.7150/thno.9717; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yoon HJ, 2007, BIOCHEM BIOPH RES CO, V358, P954, DOI 10.1016/j.bbrc.2007.05.042	57	57	62	1	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1549-9634	1549-9642		NANOMED-NANOTECHNOL	Nanomed.-Nanotechnol. Biol. Med.	APR	2016	12	3					643	653		10.1016/j.nano.2015.10.011			11	Nanoscience & Nanotechnology; Medicine, Research & Experimental	Science & Technology - Other Topics; Research & Experimental Medicine	DJ0WB	WOS:000373924000007	26582736	Other Gold			2021-06-18	
J	Lidster, K; Jefferys, JG; Blumcke, I; Crunelli, V; Flecknell, P; Frenguelli, BG; Gray, WP; Kaminski, R; Pitkanen, A; Ragan, I; Shah, M; Simonato, M; Treyelyan, A; Volk, H; Walker, M; Yates, N; Prescott, MJ				Lidster, Katie; Jefferys, John G.; Bluemcke, Ingmar; Crunelli, Vincenzo; Flecknell, Paul; Frenguelli, Bruno G.; Gray, William P.; Kaminski, Rafal; Pitkanen, Asia; Ragan, Ian; Shah, Mala; Simonato, Michele; Treyelyan, Andrew; Volk, Holger; Walker, Matthew; Yates, Neil; Prescott, Mark J.			Opportunities for improving animal welfare in rodent models of epilepsy and seizures	JOURNAL OF NEUROSCIENCE METHODS			English	Article						3Rs; Animal model; Epilepsy; Mouse; Rat; Refinement; Seizure	TEMPORAL-LOBE EPILEPSY; JOINT-WORKING-GROUP; EARLY-LIFE SEIZURES; GENETIC ABSENCE EPILEPSY; KAINATE-INDUCED EPILEPSY; TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; KAINIC ACID; ENVIRONMENTAL ENRICHMENT; LABORATORY RODENTS	Animal models of epilepsy and seizures, mostly involving mice and rats, are used to understand the pathophysiology of the different forms of epilepsy and their comorbidities, to identify biomarkers, and to discover new antiepileptic drugs and treatments for comorbidities. Such models represent an important area for application of the 3Rs (replacement, reduction and refinement of animal use). This report provides background information and recommendations aimed at minimising pain, suffering and distress in rodent models of epilepsy and seizures in order to improve animal welfare and optimise the quality of studies in this area. The report includes practical guidance on principles of choosing a model, induction procedures, in vivo recordings, perioperative care, welfare assessment, humane endpoints, social housing, environmental enrichment, reporting of studies and data sharing. In addition, some model specific welfare considerations are discussed, and data gaps and areas for further research are identified. The guidance is based upon a systematic review of the scientific literature, survey of the international epilepsy research community, consultation with veterinarians and animal care and welfare officers, and the expert opinion and practical experience of the members of a Working Group convened by the United Kingdom's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). (C) 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Lidster, Katie; Prescott, Mark J.] Natl Ctr Replacement Refinement & Reduct Anim Res, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England; [Jefferys, John G.] Univ Oxford, Dept Pharmacol, S Parks Rd, Oxford OX1 3QT, England; [Bluemcke, Ingmar] Univ Erlangen Nurnberg, Inst Neuropathol, D-91054 Erlangen, Germany; [Crunelli, Vincenzo] Cardiff Univ, Neurosci Div, Sch Biosci, Cardiff CF10 3AX, S Glam, Wales; [Flecknell, Paul] Newcastle Univ, Sch Med, Comparat Biol Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Frenguelli, Bruno G.] Univ Warwick, Sch Life Sci, Coventry CV4 7AL, W Midlands, England; [Gray, William P.] Cardiff Univ, Neurosci & Mental Hlth Res Inst, Sch Med, Cardiff CF10 3AX, S Glam, Wales; [Kaminski, Rafal] UCB Pharma, Brussels, Belgium; [Pitkanen, Asia] Univ Eastern Finland, Inst Mol Sci, Dept Neurobiol, Kuopio, Finland; [Ragan, Ian] NC3Rs Board, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England; [Shah, Mala] UCL, UCL Sch Pharm, London, England; [Simonato, Michele] Univ Ferrara, Dept Med Sci, I-44100 Ferrara, Italy; [Treyelyan, Andrew] Newcastle Univ, Sch Med, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Volk, Holger] Univ London Royal Vet Coll, Dept Clin Sci & Serv, Hatfield, Herts, England; [Walker, Matthew] UCL, Inst Neurol, London, England; [Yates, Neil] Univ Nottingham, Sch Biomed Sci, Nottingham NG7 2RD, England	Lidster, K (corresponding author), Natl Ctr Replacement Refinement & Reduct Anim Res, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England.	katie.lidster@nc3rs.org.uk	Blumcke, Ingmar/D-4705-2018; Frenguelli, Bruno/C-5007-2015; Prescott, Mark/E-4184-2010; Jefferys, John G R/AAF-1164-2021; Walker, Matthew C/C-1577-2008; Volk, Holger Andreas/B-9965-2011	Blumcke, Ingmar/0000-0001-8676-0788; Frenguelli, Bruno/0000-0001-7214-3172; Jefferys, John G R/0000-0003-0106-4412; Walker, Matthew C/0000-0002-0812-0352; Shah, Mala/0000-0002-8323-4739; Flecknell, Paul/0000-0002-1075-1129; Crunelli, Vincenzo/0000-0001-7154-9752; Volk, Holger Andreas/0000-0002-7312-638X; Prescott, Mark/0000-0002-8814-0512; Gray, William/0000-0001-7595-8887; Simonato, Michele/0000-0002-3586-2693	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0700369, MR/J013250/1, G0300356, G0802162, MR/L010305/1] Funding Source: Medline; Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/L00139X/1] Funding Source: researchfish; Epilepsy Research UK [P1402, P1504] Funding Source: researchfish		Abraham J, 2012, NEUROBIOL DIS, V46, P425, DOI 10.1016/j.nbd.2012.02.006; Akman O, 2015, CNS NEUROSCI THER, V21, P181, DOI 10.1111/cns.12335; Ali A, 2012, EPILEPSIA, V53, P199, DOI 10.1111/j.1528-1167.2011.03314.x; Anna I, 2002, LAB ANIM-UK, V36, P243, DOI 10.1258/002367702320162379; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arcieri S, 2014, EPILEPSIA, V55, P1978, DOI 10.1111/epi.12850; Arndt SS, 2009, PHYSIOL BEHAV, V97, P385, DOI 10.1016/j.physbeh.2009.03.008; Ashall V, 2014, ALTEX-ALTERN ANIM EX, V31, P209, DOI 10.14573/altex.1307261; Auvergne R, 2002, BRAIN RES, V954, P277, DOI 10.1016/S0006-8993(02)03355-3; BAGETTA G, 1990, NEUROPHARMACOLOGY, V29, P765, DOI 10.1016/0028-3908(90)90130-J; Bankstahl M, 2012, BEHAV BRAIN RES, V230, P182, DOI 10.1016/j.bbr.2012.02.004; Baran SW, 2010, ENRICH REC, V3, P4; Barkmeier DT, 2009, CLIN EEG NEUROSCI, V40, P234, DOI 10.1177/155005940904000405; Bartolomucci A, 2001, PHYSIOL BEHAV, V73, P401, DOI 10.1016/S0031-9384(01)00453-X; Bartolomucci A, 2004, PHYSIOL BEHAV, V82, P425, DOI 10.1016/j.physbeh.2004.04.011; Bastlund JF, 2004, J NEUROSCI METH, V138, P65, DOI 10.1016/j.jneumeth.2004.03.004; Bateson P., 2011, REV RES USING NONHUM; Baulac M., 2009, EPILEPSIA, V50, P71, DOI [10.1111/j.1528-1167.2008.01811.x, DOI 10.1111/J.1528-1167.2008.01811.X]; BAUMANS V, 1994, LAB ANIM-UK, V28, P97, DOI 10.1258/002367794780745308; Baumans V, 2005, ILAR J, V46, P162, DOI 10.1093/ilar.46.2.162; Baumans V., 2010, The UFAW handbook on the care and management of laboratory and other research animals, P276, DOI 10.1002/9781444318777.ch21; Belz EE, 2003, PHARMACOL BIOCHEM BE, V76, P481, DOI 10.1016/j.pbb.2003.09.005; Berdoy M., 2003, LAB RAT NATURAL HIST; Berg AT, 2011, EPILEPSIA, V52, P1058, DOI 10.1111/j.1528-1167.2011.03101.x; Berg AT, 2010, LANCET NEUROL, V9, P459, DOI 10.1016/S1474-4422(10)70024-7; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bernard PB, 2013, NEUROBIOL DIS, V59, P1, DOI 10.1016/j.nbd.2013.06.013; Blair RE, 2009, NEUROSCI LETT, V453, P233, DOI 10.1016/j.neulet.2009.02.035; Boggiano MM, 2008, PHYSIOL BEHAV, V95, P222, DOI 10.1016/j.physbeh.2008.04.025; Borges K, 2003, EXP NEUROL, V182, P21, DOI 10.1016/S0014-4886(03)00086-4; Bouilleret V, 1999, NEUROSCIENCE, V89, P717, DOI 10.1016/S0306-4522(98)00401-1; Bourdi M, 2011, CHEM RES TOXICOL, V24, P794, DOI 10.1021/tx200143x; BRAIN P, 1975, LIFE SCI, V16, P187, DOI 10.1016/0024-3205(75)90017-X; Brooks-Kayal AR, 2013, EPILEPSIA, V54, P44, DOI 10.1111/epi.12298; CALDECOTTHAZARD S, 1982, BRAIN RES, V251, P196, DOI 10.1016/0006-8993(82)91293-8; CALDECOTTHAZARD S, 1982, P W PHARMACOL SOC, V25, P107; Camfield CS, 2009, NEUROLOGY, V73, P1041, DOI 10.1212/WNL.0b013e3181b9c86f; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; Chapman K, 2013, REGUL TOXICOL PHARM, V67, P27, DOI 10.1016/j.yrtph.2013.04.003; Chen N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072336; Chung JI, 2013, EXP NEUROL, V249, P95, DOI 10.1016/j.expneurol.2013.08.014; Cilio MR, 2003, EPILEPSIA, V44, P518, DOI 10.1046/j.1528-1157.2003.48802.x; Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a; Coimbra NC, 2001, BRAIN RES, V888, P314, DOI 10.1016/S0006-8993(00)03103-6; COLLIER GH, 1990, J COMP PSYCHOL, V104, P53, DOI 10.1037/0735-7036.104.1.53; Culley DJ, 2004, ANESTH ANALG, V99, P1393, DOI 10.1213/01.ANE.0000135408.14319.CC; Cunliffe VT, 2014, SEIZURE, V24, P44; Curia G, 2008, J NEUROSCI METH, V172, P143, DOI 10.1016/j.jneumeth.2008.04.019; Cussler K, 2011, COST MANUAL LAB ANIM, P333; CZUCZWAR SJ, 1986, NEUROPHARMACOLOGY, V25, P465, DOI 10.1016/0028-3908(86)90169-3; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Danober L, 1998, PROG NEUROBIOL, V55, P27, DOI 10.1016/S0301-0082(97)00091-9; DESJARDINS D, 1995, PERCEPT MOTOR SKILL, V81, P635, DOI 10.2466/pms.1995.81.2.635; Doheny HC, 2002, BRIT J PHARMACOL, V135, P1425, DOI 10.1038/sj.bjp.0704606; Dugladze T, 2013, P NATL ACAD SCI USA, V110, P15073, DOI 10.1073/pnas.1313505110; Eccles M, 2001, Health Technol Assess, V5, P1; England MJ, 2012, EPILEPSY SPECTRUM; Englot DJ, 2008, J NEUROSCI, V28, P9066, DOI 10.1523/JNEUROSCI.2014-08.2008; Englot DJ, 2010, BRAIN, V133, P3764, DOI 10.1093/brain/awq316; Epps SA, 2013, BIOCHEM PHARMACOL, V85, P135, DOI 10.1016/j.bcp.2012.08.016; Esclapez M, 1999, J COMP NEUROL, V408, P449, DOI 10.1002/(SICI)1096-9861(19990614)408:4<449::AID-CNE1>3.0.CO;2-R; Ewing SG, 2013, J NEUROSCI METH, V219, P324, DOI 10.1016/j.jneumeth.2013.08.003; Fares RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053888; Faverjon S, 2002, NEUROLOGY, V59, P1356, DOI 10.1212/01.WNL.0000033588.59005.55; Ferrari PF, 1998, PHYSIOL BEHAV, V63, P821, DOI 10.1016/S0031-9384(97)00544-1; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; FLANDERA V, 1973, PHYSIOL BOHEMOSLOV, V22, P209; Fornari RV, 2012, JOVE-J VIS EXP, DOI 10.3791/3528; Franke H, 2001, PHARMACOL BIOCHEM BE, V70, P291, DOI 10.1016/S0091-3057(01)00612-8; Frankel WN, 2009, TRENDS GENET, V25, P361, DOI 10.1016/j.tig.2009.07.001; Freitas RL, 2005, EXP NEUROL, V191, P225, DOI 10.1016/j.expneurol.2004.10.009; Galanopoulou AS, 2014, NEUROBIOL DIS, V72, P123, DOI 10.1016/j.nbd.2014.09.002; Galanopoulou AS, 2013, EPILEPSIA, V54, P1, DOI 10.1111/epi.12293; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Galanopoulou AS, 2011, BIOMARK MED, V5, P615, DOI [10.2217/BMM.11.71, 10.2217/bmm.11.71]; Giorgi FS, 2014, NEUROBIOL DIS, V72, P144, DOI 10.1016/j.nbd.2014.05.010; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Gouveia K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066401; Grabenstatter HL, 2007, EPILEPSIA, V48, P2287; Graber KD, 2006, MODELS OF SEIZURES AND EPILEPSY, P477, DOI 10.1016/B978-012088554-1/50040-2; Grone BP, 2015, NAT NEUROSCI, V18, P339, DOI 10.1038/nn.3934; Guerrini R, 2014, NEUROTHERAPEUTICS, V11, P269, DOI 10.1007/s13311-014-0267-0; Guo Q, 1993, J Tradit Chin Med, V13, P281; Hannan AJ, 2014, NEUROPATH APPL NEURO, V40, P13, DOI 10.1111/nan.12102; Harhausen D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069529; HASEMAN JK, 1994, FUND APPL TOXICOL, V23, P44, DOI 10.1006/faat.1994.1077; HASHEM A, 1988, ANAESTHESIST, V37, P631; HATCH A, 1963, SCIENCE, V142, P507, DOI 10.1126/science.142.3591.507; HAU J, 1999, HUMANE ENDPOINTS ANI, P71; Hawkins P, 2004, LAB ANIM-UK, V38, P1; Hawkins P, 2011, LAB ANIM-UK, V45, P1, DOI 10.1258/la.2010.010031; Hawkins P, 2014, J NEUROSCI METH, V234, P135, DOI 10.1016/j.jneumeth.2014.02.008; Hayes KE, 2000, CONTEMP TOP LAB ANIM, V39, P18; Heinrichs SC, 2006, EPILEPSY BEHAV, V8, P5, DOI 10.1016/j.yebeh.2005.08.009; Hellier JL, 1998, EPILEPSY RES, V31, P73, DOI 10.1016/S0920-1211(98)00017-5; HELLIER JL, 2005, CURR PROTOC NEUROSCI, V9, P1; Hickman DL, 2010, J AM ASSOC LAB ANIM, V49, P155; Honndorf S, 2011, EPILEPSY RES, V94, P26, DOI 10.1016/j.eplepsyres.2010.12.012; Huang L, 2013, EPILEPSY RES, V106, P326, DOI 10.1016/j.eplepsyres.2013.06.010; Huang X, 2012, NEUROSCIENCE, V215, P90, DOI 10.1016/j.neuroscience.2012.04.011; Hubrecht R., 2010, UFAW HDB CARE MANAGE; Hurst JL, 2010, NAT METHODS, V7, P825, DOI [10.1038/NMETH.1500, 10.1038/nmeth.1500]; Hurst JL, 1997, ANIM WELFARE, V6, P329; Inostroza M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038959; Inostroza M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022372; Jedrzejko C, 2001, PSYCHOL REP, V89, P188, DOI 10.2466/PR0.89.5.188-190; Jimenez-Pacheco A, 2013, EPILEPSIA, V54, P1551, DOI 10.1111/epi.12257; Jirkof P, 2015, LAB ANIMAL, V44, P65, DOI 10.1038/laban.662; Jones J., 1999, HUM ENDPOINTS ANIM E, P40; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Kalliokoski O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111065; Kalynchuk LE, 1999, BEHAV NEUROSCI, V113, P766, DOI 10.1037/0735-7044.113.4.766; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kilkenny C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007824; Koh S, 2007, EPILEPSY BEHAV, V10, P26, DOI 10.1016/j.yebeh.2006.11.008; Koppel BS, 2014, NEUROBIOL DIS, V72, P193, DOI 10.1016/j.nbd.2014.08.033; Kotloski RJ, 2015, EXP NEUROL, V264, P121, DOI 10.1016/j.expneurol.2014.11.012; Kulesskaya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024755; Langford DJ, 2010, NAT METHODS, V7, P447, DOI [10.1038/NMETH.1455, 10.1038/nmeth.1455]; Latham N, 2004, APPL ANIM BEHAV SCI, V86, P261, DOI 10.1016/j.applanim.2004.02.006; Leach MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035656; Leclercq K, 2015, EPILEPSIA, V56, P310, DOI 10.1111/epi.12893; Levesque M, 2013, NEUROSCI BIOBEHAV R, V37, P2887, DOI 10.1016/j.neubiorev.2013.10.011; Lewis MH, 2004, MENT RETARD DEV D R, V10, P91, DOI 10.1002/mrdd.20017; Li Z, 2013, NEUROREPORT, V24, P785, DOI 10.1097/WNR.0b013e328363fed3; LIU Z, 1994, EPILEPSY RES, V19, P191, DOI 10.1016/0920-1211(94)90062-0; Loscher W, 2007, EPILEPSIA, V48, P1245, DOI 10.1111/j.1528-1167.2007.01093.x; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Long JJA, 2009, EXP NEUROL, V219, P308, DOI 10.1016/j.expneurol.2009.05.036; Longo B, 2003, EXP NEUROL, V181, P57, DOI 10.1016/S0014-4886(02)00046-8; Loo P. L. P. van, 2001, Journal of Applied Animal Welfare Science, V4, P91, DOI 10.1207/S15327604JAWS0402_1; Luttjohann A, 2009, PHYSIOL BEHAV, V98, P579, DOI 10.1016/j.physbeh.2009.09.005; Maheshwari A, 2014, PROG BRAIN RES, V213, P223, DOI 10.1016/B978-0-444-63326-2.00012-0; Manno I, 2011, EPILEPSIA, V52, pE113, DOI 10.1111/j.1528-1167.2011.03166.x; Manser CE, 1998, LAB ANIM, V32, P36, DOI 10.1258/002367798780559473; Manser CE, 1998, LAB ANIM, V32, P23, DOI 10.1258/002367798780559365; Manser CE, 1996, LAB ANIM, V30, P1, DOI 10.1258/002367796780744974; Mantegazza M, 2010, EPILEPSY RES, V92, P1, DOI 10.1016/j.eplepsyres.2010.08.003; Mares J, 2009, PHYSIOL RES, V58, P279, DOI 10.33549/physiolres.931270; Mares P, 2012, PHYSIOL RES, V61, pS103, DOI 10.33549/physiolres.932370; Mares P, 2014, N-S ARCH PHARMACOL, V387, P753, DOI 10.1007/s00210-014-0987-z; Martin BS, 2008, EPILEPSIA, V49, P248, DOI 10.1111/j.1528-1167.2007.01384.x; Martin B, 2010, P NATL ACAD SCI USA, V107, P6127, DOI 10.1073/pnas.0912955107; Mazarati AM, 2009, NEUROBIOL DIS, V34, P457, DOI 10.1016/j.nbd.2009.02.018; McIntyre DC, 2006, MODELS OF SEIZURES AND EPILEPSY, P351, DOI 10.1016/B978-012088554-1/50030-X; McKhann GM, 2003, NEUROSCIENCE, V122, P551, DOI 10.1016/S0306-4522(03)00562-1; McLin JP, 2006, EUR J NEUROSCI, V24, P2191, DOI 10.1111/j.1460-9568.2006.05111.x; Meijer MK, 2006, ANIM WELFARE, V15, P31; Mellanby J, 1999, BEHAV BRAIN RES, V100, P113, DOI 10.1016/S0166-4328(98)00118-1; MELLANBY J, 1981, J NEUROL NEUROSUR PS, V44, P1084, DOI 10.1136/jnnp.44.12.1084; MELLANBY J, 1977, J NEUROL NEUROSUR PS, V40, P404, DOI 10.1136/jnnp.40.4.404; Morelli E, 2014, EXP NEUROL, V261, P320, DOI 10.1016/j.expneurol.2014.05.010; Morton, 1999, HUMANE ENDPOINTS ANI, P5; Morton D B, 2000, ILAR J, V41, P80; Morton DB, 2003, LAB ANIM-UK, V37, P261, DOI 10.1258/002367703322389861; Morton DB, 2001, LAB ANIM-UK, V35, P1, DOI 10.1258/0023677011911345; Muller CJ, 2009, GENES BRAIN BEHAV, V8, P481, DOI 10.1111/j.1601-183X.2009.00490.x; National Research Council, 2011, GUIDE CARE USE LAB A; Oliver V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097882; Panayiotopoulos C., 2007, CLIN GUIDE EPILEPTIC; Park DW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6258; Perez-Mendes P, 2011, EPILEPSY RES, V96, P45, DOI 10.1016/j.eplepsyres.2011.04.015; PERSINGER MA, 1988, PHYSIOL BEHAV, V44, P27, DOI 10.1016/0031-9384(88)90342-3; Persinger MA, 1996, INT J NEUROSCI, V86, P271, DOI 10.3109/00207459608986718; Perucca E, 2014, NEUROBIOL DIS, V72, P217, DOI 10.1016/j.nbd.2014.05.011; Peters HC, 2005, NAT NEUROSCI, V8, P51, DOI 10.1038/nn1375; PIERSON MG, 1988, HEARING RES, V32, P1, DOI 10.1016/0378-5955(88)90142-6; Pitkanen A, 2006, MODELS OF SEIZURES AND EPILEPSY, P1; Pitkanen A, 2014, NEUROBIOL DIS, V72, P224, DOI 10.1016/j.nbd.2014.05.037; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Pitkanen A, 2013, EPILEPSIA, V54, P35, DOI 10.1111/epi.12297; Poole T, 1997, LAB ANIM-UK, V31, P116, DOI 10.1258/002367797780600198; Prescott M J, 2010, Adv Sci Res, V5, P11, DOI 10.5194/asr-5-11-2010; Prescott MJ, 2010, J NEUROSCI METH, V193, P167, DOI 10.1016/j.jneumeth.2010.09.003; Qiao X, 2013, EPILEPSY RES, V106, P17, DOI 10.1016/j.eplepsyres.2013.06.006; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rice ASC, 2008, PAIN, V139, P243, DOI 10.1016/j.pain.2008.08.017; Richardson CA, 2005, ATLA-ALTERN LAB ANIM, V33, P119, DOI 10.1177/026119290503300207; Riljak V, 2015, PHYSIOL RES, V64, P263, DOI 10.33549/physiolres.932793; Robinson V, 2004, ATLA-ALTERN LAB ANIM, V32, P373, DOI 10.1177/026119290403201s61; Rutten A, 2002, EUR J NEUROSCI, V16, P501, DOI 10.1046/j.1460-9568.2002.02103.x; Castelhano ASS, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00036; Scharfman HE, 2005, EXP NEUROL, V196, P73, DOI 10.1016/j.expneurol.2005.07.007; Scharfman HE, 2014, NEUROBIOL DIS, V72, P180, DOI 10.1016/j.nbd.2014.07.004; Schauwecker PE, 2011, EPILEPSY RES, V97, P1, DOI 10.1016/j.eplepsyres.2011.09.005; Schridde U, 2004, GENES BRAIN BEHAV, V3, P1, DOI 10.1111/j.1601-1848.2004.00034.x; Sena ES, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000344; Shavit Y, 2005, ANESTH ANALG, V101, P1112, DOI 10.1213/01.ane.0000167771.98680.a7; Sherwin CM, 1997, ANIM BEHAV, V53, P67, DOI 10.1006/anbe.1996.0278; Shetty AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043286; Sillanpaa M, 2010, NEW ENGL J MED, V363, P2522, DOI 10.1056/NEJMoa0911610; Simeone KA, 2014, EXP NEUROL, V251, P84, DOI 10.1016/j.expneurol.2013.11.005; Simonato M, 2014, LANCET NEUROL, V13, P949, DOI 10.1016/S1474-4422(14)70076-6; Sotocinal SG, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-55; Sperber EF, 1999, DEV BRAIN RES, V116, P59, DOI 10.1016/S0165-3806(99)00075-9; Stables James P., 2003, Epilepsia, V44, P1472, DOI 10.1111/j.0013-9580.2003.32803.x; STAFSTROM CE, 1993, EPILEPSIA, V34, P420, DOI 10.1111/j.1528-1157.1993.tb02582.x; Stewart LS, 2012, INT J NEUROSCI, V122, P449, DOI 10.3109/00207454.2012.677881; Stokes EL, 2009, LAB ANIM-UK, V43, P149, DOI 10.1258/la.2008.008020; Sunderam S, 2007, J NEUROSCI METH, V163, P373, DOI 10.1016/j.jneumeth.2007.03.007; Szabo CA, 2012, COMPARATIVE MED, V62, P535; Tabb K, 2007, EPILEPSY RES, V74, P140, DOI 10.1016/j.eplepsyres.2007.02.006; THOMPSON JL, 1991, EPILEPSIA, V32, P161, DOI 10.1111/j.1528-1157.1991.tb05239.x; Tremoleda JL, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-44; TURSKI L, 1989, SYNAPSE, V3, P154, DOI 10.1002/syn.890030207; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Van de Weerd HA, 2001, BEHAV PROCESS, V53, P11, DOI 10.1016/S0376-6357(00)00135-2; Van Loo PLP, 2007, LAB ANIM-UK, V41, P441, DOI 10.1258/002367707782314328; Van Loo PLP, 2004, LAB ANIM-UK, V38, P178, DOI 10.1258/002367704322968867; van Luijtelaar G, 2014, CURR MED CHEM, V21, P704; van Luijtelaar G, 2011, NEUROSCI LETT, V497, P177, DOI 10.1016/j.neulet.2011.02.034; Van Vlissingen JMF, 1999, HUMANE ENDPOINTS ANI, P89; Vesterinen HM, 2010, MULT SCLER J, V16, P1044, DOI 10.1177/1352458510379612; Viventi J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000738; Voikar V, 2005, GENES BRAIN BEHAV, V4, P240, DOI 10.1111/j.1601-183X.2004.00103.x; Wang DD, 2012, EPILEPSY BEHAV, V24, P314, DOI 10.1016/j.yebeh.2012.03.035; Wasterlain CG, 2013, HAND CLINIC, V111, P427, DOI 10.1016/B978-0-444-52891-9.00046-4; Weiergraber M, 2005, BRAIN RES PROTOC, V14, P154, DOI 10.1016/j.brainresprot.2004.12.006; Williams P, 2006, J NEUROSCI METH, V155, P39, DOI 10.1016/j.jneumeth.2005.12.035; Wolfensohn S, 2013, J PHARMACOL TOX MET, V67, P9, DOI 10.1016/j.vascn.2012.09.001; WOZNIAK DF, 1991, EXP NEUROL, V114, P250, DOI 10.1016/0014-4886(91)90042-B; Wu C, 2008, J NEUROSCI METH, V171, P126, DOI 10.1016/j.jneumeth.2008.03.001; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu J, 2013, EPILEPSY RES, V106, P311, DOI 10.1016/j.eplepsyres.2013.07.002; Yang J, 2006, J NEUROSCI, V26, P406, DOI 10.1523/JNEUROSCI.4413-05.2006; Yin P, 2013, EPILEPSY BEHAV, V27, P9, DOI 10.1016/j.yebeh.2012.12.015; Young D, 1999, NAT MED, V5, P448; YOUNG GB, 1983, BRAIN, V106, P537, DOI 10.1093/brain/106.3.537; Zayachkivsky A, 2013, J NEUROPHYSIOL, V109, P900, DOI 10.1152/jn.00593.2012; Zhao Q, 2006, MODELS OF SEIZURES AND EPILEPSY, P341, DOI 10.1016/B978-012088554-1/50029-3	233	57	58	1	26	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	FEB 15	2016	260				SI		2	25		10.1016/j.jneumeth.2015.09.007			24	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	DE7QN	WOS:000370831900002	26376175	Green Published, Green Accepted, Other Gold			2021-06-18	
J	Barlow, KM				Barlow, Karen M.			Postconcussion Syndrome: A Review	JOURNAL OF CHILD NEUROLOGY			English	Article						mild traumatic brain injury; children; pathophysiology; outcome; management	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYMPTOMS; SPORTS-RELATED CONCUSSION; MINOR HEAD-INJURY; GOOD-OLD-DAYS; TRANSCRANIAL MAGNETIC STIMULATION; SLEEP-WAKE DISTURBANCES; TENSOR IMAGING FINDINGS; QUALITY-OF-LIFE; SEX-DIFFERENCES	Postconcussion syndrome is a symptom complex with a wide range of somatic, cognitive, sleep, and affective features, and is the most common consequence of traumatic brain injury. Between 14% and 29% of children with mild traumatic brain injury will continue to have postconcussion symptoms at 3 months, but the pathophysiological mechanisms driving this is poorly understood. The relative contribution of injury factors to postconcussion syndrome decreases over time and, instead, premorbid factors become important predictors of symptom persistence by 3 to 6 months postinjury. The differential diagnoses include headache disorder, cervical injury, anxiety, depression, somatization, vestibular dysfunction, and visual dysfunction. The long-term outcome for most children is good, although there is significant morbidity in the short term. Management strategies target problematic symptoms such as headaches, sleep and mood disturbances, and cognitive complaints.	[Barlow, Karen M.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Pediat & Clin Neurosci, Calgary, AB, Canada	Barlow, KM (corresponding author), Univ Calgary, Alberta Childrens Hosp, Dept Pediat & Clin Neurosci, 2888 Shaganappi Trail NW, Calgary, AB, Canada.	karen.barlow@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Meijer, Anna/K-5118-2016; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507	Alberta Children's Hospital Foundation; Clinical Neurotrauma Grant Canadian Institutes of Health Research [293375]; Faculty of Medicine, University of Calgary (Internal Award)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Alberta Children's Hospital Foundation Clinical Neurotrauma Grant Canadian Institutes of Health Research (Grant number 293375) Faculty of Medicine, University of Calgary (Internal Award).	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Birmaher B, 1999, J AM ACAD CHILD PSY, V38, P1230, DOI 10.1097/00004583-199910000-00011; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Blume H, 2012, CURR OPIN PEDIATR, V24, P724, DOI 10.1097/MOP.0b013e328359e4cc; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casson IR, 2011, SPORTS HEALTH, V3, P11, DOI 10.1177/1941738110391413; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chan RCK, 2001, BRAIN INJURY, V15, P71, DOI 10.1080/02699050118215; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Datta SGS, 2009, NEUROL INDIA, V57, P594, DOI 10.4103/0028-3886.57810; Daviss WB, 2006, J CHILD PSYCHOL PSYC, V47, P927, DOI 10.1111/j.1469-7610.2006.01646.x; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Greiffenstein MF, 2008, CLIN NEUROPSYCHOL, V22, P565, DOI 10.1080/13854040701377810; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Guzel A, 2010, AM J EMERG MED, V28, P399, DOI 10.1016/j.ajem.2008.12.025; Han SD, 2009, J HEAD TRAUMA REHAB, V24, P57, DOI 10.1097/HTR.0b013e3181957055; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Krivitzky LS, 2011, J INT NEUROPSYCH SOC, V17, P1143, DOI 10.1017/S1355617711001226; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Len TK, 2013, BRAIN INJURY, V27, P346, DOI 10.3109/02699052.2012.743185; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Manber R, 2008, SLEEP, V31, P489, DOI 10.1093/sleep/31.4.489; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Max JE, 2013, J NEUROPSYCH CLIN N, V25, P187, DOI 10.1176/appi.neuropsych.12010011; Mayer CL, 2013, HEADACHE, V53, P1523, DOI 10.1111/head.12173; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Miano S, 2008, NEUROL SCI, V29, P285, DOI 10.1007/s10072-008-0983-5; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Owens JA, 2000, SLEEP, V23, P1043; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Pickering A, 2012, EMERG MED J, V29, P451, DOI 10.1136/emj.2010.094755; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Senior HEJ, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-89; Shahim P, 2014, JAMA NEUROL; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Simon R, 2005, J CLIN ONCOL, V23, P7332, DOI 10.1200/JCO.2005.02.8712; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smyth K, 2014, DEV MED CHILD NEUROL, V56, P73, DOI 10.1111/dmcn.12263; Soo C, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005239.pub2; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Styrke J, 2013, J REHABIL MED, V45, P749, DOI 10.2340/16501977-1215; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Thiagarajan P, 2014, NEUROREHABILITATION, V34, P129, DOI 10.3233/NRE-131025; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Geijlswijk IM, 2010, PSYCHOPHARMACOLOGY, V212, P379, DOI 10.1007/s00213-010-1962-0; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wolfson AR, 2003, SLEEP, V26, P213, DOI 10.1093/sleep/26.2.213; WOOD A, 1995, J CHILD PSYCHOL PSYC, V36, P327, DOI 10.1111/j.1469-7610.1995.tb01828.x; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yaeger K, 2014, AM J ROENTGENOL, V202, P614, DOI 10.2214/AJR.13.11091; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220; Zonfrillo MR, 2014, J NEUROTRAUM, V31, P722, DOI 10.1089/neu.2013.3088	118	57	58	2	33	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0883-0738	1708-8283		J CHILD NEUROL	J. Child Neurol.	JAN	2016	31	1			SI		57	67		10.1177/0883073814543305			11	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	CY8HW	WOS:000366650400006	25330797				2021-06-18	
J	Combs, HL; Berry, DTR; Pape, T; Babcock-Parziale, J; Smith, B; Schleenbaker, R; Shandera-Ochsner, A; Harp, JP; High, WM				Combs, Hannah L.; Berry, David T. R.; Pape, Theresa; Babcock-Parziale, Judith; Smith, Bridget; Schleenbaker, Randal; Shandera-Ochsner, Anne; Harp, Jordan P.; High, Walter M., Jr.			The Effects of Mild Traumatic Brain Injury, Post-Traumatic Stress Disorder, and Combined Mild Traumatic Brain Injury/Post-Traumatic Stress Disorder on Returning Veterans	JOURNAL OF NEUROTRAUMA			English	Article						assessment; mild TBI; PTSD; veterans	MISERABLE MINORITY; PROCESSING SPEED; BASE RATES; SYMPTOMS; PTSD; PERFORMANCE; DEPLOYMENT; HEALTH; MEMORY; IRAQ	United States veterans of the Iraqi (Operation Iraqi Freedom [OIF]) and Afghanistan (Operation Enduring Freedom [OEF]) conflicts have frequently returned from deployment after sustaining mild traumatic brain injury (mTBI) and enduring stressful events resulting in post-traumatic stress disorder (PTSD). A large number of returning service members have been diagnosed with both a history of mTBI and current PTSD. Substantial literature exists on the neuropsychological factors associated with mTBI and PTSD occurring separately; far less research has explored the combined effects of PTSD and mTBI. The current study employed neuropsychological and psychological measures in a sample of 251 OIF/OEF veterans to determine whether participants with a history of mTBI and current PTSD (mTBI+PTSD) have poorer cognitive and psychological outcomes than participants with mTBI only (mTBI-o), PTSD only (PTSD-o), or veteran controls (VC), when groups are comparable on intelligence quotient, education, and age. The mTBI+PTSD group performed more poorly than VC, mTBI-o, and PTSD-o groups on several neuropsychological measures. Effect size comparisons suggest small deleterious effects for mTBI-o on measures of processing speed and visual attention and small effects for PTSD-o on measures of verbal memory, with moderate effects for mTBI+PTSD on the same variables. Additionally, the mTBI+PTSD group was significantly more psychologically distressed than the PTSD-o group, and PTSD-o group was more distressed than VC and mTBI-o groups. These findings suggest that veterans with mTBI+PTSD perform significantly lower on neuropsychological and psychiatric measures than veterans with mTBI-o or PTSD-o. The results also raise the possibility of mild but persisting cognitive changes following mTBI sustained during deployment.	[Combs, Hannah L.; Berry, David T. R.; Shandera-Ochsner, Anne; Harp, Jordan P.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; [Schleenbaker, Randal; High, Walter M., Jr.] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY USA; [Pape, Theresa; Smith, Bridget] Edward Hines Jr Hosp, Hines, IL USA; [Pape, Theresa; Smith, Bridget] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Babcock-Parziale, Judith] Vet Affairs Hlth Care Syst, Southern Arizona Dept, Tucson, AZ USA; [Schleenbaker, Randal; High, Walter M., Jr.] Lexington Vet Affairs Med Ctr, Lexington, KY USA; [Shandera-Ochsner, Anne] Mayo Clin, Dept Psychiat & Psychol, Jacksonville, FL 32224 USA	High, WM (corresponding author), Lexington VAMC, 1101 Vet Dr, Lexington, KY 40502 USA.	walter.high@va.gov		Bender Pape, Theresa/0000-0001-7738-5963	Department of Veterans Affairs Office of Research and Development, Health Services Research and Development (HSRD) service [VA ORD HSRD SDR 08-377]	This research was supported by grant number VA ORD HSR&D SDR 08-377 from the Department of Veterans Affairs Office of Research and Development, Health Services Research and Development (HSR&D) service. The views expressed in this publication are those of the authors and do not necessarily represent the policies nor views of the U.S. Department of Veterans Affairs or the United States Government. The authors gratefully acknowledge Jordan Harp, M.S., and Shonna Jenkins, for their valuable insight and assistance with this project.. This manuscript is based on a thesis submitted by Hannah L. Combs in partial fulfillment of the requirements for a master's degree in clinical psychology at the University of Kentucky.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barrett DH, 1996, AM J PSYCHIAT, V153, P1492; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT, 1996, BDI 2 BECK DEPRESSIO; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Ben-Porath YS, 2008, J PERS ASSESS, V90, P119, DOI 10.1080/00223890701845120; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Brady KT, 1997, J CLIN PSYCHIAT, V58, P12; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Campbell TA, 2009, PSYCHIAT ANN, V39, P796, DOI 10.3928/00485713-20090728-01; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Conners CK, 2000, CONNERS CONTINUOUS P, V5; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gordon SN, 2011, CLIN NEUROPSYCHOL, V25, P337, DOI 10.1080/13854046.2010.550634; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; Mason LH, 2013, J PERS ASSESS, V95, P585, DOI 10.1080/00223891.2013.819512; Miller HA., 2001, M FAST MILLER FORENS; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; O'Neil ME, 2014, J INT NEUROPSYCH SOC, V20, P249, DOI [10.1017/S1355617714000204, 10.1017/S135561771300146X]; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rasch D., 2004, PSYCHOL SCI, V46, P175; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Samuelson KW, 2010, CHILD NEUROPSYCHOL, V16, P119, DOI 10.1080/09297040903190782; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed	57	57	57	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2015	32	13					956	966		10.1089/neu.2014.3585			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0SU	WOS:000363964200004	25350012	Green Published			2021-06-18	
J	Eckert, A; Huang, L; Gonzalez, R; Kim, HS; Hamblin, MH; Lee, JP				Eckert, Auston; Huang, Lei; Gonzalez, Rodolfo; Kim, Hye-Sun; Hamblin, Milton H.; Lee, Jean-Pyo			Bystander Effect Fuels Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells to Quickly Attenuate Early Stage Neurological Deficits After Stroke	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Inflammation; Blood-brain barrier; Cellular therapy; Stem cell transplantation; Induced pluripotent stem cells; Stroke; Neural stem cell	BLOOD-BRAIN-BARRIER; CEREBRAL-ARTERY OCCLUSION; ISCHEMIC-STROKE; MATRIX METALLOPROTEINASES; TRAUMATIC BRAIN; RAT MODEL; PROTEIN; INJURY; MICE; MATRIX-METALLOPROTEINASE-9	Present therapies for stroke rest with tissue plasminogen activator (tPA), the sole licensed antithrombotic on the market; however, tPA's effectiveness is limited in that the drug not only must be administered less than 3-5 hours after stroke but often exacerbates blood-brain barrier (BBB) leakage and increases hemorrhagic incidence. A potentially promising therapy for stroke is transplantation of human induced pluripotent stem cell-derived neural stem cells (hiPSC-NSCs). To date, the effects of iPSCs on injuries that take place during early stage ischemic stroke have not been well studied. Consequently, we engrafted iPSC-NSCs into the ipsilesional hippocampus, a natural niche of NSCs, at 24 hours after stroke (prior to secondary BBB opening and when inflammatory signature is abundant). At 48 hours after stroke (24 hours after transplant), hiPSC-NSCs had migrated to the stroke lesion and quickly improved neurological function. Transplanted mice showed reduced expression of proinflammatory factors (tumor necrosis factor-a, interleukin 6 [IL-6], IL-1 beta, monocyte chemotactic protein 1, macrophage inflammatory protein la), microglial activation, and adhesion molecules (intercellular adhesion molecule 1, vascular cell adhesion molecule 1) and attenuated BBB damage. We are the first to report that engrafted hiPSC-NSCs rapidly improved neurological function (less than 24 hours after transplant). Rapid hipSC-NSC therapeutic activity is mainly due to a bystander effect that elicits reduced inflammation and BBB damage.	[Eckert, Auston; Huang, Lei; Hamblin, Milton H.; Lee, Jean-Pyo] Tulane Univ, Sch Med, Dept Neurol, Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70112 USA; [Gonzalez, Rodolfo; Lee, Jean-Pyo] Sanford Burnham Inst Med Res Neurosci Aging & Ste, La Jolla, CA USA; [Kim, Hye-Sun] Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul, South Korea	Lee, JP (corresponding author), Tulane Univ, Sch Med, Dept Neurol, Ctr Stem Cell Res & Regenerat Med, 1430 Tulane Ave,SL99, New Orleans, LA 70112 USA.	jeanpyol@tulane.edu			Tulane Center for Stem Cell Research and Regenerative Medicine	We thank Dr. Edward Neuwelt, Oregon Health and Science University, for helpful scientific discussion. We thank Gustavo Vallim and Ryan Park, Tulane University, for technical assistance. This work was supported by startup funds from the Tulane Center for Stem Cell Research and Regenerative Medicine.	Asahi M, 2001, J NEUROSCI, V21, P7724; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Cartwright P, 2005, DEVELOPMENT, V132, P885, DOI 10.1242/dev.01670; Castellanos M, 2003, STROKE, V34, P40, DOI 10.1161/01.STR.0000046764.57344.31; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Chang DI, 2003, J CEREBR BLOOD F MET, V23, P1408, DOI 10.1097/01.WCB.0000091765.61714.30; Chau MJ, 2014, STEM CELLS, V32, P3075, DOI 10.1002/stem.1802; Chen SJ, 2010, STEM CELLS DEV, V19, P1757, DOI 10.1089/scd.2009.0452; Clark WM, 1997, NEUROL RES, V19, P641; Darsalia V, 2011, J CEREBR BLOOD F MET, V31, P235, DOI 10.1038/jcbfm.2010.81; DEFILIPPI P, 1992, J BIOL CHEM, V267, P18303; Emanueli C, 2003, BRIT J PHARMACOL, V140, P614, DOI 10.1038/sj.bjp.0705458; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hu Xueyou, 2010, J Vis Exp, DOI 10.3791/2445; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Kang SS, 2013, NEUROBIOL DIS, V49, P68, DOI 10.1016/j.nbd.2012.08.020; Kawai H, 2010, J CEREBR BLOOD F MET, V30, P1487, DOI 10.1038/jcbfm.2010.32; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Knowland D, 2014, NEURON, V82, P603, DOI 10.1016/j.neuron.2014.03.003; Kuntz M, 2014, J CEREBR BLOOD F MET, V34, P95, DOI 10.1038/jcbfm.2013.169; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Liu SP, 2014, STEM CELLS DEV, V23, P421, DOI 10.1089/scd.2013.0182; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lu YY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3852; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mishiro K, 2012, NEUROSCIENCE, V205, P39, DOI 10.1016/j.neuroscience.2011.12.042; NAGASAWA H, 1989, STROKE, V20, P1037, DOI 10.1161/01.STR.20.8.1037; O'Neill M J, 2001, Curr Protoc Neurosci, VChapter 9, DOI [10.1002/0471142301.ns0905s12, 10.1002/0471142301.ns0906s12]; Oki K, 2012, STEM CELLS, V30, P1120, DOI 10.1002/stem.1104; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Pettigrew LC, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-47; Polentes J, 2012, CELL TRANSPLANT, V21, P2587, DOI 10.3727/096368912X653228; Quinn LP, 2007, J NEUROSCI METH, V164, P43, DOI 10.1016/j.jneumeth.2007.03.021; RISAU W, 1990, TRENDS NEUROSCI, V13, P174, DOI 10.1016/0166-2236(90)90043-A; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Rossi B, 2011, J LEUKOCYTE BIOL, V89, P539, DOI 10.1189/jlb.0710432; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Virley D, 2000, J CEREBR BLOOD F MET, V20, P563, DOI 10.1097/00004647-200003000-00015; Wang XY, 2003, NAT MED, V9, P1313, DOI 10.1038/nm926; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Yuan T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt224	51	57	60	1	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	JUL	2015	4	7					841	851		10.5966/sctm.2014-0184			11	Cell & Tissue Engineering	Cell Biology	CN2ST	WOS:000358272900023	26025980	DOAJ Gold, Green Published			2021-06-18	
J	Strain, JF; Womack, KB; Didehbani, N; Spence, JS; Conover, H; Hart, J; Kraut, MA; Cullum, CM				Strain, Jeremy F.; Womack, Kyle B.; Didehbani, Nyaz; Spence, Jeffrey S.; Conover, Heather; Hart, John, Jr.; Kraut, Michael A.; Cullum, C. Munro			Imaging Correlates of Memory and Concussion History in Retired National Football League Athletes	JAMA NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; HIPPOCAMPAL HEAD ATROPHY; ALZHEIMERS-DISEASE; DEPRESSIVE SYMPTOMS; VOLUME; IMPACT; SEGMENTATION; ASSOCIATION; DYSFUNCTION	IMPORTANCE To our knowledge, this is the first study to show an association between concussion, cognition, and anatomical structural brain changes across the age spectrum in former National Football League athletes. OBJECTIVE To assess the relationship of hippocampal volume, memory performance, and the influence of concussion history in retired National Football League athletes with and without mild cognitive impairment (MCI). DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study assessed differences between groups, mean hippocampal volumes, and memory performance by computing age quintiles based on group-specific linear regression models corrected for multiple comparisons for both athletes and control participants. The study was conducted starting in November 2010 and is ongoing at a research center in the northern region of Texas. This current analysis was conducted from October 9, 2013, to August 21, 2014. Participants included 28 retired National Football League athletes, 8 of whom had MCI and a history of concussion, 21 cognitively healthy control participants, and 6 control participants with MCI without concussion. MAIN OUTCOMES AND MEASURES Hippocampal volume, age, California Verbal Learning Test scores, and the number of grade 3 (G3) concussions. In addition, the number of games played was examined as an objective variable pertaining to football history. RESULTS The mean (SD) age was 58.1 (13) years for the 28 former athletes and 59.0 (12) years for the 27 control participants. Retired athletes with concussion history but without cognitive impairment had normal but significantly lower California Verbal Learning Test scores compared with control participants (mean [SD], 52.5 [8] vs 60.24 [7]; P = .002); those with a concussion history and MCI performed worse (mean [SD], 37 [8.62]) compared with both control participants (P < .001) and athletes without memory impairment (P < .001). Among the athletes, 17 had a G3 concussion and 11 did not. Older retired athletes with at least 1 G3 concussion had significantly smaller bilateral hippocampal volumes compared with control participants at the 40th age percentile (left, P = .04; right, P = .03), 60th percentile (left, P = .009; right, P = .01), and 80th percentile (left, P = .001; right, P = .002) and a smaller right hippocampal volume compared with athletes without a G3 concussion at the 40th percentile (P = .03), 60th percentile (P = .02), and 80th percentile (P = .02). Athletes with a history of G3 concussion were more likely to have MCI (7 of 7) compared with retired athletes without a history of G3 concussion (1 of 5) older than 63 years (P = .01). In addition, the left hippocampal volume in retired athletes with MCI and concussion was significantly smaller compared with control participants with MCI (P = .03). CONCLUSION AND RELEVANCE Prior concussion that results in loss of consciousness is a risk factor for increased hippocampal atrophy and the development of MCI. In individuals with MCI, hippocampal volume loss appears greater among those with a history of concussion.	[Strain, Jeremy F.; Didehbani, Nyaz; Spence, Jeffrey S.; Conover, Heather; Hart, John, Jr.; Kraut, Michael A.] Univ Texas Dallas, Sch Behav & Brain Sci, Ctr BrainHlth, Dallas, TX 75230 USA; [Womack, Kyle B.; Hart, John, Jr.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Womack, Kyle B.; Hart, John, Jr.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Kraut, Michael A.] Johns Hopkins Sch Med, Dept Radiol, Baltimore, MD USA	Cullum, CM (corresponding author), Univ Texas SW Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	munro.cullum@utsouthwestern.edu	Womack, Kyle/O-5422-2018; Cullum, C. Munro/AAC-2496-2019	Womack, Kyle/0000-0002-6060-9075; Cullum, C. Munro/0000-0001-9706-5465; Didehbani, Nyaz/0000-0001-6121-5759	BrainHealth Institute for Athletes at the Center for BrainHealth; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30Ag12300-19]; University of Texas at Dallas; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG012300] Funding Source: NIH RePORTER	This project was supported by the BrainHealth Institute for Athletes at the Center for BrainHealth, a research center at The University of Texas at Dallas, and grant P30Ag12300-19 from the National Institute on Aging.	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blasko I, 2008, NEUROBIOL AGING, V29, P1, DOI 10.1016/j.neurobiolaging.2006.09.002; Buffalo EA, 1998, HIPPOCAMPUS, V8, P330, DOI 10.1002/(SICI)1098-1063(1998)8:4<330::AID-HIPO3>3.3.CO;2-2; Chen KHM, 2010, BRAIN COGNITION, V72, P400, DOI 10.1016/j.bandc.2009.11.007; Chetelat G, 2003, BRAIN, V126, P1955, DOI 10.1093/brain/awg196; Convit A, 1997, NEUROBIOL AGING, V18, P131, DOI 10.1016/S0197-4580(97)00001-8; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Devanand DP, 2007, NEUROLOGY, V68, P828, DOI 10.1212/01.wnl.0000256697.20968.d7; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Du AT, 2001, J NEUROL NEUROSUR PS, V71, P441, DOI 10.1136/jnnp.71.4.441; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; Grundman M, 2004, ARCH NEUROL-CHICAGO, V61, P59, DOI 10.1001/archneur.61.1.59; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Ibarretxe-Bilbao N, 2008, J NEUROL, V255, P1324, DOI 10.1007/s00415-008-0885-8; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; IVERSON GL, 2012, REHABIL RES PRACT, V2012, DOI DOI 10.1155/2012/316575; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kaplan E., 1983, BOSTON NAMING TEST; Kelly JP, 1997, NEUROLOGY, V48, P581; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kraut MA, 2002, J COGNITIVE NEUROSCI, V14, P24, DOI 10.1162/089892902317205294; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Loring D W, 1990, Arch Clin Neuropsychol, V5, P1, DOI 10.1016/0887-6177(90)90002-7; Lucarelli RT, 2013, AM J NEURORADIOL, V34, P752, DOI 10.3174/ajnr.A3308; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Maller JJ, 2014, J NEUROL NEUROPHYSIO, V5, P1; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Vanderploeg RD, 2014, J CLIN EXP NEUROPSYC, V36, P58, DOI 10.1080/13803395.2013.864600; Vythilingam M, 2005, PSYCHIAT RES-NEUROIM, V139, P89, DOI 10.1016/j.pscychresns.2005.04.003; Whitwell JL, 2001, AM J NEURORADIOL, V22, P1483; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	49	57	57	0	44	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JUL	2015	72	7					773	780		10.1001/jamaneurol.2015.0206			8	Clinical Neurology	Neurosciences & Neurology	CM8EP	WOS:000357931000010	25985094	Green Accepted, Bronze			2021-06-18	
J	Meagher, AD; Beadles, CA; Doorey, J; Charles, AG				Meagher, Ashley D.; Beadles, Christopher A.; Doorey, Jennifer; Charles, Anthony G.			Racial and ethnic disparities in discharge to rehabilitation following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						trauma; traumatic brain injury; disparities; level of rehabilitation	INSTITUTE-OF-MEDICINE; UNEQUAL TREATMENT; HEALTH-CARE; UNITED-STATES; HEAD-INJURY; OUTCOMES	OBJECT Disparities in access to inpatient rehabilitation services after traumatic brain injury (TBI) have been identified, but less well described is the likelihood of discharge to a higher level of rehabilitation for Hispanic or black patients compared with non-Hispanic white patients. The authors investigate racial disparities in discharge destination (inpatient rehabilitation vs skilled nursing facility vs home health vs home) following TBI by using a nationwide database and methods to address racial differences in prehospital characteristics. METHODS Analysis of discharge destination for adults with moderate to severe TBI was performed using National Trauma Data Bank data for the years 2007-2010. The authors performed propensity score weighting followed by ordered logistic regression in their analytical sample and in a subgroup analysis of older adults with Medicare. Likelihood of discharge to a higher level of rehabilitation based on race/ethnicity accounting for prehospital and in-hospital variables was determined. RESULTS The authors identified 299,205 TBI incidents: 232,392 non-Hispanic white, 29,611 Hispanic, and 37,202 black. Propensity weighting resulted in covariate balance among racial groups. Hispanic (adjusted OR 0.71, 95% Cl 0.68-0.75) and black (adjusted OR 0.94, 95% Cl 0.91-0.97) populations were less likely to be discharged to a higher level of rehabilitation than were non-Hispanic whites. The subgroup analysis indicated that Hispanic (adjusted OR 0.79, 95% Cl 0.71-0.86) and black (OR 0.87, 95% Cl 0.81-0.94) populations were still less likely to receive a higher level of rehabilitation, despite uniform insurance coverage (Medicare). CONCLUSIONS Adult Hispanic and black patients with TBI are significantly less likely to receive intensive rehabilitation than their non-Hispanic white counterparts; notably, this difference persists in the. Medicare population (age >= 65 years), indicating that uniform insurance coverage alone does not account for the disparity. Given that insurance coverage and a wide range of prehospital characteristics do not eliminate racial disparities in discharge destination, it is crucial that additional unmeasured patient, physician, and institutional factors be explored to eliminate them.	[Meagher, Ashley D.; Doorey, Jennifer; Charles, Anthony G.] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA; [Meagher, Ashley D.; Beadles, Christopher A.; Charles, Anthony G.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA; [Beadles, Christopher A.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC 27599 USA; [Doorey, Jennifer; Charles, Anthony G.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Beadles, Christopher A.] Ctr Hlth Serv Res Primary Care, Dept Vet Affairs, Med Ctr, Durham, NC USA	Charles, AG (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, UNC Sch Med, 4008 Burnett Womack Bldg,CB 7228, Chapel Hill, NC 27599 USA.	anthchar@med.unc.edu		Meagher, Ashley/0000-0003-2429-2274; Beadles, Christopher/0000-0001-6410-1722	National Research Service Award Post-Doctoral Traineeship from the Agency for Health Care Research and Quality - Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill [5T32-HS000032]; NIH CTSA at UNCUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [2KR391203]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32HS000032] Funding Source: NIH RePORTER	DISCLOSURE This research was partially supported by a National Research Service Award Post-Doctoral Traineeship from the Agency for Health Care Research and Quality sponsored by the Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Grant No. 5T32-HS000032 (salary support for Drs. Meagher and Beadles), and NIH CTSA at UNC Grant No. 2KR391203 (data acquisition).	Alban RF, 2010, AM SURGEON, V76, P1108; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P287, DOI 10.1016/S0033-3549(04)50252-2; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Ennis SR., HISPANIC POPULATION; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Greenwood RJ, 2004, BRIT J NEUROSURG, V18, P462, DOI 10.1080/02688690400012327; Haider AH, 2013, J TRAUMA ACUTE CARE, V74, P1195, DOI 10.1097/TA.0b013e31828c331d; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Nelson A, 2002, J NATL MED ASSOC, V94, P666; Nelson AR, 2003, ANN THORAC SURG, V76, pS1377, DOI 10.1016/S0003-4975(03)01205-0; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rastogi S, BLACK POPULATION 201; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0	21	57	57	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2015	122	3					595	601		10.3171/2014.10.JNS14187			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CC3RJ	WOS:000350266600015	25415069	Bronze			2021-06-18	
J	Yuruker, V; Naziroglu, M; Senol, N				Yuruker, Vehbi; Naziroglu, Mustafa; Senol, Nilgun			Reduction in traumatic brain injury-induced oxidative stress, apoptosis, and calcium entry in rat hippocampus by melatonin: Possible involvement of TRPM2 channels	METABOLIC BRAIN DISEASE			English	Article						Apoptosis; Calcium ion entry; TRPM2 channels; Melatonin; Traumatic brain injury; Oxidative stress	DORSAL-ROOT GANGLION; SPINAL-CORD-INJURY; MOLECULAR-MECHANISMS; EXOGENOUS MELATONIN; FUNCTIONAL RECOVERY; N-ACETYLCYSTEINE; CATION CHANNELS; ADP-RIBOSE; ACTIVATION; RECEPTOR	Melatonin, which is a very effective reactive oxygen species (ROS) scavenger, acts through a direct reaction with free radicals. Ca2+ entry induced by traumatic brain injury (TBI) has deleterious effects on human hippocampal function. TRPM2 is a Ca2+ permeable non-selective channel in hippocampal neurons, and its activation of during oxidative stress has been linked to cell death. Despite the importance of oxidative stress in TBI, its role in apoptosis and Ca2+ entry in TBI is poorly understood. Therefore, we tested the effects of melatonin on apoptosis, oxidative stress, and Ca2+ entry through the TRPM2 channel in the hippocampal neurons of TBI-induced rats. Thirty-two rats were divided into the following four groups: control, melatonin, TBI, and TBI + melatonin groups. Melatonin (5 mg/kg body weight) was intraperitoneally given to animals in the melatonin group and the TBI + melatonin group after 1 h of brain trauma. Hippocampal neurons were freshly isolated from the four groups, incubated with a nonspecific TRPM2 blocker (2-aminoethyl diphenylborinate, 2-APB), and then stimulated with cumene hydroperoxide. Apoptosis, caspase-3, caspase-9, intracellular ROS production, mitochondrial membrane depolarization and intracellular free Ca2+ ([Ca2+](i)) values were high in the TBI group, and low in the TBI + melatonin group. The [Ca2+](i) concentration was decreased in the four groups by 2-APB. In our TBI experimental model, TRPM2 channels were involved in Ca2+ entry-induced neuronal death, and the negative modulation of the activity of this channel by melatonin pretreatment may account for the neuroprotective activity of TRPM2 channels against oxidative stress, apoptosis, and Ca2+ entry.	[Yuruker, Vehbi; Senol, Nilgun] Suleyman Demirel Univ, Fac Med, Dept Neurosurg, TR-32260 Isparta, Turkey; [Naziroglu, Mustafa] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey	Naziroglu, M (corresponding author), Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.	mustafanaziroglu@sdu.edu.tr			Scientific Research Project Unit of Suleyman Demirel UniversitySuleyman Demirel University [BAP-3265-TU-2-12]	The study was partially supported by Scientific Research Project Unit of Suleyman Demirel University (BAP-3265-TU-2-12). The authors wish thanks to Technician Fatih Sahin (Neuroscience Research Center, Suleyman Demirel University) for excellent performance on the analyses of current study. Abstract of the study will be submitted in 5th International Congress on Cell Membranes and Oxidative Stress: Focus on Calcium Signaling and TRP Channels, 9-12 September 2014, Isparta Turkey. (http://www.cmos.org.tr/2014/).	Akpinar A, 2014, J MEMBRANE BIOL, V247, P451, DOI 10.1007/s00232-014-9652-1; Argun M, 2014, EYE, V28, P752, DOI 10.1038/eye.2014.50; Belrose JC, 2012, MOL BRAIN, V5, DOI 10.1186/1756-6606-5-11; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Carrasco C, 2013, CELL BIOCHEM FUNCT, V31, P585, DOI 10.1002/cbf.2942; Celik O, 2012, PHYSIOL BEHAV, V107, P458, DOI 10.1016/j.physbeh.2012.09.013; Chang CF, 2012, J PINEAL RES, V52, P312, DOI 10.1111/j.1600-079X.2011.00945.x; Cook NL, 2010, J MOL NEUROSCI, V42, P192, DOI 10.1007/s12031-010-9347-8; Dilek M, 2010, J MEMBRANE BIOL, V233, P135, DOI 10.1007/s00232-010-9233-x; Ekmekcioglu C, 2006, BIOMED PHARMACOTHER, V60, P97, DOI 10.1016/j.biopha.2006.01.002; Ersahin M, 2012, J PINEAL RES, V52, P340, DOI 10.1111/j.1600-079X.2011.00948.x; Espino J, 2013, J PINEAL RES, V54, P442, DOI 10.1111/jpi.12042; Espino J, 2011, J PINEAL RES, V51, P195, DOI 10.1111/j.1600-079X.2011.00876.x; Espino J, 2011, AGE, V33, P497, DOI 10.1007/s11357-010-9194-0; Espino J, 2010, J MEMBRANE BIOL, V233, P105, DOI 10.1007/s00232-010-9230-0; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; Ghazizadeh V, 2014, METAB BRAIN DIS; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gurkoff G, 2013, PHARMACEUTICALS, V6, P788, DOI 10.3390/ph6070788; Iuvone PM, 2014, ADV EXP MED BIOL, V801, P765, DOI 10.1007/978-1-4614-3209-8_96; Maharaj DS, 2006, J NEUROCHEM, V96, P78, DOI 10.1111/j.1471-4159.2005.03532.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Naziroglu M, 2014, NEUROSCIENCE, V263, P27, DOI 10.1016/j.neuroscience.2014.01.006; Naziroglu M, 2013, NEUROSCIENCE, V242, P151, DOI 10.1016/j.neuroscience.2013.03.032; Naziroglu M, 2008, NEUROCHEM RES, V33, P1256, DOI 10.1007/s11064-007-9577-5; Naziroglu M, 2008, J NEUROL SCI, V270, P152, DOI 10.1016/j.jns.2008.03.003; Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x; Naziroglu M, 2007, CELL BIOCHEM FUNCT, V25, P383, DOI 10.1002/cbf.1310; Naziroglu M, 2013, MUSCLE NERVE, V48, P945, DOI 10.1002/mus.23844; Naziroglu M, 2012, J RECEPT SIG TRANSD, V32, P290, DOI 10.3109/10799893.2012.737002; Naziroglu M, 2012, NEUROCHEM RES, V37, P2065, DOI 10.1007/s11064-012-0850-x; Naziroglu M, 2011, NEUROCHEM RES, V36, P355, DOI 10.1007/s11064-010-0347-4; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Pandi-Perumal SR, 2013, NEUROTOX RES, V23, P267, DOI 10.1007/s12640-012-9337-4; Paredes SD, 2007, MOL CELL BIOCHEM, V304, P305, DOI 10.1007/s11010-007-9513-7; Park K, 2010, J PINEAL RES, V48, P270, DOI 10.1111/j.1600-079X.2010.00751.x; Park S, 2012, J PINEAL RES, V52, P107, DOI 10.1111/j.1600-079X.2011.00925.x; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; Royano Sergio, 2010, CELL MEMBR FREE RADI, V3, P99; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Schafer M.K.E., 2014, CELL TISSUE RES; Senol N, 2014, NEURAL REGEN RES, V9, P1112, DOI 10.4103/1673-5374.135312; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Springer JE, 2002, J BIOCHEM MOL BIOL, V35, P94; Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x; Uguz AC, 2012, NEUROCHEM RES, V37, P1631, DOI 10.1007/s11064-012-0758-5; VITTE PA, 1988, J PINEAL RES, V5, P437, DOI 10.1111/j.1600-079X.1988.tb00787.x	49	57	60	0	18	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0885-7490	1573-7365		METAB BRAIN DIS	Metab. Brain Dis.	FEB	2015	30	1					223	231		10.1007/s11011-014-9623-3			9	Endocrinology & Metabolism; Neurosciences	Endocrinology & Metabolism; Neurosciences & Neurology	AZ2GS	WOS:000348053100027	25339252				2021-06-18	
J	Proto, DA; Pastorek, NJ; Miller, BI; Romesser, JM; Sim, AH; Linck, JF				Proto, Daniel A.; Pastorek, Nicholas J.; Miller, Brian I.; Romesser, Jennifer M.; Sim, Anita H.; Linck, John F.			The Dangers of Failing One or More Performance Validity Tests in Individuals Claiming Mild Traumatic Brain Injury-Related Postconcussive Symptoms	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild TBI; Effort; Performance validity; Neuropsychological assessment	RESPONSE BIAS SCALE; MALINGERING DETECTION; TEST FAILURE; VALIDATION; RECOGNITION; INDICATORS; EDUCATION; BATTERY; ISSUES; NORMS	Evaluating performance validity is important in any neuropsychological assessment, and prior research recommends a threshold for invalid performance of two or more performance validity test (PVT) failures. However, extant findings also indicate that failing a single PVT is associated with significant changes in neuropsychological performance. The current study sought to determine if there is an appreciable difference in neuropsychological testing results between individuals failing different numbers of PVTs. In a sample of veterans with reported histories of mild traumatic brain injury (mTBI; N = 178), analyses revealed that individuals failing only one PVT performed significantly worse than individuals failing no PVTs on measures of verbal learning and memory, processing speed, and cognitive flexibility. Additionally, individuals failing one versus two PVTs significantly differed only on delayed free recall scores. The current findings suggest that failure of even one PVT should elicit consideration of performance invalidity, particularly in individuals with histories of mTBI.	[Proto, Daniel A.; Miller, Brian I.] Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; [Proto, Daniel A.; Miller, Brian I.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Pastorek, Nicholas J.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Romesser, Jennifer M.] George E Wahlen Vet Affairs Med Ctr, Salt Lake City, UT USA; [Sim, Anita H.] Minneapolis Vet Affairs Hlth Care Syst, Dept Phys Med & Rehabil, Minneapolis, MN USA; [Linck, John F.] Oklahoma City Vet Affairs Med Ctr, Oklahoma City, OK USA	Pastorek, NJ (corresponding author), Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.	nicholas.pastorek@va.gov			Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs; VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks [B6812C]; Minnesota Veterans Medical Research & Education Foundation	This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; B6812C (PI-Levin HS) VA RR&D Traumatic Brain Injury Center of Excellence, Neurorehabilitation: Neurons to Networks; Minnesota Veterans Medical Research & Education Foundation. No pharmaceutical or corporate funding was used in the preparation of this manuscript or collection of data.	Allen L.M., 1997, CARB 97 MANUAL COMPU; Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bordini EJ, 2002, NEUROREHABILITATION, V17, P93; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis DC, 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Gouvier WD, 1999, STUD NEUROPSYCHOL DE, P27; Gouvier WD, 1998, CRIT ISS NE, P55; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, GREENS WORD MEMORY T; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K. W., 2007, ASSESSMENT MALINGERE; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2013, CLIN NEUROPSYCHOL, V27, P108, DOI 10.1080/13854046.2012.739646; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; Heaton R., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Meyers JE, 2004, ARCH CLIN NEUROPSYCH, V19, P637, DOI 10.1016/j.acn.2003.08.007; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2014, ARCH CLIN NEUROPSYCH, V29, P224, DOI 10.1093/arclin/acu001; Meyers JE, 2011, ARCH CLIN NEUROPSYCH, V26, P8, DOI 10.1093/arclin/acq083; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Orey SA, 2000, ARCH CLIN NEUROPSYCH, V15, P335, DOI 10.1016/S0887-6177(99)00024-4; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh TN, 1996, TEST MEMORY MALINGER; *US GOV ACC OFF, 2008, GAO08276; Van Dyke SA, 2013, CLIN NEUROPSYCHOL, V27, P1234, DOI 10.1080/13854046.2013.835447; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Webb JW, 2012, CLIN NEUROPSYCHOL, V26, P1377, DOI 10.1080/13854046.2012.728248; Wechsler D, 2008, WAIS 4 ADM SCORING M; Whitney KA, 2008, ARCH CLIN NEUROPSYCH, V23, P777, DOI 10.1016/j.acn.2008.09.001; Young JC, 2012, CLIN NEUROPSYCHOL, V26, P147, DOI 10.1080/13854046.2011.647083; Young JC, 2011, ARCH CLIN NEUROPSYCH, V26, P194, DOI 10.1093/arclin/acr015	57	57	57	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2014	29	7					614	624		10.1093/arclin/acu044			11	Psychology, Clinical; Psychology	Psychology	AU9DA	WOS:000345890600002	25252598	Green Published			2021-06-18	
J	Liu, L; Sun, TY; Liu, ZL; Chen, XR; Zhao, LL; Qu, GQ; Li, QJ				Liu, Liang; Sun, Tingyi; Liu, Zilong; Chen, Xiaorui; Zhao, Lili; Qu, Guoqiang; Li, Qingjie			Traumatic Brain Injury Dysregulates MicroRNAs to Modulate Cell Signaling in Rat Hippocampus	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; AMYLOID PRECURSOR PROTEIN; ALPHA-SYNUCLEIN; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; POSTTRANSCRIPTIONAL REGULATION; LEWY BODIES; EXPRESSION; GENDER; CASK	Traumatic brain injury (TBI) is a common cause for cognitive and communication problems, but the molecular and cellular mechanisms are not well understood. Epigenetic modifications, such as microRNA (miRNA) dysregulation, may underlie altered gene expression in the brain, especially hippocampus that plays a major role in spatial learning and memory and is vulnerable to TBI. To advance our understanding of miRNA in pathophysiological processes of TBI, we carried out a time-course microarray analysis of microRNA expression profile in rat ipsilateral hippocampus and examined histological changes, apoptosis and synapse ultrastructure of hippocampus post moderate TBI. We found that 10 out of 156 reliably detected miRNAs were significantly and consistently altered from one hour to seven days after injury. Bioinformatic and gene ontology analyses revealed 107 putative target genes, as well as several biological processes that might be initiated by those dysregulated miRNAs. Among those differentially expressed microRNAs, miR-144, miR-153 and miR-340-5p were confirmed to be elevated at all five time points after TBI by quantitative RT-PCR. Western blots showed three of the predicated target proteins, calcium/calmodulin-dependent serine protein kinase (CASK), nuclear factor erythroid 2-related factor 2 (NRF2) and alpha-synuclein (SNCA), were concurrently down-regulated, suggesting that miR-144, miR-153 and miR-340-5p may play important roles collaboratively in the pathogenesis of TBI-induced cognitive and memory impairments. These microRNAs might serve as potential targets for progress assessment and intervention against TBI to mitigate secondary damage to the brain.	[Liu, Liang; Sun, Tingyi; Liu, Zilong; Chen, Xiaorui; Zhao, Lili; Qu, Guoqiang] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430074, Peoples R China; [Liu, Liang] China Univ Polit Sci & Law, Minist Educ, Key Lab Evidence Sci, Beijing, Peoples R China; [Li, Qingjie] Univ Texas Med Branch, Dept Internal Med, Galveston, TX 77555 USA	Liu, ZL (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Forens Med, Wuhan 430074, Peoples R China.	lzlongfy@gmail.com; quli@utmb.edu			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81102304]; Ministry of Education of ChinaMinistry of Education, China [20090142120054]; Foundation of Huazhong University of Science and Technology [20100573]	This work was supported by grants from the National Natural Science Foundation of China (grant number: 81102304) (http://www.nsfc.gov.cn/), Doctoral Fund of Ministry of Education of China (grant number: 20090142120054) (http://www.cutech.edu.cn/cn/index.htm), and Foundation of Huazhong University of Science and Technology (grant number: 20100573) (http://kfy.hust.edu.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Baba M, 1998, AM J PATHOL, V152, P879; Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Cabin DE, 2002, J NEUROSCI, V22, P8797; Calkins MJ, 2009, ANTIOXID REDOX SIGN, V11, P497, DOI [10.1089/ars.2008.2242, 10.1089/ARS.2008.2242]; Carasatorre Mariana, 2013, Curr Top Behav Neurosci, V15, P73, DOI 10.1007/7854_2012_229; Chao HW, 2008, J CELL BIOL, V182, P141, DOI 10.1083/jcb.200712094; Chen KY, 2011, MOL CELL NEUROSCI, V48, P171, DOI 10.1016/j.mcn.2011.07.009; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cheng C, 2013, J BIOL CHEM, V288, P13748, DOI 10.1074/jbc.M112.381392; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Craig AM, 2007, CURR OPIN NEUROBIOL, V17, P43, DOI 10.1016/j.conb.2007.01.011; Dharap A, 2010, J NEUROCHEM, V113, P1685, DOI 10.1111/j.1471-4159.2010.06735.x; Doxakis E, 2010, J BIOL CHEM, V285, P12726, DOI 10.1074/jbc.M109.086827; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Fairless R, 2008, J NEUROSCI, V28, P12969, DOI 10.1523/JNEUROSCI.5294-07.2008; Fanselow MS, 2010, NEURON, V65, P7, DOI 10.1016/j.neuron.2009.11.031; Farrer M, 2004, ANN NEUROL, V55, P174, DOI 10.1002/ana.10846; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fineberg SK, 2009, NEURON, V64, P303, DOI 10.1016/j.neuron.2009.10.020; Fortin DL, 2005, J NEUROSCI, V25, P10913, DOI 10.1523/JNEUROSCI.2922-05.2005; Hata Y, 1996, J NEUROSCI, V16, P2488; Hsu LJ, 1998, J NEUROCHEM, V71, P338; Hsueh YP, 1999, J NEUROSCI, V19, P7415, DOI 10.1523/JNEUROSCI.19-17-07415.1999; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Hu ZH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039357; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Jeyifous O, 2009, NAT NEUROSCI, V12, P1011, DOI 10.1038/nn.2362; Kim TH, 2010, HISTOPATHOLOGY, V57, P734, DOI 10.1111/j.1365-2559.2010.03686.x; Krichevsky Anna M, 2007, ScientificWorldJournal, V7, P155; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li XH, 2012, NEUROSCI LETT, V514, P46, DOI 10.1016/j.neulet.2012.02.054; Liang CL, 2012, BRAIN RES, V1455, P103, DOI 10.1016/j.brainres.2011.10.051; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mondello S, 2013, NEUROLOGY, V80, P1662, DOI 10.1212/WNL.0b013e3182904d43; Nemani VM, 2010, NEURON, V65, P66, DOI 10.1016/j.neuron.2009.12.023; Nistico R, 2012, MOL NEUROBIOL, V46, P572, DOI 10.1007/s12035-012-8324-3; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; Patuzzo C, 2012, BALK J MED GENET, V15, P51, DOI 10.2478/v10034-012-0019-6; Persengiev S, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.03.014; Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rau CS, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-181; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; Sassen S, 2008, VIRCHOWS ARCH, V452, P1, DOI 10.1007/s00428-007-0532-2; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Su E, 2010, DEV NEUROSCI-BASEL, V32, P385, DOI 10.1159/000321342; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Xu JZ, 2011, INT J CANCER, V129, P2527, DOI 10.1002/ijc.25917; Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhang Y, 2011, J CELL BIOCHEM, V112, P2435, DOI 10.1002/jcb.23168	66	57	57	2	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2014	9	8							e103948	10.1371/journal.pone.0103948			19	Multidisciplinary Sciences	Science & Technology - Other Topics	AM4GX	WOS:000339812700068	25089700	DOAJ Gold, Green Published			2021-06-18	
J	Liu, Y; Zhang, R; Yan, K; Chen, FF; Huang, WY; Lv, BK; Sun, CM; Xu, LM; Li, F; Jiang, XD				Liu, Yi; Zhang, Run; Yan, Ke; Chen, Fanfan; Huang, Weiyi; Lv, Bingke; Sun, Chengmei; Xu, Limin; Li, Feng; Jiang, Xiaodan			Mesenchymal stem cells inhibit lipopolysaccharide-induced inflammatory responses of BV2 microglial cells through TSG-6	JOURNAL OF NEUROINFLAMMATION			English	Article							ANTIINFLAMMATORY PROTEIN TSG-6; MARROW STROMAL CELLS; IMMUNE-RESPONSES; NITRIC-OXIDE; BRAIN; SYSTEM; INJURY; TRANSPLANTATION; DIFFERENTIATION; MACROPHAGES	Microglia are the primary immunocompetent cells in brain tissue and microglia-mediated inflammation is associated with the pathogenesis of various neuronal disorders. Recently, many studies have shown that mesenchymal stem cells (MSCs) display a remarkable ability to modulate inflammatory and immune responses through the release of a variety of bioactive molecules, thereby protecting the central nervous system. Previously, we reported that MSCs have the ability to modulate inflammatory responses in a traumatic brain injury model and that the potential mechanisms may be partially attributed to upregulated TNF-alpha stimulated gene/protein 6 (TSG-6) expression. However, whether TSG-6 exerts an anti-inflammatory effect by affecting microglia is not fully understood. In this study, we investigated the anti-inflammatory effects of MSCs and TSG-6 in an in vitro lipopolysaccharide (LPS)-induced BV2 microglial activation model. We found that MSCs and TSG-6 significantly inhibited the expression of pro-inflammatory mediators in activated microglia. However, MSC effects on microglia were attenuated when TSG-6 expression was silenced. In addition, we found that the activation of nuclear factor (NF)-kappa B and mitogen-activated protein kinase (MAPK) pathways in LPS-stimulated BV2 microglial cells was significantly inhibited by TSG-6. Furthermore, we found that the presence of CD44 in BV2 microglial cells was essential for MSC- and TSG-6-mediated inhibition of pro-inflammatory gene expression and of NF-kappa B and MAPK activation in BV2 microglial cells. The results of this study suggest that MSCs can modulate microglia activation through TSG-6 and that TSG-6 attenuates the inflammatory cascade in activated microglia. Our study indicates that novel mechanisms are responsible for the immunomodulatory effect of MSCs on microglia and that MSCs, as well as TSG-6, might be promising therapeutic agents for the treatment of neurotraumatic injuries or neuroinflammatory diseases associated with microglial activation.	[Liu, Yi; Zhang, Run; Yan, Ke; Chen, Fanfan; Huang, Weiyi; Lv, Bingke; Sun, Chengmei; Xu, Limin; Li, Feng; Jiang, Xiaodan] Southern Med Univ, Zhujiang Hosp,Natl Key Clin Specialty, Neurosurg Inst Guandong Prov,Dept Neurosurg, Guangdong Prov Key Lab Brain Funct Repair & Regen, Guangzhou 510282, Guangdong, Peoples R China	Jiang, XD (corresponding author), Southern Med Univ, Zhujiang Hosp,Natl Key Clin Specialty, Neurosurg Inst Guandong Prov,Dept Neurosurg, Guangdong Prov Key Lab Brain Funct Repair & Regen, 253 Gongye Rd, Guangzhou 510282, Guangdong, Peoples R China.	jiangxiao_dan@163.com		li, feng/0000-0002-2010-8081	funds for National Key Clinic Department; Funds for Key Natural Science Foundation of Guangdong [S2013020012754]; Educational Commission of Guangdong [2013CXZDA008]; Key Project of Health Collaborative Innovation of Guangzhou [201400000003-2]; Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81171179, 81272439]	This work was supported by grants from the funds for National Key Clinic Department, the Natural Science Fund of China (number: 81171179, number: 81272439), the Funds for Key Natural Science Foundation of Guangdong (number:. S2013020012754), the Educational Commission of Guangdong (number: 2013CXZDA008), and the Key Project of Health Collaborative Innovation of Guangzhou (number: 201400000003-2) to Professor Xiaodan Jiang.	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Ahn JO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074897; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Baranova NS, 2011, J BIOL CHEM, V286, P25675, DOI 10.1074/jbc.M111.247395; Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Chen ML, 2013, BRAIN RES, V1532, P63, DOI 10.1016/j.brainres.2013.07.037; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Gibbons HM, 2006, BRAIN RES, V1084, P1, DOI 10.1016/j.brainres.2006.02.032; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Kawana H, 2008, J IMMUNOL, V180, P4235, DOI 10.4049/jimmunol.180.6.4235; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Kota DJ, 2013, DIABETES, V62, P2048, DOI 10.2337/db12-0931; Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood-2002-07-2104; Kumar A, 2014, FREE RADICAL BIO MED, V73, P51, DOI 10.1016/j.freeradbiomed.2014.04.014; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Lee KW, 2013, J ETHNOPHARMACOL, V147, P286, DOI 10.1016/j.jep.2013.02.033; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Lesley J, 2004, J BIOL CHEM, V279, P25745, DOI 10.1074/jbc.M313319200; Liang J, 2009, MULT SCLER J, V15, P644, DOI 10.1177/1352458509104590; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Milner CM, 2003, J CELL SCI, V116, P1863, DOI 10.1242/jcs.00407; Muto J, 2009, MOL IMMUNOL, V47, P449, DOI 10.1016/j.molimm.2009.08.026; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Park S, 2014, LIFE SCI, V103, P59, DOI 10.1016/j.lfs.2014.04.003; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Raffaghello L, 2008, STEM CELLS, V26, P151, DOI 10.1634/stemcells.2007-0416; Rahmat Z, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt160; Ramasamy R, 2007, TRANSPLANTATION, V83, P71, DOI 10.1097/01.tp.0000244572.24780.54; Ransohoff RM, 2010, NATURE, V468, P253, DOI 10.1038/nature09615; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roubelakis MG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054747; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Scuteri A, 2011, CURR STEM CELL RES T, V6, P82, DOI 10.2174/157488811795495486; Shi FS, 2013, J NEUROIMMUNOL, V260, P121, DOI 10.1016/j.jneuroim.2013.04.016; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Sun LY, 2009, STEM CELLS, V27, P1421, DOI 10.1002/stem.68; Nguyen TTN, 2013, J BIOL CHEM, V288, P5645, DOI 10.1074/jbc.M112.410126; Tuo JS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-59; Vallabhapurapu S, 2009, ANNU REV IMMUNOL, V27, P693, DOI 10.1146/annurev.immunol.021908.132641; Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043768; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	48	57	59	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 4	2014	11								135	10.1186/1742-2094-11-135			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AN5UQ	WOS:000340657200001	25088370	DOAJ Gold, Green Published			2021-06-18	
J	Kelly, DF; Chaloner, C; Evans, D; Mathews, A; Cohan, P; Wang, C; Swerdloff, R; Sim, MS; Lee, J; Wright, MJ; Kernan, C; Barkhoudarian, G; Yuen, KCJ; Guskiewicz, K				Kelly, Daniel F.; Chaloner, Charlene; Evans, Diana; Mathews, Amy; Cohan, Pejman; Wang, Christina; Swerdloff, Ronald; Sim, Myung-Shin; Lee, Jihey; Wright, Mathew J.; Kernan, Claudia; Barkhoudarian, Garni; Yuen, Kevin C. J.; Guskiewicz, Kevin			Prevalence of Pituitary Hormone Dysfunction, Metabolic Syndrome, and Impaired Quality of Life in Retired Professional Football Players: A Prospective Study	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone deficiency; hypogonadism; metabolic syndrome; mild traumatic brain injury; professional football	TRAUMATIC BRAIN-INJURY; GH REPLACEMENT THERAPY; BODY-MASS INDEX; GROWTH-HORMONE; DEFICIENT ADULTS; LONG-TERM; HYPOPITUITARY PATIENTS; RECURRENT CONCUSSION; SUBARACHNOID HEMORRHAGE; STIMULATION TESTS	Hypopituitarism is common after moderate and severe traumatic brain injury (TBI). Herein, we address the association between mild TBI (mTBI) and pituitary and metabolic function in retired football players. Retirees 30-65 years of age, with one or more years of National Football League (NFL) play and poor quality of life (QoL) based on Short Form 36 (SF-36) Mental Component Score (MCS) were prospectively enrolled. Pituitary hormonal and metabolic syndrome (MetS) testing was performed. Using a glucagon stimulation test, growth hormone deficiency (GHD) was defined with a standard cut point of 3 ng/mL and with a more stringent body mass index (BMI)-adjusted cut point. Subjects with and without hormonal deficiency (HD) were compared in terms of QoL, International Index of Erectile Function (IIEF) scores, metabolic parameters, and football career data. Of 74 subjects, 6 were excluded because of significant non-football-related TBIs. Of the remaining 68 subjects (mean age, 47.3 +/- 10.2 years; median NFL years, 5; median NFL concussions, 3; mean BMI, 33.8 +/- 6.0), 28 (41.2%) were GHD using a peak GH cutoff of < 3 ng/mL. However, with a BMI-adjusted definition of GHD, 13 of 68 (19.1%) were GHD. Using this BMI-adjusted definition, overall HD was found in 16 (23.5%) subjects: 10 (14.7%) with isolated GHD; 3 (4.4%) with isolated hypogonadism; and 3 (4.4%) with both GHD and hypogonadism. Subjects with HD had lower mean scores on the IIEF survey (p = 0.016) and trended toward lower scores on the SF-36 MCS (p = 0.113). MetS was present in 50% of subjects, including 5 of 6 (83%) with hypogonadism, and 29 of 62 (46.8%) without hypogonadism (p = 0.087). Age, BMI, median years in NFL, games played, number of concussions, and acknowledged use of performance-enhancing steroids were similar between HD and non-HD groups. In summary, in this cohort of retired NFL players with poor QoL, 23.5% had HD, including 19% with GHD (using a BMI-adjusted definition), 9% with hypogonadism, and 50% had MetS. Although the cause of HD is unclear, these results suggest that GHD and hypogonadism may contribute to poor QoL, erectile dysfunction, and MetS in this population. Further study of pituitary function is warranted in athletes sustaining repetitive mTBI.	[Kelly, Daniel F.; Chaloner, Charlene; Sim, Myung-Shin; Lee, Jihey; Barkhoudarian, Garni] St Johns Hlth Ctr, John Wayne Canc Inst, Brain Tumor Ctr, Santa Monica, CA 90404 USA; [Kelly, Daniel F.; Chaloner, Charlene; Sim, Myung-Shin; Lee, Jihey; Barkhoudarian, Garni] St Johns Hlth Ctr, John Wayne Canc Inst, Pituitary Disorders Program, Santa Monica, CA 90404 USA; [Evans, Diana; Wang, Christina; Swerdloff, Ronald; Wright, Mathew J.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA; [Evans, Diana; Wang, Christina; Swerdloff, Ronald; Wright, Mathew J.] Los Angeles Biomed Res Inst, Torrance, CA 90509 USA; [Mathews, Amy; Guskiewicz, Kevin] Univ N Carolina, Ctr Study Retired Athletes, Chapel Hill, NC USA; [Cohan, Pejman] UCLA Sch Med, Div Endocrinol, Dept Med, Los Angeles, CA USA; [Kernan, Claudia] UCLA Semel Inst Neurosci & Human Behav, Los Angeles, CA USA; [Yuen, Kevin C. J.] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol, Portland, OR 97201 USA	Kelly, DF (corresponding author), St Johns Hlth Ctr, John Wayne Canc Inst, Brain Tumor Ctr, 2200 Santa Monica Blvd, Santa Monica, CA 90404 USA.	kellyd@jwci.org		Guskiewicz, Kevin/0000-0002-8682-2130	National Operating Committee on Standards for Athletic Equipment (NOCSAE); Pfizer, Inc.Pfizer; General Clinical Research CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1 RR00425]; UCLA Clinical and Translational Science Institute at Los Angeles Biomedical Research Institute (LA BioMed) [1UL1TR000124]; Harbor-UCLA Medical Center; Endocrine, Metabolism and Nutrition Training Grant [T32 DK007571]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000124] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32DK007571] Funding Source: NIH RePORTER	This study was funded by the National Operating Committee on Standards for Athletic Equipment (NOCSAE) and by Pfizer, Inc., and, in part, by the General Clinical Research Center (MO1 RR00425) and the UCLA Clinical and Translational Science Institute (1UL1TR000124) at Los Angeles Biomedical Research Institute (LA BioMed) and Harbor-UCLA Medical Center, and the Endocrine, Metabolism and Nutrition Training Grant (T32 DK007571). The authors thank Andrew Leung and Mari Lajoie of the Endocrine and Metabolic Research Laboratory for the hormonal analyses and the nurses at the former GCRC (now the Clinical and Translational Research Center) at LA BioMed and Harbor-UCLA for their skillful nursing assistance.	Abs R, 2005, GROWTH HORM IGF RES, V15, P349, DOI 10.1016/j.ghir.2005.06.018; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Akanji AO, 2012, METAB SYNDR RELAT D, V10, P3, DOI 10.1089/met.2011.0083; Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644; Alexander GM, 1998, HORM BEHAV, V33, P85, DOI 10.1006/hbeh.1998.1439; Allan CA, 2010, CURR OPIN ENDOCRINOL, V17, P224, DOI 10.1097/MED.0b013e3283398ee2; Arwert LI, 2005, NEUROENDOCRINOLOGY, V81, P31, DOI 10.1159/000084872; Arwert LI, 2005, HORM BEHAV, V47, P343, DOI 10.1016/j.yhbeh.2004.11.015; Attanasio AF, 2010, J CLIN ENDOCR METAB, V95, P74, DOI 10.1210/jc.2009-1326; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Berg C, 2010, EUR J ENDOCRINOL, V162, P477, DOI 10.1530/EJE-09-0824; Blum WF, 2003, J CLIN ENDOCR METAB, V88, P4158, DOI 10.1210/jc.2002-021792; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bonert VS, 2004, J CLIN ENDOCR METAB, V89, P3397, DOI 10.1210/jc.2003-032213; Brand JS, 2011, INT J EPIDEMIOL, V40, P189, DOI 10.1093/ije/dyq158; Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P3995, DOI 10.1210/jc.2009-0438; Casson IR, 2011, SPORTS HEALTH, V3, P11, DOI 10.1177/1941738110391413; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Conceicao FL, 2003, GROWTH HORM IGF RES, V13, P347, DOI 10.1016/S1096-6374(03)00124-2; Cook DM, 2009, ENDOCR PRACT, V15, P580, DOI 10.4158/EP.15.6.580; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Corona G, 2007, J SEX MED, V4, P1038, DOI 10.1111/j.1743-6109.2007.00529.x; Deijen JB, 1996, PSYCHONEUROENDOCRINO, V21, P313, DOI 10.1016/0306-4530(95)00050-X; Di Somma C, 2010, J ENDOCRINOL INVEST, V33, P171, DOI [10.3275/6519, 10.1007/BF03346577]; Dubourg J, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11182; Feldt-Rasmussen U, 2004, GROWTH HORM IGF RES, V14, pS51, DOI 10.1016/j.ghir.2004.03.013; Giusti M, 1998, EUR J CLIN INVEST, V28, P13; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; HOFFMAN DM, 1994, LANCET, V344, P482, DOI 10.1016/S0140-6736(94)91821-X; Hong JW, 2011, HORM METAB RES, V43, P48, DOI 10.1055/s-0030-1265217; Horn S, 2009, AM J PHYS MED REHAB, V88, P192, DOI 10.1097/PHM.0b013e318198b622; Howell S, 2001, HORM RES, V56, P86, DOI 10.1159/000048142; Ives JC, 2007, J ATHL TRAINING, V42, P431; KARLBERG J, 1995, ACTA OBSTET GYN SCAN, V74, P367, DOI 10.3109/00016349509024430; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Koltowska-Haggstrom M, 2005, HORM RES, V64, P46, DOI 10.1159/000087444; Laaksonen DE, 2005, J CLIN ENDOCR METAB, V90, P712, DOI 10.1210/jc.2004-0970; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mahajan T, 2004, EUR J ENDOCRINOL, V151, P325, DOI 10.1530/eje.0.1510325; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Mukherjee A, 2005, J CLIN ENDOCR METAB, V90, P1542, DOI 10.1210/jc.2004-0832; Oliveira CRP, 2011, ARQ BRAS CARDIOL, V97, P434, DOI 10.1590/S0066-782X2011001400012; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Qoubaitary A, 2005, EXPERT OPIN PHARMACO, V6, P1493, DOI 10.1517/14656566.6.9.1493; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; Rosen RC, 1999, INT J IMPOT RES, V11, P319, DOI 10.1038/sj.ijir.3900472; Scacchi M, 2010, EUR J ENDOCRINOL, V163, P201, DOI 10.1530/EJE-10-0160; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Svensson J, 2004, GROWTH HORM IGF RES, V14, P207, DOI 10.1016/j.ghir.2003.12.001; Tanriverdi F, 2010, PITUITARY, V13, P111, DOI 10.1007/s11102-009-0204-0; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Vahl N, 1997, AM J PHYSIOL-ENDOC M, V272, pE1108; Wang C, 2004, J CLIN ENDOCR METAB, V89, P2085, DOI 10.1210/jc.2003-032006; Wang C, 2011, DIABETES CARE, V34, P1669, DOI 10.2337/dc10-2339; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 2001, SF 36 PHYS MENTAL HL, V2; Wiren L, 1998, CLIN ENDOCRINOL, V48, P613, DOI 10.1046/j.1365-2265.1998.00462.x; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	81	57	57	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1161	1171		10.1089/neu.2013.3212			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500005	24552537	Green Published			2021-06-18	
J	Minassian, A; Geyer, MA; Baker, DG; Nievergelt, CM; O'Connor, DT; Risbrough, VB				Minassian, Arpi; Geyer, Mark A.; Baker, Dewleen G.; Nievergelt, Caroline M.; O'Connor, Daniel T.; Risbrough, Victoria B.		Marine Resiliency Study Team	Heart Rate Variability Characteristics in a Large Group of Active-Duty Marines and Relationship to Posttraumatic Stress	PSYCHOSOMATIC MEDICINE			English	Article						sympathetic nervous system; PTSD; vagal tone; combat; depression; parasympathetic	TRAUMATIC BRAIN-INJURY; CARDIAC VAGAL TONE; PREPULSE INHIBITION; AFGHANISTAN; DISORDER; IRAQ; REST; PHOTOPLETHYSMOGRAPHY; SCHIZOPHRENIA; METAANALYSIS	Objective Heart rate variability (HRV), thought to reflect autonomic nervous system function, is lowered under conditions such as posttraumatic stress disorder (PTSD). The potential confounding effects of traumatic brain injury (TBI) and depression in the relationship between HRV and PTSD have not been elucidated in a large cohort of military service members. Here we describe HRV associations with stress disorder symptoms in a large study of Marines while accounting for well-known covariates of HRV and PTSD including TBI and depression. Methods Four battalions of male active-duty Marines (n = 2430) were assessed 1 to 2 months before a combat deployment. HRV was measured during a 5-minute rest. Depression and PTSD were assessed using the Beck Depression Inventory and Clinician-Administered PTSD Scale, respectively. Results When adjusting for covariates, including TBI, regression analyses showed that lower levels of high-frequency HRV were associated with a diagnosis of PTSD ( = -0.20, p = .035). Depression and PTSD severity were correlated (r = 0.49, p < .001); however, participants with PTSD but relatively low depression scores exhibited reduced high frequency compared with controls (p = .012). Marines with deployment experience (n = 1254) had lower HRV than did those with no experience (p = .033). Conclusions This cross-sectional analysis of a large cohort supports associations between PTSD and reduced HRV when accounting for TBI and depression symptoms. Future postdeployment assessments will be used to determine whether predeployment HRV can predict vulnerability and resilience to the serious psychological and physiological consequences of combat exposure.	[Minassian, Arpi; Geyer, Mark A.; Baker, Dewleen G.; Nievergelt, Caroline M.; Risbrough, Victoria B.] Vet Adm, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92136 USA; [Minassian, Arpi; Geyer, Mark A.; Baker, Dewleen G.; Nievergelt, Caroline M.; Risbrough, Victoria B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [O'Connor, Daniel T.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Geyer, Mark A.; Baker, Dewleen G.; Nievergelt, Caroline M.; Risbrough, Victoria B.] VA San Diego Healthcare Syst, San Diego, CA USA	Minassian, A (corresponding author), Vet Adm, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92136 USA.	aminassian@ucsd.edu	Baker, Dewleen/O-4957-2019; Risbrough, Victoria/X-3344-2019	Baker, Dewleen/0000-0002-1736-9838; Nievergelt, Caroline/0000-0001-5766-8923	VA Health Service Research and Development [SDR 09-0128]; Marine Corps; Navy Bureau of Medicine and Surgery; Center of Excellence for Stress and Mental Health; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH093500]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH093500] Funding Source: NIH RePORTER	This study was funded by VA Health Service Research and Development (Project No. SDR 09-0128; D. G. B., M. A. G., V. B. R.), the Marine Corps (D. G. B., M. A. G., V. B. R.), Navy Bureau of Medicine and Surgery (D. G. B., M. A. G., V. B. R., A. M.), the Center of Excellence for Stress and Mental Health (D. G. B., M. A. G., V. B. R., A. M.), and the National Institutes of Health (MH093500; D. G. B., M. A. G., V. B. R., C.M.N.). The authors have no conflict of interest to declare.	Agorastos A, 2013, STRESS, V16, P300, DOI 10.3109/10253890.2012.751369; AKSELROD S, 1985, AM J PHYSIOL, V249, pH867; Allen J, 2007, PHYSIOL MEAS, V28, pR1, DOI 10.1088/0967-3334/28/3/R01; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Baker DG, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110134; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Berntson GG, 2007, BIOL PSYCHOL, V74, P295, DOI 10.1016/j.biopsycho.2006.08.006; Berntson GG, 1997, PSYCHOPHYSIOLOGY, V34, P623, DOI 10.1111/j.1469-8986.1997.tb02140.x; Bilchick KC, 2006, J CARDIOVASC ELECTR, V17, P691, DOI 10.1111/j.1540-8167.2006.00501.x; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Camm AJ, 1996, EUR HEART J, V17, P354; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carney RM, 2005, PSYCHOSOM MED, V67, pS29, DOI 10.1097/01.psy.0000162254.61556.d5; Chang C, 2013, NEUROIMAGE, V68, P93, DOI 10.1016/j.neuroimage.2012.11.038; Cohen H, 2000, PSYCHIAT RES, V96, P1, DOI 10.1016/S0165-1781(00)00195-5; Cyranowski JM, 2011, PSYCHOSOM MED, V73, P336, DOI 10.1097/PSY.0b013e318213925d; Dinas PC, 2013, INT J CARDIOL, V163, P109, DOI 10.1016/j.ijcard.2011.10.140; Eckberg DL, 1997, CIRCULATION, V96, P3224, DOI 10.1161/01.CIR.96.9.3224; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Falush D, 2003, GENETICS, V164, P1567; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Geyer MA, 2001, PSYCHOPHARMACOLOGY, V156, P117, DOI 10.1007/s002130100811; Henry BL, 2010, J PSYCHIATR RES, V44, P168, DOI 10.1016/j.jpsychires.2009.07.011; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jennings JR, 1998, BIOL PSYCHOL, V47, P227, DOI 10.1016/S0301-0511(97)00028-8; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; King ML, 1997, BRAIN INJURY, V11, P445; KOLLAI M, 1992, BRIT J PSYCHIAT, V161, P831, DOI 10.1192/bjp.161.6.831; Koskinen T, 2009, AUTON NEUROSCI-BASIC, V145, P81, DOI 10.1016/j.autneu.2008.10.011; Lee EAD, 2012, BIOL RES NURS, V14, P412, DOI 10.1177/1099800412454453; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; Malaspina D, 1997, BIOL PSYCHIAT, V41, P612, DOI 10.1016/S0006-3223(96)00161-8; Malik M., 1995, HEART RATE VARIABILI; Mazic S, 2009, GEN PHYSIOL BIOPHYS, V28, P200; Nievergelt Caroline M, 2013, Investig Genet, V4, P13, DOI 10.1186/2041-2223-4-13; Nunan D, 2010, PACE, V33, P1407, DOI 10.1111/j.1540-8159.2010.02841.x; PAGANI M, 1986, CIRC RES, V59, P178, DOI 10.1161/01.RES.59.2.178; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schapkin SA, 2012, INT J BEHAV MED, V19, P359, DOI 10.1007/s12529-011-9181-6; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Selvaraj N., 2008, Journal of Medical Engineering & Technology, V32, P479, DOI 10.1080/03091900701781317; Selvaraj N, 2007, IFMBE PROC, V15, P391; Shah AJ, 2013, BIOL PSYCHIAT, V73, P1103, DOI 10.1016/j.biopsych.2013.01.019; Singh JP, 2001, AUTON NEUROSCI-BASIC, V90, P122, DOI 10.1016/S1566-0702(01)00277-6; Sondermeijer HP, 2002, AM J CARDIOL, V90, P906, DOI 10.1016/S0002-9149(02)02725-X; Tabachnick B.G., 1989, USING MULTIVARIATE S; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Teng XF, 2003, JAP IEEE EMBS AS PAC; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; Thayer JF, 2009, NEUROSCI BIOBEHAV R, V33, P81, DOI 10.1016/j.neubiorev.2008.08.004; Tsuji H, 1996, J AM COLL CARDIOL, V28, P1539, DOI 10.1016/S0735-1097(96)00342-7; Tucker P, 2012, PSYCHOSOM MED, V74, P160, DOI 10.1097/PSY.0b013e318240a801; van Zyl LT, 2008, BIOPSYCHOSOC MED, V2, DOI 10.1186/1751-0759-2-12; Wang XL, 2009, PSYCHOPHYSIOLOGY, V46, P458, DOI 10.1111/j.1469-8986.2009.00793.x; Yeragani VK, 2005, DEPRESS ANXIETY, V21, P130, DOI 10.1002/da.20061; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zhang J, 2007, J MANIP PHYSIOL THER, V30, P374, DOI 10.1016/j.jmpt.2007.04.001	59	57	61	1	33	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0033-3174	1534-7796		PSYCHOSOM MED	Psychosom. Med.	MAY	2014	76	4					292	301		10.1097/PSY.0000000000000056			10	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	AI0AG	WOS:000336507600007	24804881	Green Accepted, Green Published			2021-06-18	
J	Wang, C; Klechikov, AG; Gharibyan, AL; Warmlander, SKTS; Jarvet, J; Zhao, LN; Jia, XE; Shankar, SK; Olofsson, A; Brannstrom, T; Mu, YG; Graslund, A; Morozova-Roche, LA				Wang, Chao; Klechikov, Alexey G.; Gharibyan, Anna L.; Warmlander, Sebastian K. T. S.; Jarvet, Juri; Zhao, Lina; Jia, Xueen; Shankar, S. K.; Olofsson, Anders; Brannstrom, Thomas; Mu, Yuguang; Graslund, Astrid; Morozova-Roche, Ludmilla A.			The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade	ACTA NEUROPATHOLOGICA			English	Article						A beta; Alzheimer's disease; Amyloid; Cytotoxicity; Neuroinflammation; S100A9; Traumatic brain injury	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRAUMATIC BRAIN-INJURY; MICROGLIAL ACTIVATION; BETA-PEPTIDE; PROTEINS; EXPRESSION; MRP14; CYTOTOXICITY; AGGREGATION; NEUROPATHOLOGY	Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with A beta. In traumatic brain injury (TBI) S100A9 itself rapidly forms amyloid plaques, which were reactive with oligomer-specific antibodies, but not with A beta and amyloid fibrillar antibodies. They may serve as precursor-plaques for AD, implicating TBI as an AD risk factor. S100A9 was observed in some hippocampal and cortical neurons in TBI, AD and non-demented aging. In vitro S100A9 forms neurotoxic linear and annular amyloids resembling A beta protofilaments. S100A9 amyloid cytotoxicity and native S100A9 pro-inflammatory signaling can be mitigated by its co-aggregation with A beta, which results in a variety of micron-scale amyloid complexes. NMR and molecular docking demonstrated transient interactions between native S100A9 and A beta. Thus, abundantly present in AD brain pro-inflammatory S100A9, possessing also intrinsic amyloidogenic properties and ability to modulate A beta aggregation, can serve as a link between the AD amyloid and neuroinflammatory cascades and as a prospective therapeutic target.	[Wang, Chao; Klechikov, Alexey G.; Gharibyan, Anna L.; Jia, Xueen; Olofsson, Anders; Morozova-Roche, Ludmilla A.] Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden; [Warmlander, Sebastian K. T. S.; Jarvet, Juri; Graslund, Astrid] Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; [Jarvet, Juri] NICPB, EE-12618 Tallinn, Estonia; [Zhao, Lina; Mu, Yuguang] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore; [Shankar, S. K.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore 560029, Karnataka, India; [Brannstrom, Thomas] Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden	Morozova-Roche, LA (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	ludmilla.morozova-roche@medchem.umu.se	Zhao, Li Na/AAF-1190-2021; Jarvet, Juri/A-7330-2008; Gharibyan, Anna L./B-3401-2010; Klechikov, Alexey/D-5110-2018	Zhao, Li Na/0000-0001-6552-0929; Jarvet, Juri/0000-0002-7863-1887; Gharibyan, Anna L./0000-0001-9070-6215; Morozova-Roche, Ludmilla A./0000-0001-5886-2023	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Insamlingsstiftelsen; Kempe foundation. A. G; Swedish Institute for his fellowship; Magnus Berg-vall Foundation	We are deeply grateful to Rakez Kayed for a gift of A11 and fibrillar antibodies. We thank Thomas Hockenstrom for usage of an Aperio scanscope and Maria Johansson, Kristoffer Brannstrom and Ulla-Stina Spetz for invaluable technical help. L. A. M- R., T. B. and A. G. acknowledge support from the Swedish Medical Research Council, and L. A. M- R. from the Insamlingsstiftelsen and the Kempe foundation. A. G. K. thanks the Swedish Institute for his fellowship. S. W. received funding from the Magnus Berg-vall Foundation. Y. Mu thanks the support of the IDA Cloud Computing Call, NTU Tier 1 grant RG 23/11, Nanyang Analytics NTU HPC Cluster and the A* STAR Computational Resource Centre (http://www.acrc.astar.edu.sg) for the use of its high performance computing facilities.	Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495; Bhaskar K, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-14; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Botelho HM, 2012, J BIOL CHEM, V287, P42233, DOI 10.1074/jbc.M112.396416; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Carvalho SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076629; Cole GM, 2010, CNS NEUROL DISORD-DR, V9, P140, DOI 10.2174/187152710791011991; Cooper JR, 2009, CURR OPIN CELL BIOL, V21, P68, DOI 10.1016/j.ceb.2009.01.005; Danielsson J, 2006, MAGN RESON CHEM, V44, pS114, DOI 10.1002/mrc.1814; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Eremenko E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058218; Fezoui Y, 2000, AMYLOID, V7, P166, DOI 10.3109/13506120009146831; Fritz G, 2010, FEBS J, V277, P4578, DOI 10.1111/j.1742-4658.2010.07887.x; Gandy S, 2013, NEURON, V78, P575, DOI 10.1016/j.neuron.2013.05.007; Glass G, 2009, J HISTOCHEM CYTOCHEM, V57, P899, DOI 10.1369/jhc.2009.953612; Ha TY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008840; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Itou H, 2002, J MOL BIOL, V316, P265, DOI 10.1006/jmbi.2001.5340; Jan A, 2012, METHODS MOL BIOL, V849, P227, DOI 10.1007/978-1-61779-551-0_16; Jia XE, 2011, J MOL BIOL, V414, P699, DOI 10.1016/j.jmb.2011.09.044; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Krebs MRH, 2004, PROTEIN SCI, V13, P1933, DOI 10.1110/ps.04707004; Kummer MP, 2012, J NEUROSCI, V32, P17824, DOI 10.1523/JNEUROSCI.1504-12.2012; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Park KM, 2008, J BIOL CHEM, V283, P33069, DOI 10.1074/jbc.M802209200; Pellarin R, 2010, J AM CHEM SOC, V132, P14960, DOI 10.1021/ja106044u; Pirici D, 2009, J HISTOCHEM CYTOCHEM, V57, P567, DOI 10.1369/jhc.2009.953240; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Rogers J, 2001, NEUROCHEM INT, V39, P333, DOI 10.1016/S0197-0186(01)00040-7; Ryu MJ, 2012, J BIOL CHEM, V287, P22948, DOI 10.1074/jbc.M112.357772; Schlachetzki JCM, 2009, CURR ALZHEIMER RES, V6, P554, DOI 10.2174/156720509790147179; Schluesener HJ, 1998, ACTA NEUROPATHOL, V96, P575, DOI 10.1007/s004010050938; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Shepherd CE, 2006, NEUROBIOL AGING, V27, P1554, DOI 10.1016/j.neurobiolaging.2005.09.033; Swindell WR, 2013, SCI REP-UK, V3, DOI 10.1038/srep01215; Vivekanandan S, 2011, BIOCHEM BIOPH RES CO, V411, P312, DOI 10.1016/j.bbrc.2011.06.133; Vogl T, 2006, BBA-MOL CELL RES, V1763, P1298, DOI 10.1016/j.bbamcr.2006.08.028; Vogl T, 2012, INT J MOL SCI, V13, P2893, DOI 10.3390/ijms13032893; Wahlstrom A, 2008, FEBS J, V275, P5117, DOI 10.1111/j.1742-4658.2008.06643.x; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Warmlander S, 2013, CHEMBIOCHEM, V14, P1692, DOI 10.1002/cbic.201300262; Yanamandra K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005562; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032953; Zhao LN, 2013, RSC ADV, V3, P24081, DOI 10.1039/c3ra43665a	48	57	59	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	APR	2014	127	4					507	522		10.1007/s00401-013-1208-4			16	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	AD0XJ	WOS:000332957400004	24240735	Green Published, Other Gold			2021-06-18	
J	Gutierrez, GM; Conte, C; Lightbourne, K				Gutierrez, Gregory M.; Conte, Catherine; Lightbourne, Kristian			The Relationship Between Impact Force, Neck Strength, and Neurocognitive Performance in Soccer Heading in Adolescent Females	PEDIATRIC EXERCISE SCIENCE			English	Article						adolescent; strength; exercise training; gender; sport medicine; biomechanics	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; SEGMENT DYNAMIC STABILIZATION; RISK COMPENSATION; CONCUSSION; PLAYERS; SPORT; ACCELERATION; BIOMECHANICS; PREVENTION	Head impacts are common in contact sports, but only recently has there been a rising awareness of the effects of subconcussive impacts in adolescent athletes. A better understanding of how to attenuate head impacts is needed and therefore, this study investigated the relationship between neck strength, impact, and neurocognitive function in an acute bout of soccer heading in a sample of female high school varsity soccer players. Seventeen participants completed the ImPACT neurocognitive test and had their isometric neck strength tested (flexion, extension, and bilateral flexion) before heading drills. Each participant was outfitted with custom headgear with timing switches and a three-dimensional accelerometer affixed to the back of the head, which allowed for measurement of impact during heading. Participants performed a series of 15 directional headers, including 5 forward, 5 left and 5 right headers in a random order, then completed the ImPACT test again. Neurocognitive tests revealed no significant changes following heading. However, there were statistically significant, moderate, negative correlations (r = -0.500:-0.757, p < .05) between neck strength and resultant header acceleration, indicating that those with weaker necks sustained greater impacts. This suggests neck strengthening may be an important component of any head injury prevention/reduction program.	[Gutierrez, Gregory M.] NYU, Dept Phys Therapy, New York, NY 10003 USA; [Conte, Catherine] Ossining High Sch, Sci Res Program, Ossining, NY USA; [Lightbourne, Kristian] NYU, Polytech Inst, Dept Technol Management & Innovat, Brooklyn, NY USA	Gutierrez, GM (corresponding author), NYU, Dept Phys Therapy, New York, NY 10003 USA.			Gutierrez, Gregory/0000-0002-4261-8066			Broglio SP, 2012, CURR OPIN PEDIATR, V24, P702, DOI 10.1097/MOP.0b013e3283595616; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; Dezman ZDW, 2013, SPORTS HEALTH, V5, P320, DOI 10.1177/1941738113480935; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Mansell J, 2005, J ATHL TRAINING, V40, P310; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mehnert Michael J, 2005, Pain Physician, V8, P391; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Phillips RO, 2011, RISK ANAL, V31, P1187, DOI 10.1111/j.1539-6924.2011.01589.x; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Reilly T., 1976, J HUMAN MOVEMENT STU, V2, P87; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0	32	57	57	1	57	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0899-8493	1543-2920		PEDIATR EXERC SCI	Pediatr. Exerc. Sci.	FEB	2014	26	1					33	40		10.1123/pes.2013-0102			8	Pediatrics; Physiology; Sport Sciences	Pediatrics; Physiology; Sport Sciences	AE7BK	WOS:000334151500005	24091298				2021-06-18	
J	Wali, B; Ishrat, T; Won, S; Stein, DG; Sayeed, I				Wali, Bushra; Ishrat, Tauheed; Won, Soonmi; Stein, Donald G.; Sayeed, Iqbal			Progesterone in experimental permanent stroke: a dose-response and therapeutic time-window study	BRAIN			English	Article						dose response; functional recovery; progesterone; stroke; therapeutic time window	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; VITAMIN-D HORMONE; COMBINATION TREATMENT; ISCHEMIC-STROKE; FOCAL ISCHEMIA; INFARCT VOLUME; HEART-DISEASE; ALLOPREGNANOLONE; NEUROPROTECTION	Currently, the only approved treatment for ischaemic stroke is tissue plasminogen activator, a clot-buster. This treatment can have dangerous consequences if not given within the first 4 h after stroke. Our group and others have shown progesterone to be beneficial in preclinical studies of stroke, but a progesterone dose-response and time-window study is lacking. We tested male Sprague-Dawley rats (12 months old) with permanent middle cerebral artery occlusion or sham operations on multiple measures of sensory, motor and cognitive performance. For the dose-response study, animals received intraperitoneal injections of progesterone (8, 16 or 32 mg/kg) at 1 h post-occlusion, and subcutaneous injections at 6 h and then once every 24 h for 7 days. For the time-window study, the optimal dose of progesterone was given starting at 3, 6 or 24 h post-stroke. Behavioural recovery was evaluated at repeated intervals. Rats were killed at 22 days post-stroke and brains extracted for evaluation of infarct volume. Both 8 and 16 mg/kg doses of progesterone produced attenuation of infarct volume compared with the placebo, and improved functional outcomes up to 3 weeks after stroke on locomotor activity, grip strength, sensory neglect, gait impairment, motor coordination and spatial navigation tests. In the time-window study, the progesterone group exhibited substantial neuroprotection as late as 6 h after stroke onset. Compared with placebo, progesterone showed a significant reduction in infarct size with 3- and 6-h delays. Moderate doses (8 and 16 mg/kg) of progesterone reduced infarct size and improved functional deficits in our clinically relevant model of stroke. The 8 mg/kg dose was optimal in improving motor, sensory and memory function, and this effect was observed over a large therapeutic time window. Progesterone shows promise as a potential therapeutic agent and should be examined for safety and efficacy in a clinical trial for ischaemic stroke.	[Wali, Bushra; Ishrat, Tauheed; Won, Soonmi; Stein, Donald G.; Sayeed, Iqbal] Emory Univ, Brain Res Lab, Dept Emergency Med, Atlanta, GA 30322 USA	Sayeed, I (corresponding author), Emory Univ, Brain Res Lab, Dept Emergency Med, 1365B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	isayeed@emory.edu	Stein, Donald/AAJ-5139-2020		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UO1 NS062676]; American Heart AssociationAmerican Heart Association [11SDG5430002]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS062676] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grants UO1 NS062676 to D.G.S. and American Heart Association grant 11SDG5430002 to I.S.	Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Asbury ET, 1998, BEHAV BRAIN RES, V97, P99, DOI 10.1016/S0166-4328(98)00031-X; Atif F, 2013, NEUROPHARMACOLOGY, V67, P78, DOI 10.1016/j.neuropharm.2012.10.004; BETZ AL, 1990, STROKE, V21, P1199, DOI 10.1161/01.STR.21.8.1199; Bitran D, 1996, PSYCHOPHARMACOLOGY, V125, P65, DOI 10.1007/BF02247394; BITRAN D, 1993, PHARMACOL BIOCHEM BE, V45, P423, DOI 10.1016/0091-3057(93)90260-Z; BITRAN D, 1995, J NEUROENDOCRINOL, V7, P171, DOI 10.1111/j.1365-2826.1995.tb00744.x; BIXO M, 1990, PSYCHONEUROENDOCRINO, V15, P159, DOI 10.1016/0306-4530(90)90025-5; Cekic M, 2011, NEUROBIOL AGING, V32, P864, DOI 10.1016/j.neurobiolaging.2009.04.017; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Chen JL, 1999, J NEUROL SCI, V171, P24, DOI 10.1016/S0022-510X(99)00247-6; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; DELCKER A, 1993, EUR ARCH PSY CLIN N, V242, P179, DOI 10.1007/BF02189960; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Durukan A, 2007, PHARMACOL BIOCHEM BE, V87, P179, DOI 10.1016/j.pbb.2007.04.015; Encarnacion A, 2011, J NEUROSCI METH, V196, P247, DOI 10.1016/j.jneumeth.2011.01.010; Fisher M, 2005, STROKE, V36, P1808, DOI 10.1161/01.STR.0000173403.60553.27; Fisher M, 2003, STROKE, V34, P1539, DOI 10.1161/01.STR.0000072983.64326.53; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gibson CL, 2011, BRAIN, V134, P2125, DOI 10.1093/brain/awr132; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Hankey GJ, 1999, ARCH NEUROL-CHICAGO, V56, P748, DOI 10.1001/archneur.56.6.748; Hetze S, 2012, J NEUROSCI METH, V206, P7, DOI 10.1016/j.jneumeth.2012.02.001; Hua F, 2012, HORM BEHAV, V61, P642, DOI 10.1016/j.yhbeh.2012.02.017; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Ishrat T, 2012, NEUROSCIENCE, V210, P442, DOI 10.1016/j.neuroscience.2012.03.008; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; Kumon Y, 2000, J NEUROSURG, V92, P848, DOI 10.3171/jns.2000.92.5.0848; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Muntner P, 2006, AM J EPIDEMIOL, V163, P913, DOI 10.1093/aje/kwj124; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Parkkinen S, 2013, STROKE RES TREAT, V2013, DOI 10.1155/2013/410972; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Reddy DS, 1997, BRAIN RES, V752, P61, DOI 10.1016/S0006-8993(96)01447-3; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Savitz SI, 2011, STROKE, V42, P825, DOI 10.1161/STROKEAHA.110.601914; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; VanLandingham JW, 2008, J CEREBR BLOOD F MET, V28, P1786, DOI 10.1038/jcbfm.2008.73; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang JP, 2010, BEHAV BRAIN RES, V209, P119, DOI 10.1016/j.bbr.2010.01.026; Wang YG, 2008, J CEREBR BLOOD F MET, V28, P1936, DOI 10.1038/jcbfm.2008.82; Won S, 2013, STROKE, V44; Wong R, 2013, J NEUROENDO IN PRESS; Wong R, 2013, J CEREBR BLOOD F MET, V33, P1362, DOI 10.1038/jcbfm.2013.120; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; Yousuf S, 2013, NEUROSCIENCE, V239, P92, DOI 10.1016/j.neuroscience.2012.10.017	73	57	58	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2014	137		2				486	502		10.1093/brain/awt319			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AA7QB	WOS:000331290900017	24374329	Green Published, Bronze			2021-06-18	
J	Fischer, BL; Parsons, M; Durgerian, S; Reece, C; Mourany, L; Lowe, MJ; Beall, EB; Koenig, KA; Jones, SE; Newsome, MR; Scheibel, RS; Wilde, EA; Troyanskaya, M; Merkley, TL; Walker, M; Levin, HS; Rao, SM				Fischer, Barbara L.; Parsons, Michael; Durgerian, Sally; Reece, Christine; Mourany, Lyla; Lowe, Mark J.; Beall, Erik B.; Koenig, Katherine A.; Jones, Stephen E.; Newsome, Mary R.; Scheibel, Randall S.; Wilde, Elisabeth A.; Troyanskaya, Maya; Merkley, Tricia L.; Walker, Mark; Levin, Harvey S.; Rao, Stephen M.			Neural Activation during Response Inhibition Differentiates Blast from Mechanical Causes of Mild to Moderate Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast-related TBI; brain activation; fMRI; inhibitory control; mechanical TBI; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; DEFAULT MODE; NEUROPSYCHOLOGICAL OUTCOMES; NETWORK; IRAQ; AFGHANISTAN; COMPLAINTS; PRESSURE; VETERANS; EXPOSURE	Military personnel involved in Operations Enduring Freedom and Iraqi Freedom (OEF/OIF) commonly experience blast-induced mild to moderate traumatic brain injury (TBI). In this study, we used task-activated functional MRI (fMRI) to determine if blast-related TBI has a differential impact on brain activation in comparison with TBI caused primarily by mechanical forces in civilian settings. Four groups participated: (1) blast-related military TBI (milTBI; n=21); (2) military controls (milCON; n=22); (3) non-blast civilian TBI (civTBI; n=21); and (4) civilian controls (civCON; n=23) with orthopedic injuries. Mild to moderate TBI (MTBI) occurred 1 to 6 years before enrollment. Participants completed the Stop Signal Task (SST), a measure of inhibitory control, while undergoing fMRI. Brain activation was evaluated with 2 (mil, civ)x2 (TBI, CON) analyses of variance, corrected for multiple comparisons. During correct inhibitions, fMRI activation was lower in the TBI than CON subjects in regions commonly associated with inhibitory control and the default mode network. In contrast, inhibitory failures showed significant interaction effects in the bilateral inferior temporal, left superior temporal, caudate, and cerebellar regions. Specifically, the milTBI group demonstrated more activation than the milCON group when failing to inhibit; in contrast, the civTBI group exhibited less activation than the civCON group. Covariance analyses controlling for the effects of education and self-reported psychological symptoms did not alter the brain activation findings. These results indicate that the chronic effects of TBI are associated with abnormal brain activation during successful response inhibition. During failed inhibition, the pattern of activation distinguished military from civilian TBI, suggesting that blast-related TBI has a unique effect on brain function that can be distinguished from TBI resulting from mechanical forces associated with sports or motor vehicle accidents. The implications of these findings for diagnosis and treatment of TBI are discussed.	[Fischer, Barbara L.] Wm S Middleton Mem Vet Affairs Hosp, GRECC, Madison, WI USA; [Parsons, Michael; Reece, Christine; Mourany, Lyla; Rao, Stephen M.] Cleveland Clin, Neurol Inst, Cleveland, OH 44195 USA; [Durgerian, Sally] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Lowe, Mark J.; Beall, Erik B.; Koenig, Katherine A.; Jones, Stephen E.] Cleveland Clin, Imaging Inst, Cleveland, OH 44195 USA; [Newsome, Mary R.; Scheibel, Randall S.; Wilde, Elisabeth A.; Troyanskaya, Maya; Merkley, Tricia L.; Levin, Harvey S.] Vet Affairs Med Ctr, Houston, TX 77030 USA; [Newsome, Mary R.; Scheibel, Randall S.; Wilde, Elisabeth A.; Troyanskaya, Maya; Merkley, Tricia L.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Walker, Mark] Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA; [Walker, Mark] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA	Rao, SM (corresponding author), Cleveland Clin, Schey Ctr Cognit Neuroimaging, Neurol Inst, 9500 Euclid Ave U10, Cleveland, OH 44195 USA.	raos2@ccf.org	Merkley, Tricia/AAN-2989-2020; Koenig, Katherine/K-1564-2019; Rao, Stephen M/A-2460-2010	Rao, Stephen M/0000-0002-6463-7460; Durgerian, Sally/0000-0003-3931-9679; Merkley, Tricia/0000-0002-0897-8391; Koenig, Katherine/0000-0002-1504-7130	U.S. Department of DefenseUnited States Department of Defense [W81XWH-08-2-0124, W81XWH-10-1-0609]; Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development Project [B6812C]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER	This study was supported by grants from the U.S. Department of Defense (W81XWH-08-2-0124, W81XWH-10-1-0609).; Supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Rehabilitation Research and Development Project #B6812C Traumatic Brain Injury Center of Excellence.	[Anonymous], 1944, ARM IND TEST GEN AB; Aron AR, 2006, J NEUROSCI, V26, P2424, DOI 10.1523/JNEUROSCI.4682-05.2006; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Binder JR, 2011, TRENDS COGN SCI, V15, P527, DOI 10.1016/j.tics.2011.10.001; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Brunetti M, 2010, NEUROSCIENCE, V168, P670, DOI 10.1016/j.neuroscience.2010.04.024; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Delis DC, 2000, CALIFORNIA VERBAL LE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dimoska-Di Marco A, 2011, J CLIN EXP NEUROPSYC, V33, P471, DOI 10.1080/13803395.2010.533158; Dockree PM, 2011, INT J PSYCHOPHYSIOL, V82, P53, DOI 10.1016/j.ijpsycho.2011.01.004; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Floden D, 2006, J COGNITIVE NEUROSCI, V18, P1843, DOI 10.1162/jocn.2006.18.11.1843; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Green P., 2005, WORD MEMORY TEST WIN; Hammeke T. A., 2003, NEUROPSYCHIATRY, P1149; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Kuo JR, 2012, ARCH GEN PSYCHIAT, V69, P1080, DOI 10.1001/archgenpsychiatry.2012.73; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Liberzon I, 1999, BIOL PSYCHIAT, V45, P817, DOI 10.1016/S0006-3223(98)00246-7; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Matthews S, 2011, PSYCHIAT RES-NEUROIM, V191, P76, DOI 10.1016/j.pscychresns.2010.09.013; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Minamoto T, 2010, BRAIN RES, V1335, P63, DOI 10.1016/j.brainres.2010.03.088; O'Connor DA, 2012, NEUROIMAGE, V62, P1841, DOI 10.1016/j.neuroimage.2012.05.040; Packard MG, 2002, ANNU REV NEUROSCI, V25, P563, DOI 10.1146/annurev.neuro.25.112701.142937; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smith A., 1968, LEARNING DISORDERS, P83; Spitzer RL, 1990, STRUCTURED CLIN INTE; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Stoodley CJ, 2010, CORTEX, V46, P831, DOI 10.1016/j.cortex.2009.11.008; Swick D, 2012, J INT NEUROPSYCH SOC, V18, P917, DOI 10.1017/S1355617712000458; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weathers F.W., 1993, 9 ANN C ISTSS SAN AN; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; Zhang S, 2012, HUM BRAIN MAPP, V33, P89, DOI 10.1002/hbm.21197	64	57	57	0	27	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					169	179		10.1089/neu.2013.2877			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600003	24020449	Green Published			2021-06-18	
J	Carvalho, AF; Miskowiak, KK; Hyphantis, TN; Kohler, CA; Alves, GS; Bortolato, B; Sales, PMG; Machado-Vieira, R; Berk, M; McIntyre, RS				Carvalho, Andre F.; Miskowiak, Kamilla K.; Hyphantis, Thomas N.; Koehler, Cristiano A.; Alves, Gilberto S.; Bortolato, Beatrice; Sales, Paulo Marcelo G.; Machado-Vieira, Rodrigo; Berk, Michael; McIntyre, Roger S.			Cognitive Dysfunction in Depression - Pathophysiology and Novel Targets	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Brain-derived neurotrophic factor; cognition; cytokine; erythropoietin; inflammation; major depressive disorder; novel targets; oxidative stress; S-adenosyl-L-methionine	NITRIC-OXIDE SYNTHASE; TREATMENT-RESISTANT DEPRESSION; ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; MAJOR DEPRESSION; OXIDATIVE STRESS; DOUBLE-BLIND; N-ACETYLCYSTEINE; HIPPOCAMPAL VOLUME; GLUCOCORTICOID-RECEPTOR	Major depressive disorder (MDD) is associated with cognitive dysfunction encompassing several domains, including memory, executive function, processing speed and attention. Cognitive deficits persist in a significant proportion of patients even in remission, compromising psychosocial functioning and workforce performance. While monoaminergic antidepressants may improve cognitive performance in MDD, most antidepressants have limited clinical efficacy. The overarching aims of this review were: (1) to synthesize extant literature on putative biological pathways related to cognitive dysfunction in MDD and (2) to review novel neurotherapeutic targets for cognitive enhancement in MDD. We found that reciprocal and overlapping biological pathways may contribute to cognitive dysfunction in MDD, including an hyperactive hypothalamic-pituitary-adrenal axis, an increase in oxidative and nitrosative stress, inflammation (e.g., enhanced production of pro-inflammatory cytokines), mitochondrial dysfunction, increased apoptosis as well as a diminished neurotrophic support. Several promising neurotherapeutic targets were identified such as minocycline, statins, anti-inflammatory compounds, N-acetylcysteine, omega-3 poliunsaturated fatty acids, erythropoietin, thiazolidinediones, glucagon-like peptide-1 analogues, S-adenosyl-l-methionine (SAMe), cocoa flavonols, creatine monohydrate and lithium. Erythropoietin and SAMe had pro-cognitive effects in randomized controlled trials (RCT) involving MDD patients. Despite having preclinical and/or preliminary evidences from trials suggesting possible efficacy as novel cognitive enhancing agents for MDD, no RCT to date was performed for most of the other therapeutic targets reviewed herein. In conclusion, multiple biological pathways are involved in cognitive dysfunction in MDD. RCTs testing genuinely novel pro-cognitive compounds for MDD are warranted.	[Carvalho, Andre F.; Alves, Gilberto S.; Sales, Paulo Marcelo G.] Univ Fed Ceara, Fac Med, Translat Psychiat Res Grp, BR-60430040 Fortaleza, Ceara, Brazil; [Miskowiak, Kamilla K.] Rigshosp, Copenhagen Univ Hosp, Psychiat Ctr Copenhagen, DK-2100 Copenhagen, Denmark; [Hyphantis, Thomas N.] Univ Ioaninna, Sch Med, Dept Psychiat, Ioaninna, Greece; [Koehler, Cristiano A.] Fed Univ Rio Grande Norte UFRN, Brain Inst ICe, Memory Res Lab, Natal, RN, Brazil; [Bortolato, Beatrice] Univ Padua, Dept Neurosci, Padua, Italy; [Machado-Vieira, Rodrigo] NIMH, Expt Therapeut & Pathophysiol Branch, Div Intramural Res Program, NIH, Bethesda, MD 20892 USA; [Berk, Michael] Deakin Univ, Sch Med, IMPACT Strateg Res Ctr, Geelong, Vic 3217, Australia; [Berk, Michael] Barwon Hlth, Geelong, Vic, Australia; [Berk, Michael] Univ Melbourne, Dept Psychiat, Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [Berk, Michael] Univ Melbourne, Orygen Youth Hlth Res Ctr, Parkville, Vic 3052, Australia; [McIntyre, Roger S.] Univ Toronto, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada; [McIntyre, Roger S.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [McIntyre, Roger S.] Univ Toronto, Dept Pharmacol, Toronto, ON, Canada	Carvalho, AF (corresponding author), Univ Fed Ceara, Fac Med, Dept Clin Med, Rua Prof Costa Mendes,1608,4o Andar, BR-60430040 Fortaleza, Ceara, Brazil.	andrefc7@terra.com.br	Berk, Michael/M-3585-2019; Berk, Michael/M-7891-2013; Machado-Vieira, Rodrigo/D-8293-2012; McIntyre, Roger/AAU-1000-2020; Kohler, Cristiano/A-6381-2013	Berk, Michael/0000-0002-5554-6946; Berk, Michael/0000-0002-5554-6946; Machado-Vieira, Rodrigo/0000-0002-4830-1190; McIntyre, Roger/0000-0003-4733-2523; Kohler, Cristiano/0000-0003-0503-5264; Miskowiak, Kamilla/0000-0003-2572-1384	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Level II)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF); CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	AFC is supported by a research fellowship award from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; Level II). CAK is supported by a postdoctoral fellowship from CAPES.	Adcock KH, 2002, DEV NEUROSCI-BASEL, V24, P382, DOI 10.1159/000069043; Ahuja M, 2008, TOXICOLOGY, V244, P111, DOI 10.1016/j.tox.2007.11.003; Aizenstein HJ, 2009, AM J GERIAT PSYCHIAT, V17, P30, DOI 10.1097/JGP.0b013e31817b60af; Akpinar A, 2013, PROG NEURO-PSYCHOPH, V46, P120, DOI 10.1016/j.pnpbp.2013.07.003; Aktan F, 2004, LIFE SCI, V75, P639, DOI 10.1016/j.lfs.2003.10.042; Alonso J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065858; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, V5th; Anacker C, 2011, MOL PSYCHIATR, V16, P738, DOI 10.1038/mp.2011.26; Anderson G, 2014, CURR PHARM DESIGN, V20, P3812, DOI 10.2174/13816128113196660738; Arnone D, 2012, EUR NEUROPSYCHOPHARM, V22, P1, DOI 10.1016/j.euroneuro.2011.05.003; Bayramgurler D, 2013, PHYSIOL BEHAV, V119, P145, DOI 10.1016/j.physbeh.2013.06.010; Bergman J, 2013, CLIN NEUROPHARMACOL, V36, P73, DOI 10.1097/WNF.0b013e31828ef969; Berk M, 2014, J CLIN PSYCHIAT, V75, P628, DOI 10.4088/JCP.13m08454; Berk M, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-200; Berk M, 2013, TRENDS PHARMACOL SCI, V34, P167, DOI 10.1016/j.tips.2013.01.001; Bhagwagar Z, 2008, INT J NEUROPSYCHOPH, V11, P255, DOI 10.1017/S1461145707007924; Bhagwagar Z, 2006, AM J PSYCHIAT, V163, P1580, DOI 10.1176/appi.ajp.163.9.1580; Bhattacharya P, 2014, LIFE SCI, V100, P97, DOI 10.1016/j.lfs.2014.01.085; Bonora M, 2014, CELL DEATH DIFFER, V21, P1198, DOI 10.1038/cdd.2014.35; Bora E, 2013, PSYCHOL MED, V43, P2017, DOI 10.1017/S0033291712002085; Bora E, 2012, J AFFECT DISORDERS, V138, P9, DOI 10.1016/j.jad.2011.03.049; Borre Y, 2012, EUR J PHARMACOL, V697, P59, DOI 10.1016/j.ejphar.2012.09.005; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Bufalino C, 2013, BRAIN BEHAV IMMUN, V31, P31, DOI 10.1016/j.bbi.2012.04.009; Buist-Bouwman MA, 2008, ACTA PSYCHIAT SCAND, V118, P451, DOI 10.1111/j.1600-0447.2008.01285.x; Bukh Jens Drachmann, 2011, Clin Pract Epidemiol Ment Health, V7, P140, DOI 10.2174/1745017901107010140; Cao L, 2012, NEUROSCIENCE, V220, P85, DOI 10.1016/j.neuroscience.2012.06.044; Carloni S, 2014, J PINEAL RES, V57, P192, DOI 10.1111/jpi.12156; Carvalho AF, 2014, PSYCHOTHER PSYCHOSOM, V83, P70, DOI 10.1159/000357500; Carvalho LA, 2008, STRESS, V11, P411, DOI 10.1080/10253890701850759; Caspi A, 2010, AM J PSYCHIAT, V167, P509, DOI 10.1176/appi.ajp.2010.09101452; Cassano P, 2006, PHARMACOGENOMICS J, V6, P381, DOI 10.1038/sj.tpj.6500385; Catena-Dell'Osso M, 2011, CURR MED CHEM, V18, P245, DOI 10.2174/092986711794088353; Celik C, 2010, PROG NEURO-PSYCHOPH, V34, P372, DOI 10.1016/j.pnpbp.2010.01.002; Chakravarty S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063302; Chen FH, 2013, SYNAPSE, V67, P127, DOI 10.1002/syn.21622; Christensen MV, 2006, NORD J PSYCHIAT, V60, P79, DOI 10.1080/08039480600600300; Christian KM, 2014, ANNU REV NEUROSCI, V37, P243, DOI 10.1146/annurev-neuro-071013-014134; Cimino A, 2005, NEUROTOXICOLOGY, V26, P929, DOI 10.1016/j.neuro.2005.03.009; Cipriani A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3646; Cumurcu BE, 2009, PSYCHIAT CLIN NEUROS, V63, P639, DOI 10.1111/j.1440-1819.2009.02004.x; Dantzer R, 2011, PSYCHONEUROENDOCRINO, V36, P426, DOI 10.1016/j.psyneuen.2010.09.012; Dantzer R, 2009, IMMUNOL ALLERGY CLIN, V29, P247, DOI 10.1016/j.iac.2009.02.002; de Quervain DJF, 2000, NAT NEUROSCI, V3, P313, DOI 10.1038/73873; Dean OM, 2012, PSYCHIAT CLIN NEUROS, V66, P514, DOI 10.1111/j.1440-1819.2012.02392.x; Della FP, 2013, METAB BRAIN DIS, V28, P93, DOI 10.1007/s11011-012-9375-x; Dias-Ferreira E, 2009, SCIENCE, V325, P621, DOI 10.1126/science.1171203; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI 10.1517/14728220802517901 ; Dong SZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031211; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Dunn AJ, 2005, NEUROSCI BIOBEHAV R, V29, P891, DOI 10.1016/j.neubiorev.2005.03.023; Elenkov IJ, 2006, NEUROIMMUNOMODULAT, V13, P257, DOI 10.1159/000104853; Fanous AH, 2004, NEUROTOX RES, V6, P43, DOI 10.1007/BF03033295; Faridhosseini F, 2014, HUM PSYCHOPHARM CLIN, V29, P216, DOI 10.1002/hup.2401; Fava M, 2012, J PSYCHIATR RES, V46, P1553, DOI 10.1016/j.jpsychires.2012.08.013; Mello BSF, 2013, J PSYCHIATR RES, V47, P1521, DOI 10.1016/j.jpsychires.2013.06.008; Flint J, 2014, NEURON, V81, P484, DOI 10.1016/j.neuron.2014.01.027; Fossati P, 2002, J AFFECT DISORDERS, V68, P261, DOI 10.1016/S0165-0327(00)00362-1; Galecki P, 2007, PSYCHIATR POL, V41, P615; Galecki P, 2014, PSYCHIAT RES, V215, P488, DOI 10.1016/j.psychres.2013.12.017; Galecki P, 2012, J AFFECT DISORDERS, V138, P360, DOI 10.1016/j.jad.2012.01.016; Galecki P, 2009, HUM PSYCHOPHARM CLIN, V24, P277, DOI 10.1002/hup.1014; Gao SF, 2014, PSYCHONEUROENDOCRINO, V47, P136, DOI 10.1016/j.psyneuen.2014.05.009; Gao Y, 2013, INT J GERIATR PSYCH, V28, P441, DOI 10.1002/gps.3845; Gardner A, 2003, J AFFECT DISORDERS, V76, P55, DOI 10.1016/S0165-0327(02)00067-8; Ghanizadeh A, 2013, DEPRESS ANXIETY, V30, P1084, DOI 10.1002/da.22195; Gold PW, 2013, MOL PSYCHIATR, V18, P154, DOI 10.1038/mp.2012.167; Goncalves JF, 2010, CHEM-BIOL INTERACT, V186, P53, DOI 10.1016/j.cbi.2010.04.011; Gos T, 2013, J PSYCHIATR RES, V47, P1694, DOI 10.1016/j.jpsychires.2013.07.005; Gould E, 1997, J NEUROSCI, V17, P2492; Grosso G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096905; Hajek T, 2012, J PSYCHIATR NEUROSCI, V37, P333, DOI 10.1503/jpn.110143; Hasselbalch BJ, 2012, NEUROPSYCHOLOGY, V26, P642, DOI 10.1037/a0029301; Hasselbalch BJ, 2011, J AFFECT DISORDERS, V134, P20, DOI 10.1016/j.jad.2010.11.011; Heiser P, 2008, EUR NEUROPSYCHOPHARM, V18, P860, DOI 10.1016/j.euroneuro.2008.07.003; Herken H, 2007, ARCH MED RES, V38, P247, DOI 10.1016/j.arcmed.2006.10.005; Herrera-Guzman I, 2010, J AFFECT DISORDERS, V123, P341, DOI 10.1016/j.jad.2009.10.009; Herrera-Guzman I, 2009, J PSYCHIATR RES, V43, P855, DOI 10.1016/j.jpsychires.2008.10.015; Hinwood M, 2013, CEREB CORTEX, V23, P1784, DOI 10.1093/cercor/bhs151; Hock C, 2000, MOL PSYCHIATR, V5, P510, DOI 10.1038/sj.mp.4000743; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7; Homberg JR, 2014, NEUROSCI BIOBEHAV R, V43, P35, DOI 10.1016/j.neubiorev.2014.03.012; Hurley LL, 2013, NEUROTOX RES, V23, P131, DOI 10.1007/s12640-012-9348-1; Ikenouchi-Sugita A, 2009, PROG NEURO-PSYCHOPH, V33, P1451, DOI 10.1016/j.pnpbp.2009.07.028; Iseme RA, 2014, NEUROSCI BIOBEHAV R, V40, P62, DOI 10.1016/j.neubiorev.2014.01.008; Jaeger J, 2006, PSYCHIAT RES, V145, P39, DOI 10.1016/j.psychres.2005.11.011; Jang SW, 2010, P NATL ACAD SCI USA, V107, P3876, DOI 10.1073/pnas.0912531107; Juan WS, 2014, J PINEAL RES; Juruena MF, 2014, EPILEPSY BEHAV, V38, P148, DOI 10.1016/j.yebeh.2013.10.020; Keilp JG, 2001, AM J PSYCHIAT, V158, P735, DOI 10.1176/appi.ajp.158.5.735; Kendler KS, 2014, AM J PSYCHIAT, V171, P426, DOI 10.1176/appi.ajp.2013.13101375; Kernt M, 2010, CLIN OPHTHALMOL, V4, P591; Kessler RC, 2013, ANNU REV PUBL HEALTH, V34, P119, DOI 10.1146/annurev-publhealth-031912-114409; Khairova RA, 2009, INT J NEUROPSYCHOPH, V12, P561, DOI 10.1017/S1461145709009924; Kilic FS, 2012, NEUROSCIENCES, V17, P39; Kim SW, 2010, NEUROTOX RES, V17, P39, DOI 10.1007/s12640-009-9075-4; Kim SS, 2004, ARCH PHARM RES, V27, P314, DOI 10.1007/BF02980066; Klengel T, 2013, NAT NEUROSCI, V16, P33, DOI 10.1038/nn.3275; Krab LC, 2008, JAMA-J AM MED ASSOC, V300, P287, DOI 10.1001/jama.300.3.287; Kreisel T, 2014, MOL PSYCHIATR, V19, P699, DOI 10.1038/mp.2013.155; Krishnan R, 2007, BRIT J DERMATOL, V157, P1275, DOI 10.1111/j.1365-2133.2007.08205.x; Ladd CO, 2004, BIOL PSYCHIAT, V55, P367, DOI 10.1016/j.biopsych.2003.10.007; Lahr Denise, 2007, Cogn Neuropsychiatry, V12, P25, DOI 10.1080/13546800600714791; Lampe IK, 2004, PSYCHIAT RES, V125, P73, DOI 10.1016/j.psychres.2003.12.004; Landro NI, 2001, NEUROPSY NEUROPSY BE, V14, P233; Larsen MH, 2010, J PSYCHIATR RES, V44, P808, DOI 10.1016/j.jpsychires.2010.01.005; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lee BH, 2007, J AFFECT DISORDERS, V101, P239, DOI 10.1016/j.jad.2006.11.005; Levkovitz Y, 2012, J AFFECT DISORDERS, V136, P1174, DOI 10.1016/j.jad.2011.04.059; Levkovitz Y, 2010, J CLIN PSYCHIAT, V71, P138, DOI 10.4088/JCP.08m04666yel; Lin PY, 2014, PHARMACOL BIOCHEM BE, V124, P174, DOI 10.1016/j.pbb.2014.06.006; Liu RJ, 2008, P NATL ACAD SCI USA, V105, P359, DOI 10.1073/pnas.0706679105; Liu Y, 2012, J AFFECT DISORDERS, V139, P230, DOI 10.1016/j.jad.2011.08.003; Lopresti AL, 2012, J PSYCHOPHARMACOL, V26, P1512, DOI 10.1177/0269881112458732; Luca M, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/230797; Ludka FK, 2013, EUR NEUROPSYCHOPHARM, V23, P400, DOI 10.1016/j.euroneuro.2012.05.005; Madhoo M, 2014, NEUROPSYCHOPHARMACOL, V39, P1388, DOI 10.1038/npp.2013.334; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P702, DOI 10.1016/j.pnpbp.2010.12.017; MAES M, 1991, ACTA PSYCHIAT SCAND, V84, P379, DOI 10.1111/j.1600-0447.1991.tb03163.x; Maes M, 2013, J AFFECT DISORDERS, V149, P23, DOI 10.1016/j.jad.2012.06.039; Maes M, 2012, PSYCHIAT RES, V196, P243, DOI 10.1016/j.psychres.2011.09.029; Maes M, 2012, PROG NEURO-PSYCHOPH, V36, P169, DOI 10.1016/j.pnpbp.2011.09.006; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P664, DOI 10.1016/j.pnpbp.2010.06.014; Maes M, 2009, NEUROENDOCRINOL LETT, V30, P715; Maes M, 2009, METAB BRAIN DIS, V24, P27, DOI 10.1007/s11011-008-9118-1; Malhi GS, 2013, CNS DRUGS, V27, P135, DOI 10.1007/s40263-013-0039-0; Marazziti D, 2011, CURR MED CHEM, V18, P4715, DOI 10.2174/092986711797379221; MARCOS T, 1994, J AFFECT DISORDERS, V32, P133, DOI 10.1016/0165-0327(94)90071-X; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Mauer S, 2014, AUST NZ J PSYCHIAT, V48, P809, DOI 10.1177/0004867414536932; Mazereeuw G, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.014; McEwen BS, 2013, NEURON, V79, P16, DOI 10.1016/j.neuron.2013.06.028; McEwen BS, 2010, ANN NY ACAD SCI, V1204, pE38, DOI 10.1111/j.1749-6632.2010.05568.x; McIntyre R. S., 2014, INT J NEUROPSYCHOPH, V30, P1; McIntyre RS, 2007, EXPERT OPIN PHARMACO, V8, P1615, DOI 10.1517/14656566.8.11.1615; McIntyre RS, 2013, DEPRESS ANXIETY, V30, P515, DOI 10.1002/da.22063; McIntyre RS, 2013, BEHAV BRAIN RES, V237, P164, DOI 10.1016/j.bbr.2012.09.021; McIntyre RS, 2010, ADV THER, V27, P63, DOI 10.1007/s12325-010-0011-z; McKinnon MC, 2009, J PSYCHIATR NEUROSCI, V34, P41; McMorris T, 2006, PSYCHOPHARMACOLOGY, V185, P93, DOI 10.1007/s00213-005-0269-z; Michel TM, 2007, PSYCHIAT RES, V151, P145, DOI 10.1016/j.psychres.2006.04.013; Michel TM, 2010, WORLD J BIOL PSYCHIA, V11, P314, DOI 10.3109/15622970802123695; Miracle AD, 2006, NEUROBIOL LEARN MEM, V85, P213, DOI 10.1016/j.nlm.2005.10.005; Miskowiak K, 2008, EXP BRAIN RES, V184, P313, DOI 10.1007/s00221-007-1102-1; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; Miskowiak KW, 2014, NEUROPSYCHOPHARMACOL, V39, P1399, DOI 10.1038/npp.2013.335; Mohamed RH, 2011, BRAIN RES BULL, V86, P22, DOI 10.1016/j.brainresbull.2011.07.001; Molendijk ML, 2014, MOL PSYCHIATR, V19, P791, DOI 10.1038/mp.2013.105; MONROE SM, 1991, PSYCHOL BULL, V110, P406, DOI 10.1037/0033-2909.110.3.406; Montezuma K, 2012, NEUROPHARMACOLOGY, V62, P485, DOI 10.1016/j.neuropharm.2011.09.004; Mowla Arash, 2008, Depress Anxiety, V25, pE92, DOI 10.1002/da.20343; Moylan S, 2013, MOL PSYCHIATR, V18, P595, DOI 10.1038/mp.2012.33; Moylan S, 2014, NEUROSCI BIOBEHAV R, V45, P46, DOI 10.1016/j.neubiorev.2014.05.007; Mueller A, 2011, NEUROPSYCHOPHARMACOL, V36, P1332, DOI 10.1038/npp.2011.11; Murri MB, 2014, PSYCHONEUROENDOCRINO, V41, P46, DOI 10.1016/j.psyneuen.2013.12.004; Musselman D, 2013, NEUROPSYCHOPHARMACOL, V38, P1921, DOI 10.1038/npp.2013.85; Myint AM, 2003, MED HYPOTHESES, V61, P519, DOI 10.1016/S0306-9877(03)00207-X; Na KS, 2014, PROG NEURO-PSYCHOPH, V48, P79, DOI 10.1016/j.pnpbp.2013.09.006; Naismith SL, 2003, J CLIN EXP NEUROPSYC, V25, P866, DOI 10.1076/jcen.25.6.866.16472; Nakasujja N, 2013, NEUROLOGY, V80, P196, DOI 10.1212/WNL.0b013e31827b9121; NEMEROFF CB, 1992, ARCH GEN PSYCHIAT, V49, P384; NEMEROFF CB, 1984, SCIENCE, V226, P1342, DOI 10.1126/science.6334362; Neumeister A, 2005, BIOL PSYCHIAT, V57, P935, DOI 10.1016/j.biopsych.2005.01.016; Newcomer JW, 1999, ARCH GEN PSYCHIAT, V56, P527, DOI 10.1001/archpsyc.56.6.527; Nicoletti VG, 2005, NEUROCHEM RES, V30, P737, DOI 10.1007/s11064-005-6867-7; Nierenberg AA, 2013, AUST NZ J PSYCHIAT, V47, P26, DOI 10.1177/0004867412449303; Noble M, 1996, PERSPECT DEV NEUROBI, V3, P121; O'Neil A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-154; Oberlander TF, 2008, EPIGENETICS-US, V3, P97, DOI 10.4161/epi.3.2.6034; Oliveira RMW, 2008, BRAZ J MED BIOL RES, V41, P333, DOI 10.1590/S0100-879X2008000400012; Orio L, 2010, NEUROTOX RES, V18, P187, DOI 10.1007/s12640-009-9120-3; Ormel J, 2013, NEUROSCI BIOBEHAV R, V37, P59, DOI 10.1016/j.neubiorev.2012.09.004; Ownby RL, 2006, ARCH GEN PSYCHIAT, V63, P530, DOI 10.1001/archpsyc.63.5.530; Oxenkrug G, 2012, AGING DIS, V3, P330; Palta P, 2014, PSYCHOSOM MED, V76, P12, DOI 10.1097/PSY.0000000000000009; Papakostas GI, 2010, AM J PSYCHIAT, V167, P942, DOI 10.1176/appi.ajp.2009.09081198; Pariante CM, 2001, BIOL PSYCHIAT, V49, P391, DOI 10.1016/S0006-3223(00)01088-X; Parsaik AK, 2014, J AFFECT DISORDERS, V160, P62, DOI 10.1016/j.jad.2013.11.026; Pasco JA, 2010, PSYCHOTHER PSYCHOSOM, V79, P323, DOI 10.1159/000319530; Pearce EF, 2014, ANN PHARMACOTHER, V48, P758, DOI 10.1177/1060028014528305; Porter RJ, 2003, BRIT J PSYCHIAT, V182, P214, DOI 10.1192/bjp.182.3.214; Post RM, 2007, NEUROSCI BIOBEHAV R, V31, P858, DOI 10.1016/j.neubiorev.2007.04.003; Price JF, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1198; Raison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Raison CL, 2003, AM J PSYCHIAT, V160, P1554, DOI 10.1176/appi.ajp.160.9.1554; Ravnkilde B, 2002, SCAND J PSYCHOL, V43, P239, DOI 10.1111/1467-9450.00292; Rigucci S, 2010, WORLD J BIOL PSYCHIA, V11, P165, DOI [10.1080/15622970903131571, 10.3109/15622970903131571]; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Roitman S, 2007, BIPOLAR DISORD, V9, P754, DOI 10.1111/j.1399-5618.2007.00532.x; Rothermundt M, 2001, J AFFECT DISORDERS, V66, P89, DOI 10.1016/S0165-0327(00)00321-9; ROY A, 1981, ARCH GEN PSYCHIAT, V38, P301; Sacktor N, 2011, NEUROLOGY, V77, P1135, DOI 10.1212/WNL.0b013e31822f0412; Sanmukhani J, 2014, PHYTOTHER RES, V28, P579, DOI 10.1002/ptr.5025; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sapolsky RM, 2000, BIOL PSYCHIAT, V48, P755, DOI 10.1016/S0006-3223(00)00971-9; Sarandol A, 2007, HUM PSYCHOPHARM CLIN, V22, P67, DOI 10.1002/hup.829; Sargin D, 2010, BEST PRACT RES-CLIN, V24, P573, DOI 10.1016/j.bpa.2010.10.005; Sato H, 2010, J CLIN BIOCHEM NUTR, V47, P224, DOI 10.3164/jcbn.10-58; Schildknecht S, 2011, J BIOL CHEM, V286, P4991, DOI 10.1074/jbc.M110.169565; Seo JS, 2012, J NEUROSCI, V32, P9690, DOI 10.1523/JNEUROSCI.0794-12.2012; Sepanjnia K, 2012, NEUROPSYCHOPHARMACOL, V37, P2093, DOI 10.1038/npp.2012.58; Shea A, 2005, PSYCHONEUROENDOCRINO, V30, P162, DOI 10.1016/j.psyneuen.2004.07.001; Sievers C, 2014, EUR NEUROPSYCHOPHARM, V24, P890, DOI 10.1016/j.euroneuro.2014.01.008; Simons CJP, 2009, ACTA PSYCHIAT SCAND, V120, P45, DOI 10.1111/j.1600-0447.2008.01339.x; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Sironi L, 2006, NEUROBIOL DIS, V22, P445, DOI 10.1016/j.nbd.2005.12.004; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Slavich GM, 2011, J PSYCHIATR RES, V45, P1146, DOI 10.1016/j.jpsychires.2011.03.004; Smaga I, 2012, PROG NEURO-PSYCHOPH, V39, P280, DOI 10.1016/j.pnpbp.2012.06.018; SMITH MA, 1995, J NEUROSCI, V15, P1768; Soczynska JK, 2012, BEHAV BRAIN RES, V235, P302, DOI 10.1016/j.bbr.2012.07.026; Sokolov AN, 2013, NEUROSCI BIOBEHAV R, V37, P2445, DOI 10.1016/j.neubiorev.2013.06.013; Srivastava N, 2002, J AFFECT DISORDERS, V72, P45, DOI 10.1016/S0165-0327(01)00421-9; Stafford L, 2011, J CLIN PSYCHIAT, V72, P1229, DOI 10.4088/JCP.09m05825blu; Stefanescu C, 2012, J AFFECT DISORDERS, V143, P34, DOI 10.1016/j.jad.2012.05.022; Stewart WF, 2003, JAMA-J AM MED ASSOC, V289, P3135, DOI 10.1001/jama.289.23.3135; Stotland NL, 2012, PSYCHIAT CLIN N AM, V35, P37, DOI 10.1016/j.psc.2011.11.007; Stroud CB, 2011, J ABNORM PSYCHOL, V120, P142, DOI 10.1037/a0021659; Swiger KJ, 2013, MAYO CLIN PROC, V88, P1213, DOI 10.1016/j.mayocp.2013.07.013; Takebayashi M, 2010, J NEURAL TRANSM, V117, P1119, DOI 10.1007/s00702-010-0452-1; Talarowska M, 2015, ADV MED SCI-POLAND, V60, P1, DOI 10.1016/j.advms.2014.06.001; Talarowska Monika, 2014, Med Sci Monit, V20, P110, DOI 10.12659/MSM.889853; Talarowska M, 2012, NEUROSCI LETT, V510, P127, DOI 10.1016/j.neulet.2012.01.018; Tomaz VS, 2014, NEUROSCIENCE, V268, P236, DOI 10.1016/j.neuroscience.2014.03.025; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Tseng PT, 2013, PROG NEURO-PSYCHOPH, V40, P334, DOI 10.1016/j.pnpbp.2012.09.009; Turner CA, 2012, NEURON, V76, P160, DOI 10.1016/j.neuron.2012.08.037; Udina M, 2012, J CLIN PSYCHIAT, V73, P1128, DOI 10.4088/JCP.12r07694; van der Vaart T, 2013, LANCET NEUROL, V12, P1076, DOI 10.1016/S1474-4422(13)70227-8; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Voloboueva LA, 2011, J NEUROSCI RES, V89, P1989, DOI 10.1002/jnr.22768; Vythilingam M, 2004, BIOL PSYCHIAT, V56, P101, DOI 10.1016/j.biopsych.2004.04.002; Wagner S, 2012, ACTA PSYCHIAT SCAND, V125, P281, DOI 10.1111/j.1600-0447.2011.01762.x; Wang YP, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-95; Wang Y, 2011, NEUROSCI LETT, V499, P74, DOI 10.1016/j.neulet.2011.05.035; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Willner P, 2013, NEUROSCI BIOBEHAV R, V37, P2331, DOI 10.1016/j.neubiorev.2012.12.007; Wirtz PH, 2014, J AM COLL CARDIOL, V63, P2297, DOI 10.1016/j.jacc.2014.02.580; World Health Organization, 1992, ICD 10 CLASS MENT BE; Xie L, 2009, INT IMMUNOPHARMACOL, V9, P575, DOI 10.1016/j.intimp.2009.01.025; Yamamoto T, 2012, APPL NEUROPSYCH-ADUL, V19, P183, DOI 10.1080/09084282.2011.643959; Yatham LN, 2013, BIPOLAR DISORD, V15, P1, DOI 10.1111/bdi.12025; Yi SY, 2012, PSYCHIAT RES, V200, P318, DOI 10.1016/j.psychres.2012.05.035; You JM, 2009, CAN J PHYSIOL PHARM, V87, P440, DOI [10.1139/y09-027, 10.1139/Y09-027]; Yuen EY, 2012, NEURON, V73, P962, DOI 10.1016/j.neuron.2011.12.033; Zannas AS, 2014, GENES BRAIN BEHAV, V13, P25, DOI 10.1111/gbb.12104; Zell R, 1997, MOL CELL BIOCHEM, V177, P61, DOI 10.1023/A:1006896832582; Zhang M, 2006, ACTA PHARMACOL SIN, V27, P1071, DOI 10.1111/j.1745-7254.2006.00322.x; Zhang WT, 2010, STROKE, V41, P2341, DOI 10.1161/STROKEAHA.110.586081; Zhou JF, 2008, J PINEAL RES, V45, P157, DOI 10.1111/j.1600-079X.2008.00570.x; Zhou W, 2014, EUR PSYCHIAT, V29, P419, DOI 10.1016/j.eurpsy.2013.10.005; Zhu FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093966; Zimmermann P, 2011, AM J PSYCHIAT, V168, P1107, DOI 10.1176/appi.ajp.2011.10111577; Zunszain PA, 2011, PROG NEURO-PSYCHOPH, V35, P722, DOI 10.1016/j.pnpbp.2010.04.011	257	57	59	1	48	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2014	13	10					1819	1835					17	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CA0GG	WOS:000348594400017	25470397				2021-06-18	
J	Bayen, E; Pradat-Diehl, P; Jourdan, C; Ghout, I; Bosserelle, V; Azerad, S; Weiss, JJ; Joel, ME; Aegerter, P; Azouvi, P				Bayen, Eleonore; Pradat-Diehl, Pascale; Jourdan, Claire; Ghout, Idir; Bosserelle, Vanessa; Azerad, Sylvie; Weiss, Jean-Jacques; Joel, Marie-Eve; Aegerter, Philippe; Azouvi, Philippe		Steering Comm PariS-TBI Study	Predictors of Informal Care Burden 1 Year After a Severe Traumatic Brain Injury: Results From the PariS-TBI study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						dysexecutive syndrome; GOS-E; informal care; SF-36; traumatic brain injury; Zarit Burden Inventory	FAMILY CAREGIVERS; LIFE SATISFACTION; HEAD-INJURY; EXECUTIVE DYSFUNCTION; COGNITIVE DEFICITS; HEALTH SURVEY; FOLLOW-UP; COMMUNITY; PROGRAM; DISABILITY	Objective: To investigate predictors of informal care burden 1 year after a severe traumatic brain injury (TBI). Participants: Patients (N = 66) aged 15 years or older with severe TBI (Glasgow Coma Scale score of 8 or less) and their primary informal caregivers. Setting: Multicenter inception cohort study over 22 months in Paris and the surrounding area (PariS-TBI study). Main measures: Patients' preinjury characteristics; injury severity data; outcome measures at discharge from intensive care and 1 year after the injury; Dysexecutive Questionnaire; Medical Outcome Study Short Form-36; Zarit Burden Inventory. Results: Among the 257 survivors at discharge from acute care, 66 patient-caregiver couples were included. Primary informal caregivers were predominantly women (73%), of middle age (age, 50 years), supporting male patients (79%), of mean age of 38 years. The majority (56%) of caregivers experienced significant burden, and 44% were at risk of depression. Caregivers' impaired health status and perceived burden significantly correlated with patients' global disability (as assessed with the Glasgow Outcome Scale-Extended) and impairments of executive functions (as assessed with the Dysexecutive Questionnaire). A focused principal component analysis suggested that disability and executive dysfunctions were independent predictors of perceived burden, whereas demographics, injury severity, and Glasgow Outcome Scale at discharge from acute care did not significantly correlate with caregiver's burden. Conclusion: Global handicap and impairments of executive functions are independent significant predictors of caregiver burden 1 year after TBI.	[Bayen, Eleonore; Pradat-Diehl, Pascale] Grp Hosp Pitie Salpetriere, AP HP, Serv Med Phys & Readaptat, F-75634 Paris, France; [Bayen, Eleonore; Joel, Marie-Eve] Univ Paris 09, Lab Econ & Gest Org Sante LEDa LEGOS, Paris, France; [Bayen, Eleonore; Pradat-Diehl, Pascale] Univ Paris 06, UFR Med, Paris, France; [Pradat-Diehl, Pascale; Jourdan, Claire; Azouvi, Philippe] Univ Paris 06, Unite ER 6, Paris, France; [Jourdan, Claire; Azouvi, Philippe] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, Garches, France; [Jourdan, Claire; Azouvi, Philippe] Univ Versailles St Quentin, UFR Med, EA 4497, Guyancourt, France; [Ghout, Idir; Bosserelle, Vanessa; Azerad, Sylvie; Aegerter, Philippe] Hop Ambroise Pare, AP HP, Unite Rech Clin Paris Ouest, Boulogne, France; [Bosserelle, Vanessa; Azerad, Sylvie; Weiss, Jean-Jacques] Ctr Ressources Francilien Traumatisme Cranien, Paris, France; [Aegerter, Philippe] Univ Versailles St Quentin, UPRES EA 2506, Guyancourt, France	Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, 104 Bd Raymond Poincare, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr		tazarourte, karim/0000-0002-3376-1258; AEGERTER, Philippe/0000-0002-9156-5028	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM-04-084]; AP-HP (Departement de la Recherche Clinique et du Developpement); Fondation Garches and the French Society of Physical Medicine and Rehabilitation (SOFMER)	PariS-TBI study has been funded by a grant of French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004, AOM-04-084), supported by AP-HP (Departement de la Recherche Clinique et du Developpement). The authors thank all patients and family participants who took the time to share their experience and all members of the CRFTC Steering Committee (Centre Ressource Francilien des Traumatises Craniens) for their valuable help.; The authors also thank Prof Pernot, Dr Dulou, Prof Tadie, Prof Truelle, Dr Carli, and Dr Welschbillig for their participation in the study. The first author thanks the Fondation Garches and the French Society of Physical Medicine and Rehabilitation (SOFMER) for their grant support.	Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Andrieu S, 2003, REV MED INTERNE, V24, p351S, DOI 10.1016/S0248-8663(03)80695-1; [Anonymous], 1999, JAMA, V282, P974; Azouvi Philippe, 2009, Rev Prat, V59, P1087; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bachner YG, 2007, AGING MENT HEALTH, V11, P678, DOI 10.1080/13607860701529965; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Brehaut JC, 2004, PEDIATRICS, V114, P182; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Centre Ressources Francilien du Traumatisme Cranien, 2012, FORM SEM 2012; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Davin B, 2005, REV EPIDEMIOL SANTE, V53, P509, DOI 10.1016/S0398-7620(05)84728-5; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Falissard B, 2011, ANALYSIS OF QUESTIONNAIRE DATA WITH R; Falissard B, 1999, J COMPUT GRAPH STAT, V8, P906, DOI 10.2307/1390833; Hart T, 2003, ARCH PHYS MED REHAB, V84, P221, DOI 10.1053/apmr.2003.50023; Haute Autorite de Sante, 2004, SORT MOND HOSP RET D; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Higginson IJ, 2008, HEALTH QUAL LIFE OUT, V6, DOI 10.1186/1477-7525-6-42; Institut national de la statistique et des etudes economiques, ENQ HAND SANT 2008 V; Institut national de la statistique et des etudes economiques, 2012, NOM PROF CAT SOC; Institut national de la statistique et des etudes economiques, ENQ HAND SANT 2008 A; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Jennett B, 1979, Acta Neurochir Suppl (Wien), V28, P149; Joel Marie-Eve, 2003, Psychol Neuropsychiatr Vieil, V1, P259; Joel ME, 2003, REV EPIDEMIOL SANTE, V51, P574; Jourdan C, NEUROREHABI IN PRESS; Katz S, 2005, BRAIN INJURY, V19, P59, DOI 10.1080/02699050410001719970; Kozlowski O., 2002, Annales de Readaptation et de Medecine Physique, V45, P466, DOI 10.1016/S0168-6054(02)00297-0; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Leplege A, 1998, J CLIN EPIDEMIOL, V51, P1013, DOI 10.1016/S0895-4356(98)00093-6; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; RANKIN ED, 1994, GERONTOLOGIST, V34, P828, DOI 10.1093/geront/34.6.828; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Roche V, 2009, AM J MED SCI, V337, P199, DOI 10.1097/MAJ.0b013e31818b114d; Rosenberg PB, 2005, AM J GERIAT PSYCHIAT, V13, P822, DOI 10.1176/appi.ajgp.13.9.822; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Schreiner AS, 2006, AGING MENT HEALTH, V10, P107, DOI 10.1080/13607860500312142; Sinnakaruppan I, 2005, BRAIN INJURY, V19, P283, DOI 10.1080/02699050400003924; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SF 36 HLTH SURV MAN; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wrona RM, 2010, DISABIL REHABIL, V32, P650, DOI 10.3109/09638280903186327; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	65	57	57	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2013	28	6					408	418		10.1097/HTR.0b013e31825413cf			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	299AA	WOS:000330365200004	22691963				2021-06-18	
J	Valdeolivas, S; Pazos, MR; Bisogno, T; Piscitelli, F; Iannotti, FA; Allara, M; Sagredo, O; Di Marzo, V; Fernandez-Ruiz, J				Valdeolivas, S.; Pazos, M. R.; Bisogno, T.; Piscitelli, F.; Iannotti, F. A.; Allara, M.; Sagredo, O.; Di Marzo, V.; Fernandez-Ruiz, J.			The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG	CELL DEATH & DISEASE			English	Article						endocannabinoids; CB1 and CB2 receptors; diacyl-glycerol lipase; monoacyl-glycerol lipase; cyclooxygenase-2; Huntington's disease; malonate; neuroprotection	TRAUMATIC BRAIN-INJURY; HUNTINGTONS-DISEASE; ENDOCANNABINOID 2-ARACHIDONOYLGLYCEROL; CANNABINOID RECEPTORS; ALZHEIMERS-DISEASE; BASAL GANGLIA; IN-VIVO; MODEL; COX-2; NEURODEGENERATION	The cannabinoid CB2 receptor, which is activated by the endocannabinoid 2-arachidonoyl-glycerol (2-AG), protects striatal neurons from apoptotic death caused by the local administration of malonate, a rat model of Huntington's disease (HD). In the present study, we investigated whether endocannabinoids provide tonic neuroprotection in this HD model, by examining the effect of O-3841, an inhibitor of diacylglycerol lipases, the enzymes that catalyse 2-AG biosynthesis, and JZL184 or OMDM169, two inhibitors of 2-AG inactivation by monoacylglycerol lipase (MAGL). The inhibitors were injected in rats with the striatum lesioned with malonate, and several biochemical and morphological parameters were measured in this brain area. Similar experiments were also conducted in vitro in cultured M-213 cells, which have the phenotypic characteristics of striatal neurons. O-3841 produced a significant reduction in the striatal levels of 2-AG in animals lesioned with malonate. However, surprisingly, the inhibitor attenuated malonate-induced GABA and BDNF deficiencies and the reduction in Nissl staining, as well as the increase in GFAP immunostaining. In contrast, JZL184 exacerbated malonate-induced striatal damage. Cyclooxygenase-2 (COX-2) was induced in the striatum 24 h after the lesion simultaneously with other pro-inflammatory responses. The COX-2-derived 2-AG metabolite, prostaglandin E-2 glyceryl ester (PGE(2)-G), exacerbated neurotoxicity, and this effect was antagonized by the blockade of PGE(2)-G action with AGN220675. In M-213 cells exposed to malonate, in which COX-2 was also upregulated, JZL184 worsened neurotoxicity, and this effect was attenuated by the COX-2 inhibitor celecoxib or AGN220675. OMDM169 also worsened neurotoxicity and produced measurable levels of PGE(2)-G. In conclusion, the inhibition of 2-AG biosynthesis is neuroprotective in rats lesioned with malonate, possibly through the counteraction of the formation of pro-neuroinflammatory PGE(2)-G, formed from COX-2-mediated oxygenation of 2-AG. Accordingly, MAGL inhibition or the administration of PGE(2)-G aggravates the malonate toxicity.	[Valdeolivas, S.; Pazos, M. R.; Sagredo, O.; Fernandez-Ruiz, J.] Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Med, IUIN, E-28040 Madrid, Spain; [Valdeolivas, S.; Pazos, M. R.; Sagredo, O.; Fernandez-Ruiz, J.] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain; [Valdeolivas, S.; Pazos, M. R.; Sagredo, O.; Fernandez-Ruiz, J.] IRYCIS, Madrid, Spain; [Bisogno, T.; Piscitelli, F.; Iannotti, F. A.; Allara, M.; Di Marzo, V.] CNR, Endocannabinoid Res Grp, Inst Biomol Chem, I-80078 Naples, Italy	Sagredo, O (corresponding author), Univ Complutense Madrid, Dept Biochem & Mol Biol, Fac Med, E-28040 Madrid, Spain.	onintza@med.ucm.es; vdimarzo@icmib.na.cnr.it; jjfr@med.ucm.es	Pazos, Ruth/D-6797-2019; SAGREDO, ONINTZA/I-9094-2016; Bisogno, Tiziana/B-7891-2015; iannotti, fabio a/K-5704-2016; Piscitelli, Fabiana/A-7100-2014; Di Marzo, Vincenzo/AAD-7742-2019; Valdeolivas Rojas, Sara/I-9361-2016; FERNANDEZ RUIZ, JOSE JAVIER/S-3875-2018	Pazos, Ruth/0000-0001-7613-795X; SAGREDO, ONINTZA/0000-0003-0452-3223; iannotti, fabio a/0000-0003-4480-8370; Di Marzo, Vincenzo/0000-0002-1490-3070; Valdeolivas Rojas, Sara/0000-0003-1379-6602; Piscitelli, Fabiana/0000-0001-9343-4622; FERNANDEZ RUIZ, JOSE JAVIER/0000-0002-4490-0604	CIBERNEDInstituto de Salud Carlos III [CB06/05/0089]; MICINNSpanish GovernmentEuropean Commission [SAF2009/11847]; CAM [S2011/BMD-2308]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA009789]; 'Programa FPI-Ministerio de Ciencia e Innovacion'; Complutense University-Predoctoral Program; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA009789] Funding Source: NIH RePORTER	This work was supported by grants from CIBERNED (CB06/05/0089), MICINN (SAF2009/11847) and CAM (S2011/BMD-2308) to SV, MRP, OS and JFR, and by NIH (grant nr. DA009789) to VDM. MRP was a predoctoral fellow supported by the 'Programa FPI-Ministerio de Ciencia e Innovacion' and SV was supported by the Complutense University-Predoctoral Program. We are indebted to Yolanda Garcia Movellan and Davide Castelluccio for technical and administrative assistance.	Bisogno T, 2003, J CELL BIOL, V163, P463, DOI 10.1083/jcb.200305129; Bisogno T, 2006, BBA-MOL CELL BIOL L, V1761, P205, DOI 10.1016/j.bbalip.2005.12.009; Bisogno T, 1997, BIOCHEM J, V322, P671, DOI 10.1042/bj3220671; Bisogno T, 2008, NEUROCHEM INT, V52, P307, DOI 10.1016/j.neuint.2007.06.031; Bisogno T, 2007, PHARMACOL RES, V56, P428, DOI 10.1016/j.phrs.2007.09.002; Blankman JL, 2007, CHEM BIOL, V14, P1347, DOI 10.1016/j.chembiol.2007.11.006; Blazquez C, 2011, BRAIN, V134, P119, DOI 10.1093/brain/awq278; Brown GC, 2007, BIOCHEM SOC T, V35, P1119, DOI 10.1042/BST0351119; Burgunder JM, 2013, TRANSL NEURODEGENER, V2, DOI 10.1186/2047-9158-2-2; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; De Yebenes J., 201002422724 EUDRACT; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Du H, 2001, BRIT J PHARMACOL, V163, P1533; Fernandez-Ruiz J, 2011, BRIT J PHARMACOL, V163, P1365, DOI 10.1111/j.1476-5381.2011.01365.x; Gatta L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031111; GIORDANO M, 1993, EXP NEUROL, V124, P395, DOI 10.1006/exnr.1993.1213; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hoozemans JJM, 2008, CURR PHARM DESIGN, V14, P1419, DOI 10.2174/138161208784480171; Hu SSJ, 2008, BRIT J PHARMACOL, V153, P1538, DOI 10.1038/bjp.2008.33; Kozak KR, 2004, CURR PHARM DESIGN, V10, P659, DOI 10.2174/1381612043453081; Kreutz S, 2009, GLIA, V57, P286, DOI 10.1002/glia.20756; Lastres-Becker I, 2003, J NEUROCHEM, V84, P1097, DOI 10.1046/j.1471-4159.2003.01595.x; Lastres-Becker I, 2001, NEUROREPORT, V12, P2125, DOI 10.1097/00001756-200107200-00017; Lastres-Becker I, 2004, NEUROREPORT, V15, P2375, DOI 10.1097/00001756-200410250-00015; Lastres-Becker I, 2003, NEUROREPORT, V14, P813, DOI 10.1097/00001756-200305060-00007; Long JZ, 2009, NAT CHEM BIOL, V5, P37, DOI 10.1038/nchembio.129; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marsicano G, 2002, NATURE, V418, P530, DOI 10.1038/nature00839; McMurray CT, 2001, TRENDS NEUROSCI, V24, pS32, DOI 10.1016/S0166-2236(00)01997-4; Mechoulam R, 2007, MOL NEUROBIOL, V36, P68, DOI 10.1007/s12035-007-8008-6; Minghetti L, 2004, J NEUROPATH EXP NEUR, V63, P901, DOI 10.1093/jnen/63.9.901; Minghetti L, 2007, J NEUROPATH EXP NEUR, V66, P363, DOI 10.1097/nen.0b013e3180517477; Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200; O'Sullivan SE, 2010, IMMUNOBIOLOGY, V215, P611, DOI 10.1016/j.imbio.2009.09.007; Ortar G, 2008, J MED CHEM, V51, P6970, DOI 10.1021/jm800978m; Palazuelos J, 2009, BRAIN, V132, P3152, DOI 10.1093/brain/awp239; Palkovits M., 1988, MAPS GUIDE MICRODISS; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pazos MR, 2008, CURR PHARM DESIGN, V14, P2317, DOI 10.2174/138161208785740108; Pintor A, 2006, NEUROPHARMACOLOGY, V51, P1004, DOI 10.1016/j.neuropharm.2006.06.013; Piro JR, 2012, CELL REP, V1, P617, DOI 10.1016/j.celrep.2012.05.001; Sagredo O, 2007, EUR J NEUROSCI, V26, P843, DOI 10.1111/j.1460-9568.2007.05717.x; Sagredo Onintza, 2012, Recent Pat CNS Drug Discov, V7, P41; Sagredo O, 2011, J NEUROSCI RES, V89, P1509, DOI 10.1002/jnr.22682; Sagredo O, 2009, GLIA, V57, P1154, DOI 10.1002/glia.20838; Sang N, 2007, J NEUROCHEM, V102, P1966, DOI 10.1111/j.1471-4159.2007.04668.x; Stahel PF, 2008, PPAR RES, V2008, DOI 10.1155/2008/538141; Sun Y, 2007, PPAR RES, V2007, DOI 10.1155/2007/23513; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Toulmond S, 2004, BRIT J PHARMACOL, V141, P689, DOI 10.1038/sj.bjp.0705662; Tzeng Shun-Fen, 2005, Current Drug Targets - Inflammation and Allergy, V4, P335, DOI 10.2174/1568010054022051; Valdeolivas S, 2012, ACS CHEM NEUROSCI, V3, P400, DOI 10.1021/cn200114w; Walker FO, 2007, LANCET, V369, P218, DOI 10.1016/S0140-6736(07)60111-1; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Woodward DF, 2008, PHARMACOL THERAPEUT, V120, P71, DOI 10.1016/j.pharmthera.2008.08.001; Wright BLC, 2007, CURR MOL MED, V7, P579, DOI 10.2174/156652407781695738; Yang HW, 2008, CURR PHARM DESIGN, V14, P1443, DOI 10.2174/138161208784480144; Zhang J, 2008, J BIOL CHEM, V283, P22601, DOI 10.1074/jbc.M800524200	59	57	57	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	OCT	2013	4								e862	10.1038/cddis.2013.387			12	Cell Biology	Cell Biology	251XK	WOS:000326967100048	24136226	DOAJ Gold, Green Published			2021-06-18	
J	Jourdan, C; Bosserelle, V; Azerad, S; Ghout, I; Bayen, E; Aegerter, P; Weiss, JJ; Mateo, J; Lescot, T; Vigue, B; Tazarourte, K; Pradat-Diehl, P; Azouvi, P				Jourdan, C.; Bosserelle, V.; Azerad, S.; Ghout, I.; Bayen, E.; Aegerter, P.; Weiss, J. J.; Mateo, J.; Lescot, T.; Vigue, B.; Tazarourte, K.; Pradat-Diehl, P.; Azouvi, P.		PariS-TBI Study	Predictive factors for 1-year outcome of a cohort of patients with severe traumatic brain injury (TBI): Results from the PariS-TBI study	BRAIN INJURY			English	Article						Brain injury; craniocerebral trauma; disability; dysexecutive questionnaire; outcome	ECOLOGICAL VALIDITY; EXECUTIVE DYSFUNCTION; EMPLOYMENT; RETURN; WORK; REHABILITATION; MODERATE; PEOPLE; MODELS; TESTS	Objectives: To assess outcome and predicting factors 1 year after a severe traumatic brain injury (TBI). Methods: Multi-centre prospective inception cohort study of patients aged 15 or older with a severe TBI in the Parisian area, France. Data were collected prospectively starting the day of injury. One-year evaluation included the relatives-rating of the Dysexecutive Questionnaire (DEX-R), the Glasgow Outcome Scale-Extended (GOSE) and employment. Univariate and multivariate tests were computed. Results: Among 257 survivors, 134 were included (mean age 36 years, 84% men). Good recovery concerned 19%, moderate disability 43% and severe disability 38%. Among patients employed pre-injury, 42% were working, 28% with no job change. DEX-R score was significantly associated with length of education only. Among initial severity measures, only the IMPACT prognostic score was significantly related to GOSE in univariate analyses, while measures relating to early evolution were more significant predictors. In multivariate analyses, independent predictors of GOSE were length of stay in intensive care (LOS), age and education. Independent predictors of employment were LOS and age. Conclusions: Age, education and injury severity are independent predictors of global disability and return to work 1 year after a severe TBI.	[Jourdan, C.; Azouvi, P.] Hop Raymond Poincare, APHP, Serv Med Phys & Readaptat, F-92380 Garches, France; [Jourdan, C.; Aegerter, P.; Azouvi, P.] Univ Versailles St Quentin Yvelines, Versailles, France; [Jourdan, C.; Bayen, E.; Pradat-Diehl, P.; Azouvi, P.] UPMC, Unite ER 6, Paris, France; [Bosserelle, V.; Azerad, S.; Weiss, J. J.] Hop Broussais, APHP, CRFTC, F-75674 Paris, France; [Bosserelle, V.; Azerad, S.; Ghout, I.; Aegerter, P.] Hop Ambroise Pare, APHP, URC, Boulogne, France; [Bayen, E.; Pradat-Diehl, P.] Univ Paris 06, Paris, France; [Bayen, E.; Pradat-Diehl, P.] Grp Hosp Pitie Salpetriere, APHP, Serv Med Phys & Readaptat, F-75634 Paris, France; [Mateo, J.] Hop Lariboisiere, APHP, Dept Anesthesiol, F-75475 Paris, France; [Mateo, J.] Hop Lariboisiere, APHP, SAMU, F-75475 Paris, France; [Lescot, T.] Grp Hosp Pitie Salpetriere, APHP, Dept Anesthesiol, F-75634 Paris, France; [Vigue, B.] Hop Bicetre, APHP, Dept Anesthesiol & Soins Intensifs, Le Kremlin Bicetre, France; [Tazarourte, K.] Hop Marc Jacquet, SAMU 77, Mobile Care Unit, Melun, France	Azouvi, P (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, 104 Bd Raymond Poincare, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr		AEGERTER, Philippe/0000-0002-9156-5028; tazarourte, karim/0000-0002-3376-1258	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM04084]; AP-HP (Departement de la Recherche Clinique et du Developpement); Unite de Recherche Clinique Paris-Ouest	This study was funded by a grant of the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004, AOM04084), sponsored by AP-HP (Departement de la Recherche Clinique et du Developpement) and carried out with the support of Unite de Recherche Clinique Paris-Ouest. The authors report no conflicts of interest.	Ananth CV, 1997, INT J EPIDEMIOL, V26, P1323, DOI 10.1093/ije/26.6.1323; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bayen E, 2012, J HEAD TRAUMA REHABI; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Boelen DHE, 2009, NEUROPSYCHOL REHABIL, V19, P625, DOI 10.1080/09602010802613853; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2011, PSYCHIAT RES, V185, P340, DOI 10.1016/j.psychres.2010.06.009; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Gerstorf D, 2008, AGING NEUROPSYCHOL C, V15, P424, DOI 10.1080/13825580701640374; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Harrell Frank E., 2001, REGRESSION MODELING; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Jourdan C, 2013, NEUROREHAB NEURAL RE, V27, P35, DOI 10.1177/1545968312440744; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Sample PL, 2005, J HEAD TRAUMA REHAB, V20, P270, DOI 10.1097/00001199-200505000-00009; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Sherer M, 1999, BRAIN INJURY, V13, P973; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014	44	57	58	0	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2013	27	9					1000	1007		10.3109/02699052.2013.794971			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	180HZ	WOS:000321586100003	23730948				2021-06-18	
J	Prichep, LS; McCrea, M; Barr, W; Powell, M; Chabot, RJ				Prichep, Leslie S.; McCrea, Michael; Barr, William; Powell, Matthew; Chabot, Robert J.			Time Course of Clinical and Electrophysiological Recovery After Sport-Related Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						electroencephalography; mTBI; neuroimaging; sports concussion; TBI Index	TRAUMATIC BRAIN-INJURY; SYMPTOMS; SEVERITY; MODERATE	Background and Purpose: Recent neuroimaging studies suggest that abnormalities in brain function after concussion exist beyond the point of observed clinical recovery. This study investigated the relationship between an index of brain dysfunction (traumatic brain injury [TBI] Index), concussion severity, and outcome. Methods: EEG was collected from forehead locations in 65 male athletes with concussion within 24 hours of concussion, with follow-up at 8 and 45 days postinjury. Neurocognitive and symptom assessments were also performed and used to classify subjects in mild or moderate concussion categories. Time to return to play was recorded. Results: The TBI Index was higher in the moderate than mild concussion group at injury, day 8, and day 45. The moderate group had increased symptoms and decreased cognitive performance only at the time of injury. At the time of injury, only the TBI Index was significantly associated with the length of time to return to play. Conclusions: Recovery of brain function after sport-related concussion may extend well beyond the time course of clinical recovery and be related to clinical severity. An index of brain dysfunction may be an objective indicator of injury, recovery, and readiness to return to play. The relatively small sample indicates the need for further study on the time course of physiological recovery.	[Prichep, Leslie S.; Chabot, Robert J.] NYU, Sch Med, Dept Psychiat, Brain Res Labs, New York, NY 10016 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Barr, William] NYU, Langone Med Ctr, Dept Neurol, New York, NY 10016 USA; [Barr, William] NYU, Langone Med Ctr, Dept Psychiat, New York, NY USA; [Powell, Matthew] Marshfield Clin Fdn Med Res & Educ, Dept Neuropsychol, Minocqua, WI USA	Prichep, LS (corresponding author), NYU, Sch Med, Dept Psychiat, Brain Res Labs, 550 First Ave, New York, NY 10016 USA.	leslie.prichep@nyumc.org		Barr, William/0000-0001-7711-7758	BrainScope, Inc	This research was supported by a clinical research grant from BrainScope, Inc, as an investigator-initiated study. Drs Prichep, Barr, and Chabot serve as consultants to BrainScope, Inc, and Dr Prichep and NYU School of Medicine hold financial interest in BrainScope, Inc, through patented technology. Aside from the author investigators, representatives from BrainScope, Inc, had no role in the conduct of the studies, analysis of the data, or preparation of manuscripts.	Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V2, P24; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kohavi R, 1995, INT JOINT C ART INT; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Malloy P.F., 1998, SEMIN CLIN NEUROPSYC, V3, P186; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Naunheim RS, 2010, BRAIN INJURY, V24, P1324, DOI 10.3109/02699052.2010.506862; Pardini JE, 2010, NEUROSURGERY, V67, P1020, DOI 10.1227/NEU.0b013e3181ee33e2; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	40	57	57	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					266	273		10.1097/HTR.0b013e318247b54e			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900004	22588360				2021-06-18	
J	Berdichevsky, Y; Dryer, AM; Saponjian, Y; Mahoney, MM; Pimentel, CA; Lucini, CA; Usenovic, M; Staley, KJ				Berdichevsky, Yevgeny; Dryer, Alexandra M.; Saponjian, Yero; Mahoney, Mark M.; Pimentel, Corrin A.; Lucini, Corrina A.; Usenovic, Marija; Staley, Kevin J.			PI3K-Akt Signaling Activates mTOR-Mediated Epileptogenesis in Organotypic Hippocampal Culture Model of Post-Traumatic Epilepsy	JOURNAL OF NEUROSCIENCE			English	Article							TEMPORAL-LOBE EPILEPSY; MAMMALIAN TARGET; STATUS EPILEPTICUS; INTERICTAL SPIKES; BRAIN-INJURY; MOUSE MODEL; CELL-DEATH; IN-VITRO; RAPAMYCIN; SEIZURES	mTOR is activated in epilepsy, but the mechanisms of mTOR activation in post-traumatic epileptogenesis are unknown. It is also not clear whether mTOR inhibition has an anti-epileptogenic, or merely anticonvulsive effect. The rat hippocampal organotypic culture model of post-traumatic epilepsy was used to study the effects of long-term (four weeks) inhibition of signaling pathways that interact with mTOR. Ictal activity was quantified by measurement of lactate production and electrical recordings, and cell death was quantified with lactate dehydrogenase (LDH) release measurements and Nissl-stained neuron counts. Lactate and LDH measurements were well correlated with electrographic activity and neuron counts, respectively. Inhibition of PI3K and Akt prevented activation of mTOR, and was as effective as inhibition of mTOR in reducing ictal activity and cell death. A dual inhibitor of PI3K and mTOR, NVP-BEZ235, was also effective. Inhibition of mTOR with rapamycin reduced axon sprouting. Late start of rapamycin treatment was effective in reducing epileptic activity and cell death, while early termination of rapamycin treatment did not result in increased epileptic activity or cell death. The conclusions of the study are as follows: (1) the organotypic hippocampal culture model of post-traumatic epilepsy comprises a rapid assay of anti-epileptogenic and neuroprotective activities and, in this model (2) mTOR activation depends on PI3K-Akt signaling, and (3) transient inhibition of mTOR has sustained effects on epilepsy.	[Berdichevsky, Yevgeny; Saponjian, Yero; Usenovic, Marija; Staley, Kevin J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA; [Berdichevsky, Yevgeny; Staley, Kevin J.] Harvard Univ, Sch Med, Boston, MA 02129 USA; [Dryer, Alexandra M.] Lehigh Univ, Dept Elect & Comp Engn, Bethlehem, PA 18015 USA; [Mahoney, Mark M.; Pimentel, Corrin A.; Lucini, Corrina A.] Lehigh Univ, Bioengn Program, Bethlehem, PA 18015 USA	Staley, KJ (corresponding author), MGH Neurol, CNY 114,Room 2600,114 16th St, Charlestown, MA 02129 USA.	Staley.Kevin@mgh.harvard.edu		Berdichevsky, Yevgeny/0000-0001-7539-601X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS072258, R01 NS077908]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072258, R01NS034360, R01NS077908, R01NS034700] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grants R21 NS072258 and R01 NS077908 (National Institute of Neurological Disorders and Stroke).	Berdichevsky Y, 2012, NEUROBIOL DIS, V45, P774, DOI 10.1016/j.nbd.2011.11.001; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Borders EB, 2010, AM J HEALTH-SYST PH, V67, P2095, DOI 10.2146/ajhp100020; Buckmaster PS, 2009, J NEUROSCI, V29, P8259, DOI 10.1523/JNEUROSCI.4179-08.2009; Caron E, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.108; Castillo M, 2001, AM J NEURORADIOL, V22, P152; CHAPMAN AG, 1977, J NEUROCHEM, V28, P1025, DOI 10.1111/j.1471-4159.1977.tb10665.x; Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001; Chueh SCJ, 2005, TRANSPL INT, V18, P261, DOI 10.1111/j.1432-2277.2004.00039.x; Chung RS, 2003, J NEUROSCI, V23, P3336; Crino PB, 2011, TRENDS MOL MED, V17, P734, DOI 10.1016/j.molmed.2011.07.008; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; Daoud D, 2007, EPILEPSIA, V48, P834, DOI 10.1111/j.1528-1167.2006.00976.x; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; DURING MJ, 1994, J NEUROCHEM, V62, P2356; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; FUJIKAWA DG, 1988, BRAIN RES, V454, P51; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Huang XX, 2010, NEUROBIOL DIS, V40, P193, DOI 10.1016/j.nbd.2010.05.024; Kadam SD, 2010, J NEUROSCI, V30, P404, DOI 10.1523/JNEUROSCI.4093-09.2010; Lew FH, 2011, EPILEPSIA, V52, P2326, DOI 10.1111/j.1528-1167.2011.03315.x; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; McDaniel SS, 2011, NEUROSCI LETT, V497, P231, DOI 10.1016/j.neulet.2011.02.037; Mercimek-Mahmutoglu S, 2012, PEDIATRICS, V129, pE1368, DOI 10.1542/peds.2011-0123; MILLER LDP, 1994, NEUROSCIENCE, V63, P471, DOI 10.1016/0306-4522(94)90544-4; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Ruegg S, 2007, EPILEPSY RES, V77, P85, DOI 10.1016/j.eplepsyres.2007.09.009; Sabolek HR, 2012, J NEUROSCI, V32, P3009, DOI 10.1523/JNEUROSCI.5853-11.2012; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sliwa A, 2012, NEUROSCI LETT, V509, P105, DOI 10.1016/j.neulet.2011.12.051; Staley BA, 2011, PEDIATRICS, V127, pE117, DOI 10.1542/peds.2010-0192; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Talos DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035885; Tang HY, 2012, BIOCHEM BIOPH RES CO, V420, P199, DOI 10.1016/j.bbrc.2012.02.143; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; Ulfig N, 1998, CELL TISSUE RES, V291, P433, DOI 10.1007/s004410051013; van Vliet EA, 2012, EPILEPSIA, V53, P1254, DOI 10.1111/j.1528-1167.2012.03513.x; Wasterlain CG, 2010, NEUROCHEM RES, V35, P2193, DOI 10.1007/s11064-010-0339-4; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Zeng LH, 2009, J NEUROSCI, V29, P6964, DOI 10.1523/JNEUROSCI.0066-09.2009; Zhang B, 2012, EPILEPSIA, V53, P506, DOI 10.1111/j.1528-1167.2011.03384.x	44	57	59	0	20	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAY 22	2013	33	21					9056	9067		10.1523/JNEUROSCI.3870-12.2013			12	Neurosciences	Neurosciences & Neurology	150LF	WOS:000319391200015	23699517	Green Published, Bronze, Green Accepted			2021-06-18	
J	Woods, AS; Colsch, B; Jackson, SN; Post, J; Baldwin, K; Roux, A; Hoffer, B; Cox, BM; Hoffer, M; Rubovitch, V; Pick, CG; Schultz, JA; Balaban, C				Woods, Amina S.; Colsch, Benoit; Jackson, Shelley N.; Post, Jeremy; Baldwin, Kathrine; Roux, Aurelie; Hoffer, Barry; Cox, Brian M.; Hoffer, Michael; Rubovitch, Vardit; Pick, Chaim G.; Schultz, J. Albert; Balaban, Carey			Gangliosides and Ceramides Change in a Mouse Model of Blast Induced Traumatic Brain Injury	ACS CHEMICAL NEUROSCIENCE			English	Article							TANDEM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; PRESSURE; SYSTEM	Explosive detonations generate atmospheric pressure changes that produce nonpenetrating blast induced "mild" traumatic brain injury (bTBI). The structural basis for mild bTBI has been extremely controversial. The present study applies matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging to track the distribution of gangliosides in mouse brain tissue that were exposed to very low level of explosive detonations (2.5-5.5 psi peak overpressure). We observed major increases of the ganglioside GM2 in the hippocampus, thalamus, and hypothalamus after a single blast exposure. Moreover, these changes were accompanied by depletion of ceramides. No neurological or brain structural signs of injury could be inferred using standard light microscopic techniques. The first source of variability is generated by the Latency between blast and tissue sampling (peak intensity of the blast wave). These findings suggest that subtle molecular changes in intracellular membranes and plasmalemma compartments may be biomarkers for biological responses to mild bTBI. This is also the first report of a GM2 increase in the brains of mature mice from a nongenetic etiology.	[Woods, Amina S.; Colsch, Benoit; Jackson, Shelley N.; Post, Jeremy; Baldwin, Kathrine; Roux, Aurelie] NIDA, IRP, Struct Biol Unit, NIH, Baltimore, MD 21224 USA; [Hoffer, Barry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Cox, Brian M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Hoffer, Michael] US Naval Hosp, San Diego, CA USA; [Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, IL-69978 Tel Aviv, Israel; [Balaban, Carey] Univ Pittsburgh, Pittsburgh, PA USA; [Woods, Amina S.; Post, Jeremy; Cox, Brian M.] Ctr Neurosci & Regenerat Med, Rockville, MD USA; [Schultz, J. Albert] Ionwerks Inc, Houston, TX USA	Woods, AS (corresponding author), NIDA, IRP, NIH, 333 Cassell Dr,Room 1120, Baltimore, MD 21224 USA.	awoods@mail.nih.gov	Balaban, Carey/O-6586-2019; Balaban, Carey/I-3467-2017	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	Intramural Research Program of the National Institute on Drug Abuse, NIH; Center for Neuroscience and Regenerative Medicine, Bethesda, MD (Department of Defense) through the Henry M. Jackson Foundation for the Advancement of Military Medicine; Office of National Drug Control Policy (ONDCP); SBIR Phase II NIH-NIDA [1RC3DA031431]; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [ZIADA000593, RC3DA031431, ZIADA000589] Funding Source: NIH RePORTER	This research was supported by the Intramural Research Program of the National Institute on Drug Abuse, NIH, and by the Center for Neuroscience and Regenerative Medicine, Bethesda, MD (Department of Defense) through the Henry M. Jackson Foundation for the Advancement of Military Medicine. The authors thank the Office of National Drug Control Policy (ONDCP) for instrumentation funding, without which this and other projects could not have been accomplished. J.A.S. and C.B. acknowledge funding from SBIR Phase II NIH-NIDA grant 1RC3DA031431.	ARGOV Z, 1984, ANN NEUROL, V16, P14, DOI 10.1002/ana.410160105; Bodennec J, 2000, J LIPID RES, V41, P1524; Colsch B, 2011, ACS CHEM NEUROSCI, V2, P213, DOI 10.1021/cn100096h; Colsch B, 2010, GLYCOBIOLOGY, V20, P661, DOI 10.1093/glycob/cwq031; FOLCH J, 1957, J BIOL CHEM, V226, P497; Franklin KBJ, 2007, MOUSE BRAIN STEREOTA; Han XL, 2002, ANAL BIOCHEM, V302, P199, DOI 10.1006/abio.2001.5536; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holthuis JCM, 2001, PHYSIOL REV, V81, P1689; Hsu FF, 2002, J AM SOC MASS SPECTR, V13, P558, DOI 10.1016/S1044-0305(02)00358-6; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; O'Connor PB, 2002, J AM SOC MASS SPECTR, V13, P402, DOI 10.1016/S1044-0305(02)00351-3; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; ROSEBUSH PI, 1995, J CLIN PSYCHIAT, V56, P347; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Sugiura Y, 2009, J LIPID RES, V50, P1776, DOI 10.1194/jlr.M900047-JLR200; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Xu YH, 2010, J LIPID RES, V51, P1643, DOI 10.1194/jlr.R003996; Yu RK, 2004, J LIPID RES, V45, P783, DOI 10.1194/jlr.R3000020-JLR200	24	57	57	1	55	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	APR	2013	4	4					594	600		10.1021/cn300216h			7	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	129VV	WOS:000317873000009	23590251	Green Published			2021-06-18	
J	Fricker, M; Vilalta, A; Tolkovsky, AM; Brown, GC				Fricker, Michael; Vilalta, Anna; Tolkovsky, Aviva M.; Brown, Guy C.			Caspase Inhibitors Protect Neurons by Enabling Selective Necroptosis of Inflamed Microglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIC BRAIN-INJURY; PRIMARY PHAGOCYTOSIS; CELL-DEATH; CEREBRAL-ISCHEMIA; VIABLE NEURONS; RIP1 KINASE; TNF-ALPHA; NEURODEGENERATION; ACTIVATION; APOPTOSIS	Microglia are resident brain macrophages, which can cause neuronal loss when activated in infectious, ischemic, traumatic, and neurodegenerative diseases. Caspase-8 has both prodeath and prosurvival roles, mediating apoptosis and/or preventing RIPK1-mediated necroptosis depending on cell type and stimulus. We found that inflammatory stimuli (LPS, lipoteichoic acid, or TNF-alpha) caused an increase in caspase-8 IETDase activity in primary rat microglia without inducing apoptosis. Inhibition of caspase-8 with either Z-VAD-fmk or IETD-fmk resulted in necrosis of activated microglia. Inhibition of caspases with Z-VAD-fmk did not kill non-activated microglia, or astrocytes and neurons in any condition. Necrostatin-1, a specific inhibitor of RIPK1, prevented microglial caspase inhibition-induced death, indicating death was by necroptosis. In mixed cerebellar cultures of primary neurons, astrocytes, and microglia, LPS induced neuronal loss that was prevented by inhibition of caspase-8 (resulting in microglial necroptosis), and neuronal death was restored by rescue of microglia with necrostatin-1. We conclude that the activation of caspase-8 in inflamed microglia prevents their death by necroptosis, and thus, caspase-8 inhibitors may protect neurons in the inflamed brain by selectively killing activated microglia.	[Fricker, Michael; Vilalta, Anna; Brown, Guy C.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Tolkovsky, Aviva M.] Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge CB2 OPY, England	Fricker, M (corresponding author), Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW 2305, Australia.	michael.fricker@gmail.com		Fricker, Michael/0000-0002-8587-1774; Brown, Guy/0000-0002-3610-1730; Vilalta, Anna/0000-0002-2183-072X	Wellcome Trust GrantWellcome Trust [RG50995]	This work was supported by Wellcome Trust Grant RG50995.	Burguillos MA, 2011, NATURE, V472, P319, DOI 10.1038/nature09788; Ciechomska Iwona A., 2008, V445, P175, DOI 10.1007/978-1-59745-157-4_12; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Degterev A, 2013, CELL DEATH DIFFER, V20, P366, DOI 10.1038/cdd.2012.133; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Feng YZ, 2003, EUR J PHARMACOL, V481, P169, DOI 10.1016/j.ejphar.2003.09.016; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Fricker M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-196; Fricker M, 2012, J NEUROSCI, V32, P2657, DOI 10.1523/JNEUROSCI.4837-11.2012; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Green DR, 2011, MOL CELL, V44, P9, DOI 10.1016/j.molcel.2011.09.003; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Inoue S, 2006, ANESTH ANALG, V102, P1548, DOI 10.1213/01.ane.0000202381.40516.8d; Kaiser WJ, 2005, J IMMUNOL, V174, P4942, DOI 10.4049/jimmunol.174.8.4942; Kinsner A, 2005, J NEUROCHEM, V95, P1132, DOI 10.1111/j.1471-4159.2005.03422.x; Neher JJ, 2007, BIOCHEM SOC T, V35, P1166, DOI 10.1042/BST0351166; Neher JJ, 2011, J IMMUNOL, V186, P4973, DOI 10.4049/jimmunol.1003600; Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Rebe C, 2007, BLOOD, V109, P1442, DOI 10.1182/blood-2006-03-011585; Solorzano CC, 1997, SHOCK, V7, P427, DOI 10.1097/00024382-199706000-00007; Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Venero JL, 2011, CELL DEATH DIFFER, V18, P1679, DOI 10.1038/cdd.2011.107; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Wiessner C, 2000, CELL MOL BIOL, V46, P53	28	57	60	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2013	288	13					9145	9152		10.1074/jbc.M112.427880			8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	116DG	WOS:000316862200034	23386613	Green Published, Other Gold			2021-06-18	
J	Zhang, MR; Red, SD; Lin, AH; Patel, SS; Sereno, AB				Zhang, Marsha R.; Red, Stuart D.; Lin, Angela H.; Patel, Saumil S.; Sereno, Anne B.			Evidence of Cognitive Dysfunction after Soccer Playing with Ball Heading Using a Novel Tablet-Based Approach	PLOS ONE			English	Article							NEUROPSYCHOLOGICAL CONSEQUENCE; TASK-PERFORMANCE; PLAYERS; SCHIZOPHRENIA; ASSOCIATIONS; EXERCISE; FEMALE	Does frequent head-to-ball contact cause cognitive dysfunctions and brain injury to soccer players? An iPad-based experiment was designed to examine the impact of ball-heading among high school female soccer players. We examined both direct, stimulus-driven, or reflexive point responses (Pro-Point) as well as indirect, goal-driven, or voluntary point responses (Anti-Point), thought to require cognitive functions in the frontal lobe. The results show that soccer players were significantly slower than controls in the Anti-Point task but displayed no difference in Pro-Point latencies, indicating a disruption specific to voluntary responses. These findings suggest that even subconcussive blows in soccer can result in cognitive function changes that are consistent with mild traumatic brain injury of the frontal lobes. There is great clinical and practical potential of a tablet-based application for quick detection and monitoring of cognitive dysfunction.	[Zhang, Marsha R.; Red, Stuart D.; Lin, Angela H.; Patel, Saumil S.; Sereno, Anne B.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA; [Patel, Saumil S.] Baylor Coll Med, Houston, TX 77030 USA	Sereno, AB (corresponding author), Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.	Anne.B.Sereno@uth.tmc.edu		Patel, Saumil/0000-0002-2386-8940	NSFNational Science Foundation (NSF) [BS 0924636]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30EY010608]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY010608] Funding Source: NIH RePORTER; Division Of Behavioral and Cognitive SciNational Science Foundation (NSF)NSF - Directorate for Social, Behavioral & Economic Sciences (SBE) [0924636] Funding Source: National Science Foundation	This work was supported in part by NSF BS 0924636 and NIH P30EY010608 grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Audiffren M, 2008, ACTA PSYCHOL, V129, P410, DOI 10.1016/j.actpsy.2008.09.006; Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Broerse A, 2001, PSYCHIAT RES, V103, P167, DOI 10.1016/S0165-1781(01)00275-X; Everling S, 1998, NEUROPSYCHOLOGIA, V36, P885, DOI 10.1016/S0028-3932(98)00020-7; Gooding DC, 2004, PSYCHOL MED, V34, P921, DOI 10.1017/S003329170300165X; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Hill SK, 2008, SCHIZOPHRENIA BULL, V34, P494, DOI 10.1093/schbul/sbm112; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V22, P1; Kelly JC, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/371970; Khatoon S, 2002, VISION RES, V42, P2693, DOI 10.1016/S0042-6989(02)00327-9; Kim N, 2011, MAKING SOCCER SAFER; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Lambourne K, 2010, BRAIN RES, V1341, P12, DOI 10.1016/j.brainres.2010.03.091; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Rieder C, 2011, ARCH CLIN NEUROPSYCH, V26, P583, DOI 10.1093/arclin/acr055; Rutherford A, 2003, NEUROPSYCHOL REV, V13; Sereno A.B., 2009, ENCY NEUROSCIENCE, P117; SERENO AB, 1995, BIOL PSYCHIAT, V37, P394, DOI 10.1016/0006-3223(94)00127-O; Shrestha Y, 2011, TABLET BASED STIMULU, P64; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Toni I, 2001, EXP BRAIN RES, V141, P359, DOI 10.1007/s002210100877; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wise SP, 2000, TRENDS NEUROSCI, V23, P271, DOI 10.1016/S0166-2236(00)01570-8; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	29	57	57	0	26	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 27	2013	8	2							e57364	10.1371/journal.pone.0057364			4	Multidisciplinary Sciences	Science & Technology - Other Topics	098BN	WOS:000315519000097	23460843	DOAJ Gold, Green Published			2021-06-18	
J	Pop, V; Sorensen, DW; Kamper, JE; Ajao, DO; Murphy, MP; Head, E; Hartman, RE; Badaut, J				Pop, Viorela; Sorensen, Dane W.; Kamper, Joel E.; Ajao, David O.; Murphy, M. Paul; Head, Elizabeth; Hartman, Richard E.; Badaut, Jerome			Early brain injury alters the blood-brain barrier phenotype in parallel with beta-amyloid and cognitive changes in adulthood	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						amyloid; claudin 5; endothelial; juvenile; P-glycoprotein; traumatic brain injury	P-GLYCOPROTEIN EXPRESSION; ALZHEIMERS-DISEASE; DEPOSITION; IMPAIRMENT; PATHOLOGY	Clinical studies suggest that traumatic brain injury (TBI) hastens cognitive decline and development of neuropathology resembling brain aging. Blood-brain barrier (BBB) disruption following TBI may contribute to the aging process by deregulating substance exchange between the brain and blood. We evaluated the effect of juvenile TBI (jTBI) on these processes by examining long-term alterations of BBB proteins, beta-amyloid (A beta) neuropathology, and cognitive changes. A controlled cortical impact was delivered to the parietal cortex of male rats at postnatal day 17, with behavioral studies and brain tissue evaluation at 60 days post-injury (dpi). Immunoglobulin G extravasation was unchanged, and jTBI animals had higher levels of tight-junction protein claudin 5 versus shams, suggesting the absence of BBB disruption. However, decreased P-glycoprotein (P-gp) on cortical blood vessels indicates modifications of BBB properties. In parallel, we observed higher levels of endogenous rodent A beta in several brain regions of the jTBI group versus shams. In addition at 60 dpi, jTBI animals displayed systematic search strategies rather than relying on spatial memory during the water maze. Together, these alterations to the BBB phenotype after jTB1 may contribute to the accumulation of toxic products, which in turn may induce cognitive differences and ultimately accelerate brain aging. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 205-214; doi:10.1038/jcbfm.2012.154; published online 14 November 2012	[Pop, Viorela; Sorensen, Dane W.; Badaut, Jerome] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92354 USA; [Sorensen, Dane W.; Ajao, David O.; Badaut, Jerome] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Kamper, Joel E.; Hartman, Richard E.] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA; [Murphy, M. Paul; Head, Elizabeth] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40506 USA	Badaut, J (corresponding author), Loma Linda Univ, Sch Med Coleman Pavil, Dept Pediat Pharmacol & Physiol, Room A1120 11175,Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu	Hartman, Richard/C-5767-2008; Kamper, Joel/V-2450-2019	Hartman, Richard/0000-0001-9235-3169; Kamper, Joel/0000-0001-5098-5176	NSFNational Science Foundation (NSF) [MRI-DBI 0923559]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG005119] Funding Source: NIH RePORTER	The authors thank Dr Andre Obenaus (Loma Linda University) for project assistance and Monica Rubalcava for a portion of imaging performed at the Loma Linda University School of Medicine Advanced Imaging and Microscopy Core (LLUSM AIM) supported by NSF Grant, MRI-DBI 0923559 (to SM Wilson).	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Andras IE, 2010, MOL CELL NEUROSCI, V43, P232, DOI 10.1016/j.mcn.2009.11.004; Babikian T, 2010, DEV NEUROSCI-BASEL, V32, P431, DOI 10.1159/000320667; Bart J, 2007, BRIT J CANCER, V97, P322, DOI 10.1038/sj.bjc.6603864; Bertolizio G, 2011, PEDIATR ANESTH, V21, P1198, DOI 10.1111/j.1460-9592.2011.03695.x; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Brenn Anja, 2011, Int J Alzheimers Dis, V2011, P690121, DOI 10.4061/2011/690121; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Cirrito JR, 2005, J CLIN INVEST, V115, P3285, DOI 10.1172/JCI25247; del Valle J, 2011, NEURODEGENER DIS, V8, P421, DOI 10.1159/000324757; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Honer WG, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.38; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Istrate AN, 2012, BIOPHYS J, V102, P136, DOI 10.1016/j.bpj.2011.11.4006; Jicha GA, 2006, ARCH NEUROL-CHICAGO, V63, P674, DOI 10.1001/archneur.63.5.674; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kooij G, 2010, J AUTOIMMUN, V34, P416, DOI 10.1016/j.jaut.2009.10.006; Liao CW, 2008, PARASITE IMMUNOL, V30, P525, DOI 10.1111/j.1365-3024.2008.01048.x; Lin JL, 2010, J CEREBR BLOOD F MET, V30, P1121, DOI 10.1038/jcbfm.2009.277; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Miller DS, 2010, TRENDS PHARMACOL SCI, V31, P246, DOI 10.1016/j.tips.2010.03.003; Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3; Nicolakakis N, 2011, J CEREBR BLOOD F MET, V31, P1354, DOI 10.1038/jcbfm.2011.43; Papp KV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021688; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2012, NEUROBIOL AGING, V33, P108, DOI 10.1016/j.neurobiolaging.2010.02.008; Robinson JL, 2011, BRAIN, V134, P3705, DOI 10.1093/brain/awr308; Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P1034, DOI 10.1097/NEN.0b013e3181f46e25; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012; Tian LL, 2012, BRAIN RES, V1440, P47, DOI 10.1016/j.brainres.2011.12.059; Ueno M, 2010, CURR MED CHEM, V17, P1125, DOI 10.2174/092986710790827816; van Assema DME, 2012, BRAIN, V135, P181, DOI 10.1093/brain/awr298; van Groen T, 2005, STROKE, V36, P1551, DOI 10.1161/01.STR.0000169933.88903.cf; Vogelgesang S, 2002, PHARMACOGENETICS, V12, P535, DOI 10.1097/00008571-200210000-00005; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	38	57	57	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2013	33	2					205	214		10.1038/jcbfm.2012.154			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	087CT	WOS:000314739600008	23149553	Green Published, Bronze			2021-06-18	
J	Douglas, JM				Douglas, Jacinta M.			Conceptualizing self and maintaining social connection following severe traumatic brain injury	BRAIN INJURY			English	Article						Self-concept; identity; narrative self; rehabilitation; outcome; quality-of-life	QUALITY-OF-LIFE; HEAD-INJURY; PEOPLE; REHABILITATION; QUESTIONNAIRE; PERSPECTIVES; INTERVIEWS; EXPERIENCE; NARRATIVES; AWARENESS	Primary objective: To explore how adults who have sustained severe traumatic brain injury (TBI) conceptualize self several years after injury. Design: Self-conceptualization was explored from the perspective of the injured individual within a constructivist Grounded Theory approach using in-depth interviews. Qualitative analysis moved through a process of data-driven open and focused coding, identification of emergent self-related categories and exploration of relations between these categories. Participants: Sixteen men and four women with severe-very severe injury participated in the study. Severity of injury was indexed by either a Glasgow Coma Scale (GCS) score <= 8 or duration of post-traumatic amnesia (PTA) >= 14 days. At the time of interview, the average age of participants was 35.2 years and a minimum of 5 years had elapsed since injury. Main outcomes and results: Three main themes emerged from the data. The first two themes together described a model of self-concept. The third theme captured the insider's perspective on factors that had helped to create and maintain a sense of connection between self and society. Conclusion: Conceptualization of self after brain injury is a dynamic and multi-faceted process. Insight into the process can guide the development of therapeutic endeavours to facilitate the ongoing construction of self after severe TBI.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3086, Australia.	j.douglas@latrobe.edu.au		Douglas, Jacinta/0000-0003-0940-6624	La Trobe University, Faculty of Health Sciences, Clinical Research Fellowship	This project was supported by a La Trobe University, Faculty of Health Sciences, Clinical Research Fellowship awarded to the author.	Bagiella E, 2010, J HEAD TRAUMA REHAB, V25, P375, DOI 10.1097/HTR.0b013e3181d27fe3; Bluff R., 2005, QUALITATIVE RES HLTH, P147; Browne J., 2004, HDB RES METHODS NURS, P624; Campbell JD, 1996, J PERS SOC PSYCHOL, V70, P141, DOI 10.1037/0022-3514.70.1.141; Cantor JB, 2005, J HEAD TRAUMA REHAB, V20, P527, DOI 10.1097/00001199-200511000-00005; Carlsson E, 2007, QUAL HEALTH RES, V17, P1361, DOI 10.1177/1049732307306926; Chamberlain DJ, 2006, J ADV NURS, V54, P407, DOI 10.1111/j.1365-2648.2006.03840.x; CHARMAZ K, 1990, SOC SCI MED, V30, P1161, DOI 10.1016/0277-9536(90)90256-R; Charmaz K, 2006, CONSTRUCTING GROUNDE; Charmaz K., 2009, DEV GROUNDED THEORY, P127; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2007, J HEAD TRAUMA REHAB, V22, P31, DOI 10.1097/00001199-200701000-00004; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Douglas JM, 2006, BRAIN IMPAIR, V7, P107, DOI DOI 10.1375/BRIM.7.2.107; Gardner W. L., 2005, SOCIAL OUTCAST OSTRA, P227; Gracey F, 2008, NEUROPSYCHOL REHABIL, V18, P627, DOI 10.1080/09602010802041238; HADORN DC, 1995, J CLIN EPIDEMIOL, V48, P619, DOI 10.1016/0895-4356(94)00186-T; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; Klein SB, 2010, WIRES COGN SCI, V1, P172, DOI 10.1002/wcs.25; Klinger L, 2005, J OCCUP SCI, V12, P9, DOI 10.1080/14427591.2005.9686543; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; Lloyd V, 2006, QUAL HEALTH RES, V16, P1386, DOI 10.1177/1049732306293846; McAdams Dan P. Ruthellen, 2006, IDENTITY STORY CREAT; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; Minichiello V, 2004, HDB RES METHODS NURS, P411; Morf C, 2005, SELF IDENTITY, V4, P97; Morse J., 2002, READ ME 1 USERS GUID; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Ouellet MC, 2009, J HEAD TRAUMA REHAB, V24, P262, DOI 10.1097/HTR.0b013e3181a68b73; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; QSR International Pty Ltd, 2006, NVIVO QUAL DAT AN SO; Sabat Ayesha, 2006, S Afr J Commun Disord, V53, P17; Shaddon B., 2008, LIFE STORIES NARRATI; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stein KF, 1996, J PSYCHOTHER INTEGR, V6, P349, DOI 10.1037/h0101118; Suls J, 2002, CURR DIR PSYCHOL SCI, V11, P159, DOI 10.1111/1467-8721.00191; Suls J., 2000, HDB SOCIAL COMP; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Whitbourne SK, 2002, IDENTITY, V2, P29, DOI DOI 10.1207/S1532706XID0201_; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2001, INT CLASS FUNCT DIS; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; Ylvisaker M, 2000, BRAIN IMPAIR, V1, P12, DOI DOI 10.1375/BRIM.1.1.12	59	57	57	1	24	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					60	74		10.3109/02699052.2012.722254			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300007	23252437				2021-06-18	
J	Clayton, EH; Genin, GM; Bayly, PV				Clayton, Erik H.; Genin, Guy M.; Bayly, Philip V.			Transmission, attenuation and reflection of shear waves in the human brain	JOURNAL OF THE ROYAL SOCIETY INTERFACE			English	Article						traumatic brain injury; magnetic resonance imaging; MR elastography; displacement; strain; blast	MAGNETIC-RESONANCE ELASTOGRAPHY; ACOUSTIC STRAIN WAVES; DIFFUSE AXONAL INJURY; MR ELASTOGRAPHY; VISCOELASTIC PROPERTIES; HEAD INJURY; DEFORMATION; ACCELERATION; IMPACT; FLOW	Traumatic brain injuries (TBIs) are caused by acceleration of the skull or exposure to explosive blast, but the processes by which mechanical loads lead to neurological injury remain poorly understood. We adapted motion-sensitive magnetic resonance imaging methods to measure the motion of the human brain in vivo as the skull was exposed to harmonic pressure excitation (45, 60 and 80 Hz). We analysed displacement fields to quantify the transmission, attenuation and reflection of distortional (shear) waves as well as viscoelastic material properties. Results suggest that internal membranes, such as the falx cerebri and the tentorium cerebelli, play a key role in reflecting and focusing shear waves within the brain. The skull acts as a low-pass filter over the range of frequencies studied. Transmissibility of pressure waves through the skull decreases and shear wave attenuation increases with increasing frequency. The skull and brain function mechanically as an integral structure that insulates internal anatomic features; these results are valuable for building and validating mathematical models of this complex and important structural system.	[Clayton, Erik H.; Genin, Guy M.; Bayly, Philip V.] Washington Univ, Dept Mech Engn & Mat Sci, St Louis, MO 63130 USA; [Bayly, Philip V.] Washington Univ, Dept Biomed Engn, St Louis, MO 63130 USA	Clayton, EH (corresponding author), Washington Univ, Dept Mech Engn & Mat Sci, 1 Brookings Dr,Campus Box 1185, St Louis, MO 63130 USA.	clayton@wustl.edu		Bayly, Philip/0000-0003-4303-0704	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS055951]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055951] Funding Source: NIH RePORTER	Financial support for this study was provided by NIH grant R01 NS055951 (Bayly). The authors gratefully acknowledge Dr Bradley Bolster and Dr Agus Priatna at Siemens Healthcare for supporting MR pulse sequence development as well as technologists Glenn Foster, Scott Love and Mark Nolte at Washington University's Center for Clinical Imaging Research for assistance with MRI data acquisition.	Abney TM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022063; Auld BA., 1990, ACOUSTIC FIELDS WAVE; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Braun J, 2001, MAGN RESON IMAGING, V19, P703, DOI 10.1016/S0730-725X(01)00387-3; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; EHMAN RL, 1990, MAGNET RESON MED, V14, P293, DOI 10.1002/mrm.1910140214; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Green MA, 2008, NMR BIOMED, V21, P755, DOI 10.1002/nbm.1254; Grimm R. C., 2006, MRE WAVE VERSION 1 J; Hamhaber U, 2007, ACTA BIOMATER, V3, P127, DOI 10.1016/j.actbio.2006.08.007; Hamhaber U, 2010, J MAGN RESON IMAGING, V32, P577, DOI 10.1002/jmri.22294; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Holbourn AHS, 1943, LANCET, V2, P438; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Klatt D, 2007, PHYS MED BIOL, V52, P7281, DOI 10.1088/0031-9155/52/24/006; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; KNUTSSON H, 1994, IEEE IMAGE PROC, P36, DOI 10.1109/ICIP.1994.413270; Kolsky H., 1963, STRESS WAVES SOLIDS; Kruse SA, 2000, PHYS MED BIOL, V45, P1579, DOI 10.1088/0031-9155/45/6/313; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Manduca A, 2001, MED IMAGE ANAL, V5, P237, DOI 10.1016/S1361-8415(00)00039-6; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McCracken P, 2004, LECT NOTES COMPUT SC, V3217, P1081; McCracken P. J., 2003, MR ELASTOGRAPHY STUD, P799; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MORAN PR, 1991, RADIOLOGY, V180, P115, DOI 10.1148/radiology.180.1.2052676; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Muthupillai R, 1996, MAGN RESON MED, V36, P266, DOI 10.1002/mrm.1910360214; Nyein MK, 2010, P NATL ACAD SCI USA, V107, P20703, DOI 10.1073/pnas.1014786107; Okamoto RJ, 2011, PHYS MED BIOL, V56, P6379, DOI 10.1088/0031-9155/56/19/014; PERMAN WH, 1986, J COMPUT ASSIST TOMO, V10, P473; Romano A, 2012, MAGN RESON MED, V68, P1410, DOI 10.1002/mrm.24141; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Sack I, 2008, NMR BIOMED, V21, P265, DOI 10.1002/nbm.1189; Sinkus R, 2000, PHYS MED BIOL, V45, P1649, DOI 10.1088/0031-9155/45/6/317; Sinkus R, 2005, MAGN RESON IMAGING, V23, P159, DOI 10.1016/j.mri.2004.11.060; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Streitberger KJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029888; Streitberger KJ, 2011, NMR BIOMED, V24, P385, DOI 10.1002/nbm.1602; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; van Dommelen JAW, 2010, J MECH BEHAV BIOMED, V3, P158, DOI 10.1016/j.jmbbm.2009.09.001; Whitham G.B., 1974, LINEAR NONLINEAR WAV; Wuerfel J, 2010, NEUROIMAGE, V49, P2520, DOI 10.1016/j.neuroimage.2009.06.018; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034	48	57	58	0	28	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1742-5689	1742-5662		J R SOC INTERFACE	J. R. Soc. Interface	NOV 7	2012	9	76					2899	2910		10.1098/rsif.2012.0325			12	Multidisciplinary Sciences	Science & Technology - Other Topics	012XD	WOS:000309269100014	22675163	Bronze, Green Published			2021-06-18	
J	Sashindranath, M; Sales, E; Daglas, M; Freeman, R; Samson, AL; Cops, EJ; Beckham, S; Galle, A; McLean, C; Morganti-Kossmann, C; Rosenfeld, JV; Madani, R; Vassalli, JD; Su, EMJ; Lawrence, DA; Medcalf, RL				Sashindranath, Maithili; Sales, Eunice; Daglas, Maria; Freeman, Roxann; Samson, Andre L.; Cops, Elisa J.; Beckham, Simone; Galle, Adam; McLean, Catriona; Morganti-Kossmann, Cristina; Rosenfeld, Jeffrey V.; Madani, Rime; Vassalli, Jean-Dominique; Su, Enming J.; Lawrence, Daniel A.; Medcalf, Robert L.			The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans	BRAIN			English	Article						neurovascular unit; traumatic brain injury; tissue plasminogen activator; plasminogen activator inhibitor-1; matrix metalloproteinase-3	RECEPTOR-RELATED PROTEIN; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS LESIONS; FOCAL CEREBRAL-ISCHEMIA; MATRIX METALLOPROTEINASES; BARRIER BREAKDOWN; BLOOD; STROKE; TPA; EXPRESSION	The neurovascular unit provides a dynamic interface between the circulation and central nervous system. Disruption of neurovascular integrity occurs in numerous brain pathologies including neurotrauma and ischaemic stroke. Tissue plasminogen activator is a serine protease that converts plasminogen to plasmin, a protease that dissolves blood clots. Besides its role in fibrinolysis, tissue plasminogen activator is abundantly expressed in the brain where it mediates extracellular proteolysis. However, proteolytically active tissue plasminogen activator also promotes neurovascular disruption after ischaemic stroke; the molecular mechanisms of this process are still unclear. Tissue plasminogen activator is naturally inhibited by serine protease inhibitors (serpins): plasminogen activator inhibitor-1, neuroserpin or protease nexin-1 that results in the formation of serpin:protease complexes. Proteases and serpin:protease complexes are cleared through high-affinity binding to low-density lipoprotein receptors, but their binding to these receptors can also transmit extracellular signals across the plasma membrane. The matrix metalloproteinases are the second major proteolytic system in the mammalian brain, and like tissue plasminogen activators are pivotal to neurological function but can also degrade structures of the neurovascular unit after injury. Herein, we show that tissue plasminogen activator potentiates neurovascular damage in a dose-dependent manner in a mouse model of neurotrauma. Surprisingly, inhibition of activity following administration of plasminogen activator inhibitor-1 significantly increased cerebrovascular permeability. This led to our finding that formation of complexes between tissue plasminogen activator and plasminogen activator inhibitor-1 in the brain parenchyma facilitates post-traumatic cerebrovascular damage. We demonstrate that following trauma, the complex binds to low-density lipoprotein receptors, triggering the induction of matrix metalloproteinase-3. Accordingly, pharmacological inhibition of matrix metalloproteinase-3 attenuates neurovascular permeability and improves neurological function in injured mice. Our results are clinically relevant, because concentrations of tissue plasminogen activator: plasminogen activator inhibitor-1 complex and matrix metalloproteinase-3 are significantly elevated in cerebrospinal fluid of trauma patients and correlate with neurological outcome. In a separate study, we found that matrix metalloproteinase-3 and albumin, a marker of cerebrovascular damage, were significantly increased in brain tissue of patients with neurotrauma. Perturbation of neurovascular homeostasis causing oedema, inflammation and cell death is an important cause of acute and long-term neurological dysfunction after trauma. A role for the tissue plasminogen activator-matrix metalloproteinase axis in promoting neurovascular disruption after neurotrauma has not been described thus far. Targeting tissue plasminogen activator: plasminogen activator inhibitor-1 complex signalling or downstream matrix metalloproteinase-3 induction may provide viable therapeutic strategies to reduce cerebrovascular permeability after neurotrauma.	[Sashindranath, Maithili; Sales, Eunice; Daglas, Maria; Freeman, Roxann; Samson, Andre L.; Cops, Elisa J.; Beckham, Simone; Galle, Adam; Medcalf, Robert L.] Monash Univ, Australian Ctr Blood Dis, Melbourne, Vic 3004, Australia; [McLean, Catriona] Alfred Hosp, Dept Pathol, Melbourne, Vic 3004, Australia; [Morganti-Kossmann, Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Alfred Hosp, Dept Surg, Melbourne, Vic 3004, Australia; [Madani, Rime; Vassalli, Jean-Dominique] Univ Geneva, Fac Med, Dept Genet Med & Dev, CH-1211 Geneva 4, Switzerland; [Su, Enming J.; Lawrence, Daniel A.] Univ Michigan, Div Cardiovasc Med, Dept Internal Med, Ann Arbor, MI 48109 USA	Medcalf, RL (corresponding author), Monash Univ, Australian Ctr Blood Dis, Level 6,Burnet Bldg,89 Commercial Rd, Melbourne, Vic 3004, Australia.	robert.medcalf@monash.edu	Sashindranath, Maithili/AAI-7408-2021; Medcalf, Robert L/E-9632-2011; Rosenfeld, Jeffrey V/B-7249-2011	Sashindranath, Maithili/0000-0002-9712-4784; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Lawrence, Daniel/0000-0003-3126-1935; Samson, Andre/0000-0002-0637-2716	National Health and Medical Research Council (NHMRC) of AustraliaNational Health and Medical Research Council of Australia [606660]; Victorian Neurotrauma Initiative [D0-34]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL55374, HL54710, HL089407]; Neurotrauma Tissue/Fluid Bank; Victorian Brain Bank Network; Mental Health Research Institute; Alfred Hospital; National Trauma Research Institute; Victorian Forensic Institute of Medicine; Victorian Neurotrauma Initiative; Transport Accident Commission (TAC); NHMRC of AustraliaNational Health and Medical Research Council of Australia; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL089407, P01HL054710, R01HL055374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079639] Funding Source: NIH RePORTER	Grant numbers 606660 and D0-34 awarded to R.L.M from the National Health and Medical Research Council (NHMRC) of Australia and the Victorian Neurotrauma Initiative, respectively, and by grant numbers HL55374, HL54710, and HL089407 awarded to D. A. L from the National Institutes of Health. Tissues were received from the Neurotrauma Tissue/Fluid Bank, supported by the Victorian Brain Bank Network, Mental Health Research Institute, The Alfred Hospital, the National Trauma Research Institute, Victorian Forensic Institute of Medicine and funded by Victorian Neurotrauma Initiative, the Transport Accident Commission (TAC) and the NHMRC of Australia.	Alvarez JI, 2011, BBA-MOL BASIS DIS, V1812, P252, DOI 10.1016/j.bbadis.2010.06.017; Armstead WM, 2006, NAT NEUROSCI, V9, P1150, DOI 10.1038/nn1757; Armstead WM, 2011, NEUROL RES, V33, P726, DOI 10.1179/016164110X12807570509853; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fanne R Abu, 2010, NEUROPHARMACOLOGY, V58, P972, DOI DOI 10.1016/J.NEUROPHARM.2009.12.017; Gary AR, 2002, GLIA, V39, P279; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Gveric D, 2005, AM J PATHOL, V166, P1143, DOI 10.1016/S0002-9440(10)62334-6; Gveric D, 2003, BRAIN, V126, P1590, DOI 10.1093/brain/awg167; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Johansson L, 2000, STROKE, V31, P26, DOI 10.1161/01.STR.31.1.26; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Lemarchant S, 2012, NEUROPHARMACOLOGY, V62, P749, DOI 10.1016/j.neuropharm.2011.10.020; Lillis AP, 2008, PHYSIOL REV, V88, P887, DOI 10.1152/physrev.00033.2007; Lo EH, 2004, STROKE, V35, P354, DOI 10.1161/01.STR.0000115164.80010.8A; MacPherson LJ, 1997, J MED CHEM, V40, P2525, DOI 10.1021/jm960871c; Macrez R, 2011, STROKE, V42, P2315, DOI 10.1161/STROKEAHA.110.606293; Madani R, 1999, EMBO J, V18, P3007, DOI 10.1093/emboj/18.11.3007; Maeda A, 1996, J NEUROPATH EXP NEUR, V55, P300, DOI 10.1097/00005072-199603000-00005; Mori T, 2001, NEUROREPORT, V12, P4117, DOI 10.1097/00001756-200112210-00051; Nilsson TK, 2005, THROMB RES, V116, P249, DOI 10.1016/j.thromres.2004.12.005; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; PHILIPS M, 1984, BIOCHIM BIOPHYS ACTA, V802, P99, DOI 10.1016/0304-4165(84)90039-4; Polavarapu R, 2007, BLOOD, V109, P3270, DOI 10.1182/blood-2006-08-043125; Sashindranath M, 2011, LAB INVEST, V91, P1079, DOI 10.1038/labinvest.2011.67; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Su EJ, 2008, NAT MED, V14, P731, DOI 10.1038/nm1787; Suzuki Y, 2007, J THROMB HAEMOST, V5, P1732, DOI 10.1111/j.1538-7836.2007.02628.x; Suzuki Y, 2009, BLOOD, V114, P3352, DOI 10.1182/blood-2009-02-203919; Tomkins O, 2011, CARDIOVASC PSYCHIAT, V2011; Tsuji K, 2005, STROKE, V36, P1954, DOI 10.1161/01.STR.0000177517.01203.eb; Verma A, 2000, J HEAD TRAUMA REHAB, V15, P1149, DOI 10.1097/00001199-200010000-00008; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yang D, 2009, J NEUROSCI, V29, P8669, DOI 10.1523/JNEUROSCI.1117-09.2009; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Yepes M, 2003, J CLIN INVEST, V112, P1533, DOI 10.1172/JCI200319212; Zaheer Z, 2011, THER ADV CHRONIC DIS, V2, P119, DOI 10.1177/2040622310394032; Zhang C, 2009, J CEREBR BLOOD F MET, V29, P1946, DOI 10.1038/jcbfm.2009.174; Zhang C, 2009, AM J PATHOL, V174, P586, DOI 10.2353/ajpath.2009.080661; Zhang XH, 2007, AM J PATHOL, V171, P1281, DOI 10.2353/ajpath.2007.070472; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	49	57	59	0	27	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	NOV	2012	135		11				3251	3264		10.1093/brain/aws178			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	044SV	WOS:000311644800013	22822039	Green Published, Other Gold			2021-06-18	
J	Viola-Saltzman, M; Watson, NF				Viola-Saltzman, Mari; Watson, Nathaniel F.			Traumatic Brain Injury and Sleep Disorders	NEUROLOGIC CLINICS			English	Article						Traumatic brain injury; Concussion; Insomnia; Fatigue; Hypersomnia; Sleep apnea; Restless legs syndrome	EXCESSIVE DAYTIME SLEEPINESS; KLEINE-LEVIN-SYNDROME; MINOR HEAD-INJURY; CIRCADIAN-RHYTHM; UNITED-STATES; DISTURBANCES; INSOMNIA; PREVALENCE; VETERANS; COMPLAINTS	Sleep disturbance is common after traumatic brain injury (TBI). Insomnia, fatigue, and sleepiness are the most frequent post-TBI sleep complaints with narcolepsy (with or without cataplexy), sleep apnea (obstructive or central), periodic limb movement disorder, and parasomnias occurring less commonly. In addition, depression, anxiety, and pain are common TBI comorbidities with substantial influence on sleep quality. Diagnosis of sleep disorders after TBI may involve polysomnography, multiple sleep latency testing, or actigraphy. Treatment is disorder-specific and includes the use of medications, continuous positive airway pressure, or behavioral modifications. Unfortunately, treatment of sleep disorders associated with TBI often does not improve sleepiness or neuropsychologic function.	[Watson, Nathaniel F.] Univ Washington, Med Sleep Ctr, Seattle, WA 98104 USA; [Viola-Saltzman, Mari] N Shore Univ HealthSyst, Pritzker Sch Med, Dept Neurol, Evanston, IL 60201 USA	Watson, NF (corresponding author), Univ Washington, Med Sleep Ctr, 325 9th Ave,Box 359803, Seattle, WA 98104 USA.	nwatson@uw.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23 HL083350] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL083350] Funding Source: NIH RePORTER		[Anonymous], 2005, INT CLASS SLEEP DIS, p[xviii, 297]; Llompart-Pou JA, 2010, NEUROCRIT CARE, V13, P211, DOI 10.1007/s12028-010-9399-1; Arnulf I, 2005, BRAIN, V128, P2763, DOI 10.1093/brain/awh620; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; BRICOLO A, 1968, ACTA NEUROL SCAND, V44, P512, DOI 10.1111/j.1600-0404.1968.tb05589.x; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; Carter KA, 2010, J CLIN SLEEP MED, V6, P205; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Dauvilliers Y, 2003, J NEUROL NEUROSUR PS, V74, P1667, DOI 10.1136/jnnp.74.12.1667; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kelly JP, 1997, NEUROLOGY, V48, P581; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leduc BE, 2007, ARCH PHYS MED REHAB, V88, P333, DOI 10.1016/j.apmr.2006.12.025; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Pillar G, 2003, PEDIATR NEUROL, V29, P131, DOI 10.1016/S0887-8994(03)00149-8; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schenck CH, 1997, SLEEP, V20, P972, DOI 10.1093/sleep/20.11.972; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Theodorou AA, 2007, J CLIN SLEEP MED, V3, P347; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; WINSTON SR, 1979, J IOWA MED SOC, V69, P393; Zollman FS, 2012, J HEAD TRAUMA REHAB, V27, P135, DOI 10.1097/HTR.0b013e3182051397	55	57	61	0	32	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	NOV	2012	30	4					1299	+		10.1016/j.ncl.2012.08.008			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	047XI	WOS:000311874400016	23099139	Green Accepted			2021-06-18	
J	Timaru-Kast, R; Luh, C; Gotthardt, P; Huang, CS; Schafer, MK; Engelhard, K; Thal, SC				Timaru-Kast, Ralph; Luh, Clara; Gotthardt, Philipp; Huang, Changsheng; Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.			Influence of Age on Brain Edema Formation, Secondary Brain Damage and Inflammatory Response after Brain Trauma in Mice	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; TUMOR-NECROSIS-FACTOR; PROSPECTIVE MULTICENTER TRIAL; NF-KAPPA-B; OXIDATIVE STRESS; GENE-EXPRESSION; OLDER-ADULTS; HEAD-INJURY; ENVIRONMENTAL ENRICHMENT; NEURONAL DEATH	After traumatic brain injury (TBI) elderly patients suffer from higher mortality rate and worse functional outcome compared to young patients. However, experimental TBI research is primarily performed in young animals. Aim of the present study was to clarify whether age affects functional outcome, neuroinflammation and secondary brain damage after brain trauma in mice. Young (2 months) and old (21 months) male C57Bl6N mice were anesthetized and subjected to a controlled cortical impact injury (CCI) on the right parietal cortex. Animals of both ages were randomly assigned to 15 min, 24 h, and 72 h survival. At the end of the observation periods, contusion volume, brain water content, neurologic function, cerebral and systemic inflammation (CD3+ T cell migration, inflammatory cytokine expression in brain and lung, blood differential cell count) were determined. Old animals showed worse neurological function 72 h after CCI and a high mortality rate (19.2%) compared to young (0%). This did not correlate with histopathological damage, as contusion volumes were equal in both age groups. Although a more pronounced brain edema formation was detected in old mice 24 hours after TBI, lack of correlation between brain water content and neurological deficit indicated that brain edema formation is not solely responsible for age-dependent differences in neurological outcome. Brains of old naive mice were about 8% smaller compared to young naive brains, suggesting age-related brain atrophy with possible decline in plasticity. Onset of cerebral inflammation started earlier and primarily ipsilateral to damage in old mice, whereas in young mice inflammation was delayed and present in both hemispheres with a characteristic T cell migration pattern. Pulmonary interleukin 1 beta expression was up-regulated after cerebral injury only in young, not aged mice. The results therefore indicate that old animals are prone to functional deficits and strong ipsilateral cerebral inflammation without major differences in morphological brain damage compared to young.	[Timaru-Kast, Ralph; Luh, Clara; Gotthardt, Philipp; Huang, Changsheng; Schaefer, Michael K.; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anaesthesiol, Mainz, Germany; [Huang, Changsheng; Schaefer, Michael K.; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Focus Program Translat Neurosci, Mainz, Germany	Timaru-Kast, R (corresponding author), Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Anaesthesiol, Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Huang, Changsheng/0000-0003-0535-1865	Focus Program Translational Neurosciences of the Johannes Gutenberg-University	This work was supported by grants from the Focus Program Translational Neurosciences of the Johannes Gutenberg-University to SCT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], PLOS ONE; Arnett HA, 2003, J NEUROSCI, V23, P9824; Ashcroft GS, 2002, BIOGERONTOLOGY, V3, P337, DOI 10.1023/A:1021399228395; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; Barnes CJ, 1998, AGING-CLIN EXP RES, V10, P455, DOI 10.1007/BF03340159; Barreto G, 2010, J NEUROSURG ANESTH, V22, P214, DOI 10.1097/ANA.0b013e3181d56c98; Bieber AJ, 2003, ANN NEUROL, V53, P680, DOI 10.1002/ana.10578; Buchhold B, 2007, RESTOR NEUROL NEUROS, V25, P467; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Campbell SJ, 2007, NEUROPATH APPL NEURO, V33, P108, DOI 10.1111/j.1365-2990.2006.00773.x; Castillo-Ruiz MM, 2007, EXP GERONTOL, V42, P343, DOI 10.1016/j.exger.2006.10.008; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; COTMAN CW, 1979, MECH AGEING DEV, V9, P103, DOI 10.1016/0047-6374(79)90124-6; Felzien LK, 2001, BRAIN RES, V890, P137, DOI 10.1016/S0006-8993(00)03090-0; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Franceschi C, 2007, MECH AGEING DEV, V128, P92, DOI 10.1016/j.mad.2006.11.016; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gilmer LK, 2010, J NEUROTRAUM, V27, P939, DOI 10.1089/neu.2009.1181; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Gruver AL, 2007, J PATHOL, V211, P144, DOI 10.1002/path.2104; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Korhonen P, 1997, NEUROSCI LETT, V225, P61, DOI 10.1016/S0304-3940(97)00190-0; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Markus TM, 2005, ANN NEUROL, V58, P950, DOI 10.1002/ana.20676; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Popa-Wagner A, 2007, ACTA NEUROPATHOL, V113, P277, DOI 10.1007/s00401-006-0164-7; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Popa-Wagner A, 2010, CURR NEUROVASC RES, V7, P251, DOI 10.2174/156720210792231813; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Sandhir R, 2010, NEUROCHEM INT, V56, P188, DOI 10.1016/j.neuint.2009.10.002; Sandhu SK, 2002, BIOGERONTOLOGY, V3, P161, DOI 10.1023/A:1015643107449; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Sharman KG, 2002, NEUROBIOL AGING, V23, P633, DOI 10.1016/S0197-4580(01)00329-3; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; UNTERBERG A, 1994, ACTA NEUROCHIR, P431; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Williams B, 2007, NEUROSCI LETT, V413, P110, DOI 10.1016/j.neulet.2006.11.040; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	79	57	61	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 30	2012	7	8							e43829	10.1371/journal.pone.0043829			15	Multidisciplinary Sciences	Science & Technology - Other Topics	997ZH	WOS:000308206500024	22952778	DOAJ Gold, Green Published			2021-06-18	
J	Choi, KE; Hall, CL; Sun, JM; Wei, L; Mohamad, O; Dix, TA; Yu, SP				Choi, Ko-Eun; Hall, Casey L.; Sun, Jin-Mei; Wei, Ling; Mohamad, Osama; Dix, Thomas A.; Yu, Shan P.			A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice	FASEB JOURNAL			English	Article						neurotensin analog; brain protection; autophagy; sensorimotor function	MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; SUBARACHNOID HEMORRHAGE; NEUROTENSIN ANALOG; BODY-TEMPERATURE; ARTERY INFARCTION; BRAIN TEMPERATURE; HYPOXIC-ISCHEMIA; EMERGING ROLE; ACUTE-PHASE	Compelling evidence from preclinical and clinical studies has shown that mild to moderate hypothermia is neuroprotective against ischemic stroke. Clinical applications of hypothermia therapy, however, have been hindered by current methods of physical cooling, which is generally inefficient and impractical in clinical situations. In this report, we demonstrate the potential of pharmacologically induced hypothermia (PIH) by the novel neurotensin receptor 1 (NTR1) agonist ABS-201 in a focal ischemic model of adult mice. ABS-201 (1.5-2.5 mg/kg, i.p.) reduces body and brain temperature by 2-5 degrees C in 15-30 min in a dose-dependent manner without causing shivering or altering physiological parameters. Infarct volumes at 24 h after stroke are reduced by similar to 30-40% when PIH therapy is initiated either immediately after stroke induction or after 30-60 min delay. ABS-201 treatment increases bcl-2 expression, decreases caspase-3 activation, and TUNEL-positive cells in the peri-infarct region, and suppresses autophagic cell death compared to stroke controls. The PIH therapy using ABS-201 improves recovery of sensorimotor function as tested 21 d after stroke. These results suggest that PIH induced by neurotensin analogs represented by ABS-201 are promising candidates for treatment of ischemic stroke and possibly for other ischemic or traumatic injuries. Choi, K.-E., Hall, C. L., Sun, J.-M., Wei, L., Mohamad, O., Dix, T. A., Yu, S. P. A novel stroke therapy of pharmacologically induced hypothermia after focal cerebral ischemia in mice. FASEB J. 26, 2799-2810 (2012). www.fasebj.org	[Choi, Ko-Eun; Sun, Jin-Mei; Wei, Ling; Mohamad, Osama; Yu, Shan P.] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Hall, Casey L.; Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Dix, Thomas A.; Yu, Shan P.] Med Univ S Carolina, Dept Pharmaceut & Biomed Sci, Charleston, SC 29425 USA; [Dix, Thomas A.] Halimed Pharmaceut, Charleston, SC USA	Yu, SP (corresponding author), Emory Univ, Sch Med, Dept Anesthesiol, 101 Woodruff Cir,Woodruff Mem Res Bldg,Ste 620, Atlanta, GA 30322 USA.	spyu@emory.edu			U.S. National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS057255, NS058710, NS062097, R41NS073378, GM079044, MH65099]; Yerkes National Primate Center/NIH [P51]; NIH from National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R43GM079044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R44MH065099, R41MH065099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058710, R01NS062097, R01NS057255, R41NS073378] Funding Source: NIH RePORTER	This work was supported by U.S. National Institutes of Health (NIH) grants NS057255, NS058710, NS062097, R41NS073378 (S.P.Y., L. W.), GM079044 (S.P.Y., T. A. D.), and MH65099 (T. A. D.) and by a Yerkes National Primate Center/NIH P51 pilot grant. This work was also supported by NIH grant C06 RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources.	BABCOCK AM, 1993, BRAIN RES BULL, V32, P373, DOI 10.1016/0361-9230(93)90202-M; Battin MR, 2009, PEDIATRICS, V123, P1031, DOI 10.1542/peds.2008-1610; CARRAWAY R, 1975, J BIOL CHEM, V250, P1912; Dawaliby R, 2010, MOL BIOL CELL, V21, P4173, DOI 10.1091/mbc.E09-09-0782; Den Hertog H. M., 2009, COCHRANE DB SYST REV, V21; Dubuc I, 1999, J NEUROSCI, V19, P503; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Feigin V, 2003, LANCET NEUROL, V2, P529, DOI 10.1016/S1474-4422(03)00500-3; Feigin VL, 2002, J CLIN NEUROSCI, V9, P502, DOI 10.1054/jocn.2001.1072; Froehler MT, 2010, EXPERT REV CARDIOVAS, V8, P593, DOI 10.1586/ERC.09.129; Ginet V, 2009, AM J PATHOL, V175, P1962, DOI 10.2353/ajpath.2009.090463; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Gonzalez-Ibarra Fernando Pavel, 2011, Front Neurol, V2, P4, DOI 10.3389/fneur.2011.00004; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hammer MD, 2003, NEUROLOGIST, V9, P280, DOI 10.1097/01.nrl.0000094628.29312.2b; Hughes FM, 2010, J MED CHEM, V53, P4623, DOI 10.1021/jm100092s; Humeau A, 2007, MED BIOL ENG COMPUT, V45, P421, DOI 10.1007/s11517-007-0170-5; ILLIEVICH UM, 1994, ANESTH ANALG, V78, P905; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Katz LM, 2004, CRIT CARE MED, V32, P806, DOI 10.1097/01.CCM.0000114998.00860.FD; Katz LM, 2001, ACAD EMERG MED, V8, P1115, DOI 10.1111/j.1553-2712.2001.tb01126.x; Kokko KP, 2005, NEUROPHARMACOLOGY, V48, P417, DOI 10.1016/j.neuropharm.2004.10.008; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lampe JW, 2011, ANNU REV MED, V62, P79, DOI 10.1146/annurev-med-052009-150512; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Linares G, 2009, CRIT CARE MED, V37, pS243, DOI 10.1097/CCM.0b013e3181aa5de1; MacLellan CL, 2006, STROKE, V37, P1266, DOI 10.1161/01.STR.0000217268.81963.78; Macleod MR, 2010, INT J STROKE, V5, P489, DOI 10.1111/j.1747-4949.2010.00520.x; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Martinet W, 2006, AUTOPHAGY, V2, P55, DOI 10.4161/auto.2217; Miyazawa T, 2003, NEUROL RES, V25, P457, DOI 10.1179/016164103101201850; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; Mizushima N, 2007, AUTOPHAGY, V3, P542; Nagel Simon, 2008, Expert Rev Neurother, V8, P1255, DOI 10.1586/14737175.8.8.1255; NEMEROFF CB, 1979, P NATL ACAD SCI USA, V76, P5368, DOI 10.1073/pnas.76.10.5368; NEMEROFF CB, 1980, BIOL PSYCHIAT, V15, P283; Ogle ME, 2012, NEUROBIOL DIS, V45, P733, DOI 10.1016/j.nbd.2011.10.020; Ohta H, 2007, NEUROSCI RES, V57, P424, DOI 10.1016/j.neures.2006.12.002; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Puyal J, 2009, ANN NEUROL, V66, P378, DOI 10.1002/ana.21714; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Schubert GA, 2008, J NEUROTRAUM, V25, P539, DOI 10.1089/neu.2007.0500; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Schwab S, 1998, ACT NEUR S, V71, P131; Shoji JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015650; Smith KE, 2011, BEHAV BRAIN RES, V224, P344, DOI 10.1016/j.bbr.2011.06.014; Sun J., 2011, SOC NEUR ANN M SESS; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tang XN, 2010, AGEING RES REV, V9, P61, DOI 10.1016/j.arr.2009.10.002; Thome C, 2005, NEUROL RES, V27, P229, DOI 10.1179/016164105X25252; Tian FF, 2010, AUTOPHAGY, V6, P1107, DOI 10.4161/auto.6.8.13427; Torok E, 2009, NEUROSURGERY, V65, P352, DOI 10.1227/01.NEU.0000345632.09882.FF; Torup L, 2003, NEUROSCI LETT, V351, P173, DOI 10.1016/j.neulet.2003.08.008; Tyler-McMahon BM, 2000, EUR J PHARMACOL, V390, P107, DOI 10.1016/S0014-2999(99)00877-8; Tyler-McMahon BM, 2000, REGUL PEPTIDES, V93, P125, DOI 10.1016/S0167-0115(00)00183-X; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Wei L, 2004, BRAIN RES, V1022, P54, DOI 10.1016/j.brainres.2004.06.080; Yanagawa Y, 2002, RESUSCITATION, V53, P93, DOI 10.1016/S0300-9572(01)00499-3; Yenari MA, 2010, STROKE, V41, pS72, DOI 10.1161/STROKEAHA.110.595371; Zhang F, 2009, J CEREBR BLOOD F MET, V29, P1022, DOI 10.1038/jcbfm.2009.28; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	69	57	59	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2012	26	7					2799	2810		10.1096/fj.11-201822			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	967MP	WOS:000305912500009	22459147	Green Published			2021-06-18	
J	Grauwmeijer, E; Heijenbrok-Kal, MH; Haitsma, IK; Ribbers, GM				Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Haitsma, Ian K.; Ribbers, Gerard M.			A Prospective Study on Employment Outcome 3 Years After Moderate to Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Employment; Prognosis; Prospective studies; Rehabilitation	FUNCTIONAL ASSESSMENT MEASURE; ASSESSMENT MEASURE FIM+FAM; GLASGOW COMA SCALE; INTERRATER RELIABILITY; HEAD-INJURY; FOLLOW-UP; RETURN; WORK; TBI; REHABILITATION	Objectives: To evaluate the employment outcome in patients with moderate to severe traumatic brain injury (TBI) and to identify which patients are at risk of unemployment 3 years after injury. Design: Prospective cohort study. Setting: Patients with moderate and severe TBI discharged from the neurosurgery departments of 3 level 1 trauma centers in The Netherlands. Participants: Patients aged 18 to 65 years (N=113; mean age +/- SD, 33.2 +/- 13.1y; 73% men) who were hospitalized with moderate (26% of patients) to severe (74% of patients) TBI. Interventions: Not applicable. Main Outcome Measures: The main outcome measure was employment status. Potential predictors included patient characteristics, injury severity factors, functional outcome measured at discharge from the acute hospital with the Glasgow Outcome Scale (GOS), Barthel Index (BO, and FIM, and cognitive functioning measured with the Functional Assessment Measure (FAM). Results: Ninety-four patients (83%) completed the 3-year follow-up. The employment rate dropped from 80% preinjury to 15% at 3 months postinjury and gradually increased to 55% after 3 years. The employment rate significantly increased from 3 months up to I year, but it did not change significantly from 1 to 3 years postinjury. Age, length of hospital stay, discharge to a nursing home (vs home), psychiatric symptoms, and BI, GOS, FIM, and FAM scores were found to be significant univariate determinants for employment status. By using multiple logistic regression analysis, the FAM score (adjusted odds ratio 1.1; P<.000) and psychiatric symptoms (adjusted odds ratio .08; P<.019) were selected as independent predictors for employment status. A FAM cutoff score of less than 65 to identify patients at risk of long-term unemployment had a good diagnostic value. Conclusions: Patients with TBI with psychiatric symptoms and impaired cognitive functioning at hospital discharge are at the highest risk of long-term unemployment. These factors should be the focus of vocational rehabilitation. (c) 2012 by the American Congress of Rehabilitation Medicine	[Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Rijndam Rehabil Ctr, Rotterdam, Netherlands; [Grauwmeijer, Erik; Heijenbrok-Kal, Majanka H.; Ribbers, Gerard M.] Erasmus MC, Dept Rehabil Med & Phys Therapy, Rotterdam, Netherlands; [Haitsma, Ian K.] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands	Ribbers, GM (corresponding author), Rotterdam NeuroRehabil Res, POB 23181, NL-3001 KD Rotterdam, Netherlands.	g.ribbers@rijndam.nl	Ribbers, Gerard/N-3623-2019; Ribbers, Gerard M/C-1454-2014	Ribbers, Gerard M/0000-0002-6114-349X; Heijenbrok-Kal, Majanka H./0000-0002-2982-4404			Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Collin C, 1988, Int Disabil Stud, V10, P61; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1975, LANCET, V1, P480; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAHONEY F I, 1965, Md State Med J, V14, P61; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Possl O, 2001, BRAIN INJURY, V15, P15; Ribbers GM, 2007, J HEAD TRAUMA REHAB, V22, P234, DOI 10.1097/01.HTR.0000281839.07968.32; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wright J, CTR OUTCOME MEASUREM	36	57	58	0	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2012	93	6					993	999		10.1016/j.apmr.2012.01.018			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	952JQ	WOS:000304789200011	22502806				2021-06-18	
J	Messe, A; Caplain, S; Pelegrini-Issac, M; Blancho, S; Montreuil, M; Levy, R; Lehericy, S; Benali, H				Messe, Arnaud; Caplain, Sophie; Pelegrini-Issac, Melanie; Blancho, Sophie; Montreuil, Michele; Levy, Richard; Lehericy, Stephane; Benali, Habib			Structural integrity and postconcussion syndrome in mild traumatic brain injury patients	BRAIN IMAGING AND BEHAVIOR			English	Article						Mild TBI; Postconcussion syndrome; Structural integrity; Diffuse axonal injury	DIFFUSE AXONAL INJURY; POST-CONCUSSION SYMPTOMS; TENSOR IMAGING DETECTS; MINOR HEAD-INJURY; FOLLOW-UP; QUESTIONNAIRE; EPIDEMIOLOGY; DIAGNOSIS; RELIABILITY; IMPAIRMENT	The presence of a postconcussion syndrome (PCS) induces substantial socio-professional troubles in mild traumatic brain injury (mTBI) patients. Although the exact origin of these disorders is not known, they may be the consequence of diffuse axonal injury (DAI) impacting structural integrity. In the present study, we compared structural integrity at the subacute and late stages after mTBI and in case of PCS, using diffusion-weighted imaging (DWI). Fifty-three mTBI patients were investigated and compared with 40 healthy controls. All patients underwent a DWI examination at the subacute (8-21 days) and late (6 months) phases after injury. MTBI patients with PCS were detected at the subacute phase using the ICD-10 classification. Groupwise differences in structural integrity were investigated using Tract-Based Spatial Statistics (TBSS). A loss of structural integrity was found in mTBI patients at the subacute phase but partially resolved over time. Moreover, we observed that mTBI patients with PCS had greater and wider structural impairment than patients without PCS. These damages persisted over time for PCS patients, while mTBI patients without PCS partly recovered. In conclusion, our results strengthen the relationship between structural integrity and PCS.	[Messe, Arnaud; Pelegrini-Issac, Melanie; Benali, Habib] Univ Paris 06, INSERM, UMRS 678, Lab Imagerie Fonct, F-75634 Paris, France; [Messe, Arnaud; Pelegrini-Issac, Melanie; Lehericy, Stephane; Benali, Habib] Univ Paris 11, DSV I2BM NeuroSpin, F-91191 Gif Sur Yvette, France; [Caplain, Sophie; Montreuil, Michele] Univ Paris 08, EA 2027, F-93526 St Denis, France; [Blancho, Sophie] Inst Rech Moelle Epiniere & Encephale, F-75015 Paris, France; [Levy, Richard; Lehericy, Stephane] Univ Paris 06, CNRS, UMRS 975,CRICM, Grp Hosp Pitie Salpetriere,UMR 7225, F-75634 Paris, France; [Levy, Richard] Hop St Antoine, Assistance Publ Hop Paris, F-75012 Paris, France; [Lehericy, Stephane] Univ Paris 06, CENIR, Ctr Neuroimaging Res, CHU Pitie Salpetriere, F-75013 Paris, France; [Benali, Habib] Univ Montreal, MIC UNF, Montreal, PQ H3W 1W5, Canada	Messe, A (corresponding author), Univ Paris 06, INSERM, UMRS 678, Lab Imagerie Fonct, F-75634 Paris, France.	Arnaud.Messe@imed.jussieu.fr	Levy, Richard/D-8411-2011; Messe, Arnaud/I-1738-2019	Messe, Arnaud/0000-0001-9081-3088; Pelegrini-Issac, Melanie/0000-0003-3260-5795	GMF (Garantie Mutuelle des Fonctionnaires)	This study was initiated by the IRME (Institut pour la Recherche sur la Moelle Epiniere et l'Encephale) and supported by a grant from the GMF (Garantie Mutuelle des Fonctionnaires).	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Azouvi P, 2001, REV NEUROPSYCHOL, V11, P383; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2010, J HEAD TRAUMA REHAB, V25, P225, DOI 10.1097/HTR.0b013e3181e7f784; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2010, PSYCHOL INJ LAW, V3, P36, DOI 10.1007/s12207-010-9064-1; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Budde MD, 2007, MAGN RESON MED, V57, P688, DOI 10.1002/mrm.21200; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Concha L, 2010, J NEUROSCI, V30, P996, DOI 10.1523/JNEUROSCI.1619-09.2010; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FitzGerald DB, 2011, INT J PSYCHOPHYSIOL, V82, P79, DOI 10.1016/j.ijpsycho.2011.02.011; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2008, MILD TRAUMATIC BRAIN; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mori S., 2005, MRI ATLAS HUMAN WHIT; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; von Wild KRH, 2008, ACT NEUR S, V101, P55; *WHO, 1993, INT CLASS DIS HLTH R; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5	54	57	57	0	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2012	6	2			SI		283	292		10.1007/s11682-012-9159-2			10	Neuroimaging	Neurosciences & Neurology	967LI	WOS:000305908900009	22477019				2021-06-18	
J	Adelson, PD; Pineda, J; Bell, MJ; Abend, NS; Berger, RP; Giza, CC; Hotz, G; Wainwright, MS				Adelson, P. David; Pineda, Jose; Bell, Michael J.; Abend, Nicholas S.; Berger, Rachel P.; Giza, Christopher C.; Hotz, Gillian; Wainwright, Mark S.			Common Data Elements for Pediatric Traumatic Brain Injury: Recommendations from the Working Group on Demographics and Clinical Assessment	JOURNAL OF NEUROTRAUMA			English	Article						clinical studies; common data elements; data coding; data collection; pediatric; standardization; traumatic brain injury	CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; PROGNOSTIC VALUE; PSYCHOLOGICAL HEALTH; CEREBROSPINAL-FLUID; SECONDARY INSULTS; COMA SCALE; SEVERITY; CHILDREN; PREVALENCE	The Common Data Elements (CDEs) initiative is a National Institutes of Health (NIH) interagency effort to standardize naming, definitions, and data structure for clinical research variables. Comparisons of the results of clinical studies of neurological disorders have been hampered by variability in data coding, definitions, and procedures for sample collection. The CDE project objective is to enable comparison of future clinical trials results in major neurological disorders, including traumatic brain injury (TBI), stroke, multiple sclerosis, and epilepsy. As part of this effort, recommendations for CDEs for research on TBI were developed through a 2009 multi-agency initiative. Following the initial recommendations of the Working Group on Demographics and Clinical Assessment, a separate workgroup developed recommendations on the coding of clinical and demographic variables specific to pediatric TBI studies for subjects younger than 18 years. This article summarizes the selection of measures by the Pediatric TBI Demographics and Clinical Assessment Working Group. The variables are grouped into modules which are grouped into categories. For consistency with other CDE working groups, each variable was classified by priority (core, supplemental, and emerging). Templates were produced to summarize coding formats, guide selection of data points, and provide procedural recommendations. This proposed standardization, together with the products of the other pediatric TBI working groups in imaging, biomarkers, and outcome assessment, will facilitate multi-center studies, comparison of results across studies, and high-quality meta-analyses of individual patient data.	[Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Pineda, Jose] Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO 63110 USA; [Pineda, Jose] Washington Univ, Sch Med, Dept Neurol, Div Crit Care Med, St Louis, MO 63110 USA; [Bell, Michael J.; Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Bell, Michael J.; Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Pediat, Pittsburgh, PA 15213 USA; [Bell, Michael J.; Berger, Rachel P.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Dept Crit Care Med, Pittsburgh, PA 15213 USA; [Abend, Nicholas S.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Neurol, Philadelphia, PA 19104 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Div Neurol,Dept Pediat, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Mattel Childrens Hosp, Dept Neurosurg,UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Hotz, Gillian] Univ Miami, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Div Neurol, Feinberg Sch Med, Chicago, IL 60611 USA; [Wainwright, Mark S.] Northwestern Univ, Dept Pediat, Div Crit Care, Feinberg Sch Med, Chicago, IL 60611 USA	Wainwright, MS (corresponding author), Childrens Mem Hosp, Div Neurol 51, 2300 Childrens Plaza, Chicago, IL 60614 USA.	m-wainwright@northwestern.edu	Adelson, David/W-2083-2019; Pineda, Jose/W-2806-2019		NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 042691]; U.S. Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR); National Institute on Disability and Rehabilitation Research; Department of Veterans AffairsUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; Defense Centers of Excellence; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	The meetings and activities of the pediatric WG Demographics and Clinical Assessment group were supported by funding in the context of the interagency initiative towards an integrated approach to Research in Psychological Health and Traumatic Brain Injury (NIH-NINDS; the National Institute on Disability and Rehabilitation Research; the Department of Veterans Affairs; the Defense and Veterans Brain Injury Center, and the Defense Centers of Excellence). The development of CDEs was further supported by a supplemental grant from NIH-NINDS (NS 042691).; This project was jointly supported by the NIH/NINDS and the U.S. Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR).	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bhopal R, 1998, AM J PUBLIC HEALTH, V88, P1303, DOI 10.2105/AJPH.88.9.1303; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Chambers IR, 2006, J NEUROL NEUROSUR PS, V77, P234, DOI 10.1136/jnnp.2005.072215; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cohen MJ, 2010, CRIT CARE, V14, DOI 10.1186/cc8864; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Haque IU, 2007, PEDIATR CRIT CARE ME, V8, P138, DOI 10.1097/01.PCC.0000257039.32593.DC; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holden KR, 1999, J CHILD NEUROL, V14, P708, DOI 10.1177/088307389901401104; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kennedy J., 2009, J REHABIL RES DEV, V44, P895; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Looney CB, 2007, RADIOLOGY, V242, P535, DOI 10.1148/radiol.2422060133; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas Andrew I R, 2009, Crit Care, V13, P1016, DOI 10.1186/cc8163; Maguire S, 2009, ARCH DIS CHILD, V94, P860, DOI 10.1136/adc.2008.150110; Marcin JP, 2002, CRIT CARE MED, V30, pS457, DOI 10.1097/00003246-200211001-00011; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; Pollina J, 2001, PEDIATR NEUROSURG, V35, P113, DOI 10.1159/000050403; PRYOR HB, 1968, J PEDIATR-US, V73, P593, DOI 10.1016/S0022-3476(68)80275-6; Rooks VJ, 2008, AM J NEURORADIOL, V29, P1082, DOI 10.3174/ajnr.A1004; Shore PM, 2006, CRIT CARE MED, V34, P1981, DOI 10.1097/01.CCM.0000220765.22184.ED; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Wynia MK, 2010, NEW ENGL J MED, V362, P846, DOI 10.1056/NEJMsb0910799	54	57	57	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					639	653		10.1089/neu.2011.1952			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500004	21939389	Green Published			2021-06-18	
J	Andelic, N; Stevens, LF; Sigurdardottir, S; Arango-Lasprilla, JC; Roe, C				Andelic, Nada; Stevens, Lillian Flores; Sigurdardottir, Solrun; Arango-Lasprilla, Juan Carlos; Roe, Cecilie			Associations between disability and employment 1 year after traumatic brain injury in a working age population	BRAIN INJURY			English	Article						Traumatic brain injury; ICF; disability; employment; outcome	PREDICTING RETURN; MULTIPLE INJURIES; HEALTH; ICF; OUTCOMES; CLASSIFICATION; MODEL	Objective: To investigate associations between disability and employment 1 year after traumatic brain injury (TBI) using the International Classification of Functioning, Disability and Health (ICF) as a conceptual model. Design and methods: A prospective study including 93 patients with moderate-to-severe TBI (aged 16-55 year). Disability components of the ICF model (impairments, activity limitations and participation restrictions) and personal factors (age, gender, pre-injury employment status) were used as independent variables. The outcome measure was employment at 1 year post-injury categorized into unemployed and employed groups. Results: Personal factors, impairments (brain injury severity, overall trauma severity and number of impaired body functions) and activity limitations (motor and cognitive abilities) accounted for 57% of the variance in employment outcome. Multivariate analyses showed that the probabilities of being employed 1 year post-injury were 95% lower for patients who were unemployed pre-injury (OR = 0.05), 74% lower for those with more severe brain injury (OR = 0.26) and 82% lower for those with more cognitive limitations (OR = 0.18). Conclusion: Rehabilitation professionals should take into account the importance of the ICF model when planning vocational rehabilitation interventions for individuals with TBI and focus on targeting modifiable aspects related to employment outcome, such as the individual's cognitive ability.	[Andelic, Nada; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway; [Stevens, Lillian Flores; Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Nesoddtangen, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway	Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	nadand@ous-hf.no		Andelic, Nada/0000-0002-3719-4406	Norwegian Health South-East Authority	The authors would like to thank all the patients for their participation. Special thanks are given to Tone Jerstad (Neuroradiologist, Oslo University Hospital, Ulleval) for the CT assessments and Morten Hestnes (Trauma Register, Oslo University Hospital, Ulleval) for the extraction of trauma scores. This study was supported by grants from the Norwegian Health South-East Authority.	Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Arango-Lasprilla JC, 2010, J HEAD TRAUMA REHAB, V25, P128, DOI 10.1097/HTR.0b013e3181d36ca3; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL 1990; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Catalano D, 2006, NEUROREHABILITATION, V21, P279; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johansson U, 2001, DISABIL REHABIL, V23, P474; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; O'Donovan MA, 2009, DISABIL REHABIL, V31, P2073, DOI 10.3109/09638280902918738; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Pistarini C, 2011, FUNCTIONING DISABILI; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Ptyushkin P, 2010, BRAIN INJURY, V24, P1519, DOI 10.3109/02699052.2010.523054; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skaga NO, 2006, J TRAUMA, V60, P538, DOI 10.1097/01.ta.0000205613.52586.d1; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Uniform Data System for Medical Rehabilitation, 1996, GUID UN DAT SET MED; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; World Health Organization, 2001, INT CLASS FUNCT DIS	42	57	58	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2012	26	3					261	269		10.3109/02699052.2012.654589			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	899XD	WOS:000300849100006	22372413				2021-06-18	
J	Chu, XP; Xiong, ZG				Chu, Xiang-Ping; Xiong, Zhi-Gang			Physiological and Pathological Functions of Acid-Sensing Ion Channels in the Central Nervous System	CURRENT DRUG TARGETS			English	Article						Acid-sensing ion channel; acidosis; CNS; neuron; function; neurological disease	BRAIN PHENOBARBITAL UPTAKE; INDUCED NEURONAL DEATH; STATUS EPILEPTICUS; RETINAL FUNCTION; SENSORY NEURONS; EXTRACELLULAR ACIDOSIS; HIPPOCAMPAL-NEURONS; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; ACTIVATED CURRENTS	Protons are important signals for neuronal function. In the central nervous system (CNS), proton concentrations change locally when synaptic vesicles release their acidic contents into the synaptic cleft, and globally in ischemia, seizures, traumatic brain injury, and other neurological disorders due to lactic acid accumulation. The finding that protons gate a distinct family of ion channels, the acid-sensing ion channels (ASICs), has shed new light on the mechanism of acid signaling and acidosis-associated neuronal injury. Accumulating evidence has suggested that ASICs play important roles in physiological processes such as synaptic plasticity, learning/memory, fear conditioning, and retinal integrity, and in pathological conditions such as brain ischemia, multiple sclerosis, epileptic seizures, and malignant glioma. Thus, targeting these channels may lead to novel therapeutic interventions for neurological disorders. The goal of this review is to provide an update on recent advances in our understanding of the functions of ASICs in the CNS.	[Chu, Xiang-Ping] Univ Missouri, Sch Med, Dept Basic Med Sci, Kansas City, MO 64108 USA; [Xiong, Zhi-Gang] Anhui Med Univ, Sch Pharm, Hefei, Peoples R China; [Xiong, Zhi-Gang] Morehouse Sch Med, Dept Neurobiol, Atlanta, GA 30310 USA	Chu, XP (corresponding author), Univ Missouri, Sch Med, Dept Basic Med Sci, 2411 Holmes St, Kansas City, MO 64108 USA.	chux@umkc.edu; zxiong@msm.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS49470, R01NS47506]; American Heart AssociationAmerican Heart Association [0840132N, 0735092N]; University of Missouri Research Board; University of Missouri-Kansas City School of Medicine Start-up Funding; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049470, R01NS047506, R56NS047506] Funding Source: NIH RePORTER; National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [S21MD000101] Funding Source: NIH RePORTER	The work in author's laboratories has been supported by National Institute of Health (R01NS49470 and R01NS47506 to Z-G Xiong), American Heart Association Established Investigator Award (0840132N to Z-G Xiong) and Scientist Development Grant (0735092N to X-P Chu), University of Missouri Research Board and University of Missouri-Kansas City School of Medicine Start-up Funding (X-P Chu).	Ali A, 2004, EPILEPSY BEHAV, V5, P322, DOI 10.1016/j.yebeh.2004.01.005; Ali A, 2006, PHARMACOL REP, V58, P242; Arias RL, 2008, NEUROBIOL DIS, V31, P334, DOI 10.1016/j.nbd.2008.05.008; Back T, 2000, ANN NEUROL, V47, P485, DOI 10.1002/1531-8249(200004)47:4<485::AID-ANA12>3.3.CO;2-#; Baron A, 2002, J PHYSIOL-LONDON, V539, P485, DOI 10.1113/jphysiol.2001.014837; Benson CJ, 1999, CIRC RES, V84, P921; Benveniste M, 2005, NEW ENGL J MED, V352, P85, DOI 10.1056/NEJMcibr045010; Berdiev BK, 2003, J BIOL CHEM, V278, P15023, DOI 10.1074/jbc.M300991200; BEVAN S, 1991, J PHYSIOL-LONDON, V433, P145, DOI 10.1113/jphysiol.1991.sp018419; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; Chang SY, 2007, SOC NEUR ABSTR, V257, P5; Chen CC, 2002, P NATL ACAD SCI USA, V99, P8992, DOI 10.1073/pnas.122245999; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHESLER M, 1988, NEUROSCIENCE, V27, P941, DOI 10.1016/0306-4522(88)90197-2; CHESLER M, 1990, PROG NEUROBIOL, V34, P401, DOI 10.1016/0301-0082(90)90034-E; Cho JH, 2008, J NEUROPHYSIOL, V99, P426, DOI 10.1152/jn.00940.2007; Coryell MW, 2007, BIOL PSYCHIAT, V62, P1140, DOI 10.1016/j.biopsych.2007.05.008; Coryell MW, 2009, J NEUROSCI, V29, P5381, DOI 10.1523/JNEUROSCI.0360-09.2009; Coryell MW, 2008, J NEUROSCI, V28, P13738, DOI 10.1523/JNEUROSCI.3907-08.2008; CROWELL JW, 1961, AM J PHYSIOL, V200, P743; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; de la Rosa DA, 2003, J PHYSIOL-LONDON, V546, P77, DOI 10.1113/jphysiol.2002.030692; de la Rosa DA, 2000, ANNU REV PHYSIOL, V62, P573, DOI 10.1146/annurev.physiol.62.1.573; Duan B, 2011, J NEUROSCI, V31, P2101, DOI 10.1523/JNEUROSCI.4351-10.2011; Dwyer JM, 2009, PSYCHOPHARMACOLOGY, V203, P41, DOI 10.1007/s00213-008-1373-7; Ettaiche M, 2004, J NEUROSCI, V24, P1005, DOI 10.1523/JNEUROSCI.4698-03.2004; Ettaiche M, 2006, J NEUROSCI, V26, P5800, DOI 10.1523/JNEUROSCI.0344-06.2006; Ettaiche M, 2009, INVEST OPHTH VIS SCI, V50, P2417, DOI 10.1167/iovs.08-3028; Friese MA, 2007, NAT MED, V13, P1483, DOI 10.1038/nm1668; Gao J, 2005, NEURON, V48, P635, DOI 10.1016/j.neuron.2005.10.011; Gao J, 2004, BRAIN RES, V1017, P197, DOI 10.1016/j.brainres.2004.05.046; Gonzales EB, 2009, NATURE, V460, P599, DOI 10.1038/nature08218; GRANTYN R, 1989, DEV BRAIN RES, V49, P150, DOI 10.1016/0165-3806(89)90070-9; Grunder Stefan, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P73; Gu L, 2010, NEUROSCI LETT, V479, P63, DOI 10.1016/j.neulet.2010.05.029; Herrera Y, 2008, J PHARMACOL EXP THER, V327, P491, DOI 10.1124/jpet.108.143974; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Hu R, 2011, ANN SURG, V254, P353, DOI 10.1097/SLA.0b013e31822645b4; Huang YZ, 2004, CELL, V118, P665, DOI 10.1016/j.cell.2004.09.004; Jasti J, 2007, NATURE, V449, P316, DOI 10.1038/nature06163; Jetti SK, 2010, NITRIC OXIDE-BIOL CH, V22, P213, DOI 10.1016/j.niox.2009.12.006; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Kapoor N, 2009, J BIOL CHEM, V284, P24526, DOI 10.1074/jbc.M109.037390; KOVALCHUK YN, 1990, NEUROSCI LETT, V115, P237, DOI 10.1016/0304-3940(90)90461-H; Krishtal O, 2003, TRENDS NEUROSCI, V26, P477, DOI 10.1016/S0166-2236(03)00210-8; KRISHTAL OA, 1981, NEUROSCIENCE, V6, P2599, DOI 10.1016/0306-4522(81)90105-6; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; Li MH, 2010, J PHYSIOL-LONDON, V588, P3883, DOI 10.1113/jphysiol.2010.192922; Li MH, 2010, J CEREBR BLOOD F MET, V30, P1247, DOI 10.1038/jcbfm.2010.30; Lin WH, 2002, J NEUROPHYSIOL, V88, P133, DOI 10.1152/jn.2002.88.1.133; LJUNGGREN B, 1974, BRAIN RES, V77, P173, DOI 10.1016/0006-8993(74)90782-3; Mari Y, 2010, CELL CALCIUM, V48, P70, DOI 10.1016/j.ceca.2010.07.002; Maysami S., 2009, SOC NEUR ANN M, P2378; Meng QY, 2009, NEUROSCIENCE, V159, P1126, DOI 10.1016/j.neuroscience.2009.01.069; N'Gouemo P, 2008, BRAIN RES, V1222, P230, DOI 10.1016/j.brainres.2008.05.010; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581; Page AJ, 2005, GUT, V54, P1408, DOI 10.1136/gut.2005.071084; PAPP LA, 1993, AM J PSYCHIAT, V150, P1149; Picloplichko VI, 2006, P NATL ACAD SCI USA, V103, P11376, DOI 10.1073/pnas.0600768103; Pignataro G, 2007, BRAIN, V130, P151, DOI 10.1093/brain/awl325; Pignataro Giuseppe, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P1; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; REHNCRONA S, 1985, ANN EMERG MED, V14, P770, DOI 10.1016/S0196-0644(85)80055-X; Render James A, 2010, Int J Physiol Pathophysiol Pharmacol, V2, P69; Revici E., 1949, B I APPL BIOL, V1, P21; Samways DSK, 2009, CELL CALCIUM, V45, P319, DOI 10.1016/j.ceca.2008.12.002; Sherwood TW, 2011, J NEUROSCI, V31, P9723, DOI 10.1523/JNEUROSCI.1665-11.2011; Sherwood TW, 2009, J NEUROSCI, V29, P14371, DOI 10.1523/JNEUROSCI.2186-09.2009; Siesjo BK, 1996, ADV NEUROL, V71, P209; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SIMON RP, 1985, J PHARMACOL EXP THER, V234, P830; SIMON RP, 1987, J CEREBR BLOOD F MET, V7, P783, DOI 10.1038/jcbfm.1987.134; Sluka KA, 2003, PAIN, V106, P229, DOI 10.1016/S0304-3959(03)00269-0; Sluka KA, 2009, CURR OPIN DRUG DISC, V12, P693; SOMJEN GG, 1984, BRAIN RES, V311, P186, DOI 10.1016/0006-8993(84)91416-1; Stys PK, 1998, NEUROSCIENCE, V82, P21; Sutherland S P, 2000, Prog Brain Res, V129, P21; TANG CM, 1990, P NATL ACAD SCI USA, V87, P6445, DOI 10.1073/pnas.87.16.6445; TOMBAUGH GC, 1993, J NEUROCHEM, V61, P793, DOI 10.1111/j.1471-4159.1993.tb03589.x; TRAYNELIS SF, 1990, NATURE, V345, P347, DOI 10.1038/345347a0; UENO S, 1992, J PHYSIOL-LONDON, V447, P309, DOI 10.1113/jphysiol.1992.sp019004; Ugawa S, 2003, J NEUROSCI, V23, P3616; Ugawa S, 2002, J CLIN INVEST, V110, P1185, DOI 10.1172/JCI200215709; Ugawa Shinya, 2003, Anatomical Science International, V78, P205, DOI 10.1046/j.0022-7722.2003.00062.x; URBANICS R, 1978, PFLUG ARCH EUR J PHY, V378, P47, DOI 10.1007/BF00581957; Varming T, 1999, NEUROPHARMACOLOGY, V38, P1875, DOI 10.1016/S0028-3908(99)00079-9; Vergo S, 2011, BRAIN, V134, P571, DOI 10.1093/brain/awq337; Vila-Carriles WH, 2006, J BIOL CHEM, V281, P19220, DOI 10.1074/jbc.M603100200; Voilley Nicolas, 2004, Current Drug Targets - Inflammation and Allergy, V3, P71, DOI 10.2174/1568010043483980; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; Waxman SG, 2006, NAT REV NEUROSCI, V7, P932, DOI 10.1038/nrn2023; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wemmie JA, 2004, P NATL ACAD SCI USA, V101, P3621, DOI 10.1073/pnas.0308753101; Wemmie JA, 2003, J NEUROSCI, V23, P5496; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Weng JY, 2010, J NEUROSCI, V30, P6548, DOI 10.1523/JNEUROSCI.0582-10.2010; Wong HK, 2008, HUM MOL GENET, V17, P3223, DOI 10.1093/hmg/ddn218; Wu LJ, 2004, J BIOL CHEM, V279, P43716, DOI 10.1074/jbc.M403557200; Wu WL, 2010, GENES BRAIN BEHAV, V9, P603, DOI 10.1111/j.1601-183X.2010.00591.x; Xiong ZG, 2004, CELL, V118, P687, DOI 10.1016/j.cell.2004.08.026; Xiong ZG, 2007, FRONT BIOSCI-LANDMRK, V12, P1376, DOI 10.2741/2154; Xu TL, 2007, CURR MED CHEM, V14, P1753; Yermolaieva O, 2004, P NATL ACAD SCI USA, V101, P6752, DOI 10.1073/pnas.0308636100; Zha XM, 2006, P NATL ACAD SCI USA, V103, P16556, DOI 10.1073/pnas.0608018103; Zha XM, 2009, J NEUROSCI, V29, P8438, DOI 10.1523/JNEUROSCI.1284-09.2009; Ziemann AE, 2008, NAT NEUROSCI, V11, P816, DOI 10.1038/nn.2132; Ziemann AE, 2009, CELL, V139, P1012, DOI 10.1016/j.cell.2009.10.029	110	57	59	0	7	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-4501	1873-5592		CURR DRUG TARGETS	Curr. Drug Targets	FEB	2012	13	2					263	271		10.2174/138945012799201685			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	204ND	WOS:000323371100011	22204324	Green Accepted			2021-06-18	
J	Donnell, AJ; Kim, MS; Silva, MA; Vanderploeg, RD				Donnell, Alison J.; Kim, Michelle S.; Silva, Marc A.; Vanderploeg, Rodney D.			Incidence of Postconcussion Symptoms in Psychiatric Diagnostic Groups, Mild Traumatic Brain Injury, and Comorbid Conditions	CLINICAL NEUROPSYCHOLOGIST			English	Article						Head injuries; Psychiatric diagnoses; Veterans' health	POST-CONCUSSION SYMPTOMS; BLAST	The constellation of physical, cognitive, and emotional symptoms, collectively known as postconcussion syndrome (PCS), is not uniquely associated with concussion, making the etiology of chronic postconcussion symptoms controversial. The current study compared percentages of individuals meeting symptom-based criteria for PCS in a population-based sample of veterans composed of subgroups with various psychiatric diagnoses, a history of mild traumatic brain injury (MTBI), and healthy controls. Participants were identified from 4462 randomly sampled male U. S. Army veterans who served during the Vietnam era. Only 32% of veterans with a history of MTBI met DSM-IV symptom criteria for PCS as compared to 40% of those diagnosed with post-traumatic stress disorder (PTSD), 50% with generalized anxiety disorder (GAD), 57% with major depressive disorder (MDD), and 91% with somatization disorder. Results were consistent with existing literature showing that the PCS symptoms are not unique to concussion, and also provide important base-rate information for neuropsychologists practicing in both clinical and personal injury forensic settings.	[Vanderploeg, Rodney D.] James A Haley Vet Hosp, Psychol Serv 116B, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Donnell, Alison J.] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA; [Donnell, Alison J.; Vanderploeg, Rodney D.] Def & Vet Brain Injury Ctr, Tampa, FL USA; [Vanderploeg, Rodney D.] James A Haley Vet Hosp, HSR&D RR&D Ctr Excellence Maximizing Rehabil Outc, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Neurosci, Tampa, FL USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, Dept Mental Hlth & Behav Sci, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.vanderploeg@va.gov	Silva, Marc A./J-1874-2019	Silva, Marc A./0000-0002-3879-6054	Department of Veterans Affairs, Veterans Health Administration (VHA)US Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; James A. Haley Veterans' HospitalUS Department of Veterans Affairs	The research reported here was supported by the Department of Veterans Affairs, Veterans Health Administration (VHA), and the Defense and Veterans Brain Injury Center (DVBIC). Further support was provided by the James A. Haley Veterans' Hospital. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Veterans Affairs, or U.S. Government.	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 1988, JAMA, V259, P2701; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; GREIFFENSTEIN MF, 2005, FORENSIC NEUROPSYCHO, P29; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Larrabee G, 2005, FORENSIC NEUROPSYCHO, P209; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; McCrea M. A., 2007, OXFORD WORKSHOP SERI; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; ROBINS L, 1987, DIAGNOSTIC INTERVIEW; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; World Health Organization, 1992, ICD 10 INT STAT CLAS	32	57	57	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	7					1092	1101		10.1080/13854046.2012.713984			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	027DE	WOS:000310331200003	22935025				2021-06-18	
J	Ma, HY; Yu, B; Kong, L; Zhang, YY; Shi, YX				Ma, Haiying; Yu, Bo; Kong, Li; Zhang, Yuanyuan; Shi, Yuxiu			Neural Stem Cells Over-Expressing Brain-Derived Neurotrophic Factor (BDNF) Stimulate Synaptic Protein Expression and Promote Functional Recovery Following Transplantation in Rat Model of Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Neural stem cell; Traumatic brain injury; Transplantation; Brain-derived neurotrophic factor; Synaptogenesis	RETINAL GANGLION-CELLS; SPINAL-CORD; GROWTH-FACTOR; GENE-TRANSFER; GAP-43; DIFFERENTIATION; SYNAPTOPHYSIN; SURVIVAL; HIPPOCAMPUS; INCREASES	Brain-derived neurotrophic factor (BDNF) plays an essential regulatory role in the survival and differentiation of various neural cell types during brain development and after injury. In this study, we used neural stem cells (NSCs) genetically modified to encode BDNF gene (BDNF/NSCs) and naive NSCs transplantation and found that BDNF/NSCs significantly improved neurological motor function following traumatic brain injury (TBI) on selected behavioral tests. Our data clearly demonstrate that the transplantation of BDNF/NSCs causes overexpression of BDNF in the brains of TBI rats. The number of surviving engrafted cells and the proportion of engrafted cells with a neuronal phenotype were significantly greater in BDNF/NSCs than in naive NSCs-transplanted rats. The expression of pre- and post-synaptic proteins and a regeneration-associated gene in the BDNF/NSCs-transplanted rats was significantly increased compared to that in NSCs-transplanted rats, especially at the early stage of post-transplantation. These data suggest that neurite growth and overexpression of synaptic proteins in BDNF/NSC-stransplanted rats are associated with the overexpression of BDNF, which is hypothesized to be one of the mechanisms underlying the improved functional recovery in motor behavior at the early stage of cell transplantation following TBI. Therefore, the protective effect of the BDNF-modified NSCs transplantation is greater than that of the naive NSCs transplantation.	[Ma, Haiying; Kong, Li; Shi, Yuxiu] China Med Univ, Dept Histol & Embryol, Shenyang, Liaoning, Peoples R China; [Ma, Haiying; Kong, Li; Shi, Yuxiu] China Med Univ, Inst Pathol & Pathophysiol, Shenyang, Liaoning, Peoples R China; [Ma, Haiying; Kong, Li; Zhang, Yuanyuan] Dalian Med Univ, Dept Histol & Embryol, Dalian, Liaoning, Peoples R China; [Yu, Bo] China Med Univ, Shengjing Hosp, Shenyang, Liaoning, Peoples R China; [Zhang, Yuanyuan] Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA	Shi, YX (corresponding author), China Med Univ, Dept Histol & Embryol, Shenyang, Liaoning, Peoples R China.	yuxishi@163.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30850001]; Education Bureau, Liaoning Province, China [20072167, 2008779, 2008851]	We thank Professor Xuehu Ma from the Stem Cell and Tissue Engineering Laboratory of the Dalian University of Technology for his support in culturing the NSCs. This work was supported by grants No. 30850001 from the National Nature Science Foundation of China and Nos. 20072167, 2008779 and 2008851 from the S&T Research Project of Education Bureau, Liaoning Province, China.	AEBISCHER P, 1994, EXP NEUROL, V126, P151, DOI 10.1006/exnr.1994.1053; AHMED S, 1995, J NEUROSCI, V15, P5765; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Bamji SX, 2006, J CELL BIOL, V174, P289, DOI 10.1083/jcb.200601087; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Benninger Y, 2000, BRAIN PATHOL, V10, P330; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bockers TM, 2001, J BIOL CHEM, V276, P40104, DOI 10.1074/jbc.M102454200; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Bramham CR, 2005, PROG NEUROBIOL, V76, P99, DOI 10.1016/j.pneurobio.2005.06.003; Fauza DO, 2008, SURGERY, V144, P367, DOI 10.1016/j.surg.2008.05.009; Fournier AE, 1997, J NEUROSCI RES, V47, P561, DOI 10.1002/(SICI)1097-4547(19970315)47:6<561::AID-JNR1>3.3.CO;2-Q; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Islam O, 2009, CURR NEUROVASC RES, V6, P42, DOI 10.2174/156720209787466028; Iwamoto Y, 1996, NEUROREPORT, V7, P609, DOI 10.1097/00001756-199601310-00056; JACOBS KM, 1993, J COMP NEUROL, V336, P151, DOI 10.1002/cne.903360112; Kaplan GB, 2010, BEHAV PHARMACOL, V21, P427, DOI 10.1097/FBP.0b013e32833d8bc9; Klocker N, 2001, NEUROBIOL DIS, V8, P103, DOI 10.1006/nbdi.2000.0329; Kwon BK, 2007, SPINE, V32, P1164, DOI 10.1097/BRS.0b013e318053ec35; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liebau S, 2007, STEM CELLS, V25, P1720, DOI 10.1634/stemcells.2006-0823; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029; Ma XH, 2010, CRYOBIOLOGY, V60, P184, DOI 10.1016/j.cryobiol.2009.10.013; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Modo M, 2002, STROKE, V33, P2270, DOI 10.1161/01.STR.0000027693.50675.C5; Moro K, 2006, BRAIN RES, V1076, P1, DOI 10.1016/j.brainres.2005.12.119; Mothe AJ, 2008, EXP NEUROL, V213, P176, DOI 10.1016/j.expneurol.2008.05.024; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Stanisz AM, 2000, ANN NY ACAD SCI, V917, P268; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Valtorta F, 2004, BIOESSAYS, V26, P445, DOI 10.1002/bies.20012; Willson ML, 2008, BRAIN, V131, P1099, DOI 10.1093/brain/awn024; Ying Z, 2008, NEUROSCIENCE, V155, P1070, DOI 10.1016/j.neuroscience.2008.06.057; Zaheer A, 1995, NEUROCHEM RES, V20, P1457, DOI 10.1007/BF00970594; Zhang L, 2009, NEUROCHEM RES, V34, P2030, DOI 10.1007/s11064-009-9992-x	47	57	66	2	24	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JAN	2012	37	1					69	83		10.1007/s11064-011-0584-1			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	920KT	WOS:000302404000010	21901549				2021-06-18	
J	Rohling, ML; Larrabee, GJ; Millis, SR				Rohling, Martin L.; Larrabee, Glenn J.; Millis, Scott R.			The "Miserable Minority" Following Mild Traumatic Brain Injury: Who Are They and do Meta-Analyses Hide Them?	CLINICAL NEUROPSYCHOLOGIST			English	Article						Mild traumatic brain injury; Miserable minority; Meta-analysis; Post-concussion syndrome	COGNITIVE PERFORMANCE; DIAGNOSIS THREAT; BASE RATES; SYMPTOMS; VALIDITY; OUTCOMES; MYTHS	Ruff et al. (1994; Ruff, Camenzuli, & Mueller, 1996) hypothesized that some mild traumatic brain injury (MTBI) patients will suffer chronic symptomatic complaints and impairments, identifying this subgroup as the "miserable minority.'' However, several meta-analyses of the effects of MTBI have been published (e. g., Rohling et al., 2011) showing no significant cognitive impairments following recovery. Recently Pertab, James, and Bigler (2009) suggested that meta-analysis might be obscuring impairments in some MTBI patients, presenting a hypothetical score distribution to illustrate their claim. Our statistical analyses of their hypothetical figure and of several other potential distributions containing an impaired subgroup that varied as a function of effect size and base rate of occurrence did not support the existence of a miserable minority that is obscured in meta-analyses by the larger group of MTBI patients experiencing full recovery. Indeed, given our recent published MTBI effect size of -0.07 (Rohling et al., 2011), for an impaired subgroup to exist, the level of impairment would have to be just under a tenth of a standard deviation, equivalent to a WMS-IV Index score value of 1 point. At effect sizes this small, any cut score chosen on a test to diagnose patients would result in more false positives than true positives. This greatly increases the risk of misdiagnosis in persons who are susceptible to misattribution, expectancy effects, and "diagnosis threat,'' thereby increasing the risk of iatrogenic illness.	[Rohling, Martin L.] Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; [Millis, Scott R.] Wayne State Univ, Sch Med, Detroit, MI USA	Rohling, ML (corresponding author), Univ S Alabama, Dept Psychol, Suite 2000 Univ Commons, Mobile, AL 36688 USA.	mrohling@usouthal.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brulot MM, 1997, CLIN NEUROPSYCHOL, V11, P391, DOI 10.1080/13854049708400468; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Greiffenstein M, 2009, CLIN NEUROPSYCHOL, V23, P286, DOI 10.1080/13854040802104873; Heaton R.K., 1991, COMPREHENSIVE NORMS; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Rohling ML, 2011, PSYCHOL BULL, V137, P708, DOI 10.1037/a0023327; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	39	57	57	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2012	26	2					197	213		10.1080/13854046.2011.647085			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	936EO	WOS:000303573900002	22256957				2021-06-18	
J	Cullen, DK; Vernekar, VN; LaPlaca, MC				Cullen, D. Kacy; Vernekar, Varadraj N.; LaPlaca, Michelle C.			Trauma-Induced Plasmalemma Disruptions in Three-Dimensional Neural Cultures Are Dependent on Strain Modality and Rate	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; cell mechanics; compression; injury biomechanics; membrane permeability; neuron; neurotrauma; shear; strain rate; 3-D culture; traumatic brain injury	DIFFUSE AXONAL INJURY; BRAIN-INJURY; NEURONAL INJURY; MEMBRANE DISRUPTION; SIGNAL-TRANSDUCTION; CORTICAL-NEURONS; CNS INJURY; CELL-DEATH; CALCIUM; MECHANISMS	Traumatic brain injury (TBI) results from cell dysfunction or death following supra-threshold physical loading. Neural plasmalemma compromise has been observed following traumatic neural insults; however, the biomechanical thresholds and time-course of such disruptions remain poorly understood. In order to investigate trauma-induced membrane disruptions, we induced dynamic strain fields (0.50 shear or compressive strain at 1, 10, or 30 sec(-1) strain rate) in 3-D neuronal-astrocytic co-cultures (>500 mu m thick). Impermeant dyes were present during mechanical loading and entered cells in a strain rate-dependent manner for both shear and compression. Real-time imaging revealed increased membrane permeability in a sub-population of cells immediately upon deformation. Alterations in cell membrane permeability, however, were transient and biphasic over the ensuing hour post-insult, suggesting initial membrane damage and rapid repair, followed by a phase of secondary membrane degradation. At 48 h post-insult, cell death increased significantly in the high-strain-rate group, but not after quasi-static loading, suggesting that cell survival relates to the initial extent of transient structural compromise. Cells were more sensitive to bulk shear deformation than compression with respect to acute permeability changes and subsequent cell survival. These results provide insight into the temporally varying alterations in membrane stability following traumatic loading and provide a basis for elucidating physical cellular tolerances.	[LaPlaca, Michelle C.] Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA; [Cullen, D. Kacy] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Vernekar, Varadraj N.; LaPlaca, Michelle C.] Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	LaPlaca, MC (corresponding author), Emory Univ, Georgia Inst Technol, Coulter Dept Biomed Engn, Petit Inst Bioengn & Biosci, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			National Science Foundation (NSF)National Science Foundation (NSF) [BES-0093830, EEC-9731643]; National Institutes of Health/National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB001014]; Southern Consortium for Injury Biomechanics at the University of Alabama Birmingham-Injury Control Research Center through National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000191]; National Highway Traffic Safety Administration [TNH22-01-H-07551]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001014] Funding Source: NIH RePORTER	The authors thank Drs. Albert King and Liying Zhang at Wayne State University for finite element modeling, Dr. Crystal M. Simon for input regarding experimental design and data analysis, and Christopher E. Gonzales and Rebekah M. Hamrick for technical assistance. This work was partially supported by the National Science Foundation (NSF) (CAREER Award BES-0093830), National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering (EB001014), NSF (EEC-9731643), and the Southern Consortium for Injury Biomechanics at the University of Alabama Birmingham-Injury Control Research Center, through a grant from the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, award R49/CE000191, and Cooperative Agreement TNH22-01-H-07551 with the National Highway Traffic Safety Administration. This work made use of shared facilities from the Georgia Tech/Emory Center (GTEC) for the Engineering of Living Tissues, an ERC (EEC-9731643).	Adibhatla RM, 2008, BMB REP, V41, P560, DOI 10.5483/BMBRep.2008.41.8.560; Adibhatla RM, 2006, AAPS J, V8, pE314; BARTOLETTI DC, 1989, FEBS LETT, V256, P4, DOI 10.1016/0014-5793(89)81707-7; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CHANG DC, 1990, BIOPHYS J, V58, P1, DOI 10.1016/S0006-3495(90)82348-1; Cullen DK, 2007, BRAIN RES, V1158, P103, DOI 10.1016/j.brainres.2007.04.070; Cullen DK, 2007, ANN BIOMED ENG, V35, P835, DOI 10.1007/s10439-007-9292-z; Cullen DK, 2006, J NEUROTRAUM, V23, P1304, DOI 10.1089/neu.2006.23.1304; Cullen D. Kacy, 2011, Critical Reviews in Biomedical Engineering, V39, P201; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P265, DOI 10.1097/00002826-200109000-00003; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holbourn AHS, 1943, LANCET, V2, P438; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Irons HR, 2008, J NEURAL ENG, V5, P333, DOI 10.1088/1741-2560/5/3/006; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Koob AO, 2005, J NEUROTRAUM, V22, P1092, DOI 10.1089/neu.2005.22.1092; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Liao SL, 2001, NEUROREPORT, V12, P3519, DOI 10.1097/00001756-200111160-00029; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McNeil PL, 2000, J CELL SCI, V113, P1891; McNeil PL, 2003, P NATL ACAD SCI USA, V100, P4592, DOI 10.1073/pnas.0736739100; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; Nehrt A, 2007, NEUROSCIENCE, V146, P1504, DOI 10.1016/j.neuroscience.2007.02.015; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; SAHAY KB, 1992, J BIOMECH, V25, P319, DOI 10.1016/0021-9290(92)90029-Z; Schlicher RK, 2006, ULTRASOUND MED BIOL, V32, P915, DOI 10.1016/j.ultrasmedbio.2006.02.1416; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Shi R, 2001, J NEUROCYTOL, V30, P829, DOI 10.1023/A:1019645505848; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Togo T, 2000, ZYGOTE, V8, pS31; Villa PG, 1998, J CELL SCI, V111, P713; Vosler PS, 2008, MOL NEUROBIOL, V38, P78, DOI 10.1007/s12035-008-8036-x; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	61	57	58	0	15	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2219	2233		10.1089/neu.2011.1841			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600003	22023556	Green Published			2021-06-18	
J	Molloy, C; Conroy, RM; Cotter, DR; Cannon, M				Molloy, Charlene; Conroy, Ronan M.; Cotter, David R.; Cannon, Mary			Is Traumatic Brain Injury A Risk Factor for Schizophrenia? A Meta-Analysis of Case-Controlled Population-Based Studies	SCHIZOPHRENIA BULLETIN			English	Article						traumatic brain injury; psychosis; systematic review; meta-analysis	HEAD-INJURY; PSYCHIATRIC-ILLNESS; PSYCHOSIS; ASSOCIATION; DISORDER; CHILDHOOD; EPILEPSY	Traumatic brain injury (TBI) is known to lead to a range of adverse psychiatric sequelae but the question of whether TBI is a risk factor for psychosis and, in particular, schizophrenia remains unclear. Studies examining this issue have yielded conflicting results. We carried out a systematic review of the literature on TBI and psychosis in order to identify all population-based controlled studies which provide estimates of risk for schizophrenia following TBI. Odds ratios (ORs) were combined using random effects meta-analysis. Our literature search yielded 172 studies which were considered to be potentially relevant. From these, we identified 9 studies that could provide estimates of risk in the form of ORs. The pooled analysis revealed a significant association between TBI and schizophrenia (OR = 1.65; 95% CI = 1.17-2.32), with significant heterogeneity between the studies. Estimates from the family studies (OR = 2.8: 95% CI =1.76-4.47) were higher than those from the cohort/nested case-control studies (OR = 1.42: 95% CI = 1.02-1.97) by a factor of almost 2. There did not appear to be a dose-response relationship between severity of head injury and subsequent risk of schizophrenia. This meta-analysis supports an increased risk of schizophrenia following TBI, with a larger effect in those with a genetic predisposition to psychosis. Further epidemiological and neuroscientific studies to elucidate the mechanisms underlying this association are warranted.	[Cannon, Mary] Beaumont Hosp, Dept Psychiat, Royal Coll Surg Ireland, Educ & Res Ctr, Dublin 9, Ireland; [Conroy, Ronan M.] Royal Coll Surgeons Ireland, Dept Epidemiol & Biostat, Dublin 2, Ireland	Cannon, M (corresponding author), Beaumont Hosp, Dept Psychiat, Royal Coll Surg Ireland, Educ & Res Ctr, Dublin 9, Ireland.	marycannon@rcsi.ie	cotter, david r/D-8249-2012; Cannon, Mary/D-8227-2012; Conroy, Ronan/C-6416-2008	Cannon, Mary/0000-0002-0910-299X; cotter, david/0000-0003-4308-0648; Conroy, Ronan/0000-0001-5983-8682	European CommunityEuropean Commission [HEALTH-F2-2009-241909]; Health Research Board Ireland [CSA/2004/1]; NARSAD Essel FoundationNARSAD; Stanley Medical Research Institute; Health Research Board Ireland; NARSADNARSAD; Science Foundation IrelandScience Foundation IrelandEuropean Commission	European Community's Seventh Framework Program (HEALTH-F2-2009-241909; Project EU-GEI). M. C. is supported by a Clinician Scientist Award from the Health Research Board Ireland (CSA/2004/1) and also recieves support from a 2009 NARSAD Essel Foundation Independent Investigator Award and The Stanley Medical Research Institute. D. C. is supported by the Health Research Board Ireland, NARSAD, Science Foundation Ireland, and the Stanley Medical Research Institute.	AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; Arseneault L, 2004, BRIT J PSYCHIAT, V184, P110, DOI 10.1192/bjp.184.2.110; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cannon M, 2005, SCHIZOPHR RES, V79, P5, DOI 10.1016/j.schres.2005.05.027; Cannon M, 2002, ARCH GEN PSYCHIAT, V59, P449, DOI 10.1001/archpsyc.59.5.449; Chen Y-H, 2010, PSYCHOL MED     0922, DOI [10.1017/S00332917, DOI 10.1017/S00332917]; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; Davison K, 1969, BRIT J PSYCHIAT, pS113; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fleminger S, 2009, LISHMANS ORGANIC PSY, P167; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Harris RJ, 2008, STATA J, V8, P3, DOI 10.1177/1536867X0800800102; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kim E, 2008, CURR OPIN PSYCHIATR, V21, P286, DOI 10.1097/YCO.0b013e3282fbcd21; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Rutten BPF, 2009, SCHIZOPHRENIA BULL, V35, P1045, DOI 10.1093/schbul/sbp104; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; StataCorp, 2007, STAT STAT SOFTW REL; Sundram F, 2010, BRIT J PSYCHIAT, V197, P482, DOI 10.1192/bjp.bp.110.080218; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; van Os J, 2008, SCHIZOPHRENIA BULL, V34, P1066, DOI 10.1093/schbul/sbn117; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	30	57	62	0	22	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	NOV	2011	37	6					1104	1110		10.1093/schbul/sbr091			7	Psychiatry	Psychiatry	836ZD	WOS:000296158100004	21813439	Green Published, Bronze			2021-06-18	
J	Lotocki, G; Vaccari, JD; Alonso, O; Molano, JS; Nixon, R; Safavi, P; Dietrich, WD; Bramlett, HM				Lotocki, George; Vaccari, Juan de Rivero; Alonso, Ofelia; Molano, Juliana Sanchez; Nixon, Ryan; Safavi, Padideh; Dietrich, W. Dalton; Bramlett, Helen M.			Oligodendrocyte vulnerability following traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						Myelin; Oligodendrocyte; Apoptosis; Brain trauma	SPINAL-CORD-INJURY; WHITE-MATTER; HEAD-INJURY; AXONAL INJURY; APOPTOSIS; PROTEIN; DAMAGE	Experimental and clinical findings demonstrate that traumatic brain injury (TBI) results in injury to both gray and white matter structures. The purpose of this study was to document patterns of oligodendrocyte vulnerability to TBI. Sprague Dawley rats underwent sham operated procedures or moderate fluid percussion brain injury. Quantitative immunohistochemical analysis was performed on animals perfusion-fixed at 3 (n = 9) or 7 (n = 9) days post-surgery. Within the ipsilateral external capsule and corpus callosum, numbers of APC-CC1 immunoreactive oligodendrocytes were significantly decreased at 3 or 7 days post-TBI compared to sham rats (p < 0.03). At both posttraumatic survival periods, double-labeling studies indicated that oligodendrocytes showed increased Caspase 3 activation compared to sham. These data demonstrate regional patterns of oligodendrocyte vulnerability after TBI and that oligodendrocyte cell loss may be due to Caspase 3-mediated cell death mechanisms. Further studies are needed to test therapeutic interventions that prevent trauma-induced oligodendrocyte cell death, subsequent demyelination and circuit dysfunction. (c) 2011 Elsevier Ireland Ltd. All rights reserved.	[Vaccari, Juan de Rivero; Dietrich, W. Dalton; Bramlett, Helen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Lotocki, George; Vaccari, Juan de Rivero; Alonso, Ofelia; Molano, Juliana Sanchez; Nixon, Ryan; Safavi, Padideh; Dietrich, W. Dalton; Bramlett, Helen M.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Med Ctr, Bruce W Carter Dept Vet Affairs, Miami, FL USA	Bramlett, HM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 3-18, Miami, FL 33136 USA.	hbramlett@miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; Nixon, Ryan/0000-0002-5759-4415	 [NS030291];  [NS042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133, R01NS056072] Funding Source: NIH RePORTER	This work was supported by NS030291 and NS042133.	Bhat RV, 1996, GLIA, V17, P169; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Fields RD, 2008, TRENDS NEUROSCI, V31, P361, DOI 10.1016/j.tins.2008.04.001; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1998, NEUROPATHOLOGY, V3, P160; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gootjes L, 2004, DEMENT GERIATR COGN, V18, P180, DOI 10.1159/000079199; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kujala P, 1997, BRAIN, V120, P289, DOI 10.1093/brain/120.2.289; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; McDonald JW, 2002, NEUROSCIENCE, V115, P931, DOI 10.1016/S0306-4522(02)00342-1; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Salter MG, 2005, NATURE, V438, P1167, DOI 10.1038/nature04301; Schulz R, 2008, CELL TISSUE RES, V334, P327, DOI 10.1007/s00441-008-0714-5; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186	33	57	59	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUL 25	2011	499	3					143	148		10.1016/j.neulet.2011.05.056			6	Neurosciences	Neurosciences & Neurology	809WQ	WOS:000294087800001	21669255	Green Accepted			2021-06-18	
J	Adams, JH; Jennett, B; Murray, LS; Teasdale, GM; Gennarelli, TA; Graham, DI				Adams, J. Hume; Jennett, Bryan; Murray, Lilian S.; Teasdale, Graham M.; Gennarelli, Thomas A.; Graham, David I.			Neuropathological Findings in Disabled Survivors of a Head Injury	JOURNAL OF NEUROTRAUMA			English	Article						assessment by Glasgow Outcome Scale; neuropathology; permanent disability; head injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; GLASGOW OUTCOME SCALE; SUDDEN UNEXPECTED DEATH; VEGETATIVE STATE; DAMAGE; DISABILITY; EPILEPSY; CHILDREN; DIAGNOSIS	We investigated how the occurrence and severity of the main neuropathological types of traumatic brain injury (TBI) influenced the severity of disability after a head injury. Eighty-five victims, each of whom had lived at least a month after a head injury but then died, were studied. Judged by the Glasgow Outcome Scale (GOS), before death 35 were vegetative, 30 were severely and 20 were moderately disabled. Neuropathological assessment showed that 71 (84%) victims had sustained cerebral contusions, 49 (58%) had diffuse axonal injury (DAI), 57 (67%), had ischemic brain damage (IBD), 58 (68%) had symmetrical ventricular enlargement, and in 47 (55%) intracranial pressure (ICP) had been increased. Thirty-five (41%) had undergone evacuation of an intracranial hematoma. Brainstem damage was seen in only 11 (13%). Analysis (chi(2) test for trends) of the relationship between these features and outcome showed that findings of DAI, raised ICP, thalamic damage, or ventricular enlargement (all p < 0.005), and IBD (p = 0.04) were associated with an increasingly worse outcome. Conversely, moderate or severe contusions (p = 0.001) were increasingly associated with better outcomes, and evacuation of a hematoma was associated (p = 0.001) with outcomes likely to be better than vegetative. We conclude that diffuse or multifocal neuropathological patterns of TBI from primary axonal injury or secondary ischemic damage are most likely to be associated with the most severely impaired outcomes after a head injury.	[Murray, Lilian S.] Univ Glasgow, Western Infirm, Gardiner Inst, Sch Med, Glasgow G11 6NT, Lanark, Scotland; [Adams, J. Hume; Graham, David I.] Univ Glasgow, Fac Med, Inst Neurol Sci, So Gen Hosp,Dept Neuropathol, Glasgow G11 6NT, Lanark, Scotland; [Jennett, Bryan; Teasdale, Graham M.] Univ Glasgow, Fac Med, Inst Neurol Sci, So Gen Hosp,Dept Neurosurg, Glasgow G11 6NT, Lanark, Scotland; [Gennarelli, Thomas A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA	Murray, LS (corresponding author), Univ Glasgow, Western Infirm, Gardiner Inst, Sch Med, Glasgow G11 6NT, Lanark, Scotland.	Lilian.Murray@glasgow.ac.uk					ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1989, SCOT MED J, V34, P399, DOI 10.1177/003693308903400106; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; BIGLER ED, 1984, INT J NEUROSCI, V24, P295, DOI 10.3109/00207458409089820; Black M, 2002, J CLIN PATHOL, V55, P44, DOI 10.1136/jcp.55.1.44; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1993, HEAD INJURY, P137; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kloster R, 1999, J NEUROL NEUROSUR PS, V67, P439, DOI 10.1136/jnnp.67.4.439; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nashef L, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb06130.x; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Thom M, 1997, EPILEPSIA, V38, pS32, DOI 10.1111/j.1528-1157.1997.tb06123.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031	48	57	58	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					701	709		10.1089/neu.2010.1733			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100271	21401319				2021-06-18	
J	Cook, KF; Bombardier, CH; Bamer, AM; Choi, SW; Kroenke, K; Fann, JR				Cook, Karon F.; Bombardier, Charles H.; Bamer, Alyssa M.; Choi, Seung W.; Kroenke, Kurt; Fann, Jesse R.			Do Somatic and Cognitive Symptoms of Traumatic Brain Injury Confound Depression Screening?	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Diagnosis; Psychometrics; Rehabilitation	ORDINAL LOGISTIC-REGRESSION; 1ST YEAR; DSM-IV; VALIDITY; SERTRALINE; CRITERIA; IMPACT; ADULTS; PHQ-9	Objective: To evaluate whether items of the Patient Health Questionnaire 9 (PHQ-9) function differently in persons with traumatic brain injury (TBI) than in persons from a primary care sample. Design: This study was a retrospective analysis of responses to the PHQ-9 collected in 2 previous studies. Responses to the PHQ-9 were modeled using item response theory, and the presence of DIF was evaluated using ordinal logistic regression. Setting: Eight primary care sites and a single trauma center in Washington state. Participants: Participants (N=3365) were persons from 8 primary care sites (n=3000) and a consecutive sample of persons with complicated mild to severe TBI from a trauma center who were 1 year postinjury (n=365). Interventions: Not applicable. Main Outcome Measure: PHQ-9. Results: No PHQ-9 item demonstrated statistically significant or meaningful DIF attributable to TBI. A sensitivity analysis failed to show that the cumulative effects of nonsignificant DIF resulted in a systematic inflation of PHQ-9 total scores. Therefore, the results also do not support the hypothesis that cumulative DIF for PHQ-9 items spuriously inflates the numbers of persons with TBI screened as potentially having major depressive disorder. Conclusions: The PHQ-9 is a valid screener of major depressive disorder in people with complicated mild to severe TB!, and all symptoms can be counted toward the diagnosis of major depressive disorder without special concern about over-diagnosis or unnecessary treatment.	[Cook, Karon F.] Univ Washington, Rehabil Res Ctr, Sch Med, Dept Rehabil Med, Seattle, WA 98105 USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Sch Med, Seattle, WA 98105 USA; [Choi, Seung W.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Kroenke, Kurt] Indiana Univ Sch Med, VA Ctr Excellence Implementing Evidence Based Pra, Indianapolis, IN USA; [Kroenke, Kurt] Regenstrief Inst Hlth Care, Indianapolis, IN USA	Cook, KF (corresponding author), Univ Washington, Rehabil Res Ctr, Sch Med, Dept Rehabil Med, 4907 25th Ave NE, Seattle, WA 98105 USA.	karonc2@u.washington.edu		Kroenke, Kurt/0000-0002-0114-4669	Department of Education (National Institute on Disability and Rehabilitation Research) [H133B080024]; National Center for Medical Rehabilitation Research; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HD39415]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039415] Funding Source: NIH RePORTER	Supported by the Department of Education (National Institute on Disability and Rehabilitation Research) (grant no. H133B080024, and by the National Center for Medical Rehabilitation Research, the National Institute of Child Health and Human Development, and National Institutes of Health (grant no. R01 HD39415).	Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Crane PK, 2007, QUAL LIFE RES, V16, P69, DOI 10.1007/s11136-007-9185-5; Crane PK, 2006, MED CARE, V44, pS115, DOI 10.1097/01.mlr.0000245183.28384.ed; Crane PK, 2004, STAT MED, V23, P241, DOI 10.1002/sim.1713; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; Hambleton R. K., 1991, FUNDAMENTALS ITEM RE; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koenig HG, 1997, AM J PSYCHIAT, V154, P1376; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2010, GEN HOSP PSYCHIAT, V32, P345, DOI 10.1016/j.genhosppsych.2010.03.006; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Revicki DA, 1997, QUAL LIFE RES, V6, P595, DOI 10.1023/A:1018420418455; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Samejima F., 1969, PSYCHOMETRIC MONOGRA, V17; Simon GE, 2006, PSYCHOL MED, V36, P27, DOI 10.1017/S0033291705006136; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Williams JW, 2002, JAMA-J AM MED ASSOC, V287, P1160, DOI 10.1001/jama.287.9.1160; Zumbo B.D, 1999, HDB THEORY METHODS D	32	57	58	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2011	92	5					818	823		10.1016/j.apmr.2010.12.008			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	759YO	WOS:000290288000019	21530731	Green Accepted, Green Published			2021-06-18	
J	Tremblay, S; de Beaumont, L; Lassonde, M; Theoret, H				Tremblay, Sara; de Beaumont, Louis; Lassonde, Maryse; Theoret, Hugo			Evidence for the Specificity of Intracortical Inhibitory Dysfunction in Asymptomatic Concussed Athletes	JOURNAL OF NEUROTRAUMA			English	Article						afferent inhibition; intracortical inhibition; somatosensory evoked potentials; sport concussions; TMS	TRAUMATIC BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; LATENCY AFFERENT INHIBITION; SOMATOSENSORY-EVOKED POTENTIALS; MOTOR CORTEX EXCITABILITY; EXCITATORY AMINO-ACIDS; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; SPORTS CONCUSSION; LONG-TERM	Sports concussions affect thousands of individuals every year and are a major public health concern. Still, little is known about the long-term and cumulative effects of concussions on brain neurophysiology. The principal objective of this study was to investigate the long-lasting effects of multiple sports concussions on sensorimotor integration and somatosensory processing in a sample of 12 concussed athletes and 14 non-concussed athletes of similar age (mean, 23 years) and education (mean, 16 years). Right median nerve stimulation was paired with transcranial magnetic stimulation (TMS) of the left primary motor cortex to investigate sensorimotor integration with short latency afferent inhibition (SAI) and long latency afferent inhibition (LAI) at five interstimulus intervals (18, 20, 22, 100, 200 msec). Somatosensory evoked potentials (SEP) were recorded from the left centro-parietal region. We also investigated primary motor cortex inhibitory mechanisms with three TMS protocols: cortical silent period, long interval intracortical inhibition, and short interval intracortical inhibition. Motor evoked potentials were recorded from the right abductor pollicis brevis muscle. No differences were observed between groups for SAI, LAI, and SEP. However, cortical silent period duration was prolonged and long interval intracortical inhibition was enhanced in the concussed group. These findings suggest that multiple sports concussions lead to specific, long-term neurophysiological dysfunctions of intracortical inhibitory mechanisms in primary motor cortex while somatosensory processing and sensorimotor integration are spared. This study provides additional evidence for the presence of specific and stable alterations of GABA(B) receptor activity in primary motor cortex that may be of clinical value for prognosis and diagnosis.	[Tremblay, Sara; Lassonde, Maryse; Theoret, Hugo] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Tremblay, Sara; Lassonde, Maryse; Theoret, Hugo] Hop St Justine, Ctr Rech, Montreal, PQ H3T 1C5, Canada; [de Beaumont, Louis] McGill Univ, Montreal, PQ, Canada	Theoret, H (corresponding author), Univ Montreal, Dept Psychol, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	hugo.theoret@umontreal.ca	Tremblay, Sara/X-5471-2019	Theoret, Hugo/0000-0002-7458-8797	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Fonds de la Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec	This work was supported by grants from the Canadian Institutes of Health Research and the Fonds de la Recherche en Sante du Quebec.	Abbruzzese G, 1999, J PHYSIOL-LONDON, V514, P895, DOI 10.1111/j.1469-7793.1999.895ad.x; Alle H, 2009, J PHYSIOL-LONDON, V587, P5163, DOI 10.1113/jphysiol.2009.179820; Baumer T, 2007, NEUROLOGY, V69, P1976, DOI 10.1212/01.wnl.0000278109.76607.0a; Bajbouj M, 2006, BIOL PSYCHIAT, V59, P395, DOI 10.1016/j.biopsych.2005.07.036; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen R, 1999, EXP BRAIN RES, V129, P77, DOI 10.1007/s002210050938; Chen R, 2004, EXP BRAIN RES, V154, P1, DOI 10.1007/s00221-003-1684-1; Chen R, 2008, CLIN NEUROPHYSIOL, V119, P504, DOI 10.1016/j.clinph.2007.10.014; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; COOPER R, 1980, EEG TECHNOLOGY; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Di Lazzaro V, 2007, CLIN NEUROPHYSIOL, V118, P2207, DOI 10.1016/j.clinph.2007.07.005; Di Lazzaro V, 2005, J NEUROL NEUROSUR PS, V76, P1064, DOI 10.1136/jnnp.2004.051334; Di Lazzaro V, 2004, J NEUROL NEUROSUR PS, V75, P555, DOI 10.1136/jnnp.2003.018127; Di Lazzaro V, 2002, NEUROLOGY, V59, P392, DOI 10.1212/WNL.59.3.392; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Ilic TV, 2002, J PHYSIOL-LONDON, V545, P153, DOI 10.1113/jphysiol.2002.030122; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly JP, 1997, NEUROLOGY, V48, P581; Kessler KR, 2005, MOVEMENT DISORD, V20, P238, DOI 10.1002/mds.20295; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Maeda F, 2000, BRIT J PSYCHIAT, V177, P169, DOI 10.1192/bjp.177.2.169; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McDonnell MN, 2006, EXP BRAIN RES, V173, P86, DOI 10.1007/s00221-006-0365-2; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakamura H, 1997, J PHYSIOL-LONDON, V498, P817, DOI 10.1113/jphysiol.1997.sp021905; Orth M, 2005, BRAIN, V128, P1292, DOI 10.1093/brain/awh473; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RAPPAPORT M, 1990, CLIN ELECTROENCEPHAL, V21, P188, DOI 10.1177/155005949002100406; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; Richardson SP, 2009, EXP BRAIN RES, V193, P173, DOI 10.1007/s00221-008-1605-4; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rossi S, 2009, BIOL PSYCHIAT, V66, P54, DOI 10.1016/j.biopsych.2009.03.008; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Sailer A, 2003, BRAIN, V126, P1883, DOI 10.1093/brain/awg183; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.3.CO;2-O; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; Wu L, 2002, CLIN NEUROPHYSIOL, V113, P1286, DOI 10.1016/S1388-2457(02)00160-8; Yurkewicz L, 2005, J NEUROTRAUM, V22, P1428, DOI 10.1089/neu.2005.22.1428; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006; Zumsteg D, 2006, CAN J NEUROL SCI, V33, P379, DOI 10.1017/S0317167100005333	73	57	57	1	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2011	28	4					493	502		10.1089/neu.2010.1615			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	746IW	WOS:000289240200001	21219259				2021-06-18	
J	Shear, DA; Lu, XCM; Bombard, MC; Pedersen, R; Chen, ZY; Davis, A; Tortella, FC				Shear, Deborah A.; Lu, Xi-Chun May; Bombard, Matthew C.; Pedersen, Rebecca; Chen, Zhiyong; Davis, Angela; Tortella, Frank C.			Longitudinal Characterization of Motor and Cognitive Deficits in a Model of Penetrating Ballistic-Like Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; cognitive function; models of injury; penetrating ballistic-like brain injury; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN; POSTTRAUMATIC HYDROCEPHALUS; FUNCTIONAL RECOVERY; PROSPECTIVE MEMORY; PREFRONTAL CORTEX; GUNSHOT WOUNDS; ROTAROD TEST; RAT MODEL; MICE	Traumatic brain injury (TBI) produces a wide range of motor and cognitive changes. While some neurological symptoms may respond to therapeutic intervention during the initial recovery period, others may persist for many years after the initial insult, and often have a devastating impact on quality of life for the TBI victim. The aim of the current study was to develop neurobehavioral testing parameters designed to provide a longitudinal assessment of neurofunctional deficits in a rodent model of penetrating ballistic-like brain injury (PBBI). We report here a series of experiments in which unilateral frontal PBBI was induced in rats, and motor/cognitive abilities were assessed using a battery of tests ranging from 30 min to 10 weeks post-injury. The results showed that PBBI produced consistent and significant (1) neurological deficits (neuroscore examination: 30 min to 10 weeks post-PBBI), (2) sensorimotor dysfunction in the contralateral forelimb (forelimb asymmetry task: 7 and 21 days), (3) motor dysfunction (balance beam task: 3-7 days; and fixed-speed rotarod task: 3-28 days), and (4) spatial learning deficits in the Morris water maze (MWM) task out to 10 weeks post-injury. Overall, the results of this study demonstrate that PBBI produces enduring motor and cognitive deficits, and identifies the optimal task and testing parameters for facilitating longitudinal screening of promising therapeutic interventions in this brain injury model.	[Shear, Deborah A.; Lu, Xi-Chun May; Bombard, Matthew C.; Pedersen, Rebecca; Chen, Zhiyong; Davis, Angela; Tortella, Frank C.] MRMC UWI C, Walter Reed Army Inst Res, Dept Appl Neurobiol, Silver Spring, MD 20910 USA; [Bombard, Matthew C.; Pedersen, Rebecca; Davis, Angela] Geneva Fdn, Lakewood, WA USA	Shear, DA (corresponding author), MRMC UWI C, Walter Reed Army Inst Res, Dept Appl Neurobiol, Bldg 503-2W14, Silver Spring, MD 20910 USA.	Deborah.Shear@AMEDD.ARMY.MIL	Shear, Deborah/B-3607-2011	Bombard, Matthew/0000-0002-3039-5192	Department of the Army [W81XWH-08-2-0127]; U.S. Army Medical Research Acquisition Activity, Fort Detrick, MD	This work was supported by the Department of the Army, award W81XWH-08-2-0127, with the U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, as the awarding and administering acquisition office.	BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bohlen M, 2009, J NEUROSCI METH, V178, P10, DOI 10.1016/j.jneumeth.2008.11.001; Carlson JN, 1996, BRAIN RES, V707, P122, DOI 10.1016/0006-8993(95)01341-5; Carter RJ, 1999, J NEUROSCI, V19, P3248; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; COWEY A, 1974, BRAIN RES, V72, P53, DOI 10.1016/0006-8993(74)90649-0; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Daffner KR, 2000, J NEUROL NEUROSUR PS, V68, P18, DOI 10.1136/jnnp.68.1.18; DUNHAM NW, 1957, J AM PHARM ASSOC, V46, P208, DOI 10.1002/jps.3030460322; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; GLICK SD, 1976, LIFE SCI, V18, P889, DOI 10.1016/0024-3205(76)90405-7; Guyot LL, 2000, NEUROL RES, V22, P25; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; HOCHMAN MS, 1983, EPILEPSIA, V24, P11, DOI 10.1111/j.1528-1157.1983.tb04860.x; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; KATZ RT, 1989, AM J PHYS MED REHAB, V68, P91, DOI 10.1097/00002060-198904000-00009; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Lu XCM, 2009, J NEUROTRAUM, V26, P141, DOI 10.1089/neu.2008.0629; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; Martins RS, 2003, SURG NEUROL, V60, P98, DOI 10.1016/S0090-3019(03)00302-1; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Nestor SM, 2008, BRAIN, V131, P2443, DOI 10.1093/brain/awn146; O'Connor C, 2003, J NEUROTRAUM, V20, P985, DOI 10.1089/089771503770195830; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Peeling J, 2001, J Stroke Cerebrovasc Dis, V10, P166, DOI 10.1053/jscd.2001.26865; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roof RL, 2001, STROKE, V32, P2648, DOI 10.1161/hs1101.097397; Rustay NR, 2003, BEHAV BRAIN RES, V141, P237, DOI 10.1016/S0166-4328(02)00376-5; Sapsford W, 2003, J R Army Med Corps, V149, P5; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; SCHALLERT T, 2002, PHARM CEREBRAL ISCHE, P210; Schrimsher GW, 2002, J CHILD NEUROL, V17, P877, DOI 10.1177/08830738020170122001; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shear DA, 2009, PHARMACOL BIOCHEM BE, V94, P56, DOI 10.1016/j.pbb.2009.07.006; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; WATZMAN N, 1968, PSYCHOPHARMACOLOGIA, V12, P414, DOI 10.1007/BF00401346; Wei HH, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-19; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828	52	57	57	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2010	27	10					1911	1923		10.1089/neu.2010.1399			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	665OZ	WOS:000283046600015	20684676				2021-06-18	
J	Dumont, TM; Visioni, AJ; Rughani, AI; Tranmer, BI; Crookes, B				Dumont, Travis M.; Visioni, Agostino J.; Rughani, Anand I.; Tranmer, Bruce I.; Crookes, Bruce			Inappropriate Prehospital Ventilation in Severe Traumatic Brain Injury Increases In-Hospital Mortality	JOURNAL OF NEUROTRAUMA			English	Article						brain injury guidelines; hyperventilation; prehospital; traumatic brain injury	CEREBRAL-BLOOD-FLOW; HEAD-INJURY; CARBON-DIOXIDE; PRESSURE AUTOREGULATION; HEMORRHAGIC-SHOCK; HYPERVENTILATION; OXYGENATION; CIRCULATION; METABOLISM; MANAGEMENT	In the setting of acute brainstem herniation in traumatic brain injury (TBI), the use of hyperventilation to reduce intracranial pressure may be life-saving. However, undue use of hyperventilation is thought to increase the incidence of secondary brain injury through direct reduction of cerebral blood flow. This is a retrospective review determining the effect of prehospital hyperventilation on in-hospital mortality following severe TBI. All trauma patients admitted directly to a single level 1 trauma center from January 2000 to January 2007 with an initial Glasgow Coma Scale (GCS) score <= 8 were included in the study (n = 77). Patients without documented or with late (> 20 min) arterial blood gas at presentation (n = 12) were excluded from the study. The remaining population (n = 65) was sorted into three groups based on the initial partial pressure of carbon dioxide: hypocarbic (Pco(2) < 35mm Hg), normocarbic (Pco(2) 35-45mm Hg), and hypercarbic (Pco(2) > 45mm Hg). Outcome was based on mortality during hospital admission. Survival was found to be related to admission Pco(2) in head trauma patients requiring intubation (p = 0.045). Patients with normocarbia on presenting arterial blood gas testing had in-hospital mortality of 15%, significantly improved over patients presenting with hypocarbia (in-hospital mortality 77%) or hypercarbia (in-hospital mortality 61%). Although there are many reports of the negative impact of prophylactic hyperventilation following severe TBI, this modality is frequently utilized in the prehospital setting. Our results suggest that abnormal Pco2 on presentation after severe head trauma is correlated with increased in-hospital mortality. We advocate normoventilation in the prehospital setting.	[Dumont, Travis M.; Visioni, Agostino J.; Rughani, Anand I.; Tranmer, Bruce I.] Univ Vermont, Coll Med, Dept Surg, Div Neurosurg, Burlington, VT 05401 USA; [Crookes, Bruce] Univ Vermont, Coll Med, Dept Surg, Div Trauma Surg, Burlington, VT 05401 USA	Dumont, TM (corresponding author), Univ Vermont, Coll Med, Dept Surg, Div Neurosurg, Fletcher 5th Floor, Burlington, VT 05401 USA.	Travis.Dumont@vtmednet.org					*AM ASS NEUR SURG, 2006, J NEUROTRAUM, V17, P513; *AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS87; *AM ASS NEUR SURG, 2000, J NEUROTRAUM, V17, P573; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; [Anonymous], 2000, J Neurotrauma, V17, P563; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bhende M S, 2001, Prehosp Emerg Care, V5, P208, DOI 10.1080/10903120190940146; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; CROCKARD HA, 1973, BMJ-BRIT MED J, V4, P634, DOI 10.1136/bmj.4.5893.634; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Deakin CD, 2004, J TRAUMA, V57, P65, DOI 10.1097/01.TA.0000103984.70306.22; Deem S, 2006, RESP CARE, V51, P357; di Bartolomeo S, 2003, EUR J EMERG MED, V10, P268, DOI 10.1097/01.mej.0000103466.32882.7b; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; GORDON E, 1971, ACTA ANAESTH SCAND, V15, P193, DOI 10.1111/j.1399-6576.1971.tb05461.x; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Lal Dave, 2003, Prehosp Disaster Med, V18, P20; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LUNDBERG N, 1959, Acta Psychiatr Scand Suppl, V34, P1; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; ROSSANDA M, 1972, EUR NEUROL, V8, P169, DOI 10.1159/000114573; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; TEASDALE G, 1974, LANCET, V2, P81; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; VICARIO SJ, 1983, ANN EMERG MED, V12, P145, DOI 10.1016/S0196-0644(83)80554-X; Zauner A, 2002, J NEUROSURG, V97, P643, DOI 10.3171/jns.2002.97.3.0643	45	57	59	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1233	1241		10.1089/neu.2009.1216			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100008	20373856				2021-06-18	
J	Pauly, S; Klatte, F; Strobel, C; Schmidmaier, G; Greiner, S; Scheibel, M; Wildemann, B				Pauly, S.; Klatte, F.; Strobel, C.; Schmidmaier, G.; Greiner, S.; Scheibel, M.; Wildemann, B.			CHARACTERIZATION OF TENDON CELL CULTURES OF THE HUMAN ROTATOR CUFF	EUROPEAN CELLS & MATERIALS			English	Article						Rotator cuff; tendon healing; tenocyte; tendon-like cells; cell culture; tendon-bone	MEDIAL COLLATERAL LIGAMENT; DOUBLE-ROW REPAIR; GROWTH-FACTORS; IN-VITRO; TENASCIN-C; MUSCULOSKELETAL TISSUES; GENE-EXPRESSION; ASCORBIC-ACID; FIBROBLASTS; COLLAGEN	Rotator cuff tears are common soft tissue injuries of the musculoskeletal system that heal by formation of repair tissue and may lead to high retear rates and joint dysfunction. In particular, tissue from chronic, large tendon tears is or such degenerative nature that it may be prone to retear after surgical repair. Besides several biomechanical approaches, biologically based strategies such as application of growth factors may be promising for increasing cell activity and production of extracellular tendon matrix at the tendon-to-bone unit. As it precondition for subsequent experimental growth factor application, the aim of the present study was to establish and characterize a human rotator cuff tendon cell culture. Long head biceps (LHB)- and supraspinatus muscle (SSP)- tendon samples from donor patients undergoing shoulder surgery were cultivated and examined at the RNA level for expression of collagen type-I, -II and -III, biglycan, decorin, tenascin-C, aggrecan, osteocalcin, tenomodulin and scleraxis (by Real-time PCR). Finally, results were compared to chondrocytes and osteoblasts as control cells. An expression pattern was found which may reflect a human rotator cuff tenocyte-like cell culture. Both SSP and LHB tenocyte-like cells differed from chondrocyte cell cultures in terms of reduced expression of collagen type-II (p <= 0.05) and decorin while higher levels of collagen type-I were seen (P <= 0.05). With respect to osteoblasts, tenocyte-like cells expressed lower levels of osteocalcin (p <= 0.05) as well as tenascin C, biglycan and collagen type-III. Expression of scleraxis, tenomodulin and aggrecan was similar between all cell types. This study represents a characterization of tenocyte-like cells from the human rotator cuff as close as possible. It helps analyzing their biological properties and allows further studies to improve production of tendon matrix and osteofibroblastic integration at the tendon-bone unit following tendon repair.	[Pauly, S.; Klatte, F.; Strobel, C.; Schmidmaier, G.; Greiner, S.; Scheibel, M.; Wildemann, B.] Charite, Ctr Musculoskeletal Surg, Julius Wolff Inst, D-13353 Berlin, Germany; [Klatte, F.; Strobel, C.; Wildemann, B.] Charite, Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany	Wildemann, B (corresponding author), Charite, Ctr Musculoskeletal Surg, Julius Wolff Inst, Augustenburger Pl 1, D-13353 Berlin, Germany.	britt.wildemann@charite.de	Klatte-Schulz, Franka/B-6734-2017; Wildemann, Britt/G-7732-2012	Wildemann, Britt/0000-0002-8365-1188; Klatte-Schulz, Franka/0000-0001-6079-228X	European Society for Shoulder and Elbow Surgery (ESSES/SECEC)	The authors gratefully thank the European Society for Shoulder and Elbow Surgery (ESSES/SECEC, a non-profit organization) for generously providing a research grant. We thank Dr. Schulze-Tanzil and colleagues for the discussion regarding the tendon cell culture. We furthermore thank Dr. Ringe and colleagues for kindly providing primal chondrocyte cell cultures serving as a control.	Almarza AJ, 2008, ANN BIOMED ENG, V36, P1927, DOI 10.1007/s10439-008-9565-1; Angel MJ, 2006, SPORTS MED ARTHROSC, V14, P138, DOI 10.1097/00132585-200609000-00005; Anitua E, 2006, J BIOMED MATER RES A, V77A, P285, DOI 10.1002/jbm.a.30585; Archambault JM, 2007, J ORTHOP RES, V25, P617, DOI 10.1002/jor.20347; Batten ML, 1996, J ORTHOPAED RES, V14, P736, DOI 10.1002/jor.1100140509; Bayne O., 1984, SURG SHOULDER, P167; Baysal D, 2005, AM J SPORT MED, V33, P1346, DOI 10.1177/0363546505275130; Bishop J, 2006, J SHOULDER ELB SURG, V15, P290, DOI 10.1016/j.jse.2005.09.017; Blevins FT, 1997, ORTHOP CLIN N AM, V28, P1, DOI 10.1016/S0030-5898(05)70260-1; Boileau P, 2005, J BONE JOINT SURG AM, V87A, P1229, DOI 10.2106/JBJS.D.02035; Brune T, 2007, EUR CELLS MATER, V14, P78, DOI 10.22203/eCM.v014a08; Chang J, 2000, PLAST RECONSTR SURG, V105, P148, DOI 10.1097/00006534-200001000-00025; Chiquet-Ehrismann R, 2004, INT J BIOCHEM CELL B, V36, P1085, DOI 10.1016/j.biocel.2004.01.007; Choi KM, 2008, J BIOSCI BIOENG, V105, P586, DOI 10.1263/jbb.105.586; Chuen FS, 2004, J HISTOCHEM CYTOCHEM, V52, P1151, DOI 10.1369/jhc.3A6232.2004; Cole BJ, 2007, J SHOULDER ELB SURG, V16, P579, DOI 10.1016/j.jse.2006.12.011; Costa MA, 2006, TISSUE ENG, V12, P1937, DOI 10.1089/ten.2006.12.1937; de Mos M, 2008, AM J SPORT MED, V36, P1171, DOI 10.1177/0363546508314430; Edom-Vovard F, 2002, DEV BIOL, V247, P351, DOI 10.1006/dbio.2002.0707; Ehlers TW, 1998, COMP BIOCHEM PHYS A, V121, P355, DOI 10.1016/S1095-6433(98)10144-7; Flatow EL, 1996, J BONE JOINT SURG AM, V78A, P1785, DOI 10.2106/00004623-199611000-00028; Fu SC, 2008, J ORTHOP RES, V26, P374, DOI 10.1002/jor.20483; FUKUDA H, 1990, CLIN ORTHOP RELAT R, P75; GERBER C, 1994, J BONE JOINT SURG BR, V76B, P371; Gigante A, 2004, J SHOULDER ELB SURG, V13, P328, DOI 10.1016/j.jse.2003.12.015; GOUTALLIER D, 1994, CORROSION, V304, P78; GUMINA S, 2009, MUSCULOSKELET SUR S1, V93, pS65; GUOGUANG Y, 2004, J BIOMECH, V37, P1543; HEFTI F, 1995, ORTHOPADE, V24, P237; Hsu C, 2004, J HAND SURG-AM, V29A, P551, DOI 10.1016/j.jhsa.2004.04.020; Ibold Y, 2009, TISSUE CELL, V41, P249, DOI 10.1016/j.tice.2008.12.001; Itaya T, 2009, J PERIODONTAL RES, V44, P425, DOI 10.1111/j.1600-0765.2008.01137.x; Jarvinen TAH, 2000, SCAND J MED SCI SPOR, V10, P376, DOI 10.1034/j.1600-0838.2000.010006376.x; Jelinsky SA, 2010, J ORTHOP RES, V28, P289, DOI 10.1002/jor.20999; Kannus P, 2000, SCAND J MED SCI SPOR, V10, P312, DOI 10.1034/j.1600-0838.2000.010006312.x; Kannus P, 1998, HISTOCHEM J, V30, P799, DOI 10.1023/A:1003448106673; Kardestuncer T, 2006, CLIN ORTHOP RELAT R, P234, DOI 10.1097/01.blo.0000205879.50834.fe; Klein MB, 2002, J HAND SURG-AM, V27A, P615, DOI 10.1053/jhsu.2002.34004; Lafosse L, 2007, J BONE JOINT SURG AM, V89A, P1533, DOI 10.2106/JBJS.F.00305; LEE J, 1995, J ORTHOP RES, V13, P435, DOI 10.1002/jor.1100130318; Li F, 2008, CELL MOTIL CYTOSKEL, V65, P332, DOI 10.1002/cm.20263; Lorbach O, 2008, AM J SPORT MED, V36, P1504, DOI 10.1177/0363546508314424; Maffulli N, 2000, AM J SPORT MED, V28, P499, DOI 10.1177/03635465000280040901; Maffulli N, 2002, BRIT J SPORT MED, V36, P315, DOI 10.1136/bjsm.36.5.315; Mahar A, 2007, ARTHROSCOPY, V23, P1265, DOI 10.1016/j.arthro.2007.07.010; Martin JA, 2003, BIORHEOLOGY, V40, P321; Marui T, 1997, J ORTHOPAED RES, V15, P18, DOI 10.1002/jor.1100150104; Matthews TJW, 2006, J BONE JOINT SURG BR, V88B, P489, DOI 10.1302/0301-620X.88B4.16845; Mazzocca AD, 2007, J SHOULDER ELB SURG, V16, p222S, DOI 10.1016/j.jse.2007.02.113; Molloy T, 2003, SPORTS MED, V33, P381, DOI 10.2165/00007256-200333050-00004; Neumann K, 2007, J CELL BIOCHEM, V102, P626, DOI 10.1002/jcb.21319; PATTE D, 1990, CLIN ORTHOP RELAT R, P81; PAULY S, 2010, ARTHROSCOPY IN PRESS; Rahaman MN, 2005, BIOTECHNOL BIOENG, V91, P261, DOI 10.1002/bit.20292; Rees SG, 2000, BIOCHEM J, V350, P181, DOI 10.1042/0264-6021:3500181; Riley GP, 1996, AM J PATHOL, V149, P933; Rios CG, 2007, TECH ORTHOP, V22, P2, DOI 10.1097/01.bto.0000261728.04529.0b; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; Salingcarnboriboon R, 2003, EXP CELL RES, V287, P289, DOI 10.1016/S0014-4827(03)00107-1; Schulze-Tanzil G, 2004, HISTOCHEM CELL BIOL, V122, P219, DOI 10.1007/s00418-004-0694-9; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; Scutt N, 2008, J Orthop Surg Res, V3, P32, DOI 10.1186/1749-799X-3-32; Severud EL, 2003, ARTHROSCOPY, V19, P234, DOI 10.1053/jars.2003.50036; Shukunami C, 2006, DEV BIOL, V298, P234, DOI 10.1016/j.ydbio.2006.06.036; Son E, 2007, NUTRITION, V23, P745, DOI 10.1016/j.nut.2007.06.013; STOLL C, 2010, J ORTHOP RE IN PRESS; Takahashi S, 2002, TOHOKU J EXP MED, V198, P207, DOI 10.1620/tjem.198.207; Tempfer H, 2009, ACTA ORTHOP, V80, P357, DOI 10.3109/17453670902988360; Theisen C, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-9; Thomopoulos S, 2005, J HAND SURG-AM, V30A, P441, DOI 10.1016/j.jhsa.2004.12.006; Thomopoulos S, 2007, J ORTHOP RES, V25, P1358, DOI 10.1002/jor.20444; Tsai AD, 2003, J CELL BIOCHEM, V90, P777, DOI 10.1002/jcb.10666; Wang B, 2008, BIOMATERIALS, V29, P2954, DOI 10.1016/j.biomaterials.2008.03.038; Wolf EM, 2004, ARTHROSCOPY, V20, P5, DOI 10.1016/j.arthro.2003.11.001; WONG M, 1992, J BIOL CHEM, V267, P5592; Yang GG, 2004, J BIOMECH, V37, P1543, DOI 10.1016/j.jbiomech.2004.01.005; Yao L, 2006, TISSUE ENG, V12, P1843, DOI 10.1089/ten.2006.12.1843; Yokota A, 2005, J SHOULDER ELB SURG, V14, p72S, DOI 10.1016/j.jse.2004.09.021; Yoon J. H., 2005, Journal of Musculoskeletal & Neuronal Interactions, V5, P22	79	57	58	0	16	AO RESEARCH INSTITUTE DAVOS-ARI	DAVOS	CLAVADELERSTRASSE 8, DAVOS, CH 7270, SWITZERLAND	1473-2262			EUR CELLS MATER	Eur. Cells Mater.	JUL-DEC	2010	20						84	97		10.22203/eCM.v020a08			14	Cell & Tissue Engineering; Engineering, Biomedical; Materials Science, Biomaterials; Orthopedics	Cell Biology; Engineering; Materials Science; Orthopedics	652LA	WOS:000282006700005	20661865	DOAJ Gold			2021-06-18	
J	Walker, PA; Harting, MT; Jimenez, F; Shah, SK; Pati, S; Dash, PK; Cox, CS				Walker, Peter A.; Harting, Matthew T.; Jimenez, Fernando; Shah, Shinil K.; Pati, Shibani; Dash, Pramod K.; Cox, Charles S., Jr.			Direct Intrathecal Implantation of Mesenchymal Stromal Cells Leads to Enhanced Neuroprotection via an NF kappa B-Mediated Increase in Interleukin-6 Production	STEM CELLS AND DEVELOPMENT			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS; INFLAMMATORY RESPONSE; ISCHEMIC BRAIN; RAT; TRANSPLANTATION	Mesenchymal stromal cell (MSC) therapy has shown promise for the treatment of traumatic brain injury (TBI). Although the mechanism(s) by which MSCs offer protection is unclear, initial in vivo work has suggested that modulation of the locoregional inflammatory response could explain the observed benefit. We hypothesize that the direct implantation of MSCs into the injured brain activates resident neuronal stem cell (NSC) niches altering the intracerebral milieu. To test our hypothesis, we conducted initial in vivo studies, followed by a sequence of in vitro studies. In vivo: Sprague-Dawley rats received a controlled cortical impact (CCI) injury with implantation of 1 million MSCs 6 h after injury. Brain tissue supernatant was harvested for analysis of the proinflammatory cytokine profile. In vitro: NSCs were transfected with a firefly luciferase reporter for NF kappa B and placed in contact culture and transwell culture. Additionally, multiplex, quantitative PCR, caspase 3, and EDU assays were completed to evaluate NSC cytokine production, apoptosis, and proliferation, respectively. In vivo: Brain supernatant analysis showed an increase in the proinflammatory cytokines IL-1 alpha, IL-1 beta, and IL-6. In vitro: NSC N kappa B activity increased only when in contact culture with MSCs. When in contact with MSCs, NSCs show an increase in IL-6 production as well as a decrease in apoptosis. Direct implantation of MSCs enhances neuroprotection via activation of resident NSC NF kappa B activity (independent of PI3 kinase/AKT pathway) leading to an increase in IL-6 production and decrease in apoptosis. In addition, the observed NF kappa B activity depends on direct cell contact.	[Walker, Peter A.; Harting, Matthew T.; Jimenez, Fernando; Shah, Shinil K.; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Pediat Surg, Houston, TX 77030 USA; [Walker, Peter A.; Harting, Matthew T.; Shah, Shinil K.; Pati, Shibani; Cox, Charles S., Jr.] Univ Texas Med Sch Houston, Dept Surg, Houston, TX 77030 USA; [Dash, Pramod K.] Univ Texas Med Sch Houston, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Shah, Shinil K.; Cox, Charles S., Jr.] Texas A&M Univ, Michael E DeBakey Inst Comparit Cardiovasc Sci &, College Stn, TX USA	Cox, CS (corresponding author), Univ Texas Med Sch Houston, Dept Pediat Surg, 6431 Fannin St,MSB 5-236, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002; Harting, Matthew/0000-0002-8929-8311	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH T32 GM 08 79201, M01 RR 02558]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024148, M01RR002558] Funding Source: NIH RePORTER	This work was supported by grants NIH T32 GM 08 79201; M01 RR 02558; Texas Higher Education Coordinating	Adams SD, 2008, J TRAUMA, V65, P170, DOI 10.1097/TA.0b013e31805824ca; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Deng J, 2006, STEM CELLS, V24, P1054, DOI 10.1634/stemcells.2005-0370; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Fischer UM, 2009, STEM CELLS DEV, V18, P683, DOI 10.1089/scd.2008.0253; Gao JZ, 2001, CELLS TISSUES ORGANS, V169, P12, DOI 10.1159/000047856; Harting MT, 2008, CYTOTHERAPY, V10, P243, DOI 10.1080/14653240801950000; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lim JH, 2007, J VET SCI, V8, P275, DOI 10.4142/jvs.2007.8.3.275; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Nijboer CH, 2008, STROKE, V39, P2578, DOI 10.1161/STROKEAHA.108.516401; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 1999, GLIA, V25, P343; Penolazzi L, 2008, CELL BIOL INT, V32, P320, DOI 10.1016/j.cellbi.2007.08.030; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walczak P, 2008, STROKE, V39, P1569, DOI 10.1161/STROKEAHA.107.502047; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	27	57	62	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	JUN	2010	19	6					867	876		10.1089/scd.2009.0188			10	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	614CX	WOS:000279033900011	19775197	Green Published, Green Accepted			2021-06-18	
J	Beirowski, B; Nogradi, A; Babetto, E; Garcia-Alias, G; Coleman, MP				Beirowski, Bogdan; Nogradi, Antal; Babetto, Elisabetta; Garcia-Alias, Guillermo; Coleman, Michael P.			Mechanisms of Axonal Spheroid Formation in Central Nervous System Wallerian Degeneration	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axon; Axonal degeneration; Axonal transport; Neuroaxonal dystrophy; Neurodegeneration; Neuroprotection	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; MULTIPLE-SCLEROSIS; WHITE-MATTER; OPTIC-NERVE; MOUSE MODEL; PERIPHERAL-NERVE; SELF-DESTRUCTION; SODIUM-CHANNELS; CALCIUM INFLUX	Wallerian degeneration of the CNS is accompanied by axonal dystrophy or swelling. To understand the mechanisms by which swellings arise, we studied their spatiotemporal dynamics, ultrastructure, composition, and the conditions that affect their formation in vivo and ex vivo. In contrast to peripheral nerve axons, lesioned optic nerve (ON) axons in vivo developed focal swellings asynchronously within 6 hours, long before there is any axon fragmentation. Axons in ON, spinal cord dorsal column, and corpus callosum all showed marked gradients with more swellings in proximal regions of their distal stumps early after lesion. Time-lapse imaging of a validated ex vivo system showed that multiple focal swellings arise after around 1 hour close to the injury site, followed by anterograde wave-like progression on continuous ON axon stumps. Swellings were largely stable but occasionally seemed to fuse with neighboring swellings. Their ultrastructural appearances resembled disease-associated spheroids. Although accumulation of axonal markers suggested transport deficits, large accumulations of mitochondria were not observed. Early swelling formation was decreased in Wld(S) gene-expressing rodents and by removing extracellular calcium. Several pharmacologic agents that inhibit axon loss in vitro and/or in vivo also prevented early formation of axonal spheroids in acute ON explants. Because axonal swellings are hallmarks of many neurodegenerative conditions, these data suggest that they are a manifestation of Wallerian-like degeneration in some cases. Thus, Wallerian-like degeneration may be a more common component mechanism in CNS diseases than previously thought.	[Beirowski, Bogdan; Babetto, Elisabetta; Coleman, Michael P.] Babraham Inst, Cambridge, England; [Nogradi, Antal] Univ Szeged, Dept Ophthalmol, Neuromorphol Lab, Szeged, Hungary; [Garcia-Alias, Guillermo; Coleman, Michael P.] Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge CB2 1TN, England	Beirowski, B (corresponding author), Washington Univ, Sch Med, Dept Genet, 660 S Euclid Ave, St Louis, MO 63110 USA.	bbeirowski@wustl.edu	Garcia-Alias, Guillermo/AAB-8595-2021; Nogradi, Antal/A-7045-2008	Nogradi, Antal/0000-0002-0520-5350; Babetto, Elisabetta/0000-0002-6385-8288	Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC); German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [BMBF-LPD 9901/8-128]; Wellcome TrustWellcome TrustEuropean Commission [069652/Z/02/Z]	Supported by Biotechnology and Biological Sciences Research Council, Grant No. BMBF-LPD 9901/8-128 from the German Federal Ministry of Education and Research (to B. B.), and Grant No. 069652/Z/02/Z from the Wellcome Trust (to A.N.)	Adalbert R, 2009, BRAIN, V132, P402, DOI 10.1093/brain/awn312; Agrawal SK, 1996, J NEUROSCI, V16, P545; Beirowski B, 2004, J NEUROSCI METH, V134, P23, DOI 10.1016/j.jneumeth.2003.10.016; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Beirowski B, 2008, EUR J NEUROSCI, V28, P1166, DOI 10.1111/j.1460-9568.2008.06426.x; Beirowski B, 2009, J NEUROSCI, V29, P653, DOI 10.1523/JNEUROSCI.3814-08.2009; BUCKMASTER EA, 1995, EUR J NEUROSCI, V7, P1596, DOI 10.1111/j.1460-9568.1995.tb01155.x; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Cheng CLY, 1988, J NEUROTRAUM, V5, P47, DOI 10.1089/neu.1988.5.47; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Coleman MP, 2005, J NEUROL SCI, V233, P133, DOI 10.1016/j.jns.2005.03.028; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; Couto LA, 2004, J NEUROSCI RES, V77, P410, DOI 10.1002/jnr.20170; Dewar D, 1999, EUR J PHARMACOL, V375, P41, DOI 10.1016/S0014-2999(99)00280-0; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; Edgar JM, 2004, J CELL BIOL, V166, P121, DOI 10.1083/jcb.200312012; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Ferri A, 2003, CURR BIOL, V13, P669, DOI 10.1016/S0960-9822(03)00206-9; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GEORGE R, 1994, J NEUROCYTOL, V23, P657, DOI 10.1007/BF01181641; Giordana MT, 2002, NEUROPATH APPL NEURO, V28, P35, DOI 10.1046/j.1365-2990.2002.00372.x; Glass JD, 2002, J NEUROL SCI, V196, P9, DOI 10.1016/S0022-510X(02)00013-8; Griffiths I, 1998, SCIENCE, V280, P1610, DOI 10.1126/science.280.5369.1610; Howell GR, 2007, J CELL BIOL, V179, P1523, DOI 10.1083/jcb.200706181; Irvine KA, 2006, J NEUROIMMUNOL, V175, P69, DOI 10.1016/j.jneuroim.2006.03.002; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Komatsu M, 2007, P NATL ACAD SCI USA, V104, P14489, DOI 10.1073/pnas.0701311104; Kornek B, 2001, BRAIN, V124, P1114, DOI 10.1093/brain/124.6.1114; LAWSON LJ, 1994, J NEUROCYTOL, V23, P729, DOI 10.1007/BF01268086; Liberski PP, 1999, ACTA NEUROPATHOL, V97, P329, DOI 10.1007/s004010050995; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; Mack TGA, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn770; Mancardi G, 2001, J NEUROL SCI, V184, P41, DOI 10.1016/S0022-510X(00)00490-1; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCarran WJ, 2007, J NEUROSCI, V27, P4220, DOI 10.1523/JNEUROSCI.5542-06.2007; Medana I, 2001, AM J PATHOL, V159, P809, DOI 10.1016/S0002-9440(10)61755-5; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mi WQ, 2005, BRAIN, V128, P405, DOI 10.1093/brain/awh368; Miller BR, 2009, NAT NEUROSCI, V12, P387, DOI 10.1038/nn.2290; Misgeld T, 2007, NAT METHODS, V4, P559, DOI 10.1038/NMETH1055; Moeller JJ, 2008, ACTA NEUROPATHOL, V116, P331, DOI 10.1007/s00401-008-0362-6; MUKOYAMA M, 1989, ACTA NEUROPATHOL, V79, P294, DOI 10.1007/BF00294664; Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309; Nishiyama J, 2007, AUTOPHAGY, V3, P591, DOI 10.4161/auto.4964; NIXON RA, 1986, J NEUROSCI, V6, P1252; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Ohara S, 2004, EXP NEUROL, V187, P289, DOI 10.1016/j.expneurol.2004.03.002; OKAMOTO K, 1990, ACTA NEUROPATHOL, V80, P222, DOI 10.1007/BF00308929; Ouardouz M, 2003, NEURON, V40, P53, DOI 10.1016/j.neuron.2003.08.016; Oya Y, 1998, ACTA NEUROPATHOL, V96, P29, DOI 10.1007/s004010050857; Pease ME, 2000, INVEST OPHTH VIS SCI, V41, P764; PERRY VH, 1991, EUR J NEUROSCI, V3, P102, DOI 10.1111/j.1460-9568.1991.tb00815.x; PERRY VH, 1992, EUR J NEUROSCI, V4, P1000, DOI 10.1111/j.1460-9568.1992.tb00126.x; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pilling AD, 2006, MOL BIOL CELL, V17, P2057, DOI 10.1091/mbc.E05-06-0526; Probst A, 2000, ACTA NEUROPATHOL, V99, P469, DOI 10.1007/s004010051148; Raff MC, 2002, SCIENCE, V296, P868, DOI 10.1126/science.1068613; Ramaglia V, 2008, AM J PATHOL, V172, P1043, DOI 10.2353/ajpath.2008.070660; Ramon y Cajal S, 1928, DEGENERATION REGENER; Ren Y, 2000, J NEUROSCI METH, V102, P165, DOI 10.1016/S0165-0270(00)00304-6; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sajadi A, 2004, CURR BIOL, V14, P326, DOI 10.1016//j.cub.2004.01.053; Sasaki S, 1999, ACTA NEUROPATHOL, V97, P463, DOI 10.1007/s004010051015; Sasaki Y, 2009, J NEUROSCI, V29, P6526, DOI 10.1523/JNEUROSCI.1429-09.2009; Saxena S, 2007, PROG NEUROBIOL, V83, P174, DOI 10.1016/j.pneurobio.2007.07.007; SCHLAEPFER WW, 1977, BRAIN RES, V136, P1, DOI 10.1016/0006-8993(77)90126-3; Sievers C, 2003, NEUROSCI RES, V46, P161, DOI 10.1016/S0168-0102(03)00039-7; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Stokin GB, 2005, SCIENCE, V307, P1282, DOI 10.1126/science.1105681; STOLL G, 1989, J NEUROCYTOL, V18, P671, DOI 10.1007/BF01187086; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; STYS PK, 1991, ANN NEUROL, V30, P375, DOI 10.1002/ana.410300309; Takeuchi H, 2005, J BIOL CHEM, V280, P10444, DOI 10.1074/jbc.M413863200; Teng YD, 1997, J NEUROSCI, V17, P4359; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; TSAO JW, 1994, EUR J NEUROSCI, V6, P516, DOI 10.1111/j.1460-9568.1994.tb00295.x; Tseng KW, 2008, J COMP NEUROL, V507, P1053, DOI 10.1002/cne.21606; Valverde F, 1998, GOLGI ATLAS OF THE POSTNATAL MOUSE BRAIN, P1; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Waller A, 1850, PHILOS T R SOC LOND, V140, P423, DOI [10.1098/rspl.1843.0224, DOI 10.1098/RSTL.1850.0021, 10.1098/rstl.1850.0021]; Wang QJ, 2006, J NEUROSCI, V26, P8057, DOI 10.1523/JNEUROSCI.2261-06.2006; WAXMAN SG, 1993, BRAIN RES, V614, P137, DOI 10.1016/0006-8993(93)91027-P; Waxman SG, 2006, NAT REV NEUROSCI, V7, P932, DOI 10.1038/nrn2023; Williamson TL, 1999, NAT NEUROSCI, V2, P50; Wirths O, 2006, ACTA NEUROPATHOL, V111, P312, DOI 10.1007/s00401-006-0041-4; Wirths O, 2007, NEUROBIOL AGING, V28, P1689, DOI 10.1016/j.neurobiolaging.2006.07.021; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yahata N, 2009, J NEUROSCI, V29, P6276, DOI 10.1523/JNEUROSCI.4304-08.2009; Yang Y, 2007, EUR J NEUROSCI, V26, P2979, DOI 10.1111/j.1460-9568.2007.05914.x; Yue ZY, 2008, AUTOPHAGY, V4, P94, DOI 10.4161/auto.5202; Zhai QW, 2003, NEURON, V39, P217, DOI 10.1016/S0896-6273(03)00429-X	100	57	58	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2010	69	5					455	472		10.1097/NEN.0b013e3181da84db			18	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	594WV	WOS:000277571500004	20418780	Bronze			2021-06-18	
J	Oddo, M; Frangos, S; Maloney-Wilensky, E; Kofke, WA; Le Roux, PD; Levine, JM				Oddo, Mauro; Frangos, Suzanne; Maloney-Wilensky, Eileen; Kofke, W. Andrew; Le Roux, Peter D.; Levine, Joshua M.			Effect of Shivering on Brain Tissue Oxygenation During Induced Normothermia in Patients With Severe Brain Injury	NEUROCRITICAL CARE			English	Article						Induced normothermia; Fever control; Temperature management; Surface cooling; Shivering; Brain tissue oxygenation; Brain injury; SAH; TBI; Neurointensive care; Neurocritical care	INTENSIVE-CARE-UNIT; SUBARACHNOID HEMORRHAGE; CEREBRAL OXYGENATION; ADDITIVELY REDUCE; BODY-TEMPERATURE; CLINICAL-TRIAL; MEPERIDINE; THRESHOLD; HYPERTHERMIA; HYPOTHERMIA	Background We analyzed the impact of shivering on brain tissue oxygenation (PbtO(2)) during induced normothermia in patients with severe brain injury. Methods We studied patients with severe brain injury who developed shivering during induced normothermia. Induced normothermia was applied to treat refractory fever (body temperature [BT] >= 38.3 degrees C, refractory to conventional treatment) using a surface cooling device with computerized adjustment of patient BT target to 37 +/- 0.5 degrees C. PbtO(2), intracranial pressure, mean arterial pressure, cerebral perfusion pressure, and BT were monitored continuously. Circulating water temperature of the device system was measured to assess the intensity of cooling. Results Fifteen patients (10 with severe traumatic brain injury, 5 with aneurysmal subarachnoid hemorrhage) were treated with induced normothermia for an average of 5 +/- 2 days. Shivering caused a significant decrease in PbtO(2) levels both in SAH and TBI patients. Compared to baseline, shivering was associated with an overall reduction of PbtO(2) from 34.1 +/- 7.3 to 24.4 +/- 5.5 mmHg (P < 0.001). A significant correlation was found between the magnitude of shivering-associated decrease of PbtO(2) (Delta PbtO(2)) and circulating water temperature (R = 0.82, P < 0.001). Conclusion In patients with severe brain injury treated with induced normothermia, shivering was associated with a significant decrease of PbtO(2), which correlated with the intensity of cooling. Monitoring of therapeutic cooling with computerized thermoregulatory systems may help prevent shivering and optimize the management of induced normothermia. The clinical significance of shivering-induced decrease in brain tissue oxygenation remains to be determined.	[Levine, Joshua M.] Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA; [Oddo, Mauro; Frangos, Suzanne; Maloney-Wilensky, Eileen; Kofke, W. Andrew; Le Roux, Peter D.; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Neurosurg, Philadelphia, PA 19104 USA; [Kofke, W. Andrew; Levine, Joshua M.] Univ Penn, Med Ctr, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Levine, JM (corresponding author), Univ Penn, Med Ctr, Dept Neurol, Philadelphia, PA 19104 USA.	mauro.oddo@chuv.ch; Joshua.Levine@uphs.upenn.edu	Oddo, Mauro/R-3370-2016	Oddo, Mauro/0000-0002-6155-2525			Badjatia N, 2007, NEUROCRIT CARE, V6, P186, DOI 10.1007/s12028-007-0011-2; Bhatia A, 2007, INTENS CARE MED, V33, P1322, DOI 10.1007/s00134-007-0660-9; Bilotta F, 2001, ANAESTHESIA, V56, P514, DOI 10.1046/j.1365-2044.2001.02057.x; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CROSSLEY AWA, 1994, ANAESTHESIA, V49, P205; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Doufas AG, 2004, NEUROCRIT CARE, V1, P489, DOI 10.1385/NCC:1:4:489; Eberhart LHJ, 2005, ANESTH ANALG, V101, P1849, DOI 10.1213/O1.ANE.0000184128.41795.FE; Geocadin RG, 2005, NEUROCRIT CARE, V3, P63, DOI 10.1385/NCC:3:1:063; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Hata JS, 2008, NEUROCRIT CARE, V9, P37, DOI 10.1007/s12028-007-9015-1; Haugk M, 2007, RESUSCITATION, V75, P76, DOI 10.1016/j.resuscitation.2007.03.001; Holtzclaw Barbara J, 2004, AACN Clin Issues, V15, P267, DOI 10.1097/00044067-200404000-00012; IMRIE MM, 1990, BRIT J ANAESTH, V64, P346, DOI 10.1093/bja/64.3.346; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Kurz A, 1997, ANESTHESIOLOGY, V86, P1046, DOI 10.1097/00000542-199705000-00007; Marion DW, 2004, CRIT CARE MED, V32, pS43, DOI 10.1097/01.CCM.0000110731.69637.16; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mazzeo AT, 2007, J NEUROL SCI, V261, P1, DOI 10.1016/j.jns.2007.04.026; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Oddo M, 2009, STROKE, V40, P1913, DOI 10.1161/STROKEAHA.108.534115; Oddo M, 2009, STROKE, V40, P1275, DOI 10.1161/STROKEAHA.108.527911; Sagir O, 2007, ACTA ANAESTH SCAND, V51, P44, DOI 10.1111/j.1399-6576.2006.01196.x; Sessler DI, 2001, ANESTHESIOLOGY, V95, P531, DOI 10.1097/00000542-200108000-00040; Thoresen M, 2001, PEDIATR RES, V50, P405, DOI 10.1203/00006450-200109000-00017; Thoresen M, 2001, PEDIATR RES, V49, P594, DOI 10.1203/00006450-200104000-00024; Tsai YC, 2001, ANESTH ANALG, V93, P1288, DOI 10.1097/00000539-200111000-00052; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	35	57	62	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2010	12	1					10	16		10.1007/s12028-009-9280-2			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	571HL	WOS:000275742800003	19821062				2021-06-18	
J	Talving, P; Plurad, D; Barmparas, G; DuBose, J; Inaba, K; Lam, L; Chan, L; Demetriades, D				Talving, Peep; Plurad, David; Barmparas, Galinos; DuBose, Joseph; Inaba, Kenji; Lam, Lydia; Chan, Linda; Demetriades, Demetrios			Isolated Severe Traumatic Brain Injuries: Association of Blood Alcohol Levels With the Severity of Injuries and Outcomes	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Injury; Traumatic brain injury; Alcohol; Intoxication; Complications; Outcomes	753 CONSECUTIVE DEATHS; BETA-BLOCKER EXPOSURE; SEVERE HEAD-INJURY; IMPROVED SURVIVAL; ACUTE ETHANOLISM; HOSPITAL COURSE; UNITED-STATES; INTOXICATION; PREVALENCE; ABUSE	Background: Traumatic brain injury is a common cause of death after traumatic insults. Alcohol intoxication is a recognized contributor to the occurrence of these injuries. The specific effects of alcohol exposure on injury severity and subsequent outcomes,. however, remain controversial. The ann of this study was to investigate the relationship between blood alcohol levels (BAL) and Outcomes in patients with isolated severe traumatic brain injuries (sTBI). Methods: During the calendar year 2003, as part of a pilot project, the Los Angeles County Department of Health Services obtained routine BAL on all patients transported to any of its 13 trauma centers. This Study analyzes the effect of BAL on outcomes in patients with isolated sTBI (head Abbreviated Injury Scale (AIS) score >= 3; extracranial AIS score <3). The Low/No ethanol (ETOH) group included patients with negative or low (<0.08 mg/dL) BAL. Patients with BAL >= 0.08 mg/dL constituted the high ETOH group. Logistic regression was performed to determine whether alcohol levels had an independent association with outcomes. Results: There were 815 patients with isolated severe head injuries. Overall, 468 patients (57%) constituted the Low/No ETCH group, and 347 (43%) the high ETCH group. Alcohol levels were not significantly associated with severity of injury. hypotension at admission. Glasgow Coma Scale score, incidence of major complications, and intensive care unit or hospital length of stay. However, adjusted mortality was significantly lower in the high ETOH group when compared with the Low/No ETCH (8.9%.vs. 17.1%; adjusted odds ratio: 0.60, 95% confidence interval: 0.37-0.96, p = 0.037). In the subgroup of patients with Injury Severity Score > 15 the relative risk for mortality in the high ETOH group was significantly lower than in patients with Low/No ETOH. There was also an increased Survival with high ETOH in patients with Injury Severity Score >25, but this was not statistically significant. Conclusions: Among patients with isolated sTBL BAL do not seem to be associated with overall injury severity, head injury severity, or the occurrence of major morbidities. Similarly, hospital and intensive care unit lengths are not affected by high admission BAL level. The adjusted overall in hospital mortality, however, is significantly lower in patients presenting with the high BAL (>= 0.08 g/dL) after isolated sTBI.	[Talving, Peep; Plurad, David; Barmparas, Galinos; DuBose, Joseph; Inaba, Kenji; Lam, Lydia; Chan, Linda; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA 90033 USA	Demetriades, D (corresponding author), LAC USC, Med Ctr, IPT C4E100,1200 N State St, Los Angeles, CA 90033 USA.	demetria@usc.edu	Talving, Peep/E-6015-2013; Barmparas, Galinos/L-6530-2019; Talving, Peep/G-8621-2015; INABA, KENJI/AAC-8532-2020	Talving, Peep/0000-0002-9741-2073; 			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; ChathamShowalter PE, 1996, PSYCHOSOMATICS, V37, P285, DOI 10.1016/S0033-3182(96)71567-0; Chen SC, 1999, J TRAUMA, V47, P881, DOI 10.1097/00005373-199911000-00011; Christensen M A, 2001, J Neurosci Nurs, V33, P184; Cornwell EE, 1998, AM SURGEON, V64, P461; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Demetriades D, 2004, J AM COLL SURGEONS, V199, P687, DOI 10.1016/j.jamcollsurg.2004.07.017; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Enderson BL, 2007, J TRAUMA, V62, P33; FELL JC, 1989, HEALTH EDUC QUART, V16, P335, DOI 10.1177/109019818901600303; Flaherty S, 2003, J TRAUMA, V54, P70; Golan JD, 2007, J TRAUMA, V63, P365, DOI 10.1097/TA.0b013e31811ec178; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HERVE C, 1986, J TRAUMA, V26, P1123, DOI 10.1097/00005373-198612000-00013; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Janis GC, 1998, ALCOHOL CLIN EXP RES, V22, P2055, DOI 10.1097/00000374-199812000-00023; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Madan AK, 1999, J TRAUMA, V47, P568, DOI 10.1097/00005373-199909000-00026; *NAT HIGHW TRAFF S, 1985, DOTHS806569 US DEP T; NATH FP, 1986, INJURY, V17, P150, DOI 10.1016/0020-1383(86)90320-7; *NIH, 2001, ALC TRANSP SAF; *NIH, 1999, ALC WORKSPL; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Plurad D, 2006, J AM COLL SURGEONS, V202, P919, DOI 10.1016/j.jamcollsurg.2006.02.024; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; Pryor JP, 2007, J TRAUMA, V62, P61; Rootman DB, 2007, J TRAUMA, V62, P755, DOI 10.1097/TA.0b013e318031aa7f; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; Soderstrom C A, 1988, Md Med J, V37, P541; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Tate PS, 1999, BRAIN INJURY, V13, P767; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x	51	57	58	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2010	68	2					357	362		10.1097/TA.0b013e3181bb80bf			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	555FC	WOS:000274492600027	20154549				2021-06-18	
J	Goodrich-Hunsaker, NJ; Livingstone, SA; Skelton, RW; Hopkins, RO				Goodrich-Hunsaker, Naomi J.; Livingstone, Sharon A.; Skelton, Ronald W.; Hopkins, Ramona O.			Spatial Deficits in a Virtual Water Maze in Amnesic Participants with Hippocampal Damage	HIPPOCAMPUS			English	Article						hippocampus; amnesia; spatial navigation	TRAUMATIC BRAIN-INJURY; MEDIAL TEMPORAL-LOBE; HUMAN NAVIGATION; CAUDATE-NUCLEUS; TOPOGRAPHICAL DISORIENTATION; PLACE NAVIGATION; NEURAL-NETWORKS; MEMORY; HUMANS; PERFORMANCE	The Morris water maze is a standard paradigm for the testing of hippocampal function in laboratory animals. Virtual versions of the Morris water maze are now available and can be used to assess spatial learning and memory ability in both healthy and brain injured participants. To evaluate the importance of the hippocampus in spatial learning and memory, we tested five amnesic participants with selective hippocampal damage using a virtual water maze called the Arena Maze. The amnesic participants with hippocampal damage were impaired on the invisible platform (place) task that required them to use distal cues, but were able to navigate almost as well as comparison participants when the invisible platform was marked by a single proximal cue. These results not only confirm that the hippocampus plays a necessary role in human navigation in large-scale environments but also provides a new link between the mnemonic and navigational roles of the hippocampus. (C) 2009 Wiley-Liss, Inc.	[Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Goodrich-Hunsaker, Naomi J.] Brigham Young Univ, Dept Physiol & Dev Biol, Provo, UT 84602 USA; [Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Livingstone, Sharon A.; Skelton, Ronald W.] Univ Victoria, Dept Psychol, Victoria, BC, Canada; [Hopkins, Ramona O.] Latter Day St Hosp, Dept Med, Div Pulm & Crit Care, Salt Lake City, UT 84143 USA; [Hopkins, Ramona O.] Intermt Med Ctr, Div Pulm & Crit Care, Dept Med, Murray, UT USA	Goodrich-Hunsaker, NJ (corresponding author), Brigham Young Univ, Dept Psychol, 1082 SWKT, Provo, UT 84602 USA.		Skelton, Ronald/E-5605-2012				Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Astur RS, 2002, BEHAV BRAIN RES, V132, P77, DOI 10.1016/S0166-4328(01)00399-0; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Bohbot VD, 2004, NEUROPSYCHOLOGY, V18, P418, DOI 10.1037/0894-4105.18.3.418; Cornwell BR, 2008, J NEUROSCI, V28, P5983, DOI 10.1523/JNEUROSCI.5001-07.2008; Dolleman-van der Weel MJ, 2009, BRAIN STRUCT FUNCT, V213, P329, DOI 10.1007/s00429-008-0200-6; Driscoll I, 2005, HORM BEHAV, V47, P326, DOI 10.1016/j.yhbeh.2004.11.013; Etchamendy N, 2007, HIPPOCAMPUS, V17, P595, DOI 10.1002/hipo.20303; Gron G, 2000, NAT NEUROSCI, V3, P404; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hartley T, 2003, NEURON, V37, P877, DOI 10.1016/S0896-6273(03)00095-3; Hopkins RO, 2004, NEUROPSYCHOLOGIA, V42, P1877, DOI 10.1016/j.neuropsychologia.2004.05.008; Iaria G, 2003, J NEUROSCI, V23, P5945; Jacobs WJ, 1998, LEARN MOTIV, V29, P288, DOI 10.1006/lmot.1998.1008; Kesner RP, 2006, BIOL PSYCHOL, V73, P3, DOI 10.1016/j.biopsycho.2006.01.004; King JA, 2004, NEUROPSYCHOLOGY, V18, P405, DOI 10.1037/0894-4105.18.3.405; Kumaran D, 2005, J NEUROSCI, V25, P7254, DOI 10.1523/JNEUROSCI.1103-05.2005; Livingstone SA, 2007, BEHAV BRAIN RES, V185, P21, DOI 10.1016/j.bbr.2007.07.015; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; Maguire EA, 1997, J NEUROSCI, V17, P7103; Mellet E, 2000, NEUROIMAGE, V12, P588, DOI 10.1006/nimg.2000.0648; Meyers J., 1995, REY COMPLEX FIGURE T; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Moscovitch M, 2005, J ANAT, V207, P35, DOI 10.1111/j.1469-7580.2005.00421.x; Nadel L, 2004, NEUROPSYCHOLOGY, V18, P473, DOI 10.1037/0894-4105.18.3.473; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Parron C, 2004, BEHAV BRAIN RES, V154, P345, DOI 10.1016/j.bbr.2004.03.006; Parslow DM, 2004, NEUROPSYCHOLOGY, V18, P450, DOI 10.1037/0894-4105.18.3.450; Rauchs G, 2008, HIPPOCAMPUS, V18, P503, DOI 10.1002/hipo.20411; Rosenbaum RS, 2004, HIPPOCAMPUS, V14, P826, DOI 10.1002/hipo.10218; ROSS ED, 1980, ARCH NEUROL-CHICAGO, V37, P193, DOI 10.1001/archneur.1980.00500530031001; Rowland LM, 2005, NEUROPSYCHOPHARMACOL, V30, P633, DOI 10.1038/sj.npp.1300642; Save E, 2000, BEHAV BRAIN RES, V109, P195, DOI 10.1016/S0166-4328(99)00173-4; Shrager Y, 2007, P NATL ACAD SCI USA, V104, P2961, DOI 10.1073/pnas.0611233104; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Spiers HJ, 2007, NEUROSCIENCE, V149, P7, DOI 10.1016/j.neuroscience.2007.06.056; Spiers HJ, 2001, BRAIN, V124, P2476, DOI 10.1093/brain/124.12.2476; Spiers HJ, 2006, NEUROPSYCHOLOGIA, V44, P1674, DOI 10.1016/j.neuropsychologia.2006.03.028; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Squire LR, 1997, PHILOS T R SOC B, V352, P1663, DOI 10.1098/rstb.1997.0148; TOLMAN EC, 1948, PSYCHOL REV, V55, P1, DOI 10.1037/h0058521; Voermans NC, 2004, NEURON, V43, P427, DOI 10.1016/j.neuron.2004.07.009; Wais PE, 2006, NEURON, V49, P459, DOI 10.1016/j.neuron.2005.12.020; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1997, WMS 3 WECHSLER MEMOR	54	57	58	0	15	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1050-9631			HIPPOCAMPUS	Hippocampus		2010	20	4					481	491		10.1002/hipo.20651			11	Neurosciences	Neurosciences & Neurology	585FZ	WOS:000276811300004	19554566				2021-06-18	
J	Covassin, T; Elbin, R; Stiller-Ostrowski, JL				Covassin, Tracey; Elbin, Robert, III; Stiller-Ostrowski, Jennifer L.			Current Sport-Related Concussion Teaching and Clinical Practices of Sports Medicine Professionals	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injuries; Vienna guidelines; grading scales; position statements	MANAGEMENT; STATEMENT	Context: Various consensus and position statements recommend a multifaceted approach when diagnosing a possible concussion. The effectiveness of these materials depends largely on their content being disseminated to educators and to those in the clinical setting. Objective: To identify the concussion management methods and guidelines currently taught in the athletic training classroom and clinical settings and to track the dissemination of the Vienna guidelines throughout the educational curriculum. Design: A 17-question Internet survey. Setting: A Web link was e-mailed to the program directors and certified athletic trainers holding educational positions in athletic training at 300 accredited programs in the United States. Patients or Other Participants: 513 program directors and athletic trainers. Main Outcome Measure(s): Survey questions addressed education level, years of certification, employment setting, concussion assessment and return-to-play guidelines used in the clinical setting and the classroom, and clinical and teaching preferences for existing position statements and concussion grading systems. The Vienna guidelines' "simple" and "complex" definitions of concussions were provided with the return-to-play stepwise approach. Results: The National Athletic Trainers' Association position statement was the most widely used method of assessing, managing (61%), and making return-to-play decisions (47%) among participants. More than half of participants (66%) had never heard of the Vienna guidelines. After reading the Vienna guidelines' definitions and return-to-play criteria, nearly three-fourths of participants agreed with them. In addition, 68% said that they would use them, and 84% reported that they would teach them to students. Conclusions: The majority of program directors and certified athletic trainers used a multidimensional approach to assess and manage a concussion. The National Athletic Trainers' Association position statement and Vienna guidelines were underused in both the classroom and clinical settings.	[Covassin, Tracey; Elbin, Robert, III; Stiller-Ostrowski, Jennifer L.] Michigan State Univ, E Lansing, MI 48823 USA	Covassin, T (corresponding author), Michigan State Univ, 105 IM Sports Circle, E Lansing, MI 48823 USA.	covassin@msu.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; *BOARD CERT, 2006, ROL DEL STUD; Cantu RC, 2001, J ATHL TRAINING, V36, P244; *COL MED SOC SPORT, 1994, P MILD BRAIN INJ SPO, P106; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; *NAT ATHL TRAIN AS, 2006, ATHL TRAIN ED COMP; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Oliaro S, 2001, J ATHL TRAINING, V36, P257; SCIFERS JR, 2008, SPECIAL TESTS NEUROL, P65; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	16	57	57	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2009	44	4					400	404		10.4085/1062-6050-44.4.400			5	Sport Sciences	Sport Sciences	474EZ	WOS:000268266600009	19593422	Green Published, Bronze			2021-06-18	
J	Jackson, JC; Mitchell, N; Hopkins, RO				Jackson, James C.; Mitchell, Nathaniel; Hopkins, Ramona O.			Cognitive Functioning, Mental Health, and Quality of Life in ICU Survivors: An Overview	CRITICAL CARE CLINICS			English	Article						Cognitive impairments; Critical illness; Critical care outcomes; Psychiatric disorders; Quality of life	INTENSIVE-CARE-UNIT; POSTTRAUMATIC-STRESS-DISORDER; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; TRAUMATIC BRAIN INJURY; CRITICAL ILLNESS; RISK-FACTORS; DELIRIUM; OUTCOMES; MEMORY	Critical illness can and often does lead to significant cognitive impairment and to the development of psychological disorders. These conditions are persistent and, although they improve with time, often fail to completely abate. Although the functional correlates of cognitive and psychological morbidity (depression, anxiety, and posttraumatic stress disorder) have been studied, they may include poor quality of life, inability to return to work or to work at previously established levels, and inability to function effectively in emotional and interpersonal domains. The potential etiologies of cognitive impairment and psychological morbidity in ICU survivors are particularly poorly understood and may vary widely across patients. Potential contributors may include the potentially toxic effects of sedatives and narcotics, delirium, hypoxia, glucose dysregulation, metabolic derangements, and inflammation. Patients with preexisting vulnerabilities, including predisposing genetic factors, and frail elderly populations may be at particular risk for emergence of acceleration of conditions such as mild cognitive impairment.	[Jackson, James C.; Mitchell, Nathaniel] Vanderbilt Univ, Sch Med, Med Ctr, Ctr Hlth Serv Res, Nashville, TN 37232 USA; [Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Hopkins, Ramona O.] Intermt Med Ctr, Dept Med, Div Pulm & Crit Care, Murray, UT USA	Jackson, JC (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr, Ctr Hlth Serv Res, 6th Floor MCE,Suite 6100, Nashville, TN 37232 USA.	james.c.jackson@vanderbilt.edu					ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; Angus DC, 2003, INTENS CARE MED, V29, P368, DOI 10.1007/s00134-002-1624-8; [Anonymous], 1988, LANCET, V2, P349; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Capuzzo M, 2005, Minerva Anestesiol, V71, P167; Capuzzo M, 2004, CRIT CARE, V8, pR48, DOI 10.1186/cc2416; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Combes A, 2003, CRIT CARE MED, V31, P1373, DOI 10.1097/01.CCM.0000065188.87029.C3; Dowdy DW, 2008, CRIT CARE MED, V36, P2726, DOI 10.1097/CCM.0b013e31818781f5; Dowdy DW, 2009, CRIT CARE MED, V37, P1702, DOI 10.1097/CCM.0b013e31819fea55; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Eikelenboom P, 1999, DEMENT GERIATR COGN, V10, P319, DOI 10.1159/000017162; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Ely EW, 2001, SEMIN RESP CRIT CARE, V22, P115, DOI 10.1055/s-2001-13826; Fong TG, 2006, J GERONTOL A-BIOL, V61, P1294, DOI 10.1093/gerona/61.12.1294; FOREMAN M, 2004, PRIMARY PSYCHIAT, V11, P46; Galanakis P, 2001, INT J GERIATR PSYCH, V16, P349, DOI 10.1002/gps.327; Girard TD, 2006, DURATION DELIRIUM PA, pA739; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Heyland DK, 2000, CRIT CARE MED, V28, P3599, DOI 10.1097/00003246-200011000-00006; Hopkins RO, 2006, CURR OPIN CRIT CARE, V12, P388, DOI 10.1097/01.ccx.0000244115.24000.f5; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2005, CURR OPIN CRIT CARE, V11, P369, DOI 10.1097/01.ccx.0000166399.88635.a5; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Hopkins RO, 2005, P AM THORAC SOC, V2, pA36; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Jones C, 2000, MEMORY, V8, P81; Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45; KATON W, 1990, Journal of Clinical Psychiatry, V51, P3; Katz IR, 1996, AM J GERIAT PSYCHIAT, V4, P1, DOI 10.1097/00019442-199624410-00001; Klein E, 2003, CAN J PSYCHIAT, V48, P28; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lyketsos CG, 2005, AM J GERIAT PSYCHIAT, V13, P656, DOI 10.1176/appi.ajgp.13.8.656; MacLullich AMJ, 2009, INT REV PSYCHIATR, V21, P30, DOI 10.1080/09540260802675031; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Meagher DJ, 2001, BMJ-BRIT MED J, V322, P144, DOI 10.1136/bmj.322.7279.144; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; Nelson BJ, 2000, CRIT CARE MED, V28, P3626, DOI 10.1097/00003246-200011000-00013; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC; Pandharipande P, 2005, CURR OPIN CRIT CARE, V11, P360; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Parkin AJ, 1999, CURR BIOL, V9, pR582, DOI 10.1016/S0960-9822(99)80378-9; Pollack MH, 1996, AM J PSYCHIAT, V153, P110; Pomara N, 2005, ARCH GEN PSYCHIAT, V62, P209, DOI 10.1001/archpsyc.62.2.209; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; Schillerstrom JE, 2005, PSYCHOSOMATICS, V46, P411, DOI 10.1176/appi.psy.46.5.411; Schillerstrom JE, 2005, PSYCHOSOMATICS, V46, P508, DOI 10.1176/appi.psy.46.6.508; Sessler CN, 2001, CHEST, V120, P1390, DOI 10.1378/chest.120.4.1390; Silverstone PH, 1996, J NERV MENT DIS, V184, P43, DOI 10.1097/00005053-199601000-00008; Silverstone PH, 1996, CAN J PSYCHIAT, V41, P67, DOI 10.1177/070674379604100202; Skodol A E, 1999, Semin Clin Neuropsychiatry, V4, P64; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Starr JM, 1996, J AM GERIATR SOC, V44, P411, DOI 10.1111/j.1532-5415.1996.tb06412.x; STARR JM, 1994, DRUG SAFETY, V11, P310, DOI 10.2165/00002018-199411050-00003; STRAIN JJ, 1981, PSYCHIAT CLIN N AM, V4, P333, DOI 10.1016/0165-1781(81)90035-4; SUCHYTA MR, 2004, AM J RESP CRIT CARE, V169, pA18; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Teunissen CE, 2003, J NEUROIMMUNOL, V134, P142, DOI 10.1016/S0165-5728(02)00398-3; Toshima MT, 1992, J CARDIOPULM REHABIL, V12, P261; Trzepacz P T, 2000, Semin Clin Neuropsychiatry, V5, P132; Uldall KK, 2000, AIDS PATIENT CARE ST, V14, P95, DOI 10.1089/108729100318037; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047; Yaffe K, 2003, NEUROLOGY, V61, P76, DOI 10.1212/01.WNL.0000073620.42047.D7	85	57	58	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	JUL	2009	25	3					615	+		10.1016/j.ccc.2009.04.005			15	Critical Care Medicine	General & Internal Medicine	479ZB	WOS:000268699900014	19576534				2021-06-18	
J	Martins, ET; Linhares, MN; Sousa, DS; Schroeder, HK; Meinerz, J; Rigo, LA; Bertotti, MM; Gullo, J; Hohl, A; Dal-Pizzol, F; Walz, R				Martins, Evandro Tostes; Linhares, Marcelo Neves; Sousa, Daniel Santos; Schroeder, Humberto Kruger; Meinerz, Jardel; Rigo, Luis Antonio; Bertotti, Melina More; Gullo, Jackson; Hohl, Alexandre; Dal-Pizzol, Felipe; Walz, Roger			Mortality in Severe Traumatic Brain Injury: A Multivariated Analysis of 748 Brazilian Patients From Florianopolis City	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Severe traumatic brain injury; Prognostic models; Mortality; Logistic regression	COMA DATA-BANK; PROGNOSTIC VALUE; HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; IMPACT; CLASSIFICATION; DESIGN	Background: Traumatic brain injury (TBI) is a major cause of incapacity and mortality worldwide, with most of the burden occurring in low-income and middle-income countries. A number of clinical, demographic, and neurosurgical variables of patients with TBI were associated with their outcome. Methods: We investigated the mortality of Brazilian patients with severe TBI at the time of discharge, using a multiple logistic regression analysis. Clinical, demographic, radiologic, and neurosurgical variables, and mortality at time of discharge of all consecutive patients (n = 748) with severe TBI (admission Glasgow scale <= 8) treated in our intensive care unit were analyzed. The variables were collected in a prospective manner between January 1994 and December 2003. Results: Eighty-four percent (n = 631) of the patients were men. The mean age was 34.8 (+/- 16.3) years mid the mortality was 33.3%. After the multiple logistic regression, the adjusted odds ratio (OR) for death was higher in older (>60 years) than younger (up to 30 years) patients (OR = 2.51, 95% confidence interval [CI] 1.31-4.79, p = 0.006). The mortality was also associated with subarachnoid hemorrhage (OR = 1.86, 95% CI = 1.23-2.81, p = 0.003) on computed tomography (CT) scan; admission Glasgow Scale of 3 or 4 in comparison to 7 or 8 (OR = 3.97, 95% CI = 2.49- 6.31, p < 0.001); bilateral midryasis (OR = 11.52, 95% CI = 5.56-23.87, p < 0.0001), or anisocoria (OR = 2.65, 95% CI = 1.69-4.17, p < 0.0001) in comparison to isocoric pupils. There was a trend for higher mortality in patients with type III injury on the Marshall classification of CT (OR = 3.63, 95% CI = 0.84-15.76, p = 0.08) than in patients with normal CT. Patients without thoracic trauma disclose higher mortality than patients with associated thoracic trauma do (OR = 2.02, 95% CI = 1.19-3.41, p = 0.009). The final model presented disclosed 76.9% of overall correct prediction with the survival and death predicted at 87.6% and 55.6%, respectively. Conclusion: Age, CT findings, Glasgow coma scale, pupil examination, and the presence of thoracic trauma at admission were independently associated with mortality at the time of discharge in Brazilian patients with severe TBI.	[Martins, Evandro Tostes; Meinerz, Jardel; Rigo, Luis Antonio] Hosp Governador Celso Ramos, Unidade Terapia Intens, Florianopolis, SC, Brazil; [Martins, Evandro Tostes; Linhares, Marcelo Neves; Schroeder, Humberto Kruger; Bertotti, Melina More; Gullo, Jackson; Hohl, Alexandre; Walz, Roger] Univ Fed Santa Catarina, Dept Clin Med, NUPNEC, Florianopolis, SC, Brazil; [Linhares, Marcelo Neves; Sousa, Daniel Santos] Univ Fed Santa Catarina, Dept Cirurgia, Hosp Governador Celso Ramos, Serv Neurocirurgia, Florianopolis, SC, Brazil; [Dal-Pizzol, Felipe] Univ Extremo Sul Catarinense, Lab Lab Fisiopatol Expt, Criciuma, SC, Brazil	Walz, R (corresponding author), Univ Fed Santa Catarina, Dept Clin Med, Univ Hosp, NUPNEC, 3 Andar,Campus Univ, BR-88040970 Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Dal-Pizzol, Felipe/F-2756-2015; Hohl, Alexandre/R-9269-2019; Walz, Roger/K-9096-2013	Dal-Pizzol, Felipe/0000-0003-3003-8977; Hohl, Alexandre/0000-0002-8073-5837; Walz, Roger/0000-0002-9875-6687	CNPq (Brazilian Council for Scientific and Technologic Development, Brazil)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); FAPESC (Foundation for Scientific Research and Technology of Santa Catarina State); FEESC (Foundation for Education and Engineering of Santa Catarina)	Supported by CNPq (Brazilian Council for Scientific and Technologic Development, Brazil), FAPESC (Foundation for Scientific Research and Technology of Santa Catarina State). The FEESC (Foundation for Education and Engineering of Santa Catarina) supported the technician work of Shumaia Deguer from The Cyclops Project, UFSC.	Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Koizumi MS, 2000, ARQ NEURO-PSIQUIAT, V58, P81, DOI 10.1590/S0004-282X2000000100013; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARION DW, 2004, NEUROLOGY CLIN PRACT, P1127; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Weng GZ, 1999, SCIENCE, V284, P92, DOI 10.1126/science.284.5411.92	22	57	62	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2009	67	1					85	90		10.1097/TA.0b013e318187acee			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	470CZ	WOS:000267953100015	19590314				2021-06-18	
J	Choo, AMT; Liu, J; Liu, ZW; Dvorak, M; Tetzlaff, W; Oxland, TR				Choo, Anthony Min-Te; Liu, Jie; Liu, Zhuowei; Dvorak, Marcel; Tetzlaff, Wolfram; Oxland, Thomas R.			Modeling spinal cord contusion, dislocation, and distraction: Characterization of vertebral clamps, injury severities, and node of Ranvier deformations	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Spinal cord injury; Animal models; Injury mechanisms; Vertebral clamps; Hemorrhage; Nodes of Ranvier	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; AXONAL CONDUCTION; K+ CHANNELS; RAT; MECHANISM; DEVICE; MOUSE; PERMEABILITY; DISPLACEMENT	Spinal cord contusion and transection models are widely used for studying spinal cord injury (SCI). Clinically, however, other biomechanical injury mechanisms such as vertebral dislocation and distraction frequently occur, but these injuries are difficult to produce in animals. We mechanically characterize a vertebral clamping strategy that enables the modeling of vertebral dislocation and distraction injuries in addition to the standard contusion paradigm - in the rat cervical spine. These vertebral clamps have a stiffness of 83.6 +/- 18.9 N/mm and clamping strength 64.7 +/- 10.2 N which allows injuries to be modeled at high-speed (similar to 100 cm/s). Logistic regression indicated that a moderate-to-severe injury, with an acute mortality rate of 10%, occurs at 2.6 mm of C4/5 dorso-ventral dislocation and 4.1 mm of rostro-caudal distraction between C4 and C5. Injuries produced by dislocation and distraction exhibited features of axonal damage that were absent in contusion injuries. We conducted morphometric analysis at the nodes of Ranvier using immunohistochemistry for potassium channels (Kv1.2) in the juxtaparanodal region. Following distraction injuries, elongated nodes of Ranvier were observed up to 4 mm rostral to the lesion. In contrast, contusion injuries produced distortions in nodal geometry which were restricted to the vicinity of the lesion. The greatest deformations in node of Ranvier geometry occurred at the dislocation epicenter. Given the importance of white matter damage in SCI pathology, the distinctiveness of these injury patterns demonstrate that the dislocation and distraction injury models complement existing contusion models. Together, these three animal models span a broader clinical spectrum for more reliably gauging the potential human efficacy of therapeutic strategies. (C) 2009 Elsevier B.V. All rights reserved.	[Choo, Anthony Min-Te; Liu, Zhuowei; Oxland, Thomas R.] Vancouver Coastal Hlth Res Inst, Dept Orthopaed, Div Orthopaed Engn Res, Vancouver, BC V5Z 4E3, Canada; [Choo, Anthony Min-Te; Liu, Zhuowei; Oxland, Thomas R.] Vancouver Coastal Hlth Res Inst, Dept Mech Engn, Div Orthopaed Engn Res, Vancouver, BC V5Z 4E3, Canada; [Choo, Anthony Min-Te; Liu, Zhuowei; Oxland, Thomas R.] Univ British Columbia, Vancouver, BC V5Z 4E3, Canada; [Choo, Anthony Min-Te; Liu, Jie; Dvorak, Marcel; Tetzlaff, Wolfram; Oxland, Thomas R.] Vancouver Coastal Hlth Res Inst, Vancouver, BC V6T 1Z4, Canada; [Choo, Anthony Min-Te; Liu, Jie; Dvorak, Marcel; Tetzlaff, Wolfram; Oxland, Thomas R.] Univ British Columbia, Vancouver, BC V6T 1Z4, Canada	Oxland, TR (corresponding author), Vancouver Coastal Hlth Res Inst, Dept Orthopaed, Div Orthopaed Engn Res, 910 W 10th Ave, Vancouver, BC V5Z 4E3, Canada.	toxland@interchange.ubc.ca	Tetzlaff, Wolfram/AAY-4430-2020		Canada Research Chairs ProgramCanada Research Chairs; Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; British Columbia Neurotrauma Fund; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Rix Family Leading Edge Endowment Fund; George W. Bagby Research Fund	This work was supported by the Canada Research Chairs Program, Canada Foundation for Innovation, British Columbia Neurotrauma Fund, Canadian Institutes for Health Research, Rix Family Leading Edge Endowment Fund and the George W. Bagby Research Fund.	Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Anderson KD, 2004, J NEUROTRAUM, V21, P1371, DOI 10.1089/neu.2004.21.1371; ANDERSON TE, 1985, J NEUROSURG, V62, P115, DOI 10.3171/jns.1985.62.1.0115; ANDERSON TE, 1982, J NEUROSCI METH, V6, P327, DOI 10.1016/0165-0270(82)90033-4; BAUSSART B, 2006, NEUROBIOL DIS; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BREIG A, 1970, J BIOMECH, V3, P7, DOI 10.1016/0021-9290(70)90046-1; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; CHOO AM, 2007, THESIS U BRIT COLUMB; Choo AMT, 2003, J BIOMECH, V36, P259, DOI 10.1016/S0021-9290(02)00361-5; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; D Cardenas D, 2007, SPINAL CORD, V45, P158, DOI 10.1038/sj.sc.3101947; Dabney KW, 2004, SPINE, V29, P2357, DOI 10.1097/01.brs.0000143108.65385.74; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOHRMANN GJ, 1978, J NEUROSURG, V48, P993, DOI 10.3171/jns.1978.48.6.0993; El-Bohy AA, 1998, EXP NEUROL, V150, P143, DOI 10.1006/exnr.1997.6757; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Gensel JC, 2006, J NEUROTRAUM, V23, P36, DOI 10.1089/neu.2006.23.36; Giacobetti FB, 1997, SPINE, V22, P188, DOI 10.1097/00007632-199701150-00011; GRUNER JA, 1922, J NEUROTRAUM, V9, P126; GRUNER JA, 1922, J NEUROTRAUM, V9, P123; Harrop JS, 2001, SPINE, V26, P340, DOI 10.1097/00007632-200102150-00008; Hawryluk GWJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E14; HOWARD CV, 1998, UNBIASED STEREOLOGY; Jakeman LB, 2000, J NEUROTRAUM, V17, P299, DOI 10.1089/neu.2000.17.299; Jensen JM, 2003, J NEUROPHYSIOL, V90, P2334, DOI 10.1152/jn.00868.2002; Joshi M, 2002, J NEUROTRAUM, V19, P175, DOI 10.1089/08977150252806947; KEARNEY P A, 1988, Journal of Neurotrauma, V5, P187, DOI 10.1089/neu.1988.5.187; KIWERSKI J, 1991, PARAPLEGIA, V29, P531, DOI 10.1038/sc.1991.76; Kwon BK, 2002, SPINE, V27, P1504, DOI 10.1097/00007632-200207150-00005; Lyons R.G., 1997, UNDERSTANDING DIGITA; Maiman D J, 1989, J Spinal Disord, V2, P14; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nightingale RW, 1996, J BONE JOINT SURG AM, V78A, P412, DOI 10.2106/00004623-199603000-00013; NIKOLAIDIS N, 2001, 3 D IMAGE PROCESSING; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; Norman G.R., 2000, BIOSTATISTICS BARE E, V2nd; NOYES DH, 1987, EXP NEUROL, V95, P535, DOI 10.1016/0014-4886(87)90298-6; NOYES DH, 1987, MED BIOL ENG COMPUT, V25, P335, DOI 10.1007/BF02447434; Onifer SM, 2005, EXP NEUROL, V192, P25, DOI 10.1016/j.expneurol.2004.10.016; PANJABI MM, 1995, J SPINAL DISORD, V8, P39; Pearse DD, 2005, J NEUROTRAUM, V22, P680, DOI 10.1089/neu.2005.22.680; Rasband MN, 2001, J COMP NEUROL, V429, P166, DOI 10.1002/1096-9861(20000101)429:1<166::AID-CNE13>3.0.CO;2-Y; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SCHRIMSHER GW, 1993, EXP NEUROL, V120, P264, DOI 10.1006/exnr.1993.1060; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; SILBERSTEIN M, 1994, PARAPLEGIA, V32, P817, DOI 10.1038/sc.1994.129; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SOMERSON SK, 1987, EXP NEUROL, V96, P82, DOI 10.1016/0014-4886(87)90170-1; SOMERSON SK, 1986, ANAL ELECTROMECHANIC; Sparrey CJ, 2008, SPINE, V33, pE812, DOI 10.1097/BRS.0b013e3181894fd3; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Young W, 2002, PROG BRAIN RES, V137, P231	59	57	62	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 30	2009	181	1					6	17		10.1016/j.jneumeth.2009.04.007			12	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	463RT	WOS:000267450300002	19383514				2021-06-18	
J	Whiteneck, G; Gassaway, J; Dijkers, M; Jha, A				Whiteneck, Gale; Gassaway, Julie; Dijkers, Marcel; Jha, Amitabh			New Approach to Study the Contents and Outcomes of Spinal Cord Injury Rehabilitation: The SCIRehab Project	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Spinal cord injuries; Rehabilitation, physical; Outcomes research; Epidemiology; Practice-based evidence	LENGTH-OF-STAY; TRAUMATIC BRAIN-INJURY; STROKE REHABILITATION; INPATIENT REHABILITATION; FUNCTIONAL STATUS; BLACK-BOX; NEUROLOGIC RECOVERY; PHYSICAL-THERAPY; MOTOR; SEVERITY	Background/Objective: Limited research evidence is available to show the effectiveness of the many specific interventions provided in spinal cord injury (SCI) rehabilitation; what is available typically focuses on effects of the full rehabilitation package but not specific therapy interventions, medical procedures, patient education, or counseling. Given the problems of conducting randomized controlled trials (RCTs) in rehabilitation, practice-based evidence (PBE) research has been suggested as an alternative methodology for identifying which rehabilitation interventions are associated most strongly with positive outcomes, after controlling for patient differences. Using the PBE research methodology, the SCIRehab project attempts to "open the black box" of acute SCI rehabilitation, provide detailed information on treatments delivered by all rehabilitation disciplines, and contribute to outcomes-based guidelines for clinical decision-making. Methods: The SCIRehab project includes 1,500 patients with acute SCI, consecutively admitted to 1 of 6 US inpatient rehabilitation facilities. Details of the rehabilitation process are captured by clinicians from multiple disciplines documenting their interventions in handheld personal digital assistants after sessions with their patients. Outcome data are abstracted from medical records (clinical outcomes data) and obtained from patient interviews at 6 and 12 months after injury. Extensive patient, injury, and other treatment characteristics are abstracted from medical records. SCIRehab is the first research project to collect detailed information on individual interventions offered by the full rehabilitation team. Results: SCIRehab is the first research project to collect detailed information on individual interventions offered by the full rehabilitation team. These findings are presented in a series of 9 articles. Conclusions: To date, SCIRehab's major contribution is a system for categorizing specific contributions of each discipline and a technology for documenting that detail. After data collection is complete, future manuscripts will relate those process elements to outcomes. The SCIRehab Project is an important step toward establishing outcomes-based guidelines for SCI rehabilitation.	[Gassaway, Julie] Inst Clin Outcomes Res, Salt Lake City, UT 84102 USA; [Whiteneck, Gale; Jha, Amitabh] Craig Hosp, Englewood, CO USA; [Dijkers, Marcel] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA	Gassaway, J (corresponding author), Inst Clin Outcomes Res, 699 E S Temple, Salt Lake City, UT 84102 USA.	jgassaway@isisicor.com	Heinemann, Allen W/K-6283-2012	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596	Department of EducationUS Department of Education; NIDRR [H133A060103, H133N060005, H133N060027]	The contents of this article were developed under grants from the Department of Education and NIDRR Grants H133A060103 and H133N060005 to Craig Hospital and H133N060027 to Mount Sinai School of Medicine. However, these contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the federal government.	Abeyta N, 2009, J SPINAL CORD MED, V32, P336, DOI 10.1080/10790268.2009.11760787; AVERILL RF, 1992, HEALTH SERV RES, V27, P587; Bode RK, 2004, ARCH PHYS MED REHAB, V85, P1901, DOI 10.1016/j.apmr.2004.02.023; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1488, DOI 10.1016/j.apmr.2003.10.010; Breasted JH, 1930, E SMITH SURG PAPYRUS; Burnett DM, 2002, NEUROREHABILITATION, V17, P187; Burnett DM, 2001, ARCH PHYS MED REHAB, V82, P114, DOI 10.1053/apmr.2001.18042; Burns SP, 2005, J SPINAL CORD MED, V28, P33, DOI 10.1080/10790268.2005.11753796; Burns SP, 1997, ARCH PHYS MED REHAB, V78, P1169, DOI 10.1016/S0003-9993(97)90326-9; Cahow C, 2009, J SPINAL CORD MED, V32, P298, DOI 10.1080/10790268.2009.11760783; CAREY RG, 1988, ARCH PHYS MED REHAB, V69, P337; Celani MG, 2001, ARCH PHYS MED REHAB, V82, P589, DOI 10.1053/apmr.2001.21948; Cifu DX, 1999, ARCH PHYS MED REHAB, V80, P733, DOI 10.1016/S0003-9993(99)90219-8; Conroy B, 2005, ARCH PHYS MED REHAB, V86, pS73, DOI 10.1016/j.apmr.2005.08.129; *CONS SPIN CORD ME, CLIN PRACT GUID; Curt A, 1998, ARCH PHYS MED REHAB, V79, P81, DOI 10.1016/S0003-9993(98)90213-1; DeJong G, 2004, ARCH PHYS MED REHAB, V85, P678, DOI 10.1016/j.apmr.2003.06.033; DeJong G, 2007, ANN C AM C REH MED O; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Eastwood EA, 1999, ARCH PHYS MED REHAB, V80, P1457, DOI 10.1016/S0003-9993(99)90258-7; ELTORAI I, 2003, HIST SPINAL CORD MED; Esselman PC, 2006, AM J PHYS MED REHAB, V85, P383, DOI 10.1097/01.phm.0000202095.51037.a3; Garcia RA, 2002, AM J PHYS MED REHAB, V81, P458, DOI 10.1097/00002060-200206000-00011; Gassaway J, 2005, ARCH PHYS MED REHAB, V86, pS16, DOI 10.1016/j.apmr.2005.08.114; Gassaway J, 2009, J SPINAL CORD MED, V32, P260, DOI 10.1080/10790268.2009.11760780; Gordan W, 2009, J SPINAL CORD MED, V32, P307, DOI 10.1080/10790268.2009.11760784; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Greenwald BD, 2001, ARCH PHYS MED REHAB, V82, P1181, DOI 10.1053/apmr.2001.24891; Hatfield B, 2005, ARCH PHYS MED REHAB, V86, pS61, DOI 10.1016/j.apmr.2005.08.111; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HORN S, 1997, ONCOL ISSUES, V12, P16; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS8, DOI 10.1016/j.apmr.2005.08.116; Horn SD, 2005, ARCH PHYS MED REHAB, V86, pS101, DOI 10.1016/j.apmr.2005.09.016; Horn SD, 2002, J PEDIATR-US, V141, P496, DOI 10.1067/mpd.2002.126925; HORN SD, 1991, MED CARE, V29, P305, DOI 10.1097/00005650-199104000-00001; Horn SD, 2007, MED CARE, V45, pS50, DOI 10.1097/MLR.0b013e318070c07b; James R, 2005, ARCH PHYS MED REHAB, V86, pS82, DOI 10.1016/j.apmr.2005.07.314; Johnson K, 2009, J SPINAL CORD MED, V32, P329, DOI 10.1080/10790268.2009.11760786; Johnston MV, 2006, AM J PHYS MED REHAB, V85, P292, DOI 10.1097/01.phm.0000202079.58567.3b; LASFARGUES JE, 1995, PARAPLEGIA, V33, P62, DOI 10.1038/sc.1995.16; Latham NK, 2005, ARCH PHYS MED REHAB, V86, pS41, DOI 10.1016/j.apmr.2005.08.128; LAZAR RB, 1989, ARCH PHYS MED REHAB, V70, P819; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; Mckinley William O, 2002, J Spinal Cord Med, V25, P28; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1253, DOI 10.1016/S0003-9993(99)90025-4; McKinley WO, 2001, AM J PHYS MED REHAB, V80, P693, DOI 10.1097/00002060-200109000-00010; McKinley WO, 2000, AM J PHYS MED REHAB, V79, P138, DOI 10.1097/00002060-200003000-00005; Meade MA, 2004, ARCH PHYS MED REHAB, V85, P368, DOI 10.1016/j.apmr.2003.06.008; Middleton JW, 1998, ARCH PHYS MED REHAB, V79, P1428, DOI 10.1016/S0003-9993(98)90239-8; Muslumanoglu L, 1997, SPINAL CORD, V35, P386, DOI 10.1038/sj.sc.3100406; *NAT SPIN CORD INJ, 2008, SPIN CORD INJ FACTS; *NAT SPIN CORD INJ, 2007 ANN REP SPIN CO; Natale A, 2009, J SPINAL CORD MED, V32, P270, DOI 10.1080/10790268.2009.11760781; New PW, 2005, ARCH PHYS MED REHAB, V86, P250, DOI 10.1016/j.apmr.2004.04.028; Ozelie R, 2009, J SPINAL CORD MED, V32, P283, DOI 10.1080/10790268.2009.11760782; Pagliacci MC, 2003, ARCH PHYS MED REHAB, V84, P1266, DOI 10.1016/S0003-9993(03)00234-X; Pagliacci MC, 2003, SPINAL CORD, V41, P620, DOI 10.1038/sj.sc.3101521; Post MWM, 2005, J REHABIL RES DEV, V42, P75, DOI 10.1682/JRRD.2004.10.0133; Saboe LA, 1997, ARCH PHYS MED REHAB, V78, P644, DOI 10.1016/S0003-9993(97)90431-7; Schonherr MC, 1999, CLIN REHABIL, V13, P457, DOI 10.1191/026921599666105472; Scivoletto G, 2005, ARCH PHYS MED REHAB, V86, P512, DOI 10.1016/j.apmr.2004.05.021; Scivoletto G, 2004, CLIN REHABIL, V18, P709, DOI 10.1191/0269215504cr749oa; Scivoletto G, 2004, ARCH PHYS MED REHAB, V85, P485, DOI 10.1016/S0003-9993(03)00766-4; Seel R T, 2001, J Spinal Cord Med, V24, P241; Sipski ML, 2006, AM J PHYS MED REHAB, V85, P310, DOI 10.1097/01.phm.0000202105.87011.bf; Sipski ML, 2004, ARCH PHYS MED REHAB, V85, P1826, DOI 10.1016/j.apmr.2004.04.031; SPIVAK JM, 1994, SPINE, V19, P2302, DOI 10.1097/00007632-199410150-00009; Sumida M, 2001, ARCH PHYS MED REHAB, V82, P391, DOI 10.1053/apmr.2001.19780; Tooth L, 2003, SPINAL CORD, V41, P220, DOI 10.1038/sj.sc.3101433; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; *US AG HEALTHC QUA, 1996, 990034 AHCPR; van der Putten JMF, 2001, NEUROREHAB NEURAL RE, V15, P99, DOI 10.1177/154596830101500203; van Langeveld SA, 2008, ARCH PHYS MED REHAB, V89, P1454, DOI 10.1016/j.apmr.2007.12.044; van Langeveld Sacha A H B, 2008, J Neurol Phys Ther, V32, P2, DOI 10.1097/NPT.0b013e3181663533; Wade DT, 2001, CLIN REHABIL, V15, P229, DOI 10.1191/026921501677354949; Warschausky S, 2001, ARCH PHYS MED REHAB, V82, P329, DOI 10.1053/apmr.2001.21510; Waters RL, 1998, ARCH PHYS MED REHAB, V79, P1237, DOI 10.1016/S0003-9993(98)90268-4; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Willson D F, 2000, Pediatr Crit Care Med, V1, P127, DOI 10.1097/00130478-200010000-00007; Wilson C, 2009, J SPINAL CORD MED, V32, P319, DOI 10.1080/10790268.2009.11760785	82	57	58	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	JUN	2009	32	3					251	259		10.1080/10790268.2009.11760779			9	Clinical Neurology	Neurosciences & Neurology	474NF	WOS:000268290100006	19810627	Green Published			2021-06-18	
J	Kumar, S; Rao, SL; Chandramouli, BA; Pillai, SV				Kumar, Sanjay; Rao, Shobini L.; Chandramouli, Bangalore A.; Pillai, Shibu V.			Reduction of Functional Brain Connectivity in Mild Traumatic Brain Injury during Working Memory	JOURNAL OF NEUROTRAUMA			English	Article						EEG coherence; MTBI; working memory	CLOSED HEAD-INJURY; SHORT-TERM-MEMORY; UNIVERSITY-STUDENTS; EEG COHERENCE; SYNCHRONIZATION; ABNORMALITIES; DYSFUNCTION; ACTIVATION; CORTEX; SPECT	Working memory deficits are present in patients with mild traumatic brain injury (MTBI). Functional connectivity of different brain regions is required for adequate working memory. Brain injury is associated with disrupted connectivity due to microscopic axonal damage. In this investigation, we sought to investigate functional brain connectivity during working memory in MTBI patients. A sample of 30 MTBI patients and 30 age-, education-, and gender- matched normal controls were studied. Working memory was assessed with the Sternberg's verbal and visuo-spatial working memory tasks. Electro-encephalography ( EEG) was recorded from 128 channels while subjects performed working memory tasks and during eyes closed resting condition. EEG coherence was computed in theta; lower and upper alpha; and lower and upper beta frequency bands during the encoding, retention, and retrieval stages of working memory as well as during eyes-closed rest. We found that the MTBI patients had impaired verbal and visuo-spatial working memory. The different stages of working memory were associated with poor intrahemispheric coherence in long-range (fronto-parietal) and mid-range (fronto-temporal and temporo-parietal) regions as well as poor interhemispheric coherence in the frontal and temporal regions in the MTBI patients. The deficit in coherence was present in theta, alpha, and beta frequency bands. However, the MTBI and the control group had comparable coherence values in intra- and inter-hemispheric regions during eyes closed rest. We suggest that the inter- and intra-hemispheric functional connectivity is impaired in MTBI during working memory performance.	[Kumar, Sanjay] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England; [Kumar, Sanjay; Rao, Shobini L.] Natl Inst Mental Hlth & Neurosci, Dept Clin Psychol, Bangalore 560029, Karnataka, India; [Chandramouli, Bangalore A.; Pillai, Shibu V.] Natl Inst Mental Hlth & Neurosci, Dept Neurosurg, Bangalore 560029, Karnataka, India	Kumar, S (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	s.kumar.1@bham.ac.uk		Kumar, Sanjay/0000-0001-5018-4184	NIMHANS fellowship; Department of Biotechnology, Ministry of Science and Technology ( Government of India)Department of Biotechnology (DBT) IndiaMinistry of Science and Technology, Government of India	This work was supported by an NIMHANS fellowship for Ph. D. work to S. Kumar and a Department of Biotechnology, Ministry of Science and Technology ( Government of India) grant to S. L. Rao.	Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Chuah YML, 2004, BRAIN COGNITION, V56, P304, DOI 10.1016/j.bandc.2004.08.002; Cudmore LJ, 2000, BRAIN COGNITION, V44, P86; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Fiebach CJ, 2006, NEURON, V51, P251, DOI 10.1016/j.neuron.2006.06.007; Fiez JA, 2001, J CLIN EXP NEUROPSYC, V23, P19, DOI 10.1076/jcen.23.1.19.1221; GRAY BG, 1992, J NUCL MED, V33, P52; Hogan MJ, 2003, INT J PSYCHOPHYSIOL, V49, P147, DOI 10.1016/S0167-8760(03)00118-1; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kirchhoff BA, 2000, J NEUROSCI, V20, P6173, DOI 10.1523/JNEUROSCI.20-16-06173.2000; Klimesch W, 1996, INT J PSYCHOPHYSIOL, V24, P61, DOI 10.1016/S0167-8760(96)00057-8; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Knyazeva MG, 2001, BRAIN RES REV, V36, P119, DOI 10.1016/S0165-0173(01)00087-X; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kubler A, 2003, NEUROIMAGE, V20, P1298, DOI 10.1016/S1053-8119(03)00400-2; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; RAY WJ, 1985, SCIENCE, V228, P750, DOI 10.1126/science.3992243; Reitan RM, 2000, ARCH CLIN NEUROPSYCH, V15, P433, DOI 10.1016/S0887-6177(99)00038-4; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; SALTZBERG B, 1986, INT J BIOMED COMPUT, V18, P77, DOI 10.1016/0020-7101(86)90050-4; Sarnthein J, 1998, P NATL ACAD SCI USA, V95, P7092, DOI 10.1073/pnas.95.12.7092; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Shum DHK, 2000, J CLIN EXP NEUROPSYC, V22, P25, DOI 10.1076/1380-3395(200002)22:1;1-8;FT025; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; TEASDALE G, 1974, LANCET, V2, P81; Weiss S, 2000, NEUROREPORT, V11, P2357, DOI 10.1097/00001756-200008030-00005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wolf RC, 2006, NEUROPSYCHOLOGIA, V44, P2558, DOI 10.1016/j.neuropsychologia.2006.05.015; Woodward TS, 2006, NEUROSCIENCE, V139, P317, DOI 10.1016/j.neuroscience.2005.05.043	49	57	57	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					665	675		10.1089/neu.2008.0644			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500003	19331523				2021-06-18	
J	Kern, RS; Green, MF; Fiske, AP; Kee, KS; Lee, J; Sergi, MJ; Horan, WP; Subotnik, KL; Sugar, CA; Nuechterlein, KH				Kern, R. S.; Green, M. F.; Fiske, A. P.; Kee, K. S.; Lee, J.; Sergi, M. J.; Horan, W. P.; Subotnik, K. L.; Sugar, C. A.; Nuechterlein, K. H.			Theory of mind deficits for processing counterfactual information in persons with chronic schizophrenia	PSYCHOLOGICAL MEDICINE			English	Article						Counterfactual information; deception; sarcasm; schizophrenia; theory of mind	TRAUMATIC BRAIN-INJURY; SOCIAL-PERCEPTION; MENTALIZING ABILITY; PEOPLE; COMPREHENSION; REMISSION; COMMUNICATION; PRAGMATICS; INFERENCE; VALIDITY	Background. Interpersonal communication problems are common among persons with schizophrenia and may be linked, in part, to deficits in theory of mind (ToM), the ability to accurately perceive the attitudes, beliefs and intentions of others. Particular difficulties might be expected in the processing of counterfactual information such as sarcasm or lies. Method. The present study included 50 schizophrenia or schizo-affective out-patients and 44 demographically comparable healthy adults who were administered Part III of The Awareness of Social Inference Test (TASIT; a measure assessing comprehension of sarcasm Versus lies) as well as measures of positive and negative symptoms and community functioning. Results. TASIT data were analyzed using a 2 (group: patients versus healthy adults) x 2 (condition: sarcasm versus lie) repeated-measures ANOVA. The results show significant effects for group, condition, and the group x condition interaction. Compared to controls, patients performed significantly worse on sarcasm but not lie scenes. Within-group contrasts showed that patients performed significantly worse on sarcasm versus lie scenes; controls performed comparably on both. In patients, performance on TASIT showed a significant correlation with positive, but not negative, symptoms. The group and interaction effects remained significant when rerun with a subset of patients with low-level positive symptoms. The findings for a relationship between TASIT performance and community functioning were essentially negative. Conclusions. The findings replicate a prior demonstration of difficulty in the comprehension of sarcasm using a different test, but are not consistent with previous studies showing global ToM deficits in schizophrenia.	[Kern, R. S.; Green, M. F.; Kee, K. S.; Lee, J.; Sergi, M. J.; Horan, W. P.; Subotnik, K. L.; Nuechterlein, K. H.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Geffen Sch Med, Los Angeles, CA 90024 USA; [Kern, R. S.; Green, M. F.; Kee, K. S.; Lee, J.; Sergi, M. J.; Horan, W. P.] Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, VISN 22, Los Angeles, CA USA; [Fiske, A. P.] Univ Calif Los Angeles, Dept Anthropol, Ctr Culture Brain & Dev, Los Angeles, CA 90024 USA; [Fiske, A. P.] Univ Calif Los Angeles, Ctr Behav Evolut & Culture, Los Angeles, CA 90024 USA; [Kee, K. S.] Calif State Univ, Channel Isl, CA USA; [Sergi, M. J.] Calif State Univ Northridge, Northridge, CA 91330 USA; [Nuechterlein, K. H.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Psychol, Los Angeles, CA 90024 USA	Kern, RS (corresponding author), VA Greater Los Angeles Healthcare Syst MIRECC 210, Bldg 210,Room 116,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	rkern@ucla.edu	Horan, William/V-7495-2019; Nuechterlein, Keith H/K-8654-2012; Lee, Junghee/C-5226-2014	Lee, Junghee/0000-0001-9567-8700	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50 MH 66586]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH066286] Funding Source: NIH RePORTER	We thank the patients for their participation in the project, and Mike DeGroot, Robin Kite, Jeff Nishii, and Samantha Swain for their help in the data collection. The project was supported by an NIMH Center grant to K.H.N. (P50 MH 66586).	Andreasen N. C., 1984, SCALE ASSESSMENT POS; Andreasen N.C., 1984, SCALE ASSESSMENT NEG; AUTHER AM, 2006, GLOBAL FUNCTIIONING; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Blanchard JJ, 2006, SCHIZOPHRENIA BULL, V32, P238, DOI 10.1093/schbul/sbj013; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Brune M, 2003, SCHIZOPHR RES, V60, P57, DOI 10.1016/s0920-9964(02)00162-7; CHAPMAN LJ, 1978, J PSYCHIAT RES, V14, P303, DOI 10.1016/0022-3956(78)90034-1; Corcoran R, 1997, SCHIZOPHR RES, V24, P319, DOI 10.1016/S0920-9964(96)00117-X; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Corcoran R., 2001, SOCIAL COGNITION SCH, P149, DOI DOI 10.1037/10407-005; Cornblatt BA, 2007, SCHIZOPHRENIA BULL, V33, P688, DOI 10.1093/schbul/sbm029; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sbl029; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; DONAHOE CP, 1990, PSYCHIATRY, V53, P329; Doody GA, 1998, PSYCHOL MED, V28, P397, DOI 10.1017/S003329179700648X; Ekman P., 1976, PICTURES FACIAL AFFE; First M.B., 1996, STRUCTURED CLIN INTE; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Frith CD., 1992, COGN NEUROPSYCHOL; HAPPE FGE, 1993, COGNITION, V48, P101, DOI 10.1016/0010-0277(93)90026-R; Harrington Leigh, 2005, Cogn Neuropsychiatry, V10, P249, DOI 10.1080/13546800444000056; Herold R, 2002, PSYCHOL MED, V32, P1125, DOI 10.1017/S0033291702005433; Inoue Y, 2006, EUR ARCH PSY CLIN N, V256, P326, DOI 10.1007/s00406-006-0608-z; Jahshan CS, 2007, SCHIZOPHR RES, V89, P278, DOI 10.1016/j.schres.2006.09.004; Janssen I, 2003, ACTA PSYCHIAT SCAND, V108, P110, DOI 10.1034/j.1600-0447.2003.00092.x; Langdon R, 2002, PSYCHOL MED, V32, P1273, DOI 10.1017/S0033291702006396; Leitman DI, 2006, PSYCHOL MED, V36, P1075, DOI 10.1017/S0033291706007653; Leslie AM, 2004, TRENDS COGN SCI, V8, P528, DOI 10.1016/j.tics.2004.10.001; LESLIE AM, 1987, PSYCHOL REV, V94, P412, DOI 10.1037/0033-295X.94.4.412; Marjoram Dominic, 2005, Cogn Neuropsychiatry, V10, P347, DOI 10.1080/13546800444000092; Marjoram D, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-12; Mazza M, 2001, SCHIZOPHR RES, V47, P299, DOI 10.1016/S0920-9964(00)00157-2; McCabe R, 2004, PSYCHOL MED, V34, P401, DOI 10.1017/S0033291703001338; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 2000, METAPHOR SYMBOL, V15, P85, DOI DOI 10.1080/10926488.2000.9678866; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; MCPHEETERS HL, 1984, COMMUNITY MENT HLT J, V20, P44; Mitchley N.J., 1998, COGNITIVE NEUROPSYCH, V3, P127, DOI [DOI 10.1080/135468098396206, 10.1080/135468098396206]; Mo SL, 2008, PSYCHIAT RES, V157, P21, DOI 10.1016/j.psychres.2006.04.002; Niendam T. A., 2006, GLOBAL FUNCTIONING S; Orbelo DM, 2005, J GERIATR PSYCH NEUR, V18, P25, DOI 10.1177/0891988704272214; Pilowsky T, 2000, SCHIZOPHR RES, V42, P145, DOI 10.1016/S0920-9964(99)00101-2; Pollice R, 2002, PSYCHOPATHOLOGY, V35, P280, DOI 10.1159/000067062; Premack D., 1978, Behavioral and Brain Sciences, V4, P515, DOI 10.1017/S0140525X00076512; Randall Fiona, 2003, Cogn Neuropsychiatry, V8, P287, DOI 10.1080/135468000057; Reichenberg A, 2002, AM J PSYCHIAT, V159, P2027, DOI 10.1176/appi.ajp.159.12.2027; Sperber D, 2002, MIND LANG, V17, P3, DOI 10.1111/1468-0017.00186; Sprong M, 2007, BRIT J PSYCHIAT, V191, P5, DOI 10.1192/bjp.bp.107.035899; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; Wechsler D., 2001, WECHSLER TEST ADULT; Weiser M, 2007, J NERV MENT DIS, V195, P883, DOI 10.1097/NMD.0b013e31815928b0	56	57	57	1	17	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917			PSYCHOL MED	Psychol. Med.	APR	2009	39	4					645	654		10.1017/S0033291708003966			10	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	426EO	WOS:000264691000011	18694537	Green Accepted			2021-06-18	
J	Warner, KJ; Sharar, SR; Copass, MK; Bulger, EM				Warner, Keir J.; Sharar, Sam R.; Copass, Michael K.; Bulger, Eileen M.			PREHOSPITAL MANAGEMENT OF THE DIFFICULT AIRWAY: A PROSPECTIVE COHORT STUDY	JOURNAL OF EMERGENCY MEDICINE			English	Article						Prehospital; Difficult Airway; Intubation; Surgical Airway; Neuromuscular Blocking Agents	TRAUMATIC BRAIN-INJURY; HOSPITAL ENDOTRACHEAL INTUBATION; EMERGENCY TRACHEAL INTUBATION; NEUROMUSCULAR BLOCKING-AGENTS; EXPERIENCE; IMPACT; GUIDELINES; INTUHATION; SEQUENCE; MODERATE	The role of prehospital endotracheal intubation (ETI) remains controversial, with significant national variability in practice. The purpose of this project was to evaluate ETI management in a system of advanced life support (ALS) providers experienced in ETI and other advanced airway techniques, and describe management and outcomes of patients with a "difficult airway." Data were collected prospectively for all ETIs performed by the fire department over a 4-year period (2001-2005), and included demographics, number of laryngoscopy attempts, airway procedures, complications, and outcomes. Of 80,501 ALS patient contacts, 4091 (5.1%) underwent attempted oral ETI, with a 96.8% success rate in four or fewer attempts. The difficult airway cohort included 130 patients (3.2%), whose airway management consisted of oral ETI after more than four attempts (46%), bag-valve-mask ventilation (33%), cricothyroidotomy (8%), retrograde ETI (5%), and digital ETI (1%). Procedural success rates ranged from 14% (digital ETI) to 91% (cricothyroidotomy). Nine patients (7%) had failed airway management, of whom 5 were found in cardiac arrest. The two most common reasons subjectively reported by ALS providers for airway difficulty were anterior trachea (39%) and small mouth (30%). Overall mortality for the difficult airway cohort was 44%. Prehospital ETI can be performed with a high success rate by experienced ALS providers, but may still require advanced airway techniques in a small subset of patients. Patient anatomy is a primary factor in failed ETI. Among the advanced procedures, cricothyroidotomy had the highest success rate and should not be delayed by other interventions. (C) 2009 Elsevier Inc.	[Warner, Keir J.; Bulger, Eileen M.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; [Sharar, Sam R.] Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; [Copass, Michael K.] Univ Washington, Harborview Med Ctr, Emergency Serv, Seattle, WA 98104 USA	Warner, KJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, Box 359796,325 9th Ave, Seattle, WA 98104 USA.				Medic One Foundation, Seattle, Washington	Supported by a grant from The Medic One Foundation, Seattle, Washington.	Bair AE, 2003, J EMERG MED, V24, P151, DOI 10.1016/S0736-4679(02)00715-1; Bair AE, 2002, J EMERG MED, V23, P131, DOI 10.1016/S0736-4679(02)00501-2; Baker CC, 2005, J TRAUMA, V58, P723; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Bulger EM, 2005, J TRAUMA, V58, P718, DOI 10.1097/01.TA.0000159239.14181.BC; Bulger EM, 2002, J EMERG MED, V23, P183, DOI 10.1016/S0736-4679(02)00490-0; Caplan RA, 2003, ANESTHESIOLOGY, V98, P1269; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Garza AG, 2003, J EMERG MED, V25, P251, DOI 10.1016/S0736-4679(03)00198-7; Gruen RL, 2006, ANN SURG, V244, P371, DOI 10.1097/01.sla.0000234655.83517.56; Jaeger K, 2000, RESUSCITATION, V43, P147, DOI 10.1016/S0300-9572(99)00124-0; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Mizelle H Leland, 2002, Prehosp Emerg Care, V6, P472, DOI 10.1080/10903120290938184; Mort TC, 2004, J CLIN ANESTH, V16, P508, DOI 10.1016/j.jclinane.2004.01.007; Mort TC, 2004, ANESTH ANALG, V99, P607, DOI 10.1213/01.ANE.0000122825.04923.15; Wang HE, 2006, ACAD EMERG MED, V13, P372, DOI 10.1197/j.aem.2005.11.001; Wang HE, 2003, RESUSCITATION, V58, P49, DOI 10.1016/S0300-9572(03)00058-3; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032	21	57	58	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679			J EMERG MED	J. Emerg. Med.	APR	2009	36	3					257	265		10.1016/j.jemermed.2007.10.058			9	Emergency Medicine	Emergency Medicine	430KH	WOS:000264987500008	18439793				2021-06-18	
J	Fitzgerald, M; Bartlett, CA; Evill, L; Rodger, J; Harvey, AR; Dunlop, SA				Fitzgerald, Melinda; Bartlett, Carole A.; Evill, Lauren; Rodger, Jenny; Harvey, Alan R.; Dunlop, Sarah A.			Secondary degeneration of the optic nerve following partial transection: The benefits of lomerizine	EXPERIMENTAL NEUROLOGY			English	Article						Neurotrauma; Secondary injury; Visual System; Retinal ganglion cell; Neuronal death; Glia; Chondroitin sulphate proteoglycans; Oxidative stress	RETINAL GANGLION-CELLS; CALCIUM-CHANNEL BLOCKER; SPINAL-CORD-INJURY; OXIDATIVE STRESS; AXONAL REGENERATION; DEATH; DAMAGE; NEUROPROTECTION; ACTIVATION; MECHANISMS	Secondary degeneration is a form of 'bystander' damage that can affect neural tissue both nearby and remote from an initial injury. Partial optic nerve transection is an excellent model in which to unequivocally differentiate events occurring during secondary degeneration from those resulting from primary CNS injury. We analysed the primary injury site within the optic nerve (ON) and intact areas vulnerable to secondary degeneration. Areas affected by the primary injury showed morphological disruption, loss of beta-III tubulin axonal staining, reduced myelinated axon density, greater proteoglycan expression (phosphacan), increased microglia and macrophage numbers and increased oxidative stress. Similar, but less extreme, changes were seen in areas of the optic nerve undergoing secondary degeneration. The CNS-specific L- and T-type calcium channel blocker lomerizine alleviated some of the changes in areas vulnerable to secondary degeneration. Lomerizine reduced morphological disruption, oxidative stress and phosphacan expression, and limited early increases in macrophage numbers. However, lomerizine failed to prevent progressive de-myelination of ON axons. Within the retina, secondary retinal ganglion cell (RGC) death was significant in areas vulnerable to secondary degeneration. Lomerizine protected RGCs from secondary death at 4 weeks but did not fully restore behavioural function (optokinetic nystagmus). We conclude that blockade of calcium channels is neuroprotective and limits secondary degenerative changes following CNS injury. However such an approach may need to be combined with other treatments to ensure long-term maintenance of full visual function. (C) 2008 Elsevier Inc. All rights reserved.	[Fitzgerald, Melinda; Bartlett, Carole A.; Evill, Lauren; Rodger, Jenny; Dunlop, Sarah A.] Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; [Fitzgerald, Melinda; Bartlett, Carole A.; Evill, Lauren; Rodger, Jenny; Dunlop, Sarah A.] Univ Western Australia, Western Australian Inst Med Res, Crawley, WA 6009, Australia; [Harvey, Alan R.] Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009, Australia	Fitzgerald, M (corresponding author), Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia.	melfitz1@cyllene.uwa.edu.au	Fitzgerald, Melinda/C-4235-2011; Dunlop, Sarah A/G-9357-2013; Rodger, Jennifer/H-5735-2014; Harvey, Alan/A-4911-2008	Fitzgerald, Melinda/0000-0002-4823-8179; Rodger, Jennifer/0000-0003-3413-4229; , Alan/0000-0002-2590-831X; Dunlop, Sarah/0000-0002-1306-3962	Neurotrauma Research Program (Western Australia); NHMRCNational Health and Medical Research Council of Australia [254670]; Woodside Australia; University, State and Commonwealth Governments	This work was supported by the Neurotrauma Research Program (Western Australia) and NH&MRC. Prof. Dunlop is a Professorial Fellow (Research) and Senior Research Fellow of the NH&MRC, Australia (Grant ID: 254670). We thank Woodside Australia for supporting our research by naming us as beneficiaries of the Woodside Sustainability Award 2007. We thank Michael Archer, Marissa Penrose, Vince Clark, Daniel Haustead and Sherralee Lukehurst for assistance with myelination analyses and technical procedures. The phosphocan monoclonal antibody developed by Dr. R.U. Margolis and Dr. R.K Margolis, was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. The authors acknowledge the facilities, scientific and technical assistance of the Australian Microscopy and Microanalysis Research Facility at the Centre for Microscopy, Characterization and Analysis, the University of Western Australia, a facility funded by the University, State and Commonwealth Governments.	Abdejalil J, 2005, VISION RES, V45, P1439, DOI 10.1016/j.visres.2004.12.015; AKAIKE N, 1993, BRAIN RES, V619, P263, DOI 10.1016/0006-8993(93)91620-8; Aucoin JS, 2005, NEUROSCIENCE, V132, P73, DOI 10.1016/j.neuroscience.2004.11.047; Blair M, 2005, INVEST OPHTH VIS SCI, V46, P884, DOI 10.1167/iovs.04-0731; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Buss A, 2005, BRAIN, V128, P356, DOI 10.1093/brain/awh355; Cahill H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002055; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cui Q, 2007, NEUROSCIENCE, V146, P986, DOI 10.1016/j.neuroscience.2007.02.034; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Delgado-Garcia JM, 2000, BRAIN RES BULL, V52, P475, DOI 10.1016/S0361-9230(00)00281-1; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fu QL, 2008, INVEST OPHTH VIS SCI, V49, P975, DOI 10.1167/iovs.07-1199; Gao LM, 2006, DEV BIOL, V290, P277, DOI 10.1016/j.ydbio.2005.11.007; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Hara H, 1999, CLIN EXP PHARMACOL P, V26, P870, DOI 10.1046/j.1440-1681.1999.03154.x; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Hashimoto M, 1997, RES COMMUN MOL PATH, V97, P79; Haustead DJ, 2008, J NEUROSCI, V28, P7376, DOI 10.1523/JNEUROSCI.1135-08.2008; HOGIE M, 2008, ECOTOXICOL ENV SAF; HUNIG T, 1989, COLD SH Q B, V54, P61; Hwan AY, 2006, BIOCHEM BIOPH RES CO, V348, P560, DOI 10.1016/j.bbrc.2006.07.105; Johnson TV, 2007, INVEST OPHTH VIS SCI, V48, P3441, DOI 10.1167/iovs.06-1351; Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200; Karim MD, 2006, CURR EYE RES, V31, P273, DOI 10.1080/02713680500536647; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Kreutz MR, 1999, RESTOR NEUROL NEUROS, V14, P127; Levkovitch-Verbin H, 2000, INVEST OPHTH VIS SCI, V41, P4169; Levkovitch-Verbin H, 2001, INVEST OPHTH VIS SCI, V42, P975; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; Lobsiger CS, 2007, NAT NEUROSCI, V10, P1355, DOI 10.1038/nn1988; Maher P, 2005, INVEST OPHTH VIS SCI, V46, P749, DOI 10.1167/iovs.04-0883; McKeon RJ, 1999, J NEUROSCI, V19, P10778; Mi S, 2005, NAT NEUROSCI, V8, P745, DOI 10.1038/nn1460; Nguyen SM, 2003, ANTIOXID REDOX SIGN, V5, P629, DOI 10.1089/152308603770310293; Nickells RW, 2007, VET OPHTHALMOL, V10, P88, DOI 10.1111/j.1463-5224.2007.00564.x; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Ohlsson M, 2004, J NEURO-OPHTHALMOL, V24, P11, DOI 10.1097/00041327-200403000-00003; Petersen MS, 2006, J IMMUNOL METHODS, V309, P173, DOI 10.1016/j.jim.2005.12.002; Prilloff S, 2007, EUR J NEUROSCI, V25, P3339, DOI 10.1111/j.1460-9568.2007.05550.x; Qi XP, 2007, INVEST OPHTH VIS SCI, V48, P681, DOI 10.1167/iovs.06-0553; Sabel BA, 1999, RESTOR NEUROL NEUROS, V15, P177; Schwartz M, 2004, BRAIN RES BULL, V62, P467, DOI 10.1016/S0361-9230(03)00076-5; Shacka JJ, 2005, CNS NEUROL DISORD-DR, V4, P25, DOI 10.2174/1568007053005127; Stys PK, 2002, NEUROSCI LETT, V328, P150, DOI 10.1016/S0304-3940(02)00469-X; Tezel G, 2006, PROG RETIN EYE RES, V25, P490, DOI 10.1016/j.preteyeres.2006.07.003; Toriu N, 2000, EXP EYE RES, V70, P475, DOI 10.1006/exer.1999.0809; Vergouwen MDI, 2006, LANCET NEUROL, V5, P1029, DOI 10.1016/S1474-4422(06)70582-8; Vitellaro-Zuccarello L, 2007, NEUROSCIENCE, V144, P865, DOI 10.1016/j.neuroscience.2006.10.023; Walls GL, 1942, VERTEBRATE EYE ITS A; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004; Williams A, 2007, BRAIN, V130, P2554, DOI 10.1093/brain/awm202; Winkler T, 2003, ACTA NEUROCHIR SUPPL, V86, P425; Yamada H, 2006, BRAIN RES, V1071, P75, DOI 10.1016/j.brainres.2005.11.072; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yoo YM, 2005, NEUROSCI LETT, V382, P88, DOI 10.1016/j.neulet.2005.02.070	63	57	60	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2009	216	1					219	230		10.1016/j.expneurol.2008.11.026			12	Neurosciences	Neurosciences & Neurology	413UK	WOS:000263817800025	19118550				2021-06-18	
J	Rainey, T; Lesko, M; Sacho, R; Lecky, F; Childs, C				Rainey, Timothy; Lesko, Mehdi; Sacho, Raphael; Lecky, Fiona; Childs, Charmaine			Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: Results using a single (24 h) time-point	RESUSCITATION			English	Article						Head injury; Biomarkers; S100B; Brain damage; Outcome; Glasgow outcome score (GOS)	SEVERE HEAD-INJURY; PROTEIN S-100B; EMERGENCY; CARE; MARKERS; DAMAGE	Background and objectives: In recent years, biochemical markers have been employed to predict the outcome of patients with traumatic brain injury (TBI). In mild TBI, S100B has shown the most promise as a marker Of Outcome. The objective of this study in patients with severe TBI was to: show the range of serum S100B levels during the acute phase after trauma: determine if S100B has potential to discriminate favourable from unfavourable Outcome in patients with similar brain injury severity scores and to establish an S100B 'cut-off' predictive for death. Methods: All patients with severe TBI, admitted to this neurointensive care unit within 24h of injury were eligible for inclusion in the study. One serum blood sample was obtained from each patient at the 24 h post-injury time-point. S100B levels were measured using enzyme-linked immunosorbent assay. Injuries were coded using an internationally recognised injury severity scoring system (ISS). Three-month follow-tip was undertaken with outcome assessed using the Glasgow outcome Score (GOS). Results: One hundred patients were recruited. Serum S100B levels ranged from 0.08 to 12.62 mu g L-1 S100B levels were significantly higher in patients with a GOS of 1 (death) 2 and 3 (unfavourable outcome) compared with those with GOS 4 and 5 (good recovery). In this study a cut-off point of 0.53 mu g L-1 has sensitivity of >80% and specificity of 60% to predict unfavourable Outcome and 49% to predict death. Conclusion: In 100 patients studied with similar brain injury severity scores, serum S100B measured at the 24-h time-point after injury is significantly associated with Outcome but a cut-off 0.53 mu g L-1 does not have good prognostic performance. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Rainey, Timothy; Sacho, Raphael; Childs, Charmaine] Univ Manchester, Salford Royal NHS Fdn Trust, Sch Translat Med, Brain Injury Res Grp, Salford M6 8HD, Lancs, England; [Lesko, Mehdi; Lecky, Fiona] Univ Manchester, Salford Royal NHS Fdn Trust, TARN, Salford M6 8HD, Lancs, England	Childs, C (corresponding author), Univ Manchester, Salford Royal NHS Fdn Trust, Sch Translat Med, Brain Injury Res Grp, Clin Sci Bldg, Salford M6 8HD, Lancs, England.	charmaine.childs@manchester.ac.uk	Childs, Charmaine/G-9928-2012				Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P537; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Childs C, 2005, ANAESTHESIA, V60, P759, DOI 10.1111/j.1365-2044.2005.04193.x; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lameire Norbert, 2004, Curr Opin Crit Care, V10, P468, DOI 10.1097/01.ccx.0000144939.24897.71; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Netto CBO, 2006, ARCH MED RES, V37, P683, DOI 10.1016/j.arcmed.2005.11.005; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Raabe A, 2000, NEUROSURG REV, V23, P136, DOI 10.1007/PL00011944; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; TEASDALE G, 1974, LANCET, V2, P81; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Vissers RJ, 1999, J EMERG MED, V17, P1027, DOI 10.1016/S0736-4679(99)00136-5; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	28	57	63	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572	1873-1570		RESUSCITATION	Resuscitation	MAR	2009	80	3					341	345		10.1016/j.resuscitation.2008.11.021			5	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	420GB	WOS:000264275900011	19150161				2021-06-18	
J	Chiaretti, A; Barone, G; Riccardi, R; Antonelli, A; Pezzotti, P; Genovese, O; Tortorolo, L; Conti, G				Chiaretti, A.; Barone, G.; Riccardi, R.; Antonelli, A.; Pezzotti, P.; Genovese, O.; Tortorolo, L.; Conti, G.			NGF, DCX, and NSE upregulation correlates with severity and outcome of head trauma in children	NEUROLOGY			English	Article							NERVE GROWTH-FACTOR; NEURON-SPECIFIC ENOLASE; BRAIN-INJURY; CEREBROSPINAL-FLUID; DOUBLECORTIN EXPRESSION; NEUROTROPHIC FACTORS; FACTOR INFUSION; INFANTS; TRANSPLANTATION; PROLIFERATION	Background: Secondary brain damage after traumatic brain injury (TBI) involves neuroinflammatory mechanisms, mainly dependent on the intracerebral production of specific biomarkers, such as cytokines, neurotrophic factors, and neuron-specific enolase (NSE). NSE is associated with neuronal damage, while neurotrophic factors play a neuroprotective role due to their ability to modulate neuronal precursor biosynthesis, such as doublecortin (DCX). However, the relationships between the expression of these factors and the severity and outcome of TBI are not understood. Methods: To determine whether the concentrations of neurotrophic factors (nerve growth factor [NGF], brain-derived neurotrophic factor [BDNF], glial-derived neurotrophic factor [GDNF]), DCX, and NSE in the CSF of children with TBI correlate with the severity of brain damage and neurologic outcome, we prospectively collected CSF samples from 32 children at 2 and 48 hours after admission for severe TBI and from 32 matched controls. Severity of TBI was evaluated by Glasgow Coma Scale and neurologic outcome by Glasgow Outcome Score. Results: Early NGF, DCX, and NSE concentrations correlated significantly with the severity of head injury, whereas no correlation was found for BDNF and GDNF. Furthermore, NGF and DCX upregulation and lower NSE expression were associated with better neurologic outcomes. No significant association was found between BDNF and GDNF expression and outcome. Conclusions: Nerve growth factor (NGF), doublecortin (DCX), and neuron-specific enolase concentrations in the CSF are useful markers of brain damage following severe traumatic brain injury (TBI). NGF and DCX upregulation correlates also with better neurologic outcome and could be useful to obtain clinical and prognostic information in children with severe TBI. Neurology (R) 2009; 72:609-616	[Chiaretti, A.; Antonelli, A.; Genovese, O.; Tortorolo, L.; Conti, G.] Univ Cattolica Sacro Cuore, Pediat Intens Care Unit, I-00168 Rome, Italy; [Pezzotti, P.] Agcy Publ Hlth Lazio Region, Rome, Italy	Chiaretti, A (corresponding author), Policlin Gemelli, Largo Gemelli 1, I-00168 Rome, Italy.	achiaretti@yahoo.it		RICCARDI, RICCARDO/0000-0001-7515-6622; GENOVESE, Orazio/0000-0002-1989-1363			Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Barde Y. A., 1994, PROG CLIN BIOL RES, V390, P1855; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Celtik C, 2004, BRAIN DEV-JPN, V26, P398, DOI 10.1016/j.braindev.2003.12.007; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Chiaretti A, 2008, NEUROL RES, V30, P223, DOI 10.1179/016164107X247948; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Collin T, 2005, EXP NEUROL, V195, P71, DOI 10.1016/j.expneurol.2005.03.017; Cui Q, 2006, MOL NEUROBIOL, V33, P155, DOI 10.1385/MN:33:2:155; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Frielingsdorf H, 2007, NEUROBIOL DIS, V26, P47, DOI 10.1016/j.nbd.2006.11.015; Gustafsson E, 2003, EUR J NEUROSCI, V17, P2667, DOI 10.1046/j.1460-9568.2003.02713.x; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Ong J, 2005, PEDIATR RES, V58, P600, DOI 10.1203/01.PDR.0000179381.86809.02; Robertson Charlene M. T., 2001, Pediatr Crit Care Med, V2, P145, DOI 10.1097/00130478-200104000-00009; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Winner B, 2008, J NEUROPATH EXP NEUR, V67, P105, DOI 10.1097/nen.0b013e3181630cff; Wong V, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e36; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	39	57	69	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	FEB 17	2009	72	7					609	616		10.1212/01.wnl.0000342462.51073.06			8	Clinical Neurology	Neurosciences & Neurology	407TB	WOS:000263386100007	19221293				2021-06-18	
J	Catale, C; Marique, P; Closset, A; Meulemans, T				Catale, Corinne; Marique, Patricia; Closset, Annette; Meulemans, Thierry			Attentional and executive functioning following mild traumatic brain injury in children using the Test for Attentional Performance (TAP) battery	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Children; Executive functions; Attentional functions; Test for Attentional Performance	CLOSED-HEAD INJURY; DEFICIT HYPERACTIVITY DISORDER; YOUNG-CHILDREN; ADOLESCENTS; CHILDHOOD	The interpretation of the data regarding cognitive outcome in children who have suffered from mild traumatic brain injury (MTBI) remains currently controversial. The aim of the present study is to explore attentional and executive functioning in 6-12-year-old children who experienced a MTBI. A total of 15 children with MTBI and 15 matched noninjured children participated in the study. Attentional tasks using the Test for Attentional Performance battery were administered one year after the injury. In comparison to the noninjury children, MTBI children performed less accurately on selective attentional and updating tasks. These preliminary findings support the view that MTBI can have an impact on specific attentional functioning in children one year postinjury.	[Catale, Corinne; Closset, Annette; Meulemans, Thierry] Univ Liege, Neuropsychol Unit, B-4000 Liege, Belgium; [Marique, Patricia] Ctr Neurol William Lennox, Ottignies, Belgium; [Closset, Annette] Ctr Hosp Reg Citadelle, Liege, Belgium	Catale, C (corresponding author), Univ Liege, Neuropsychol Unit, Blvd Rectorat B33, B-4000 Liege, Belgium.	corinne.catale@ulg.ac.be					Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Drechsler R, 2005, J CHILD PSYCHOL PSYC, V46, P824, DOI 10.1111/j.1469-7610.2004.00384.x; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; Robin DA, 1999, APHASIOLOGY, V13, P701, DOI 10.1080/026870399401812; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Sattler J. M., 1981, ASSESSMENT CHILDRENS; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; TEASDALE G, 1974, LANCET, V2, P81; Tucha O, 2006, PSYCHOPHARMACOLOGY, V185, P315, DOI 10.1007/s00213-006-0318-2; Wechsler D., 1992, WECHSLER INTELLIGENC, V3rd; Zimmermann P, 1994, TESTS EVALUATION ATT; Zimmermann P, 2004, TESTS EVALUATION ATT; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6	26	57	57	1	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	3					331	338	PII 793898307	10.1080/13803390802134616			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	423QF	WOS:000264510100007	18608644				2021-06-18	
J	Hutchison, M; Mainwaring, LM; Comper, P; Richards, DW; Bisschop, SM				Hutchison, Michael; Mainwaring, Lynda M.; Comper, Paul; Richards, Doug W.; Bisschop, Sean M.			Differential Emotional Responses of Varsity Athletes to Concussion and Musculoskeletal Injuries	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						athletic injury; emotions; mild traumatic brain injury; sport-related concussion	SPORTS; PERFORMANCE; RECOVERY; VALIDITY	Objective: To determine if athletes with concussion and those with minor musculoskeletal injuries experienced differential emotional response to injury. Design: A prospective longitudinal cohort study. Setting: University of Toronto, Ontario, Canada. Participants: Thirty-four injured athletes from Canadian Interuniversity Sport (CIS) and 19 healthy, physically active undergraduate students participated in the Study. Intervention: All participants completed the Profile of Mood States (POMS; short version) oil 3 nonconsecutive days during a 2-week period after a baseline test. Main Outcome Measures: Emotional responses were assessed using the POMS. The 7 main Outcome Measures assessed by POMS were tension, depression, anger, vigor, fatigue, confusion, and total mood disturbance, Results: After injury, concussion produced all emotional profile characterized by significantly elevated fatigue and decreased vigor. In contrast, athletes with musculoskeletal injuries displayed a significant increase in anger that resolved to a pre-injury level within 2 weeks. Conclusions: The results revealed that both injured groups experienced emotional disturbance after injury. More importantly, the findings strongly suggest that the emotional reaction after concussion is different from that of musculoskeletal injury. Therefore, we concluded that assessing emotional reactions to Concussion is particularly important and recommend that sports medicine professionals assess and monitor emotional functioning as well as somatic complaints and neurocognitive changes during recovery.	[Hutchison, Michael; Mainwaring, Lynda M.; Richards, Doug W.] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON M5S 2W6, Canada; [Comper, Paul; Bisschop, Sean M.] Toronto Rehabil Inst, Toronto, ON, Canada	Hutchison, M (corresponding author), Univ Toronto, Fac Phys Educ & Hlth, 55 Harbord St, Toronto, ON M5S 2W6, Canada.	michael.hutchison@utoronto.ca		Bisschop, Sean/0000-0002-3307-292X			Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Brewer BW, 2000, REHABIL PSYCHOL, V45, P20, DOI 10.1037/0090-5550.45.1.20; BREWER BW, 2001, COPING SPORT INJURIE, P1; BREWER BW, 1995, ACAD ATHLETIC J, V10, P11; CHAN CS, 1988, PERCEPT MOTOR SKILL, V66, P875, DOI 10.2466/pms.1988.66.3.875; CHUTE NW, 1997, PSYCHOL RESPONSES AD; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CRONBACH LJ, 1955, PSYCHOL BULL, V52, P281, DOI 10.1037/h0040957; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; GROVE JR, 1992, INT J SPORT PSYCHOL, V23, P93; Gruneau R., 1993, HOCKEY NIGHT CANADA; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston LH, 1998, J SPORT REHABIL, V7, P267, DOI 10.1123/jsr.7.4.267; LEDDY MH, 1994, RES Q EXERCISE SPORT, V65, P347, DOI 10.1080/02701367.1994.10607639; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McDonald SA, 1990, SPORT PSYCHOL, V4, P261; MCNAIR DM, 1992, MANUAL PROFILE MOODS; Messner M. A., 1990, International Review for the Sociology of Sport, V25, P203, DOI 10.1177/101269029002500303; Morrey MA, 1999, CLIN J SPORT MED, V9, P63, DOI 10.1097/00042752-199904000-00004; NUNNELY J, 1978, PSYCHOMETRIC THEORY; Pearson L., 1992, PHYSIOTHERAPY, V78, P762, DOI DOI 10.1016/S0031-9406(10)61642-2; Quackenbush N., 1994, Journal of Sport Behavior, V17, P178; Quinn AM, 1999, J APPL SPORT PSYCHOL, V11, P210, DOI 10.1080/10413209908404201; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; SMITH AM, 1990, MAYO CLIN PROC, V65, P38, DOI 10.1016/S0025-6196(12)62108-9; Uemukai K, 1993, P 8 WORLD C SPORT PS, P500	37	57	57	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2009	19	1					13	19		10.1097/JSM.0b013e318190ba06			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	393PE	WOS:000262384400004	19124978				2021-06-18	
J	Peleg, G; Barak, O; Harel, Y; Rochberg, J; Hoofien, D				Peleg, Gil; Barak, Ohr; Harel, Yermi; Rochberg, Judith; Hoofien, Dan			Hope, dispositional optimism and severity of depression following traumatic brain injury	BRAIN INJURY			English	Article						Adult Hope Scale; Beck Depression Inventory; depression; hope; Life Orientation Test Revised; optimism; traumatic brain injury	MAJOR DEPRESSION; LIFE; HOPELESSNESS; INVENTORY; HEALTH; SATISFACTION; DISORDERS; DYSPHORIA; ANXIETY	Primary objective: To investigate the extent in which two coping variableshope and dispositional optimismare related to depression severity amongst individuals who have sustained traumatic brain injury (TBI). Methods and procedures: Sixty-five participants were administered the Beck Depression Inventory (BDI), the Adult Hope Scale (AHS), the Life Orientation Test-Revised (LOT-R) and a demographic and injury-related data questionnaire. In addition, relevant injury-related data was collected from the medical records. Main outcomes and results: High levels of depression were experienced in the study sample, while hope and dispositional optimism were significantly lower in comparison to the general population. The correlation patterns indicate that both hope and dispositional optimism negatively correlated with participants' depression levels and that they showed significant positive correlations with each other. In the case of mild depression, the hope-Pathways sub-scale of the AHS was the only variable negatively correlated to it, while in moderate-to-severe depression all coping variables were negatively correlated to it. Regression analysis revealed that the AHS and LOT-R, but not the demographic and injury-related variables, predicted depression severity. Conclusions: Clinical implications in referring persons with TBI with mild vs. severe depression to rehabilitation programmes are discussed.	[Peleg, Gil; Barak, Ohr] Tel Aviv Jaffa Acad Coll, Tel Aviv, Israel; [Barak, Ohr; Hoofien, Dan] Natl Inst Rehabil Persons Brain Injuries, Tel Aviv, Israel; [Harel, Yermi; Rochberg, Judith] Loewenstein Hosp Rehabil Ctr, Raanana, Israel; [Harel, Yermi] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Hoofien, Dan] Hebrew Univ Jerusalem, Jerusalem, Israel	Barak, O (corresponding author), Tel Aviv Jaffa Acad Coll, Dept Behav Sci, 14 Rabenu Yerucham St, IL-68182 Tel Aviv Jaffa, Israel.	obar@mta.ac.il			Tel-Aviv Jaffa academic college	This research was facilitated by a grant from the Tel-Aviv Jaffa academic college and support from the research and development funding of the national institute for the rehabilitation of persons with brain injuries in Israel.	Abramson LY, 2000, SCI OPTIMISM HOPE RE; Allison PJ, 2000, QUAL LIFE RES, V9, P951, DOI 10.1023/A:1008931906253; Arnau RC, 2007, J PERS, V75, P43, DOI 10.1111/j.1467-6494.2006.00432.x; Bailey TC, 2007, PSYCHOL REC, V57, P233, DOI 10.1007/BF03395574; Barry LC, 2007, PSYCHOSOM MED, V69, P115, DOI 10.1097/PSY.0b013e31802f2785; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Bryan FB, 2004, J SOC CLIN PSYCHOL, V23, P273, DOI 10.1521/jscp.23.2.273.31018; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chang EC, 2001, PSYCHOL AGING, V16, P524, DOI 10.1037/0882-7974.16.3.524; Chang EC, 2001, J SOC CLIN PSYCHOL, V20, P117, DOI 10.1521/jscp.20.2.117.22262; CHANG EC, 2000, OPTIMISM PESSIMISM I; Cramer KM, 1998, PSYCHOL REP, V83, P1035, DOI 10.2466/PR0.83.7.1035-1041; Curry LA, 1997, J PERS SOC PSYCHOL, V73, P1257, DOI 10.1037/0022-3514.73.6.1257; DEMBER WN, 1989, CURR PSYCHOL RES REV, V8, P102, DOI 10.1007/BF02686675; DOBROV A, 1992, DISS ABSTR; ELLIOTT TR, 1991, J PERS SOC PSYCHOL, V61, P608, DOI 10.1037/0022-3514.61.4.608; Evans S, 2000, J PSYCHOSOM RES, V49, P157, DOI 10.1016/S0022-3999(00)00157-4; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hirsch JK, 2006, SUICIDE LIFE-THREAT, V36, P661, DOI 10.1521/suli.2006.36.6.661; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOROWITZ R, 1999, DISS ABSTR; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Klausner EJ, 1998, INT J GERIATR PSYCH, V13, P707, DOI 10.1002/(SICI)1099-1166(1998100)13:10<707::AID-GPS856>3.3.CO;2-H; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kwon P, 2000, J PERS, V68, P199, DOI 10.1111/1467-6494.00095; Mateer CA, 2005, J HEAD TRAUMA REHAB, V20, P62, DOI 10.1097/00001199-200501000-00007; MELGES FT, 1969, ARCH GEN PSYCHIAT, V20, P690; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; MUIR CA, 1984, BEHAV ASSESSMENT REH; OLIVER JM, 1985, J CLIN PSYCHOL, V41, P469, DOI 10.1002/1097-4679(198507)41:4<469::AID-JCLP2270410405>3.0.CO;2-R; Pence L, 2007, J PAIN SYMPTOM MANAG, V33, P302, DOI 10.1016/j.jpainsymman.2006.08.010; PRIGATANO GP, 1999, NEUROPSYCHOLOGICAL R; RANGE LM, 1994, PSYCHOL REP, V75, P456, DOI 10.2466/pr0.1994.75.1.456; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Schwartz B, 2002, J PERS SOC PSYCHOL, V83, P1178, DOI 10.1037//0022-3514.83.5.1178; Shahar G, 2008, J PERS ASSESS, V90, P61, DOI 10.1080/00223890701693751; Snyder CR, 1998, COGNITION EMOTION, V12, P807, DOI 10.1080/026999398379448; Snyder CR, 2000, COGNITIVE THER RES, V24, P747, DOI 10.1023/A:1005547730153; SNYDER CR, 1991, J PERS SOC PSYCHOL, V60, P570, DOI 10.1037/0022-3514.60.4.570; Snyder CR, 2002, J EDUC PSYCHOL, V94, P820, DOI 10.1037//0022-0663.94.4.820; Snyder CR, 2000, APPL PREV PSYCHOL, V9, P249, DOI 10.1016/S0962-1849(00)80003-7; SNYDER CR, 2000, OPTIMISM PESSIMISM I; Stanton AL, 2002, PSYCHO-ONCOLOGY, V11, P93, DOI 10.1002/pon.574; Thomas SA, 2006, BRIT J CLIN PSYCHOL, V45, P49, DOI 10.1348/014466505X34183	50	57	59	0	16	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	10					800	808	PII 914076473	10.1080/02699050903196696			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	485SP	WOS:000269144600003	19697168				2021-06-18	
J	Trabold, R; Krieg, S; Scholler, K; Plesnila, N				Trabold, Raimund; Krieg, Sandro; Schoeller, Karsten; Plesnila, Nikolaus			Role of Vasopressin V-1a and V-2 Receptors for the Development of Secondary Brain Damage after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						antidiuretic hormone; arginine vasopressin; argipressin; AVP; brain edema; controlled cortical impact; mice; traumatic brain injury	CONTROLLED CORTICAL IMPACT; ARGININE-VASOPRESSIN; RAT-BRAIN; SUBARACHNOID HEMORRHAGE; ANTAGONIST SR-49059; CEREBRAL-ARTERIES; WATER TRANSPORT; STROKE PATIENTS; MESSENGER-RNA; NITRIC-OXIDE	Brain edema is still one of the most deleterious sequels of traumatic brain injury (TBI), and its pathophysiology is not sufficiently understood. The goal of the Current study was to investigate the role of arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), an important regulator of tissue water homeostasis, for the formation of post-traumatic brain edema, intracranial pressure (ICP), brain damage, and functional deficits following brain trauma. C57/B16 mice (n = 112) were subjected to controlled cortical impact (CCI; 8 m/s, 1 mm). At 3 min after trauma, animals received 500 ng of the AVP V-1a-receptor antogonist (deamino-Pen(1), O-Me-Tyr(2), Arg(8)]Vasopressin) or 500ng of the AVP V-2-receptor antagonist (adamantaneacetyl(1), O-Et-D-Tyr(2),Val(4), Abu(6),Arg(8,9)]-Vasopressin) by intracerebroventricular injection. After trauma, cerebral water content (24 h), ICP (24 h), contusion volume (24 h and 7 days), and functional outcome (1-7 days) were assessed (n = 8 per experimental group). Post-traumatic inhibition of AVP V-1a receptors reduced ICP by 29% (p < 0.05), brain water content by 45% (p < 0.05), and secondary contusion expansion by 37% (p < 0.05), and it significantly improved motor function 6 and 7 days after trauma (p < 0.05). Inhibition of AVP V-2 receptors had no significant effect. The current results demonstrate that vasopressin V-1a receptors are involved in the pathogenesis of brain edema formation and the subsequent development of secondary brain damage after traumatic brain injury. Accordingly, our Study suggests that vasopressin V-1a receptors may represent a novel therapeutic target for the treatment of post-traumatic brain edema and secondary brain damage.	Univ Munich, Dept Neurosurg, Lab Expt Neurosurg, Munich, Germany; Univ Munich, Inst Surg Res, Med Ctr Grosshadern, D-8000 Munich, Germany	Plesnila, N (corresponding author), Klinikum Univ Muenchen Grosshadern, Marchioninistr 15, D-81366 Munich, Germany.	plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019; Krieg, Sandro M. M/L-8902-2016; Krieg, Sandro M./W-2389-2019	Krieg, Sandro M. M/0000-0003-4050-1531; Krieg, Sandro M./0000-0003-4050-1531			Barreca T, 2001, CEREBROVASC DIS, V11, P113, DOI 10.1159/000047622; Bemana I, 1999, NEUROSURGERY, V44, P148, DOI 10.1097/00006123-199901000-00091; Cintra ED, 2004, ARQ NEURO-PSIQUIAT, V62, P226, DOI 10.1590/S0004-282X2004000200007; DELBIGIO MR, 1990, ACT NEUR S, V51, P14; FARACI FM, 1988, AM J PHYSIOL, V255, pH70; Fernandez N, 2001, BRIT J PHARMACOL, V132, P1837, DOI 10.1038/sj.bjp.0704034; GarciaVillalon AL, 1996, BRIT J PHARMACOL, V118, P1848, DOI 10.1111/j.1476-5381.1996.tb15613.x; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hernando F, 2001, ENDOCRINOLOGY, V142, P1659, DOI 10.1210/en.142.4.1659; Hertz L, 2000, J NEUROSCI RES, V62, P480, DOI 10.1002/1097-4547(20001115)62:4<480::AID-JNR2>3.0.CO;2-K; Hertz L, 2000, AM J PHYSIOL-ENDOC M, V278, pE1175; Huang Wei-dong, 2003, Chin J Traumatol, V6, P139; JOYNT RJ, 1981, ANN NEUROL, V9, P182, DOI 10.1002/ana.410090212; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KATO Y, 1995, DIFFERENTIATION, V59, P163, DOI 10.1046/j.1432-0436.1995.5930163.x; KATUSIC ZS, 1984, CIRC RES, V55, P575, DOI 10.1161/01.RES.55.5.575; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P303; Knepper MA, 1997, CURR OPIN CELL BIOL, V9, P560, DOI 10.1016/S0955-0674(97)80034-8; Laszlo FA, 1999, EUR J PHARMACOL, V364, P115, DOI 10.1016/S0014-2999(98)00836-X; LATZKOVITS L, 1993, AM J PHYSIOL, V264, pC603; Liu X, 1996, Chin Med Sci J, V11, P93; LIU XF, 1991, CHINESE MED J-PEKING, V104, P480; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MANNING M, 1987, NATURE, V329, P839, DOI 10.1038/329839a0; MARTIN DA, 1990, STROKE, V21, P1689; MATHER HM, 1981, J NEUROL NEUROSUR PS, V44, P216, DOI 10.1136/jnnp.44.3.216; NAKAI M, 1987, J PHYSIOL-LONDON, V387, P441, DOI 10.1113/jphysiol.1987.sp016583; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; ONOUE H, 1994, AM J PHYSIOL, V267, pH880; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Raggenbass M, 1998, PROG BRAIN RES, V119, P263; REEDER RF, 1986, J NEUROSURG, V64, P941, DOI 10.3171/jns.1986.64.6.0941; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; SUZUKI Y, 1992, J NEUROSURG, V77, P424, DOI 10.3171/jns.1992.77.3.0424; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; TENEDIEVA VD, 1994, ACTA NEUROCHIR, P387; Tribollet E, 1999, NEUROENDOCRINOLOGY, V69, P113, DOI 10.1159/000054409; Vajda Z, 2001, NEUROSURGERY, V49, P697, DOI 10.1097/00006123-200109000-00031; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Xu Miao, 2007, Chin J Traumatol, V10, P90; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	46	57	59	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1459	1465		10.1089/neu.2008.0597			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500007	19118456				2021-06-18	
J	Whelan-Goodinson, R; Ponsford, J; Schonberger, M				Whelan-Goodinson, Rochelle; Ponsford, Jennie; Schoenberger, Michael			ASSOCIATION BETWEEN PSYCHIATRIC STATE AND OUTCOME FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; psychiatric disorders; outcome	MAJOR DEPRESSION; NATURAL-HISTORY; ALCOHOL; DISORDERS; AGE; REHABILITATION; PREDICTION; MODERATE	Objective: This study aimed to explore the relationship between current post-traumatic brain injury psychiatric disorders and psychosocial outcome. Design: A total of 100 participants and 87 significant others were interviewed using the Structured Clinical Interview for DSM-IV Diagnosis. Participants: Participants with mild to very severe traumatic brain injury up to 5.5 years post-injury. Methods: The Sydney Psychosocial Reintegration Scale assessed changes in vocational status, relationship status and independent living status. Results: The vocational domain of the Sydney Psychosocial Reintegration Scale revealed the greatest degree of change. Current depression and/or anxiety contributed significantly more variance to the regression models than did any other variables. Pre-injury psychiatric disorders and substance use disorders were not predictive of any outcome variables. Longer post-traumatic amnesia duration, fewer years of education, male gender and greater time post-injury were predictive of certain outcome domains. There were no significant differences between traumatic brain injury participants' self-report and the reports of their significant others regarding psychiatric symptoms or outcome measures. Conclusion: The presence of current depression and anxiety are strongly related to poor outcome in terms of vocational status, relationship status and independence. The causative direction of these relationships is unclear. Using a 3-domain outcome measure has shed some light on the factors that contribute to different aspects of outcome following traumatic brain injury.	[Whelan-Goodinson, Rochelle; Ponsford, Jennie; Schoenberger, Michael] Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, AU-3800 Clayton, Vic, Australia; [Ponsford, Jennie; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, AU-3800 Clayton, Vic, Australia.	jennie.ponsford@med.monash.edu.au					Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; DAWE S, 2002, MONOGRAPH SERIES COM, V48; Deb S, 1999, AM J PSYCHIAT, V156, P374; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FIRST MB, 2004, COMPUTER ASSISTED SC; Fleming J, 1999, BRAIN INJURY, V13, P417; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; GAVIN DR, 1989, BRIT J ADDICT, V84, P301; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TURNER GR, 2004, COGNITIVE BEHAV REHA; WHELANGOODINSON R, J HEAD TRAU IN PRESS	38	57	58	0	4	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV	2008	40	10					850	857		10.2340/16501977-0271			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	400EN	WOS:000262850900011	19242623	DOAJ Gold			2021-06-18	
J	Cohen, JE; Gomori, JM; Segal, R; Spivak, A; Margolin, E; Sviri, G; Raiz, G; Fraifeld, S; Spektor, S				Cohen, Jose E.; Gomori, John M.; Segal, Ricardo; Spivak, Alex; Margolin, Emil; Sviri, Gil; Raiz, Gustavo; Fraifeld, Shifra; Spektor, Sergey			Results of endovascular treatment of traumatic intracranial aneurysms	NEUROSURGERY			English	Article						cerebral aneurysm; embolization; intracranial hemorrhage; subarachnoid hemorrhage; traumatic brain injury	CEREBRAL-ARTERY ANEURYSM; GUNSHOT WOUNDS; HEAD; ANGIOGRAPHY; MANAGEMENT; CHILDHOOD; DIAGNOSIS; PITFALLS; VESSELS; INJURY	OBJECTIVE: To present results of early angiographic diagnosis and endovascular treatment of traumatic intracranial aneurysms (TICA). METHODS: From June 2002 to December 2006, diagnostic angiography was performed on patients with moderate to severe traumatic brain injury that involved a cranial base fracture or a penetrating brain injury with a tract from the penetrating agent that entered at the pterional area, went through the middle cerebral artery candelabra, and crossed the midline. TICAs were treated by various endovascular techniques during the same angiographic procedure. RESULTS: Thirty-four patients with traumatic brain injury underwent angiography (25 penetrating brain injuries, nine blunt injuries); 13 TICAs were diagnosed (10 penetrating brain injuries, three blunt injuries). The Glasgow Coma Scale score at diagnosis ranged from 5 to 15. Angiography was performed for screening in eight patients and for clinical indications in five patients; 11 TICAs were diagnosed before rupture. Seven aneurysms were located on branches of the middle cerebral artery, two on pericallosal branches of the anterior cerebral artery, and four on the internal carotid artery. No recanalization was detected in 12 patients. One patient treated with a bare stent and coiling had a growing intracavernous pseudoaneurysm; therefore, internal carotid artery occlusion with extracranial-intracranial microvascular bypass was performed. Six patients refused angiographic follow-up, but computed tomographic angiography has failed to show recanalization. No patient presented with delayed bleeding (mean follow-up, 2.6 yr). There were no procedure-related complications or mortality. CONCLUSION: Early angiographic diagnosis with immediate endovascular treatment provided an effective approach for TICA detection and management. Endovascular therapy is versatile and offers a valuable alternative to surgery, allowing early aneurysm exclusion with excellent results.	[Cohen, Jose E.] Hadassah Hebrew Univ Hosp, Dept Neurosurg, Sect Endovasc Neurosurg & Intervent Neuroradiol, Jerusalem, Israel; [Cohen, Jose E.; Gomori, John M.] Hadassah Hebrew Univ Hosp, Dept Radiol, Sect Endovasc Neurosurg & Intervent Neuroradiol, Jerusalem, Israel; [Sviri, Gil] Rambam Med Ctr, Dept Neurosurg, Haifa, Israel; [Raiz, Gustavo] Chaim Sheba Med Ctr, Dept Neurosurg, IL-52621 Tel Hashomer, Israel	Cohen, JE (corresponding author), Kiryat Hadassih,POB 12000, IL-91120 Jerusalem, Israel.	jcohenns@yahoo.com					AARABI B, 1995, NEUROSURG CLIN N AM, V6, P775; AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; [Anonymous], 2001, J TRAUMA, V51, pS26; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CASEY ATH, 1994, BRIT J NEUROSURG, V8, P97, DOI 10.3109/02688699409002401; Cohen JE, 2005, J NEUROSURG, V102, P555, DOI 10.3171/jns.2005.102.3.0555; CROWELL RM, 1995, SURG MANAGEMENT NEUR, P377; Davis PC, 2007, AM J NEURORADIOL, V28, P1619; Eckard DA, 2000, AM J NEURORADIOL, V21, P137; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; Guillaume DJ, 2005, OPERATIVE NEUROSURGE, P1224; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HOLMES B, 1993, J TRAUMA, V35, P855, DOI 10.1097/00005373-199312000-00009; Horowitz MB, 1999, SURG NEUROL, V51, P31, DOI 10.1016/S0090-3019(98)00029-9; JINKINS JR, 1992, AM J ROENTGENOL, V159, P365, DOI 10.2214/ajr.159.2.1632358; Karamessini MT, 2004, EUR J RADIOL, V49, P212, DOI 10.1016/S0720-048X(03)00173-6; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; Kocer N, 2002, AM J NEURORADIOL, V23, P442; Larson P S, 2000, Neurosurg Focus, V8, pe4; Lath R, 2002, J CLIN NEUROSCI, V9, P466, DOI 10.1054/jocn.2001.1050; LEVY ML, 1993, NEUROSURGERY, V32, P532, DOI 10.1227/00006123-199304000-00007; Lylyk P, 2002, J NEUROSURG, V97, P1306, DOI 10.3171/jns.2002.97.6.1306; Martin NA, 1998, NEUROSURG CLIN N AM, V9, P897, DOI 10.1016/S1042-3680(18)30237-7; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; Quintana F, 1996, AM J NEURORADIOL, V17, P283; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; Raju BSV, 2001, NEUROL INDIA, V49, P295; Resnick DK, 1997, NEUROSURGERY, V40, P1177, DOI 10.1097/00006123-199706000-00012; Romijn M, 2008, AM J NEURORADIOL, V29, P134, DOI 10.3174/ajnr.A0741; ROSENTHAL G, 2005, OPERATIVE NEUROSURGE, P89; SORIA ED, 1988, ANGIOLOGY, V39, P609, DOI 10.1177/000331978803900708; Tokunaga K, 2001, AM J NEURORADIOL, V22, P35; Uzan M, 1998, NEUROSURGERY, V43, P1314, DOI 10.1097/00006123-199812000-00024; VENTUREYRA ECG, 1994, CHILD NERV SYST, V10, P361, DOI 10.1007/BF00335125; Young N, 1999, NEURORADIOLOGY, V41, P93, DOI 10.1007/s002340050712	40	57	66	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2008	63	3					476	485		10.1227/01.NEU.0000324995.57376.79			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	354FZ	WOS:000259625600020	18812959				2021-06-18	
J	Cooper, DJ; Rosenfeld, JV; Murray, L; Wolfe, R; Ponsford, J; Davies, A; D'Urso, P; Pellegrino, V; Malham, G; Kossmann, T				Cooper, D. James; Rosenfeld, Jeffrey V.; Murray, Lynnette; Wolfe, Rory; Ponsford, Jennie; Davies, Andrew; D'Urso, Paul; Pellegrino, Vincent; Malham, Gregory; Kossmann, Thomas			Early decompressive craniectomy for patients with severe traumatic brain injury and refractory intracranial hypertension - A pilot randomized trial	JOURNAL OF CRITICAL CARE			English	Article						decompressive craniectomy; diffuse traumatic brain injury; intracranial hypertension	SEVERE HEAD-INJURY; GLASGOW OUTCOME SCALE; STRUCTURED INTERVIEWS; CEREBRAL EDEMA; MANAGEMENT; PROPHYLAXIS; CRANIOTOMY; GUIDELINES; CHILDREN	Purpose: The aims of this study were to test the feasibility and to assess potential recruitment rates in a pilot study preliminary to a phase III randomized trial of decompressive craniectomy surgery in patients with diffuse traumatic brain injury (TBI) and refractory intracranial hypertension. Materials and Methods:. A Study protocol was developed, inclusion and exclusion criteria were defined, and a standardized surgical technique was established. Neurologic outcomes were assessed 6 months after injury with a validated, structured questionnaire and a single trained assessor blind to treatment group. Results: During the 8-month pilot study at a level 1 trauma center in Melbourne, Australia, 69 intensive care patients with severe TBI were assessed for inclusion. Six patients were eligible, and 5 (8%) were randomized. Six months after injury, 100% of patients received outcome assessments. Key improvements to the multicenter Decompressive Craniectomy study protocol were enabled by the pilot study. Conclusions: In patients with severe TBI and refractory intracranial hypertension, the frequency of favorable neurologic outcomes (independent living) was low and similar to predicted values (40% favorable). A future multicenter phase III trial involving IS neurotrauma centers with most sites conservatively recruiting at just 25% of the pilot study rate would require at least 5 years to achieve an estimated 210-patient sample size. Collaboration With neurotrauma centers in countries other than Australia and New Zealand would be required for such a phase III trial to be successful. (c) 2008 Elsevier Inc. All rights reserved.	[Cooper, D. James; Murray, Lynnette; Davies, Andrew; Pellegrino, Vincent] Monash Univ, Alfred Hosp, Dept Intens Care, Melbourne, Vic 3004, Australia; [Rosenfeld, Jeffrey V.; Malham, Gregory] Monash Univ, Alfred Hosp, Dept Neurosurg, Melbourne, Vic 3004, Australia; [Kossmann, Thomas] Monash Univ, Alfred Hosp, Dept Trauma Surg, Melbourne, Vic 3004, Australia; [Cooper, D. James; Rosenfeld, Jeffrey V.; Malham, Gregory] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Cooper, D. James; Wolfe, Rory] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Monash Univ, Dept Psychol, Melbourne, Vic 3004, Australia; [Cooper, D. James; Rosenfeld, Jeffrey V.; Murray, Lynnette; D'Urso, Paul; Malham, Gregory; Kossmann, Thomas] Natl Trauma Res Inst, Melbourne, Vic 3004, Australia	Cooper, DJ (corresponding author), Natl Trauma Res Inst, Melbourne, Vic 3004, Australia.	j.cooper@alfred.org.au	Rosenfeld, Jeffrey V/B-7249-2011; Cooper, D. James/G-7961-2013	Cooper, D. James/0000-0002-5872-9051; Wolfe, Rory/0000-0002-2126-1045	Victorian Trauma Foundation (Melbourne, Victoria, Australia); Australian and New Zealand Intensive Care Research Foundation	The DECRA Pilot Study was funded by the Victorian Trauma Foundation (Melbourne, Victoria, Australia) and the Australian and New Zealand Intensive Care Research Foundation. We are grateful to our colleagues in Intensive Care and Neurosurgery at the Alfred Hospital for facilitating this Study, to the Australian and New Zealand Intensive Care Society Clinical Trials Group for input into trial design and for planning, coordination, and endorsement of the phase III trial, and to Cristina Morganti-Kossmann for reviewing the manuscript. Dr Cooper is a National Health and Medical Research Council practitioner fellow.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cook D, 2001, INTENS CARE MED, V27, P347, DOI 10.1007/s001340000828; Cook DJ, 2005, J CRIT CARE, V20, P364, DOI 10.1016/j.jcrc.2005.09.010; COOPER D, 2002, CURRENT OUTCOMES P 1, P1; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; GAAB MR, 1990, ACT NEUR S, V51, P326; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kunze E, 1998, ACT NEUR S, V71, P16; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MENON D, 2000, NEUROANESTHESIA NEUR, P301; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Messing-Junger AM, 2003, ZBL NEUROCHIR, V64, P171; Munch E, 2000, NEUROSURGERY, V47, P315; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; MYBURGH J, 2007, J TRAUMA; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	35	57	60	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	SEP	2008	23	3					387	393		10.1016/j.jcrc.2007.05.002			7	Critical Care Medicine	General & Internal Medicine	347EW	WOS:000259124400017	18725045				2021-06-18	
J	Schumann, J; Alexandrovich, GA; Biegon, A; Yaka, R				Schumann, Johanna; Alexandrovich, G. Alexander; Biegon, Anat; Yaka, Rami			Inhibition of NR2B phosphorylation restores alterations in NMDA receptor expression and improves functional recovery following traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						closed head injury; MAPK; NMDA receptor; NR2B; tyrosine phosphorylation	D-ASPARTATE RECEPTOR; LONG-TERM POTENTIATION; CLOSED-HEAD INJURY; EXCITATORY AMINO-ACIDS; INCREASES TYROSINE PHOSPHORYLATION; TRANSIENT GLOBAL-ISCHEMIA; FOCAL CEREBRAL-ISCHEMIA; POSTSYNAPTIC DENSITIES; SYNAPTIC PLASTICITY; RAT-BRAIN	Traumatic brain injury (TBI) triggers a massive glutamate efflux, hyperactivation of N-methyl-D-aspartate receptors (NMDARs) and neuronal cell death. Previously it was demonstrated that, 15 min following experimentally induced closed head injury (CHI), the density of activated NMDARs increases in the hippocampus, and decreases in the cortex at the impact site. Here we show that CHI-induced alterations in activated NMDARs correlate with changes in the expression levels of the major NMDARs subunits. In the hippocampus, the expression of NR1, NR2A, and NR2B subunits as well as the GluR1 subunit of the AMPA receptor (AMPAR) were increased, while in the cortex at the impact site, we found a decrease in the expression of these subunits. We demonstrate that CHI-induced increase in the expression of NMDAR subunits and GluR1 in the hippocampus, but not in the cortex, is associated with an increase in NR2B tyrosine phosphorylation. Furthermore, inhibition of NR2B-phosphorylation by the tyrosine kinase inhibitor PP2 restores the expression of this subunit to its normal levels. Finally, a single injection of PP2, prior to the induction of CHI, resulted in a significant improvement in long-term recovery of motor functions observed in CHI mice. These results provide a new mechanism by which acute trauma contributes to the development of secondary damage and functional deficits in the brain, and suggests a possible role for Src tyrosine kinase inhibitors as preoperative therapy for planned neurosurgical procedures.	[Schumann, Johanna; Alexandrovich, G. Alexander; Yaka, Rami] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; [Biegon, Anat] Brookhaven Natl Lab, Upton, NY 11973 USA	Yaka, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	yaka@md.huji.ac.il			Israel Science FoundationIsrael Science Foundation [292/05]; Ministry of Health [6029-6]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 050285-01 A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050285] Funding Source: NIH RePORTER	We thank Prof. Esther Shohami for helpful discussions and critical reading of the manuscript. This research was supported by the Israel Science Foundation (grant no. 292/05 R.Y.), Ministry of Health (grant no. 6029-6 R.Y.), and the National Institutes of Health (grant no. R01 NS 050285-01 A2, to A.B.).	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 1996, ACT NEUR S, V67, P6; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Besshoh S, 2005, J NEUROCHEM, V93, P186, DOI 10.1111/j.1471-4159.2004.03009.x; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; Chen SJ, 1996, J NEUROCHEM, V67, P194; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cheung HH, 2000, J CEREBR BLOOD F MET, V20, P505, DOI 10.1097/00004647-200003000-00009; Cheung HH, 2003, J NEUROCHEM, V86, P1441, DOI 10.1046/j.1471-4159.2003.01951.x; Crossthwaite AJ, 2004, J NEUROCHEM, V88, P1127, DOI 10.1046/j.1471-4159.2004.02257.x; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; Dickerson J, 2006, NEUROPSYCHOPHARMACOL, V31, P1420, DOI 10.1038/sj.npp.1300878; Dunah AW, 2001, J NEUROSCI, V21, P5546; Dunah AW, 2004, MOL PHARMACOL, V65, P121, DOI 10.1124/mol.65.1.121; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Gascon S, 2008, MOL PSYCHIATR, V13, P99, DOI 10.1038/sj.mp.4002017; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Goebel SM, 2005, MOL BRAIN RES, V142, P65, DOI 10.1016/j.molbrainres.2005.09.012; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Hallett PJ, 2006, J NEUROSCI, V26, P4690, DOI 10.1523/JNEUROSCI.0792-06.2006; Hashimoto R, 2003, FEBS LETT, V538, P145, DOI 10.1016/S0014-5793(03)00167-4; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jadhav V, 2007, J NEUROSURG, V106, P680, DOI 10.3171/jns.2007.106.4.680; Jadhav V, 2007, SURG NEUROL, V67, P15, DOI 10.1016/j.surneu.2006.07.014; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lan JY, 2001, J NEUROSCI, V21, P6058; Lavezzari G, 2004, J NEUROSCI, V24, P6383, DOI 10.1523/JNEUROSCI.1890-04.2004; Lavezzari G, 2003, NEUROPHARMACOLOGY, V45, P729, DOI 10.1016/S0028-3908(03)00308-3; Lu YM, 1998, SCIENCE, V279, P1363, DOI 10.1126/science.279.5355.1363; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Nakazawa T, 2001, J BIOL CHEM, V276, P693, DOI 10.1074/jbc.M008085200; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Osteen CL, 2004, NEUROSCIENCE, V128, P305, DOI 10.1016/j.neuroscience.2004.06.034; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Salter MW, 2004, NAT REV NEUROSCI, V5, P317, DOI 10.1038/nrn1368; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Schilstrom B, 2006, J NEUROSCI, V26, P8549, DOI 10.1523/JNEUROSCI.5179-05.2006; Sheng M, 2001, CELL, V105, P825, DOI 10.1016/S0092-8674(01)00406-8; Shohami E, 2003, J CEREBR BLOOD F MET, V23, P728, DOI 10.1097/01.WCB.0000067704.86573.83; Simpkins KL, 2003, J NEUROSCI, V23, P11322; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Sucher NJ, 1996, TRENDS PHARMACOL SCI, V17, P348, DOI 10.1016/S0165-6147(96)10046-8; Sun LX, 1998, FEBS LETT, V441, P392, DOI 10.1016/S0014-5793(98)01590-7; Takagi N, 1999, J CEREBR BLOOD F MET, V19, P880, DOI 10.1097/00004647-199908000-00007; Takagi N, 1997, J NEUROCHEM, V69, P1060; Vissel B, 2001, NAT NEUROSCI, V4, P587, DOI 10.1038/88404; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Wang YT, 1996, P NATL ACAD SCI USA, V93, P1721, DOI 10.1073/pnas.93.4.1721; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yaka R, 2003, ALCOHOL CLIN EXP RES, V27, P1736, DOI 10.1097/01.ALC.0000095924.87729.D8; Yaka R, 2003, J NEUROSCI, V23, P3623; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhu JJ, 2002, CELL, V110, P443, DOI 10.1016/S0092-8674(02)00897-8	76	57	58	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2008	25	8					945	957		10.1089/neu.2008.0521			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	343ZT	WOS:000258895700001	18721106	Green Published			2021-06-18	
J	Bornhofen, C; McDonald, S				Bornhofen, Cristina; McDonald, Skye			Comparing strategies for treating emotion perception deficits in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; emotions; social perception; teaching methods; traumatic brain injury	ANXIETY STRESS SCALES; PSYCHOMETRIC PROPERTIES; FACIAL EXPRESSION; HEAD TRAUMA; SOCIAL-BEHAVIOR; RECOGNITION; REHABILITATION; COMMUNITY; COMMUNICATION; ADJUSTMENT	Objective: To compare the efficacy of 2 strategies, errorless learning (EL) and self-instruction training (SIT), for remediating emotion perception deficits in individuals with traumatic brain injury (TBI). Design: Randomized controlled trial comparing groups receiving 25 hours (across 10 weeks) of treatment with either EL or SIT with waitlist control. Setting and Participants: Eighteen adult outpatient volunteers with severe TBI who were at least 6 months postinjury. Main Outcomes Measures: Photograph-based emotion recognition tasks, The Awareness of Social Inferences Test, and questionnaire measures, for example, the Sydney Psychosocial Reintegration Scale. Results: Both treatment groups showed modest improvement in emotion perception ability. Limited evidence suggests that SIT may be a favorable approach for this type of remediation. Conclusions: Although further research is needed, there are reasons for optimism regarding rehabilitation of emotion perception following TBI.	[Bornhofen, Cristina; McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bornhofen, C (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	cristinab@iinet.net.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			Adolphs Ralph, 2002, Behav Cogn Neurosci Rev, V1, P21, DOI 10.1177/1534582302001001003; Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; BIRD K, 2001, PROGRAM CONTRAST ANA; Bornhofen C, 2008, NEUROPSYCHOL REHABIL, V18, P22, DOI 10.1080/09602010601061213; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; BRAUNLINGMCMORROW D, 1986, J REHABIL, V52, P39; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; Browder DM, 2000, EDUC TRAIN MENT RET, V35, P78; Brown TA, 1997, BEHAV RES THER, V35, P79, DOI 10.1016/S0005-7967(96)00068-X; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; Cardinal RN, 2002, NEUROSCI BIOBEHAV R, V26, P321, DOI 10.1016/S0149-7634(02)00007-6; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Critchley H, 2000, HUM BRAIN MAPP, V9, P93, DOI 10.1002/(SICI)1097-0193(200002)9:2<93::AID-HBM4>3.0.CO;2-Z; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Duchaine BC, 2003, PERCEPTION, V32, P827, DOI 10.1068/p5067; Ekman P., 1975, UNMASKING FACE GUIDE; Ekman P., 1976, PICTURES FACIAL AFFE; Elfenbein HA, 2002, PSYCHOL BULL, V128, P203, DOI 10.1037//0033-2909.128.2.203; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; Giles G M, 1988, Brain Inj, V2, P75, DOI 10.3109/02699058809150933; GRATTAN LM, 2002, REHABILITATION NEURR; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Hughes C, 1996, AM J MENT RETARD, V100, P565; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Keane J, 2002, NEUROPSYCHOLOGIA, V40, P655, DOI 10.1016/S0028-3932(01)00156-7; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; Kern RS, 2003, PSYCHOL MED, V33, P433, DOI 10.1017/S0033291702007298; Kubu CS, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P451; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; Ley P., 1972, QUANTITATIVE ASPECTS; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; LOWE MR, 1978, BEHAV THER, V9, P535, DOI 10.1016/S0005-7894(78)80126-9; McClelland JL, 2002, PHYSIOL BEHAV, V77, P657, DOI 10.1016/S0031-9384(02)00916-2; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; MCDONALD S, 2003, BRAIN IMPAIR, V4, P36, DOI DOI 10.1375/brim.4.1.36.27032; McDonald S, 2006, DISABIL REHABIL, V28, P1529, DOI 10.1080/09638280600646185; MEICHENBAUM D, 1973, BEHAV THER, V4, P515, DOI 10.1016/S0005-7894(73)80003-6; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; O'Carroll RE, 1999, PSYCHOL MED, V29, P105, DOI 10.1017/S0033291798007673; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Phillips ML, 2003, BRIT J PSYCHIAT, V182, P190, DOI 10.1192/bjp.182.3.190; Pope JW, 2006, J CLIN EXP NEUROPSYC, V28, P101, DOI 10.1080/13803390490918138; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; PRIGATANO GP, 1999, PRINCIPLES NEUROPSCH; *PSYCH CORP, 1997, WECHSL MEM SCAL 3 ED; *PSYCH CORP, 1997, WECHS AD INT SCAL 3; *PSYCH CORP, 2001, WECHS TEST ADULT REA; Roudier M, 1998, J NEUROL SCI, V154, P151, DOI 10.1016/S0022-510X(97)00222-0; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE R, 2002, 4 SYDN U; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Winter J, 1999, INT J GERIATR PSYCH, V14, P987; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408	73	57	58	2	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2008	23	2					103	115		10.1097/01.HTR.0000314529.22777.43			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	280KW	WOS:000254426700005	18362764				2021-06-18	
J	Lu, KT; Cheng, NC; Wu, CY; Yang, YL				Lu, Kwok-Tung; Cheng, Nai-Chi; Wu, Chang-Yen; Yang, Yi-Ling			NKCC1-mediated traumatic brain injury-induced brain edema and neuron death via Raf/MEK/MAPK cascade	CRITICAL CARE MEDICINE			English	Article						rats; traumatic brain injury; Na+-K+-2CI(-) co-transporter isoform 1; mitogen-activated protein kinase	K-CL COTRANSPORTER; CEREBRAL-ARTERY OCCLUSION; ACTIVATED PROTEIN-KINASES; NA+-K+-2CL(-) COTRANSPORTER; NA-K-2CL COTRANSPORTER; DAMAGE; TRANSPORTERS; STIMULATION; INHIBITION; EXPRESSION	Objective. Brain edema is one of the characteristic features of patients with severe traumatic brain injury. The aim of this study was to examine the effects. of Na+-K+-2CI(-) co-transporter on traumatic brain injury-induced brain edema and neuron damage and to elucidate the relationship between Na+-K+-2CI(-) co-transporter and mitogen-activated protein kinase (MAPK) cascade. Design: Laboratory investigation. Setting: University research laboratory. Subjects: Male Wistar rats weighing 350-400 g. Interventions: Anesthetized animals were subjected to a weight-drop device (450-g weight, 1.8-m height) to induce traumatic brain injury. Measurements and Main Results: The expression of Na+-K(+)2CI(-) co-transporter and phosphorylation of MAPK cascade were determined by Western blot test. We also analyzed the degree of brain edema and neuronal damage in this study. We found that the messenger RNA and protein of Na+-K+-2CI(-) co-transporter were up-regulated mainly in hippocampus neurons from 2 to 24 hrs after traumatic brain injury. After traumatic brain injury, animals displayed severe brain edema and neuron damage. The phosphorylation of extracellular signal-regulated kinase, MAPK kinase, and Raf also was significantly elevated after traumatic brain injury. Bumetanide (15.2 mg/kg), a specific Na+-K+-2CI(-) co-transporter inhibitor, significantly attenuated the neuronal damage and brain edema after traumatic brain injury by decreasing the phosphorylation of Raf/MEK/ERK cascade proteins. Conclusions. The present study suggests that Na+-K+-2CI(-) co-transporter plays an important role in TBI-induced brain edema and neuronal damage via activation of MAPK cascade.	[Lu, Kwok-Tung] Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan; [Cheng, Nai-Chi; Wu, Chang-Yen; Yang, Yi-Ling] Natl Chia Yi Normal Univ, Inst Biotechnol, Chiayi, Taiwan	Lu, KT (corresponding author), Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan.	ylyang@mail.ncyu.edu.tw					Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Beck J, 2003, J NEUROSCI, V23, P5061; Busse S, 2005, BRAIN RES, V1046, P116, DOI 10.1016/j.brainres.2005.03.055; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; DAVIES PF, 1995, PHYSIOL REV, V75, P519; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HOSSMANN KA, 1989, NEUROSURG REV, V12, P263, DOI 10.1007/BF01780838; Ikebe M, 2001, J AM SOC NEPHROL, V12, P423, DOI 10.1681/ASN.V123423; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; Lu J, 2005, ACT NEUR S, V95, P281; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 2000, NEUROTRAUMA, V17, P143; O'Donnell ME, 2006, J CEREBR BLOOD F MET, V26, P1234, DOI 10.1038/sj.jcbfm.9600278; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; Obermuller N, 1996, J CLIN INVEST, V98, P635, DOI 10.1172/JCI118834; ODONNELL ME, 1995, AM J PHYSIOL-CELL PH, V268, pC747; Panet R, 2006, J CELL PHYSIOL, V206, P578, DOI 10.1002/jcp.20506; Panet R, 2002, J CELL PHYSIOL, V190, P227, DOI 10.1002/JCP.10055; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Ringel F, 2000, J NEUROCHEM, V75, P125, DOI 10.1046/j.1471-4159.2000.0750125.x; Schomberg SL, 2001, J NEUROPHYSIOL, V85, P2563; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; Sun DD, 1998, AM J PHYSIOL-CELL PH, V275, pC772; TROPPER JN, 1997, J CLIN INVEST, V99, P2941; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Wu DC, 2000, J CEREBR BLOOD F MET, V20, P1320, DOI 10.1097/00004647-200009000-00007; Yang YL, 2005, NEUROSCIENCE, V134, P247, DOI 10.1016/j.neuroscience.2005.04.003	38	57	62	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2008	36	3					917	922		10.1097/CCM.0B013E31816590C4			6	Critical Care Medicine	General & Internal Medicine	266QD	WOS:000253450500035	18431281				2021-06-18	
J	Simpkins, JW; Singh, M				Simpkins, James W.; Singh, Meharvan			More than a decade of estrogen neuroprotection	ALZHEIMERS & DEMENTIA			English	Article; Proceedings Paper	Leon Thal Symposium on the Prevention of Dementia (LTS 07)	DEC 02-04, 2007	Las Vegas, NV	Lou Ruvo Brain Inst		estrogens; estradiol; neuroprotection; Alzheimer's disease; stroke; mitochondria; cell signaling	HORMONE REPLACEMENT THERAPY; TRAUMATIC BRAIN-INJURY; NIGROSTRIATAL DOPAMINERGIC SYSTEM; GLOBAL COGNITIVE FUNCTION; HEALTH INITIATIVE MEMORY; CEREBRAL-BLOOD-FLOW; SPINAL-CORD-INJURY; POSTMENOPAUSAL WOMEN; ISCHEMIC DAMAGE; VENOUS THROMBOEMBOLISM	Considerable evidence has emerged through more than a decade of research supporting the neuroprotective and cognition-preserving effects of estrogens. Such basic research coupled with various epidemiological studies led quickly to the assessment of Premarin for the treatment of mild to moderate Alzheimer's disease (AD), initiated by the Alzheimer's Disease Cooperative Study Group and headed by Dr. Leon Thal. While this and subsequent trials with Premarin (Wyeth Research, Monmouth Junction, New Jersey) and PremPro (Wyeth Research), a conjugated equine estrogen preparation plus medoxyprogresterone acetate, have not supported the use of estrogens in treating advanced AD, considerable inferences have been made from these placebo controlled trials of estrogens. Here, we aimed to put these AD trials of estrogens in perspective by considering the potential mechanisms of these potent neuroprotective estrogens, the role of estrogens in other neurodegenerative conditions, such as cerebral ischemia, and based on our current understanding of estrogen neurobiology, offer insight into the design of future clinical trails of estrogens for neuronal protection. (c) 2008 The Alzheimer's Association. All rights reserved.	[Simpkins, James W.; Singh, Meharvan] Univ N Texas, Hlth Sci Ctr, Inst Aging & Alzgheimers Dis Res, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA	Simpkins, JW (corresponding author), Univ N Texas, Hlth Sci Ctr, Inst Aging & Alzgheimers Dis Res, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA.	jsimpkin@hsc.unt.edu		Singh, Meharvan/0000-0002-8072-1769	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG022550, P01AG027956, P01AG010485] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10485, AG27956, AG22550] Funding Source: Medline		Anderson LI, 2005, NEUROSCIENCE, V130, P369, DOI 10.1016/j.neuroscience.2004.09.033; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; BISHOP J, 1994, MOL CELL NEUROSCI, V5, P303, DOI 10.1006/mcne.1994.1036; Bracamonte MP, 2001, TRENDS ENDOCRIN MET, V12, P204, DOI 10.1016/S1043-2760(01)00406-4; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brinton RD, 2005, ANN NY ACAD SCI, V1052, P57, DOI 10.1196/annals.1347.005; Budziszewska B, 2001, EXP CLIN ENDOCR DIAB, V109, P168, DOI 10.1055/s-2001-14841; Canonico M, 2007, CIRCULATION, V115, P840, DOI 10.1161/CIRCULATIONAHA.106.642280; Carswell HVO, 2000, J CEREBR BLOOD F MET, V20, P931, DOI 10.1097/00004647-200006000-00005; Carswell HVO, 2000, AM J PHYSIOL-HEART C, V278, pH290; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Chen JF, 2001, ANESTH ANALG, V92, P1520, DOI 10.1097/00000539-200106000-00033; D'Astous M, 2004, NEUROPHARMACOLOGY, V47, P1180, DOI 10.1016/j.neuropharm.2004.08.020; Disshon KA, 2000, BRAIN RES, V868, P95, DOI 10.1016/S0006-8993(00)02329-5; Dluzen DE, 1996, NEUROTOXICOL TERATOL, V18, P603, DOI 10.1016/0892-0362(96)00086-4; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959; FALKEBORN M, 1993, ARCH INTERN MED, V153, P1201, DOI 10.1001/archinte.153.10.1201; FINUCANE FF, 1993, ARCH INTERN MED, V153, P73, DOI 10.1001/archinte.153.1.73; Gajjar TM, 2003, J NEURAL TRANSM, V110, P1215, DOI 10.1007/s00702-003-0045-3; Galanopoulou AS, 2003, NEUROSCI LETT, V342, P201, DOI 10.1016/S0304-3940(03)00282-9; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 1997, J STEROID BIOCHEM, V63, P229, DOI 10.1016/S0960-0760(97)00124-6; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harman S Mitchell, 2006, Gend Med, V3, P254, DOI 10.1016/S1550-8579(06)80214-7; Haynes LE, 2003, NEUROSCIENCE, V120, P799, DOI 10.1016/S0306-4522(03)00167-2; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; Heron P, 2001, METAB BRAIN DIS, V16, P187, DOI 10.1023/A:1012593027961; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; Hoibraaten E, 2001, THROMB HAEMOSTASIS, V85, P775; Horstink MWIM, 2003, ADV NEUROL, V91, P107; Horvath KM, 2002, NEUROSCIENCE, V110, P489, DOI 10.1016/S0306-4522(01)00560-7; Jamous MA, 2005, J NEUROSURG, V103, P1046, DOI 10.3171/jns.2005.103.6.1046; Jamous MA, 2005, J NEUROSURG, V103, P1052, DOI 10.3171/jns.2005.103.6.1052; Johnson AB, 2006, J NEUROIMMUNOL, V174, P82, DOI 10.1016/j.jneuroim.2006.01.019; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Jung ME, 2002, ALCOHOL, V26, P83, DOI 10.1016/S0741-8329(01)00199-9; Kalkbrenner KA, 2003, BRAIN RES, V964, P244, DOI 10.1016/S0006-8993(02)04065-9; Koh KK, 2003, INT J CARDIOL, V87, P1; Kruman II, 1999, EXP NEUROL, V160, P28, DOI 10.1006/exnr.1999.7190; Liao SL, 2001, NEUROSCI LETT, V297, P159, DOI 10.1016/S0304-3940(00)01704-3; Maki PM, 2001, AM J PSYCHIAT, V158, P227, DOI 10.1176/appi.ajp.158.2.227; Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513; Marder K, 1998, NEUROLOGY, V50, P1141, DOI 10.1212/WNL.50.4.1141; McCullough LD, 2001, STROKE, V32, P796, DOI 10.1161/01.STR.32.3.796; Mickley KR, 2004, NEUROENDOCRINOLOGY, V79, P305, DOI 10.1159/000079710; Mohamed MK, 2000, EUR J ENDOCRINOL, V142, P307, DOI 10.1530/eje.0.1420307; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; PAGANINIHILL A, 1994, AM J EPIDEMIOL, V140, P256, DOI 10.1093/oxfordjournals.aje.a117244; PEREZ E, 2006, DRUG DEVELOP RES, V68, P1; PHILLIPS SM, 1992, PSYCHONEUROENDOCRINO, V17, P485, DOI 10.1016/0306-4530(92)90007-T; Prokai L, 2003, P NATL ACAD SCI USA, V100, P11741, DOI 10.1073/pnas.2032621100; Rabbani O, 1997, EXP NEUROL, V146, P179, DOI 10.1006/exnr.1997.6516; Ramirez AD, 2003, NEUROENDOCRINOLOGY, V77, P223, DOI 10.1159/000070277; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Reibel S, 2000, NEUROSCI LETT, V281, P79, DOI 10.1016/S0304-3940(00)00784-9; Resnick SM, 1998, HORM BEHAV, V34, P171, DOI 10.1006/hbeh.1998.1476; Resnick SM, 2001, ANN NY ACAD SCI, V949, P203; Rocca WA, 2007, NEUROLOGY, V69, P1074, DOI 10.1212/01.wnl.0000276984.19542.e6; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Sherwin BB, 1997, NEUROLOGY, V48, pS21, DOI 10.1212/WNL.48.5_Suppl_7.21S; Sherwin BB, 1998, P SOC EXP BIOL MED, V217, P17; Shi J, 2001, STROKE, V32, P987, DOI 10.1161/01.STR.32.4.987; Shughrue PJ, 2003, NEUROSCIENCE, V116, P851, DOI 10.1016/S0306-4522(02)00790-X; Shughrue PJ, 2004, EXP NEUROL, V190, P468, DOI 10.1016/j.expneurol.2004.08.009; Shumaker SA, 2004, JAMA-J AM MED ASSOC, V291, P2947, DOI 10.1001/jama.291.24.2947; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Sierra A, 2003, ENDOCRINE, V21, P43, DOI 10.1385/ENDO:21:1:43; SIMERLY RB, 1991, MOL ENDOCRINOL, V5, P424, DOI 10.1210/mend-5-3-424; Simpkins JW, 2004, J WOMENS HEALTH, V13, P1165, DOI 10.1089/jwh.2004.13.1165; Simpkins JW, 1997, J NEUROSURG, V87, P724, DOI 10.3171/jns.1997.87.5.0724; SINGH M, 1994, BRAIN RES, V644, P305, DOI 10.1016/0006-8993(94)91694-2; SINGH M, 2005, FUTURE ESTROGEN HORM; Sohrabji F, 2006, ENDOCRINE, V29, P191, DOI 10.1385/ENDO:29:2:191; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sudo S, 1997, NEUROSCI RES, V29, P345, DOI 10.1016/S0168-0102(97)00106-5; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Thakur MK, 2007, NEUROCHEM INT, V50, P314, DOI 10.1016/j.neuint.2006.08.019; Toung TK, 2000, STROKE, V31, P2701, DOI 10.1161/01.STR.31.11.2701; Velisek L, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.43.s.5.3.x; Veliskova J, 2000, EPILEPSIA, V41, pS30, DOI 10.1111/j.1528-1157.2000.tb01553.x; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Watanabe Y, 2001, AM J PHYSIOL-HEART C, V281, pH155; Yang SH, 2000, STROKE, V31, P745, DOI 10.1161/01.STR.31.3.745; Yang SH, 2001, J CEREBR BLOOD F MET, V21, P174, DOI 10.1097/00004647-200102000-00009; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zhao LQ, 2006, J PHARMACOL EXP THER, V319, P1124, DOI 10.1124/jpet.106.109504	97	57	60	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JAN	2008	4	1		1			S131	S136		10.1016/j.jalz.2007.10.009			6	Clinical Neurology	Neurosciences & Neurology	256AI	WOS:000252699700023	18631989				2021-06-18	
J	Thompson, HJ; Rivara, FP; Jurkovich, GJ; Wang, J; Nathens, AB; MacKenzie, EJ				Thompson, Hilaire J.; Rivara, Frederick P.; Jurkovich, Gregory J.; Wang, Jin; Nathens, Avery B.; MacKenzie, Ellen J.			Evaluation of the effect of intensity of care on mortality after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						head injury; critical care consultation; specialty care consultation; pulmonary artery catheter; older adult	PULMONARY-ARTERY CATHETER; ELDERLY-PATIENTS; OLDER PATIENTS; HOSPITAL MORTALITY; HIP-FRACTURES; OF-LIFE; ILL; OUTCOMES; AGE; SURVIVAL	Objectives: To evaluate the effect of age on intensity of care provided to traumatically brain-injured adults and to determine the influence of intensity of care on mortality at discharge and 12 months postinjury, controlling for injury severity. Design: Cohort study using the National Study on the Costs and Outcomes of Trauma (NSCOT) database. Risk ratio and Poisson regression analyses were performed using data weighted according to the population of eligible patients. Setting and Patients: A total of 18 level 1 and 51 level 2 non-trauma centers located in 14 states in the United States and 1,776 adults aged 25-84 yrs with a diagnosis of traumatic brain injury. Measurements: Injury severity was determined by the motor component of the Glasgow Coma Scale score, the Injury Severity Score, pupillary reactivity, and presence of midline shift. Factors evaluated as contributing to intensity of care included: admission to the intensive care unit, mechanical ventilation, placement of an intracranial pressure monitor, placement of a jugular bulb catheter, placement of a pulmonary artery catheter, critical care consultation, the number of specialty care consultations, mannitol use, treatment with barbiturate coma, decompressive craniectomy, number of nonneurosurgical procedures performed, the presence of a do-not-resuscitate order, and withdrawal of therapy. Main Results: Controlling for injury-related factors, sex, and comorbidity, as age increased, the overall likelihood of receiving various interventions decreased. After controlling for injury severity, sex, and comorbidity, factors associated with higher risk of in-hospital death were: being aged 75-84 yrs (relative risk [RR] 1.32, 95% confidence interval [CI] 1.13, 1.55), pulmonary artery catheter use (RR 1.56, 95% CI 1.30,1.86), intubation (RR 4.17, 95% Cl 2.28, 7.61), the presence of a do-not-resuscitate order (RR 3.21, 95% CI 2.21, 4.65), and withdrawal of,therapy (RR 2.33, 95% CI 1.69, 3.23). In contrast, a higher number of specialty care consultations (surgical consults: RR 0.63, 95% CI 0.54, 0.74; medical consults: RR 0.87, 95% CI 0.79, 0.95; and other consults: RR 0.43, 95% Cl 0.26, 0.69) were associated with decreased risk of death. The results were similar for factors associated with death at 12 months, with the exception that the number of medical consultations was not significant, whereas the number of nonneurosurgical procedures performed was associated with lower risk of death (RR 0.96, 95% Cl 0.92, 0.99), as was obtaining critical care consultation services (RR 0.84, 95% CI 0.71, 1.0). Conclusions: There is a lower intensity of care provided to older adults with traumatic brain injury. Although the specific contributions of specialists to patient management are unknown, their consultation was associated with decreased risk of inhospital death and death within 12 months. It is important that careproviders have an increased awareness of the potential contribution of multidisciplinary clinical decision making to patient outcomes in older traumatically brain-injured patients.	[Thompson, Hilaire J.] Univ Washington, Sch Nursing, Seattle, WA 98195 USA; [Rivara, Frederick P.; Jurkovich, Gregory J.; Wang, Jin] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Nathens, Avery B.] Univ Toronto, Sch Med, Toronto, ON, Canada; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Thompson, HJ (corresponding author), Univ Washington, Sch Nursing, Seattle, WA 98195 USA.	hilairet@u.washington.edu			NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K12RR023265] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K12 RR023265-03, K12 RR023265, 5 K12 RR023265-04] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [L30 NR010534-02, L30 NR010534] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR316840] Funding Source: Medline		Adnet F, 2001, CRIT CARE MED, V29, P891, DOI 10.1097/00003246-200104000-00042; ANG DN, 2007, AM COLL SURG 93 ANN; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHELLURI L, 1995, ARCH INTERN MED, V155, P1013, DOI 10.1001/archinte.155.10.1013; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Donohue JT, 2007, J TRAUMA, V62, P419, DOI 10.1097/01.ta.0000219286.88179.18; Fallon WF, 2006, J TRAUMA, V61, P1040, DOI 10.1097/01.ta.0000238652.48008.59; Fisher A, 2006, J ORTHOP TRAUMA, V20, P179; Fisher AA, 2006, J ORTHOP TRAUMA, V20, P172, DOI 10.1097/01.bot.0000202220.88855.16; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Friese RS, 2006, CRIT CARE MED, V34, P1597, DOI 10.1097/01.CCM.0000217918.03343.AA; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1999, ANN INTERN MED, V131, P721, DOI 10.7326/0003-4819-131-10-199911160-00002; Hanson CW, 1999, CRIT CARE MED, V27, P270, DOI 10.1097/00003246-199902000-00030; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacoby SF, 2006, J NURS SCHOLARSHIP, V38, P133, DOI 10.1111/j.1547-5069.2006.00090.x; KASS JE, 1992, CRIT CARE MED, V20, P1666, DOI 10.1097/00003246-199212000-00011; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; Lane P, 2003, ACAD EMERG MED, V10, P244, DOI 10.1111/j.1553-2712.2003.tb01998.x; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MAYEROAKES SA, 1991, J AM GERIATR SOC, V39, P862, DOI 10.1111/j.1532-5415.1991.tb04452.x; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murdoch SD, 2000, BRIT J ANAESTH, V85, P611, DOI 10.1093/bja/85.4.611; Nathens AB, 2006, ANN SURG, V244, P545, DOI 10.1097/01.sla.0000239005.26353.49; NICOLAS F, 1987, INTENS CARE MED, V13, P9, DOI 10.1007/BF00263549; Nierman DM, 2001, CRIT CARE MED, V29, P1853, DOI 10.1097/00003246-200110000-00001; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PERMINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; ROZZELLE CJ, 1995, J AM GERIATR SOC, V43, P240, DOI 10.1111/j.1532-5415.1995.tb07329.x; Rubin DB., 1987, MULTIPLE IMPUTATION; Sakr Y, 2005, CHEST, V128, P2722, DOI 10.1378/chest.128.4.2722; Scheetz Linda J, 2004, Prehosp Emerg Care, V8, P268, DOI 10.1016/j.prehos.2003.12.027; Shinoda-Tagawa T, 2003, INJURY PREV, V9, P214, DOI 10.1136/ip.9.3.214; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson BT, 2004, CRIT CARE MED, V32, P1781, DOI 10.1097/01.CCM.0000126895.66850.14; U.S. Bureau of the Census, 2004, PROJ POP US AG SEX 2; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; WU AW, 1990, J AM GERIATR SOC, V38, P621, DOI 10.1111/j.1532-5415.1990.tb01419.x	51	57	58	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2008	36	1					282	290		10.1097/01.CCM.0000297884.86058.8A			9	Critical Care Medicine	General & Internal Medicine	291YA	WOS:000255232100040	18007264	Green Accepted			2021-06-18	
J	Livingstone, SA; Skelton, RW				Livingstone, Sharon A.; Skelton, Ronald W.			Virtual environment navigation tasks and the assessment of cognitive deficits in individuals with brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						spatial navigation; traumatic brain injury; virtual reality; Morris water maze; hippocampus; learning and memory; spatial cognition; allocentric and egocentric strategies; wayfinding; landmark	UNILATERAL TEMPORAL LOBECTOMY; HUMAN SPATIAL NAVIGATION; MORRIS WATER MAZE; TOPOGRAPHICAL DISORIENTATION; HEAD-INJURY; HIPPOCAMPAL FUNCTION; ALZHEIMERS-DISEASE; MEMORY DEFICITS; FRONTAL LOBES; LESIONS	Navigation in real environments is often impaired by traumatic brain injury TBI). These deficits in wayfinding appear to be due to disruption of cognitive processes underlying navigation and may in turn be due to damage to the hippocampus and frontal lobes. These wayfinding problems after TBI were investigated using a virtual simulation of a Morris Water Maze (MWM), a standard test of hippocampal function in laboratory animals. The virtual environment consisted of a large virtual arena in a very large virtual room whose walls provided views of a naturalistic landscape. Eleven community-dwelling TBI survivors and 12 comparison participants, matched for gender, age and education were tested to see if they could find a location in the arena marked by one of the following: (a) a visible platform, (b) a single proximal object, (c) a single proximal object among seven other distracter objects, or (d) distal features inside and outside the room. The proximal objects allowed participants to use egocentric (body-centered) navigational strategies that rely on relatively simple stimulus-response associations. The absence of proximal cues forced the participants to rely on distal features of the environment (room walls, landscape elements) and tested their ability to use allocentric (world-based) navigational strategies requiring cognitive mapping. Results indicated that the navigation of TBI survivors was not impaired when the proximal cues were present but was impaired when proximal cues were absent. These results provide more evidence that the navigational deficit after TBI is due to an inability to form, remember or use cognitive maps. (C) 2007 Elsevier B.V. All rights reserved.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada	Skelton, RW (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.	skelton@uvic.ca	Skelton, Ronald/E-5605-2012				Aguirre GK, 1999, BRAIN, V122, P1613, DOI 10.1093/brain/122.9.1613; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Barrash J, 1998, J CLIN EXP NEUROPSYC, V20, P807, DOI 10.1076/jcen.20.6.807.1114; BARRASH J, 1994, DEV NEUROPSYCHOL, V10, P189, DOI 10.1080/87565649409540578; Barrash J, 2000, NEUROPSYCHOLOGIA, V38, P820, DOI 10.1016/S0028-3932(99)00131-1; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bohbot VD, 2004, NEUROPSYCHOLOGY, V18, P418, DOI 10.1037/0894-4105.18.3.418; Bohbot VD, 2000, ANN NY ACAD SCI, V911, P355; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; Burgess N, 1999, HIPPOCAMPAL PARIETAL, P3; Cherrier MM, 2001, NEUROPSY NEUROPSY BE, V14, P159; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; Ekstrom AD, 2003, NATURE, V425, P184, DOI 10.1038/nature01964; Feigenbaum JD, 1996, NEUROPSYCHOLOGIA, V34, P163, DOI 10.1016/0028-3932(95)00107-7; Grubb NR, 2000, STROKE, V31, P1509, DOI 10.1161/01.STR.31.7.1509; GRUSSER O, 1991, GETTING LOST WORLD T, V12; HABIB M, 1987, CORTEX, V23, P73, DOI 10.1016/S0010-9452(87)80020-5; Hamilton DA, 2004, BEHAV BRAIN RES, V154, P385, DOI 10.1016/j.bbr.2004.03.005; Iaria G, 2003, J NEUROSCI, V23, P5945; Jacobs LF, 2003, PSYCHOL REV, V110, P285, DOI 10.1037/0033-295X.110.2.285; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; KOLB B, 1987, BEHAV BRAIN RES, V23, P127, DOI 10.1016/0166-4328(87)90050-7; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORROW L, 1988, NEUROPSYCHOLOGY SPAT, P5; Nadel L, 2004, NEUROPSYCHOLOGY, V18, P473, DOI 10.1037/0894-4105.18.3.473; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE O, 1978, HIPPOCAMPUS COGNITIV; PANG D, 1989, PHYS PATHOPHYSIOLOGY, P1; Paterson A, 1944, BRAIN, V67, P331, DOI 10.1093/brain/67.4.331; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; REITAN RM, 1994, NEUROPSYCHOL REV, V4, P161, DOI 10.1007/BF01874891; Rizzo AA, 2004, NEUROPSYCHOL REHABIL, V14, P207, DOI 10.1080/09602010343000183; Skelton RW, 2006, BRAIN INJURY, V20, P189, DOI 10.1080/02699050500456410; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Spiers HJ, 2001, BRAIN, V124, P2476, DOI 10.1093/brain/124.12.2476; Spreen O., 1998, COMPENDIUM NEUROPSYC; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUNDERLAND T, 1989, J AM GERIATR SOC, V37, P725, DOI 10.1111/j.1532-5415.1989.tb02233.x; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TOLMAN EC, 1948, PSYCHOL REV, V55, P189, DOI 10.1037/h0061626; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; White NM, 2002, NEUROBIOL LEARN MEM, V77, P125, DOI 10.1006/nlme.2001.4008; WILSON B, 1991, RIVERMEAD BEHAV MEMO, P1; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020; WOLFKLEIN GP, 1989, J AM GERIATR SOC, V37, P730, DOI 10.1111/j.1532-5415.1989.tb02234.x	57	57	60	1	26	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	DEC 11	2007	185	1					21	31		10.1016/j.bbr.2007.07.015			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	232PF	WOS:000251030900003	17727970				2021-06-18	
J	Himmelseher, S				Himmelseher, Sabine			Hypertonic saline solutions for treatment of intracranial hypertension	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral edema; critical care; hypertonic-hyperoncotic saline solution; hypertonic saline solution; intracranial hypertension; osmolar load	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; HYDROXYETHYL STARCH 130/0.4; SMALL-VOLUME RESUSCITATION; ACUTE ISCHEMIC-STROKE; SODIUM-CHLORIDE; 20-PERCENT MANNITOL; 7.5-PERCENT SALINE; CLINICAL-TRIAL; PRESSURE	Purpose of review This review aims to provide an update on recent knowledge gained on hypertonic saline solutions for the treatment of intracranial hypertension. Explanatory approaches to the mechanisms underlying the edema-reducing effects of the solutions are outlined, practical aspects of use are presented, and trials that assessed their clinical utility are highlighted. Recent findings With an established trauma system, hypertonic saline added to conventional fluid resuscitation did not improve long-term outcome in multiple injury with hypotension and brain trauma. In intensive care, hypertonic saline reduced intracranial hypertension after subarachnoid haemorrhage, brain trauma, and a variety of other brain diseases, including cerebral edema in acute liver failure. Summary Hypertonic saline solutions have evolved as an alternative to mannitol or may be used in otherwise refractory intracranial hypertension to treat raised intracranial pressure. With high osmolar loads, the efficacy of the solution is enhanced, but no simple relationship between the saline concentration and the clinical effects of a solution is established. Caution is advised with high osmolar loads because they carry increased risks for potentially deleterious consequences of hypernatremia or may induce osmotic blood-brain barrier opening with possibly harmful extravasation of the hypertonic solution into the brain tissue.	[Himmelseher, Sabine] Klinikum Rechts Der Isar, Dept Anaesthesiol, D-81675 Munich, Germany	Himmelseher, S (corresponding author), Klinikum Rechts Der Isar, Anasthesiol Klin, Ismaningerstr 22, D-81675 Munich, Germany.	s.himmelseher@gmx.de					Abbott R, 2005, BRIT MED J, V331, P829, DOI 10.1136/bmj.331.7520.829; Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; Al-Rawi PG, 2005, ACTA NEUROCHIR SUPPL, V95, P123; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bentsen G, 2004, ACTA ANAESTH SCAND, V48, P1089, DOI 10.1111/j.1399-6576.2004.00497.x; Bentsen G, 2006, CRIT CARE MED, V34, P2912, DOI 10.1097/01.CCM.0000245665.46789.7C; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; Boldt J, 2004, CAN J ANAESTH, V51, P500, DOI 10.1007/BF03018316; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Chang Y, 2006, J APPL PHYSIOL, V100, P1445, DOI 10.1152/japplphysiol.00763.2005; Chen CH, 2006, J CEREBR BLOOD F MET, V26, P951, DOI 10.1038/sj.jcbfm.9600248; Claassen J, 2002, STROKE, V33, P1225, DOI 10.1161/01.STR.0000015624.29071.1F; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Copp J, 2005, AM J PHYSIOL-CELL PH, V288, pC403, DOI 10.1152/ajpcell.00095.2004; Degos V, 2006, ANESTH ANALG, V103, P1229, DOI 10.1213/01.ane.0000237401.22688.22; Detry O, 2006, WORLD J GASTROENTERO, V12, P7405, DOI 10.3748/wjg.v12.i46.7405; Dieterich HJ, 2006, CRIT CARE MED, V34, P1775, DOI 10.1097/01.CCM.0000218814.77568.BC; Dieterich HJ, 2003, ANESTH ANALG, V96, P1150, DOI 10.1213/01.ANE.0000050771.72895.66; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; Erard AC, 2003, ANN FR ANESTH, V22, P18, DOI 10.1016/S0750-7658(02)00004-7; Farstad M, 2006, ACTA ANAESTH SCAND, V50, P855, DOI 10.1111/j.1399-6576.2006.01064.x; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Haeberle HA, 2006, J CLIN ANESTH, V18, P96, DOI 10.1016/j.jclinane.2005.06.010; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Haynes GR, 2004, ANESTH ANALG, V99, P620, DOI 10.1213/01.ANE.0000130904.08524.4A; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Huang SJ, 2006, SURG NEUROL, V66, pS26, DOI 10.1016/j.surneu.2006.07.007; Huang SJ, 2006, SURG NEUROL, V65, P539, DOI 10.1016/j.surneu.2005.11.019; Kasuya H, 2003, STROKE, V34, P956, DOI 10.1161/01.STR.0000064321.10700.63; Kreimeier U, 2002, ACTA ANAESTH SCAND, V46, P625, DOI 10.1034/j.1399-6576.2002.460601.x; Lang F, 1998, PHYSIOL REV, V78, P247; Larive LL, 2004, NEUROCRIT CARE, V1, P435, DOI 10.1385/NCC:1:4:435; Lescot T, 2005, INTENS CARE MED, V31, P1042, DOI 10.1007/s00134-005-2709-y; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; Martin RJ, 2004, J NEUROL NEUROSUR PS, V75, P22, DOI 10.1136/jnnp.2004.045906; Mortimer Diane Schretzman, 2006, J Neurosci Nurs, V38, P142; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; Neff TA, 2003, ANESTH ANALG, V96, P1453, DOI 10.1213/01.ANE.0000061582.09963.FD; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Prough DS, 2006, SHOCK, V26, P290, DOI 10.1097/01.shk.0000225405.66693.49; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; Raghavan M, 2006, NEUROCRIT CARE, V4, P179, DOI 10.1385/NCC:4:2:179; Rhoney Denise H, 2006, Nutr Clin Pract, V21, P462, DOI 10.1177/0115426506021005462; Sirtl CJ, 2001, J PHARM THER, V1, P4; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; Suarez Jose I, 2004, Cleve Clin J Med, V71 Suppl 1, pS9; Takefuji S, 2007, EXP NEUROL, V204, P88, DOI 10.1016/j.expneurol.2006.09.025; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P507; Thomale UW, 2004, J NEUROTRAUM, V21, P1737; Toung TJK, 2007, CRIT CARE MED, V35, P526, DOI 10.1097/01.CCM.0000253309.44567.A6; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vialet R, 2005, J NEUROSURG ANESTH, V17, P106, DOI 10.1097/01.ana.0000163200.48483.56; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vincent JL, 2007, ANESTH ANALG, V104, P484, DOI 10.1213/01.ane.0000258224.44806.dd; Wakai A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub4; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Watts DD, 2004, PREHOSP EMERG CARE, V8, P1350; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; Wiedermann CJ, 2003, PATHOPHYSIOL HAEMO T, V33, P225, DOI 10.1159/000081513; Woessner R, 2003, PATHOPHYSIOL HAEMO T, V33, P121, DOI 10.1159/000077819; Yildizdas D, 2006, INDIAN PEDIATR, V43, P771	63	57	67	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2007	20	5					414	426		10.1097/ACO.0b013e3282eff9ea			13	Anesthesiology	Anesthesiology	V42SF	WOS:000209632800004	17873594				2021-06-18	
J	Jacobs, R; Harvey, AS; Anderson, V				Jacobs, Rani; Harvey, A. Simon; Anderson, Vicki			Executive function following focal frontal lobe lesions: Impact of timing of lesion on outcome	CORTEX			English	Article						executive functional; frontal lesions; childhood; injury age	TRAUMATIC BRAIN-INJURY; DEVELOPMENTAL-CHANGES; HEAD-INJURY; EARLY ONSET; CHILDREN; CHILDHOOD; BEHAVIOR; CORTEX; RECOVERY; INFANTS	While it is generally agreed that outcome following cerebral insult during childhood differs from that seen following similar pathology in adulthood, the specific relationship between timing of cerebral lesion and outcome, and the mechanism associated with observed neurobehavioral changes, remains controversial. Data from children with focal lesions suggests a non-linear relationship between age at injury and language function (e.g., Bates et al., 1999). With respect to executive function, animal models also demonstrate a non-linear relationship, and suggest that outcome is tightly linked to underlying neuronal changes (e.g., Kolb et al., 2000). Whether these models easily translate to humans, where brain morphology, cognitive function and environmental influences are more complex, is not clear. To date, focal lesion research in children has been restricted to individual case studies or, to samples of children with lesions to regions subsuming language function, or those who have undergone hemispherectomy for the treatment of intractable epilepsy. This study aimed to build on current knowledge, investigating executive function in 38 children with focal lesions involving prefrontal cortex. Aetiology and timing of lesions was diverse. Results are consistent with animal research suggesting a non-linear relationship between age at injury and outcome, with "critical periods" during development when the frontal lobes are particularly vulnerable to insult, and others when outcome is more optimal. Our findings indicate that children with prenatal lesions are at greatest risk of neurobehavioral deficits. Children with lesions sustained in middle childhood demonstrate least severe impairments across executive domains, possibly due to a period of peak synaptogenesis and dendritic arborization during this developmental stage, in keeping with animal models and research investigating frontal lobe development.	Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia; Royal Childrens Hosp, Dept Neurol, Parkville, Vic 3052, Australia	Jacobs, R (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	rani.jacobs@mcri.edu.au					ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; Andersen J, 2001, J HYDROL, V247, P200, DOI 10.1016/S0022-1694(01)00384-5; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson P, 1996, CLIN NEUROPSYCHOL, V10, P54, DOI 10.1080/13854049608406663; ANDERSON P, 2001, THESIS U MELBOURNE; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; ANDERSON V, 2001, PEDIAT NEUROPSYCHOLO; ARAM DM, 1994, NEUROPSYCHOLOGIA, V32, P85, DOI 10.1016/0028-3932(94)90071-X; AYLWARD GP, 1992, J DEV BEHAV PEDIATR, V13, P222; BASSER LS, 1962, BRAIN, V85, P427, DOI 10.1093/brain/85.3.427; Bates E, 1997, DEV NEUROPSYCHOL, V13, P275, DOI 10.1080/87565649709540682; BATES E, 1999, DEV DISORDERS; BERTENTHAL BI, 1987, CHILD DEV, V58, P560, DOI 10.2307/1130198; CORBALLIS MC, 1978, BEHAV BRAIN SCI, V1, P261, DOI 10.1017/S0140525X00074471; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dawson G, 2000, DEV PSYCHOPATHOL, V12, P695, DOI 10.1017/S0954579400004089; Dennis M., 1989, CLIN NEUROPSYCHOLOGY; DENNIS M, 2000, PATIENT BASED APPROA; Diamond A, 1996, DEV PSYCHOBIOL, V29, P315, DOI 10.1002/(SICI)1098-2302(199605)29:4<315::AID-DEV2>3.0.CO;2-T; DIAMOND A, 1985, CHILD DEV, V56, P868, DOI 10.1111/j.1467-8624.1985.tb00160.x; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; DIAMOND A, 1986, NEUR ABSTR, V12, P742; ESCALONA SK, 1982, PEDIATRICS, V70, P670; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 1999, DEV NEUROPSYCHOL, V15, P157, DOI 10.1080/87565649909540744; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; GADDES WH, 1975, BRAIN LANG, V2, P257, DOI 10.1016/S0093-934X(75)80070-8; Gioia G.A., 2000, BEHAV RATING INVENTO; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.1111/j.1467-8624.1987.tb01404.x; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Hebb DO, 1940, ARCH NEURO PSYCHIATR, V44, P421, DOI 10.1001/archneurpsyc.1940.02280080181011; HEBB DO, 1947, AM PSYCHOL, V2, P737; HUDSPETH WJ, 1992, INT J PSYCHOPHYSIOL, V12, P19, DOI 10.1016/0167-8760(92)90039-E; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; JACOBS R, 2001, CLIN NEUROPSYCHOL, V2, P101; Kelly T., 2000, CLIN NEUROPSYCHOL, V1, P38; Kennard MA, 1936, AM J PHYSIOL, V115, P138; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477; Kennard MA, 1942, ARCH NEURO PSYCHIATR, V48, P227, DOI 10.1001/archneurpsyc.1942.02290080073002; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; KOLB B, 1985, BEHAV NEUROSCI, V99, P691, DOI 10.1037/0735-7044.99.4.691; Kolb B, 1997, BEHAV BRAIN RES, V89, P61, DOI 10.1016/S0166-4328(97)00058-2; KOLB B, 1993, BEHAV NEUROSCI, V107, P799, DOI 10.1037/0735-7044.107.5.799; KOLB B, 1981, J COMP PHYSIOL PSYCH, V95, P863, DOI 10.1037/h0077849; Kolb B, 1998, BEHAV BRAIN RES, V91, P143, DOI 10.1016/S0166-4328(97)00111-3; KOLB B, 1994, BRAIN RES, V645, P85, DOI 10.1016/0006-8993(94)91641-1; KOLB B, 2002, PRINCIPLES FRONTAL L; KOLB B, 1998, NEUROSCI BIOBEHAV R, V22, P123; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; Milner B, 1974, Neurosci Res Program Bull, V12, P213; MOSHER F, 1986, PHILOS TRANSCRIPTS B, V298, P199; NASS R, 1989, BRAIN COGNITION, V9, P258, DOI 10.1016/0278-2626(89)90035-3; Northam EA, 2001, DIABETES CARE, V24, P1541, DOI 10.2337/diacare.24.9.1541; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; Pentland LM, 2000, CHILD NEUROPSYCHOL, V6, P87, DOI 10.1076/chin.6.2.87.7055; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROVET JF, 1987, DIABETES CARE, V10, P510, DOI 10.2337/diacare.10.4.510; Rutherford M A, 1997, Eur J Paediatr Neurol, V1, P13, DOI 10.1016/S1090-3798(97)80005-0; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Smibert E, 1996, BRIT J CANCER, V73, P825, DOI 10.1038/bjc.1996.145; Stuss DT, 2002, PRINCIPLES FRONTAL L; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; THATCHER R, 1997, DEV PREFRONTAL CORTE; VarghaKhadem F, 1997, BRAIN, V120, P159, DOI 10.1093/brain/120.1.159; VARGHAKHADEM F, 1985, BRAIN, V108, P677, DOI 10.1093/brain/108.3.677; VARGHAKHADEM F, 1994, J CHILD NEUROL, V9, pS67; Webb SJ, 2001, DEV NEUROPSYCHOL, V19, P147, DOI 10.1207/S15326942DN1902_2; WECHSLER D, 1991, MANUAL WECHSLER SCAL, V3; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	86	57	59	0	26	ELSEVIER MASSON, CORP OFF	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	AUG	2007	43	6					792	805		10.1016/S0010-9452(08)70507-0			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	194VG	WOS:000248371300012	17710830				2021-06-18	
J	Jacobson, I; Tegner, Y				Jacobson, I.; Tegner, Y.			Injuries among Swedish female elite football players: a prospective population study	SCANDINAVIAN JOURNAL OF MEDICINE & SCIENCE IN SPORTS			English	Article						soccer; sport injuries; women; injury incidence	SOCCER INJURIES; EUROPEAN FOOTBALL; MENSTRUAL-CYCLE; RISK-FACTORS; IMPACT; SYMPTOMS; HISTORY; OUTDOOR; BRAIN; HEAD	Injury occurrence in all 12 female elite senior football teams in premiere league was registered during 1 year. Of 269 players, 129 (48%) sustained 237 injuries. The total injury incidence was 4.6/1000 h of football. The injury incidence during practice was 2.7 and during the game time was 13.9/1000 h. The highest injury incidence during practice was to the knee (0.8/1000 h) and thigh (0.5/1000 h), and during game time was to the knee (4.4/1000 h) and head (2.2/1000 h). In total, the location for the highest injury incidence was the knee with 1.5 injuries/1000 h of football. The majority of injuries (82%) were localized to the lower extremities. Sixty-six injuries (28%) were re-occurring injuries (re-injuries). The incidence of traumatic injuries was 3.3/1000 h of football and for overuse injuries 1.3/1000 h. Overuse injuries occurred mainly during the preseason and at the beginning of the spring season. Thirty-nine percent of the injuries were slight or minor causing absence from practice or game time of less than 1 week, 39% were moderate (absence 7-28 days) and 22% were major (absence more than 28 days). The major injuries occurred often owing to trauma and were mainly to the knee.	Lulea Univ Technol, Inst Hlth Sci, S-96136 Boden, Sweden	Jacobson, I (corresponding author), Lulea Univ Technol, Inst Hlth Sci, S-96136 Boden, Sweden.	inger.jacobson@ltu.se		Tegner, Yelverton/0000-0003-3628-0705			ANDREASEN I, 1992, SCAND J MED SCI SPOR, P62; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BACKOUS DD, 1988, AM J DIS CHILD, V142, P839, DOI 10.1001/archpedi.1988.02150080045019; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BENKIBLER W, 1993, MED SCI SPORT EXER, V25, P1330; BRYNHILDSEN J, 1990, INT J SPORTS MED, V11, P489, DOI 10.1055/s-2007-1024843; Brynhildsen J, 1997, ACTA OBSTET GYN SCAN, V76, P873, DOI 10.3109/00016349709024368; Brynhildsen JO, 1997, SCAND J MED SCI SPOR, V7, P348; Chomiak J, 2000, AM J SPORT MED, V28, pS58; Dvorak J, 2000, AM J SPORT MED, V28, pS69; Dvorak J, 2000, AM J SPORT MED, V28, pS3; EKSTRAND J, 1983, AM J SPORT MED, V11, P63, DOI 10.1177/036354658301100203; Ekstrand J, 2004, SCAND J MED SCI SPOR, V14, P34, DOI 10.1111/j.1600-0838.2003.00330.x; Ekstrand J, 2003, SCAND J MED SCI SPOR, V13, P147, DOI 10.1034/j.1600-0838.2003.00129.x; EKSTRAND J, 1983, MED SCI SPORT EXER, V15, P267, DOI 10.1249/00005768-198315030-00014; EKSTRAND J, 1982, THESIS LINKOPING U L; ENGSTROM B, 1990, AM J SPORT MED, V18, P101, DOI 10.1177/036354659001800118; ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408; Hagglund M, 2003, SCAND J MED SCI SPOR, V13, P364, DOI 10.1046/j.1600-0838.2003.00327.x; HOFF GL, 1986, AM J SPORT MED, V14, P231, DOI 10.1177/036354658601400309; INKLAAR H, 1994, SPORTS MED, V18, P81, DOI 10.2165/00007256-199418020-00002; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Junge A, 2000, AM J SPORT MED, V28, pS40; Junge A, 2000, AM J SPORT MED, V28, pS16; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; MAEHLUM S, 1986, PHYSICIAN SPORTSMED, V14, P73, DOI 10.1080/00913847.1986.11709124; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MOLLERNIELSEN J, 1989, MED SCI SPORT EXER, V21, P126; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; NIELSEN JM, 1991, SPORTS MED, V12, P152, DOI 10.2165/00007256-199112030-00002; Nilsson S, 1978, Am J Sports Med, V6, P358, DOI 10.1177/036354657800600608; Ostenberg A, 2000, SCAND J MED SCI SPOR, V10, P279, DOI 10.1034/j.1600-0838.2000.010005279.x; Peterson L, 2000, AM J SPORT MED, V28, pS51; Poulsen T D, 1991, Br J Sports Med, V25, P151; ROOS H, 1995, ACTA ORTHOP SCAND, V66, P107, DOI 10.3109/17453679508995501; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109	43	57	59	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-7188	1600-0838		SCAND J MED SCI SPOR	Scand. J. Med. Sci. Sports	FEB	2007	17	1					84	91		10.1111/j.1600-0838.2006.00524.x			8	Sport Sciences	Sport Sciences	118SY	WOS:000242963200012	17305943	Green Published, Bronze			2021-06-18	
J	Mannion, RJ; Cross, J; Bradley, P; Coles, JP; Chatfield, D; Carpenter, A; Pickard, JD; Menon, DK; Hutchinson, PJ				Mannion, Richard J.; Cross, Justin; Bradley, Peter; Coles, Jonathan P.; Chatfield, Doris; Carpenter, Adrian; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.			Mechanism-based MRI classification of traumatic brainstem injury and its relationship to outcome	JOURNAL OF NEUROTRAUMA			English	Article						brainstem; injury; MRI; outcome; traumatic	SEVERE HEAD-INJURY; PROGNOSIS	While computed tomography (CT) is the appropriate technique for the urgent detection of hematomas and contusions in the cerebral hemispheres, it is much less effective at documenting diffuse injury and posterior fossa lesions, and is therefore only partially predictive of outcome. More recently, magnetic resonance imaging (MRI) has been used, particularly to examine posterior fossa structures, but the relationship between brainstem injury and outcome is unclear and the types of brainstem injury are poorly understood. The aim of this study was to use acute MRI to examine the types of brainstem injury following severe traumatic brain injury (TBI) and their relationship to supratentorial injury. We also aimed to correlate these findings with outcome at 6 months (Glasgow Outcome Scale [GOS] score). Forty-six patients (mean age, 34 years, range, 16-70 years; 76% male) admitted to a regional neurocritical care unit with TBI requiring ventilation underwent CT and MRI (T2, FLAIR, gradient echo) scanning within 3 days (median, I day) of injury. GOS was ascertained by outpatient interview. Brainstem lesions were detected in 13 patients by MRI, only two of which were detected by CT. Eleven out of 13 patients with brainstem injury had an unfavorable outcome (death, vegetative state, or severe disability), of whom five died. Of the 33 patients without brainstem lesions, 18 had an unfavorable outcome, of whom four died. The direct relationship between brainstem lesions and unfavorable outcome was statistically significant (p < 0.05, chisquared test). With regard to supratentorial injury, all but two brainstem lesions were seen either in the context of severe diffuse axonal injury or a significant mass lesion, and all of these patients had a poor outcome. However, the two patients with brainstem injury and good outcome had relatively few supratentorial abnormalities. From these observations, we have devised a simple classification system that is useful clinically and has potential associations with outcome. Poor prognosis is common following major TBI but is more common in those with brainstem injury. However, brainstem injury is not an absolute indicator of poor outcome. Understanding the anatomy and extent of brainstem injury, as well as its relationship to supratentorial abnormalities, will facilitate a more accurate use of early MRI as a prognostic tool and assist in the counseling of families.	Addenbrookes Hosp, NHS Trust, Wolfson Brain Injury Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Fdn Trust, Dept Acad Neurosurg, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Fdn Trust, Dept Anaesthet, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Fdn Trust, Dept Radiol, Cambridge CB2 2QQ, England	Mannion, RJ (corresponding author), Addenbrookes Hosp, NHS Trust, Wolfson Brain Injury Unit, Box 166,Hills Rd, Cambridge CB2 2QQ, England.	richard.mannion@nhs.net			Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0600986, G0601025, G9439390] Funding Source: Medline		Aguas J, 2005, NEUROCIRUGIA, V16, P14; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; GENNARELLI TA, 2003, J EMERG MED S, V1, P5; Gerber DJ, 2004, BRAIN INJURY, V18, P1083, DOI 10.1080/02699050410001672341; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Wedekind C, 2002, BRIT J NEUROSURG, V16, P256, DOI 10.1080/02688690220148842; Woischneck D, 2003, CHILD NERV SYST, V19, P174, DOI 10.1007/s00381-002-0703-z	15	57	63	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					128	135		10.1089/neu.2006.0127			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100012	17263676				2021-06-18	
J	Piazza, O; Storti, MP; Cotena, S; Stoppa, F; Perrotta, D; Esposito, G; Pirozzi, N; Tufano, R				Piazza, O.; Storti, M. P.; Cotena, S.; Stoppa, F.; Perrotta, D.; Esposito, G.; Pirozzi, N.; Tufano, R.			S100B is not a reliable prognostic index in paediatric TBI	PEDIATRIC NEUROSURGERY			English	Article						traumatic brain injury, children; S100B; traumatic brain injury, prognosis	NEURON-SPECIFIC-ENOLASE; TRAUMATIC BRAIN-INJURY; SERUM S100B; CARDIAC-ARREST; HEAD TRAUMA; PROTEIN; CHILDREN; RELEASE; MARKER; S-100B	Background: As far as paediatric traumatic brain injury is concerned, it is difficult to quantify the extent of the primary insult, to monitor secondary changes and to predict neurological outcomes by means of the currently used diagnostic tools: physical examination, Glasgow Coma Scale (GCS) score and computed tomography. For this reason, several papers focused on the use of biochemical markers (S100B, neuron-specific enolase) to detect and define the severity of brain damage and predict outcome after traumatic head injury or cardiac arrest. Objective: The aim of this paper is measuring the range of S100B serum concentrations in children affected by traumatic brain injury and describing the possible roles of this protein in the reaction to trauma. Methods: Fifteen children aged 1-15 years were included in the study. Traumatic brain injury severity was defined by paediatric GCS score as mild (9 patients), moderate (2 patients) or severe (4 patients). Blood samples for S100B serum measurement were taken at emergency department admission and after 48 h. Results: The serum S100B concentration was higher in the group of severe trauma patients, who scored the lowest on the GCS at admission, and among them, the highest values were reported by the children with concomitant peripheral lesions. Conclusions: The role of S100B in paediatric traumatic brain injury has not been clarified yet, and the interpretation of its increase when the head trauma is associated with other injuries needs the understanding of the physiopathological mechanisms that rule its release in the systemic circulation. The levels of S100B in serum after a brain injury could be related to the mechanical discharge from a destroyed blood-brain barrier, or they could be due to the active expression by the brain, as a part of its involvement in the systemic inflammatory reaction. Early increase of this protein is not a reliable prognostic index of neurological outcome after pediatric traumatic brain injury, since even very elevated values are compatible with a complete neurological recovery. Copyright (C) 2007 S. Karger AG, Basel.	Univ Naples Federico II, IT-80131 Naples, Italy; IRCCS G Pascale, Dept Clin Pathol, Naples, Italy; Bambino Gesu Pediat Hosp, Emergency Dept, Rome, Italy	Cotena, S (corresponding author), Univ Naples Federico II, Via Pansini 5, IT-80131 Naples, Italy.	si_mi@inwind.it	Piazza, Ornella/Q-2716-2019; Piazza, Ornella/G-5339-2012	Piazza, Ornella/0000-0002-0316-5930			Abdul-Khaliq H, 2003, RESTOR NEUROL NEUROS, V21, P141; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bemana I, 1997, ACT NEUR S, V70, P194; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Cecchetti C, 2003, Minerva Anestesiol, V69, P907; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Guan Wei, 2003, Chin J Traumatol, V6, P218; HUANG W, 2001, CHIN J TRAUMATOL, V41, P161; Ikeda Y, 1997, ACTA NEUROCHIR, V139, P1173, DOI 10.1007/BF01410978; ISPIDA K, 2003, J CARDIOTHOR VASC AN, V17, P4; Kagawa M, 1996, J NEUROTRAUM, V13, P273, DOI 10.1089/neu.1996.13.273; KOCHANEK PM, 2002, YB INTENSIVE CARE EM, P688; Koide Masaaki, 2002, Jpn J Thorac Cardiovasc Surg, V50, P280; Li YK, 2000, J NEUROCHEM, V74, P143; Liu L, 2005, J NEUROCHEM, V92, P546, DOI 10.1111/j.1471-4159.2004.02909.x; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Maschmann J, 2000, ACTA PAEDIATR, V89, P553, DOI 10.1080/080352500750027844; McKeating EG, 1998, ACT NEUR S, V71, P117; Missler U, 1999, CLIN CHEM, V45, P138; Mrak RE, 2001, NEUROBIOL AGING, V22, P915, DOI 10.1016/S0197-4580(01)00293-7; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nagdyman N, 2001, PEDIATR RES, V49, P502, DOI 10.1203/00006450-200104000-00011; Ozatik MA, 2002, PERFUSION-UK, V17, P335, DOI 10.1191/0267659102pf597oa; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Piazza O, 2005, Minerva Chir, V60, P477; PIAZZA O, 2006, ACUTE PAIN, V8, P87; Pietrini D, 2004, Minerva Anestesiol, V70, P549; Sahlein DH, 2003, NEUROSURGERY, V53, P1243, DOI 10.1227/01.NEU.0000093493.16850.11; Sheng JG, 1996, NEUROBIOL AGING, V17, P761; Snyder-Ramos SA, 2004, ANAESTHESIA, V59, P344, DOI 10.1111/j.1365-2044.2004.03663.x; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Verdu A, 2001, REV NEUROLOGIA, V32, P714, DOI 10.33588/rn.3208.2000582; Whitelaw A, 2001, ARCH DIS CHILD-FETAL, V84, pF90, DOI 10.1136/fn.84.2.F90; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; YANG Y, 2002, CHIN J TRAUMATOL ENG, V5, P529	43	57	57	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.		2007	43	4					258	264		10.1159/000103304			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	190PQ	WOS:000248071700002	17627141				2021-06-18	
J	Ardeshiri, A; Kelley, MH; Korner, IP; Hurn, PD; Herson, PS				Ardeshiri, A.; Kelley, M. H.; Korner, I. P.; Hurn, P. D.; Herson, P. S.			Mechanism of progesterone neuroprotection of rat cerebellar Purkinje cells following oxygen-glucose deprivation	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						allopregnanolone; excitotoxicity; GABA(A) receptor; ischemia	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; NEURONAL DAMAGE; CARDIAC-ARREST; GRANULE CELLS; IN-VIVO; ISCHEMIA; DEATH; ALLOPREGNANOLONE; CURRENTS	The survival of rat Purkinje cell (PCs) cerebellar cultures was used to test the hypothesis that progesterone is protective against oxygen-glucose deprivation through potentiation of GABA(A) receptor activity. Electrophysiological recordings confirm that PCs develop robust excitatory and inhibitory synapses in culture. Exposure of cultured PCs to increasing concentrations of progesterone during oxygen-glucose deprivation revealed a concentration-dependent protection by progesterone, with significant protection observed at physiological concentrations, as low as 10 nM. The concurrent application of the GABA(A) receptor antagonist picrotoxin (100 mu M) completely abolished the neuroprotection afforded by progesterone, indicating that progesterone is neuroprotective through activation of GABA(A) receptors. Progesterone potentiates GABA(A) receptor activity indirectly through its metabolites, such as allopregnanolone (ALLO). Therefore, ALLO was applied to PC cultures and was observed to produce significant protection at all concentrations tested, from 10 to 1000 nM. Finally, the inhibition of progesterone metabolism with finasteride abolished the protection afforded by progesterone without having any effect on the neuroprotection caused by ALLO. These data indicate that progesterone protects cerebellar PCs at physiological concentrations through a GABA-active metabolite.	Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97201 USA	Herson, PS (corresponding author), Oregon Hlth Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS058792-01A1, 1 R21 NS052591, R21 NS052591-02, R21 NS052591, R01 NS058792] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058792, R21NS052591] Funding Source: NIH RePORTER		BAIMBRIDGE KG, 1982, BRAIN RES, V245, P223, DOI 10.1016/0006-8993(82)90804-6; Barakat L, 2002, J PHYSIOL-LONDON, V541, P753, DOI 10.1113/jphysiol.2001.015834; Beaman-Hall CM, 1998, J NEUROCHEM, V71, P1993; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; BRASKO J, 1995, BRAIN RES, V699, P133, DOI 10.1016/0006-8993(95)01015-N; BRORSON JR, 1994, J NEUROSCI, V14, P187; BUTCHER RL, 1974, ENDOCRINOLOGY, V94, P1704, DOI 10.1210/endo-94-6-1704; Caesar K, 2003, P NATL ACAD SCI USA, V100, P16000, DOI 10.1073/pnas.2635195100; Celotti F, 1997, BRAIN RES BULL, V44, P365, DOI 10.1016/S0361-9230(97)00216-5; CELOTTI F, 1992, FRONT NEUROENDOCRIN, V13, P163; Cervantes M, 2002, ARCH MED RES, V33, P6, DOI 10.1016/S0188-4409(01)00347-2; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Fonnum F, 2000, TOXICOL LETT, V112, P9, DOI 10.1016/S0378-4274(99)00246-5; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Gonzalez-Vidal MD, 1998, ARCH MED RES, V29, P117; GRUOL DL, 1983, BRAIN RES, V263, P223, DOI 10.1016/0006-8993(83)90315-3; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; HIRANO T, 1986, P NATL ACAD SCI USA, V83, P4957, DOI 10.1073/pnas.83.13.4957; HIRANO T, 1993, J NEUROPHYSIOL, V70, P1316; HORN M, 1992, ACTA NEUROPATHOL, V85, P79, DOI 10.1007/BF00304636; Jiang N, 1996, BRAIN RES, V735, P101, DOI 10.1016/0006-8993(96)00605-1; KONNERTH A, 1990, P NATL ACAD SCI USA, V87, P2662, DOI 10.1073/pnas.87.7.2662; LIEB K, 1995, EXP NEUROL, V134, P222, DOI 10.1006/exnr.1995.1052; LINDEN DJ, 1991, NEURON, V7, P81, DOI 10.1016/0896-6273(91)90076-C; LIU M, 2006, IN PRESS J CEREB BLO; LIU M, 2004, PHARM CEREBRAL ISCHE; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Mellon SH, 2001, INT REV NEUROBIOL, V46, P33; Morali G, 2005, NEUROSCI LETT, V382, P286, DOI 10.1016/j.neulet.2005.03.066; Murphy SJ, 2002, J CEREBR BLOOD F MET, V22, P1181; NEQUIN LG, 1979, BIOL REPROD, V20, P659, DOI 10.1095/biolreprod20.3.659; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Sarna JR, 2003, PROG NEUROBIOL, V70, P473, DOI 10.1016/S0301-0082(03)00114-X; SATO M, 1990, ACTA NEUROPATHOL, V80, P527, DOI 10.1007/BF00294614; Sayeed I, 2006, ANN EMERG MED, V47, P381, DOI 10.1016/j.annemergmed.2005.12.011; Schwartz-Bloom RD, 2001, J NEUROCHEM, V77, P353, DOI 10.1046/j.1471-4159.2001.00274.x; Slemmer JE, 2005, PROG BRAIN RES, V148, P367, DOI 10.1016/S0079-6123(04)48029-7; Southan AP, 1998, BRIT J PHARMACOL, V125, P1375, DOI 10.1038/sj.bjp.0702218; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Stoffel-Wagner B, 2001, EUR J ENDOCRINOL, V145, P669, DOI 10.1530/eje.0.1450669; Trouillas P, 1997, J NEUROL SCI, V145, P205, DOI 10.1016/S0022-510X(96)00231-6; Tsutsui K, 2003, CEREBELLUM, V2, P215, DOI 10.1080/14734220310016169; Welsh JP, 2002, ADV NEUROL, V89, P331; Yamashita A, 2006, NEUROSCI RES, V55, P264, DOI 10.1016/j.neures.2006.03.007	53	57	62	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	NOV	2006	24	9					2567	2574		10.1111/j.1460-9568.2006.05142.x			8	Neurosciences	Neurosciences & Neurology	104JA	WOS:000241953500014	17100844	Green Accepted			2021-06-18	
J	Meares, S; Shores, EA; Batchelor, J; Baguley, IJ; Chapman, J; Gurka, J; Marosszeky, JE				Meares, Susanne; Shores, E. Arthur; Batchelor, Jennifer; Baguley, Ian J.; Chapman, Jennifer; Gurka, Joseph; Marosszeky, Jeno E.			The relationship of psychological and cognitive factors and opioids in the development of the postconcussion syndrome in general trauma patients with mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain concussion; head injury; minor; neuropsychological; acute stress disorder; narcotic	ACUTE STRESS DISORDER; POST-CONCUSSION SYMPTOMS; HEAD-INJURY; SCALE; QUESTIONNAIRE; SENSITIVITY; COMPLAINTS; CRITERIA; MODERATE; TIME	The relationship of psychological and cognitive factors in the development of the postconcussion syndrome (PCS) following mild uncomplicated traumatic brain injury (mTBI) has received little study. This may be because of the widely held belief that neurological factors are the cause of early PCS symptoms, whereas psychological factors are responsible for enduring symptoms. To further understand these relationships, the association between PCS and neuropsychological and psychological outcome was investigated in 122 general trauma patients, many of whom had orthopedic injuries, around 5 days following mTBI. Apart from verbal fluency, participants with a PCS did not differ in their performances on neuropsychological measures compared to those without a PCS. Individuals with a PCS reported significantly more psychological symptoms. Large effect sizes present on the psychological measures showed that the difference between participants with a PCS and without was greater on psychological than on neuropsychological measures. Analyses also revealed a relationship between opioid analgesia and depression, anxiety and stress, and opioids and reduced learning. The results suggest,that psychological factors are present much earlier than has previously been considered in the development of the PCS.	Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia; Westmead Hosp, Dept Rehabil Med, Westmead, NSW, Australia	Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	ashores@psy.mq.edu.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Batchelor, Jennifer/0000-0003-4438-4993; Meares, Susanne/0000-0002-3859-9974; Shores, Edwin A/0000-0003-1553-5131			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Axelrod BN, 1998, ARCH CLIN NEUROPSYCH, V13, P543, DOI 10.1016/S0887-6177(97)00044-9; Axelrod BN, 1996, PSYCHOL ASSESSMENT, V8, P422, DOI 10.1037/1040-3590.8.4.422; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; BARONA A, 1986, INT J CLIN NEUROPSYC, V8, P169; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1991, BRIT J PSYCHIAT, V159, P860, DOI 10.1192/bjp.159.6.860; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cartlidge N E, 1981, HEAD INJURY; Cattelani R, 1996, BRAIN INJURY, V10, P187, DOI 10.1080/026990596124502; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dubois B, 2000, NEUROLOGY, V55, P1621, DOI 10.1212/WNL.55.11.1621; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HORN GJ, 1996, DISS ABSTR INT, V56, P4583; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; KAOUA BN, 2002, J CLIN EXPT NEUROPSY, V24, P713; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIDVALL H F, 1974, Acta Neurologica Scandinavica Supplementum, V50, P1; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCauley SR, 2001, J NEUROL NEUROSUR PS, V71, P643, DOI 10.1136/jnnp.71.5.643; Melzack R., 2001, HDB PAIN ASSESSMENT; MILLER EN, 1999, CALCAP CALIFORNIA CO; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; RUTHERFORD WH, 1989, MILD HEAD INJURY; Shores E A, 1995, Appl Neuropsychol, V2, P167; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WADDELL PA, 1984, ACTA NEUROL SCAND, V69, P270, DOI 10.1111/j.1600-0404.1984.tb07812.x; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; *WHO, 1993, ICD10 CLASS MENT BEH; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zacny JP, 1995, EXP CLIN PSYCHOPHARM, V3, P432, DOI 10.1037/1064-1297.3.4.432; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	78	57	57	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2006	12	6					792	801		10.1017/S1355617706060978			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	104CA	WOS:000241932300004	17064443				2021-06-18	
J	Conde, JR; Streit, WJ				Conde, Jessica R.; Streit, Wolfgang J.			Effect of aging on the microglial response to peripheral nerve injury	NEUROBIOLOGY OF AGING			English	Article						microglia; aging; senescence; facial nerve axotomy; microglial proliferation; H-3-thymidine; programmed cell death; TUNEL	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; FACIAL-NERVE; AGED RATS; FOOD RESTRICTION; CEREBRAL-CORTEX; ADVANCING AGE; SPINAL-CORD; CELLS; ACTIVATION	Microglial morphology and immunophenotype have been studied extensively in aging-related neurodegenerative diseases, but to a lesser extent in the normally aged CNS, and little is known about how aging affects the ability of microglia to respond to neuronal injury. The goal of the current study was to determine if aging affects the ability of microglia to divide during the early response to facial nerve axotomy. In addition, we investigated the incidence of microglial cell death during later post-axotomy time points to determine if aging had an effect on microglial turnover. We employed DNA labeling with H-3-thymidine, TUNEL and lectin histochemistry after facial nerve axotomy in young (3 months), middle-aged (15 months), and old (30 months) Fisher344-Brown Norway hybrid rats. Proliferation of microglia in old rats remained significantly higher than in young rats 4 days after injury, suggesting that regulation of microglial proliferation changes with aging. There was no aging-related difference in microglial TUNEL staining at 7, 14 or 21 days post-axotomy. Lectin histochemistry in the unoperated facial nucleus revealed aging-related morphological changes in resting microglia, including hypertrophy of the cytoplasm with dense perinuclear staining. Aging-related differences in activated microglia on the lesioned side were more subtle, although many activated microglia of aged animals continued to exhibit dense perinuclear lectin reactivity. We propose that aging-related changes in morphology in conjunction with a less regulated proliferative response in the aged facial nucleus may be a reflection of microglial senescence. (c) 2005 Elsevier Inc. All rights reserved.	Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA	Streit, WJ (corresponding author), Univ Florida, Coll Med, Dept Neurosci, McKnight Brain Inst, POB 100244, Gainesville, FL 32610 USA.	jconde@ufl.edu; streit@mbi.ufl.edu			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG023665] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 023665] Funding Source: Medline		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Badan I, 2003, J CEREBR BLOOD F MET, V23, P845, DOI 10.1097/01.WCB.0000071883.63724.A7; BARRON KD, 1990, BRAIN RES, V523, P219, DOI 10.1016/0006-8993(90)91490-8; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Cammermeyer J, 1965, Ergeb Anat Entwicklungsgesch, V38, P1; Chen SZ, 2002, J NEUROIMMUNOL, V133, P46, DOI 10.1016/S0165-5728(02)00354-5; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; DELRIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P489; DiPatre PL, 1997, J NEUROPATH EXP NEUR, V56, P143, DOI 10.1097/00005072-199702000-00004; GEHRMANN J, 1995, J NEUROPATH EXP NEUR, V54, P680, DOI 10.1097/00005072-199509000-00010; Gong Y, 2004, STROKE, V35, P2571, DOI 10.1161/01.STR.0000145485.67827.d0; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hurley SD, 2003, NEUROBIOL AGING, V24, P511, DOI 10.1016/S0197-4580(02)00097-0; Jones LL, 1997, J NEUROCYTOL, V26, P755, DOI 10.1023/A:1018514415073; JORDAN FL, 1988, BRAIN RES REV, V13, P165, DOI 10.1016/0165-0173(88)90019-7; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; Kim KY, 2004, NEUROBIOL AGING, V25, P491, DOI 10.1016/j.neurobiolaging.2003.07.005; KREUTZBERG GW, 1966, ACTA NEUROPATHOL, V7, P149, DOI 10.1007/BF00686781; KREUTZBERG GW, 1968, ACTA NEUROPATH BER S, V4, P141; Kullberg S, 2001, BRAIN RES, V899, P169, DOI 10.1016/S0006-8993(01)02222-3; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Morgan TE, 1997, FREE RADICAL BIO MED, V23, P524, DOI 10.1016/S0891-5849(97)00120-2; Morgan TE, 1999, NEUROSCIENCE, V89, P687, DOI 10.1016/S0306-4522(98)00334-0; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; OGURA K, 1994, NEUROREPORT, V5, P1224, DOI 10.1097/00001756-199406020-00016; Peinado MA, 1998, MICROSC RES TECHNIQ, V43, P34, DOI 10.1002/(SICI)1097-0029(19981001)43:1<34::AID-JEMT6>3.0.CO;2-G; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Peters A, 2002, CEREB CORTEX, V12, P27, DOI 10.1093/cercor/12.1.27; RAIVICH G, 1993, J HISTOCHEM CYTOCHEM, V41, P579, DOI 10.1177/41.4.8450197; Raivich Gennadij, 2002, P166; Rogers J, 2002, GLIA, V40, P260, DOI 10.1002/glia.10153; Rozovsky I, 1998, NEUROBIOL AGING, V19, P97, DOI 10.1016/S0197-4580(97)00169-3; Sheffield LG, 1998, NEUROBIOL AGING, V19, P47, DOI 10.1016/S0197-4580(97)00168-1; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Sloane JA, 1999, NEUROBIOL AGING, V20, P395, DOI 10.1016/S0197-4580(99)00066-4; Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; Streit WJ, 2005, BRAIN RES REV, V48, P234, DOI 10.1016/j.brainresrev.2004.12.013; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; Streit WJ, 2004, J NEUROSCI RES, V77, P1, DOI 10.1002/jnr.20093; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Streppel M, 1998, NEUROBIOL AGING, V19, P83, DOI 10.1016/S0197-4580(97)00163-2; Strohmeyer R, 2001, J ALZHEIMERS DIS, V3, P131, DOI 10.3233/JAD-2001-3118; Stuesse SL, 2000, NEUROSCI LETT, V287, P121, DOI 10.1016/S0304-3940(00)01142-3; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; SVENSSON M, 1994, J ANAT, V185, P537; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Tseng GF, 1996, BRAIN RES, V715, P32, DOI 10.1016/0006-8993(95)01418-7; VAUGHAN DW, 1974, J NEUROCYTOL, V3, P405, DOI 10.1007/BF01098730; VAUGHAN DW, 1990, ANAT REC, V228, P211, DOI 10.1002/ar.1092280212; VAUGHAN DW, 1992, J COMP NEUROL, V323, P219, DOI 10.1002/cne.903230207	55	57	57	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	OCT	2006	27	10					1451	1461		10.1016/j.neurobiolaging.2005.07.012			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	084MN	WOS:000240537200012	16159684				2021-06-18	
J	Hang, CH; Chen, G; Shi, JX; Zhang, X; Li, JS				Hang, Chun-Hua; Chen, Gang; Shi, Ji-Xin; Zhang, Xin; Li, Jing-Song			Cortical expression of nuclear factor kappa B after human brain contusion	BRAIN RESEARCH			English	Article						traumatic brain injury; NF-kappa B; cerebral inflammation; human	TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; RAT-BRAIN; UP-REGULATION; FACTOR-ALPHA; INJURY; ACTIVATION; NEURONS; NEUROPROTECTION; INFLAMMATION	The aim of current study was to analyze the binding activity and the temporal and cellular expression of nuclear factor kappa B (NF-kappa B) in human contused brain. Eighteen contused brain samples were obtained from 17 patients undergoing surgery for brain contusions 5-80 h after trauma. NF-kappa B binding activity was detected by electrophoretic mobility shift assay (EMSA), and temporal and cellular expression of NF-kappa B subunits p65 and p50 was analyzed by immunohistochemistry. The results showed that a progressive upregulation of NF-kappa B activity occurred in the area surrounding the injured brain with the time from brain trauma to operation. The maximal expression of NF-kappa B was detected after 48 h postinjury. The expression of NF-kappa B p65 was mainly located at glial and vascular endothelial cells without expression at neurons. The expression of NF-kappa B p50 was mainly located at glial cells, a little at neurons and no expression at vascular endothelial cells. Within 24 h postinjury, both NF-kappa B p65 and p50 immunoreactivity was mainly observed in the nucleus of cells. After 24 h postinjury, NF-kappa B p65 labeling was found in the both nucleus and cytoplasm of glial and endothelial cells; otherwise, p50 labeling was primarily found in the nucleus of glial cells and in the nucleus, cytoplasm and process of neurons. It is concluded that NF-kappa B could be highly upregulated at human contused brain and the cellular pattern of p65 and p50 expression might be closely associated with the cell functions. (c) 2006 Elsevier B.V. All rights reserved.	Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, Nanjing 210002, Jiangsu Prov, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hang1965@public1.ptt.js.cn		Chen, Gang/0000-0002-0758-1907			Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Beauparlant Pierre, 1996, Cytokine and Growth Factor Reviews, V7, P175, DOI 10.1016/1359-6101(96)00020-2; Bonetti B, 1999, AM J PATHOL, V155, P1433, DOI 10.1016/S0002-9440(10)65456-9; Clemens JA, 1997, STROKE, V28, P1073, DOI 10.1161/01.STR.28.5.1073; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; KALTSCHMIDT C, 1994, J NEUROIMMUNOL, V55, P99, DOI 10.1016/0165-5728(94)90151-1; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nomoto Y, 2001, NEUROSURGERY, V48, P158, DOI 10.1097/00006123-200101000-00027; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pennypacker KR, 2001, EXP NEUROL, V172, P307, DOI 10.1006/exnr.2001.7817; SALMINEN A, 1995, BIOCHEM BIOPH RES CO, V212, P939, DOI 10.1006/bbrc.1995.2060; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; SELMAJ KW, 1990, J IMMUNOL, V144, P129; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Taglialatela G, 1997, J NEUROSCI RES, V47, P155; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	32	57	58	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 13	2006	1109						14	21		10.1016/j.brainres.2006.06.045			8	Neurosciences	Neurosciences & Neurology	086ZP	WOS:000240712100002	16857176				2021-06-18	
J	Milders, M; Ietswaart, M; Crawford, JR; Currie, D				Milders, Maarten; Ietswaart, Magdalena; Crawford, John R.; Currie, David			Impairments in theory of mind shortly after traumatic brain injury and at 1-year follow-up	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; theory of mind; executive function; recovery; follow-up	CLOSED-HEAD INJURY; SOCIAL COGNITION; PSYCHOSOCIAL ADJUSTMENT; FRONTOTEMPORAL DEMENTIA; LANGUAGE IMPAIRMENT; ACQUIRED THEORY; CHILDREN; PERFORMANCE; DISEASE; BELIEF	Most studies into acquired theory of mind (ToM) deficits assessed patients once, long after the onset of brain injury. As a result, the time course of acquired ToM impairments is largely unknown. The present study examined whether ToM impairments following traumatic brain injury (TBI) recover, remain stable, or worsen over time. Because of the alleged association between ToM and social communication, ToM impairments may deteriorate because of changes in patients' social environment following injury, ToM ability and executive functioning were assessed shortly after injury and at I-year follow-up. Compared with the orthopedic control group, the TBI group was impaired on ToM and executive functioning tasks at both assessments. Furthermore, the ToM impairments in the TBI group remained stable over time.	Univ Aberdeen, Sch Psychol, Aberdeen AB24 2UB, Scotland; Aberdeen Royal Infirm, Dept Neurosurg, Aberdeen, Scotland	Milders, M (corresponding author), Univ Aberdeen, Sch Psychol, Aberdeen AB24 2UB, Scotland.	m.milders@abdn.ac.uk	Crawford, John R/A-4165-2008; Milders, Maarten/C-5560-2008	Crawford, John R/0000-0003-3403-3428; Ietswaart, Magdalena/0000-0003-4576-9393			Bach LJ, 2000, COGN NEUROPSYCHIATRY, V5, P175, DOI DOI 10.1080/13546800050083520; BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Braun C M, 1989, Brain Inj, V3, P345, DOI 10.3109/02699058909004559; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Carlson SM, 2004, DEV PSYCHOL, V40, P1105, DOI 10.1037/0012-1649.40.6.1105; Channon S, 2005, BRAIN LANG, V93, P123, DOI 10.1016/j.bandl.2004.09.002; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; DOWNES JJ, 1993, BRAIN, V116, P887, DOI 10.1093/brain/116.4.887; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gregory C, 2002, BRAIN, V125, P752, DOI 10.1093/brain/awf079; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; LEEKAM SR, 1991, COGNITION, V40, P203, DOI 10.1016/0010-0277(91)90025-Y; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Martin I, 2003, BRAIN LANG, V85, P451, DOI 10.1016/S0093-934X(03)00070-1; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 1999, BRAIN LANG, V68, P486, DOI 10.1006/brln.1999.2124; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Miller CA, 2004, INT J LANG COMM DIS, V39, P191, DOI 10.1080/13682820310001616994; OZONOFF S, 1995, J AUTISM DEV DISORD, V25, P415, DOI 10.1007/BF02179376; Perner J, 1999, TRENDS COGN SCI, V3, P337, DOI 10.1016/S1364-6613(99)01362-5; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Samson D, 2004, NAT NEUROSCI, V7, P499, DOI 10.1038/nn1223; Sarfati Y, 2000, PSYCHOPATHOLOGY, V33, P246, DOI 10.1159/000029153; Shallice, 1997, HAYLING BRIXTON TEST; Siegal M, 1996, BRAIN LANG, V53, P40, DOI 10.1006/brln.1996.0035; Snowden JS, 2003, NEUROPSYCHOLOGIA, V41, P688, DOI 10.1016/S0028-3932(02)00221-X; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; Surian L, 2001, BRAIN LANG, V78, P224, DOI 10.1006/brln.2001.2465; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Wechsler D., 1998, MANUAL WECHSLER ADUL; Ziatas K, 1998, J CHILD PSYCHOL PSYC, V39, P755, DOI 10.1017/S0021963098002510	43	57	58	0	19	AMER PSYCHOLOGICAL ASSOC/EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	2006	20	4					400	408		10.1037/0894-4105.20.4.400			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	066SQ	WOS:000239250800002	16846258				2021-06-18	
J	Keenan, HT; Runyan, DK; Nocera, M				Keenan, HT; Runyan, DK; Nocera, M			Child outcomes and family characteristics 1 year after severe inflicted or noninflicted traumatic brain injury	PEDIATRICS			English	Article						traumatic brain injury; child abuse; outcomes; shaken infant syndrome	PEDIATRIC INTENSIVE-CARE; YOUNG-CHILDREN; PRACTICAL SCALE; HEAD-INJURY; COMA; TERM	OBJECTIVE. To assess outcomes 1 year after severe traumatic brain injury (TBI) among young children and to compare outcomes between children with inflicted versus noninflicted injuries. STUDY DESIGN. Prospective cohort study. METHODS. All North Carolina-resident children who were hospitalized between January 2000 and December 2001 in any of the state's 9 PICUs and who survived a severe TBI that occurred on or before their second birthday were eligible to participate. Child health status, child use of ancillary medical resources, and family characteristics were determined through maternal caregiver interviews similar to 1 year after injury. Comparisons were made between family characteristics and child outcomes according to injury type. RESULTS. Seventy-two interviews of maternal caregivers were completed among 112 survivors (64.3%). Children with inflicted injuries (n = 41) had worse outcomes than did children with noninflicted injuries (n = 31), as measured with the Pediatric Outcome Performance Category and Stein-Jessup Functional Status II ( Revised) tools. However, similar to 50% of children with inflicted injuries had only mild deficits or better. Children with inflicted injuries had a higher use of ancillary medical resources. Families caring for the children did not differ substantively, with a large proportion of single, working, minority mothers. CONCLUSIONS. Children with inflicted TBIs had worse outcomes than did children with other TBIs 1 year after injury. However, outcomes for these children were better than those reported previously. Many families caring for children after severe TBI are socially disadvantaged. Interventions to improve child outcomes may include enhanced family support.	Univ Utah, Intermt Injury Res Control Ctr, Salt Lake City, UT 84158 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84158 USA; Univ N Carolina, Dept Social Med, Chapel Hill, NC 27514 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27514 USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27514 USA	Keenan, HT (corresponding author), Univ Utah, Intermt Injury Res Control Ctr, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu	Runyan, Desmond/S-3974-2016	Runyan, Desmond/0000-0001-5571-9029	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD041040-01A2, K23 HD041040, K23 HD041040-03] Funding Source: Medline; ODCDC CDC HHS [R49/CCR402444] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD041040] Funding Source: NIH RePORTER		Aitken ME, 2004, ARCH PHYS MED REHAB, V85, P567, DOI 10.1016/j.apmr.2003.06.018; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Bayley N., 2006, BAYLEY SCALES INFANT; COLEMAN JS, 1988, AM J SOCIOL, V94, pS95, DOI 10.1086/228943; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; JENNETT B, 1975, LANCET, V1, P480; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; *NATL CTR INJ PREV, 2005, TRAUM BRAIN INJ US; RUNYAN D, 2001, WELL BEING CHILDREN; Runyan DK, 1998, PEDIATRICS, V101, P12, DOI 10.1542/peds.101.1.12; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; Simpson L, 2005, AMBUL PEDIATR, V5, P6, DOI 10.1367/A04-119R.1; SPARROW SS, 1984, VINELAND ADAPTIVE BH; STEIN REK, 1990, MED CARE, V28, P1041, DOI 10.1097/00005650-199011000-00006; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	28	57	57	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2006	117	2					317	324		10.1542/peds.2005-0979			8	Pediatrics	Pediatrics	014PC	WOS:000235491100008	16452349	Green Accepted			2021-06-18	
J	Worringham, CJ; Wood, JM; Kerr, GK; Silburn, PA				Worringham, CJ; Wood, JM; Kerr, GK; Silburn, PA			Predictors of driving assessment outcome in Parkinson's disease	MOVEMENT DISORDERS			English	Article						vision; psychomotor performance; driving; prediction; risk factors	TRAUMATIC BRAIN-INJURY; CONTRAST SENSITIVITY; PERFORMANCE; OLDER; DRIVERS; ABILITY; PEOPLE; DISCRIMINATION; ACCIDENTS; ATROPHY	This study evaluated selected clinical and functional tests as predictors of driving safety outcomes in Parkinson's disease (PD) patients. A total of 25 PD patients and 21 age-matched controls, all regular drivers, underwent neurological evaluation and assessment of cognitive, visual, and motor function and a standardized, on-road driving assessment. The capacity of the tests to predict pass/fail driving outcomes was determined by selecting a subset with the highest predictive value from each domain and then subjecting these subsets to discriminant function analysis. Accuracy, sensitivity, specificity, and positive and negative predictive values were determined. Three relatively simple tests from the larger battery predicted passes with relatively high sensitivity (PD, 72.7%; controls, 93.8%; both combined, 85.2%); and moderate specificity (PD, 64.3%; controls, 60.0%; both combined. 63.2%). These tests assessed motor performance (Purdue Pegboard test), contrast sensitivity (Pelli-Robson test), and cognitive function (verbal version of Symbol Digit Modalities test). Adding time since diagnosis for the PD group increased sensitivity to 90.9% and specificity to 71.4%. These simple tests confer more objectivity and predictive power to clinical recommendations for driving, they reflect distinct functions that are necessary for safe driving, and they may be especially useful when on-road assessments are not feasible. (C) 2005 Movement Disorder Society.	Queensland Univ Technol, Sch Human Movement Studies, Kelvin Grove, Qld 4059, Australia; Queensland Univ Technol, Sch Optometry, Kelvin Grove, Qld, Australia; Princess Alexandra Hosp, Dept Neurol, Brisbane, Qld 4102, Australia	Worringham, CJ (corresponding author), Queensland Univ Technol, Sch Human Movement Studies, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.	c.worringham@qut.edu.au	Kerr, Graham/I-9705-2012; Silburn, Peter A/A-3614-2011	Kerr, Graham/0000-0002-1008-256X; , Joanne/0000-0002-0776-7736			*AUSTR INC, 2003, ASS FITN DRIV COMM P; Beck A. T., 1996, BECK DEPRESSION INVE; Beck AT., 1990, BECK ANXIETY INVENTO; Borromei A, 1999, FUNCT NEUROL, V14, P227; BULLIMORE MA, 1993, INVEST OPHTH VIS SCI, V34, P3526; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; De Raedt R, 2001, ACCIDENT ANAL PREV, V33, P809, DOI 10.1016/S0001-4575(00)00095-6; DUBINSKY RM, 1991, NEUROLOGY, V41, P517, DOI 10.1212/WNL.41.4.517; Fox GK, 1997, J AM GERIATR SOC, V45, P949, DOI 10.1111/j.1532-5415.1997.tb02965.x; Gallo JJ, 1999, J AM GERIATR SOC, V47, P335, DOI 10.1111/j.1532-5415.1999.tb02998.x; Gimenez-Roldan S, 1998, Neurologia, V13, P13; GOUVIER WD, 1989, ARCH PHYS MED REHAB, V70, P745; Heikkila VM, 1998, J NEUROL NEUROSUR PS, V64, P325, DOI 10.1136/jnnp.64.3.325; Homann CN, 2003, J NEUROL, V250, P1439, DOI 10.1007/s00415-003-0239-5; Hughes AJ, 2001, NEUROLOGY, V57, P1497, DOI 10.1212/WNL.57.8.1497; HUNT LA, 1995, OPTOMETRY VISION SCI, V72, P92, DOI 10.1097/00006324-199502000-00008; Lafayette Instruments, 1999, QUICK REF GUID PURD; LINGS S, 1992, ACTA NEUROL SCAND, V86, P33, DOI 10.1111/j.1600-0404.1992.tb08050.x; *MA GEN HOSP, 2001, LONG SHOULD 2 DRIV B; MADELEY P, 1990, J NEUROL NEUROSUR PS, V53, P580, DOI 10.1136/jnnp.53.7.580; Mallon K, 2004, AM J OCCUP THER, V58, P279, DOI 10.5014/ajot.58.3.279; MCCLAY P, 1989, INT DISABILITY STUDI, V11, P50; Meindorfner C, 2005, MOVEMENT DISORD, V20, P832, DOI 10.1002/mds.20412; O'Suilleabhain P, 2001, J NEUROL NEUROSUR PS, V71, P607, DOI 10.1136/jnnp.71.5.607; Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881; PELLI DG, 1988, CLIN VISION SCI, V2, P187; Pieri V, 2000, J NEUROL SCI, V172, P7, DOI 10.1016/S0022-510X(99)00204-X; Radford K, 2004, DISABIL REHABIL, V26, P65, DOI 10.1080/09638280310001629633; Radford KA, 2004, BRAIN INJURY, V18, P775, DOI 10.1080/02699050310001657394; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Shinar D, 1998, HUM FACTORS, V40, P647, DOI 10.1518/001872098779649346; Smiley-Oyen AL, 2003, EXP BRAIN RES, V152, P453, DOI 10.1007/s00221-003-1570-x; Smith A, 1995, SYMBOL DIGIT MODALIT; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; Stutts JC, 1998, ACCIDENT ANAL PREV, V30, P337, DOI 10.1016/S0001-4575(97)00108-5; van Elst LT, 1997, BRAIN, V120, P2219, DOI 10.1093/brain/120.12.2219; Wood JM, 2005, J NEUROL NEUROSUR PS, V76, P176, DOI 10.1136/jnnp.2004.047118; Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664; Wood JM, 2001, OPTOMETRY VISION SCI, V78, P343, DOI 10.1097/00006324-200105000-00018; Woodward TS, 2002, NEUROPSYCHOLOGIA, V40, P1948, DOI 10.1016/S0028-3932(02)00068-4; Zesiewicz TA, 2002, NEUROLOGY, V59, P1787, DOI 10.1212/01.WNL.0000035636.83680.C6	42	57	59	0	6	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0885-3185			MOVEMENT DISORD	Mov. Disord.	FEB	2006	21	2					230	235		10.1002/mds.20709			6	Clinical Neurology	Neurosciences & Neurology	016DW	WOS:000235601900014	16161149	Green Published			2021-06-18	
J	Anson, K; Ponsford, J				Anson, K; Ponsford, J			Who benefits? Outcome following a coping skills group intervention for traumatically brain injured individuals	BRAIN INJURY			English	Article						coping; psychological outcome; cognitive behaviour therapy and self-awareness	SICKNESS IMPACT PROFILE; CLOSED-HEAD-INJURY; SELF-AWARENESS; DEPRESSION SCALE; HOSPITAL ANXIETY; IMPAIRED AWARENESS; ADULTS; DEFICITS; REHABILITATION; AGGRESSION	Primary objective: To investigate the variables associated with positive psychological outcome following a group intervention for 33 individuals with traumatic brain injury. Research design: Evaluation study which used multiple regression analysis to examine the variables associated with change in psychological adjustment following a 10-session cognitive behaviour therapy-based group. Methods and procedures: The predictor variables were age at injury, time since injury, injury severity, self-awareness, premorbid intellectual function, memory function, executive function and level of depression and anxiety prior to intervention. Main outcomes and results: The predictor variables contributed a significant proportion of the variance in percentage change in depression. The major finding was that better outcomes following intervention were associated with greater self-awareness of injury-related deficits. Conclusions: The present study identified a number of variables that were associated with improvement in depression following psychological intervention and may assist future treatment resources to be directed most effectively.	Epworth Hosp Melbourne, Melbourne, Vic, Australia	Anson, K (corresponding author), 36 Auburn Parade, E Hawthorn, Vic 3123, Australia.	katie.anson@gmail.com					Aeschleman S. R., 1999, J RATION-EMOT COGN-B, V17, P51, DOI DOI 10.1023/A:1023073130972; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Bennett T L, 1997, Appl Neuropsychol, V4, P55, DOI 10.1207/s15324826an0401_7; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blascovich J., 1991, MEASURES PERSONALITY, V1, P115, DOI DOI 10.1016/B978-0-12-590241-0.50008-3; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Christensen B., 1994, ADV MED PSYCHOTHER, V7, P23; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DOYLE M, 2001, EPW INN REH C MELB A; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; Frydenberg E., 1996, COPING SCALE ADULTS; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GrayLittle B, 1997, PERS SOC PSYCHOL B, V23, P443, DOI 10.1177/0146167297235001; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Holosko M, 1989, CANADIAN J REHABILIT, V2, P145; Hubble M. A., 1999, HEART SOUL CHANGE WH; Johnston M, 2000, J PSYCHOSOM RES, V48, P579, DOI 10.1016/S0022-3999(00)00102-1; Khan-Bourne N, 2003, NEUROPSYCHOL REHABIL, V13, P89, DOI 10.1080/09602010244000318; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; O'Leary CA, 2000, BEHAV INTERVENT, V15, P205, DOI 10.1002/1099-078X(200007/09)15:3<205::AID-BIN56>3.3.CO;2-B; OWNSWORTH T, 2001, ASSBI 24 BRAIN IMP C; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP., 1999, PRINCIPLES NEUROPSYC, P244; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Rosenberg M., 1986, CONCEIVING SELF; Scheutzow MH, 1999, BRAIN INJURY, V13, P705; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Simmond M, 2003, BRAIN INJURY, V17, P325, DOI 10.1080/0269905021000013219; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Spielberger C.D., 1999, STATE TRAIT ANGER EX; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tabachnick BG, 2013, USING MULTIVARIATE S; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wilson, 1991, NATL ADULT READING T; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wiseman-Hakes C, 1998, J HEAD TRAUMA REHAB, V13, P23, DOI 10.1097/00001199-199812000-00005	62	57	57	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					1	13		10.1080/02699050500309791			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000001	16403695				2021-06-18	
J	Danckert, JA; Allman, AAA				Danckert, JA; Allman, AAA			Time flies when you're having fun: Temporal estimation and the experience of boredom	BRAIN AND COGNITION			English	Article						attention; temporal perception; boredom	SCALAR EXPECTANCY-THEORY; TRAUMATIC BRAIN-INJURY; ATTENTIONAL BLINK; PRONENESS; PERCEPTION; REPRESENTATION; WORK; TASK	Boredom is a common experience in healthy individuals and may be elevated in various neurological or psychiatric conditions. As yet, very little is known about the cognitive or neural bases of the subjective experience of boredom. We examined temporal perception and the temporal allocation of attention in healthy individuals reporting high- or low-levels of boredom. We found no difference in high- or low-boredom-prone individuals in the temporal allocation of attention, while individuals who experienced low-levels of boredom tended to underestimate time more so than high-boredom-prone individuals. Furthermore, high-boredom-prone individuals demonstrated higher error values when estimating time indicating that the subjective perception of the passage of time may be a critical component to the experience of boredom. (c) 2005 Elsevier Inc. All rights reserved.	Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada	Danckert, JA (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	jdancker@uwaterloo.ca					Conti R, 2001, J PERS, V69, P1, DOI 10.1111/1467-6494.00134; Coull JT, 2004, SCIENCE, V303, P1506, DOI 10.1126/science.1091573; DAMRADFRYE R, 1989, J PERS SOC PSYCHOL, V57, P315; DRORY A, 1982, PERS PSYCHOL, V35, P141, DOI 10.1111/j.1744-6570.1982.tb02190.x; FARMER R, 1986, J PERS ASSESS, V50, P4, DOI 10.1207/s15327752jpa5001_2; FISHER CD, 1993, HUM RELAT, V46, P395, DOI 10.1177/001872679304600305; GIBBON J, 1977, PSYCHOL REV, V84, P279, DOI 10.1037/0033-295X.84.3.279; Gordon A., 1997, PSYCHOL STUD, V42, P85; Hamilton J. A., 1981, PROGR EXPT PERSONALI, V10, P281; HAMILTON JA, 1984, PERS INDIV DIFFER, V5, P183, DOI 10.1016/0191-8869(84)90050-3; Harrington DL, 1998, J NEUROSCI, V18, P1085; Ivry RB, 1996, CURR OPIN NEUROBIOL, V6, P851, DOI 10.1016/S0959-4388(96)80037-7; Ivry RB, 2004, CURR OPIN NEUROBIOL, V14, P225, DOI 10.1016/j.conb.2004.03.013; Kass SJ, 2001, PERCEPT MOTOR SKILL, V92, P969, DOI 10.1177/003151250109203c01; Kass Steven J, 2003, J Atten Disord, V7, P83, DOI 10.1177/108705470300700202; KRAGERER FA, 2002, NEUROPSYCHOLOGIA, V40, P357; LEONG FTL, 1993, PERS INDIV DIFFER, V14, P233, DOI 10.1016/0191-8869(93)90193-7; London H., 1974, THOUGHT FEELING, P44, DOI [10.4324/9781315135656-8, DOI 10.4324/9781315135656-8]; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Rakitin BC, 1998, J EXP PSYCHOL-ANIM B, V24, P15, DOI 10.1037/0097-7403.24.1.15; RAYMOND JE, 1992, J EXP PSYCHOL HUMAN, V18, P849, DOI 10.1037/0096-1523.18.3.849; Rizzo M, 2001, NEUROLOGY, V57, P795, DOI 10.1212/WNL.57.5.795; Rolls ET, 1999, BRAIN EMOTION; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; SMITH RP, 1981, HUM FACTORS, V23, P329; Sommers J, 2000, J CLIN PSYCHOL, V56, P149, DOI 10.1002/(SICI)1097-4679(200001)56:1<149::AID-JCLP14>3.0.CO;2-Y; Todman M, 2003, PSYCHIATRY, V66, P146, DOI 10.1521/psyc.66.2.146.20623; Vodanovich SJ, 2003, J PSYCHOL, V137, P569, DOI 10.1080/00223980309600636; VODANOVICH SJ, 1991, PSYCHOL REP, V69, P1139, DOI 10.2466/PR0.69.8.1139-1146; VODANOVICH SJ, 1990, J PERS ASSESS, V55, P115, DOI 10.1207/s15327752jpa5501&2_11; Wallace JC, 2003, PERS INDIV DIFFER, V34, P635, DOI 10.1016/S0191-8869(02)00050-8; Walsh K. W, 1991, UNDERSTANDING BRAIN; Walsh V, 2003, TRENDS COGN SCI, V7, P483, DOI 10.1016/j.tics.2003.09.002; Walsh V, 2003, TRENDS COGN SCI, V7, P335, DOI 10.1016/S1364-6613(03)00166-9; WATT JD, 1991, PSYCHOL REP, V69, P323, DOI 10.2466/PR0.69.5.323-327; Watt JD, 1999, J PSYCHOL, V133, P303, DOI 10.1080/00223989909599743	36	57	62	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	DEC	2005	59	3					236	245		10.1016/j.bandc.2005.07.002			10	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	997GV	WOS:000234234400003	16168546				2021-06-18	
J	King, JT; Carlier, PM; Marion, DW				King, JT; Carlier, PM; Marion, DW			Early Glasgow Outcome Scale scores predict long-term functional outcome in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Outcome Scale; head injuries closed; outcomes; prognosis; trauma	SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; ACUTE SUBDURAL-HEMATOMA; MODERATE HYPOTHERMIA; ANALYSIS RPA; METASTASES; MANAGEMENT; PROGRAM; SURGERY	Patients sustaining severe traumatic brain injury (TBI) have variable long-term outcomes. We examined the association between Glasgow Outcome Scale (GOS) assessed at 3 months and long-term outcomes at 12 months after TBI. We studied 159 patients with severe, closed traumatic brain injuries (Glasgow Coma Scale [GCS] <= 8) who were treated at an academic medical center and survived for a minimum of 3 months after TBI. Demographics and admission clinical data and GOS at 3 and 12 months were analyzed. Multivariate logistic regression was used to asses the relationship between 3-month GOS, demographics, and clinical data and a poor outcome, defined as GOS 1-3 assessed at 12 months after injury. The patient population was predominantly male (77%), with a median age of 30 years and a median admission GCS of 6. The logistic regression model showed that the GOS at 3 months was the best predictor of 12-month outcomes (odds ratio = 15.22, p < 0.001). The presence of prolonged hypotension, diffuse axonal injury (DAI), and fixed and dilated pupils on admission were also significant independent predictors of poor 12-month outcome (for all, p <= 0.047). The adjusted logistic model showed a steep gradient of long-term recovery potential depending upon GOS at 3 months, ranging from an 89.4% chance of poor outcome for patients with a GOS of 2, to a 0.11% chance of poor outcome for those with a GOS of 5. The 3-month GOS is a powerful independent predictor of long-term outcome for patients with severe TBI. Prolonged hypotension, DAI, and the presence of fixed and dilated pupils were also independent predictors of poor outcome.	VA Connecticut Healthcare Syst 112, Neurosurg Sect, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Neurosurg, New Haven, CT USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Brain Trauma Fdn, New York, NY USA	King, JT (corresponding author), VA Connecticut Healthcare Syst 112, Neurosurg Sect, 950 Campbell Ave, West Haven, CT 06516 USA.	Joseph.KingJr@med.va.gov	Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23 NS02169-06] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS002169] Funding Source: NIH RePORTER		Agboola O, 1998, INT J RADIAT ONCOL, V42, P155, DOI 10.1016/S0360-3016(98)00198-9; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bullock MR, 1996, J NEUROTRAUM, V13, P643; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Gaspar LE, 2000, INT J RADIAT ONCOL, V47, P1001, DOI 10.1016/S0360-3016(00)00547-2; HAGEN C, 1972, RANCHO AMIGOS HOSP L; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; JENNETT B, 1975, LANCET, V1, P480; Karnofsky DA., 1949, EVALUATION CHEMOTHER, P191; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KEITH RA, 1987, ADV CLIN REHABILITAT, P6; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504; Nissen JJ, 1999, J NEUROL NEUROSUR PS, V67, P796, DOI 10.1136/jnnp.67.6.796; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; RaeGrant AD, 1996, J TRAUMA, V40, P401, DOI 10.1097/00005373-199603000-00013; RANKIN J, 1957, Scott Med J, V2, P200; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; WALKER MD, 1980, NEW ENGL J MED, V303, P1323, DOI 10.1056/NEJM198012043032303; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	30	57	58	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					947	954		10.1089/neu.2005.22.947			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600002	16156710				2021-06-18	
J	O'Connor, C; Colantonio, A; Polatajko, H				O'Connor, C; Colantonio, A; Polatajko, H			Long term symptoms and limitations of activity of people with traumatic brain injury: A ten-year follow-up	PSYCHOLOGICAL REPORTS			English	Article							HEAD-INJURY; YOUNG-ADULTS; MILD; INDIVIDUALS; IMPAIRMENT; DEPRESSION; COMPLAINTS; RECOVERY; MODERATE; OUTCOMES	This study examined the effect of Traumatic Brain Injury 10 years post-injury. Frequencies of head injury symptoms and activity limitation by level of severity were measured in a consecutive series of 61 adults who were admitted to a tertiary-care center for traumatic brain injury. Irritability and Anxiety were the most frequently reported symptoms from the Head Injury Symptom Checklist. Bothered by noise and Bothered by light were the least frequently reported. Trouble hearing what is said in a group conversation and Trouble hearing what is said in a one-to-one conversation were the most commonly reported limitations of activity from the Health and Activity Limitations Survey. Overall, this study illustrates that symptoms remain many years following brain injury, irrespective of the injury's severity.	Univ Toronto, Toronto Rehabil Inst, Grad Dept Rehabil Sci, Dept Occupat Therapy, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M5S 1A1, Canada	Colantonio, A (corresponding author), Ctr Funct & Wellbeing, Rehabil Sci Bldg,500 Univ Ave,Room 950, Toronto, ON M5G 1V7, Canada.			Colantonio, Angela/0000-0003-2094-4765			Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hillier SL, 1997, BRAIN INJURY, V11, P661; Hoofien D, 2001, BRAIN INJURY, V15, P189; JENNETT B, 1977, LANCET, V1, P878; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ocana M, 2000, BRAIN COGNITION, V44, P83, DOI 10.1006/brcg.1999.1211; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Ruttan LA, 2003, J CLIN EXP NEUROPSYC, V25, P407, DOI 10.1076/jcen.25.3.407.13812; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; *STAT CAN, 1988, HLTH ACT LIM SURV US; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2	35	57	57	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-2941	1558-691X		PSYCHOL REP	Psychol. Rep.	AUG	2005	97	1					169	179		10.2466/PR0.97.5.169-179			11	Psychology, Multidisciplinary	Psychology	970MT	WOS:000232315000026	16279322				2021-06-18	
J	Withnall, C; Shewchenko, N; Wonnacott, M; Dvorak, J				Withnall, C; Shewchenko, N; Wonnacott, M; Dvorak, J			Effectiveness of headgear in football	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL SOCCER PLAYERS; BRAIN-INJURY; CONCUSSION; IMPACT; SKILL	Objectives: Commercial headgear is currently being used by football players of all ages and skill levels to provide protection from heading and direct impact. The clinical and biomechanical effectiveness of the headgear in attenuating these types of impact is not well defined or understood. This study was conducted to determine whether football headgear has an effect on head impact responses. Methods: Controlled laboratory tests were conducted with a human volunteer and surrogate head/neck system. The impact attenuation of three commercial headgears during ball impact speeds of 6-30 m/s and in head to head contact with a closing speed of 2-5 m/s was quantified. The human subject, instrumented to measure linear and angular head accelerations, was exposed to low severity impacts during heading in the unprotected and protected states. High severity heading contact and head to head impacts were studied with a biofidelic surrogate headform instrumented to measure linear and angular head responses. Subject and surrogate responses were compared with published injury assessment functions associated with mild traumatic brain injury (MTBI). Results: For ball impacts, none of the headgear provided attenuation over the full range of impact speeds. Head responses with or without headgear were not significantly different (p>0.05) and remained well below levels associated with MTBI. In head to head impact tests the headgear provided an overall 33% reduction in impact response. Conclusion: The football headgear models tested did not provide benefit during ball impact. This is. probably because of the large amount of ball deformation relative to headband thickness. However, the headgear provided measurable benefit during head to head impacts.	FIFA Med Assessment & Res Ctr, Zurich, Switzerland		withnall@biokinetics.com					Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2003, J ATHL TRAINING, V38, P220; CPSC, 2002, SOCC HEAD INJ CAL YE; DIMASI FP, 1995, HS808282 DOT NAT HIG; Dvorak J, 2000, AM J SPORT MED, V28, pS3; *FULL90SPORTS, 2003, SOCC REB SPEED COMP; *FULL90SPORTS, 2003, RED HEAD INJ SOCC; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HUBBARD R, 1974, HYBRID, V3, P95; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Junge A, 2000, AM J SPORT MED, V28, pS47; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; MERTZ HJ, 1971, 15TH P STAPP CAR CRA, P207; Newman J., 1999, INT RES COUNC BIOM I; Newman J, 2000, 44 STAPP CAR CRASH C; Peterson L, 2000, AM J SPORT MED, V28, pS51; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; *SAE, 1995, SAE HDB; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; ZIEJEWSKI M, 2003, BRAIN INJ ASS 20 ANN	33	57	57	2	24	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	AUG	2005	39			1			I40	I48		10.1136/bjsm.2005.019174			9	Sport Sciences	Sport Sciences	954KI	WOS:000231153600006	16046355	Green Published, Bronze			2021-06-18	
J	Brewer, BR; Fagan, M; Klatzky, RL; Matsuoka, Y				Brewer, BR; Fagan, M; Klatzky, RL; Matsuoka, Y			Perceptual limits for a robotic rehabilitation environment using visual feedback distortion	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						feedback distortion; kinesthetic perception; perception of effort; rehabilitation robotics	MANUAL DISCRIMINATION; WEIGHT; INFORMATION; MECHANISMS; RESOLUTION; THERAPY; FORCE; SENSE	Imperceptible visual distortion, in the form of a disguised progression of performance goals, may be a helpful addition to rehabilitation after stroke and other brain injuries. This paper describes work that has been done to lay the groundwork for testing this hypothesis. We have constructed and validated an experimental environment that provides controllable visual distortion and allows precise force and position measurements. To estimate the amount of visual distortion that should be imperceptible, we measured the limits for force and distance/position perception in our rehabilitation environment for young and elderly unimpaired subjects and for a single traumatic brain injury (TBI) patient. We found the Just Noticeable Difference (JND) for produced force to be 19.7% (0.296 N) and the JND for movement distance/finger position to be 13.0% (3.99 mm) for young subjects (ages 18-35). For elderly subjects (ages 61-80), the JND for force was measured to be 31.0% (0.619 N) and the JND for distance/position was 16.1% (5.01 mm). JNDs of 46.0% (0.920 N) and 45.0% (14.8 mm) were found for the motor-impaired individual. In addition, a subject's rating of effort was found to be profoundly influenced by visual feedback concerning the force magnitude. Even when this feedback was distorted, it accounted for 99% of the variance of the effort rating. These results indicate that substantial visual distortions should be imperceptible to the subject, and that visual feedback can be used to influence the subject's perceived experience in our robotic environment. This means that we should be able to use imperceptible visual distortion to alter a patient's perception of therapeutic exercise in a robotic environment.	Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Mech Engn, Pittsburgh, PA 15213 USA	Klatzky, RL (corresponding author), Carnegie Mellon Univ, Inst Robot, Pittsburgh, PA 15213 USA.	klatzky@cmu.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A020502] Funding Source: Medline		Allin S, 2002, 10TH SYMPOSIUM ON HAPTIC INTERFACES FOR VIRTUAL ENVIRONMENT AND TELEOPERATOR SYSTEMS, PROCEEDINGS, P299, DOI 10.1109/HAPTIC.2002.998972; Atkinson J. W., 1964, INTRO MOTIVATION; BANDURA A, 1983, J PERS SOC PSYCHOL, V45, P1017, DOI 10.1037/0022-3514.45.5.1017; BANDURA A, 1986, ORGAN BEHAV HUM DEC, V38, P92, DOI 10.1016/0749-5978(86)90028-2; BERLINER JE, 1973, J ACOUST SOC AM, V53, P1270, DOI 10.1121/1.1913465; Boian R., 2002, P 1 INT WORKSH VIRT, P77; Brewer BR, 2003, P ANN INT IEEE EMBS, V25, P1613, DOI 10.1109/IEMBS.2003.1279676; BREWER BR, 2004, P INT C ROB AUT ICRA, V2, P2080; BREWER BR, 2003, P 8 INT C REH ROB DA, P258; BRODIE EE, 1984, PERCEPT PSYCHOPHYS, V36, P477, DOI 10.3758/BF03207502; DURLACH NI, 1989, PERCEPT PSYCHOPHYS, V46, P293, DOI 10.3758/BF03208094; DURLACH NI, 1989, PERCEPT PSYCHOPHYS, V46, P29, DOI 10.3758/BF03208071; ELLIOTT ES, 1988, J PERS SOC PSYCHOL, V54, P5, DOI 10.1037/0022-3514.54.1.5; Ernst MO, 2002, NATURE, V415, P429, DOI 10.1038/415429a; Fagan M, 2003, 11TH SYMPOSIUM ON HAPTIC INTERFACES FOR VIRTUAL ENVIRONMENT AND TELEOPERATOR SYSTEMS - HAPTICS 2003, PROCEEDINGS, P159, DOI 10.1109/HAPTIC.2003.1191263; Fitzgibbons PJ, 2001, J ACOUST SOC AM, V109, P2955, DOI 10.1121/1.1371760; FLEISHMAN EA, 1984, ERGONOMICS, V27, P947, DOI 10.1080/00140138408963573; Gescheider GA, 1996, SOMATOSENS MOT RES, V13, P73, DOI 10.3109/08990229609028914; HELLER MA, 1983, PERCEPTION, V12, P607, DOI 10.1068/p120607; HOGAN JC, 1980, J APPL PSYCHOL, V65, P672, DOI 10.1037/0021-9010.65.6.672; JARIC S, 1994, EXP BRAIN RES, V100, P353; JONES LA, 1989, PERCEPTION, V18, P681, DOI 10.1068/p180681; JONES LA, 1990, EXP BRAIN RES, V79, P150; LACKNER JR, 1974, PERCEPT MOTOR SKILL, V38, P1251, DOI 10.2466/pms.1974.38.3c.1251; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Lum PS, 2002, ARCH PHYS MED REHAB, V83, P952, DOI 10.1053/apmr.2001.33101; PANG XD, 1991, PERCEPT PSYCHOPHYS, V49, P531, DOI 10.3758/BF03212187; RAJ DV, 1985, BRAIN, V108, P95, DOI 10.1093/brain/108.1.95; Reinkensmeyer DJ, 2000, J REHABIL RES DEV, V37, P653; ROSS HE, 1987, Q J EXP PSYCHOL-A, V39, P77, DOI 10.1080/02724988743000042; Shinomori K, 2001, J OPT SOC AM A, V18, P310, DOI 10.1364/JOSAA.18.000310; SKIDMORE ER, 2003, THESIS U PITTSBURGH; TAN HZ, 1989, J ACOUST SOC AM, V86, P981, DOI 10.1121/1.398733; TAN HZ, 1995, PERCEPT PSYCHOPHYS, V57, P495, DOI 10.3758/BF03213075; TAUB E, 1994, PL S BEHAV, P185; Volpe BT, 2001, CURR OPIN NEUROL, V14, P745, DOI 10.1097/00019052-200112000-00011; Williams JG, 2001, PREV MED, V32, P103, DOI 10.1006/pmed.2000.0792	37	57	59	0	9	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	MAR	2005	13	1					1	11		10.1109/TNSRE.2005.843443			11	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	907VU	WOS:000227747000001	15813400				2021-06-18	
J	Hart, T; Whyte, J; Polansky, M; Kersey-Matusiak, G; Fidler-Sheppard, R				Hart, T; Whyte, J; Polansky, M; Kersey-Matusiak, G; Fidler-Sheppard, R			Community outcomes following traumatic brain injury - Impact of race and preinjury status	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		community integration; outcome measurement; race; traumatic brain injury	SPINAL-CORD-INJURY; BLACK-WHITE DIFFERENCES; QUALITY-OF-LIFE; INTEGRATION QUESTIONNAIRE; PRACTICAL SCALE; RATING-SCALE; HEAD TRAUMA; MODEL; SATISFACTION; RETURN	Objective: To investigate the contribution of preinjury differences and potential biases in outcome measurement in explaining outcome differences between white and African American persons with moderate and severe traumatic brain injury (TBI). Design: Prospective, 2 group longitudinal study with retrospective self-assessment of preinjury status. Setting: Inpatient and outpatient TBI rehabilitation program: Participants: Ninety-four persons with moderate and severe TBI (55 whites and 39 African Americans) who provided data on both preinjury status and. 1-year outcome. Measures: Community Integration Questionnaire, aggression and depression subscales of Neurobehavioral Functioning Inventory-Revised, Satisfaction With Life Scale, other questions on demographic and social status; all measures were selected by a biracial focus group. Results: Whites and African Americans did not differ significantly on demographic factors ' except gender; nor on retrospective, self-reported preinjury status on any of the outcome measures. At 1 year post-TBI, African Americans reported significantly lower social integration subscale scores than whites. African Americans may also have lost more income than did whites. All other outcome measures were comparable between, group's and showed declines in community productivity, increases in depression symptoms, and lower satisfaction with life for both whites and African limericans compared to preinjury A higher rate of change in living situation post-TBI may partially account for lower levels of social integration for African Americans. Conclusion: Whites and African Americans who are comparable prior to injury may experience generally similar outcomes, but differences in social and financial outcomes require further investigation.	Moss Rehabilitat Res Inst, Philadelphia, PA 19141 USA; Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA USA; Holy Family Univ, MCP Hahnemann Sch Publ Hlth, Philadelphia, PA USA; Holy Family Univ, Sch Nursing, Philadelphia, PA USA	Hart, T (corresponding author), Moss Rehabilitat Res Inst, 1200 W Tabor Rd,Korman Suite 213, Philadelphia, PA 19141 USA.	thart@einstein.edu		Whyte, John/0000-0002-4381-1474			Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; Hart T, 2003, REHABIL PSYCHOL, V48, P86, DOI 10.1037/0090-5550.48.2.86; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; *KESSL MED REH RES, 2002, TRAUM BRAIN INJ FACT, V8; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Neville HA, 2000, REHABIL PSYCHOL, V45, P89, DOI 10.1037/0090-5550.45.1.89; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Putzke JD, 2002, ARCH PHYS MED REHAB, V83, P1603, DOI 10.1053/apmr.2002.35115; Raley RK, 1996, AM SOCIOL REV, V61, P973, DOI 10.2307/2096303; RALEY RK, 1995, J FAM ISSUES, V16, P77, DOI 10.1177/019251395016001005; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Sue S, 1999, AM PSYCHOL, V54, P1070, DOI 10.1037/0003-066X.54.12.1070; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uswatte G, 1997, REHABIL PSYCHOL, V42, P61, DOI 10.1037/0090-5550.42.1.61; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Yeates KO, 2002, J PEDIATR PSYCHOL, V27, P393, DOI 10.1093/jpepsy/27.4.393	34	57	57	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2005	20	2					158	172		10.1097/00001199-200503000-00004			15	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	910VV	WOS:000227961200004	15803039				2021-06-18	
J	Rotondi, AJ; Sinkule, J; Spring, M				Rotondi, AJ; Sinkule, J; Spring, M			An interactive web-based intervention for persons with TBI and their families - Use and evaluation by female significant others	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; social support; Web site; intervention; female significant other; telehealth	TRAUMATIC BRAIN-INJURY; COMPUTER-MEDIATED COMMUNICATION; SEVERE HEAD-INJURY; SOCIAL SUPPORT; RELATIVES; CAREGIVERS; SYMPTOMS; DISTRESS; SPOUSES; TELEREHABILITATION	Objective: To assess the feasibility of providing in-home adjunctive and supportive services to per sons with traumatic brain injury (TBI) and their families via a Web site. Design: Nineteen families were provided with access to the Web site intervention for 6 months. Those who needed it were provided with a computer and Internet service in their homes. Participants: Adult women who were the significant others of adult males with moderate-to-severe TBI. Main Outcome Measure: Value and ease of use of the Web site. Each participant's usage of the Web site was automatically tracked including each page visited, time of day, and time spent on the page. Results: Female significant others found the Web site to be valuable and easy to use, and used it throughout the 6-month period. The on-line support group was the most used and valued module. Conclusions: Family caregivers will use Web-based interventions to help meet their needs for social support, information, and guidance following the return home of persons with TBI.	Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA; George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; Univ Pittsburgh, Dept Informat Sci, Pittsburgh, PA 15260 USA	Rotondi, AJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, 3550 Terrace St, Pittsburgh, PA 15261 USA.	rotondi@pitt.edu					Acorn S, 1992, J Neurosci Nurs, V24, P324; ACORN S, 1993, J ADV NURS, V18, P39, DOI 10.1046/j.1365-2648.1993.18010039.x; Alemi F, 1997, J MED SYST, V21, P119, DOI 10.1023/A:1022846408428; ALEMI F, 1996, MED CARE, V34, P10; Brennan P F, 1994, Int J Technol Assess Health Care, V10, P258; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Bull M J, 1990, West J Nurs Res, V12, P758, DOI 10.1177/019394599001200605; Campbell C H, 1988, Rehabil Nurs, V13, P320; CARNWATH TCM, 1987, BRIT MED J, V294, P409, DOI 10.1136/bmj.294.6569.409; Dew MA, 2004, J HEART LUNG TRANSPL, V23, P745, DOI 10.1016/j.healun.2003.07.002; DUCK SW, 1990, PERSONAL RELATIONSHI; Dunham PJ, 1998, AM J COMMUN PSYCHOL, V26, P281, DOI 10.1023/A:1022132720104; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P49, DOI 10.1037/0090-5550.47.1.49; GRAY JM, 1994, CLIN REHABIL, V8, P188, DOI DOI 10.1080/09602010902949207; Gustafson D H, 1992, Proc Annu Symp Comput Appl Med Care, P161; Gustafson David, 1993, Journal of Psychosocial Oncology, V11, P69; Gustafson DH, 1999, AM J PREV MED, V16, P23, DOI 10.1016/S0749-3797(98)00104-4; Hare A.Paul., 1962, HDB SMALL GROUP RES; HARE AP, 1962, HDB SMALL GROUP RES, P60; HORRIGAN J, 2003, EVER SHIFTING INTERN; JACOBS HE, 1989, NEUROPSYCHOLOGICAL T, P297; JOHNSON CL, 1983, GERONTOLOGIST, V23, P612, DOI 10.1093/geront/23.6.612; KIESLER S, 1984, AM PSYCHOL, V39, P1123, DOI 10.1037/0003-066X.39.10.1123; Kim M. S., 1991, ANN M INT COMM ASS M; King RB, 1996, STROKE, V27, P1467, DOI 10.1161/01.STR.27.9.1467; KOLLOCK P, 1999, COMMUNITIES CYBERSPA, P109; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kristjanson L J, 1995, J Nurs Meas, V3, P109; Leathem J, 1996, BRAIN INJURY, V10, P27; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levy L. H., 1979, SELF HELP GROUPS COP, P234; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Liss HJ, 2002, REHABIL PSYCHOL, V47, P8, DOI 10.1037/0090-5550.47.1.8; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McKay HG, 2002, REHABIL PSYCHOL, V47, P31, DOI 10.1037/0090-5550.47.1.31; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; PIERCE G, 1994, COMMUNICATION SOCIAL, P241; RICE RE, 1987, COMMUN RES, V14, P85, DOI 10.1177/009365087014001005; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; ROBERTS LJ, 1991, AM J COMMUN PSYCHOL, V19, P715, DOI 10.1007/BF00938041; Rogers P M, 1984, J Neurosurg Nurs, V16, P343; Rolnick SJ, 1999, NURS OUTLOOK, V47, P78, DOI 10.1016/S0029-6554(99)90074-X; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rosenthal M., 1989, TRAUMATIC BRAIN INJU, P191; SPOONER T, 2001, AFRICAN AM INTERNET; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WESOLOWSKI MD, 1994, PRACTICAL GUIDE HEAD; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Winzelberg A, 1997, COMPUT HUM BEHAV, V13, P393, DOI 10.1016/S0747-5632(97)00016-2; ZEIGLER EA, 1987, J REHABIL, V53, P50	66	57	57	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2005	20	2					173	185		10.1097/00001199-200503000-00005			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	910VV	WOS:000227961200005	15803040				2021-06-18	
J	Voulgaris, SG; Partheni, M; Kaliora, H; Haftouras, N; Pessach, IS; Polyzoidis, KS				Voulgaris, SG; Partheni, M; Kaliora, H; Haftouras, N; Pessach, IS; Polyzoidis, KS			Early cerebral monitoring using the transcranial Doppler pulsatility index in patients with severe brain trauma	MEDICAL SCIENCE MONITOR			English	Article						traumatic brain injury; transcranial Doppler; pulsatility index; CPP; ICP	BLOOD-FLOW-VELOCITY; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; MANAGEMENT; INJURY	Background: The early posttraumatic period is critical in patients with traurnatic brain injury (TBI) because of the increased risk of secondary ischemic injuries to the injured brain. For these patients, cerebral perfusion pressure (CPP) monitoring is recommended. This, however, requires an invasive device to measure intracranial pressure (ICP). Transcranial Doppler (TCD) ultrasonography is an effective, noninvasive method for the detection of cerebral hemodynamic changes. Use of the dimensionless TCD-pulsatility index (PI) has the advantage of eliminating errors in measurements due to insonation angle variations. Material/Methods: We investigated 37 patients with severe TBI (GCS less than or equal to8 on admission). The TCD parameters included the systolic, diastolic, and mean velocities of the middle cerebral artery (MCV) and the pulsatility index (PI). Mean arterial pressure (MAT), ICP, CPP, and simultaneous arterial and venous blood gases were also measured. Results: We observed a strong correlation between ICP and PI (r=0.82, p<0.0001) for ICP values >20 mmHG. The correlation of CPP to PI were also statistically significant (P<0.0001). The strongest inverse correlation between CPP and PI was obtained (r=0.86, p<0.0001) for CPP values below 70 mmHg. Conclusions: Pulsatility index measurements permit the early identification of patients with low CPP and high risk of cerebral ischemia. In emergency situations it can be used alone when ICP monitoring is contraindicated or not readily available.	Univ Ioannina, Neurosurg Clin, Sch Med, GR-45110 Ioannina, Greece; Univ Patras, Neurosurg Clin, Patras, Greece	Voulgaris, SG (corresponding author), Univ Ioannina, Neurosurg Clin, Sch Med, GR-45110 Ioannina, Greece.						Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BOKINIEC R, 2004, MED SCI MONIT S2, V10, P14; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHAN KH, 1993, NEUROSURGERY, V32, P547; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; HASSLER W, 1988, J NEUROSURG, V68, P745; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; Lewis SB, 2001, NEUROSURGERY, V49, P1485, DOI 10.1097/00006123-200112000-00044; LINDEGAARD KF, 1992, TRANSCRANIAL DOPPLER, P67; McQuire JC, 1998, J NEUROSURG, V89, P526, DOI 10.3171/jns.1998.89.4.0526; Murillo-Cabezas F, 2002, NEUROCIRUGIA, V13, P196; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; Rosner MJ, 1996, CRIT CARE MED, V24, P1274, DOI 10.1097/00003246-199607000-00040; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Shigemori M, 1992, Acta Neurochir Suppl (Wien), V55, P6; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Tan H, 2001, Chin J Traumatol, V4, P156; Ursino M, 1998, J NEUROSURG, V89, P255, DOI 10.3171/jns.1998.89.2.0255; 2000, J NEUROTRAUMA, V17, P479	24	57	59	0	1	INT SCIENTIFIC INFORMATION, INC	MELVILLE	150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	FEB	2005	11	2					CR49	CR52					4	Medicine, Research & Experimental	Research & Experimental Medicine	897UA	WOS:000227029700008	15668630				2021-06-18	
J	Hauser, CJ				Hauser, CJ			Preclinical models of traumatic, hemorrhagic shock	SHOCK			English	Article; Proceedings Paper	Symposium on the Translational Biology of Shock and Sepsis	JUN 04-06, 2004	Lunenburg, CANADA			hemorrhagic shock; shock syndromes; tissue hypoperfusion; acidosis	BRAIN-INJURY; GUINEA-PIGS; NITRIC-OXIDE; LUNG INJURY; UNCONTROLLED HEMORRHAGE; INFLAMMATORY RESPONSE; NEUTROPHIL ACTIVATION; COMPLEMENT ACTIVATION; EXOGENOUS UBIQUITIN; FLUID RESUSCITATION		Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Trauma, Newark, NJ 07103 USA	Hauser, CJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Surg, Div Trauma, MSB G-524,185 S Orange Ave, Newark, NJ 07103 USA.	hausercj@UMDNJ.edu	Hauser, Carl J./Y-1189-2019	Hauser, Carl/0000-0003-3167-1846	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM059179] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-59179] Funding Source: Medline		AbdelZaher AO, 1996, JPN J PHARMACOL, V72, P247, DOI 10.1254/jjp.72.247; Adachi T, 1998, SHOCK, V9, P204, DOI 10.1097/00024382-199803000-00008; Adams CA, 2002, SHOCK, V18, P513, DOI 10.1097/00024382-200212000-00005; Aguilar MM, 1998, J TRAUMA, V45, P14, DOI 10.1097/00005373-199807000-00003; Alam HB, 2004, RESUSCITATION, V60, P91, DOI 10.1016/j.resuscitation.2003.08.006; Alam HB, 2003, J TRAUMA, V54, P1077, DOI 10.1097/01.TA.0000068258.99048.70; Anderson JT, 1997, J TRAUMA, V42, P592, DOI 10.1097/00005373-199704000-00003; Anderson JT, 1997, J TRAUMA, V42, P600; Block EFJ, 2004, J TRAUMA, V56, P999; Boura C, 2003, SHOCK, V19, P176, DOI 10.1097/00024382-200302000-00015; BROWN WJ, 1972, AM J PATHOL, V67, P41; Brundage SI, 2003, J SURG RES, V113, P74, DOI 10.1016/S0022-4804(03)00129-X; Bruscagin V, 2002, J TRAUMA, V52, P1147, DOI 10.1097/00005373-200206000-00021; CHA SC, 1992, CAN J PHYSIOL PHARM, V70, P669, DOI 10.1139/y92-085; Chang EF, 2003, J NEUROSCI, V23, P3689; Chiara O, 2003, CRIT CARE MED, V31, P1915, DOI 10.1097/01.CCM.0000074725.62991.42; Claridge JA, 2002, CRIT CARE MED, V30, P1815, DOI 10.1097/00003246-200208000-00024; Clasper JC, 2002, INJURY, V33, P157, DOI 10.1016/S0020-1383(01)00136-X; Cruz RJ, 2001, INJURY, V32, P17, DOI 10.1016/S0020-1383(00)00097-8; DEITCH EA, 1994, SHOCK, V1, P141, DOI 10.1097/00024382-199402000-00010; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; DEMARIA EJ, 1987, J SURG RES, V43, P45, DOI 10.1016/0022-4804(87)90045-X; DEMLING RH, 1975, SURGERY, V77, P512; Diehl KH, 2001, J APPL TOXICOL, V21, P15, DOI 10.1002/jat.727; Dingley J, 1999, CRIT CARE MED, V27, P2435, DOI 10.1097/00003246-199911000-00019; Dodd KT, 1997, J TRAUMA, V43, P656, DOI 10.1097/00005373-199710000-00016; Doucet JJ, 2004, J TRAUMA, V56, P501, DOI 10.1097/01.TA.0000114536.98447.F7; Driessen B, 2003, CRIT CARE MED, V31, P1771, DOI 10.1097/01.CCM.0000063476.79749.C1; Eckhoff DE, 2002, SURGERY, V132, P302, DOI 10.1067/msy.2002.125718; Eissner B, 2002, EUR SURG RES, V34, P61, DOI 10.1159/000048889; Gonzalez RJ, 2001, J TRAUMA, V51, P1069, DOI 10.1097/00005373-200112000-00008; GORANSSON AM, 1982, ACTA CHIR SCAND, P153; Gorbunov NV, 2004, CRIT CARE MED, V32, P1028, DOI 10.1097/01.CCM.0000120051.79520.B6; Guan J, 2002, J TRAUMA, V52, P104, DOI 10.1097/00005373-200201000-00018; Harkness JE, 1989, BIOL MED RABBITS ROD; HEIDEMAN M, 1978, J TRAUMA, V18, P696, DOI 10.1097/00005373-197810000-00002; HESS JR, 1993, J APPL PHYSIOL, V74, P1769; Hewitt PM, 2002, INJURY, V33, P673, DOI 10.1016/S0020-1383(02)00095-5; JANSSON I, 1985, J TRAUMA, V25, P288, DOI 10.1097/00005373-198504000-00002; Jarrar D, 2000, ANN SURG, V231, P399, DOI 10.1097/00000658-200003000-00013; JONSSON A, 1979, AVIAT SPACE ENVIR MD, V50, P325; Kelly ME, 2003, J TRAUMA, V55, P94, DOI 10.1097/01.TA.0000029042.37577.A6; Kneidinger R, 1996, J LAB CLIN MED, V128, P515, DOI 10.1016/S0022-2143(96)90049-9; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Knoferl MW, 2001, SHOCK, V16, P479, DOI 10.1097/00024382-200116060-00013; KOCH T, 1993, CRIT CARE MED, V21, P1758, DOI 10.1097/00003246-199311000-00027; Krausz MM, 2003, SHOCK, V20, P444, DOI 10.1097/01.shk.0000094560.76615.91; Kretschmar K, 1991, Acta Histochem Suppl, V41, P265; Kuebler JF, 2003, SHOCK, V20, P144, DOI 10.1097/01.shk.0000072127.33223.f1; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; Lin YS, 2000, EUR J PHARMACOL, V394, P139, DOI 10.1016/S0014-2999(00)00126-6; Liu FF, 1996, RADIOTHER ONCOL, V40, P75, DOI 10.1016/0167-8140(96)01733-1; Liu LM, 2004, SHOCK, V21, P93, DOI 10.1097/01.shk.0000097247.97298.0e; Lomas JL, 2003, SHOCK, V19, P358, DOI 10.1097/00024382-200304000-00011; Lu Qi, 2004, Di Yi Jun Yi Da Xue Xue Bao, V24, P325; Mackrell PJ, 2001, SURGERY, V130, P826, DOI 10.1067/msy.2001.116669; Majetschak M, 2004, J TRAUMA, V56, P991, DOI 10.1097/01.TA.0000127770.29009.5A; Malhotra AK, 2004, J TRAUMA, V56, P1049, DOI 10.1097/01.TA.0000127765.75643.66; MARTINS MA, 1990, CRIT CARE MED, V18, P515, DOI 10.1097/00003246-199005000-00011; McDonough KH, 2002, J TRAUMA, V53, P541, DOI 10.1097/00005373-200209000-00024; McDonough KH, 2000, J TRAUMA, V48, P1122, DOI 10.1097/00005373-200006000-00020; MEI JM, 1995, SHOCK, V4, P421; Mousavi M, 2001, INJURY, V32, P679, DOI 10.1016/S0020-1383(01)00048-1; Munster AMB, 2001, BLOOD COAGUL FIBRIN, V12, P477, DOI 10.1097/00001721-200109000-00008; NAKANE T, 1985, P NATL ACAD SCI USA, V82, P1247, DOI 10.1073/pnas.82.4.1247; Nielsen VG, 2001, ANESTH ANALG, V93, P1106, DOI 10.1097/00000539-200111000-00007; Nielsen VG, 2001, J CRIT CARE, V16, P64, DOI 10.1053/jcrc.2001.26292; Nwariaku F, 1996, J TRAUMA, V40, P564, DOI 10.1097/00005373-199604000-00007; Oda J, 2002, J TRAUMA, V52, P625, DOI 10.1097/00005373-200204000-00003; Pape HC, 1998, J TRAUMA, V45, P720, DOI 10.1097/00005373-199810000-00017; Pape HC, 1998, INTENS CARE MED, V24, P590, DOI 10.1007/s001340050620; PAPE HC, 1995, EUR J SURG, V161, P304; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; Premier RR, 1998, IMMUNOLOGY, V94, P363, DOI 10.1046/j.1365-2567.1998.00522.x; PRETORIUS JP, 1987, J TRAUMA, V27, P1344, DOI 10.1097/00005373-198712000-00005; REDL H, 1991, AM J PATHOL, V139, P461; REDL H, 1989, RESUSCITATION, V17, P77, DOI 10.1016/0300-9572(89)90081-6; REDL H, 1995, SHOCK, V3, P395; ROUHANA SW, 1985, J TRAUMA, V25, P490, DOI 10.1097/00005373-198506000-00004; Sato S, 1997, SHOCK, V8, P136, DOI 10.1097/00024382-199708000-00013; Schlag G, 1999, CRIT CARE MED, V27, P1900, DOI 10.1097/00003246-199909000-00031; SCHMAND JF, 1994, CRIT CARE MED, V22, P1076, DOI 10.1097/00003246-199407000-00005; SCHMIDT GH, 1967, J SURG RES, V7, P513, DOI 10.1016/0022-4804(67)90020-0; Soller BR, 2003, J SURG RES, V114, P195, DOI 10.1016/S0022-4804(03)00251-8; STAUB NC, 1974, LYMPHOLOGY, V7, P96; Strong VEM, 2000, SHOCK, V14, P374; Swafford AN, 2003, SHOCK, V20, P237, DOI 10.1097/00024382-200309000-00007; Szebeni J, 2003, SHOCK, V20, P347, DOI 10.1097/01.shk.0000082444.66379.17; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; van Iterson M, 2003, J TRAUMA, V55, P1111, DOI 10.1097/01.TA.0000101391.58216.DD; VEDDER NB, 1988, J CLIN INVEST, V81, P939, DOI 10.1172/JCI113407; WADE L, 1970, AM J VET RES, V31, P1375; White DJ, 2004, CRIT CARE MED, V32, P1338, DOI 10.1097/01.CCM.0000128571.39037.09; Wichmann MW, 1996, ARCH SURG-CHICAGO, V131, P995; WIGGERS CJ, 1950, PHYSL SHOCK, P121; York GB, 2003, J TRAUMA, V55, P873, DOI 10.1097/01.TA.0000092681.17874.6F; Zakaria ER, 2004, SHOCK, V21, P248, DOI 10.1097/01.shk.0000111824.07309.19	98	57	58	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock		2005	24			1			24	32		10.1097/01.shk.0000191387.18818.43			9	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	999XR	WOS:000234425400005	16374369				2021-06-18	
J	Signoretti, S; Marmarou, A; Tavazzi, B; Dunbar, J; Amorini, AM; Lazzarino, G; Vagnozzi, R				Signoretti, S; Marmarou, A; Tavazzi, B; Dunbar, J; Amorini, AM; Lazzarino, G; Vagnozzi, R			The protective effect of Cyclosporin A upon N-acetylaspartate and mitochondrial dysfunction following experimental diffuse traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						energetic metabolism; high-performance liquid chromatography; magnetic resonance spectroscopy; mitochondrial dysfunction; N-acetylaspartate; traumatic brain injury	MAGNETIC-RESONANCE-SPECTROSCOPY; PERMEABILITY TRANSITION PORE; EXCITATORY AMINO-ACIDS; INDUCED AXONAL INJURY; RAT-BRAIN; ACETYL-ASPARTATE; P-GLYCOPROTEIN; CELL-DEATH; NERVOUS-SYSTEM; IN-VIVO	Pre- and post-injury Cyclosporin A (CsA) administration has shown neuroprotective properties by ameliorating mitochondrial damage. The aim of this study was to assess the effect of CsA upon N-acetylaspartate (NAA) reduction and ATP loss, two sensitive markers of mitochondrial dysfunction and bioenergetic impairment. Adult male Sprague-Dawley rats were exposed to impact acceleration traumatic brain injury (2 m/450 g) and randomized into the following experimental groups: intrathecal CsA/vehicle treated (n = 12), intravenous CsA/vehicle treated (n = 18) and sham (n = 12). Intrathecal treatment consisted of post-injury (30 min) cisternal bolus of CsA or Vehicle (0.15 mL, 10 mg/kg). Intravenous administration consisted of 30 min post-injury continuous 1hour infusion of either 20 or 35 mg/kg CsA or Vehicle. Quantitative HPLC analysis of whole brain samples was performed 6 h post-injury for levels of NAA and ATP. Following intrathecal delivery CsA demonstrated significant neuroprotection blunting a 30% NAA reduction (p < 0.001) and restoring 26% of the ATP loss (p < 0.005). The 20 mg/kg intravenous dose failed to ameliorate the biochemical damages while the 35 mg/kg dosage showed 36% NAA recovery and 39% ATP restoration (P < 0.001). In conclusion, CsA is capable of restoring ATP and blunting NAA reduction. Intravenous infusion of 35 mg/kg appears to be the optimal therapeutic strategy in this model. These findings contribute to the notion that CsA achieves neuroprotection, preserving mitochondrial function, and provides a rationale for the assessment of CsA in the clinical setting where MR spectroscopy can monitor NAA and ATP in brain-injured patients.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; Univ Catania, Div Biochem Mol Biol & Pharmacol, Dept Chem Sci, I-95124 Catania, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00173 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA.	marmarou@abic.vcu.edu	Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; lazzarino, giuseppe/0000-0002-5917-7279; AMORINI, Angela Maria/0000-0003-3525-9955	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS 12587, 2R01 NS 19235] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, R01NS019235] Funding Source: NIH RePORTER		Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bart J, 2000, CANCER TREAT REV, V26, P449, DOI 10.1053/ctrv.2000.0194; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BRENNER RE, 1993, MAGNET RESON MED, V29, P737, DOI 10.1002/mrm.1910290605; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Capano M, 2002, BIOCHEM J, V363, P29, DOI 10.1042/bj3630029; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CEFALU WT, 1985, J NEUROCHEM, V45, P1954, DOI 10.1111/j.1471-4159.1985.tb10557.x; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; Davie CA, 1997, J NEUROL NEUROSUR PS, V63, P736, DOI 10.1136/jnnp.63.6.736; de Perrot M, 2000, TRANSPLANTATION, V70, P1259, DOI 10.1097/00007890-200010270-00025; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; Dohgu S, 2000, CELL MOL NEUROBIOL, V20, P781, DOI 10.1023/A:1007015228318; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; DUX E, 1987, NEUROSCI LETT, V78, P295, DOI 10.1016/0304-3940(87)90376-4; EBISU T, 1994, J CEREBR BLOOD F MET, V14, P373, DOI 10.1038/jcbfm.1994.48; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Falini A, 1998, AM J NEURORADIOL, V19, P648; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 1998, J NEUROSCI, V18, P5151; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; HEALES SJR, 1995, NEUROCHEM RES, V20, P31; Jenkins BG, 1996, J CEREBR BLOOD F MET, V16, P450, DOI 10.1097/00004647-199605000-00011; Kalra S, 1998, NEUROREPORT, V9, P1757, DOI 10.1097/00001756-199806010-00016; Khodorov B, 1996, FEBS LETT, V393, P135, DOI 10.1016/0014-5793(96)00873-3; Kochi S, 2000, LIFE SCI, V66, P2255, DOI 10.1016/S0024-3205(00)00554-3; Kristal BS, 2000, DEV NEUROSCI-BASEL, V22, P376, DOI 10.1159/000017463; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; Lemaire M, 1996, CANCER CHEMOTH PHARM, V38, P481, DOI 10.1007/s002800050515; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MEIJER AJ, 1974, BIOCHIM BIOPHYS ACTA, V346, P213, DOI 10.1016/0304-4173(74)90001-9; MIYAMOTO S, 1998, J ARTIF ORGANS, V1, P10; MOFFETT JR, 1993, J HISTOCHEM CYTOCHEM, V41, P559, DOI 10.1177/41.4.8450195; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PATEL TB, 1979, BIOCHEM J, V184, P539, DOI 10.1042/bj1840539; Patt S, 1999, EXP TOXICOL PATHOL, V51, P119, DOI 10.1016/S0940-2993(99)80084-0; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Regina A, 1999, J NEUROCHEM, V73, P1954; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Rooney WD, 1998, NEUROLOGY, V50, P1800, DOI 10.1212/WNL.50.6.1800; Sager TN, 1999, J CEREBR BLOOD F MET, V19, P164; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; SAKATA A, 1994, BIOCHEM PHARMACOL, V48, P1989, DOI 10.1016/0006-2952(94)90601-7; SARAGEA M, 1965, MED PHARMACOL EXP, V13, P74; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SHIINO A, 1993, SURG NEUROL, V39, P143, DOI 10.1016/0090-3019(93)90093-G; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SIMMONS ML, 1991, NEUROSCIENCE, V45, P37, DOI 10.1016/0306-4522(91)90101-S; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; SZABO I, 1991, J BIOL CHEM, V266, P3376; Tasch E, 1999, ANN NEUROL, V45, P568, DOI 10.1002/1531-8249(199905)45:5<568::AID-ANA4>3.0.CO;2-P; Tavazzi B, 2000, ANAL BIOCHEM, V277, P104, DOI 10.1006/abio.1999.4386; TRUCKENMILLER ME, 1985, J NEUROCHEM, V45, P1658, DOI 10.1111/j.1471-4159.1985.tb07240.x; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; Tymianski Michael, 1996, Neurosurgery (Baltimore), V38, P1176, DOI 10.1097/00006123-199606000-00028; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Warren KE, 2000, CANCER CHEMOTH PHARM, V45, P207, DOI 10.1007/s002800050031; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yamamoto T, 1999, ACT NEUR S, V75, P17; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zaidan E, 1999, J NEUROCHEM, V73, P2214; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	95	57	59	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2004	21	9					1154	1167		10.1089/neu.2004.21.1154			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	855HC	WOS:000223962900005	15453986				2021-06-18	
J	Wurm, G; Tomancok, B; Nussbaumer, K; Adelwohrer, C; Holl, K				Wurm, G; Tomancok, B; Nussbaumer, K; Adelwohrer, C; Holl, K			Reduction of ischemic sequelae following spontaneous subarachnoid hemorrhage: a double-blind, randomized comparison of enoxaparin versus placebo	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						subarachnoid hemorrhage; low-molecular-weight heparin; cerebral vasospasm	MOLECULAR-WEIGHT HEPARIN; TRAUMATIC BRAIN INJURY; VENOUS THROMBOEMBOLISM; CEREBRAL VASOSPASM; PREVENTION; MANAGEMENT; SURGERY; PROLIFERATION; COMPLICATIONS; PROPHYLAXIS	Background: Cerebral vasospasm, including its ischemic sequelae, remains a leading cause of death and disability following subarachnoid hemorrhage (SAH). This study was designed to evaluate whether the low-molecular-weight heparin (LMWH) enoxaparin reduces the occurrence of cerebral vasospasm and ischemia following spontaneous SAH. Methods: A prospective, double-blind, randomized study was conducted in 120 consecutive patients with SAH (Hunt Hess Scale (HHS) I-III). Patients received one subcutaneous injection per day of either 20 mg enoxaparin or placebo for 3 weeks following SAH. Efficacy endpoints were the occurrence of cerebral vasospasm, delayed ischemic deficit (DID), cerebral infarction, and overall outcome at I year following SAH. Results: At 1-year follow-up, enoxaparin significantly reduced DID and cerebral infarction. Delayed ischemic deficit occurred in 8.8% of the enoxaparin group versus 66.7% of the placebo group (P < 0.001), while 3.5% of vasospasm-related cerebral infarctions occurred in enoxaparin-treated patients and 28.3% in placebo-treated patients (P < 0.001). Severe shunt-dependent hydrocephalus was significantly lower in the enoxaparin group (1.8% versus 16.7%; P = 0.019). Compared with the placebo group, the enoxaparin group had fewer intracranial bleeding events and better overall outcomes at 1-year follow-up. Although there was potential bias as a result of patients in the placebo group being more severely affected (in terms of HHS), treatment with enoxaparin for 3 weeks improved long-term outcome following SAH. Conclusions: Enoxaparin is safe and effective in reducing cerebral vasospasm and ischemia following SAH (Hunt Hess grades I-III), resulting in a better long-term outcome for the patient. (C) 2004 Elsevier B.V. All rights reserved.	Landesnervenklin Wagner Jauregg, Dept Neurosurg, A-4020 Linz, Austria; Landesnervenklin Wagner Jauregg, Dept Neuroradiol, A-4020 Linz, Austria; Landesnervenklin Wagner Jauregg, Dept Neurol, A-4020 Linz, Austria	Nussbaumer, K (corresponding author), Landesnervenklin Wagner Jauregg, Dept Neurosurg, Wagner Jauregg Weg 15, A-4020 Linz, Austria.	gabriele.wurm@gespag.at					AASLID R, 1984, J NEUROSURG, V60, P37, DOI 10.3171/jns.1984.60.1.0037; Agnelli G, 1999, THROMB HAEMOSTASIS, V82, P925; BAZZONI G, 1993, J LAB CLIN MED, V121, P268; BLASBERG R, 1981, NEUROSURGERY, V9, P686, DOI 10.1227/00006123-198112000-00012; Charpentier C, 1999, STROKE, V30, P1402, DOI 10.1161/01.STR.30.7.1402; CHIMOWITZ MI, 1987, STROKE, V18, P1169, DOI 10.1161/01.STR.18.6.1169; CLOWES AW, 1985, LAB INVEST, V52, P611; Cupitt JM, 2001, ANAESTHESIA, V56, P780; Fareed J, 2000, SEMIN THROMB HEMOST, V26, P5, DOI 10.1055/s-2000-9498; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FRIM DM, 1992, NEUROSURGERY, V30, P830, DOI 10.1227/00006123-199206000-00002; Gikakis N, 1996, CIRCULATION, V94, P341; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; HOOVER RL, 1980, CIRC RES, V47, P578, DOI 10.1161/01.RES.47.4.578; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Hutter BO, 1999, ACT NEUR S, V72, P157; Hutter BO, 2001, J NEUROSURG, V94, P241, DOI 10.3171/jns.2001.94.2.0241; Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327; JENNETT B, 1975, LANCET, V1, P480; Jonas S, 1997, ANN NY ACAD SCI, V825, P389, DOI 10.1111/j.1749-6632.1997.tb48449.x; Juvela S, 2000, J NEUROSURG, V92, P390, DOI 10.3171/jns.2000.92.3.0390; KAPP JP, 1982, SURG NEUROL, V18, P40, DOI 10.1016/0090-3019(82)90011-8; KARNOFSKY DA, 1951, ARCH INTERN MED, V87, P477, DOI 10.1001/archinte.1951.03810040002001; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; Libersan D, 1998, CARDIOVASC RES, V37, P656, DOI 10.1016/S0008-6363(97)00292-7; MACDONALD RL, 1994, J NEUROSURG, V80, P433, DOI 10.3171/jns.1994.80.3.0433; Macdonald RL, 1999, NEUROSURGERY, V45, P245, DOI 10.1097/00006123-199908000-00008; MAHONEY F I, 1965, Md State Med J, V14, P61; Mary V, 2001, STROKE, V32, P993, DOI 10.1161/01.STR.32.4.993; MAYBERG MR, 1994, STROKE, V25, P2315, DOI 10.1161/01.STR.25.11.2315; NAGY Z, 1995, STROKE, V26, P265, DOI 10.1161/01.STR.26.2.265; Okada Y, 1999, NEUROSURGERY, V45, P443, DOI 10.1097/00006123-199909000-00005; Persson L, 1999, ACT NEUR S, V72, P73; Pratt J, 1998, HAEMOSTASIS, V28, P78; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; TEKKOK IH, 1994, ACTA NEUROCHIR, V127, P112, DOI 10.1007/BF01808557; Treggiari-Venzi MM, 2001, NEUROSURGERY, V48, P249, DOI 10.1097/00006123-200102000-00001; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; Weir B, 1999, ACT NEUR S, V72, P27; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; YAMAMOTO Y, 1992, NEUROSURGERY, V30, P337, DOI 10.1227/00006123-199203000-00005	41	57	59	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	MAR	2004	106	2					97	103		10.1016/j.clineuro.2004.01.006			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	805BI	WOS:000220341400005	15003298				2021-06-18	
J	Hecht, JS				Hecht, JS			Occipital nerve blocks in postconcussive headaches - A retrospective review and report of ten patients	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; brain injuries; cervicogenic headache; headache; bead injuries; occipital nerve block; occipital neuralgia; pain therapy; postconcussive syndrome; whiplash	BASILAR ARTERY MIGRAINE; TENSION-TYPE HEADACHE; CERVICOGENIC HEADACHE; POSTTRAUMATIC HEADACHE; CERVICAL-SPINE; ANESTHETIC BLOCKADES; DIAGNOSTIC-CRITERIA; HISTORICAL COHORT; WHIPLASH INJURIES; BOTULINUM-TOXIN	Headaches are common following traumatic brain injuries of all severities. Pain generators may be in the head itself or the neck. Headache assessment is discussed. Diagnosis and treatment of cervical headaches syndromes and, in particular, occipital neuralgia are reviewed. Finally, a retrospective study of 10 postconcussive patients with headaches who were treated with greater occipital nerve blocks is presented. Following the injection(s), 80% had a "good" response and 20% had a "partial" response. Occipital nerve block is a useful diagnostic and treatment modality in the setting of postconcussive headaches.	Univ Tennessee, Grad Sch Med, Div Surg Rehabil, Dept Surg, Knoxville, TN 37920 USA	Hecht, JS (corresponding author), Univ Tennessee, Grad Sch Med, Div Surg Rehabil, Dept Surg, 1932 Alcoa Highway,Suite C580, Knoxville, TN 37920 USA.	jhecht@tennessee.edu					Anthony KRN, 2000, CORAL REEFS, V19, P59, DOI 10.1007/s003380050227; Antonaci F, 1997, FUNCT NEUROL, V12, P11; Astin JA, 2002, CEPHALALGIA, V22, P617, DOI 10.1046/j.1468-2982.2002.00423.x; Barre J-A., 1926, REV NEUROL, V33, P1246; Becser N, 1998, SPINE, V23, P1435, DOI 10.1097/00007632-199807010-00001; BLUME HG, 1976, ADV PAIN RES THER, V7, P691; BOGDUK N, 1985, MED J AUSTRALIA, V143, P202, DOI 10.5694/j.1326-5377.1985.tb122915.x; BOGDUK N, 1986, J NEUROL NEUROSUR PS, V49, P775, DOI 10.1136/jnnp.49.7.775; BOGDUK N, 1985, CURRENT THERAPY NEUR, P175; Bono G, 2000, CLIN EXP RHEUMATOL, V18, pS23; BOVIM G, 1992, PAIN, V49, P315, DOI 10.1016/0304-3959(92)90237-6; BOVIM G, 1992, PAIN, V51, P43, DOI 10.1016/0304-3959(92)90007-X; Caputi CA, 1998, HEADACHE, V38, P57; Chouret E E, 1967, Headache, V7, P33, DOI 10.1111/j.1526-4610.1967.hed0701033.x; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Deyo RA, 1996, SPINE, V21, P2840, DOI 10.1097/00007632-199612150-00007; Diener H C, 2001, Curr Med Res Opin, V17 Suppl 1, ps17, DOI 10.1185/0300799039117003; DREYER SJ, 2000, PAIN PROCEDURES CLIN; DROZ J, 1985, SWISS ANN CHIROPRAC, V8; DUBUISSON D, 1995, J NEUROSURG, V82, P581, DOI 10.3171/jns.1995.82.4.0581; Dumas JP, 2001, CEPHALALGIA, V21, P884, DOI 10.1046/j.1468-2982.2001.00264.x; DUTTON CB, 1969, AM J MED, V47, P141, DOI 10.1016/0002-9343(69)90248-4; ELKIND AH, 1989, CLIN J PAIN, V5, P77, DOI 10.1097/00002508-198903000-00014; ERLINGTON G, 2002, J NEUROL NEURSURG S2, V72, P10; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; Evers S, 2002, CEPHALALGIA, V22, P699, DOI 10.1046/j.1468-2982.2002.00390.x; Fredriksen TA, 2003, FUNCT NEUROL, V18, P17; Freund BJ, 2002, CLIN J PAIN, V18, pS163, DOI 10.1097/00002508-200211001-00008; Gilkey SJ, 1997, HEADACHE, V37, P583, DOI 10.1046/j.1526-4610.1997.3709583.x; Goadsby PJ, 2002, J NEUROL NEUROSUR PS, V72, P2; GREENE WB, 2001, ESSENTIALS MUSCULOSK, P230; GREENE WB, 2001, ESSENTIALS MUSCULOSK, P478; Hachinski V, 2000, ARCH NEUROL-CHICAGO, V57, P1780, DOI 10.1001/archneur.57.12.1780; Haldeman S, 2001, Spine J, V1, P31, DOI 10.1016/S1529-9430(01)00024-9; Hammond S R, 1978, Clin Exp Neurol, V15, P258; HORN LJ, 1992, REHABILTATION POSTCO, P69; HOROWITZ MB, 1993, CEPHALALGIA, V13, P354, DOI 10.1046/j.1468-2982.1993.1305354.x; HOWE DH, 1983, J ROY COLL GEN PRACT, V33, P574; HUNTER CR, 1949, AM J SURG, V78, P743, DOI 10.1016/0002-9610(49)90316-5; JACOME DE, 1986, HEADACHE, V26, P515, DOI 10.1111/j.1526-4610.1986.hed2610515.x; JENSEN OK, 1990, CEPHALALGIA, V10, P241, DOI 10.1046/j.1468-2982.1990.1005241.x; JOSEPH B, 1994, SPINE, V19, P454, DOI 10.1097/00007632-199402001-00013; JOSEY AI, 1949, JAMA-J AM MED ASSOC, V140, P944, DOI 10.1001/jama.1949.02900460014005; Keidel M, 2001, PAIN, V92, P319, DOI 10.1016/S0304-3959(01)00272-X; KOVACS A, 1955, ACTA RADIOL, V43, P1; KRANZLIN P, 1993, ANN POSTGRADUATE COU, V13; Lake AE, 2002, NEUROLOGY, V59, pS8, DOI 10.1212/WNL.59.5_suppl_2.S8; Lavin PJ, 2001, HEADACHE, V41, P902, DOI 10.1046/j.1526-4610.2001.01165.x; Lennard T, 2000, PAIN PROCEDURES CLIN; Lewis DW, 2002, NEUROLOGY, V59, P490, DOI 10.1212/WNL.59.4.490; LEWIS RC, 1956, MISSOURI MED, V53, P1059; Limmroth V, 2002, NEUROLOGY, V59, P1011, DOI 10.1212/WNL.59.7.1011; Loder E, 2002, CLIN J PAIN, V18, pS169, DOI 10.1097/00002508-200211001-00009; LORD SM, 1994, J NEUROL NEUROSUR PS, V57, P1187, DOI 10.1136/jnnp.57.10.1187; MACNAB I, 1964, J BONE JOINT SURG AM, V46, P1797, DOI 10.2106/00004623-196446080-00021; Magnusson T, 1996, HEADACHE, V36, P32, DOI 10.1046/j.1526-4610.1996.3601032.x; MAGNUSSON T, 1994, CEPHALALGIA, V14, P223, DOI 10.1046/j.1468-2982.1994.014003223.x; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; May A, 2003, BRIT MED BULL, V65, P223, DOI 10.1093/bmb/65.1.223; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Melchart D, 2003, J INTERN MED, V253, P181, DOI 10.1046/j.1365-2796.2003.01081.x; Merskey H, 1994, CERVICOGENIC HEADACH; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; Murphy J P, 1969, Md State Med J, V18, P62; Obelieniene D, 1998, CEPHALALGIA, V18, P559, DOI 10.1046/j.1468-2982.1998.1808559.x; OCONNOR AJ, 2003, CERVICOGENIC HEADACH; OH M, 1999, ACNS PAIN SECT N APR, P3; OKEDA Y, 2001, DJ ANESTHESIA, V18, P829; OLESEN J, INT HEADACHE CLASSIF; OMMAYA AK, 1984, BIOMECHANICS IMPACT; ONOFRIO BM, 1972, J NEUROSURG, V36, P751, DOI 10.3171/jns.1972.36.6.0751; PEARCE JMS, 1995, J NEUROL NEUROSUR PS, V58, P698, DOI 10.1136/jnnp.58.6.698; Peres MFP, 2002, CEPHALALGIA, V22, P520, DOI 10.1046/j.1468-2982.2002.00410.x; POLETTI CE, 1990, NEUROSURGERY, V27, P288, DOI 10.1227/00006123-199008000-00019; Pollmann W, 1997, CEPHALALGIA, V17, P801, DOI 10.1046/j.1468-2982.1997.1708801.x; Radanov BP, 1996, PAIN, V64, P429, DOI 10.1016/0304-3959(95)00148-4; ROHEN J, 2002, COLOR ATLAS ANATOMY, P227; Saper JR, 2002, HEADACHE, V42, P470, DOI 10.1046/j.1526-4610.2002.02122.x; Silverman Steven B, 2002, Curr Pain Headache Rep, V6, P308, DOI 10.1007/s11916-002-0052-3; SJAASTAD O, 1983, CEPHALALGIA, V3, P249, DOI 10.1046/j.1468-2982.1983.0304249.x; Sjaastad O, 1998, HEADACHE, V38, P442, DOI 10.1046/j.1526-4610.1998.3806442.x; Sjaastad O, 2002, CEPHALALGIA, V22, P667, DOI 10.1046/j.1468-2982.2002.00408.x; SJAASTAD O, 1990, HEADACHE, V30, P725, DOI 10.1111/j.1526-4610.1990.hed3011725.x; STECHISON MT, 1994, ACTA NEUROCHIR, V131, P236, DOI 10.1007/BF01808620; STEVANS JM, 1996, CHIROPRAC TECH, V8, P12; STURZENEGGER MH, 1985, HEADACHE, V25, P408; TOLLISON CD, 1992, PAINFUL CERVICAL TRA; Travell J.G., 1992, MYOFASCIAL PAIN DYSF, V1; Turk Z, 1987, MANUAL MED, V3, P15; Valenca MM, 2002, ARQ NEURO-PSIQUIAT, V60, P542, DOI 10.1590/S0004-282X2002000400005; Vincent M, 1998, FUNCT NEUROL, V13, P78; Vincent MB, 1998, ARQ NEURO-PSIQUIAT, V56, P720, DOI 10.1590/S0004-282X1998000500004; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x; ZASLER N, 1996, MED REHABILITATION T, P145	95	57	59	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					58	71		10.1097/00001199-200401000-00006			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000006	14732831				2021-06-18	
J	Lee, Y; Aono, M; Laskowitz, D; Warner, DS; Pearlstein, RD				Lee, Y; Aono, M; Laskowitz, D; Warner, DS; Pearlstein, RD			Apolipoprotein E protects against oxidative stress in mixed neuronal-glial cell cultures by reducing glutamate toxicity	NEUROCHEMISTRY INTERNATIONAL			English	Article						apolipoprotein E; neuronal-glial cell culture; lactate dehydrogenase	E-DEFICIENT MICE; CENTRAL-NERVOUS-SYSTEM; DENSITY-LIPOPROTEIN RECEPTOR; AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; E MESSENGER-RNA; ALZHEIMERS-DISEASE; LIPID-PEROXIDATION; CEREBRAL-ISCHEMIA; E IMMUNOREACTIVITY	Apolipoprotein E (ApoE) deficiency has been shown to adversely affect outcome after transient cerebral ischemia and head trauma. Since oxidative stress contributes to these injuries, the ability of ApoE to reduce irreversible oxidative damage was studied in primary mixed neuronal-glial cell cultures. Cells (13-16 days in vitro) were exposed to 50 muM hydrogen peroxide (H2O2) for 30 min, and toxicity was determined by the release of lactate dehydrogenase (LDH) 24 h after exposure. The presence of recombinant human ApoE2 (100, 300, or 1000 nM) in the culture media partially protected against oxidative injury. This protection was not reversed by pre-treatment with receptor associated protein. The NMDA receptor antagonist, MK-801, also provided partial protection against H2O2 toxicity. The degree of protection was similar to that conferred by ApoE treatment. The protective effects of ApoE and MK-801 were not additive; no ApoE protection was observed in cultures treated with MK-801 prior to H2O2 exposure. ApoE treatment had no effect on H2O2 stimulated glutamate release, but did increase the rate of glutamate uptake via the high affinity glutamate transporter in H2O2 treated cultures. Pre-treatment with ApoE also conferred partial protection against glutamate-induced LDH release. Taken together, these findings suggest that ApoE protects mixed neuronal-glial cell cultures against irreversible oxidative injury from H2O2 by reducing secondary glutamate excitotoxicity. (C) 2003 Elsevier Science Ltd. All rights reserved.	Duke Univ, Med Ctr, Dept Surg, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA	Pearlstein, RD (corresponding author), Duke Univ, Med Ctr, Dept Surg, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001949] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01 HL4244-12] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS01949] Funding Source: Medline		AAMAR S, 1992, J NEUROCHEM, V59, P1287, DOI 10.1111/j.1471-4159.1992.tb08439.x; ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Ali SM, 1996, MOL BRAIN RES, V38, P37, DOI 10.1016/0169-328X(95)00301-8; AMADOR E, 1963, CLIN CHEM, V9, P391; Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Beffert U, 1998, BRAIN RES REV, V27, P119, DOI 10.1016/S0165-0173(98)00008-3; Bellomo G, 1987, Mol Toxicol, V1, P281; BOYLES JK, 1990, J BIOL CHEM, V265, P17805; CARLSSON J, 1991, CLIN CHIM ACTA, V196, P167, DOI 10.1016/0009-8981(91)90070-S; Chapman S, 1998, J NEUROCHEM, V70, P708; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Gordon I, 1996, NEUROSCI LETT, V206, P212, DOI 10.1016/S0304-3940(96)12470-8; Gordon I, 1996, MOL CHEM NEUROPATHOL, V28, P97, DOI 10.1007/BF02815210; Gutman CR, 1997, J NEUROSCI, V17, P6114; HALL ED, 1995, EXP NEUROL, V135, P17, DOI 10.1006/exnr.1995.1062; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; HINSHAW DB, 1993, BRAIN RES, V615, P13, DOI 10.1016/0006-8993(93)91110-E; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 1996, NEUROPATH APPL NEURO, V22, P342, DOI 10.1111/j.1365-2990.1996.tb01113.x; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Hu JR, 1998, J NEUROCHEM, V71, P1626; Igbavboa U, 1997, J NEUROCHEM, V69, P1661; Iwata E, 1997, MOL BRAIN RES, V50, P213, DOI 10.1016/S0169-328X(97)00190-3; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KIDA E, 1995, BRAIN RES, V674, P341, DOI 10.1016/0006-8993(94)01467-V; Kleifeld O, 1998, INT J DEV NEUROSCI, V16, P755, DOI 10.1016/S0736-5748(98)00084-7; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Laskowitz DT, 1997, J NEUROIMMUNOL, V76, P70, DOI 10.1016/S0165-5728(97)00021-0; Laskowitz DT, 1998, NEUROREPORT, V9, P615, DOI 10.1097/00001756-199803090-00010; Lei BP, 1997, NEUROSCI LETT, V222, P91, DOI 10.1016/S0304-3940(97)13349-3; Lei BP, 1998, BRAIN RES PROTOC, V3, P33, DOI 10.1016/S1385-299X(98)00018-X; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; Mailly F, 1999, J NEUROCHEM, V73, P1181, DOI 10.1046/j.1471-4159.1999.0731181.x; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; Metzger RE, 1996, J NEUROPATH EXP NEUR, V55, P372, DOI 10.1097/00005072-199603000-00013; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Montine TJ, 1999, EXP NEUROL, V158, P234, DOI 10.1006/exnr.1999.7067; Pearlstein RD, 1998, J NEUROCHEM, V70, P2012; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1991, MOL BRAIN RES, V9, P191, DOI 10.1016/0169-328X(91)90002-F; POIRIER J, 1991, MOL BRAIN RES, V11, P97, DOI 10.1016/0169-328X(91)90111-A; Pratico D, 1999, J NEUROCHEM, V73, P736, DOI 10.1046/j.1471-4159.1999.0730736.x; RAGHU G, 1986, BRIT J EXP PATHOL, V67, P105; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; STARKE PE, 1985, J BIOL CHEM, V260, P99; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Veinbergs I, 1999, PROG NEURO-PSYCHOPH, V23, P519, DOI 10.1016/S0278-5846(99)00013-5; WEI EP, 1987, PHYSIOLOGIST, V30, P122; Williams KR, 1998, NEUROBIOL DIS, V5, P271, DOI 10.1006/nbdi.1998.0198; Yamauchi K, 1999, CLIN CHEM, V45, P497	67	57	60	1	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186			NEUROCHEM INT	Neurochem. Int.	JAN	2004	44	2					107	118		10.1016/S0197-0186(03)00112-8			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	725RN	WOS:000185556300006	12971913				2021-06-18	
J	Pelinka, LE; Harada, N; Szalay, L; Jafarmadar, M; Redl, H; Bahrami, S				Pelinka, LE; Harada, N; Szalay, L; Jafarmadar, M; Redl, H; Bahrami, S			Release of S100B differs during ischemia and reperfusion of the liver, the gut, and the kidney in rats	SHOCK			English	Article						S100 protein; astrocytes; blood brain barrier; non-neuronal damage; extracranial trauma	NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; S-100 PROTEIN RELEASE; HEMORRHAGIC-SHOCK; CARDIAC MYOCYTES; SKELETAL-MUSCLE; SERUM S100B; INDUCTION; MARKER; S100-BETA	S100B, an acknowledged marker of brain damage, is increased post-traumatically in plasma. The aim of this study was to investigate the diagnostic value of S100B release in experimental local extracranial ischemia and reperfusion. Anesthetized rats underwent laparotomy and ligation of the afferent blood vessels to the liver, gut, or kidney to achieve local ischemia in each organ separately. After 60 min of ischemia, ligatures were removed and resuscitation was performed for 3 h. S100B was determined in plasma by immunoluminometric assay 55, 65, and 240 min after the onset of ischemia (5 min before reperfusion and 5 min and 3 h after the onset of reperfusion). During ischemia of the liver, S100B increased before ligature removal and reperfusion, reaching significance early after the onset of reperfusion and remaining almost unchanged throughout reperfusion. In contrast, S100B did not increase during ischemia of the gut or kidney before ligature removal or during early reperfusion but increased significantly to similar levels as during reperfusion of the liver 240 min after the onset of ischemia (after 3 h of reperfusion). Our findings show for the first time that S100B increases during local extracranial ischemia and reperfusion. These experimental findings support the concept that brain damage is not necessarily the cause of increased S100B. Although S100B has been an acknowledged marker of brain damage for years, our experimental clinically relevant data indicate that S100B is, in fact, not specific as a marker of brain damage in the setting of local ischemia and reperfusion of the liver, gut, and kidney because local ischemia and reperfusion of these organs cause an S100B increase per se.	Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; Res Ctr Allgemeine Unfallversicherungsansalt, A-1200 Vienna, Austria; Fukuoka Univ, Inst Pharmacol, Fukuoka 81401, Japan; Univ Szeged, Inst Surg Res, H-6720 Szeged, Hungary	Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.		Redl, Heinz/AAD-8157-2019	Bahrami, Soheyl/0000-0002-4563-6251			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Egerbacher M, 1997, EUR ARCH OTO-RHINO-L, V254, P449, DOI 10.1007/BF02439977; Egerbacher M, 1997, ARCH HISTOL CYTOL, V60, P121, DOI 10.1679/aohc.60.121; Grocott HP, 2001, BRAIN CARDIAC SURG, P113; HAIMOTO H, 1987, LAB INVEST, V57, P489; Harada N, 1999, CRIT CARE MED, V27, P1958, DOI 10.1097/00003246-199909000-00040; HomerVanniasinkam S, 1997, EUR J VASC ENDOVASC, V14, P195, DOI 10.1016/S1078-5884(97)80191-8; Horie Y, 1996, GASTROENTEROLOGY, V111, P666, DOI 10.1053/gast.1996.v111.pm8780571; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; KAHN HJ, 1983, AM J CLIN PATHOL, V79, P341, DOI 10.1093/ajcp/79.3.341; KAHN HJ, 1991, MODERN PATHOL, V4, P698; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Leonardi R, 2000, ARCH ORAL BIOL, V45, P411, DOI 10.1016/S0003-9969(99)00144-2; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Molina R, 2002, TUMOR BIOL, V23, P39, DOI 10.1159/000048687; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; NAKAMURA Y, 1983, ARCH PATHOL LAB MED, V107, P118; Novak L, 1999, J TRAUMA, V47, P834, DOI 10.1097/00005373-199911000-00003; Parker TG, 1998, CAN J APPL PHYSIOL, V23, P377, DOI 10.1139/h98-022; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Strauss GI, 2001, LIVER TRANSPLANT, V7, P964, DOI 10.1053/jlts.2001.28742; Sun ZW, 2000, SHOCK, V13, P209, DOI 10.1097/00024382-200003000-00007; SUZUKI F, 1985, BIOCHIM BIOPHYS ACTA, V845, P311, DOI 10.1016/0167-4889(85)90193-4; SUZUKI F, 1986, BIOCHIM BIOPHYS ACTA, V889, P84, DOI 10.1016/0167-4889(86)90011-X; Tsoporis JN, 2003, AM J PHYSIOL-HEART C, V284, pH193, DOI 10.1152/ajpheart.00161.2002; Tsoporis JN, 1997, J BIOL CHEM, V272, P31915, DOI 10.1074/jbc.272.50.31915; Wanner GA, 1996, SHOCK, V5, P34, DOI 10.1097/00024382-199601000-00008; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217; ZIMMER DB, 1991, CELL MOTIL CYTOSKEL, V20, P325, DOI 10.1002/cm.970200408; ZIMMER DB, 1987, AM J PHYSIOL, V252, P285	34	57	61	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1073-2322			SHOCK	Shock	JAN	2004	21	1					72	76		10.1097/01.shk.0000101672.49265.14			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	756LD	WOS:000187465800012	14676687				2021-06-18	
J	Rao, KVR; Chen, M; Simard, JM; Norenberg, MD				Rao, KVR; Chen, M; Simard, JM; Norenberg, MD			Suppression of ammonia-induced astrocyte swelling by cyclosporin A	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						aquaporin 4; ammonia toxicity; astrocytes; brain edema; cyclosporin A; cell swelling; fulminant hepatic failure; hepatic encephalopathy; mitochondrial permeability transition	MITOCHONDRIAL PERMEABILITY TRANSITION; CEREBRAL CORTICAL SLICES; TRAUMATIC BRAIN-INJURY; ACETYL-L-CARNITINE; HEPATIC-ENCEPHALOPATHY; CULTURED ASTROCYTES; RAT ASTROCYTES; LIVER-FAILURE; INTRACRANIAL HYPERTENSION; NONSYNAPTIC MITOCHONDRIA	Brain edema is a serious complication of hepatic encephalopathy associated with fulminant hepatic failure (FHF). A major component of the edema seems to be cytotoxic, involving astrocyte swelling. Although the mechanism of brain edema in FHF is incompletely understood, it is generally believed that ammonia is involved critically in this process. Recent studies have shown that exposure of cultured astrocytes to ammonia results in the mitochondrial permeability transition (MPT), a phenomenon associated with mitochondrial failure and subsequent cellular dysfunction. The present study examined the potential role of the MPT in the astrocyte swelling associated with ammonia toxicity. Treatment of cultured astrocytes with ammonia (5 mM) caused a time-dependent increase in astrocyte cell volume (swelling), which was completely inhibited by the MPT inhibitor cyclosporin A (CsA). In this study, CsA also inhibited the ammonia-induced aquaporin 4 (AQP4) upregulation, which had been shown previously to be increased in cultured astrocytes by ammonia treatment. These findings suggest that the MPT plays a significant role in the ammonia-induced astrocyte swelling and may contribute to the brain edema associated with FHF. (C) 2003 Wiley-Liss, Inc.	Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; Vet Affairs Med Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA	Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS034951] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34951, NS30291] Funding Source: Medline		Allert N, 1998, BRAIN RES, V782, P261, DOI 10.1016/S0006-8993(97)01288-2; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bai G, 2001, J NEUROSCI RES, V66, P981, DOI 10.1002/jnr.10056; BENDER AS, 1993, J NEUROCHEM, V61, P1506, DOI 10.1111/j.1471-4159.1993.tb13646.x; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.3.CO;2-G; BENJAMIN AM, 1978, J NEUROCHEM, V30, P131, DOI 10.1111/j.1471-4159.1978.tb07044.x; BLEI AT, 1994, HEPATOLOGY, V19, P1437, DOI 10.1002/hep.1840190619; Blei AT, 1999, J HEPATOL, V31, P771, DOI 10.1016/S0168-8278(99)80361-4; BLEI AT, 1991, HEPATOLOGY, V13, P376, DOI 10.1016/0270-9139(91)92455-H; BRUSILOW SW, 1986, NEW ENGL J MED, V314, P786; CLEMMESEN JO, 1999, HEPATOLOGY, V19, P1437; Cordoba J, 1996, SEMIN LIVER DIS, V16, P271, DOI 10.1055/s-2007-1007240; Desjardins P, 2002, NEUROCHEM INT, V41, P109, DOI 10.1016/S0197-0186(02)00031-1; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; FAFFMICHALAK L, 1991, METAB BRAIN DIS, V6, P187, DOI 10.1007/BF00996918; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1998, J NEUROSCI, V18, P5151; GANZ R, 1989, METAB BRAIN DIS, V4, P213, DOI 10.1007/BF01000297; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755; HINDFELT B, 1977, J CLIN INVEST, V59, P386, DOI 10.1172/JCI108651; Kimelberg H., 1993, ASTROCYTES PHARM FUN, P193; Kimelberg HK, 1998, CONTRIB NEPHROL, V123, P240, DOI 10.1159/000059916; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KIMELBERG HK, 1988, NEUROMETHODS NEUROAN, V9, P129; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kosenko E, 1997, METAB BRAIN DIS, V12, P69, DOI 10.1007/BF02676355; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Murthy CRK, 2002, NEUROCHEM INT, V41, P171, DOI 10.1016/S0197-0186(02)00039-6; Nielsen S, 1997, J NEUROSCI, V17, P171; Norenberg MD, 1997, GLIA, V21, P124; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; NORENBERG MD, 1994, ACTA NEUROCHIR, P24; NORENBERG MD, 1977, LAB INVEST, V36, P618; NORENBERG MD, 2001, ASTROCYTES AGING BRA, P477; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; OLSON JE, 1992, CAN J PHYSIOL PHARM, V70, pS350, DOI 10.1139/y92-282; Perillan PR, 2002, J BIOL CHEM, V277, P1974, DOI 10.1074/jbc.M107984200; Pfeuffer J, 1998, BBA-MOL CELL RES, V1448, P27, DOI 10.1016/S0167-4889(98)00111-6; PILBEAM CM, 1983, J PATHOL, V140, P347, DOI 10.1002/path.1711400404; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Qureshi K, 1998, NEUROCHEM RES, V23, P855, DOI 10.1023/A:1022406911604; Rao KVR, 1997, NEUROSCI LETT, V224, P83; Rao KVR, 2003, NEUROCHEM INT, V43, P517, DOI 10.1016/S0197-0186(03)00042-1; Rao KVR, 2002, J NEUROCHEM, V81, P19; Rao KVR, 2001, METAB BRAIN DIS, V16, P67, DOI 10.1023/A:1011666612822; Rao KVR, 2001, J NEUROCHEM, V78, P25; RAO KVR, 2002, INCREASED EXPRESSION; RATNAKUMARI L, 1989, NEUROCHEM RES, V14, P221, DOI 10.1007/BF00971314; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SWAIN M, 1992, HEPATOLOGY, V15, P449, DOI 10.1002/hep.1840150316; TAKAHASHI H, 1991, AM J PHYSIOL, V261, pH825; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; TRABER P, 1989, GASTROENTEROLOGY, V96, P885; Trost LC, 1997, TOXICOL APPL PHARM, V147, P431, DOI 10.1006/taap.1997.8313; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; VOORHIES TM, 1983, PEDIATR RES, V17, P970, DOI 10.1203/00006450-198312000-00009; White RJ, 1996, J NEUROSCI, V16, P5688; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; Zielinska M, 2003, NEUROCHEM INT, V43, P299, DOI 10.1016/S0197-0186(03)00015-9; Zieminska E, 2000, NEUROTOXICOLOGY, V21, P295; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; Zwingmann C, 2000, DEV NEUROSCI-BASEL, V22, P463, DOI 10.1159/000017476	65	57	57	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 15	2003	74	6					891	897		10.1002/jnr.10755			7	Neurosciences	Neurosciences & Neurology	750KW	WOS:000186990700011	14648594				2021-06-18	
J	Wilson, MS; Gibson, CJ; Hamm, RJ				Wilson, MS; Gibson, CJ; Hamm, RJ			Haloperidol, but not olanzapine, impairs cognitive performance after traumatic brain injury in rats	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; dopamine; D2-like dopamine receptors; haloperidol; olanzapine; antipsychotic agents	MOTOR CORTEX INJURY; CLOSED HEAD-INJURY; ANTIPSYCHOTIC-DRUGS; WATER MAZE; AMPHETAMINE; ACQUISITION	Objective: Traumatic brain injury can cause a variety of impairments, including persistent alterations in personality, mood, and cognition. Antipsychotic agents are frequently used to treat pathologic behaviors in traumatic brain injury patients, but the influence of prolonged administration of such drugs on cognition after injury is unknown. The effects of two antipsychotic drugs on cognitive recovery after traumatic brain injury were assessed using the fluid percussion model in rats. Design: The typical antipsychotic, haloperidol, and the third-generation antipsychotic, olanzapine, were administered via intraperitoneal injection beginning 24 hr after injury and continuing daily for the duration of the study. Morris water maze performance was assessed on days 11-15 postinjury. Results: Haloperidol, an antagonist acting on D2-like dopamine receptors, exacerbated the cognitive deficits induced by injury, as injured rats treated with 0.30 mg/kg haloperidol performed worse in the Morris water maze than injured rats treated with vehicle. Conclusions: Our results demonstrate the importance of the D2 receptor in cognitive recovery after traumatic brain injury. Also, the data illustrate that some classes of antipsychotic drugs may influence cognitive recovery, and further research is needed to determine the optimal pharmacologic treatment of aggression, agitation, and other pathologic behaviors in patients with traumatic brain injury.	Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; Creighton Univ, Dept Psychol, Omaha, NE 68178 USA	Hamm, RJ (corresponding author), Virginia Commonwealth Univ, Dept Psychol, 808 W Franklin St, Richmond, VA 23284 USA.						Andersson C, 2002, NEUROPSYCHOPHARMACOL, V27, P143, DOI 10.1016/S0893-133X(02)00287-7; Bai O, 2003, J NEUROSCI RES, V71, P127, DOI 10.1002/jnr.10440; Bascunana H, 2000, REV NEUROLOGIA, V30, P850, DOI 10.33588/rn.3009.99434; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Fava M, 1997, PSYCHIAT CLIN N AM, V20, P427, DOI 10.1016/S0193-953X(05)70321-X; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; Fowler S B, 1995, J Neurosci Nurs, V27, P119; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Maguire GA, 2002, AM J HEALTH-SYST PH, V59, pS4, DOI 10.1093/ajhp/59.suppl_5.S4; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; PLOEGER GE, 1994, BEHAV NEUROSCI, V108, P927, DOI 10.1037/0735-7044.108.5.927; Stanislav SW, 1997, BRAIN INJURY, V11, P335, DOI 10.1080/026990597123494; Terry AV, 2002, PSYCHOPHARMACOLOGY, V164, P360, DOI 10.1007/s00213-002-1230-z; VINCENT FM, 1986, NEUROSURGERY, V18, P190, DOI 10.1227/00006123-198602000-00013; Wilkinson R, 1999, BRAIN INJURY, V13, P1025; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	20	57	57	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2003	82	11					871	879		10.1097/01.PHM.0000091982.33232.CB			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	734TX	WOS:000186075000009	14566156				2021-06-18	
J	Pelinka, LE; Szalay, L; Jafarmadar, M; Schmidhammer, R; Redl, H; Bahrami, S				Pelinka, LE; Szalay, L; Jafarmadar, M; Schmidhammer, R; Redl, H; Bahrami, S			Circulating S100B is increased after bilateral femur fracture without brain injury in the rat	BRITISH JOURNAL OF ANAESTHESIA			English	Article						blood, protein S100; brain, traumatic injury; complications, long bone injury	CARDIAC-SURGERY; CEREBRAL-DAMAGE; SERUM S100B; PROTEIN; MARKER; TRAUMA	Background. S100B is an acknowledged marker of brain damage. However, trauma without brain damage also causes an increase in S100B. S100B concentrations are highest in multiple trauma patients with long bone fractures. Clinically, extensive long bone fractures are associated with haemorrhagic shock and haemorrhagic shock per se is associated with increased S100B. The aim of our experimental study was to verify the S100B increase in long bone fracture without haemorrhagic shock. Methods and results. Bilateral femur fracture was carried out in 10 anaesthetized rats. Blood samples were drawn for immuno-luminometrical S100B measurement 5, 15, 30, 120, and 240 min after fracture. Mean arterial pressure (MAP), heart rate, and body temperature were monitored continuously. S100B increased after bilateral femur fracture and reached a peak 30-120 min after fracture (P<0.001). MAP remained at a level which is not associated with shock in rats. Heart rate and body temperature remained unchanged. Autopsy verified open bilateral femur fracture surrounded only by small zones of clotted blood. Conclusions. S100B is increased in bilateral femur fracture without haemorrhagic shock in rats. This finding suggests that bone marrow is a potential extracerebral source of S100B.	Workers Compensat Board AUVA, Ludwig Boltzman Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; Workers Compensat Board AUVA, Res Unit, A-1200 Vienna, Austria; Szent Gyorgyi Univ, Inst Expt Surg, H-6721 Szeged, Hungary	Pelinka, LE (corresponding author), Workers Compensat Board AUVA, Ludwig Boltzman Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.		Redl, Heinz/AAD-8157-2019	Bahrami, Soheyl/0000-0002-4563-6251			Ali MS, 2000, BRIT J ANAESTH, V85, P287, DOI 10.1093/bja/85.2.287; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Kuzumi E, 2000, BRIT J ANAESTH, V85, P936; Missler U, 2002, CLIN CHIM ACTA, V321, P29, DOI 10.1016/S0009-8981(02)00061-X; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055	8	57	60	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	OCT	2003	91	4					595	597		10.1093/bja/aeg225			3	Anesthesiology	Anesthesiology	726JT	WOS:000185596500024	14504167				2021-06-18	
J	Vitaz, TW; Jenks, J; Raque, GH; Shields, CB; Ullman, JS; Andrews, BT				Vitaz, TW; Jenks, J; Raque, GH; Shields, CB; Ullman, JS; Andrews, BT			Outcome following moderate traumatic brain injury	SURGICAL NEUROLOGY			English	Article						moderate traumatic brain injury; outcome; neurologic recovery; clinical pathway	HEAD-INJURY; TRACHEOSTOMY; GASTROSTOMY	BACKGROUND Little is known about the outcome following moderate traumatic brain injury (TBI) (GCS 9-12). Most patients regain consciousness; however, the full magnitude of long-term cognitive and functional deficits is unknown. METHODS We conducted a prospective observational study evaluating the outcome of patients suffering moderate TBI between October 1995 and March 1998. Long-term outcome was assessed by telephone interviews. RESULTS A total of 79 consecutive patients were included. Average length of ICU and total hospital stay was 9.1 and 15.8 days respectively. The median GCS at 24 hours was 10 with 67% improving to GCS 15 by time of discharge. The presence of multisystem trauma did not affect outcome; however, age, greater than or equal to45, initiation of enteral feeding after postinjury day 4 and the presence of pneumonia were all associated with longer lengths of stay and increased complication rates. Fifty-six (71%) patients were contacted for follow-up at an average of 27.5 months. GOS scores were 5 in 44%, 4 in 41%, 3 in 9%, 1 in 6%. Seventy-four percent of patients employed premorbidly returned to full-time work. Questions regarding cognitive and functional status revealed significant problems in the majority of patients. CONCLUSIONS Pneumonia, age greater than or equal to45 years and a delay in initiation of enteral feeding all increased the duration of acute care hospital stay following moderate TBI. In addition, cognitive, emotional, and functional problems following such injuries are extensive and long lasting. Physicians must be knowledgeable of these long-term sequela so they can provide the appropriate support and treatment to these patients. (C) 2003 Elsevier Inc. All rights reserved.	Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Hlth Care, Louisville, KY USA	Vitaz, TW (corresponding author), 210 E Gray St,Suite 1102, Louisville, KY USA.		Ullman, Jamie/AAP-5983-2020				Armstrong PA, 1998, SURGERY, V124, P763, DOI 10.1067/msy.1998.91224; Aronson B, 1996, J Contin Educ Nurs, V27, P215; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; DAMELIO LF, 1994, AM SURGEON, V60, P180; ELOVIC E, 1996, MED REHABILITATION T, P133; FRANKOWSKI RF, 1985, EPIDEMIOLOGICAL DE 1, P33; IBARRA VA, 1997, SPINE, V22, P353; JENNETT B, 1975, LANCET, V1, P480; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; Kitchiner D, 1996, ARCH DIS CHILD, V75, P166, DOI 10.1136/adc.75.2.166; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ross BJ, 1996, AM SURGEON, V62, P19; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Spatt J, 1997, ACTA NEUROL SCAND, V95, P173, DOI 10.1111/j.1600-0404.1997.tb00091.x; Zevola D R, 1997, Crit Care Nurse, V17, P20	16	57	62	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	OCT	2003	60	4					285	291		10.1016/S0090-3019(03)00378-1			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	724DT	WOS:000185472400004	14505837				2021-06-18	
J	Long, Y; Zou, LL; Liu, H; Lu, H; Yuan, XQ; Robertson, CS; Yang, KY				Long, Y; Zou, LL; Liu, H; Lu, H; Yuan, XQ; Robertson, CS; Yang, KY			Altered expression of randomly selected genes in mouse hippocampus after traumatic brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						microarray; hippocampus; gene expression; brain; trauma	CORTICAL IMPACT INJURY; SERINE-PROTEASE INHIBITORS; PLATELET-ACTIVATING-FACTOR; CENTRAL-NERVOUS-SYSTEM; MESSENGER-RNA; CELL-DEATH; RAT-BRAIN; MICROARRAY ANALYSIS; KINASE-C; UTEROGLOBIN	Using a cDNA microarray method, we analyzed gene expression profiles in mouse hippocampus after traumatic brain injury (TBI). Of 6,400 randomly selected arrayed genes and expressed sequence tags from a mouse cDNA library, 253 were found to be differentially expressed (106 increased and 147 decreased). Genes involved in cell homeostasis and calcium signaling were primarily up-regulated while those encoding mitochondrial enzymes, metabolic molecules, and structural proteins were predominantly down-regulated. Equal numbers of genes related to inflammatory reactions showed increased or decreased expression. Importantly, a large proportion of the dysregulated genes we identified have not been reported as differentially expressed in TBI models. Semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR) analyses of representative genes confirmed the validity of the corresponding microarray findings. Thus, our microarray-based evaluation of gene expression in traumatically injured hippocampus identified both known and novel genes that respond to TBI. Further investigation of these candidate molecules may suggest new ways to attenuate the traumatic effects of brain injury. (C) 2002 Wiley-Liss, Inc.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; PADRECC, Neurol Care Line, VA Med Ctr, Houston, TX USA	Yang, KY (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660, R01NS035502] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660, R01-NS35502-04] Funding Source: Medline		Almeida A, 2001, J NEUROCHEM, V77, P676, DOI 10.1046/j.1471-4159.2001.00276.x; Bazan NG, 1998, PROG BRAIN RES, V118, P281; Berger P, 1999, MOL CELL NEUROSCI, V14, P455, DOI 10.1006/mcne.1999.0804; Cirelli C, 1999, J SLEEP RES, V8, P44; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Garbett EA, 1999, J CLIN PATHOL-MOL PA, V52, P140, DOI 10.1136/mp.52.3.140; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A; He XP, 2001, NEUROSCI RES, V39, P455, DOI 10.1016/S0168-0102(01)00200-0; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hirschberg DL, 1998, J NEUROIMMUNOL, V89, P88, DOI 10.1016/S0165-5728(98)00118-0; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Larson RA, 2000, J VASC SURG, V32, P1111, DOI 10.1067/mva.2000.111282; Li MD, 2000, J NEUROSCI, V20, P1318; Llanos S, 1998, J NEUROCHEM, V70, P2315; MANTILE G, 1993, J BIOL CHEM, V268, P20343; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Merched A, 1998, FEBS LETT, V425, P225, DOI 10.1016/S0014-5793(98)00234-8; Mirnics K, 2001, TRENDS NEUROSCI, V24, P479, DOI 10.1016/S0166-2236(00)01862-2; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Nakaya N, 1998, NEUROSCI RES, V32, P221, DOI 10.1016/S0168-0102(98)00091-1; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Oh YJ, 1997, MOL BRAIN RES, V51, P133, DOI 10.1016/S0169-328X(97)00229-5; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raivich Gennadij, 1996, Keio Journal of Medicine, V45, P239; RINA S, 2001, BRAIN RES, V911, P1; Sapirstein A, 2000, NEUROCHEM RES, V25, P745, DOI 10.1023/A:1007583708713; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C; Takeshi K, 1999, J CLIN MICROBIOL, V37, P4093, DOI 10.1128/JCM.37.12.4093-4098.1999; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Ueda T, 1999, J NEUROCHEM, V73, P2119; Uhl E, 1999, STROKE, V30, P880, DOI 10.1161/01.STR.30.4.880; Velazquez I, 2001, ARCH BIOCHEM BIOPHYS, V389, P7, DOI 10.1006/abbi.2001.2293; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; WEKERLE H, 1993, INTERVIROLOGY, V35, P95, DOI 10.1159/000150299; Whitney LW, 2001, J NEUROIMMUNOL, V121, P40, DOI 10.1016/S0165-5728(01)00438-6; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Zhang KZ, 2000, P NATL ACAD SCI USA, V97, P3637, DOI 10.1073/pnas.070045897; Zou LL, 1998, J NEUROCHEM, V71, P887	48	57	62	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAR 1	2003	71	5					710	720		10.1002/jnr.10524			11	Neurosciences	Neurosciences & Neurology	650CK	WOS:000181244700010	12584729				2021-06-18	
J	Shih, HC; Hu, SC; Yang, CC; Ko, TJ; Wu, JK; Lee, CH				Shih, HC; Hu, SC; Yang, CC; Ko, TJ; Wu, JK; Lee, CH			Alcohol intoxication increases morbidity in drivers involved in motor vehicle accidents	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						alcohol intoxication; morbidity; trauma	TRAUMATIC BRAIN INJURY; HEMORRHAGIC-SHOCK; ETHANOL; SEVERITY; CONSUMPTION	We prospectively examined the correlation of alcohol intoxication with injury severity, morbidity, and mortality in drivers involved in motor vehicle accidents in a prospective cohort study. The study enrolled 923 injured patients, of whom 421 were legally intoxicated (blood alcohol concentration [BAC] greater than or equal to 50 mg/dL) and 502 were nonintoxicated (BAC < 50 mg/dL). The intoxicated drivers had a significantly higher injury severity score (ISS), lower Glasgow Coma Score, lower systolic blood pressure; higher rate in old age, male sex, greater rate of habitual drinking, greater lack of use of safety gear, and greater accident-related morbidity. After logistic regression analysis, alcohol intoxication was not associated with severe injury (ISS greater than or equal to 9); however, alcohol intoxication analyzed either as a preinjury or postinjury risk factor, was one of the predictors for morbidity. Severe head injury was the only predictor of mortality. In conclusion, although alcohol intoxication is not associated with an increased incidence of severe injury or mortality in drivers involved in motor vehicle crashes, it is one of the significant predictors for morbidity after injury. Copyright 2003, Elsevier Science (USA). All rights reserved.	Vet Gen Hosp, Dept Emergency Med, Taipei, Taiwan; Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan	Shih, HC (corresponding author), Vet Gen Hosp, Dept Emergency Med, 201 Shih Pai Rd,Sec 2, Taipei, Taiwan.						BALLIN JC, 1986, JAMA-J AM MED ASSOC, V255, P522; BLOMQVIST S, 1987, J TRAUMA, V27, P40, DOI 10.1097/00005373-198701000-00007; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; DESIDERIO MA, 1987, J TRAUMA, V27, P267, DOI 10.1097/00005373-198703000-00007; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; GARRISON HG, 1984, ANN EMERG MED, V13, P26, DOI 10.1016/S0196-0644(84)80379-0; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; JURKOVICH GJ, 1993, JAMA-J AM MED ASSOC, V270, P51, DOI 10.1001/jama.270.1.51; KOLELEGA HS, 1995, PSYCHOPHARMACOLOGY, V118, P233; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MCCALL D, 1989, BIOCHEM PHARMACOL, V38, P2593, DOI 10.1016/0006-2952(89)90543-1; Soderstrom CA, 1997, J TRAUMA, V42, P67, DOI 10.1097/00005373-199701000-00012; SPAITE DW, 1995, J TRAUMA, V38, P287, DOI 10.1097/00005373-199502000-00028; Szabo G, 1999, ALCOHOL ALCOHOLISM, V34, P830, DOI 10.1093/alcalc/34.6.830; SZABO G, 1994, J CLIN IMMUNOL, V14, P340, DOI 10.1007/BF01546318; THAL ER, 1985, ARCH SURG-CHICAGO, V120, P708; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; Vinson D C, 1995, Arch Fam Med, V4, P505, DOI 10.1001/archfami.4.6.505; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	24	57	58	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0735-6757			AM J EMERG MED	Am. J. Emerg. Med.	MAR	2003	21	2					91	94		10.1053/ajem.2003.50025			4	Emergency Medicine	Emergency Medicine	663VQ	WOS:000182027400001	12671806				2021-06-18	
J	Brenner, T; Freier, MC; Holshouser, BA; Burley, T; Ashwal, S				Brenner, T; Freier, MC; Holshouser, BA; Burley, T; Ashwal, S			Predicting neuropsychologic outcome after traumatic brain injury in children	PEDIATRIC NEUROLOGY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; CLOSED HEAD-INJURY; MR SPECTROSCOPY; PROTON; PERFORMANCE; SEVERITY; INFANTS; MEMORY; CHILDHOOD; AGE	The ability to predict long-term neurologic and neuropsychologic outcomes in 22 children, ages 1 week to 14 years at the time of traumatic brain injury, was investigated using proton magnetic resonance spectroscopy acquired post injury and compared with standardized neurologic, intellectual, and neuropsychologic testing done 1-7 years later. Clinical indicators of acute injury severity including age at injury, electroencephalography, spectroscopy metabolite ratio variables (N-acetyl aspartate/choline, choline/creatine) and lactate presence accurately classified children as functioning above or below the average range for most intellectual and neuropsychologic outcome measures. Combined clinical and spectroscopy variables accounted for approximately 50% of the variance in cognitive and neuropsychologic outcome confirming the validity of their predictive use. Of the injury severity indictors, presence of lactate is a particularly important prognostic marker of poor long-term intellectual and neuropsychologic functioning. Our findings indicate the potential for providing accurate estimates of long-term intellectual and neuropsychologic function after traumatic brain injury in infants and children using proton magnetic resonance spectroscopy in combination with clinical variables. (C) 2003 by Elsevier Inc. All rights reserved.	Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Psychol, Loma Linda, CA 92350 USA; Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA 92350 USA	Ashwal, S (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Div Child Neurol, Coleman Pavill,11175 Campus St, Loma Linda, CA 92350 USA.						Ashwal S, 1996, J THORAC CARDIOV SUR, V112, P403, DOI 10.1016/S0022-5223(96)70268-4; Ashwal S, 1997, ANN NEUROL, V41, P470, DOI 10.1002/ana.410410410; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; AULD KL, 1995, PEDIATR NEUROL, V12, P323, DOI 10.1016/0887-8994(95)00062-K; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; CHOI SC, 1996, NEUROTRAUMA, P779; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1995, J HEAD TRAUMA REHAB, V10, P13, DOI 10.1097/00001199-199510000-00004; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GOLDEN CJ, 1985, LURIA NEBRASKA NEURO; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT B, 1975, LANCET, V1, P480; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KIMURA H, 1995, RADIOLOGY, V194, P483, DOI 10.1148/radiology.194.2.7529934; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Korkman M, 1998, NEPSY DEV NEUROPSYCH; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kreis R, 1996, J CLIN INVEST, V97, P1142, DOI 10.1172/JCI118528; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; MINER ME, 1986, NEURAL TRAUMA TREATM, P233; Shevell M I, 1999, Semin Pediatr Neurol, V6, P68, DOI 10.1016/S1071-9091(99)80033-3; *US CENS BUR, 2000, POP PROJ PROGR POP D; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANDERKNAAP MS, 1990, RADIOLOGY, V176, P509, DOI 10.1148/radiology.176.2.2164237; Wechsler D., 1989, MANUAL WECHSLER PRES; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D., 1991, MANUAL WECHSLER INTE; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92	43	57	59	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	FEB	2003	28	2					104	114	PII S0887-8994(02)00491-5	10.1016/S0887-8994(02)00491-5			11	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	670NU	WOS:000182415600004	12699860				2021-06-18	
J	Yan, HQ; Kline, AE; Ma, XC; Li, YM; Dixon, CE				Yan, HQ; Kline, AE; Ma, XC; Li, YM; Dixon, CE			Traumatic brain injury reduces dopamine transporter protein expression in the rat frontal cortex	NEUROREPORT			English	Article						dopamine transporter (DAT); frontal cortex; rat; traumatic brain injury (TBI); Western blot	SUBSTANTIA-NIGRA; TYROSINE-HYDROXYLASE; PARKINSONS-DISEASE; PREFRONTAL CORTEX; CEREBRAL-CORTEX; MESSENGER-RNA; COCAINE; INNERVATION; AMPHETAMINE; NUCLEUS	Disturbances in dopamine neurotransmission contribute to frontal lobe dysfunction after traumatic brain injury. The changes in dopamine neurotransmission may be mediated by alterations in the dopamine transporter, which plays a key role in maintaining dopamine homeostasis. To determine whether the dopamine transporter system is altered after traumatic brain injury, dopamine transporter protein was examined bilaterally in the rat frontal cortex by Western blot at 1, 7 and 28 days after controlled cortical impact or sham injury (n = 6/group). Dopamine transporter protein expression was decreased in the injured (ipsilateral) cortex at 7 days and bilaterally at 28 days in injured vs sham control rats. The decrease in dopamine transporter protein levels may reflect a traumatic brain-injury-induced down-regulation of dopamine transporter and/or a loss of dopaminergic fibers.	Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurol Surg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125, P50NS030318, P01NS030318, R01NS033150, P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS40125, NS30318] Funding Source: Medline		BANNON MJ, 1992, P NATL ACAD SCI USA, V89, P7095, DOI 10.1073/pnas.89.15.7095; BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; DESCARRIES L, 1987, NEUROSCIENCE, V21, P807, DOI 10.1016/0306-4522(87)90038-8; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Harrington KA, 1996, MOL BRAIN RES, V36, P157, DOI 10.1016/0169-328X(95)00278-Z; Joyce JN, 1997, MOVEMENT DISORD, V12, P885, DOI 10.1002/mds.870120609; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2001, HEAD TRAUMA, P65; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; KUHAR MJ, 1991, TRENDS NEUROSCI, V14, P299, DOI 10.1016/0166-2236(91)90141-G; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; MOGHADDAM B, 1989, SYNAPSE, V4, P156, DOI 10.1002/syn.890040209; NIZNIK HB, 1991, J NEUROCHEM, V56, P192, DOI 10.1111/j.1471-4159.1991.tb02580.x; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; SIMON H, 1980, NATURE, V286, P150, DOI 10.1038/286150a0; Tang YP, 1997, EUR J NEUROSCI, V9, P1720, DOI 10.1111/j.1460-9568.1997.tb01529.x; UHL GR, 1994, ANN NEUROL, V35, P494, DOI 10.1002/ana.410350421; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	25	57	63	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	OCT 28	2002	13	15					1899	1901		10.1097/00001756-200210280-00013			3	Neurosciences	Neurosciences & Neurology	619ML	WOS:000179479700013	12395087				2021-06-18	
J	Braun, H; Schafer, K; Hollt, V				Braun, H; Schafer, K; Hollt, V			beta III tubulin-expressing neurons reveal enhanced neurogenesis in hippocampal and cortical structures after a contusion trauma in rats	JOURNAL OF NEUROTRAUMA			English	Article						beta III tubulin; cortex; hippocampus; neurogenesis; neurotrauma; neuronal cell death; tissue recovery	CENTRAL-NERVOUS-SYSTEM; ADULT MAMMALIAN BRAIN; DENTATE GYRUS; SUBVENTRICULAR ZONE; AXONAL REGENERATION; SENSORY NEURONS; STEM-CELLS; PROLIFERATION; STROKE; DIFFERENTIATION	Neurogenesis is not only restricted to embryonic development, but also occurs in adult mammalian brains, including human. In this study, evidence is provided, that neurogenesis is involved in the repair of hippocampal and cortical structures after CNS injury. Cortical contusion was induced in 8-week-old Wistar rats. This trauma resulted in a primary cortical lesion and ipsilateral distant remote hippocampal damage, involving primarily CA3-pyramidal cells. The progression of injury was followed over a time course of 7 days, using Nissl-staining and a monoclonal antibody against betaIII tubulin-a specific marker for neurogenic cells. Nissl staining showed a partial recovery of damaged cortical and hippocampal cells at day 7. This recovery was accompanied by an increase of neurogenic cells in these structures, particularly in the dentate gyrus and the neocortical areas. Taken together, these findings provide evidence for the involvement of neurogenesis in the repair processes after traumatic brain injury.	Univ Magdeburg, Inst Pharmakol & Toxikol, D-39106 Magdeburg, Germany	Hollt, V (corresponding author), Otto Von Guericke Univ, Inst Pharmakol & Toxikol, Leipziger Str 44, D-39120 Magdeburg, Germany.						Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Cao Y, 1999, STROKE, V30, P2331, DOI 10.1161/01.STR.30.11.2331; Doetsch F, 1997, J NEUROSCI, V17, P5046; Fanarraga ML, 1999, EUR J NEUROSCI, V11, P517; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; GATES MA, 1995, J COMP NEUROL, V361, P249, DOI 10.1002/cne.903610205; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gu WG, 2000, J CEREBR BLOOD F MET, V20, P1166, DOI 10.1097/00004647-200008000-00002; Hailer NP, 1999, EUR J NEUROSCI, V11, P3359, DOI 10.1046/j.1460-9568.1999.00808.x; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; KAPLAN MS, 1985, ANN NY ACAD SCI, V457, P173, DOI 10.1111/j.1749-6632.1985.tb20805.x; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; LEE VM, 1994, DEV BRAIN RES, V83, P209, DOI 10.1016/0165-3806(94)00139-1; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Luskin MB, 1998, J NEUROBIOL, V36, P221; Magavi SS, 2000, NATURE, V405, P951; MOSKOWITZ PF, 1993, J NEUROSCI RES, V34, P129, DOI 10.1002/jnr.490340113; MOSKOWITZ PF, 1995, J NEUROSCI, V15, P1545; Parent JM, 1997, J NEUROSCI, V17, P3727; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Roskams AJI, 1998, NEUROSCIENCE, V83, P191, DOI 10.1016/S0306-4522(97)00344-8; Roy NS, 2000, NAT MED, V6, P271; Rumbach L, 2000, NEUROLOGY, V54, P350, DOI 10.1212/WNL.54.2.350; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Weiller C, 1998, EXP BRAIN RES, V123, P13, DOI 10.1007/s002210050539; Weinstein DE, 1996, BRAIN RES, V743, P11, DOI 10.1016/S0006-8993(96)00979-1	35	57	58	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2002	19	8					975	983		10.1089/089771502320317122			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	585JC	WOS:000177520800007	12225657				2021-06-18	
J	Cicerone, KD; Azulay, J				Cicerone, KD; Azulay, J			Diagnostic utility of attention measures in postconcussion syndrome	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN INJURY; MILD HEAD-INJURY; SENSITIVITY	Neuropsychological evaluation may be of particular relevance in the detection of subtle cognitive impairments after mild traumatic brain injury (MTBI), including the subgroup of MTBI patients with a persistent postconcussion syndrome (PCS). Attention measures may be the most sensitive indicators of dysfunction associated with MTBI; however, previous studies have typically relied on the analysis of overall group differences, which may not reflect the diagnostic accuracy of attention measures when applied to individuals with MTBI. In the present study, subjects with persistent symptoms at least 3 months following a mild traumatic brain injury were compared with a sample of community living, normal control subjects in order to evaluate the sensitivity, specificity, and diagnostic accuracy of attention measures. Patients with PCS, screened with conservative inclusion and exclusion criteria, and a matched normal control group were administered six clinical tests of attention: Digit Span, Trail Making Test, Part A and Part B, Stroop Color-Word Test, Continuous Performance Test of Attention (CPTA), Paced Auditory Serial Addition Test (PASAT), and Ruff 2 & 7 Selective Attention Test. Consistent with prior research, these measures exhibited a wide range of sensitivity and specificity to possible cognitive impairment among patients. Attention measures may be the most sensitive indicators of dysfunction associated with PCS. Measures with high specificity (e.g., Stroop Color, and 2 & 7 Processing Speed) were shown to have strong positive predictive value, while measures with high sensitivity (e.g., CPTA) demonstrated strong negative predictive value for diagnosing PCS. Examination of the Odds Ratios indicated that measures assessing processing speed had a reliable, positive association with PCS, while measures without a processing speed component did not. Implications for making informed clinical decisions are discussed.	JFK Johnson Rehabil Inst, Edison, NJ 08820 USA	Cicerone, KD (corresponding author), JFK Johnson Rehabil Inst, 2048 Oak Tree Rd, Edison, NJ 08820 USA.	kcicerone@solarishs.org					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; [Anonymous], 1996, Neurology, V47, P592; BATCHELOR J, 1995, CLIN NEUROPSYCHOL, V9, P180, DOI 10.1080/13854049508401600; Bieliauskas LA, 1997, J CLIN EXP NEUROPSYC, V19, P889, DOI 10.1080/01688639708403769; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BRADSHAW M, 1999, J INT NEUROPSYCH SOC, V6, P186; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; CICERONE KD, 2002, UNPUB NATURE ATTENTI; GOLDEN C, 1978, STROOP COLOR WONT TE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Heaton R.K., 1991, COMPREHENSIVE NORMS; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; Ivnik RJ, 2000, NEUROPSYCHOLOGY, V14, P163, DOI 10.1037/0894-4105.14.2.163; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Reason J., 1993, ATTENTION SELECTION, P406; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; Ruff R.M., 1996, RUFF 2 7 SELECTIVE A; Ruff RM, 1999, BRAIN INJURY, V13, P943; Sackett D.L., 2000, EVIDENCE BASED MED, V2nd; SCHMIDT M, 1994, ARCH CLIN NEUROPSYCH, V9, P383, DOI 10.1016/0887-6177(94)90002-7; Simpson A, 2000, NEUROPSYCHOLOGY, V14, P310, DOI 10.1037//0894-4105.14.2.310; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wolfson D., 1993, HALSTEAD REITAN NEUR; Wong TM, 1999, ARCH CLIN NEUROPSYCH, V14, P728	28	57	58	0	8	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2002	16	3					280	289		10.1076/clin.16.3.280.13849			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	664UZ	WOS:000182081500007	12607141				2021-06-18	
J	Struchen, MA; Atchison, TB; Roebuck, TM; Caroselli, JS; Sander, AM				Struchen, MA; Atchison, TB; Roebuck, TM; Caroselli, JS; Sander, AM			A multidimensional measure of caregiving appraisal: Validation of the caregiver appraisal scale in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						adult; assessment; brain injury; caregivers; family	BLUNT HEAD-INJURY; FAMILY CAREGIVERS; BEHAVIORAL-CHANGE; RELATIVES VIEW; FOLLOW-UP; BURDEN	Objective: To investigate the factor structure and concurrent validity of the Caregiver Appraisal Scale (CA,S) in a sample of caregivers of adults with traumatic brain injury (TBI). Design: Prospective cohort study, Setting: Two sites: (1) Outpatient clinics associated with a comprehensive inpatient brain injury rehabilitation program and (2) a comprehensive residential postacute rehabilitation program in the Southern United States. Participants: One hundred forty-nine caregivers of adults with TBI enrolled in the TBI Model Systems Project and 92 caregivers of adults with TBI admitted to a residential postacute rehabilitation program. Most caregivers were women and either parents or spouses of the injured person. Main Outcome Measures: Caregiver Appraisal Scale (CAS) Subjective Burden Scale (SBS); Objective Burden Scale (OBS); General Health Questionnaire (GHQ), Results: Principal components analysis with varimax rotation yielded four factors: perceived burden (PB). caregiver relationship satisfaction (CRS), caregiving ideology (CI), and caregiving mastery, (CM), which were found to be fairly stable across treatment settings. Adequate concurrent validity was demonstrated for the perceived burden factor, and adequate internal consistency was found for three of four scales, Conclusions: Preliminary support for the use of the CAS in caregivers of adults with TBI was obtained. However, further scale development, particularly for the CM factor, will Likely improve the stability and usefulness of this instrument.	Baylor Coll Med, Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX 77030 USA; Univ Houston, Houston, TX USA; Transit Learning Ctr, Galveston, TX USA	Struchen, MA (corresponding author), Baylor Coll Med, Inst Rehabil & Res, Brain Injury Res Ctr, 2455 S Braeswood, Houston, TX 77030 USA.						ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Brooks D N, 1979, Int Rehabil Med, V1, P160; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Holroyd J., 1987, MANUAL QUESTIONNAIRE; HOLROYD J, 1985, QUESTIONNAIRE RESOUR; Holroyd J., 1974, J COMMUNITY PSYCHOL, V2, P92, DOI [10.1002/1520-6629(197401)2:13.0.CO;2-A., DOI 10.1002/1520-6629(197401)2:13.0.CO;2-A]; Hughes C B, 1996, J Pediatr Nurs, V11, P347, DOI 10.1016/S0882-5963(96)80079-0; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; KINNEY JM, 1995, J APPL GERONTOL, V14, P3, DOI 10.1177/073346489501400101; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lawton M., 1989, J GERONTOL, V44, P61, DOI [DOI 10.1093/GER0NJ/44.3.P61, 10.1093/geronj/44.3.P61]; LAWTON MP, 1991, J GERONTOL, V46, P181; Lazarus R.S., 1984, STRESS APPRAISAL COP; LEVINE MS, 1997, QUANTITATIVE APPL SO; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Minnes P, 2000, BRAIN INJURY, V14, P737; *NAT I HLTH, 2001, PREMIER OUTLOOK PERI, V2, P7; *NIH, REH PERS TRAUM BRAIN; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Panting A., 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Smith A M, 1998, Rehabil Nurs, V23, P252; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Zarit S., 1987, MEMORY BEHAV PROBLEM; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	45	57	58	2	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					132	154		10.1097/00001199-200204000-00005			23	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500005	11909511				2021-06-18	
J	Macmillan, PJ; Hart, RP; Martelli, MF; Zasler, ND				Macmillan, PJ; Hart, RP; Martelli, MF; Zasler, ND			Pre-injury status and adaptation following traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; IMPACT	There are an estimated two million traumatic brain injuries (TBI) each year in the US. Behavioural and psychosocial sequelae are the most disabling consequences of TBI, but relatively little empirical data exist that identify factors underlying the variability in patient outcomes. There is an increasing appreciation that pre-injury coping liabilities are likely to contribute to persistent disability and that outcome reflects the combined effects of pre-morbid, injury-related, and post-injury factors. Despite this, most outcome studies focus On the effects of injury-related and post-injury variables. The present study evaluated outcome in 45 adults who suffered a moderate or severe TBI at least 2 years earlier. It was hypothesized that severity of pre-morbid psychiatric and substance abuse problems and less social support following brain injury would be associated with poorer post-injury adaptation as measured by employment status, independent living status, and neurobehavioural symptomatology. The authors found that pre-injury psychiatric and substance abuse histories predicted employment status and that pre-injury substance abuse predicted independent living status. Social support following TBI predicted significant other's assessment of the patients' neurobehavioural status. None of the independent variables were found to predict patient assessment of his or her own neurobehavioural functioning. These findings support the premise that pre-morbid coping liabilities are related to the degree of post-injury disability.	Sheltering Arms Phys Rehabil, Richmond, VA USA; Coll William & Mary, Williamsburg, VA USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Concuss Care Ctr Virginia Ltd, Richmond, VA USA; Tree Life, Richmond, VA USA	Martelli, MF (corresponding author), Concuss Care Ctr Virginia, Rehabil Neuropsychol, 10120 W Broad St,Suite GH&I, Glen Allen, VA 23060 USA.	mikefm@erols.com					ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Atkinson JS, 2000, AM J DRUG ALCOHOL AB, V26, P355, DOI 10.1081/ADA-100100249; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Ettner SL, 1997, IND LABOR RELAT REV, V51, P64, DOI 10.2307/2525035; GANS J, 1983, SEMINARS NEUROLOGY, V3, P201; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KAY T, 1992, REHABILITATION POST, P109; KREUTZER J S, 1990, Brain Injury, V4, P1, DOI 10.3109/02699059009026142; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Lazarus, 1976, PATTERNS ADJUSTMENT; Lazarus R.S., 1984, STRESS APPRAISAL COP; LAZARUS RS, 1993, PSYCHOSOM MED, V55, P234, DOI 10.1097/00006842-199305000-00002; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Lubben JE., 1988, FAMILY COMMUNITY HLT, V11, P42, DOI [10.1097/00003727-198811000-00008, DOI 10.1097/00003727-198811000-00008]; Martelli MF, 1998, NEUROREHABILITATION, V11, P51, DOI 10.1016/S1053-8135(98)00009-2; MARTELLI MF, 1996, NAT AC NEUR ANN M NE; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Rutherford WH, 1989, MILD HEAD INJURY, P229; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; *SPSS INC, 1999, SPSS WIND REL 10 0; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Zasler ND, 1997, ARCH PHYS MED REHAB, V78, pS12, DOI 10.1016/S0003-9993(97)90150-7	31	57	59	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2002	16	1					41	49		10.1080/0269905011008812			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	515BM	WOS:000173475600004	11796098				2021-06-18	
J	Cannon, ML; Glazier, SS; Bauman, LA				Cannon, ML; Glazier, SS; Bauman, LA			Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion - Case report	JOURNAL OF NEUROSURGERY			English	Article						propofol; head injury; metabolic acidosis; rhabdomyolysis; multiorgan system failure	FATAL MYOCARDIAL FAILURE; INTENSIVE-CARE UNIT; MIDAZOLAM; SEDATION; CHILDREN; PATIENT; EFFICACY	The authors present the hospital course of a 13-year-old girl with a closed head injury who received a prolonged infusion of propofol for sedation and, subsequently, died as a result of severe metabolic acidosis, rhabdomyolysis, and cardiovascular collapse. The patient had been treated for 4 days at a referring hospital for a severe closed head injury sustained in a fall from a bicycle. During treatment for elevations of intracranial pressure, she received a continuous propofol infusion (100 mug/kg/min). The patient began to exhibit severe high anion gap/low lactate metabolic acidosis, and was transferred to the pediatric intensive care unit at the authors' institution. On arrival there, the patient's Glasgow Coma Scale score was 3 and this remained unchanged during her brief stay. The severe metabolic acidosis was unresponsive to maximum therapy. Acute renal failure ensued as a result of rhabdomyolysis, and myocardial dysfunction with bizarre, wide QRS complexes developed without hyperkalemia. The patient died of myocardial collapse with severe metabolic acidosis and multisystem organ failure (involving renal, hepatic, and cardiac systems) approximately 15 hours after admission to the authors' institution. This patient represents another case of severe metabolic acidosis, rhabdomyolysis, and cardiovascular collapse observed after a prolonged propofol infusion in a pediatric patient. The authors suggest selection of other pharmacological agents for long-term sedation in pediatric patients.	Wake Forest Univ, Sch Med, Sect Pediat Anesthesiol & Crit Care, Dept Anesthesiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Neurosurg, Winston Salem, NC 27157 USA	Cannon, ML (corresponding author), Wake Forest Univ, Sch Med, Sect Pediat Anesthesiol & Crit Care, Dept Anesthesiol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	mlcannon@wfubmc.edu					AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; BRAY RJ, 1995, ANAESTHESIA, V50, P94, DOI 10.1111/j.1365-2044.1995.tb04544.x; BRUSSEL T, 1989, ANESTH ANALG, V69, P35; Canivet J L, 1994, Acta Anaesthesiol Belg, V45, P19; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; DEARLOVE O, 1995, ANAESTHESIA, V50, P916, DOI 10.1111/j.1365-2044.1995.tb05874.x; FULTON B, 1995, DRUGS, V50, P636, DOI 10.2165/00003495-199550040-00006; GROUNDS RM, 1987, BRIT MED J, V294, P397, DOI 10.1136/bmj.294.6569.397; Hanna JP, 1998, NEUROLOGY, V50, P301, DOI 10.1212/WNL.50.1.301; HAWKINS WJ, 1995, ANAESTHESIA, V50, P564, DOI 10.1111/j.1365-2044.1995.tb06056.x; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; Ito H, 1999, ACTA ANAESTH SCAND, V43, P153, DOI 10.1034/j.1399-6576.1999.430206.x; KANTO J, 1989, CLIN PHARMACOKINET, V17, P308, DOI 10.2165/00003088-198917050-00002; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KENNEDY TL, 1997, 5 MINUTE PEDIAT CONS, P660; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Perrier ND, 2000, CRIT CARE MED, V28, P3071, DOI 10.1097/00003246-200008000-00066; Plotz FB, 1996, ANAESTH INTENS CARE, V24, P724; Reed MD, 1996, CRIT CARE MED, V24, P175, DOI 10.1097/00003246-199601000-00030; Sanchez-Izquierdo-Riera JA, 1998, ANESTH ANALG, V86, P1219, DOI 10.1097/00000539-199806000-00016; Sitar SM, 1999, ANESTHESIOLOGY, V90, P1446, DOI 10.1097/00000542-199905000-00030; STRICKLAND RA, 1995, CRIT CARE MED, V23, P405, DOI 10.1097/00003246-199502000-00029; Susla GM, 1998, CRIT CARE MED, V26, P1959, DOI 10.1097/00003246-199812000-00019; vanStraaten EA, 1996, INTENS CARE MED, V22, P997, DOI 10.1007/BF02044132; Zhou WG, 1997, ANESTHESIOLOGY, V86, P670, DOI 10.1097/00000542-199703000-00020; Zhou WG, 1999, ANESTH ANALG, V89, P604, DOI 10.1097/00000539-199909000-00011	26	57	59	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	2001	95	6					1053	1056		10.3171/jns.2001.95.6.1053			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	499HA	WOS:000172564600022	11765823				2021-06-18	
J	Igarashi, T; Huang, TT; Noble, LJ				Igarashi, T; Huang, TT; Noble, LJ			Regional vulnerability after traumatic brain injury: Gender differences in mice that overexpress human copper, zinc superoxide dismutase	EXPERIMENTAL NEUROLOGY			English	Article						controlled cortical impact; human copper, zinc superoxide dismutase; regional neuronal vulnerability; gender difference	CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; TRANSGENIC MICE; POSTTRAUMATIC HYPOTHERMIA; CONTUSION INJURY; RATS; PEGORGOTEIN; APOPTOSIS; DEFICITS; STROKE	Neuronal loss was quantified in both cortical and subcortical brain regions after traumatic brain injury in male and female nontransgenic (nTg) and transgenic (Tg) mice that overexpress human copper, zinc superoxide dismutase. Mice were euthanized at 7 days after a controlled cortical impact injury. Sections of brain were processed for immunolocalization of NeuN, a neuronal nuclear antigen, and the complement type 3 receptor, a marker of microglia/macrophages, and stained for iron. Cortical lesion volume and neuronal loss in the medial and/or lateral ventroposterior thalamic nuclei were significantly less in the nTg female compared to the nTg male (P = 0.0373 and P = 0.0023, respectively). In contrast, in CA3 of the hippocampus and laterodorsal thalamic nucleus (LD), there were no gender differences in neuronal loss between these nTg groups. Cortical lesion volume was significantly reduced in Tg males compared to nTg males (P = 0.0137) and was unchanged in the Tg females compared to the nTg females. Neuronal loss was attenuated in the CA3 and LD in the Tg females compared to the nTg females (P = 0.0252 and P = 0.0244, respectively). A similar protection was not observed in the Tg males. Microglial activation paralleled the pattern of neuronal loss and was most consistently aligned with iron deposition in the cortex and hippocampus. No overt differences were found in the pattern of microglial activation or iron staining between nTg and Tg mice nor between genders. Our findings demonstrate that neuroprotection, afforded by overexpression of copper, zinc superoxide dismutase, exhibits both regional and gender specificity. (C) 2001 Elsevier Science.	Univ Calif San Francisco, Dept Neurol Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Igarashi, T (corresponding author), Univ Calif San Francisco, Dept Neurol Sci, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DeWitt D S, 1995, New Horiz, V3, P376; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1998, ABSTR SOC NEUROSCI, V24, P496; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HILL JM, 1984, NEUROSCIENCE, V11, P595, DOI 10.1016/0306-4522(84)90046-0; HUANG TT, 2001, IN PRESS METHODS ENZ; Kinouchi H, 1998, CELL MOL NEUROBIOL, V18, P609, DOI 10.1023/A:1020213717336; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Matthews MA, 1998, BRAIN RES, V794, P1, DOI 10.1016/S0006-8993(98)00107-3; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; PRZEDBORSKI S, 1992, J NEUROCHEM, V58, P1760, DOI 10.1111/j.1471-4159.1992.tb10051.x; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; SATO M, 1998, J NEUROTRAUM, V15, P895; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Vegeto E, 2001, J NEUROSCI, V21, P1809, DOI 10.1523/JNEUROSCI.21-06-01809.2001; Yamaki T, 1997, BRAIN RES, V752, P151, DOI 10.1016/S0006-8993(96)01469-2; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	44	57	57	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2001	172	2					332	341		10.1006/exnr.2001.7820			10	Neurosciences	Neurosciences & Neurology	510QK	WOS:000173218600008	11716557				2021-06-18	
J	Hamlin, GP; Cernak, I; Wixey, JA; Vink, R				Hamlin, GP; Cernak, I; Wixey, JA; Vink, R			Increased expression of neuronal glucose transporter 3 but not glial glucose transporter 1 following severe diffuse traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						cerebellum; glucose transport; Glut1; Glut3; neurotrauma	GLUCOSE-TRANSPORTER PROTEINS; GLUT1; ISCHEMIA; LOCALIZATION	Traumatic brain injury results in an increased brain energy demand that is associated with profound changes in brain glycolysis and energy metabolism. Increased glycolysis must be met by increasing glucose supply that, in brain, is primarily mediated by two members of the facilitative glucose transporter family, Glut1 and Glut3. Glut1 is expressed in endothelial cells of the blood-brain barrier (BBB) and also in glia, while Glut3 is the primary glucose transporter expressed in neurons. However, few studies have investigated the changes in glucose transporter expression following traumatic brain injury, and in particular, the neuronal and glial glucose transporter responses to injury. This study has therefore focussed on investigating the expression of the glial specific 45-kDa isoform of Glut1 and neuronal specific Glut3 following severe diffuse traumatic brain injury in rats. Following impact-acceleration injury, Glut3 expression was found to increase by at least 300% as early as 4 h after induction of injury and remained elevated for at least 48 h postinjury. The increase in Glut3 expression was clearly evident in both the cerebral cortex and cerebellum. In contrast, expression of the glial specific 45-kDa isoform of Glut1 did not significantly change in either the cerebral cortex or cerebellum following traumatic injury. We conclude that increased glucose uptake after traumatic brain injury is primarily accounted for by increased neuronal Glut 3 glucose transporter expression and that this increased expression after trauma is part of a neuronal stress response that may be involved in increasing neuronal glycolysis and associated energy metabolism to fuel repair processes.	James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia; Univ Adelaide, Dept Pathol, Adelaide, SA 5001, Australia	Hamlin, GP (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.		AM, Robert Vink/S-5616-2019; Cernak, Ibolja/A-6399-2008; Vink, Robert/J-7351-2012; Wixey, Julie/C-7684-2011	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Wixey, Julie/0000-0002-9716-8170; Ibolja, Cernak/0000-0003-3214-698X			ASANO T, 1991, J BIOL CHEM, V266, P24632; Bastian A., 1999, FUNDAMENTAL NEUROSCI, P973; BELL GI, 1993, J BIOL CHEM, V268, P19161; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BONDY CA, 1992, MOL CELL NEUROSCI, V3, P305, DOI 10.1016/1044-7431(92)90027-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruckner BA, 1999, METABOLISM, V48, P422, DOI 10.1016/S0026-0495(99)90098-7; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; Devaskar SU, 1999, BRAIN RES, V823, P113, DOI 10.1016/S0006-8993(99)01143-9; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Duelli R, 1999, BRAIN RES, V831, P254, DOI 10.1016/S0006-8993(99)01463-8; GERHART DZ, 1995, NEUROSCIENCE, V66, P237, DOI 10.1016/0306-4522(94)00544-F; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GOODMAN JC, 1997, J NEUROTRAUM, V14, P785; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HOVDA DA, 1996, NEUROTRAUMA, P1450; KLIP A, 1994, FASEB J, V8, P43; Koehler-Stec EM, 2000, J CEREBR BLOOD F MET, V20, P192, DOI 10.1097/00004647-200001000-00024; Lee DH, 2000, DIABETES RES CLIN PR, V47, P15, DOI 10.1016/S0168-8227(99)00107-2; LEE WH, 1993, ENDOCRINOLOGY, V133, P2540, DOI 10.1210/en.133.6.2540; Leino RL, 1997, J NEUROSCI RES, V49, P617; MAHER F, 1993, J CEREBR BLOOD F MET, V13, P342, DOI 10.1038/jcbfm.1993.43; MAHER F, 1994, FASEB J, V8, P1003; MAHER F, 1995, J NEUROSCI RES, V42, P459, DOI 10.1002/jnr.490420404; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; McCall AL, 1996, J CEREBR BLOOD F MET, V16, P69, DOI 10.1097/00004647-199601000-00008; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; Thach WT, 1998, NEUROBIOL LEARN MEM, V70, P177, DOI 10.1006/nlme.1998.3846; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Urabe T, 1996, J NEUROCHEM, V67, P265; Vannucci SJ, 1998, DEV BRAIN RES, V107, P255, DOI 10.1016/S0165-3806(98)00021-2; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; VANNUCCI SJ, 1994, J NEUROCHEM, V62, P240; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	39	57	58	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2001	18	10					1011	1018		10.1089/08977150152693700			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	484NG	WOS:000171696000004	11686488				2021-06-18	
J	Friedland, JF; Dawson, DR				Friedland, JF; Dawson, DR			Function after motor vehicle accidents: A prospective study of mild head injury and posttraumatic stress	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							TRAUMATIC BRAIN INJURY; SICKNESS IMPACT PROFILE; PROSPECTIVE FOLLOW-UP; TRAFFIC ACCIDENTS; EVENT SCALE; DISORDER; VICTIMS; PREDICTORS; MORBIDITY; CONSCIOUSNESS	Relationships among mild traumatic brain injury (MTBI), posttraumatic stress (PTS), and function were examined in 99 motor vehicle accident (MVA) admissions: 64 in an MTBI group and 35 in a no-MTBI comparison group. Assessments occurred within the first month and at 6 to 9 months. At follow-up, the sample was moderately disabled on the Sickness Impact Profile (SIP), 71% satisfied on the Reintegration of Normal Living Index (RNL), and 42% had returned to work. Only the SIP Psychosocial score was significantly different for MTBI groups; 24% of the sample showed definite symptoms of PTS. This group was significantly more disabled on the SIP, less satisfied on the RNL, and less likely to return to work. The proportion of variance in outcome explained in each model ranged from 32% (Physical SIP) to 44% (RNL). Results suggest the need for clinicians to be more aware of the strong influence of PTS on functional outcomes.	Univ Toronto, Fac Med, Dept Occupat Therapy, Toronto, ON M5T 1W5, Canada	Friedland, JF (corresponding author), Univ Toronto, Fac Med, Dept Occupat Therapy, 256 McCaul St, Toronto, ON M5T 1W5, Canada.		Dawson, Deirdre R/I-8882-2014	Dawson, Deirdre R/0000-0001-7517-6121			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ANDERSSON AL, 1994, SCAND J SOC MED, V22, P299, DOI 10.1177/140349489402200409; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BLANCHARD EB, 1994, BEHAV RES THER, V32, P283, DOI 10.1016/0005-7967(94)90123-6; BLANCHARD EB, 1997, CRASH; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BROM D, 1993, J CLIN PSYCHOL, V49, P131, DOI 10.1002/1097-4679(199303)49:2<131::AID-JCLP2270490202>3.0.CO;2-2; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Butler DJ, 1999, AM FAM PHYSICIAN, V60, P524; Carlier IVE, 2000, BRIT J MED PSYCHOL, V73, P87, DOI 10.1348/000711200160327; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; DAVIDOFF DA, 1988, COGNITIVE REHABI MAR, P8; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; Fern KT, 1998, J TRAUMA, V45, P489, DOI 10.1097/00005373-199809000-00010; Goldberg D.P, 1972, DETECTION PSYCHIAT I; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Koren D, 1999, AM J PSYCHIAT, V156, P367; Kuch K, 1996, CAN J PSYCHIAT, V41, P429, DOI 10.1177/070674379604100707; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McDowell I., 1996, MEASURING HLTH OUTCO; MCFARLANE AC, 1988, J NERV MENT DIS, V176, P30, DOI 10.1097/00005053-198801000-00004; MCFARLANE AC, 1992, J NERV MENT DIS, V180, P439, DOI 10.1097/00005053-199207000-00006; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; O'Brien M, 1998, BRIT J PSYCHIAT, V173, P102, DOI 10.1192/bjp.173.2.102; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Solursh LP, 1997, CAN J PSYCHIAT, V42, P210, DOI 10.1177/070674379704200219; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; WATTS R, 1995, AUST NZ J PSYCHIAT, V29, P75, DOI 10.3109/00048679509075895; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; Wrightson P, 1998, NEW ZEAL MED J, V111, P99; ZILBERG NJ, 1982, J CONSULT CLIN PSYCH, V50, P407, DOI 10.1037/0022-006X.50.3.407; 1995, STAT CANADA	50	57	59	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUL	2001	189	7					426	434		10.1097/00005053-200107000-00003			9	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	459ED	WOS:000170237300003	11504319				2021-06-18	
J	Ronne-Engstrom, E; Cesarini, KG; Enblad, P; Hesselager, G; Marklund, N; Salci, K; Persson, L; Hillered, L				Ronne-Engstrom, E; Cesarini, KG; Enblad, P; Hesselager, G; Marklund, N; Salci, K; Persson, L; Hillered, L			Intracerebral microdialysis in neurointensive care: the use of urea as an endogenous reference compound	JOURNAL OF NEUROSURGERY			English	Article						microdialysis; urea; traumatic brain injury; cerebrovascular disease	AMINO-ACID RELEASE; QUANTITATIVE MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; HUMAN BRAIN; GLUTAMATE; ISCHEMIA; KINETICS; SEIZURE; INJURY; SPACE	Object. When evaluating the results of intracerebral microdialysis, the in vivo performance of the microdialysis probe must be considered, because this determines the fraction of the interstitial concentration obtained in the microdialysis samples. The in vivo performance is dependent on several factors, for example, the interstitial compartment's diffusion characteristics, which may vary during the course of the acute brain injury process. In the present study the authors investigated the method of controlling the in vivo performance by using urea, which is evenly distributed in all body fluid compartments, as an endogenous reference compound and by comparing the urea levels in three compartments: the brain (CNS), abdominal subcutaneous tissue (SC), and blood serum (BS). Methods. Sixty-nine patients with traumatic brain injury or cerebrovascular disease were included in the study. In 63 of these patients a CNS probe was used, an SC probe was used in 40, and both were used in 34. Urea was measured by enzymatic methods, at bedside for the microdialysis samples and in routine clinical laboratory studies for the BS samples, with the probe calibrated to give identical results. The correlation coefficient for CNS/SC urea was 0.88 (2414 samples), for CNS/BS urea it was 0.89 (180 samples), and for SC/BS urea it was 0.98 (112 samples). Conclusions. Urea levels in the CNS, SC, and BS were highly correlated, which supports the assumption that urea is evenly distributed. The CNS/SC urea ratio can therefore be used for monitoring the CNS probe's in vivo performance. Fluctuations in other substances measured with microdialysis are probably caused by biological changes in the brain, as long as the CNS/SC urea ratio remains constant.	Univ Uppsala Hosp, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden	Ronne-Engstrom, E (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Div Neurosurg, S-75185 Uppsala, Sweden.	elisabeth.ronne-engstrom@nc.uas.lul.se		Marklund, Niklas/0000-0002-9797-5626			BENVENISTE H, 1989, J NEUROCHEM, V52, P1741, DOI 10.1111/j.1471-4159.1989.tb07252.x; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; Boris-Moller F, 1998, MOL CHEM NEUROPATHOL, V35, P133, DOI 10.1007/BF02815120; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; DURING MJ, 1993, LANCET, V341, P1607; DYKSTRA KH, 1992, J NEUROCHEM, V58, P931, DOI 10.1111/j.1471-4159.1992.tb09346.x; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; GARDNER EL, 1993, J NEUROSCI METH, V48, P173, DOI 10.1016/0165-0270(93)90091-5; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; JEEJEEBHOY KN, 1995, TXB CRITICAL CARE, P1106; KEHR J, 1993, J NEUROSCI METH, V48, P251, DOI 10.1016/0165-0270(93)90096-A; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; LINDEFORS N, 1989, J PHARMACOL METHOD, V22, P141, DOI 10.1016/0160-5402(89)90011-9; LONNROTH P, 1987, AM J PHYSIOL, V253, pE228; MATHEWS CK, 1990, BIOCHEMISTRY-US, P670; METRY GS, 1993, KIDNEY INT, V44, P622, DOI 10.1038/ki.1993.290; MORRISON PF, 1991, J NEUROCHEM, V57, P103, DOI 10.1111/j.1471-4159.1991.tb02105.x; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V85, P984; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; STAHLE L, 1990, EUR J PHARMACOL, V185, P187, DOI 10.1016/0014-2999(90)90639-N; STJERNSTROM H, 1993, INTENS CARE MED, V19, P423, DOI 10.1007/BF01724886; TEASDALE G, 1974, LANCET, V2, P81; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WANG YF, 1993, PHARMACEUT RES, V10, P1411, DOI 10.1023/A:1018906821725; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5	29	57	58	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2001	94	3					397	402		10.3171/jns.2001.94.3.0397			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	405KB	WOS:000167157600004	11235942				2021-06-18	
J	Pierallini, A; Pantano, P; Fantozzi, LM; Bonamini, M; Vichi, R; Zylberman, R; Pisarri, F; Colonnese, C; Bozzao, L				Pierallini, A; Pantano, P; Fantozzi, LM; Bonamini, M; Vichi, R; Zylberman, R; Pisarri, F; Colonnese, C; Bozzao, L			Correlation between MRI findings and long-term outcome in patients with severe brain trauma	NEURORADIOLOGY			English	Article						traumatic brain injury; magnetic resonance imaging; pulse sequences	SEVERE HEAD-INJURY; DISABILITY RATING-SCALE; DIFFUSE AXONAL INJURY; COMPUTERIZED-TOMOGRAPHY; PREDICTING SURVIVAL; RECOVERY; HEMORRHAGE; DIAGNOSIS; FLAIR; VARIABLES	Our aim was to relate MRT. findings in patients with severe traumatic brain injury (TBI) to clinical severity and long-term outcome. We studied 37 patients with severe TBI, who were submitted to clinical assessment for disability and cognition and to MRI 60-90 days after trauma. Clinical assessment was also performed 3, 6 and 12 months later. The number and volume of lesions in various cerebral structures were calculated semiautomatically from FLAIR and fast field-echo images. Possible correlations between total and regional lesion volume and clinical deficits were then investigated. The frontal and temporal lobes were most frequently involved. Total lesion volume on FLAIR images correlated significantly with clinical outcome, whereas that on FFE images did not. Regional analysis showed that FLAIR lesion volume in the corpus callosum correlated significantly with scores on disability and cognition scales at the first clinical assessment. FLAIR lesion volume in the frontal lobes correlated significantly with clinical scores 1 year later.	Univ Rome La Sapienza, Dept Neurol Sci, Neuroradiol Sect, I-00185 Rome, Italy; Hosp San Giovanni Battista, SMOM, Rome, Italy; IRCCS Neuromed, Pozzilli, IS, Italy	Pierallini, A (corresponding author), Univ Rome La Sapienza, Dept Neurol Sci, Neuroradiol Sect, I-00185 Rome, Italy.		Patrizia, Pantano/C-8214-2009; Pierallini, Alberto/AAB-3271-2021; colonnese, claudio/AAB-9727-2020	Patrizia, Pantano/0000-0001-9659-8294; colonnese, claudio/0000-0003-4249-4689			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Brooks D N, 1979, Int Rehabil Med, V1, P160; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; DEROSIER C, 1991, J NEURORADIOLOGY, V18, P309; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; GODERSKY JC, 1990, ACT NEUR S, V51, P311; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HAJNAL JV, 1992, J COMPUT ASSIST TOMO, V16, P841, DOI 10.1097/00004728-199211000-00001; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kates R, 1996, Top Magn Reson Imaging, V8, P389; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P3255; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; Noguchi K, 1997, RADIOLOGY, V203, P257, DOI 10.1148/radiology.203.1.9122404; Noguchi K, 1997, NEURORADIOLOGY, V39, P406, DOI 10.1007/s002340050433; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE G, 1974, LANCET, V2, P81; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	38	57	59	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	DEC	2000	42	12					860	867		10.1007/s002340000447			8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	386NN	WOS:000166068600002	11198202				2021-06-18	
J	Harris, MB; Kronlage, SC; Carboni, PA; Robert, KQ; Menmuir, B; Ricciardi, JE; Chutkan, NB				Harris, MB; Kronlage, SC; Carboni, PA; Robert, KQ; Menmuir, B; Ricciardi, JE; Chutkan, NB			Evaluation of the cervical spine in the polytrauma patient	SPINE			English	Article; Proceedings Paper	27th Annual Meeting of the Cervical-Spine-Research-Society	DEC 17, 1999	SEATTLE, WA	Cervical Spine Res Soc			TRAUMA PATIENTS; BLUNT TRAUMA; FRACTURES; DIAGNOSIS; INJURIES; FLUOROSCOPY; RADIOGRAPHY; EMERGENCY; EFFICACY; VICTIMS	Study Design. Two-part study. Part One: the analysis of surveys distributed to members of the Orthopaedic Trauma Association (OTA) and 1000 surgeon members of NASS. Part Two:a prospective clinical study evaluating a new algorithm to evaluate the cerivcal spine in polytrauma patients. Objectives. To determine if there is a consensus of the optimal method for "clearing the cervical spine"; to assess the safety and efficacy of a newly proposed algorithm. Summary of Background Data. There is no uniformly accepted algorithm for "clearing the cervical spine" in the polytrauma patient or those patients with altered mental status secondary to the influence of alcohol, drugs or a closed head injury. Methods. All members of the OTA and 1000 surgeon members of NASS were sent questionnaires to assess their methods of "clearing the cervical spine" in the polytrauma patient. Their answers were collated, analyzed and compared to standard ATLS protocol guidelines. A new protocol, which includes a surgeon, controlled stretch test and flouroscopically visualized flexion-extension views, was initiated and evaluated for safety and efficacy. Results. Survey: Fifty-five percent of the members of the OTA and 31% of the NASS surgeons responded to the questionnaire. Among the responses from the NASS members, the ratio of orthopaedic spine surgeons to neurosurgeons accurately parallels the society's membership (77% ortho, 23% neuro). Sixty-nine of the OTA and 54% of the NASS responders : replied that they followed ATLS guidelines. Analysis of their responses showed only 40% compliance. Eighty-one percent of the OTA respondents utilize the standard three view cervical spine trauma services, only 31% of the NASS members adhere to this guidelines. Nearly 90% of ail respondents identified the presence of neck pain or retropharygeal soft tissue swelling as an indicator to expand their initial radiographic evaluation. There was no consensus as to management of the polytrauma patient with a closed head injury. Eighty-two percent of all respondents has seen or treated a purely ligamentous injury of the c-spine. Spective Study: Prospective clinical protocol. 35-monthperiod: enrolled 153 patients, 12,000 patients seen in trauma unit. Completed data 149/153. 8/153 unable to be cleared due to poor visualization of cervical-thoracic junction. 3/153 positive findings identified during fluoro examination. All three instability patterns verified in surgery (true positives). No untoward events to date. Conclusions. A standardized protocol to safely and effectively clear the cervical spine has yet to be established. Preliminary results of a new protocol to safely evaluate the cervical spine in the polytrauma patient are promising.	Louisiana State Univ, Hlth Sci Ctr, Sch Med, Dept Orthopaed Surg, New Orleans, LA USA; Tulane Univ, Sch Med, Dept Orthopaed Surg, New Orleans, LA 70112 USA	Harris, MB (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Orthopaed & Rehabil, Med Ctr Blvd, Winston Salem, NC 27157 USA.	miharris@wfubmc.edu					BACHULIS BL, 1987, AM J SURG, V153, P473, DOI 10.1016/0002-9610(87)90796-3; BLACKSIN MF, 1995, AM J ROENTGENOL, V165, P1201, DOI 10.2214/ajr.165.5.7572503; Chendrasekhar A, 1998, AM SURGEON, V64, P604; DAVIS JW, 1995, J TRAUMA, V39, P435; DAVIS JW, 1993, J TRAUMA, V34, P342, DOI 10.1097/00005373-199303000-00006; Emery S E, 1989, J Spinal Disord, V2, P229; FAZL M, 1990, NEUROSURGERY, V26, P674, DOI 10.1227/00006123-199004000-00019; FISCHER RP, 1984, ANN EMERG MED, V13, P905, DOI 10.1016/S0196-0644(84)80667-8; GERRELTS BD, 1991, J TRAUMA, V31, P1622, DOI 10.1097/00005373-199112000-00010; GISBERT VL, 1989, SURGERY, V106, P702; Harris MB, 1997, ORTHOPEDICS, V20, P903; Herr CH, 1998, AM J EMERG MED, V16, P346, DOI 10.1016/S0735-6757(98)90124-3; LINDSEY RW, 1993, SOUTHERN MED J, V86, P1253, DOI 10.1097/00007611-199311000-00013; MACDONALD RL, 1990, J TRAUMA, V30, P392, DOI 10.1097/00005373-199030040-00004; MILES KA, 1988, INJURY, V19, P177, DOI 10.1016/0020-1383(88)90010-1; *NAT CTR HLTH STAT, 1994, NAT HSOP AMB MED CAR; PLAISIER B, 1994, J TRAUMA, V37, P714, DOI 10.1097/00005373-199411000-00004; REID DC, 1988, J TRAUMA, V28, P1188, DOI 10.1097/00005373-198808000-00009; RINGENBERG BJ, 1988, ANN EMERG MED, V17, P792, DOI 10.1016/S0196-0644(88)80555-9; ROBERGE RJ, 1988, J TRAUMA, V28, P784, DOI 10.1097/00005373-198806000-00010; ROSS S, 1987, ANN EMERG MED, V165, P498; SCHLEEHAUF K, 1989, ANN EMERG MED, V18, P815, DOI 10.1016/S0196-0644(89)80202-1; Sees DW, 1998, J TRAUMA, V45, P768, DOI 10.1097/00005373-199810000-00026; SHAFFER MA, 1981, ANN EMERG MED, V10, P508, DOI 10.1016/S0196-0644(81)80004-2; Stiell IG, 1997, CAN MED ASSOC J, V156, P1537; TEHRANZADEH J, 1994, SKELETAL RADIOL, V23, P349, DOI 10.1007/BF02416991; WEBB JK, 1976, J BONE JOINT SURG BR, V58, P674; White A A 3rd, 1987, Instr Course Lect, V36, P513	28	57	57	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	NOV 15	2000	25	22					2884	2891		10.1097/00007632-200011150-00008			8	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	374ZA	WOS:000165373800007	11074674				2021-06-18	
J	Cernak, I; Savic, V; Kotur, J; Prokic, V; Kuljic, B; Grbovic, D; Veljovic, M				Cernak, I; Savic, V; Kotur, J; Prokic, V; Kuljic, B; Grbovic, D; Veljovic, M			Alterations in magnesium and oxidative status during chronic emotional stress	MAGNESIUM RESEARCH			English	Article						magnesium; oxidative stress; antioxidant system; chronic emotional stress	TRAUMATIC BRAIN INJURY; RATS; HOMEOSTASIS; TRANSITION; DEFICIENCY; RADICALS; SYSTEM	Magnesium and oxidative status were investigated in young volunteers exposed to chronic stress (political intolerance, awareness of potential military attacks, permanent stand-by duty and reduced holidays more than 10 years) or subchronic stress consisting of everyday mortal danger in military actions lasting more than 3 months. Significant decreases in plasma ionized Mg2+, total Mg and ionized Ca2+ concentrations were found in both groups. Similarly, both study groups exhibited oxidative stress as assessed by increased plasma superoxide anions and malondialdehyde and modified antioxidant defense. There were no significant differences between the two stress groups. A negative correlation between magnesium balance and oxidative stress was observed suggesting that the same etiological factor (chronic stress) initiate decreases in both free and total magnesium concentrations and simultaneously increase oxidative stress intensity. These findings support the need for magnesium supplementation with antioxidant vitamins for people living in conditions of chronic stress.	Mil Med Acad, YU-11002 Belgrade, Serbia	Cernak, I (corresponding author), James Cook Univ N Queensland, Dept Physiol & Pharmacol, Townsville, Qld 4811, Australia.	Ibolja.Cernak@jcu.edu.au	Cernak, Ibolja/A-6399-2008	Ibolja, Cernak/0000-0003-3214-698X			AUCLAIR C, 1985, HDB METHODS OXYGEN R, P123; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BIRCH NJ, 1993, MAGNESTUM CELL; Burke WJ, 1998, BRAIN RES, V787, P328, DOI 10.1016/S0006-8993(97)01488-1; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; CHROUSOS GP, 1988, MECH PHYSICAL EMOTIO; CLASSEN HG, 1981, ARTERY, V9, P182; CLASSEN HG, 1990, MET IONS BIOL SYST, V26, P321; DarleyUsmar V, 1996, PHARM RES-DORDR, V13, P649, DOI 10.1023/A:1016079012214; DEGROOT H, 1994, HEPATO-GASTROENTEROL, V41, P328; DESOUZA EB, 1986, BRAIN RES, V367, P77, DOI 10.1016/0006-8993(86)91581-7; Durlach J., 1994, Magnesium Research, V7, P313; Durlach J., 1988, MAGNESIUM CLIN MED, P140; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Favier A, 1997, ANN BIOL CLIN-PARIS, V55, P9; GIROTTI MJ, 1991, J TRAUMA, V31, P32, DOI 10.1097/00005373-199101000-00007; Halliwell B, 1989, FREE RADICALS BIOL M; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Henrotte Jean-Georges, 1993, Magnesium Research, V6, P21; Henrotte JG, 1997, PHYSIOL BEHAV, V61, P653, DOI 10.1016/S0031-9384(96)00506-9; Konig D, 1998, EXERC IMMUNOL REV, V4, P2; Malpuech-Brugere C, 1998, LIFE SCI, V63, P1815, DOI 10.1016/S0024-3205(98)00455-X; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MISRA HP, 1972, J BIOL CHEM, V247, P3170; MORI A, 1994, NEUROCHEM INT, V24, P201, DOI 10.1016/0197-0186(94)90076-0; Muir KW, 1998, MAGNESIUM RES, V11, P43; Oldham KM, 1998, J AM DIET ASSOC, V98, P1001, DOI 10.1016/S0002-8223(98)00230-2; Planas M, 1997, Nutr Hosp, V12, P233; PLANCER ZA, 1966, ANAL BIOCHEM, V16, P359; PORTA S, 1994, LIFE SCI, V55, pPL327, DOI 10.1016/0024-3205(94)00772-1; Regan RF, 1998, J NEUROCHEM, V70, P77; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Siemkowicz E, 1997, RESUSCITATION, V35, P53, DOI 10.1016/S0300-9572(97)00028-2; SUN M, 1978, ANAL BIOCHEM, V90, P81, DOI 10.1016/0003-2697(78)90010-6; Vigas M, 1996, Bratisl Lek Listy, V97, P63; WEGLICKI WB, 1992, AM J PHYSIOL, V263, pR734	38	57	62	0	5	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	0953-1424	1952-4021		MAGNESIUM RES	Magnes. Res.	MAR	2000	13	1					29	36					8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	298GE	WOS:000086130300004	10761188				2021-06-18	
J	Max, JE; Koele, SL; Castillo, CC; Lindgren, SD; Arndt, S; Bokura, H; Robin, DA; Smith, WL; Sato, Y				Max, JE; Koele, SL; Castillo, CC; Lindgren, SD; Arndt, S; Bokura, H; Robin, DA; Smith, WL; Sato, Y			Personality change disorder in children and adolescents following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; children and adolescents; personality change disorder	SCHOOL-AGE-CHILDREN; FRONTAL-LOBE DAMAGE; CLOSED-HEAD INJURY; PSYCHIATRIC-DISORDERS; RELIABILITY; IMPACT; SCHIZOPHRENIA; PREVALENCE; CHILDHOOD; VALIDITY	The occurrence of personality change due to traumatic brain injury (PC), and its clinical and neuroimaging correlates were investigated. Ninety-four children, ages 5 through 14 at the time of hospitalization following traumatic brain injury (TBI; severe TBI N = 37; mild-moderate TBI N = 57), were assessed. Standardized psychiatric, adaptive functioning, cognitive functioning, family functioning, family psychiatric history, severity of injury, and neuroimaging assessments were conducted. The Neuropsychiatric Rating Schedule (NPRS) was used to establish a diagnosis of PC. Approximately 40% of consecutively hospitalized severe TBI participants had ongoing persistent PC an average of 2 years postinjury. An additional approximately 20% had a history of a remitted and more transient PC. PC occurred in 5% of mild-moderate TBI but was always transient. Interrater reliability for the diagnosis of PC was good (Kappa = .70). In severe TBI participants, persistent PC was significantly associated with severity of injury, particularly impaired consciousness over 100 hr, adaptive and intellectual functioning decrements, and concurrent diagnosis of secondary attention deficit hyperactivity disorder, but was not significantly related to any psychosocial adversity variables. These findings suggest that PC is a frequent diagnosis following severe TBI in children and adolescents, but is much less common following mild-moderate TBI.	Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp, San Diego, CA USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; San Diego State Univ, Dept Commun Disorders, San Diego, CA 92182 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA; Univ Iowa, Mental Hlth Clin Res Ctr, Iowa City, IA 52242 USA; Cedar Ctr, Cedar Rapids, IA USA; Yasugi Daiichi Hosp, Dept Neurol, Shimane, Japan; Wayne State Univ, Childrens Hosp Michigan, Dept Radiol, Detroit, MI 48202 USA	Max, JE (corresponding author), 3665 Kearny Villa Rd,Suite 101, San Diego, CA 92123 USA.	jmax@ucsd.edu	Robin, Donald/F-2109-2010; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040856, P30MH043271, P50MH043271, R37MH031593, R01MH031593] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH31593, MH40856, MHCRC43271] Funding Source: Medline		ACKERLY S, 1947, P ASS RES NERVOUS ME, V27, P479; Ackerly SS, 1964, FRONTAL GRANULAR COR, P192; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Barkley R. A., 1997, ADHD NATURE SELF CON; BENDER L, 1956, PSYCHOPATHOLOGY CHIL, P66; BLACK P, 1969, LATE EFFECTS HEAD IN, P142; Blau A, 1936, ARCH NEURO PSYCHIATR, V35, P723, DOI 10.1001/archneurpsyc.1936.02260040031003; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Damasio A., 1994, DESCARTESERROR EMOTI; Damasio H., 1989, LESION ANAL NEUROPSY; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P110; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; HARRINGTON JA, 1958, J MENT SCI, V104, P1205; Hebb DO, 1940, ARCH NEURO PSYCHIATR, V44, P421, DOI 10.1001/archneurpsyc.1940.02280080181011; HEBB DO, 1945, ARCH NEURO PSYCHIATR, V54, P10, DOI 10.1001/archneurpsyc.1945.02300070020002; HJERN B, 1964, ACTA PAEDIATR SC   S, V152, P5; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Kasanin J, 1929, J NERV MENT DIS, V69, P385, DOI 10.1097/00005053-192904000-00002; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; LEMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; LISHMAN WA, 1978, ORGANIC PSYCHIAT; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1997, J AM ACAD CHILD PSY, V36, P404, DOI 10.1097/00004583-199703000-00020; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J AM ACAD PSYCHIATRY, V26, P247; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; MCCUBBIN HI, 1980, FAMILY ASSESSMENT RE, P97; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; OTTO U, 1960, PAEDOPSYCHIATRICA, V27, P6; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUNE V, 1970, ACTA PAEDIATR SC   S, V209, P1; RUSSELL WR, 1959, BRAIN MEMORY LEARNIN; Shaffer D, 1975, Ciba Found Symp, P191; Silver Jonathan M., 1994, P631; Sparrow S., 1984, VINELAND ADAPTIVE BE; Strecker EA, 1924, ARCH NEURO PSYCHIATR, V12, P443, DOI 10.1001/archneurpsyc.1924.02200040092006; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	54	57	57	0	20	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2000	6	3					279	289		10.1017/S1355617700633039			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	304DH	WOS:000086467200003	10824500				2021-06-18	
J	Truettner, J; Schmidt-Kastner, R; Busto, R; Alonso, OF; Loor, JY; Dietrich, WD; Ginsberg, MD				Truettner, J; Schmidt-Kastner, R; Busto, R; Alonso, OF; Loor, JY; Dietrich, WD; Ginsberg, MD			Expression of brain-derived neurotrophic factor, nerve growth factor, and heat shock protein HSP70 following fluid percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						brain-derived neurotrophic factor; HSP70; in situ hybridization; nerve growth factor; traumatic brain injury	CORTICAL IMPACT INJURY; FOREBRAIN CHOLINERGIC NEURONS; FOCAL CEREBRAL-ISCHEMIA; FACTOR MESSENGER-RNA; C-FOS; GENE-EXPRESSION; GLUCOSE-UTILIZATION; HIPPOCAMPAL DAMAGE; RAPID INCREASE; TIME-COURSE	Traumatic brain injury can induce the expression of stress-related and neurotrophic genes both within the injury site and in distant regions, These genes may affect severity of damage and/or be neuroprotective. We used in situ hybridization to assess the alterations in expression of the heat shock protein HSP70, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) genes in rat brain following moderate fluid-percussion (F-P) injury at various survival times, HSP70 gene expression was induced at and surrounding the injury site as early as 30 min after trauma, This elevated signal spread ventrally and laterally through the ipsilateral cortex and into the underlying white matter over the next few hours. In addition, there was elevated expression in the temporal hippocampus. BDNF was strongly upregulated in the granular cells of the dentate gyrus and in the CA3 hippocampus 2-6 h after injury, Cortical regions at and near the injury site showed no response at the mRNA level. NGF mRNA increased over the granular cells of the dentate gyrus at early time points, There was also a weaker secondary induction of the NGF gene in the contralateral dentate gyrus of some animals, Cortical response was observed in the entorhinal cortex, bilaterally, but not at the injury site. All three of the studied genes responded quickly to injury, as early as 30 min, The induction of gene expression for neurotrophins in regions remote from areas with histopathology may reflect coupling of gene expression to neuronal excitation, which may be associated with neuroprotection and plasticity.	Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol, Neurotrauma Res Ctr, Miami, FL 33101 USA	Truettner, J (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, POB 016960, Miami, FL 33101 USA.	Jessie@stroke.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30291, NS-05820] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS005820, P50NS005820, P50NS030291] Funding Source: NIH RePORTER		Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; BURES J, 1974, MORPHOLOGICAL DEV AS, P115; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CHOPP M, 1991, ACTA NEUROPATHOL, V83, P66, DOI 10.1007/BF00294432; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; COMELLI MC, 1993, NEUROSCIENCE, V55, P473, DOI 10.1016/0306-4522(93)90517-J; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; Gingrich JR, 1998, ANNU REV NEUROSCI, V21, P377, DOI 10.1146/annurev.neuro.21.1.377; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; IKEDA J, 1994, MOL BRAIN RES, V26, P249, DOI 10.1016/0169-328X(94)90097-3; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KIESSLING M, 1994, BRAIN PATHOL, V4, P77; KINOUCHI H, 1993, J CEREBR BLOOD F MET, V13, P105, DOI 10.1038/jcbfm.1993.13; Klocker N, 1998, J NEUROSCI, V18, P1038; Kobayashi NR, 1996, EUR J NEUROSCI, V8, P1018, DOI 10.1111/j.1460-9568.1996.tb01588.x; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; KOKAIA Z, 1994, EUR J NEUROSCI, V6, P587, DOI 10.1111/j.1460-9568.1994.tb00303.x; KOKAIA Z, 1993, MOL BRAIN RES, V19, P277, DOI 10.1016/0169-328X(93)90126-A; KOKAIA Z, 1995, EXP NEUROL, V136, P73, DOI 10.1006/exnr.1995.1085; LAUTERBORN JC, 1994, EXP NEUROL, V125, P22, DOI 10.1006/exnr.1994.1003; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LONGO FM, 1993, J NEUROSCI RES, V36, P325, DOI 10.1002/jnr.490360310; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Murray KD, 1996, NEUROSCIENCE, V70, P617, DOI 10.1016/S0306-4522(96)83002-8; NOWAK TS, 1993, PROG BRAIN RES, V96, P195; NOWAK TS, 1994, BRAIN PATHOL, V4, P67; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PHILLIPS HS, 1990, SCIENCE, V250, P290, DOI 10.1126/science.1688328; Plumier JCL, 1997, J CEREBR BLOOD F MET, V17, P781; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RINK A, 1995, AM J PATHOL, V147, P1575; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SchmidtKastner R, 1996, EXP BRAIN RES, V107, P331; SchmidtKastner R, 1996, NEUROSCIENCE, V74, P161, DOI 10.1016/0306-4522(96)00093-0; SIMON RP, 1991, J NEUROSCI, V11, P881; SINSON G, 1995, J NEUROCHEM, V65, P2209; SLOVITER RS, 1993, J COMP NEUROL, V330, P337, DOI 10.1002/cne.903300305; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; WHITTEMORE SR, 1988, J NEUROSCI RES, V20, P403, DOI 10.1002/jnr.490200402; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuen EC, 1996, ANN NEUROL, V40, P346, DOI 10.1002/ana.410400304	84	57	63	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					471	486		10.1089/neu.1999.16.471			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800004	10391364				2021-06-18	
J	Radanov, BP; Bicik, I; Dvorak, J; Antinnes, J; von Schulthess, GK; Buck, A				Radanov, BP; Bicik, I; Dvorak, J; Antinnes, J; von Schulthess, GK; Buck, A			Relation between neuropsychological and neuroimaging findings in patients with late whiplash syndrome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						brain damage; neuroimaging; neuropsychological testing; whiplash injury; working memory	POSITRON EMISSION TOMOGRAPHY; TRAUMATIC BRAIN INJURY; FOLLOW-UP; TECHNETIUM-99M-HMPAO SPECT; CEREBRAL SYMPTOMS; COMMON WHIPLASH; WORKING-MEMORY; DEFICITS; NECK	Objectives-The interpretation of long term cognitive impairment after whiplash injury is still a problem for many physicians. On the grounds of nuclear medicine findings previous research speculated that brain damage is responsible for cognitive problems of patients with whiplash. To test this hypothesis the relation between neuroimaging and neuropsychological findings was analysed. Methods-Twenty one patients (11 women, 10 men, mean age 42.2 (SD 8.6) years) with the late whiplash syndrome (average interval of trauma 26.1 (SD 20.7) months) referred for diagnostic action to the Department of Neurology were investigated. Assessment included computer assisted assessment of working memory and divided attention, neuroimaging (by the means of [Tc-99m]-HMPAO-SPECT, [O-15]-H2O-PET and [F-18]-FDG-PET), testing of emotional functioning (depression and anxiety ratings), and pain intensity at the time of testing. Results-On average, scoring on tests of cognitive functioning was very low. However, no significant correlations were found between regional perfusion or metabolism in any brain area and the scores of divided attention or working memory. By contrast, significant relations were found between indices of impaired emotional functioning (state anxiety) and divided attention. In addition, low scoring in divided attention was significantly correlated with pain intensity at the time of testing. Conclusions-The present data do not provide evidence of a significant relation between detectable morphological or functional brain damage and impaired cognitive performance in the late whiplash syndrome. Results indicate triggering of emotional and cognitive symptoms on the basis of initial injury of the cervical spine.	Univ Bern, Inselspital, Dept Psychiat, CH-3010 Bern, Switzerland; Univ Zurich Hosp, Div Nucl Med, CH-8091 Zurich, Switzerland; Wilhelm Schulthess Hosp, Dept Neurol, CH-8008 Zurich, Switzerland; Ochsner Fdn Hosp, Dept Orthoped Surg, New Orleans, LA 70121 USA	Radanov, BP (corresponding author), Univ Bern, Inselspital, Dept Psychiat, CH-3010 Bern, Switzerland.	radanov@pupk.unibe.ch					Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BALLA JI, 1980, AUST NZ J SURG, V50, P610, DOI 10.1111/j.1445-2197.1980.tb04207.x; Beck A.T., 1987, BECK DEPRESSION INVE; Bicik I, 1998, NEUROLOGY, V51, P345, DOI 10.1212/WNL.51.2.345; BLUM B, 1997, THESIS U ZUERICH ZUE; CAINE ED, 1986, NEUROPSYCHOLOGICAL A, P221; CASEY KL, 1994, J NEUROPHYSIOL, V71, P802; COSTA PT, 1987, J PERS, V55, P299, DOI 10.1111/j.1467-6494.1987.tb00438.x; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; EYSENCK MW, 1988, HDB LIFE STRESS COGN, P467; Fiez JA, 1996, J NEUROSCI, V16, P808; FRACKOWIAK RSJ, 1994, J ANAT, V184, P211; Goldman-Rakic P. S., 1994, MOTOR COGNITIVE FUNC, P112; HAUTZINGER M, 1992, BECK DEPRESSIONS INV; HIRSCH SA, 1988, ORTHOP CLIN N AM, V19, P791; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; KEIDEL M, 1992, NERVENARZT, V63, P731; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; Laux L., 1981, STATE TRAIT ANGSTINV; Mayou R, 1996, J PSYCHOSOM RES, V40, P461, DOI 10.1016/0022-3999(95)00586-2; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; OMMAYA K, 1995, HDB CLIN NEUROLOGY, P67; Otte A, 1996, EUR J NUCL MED, V23, P72, DOI 10.1007/BF01736993; Otte A, 1997, J NEUROL NEUROSUR PS, V63, P368, DOI 10.1136/jnnp.63.3.368; Otte A, 1997, J NUCL MED, V38, P1002; RADANOV BP, 1994, J NEUROL NEUROSUR PS, V57, P486, DOI 10.1136/jnnp.57.4.486; RADANOV BP, 1995, MEDICINE, V74, P281, DOI 10.1097/00005792-199509000-00005; Radanov BP, 1996, PAIN, V64, P429, DOI 10.1016/0304-3959(95)00148-4; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Spielberger C.D., 1970, STATE TRAIT ANXIETY; SPITZER WO, 1995, SPINE, V20, pS1; TALARAICH J, 1988, COPLANAR STEREOTACTI; TALBOT JD, 1991, SCIENCE, V251, P1355, DOI 10.1126/science.2003220; Zimmermann P., 1993, DEV ASSESSMENT REHAB, P3	37	57	59	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	1999	66	4					485	489		10.1136/jnnp.66.4.485			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	181TA	WOS:000079457400013	10201421	Bronze, Green Published			2021-06-18	
J	Moore, AN; Kampfl, AW; Zhao, X; Hayes, RL; Dash, PK				Moore, AN; Kampfl, AW; Zhao, X; Hayes, RL; Dash, PK			Sphingosine-1-phosphate induces apoptosis of cultured hippocampal neurons that requires protein phosphatases and activator protein-1 complexes	NEUROSCIENCE			English	Article						phosphatases; calcineurin; TRE sequence; c-Fos; caspase; AP-1 complexes	PROGRAMMED CELL-DEATH; TRAUMATIC BRAIN INJURY; ICE-LIKE PROTEASE; C-JUN; THYMOCYTE APOPTOSIS; CALPAIN INHIBITORS; GENE-EXPRESSION; NERVOUS-SYSTEM; KINASE-C; CERAMIDE	In this study, we report that mobilization of internal Ca2+ by sphingosine-1-phosphate, a metabolite of ceramide, induces apoptosis in cultured hippocampal neurons. This sphingosine 1-phosphate-induced apoptosis is dependent upon the activation of protein phosphatases, possibly calcineurin and phosphatase 2A (or a related phosphatase). In addition, pretreatment of neurons with double-stranded oligonucleotides containing the metallothionein phorbol-12-myristate-13-acetate response element sequence as transcription factor decoys suppressed apoptosis. In contrast, double-stranded oligonucleotides containing either the c-jun or SV40 phorbol 12-myristate-13-acetate response element sequences were ineffective. Electrophoretic mobility shift assays and supershift assays revealed that c-Fos-containing activator protein-1 complexes preferentially bound the metallothionein phorbol-12-myristate-13-acetate response element sequence-containing oligonucleotides. Furthermore, antisense oligonucleotides to c-fos and c-jun were also protective. The apoptotic death of hippocampal neurons has been hypothesized to contribute to the cognitive impairments observed following insults to the brain. While increases in intracellular calcium are thought to be key mediators of neuronal apoptosis, the biochemical cascade(s) activated as a result of increased Ca2+ which mediates apoptosis of hippocampal neurons is (are) not well understood. The findings presented in this study suggest that mobilization of internal calcium via prolonged exposure of sphingosine-1-phosphate induces apoptosis of hippocampal neurons in culture. Sustained increases in intracellular calcium activate a phosphatase cascade that includes calcineurin and a phosphatase 2A-like phosphatase, and leads to the expression of genes containing metallothionein phorbol-12-myristate-13-acetate response element (TGAGTCA)-type enhancer sequences. The expression of genes containing TGAGTCA-type enhancer sequences appears to be essential for sphingosine-1-phosphate-induced apoptosis of hippocampal neurons. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, POB 20708, Houston, TX 77225 USA.	pdash@nba19.med.uth.tmc.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH049662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49662] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457] Funding Source: Medline		ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BREWER GJ, 1989, BRAIN RES, V494, P6; CABELL L, 1993, INT J DEV NEUROSCI, V11, P357, DOI 10.1016/0736-5748(93)90007-Z; CHIASSON BJ, 1992, EUR J PHARM-MOLEC PH, V227, P451, DOI 10.1016/0922-4106(92)90167-T; Choi Dennis W., 1995, Trends in Neurosciences, V18, P58, DOI 10.1016/0166-2236(95)93870-4; COHEN P, 1988, METHOD ENZYMOL, V159, P427; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; GENESTIER L, 1994, CELL IMMUNOL, V155, P283, DOI 10.1006/cimm.1994.1122; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P374, DOI 10.1016/S0968-0004(98)01289-4; Irie F, 1998, J NEUROSCI RES, V54, P475, DOI 10.1002/(SICI)1097-4547(19981115)54:4<475::AID-JNR5>3.0.CO;2-P; JARVIS WD, 1994, CANCER RES, V54, P1707; Kampfl A, 1996, EUR J NEUROSCI, V8, P344, DOI 10.1111/j.1460-9568.1996.tb01218.x; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KROEMER G, 1995, FASEB J, V9, P1277; LEVLAM V, 1997, NEURON, V18, P1025; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MCCONKEY DJ, 1994, IMMUNOL REV, V142, P343, DOI 10.1111/j.1600-065X.1994.tb00896.x; McIntosh TK, 1996, EUR J ANAESTH, V13, P291, DOI 10.1046/j.1365-2346.1996.00981.x; Mitoma J, 1998, J NEUROSCI RES, V51, P712, DOI 10.1002/(SICI)1097-4547(19980315)51:6<712::AID-JNR5>3.0.CO;2-E; Moore AN, 1996, J BIOL CHEM, V271, P14214, DOI 10.1074/jbc.271.24.14214; MORGAN JI, 1991, REV NEUROSCI, V14, P421; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Neary JT, 1996, NEUROREPORT, V7, P2893, DOI 10.1097/00001756-199611250-00017; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; Schwarz A, 1997, J NEUROSCI, V17, P2929; SHEN H, 1995, NEUROSCI LETT, V185, P115, DOI 10.1016/0304-3940(94)11238-E; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHIBASAKI F, 1995, J CELL BIOL, V131, P735, DOI 10.1083/jcb.131.3.735; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SONNENBERG JL, 1989, NEURON, V4, P477; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Squier MKT, 1997, J IMMUNOL, V158, P3690; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; THOMBERRY NA, 1992, NATURE, V356, P768; TRUMP BF, 1995, FASEB J, V9, P219; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Waxham MN, 1996, J CEREBR BLOOD F MET, V16, P1, DOI 10.1097/00004647-199601000-00001; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147	62	57	57	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		1999	94	2					405	415		10.1016/S0306-4522(99)00288-2			11	Neurosciences	Neurosciences & Neurology	245YE	WOS:000083135600007	10579204				2021-06-18	
J	O'Neill, DF; McGlone, MR				O'Neill, DF; McGlone, MR			Injury risk in first-time snowboarders versus first-time skiers	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article								Between 1994 and 1996 we studied injury patterns in more than 22,000 first-time snowboarders and first-time skiers to determine the comparative injury risk of these two popular sports coexisting in winter resort areas. The first-time participants included in this study had no previous experience in their activity of choice and enrolled in Learn to Snowboard and Learn to Ski programs in two major northeastern ski resorts. Data were gathered from physician evaluations at the medical clinics at each mountain. Two hundred seventy-three (4%) of the first-time snowboarders (N = 6585), and 641 (4%) of the first-time skiers (N = 15,795) sustained an injury. Injuries were further evaluated by location (upper extremity, lower extremity, head, and trunk area) and severity (emergent versus nonemergent). Snowboarders had a higher percentage of upper extremity injuries (53%), while skiers had a higher percentage of lower extremity injuries (63%). Snowboarders, however, sustained a significantly higher incidence of emergent injuries (such as fracture, concussion, dislocation, lost teeth) necessitating immediate intervention. While there have been other reports describing injuries in these activities, no previous study attempted to look at the first-time participants with similar age, experience, and equipment to determine comparative risk. We conclude that for the first-time participant, snowboarding does show a higher incidence of emergent injuries.	Plymouth Sports & Orthopaed Clin, Plymouth, NH 03264 USA	O'Neill, DF (corresponding author), Plymouth Sports & Orthopaed Clin, 19 Avery St, Plymouth, NH 03264 USA.						ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; BLADIN C, 1993, AM J SPORT MED, V21, P701, DOI 10.1177/036354659302100511; Fischler L., 1996, SCHWEIZ RUNDSCH MED, V24, P777; GANONG RB, 1992, PHYSICIAN SPORTSMED, V20, P114, DOI 10.1080/00913847.1992.11947543; Giacobetti FB, 1997, AM J SPORT MED, V25, P223, DOI 10.1177/036354659702500215; JANES P, 1996, BIOMECHANICS     NOV, P16; JOHNSON RJ, 1990, POSTGRAD MED, V88, P36; MCLENNAN JC, 1991, J MUSCULOSKELETAL ME, V8, P75; Pigozzi F, 1997, ORTHOPEDICS, V20, P505; PINO EC, 1989, AM J SPORT MED, V17, P778, DOI 10.1177/036354658901700610; Schieber RA, 1996, NEW ENGL J MED, V335, P1630, DOI 10.1056/NEJM199611283352202; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5; WARME WJ, 1995, AM J SPORT MED, V23, P597, DOI 10.1177/036354659502300514	13	57	57	1	4	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	1999	27	1					94	97					4	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	159ZL	WOS:000078205800016	9934425				2021-06-18	
J	Mallinson, AI; Longridge, NS				Mallinson, AI; Longridge, NS			Dizziness from whiplash and head injury - Differences between whiplash and head injury	AMERICAN JOURNAL OF OTOLOGY			English	Article						posturography; compensation; whiplash; head injury; dizziness	POSTURAL CONTROL	Objective: Large discrepancies exist in the literature regarding incidence and types of symptomatology in whiplash. This is because of the evolution of whiplash injury over the years with the advent of head rests and seat belts. Previous authors have regarded symptoms of dizziness as a result of brainstem or cerebellar injury or both. it has been difficult in those studies to ascribe a mechanism of injury, as patients with whiplash injury only have been grouped with those who have incurred mild traumatic brain injury as a result of a significant blow to the head. The authors saw the need to delineate patients who had suffered whiplash injury from those who also had suffered mild head injury, as defined in the rehabilitation-neurosurgical literature, to attempt to define differences in symptoms. abnormalities, and mechanisms of recovery in these two groups. Study Design: The study design was a retrospective case review. Setting: The study was conducted at a tertiary-quaternary referral clinic. Patients: The records of 36 patients were reviewed. Nineteen of these patients suffered a whiplash-associated disorder and 17 suffered a mild head injury as well. These patients were referred for assessment of symptoms persisting for at least 2 years after their injury. Patients were excluded if they had not completed clinical assessment, including electronystagmography (ENG) and computerized dynamic posturography (CDP). Interventions: A Full history, otolaryngologic examination, including assessment of eye movements, corneal reflexes and gait, as well as an investigation, including ENG and CDP, and history taking and detailed recording of related complaints immediately before diagnostic work-up were performed. Main Outcome Measures: Symptoms reported by patients who had received either whiplash alone or whiplash plus mild head trauma as defined in thr literature were measured. Patients were classified according to type of accident, type of injury suffered, and degree and nature of posturographic abnormalities. Results: Patients often have similar complaints regardless of whether or not they had suffered a head injury. Although CDP showed abnormalities in both groups, standard ENG assessment, including caloric testing, showed abnormalities only in the head-injured group. The posturographic abnormalities also were analyzed in both groups, and it was found that there was a correlation between the type of posturographic abnormality and the type of injury suffered. Although ENG testing is done routinely, posturography is shown to be more sensitive in picking up abnormalities. In addition, the authors have shown that posturography can delineate the type of injury suffered by exhibiting the compensation strategy used as well as the efficacy of that compensation strategy. Conclusions: Because ENG abnormalities are limited to patients who have suffered a head injury, the inference is that these two groups of patients have suffered damage at different sites along the balance system pathways, but both of these lesions can lead to similar symptoms. Although the mechanisms of whiplash injury and how they affect the vestibular system are poorly understood, posturography testing is essential in inferring how a patient is recovering by measuring how and how well the patient is overcoming his or her deficit. This has important medical legal implications regarding legitimizing a patient's problem, prognostic factors, as well as rehabilitation plans, measures, and outcomes.	Univ British Columbia, Dept Surg, Div Otolaryngol, Vancouver, BC V5Z 1M9, Canada; Vancouver Gen Hosp, Neurotol Unit, Vancouver, BC, Canada	Longridge, NS (corresponding author), Univ British Columbia, Dept Surg, Div Otolaryngol, WP 4,805 W 12 Ave, Vancouver, BC V5Z 1M9, Canada.						BRONSTEIN AM, 1986, EXP BRAIN RES, V63, P655, DOI 10.1007/BF00237488; BRONSTEIN AM, 1990, BRAIN, V113, P767, DOI 10.1093/brain/113.3.767; CHESTER JB, 1991, SPINE, V16, P716, DOI 10.1097/00007632-199107000-00004; HINOKI M, 1985, ACTA OTOLARYNGOL S S, V419, P9; JANE JA, 1989, MILD MODERATE HEAD I, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; MACNAB I, 1964, J BONE JOINT SURG AM, V46, P1797, DOI 10.2106/00004623-196446080-00021; MALLINSON AI, 1996, J MUSCULOSKELET PAIN, V4, P105, DOI DOI 10.1300/J094V04N04_10; MERTZ HJ, 1967, SAE T, V76, P2952; NASHNER LM, 1985, BEHAV BRAIN SCI, V8, P135, DOI 10.1017/S0140525X00020008; *NEUR INT INC, 1992, EQ INT MAN; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; OOSTERVELD WJ, 1991, ACTA OTO-LARYNGOL, V111, P201, DOI 10.3109/00016489109137375; Paige G D, 1992, J Vestib Res, V2, P133; Persson L, 1996, J VESTIBUL RES-EQUIL, V6, P439; REID SE, 1984, HEAD NECK INJURIES S, P24; RUBIN AM, 1995, AM J OTOL, V16, P216; Shupert CL, 1996, J VESTIBUL RES-EQUIL, V6, P423; STURZENEGGER M, 1994, NEUROLOGY, V44, P688, DOI 10.1212/WNL.44.4.688; Vitte E, 1992, POSTURE GAIT CONTROL, V2, P176	20	57	57	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0192-9763			AM J OTOL	Am. J. Otol.	NOV	1998	19	6					814	818					5	Otorhinolaryngology	Otorhinolaryngology	178BL	WOS:000079245700025	9831160				2021-06-18	
J	Donaghy, S; Wass, PJ				Donaghy, S; Wass, PJ			Interrater reliability of the functional assessment measure in a brain injury rehabilitation program	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							FIM+FAM	Objective: To examine the interrater reliability and completion time of the Functional Assessment Measure, which is the Functional Independence Measure (FIM(TM)) plus additional items (FIM +FAM). Design: Interrater reliability study. Setting: Inpatient rehabilitation units of a postacute care brain injury rehabilitation program. Patients: A convenience sample of 53 extremely severely impaired adult survivors of traumatic brain injuries (40 men, 13 women, mean age 38yrs). Main Outcome Measures: Treatment team members' ratings of the 30 FIM+FAM items, and time taken to complete the FIMS FAM. Results: Intraclass Correlation Coefficients (ICCs) were within the good to excellent range (ICC >.60) for 29 of 30 items and for all subscales except psychosocial adjustment. Higher mean ICC values were obtained for motor domain items than for cognitive/psychosocial domain items. Treatment teams became progressively faster over a 12-week period in completing the FIM+FAM. Conclusions: The generally good to excellent range interrater reliability found in this study helps support the use of the FIM+FAM in rehabilitation settings. Further support was obtained for the finding that motor items are more reliable than cognitive and psychosocial items. Administration of the FIM+FAM can be done in a timely manner in a rehabilitation setting. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Alberta Hosp Ponoka, Brain Injury Rehabil Program, Ponoka, AB T4J 1R8, Canada	Donaghy, S (corresponding author), Alberta Hosp Ponoka, Brain Injury Rehabil Program, POB 1000, Ponoka, AB T4J 1R8, Canada.						ADAMOVICH BLB, 1992, NEUROREHABILITATION, V2, P42; BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; CICCHETTI DV, 1991, BEHAV BRAIN SCI, V14, P119, DOI 10.1017/S0140525X00065675; CICCHETTI DV, 1981, AM J MENT DEF, V86, P127; Crewes N., 1995, PSYCHOL ASSESSMENT M, P101; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pS10; HARVEY RF, 1981, ARCH PHYS MED REHAB, V74, P566; McPherson KM, 1996, DISABIL REHABIL, V18, P341, DOI 10.3109/09638289609165892; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; *STAT U NY BUFF, 1993, GUID UN DAT SET MED; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876	13	57	64	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1998	79	10					1231	1236		10.1016/S0003-9993(98)90267-2			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	128CC	WOS:000076386800007	9779676				2021-06-18	
J	Whalen, MJ; Carlos, TM; Kochanek, PM; Wisniewski, SR; Bell, MJ; Carcillo, JA; Clark, RSB; DeKosky, ST; Adelson, PD				Whalen, MJ; Carlos, TM; Kochanek, PM; Wisniewski, SR; Bell, MJ; Carcillo, JA; Clark, RSB; DeKosky, ST; Adelson, PD			Soluble adhesion molecules in CSF are increased in children with severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						ICAM-1; inflammation; meningitis; neutrophils; P-selectin; traumatic brain injury	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL BACTERIAL-MENINGITIS; CEREBRAL-ARTERY OCCLUSION; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; ENDOTHELIAL-CELLS; NEUTROPHIL ADHESION; MULTIPLE-SCLEROSIS; ICAM-1 EXPRESSION	Leukocyte-endothelial adhesion molecules, critical to the development of acute inflammation, are expressed in brain as part of the acute inflammatory response to traumatic brain injury (TBI), We measured the concentrations of the adhesion molecules P-selectin, ICAM-1, E-selectin, L-selectin, and VCAM-1 in ventricular cerebrospinal fluid (CSF) from children with severe TBI (Glasgow coma score < 8) and compared these findings with those from children with bacterial meningitis, P-selectin, an adhesion molecule associated with ischemia/reperfusion, was increased in children with TBI versus meningitis and control, Univariate and multivariate regression analyses demonstrated associations between CSF P-selectin and child abuse and age of <4 years, and a significant, independent association between CSF intercellular adhesion molecule-1 (ICAM-1) and child abuse. These results are consistent with a specific acute inflammatory component to TBI in children. Future studies of secondary injury mechanisms and therapy after TBI should assess on the roles of P-selectin and ICAM-1 in injury and repair processes in brain after TBI.	Univ Pittsburgh, Safar Ctr Resuscitat, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat, Dept Epidemiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Wisniewski, Stephen/0000-0002-3877-9860; DeKosky, Steven/0000-0003-3743-2758	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO8 NS01946-01, KO8 NS01809-01, NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001809, K08NS001946, P20NS030318, P50NS030318] Funding Source: NIH RePORTER		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Adelson PD, 1998, ACT NEUR S, V71, P104; AKIYAMA H, 1993, ACTA NEUROPATHOL, V85, P628, DOI 10.1007/BF00334673; Azuma H, 1997, J PEDIATR-US, V131, P463, DOI 10.1016/S0022-3476(97)80079-0; Barnett CC, 1996, J SURG RES, V63, P6; BELL M, 1998, CRIT CARE MED, V26, pA86; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BERG EL, 1989, IMMUNOL REV, V108, P5, DOI 10.1111/j.1600-065X.1989.tb00010.x; BIRDSALL HH, 1991, AM J PATHOL, V139, P1341; Buhrer C, 1996, ARCH DIS CHILD, V74, P288, DOI 10.1136/adc.74.4.288; CANNELLA B, 1991, LAB INVEST, V65, P23; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLARK WM, 1993, J NEUROIMMUNOL, V44, P123, DOI 10.1016/0165-5728(93)90275-4; CODY R, 1995, J NEUROTRAUM, V12, P976; DOREDUFFY P, 1995, ANN NEUROL, V37, P55, DOI 10.1002/ana.410370111; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; FASSBENDER K, 1995, STROKE, V26, P1361, DOI 10.1161/01.STR.26.8.1361; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; GAMBLE JR, 1990, SCIENCE, V249, P414; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gupta AK, 1995, J CEREB BLOOD FLOW M, V15, pS33; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HEYES MP, 1992, BRAIN, V115, P1249, DOI 10.1093/brain/115.5.1249; HINES D, 1993, SOC NEUR ABSTR, V18, P1875; Ishiguro A, 1996, PEDIATR RES, V40, P610, DOI 10.1203/00006450-199610000-00016; JANDER S, 1993, NEUROLOGY, V43, P1809, DOI 10.1212/WNL.43.9.1809; Kochanek PM, 1998, CRIT CARE MED, V26, P1788, DOI 10.1097/00003246-199811000-00013; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lindsberg PJ, 1996, CIRCULATION, V94, P939, DOI 10.1161/01.CIR.94.5.939; LO SK, 1991, J EXP MED, V173, P1493, DOI 10.1084/jem.173.6.1493; LopezCortes LF, 1997, ANN CLIN BIOCHEM, V34, P165, DOI 10.1177/000456329703400206; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; PFISTER HW, 1990, J CEREBR BLOOD F MET, V10, P914, DOI 10.1038/jcbfm.1990.148; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; RIECKMANN P, 1995, NEUROSCI LETT, V186, P61, DOI 10.1016/0304-3940(95)11282-2; RIECKMANN P, 1993, J NEUROIMMUNOL, V47, P133, DOI 10.1016/0165-5728(93)90023-R; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; SATOH JI, 1991, J NEUROPATH EXP NEUR, V50, P215, DOI 10.1097/00005072-199105000-00004; SCHURER L, 1990, ACT NEUR S, V51, P49; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHARIEF MK, 1993, J NEUROIMMUNOL, V43, P15, DOI 10.1016/0165-5728(93)90070-F; SHERMAN DG, 1995, STROKE, V26, P164; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; Sinz EH, 1998, J CEREBR BLOOD F MET, V18, P610, DOI 10.1097/00004647-199806000-00002; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Tang T, 1996, J CLIN INVEST, V97, P2485, DOI 10.1172/JCI118695; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VORA AJ, 1995, J IMMUNOL METHODS, V180, P165, DOI 10.1016/0022-1759(94)00312-K; Weber JR, 1995, J NEUROIMMUNOL, V63, P63; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Whalen MJ, 1998, ACT NEUR S, V71, P212; Wong D, 1996, J NEUROPATH EXP NEUR, V55, P225, DOI 10.1097/00005072-199602000-00011; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	64	57	61	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1998	15	10					777	787		10.1089/neu.1998.15.777			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	132LW	WOS:000076632400003	9814634				2021-06-18	
J	Nahas, Z; Arlinghaus, KA; Kotrla, KJ; Clearman, RR; George, MS				Nahas, Z; Arlinghaus, KA; Kotrla, KJ; Clearman, RR; George, MS			Rapid response of emotional incontinence to selective serotonin reuptake inhibitors	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							DAMAGE; STROKE	Emotional incontinence (EI) is a perturbing condition characterized by uncontrollable outbursts of exaggerated, involuntary facial expressions and pathological crying or laughter. There is increasing evidence that serotonergic neurotransmission may be damaged in EI. The authors report 4 pathological crying cases (3 poststroke and 1 with multiple sclerosis) and 1 case of pathological laughter after traumatic brain injury. EI improved dramatically with three different selective serotonin reuptake inhibitors (fluoxetine, sertraline, and paroxetine) in the context of these different CNS diseases.	Baylor Coll Med, Houston, TX 77030 USA				Nahas, Ziad/0000-0002-8391-5673; George, Mark/0000-0003-1767-1815			ANDERSEN G, 1994, STROKE, V25, P1050, DOI 10.1161/01.STR.25.5.1050; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; ANDERSEN G, 1995, DRUG AGING, V6, P105, DOI 10.2165/00002512-199506020-00003; BENEDEK DM, 1995, AM J PSYCHIAT, V152, P953; Derex L, 1997, STROKE, V28, P1464, DOI 10.1161/01.STR.28.7.1464; Iannaccone S, 1996, CLIN NEUROPHARMACOL, V19, P532, DOI 10.1097/00002826-199619060-00008; RASMUSSEN K, 1990, SYNAPSE, V5, P324, DOI 10.1002/syn.890050409; Robinson RG, 1997, ANNU REV MED, V48, P217; ROSS ED, 1987, J NERV MENT DIS, V175, P165, DOI 10.1097/00005053-198703000-00007; SANDYK R, 1985, CLIN NEUROPHARMACOL, V8, P377, DOI 10.1097/00002826-198512000-00009; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; Szczudlik A, 1995, Neurol Neurochir Pol, V29, P663; TORK I, 1990, ANN NY ACAD SCI, V600, P194; UDAKA F, 1984, ARCH NEUROL-CHICAGO, V41, P1095, DOI 10.1001/archneur.1984.04050210093023; VANHILTEN JJ, 1988, ARCH NEUROL-CHICAGO, V45, P936, DOI 10.1001/archneur.1988.00520330010001	15	57	58	0	2	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	1998	10	4					453	455		10.1176/jnp.10.4.453			3	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	135CR	WOS:000076783200011	9813792				2021-06-18	
J	Hibbard, MR; Uysal, S; Sliwinski, M; Gordon, WA				Hibbard, MR; Uysal, S; Sliwinski, M; Gordon, WA			Undiagnosed health issues in individuals with traumatic brain injury living in the community	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; REHABILITATION; EPILEPSY	Objectives: To examine the self-reported prevalence of long-term health issues in individuals with traumatic brain injury (TBI) living in the community. Design: A structured health interview. For individuals with TBI, the presence of a specific health-related issue with onset post-TBI and currently a problem at the time of the interview was explored. For individuals without disability, a specific health-related issue was evaluated at time of interview. For each health issue, the proportion of individuals with TBI experiencing post-TBI onset but current symptoms was contrasted with symptom reports of individuals without disability. Chi-square statistical analyses were used to determine significance. For individuals with TBI, logistic regressions were used to model the probability of having a particular health difficulty when four covariates were examined, such as age, gender, rime since onset of TBI, and duration of loss of consciousness (LOC). Setting: Urban, suburban, and rural New York State. Participants: 338 individuals with TBI and 273 individuals without disability between the ages of 18 and 65 years. Individuals with TBI were, on average, 10 years post-onset at the time of interview. Main Outcome Measures: Self-reported health issues reflective of neuroendocrine, neurological, immunosuppression, and other hearth issues. Results: Chronic health issues suggestive of ongoing neuroendocrine dysfunctions (ie, changes in hair/skin texture, body temperature changes), neurologic difficulties (ie, headaches, seizures, balance difficulties, spasticity, sleep disturbances, loss of urinary control), and arthritic complaints were significantly more common in individuals with TBI. The prevalence of many of these health-related difficulties was related to duration of LOC but not to time since injury. Age and gender effects were found, with older women with TBI more Likely to report thyroid conditions, sleep disturbances, loss of urinary control, and arthritic changes. Women also reported greater frequency of headaches, colds, weight changes, and temperature changes post TBI. Conclusion: Health issues reflective of neuroendocrine, neurological, and arthritic difficulties are common long-term health issues for individuals with TBI. Proactive patient education, ongoing health screening with appropriate medical follow-up, and timely interventions for individuals with TBI are indicated. Longitudinal studies are necessary to examine the natural course of post-TBI health difficulties.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA	Hibbard, MR (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240, New York, NY 10029 USA.						ALEXANDRE L, 1979, ACTA NEUROSURG S, V28, P188; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; Beck A.T., 1987, BECK DEPRESSION INVE; BINDER L, 1986, J CLIN EXP NEUROPSYC, V1, P323; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; CICCONE CD, 1990, PHARM REHABILITATION; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; COHEN B, 1993, J NEUROL NEUROSUR PS, V55, P313; DUNGER DB, 1980, LANCET, V1, P1277; Eames P, 1989, Brain Inj, V3, P319, DOI 10.3109/02699058909029645; GUALTIERI T, 1991, NEUROPSYCHIATRY BEHA; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; HERZOG AG, 1982, ARCH NEUROL-CHICAGO, V39, P133, DOI 10.1001/archneur.1982.00510150003001; HORN LJ, 1988, J HEAD TRAUMA REHAB, V3, P87; HORN LJ, 1988, J HEAD TRAUMA REHABI, V3, P86; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; Kowatch R A, 1989, Psychiatr Med, V7, P37; LABI M L C, 1990, Brain Injury, V4, P365, DOI 10.3109/02699059009026189; LABI MIC, 1996, MED REHABILITATION T; MANN NR, 1996, MED REHABILITATION T; MAYER NH, 1996, MED REHABILITATION T; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; OTT LG, 1985, NEUROSURGERY, V16, P725; PENROD L, 1991, Archives of Physical Medicine and Rehabilitation, V72, P793; QUATTROCHI KB, 1990, J NEUROSURG, V75, P766; SHEPARD NT, 1993, ANN OTO RHINOL LARYN, V102, P198, DOI 10.1177/000348949310200306; STEWARD DG, 1997, PHYS MED REHABIL CLI, V8, P827; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; VARGHESE G, 1992, PHYS MED REH CLIN N, V3, P407; WHYTE J, 1993, REHABILITATION MED P; ZASLER ND, 1996, MED REHABILITATION T; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004	38	57	59	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1998	13	4					47	57		10.1097/00001199-199808000-00005			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DZ	WOS:000075366000005	9651239				2021-06-18	
J	Harrison-Felix, C; Zafonte, R; Mann, N; Dijkers, M; Englander, J; Kreutzer, J				Harrison-Felix, C; Zafonte, R; Mann, N; Dijkers, M; Englander, J; Kreutzer, J			Brain injury as a result of violence: Preliminary findings from the traumatic brain injury model systems	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CIVILIAN GUNSHOT WOUNDS; SUBSTANCE-ABUSE; HEAD; COMA; MANAGEMENT; SCALE	Objectives: To identify possible risk factors that may predispose individuals to violent traumatic brain injury (TBI) and to determine the effect of etiology of injury on outcomes. Study Design: Prospective, longitudinal multicenter study. Setting: TBI Model Systems (TBIMS) located at Wayne State University/Rehabilitation Institute of Michigan, Detroit, MI; The Institute for Rehabilitation and Research, Houston, TX; Medical College of Virginia, Richmond, VA; and Santa Clara Valley Medical Center, San Jose, CA. Subjects: Individuals treated in the four TBIMS programs between 3/89 and 9/96 who met the criteria for inclusion in the TBIMS National Database and for whom the etiology was known (n = 812). Main Outcome Measures: Functional Independence Measure, Alcohol Quantity Frequency Variability Index, Community Integration Questionnaire. Results: Individuals who incur violence-related TBI tend to be male, nonwhite, unmarried, living alone, less educated, and unemployed at time of injury. They tend to have less severe brain injuries and better motor function at the time of admission to inpatient rehabilitation. At 1 year postinjury, they score lower on community integration measures; however, no difference exists in functional status. Etiology of injury was found to only play a minor role in the prediction of social and productive integration at 1 year postinjury. Conclusions: Survivors of violent and nonviolent TBI have similar functional outcomes; however, they differ in preinjury and postinjury socio-economic characteristics, injury severity, and postinjury community integration. Socio-economic factors appear to play a large role in the risk for violent injury and in community integration following injury. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Wayne State Univ, Rehabil Inst Michigan, Res Dept, Detroit, MI 48201 USA; Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Harrison-Felix, C (corresponding author), Wayne State Univ, Rehabil Inst Michigan, Res Dept, 261 Mack Blvd, Detroit, MI 48201 USA.			Dijkers, Marcel/0000-0002-8362-5596			BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; *COMM PROF HOSP AC, 1986, INT CLASS DIS; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; COTTON P, 1992, JAMA-J AM MED ASSOC, V267, P1171, DOI 10.1001/jama.267.9.1171; COWAN T, 1995, ARCH PHYS MED REHAB, V76, P797; ELOVIC E, 1996, MED REHABILITATION T, P1; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; JENNETT B, 1990, REHABILITATION ADULT, P3; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; Kraus JF, 1993, HEAD INJURY, P1; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MERCY JA, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.4.7; *NAT I DIS REH RES, 1996, J HEAD TRAUMA REHAB, V11, P1; RAMONDI A, 1970, J NEUROSURG, V32, P647; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROSENBERG ML, 1991, VIOLENCE AM PUBLIC H; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STONE JL, 1995, J TRAUMA, V38, P851, DOI 10.1097/00005373-199506000-00002; SUDDABY L, 1987, CAN J NEUROL SCI, V14, P268, DOI 10.1017/S0317167100026597; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; *TRAUM BRAIN INJ M, 1993, J HEAD TRAUMA REHAB, V8, P1; *UB FDN ACT INC, 1993, GUID UN DAT SET MED; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Zafonte RD, 1997, BRAIN INJURY, V11, P403	34	57	57	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	1998	79	7					730	737		10.1016/S0003-9993(98)90348-3			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZZ388	WOS:000074724400002	9685083				2021-06-18	
J	Cecil, KM; Lenkinski, RE; Meaney, DF; McIntosh, TK; Smith, DH				Cecil, KM; Lenkinski, RE; Meaney, DF; McIntosh, TK; Smith, DH			High-field proton magnetic resonance spectroscopy of a swine model for axonal injury	JOURNAL OF NEUROCHEMISTRY			English	Article						diffuse axonal injury; N-acetylaspartate; spectroscopy	TRAUMATIC BRAIN INJURY; L-ASPARTIC ACID; HEAD-INJURY; N-ACETYLASPARTATE; RAT-BRAIN	A miniature swine model for diffuse brain injury has recently been developed that replicates the inertial loading conditions associated with relational acceleration during automotive accidents. The swine model induces diffuse axonal pathology without macroscopic injury such as contusions and hematomas, thus affording a unique opportunity to study axonal injury with noninvasive techniques such as magnetic resonance imaging (MRI) and spectroscopy (MRS). In the present study, we evaluated this diffuse injury model with proton MRS, in vivo, using a high-field (4.0-T) MR scanner, since MRS has been demonstrated as a sensitive probe for detecting neurochemical abnormalities. Our study examined a region of the swine brain at timepoints before and after brain injury. Spectroscopic results indicate that N-acetylaspartate/creatine is diminished by at least 20% in regions of confirmed axonal pathology, whereas conventional MRI did not detect any abnormalities. These findings suggest that MRS has high sensitivity in diagnosing microscopic pathology following diffuse brain injury.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,Suite 105, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007; Lenkinski, Robert/F-9045-2014	Meaney, David/0000-0002-0954-4122; Lenkinski, Robert/0000-0001-7371-5048; Cecil, Kim/0000-0001-8233-5485	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR02305] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR002305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BIRKEN DL, 1989, NEUROSCI BIOBEHAV R, V13, P23, DOI 10.1016/S0149-7634(89)80048-X; BURRI R, 1991, DEV NEUROSCI-BASEL, V13, P403, DOI 10.1159/000112191; CECIL KM, 1997, P INT SOC MAGN RES M, P1199; CECIL KM, 1998, IN PRESS J NEUROSURG; CHOE BY, 1995, INVEST RADIOL, V30, P502, DOI 10.1097/00004424-199508000-00008; CLARKE DD, 1975, J NEUROCHEM, V24, P479, DOI 10.1111/j.1471-4159.1975.tb07665.x; DADAMO AF, 1973, J NEUROCHEM, V20, P1275, DOI 10.1111/j.1471-4159.1973.tb00097.x; FRAHM J, 1991, NMR BIOMED, V4, P201, DOI 10.1002/nbm.1940040408; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GRAHAM DI, 1988, PROG CLIN BIOL RES, V234, P159; Hochachka P. W., 1980, LIVING OXYGEN CLOSED; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KOLLER KJ, 1984, J NEUROCHEM, V43, P1136, DOI 10.1111/j.1471-4159.1984.tb12854.x; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEWIS LD, 1974, J NEUROCHEM, V23, P673, DOI 10.1111/j.1471-4159.1974.tb04390.x; Meaney DF, 1993, ASME CRASHWORTHINESS, V25, P169; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MIYAKE M, 1981, J NEUROCHEM, V36, P804, DOI 10.1111/j.1471-4159.1981.tb01665.x; MOFFETT JR, 1991, NEUROREPORT, V2, P131, DOI 10.1097/00001756-199103000-00005; PERRY TL, 1971, J NEUROCHEM, V18, P521, DOI 10.1111/j.1471-4159.1971.tb11980.x; RABINOWITZ JL, 1976, BIOCHEM J, V157, P271, DOI 10.1042/bj1570271; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; SEUBERT W, 1973, MOL CELL BIOCHEM, V1, P29, DOI 10.1007/BF01659936; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; SMITH DH, 1995, J NEUROTRAUM, V12, P967; SMITH DH, 1994, J NEUROTRAUM, V11, P128; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; URENJAK J, 1992, J NEUROCHEM, V59, P55, DOI 10.1111/j.1471-4159.1992.tb08875.x; WHEREAT AF, 1967, J BIOL CHEM, V242, P4013	36	57	63	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0022-3042			J NEUROCHEM	J. Neurochem.	MAY	1998	70	5					2038	2044					7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ZJ393	WOS:000073210500030	9572290				2021-06-18	
J	Brauer, P; Kochs, E; Werner, C; Bloom, M; Policare, R; Pentheny, S; Yonas, H; Kofke, WA; Esch, JSA				Brauer, P; Kochs, E; Werner, C; Bloom, M; Policare, R; Pentheny, S; Yonas, H; Kofke, WA; Esch, JSA			Correlation of transcranial Doppler sonography mean flow velocity with cerebral blood flow in patients with intracranial pathology	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain; blood flow; blood flow velocity; measurement technique; transcranial Doppler ultrasonography; xenon-enhanced computed tomography; carbon dioxide reactivity; acetazolamide	ULTRASOUND; ACETAZOLAMIDE; ARTERY	Several studies suggest that relative changes in cerebral blood flow (CBF) may be assessed via transcranial Doppler sonography (TCD). The present study investigates the correlation between changes In TCD-mean now velocity (Vm) and changes in CBF in patients with a variety of types intracranial pathology undergoing cerebrovascular reactivity tests. After informed consent was obtained, 32 patients presenting with stenoses of brain-supplying arteries (n = 13), cerebral vascular malformations (n = 6), surgical decompression for subarachnoid hemorrhage (n = 2), brain edema after closed head injury (n = 8), or hepatic encephalopathy (n = 3) were studied. The patients were divided into mio groups for different reactivity tests. Patients in group 1 (awake or sedated, n = 18) received a 1-g dose of acetazolamide intravenously. In group 2 (n = 14), mechanical ventilation was adjusted to produce a 20% decrease in arterial CO2 tension compared with baseline. Regional CBF was measured using xenon-enhanced computed tomography (Xe-CT). Xe-CT scans at the levels of the basal ganglia and the lateral ventricles were performed during a 4.5-min xenon wash-in period. Bilateral flow velocity was measured in the middle cerebral artery using a 2-MHz pulsed TCD system. Mean arterial blood pressure, heart rate, and end-tidal CO2 were continuously recorded during the procedure. After baseline measurements and either alteration of CO2 or application of acetazolamide, the cerebrovascular reactivity was assessed at 20 min by a second measurement of CBF, TCD, and all other physiologic variables. The correlation coefficient for relative changes of MCA territory CBF versus Vm and for the overall population was r = 0.82. In groups 1 and 2, the values were 0.39 and 0.5, respectively. Correlation coefficients did not exceed r = 0.4 in any subgroup-classification based on diagnosis. The close correlation between changes in CBF and Vm (r = 0.82) in patients with heterogenous intracranial pathology seems to show that TCD is a measure of CBF. However, in groups 1 and 2, and in subgroups formed of patients classified according to diagnoses, data dispersion suggests that the actual correlation is weaker. Relation of changes in Vm to those in CBF may depend on the underlying diagnosis. These data indicate that the correlation between Vm and CBF may vary with intracranial pathology.	Univ Hamburg, Hosp Eppendorf, Dept Anesthesiol, D-20246 Hamburg, Germany; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol CCM, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Radiol, Pittsburgh, PA 15260 USA	Brauer, P (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Anesthesiol, Martinistr 52, D-20246 Hamburg, Germany.			Bloom, Marc/0000-0002-8268-3209			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ARNOLDS BJ, 1986, ULTRASOUND MED BIOL, V12, P115, DOI 10.1016/0301-5629(86)90016-5; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; GUR D, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P68; HARTMANN A, 1991, NEUROCHIRURGIA, V34, P6; Huber P, 1967, Invest Radiol, V2, P17, DOI 10.1097/00004424-196701000-00016; KIRKHAM FJ, 1986, ULTRASOUND MED BIOL, V12, P15, DOI 10.1016/0301-5629(86)90139-0; KOFKE WA, 1995, STROKE, V26, P1603, DOI 10.1161/01.STR.26.9.1603; KONTOS HA, 1989, STROKE, V20, P1; MARKWALDER TM, 1984, J CEREBR BLOOD F MET, V4, P368, DOI 10.1038/jcbfm.1984.54; MULLER M, 1995, STROKE, V26, P96, DOI 10.1161/01.STR.26.1.96; PIEPGRAS A, 1990, STROKE, V21, P1306, DOI 10.1161/01.STR.21.9.1306; TARR RW, 1990, AM J NEURORADIOL, V11, P441	13	57	59	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	1998	10	2					80	85		10.1097/00008506-199804000-00003			6	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	ZF382	WOS:000072891900004	9559765				2021-06-18	
J	Roe, SY; McGowan, EM; Rothwell, NJ				Roe, SY; McGowan, EM; Rothwell, NJ			Evidence for the involvement of corticotrophin-releasing hormone in the pathogenesis of traumatic brain injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						amygdala; CRH antagonist; in situ hybridization; PVN; Sprague-Dawley rats	FOCAL CEREBRAL-ISCHEMIA; MESSENGER-RNA; RAT-BRAIN; ALZHEIMERS-DISEASE; FACTOR RECEPTORS; CRF; PHARMACOLOGY; PHYSIOLOGY; SECRETION; AMYGDALA	The aim of this study was to investigate the role of the neuropeptide corticotrophin-releasing hormone (CRH) in neurodegeneration induced by traumatic brain injury, using a well characterized model of lateral fluid percussion injury in male, Sprague-Dawley rats. In the first series of experiments, CRH gene expression was assessed by in situ hybridization after traumatic brain injury, A bilateral increase in CRH mRNA in the paraventricular nucleus was observed in rats subjected to traumatic brain injury compared with sham-operated controls, A maximal (40%) increase in hybridization signal was detected 2 h after trauma compared with control rat brains. In addition, marked induction of CRH transcripts was found in the ipsilateral amygdala after trauma, but no increase was detected in the ipsilateral cortex around the area of damage. In a separate experiment, the effects of the CRH antagonist, D-Phe CRH(12-41) (25 mu g total dose), or appropriate vehicle injected intracerebroventricularly, was tested on infarct volume caused by brain injury. Repeated intracerebroventricular injection of D-Phe CRH(12-41) significantly reduced, by 45%, the volume of cortical damage in injured rats compared with vehicle-treated, trauma animals. The rapid upregulation of CRH gene expression in the paraventricular nucleus and amygdala following lateral fluid percussion injury and the marked neuroprotection achieved by inhibiting CRH action suggest that CRH is involved directly in the pathogenesis of traumatic brain injury. This observation may have important implications for the development of novel therapeutic strategies for treating the neurological consequences of brain trauma and related conditions.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Rothwell, NJ (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		BALDWIN HA, 1991, PSYCHOPHARMACOLOGY, V103, P227, DOI 10.1007/BF02244208; BEHAN DP, 1995, NATURE, V378, P284, DOI 10.1038/378284a0; BERKENBOSCH F, 1987, SCIENCE, V238, P524, DOI 10.1126/science.2443979; Chalmers DT, 1996, TRENDS PHARMACOL SCI, V17, P166, DOI 10.1016/0165-6147(96)81594-X; CHEUNG RTF, 1995, J COMP NEUROL, V360, P101, DOI 10.1002/cne.903600108; DeSouza EB, 1995, PSYCHONEUROENDOCRINO, V20, P789, DOI 10.1016/0306-4530(95)00011-9; DESOUZA EB, 1990, CORTICOTROPIN RELEAS, P335; EHLERS CL, 1983, BRAIN RES, V278, P332, DOI 10.1016/0006-8993(83)90266-4; FOX MW, 1993, STROKE, V24, P1072, DOI 10.1161/01.STR.24.7.1072; JINGAMI H, 1985, FEBS LETT, V191, P63, DOI 10.1016/0014-5793(85)80994-7; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V394, P23, DOI 10.1113/jphysiol.1987.sp016858; LIGHTMAN SL, 1993, ANN NY ACAD SCI, V697, P28, DOI 10.1111/j.1749-6632.1993.tb49920.x; LYONS MK, 1991, BRAIN RES, V545, P339, DOI 10.1016/0006-8993(91)91310-W; MARROSU F, 1988, EPILEPSIA, V29, P369, DOI 10.1111/j.1528-1157.1988.tb03733.x; MCDONALD AJ, 1987, J COMP NEUROL, V262, P59, DOI 10.1002/cne.902620106; MENZAGHI F, 1994, J PHARMACOL EXP THER, V269, P564; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; OWENS MJ, 1991, PHARMACOL REV, V43, P425; Paxinos G, 1986, RAT BRAIN STEREOTAXI; RAADSHEER FC, 1995, AM J PSYCHIAT, V152, P1372; RAINNIE DG, 1992, J PHARMACOL EXP THER, V263, P846; RIVIER CL, 1986, ANNU REV PHYSIOL, V48, P475, DOI 10.1146/annurev.ph.48.030186.002355; Roe S. Y., 1995, Society for Neuroscience Abstracts, V21, P1731; Rothwell N, 1989, NEUROSCI BIOBEHAV R, V14, P263; ROTHWELL N, 1995, IMMUNE RESPONSES NER, P77; Sawchenko P. E., 1990, CORTICOTROPIN RELEAS, P29; SHARKEY J, 1989, SYNAPSE, V4, P80, DOI 10.1002/syn.890040109; STRIJBOS PJLM, 1994, BRAIN RES, V656, P405, DOI 10.1016/0006-8993(94)91485-0; SWANSON LW, 1983, NEUROENDOCRINOLOGY, V36, P165, DOI 10.1159/000123454; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9; Wong M.-L., 1995, Society for Neuroscience Abstracts, V21, P230; WONG ML, 1995, NEUROREPORT, V6, P1785, DOI 10.1097/00001756-199509000-00019; YASUI Y, 1991, J COMP NEUROL, V303, P355, DOI 10.1002/cne.903030303	37	57	60	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	FEB	1998	10	2					553	559		10.1046/j.1460-9568.1998.00064.x			7	Neurosciences	Neurosciences & Neurology	YY335	WOS:000072136800017	9749718				2021-06-18	
J	Max, JE; Castillo, CS; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG				Max, JE; Castillo, CS; Robin, DA; Lindgren, SD; Smith, WL; Sato, Y; Mattheis, PJ; Stierwalt, JAG			Predictors of family functioning after traumatic brain injury in children and adolescents	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; children; adolescents; psychiatric disorder; family function	RELIABILITY; SEVERITY; SCALE	Objective: To assess factors predictive of family outcome in the first 2 years after traumatic brain injury (TBI) in children and adolescents. Method: Subjects were children aged 6 to 14 at the time they were hospitalized after TBI. The study used a prospective follow-up design. Assessments of preinjury factors (psychiatric, family functioning, and family life events), injury factors (severity of injury), and postinjury factors (coping and development of a psychiatric disorder, never before present, i.e., "novel") were conducted using standard clinical scales. The outcome measure was family function as assessed with standardized family functioning interviews (at 12 and 24 months after TBI) and primary caretaker self-report questionnaires (at 3 and 6 months after TBI). Results: Fifty subjects enrolled, and the analyses focused on 37, 41, 43, and 42 subjects assessed at the 3-, 6-, 12-, and 24-month follow-up evaluations, respectively. The strongest influences on family functioning after childhood TBI are preinjury family functioning, the development of a "novel" psychiatric disorder in the child, and preinjury family life events or stressors. Conclusions: These data suggest that there are families, identifiable through clinical assessment, at increased risk for family dysfunction after a child's TBI. Early identification and treatment of the child's psychopathology and family dysfunction may attenuate the associated morbidity.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA; Univ Montana, Missoula, MT 59812 USA; SW Missouri State Univ, Springfield, IL USA; Cedar Ctr, Psychiat Grp, Cedar Rapids, IA USA	Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Robin, Donald/F-2109-2010	Sato, Yutaka/0000-0002-5245-232X			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BARRY CT, 1997, INT NEUR SOC 25 ANN; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; EPSTEIN NB, 1981, HDB FAMILY THERAPY, P444; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; KRAUS JF, 1987, PEDIATRICS, V79, P501; Max J. E., 1992, NEUROPSYCHIATRIC RAT; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAX JE, IN PRESS J AM ACAD C; McCubbin HI, 1980, FAMILY ASSESSMENT RE; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; TEASDALE G, 1974, LANCET, V2, P81; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609	25	57	57	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JAN	1998	37	1					83	90		10.1097/00004583-199801000-00021			8	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	YW319	WOS:000071922000020	9444904				2021-06-18	
J	Gallily, R; Yamin, A; Waksmann, Y; Ovadia, H; Weidenfeld, J; BarJoseph, A; Biegon, A; Mechoulam, R; Shohami, E				Gallily, R; Yamin, A; Waksmann, Y; Ovadia, H; Weidenfeld, J; BarJoseph, A; Biegon, A; Mechoulam, R; Shohami, E			Protection against septic shock and suppression of tumor necrosis factor alpha and nitric oxide production by dexanabinol (HU-211), a nonpsychotropic cannabinoid	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							CLOSED-HEAD INJURY; NONCOMPETITIVE NMDA ANTAGONIST; LETHAL TOXICITY; NERVOUS-SYSTEM; RAT-BRAIN; CYTOKINE; INHIBITORS; LIPOPOLYSACCHARIDE; ASTROCYTES; IMIDAZOLES	Dexanabinol, HU-211, a synthetic cannabinoid devoid of psychotropic effects, improves neurological outcome in models of brain trauma, ischemia and meningitis. Recently, HU-211 was found to inhibit brain tumor necrosis factor (TNF alpha) production after head injury. In the present study, we demonstrate the ability of HU-211 to suppress TNF alpha production and to rescue mice and rats from endotoxic shock after LPS (Escherichia coli 055:B5) inoculation. In BALB/c mice, a dose of 10 mg/kg LPS, injected i.p., caused 57% and 100% mortality, at 24 and 48 hr, respectively. HU-211, administered i.p. 30 min before lipopolysaccharide (LPS), reduced lethality to 9 and 67% at these time points (P < .05). When coinjected with D-galactoseamine (i.p.), LPS was 100% lethal within 24 hr, whereas eight hourly injections of HU-211 caused mortality of C57BL/6 mice to drop to 10% (P < .001). Administration of LPS to Sprague-Dawley rats resulted in a 30% reduction in the mean arterial blood pressure within 30 min, which persisted for 3 hr. HU-211, given 2 to 3 min before LPS, completely abolished the typical hypotensive response. Furthermore, the drug also markedly suppressed in vitro TNF alpha production and nitric oxide generation (by >90%) by both murine peritoneal macrophages and rat alveolar macrophage cell line exposed to LPS. HU-211 may, therefore, have therapeutic implications in the treatment of TNF alpha-mediated pathologies.	HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,FAC MED,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT IMMUNOL,FAC MED,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT NAT PROD,FAC MED,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,DEPT EXPT NEUROL,FAC MED,IL-91120 JERUSALEM,ISRAEL							AVRON A, 1995, J LEUKOCYTE BIOL, V57, P264; BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; Bass R, 1996, J INFECT DIS, V173, P735, DOI 10.1093/infdis/173.3.735; BAUSS F, 1987, INFECT IMMUN, V55, P1622, DOI 10.1128/IAI.55.7.1622-1625.1987; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BRENNER T, 1993, BRAIN RES, V608, P273, DOI 10.1016/0006-8993(93)91468-8; BURNETTECURLEY D, 1995, P SOC EXP BIOL MED, V209, P205; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DANTZER R, 1996, INT SOC PSYCH 27 C M, P43; DOHERTY GM, 1991, SURGERY, V110, P192; ELDRIDGE JC, 1990, BRAIN RES, V534, P135; ESHHAR N, 1993, NEUROREPORT, V5, P37; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; GLAUSER MP, 1994, CLIN INFECT DIS, V18, pS205, DOI 10.1093/clinids/18.Supplement_2.S205; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; KLEIN TW, 1995, P SOC EXP BIOL MED, V209, P205; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEHMANN V, 1987, J EXP MED, V165, P657, DOI 10.1084/jem.165.3.657; MIER JW, 1992, TUMOR NECROSIS FACTO, P221; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; NADLER V, 1993, NEUROSCI LETT, V162, P43, DOI 10.1016/0304-3940(93)90555-Y; NADLER V, 1993, BRAIN RES, V622, P79, DOI 10.1016/0006-8993(93)90804-V; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; REDDY MP, 1994, INT J IMMUNOPHARMACO, V16, P795, DOI 10.1016/0192-0561(94)90053-1; REMICK DG, 1987, LAB INVEST, V56, P583; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1996, CNS DRUG REV, V2, P429; SPANGELO BL, 1990, ENDOCRINOLOGY, V127, P779; TEALE DM, 1992, J ANTIMICROB CHEMOTH, V30, P839, DOI 10.1093/jac/30.6.839; TERASHITA ZI, 1992, J PHARMACOL EXP THER, V260, P748; TRACEY KJ, 1991, CIRC SHOCK, V35, P123; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; WAAGE A, 1992, TUMOR NECROSIS FACTO, P275; WATKINS LR, 1995, LIFE SCI, V57, P1011, DOI 10.1016/0024-3205(95)02047-M; WEIDENFELD J, 1989, NEUROENDOCRINOLOGY, V50, P132, DOI 10.1159/000125212; WOLFE TA, 1995, ANN PHARMACOTHER, V29, P36, DOI 10.1177/106002809502900108; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; XU T, 1992, LIFE SCI, V51, P1817, DOI 10.1016/0024-3205(92)90053-R	47	57	57	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	NOV	1997	283	2					918	924					7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	YF254	WOS:A1997YF25400062	9353414				2021-06-18	
J	Ohkawa, S; Fukatsu, K; Miki, S; Hashimoto, T; Sakamoto, J; Doi, T; Nagai, Y; Aono, T				Ohkawa, S; Fukatsu, K; Miki, S; Hashimoto, T; Sakamoto, J; Doi, T; Nagai, Y; Aono, T			5-aminocoumarans: Dual inhibitors of lipid peroxidation and dopamine release with protective effects against central nervous system trauma and ischemia	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; ALPHA-TOCOPHEROL; ANTIOXIDANT ACTIVITY; VITAMIN-E; FOREBRAIN ISCHEMIA; RAT-BRAIN; DERIVATIVES; INJURY; METHAMPHETAMINE; NEUROTOXICITY	A series of 2,3-dihydro-5-benzofuranamines (5-aminocoumarans) were developed for the treatment of traumatic and ischemic central. nervous system (CNS) injury. Compounds within this class were extremely effective inhibitors of lipid peroxidation in vitro and antagonized excitatory behavior coupled with peroxidative injury induced by spinal intrathecal injection of FeCl2 (mouse-FeCl2-it assay) in vivo. Selected compounds were tested for antagonistic activity on methamphetamine (MAP)-induced hypermotility resulting from dopamine release in the mouse brain. Among the compounds synthesized, compound 26n (2,3-dihydro-2,4,6,7-tetramethyl-2-[(4-phenyl-1-piperidinyl)meth]-5-benzofuranamine) exhibited potent effects in these assays (inhibition of lipid peroxidation, IC50 = 0.07 mu M; mouse-FeCl2-it assay, ID50 = 10.4 mg/kg, po; MAP-induced hypermotility, 98% inhibition, 10 mg/kg, ip). The S-(+)-form of compound 26n dihydrochloride (TAK-218), which has 30 times more potent antagonistic activity on MAP-induced hypermotility than the R-(-)-form, improved more significantly the survival rate in the cerebral ischemia model (rat, 1-3 mg/kg, ip) during the period of 1-14 days after ischemia and decreased functional disorders in the traumatic brain injury model (rat, 0.1-1 mg/kg, ip) 3-14 days after injury. These results imply a role for dopamine in deterioration of CNS function after ischemic and traumatic injury. TAK-218 is a promising compound for the treatment of stroke and CNS trauma and is now under clinical investigation.		Ohkawa, S (corresponding author), TAKEDA CHEM IND LTD, PHARMACEUT RES LABS 1, YODOGAWA KU, 17-85 JUSOHONMACHI 2 CHOME, OSAKA 532, JAPAN.						BETTS W H, 1985, Journal of Free Radicals in Biology and Medicine, V1, P273, DOI 10.1016/0748-5514(85)90131-X; BLOCK F, 1995, BRAIN RES BULL, V36, P257, DOI 10.1016/0361-9230(94)00200-K; BROMONT C, 1989, STROKE, V20, P918, DOI 10.1161/01.STR.20.7.918; BURTON GW, 1983, J AM CHEM SOC, V105, P5950, DOI 10.1021/ja00356a057; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; CADET JL, 1994, J NEUROCHEM, V62, P380; CHOI DW, 1987, J NEUROSCI, V7, P369; CLEMENS JA, 1988, LIFE SCI, V42, P707, DOI 10.1016/0024-3205(88)90463-8; CLEMENS JA, 1993, STROKE, V24, P716, DOI 10.1161/01.STR.24.5.716; DAWSON DA, 1995, NEUROSCI LETT, V185, P65, DOI 10.1016/0304-3940(94)11226-9; DEARDEN JC, 1978, EUR J MED CHEM, V13, P415; DENISOV ET, 1987, CHEM REV, V87, P1313, DOI 10.1021/cr00082a003; DIEMER NH, 1993, PROG BRAIN RES, V96, P105; FADEN AI, 1987, CLIN NEUROPHARMACOL, V10, P193, DOI 10.1097/00002826-198706000-00001; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FORT AW, 1961, J ORG CHEM, V26, P332, DOI 10.1021/jo01061a014; FUKUDA N, 1985, JPN PHARMACOL THER, V13, P5021; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; GRISAR JM, 1991, J MED CHEM, V34, P257, DOI 10.1021/jm00105a040; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL ED, 1986, EXP BRAIN RES S, V13, P63; HARIK SI, 1986, NEUROLOGY, V36, P971, DOI 10.1212/WNL.36.7.971; HEGEDUS LS, 1976, J AM CHEM SOC, V98, P3901, DOI 10.1021/ja00429a028; INGOLD KU, 1986, FEBS LETT, V205, P117, DOI 10.1016/0014-5793(86)80877-8; KAPLAN B, 1991, STROKE, V22, P1032, DOI 10.1161/01.STR.22.8.1032; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; LEROSEN AL, 1948, J AM CHEM SOC, V70, P2705, DOI 10.1021/ja01188a025; LEVIN VA, 1980, J MED CHEM, V23, P682, DOI 10.1021/jm00180a022; MUKAI K, 1987, B CHEM SOC JPN, V60, P2163, DOI 10.1246/bcsj.60.2163; MUKAI K, 1988, CHEM PHYS LIPIDS, V46, P31, DOI 10.1016/0009-3084(88)90110-7; OHKAWA S, 1991, J MED CHEM, V34, P267, DOI 10.1021/jm00105a042; OKAMOTO K, 1986, CHEM PHARM BULL, V34, P2821; OSHIRO Y, 1991, J MED CHEM, V34, P2014, DOI 10.1021/jm00111a014; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; RUBIN JJ, 1980, EXP NEUROL, V67, P472, DOI 10.1016/0014-4886(80)90119-3; SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539; SHULGIN AT, 1960, J ORG CHEM, V25, P2037, DOI 10.1021/jo01081a605; SKINNER WA, 1970, EXPERIENTIA, V26, P502, DOI 10.1007/BF01898471; Smith LI, 1940, J AM CHEM SOC, V62, P1863, DOI 10.1021/ja01864a064; TAYLOR CP, 1995, TRENDS PHARMACOL SCI, V16, P309, DOI 10.1016/S0165-6147(00)89060-4; WAUQUIER A, 1988, ANN NY ACAD SCI, V522, P478; WEINBERGER J, 1985, STROKE, V16, P864, DOI 10.1161/01.STR.16.5.864; WEINGARTEN H, 1967, J ORG CHEM, V32, P3246, DOI 10.1021/jo01285a088; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3; WOODWARD B, 1985, J MOL CELL CARDIOL, V17, P485, DOI 10.1016/S0022-2828(85)80053-5; YAO H, 1988, EXPERIENTIA, V44, P506, DOI 10.1007/BF01958929	47	57	57	0	8	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	FEB 14	1997	40	4					559	573		10.1021/jm960411j			15	Chemistry, Medicinal	Pharmacology & Pharmacy	WH748	WOS:A1997WH74800020	9046347				2021-06-18	
J	Girard, D; Brown, J; BurnettStolnack, M; Hashimoto, N; HierWellmer, S; Perlman, OZ; Seigerman, C				Girard, D; Brown, J; BurnettStolnack, M; Hashimoto, N; HierWellmer, S; Perlman, OZ; Seigerman, C			The relationship of neuropsychological status and productive outcomes following traumatic brain injury	BRAIN INJURY			English	Article							EMPLOYMENT	Neuropsychological assessment is a standard component of traumatic brain injury rehabilitation programmes; however, the relationship between neuropsychological test scores and functional abilities is not clear. The current study compared serial neuropsychological test data with functional outcomes for 152 subjects. Outcome was operationally defined for three activity settings (home, school, work) with six levels of productivity for each. Productivity was defined as one's ability to function at increasing levels of independence. Demographic and caseload variables were analysed utilizing correlation and stepwise multiple regression analyses. Significant relationships to outcome were found between certain neuropsychological test scores, and certain demographic variables. Positive outcomes were related in part to patient's speed of information processing, memory skills, and simultaneous processing abilities. Also related to positive outcomes were mechanism of injury, level of insurance funding, premorbid educational level, and negative history of substance abuse. The activity setting influenced outcome such that it appeared to be most difficult to return to work, suggesting the necessity of adequate vocational assistance. However, cognitive and demographic variables accounted for less than 30% of the total variance in outcome. Therefore, brain injury rehabilitation must be multifaceted.	ST JOSEPH MERCY HOSP,DEPT PHYS MED & REHABIL,TBI SERV,ANN ARBOR,MI 48106; UNIV MICHIGAN,MED CTR,ANN ARBOR,MI							Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; CICERONE K, 1989, 8 NAT S NAT HEAD INJ; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; HEATON RK, 1978, J NERV MENT DIS, V166, P408, DOI 10.1097/00005053-197806000-00004; MACCIOCCHI S, 1988, J HEAD TRAUMA REHABI, V3, P1; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; Vogenthaler D R, 1989, Brain Inj, V3, P355, DOI 10.3109/02699058909004560; WEHMAN P, 1989, ARCH PHYS MED REHAB, V70, P109	10	57	58	0	7	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1996	10	9					663	676		10.1080/026990596124089			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VB635	WOS:A1996VB63500004	8853869				2021-06-18	
J	Nag, S				Nag, S			Cold-injury of the cerebral cortex: Immunolocalization of cellular proteins and blood-brain barrier permeability studies	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						angiogenesis; blood-brain barrier; c-fos; c-jun; glucose transporter; cold-injury	FIBRILLARY ACIDIC PROTEIN; CENTRAL NERVOUS-SYSTEM; C-FOS EXPRESSION; GLUCOSE-TRANSPORTER; FREEZE-INJURY; MESSENGER-RNA; RAT-BRAIN; MOUSE; EDEMA; LOCALIZATION	The occurrence of blood-brain barrier (BBB) permeability alterations and neovascularization are well documented in the cerebral cortical cold-injury model. This model was used to determine whether the glucose transporter (glut1) protein was present in endothelium of cerebral vessels with breakdown of BBB to protein and when regenerating endothelial cells become immunoreactive for glut1 protein. Secondly, the protein products of c-fos and c-jun were localized to determine whether these early immediate genes are activated in this model. Observations were made over a period of 12 hours to 14 days after the cold-injury. Blood-brain barrier permeability was assessed using horseradish peroxidase (HRP) as a tracer. Since HRP may not be able to enter thrombosed vessels within the cold lesion, immunohistochemistry was used to detect extravasation of endogenous serum proteins using antisera to rat serum proteins. The proteins-glut1, GFAP, c-fos and c-jun-were localized by immunohistochemistry. Endothelium of vessels which were permeable to protein, whether in the cold-injury site or in the perilesional area, all contained glut1 protein; hence, the presence of glut1 did not appear to correlate with an intact BBB to protein. An interesting point is that in the process of neovascularization, regenerating endothelial cells become immunoreactive for glut1 at 5 days and this coincides with the presence of tight junctions in these cells. Immunoreactivity for c-fos was observed in regenerating endothelium within the lesion site, in astrocytes, and to a lesser extent in endothelial cells and neurons in the perilesional area. Few astrocytes showed immunoreactivity for c-jun at 4 and 5 days. Possibly, the growth factors generated to promote angiogenesis and repair led to activation of the c-fos gene with deposition of c-fos protein. The results suggest that during nervous system development or endothelial regeneration, the presence of glut1 in cerebral endothelium coincides with the presence of an intact BBB to protein and protein tracers. However, in pathological states presence of glut1 in cerebral endothelium does not appear to correlate with an intact BBB to protein. This model lends itself to the study of angiogenesis and repair processes in the cerebral cortex in an environment unaffected by ischemia and thus the findings may be relevant to traumatic injuries of the human cerebral cortex.	UNIV TORONTO,DEPT PATHOL,DIV NEUROPATHOL,TORONTO,ON,CANADA; TORONTO HOSP,PLAYFAIR NEUROSCI UNIT,TORONTO,ON M5T 2S8,CANADA							AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BAKER RN, 1971, J NEUROPATH EXP NEUR, V30, P668, DOI 10.1097/00005072-197110000-00010; BAUER H, 1995, DEV BRAIN RES, V86, P317, DOI 10.1016/0165-3806(95)00044-E; CANCILLA PA, 1979, LAB INVEST, V40, P74; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; CORNFORD EM, 1995, J NEUROPATH EXP NEUR, V54, P842, DOI 10.1097/00005072-199511000-00011; DICK APK, 1984, P NATL ACAD SCI-BIOL, V81, P7233, DOI 10.1073/pnas.81.22.7233; DRAGUNOW M, 1990, BRAIN RES, V527, P41, DOI 10.1016/0006-8993(90)91058-O; FARRELL CL, 1991, P NATL ACAD SCI USA, V88, P5779, DOI 10.1073/pnas.88.13.5779; GERHART DZ, 1989, J NEUROSCI RES, V22, P464, DOI 10.1002/jnr.490220413; GUERIN C, 1990, ANN NEUROL, V28, P758, DOI 10.1002/ana.410280606; HARIK SI, 1990, P NATL ACAD SCI USA, V87, P4261, DOI 10.1073/pnas.87.11.4261; HARIK SI, 1990, J NEUROSCI, V10, P3862; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; KALARIA RN, 1988, ANN NEUROL, V24, P757, DOI 10.1002/ana.410240610; KOHMURA E, 1995, MOL BRAIN RES, V28, P117, DOI 10.1016/0169-328X(94)00198-N; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P118, DOI 10.1097/00005072-199403000-00002; LIU HM, 1994, J NEUROPATH EXP NEUR, V53, P598, DOI 10.1097/00005072-199411000-00007; MAXWELL K, 1993, BRAIN RES, V41, P309; MITCHELL J, 1979, ACTA NEUROPATHOL, V46, P45, DOI 10.1007/BF00684803; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NAG S, 1988, ACTA NEUROPATHOL, V75, P547, DOI 10.1007/BF00686198; NAG S, 1984, ACTA NEUROPATHOL, V62, P178, DOI 10.1007/BF00691850; OLSON JJ, 1987, J NEUROPATH EXP NEUR, V46, P682, DOI 10.1097/00005072-198711000-00007; ORITA T, 1989, ACTA NEUROPATHOL, V77, P397, DOI 10.1007/BF00687374; ORITA T, 1988, J NEUROSURG, V68, P608, DOI 10.3171/jns.1988.68.4.0608; TAOCHENG JH, 1987, J NEUROSCI, V7, P3293; TENGVAR C, 1986, ACTA NEUROPATHOL, V71, P177, DOI 10.1007/BF00688038; UEMURA Y, 1991, BRAIN RES, V552, P99, DOI 10.1016/0006-8993(91)90665-I; VORBRODT AW, 1993, HISTOL HISTOPATHOL, V8, P51; VORBRODT AW, 1985, ACTA NEUROPATHOL, V66, P265, DOI 10.1007/BF00690958	33	57	57	0	1	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	1996	55	8					880	888		10.1097/00005072-199608000-00003			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	VA570	WOS:A1996VA57000003	8759777	Bronze			2021-06-18	
J	Wahl, M; Whalley, ET; Unterberg, A; Schilling, L; Parsons, AA; Baethmann, A; Young, AR				Wahl, M; Whalley, ET; Unterberg, A; Schilling, L; Parsons, AA; Baethmann, A; Young, AR			Vasomotor and permeability effects of bradykinin in the cerebral microcirculation	IMMUNOPHARMACOLOGY			English	Article; Proceedings Paper	14th International Symposium on Bradykinin and Related Kinins (KININ 95)	SEP 10-15, 1995	DENVER, CO			kallikrein-kinin; blood-brain barrier; cerebral microcirculation; brain oedema; Autacoids	VASOGENIC BRAIN EDEMA; KALLIKREIN-KININ SYSTEM; ANGIOTENSIN-CONVERTING ENZYME; HUMAN BASILAR ARTERY; PIAL-ARTERIES; CEREBROVASCULAR REACTIVITY; VASCULAR REACTIVITY; NITRIC-OXIDE; SUBSTANCE-P; RAT-BRAIN	All components of an intracerebral kallikrein-kinin system have been described. Thus, bradykinin (BK) acting from the parenchymal site as well as from the blood site may influence cerebral microcirculation. BK is a potent dilator of extra- and intraparenchymal cerebral arteries when acting from the perivascular site. The vasomotor effect of BK is mediated by B-2 receptors which appear to be located at the abluminal membrane of the endothelial cell. The effect of BK is mediated by NO, prostanoids, free radicals, H2O2 or leukotrienes depending on the animal species and on the location of the artery. Selective opening of the blood-brain barrier for small tracers (Na+-fluorescein; MW, 376) has been found in cats during cortical superfusion or intraarterial application of BK. This leakage is mediated by B-2 receptors located at the luminal and abluminal membrane of the endothelial cells. Formation of brain edema has been found after ventriculo-cisternal perfusion or interstitial infusion of BK. This can be explained by increase of vascular permeability and cerebral blood flow due to arterial dilatation thus enhancing driving forces for the extravasation. An increase of the BK concentration in the interstitial space of the brain up to concentrations which induce extravasation, dilatation and oedema formation has been found under several pathological conditions, Thus, BK may be involved in oedema formation after cold lesion, concussive brain injury, traumatic spinal cord and ischemic brain injury. The mediator role of BK in brain edema is further supported by therapeutic results. Brain swelling due to cold lesion or ischemia could be diminished by treatment with kallikrein-inhibitors. Similarly, dilatation of cerebral arterioles after concussive brain injury was reduced by blockade of B-2 receptors. Thus, all criteria favour BK as one mediator of vasogenic oedema.	CORTECH,DENVER,CO; DEPT NEUROSURG,BERLIN,GERMANY; DEPT NEUROSURG,MANNHEIM,GERMANY; SMITHKLINE BEECHAM,HARLOW,ESSEX,ENGLAND; INST EXPT SURG,MUNICH,GERMANY; CYCERON,CAEN,FRANCE	Wahl, M (corresponding author), UNIV MUNICH,DEPT PHYSIOL,PETTENKOFERSTR 12,D-8000 MUNICH,GERMANY.						ALMENOFF J, 1981, BIOCHEM BIOPH RES CO, V102, P206, DOI 10.1016/0006-291X(81)91508-4; Baethmann A, 1980, Adv Neurol, V28, P171; BUTT AM, 1990, J PHYSIOL-LONDON, V429, P47, DOI 10.1113/jphysiol.1990.sp018243; CHAO J, 1983, J BIOL CHEM, V258, P5173; CORREA FMA, 1986, BRAIN RES, V375, P259, DOI 10.1016/0006-8993(86)90746-8; DACEY RG, 1988, J CEREBR BLOOD F MET, V8, P254, DOI 10.1038/jcbfm.1988.56; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1988, AM J PHYSIOL, V255, pH397; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; FUXE K, 1980, ACTA PHYSIOL SCAND, V110, P321, DOI 10.1111/j.1748-1716.1980.tb06670.x; GUILLOT FL, 1990, J CEREBR BLOOD F MET, V10, P827, DOI 10.1038/jcbfm.1990.139; INAMURA T, 1994, J CEREBR BLOOD F MET, V14, P862, DOI 10.1038/jcbfm.1994.108; KAMITANI T, 1985, CIRC RES, V57, P545, DOI 10.1161/01.RES.57.4.545; KAMIYA T, 1989, J CEREB BLOOD FLO S1, V9, pS73; KARIYA K, 1981, J NEUROCHEM, V36, P2086, DOI 10.1111/j.1471-4159.1981.tb10838.x; KARIYA K, 1984, JPN J PHARMACOL, V34, P203, DOI 10.1254/jjp.34.203; KATUSIC ZS, 1989, AM J PHYSIOL, V257, pH1235; KATUSIC ZS, 1986, J PHARMACOL EXP THER, V236, P166; KONTOS HA, 1990, AM J PHYSIOL, V258, pH1261; KONTOS HA, 1984, CIRC RES, V55, P295, DOI 10.1161/01.RES.55.3.295; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MAYHAN WG, 1990, AM J PHYSIOL, V259, pH1455; MAYHAN WG, 1990, AM J PHYSIOL, V258, pH1138; OLESEN SP, 1986, ACTA PHYSIOL SCAND, V127, P233, DOI 10.1111/j.1748-1716.1986.tb07898.x; OLESEN SP, 1987, J PHYSIOL-LONDON, V387, P59, DOI 10.1113/jphysiol.1987.sp016562; PARSONS AA, 1991, PFLUG ARCH EUR J PHY, V419, pR112; PERRY DC, 1984, J NEUROCHEM, V43, P1072, DOI 10.1111/j.1471-4159.1984.tb12846.x; RAYMOND JJ, 1986, CAN J NEUROL SCI, V13, P214, DOI 10.1017/S0317167100036301; REGOLI D, 1984, J CARDIOVASC PHARM, V6, pS401, DOI 10.1097/00005344-198406002-00015; REGOLI D, 1980, PHARMACOL REV, V32, P1; ROSENBLUM WI, 1987, CIRC RES, V61, P601, DOI 10.1161/01.RES.61.4.601; SARIA A, 1983, N-S ARCH PHARMACOL, V324, P212, DOI 10.1007/BF00503897; SCHILLING L, 1993, REGULATION CEREBRAL, P113; SCHURER L, 1989, ACTA NEUROPATHOL, V77, P576, DOI 10.1007/BF00687884; SHISHEVA A, 1983, FED PROC, V43, P1021; TODA N, 1977, AM J PHYSIOL, V232, pH267; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1987, ACTA NEUROPATHOL, V73, P209, DOI 10.1007/BF00686613; UNTERBERG A, 1988, ACTA NEUROPATHOL, V76, P238, DOI 10.1007/BF00687770; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; UNTERBERG A, 1983, CEREBRAL BLOOD FLOW, P174; UNTERBERG A, 1987, THESIS MUNCHEN; UNTERBERG A, 1985, ADV NEUROSURG, V13, P326; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; WAHL M, 1979, CIRC RES, V44, P161, DOI 10.1161/01.RES.44.2.161; WAHL M, 1976, PFLUG ARCH EUR J PHY, V362, P55, DOI 10.1007/BF00588681; WAHL M, 1987, BRAIN RES, V411, P72, DOI 10.1016/0006-8993(87)90682-2; Wahl M., 1993, REGULATION CEREBRAL, P315; WHALLEY ET, 1983, PFLUG ARCH EUR J PHY, V398, P175, DOI 10.1007/BF00581069; WHALLEY ET, 1987, N-S ARCH PHARMACOL, V335, P551; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V324, P296, DOI 10.1007/BF00502627; WHALLEY ET, 1987, N-S ARCH PHARMACOL, V336, P430, DOI 10.1007/BF00164878; WHALLEY ET, 1988, BRAIN RES, V438, P1, DOI 10.1016/0006-8993(88)91318-2; WHALLEY ET, 1983, N-S ARCH PHARMACOL, V323, P66, DOI 10.1007/BF00498830; WHALLEY ET, 1987, N-S ARCH PHARMACOL, V335, P433, DOI 10.1007/BF00165559; WHALLEY ET, 1983, HYPERTENSION, V5, pV34, DOI 10.1161/01.HYP.5.6_Pt_3.V34; WHITTLE IR, 1992, ACTA NEUROCHIR, V115, P53, DOI 10.1007/BF01400591; WIEMER G, 1994, BRAIN RES, V638, P261, DOI 10.1016/0006-8993(94)90658-0; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x; YANG ST, 1991, STROKE, V22, P1177, DOI 10.1161/01.STR.22.9.1177	62	57	58	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0162-3109			IMMUNOPHARMACOLOGY	Immunopharmacology	JUN	1996	33	1-3					257	263		10.1016/0162-3109(96)00068-9			7	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	VA298	WOS:A1996VA29800053	8856159				2021-06-18	
J	HEADRICK, JP; BENDALL, MR; FADEN, AI; VINK, R				HEADRICK, JP; BENDALL, MR; FADEN, AI; VINK, R			DISSOCIATION OF ADENOSINE LEVELS FROM BIOENERGETIC STATE IN EXPERIMENTAL BRAIN TRAUMA - POTENTIAL ROLE IN SECONDARY INJURY	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						TRAUMATIC BRAIN INJURY; ADENOSINE; ADENOSINE AGONISTS	MAGNETIC-RESONANCE SPECTROSCOPY; EXPERIMENTAL HEAD-INJURY; EXCITATORY AMINO-ACIDS; ENERGY-METABOLISM; ENDOGENOUS ADENOSINE; RAT HIPPOCAMPUS; CEREBRAL-CORTEX; NMDA RECEPTORS; RELEASE; ISCHEMIA	Intracellular bioenergetic state and extracellular adenosine levels were monitored in rat brain prior to and following traumatic brain injury (TBI) using phosphorus magnetic resonance spectroscopy and microdialysis, respectively. Fluid percussion-induced TBI (2.6 +/- 0.2 atm) resulted in significant reductions in free cytosolic [Mg2+], cytosolic [ATP]/[ADP][P-i], and Delta G(ATP) and elevations in cytosolic [ADP] and [5'-AMP]. Intracellular ATP concentration and pH did not change significantly after trauma. Mitochondrial capacity for oxidative phosphorylation (indexed by V/V-max) increased significantly from similar to 0.45 prior to injury to similar to 0.58 following TBI. All metabolic changes were maximal at 2-3 h post-TBI. Conversely, extracellular adenosine concentrations increased transiently following TBI, with levels peaking at 10 min posttrauma, then declining rapidly to preinjury values by 50 min. Thus, despite pronounced long-term depression in bioenergetic status and a marked rise in [5'-AMP], formation and release of adenosine were elevated only transiently within the first hour following TBI. Since steady-state adenosine levels were essentially unchanged beyond 1 h posttrauma, mooted neuroprotective actions of endogenous adenosine would be minimized. Intracerebroventricular injections of 2-chloroadenosine (0.5 and 2.5 nmol) immediately prior to TBI dose-dependently attenuated metabolic disturbances and improved posttraumatic neurologic outcome (p < 0.05). The observations indicate that (a) TBI results in dissociation of adenosine release from intracellular bioenergetic state, a phenomenon possibly contributing to secondary injury following TBI; and Co) supplementing brain with an adenosine agonist attenuates irreversible injury.	GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007	HEADRICK, JP (corresponding author), JAMES COOK UNIV N QUEENSLAND,DEPT MOLEC SCI,TOWNSVILLE,QLD 4811,AUSTRALIA.		Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27849] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR306634] Funding Source: Medline		BERNE RM, 1974, CIRC RES, V35, P262, DOI 10.1161/01.RES.35.2.262; BURKE SP, 1988, J NEUROCHEM, V51, P1541, DOI 10.1111/j.1471-4159.1988.tb01123.x; CHEN Y, 1992, BRIT J PHARMACOL, V106, P632, DOI 10.1111/j.1476-5381.1992.tb14387.x; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORADETTI R, 1984, EUR J PHARMACOL, V104, P19; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CRONSTEIN BN, 1985, J IMMUNOL, V135, P1366; CRONSTEIN BN, 1986, J CLIN INVEST, V78, P760, DOI 10.1172/JCI112638; DRAGUNOW M, 1988, TRENDS PHARMACOL SCI, V9, P193, DOI 10.1016/0165-6147(88)90079-X; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; EVANS MC, 1987, NEUROSCI LETT, V83, P287, DOI 10.1016/0304-3940(87)90101-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FASTBOM J, 1986, NEUROSCI LETT, V65, P127, DOI 10.1016/0304-3940(86)90291-0; FREDHOLM BB, 1988, TRENDS PHARMACOL SCI, V9, P130, DOI 10.1016/0165-6147(88)90194-0; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HEADRICK JP, 1991, AM J PHYSIOL, V260, pH165; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; HOEHN K, 1990, J NEUROCHEM, V54, P256, DOI 10.1111/j.1471-4159.1990.tb13309.x; HSU SSF, 1991, AM J PHYSIOL, V261, pH398; JHAMANDAS K, 1980, CAN J PHYSIOL PHARM, V58, P1262, DOI 10.1139/y80-193; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MADISON DV, 1987, BIOPHYS J, V51, P30; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1989, CONT ISSUES NEUROLOG, V1, P35; MILLER LP, 1992, J NEUROTRAUMA, V9, P563; NAGATA H, 1984, J NEUROCHEM, V42, P1001, DOI 10.1111/j.1471-4159.1984.tb12703.x; NEWBY AC, 1984, TRENDS BIOCHEM SCI, V9, P42, DOI 10.1016/0968-0004(84)90176-2; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NIOKA S, 1991, Neurological Research, V13, P25; PARK TS, 1988, J CEREBR BLOOD F MET, V8, P822, DOI 10.1038/jcbfm.1988.138; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; PROCTOR WR, 1983, NEUROSCI LETT, V35, P197, DOI 10.1016/0304-3940(83)90550-5; ROUCHER P, 1991, J CEREBR BLOOD F MET, V11, P453, DOI 10.1038/jcbfm.1991.87; STONE TW, 1981, BRIT J PHARMACOL, V74, P171, DOI 10.1111/j.1476-5381.1981.tb09970.x; STONE TW, 1990, ADENOSINE ADENINE NU, P329; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; Van Wylen D G, 1988, Am J Physiol, V255, pH1211; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; VONLUBITZ DKJE, 1988, STROKE, V19, P1133, DOI 10.1161/01.STR.19.9.1133; WINN HR, 1981, AM J PHYSIOL, V241, pH235; WINN HR, 1980, CIRC RES, V47, P568, DOI 10.1161/01.RES.47.4.568; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; ZUCCHI R, 1990, J MOL CELL CARDIOL, V22, P815, DOI 10.1016/0022-2828(90)90092-G	57	57	58	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	1994	14	5					853	861		10.1038/jcbfm.1994.107			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	PC770	WOS:A1994PC77000018	8063880	Bronze			2021-06-18	
J	BRUDER, N; LASSEGUE, D; PELISSIER, D; GRAZIANI, N; FRANCOIS, G				BRUDER, N; LASSEGUE, D; PELISSIER, D; GRAZIANI, N; FRANCOIS, G			ENERGY-EXPENDITURE AND WITHDRAWAL OF SEDATION IN SEVERE HEAD-INJURED PATIENTS	CRITICAL CARE MEDICINE			English	Article						HEAD INJURY; ENERGY EXPENDITURE; OXYGEN CONSUMPTION; SEDATION; INDIRECT CALORIMETRY; METABOLISM; RECOVERY; MECHANICAL VENTILATION; INTENSIVE CARE UNIT; CRITICAL ILLNESS; NEUROLOGIC EMERGENCIES	RESTING METABOLIC-RATE; GAS-EXCHANGE; SYMPATHOADRENAL RESPONSES; NUTRITIONAL-REQUIREMENTS; PLASMA-CATECHOLAMINE; GENERAL-ANESTHESIA; OXYGEN-CONSUMPTION; VENTILATION; NOREPINEPHRINE; VALIDATION	Objectives: To determine the outcome of oxygen consumption (Vo(2)) and energy expenditure after cessation of sedation in severe head-injured patients and to assess its usefulness as a predictor of neurologic severity. Design: Prospective, descriptive study. Setting: Neurosurgical intensive care unit (ICU) in a university hospital. Patients: Fifteen severe head-injured patients with tracheostomies and who were mechanically ventilated and sedated at the time of the study. Interventions: None. Measurements and Main Results: Vo(2) and energy expenditure were measured, using indirect calorimetry during and after discontinuation of sedation. After the measurement period, the patients were divided into two groups. Group 1 included patients who were completely weaned from sedation; group 2 included patients who had to be sedated again using predetermined criteria. In both groups, energy expenditure was close to basal energy expenditure during sedation, and increased to 150% of basal energy expenditure during the recovery period, with maximum hourly values 80% above basal energy expenditure. In group 1, Vo(2) and energy expenditure changed from 284 +/- 44 mL/min and 1833 +/- 261 kcal/day during sedation to 390 +/- 85 mL/min and 2512 +/- 486 kcal/day for the period without sedation. During this period, there was a significant correlation between Vo(2) and mean arterial pressure. For the recovery period, there was no difference in mean or maximum Vo(2) between the two groups of patients. At 24 and 48 hrs after cessation of sedation, Vo(2) and energy expenditure decreased to 30% above basal energy expenditure. These changes may be due to the recovery of muscular activity, weaning from mechanical ventilation, or an increase in the amount of circulating catecholamines. Conclusion: In severe head-injured patients, during the first 12 hrs after the discontinuation of sedation, the patients experienced a large increase in Vo(2), energy expenditure, and mean arterial pressure. Although these changes have no prognostic value in our study, they have potential deleterious effects in head-injured patients. Methods that blunt these changes which have proven efficacious in anesthesia may be effective for intensive care patients.	CHU TIMONE, SERV NEUROCHIRURG, MARSEILLE, FRANCE	BRUDER, N (corresponding author), CHU TIMONE, DEPT ANESTHESIE REANIMAT, MARSEILLE, FRANCE.						ASKANAZI J, 1981, SURGERY, V89, P478; BOREL C, 1990, CHEST, V98, P180, DOI 10.1378/chest.98.1.180; BREDBACKA S, 1984, ACTA ANAESTH SCAND, V28, P462, DOI 10.1111/j.1399-6576.1984.tb02099.x; BRUDER N, 1991, CRIT CARE MED, V19, P43, DOI 10.1097/00003246-199101000-00013; CHIOLERO R, 1989, JPEN-PARENTER ENTER, V13, P5, DOI 10.1177/014860718901300105; CHIOLERO RL, 1989, CRIT CARE MED, V17, P328, DOI 10.1097/00003246-198904000-00006; CIOFOLO MJ, 1989, ANESTHESIOLOGY, V70, P737; CLIFTON GL, 1986, J NEUROSURG, V64, P895, DOI 10.3171/jns.1986.64.6.0895; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; DAMASK MC, 1982, ANESTHESIOLOGY, V57, P213, DOI 10.1097/00000542-198209000-00011; DELAUNAY L, 1991, BRIT J ANAESTH, V67, P397, DOI 10.1093/bja/67.4.397; DEMPSEY DT, 1985, SURG GYNECOL OBSTET, V160, P128; DERBYSHIRE DR, 1984, BRIT J ANAESTH, V56, P725, DOI 10.1093/bja/56.7.725; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; ELWYN DH, 1980, CRIT CARE MED, V8, P9, DOI 10.1097/00003246-198001000-00003; ENSINGER H, 1992, CRIT CARE MED, V20, P1250, DOI 10.1097/00003246-199209000-00011; FELLOWS IW, 1985, CLIN SCI, V69, P215, DOI 10.1042/cs0690215; GADISSEUX P, 1984, J NEUROSURG, V60, P219, DOI 10.3171/jns.1984.60.2.0219; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; HALTER JB, 1977, J CLIN ENDOCR METAB, V45, P936, DOI 10.1210/jcem-45-5-936; Harris J.A., 1919, PUBLICATIONS, V279, P223; KENNEDY SK, 1977, SURGERY, V82, P233; LEPAPE A, 1987, Annales Francaises d'Anesthesie et de Reanimation, V6, P129, DOI 10.1016/S0750-7658(87)80120-X; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; MOSS E, 1991, MONOGRAPHS ANAESTHES, V21, P247; OH TE, 1991, INTENS CARE MED, V17, P199, DOI 10.1007/BF01709877; PIEK J, 1989, CLIN NUTR, V8, P347, DOI 10.1016/0261-5614(89)90011-3; RALLEY FE, 1988, CAN J ANAESTH, V35, P332, DOI 10.1007/BF03010851; REGAN CJ, 1990, CRIT CARE MED, V18, P871, DOI 10.1097/00003246-199008000-00016; RODRIGUEZ JL, 1983, CIRCULATION, V68, P1238, DOI 10.1161/01.CIR.68.6.1238; SAVINO JA, 1985, J TRAUMA, V25, P1126, DOI 10.1097/00005373-198512000-00002; SHIKORA SA, 1990, CRIT CARE MED, V18, P157, DOI 10.1097/00003246-199002000-00006; STANLEY TH, 1980, ANESTHESIOLOGY, V53, P250, DOI 10.1097/00000542-198009000-00016; VIALE JP, 1988, ACTA ANAESTH SCAND, V32, P691, DOI 10.1111/j.1399-6576.1988.tb02810.x; WEISSMAN C, 1986, ANN SURG, V203, P408, DOI 10.1097/00000658-198604000-00012; WEISSMAN C, 1986, ANESTHESIOLOGY, V64, P673, DOI 10.1097/00000542-198606000-00001; WILLATTS SM, 1988, BRIT J ANAESTH, V61, pP502; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	39	57	58	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	1994	22	7					1114	1119		10.1097/00003246-199407000-00011			6	Critical Care Medicine	General & Internal Medicine	PA696	WOS:A1994PA69600011	8026200				2021-06-18	
J	VINK, R; GOLDING, EM; HEADRICK, JP				VINK, R; GOLDING, EM; HEADRICK, JP			BIOENERGETIC ANALYSIS OF OXIDATIVE-METABOLISM FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article							NUCLEAR-MAGNETIC-RESONANCE; CEREBRAL BLOOD-FLOW; EXPERIMENTAL HEAD-INJURY; ENERGY-METABOLISM; FREE MAGNESIUM; FLUID; PH; SPECTROSCOPY; P-31-NMR; ACIDOSIS	Studies of fluid percussion-induced traumatic brain injury have shown that moderate trauma results in ionic imbalances, with resultant increases in energy demand to restore these ion gradients. Because there are also increased rates of glucose metabolism during periods of focal decline in blood flow, it has been suggested that the mitochondria may be incapable of sufficient oxidative metabolism to cope with this increased energy demand after injury and that ATP derived from substrate level phosphorylation must meet this demand. In the present study, we used phosphorus magnetic resonance spectroscopy to determine the:mitochondrial capacity for oxidative phosphorylation after moderate brain trauma. Before injury, mean oxidative capacity was 54% +/- 1%. After injury, mean capacity increased significantly (p < 0.001) to a maximum of 61% +/- 1%, indicating that mitochondrial oxidative metabolism was enhanced after trauma. Increased oxidative capacity was accompanied by increases in ADP, AMP, and inorganic phosphate concentrations and was correlated to decreases in cytosolic phosphorylation ratio. We conclude that moderate brain trauma increases mitochondrial rate of ATP synthesis over the first 4 h posttrauma, and that during this time of increased- ATP turnover, positive feedback regulation of glycolysis by increased concentrations of ADP, AMP, and inorganic phosphate contributes to maintenance of metabolic steady state.		VINK, R (corresponding author), JAMES COOK UNIV N QUEENSLAND, DIV BIOCHEM & HUMAN PHYSIOL, TOWNSVILLE, QLD 4811, AUSTRALIA.		Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667			ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; CHANCE B, 1955, J BIOL CHEM, V217, P383; CHANCE B, 1986, FED PROC, V45, P2915; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; COHN M, 1962, J BIOL CHEM, V237, P176; CUNNINGHAM CC, 1986, BIOCHIM BIOPHYS ACTA, V885, P12, DOI 10.1016/0167-4889(86)90033-9; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EMERSON CS, 1992, NEUROREPORT, V3, P957, DOI 10.1097/00001756-199211000-00002; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HILLERED L, 1985, J CEREBR BLOOD F MET, V5, P259, DOI 10.1038/jcbfm.1985.33; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1992, CENTRAL NERVOUS SYST, P47; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JANE JA, 1992, CENTRAL NERVOUS SYST; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NIOKA S, 1990, J APPL PHYSIOL, V68, P2527; NIOKA S, 1991, Neurological Research, V13, P25; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; SUGANO T, 1974, BIOCHIM BIOPHYS ACTA, V347, P340, DOI 10.1016/0005-2728(74)90074-7; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	39	57	60	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					265	274		10.1089/neu.1994.11.265			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100003	7996581				2021-06-18	
J	PRATAPCHAND, R; SINNIAH, M; SALEM, FA				PRATAPCHAND, R; SINNIAH, M; SALEM, FA			COGNITIVE EVOKED-POTENTIAL P300 - A METRIC FOR CEREBRAL CONCUSSION	ACTA NEUROLOGICA SCANDINAVICA			English	Article										PRATAPCHAND, R (corresponding author), UNIV HOSP MALAYSIA,DEPT MED,KUBANG KERIAN 15990,MALAYSIA.						BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; CALLAWAY E, 1984, BIOL PSYCHIAT, V19, P649; Donchin E., 1979, EVOKED BRAIN POTENTI, P13, DOI DOI 10.1007/978-1-4684-3462-0_2; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GOODIN DS, 1978, ELECTROEN CLIN NEURO, V44, P447, DOI 10.1016/0013-4694(78)90029-9; GOODIN DS, 1979, BRAIN, V101, P635; GRONWALL D, 1974, LANCET, V2, P605; HAMMOND EJ, 1987, NEUROLOGY, V37, P346, DOI 10.1212/WNL.37.2.346; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; MULLIS RJ, 1985, ELECTROEN CLIN NEURO, V62, P141, DOI 10.1016/0168-5597(85)90026-7; OKADA YC, 1983, ELECTROEN CLIN NEURO, V55, P417, DOI 10.1016/0013-4694(83)90130-X; OLBRICH HM, 1986, ACTA NEUROCHIR, V80, P116, DOI 10.1007/BF01812285; OLBRICH HM, 1986, SURG NEUROL, V26, P112, DOI 10.1016/0090-3019(86)90362-9; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPANICOLAOU AC, 1984, NEUROSURGERY, V6, P676; PICTON TW, 1984, PSYCHOPHYSIOLOGY, V21, P312, DOI 10.1111/j.1469-8986.1984.tb02941.x; ROHRBAUGH JW, 1974, PERCEPT PSYCHOPHYS, V15, P368, DOI 10.3758/BF03213960; ROWE MJ, 1980, ARCH NEUROL-CHICAGO, V37, P679, DOI 10.1001/archneur.1980.00500600027002; Schoenhuber R, 1983, J Neurosurg Sci, V27, P157; SIMSON R, 1976, ELECTROEN CLIN NEURO, V40, P33, DOI 10.1016/0013-4694(76)90177-2; TEASDALE G, 1974, LANCET, V2, P81; VAUGHAN HG, 1970, ELECTROEN CLIN NEURO, V28, P360, DOI 10.1016/0013-4694(70)90228-2; WARD AA, 1966, HEAD INJURY C P, P203; Wood C C, 1980, Prog Brain Res, V54, P51, DOI 10.1016/S0079-6123(08)61605-2	25	57	60	0	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	SEP	1988	78	3					185	189		10.1111/j.1600-0404.1988.tb03643.x			5	Clinical Neurology	Neurosciences & Neurology	Q4555	WOS:A1988Q455500005	3227804				2021-06-18	
J	Guo, SW; Perets, N; Betzer, O; Ben-Shaul, S; Sheinin, A; Michaelevski, I; Popovtzer, R; Offen, D; Levenberg, S				Guo, Shaowei; Perets, Nisim; Betzer, Oshra; Ben-Shaul, Shahar; Sheinin, Anton; Michaelevski, Izhak; Popovtzer, Rachela; Offen, Daniel; Levenberg, Shulamit			Intranasal Delivery of Mesenchymal Stem Cell Derived Exosomes Loaded with Phosphatase and Tensin Homolog siRNA Repairs Complete Spinal Cord Injury	ACS NANO			English	Article						intranasal; exosome; PTEN siRNA; targeted delivery; functional recovery; complete spinal cord injury	PROMOTE FUNCTIONAL RECOVERY; STROMAL CELLS; NEUROVASCULAR PLASTICITY; REGENERATIVE GROWTH; MEDIATED DELIVERY; LOCAL TRANSLATION; RNA INTERFERENCE; TRAUMATIC BRAIN; MOTOR FUNCTION; AXON GROWTH	Individuals with spinal cord injury (SCI) usually suffer from permanent neurological deficits, while spontaneous recovery and therapeutic efficacy are limited. Here, we demonstrate that when given intranasally, exosomes derived from mesenchymal stem cells (MSC-Exo) could pass the blood brain barrier and migrate to the injured spinal cord area. Furthermore, MSC-Exo loaded with phosphatase and tensin homolog small interfering RNA (ExoPTEN) could attenuate the expression of PTEN in the injured spinal cord region following intranasal administrations. In addition, the loaded MSC-Exo considerably enhanced axonal growth and neovascularization, while reducing microgliosis and astrogliosis. The intranasal ExoPTEN therapy could also partly improve structural and electrophysiological function and, most importantly, significantly elicited functional recovery in rats with complete SCI. The results imply that intranasal ExoPTEN may be used clinically to promote recovery for SCI individuals.	[Guo, Shaowei; Ben-Shaul, Shahar; Levenberg, Shulamit] Technion Israel Inst Technol, Dept Biomed Engn, IL-3200003 Haifa, Israel; [Guo, Shaowei] Shantou Univ, Affiliated Hosp 1, Med Coll, Shantou 515041, Peoples R China; [Perets, Nisim; Sheinin, Anton; Offen, Daniel] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Offen, Daniel] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel; [Betzer, Oshra; Popovtzer, Rachela] Bar Ilan Univ, Fac Engn, IL-5290002 Ramat Gan, Israel; [Betzer, Oshra; Popovtzer, Rachela] Bar Ilan Univ, Inst Nanotechnol & Adv Mat, IL-5290002 Ramat Gan, Israel; [Michaelevski, Izhak] Ariel Univ, Dept Mol Biol, IL-40700 Ariel, Israel	Levenberg, S (corresponding author), Technion Israel Inst Technol, Dept Biomed Engn, IL-3200003 Haifa, Israel.	shulamit@bm.technion.ac.il	; Michaelevski, Izhak/G-8940-2018	Levenberg, Shulamit/0000-0001-5471-7339; Michaelevski, Izhak/0000-0002-0783-1443; Popovtzer, Rachela/0000-0002-3585-348X; Betzer, Oshra/0000-0002-4429-7024; Guo, Shaowei/0000-0002-3662-0290	J&J Shervington Fund; Israel Foundation for Spinal Cord Injury; Israel Science Foundation ISFIsrael Science Foundation [749/14]; Brainboost project; Council for Higher Education; Ministry of Science, Technology Space Israel	This work was supported by the J&J Shervington Fund (SL), the Israel Foundation for Spinal Cord Injury (SL), and the Israel Science Foundation ISF 749/14. We would like to thank the Brainboost project for supporting N.P. with a scholarship. We would like to thank the Council for Higher Education and the Ministry of Science, Technology & Space Israel, for supporting O.B. with scholarships. We wish to thank the Technion's Preclinical Research Authority and M. Tendler for their professional animal care. We thank the Technion's BCF MRI team. We thank A. Yvgi and S. Finkel for BBB scoring. We also thank J. Zavin for the cryosections, S. Landau for writing the MATLAB code, N. Cohen and T. Bronshtein for the Nanosight assistance, M. Poley and J. Shainsky for the ICP test, and Dr. Y. Posen for proofreading the article.	Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807; Anwar MA, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00098; Aung Wint Yan, 2013, Imaging Med, V5, P427; Baglio SR, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0116-z; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Betzer O., 2018, P SOC PHOTO-OPT INS, V44; Betzer O., 2017, P SOC PHOTO-OPT INS, P10077; Betzer O, 2017, ACS NANO, V11, P10883, DOI 10.1021/acsnano.7b04495; Betzer O, 2017, NANOMEDICINE-UK, V12, P1533, DOI 10.2217/nnm-2017-0022; Betzer O, 2015, SCI REP-UK, V5, DOI 10.1038/srep15400; Boudreau RL, 2011, HUM MOL GENET, V20, pR21, DOI 10.1093/hmg/ddr137; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Butts JC, 2017, P NATL ACAD SCI USA, V114, P4969, DOI 10.1073/pnas.1608254114; Christie KJ, 2010, J NEUROSCI, V30, P9306, DOI 10.1523/JNEUROSCI.6271-09.2010; De Becker A, 2016, WORLD J STEM CELLS, V8, P73, DOI 10.4252/wjsc.v8.i3.73; Didiot MC, 2016, MOL THER, V24, P1836, DOI 10.1038/mt.2016.126; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Ferguson SW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19581-x; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fleming JC, 2009, J NEUROSURG-SPINE, V11, P575, DOI 10.3171/2009.6.SPINE08915; Fleming JC, 2008, EXP NEUROL, V214, P147, DOI 10.1016/j.expneurol.2008.04.024; Gao ZB, 2013, NANOMED-NANOTECHNOL, V9, P174, DOI 10.1016/j.nano.2012.06.003; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Geremia NM, 2012, J NEUROTRAUM, V29, P539, DOI 10.1089/neu.2011.1976; Gimm O, 2000, HUM MOL GENET, V9, P1633, DOI 10.1093/hmg/9.11.1633; Gong M, 2017, ONCOTARGET, V8, P45200, DOI 10.18632/oncotarget.16778; Haney MJ, 2015, J CONTROL RELEASE, V207, P18, DOI 10.1016/j.jconrel.2015.03.033; Haraszti RA, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32570; Hengst U, 2006, J NEUROSCI, V26, P5727, DOI 10.1523/JNEUROSCI.5229-05.2006; Hengst U, 2009, NAT CELL BIOL, V11, P1024, DOI 10.1038/ncb1916; Hiebert GW, 2002, J NEUROSCI RES, V69, P160, DOI 10.1002/jnr.10275; Hong SW, 2014, NUCLEIC ACID THER, V24, P192, DOI 10.1089/nat.2013.0466; Hu YL, 2010, J CONTROL RELEASE, V147, P154, DOI 10.1016/j.jconrel.2010.05.015; Kar AN, 2013, J NEUROSCI, V33, P7165, DOI 10.1523/JNEUROSCI.2040-12.2013; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kim HS, 2012, J PROTEOME RES, V11, P839, DOI 10.1021/pr200682z; Kjell J, 2016, DIS MODEL MECH, V9, P1125, DOI 10.1242/dmm.025833; Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Lewandowski G, 2014, J NEUROSCI, V34, P9951, DOI 10.1523/JNEUROSCI.1996-14.2014; Li YQ, 2017, NAT MED, V23, P733, DOI 10.1038/nm.4331; Liu K, 2010, NAT NEUROSCI, V13, P1075, DOI 10.1038/nn.2603; Liu W, 2019, J NEUROTRAUM, V36, P469, DOI 10.1089/neu.2018.5835; Locht C, 2011, FEBS J, V278, P4668, DOI 10.1111/j.1742-4658.2011.08237.x; Long Q, 2017, P NATL ACAD SCI USA, V114, pE3536, DOI 10.1073/pnas.1703920114; M'Dahoma S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102027; Mahar M, 2018, NAT REV NEUROSCI, V19, P323, DOI 10.1038/s41583-018-0001-8; Marote A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00231; McCall J, 2012, CELL TISSUE RES, V349, P27, DOI 10.1007/s00441-012-1388-6; McKerracher L, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00051; Meng ZJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00331; Murphy AC, 2010, BRAIN BEHAV IMMUN, V24, P641, DOI 10.1016/j.bbi.2010.01.014; Ni HQ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00014; Nitzsche F, 2017, STEM CELLS, V35, P1446, DOI 10.1002/stem.2614; Ohtake Y, 2014, BIOMATERIALS, V35, P4610, DOI 10.1016/j.biomaterials.2014.02.037; Okada S, 2016, INFLAMM REGEN, V36, DOI 10.1186/s41232-016-0026-1; Otero-Ortega L, 2018, J CEREBR BLOOD F MET, V38, P767, DOI 10.1177/0271678X17708917; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Perets N, 2019, NANO LETT, V19, P3422, DOI 10.1021/acs.nanolett.8b04148; Perets N, 2018, MOL AUTISM, V9, DOI 10.1186/s13229-018-0240-6; Phinney DG, 2017, STEM CELLS, V35, P851, DOI 10.1002/stem.2575; Qu MK, 2018, J CONTROL RELEASE, V287, P156, DOI 10.1016/j.jconrel.2018.08.035; Ramachandran PS, 2013, NEUROTHERAPEUTICS, V10, P473, DOI 10.1007/s13311-013-0183-8; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rauch MF, 2009, EUR J NEUROSCI, V29, P132, DOI 10.1111/j.1460-9568.2008.06567.x; Reza-Zaldivar EE, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00317; Rocha LA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00164; Satkunendrarajah K, 2018, NATURE, V562, P419, DOI 10.1038/s41586-018-0595-z; Segal-Gavish H, 2016, AUTISM RES, V9, P17, DOI 10.1002/aur.1530; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Song JR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05827-9; Sun GD, 2018, MAT SCI ENG C-MATER, V89, P194, DOI 10.1016/j.msec.2018.04.006; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Terenzio M, 2018, SCIENCE, V359, P1416, DOI 10.1126/science.aan1053; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Walker CL, 2014, NEUROSCI LETT, V573, P64, DOI 10.1016/j.neulet.2014.02.039; Walker CL, 2012, PLOS ONE, V7, P315, DOI 10.1371/journal.pone.0030012; Wang L, 2018, CELL PHYSIOL BIOCHEM, V50, P1535, DOI 10.1159/000494652; Warren PM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06937-0; Williams AM, 2019, J NEUROTRAUM, V36, P54, DOI 10.1089/neu.2018.5711; Williams RR, 2015, CELL TRANSPLANT, V24, P115, DOI 10.3727/096368913X674657; Xin HQ, 2017, STROKE, V48, P747, DOI 10.1161/STROKEAHA.116.015204; Xin HQ, 2013, STEM CELLS, V31, P2737, DOI 10.1002/stem.1409; Xin HQ, 2013, J CEREBR BLOOD F MET, V33, P1711, DOI 10.1038/jcbfm.2013.152; Xin HQ, 2012, STEM CELLS, V30, P1556, DOI 10.1002/stem.1129; Yang JL, 2017, MOL THER-NUCL ACIDS, V7, P278, DOI 10.1016/j.omtn.2017.04.010; Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001; Yu SK, 2016, SCI REP-UK, V6, DOI 10.1038/srep33428; Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang ZG, 2019, NAT REV NEUROL, V15, P193, DOI 10.1038/s41582-018-0126-4; Zholudeva LV, 2018, TRENDS NEUROSCI, V41, P625, DOI 10.1016/j.tins.2018.06.004; Zhuang XY, 2011, MOL THER, V19, P1769, DOI 10.1038/mt.2011.164; Zukor K, 2013, J NEUROSCI, V33, P15350, DOI 10.1523/JNEUROSCI.2510-13.2013	97	56	60	23	67	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	SEP	2019	13	9					10015	10028		10.1021/acsnano.9b01892			14	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	JA5BZ	WOS:000487859600024	31454225				2021-06-18	
J	Chen, SB; Ye, JF; Chen, XR; Shi, JN; Wu, WH; Lin, WP; Lin, WB; Li, YS; Fu, HD; Li, S				Chen, Shoubo; Ye, Jingfang; Chen, Xiangrong; Shi, Jinnan; Wu, Wenhua; Lin, Wenping; Lin, Weibin; Li, Yasong; Fu, Huangde; Li, Shun			Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-kappa B pathway dependent of HDAC3	JOURNAL OF NEUROINFLAMMATION			English	Article						Spinal cord injury; Valproic acid; HDAC3; Microglia; Inflammatory; STAT1; NF-kappa B pathway	BRAIN-INJURY; ACTIVATION; INHIBITION; MICROGLIA; CELLS; POLARIZATION; ACETYLATION; EXPRESSION; AUTOPHAGY; RELEASE	Background: Microglial polarization with M1/M2 phenotype shifts and the subsequent neuroinflammatory responses are vital contributing factors for spinal cord injury (SCI)-induced secondary injury. Nuclear factor-kappa B (NF-kappa B) is considered the central transcription factor of inflammatory mediators, which plays a crucial role in microglial activation. Lysine acetylation of STAT1 seems necessary for NF-kappa B pathway activity, as it is regulated by histone deacetylases (HDACs). There have been no studies that have explained if HDAC inhibition by valproic acid (VPA) affects the NF-kappa B pathway via acetylation of STAT1 dependent of HDAC activity in the microglia-mediated central inflammation following SCI. We investigated the potential molecular mechanisms that focus on the phenotypic transition of microglia and the STAT1-mediated NF-kappa B acetylation after a VPA treatment. Methods: The Basso-Beattie-Bresnahan locomotion scale, the inclined plane test, the blood-spinal cord barrier, and Nissl staining were employed to determine the neuroprotective effects of VPA treatment after SCI. Assessment of microglia polarization and pro-inflammatory markers, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, and interferon (INF)-gamma was used to evaluate the neuroinflammatory responses and the anti-inflammatory effects of VPA treatment. Immunofluorescent staining and Western blot analysis were used to detect HDAC3 nuclear translocation, activity, and NF-kappa B signaling pathway activation to evaluate the effects of VPA treatment. The impact of STAT1 acetylation on NF-kappa B pathway and the interaction between STAT1 and NF-kappa B were assessed to evaluate anti-inflammation effects of VPA treatment and also whether these effects were dependent on a STAT1/NF-kappa B pathway to gain further insight into the mechanisms underlying the development of the neuroinflammatory response after SCI. Results: The results showed that the VPA treatment promoted the phenotypic shift of microglia from M1 to M2 phenotype and inhibited microglial activation, thus reducing the SCI-induced inflammatory factors. The VPA treatment upregulation of the acetylation of STAT1/NF-kappa B pathway was likely caused by the HDAC3 translocation to the nucleus and activity. These results indicated that the treatment with the VPA suppressed the expression and the activity of HDAC3 and enhanced STAT1, as well as NF-kappa B p65 acetylation following a SCI. The acetylation status of NF-kappa B p65 and the complex with NF-kappa B p65 and STAT1 inhibited the NF-kappa B p65 transcriptional activity and attenuated the microglia-mediated central inflammatory response following SCI. Conclusions: These results suggested that the VPA treatment attenuated the inflammatory response by modulating microglia polarization through STAT1-mediated acetylation of the NF-kappa B pathway, dependent of HDAC3 activity. These effects led to neuroprotective effects following SCI.	[Chen, Shoubo; Shi, Jinnan; Wu, Wenhua; Lin, Wenping] Fujian Med Univ, Affiliated Hosp 2, Dept Orthopaed, Quanzhou 362000, Fujian, Peoples R China; [Ye, Jingfang] Quanzhou Med Coll, Dept Nursing Fac, Quanzhou 362000, Fujian, Peoples R China; [Chen, Xiangrong; Lin, Weibin; Li, Yasong] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou 362000, Fujian, Peoples R China; [Fu, Huangde] YouJiang Med Univ Nationalities, Affiliated Hosp, Dept Neurosurg, Baise 533000, Guangxi Provinc, Peoples R China; [Li, Shun] North Sichuan Med Coll, Affiliated Hosp, Dept Neurosurg, Nanchong 637000, Sichuan, Peoples R China	Chen, XR (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou 362000, Fujian, Peoples R China.; Li, S (corresponding author), North Sichuan Med Coll, Affiliated Hosp, Dept Neurosurg, Nanchong 637000, Sichuan, Peoples R China.	xiangrong_chen281@126.com	zhang, chuengji/AAD-4591-2020		funds for Fujian Province Scientific and Technological Foundation [2060402]; Fujian Province Scientific Foundation [2017J01183]	This work was supported by grants from the funds for Fujian Province Scientific and Technological Foundation (No. 2060402) from Dr. Xiangrong Chen and Fujian Province Scientific Foundation (No. 2017J01183) from Dr. Shoubo Chen.	Bambakidis T, 2016, J NEUROTRAUM, V33, P1514, DOI 10.1089/neu.2015.4163; Chen S, 2014, NEUROCHEM RES, V39, P1621, DOI 10.1007/s11064-014-1241-2; Chen XR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0917-3; Chi JH, 2017, EUR J PHARMACOL, V796, P101, DOI 10.1016/j.ejphar.2016.12.026; Chu TC, 2015, REGEN MED, V10, P193, DOI [10.2217/RME.14.86, 10.2217/rme.14.86]; Cui XL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.270; Deng ZT, 2017, INT J NANOMED, V12, P3617, DOI 10.2147/IJN.S124661; Fang P, 2014, MOL NEUROBIOL, V49, P472, DOI 10.1007/s12035-013-8533-4; He XX, 2017, RES VET SCI, V112, P7, DOI 10.1016/j.rvsc.2016.12.011; He ZL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08052-4; Ji MM, 2015, AUTOPHAGY, V11, P2160, DOI 10.1080/15548627.2015.1082024; Jiang J, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00363; Jiang XJ, 2017, NEUROCHEM RES, V42, P3245, DOI 10.1007/s11064-017-2361-2; Kim WH, 2017, PHARMACOL REP, V69, P1030, DOI 10.1016/j.pharep.2017.04.006; Kramer OH, 2006, GENE DEV, V20, P473, DOI 10.1101/gad.364306; Kuboyama T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08535-4; Kumar H, 2017, MOL NEUROBIOL, V54, P3578, DOI 10.1007/s12035-016-9910-6; Kumar P, 2017, AM J PHYSIOL-RENAL, V313, pF781, DOI 10.1152/ajprenal.00166.2017; Lan KC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12285-8; Lee JY, 2014, J NEUROTRAUM, V31, P582, DOI 10.1089/neu.2013.3146; Leus NGJ, 2016, CURR OPIN CHEM BIOL, V33, P160, DOI 10.1016/j.cbpa.2016.06.019; Leus NGJ, 2016, BIOCHEM PHARMACOL, V108, P58, DOI 10.1016/j.bcp.2016.03.010; Li HT, 2016, MOL NEUROBIOL, V53, P4073, DOI 10.1007/s12035-015-9327-7; Li ZM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020315; Liu G, 2017, CELL MOL NEUROBIOL, V37, P843, DOI 10.1007/s10571-016-0422-8; Nakazawa H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170391; Park SY, 2014, MOL NUTR FOOD RES, V58, P738, DOI 10.1002/mnfr.201300445; Penas C, 2011, NEUROSCIENCE, V178, P33, DOI 10.1016/j.neuroscience.2011.01.012; Raible DJ, 2015, EXP NEUROL, V271, P445, DOI 10.1016/j.expneurol.2015.07.001; Sinkovics JG, 2015, INT J ONCOL, V47, P1211, DOI 10.3892/ijo.2015.3102; Song JW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00553-6; Su ZD, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4338; Suda S, 2015, BRAIN RES, V1606, P1, DOI 10.1016/j.brainres.2015.02.013; Wang CG, 2018, J CELL MOL MED, V22, P1148, DOI 10.1111/jcmm.13368; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wilson CB, 2014, BEHAV BRAIN RES, V268, P72, DOI 10.1016/j.bbr.2014.03.029; Xu HZ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/5405104; Xu Q, 2015, J MOL NEUROSCI, V55, P289, DOI 10.1007/s12031-014-0320-9; Yi HB, 2016, INT IMMUNOPHARMACOL, V36, P199, DOI 10.1016/j.intimp.2016.04.032; Zendedel A, 2018, MOL NEUROBIOL, V55, P1364, DOI 10.1007/s12035-017-0400-2; Zhang Q, 2016, MOL NEUROBIOL, V53, P662, DOI 10.1007/s12035-014-9035-8; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292	42	56	60	6	20	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAY 18	2018	15								150	10.1186/s12974-018-1193-6			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	GH0WJ	WOS:000433122600001	29776446	DOAJ Gold, Green Published			2021-06-18	
J	Tatum, WO; Rubboli, G; Kaplan, PW; Mirsatari, SM; Radhakrishnan, K; Gloss, D; Caboclo, LO; Drislane, FW; Koutroumanidis, M; Schomer, DL; Trenite, DKN; Cook, M; Beniczky, S				Tatum, W. O.; Rubboli, G.; Kaplan, P. W.; Mirsatari, S. M.; Radhakrishnan, K.; Gloss, D.; Caboclo, L. O.; Drislane, F. W.; Koutroumanidis, M.; Schomer, D. L.; Trenite, D. Kastelijn-Nolst; Cook, Mark; Beniczky, S.			Clinical utility of EEG in diagnosing and monitoring epilepsy in adults	CLINICAL NEUROPHYSIOLOGY			English	Article						EEG; Epilepsy; Epileptiform; Seizure; Guideline	TEMPORAL-LOBE EPILEPSY; JUVENILE MYOCLONIC EPILEPSY; NONCONVULSIVE STATUS EPILEPTICUS; IDIOPATHIC GENERALIZED EPILEPSY; 1ST UNPROVOKED SEIZURE; QUALITY-STANDARDS-SUBCOMMITTEE; COMPLEX PARTIAL SEIZURES; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; HIGH-FREQUENCY OSCILLATIONS	Electroencephalography (EEG) remains an essential diagnostic tool for people with epilepsy (PWE). The International Federation of Clinical Neurophysiology produces new guidelines as an educational service for clinicians to address gaps in knowledge in clinical neurophysiology. The current guideline was prepared in response to gaps present in epilepsy-related neurophysiological assessment and is not intended to replace sound clinical judgement in the care of PWE. Furthermore, addressing specific pathophysiological conditions of the brain that produce epilepsy is of primary importance though is beyond the scope of this guideline. Instead, our goal is to summarize the scientific evidence for the utility of EEG when diagnosing and monitoring PWE. (C) 2018 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.	[Tatum, W. O.] Mayo Clin, Dept Neurol, Cannaday,2 East,4500 San Pablo Rd, Jacksonville, FL 32224 USA; [Rubboli, G.] Univ Copenhagen, Danish Epilepsy Ctr, Dept Neurol, Copenhagen, Diannalund, Denmark; [Kaplan, P. W.] Johns Hopkins Univ, Baltimore, MD USA; [Mirsatari, S. M.] Western Univ, Dept Clin Neurol Sci, London, ON, Canada; [Radhakrishnan, K.] Amrita Inst Med Sci, Dept Neurol, Kochi, Kerala, India; [Gloss, D.] CAMC Dept Neurol, Charleston, WV USA; [Caboclo, L. O.] Hosp Israelita Albert Einstein, Dept Neurol, Sao Paulo, Brazil; [Drislane, F. W.; Schomer, D. L.] Harvard Univ, Dept Neurol, Beth Israel Deaconess Med Ctr, Boston, MA USA; [Koutroumanidis, M.] Kings Coll London, Guys & St Thomas NHS Trust, Dept Neurol, London, England; [Trenite, D. Kastelijn-Nolst] Univ Med Ctr, Brain Ctr, Utrecht, Netherlands; [Trenite, D. Kastelijn-Nolst] Sapienza Univ, Dept Pediat, Rome, Italy; [Cook, Mark] Univ Melbourne, Dept Neurol, Melbourne, Vic, Australia; [Beniczky, S.] Aarhus Univ Hosp, Dept Clin Neurophysiol, Aarhus, Denmark	Tatum, WO (corresponding author), Mayo Clin, Dept Neurol, Cannaday,2 East,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	tatum.william@mayo.edu	Trenite, Dorothee Nolst/ABG-5804-2020; Cook, Mark/A-7096-2010	Beniczky, Sandor/0000-0002-6035-6581; Cook, Mark/0000-0002-8875-4135			Aarabi A, 2006, CLIN NEUROPHYSIOL, V117, P328, DOI 10.1016/j.clinph.2005.10.006; Abubakr A, 2010, J CLIN NEUROSCI, V17, P1503, DOI 10.1016/j.jocn.2009.12.037; Acharya JN, 2016, J CLIN NEUROPHYSIOL, V33, P308, DOI 10.1097/WNP.0000000000000316; Airoldi L, 1999, J CLIN NEUROPHYSIOL, V16, P456, DOI 10.1097/00004691-199909000-00007; Aldenkamp AP, 2004, EPILEPSY BEHAV, V5, pS25, DOI 10.1016/j.yebeh.2003.11.005; ALIBERTI V, 1994, EPILEPSIA, V35, P297, DOI 10.1111/j.1528-1157.1994.tb02433.x; Alix JJP, 2014, SEIZURE-EUR J EPILEP, V23, P662, DOI 10.1016/j.seizure.2014.04.008; Alsaadi TM, 2004, SEIZURE-EUR J EPILEP, V13, P32, DOI 10.1016/S1059-1311(03)00072-4; Alvarez V, 2013, CRIT CARE, V17, DOI 10.1186/cc12879; Alving J, 2009, SEIZURE-EUR J EPILEP, V18, P470, DOI 10.1016/j.seizure.2009.04.005; Amantini A, 2009, NEUROPHYSIOL CLIN, V39, P85, DOI 10.1016/j.neucli.2009.01.006; Angus-Leppan H, 2007, CLIN NEUROPHYSIOL, V118, P22, DOI 10.1016/j.clinph.2006.08.014; ARROYO S, 1994, EPILEPSIA, V35, P974, DOI 10.1111/j.1528-1157.1994.tb02542.x; Arts R, 2002, CAN J NEUROL SCI, V29, P216; Asano E, 2009, BRAIN, V132, P1038, DOI 10.1093/brain/awp025; Avanzini G, 2016, EPILEPTIC DISORD, V18, pS11, DOI 10.1684/epd.2016.0835; Badawy RAB, 2013, NEUROLOGY, V80, P1901, DOI 10.1212/WNL.0b013e3182929f4f; Baldin E, 2014, EPILEPSIA, V55, P1389, DOI 10.1111/epi.12720; BARRETT G, 1992, J CLIN NEUROPHYSIOL, V9, P495, DOI 10.1097/00004691-199210000-00004; Bautista RED, 1998, NEUROLOGY, V50, P1765; Beleza P, 2009, EPILEPSIA, V50, P550, DOI 10.1111/j.1528-1167.2008.01780.x; Benbadis SR, 2009, NEUROLOGY, V73, P843, DOI 10.1212/WNL.0b013e3181b78425; Benbadis SR, 2010, EXPERT REV NEUROTHER, V10, P343, DOI 10.1586/ERN.09.157; Benbadis SR, 2004, NEUROLOGY, V63, P1728, DOI 10.1212/01.WNL.0000143273.18099.50; Benbadis SR, 2003, NEUROLOGY, V61, P1793, DOI 10.1212/01.WNL.0000098891.76373.15; Benbadis SR, 2003, J CLIN NEUROPHYSIOL, V20, P42, DOI 10.1097/00004691-200302000-00005; Beniczky S, 2013, EPILEPSIA, V54, P1743, DOI 10.1111/epi.12339; Beniczky S, 2013, EPILEPSIA, V54, P28, DOI 10.1111/epi.12270; Beniczky S, 2013, EPILEPSIA, V54, P1112, DOI 10.1111/epi.12135; Beniczky S, 2013, EPILEPSIA, V54, pe58, DOI 10.1111/epi.12120; Beniczky S, 2012, EPILEPSIA, V53, P832, DOI 10.1111/j.1528-1167.2012.03454.x; Beniczky SA, 2012, EPILEPSY BEHAV, V24, P213, DOI 10.1016/j.yebeh.2012.03.036; Benifla M, 2006, NEUROSURGERY, V59, P1203, DOI 10.1227/01.NEU.0000245615.32226.83; Berg AT, 2008, EPILEPSIA, V49, P13, DOI 10.1111/j.1528-1167.2008.01444.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; Bergey Gregory K, 2016, Continuum (Minneap Minn), V22, P38, DOI 10.1212/CON.0000000000000271; Berkovic SF, 2003, EPILEPSIA, V44, P969, DOI 10.1046/j.1528-1157.2003.59102.x; Bertram EH, 1998, EPILEPSY RES, V32, P194, DOI 10.1016/S0920-1211(98)00051-5; Bingham E, 2002, J NEUROL NEUROSUR PS, V73, P216; Binnie CD, 1999, CLIN NEUROPHYSIOL, V110, P1671, DOI 10.1016/S1388-2457(99)00125-X; BINNIE CD, 1981, NEUROLOGY, V31, P298, DOI 10.1212/WNL.31.3.298; BINNIE CD, 1994, J NEUROL NEUROSUR PS, V57, P1308, DOI 10.1136/jnnp.57.11.1308; Binnie Colin D., 1992, P299; Guaranha MSB, 2009, EPILEPSIA, V50, P2446, DOI 10.1111/j.1528-1167.2009.02126.x; Blum DE, 1996, NEUROLOGY, V47, P260, DOI 10.1212/WNL.47.1.260; Blume Warren T., 2001, Epilepsia, V42, P1212, DOI 10.1046/j.1528-1157.2001.22001.x; BLUME WT, 1993, ANN NEUROL, V34, P703, DOI 10.1002/ana.410340513; Blume WT, 2001, CURR OPIN NEUROL, V14, P193, DOI 10.1097/00019052-200104000-00010; Blumenfeld H, 2003, EPILEPSIA, V44, P7, DOI 10.1046/j.1528-1157.44.s.2.2.x; Bonakis A, 2009, EPILEPSIA, V50, P2434, DOI 10.1111/j.1528-1167.2009.02110.x; Boon P, 2002, J CLIN NEUROPHYSIOL, V19, P461, DOI 10.1097/00004691-200210000-00009; Borchers S, 2012, NAT REV NEUROSCI, V13, P63, DOI 10.1038/nrn3140; Bragin A, 2002, J NEUROSCI, V22, P2012, DOI 10.1523/JNEUROSCI.22-05-02012.2002; BRENNER RP, 1990, J CLIN NEUROPHYSIOL, V7, P249, DOI 10.1097/00004691-199004000-00007; Brigo F, 2015, EPILEPSIA, V56, pE21, DOI 10.1111/epi.12911; Brna P, 2015, EPILEPSIA, V56, P1065, DOI 10.1111/epi.12983; Brodbeck V, 2011, BRAIN, V134, P2887, DOI 10.1093/brain/awr243; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Brown P, 1999, BRAIN, V122, P461, DOI 10.1093/brain/122.3.461; Brunnhuber F, 2014, SEIZURE-EUR J EPILEP, V23, P338, DOI 10.1016/j.seizure.2014.01.009; Bubrick EJ, 2014, SEIZURE-EUR J EPILEP, V23, P699, DOI 10.1016/j.seizure.2014.05.007; Bulacio JC, 2012, EPILEPSIA, V53, P1722, DOI 10.1111/j.1528-1167.2012.03633.x; Buna DK, 1998, PHARMACOTHERAPY, V18, P235; Burkholder DB, 2016, NEUROLOGY, V86, P1524, DOI 10.1212/WNL.0000000000002592; Butler CR, 2007, ANN NEUROL, V61, P587, DOI 10.1002/ana.21111; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; Carpay JA, 1997, EPILEPSIA, V38, P595, DOI 10.1111/j.1528-1157.1997.tb01145.x; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Cascino GD, 2002, MAYO CLIN PROC, V77, P1111, DOI 10.4065/77.10.1111; CASCINO GD, 1993, NEUROLOGY, V43, P747, DOI 10.1212/WNL.43.4.747; CASCINO GD, 1995, EPILEPSIA, V36, P692, DOI 10.1111/j.1528-1157.1995.tb01048.x; Cascino GD, 2001, NEUROL CLIN, V19, P271, DOI 10.1016/S0733-8619(05)70019-0; CAVAZZUTI GB, 1980, EPILEPSIA, V21, P43, DOI 10.1111/j.1528-1157.1980.tb04043.x; Chadwick D, 2006, EPILEPSIA, V47, P58, DOI 10.1111/j.1528-1167.2006.00662.x; Chatrian GE, 1983, RECOMMENDATIONS PRAC, P11; Chen DK, 2008, EPILEPSY BEHAV, V13, P115, DOI 10.1016/j.yebeh.2008.02.018; Chowdhury FA, 2008, EUR J NEUROL, V15, P1034, DOI 10.1111/j.1468-1331.2008.02260.x; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2005, J CLIN NEUROPHYSIOL, V22, P92, DOI 10.1097/01.WNP.0000145006.02048.3A; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Cohen-Gadol AA, 2004, J NEUROSURG, V101, P55, DOI 10.3171/jns.2004.101.1.0055; Cook MJ, 2013, LANCET NEUROL, V12, P563, DOI 10.1016/S1474-4422(13)70075-9; Craciun L, 2014, ACTA NEUROL SCAND, V129, pE9, DOI 10.1111/ane.12186; Craciun L, 2015, SEIZURE-EUR J EPILEP, V30, P90, DOI 10.1016/j.seizure.2015.06.003; Crepeau AZ, 2013, NEUROLOGY, V80, P339, DOI 10.1212/WNL.0b013e31827f089d; D'Souza WJ, 2010, EPILEPSY RES, V91, P20, DOI 10.1016/j.eplepsyres.2010.06.003; Daniel SJ, 2011, SEIZURE-EUR J EPILEP, V20, P564, DOI 10.1016/j.seizure.2011.04.006; De Marchis GM, 2016, NEUROLOGY, V86, P253, DOI 10.1212/WNL.0000000000002281; Deacon C, 2003, NEUROLOGY, V61, P1686, DOI 10.1212/01.WNL.0000090566.40544.04; DECLERCK AC, 1986, EUR NEUROL, V25, P117, DOI 10.1159/000116092; DEGEN R, 1983, EPILEPSIA, V24, P557, DOI 10.1111/j.1528-1157.1983.tb03420.x; DEGEN R, 1980, ELECTROEN CLIN NEURO, V49, P577, DOI 10.1016/0013-4694(80)90398-3; DEGEN R, 1981, J NEUROL, V225, P85, DOI 10.1007/BF00313322; DEGRAAF AS, 1995, EPILEPSIA, V36, P219; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Dericioglu N, 2008, CLIN EEG NEUROSCI, V39, P20, DOI 10.1177/155005940803900109; Dericioglu N, 2010, CLIN EEG NEUROSCI, V41, P166, DOI 10.1177/155005941004100312; Derry CP, 2009, SLEEP, V32, P1637, DOI 10.1093/sleep/32.12.1637; Dhanuka AK, 2001, SEIZURE-EUR J EPILEP, V10, P374, DOI 10.1053/seiz.2001.0522; Di Gennaro G, 2012, CLIN NEUROPHYSIOL, V123, P2346, DOI 10.1016/j.clinph.2012.05.013; Diehl B, 2000, EPILEPSIA, V41, pS61, DOI 10.1111/j.1528-1157.2000.tb01536.x; Duez L, 2016, CLIN NEUROPHYSIOL, V127, P3301, DOI 10.1016/j.clinph.2016.08.006; Ebersole JS, 1999, EEG CL N SU, V50, P167; EBERSOLE JS, 1983, NEUROLOGY, V33, P853, DOI 10.1212/WNL.33.7.853; Ebersole JS, 1996, EPILEPSIA, V37, P386, DOI 10.1111/j.1528-1157.1996.tb00577.x; El Bouzidi K, 2010, NEUROLOGY, V74, P610, DOI 10.1212/WNL.0b013e3181cff6c3; El Tallawy HN, 2010, EPILEPSY RES, V88, P179, DOI 10.1016/j.eplepsyres.2009.11.001; ELAD B, 1994, ELECTROEN CLIN NEURO, V90, P313, DOI 10.1016/0013-4694(94)90150-3; Engel J, 2003, NEUROLOGY, V60, P538, DOI 10.1212/01.WNL.0000055086.35806.2D; Engel J, 2006, EPILEPSIA, V47, P1558, DOI 10.1111/j.1528-1167.2006.00215.x; Engel J, 2012, JAMA-J AM MED ASSOC, V307, P922, DOI 10.1001/jama.2012.220; England MJ, 2012, EPILEPSY SPECTRUM PR; Faulkner HJ, 2012, CLIN NEUROPHYSIOL, V123, P1732, DOI 10.1016/j.clinph.2012.01.023; Faulkner HJ, 2012, SEIZURE-EUR J EPILEP, V21, P491, DOI 10.1016/j.seizure.2012.04.015; Fernandez IS, 2013, J CLIN NEUROPHYSIOL, V30, P554, DOI 10.1097/01.wnp.0000436898.10125.70; Ferrier CH, 1999, J NEUROL NEUROSUR PS, V66, P350, DOI 10.1136/jnnp.66.3.350; Ferrier CH, 2006, EPILEPSIA, V47, P1477, DOI 10.1111/j.1528-1167.2006.00619.x; Fisch BJ, 2003, J CLIN NEUROPHYSIOL, V20, P155, DOI 10.1097/00004691-200305000-00001; Fischer MH, 1933, MED KLIN, V25, P15; Fisher RS, 2017, EPILEPSIA, V58, P522, DOI 10.1111/epi.13670; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fittipaldi F, 2001, NEUROLOGY, V56, P123, DOI 10.1212/WNL.56.1.123; Flink R, 2002, ACTA NEUROL SCAND, V106, P1, DOI 10.1034/j.1600-0404.2002.01361.x; Foldvary N, 2001, NEUROLOGY, V57, P2022, DOI 10.1212/WNL.57.11.2022; Foreman B, 2012, NEUROLOGY, V79, P1951, DOI 10.1212/WNL.0b013e3182735cd7; Fountain NB, 1998, J CLIN NEUROPHYSIOL, V15, P69, DOI 10.1097/00004691-199801000-00009; Fowle AJ, 2000, EPILEPSIA, V41, pS10, DOI 10.1111/j.1528-1157.2000.tb01529.x; Freestone DR, 2013, IEEE ENG MED BIO, P6151, DOI 10.1109/EMBC.2013.6610957; FRENCH JA, 1993, ANN NEUROL, V34, P774, DOI 10.1002/ana.410340604; Friedman DE, 2009, J CLIN NEUROPHYSIOL, V26, P213, DOI 10.1097/WNP.0b013e3181b2f2da; Gadhoumi K, 2016, J NEUROSCI METH, V260, P270, DOI 10.1016/j.jneumeth.2015.06.010; Gaspard N, 2014, EPILEPSIA, V55, P1366, DOI 10.1111/epi.12653; GASTAUT H, 1969, EPILEPSIA, VS 10, pS14; Gavaret M, 2015, NEUROPHYSIOL CLIN, V45, P105, DOI 10.1016/j.neucli.2014.11.011; Gavvala JR, 2016, JAMA-J AM MED ASSOC, V316, P2657, DOI 10.1001/jama.2016.18625; Genton P, 1995, NEUROPHYSIOL CLIN, V25, P283, DOI 10.1016/0987-7053(96)80171-7; Ghougassian DF, 2004, EPILEPSIA, V45, P928, DOI 10.1111/j.0013-9580.2004.51003.x; Gibbs EL, 1947, J NERV MENT DIS, V26, P336; GILLIAM FG, 1995, NEUROLOGY, V45, P453, DOI 10.1212/WNL.45.3.453; Giorgi FS, 2013, CLIN NEUROPHYSIOL, V124, P2101, DOI 10.1016/j.clinph.2013.04.342; Glauser T, 2017, EPILEPSY CURR; GLOOR P, 1968, BRAIN, V91, P779, DOI 10.1093/brain/91.4.779; GLOOR P, 1985, J CLIN NEUROPHYSIOL, V2, P327, DOI 10.1097/00004691-198510000-00002; Gonzalez-Martinez JA, 2016, J CLIN NEUROPHYSIOL, V33, P522, DOI 10.1097/WNP.0000000000000327; GOODIN DS, 1990, ANN NEUROL, V27, P330, DOI 10.1002/ana.410270317; Goodwin E, 2014, SEIZURE-EUR J EPILEP, V23, P480, DOI 10.1016/j.seizure.2014.02.008; Gotman J, 2004, J CLIN NEUROPHYSIOL, V21, P229, DOI 10.1097/01.WNP.0000139658.92878.2A; Greiner HM, 2016, EPILEPSY RES, V122, P73, DOI 10.1016/j.eplepsyres.2016.02.011; Guaranha MSB, 2005, EPILEPSIA, V46, P69, DOI 10.1111/j.0013-9580.2005.11104.x; Guerci JR, 1999, RADAR CONF, P119, DOI 10.1109/NRC.1999.767288; Gustafsson G, 2015, CLIN NEUROPHYSIOL, V126, P1493, DOI 10.1016/j.clinph.2014.10.015; Haider HA, 2016, NEUROLOGY, V87, P935, DOI 10.1212/WNL.0000000000003034; Halford JJ, 2011, J CLIN NEUROPHYSIOL, V28, P178, DOI 10.1097/WNP.0b013e31821215e3; Harden CL, 2003, EPILEPSIA, V44, P453, DOI 10.1046/j.1528-1157.2003.33002.x; HARDING GFA, 1994, EPILEPSIA, V35, P1208, DOI 10.1111/j.1528-1157.1994.tb01791.x; Harvey AS, 1996, ANN NEUROL, V40, P91, DOI 10.1002/ana.410400115; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; Hendriksen IJM, 2001, AVIAT SPACE ENVIR MD, V72, P1025; Heo K, 2006, EPILEPSIA, V47, P1931, DOI 10.1111/j.1528-1167.2006.00820.x; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P87, DOI 10.1097/WNP.0000000000000166; Hill NJ, 2012, JOVE-J VIS EXP, DOI 10.3791/3993; Hirfanoglu T, 2007, PEDIATR NEUROL, V36, P231, DOI 10.1016/j.pediatrneurol.2006.12.002; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirtz D, 2003, NEUROLOGY, V60, P166, DOI 10.1212/01.WNL.0000033622.27961.B6; Holmes MD, 2000, CLIN NEUROPHYSIOL, V111, P1802, DOI 10.1016/S1388-2457(00)00389-8; Holmes MD, 2004, EPILEPSIA, V45, P618, DOI 10.1111/j.0013-9580.2004.63803.x; Hopfengartner R, 2014, CLIN NEUROPHYSIOL, V125, P1346, DOI 10.1016/j.clinph.2013.12.104; Howbert JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081920; Hughes JR, 2003, CLIN ELECTROENCEPHAL, V34, P174, DOI 10.1177/155005940303400403; Husain AM, 1999, J CLIN NEUROPHYSIOL, V16, P51, DOI 10.1097/00004691-199901000-00005; Itoh Y, 2015, BRAIN DEV-JPN, V37, P49, DOI 10.1016/j.braindev.2014.03.013; Jackson AF, 2014, PSYCHOPHYSIOLOGY, V51, P1061, DOI 10.1111/psyp.12283; Jackson J H, 1890, Br Med J, V1, P821; Jackson J H, 1890, Br Med J, V1, P765; Jackson J H, 1890, Br Med J, V1, P703; Janszky J, 2000, NEUROLOGY, V54, P1470, DOI 10.1212/WNL.54.7.1470; JANZ D, 1985, ACTA NEUROL SCAND, V72, P449; JASPER H, 1955, Electroencephalogr Clin Neurophysiol Suppl, VSuppl. 4, P168; Jayakar P, 2016, EPILEPSIA, V57, P1735, DOI 10.1111/epi.13515; Jayakar P, 2014, EPILEPSIA, V55, P507, DOI 10.1111/epi.12544; Jayalakshmi SS, 2010, ACTA NEUROL SCAND, V122, P115, DOI 10.1111/j.1600-0404.2009.01270.x; Jefferys JGR, 2010, SEIZURE-EUR J EPILEP, V19, P638, DOI 10.1016/j.seizure.2010.10.026; Jeha LE, 2006, NEUROLOGY, V66, P1938, DOI 10.1212/01.wnl.0000219810.71010.9b; Jeha LE, 2007, BRAIN, V130, P574, DOI 10.1093/brain/awl364; Jeppesen J, 2010, TECHNOL HEALTH CARE, V18, P417, DOI 10.3233/THC-2010-0606; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; Jonas J, 2011, J NEUROL NEUROSUR PS, V82, P928, DOI 10.1136/jnnp.2009.200329; JOOMA R, 1995, J NEUROSURG, V83, P231, DOI 10.3171/jns.1995.83.2.0231; Kalitzin S, 2005, CLIN NEUROPHYSIOL, V116, P718, DOI 10.1016/j.clinph.2004.08.021; Kanazawa O, 1996, EPILEPSIA, V37, P50, DOI 10.1111/j.1528-1157.1996.tb00511.x; Kane N, 2014, SEIZURE-EUR J EPILEP, V23, P129, DOI 10.1016/j.seizure.2013.10.010; Kaplan PW, 2007, EPILEPSIA, V48, P39, DOI 10.1111/j.1528-1167.2007.01345.x; Kaplan PW, 2013, NEUROLOGY, V80, pS43, DOI 10.1212/WNL.0b013e3182797528; Kasteleijn-Nolst Trenite D G, 1989, Acta Neurol Scand Suppl, V125, P3; KELLAWAY P, 1980, ANN NEUROL, V8, P491, DOI 10.1002/ana.410080506; Kellaway P, 1981, CURRENT CLIN NEUROPH, P151; Keranen T, 2002, SEIZURE-EUR J EPILEP, V11, P269, DOI 10.1053/seiz.2001.0608; Kerling F, 2006, EPILEPSY BEHAV, V9, P281, DOI 10.1016/j.yebeh.2006.05.010; Khan SF, 2005, CLIN NEUROPHYSIOL, V116, P2454, DOI 10.1016/j.clinph.2005.06.024; Kharbouch A, 2011, EPILEPSY BEHAV, V22, pS29, DOI 10.1016/j.yebeh.2011.08.031; Kim DW, 2004, EPILEPSIA, V45, P641, DOI 10.1111/j.0013-9580.2004.33703.x; Kim LG, 2006, LANCET NEUROL, V5, P317, DOI 10.1016/S1474-4422(06)70383-0; Kimiskidis VK, 2014, CURR OPIN NEUROL, V27, P236, DOI 10.1097/WCO.0000000000000071; King MA, 1998, LANCET, V352, P1007, DOI 10.1016/S0140-6736(98)03543-0; King-Stephens D, 2015, EPILEPSIA, V56, P959, DOI 10.1111/epi.13010; Kipervasser S, 2007, ACTA NEUROL SCAND, V116, P221, DOI 10.1111/j.1600-0404.2007.00888.x; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Knight WA, 2013, EPILEPSY RES, V106, P396, DOI 10.1016/j.eplepsyres.2013.06.018; Koepp MJ, 2016, LANCET NEUROL, V15, P92, DOI 10.1016/S1474-4422(15)00219-7; Koutroumanidis M, 2005, EPILEPSIA, V46, P96, DOI 10.1111/j.1528-1167.2005.00320.x; Koutroumanidis M, 1998, BRAIN, V121, P1409, DOI 10.1093/brain/121.8.1409; Koutroumanidis M, 2008, EPILEPSIA, V49, P2050, DOI 10.1111/j.1528-1167.2008.01702.x; Krauss GL, 2005, NEUROLOGY, V64, P1879, DOI 10.1212/01.WNL.0000163991.97456.03; Krumholz A, 2007, NEUROLOGY, V69, P1996, DOI 10.1212/01.wnl.0000285084.93652.43; Krumholz A, 2015, NEUROLOGY, V84, P1705, DOI 10.1212/WNL.0000000000001487; Kutluay E, 2001, EPILEPSIA, V42, P1563, DOI 10.1046/j.1528-1157.2001.16401.x; Kuzniecky R, 1997, ANN NEUROL, V42, P60, DOI 10.1002/ana.410420111; Kwan SY, 2005, SEIZURE-EUR J EPILEP, V14, P470, DOI 10.1016/j.seizure.2005.07.011; Langston ME, 2015, EPILEPSY RES, V109, P163, DOI 10.1016/j.eplepsyres.2014.10.018; Lascano AM, 2016, CLIN NEUROPHYSIOL, V127, P150, DOI 10.1016/j.clinph.2015.03.025; Leach JP, 2006, J NEUROL NEUROSUR PS, V77, P1040, DOI 10.1136/jnnp.2005.084871; Lee SK, 2005, EPILEPSIA, V46, P688, DOI 10.1111/j.1528-1167.2005.56604.x; Lee SK, 2000, EPILEPSIA, V41, P1450, DOI 10.1111/j.1528-1157.2000.tb00121.x; Legriel S, 2009, NEUROCRIT CARE, V11, P338, DOI 10.1007/s12028-009-9246-4; Leitinger M, 2015, EPILEPSY BEHAV, V49, P158, DOI 10.1016/j.yebeh.2015.05.007; Leitinger M, 2016, LANCET NEUROL, V15, P1054, DOI 10.1016/S1474-4422(16)30137-5; Liava A, 2012, EPILEPSY BEHAV, V25, P68, DOI 10.1016/j.yebeh.2012.05.008; Liporace J, 1998, EPILEPSY RES, V32, P357, DOI 10.1016/S0920-1211(98)00069-2; Losey TE, 2008, J CLIN NEUROPHYSIOL, V25, P357, DOI 10.1097/WNP.0b013e31818f008a; Lu HP, 2013, IEEE T BIO-MED ENG, V60, P461, DOI 10.1109/TBME.2012.2228649; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; Luders H, 1998, EPILEPSIA, V39, P1006, DOI 10.1111/j.1528-1157.1998.tb01452.x; Maliia MD, 2016, CLIN NEUROPHYSIOL, V127, P2127, DOI 10.1016/j.clinph.2015.12.021; Marson A, 2005, LANCET, V365, P2007, DOI 10.1016/S0140-6736(05)66694-9; McBride AE, 2002, EPILEPSIA, V43, P165, DOI 10.1046/j.1528-1157.2002.24401.x; McGonigal A, 2002, J NEUROL NEUROSUR PS, V72, P549; McGonigal A, 2007, BRAIN, V130, P3169, DOI 10.1093/brain/awm218; McKhann GM, 2000, J NEUROSURG, V93, P44, DOI 10.3171/jns.2000.93.1.0044; MEDICAL R, 1991, LANCET, V337, P1175; Meeren H, 2005, ARCH NEUROL-CHICAGO, V62, P371, DOI 10.1001/archneur.62.3.371; Megevand P, 2014, J NEUROL NEUROSUR PS, V85, P38, DOI 10.1136/jnnp-2013-305515; Meinardi H, 2001, EPILEPSIA, V42, P136, DOI 10.1046/j.1528-1157.2001.32800.x; Mendez OE, 2006, J CLIN NEUROPHYSIOL, V23, P282, DOI 10.1097/01.wnp.0000228514.40227.12; de la Prida LM, 2011, EPILEPSY RES, V97, P308, DOI 10.1016/j.eplepsyres.2011.02.009; Merricks EM, 2015, BRAIN, V138, P2891, DOI 10.1093/brain/awv208; Meyer ACL, 2012, EPILEPSIA, V53, P2178, DOI 10.1111/epi.12002; Michel CM, 2004, J CLIN NEUROPHYSIOL, V21, P71, DOI 10.1097/00004691-200403000-00001; MILEY CE, 1977, ARCH NEUROL-CHICAGO, V34, P371, DOI 10.1001/archneur.1977.00500180065014; Mintzer S, 2004, EPILEPSIA, V45, P792, DOI 10.1111/j.0013-9580.2004.35703.x; Miskin C, 2015, J CHILD NEUROL, V30, P1767, DOI 10.1177/0883073815579969; Monnerat BZ, 2013, SEIZURE-EUR J EPILEP, V22, P287, DOI 10.1016/j.seizure.2013.01.019; Mormann F, 2007, BRAIN, V130, P314, DOI 10.1093/brain/awl241; Murray CJ, 1994, GLOBAL COMP ASSESSME; Musicco M, 1997, NEUROLOGY, V49, P991, DOI 10.1212/WNL.49.4.991; MUSICCO M, 1993, NEUROLOGY, V43, P478; Narechania AP, 2013, EPILEPSY BEHAV, V28, P172, DOI 10.1016/j.yebeh.2013.04.017; National Institute for Health and Care Excellance, 2012, EP DIAGN MAN; Nei M, 1999, EPILEPSIA, V40, P157, DOI 10.1111/j.1528-1157.1999.tb02069.x; Newton CR, 2012, LANCET, V380, P1193, DOI 10.1016/S0140-6736(12)61381-6; Nguyen DK, 2006, ARCH NEUROL-CHICAGO, V63, P1321, DOI 10.1001/archneur.63.9.1321; Noe K, 2013, JAMA NEUROL, V70, P1003, DOI 10.1001/jamaneurol.2013.209; Nuwer MR, 1998, ELECTROEN CLIN NEURO, V106, P259, DOI 10.1016/S0013-4694(97)00106-5; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; OGUNI H, 1994, EPILEPSIA, V35, P307, DOI 10.1111/j.1528-1157.1994.tb02435.x; Olejniczak P, 2006, J CLIN NEUROPHYSIOL, V23, P186, DOI 10.1097/01.wnp.0000220079.61973.6c; Oostenveld R, 2001, CLIN NEUROPHYSIOL, V112, P713, DOI 10.1016/S1388-2457(00)00527-7; Oxford Centre for Evidence-Based Medicine, 2009, LEVELS EVIDENCE; PALMINI A, 1992, NEUROLOGY, V42, P801, DOI 10.1212/WNL.42.4.801; PALMINI A, 1995, ANN NEUROL, V37, P476, DOI 10.1002/ana.410370410; PANAYIOTOPOULOS CP, 1989, BRAIN, V112, P1039, DOI 10.1093/brain/112.4.1039; PANAYIOTOPOULOS CP, 1992, J NEUROL NEUROSUR PS, V55, P1002, DOI 10.1136/jnnp.55.11.1002; Parisi P, 2009, SEIZURE-EUR J EPILEP, V18, P309, DOI 10.1016/j.seizure.2009.01.010; Pataraia E, 1998, EPILEPSIA, V39, P608, DOI 10.1111/j.1528-1157.1998.tb01429.x; Pavlova MK, 2009, EPILEPSY BEHAV, V16, P461, DOI 10.1016/j.yebeh.2009.08.022; Paz JT, 2015, NAT NEUROSCI, V18, P351, DOI 10.1038/nn.3950; Pedersen GL, 2013, CLIN NEUROPHYSIOL, V124, P44, DOI 10.1016/j.clinph.2012.06.010; Pedley T. A., 1980, American Journal of EEG Technology, V20, P101; Pelliccia V, 2013, EPILEPTIC DISORD, V15, P392, DOI 10.1684/epd.2013.0615; Penfield W, 1954, EPILEPSY FUNCTIONAL; PENRY JK, 1975, BRAIN, V98, P427, DOI 10.1093/brain/98.3.427; Perucca E, 2014, EPILEPSIA, V55, P1326, DOI 10.1111/epi.12725; Perucca E, 2011, LANCET NEUROL, V10, P446, DOI 10.1016/S1474-4422(11)70047-3; Peters ACB, 1998, NEUROLOGY, V50, P724, DOI 10.1212/WNL.50.3.724; Petroff OA, 2016, CLIN NEUROPHYSIOL, V127, P1108, DOI 10.1016/j.clinph.2015.08.004; Pillai J, 2006, EPILEPSIA, V47, P14, DOI 10.1111/j.1528-1167.2006.00654.x; POLKEY CE, 1994, ACTA NEUROL SCAND, V89, P183, DOI 10.1111/j.1600-0404.1994.tb05218.x; Praline J, 2007, CLIN NEUROPHYSIOL, V118, P2149, DOI 10.1016/j.clinph.2007.07.003; PRATT KL, 1968, ELECTROEN CLIN NEURO, V24, P11, DOI 10.1016/0013-4694(68)90061-8; Qiu B, 2014, EPILEPTIC DISORD, V16, P175, DOI 10.1684/epd.2014.0662; QUIRK JA, 1995, ANN NEUROL, V37, P733, DOI 10.1002/ana.410370606; QUIRK JA, 1995, ELECTROEN CLIN NEURO, V95, P260, DOI 10.1016/0013-4694(95)00118-I; Rai V, 2013, SEIZURE-EUR J EPILEP, V22, P656, DOI 10.1016/j.seizure.2013.05.002; Ramantani G, 2014, EPILEPSIA, V55, P278, DOI 10.1111/epi.12512; Ramgopal S, 2014, EPILEPSY BEHAV, V37, P291, DOI 10.1016/j.yebeh.2014.06.023; Rassi-Neto A, 1999, EPILEPSIA, V40, P856, DOI 10.1111/j.1528-1157.1999.tb00791.x; Rathore C, 2011, NEUROLOGY, V76, P1925, DOI 10.1212/WNL.0b013e31821d74b3; Ray A, 2007, CLIN NEUROPHYSIOL, V118, P69, DOI 10.1016/j.clinph.2006.09.010; RICCI S, 1993, J CLIN NEUROPHYSIOL, V10, P197, DOI 10.1097/00004691-199304000-00007; Rikir E, 2014, EPILEPSIA, V55, P918, DOI 10.1111/epi.12591; RISINGER MW, 1989, NEUROLOGY, V39, P1288, DOI 10.1212/WNL.39.10.1288; Ristic AJ, 2012, EPILEPTIC DISORD, V14, P22, DOI 10.1684/epd.2012.0484; Rittenberger JC, 2012, NEUROCRIT CARE, V16, P114, DOI 10.1007/s12028-011-9565-0; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Rosenow F, 2001, BRAIN, V124, P1683, DOI 10.1093/brain/124.9.1683; Rossetti AO, 2007, NEUROLOGY, V69, P255, DOI 10.1212/01.wnl.0000265819.36639.e0; Roupakiotis SC, 2000, SEIZURE-EUR J EPILEP, V9, P580, DOI 10.1053/seiz.2000.0462; ROWAN AJ, 1982, ELECTROEN CLIN NEURO, V54, P357, DOI 10.1016/0013-4694(82)90199-7; Rubboli G, 2008, NEUROLOGY, V70, P1933, DOI 10.1212/01.wnl.0000289193.89796.83; Rubboli G, 1999, EPILEPSIA, V40, P50, DOI 10.1111/j.1528-1157.1999.tb00907.x; Ruiz AR, 2017, JAMA NEUROL, V74, P181, DOI 10.1001/jamaneurol.2016.4990; Saab ME, 2005, CLIN NEUROPHYSIOL, V116, P427, DOI 10.1016/j.clinph.2004.08.004; Sadleir LG, 2009, EPILEPSIA, V50, P1572, DOI 10.1111/j.1528-1167.2008.02001.x; SALANOVA V, 1995, BRAIN, V118, P607, DOI 10.1093/brain/118.3.607; SALANOVA V, 1992, BRAIN, V115, P1655, DOI 10.1093/brain/115.6.1655; SALANOVA V, 1995, BRAIN, V118, P1289, DOI 10.1093/brain/118.5.1289; SALEEM SM, 1994, ACTA NEUROL SCAND, V89, P5; SALINSKY M, 1987, EPILEPSIA, V28, P331, DOI 10.1111/j.1528-1157.1987.tb03652.x; Salomon JA, 2012, LANCET, V380, P2129, DOI 10.1016/S0140-6736(12)61680-8; Sam MC, 2001, EPILEPSIA, V42, P1273, DOI 10.1046/j.1528-1157.2001.17101.x; Fernandez IS, 2012, PEDIATR NEUROL, V47, P390, DOI 10.1016/j.pediatrneurol.2012.06.016; Sandsmark DK, 2016, J HEAD TRAUMA REHAB, V31, P101, DOI 10.1097/HTR.0000000000000217; SATO S, 1973, NEUROLOGY, V23, P1335, DOI 10.1212/WNL.23.12.1335; Sauro KM, 2016, EPILEPSIA, V57, P1754, DOI 10.1111/epi.13564; Sauro KM, 2014, EPILEPSY BEHAV, V33, P7, DOI 10.1016/j.yebeh.2014.01.021; Scheffer IE, 2017, EPILEPSIA, V58, P512, DOI 10.1111/epi.13709; Scherg M, 2012, EPILEPSIA, V53, P1196, DOI 10.1111/j.1528-1167.2012.03503.x; Schmidt D, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g254; Schmidt D, 2009, EPILEPSY BEHAV, V15, P56, DOI 10.1016/j.yebeh.2009.02.030; Schomer DL, 2006, J CLIN NEUROPHYSIOL, V23, P294, DOI 10.1097/01.wnp.0000228495.29014.82; Schramm J, 2001, J NEUROSURG, V94, P33, DOI 10.3171/jns.2001.94.1.0033; Schreiner A, 2003, CLIN ELECTROENCEPHAL, V34, P140, DOI 10.1177/155005940303400307; SCOLLOLAVIZZARI G, 1977, EUR NEUROL, V15, P121, DOI 10.1159/000114829; Seeck M, 2006, NEUROLOGY, V66, P592, DOI 10.1212/01.wnl.0000199254.67398.a7; Seneviratne U, 2017, J CLIN NEUROPHYSIOL, V34, P213, DOI 10.1097/WNP.0000000000000358; Seneviratne U, 2012, EPILEPSIA, V53, P234, DOI 10.1111/j.1528-1167.2011.03344.x; Serletis D, 2014, J NEUROSURG, V121, P1239, DOI 10.3171/2014.7.JNS132306; SHEWMON DA, 1989, J CLIN EXP NEUROPSYC, V11, P675, DOI 10.1080/01688638908400924; Shibasaki H, 2005, MUSCLE NERVE, V31, P157, DOI 10.1002/mus.20234; Shihabuddin B, 1999, CLIN NEUROPHYSIOL, V110, P1452, DOI 10.1016/S1388-2457(99)00081-4; Shinnar S, 2000, ANN NEUROL, V48, P140, DOI 10.1002/1531-8249(200008)48:2<140::AID-ANA2>3.3.CO;2-P; Shinnar S, 1996, PEDIATRICS, V98, P216; Shiraishi H, 2001, EPILEPSIA, V42, P393, DOI 10.1046/j.1528-1157.2001.05300.x; Sierra-Marcos A, 2011, EPILEPSY RES, V97, P30, DOI 10.1016/j.eplepsyres.2011.06.013; Sinha SR, 2016, J CLIN NEUROPHYSIOL, V33, P303, DOI 10.1097/WNP.0000000000000308; Sirin NG, 2013, J CLIN NEUROPHYSIOL, V30, P329, DOI 10.1097/WNP.0b013e31829d7482; Sirven JI, 1996, EPILEPSIA, V37, P450, DOI 10.1111/j.1528-1157.1996.tb00590.x; Smith SJM, 2005, J NEUROL NEUROSUR PS, V76, P8; SO N, 1989, ANN NEUROL, V25, P423, DOI 10.1002/ana.410250502; Sousa NAD, 2005, ARQ NEURO-PSIQUIAT, V63, P383, DOI 10.1590/S0004-282X2005000300003; SPENCER SS, 1985, NEUROLOGY, V35, P1567, DOI 10.1212/WNL.35.11.1567; St Louis Erik K, 2016, Continuum (Minneap Minn), V22, P15, DOI 10.1212/CON.0000000000000284; Staley K, 2015, NAT NEUROSCI, V18, P367, DOI 10.1038/nn.3947; Stefan H, 2008, CLIN NEUROPHYSIOL, V119, P642, DOI 10.1016/j.clinph.2007.11.046; Stefan H, 2011, SEIZURE-EUR J EPILEP, V20, P97, DOI 10.1016/j.seizure.2010.10.035; Steriade M, 2003, EPILEPSIA, V44, P9, DOI 10.1111/j.0013-9580.2003.12006.x; Stern JM, 2006, EPILEPSY BEHAV, V8, P683, DOI 10.1016/j.yebeh.2006.03.002; Stroink H, 2006, DEV MED CHILD NEUROL, V48, P374, DOI 10.1017/S0012162206000806; Stuve O, 2001, EPILEPSIA, V42, P778, DOI 10.1046/j.1528-1157.2001.40600.x; Stypulkowski PH, 2014, BRAIN STIMUL, V7, P350, DOI 10.1016/j.brs.2014.02.002; Stypulkowski PH, 2013, STEREOT FUNCT NEUROS, V91, P220, DOI 10.1159/000345493; Sugano H, 2007, SEIZURE-EUR J EPILEP, V16, P120, DOI 10.1016/j.seizure.2006.10.010; Sutter R, 2011, EPILEPSIA, V52, P453, DOI 10.1111/j.1528-1167.2010.02888.x; Swisher CB, 2015, J CLIN NEUROPHYSIOL, V32, P147, DOI 10.1097/WNP.0000000000000157; Takahashi T, 1999, EPILEPSIA, V40, P44, DOI 10.1111/j.1528-1157.1999.tb00906.x; Tao JX, 2007, EPILEPSIA, V48, P2167, DOI 10.1111/j.1528-1167.2007.01224.x; Tao JX, 2016, JAMA-J AM MED ASSOC, V316, P1590, DOI 10.1001/jama.2016.12047; Tao JX, 2005, EPILEPSIA, V46, P669, DOI 10.1111/j.1528-1167.2005.11404.x; Tassinari CA, 2000, CLIN NEUROPHYSIOL, V111, pS94, DOI 10.1016/S1388-2457(00)00408-9; Tassinari CA, 2008, EPILEPSY COMPREHENSI, P873; Tatum WO, 2008, SEIZURE-EUR J EPILEP, V17, P631, DOI 10.1016/j.seizure.2008.04.001; Tatum WO, 2016, J CLIN NEUROPHYSIOL, V33, P328, DOI 10.1097/WNP.0000000000000319; Tatum WO, 2013, NEUROLOGY, V80, pS1, DOI 10.1212/WNL.0b013e318279730e; Tatum WO, 2013, NEUROLOGY, V80, pS12, DOI 10.1212/WNL.0b013e3182797325; Tatum WO, 2012, J CLIN NEUROPHYSIOL, V29, P356, DOI 10.1097/WNP.0b013e31826b3ab7; Tatum WO, 2011, J CLIN NEUROPHYSIOL, V28, P252, DOI 10.1097/WNP.0b013e31821c3c93; Tatum WO, 2001, J CLIN NEUROPHYSIOL, V18, P14, DOI 10.1097/00004691-200101000-00004; Tinuper P, 2004, EPILEPTIC DISORD, V6, P27; Tinuper P, 2001, BRAIN, V124, P2361, DOI 10.1093/brain/124.12.2361; Tinuper P, 1996, NEUROLOGY, V47, P76, DOI 10.1212/WNL.47.1.76; Tonini C, 2004, EPILEPSY RES, V62, P75, DOI 10.1016/j.eplepsyres.2004.08.006; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; TRAN TA, 1995, ANN NEUROL, V38, P763, DOI 10.1002/ana.410380511; TRENITE DGAK, 1987, J NEUROL NEUROSUR PS, V50, P1546, DOI 10.1136/jnnp.50.11.1546; Trenite DGAKN, 2001, EPILEPSIA, V42, P692, DOI 10.1046/j.1528-1157.2001.30600.x; Trenite DKN, 2012, EPILEPSIA, V53, P16, DOI 10.1111/j.1528-1167.2011.03319.x; Trinka E, 2015, EPILEPSIA, V56, P1515, DOI 10.1111/epi.13121; Tripathi M, 2010, EPILEPSY RES, V89, P133, DOI 10.1016/j.eplepsyres.2009.12.007; Tsuchida TN, 2016, J CLIN NEUROPHYSIOL, V33, P301, DOI 10.1097/WNP.0000000000000315; TUUNAINEN A, 1994, EPILEPSIA, V35, P1165, DOI 10.1111/j.1528-1157.1994.tb01784.x; UGAWA Y, 1989, J NEUROL NEUROSUR PS, V52, P89, DOI 10.1136/jnnp.52.1.89; Unterberger I, 2001, EPILEPSY RES, V44, P19, DOI 10.1016/S0920-1211(00)00210-2; Usui N, 2005, EPILEPSIA, V46, P1668, DOI 10.1111/j.1528-1167.2005.00262.x; Usui N, 2008, EPILEPTIC DISORD, V10, P260, DOI 10.1684/epd.2008.0223; Usui N, 2008, EPILEPSIA, V49, P1998, DOI 10.1111/j.1528-1167.2008.01697.x; Vadlamudi L, 2004, EPILEPTIC DISORD, V6, P89; van 't Klooster MA, 2015, NEUROLOGY, V85, P120, DOI 10.1212/WNL.0000000000001727; VANDONSELAAR CA, 1992, ARCH NEUROL-CHICAGO, V49, P231, DOI 10.1001/archneur.1992.00530270045017; Varelas PN, 2004, CLIN EEG NEUROSCI, V35, P173, DOI 10.1177/155005940403500406; Vaughn BV, 2004, SEMIN NEUROL, V24, P301, DOI 10.1055/s-2004-835068; VELDHUIZEN R, 1983, ELECTROEN CLIN NEURO, V55, P505, DOI 10.1016/0013-4694(83)90161-X; Velis D, 2007, EPILEPSIA, V48, P379, DOI 10.1111/j.1528-1167.2007.00920.x; Verma A, 2006, J CLIN NEUROPHYSIOL, V23, P333, DOI 10.1097/01.wnp.0000228497.89734.7a; Verrotti A, 2000, NEUROPHYSIOL CLIN, V30, P240, DOI 10.1016/S0987-7053(00)00221-5; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Viravan S, 2011, EPILEPSIA, V52, P1273, DOI 10.1111/j.1528-1167.2011.03068.x; WALCZAK TS, 1991, J EPILEPSY, V4, P25, DOI 10.1016/0896-6974(91)90118-3; Walczak TS, 1993, NEUROLOGY, V27, P330; Walker MC, 2015, SEMIN NEUROL, V35, P193, DOI 10.1055/s-0035-1552618; Waltz S, 2000, NEUROPEDIATRICS, V31, P82, DOI 10.1055/s-2000-7478; Wassmer E, 2001, DEV MED CHILD NEUROL, V43, P735, DOI 10.1017/S0012162201001347; Wennberg R, 1998, ELECTROEN CLIN NEURO, V106, P357, DOI 10.1016/S0013-4694(97)00148-X; Wennberg RA, 1998, ELECTROEN CLIN NEURO, P105; Werhahn KJ, 2015, SEIZURE-EUR J EPILEP, V29, P20, DOI 10.1016/j.seizure.2015.03.012; Westmoreland BF, 1998, EPILEPSIA, V39, pS1, DOI 10.1111/j.1528-1157.1998.tb05121.x; Westover MB, 2015, CLIN NEUROPHYSIOL, V126, P463, DOI 10.1016/j.clinph.2014.05.037; Whitehead K, 2016, CLIN NEUROPHYSIOL, V127, P1774, DOI 10.1016/j.clinph.2015.11.050; Wiebe S, 2001, NEW ENGL J MED, V345, P311, DOI 10.1056/NEJM200108023450501; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; WILLIAMSON PD, 1993, ANN NEUROL, V34, P781, DOI 10.1002/ana.410340605; WILLIAMSON PD, 1992, ANN NEUROL, V31, P193, DOI 10.1002/ana.410310210; WILLIAMSON PD, 1992, ANN NEUROL, V31, P3, DOI 10.1002/ana.410310103; WOLF P, 1986, J NEUROL NEUROSUR PS, V49, P1386, DOI 10.1136/jnnp.49.12.1386; Woods RJ, 2006, EPILEPSY BEHAV, V9, P360, DOI 10.1016/j.yebeh.2006.06.015; Worrell GA, 2004, BRAIN, V127, P1496, DOI 10.1093/brain/awh149; Worrell GA, 2002, EPILEPSIA, V43, P277, DOI 10.1046/j.1528-1157.2002.37501.x; Wu JY, 2010, NEUROLOGY, V75, P1686, DOI 10.1212/WNL.0b013e3181fc27d0; WYLLIE E, 1987, NEUROLOGY, V37, P1634, DOI 10.1212/WNL.37.10.1634; Yamada K, 2014, SEIZURE-EUR J EPILEP, V23, P703, DOI 10.1016/j.seizure.2014.05.010; Yoshimura H, 2016, J NEUROL SCI, V370, P284, DOI 10.1016/j.jns.2016.09.062; Young GB, 2005, NEUROCRIT CARE, V2, P5, DOI 10.1385/NCC:2:1:005; Young GB, 1999, J CLIN NEUROPHYSIOL, V16, P40, DOI 10.1097/00004691-199901000-00003; Zakaria T, 2012, ISRN NEUROL; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; Zeman A, 2010, CURR OPIN NEUROL, V23, P610, DOI 10.1097/WCO.0b013e32834027db; Zijlmans M, 2007, BRAIN, V130, P2343, DOI 10.1093/brain/awm141; Zijlmans M, 2012, ANN NEUROL, V71, P169, DOI 10.1002/ana.22548	443	56	59	0	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAY	2018	129	5					1056	1082		10.1016/j.clinph.2018.01.019			27	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GB3GY	WOS:000428945500027	29483017	Bronze			2021-06-18	
J	Chen, XR; Chen, CN; Fan, SN; Wu, SK; Yang, FX; Fang, ZN; Fu, HD; Li, YS				Chen, Xiangrong; Chen, Chunnuan; Fan, Sining; Wu, Shukai; Yang, Fuxing; Fang, Zhongning; Fu, Huangde; Li, Yasong			Omega-3 polyunsaturated fatty acid attenuates the inflammatory response by modulating microglia polarization through SIRT1-mediated deacetylation of the HMGB1/NF-kappa B pathway following experimental traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury; Omega-3 polyunsaturated fatty acid; Microglia polarization; Neuroinflammation; Sirtuin1; HMGB1/NF-kappa B pathway	WHITE-MATTER INJURY; NEUROLOGICAL DEFICITS; RECEPTOR 4; HMGB1; CELLS; ACTIVATION; RATS; INHIBITION; DISEASE; STRESS	Background: Microglial polarization and the subsequent neuroinflammatory response are contributing factors for traumatic brain injury (TBI)-induced secondary injury. High mobile group box 1 (HMGB1) mediates the activation of the NF-kappa B pathway, and it is considered to be pivotal in the late neuroinflammatory response. Activation of the HMGB1/NF-kappa B pathway is closely related to HMGB1 acetylation, which is regulated by the sirtuin (SIRT) family of proteins. Omega-3 polyunsaturated fatty acids (omega-3 PUFA) are known to have antioxidative and anti-inflammatory effects. We previously demonstrated that omega-3 PUFA inhibited TBI-induced microglial activation and the subsequent neuroinflammatory response by regulating the HMGB1/NF-kappa B signaling pathway. However, no studies have elucidated if omega-3 PUFA affects the HMGB1/NF-kappa B pathway in a HMGB1 deacetylation of dependent SIRT1 manner, thus regulating microglial polarization and the subsequent neuroinflammatory response. Methods: The Feeney DM TBI model was adopted to induce brain injury in rats. Modified neurological severity scores, rotarod test, brain water content, and Nissl staining were employed to determine the neuroprotective effects of omega-3 PUFA supplementation. Assessment of microglia polarization and pro-inflammatory markers, such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, IL-6, and HMGB1, were used to evaluate the neuroinflammatory responses and the anti-inflammatory effects of omega-3 PUFA supplementation. Immunofluorescent staining and western blot analysis were used to detect HMGB1 nuclear translocation, secretion, and HMGB1/NF-kappa B signaling pathway activation to evaluate the effects of omega-3 PUFA supplementation. The impact of SIRT1 deacetylase activity on HMGB1 acetylation and the interaction between HMGB1 and SIRT1 were assessed to evaluate anti-inflammation effects of omega-3 PUFAs, and also, whether these effects were dependent on a SIRT1-HMGB1/NF-kappa B axis to gain further insight into the mechanisms underlying the development of the neuroinflammatory response after TBI. Results: The results of our study showed that omega-3 PUFA supplementation promoted a shift from the M1 microglial phenotype to the M2 microglial phenotype and inhibited microglial activation, thus reducing TBI-induced inflammatory factors. In addition,omega-3 PUFA-mediated downregulation of HMGB1 acetylation and its extracellular secretion was found to be likely due to increased SIRT1 activity. We also found that treatment with omega-3 PUFA inhibited HMGB1 acetylation and induced direct interactions between SIRT1 and HMGB1 by elevating SIRT1 activity following TBI. These events lead to inhibition of HMGB1 nucleocytoplasmic translocation/extracellular secretion and alleviated HMGB1-mediated activation of the NF-kappa B pathway following TBI-induced microglial activation, thus inhibiting the subsequent inflammatory response. Conclusions: The results of this study suggest that omega-3 PUFA supplementation attenuates the inflammatory response by modulating microglial polarization through SIRT1-mediated deacetylation of the HMGB1/NF-kappa B pathway, leading to neuroprotective effects following experimental traumatic brain injury.	[Fu, Huangde] YouJiang Med Univ Nationalities, Dept Neurosurg, Affiliated Hosp, Baise 533000, Guangxi Provinc, Peoples R China; [Chen, Xiangrong; Chen, Chunnuan; Fan, Sining; Wu, Shukai; Yang, Fuxing; Fang, Zhongning; Li, Yasong] Fujian Med Univ, Affiliated Hosp 2, Clin Med Coll 2, Quanzhou 362000, Fujian, Peoples R China	Fu, HD (corresponding author), YouJiang Med Univ Nationalities, Dept Neurosurg, Affiliated Hosp, Baise 533000, Guangxi Provinc, Peoples R China.; Li, YS (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Clin Med Coll 2, Quanzhou 362000, Fujian, Peoples R China.	303880058@qq.com; 303880058@qq.com	zhang, chuengji/AAD-4591-2020		funds for Fujian Province Scientific Foundation [2015J01443]; Fujian Province Hygiene Innovation Foundation [2015-CXB-20]	This work was supported by grants from the funds for Fujian Province Scientific Foundation (no. 2015J01443) and Fujian Province Hygiene Innovation Foundation (no. 2015-CXB-20) from Dr. Xiangrong Chen.	Aryanpour R, 2017, INT IMMUNOPHARMACOL, V51, P131, DOI 10.1016/j.intimp.2017.08.007; Bai Y, 2017, EXP BIOL MED, V242, P527, DOI 10.1177/1535370216685433; Braun M, 2017, BBA-MOL BASIS DIS, V1863, P2614, DOI 10.1016/j.bbadis.2017.05.020; Cai YL, 2016, MOL NEUROBIOL, V53, P2815, DOI 10.1007/s12035-015-9158-6; Chang CY, 2013, J NUTR BIOCHEM, V24, P2127, DOI 10.1016/j.jnutbio.2013.08.004; Chen XR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0917-3; Chi JH, 2017, EUR J PHARMACOL, V796, P101, DOI 10.1016/j.ejphar.2016.12.026; Delattre AM, 2017, MOL NEUROBIOL, V54, P2090, DOI 10.1007/s12035-016-9803-8; Ding JY, 2017, J CELL MOL MED, V21, P1046, DOI 10.1111/jcmm.13048; Fang P, 2012, MOL NEUROBIOL, V45, P499, DOI 10.1007/s12035-012-8264-y; Foglio E, 2017, J CELL PHYSIOL, V232, P1135, DOI 10.1002/jcp.25576; Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6; Garmpis N, 2017, ANTICANCER RES, V37, P5355, DOI 10.21873/anticanres.11961; Godoy JA, 2014, MOL NEUROBIOL, V50, P744, DOI 10.1007/s12035-014-8645-5; Hamblin MR, 2018, J NEUROSCI RES, V96, P731, DOI 10.1002/jnr.24190; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Hopp S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0815-8; Kang KA, 2016, ONCOTARGET, V7, P40594, DOI 10.18632/oncotarget.9745; Kim YM, 2016, INT IMMUNOPHARMACOL, V41, P98, DOI 10.1016/j.intimp.2016.11.002; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kurtys E, 2016, NEUROCHEM INT, V99, P206, DOI 10.1016/j.neuint.2016.07.008; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lan KC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12285-8; Leus NGJ, 2016, CURR OPIN CHEM BIOL, V33, P160, DOI 10.1016/j.cbpa.2016.06.019; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Ma YB, 2017, MOL NEUROBIOL, V54, P3717, DOI 10.1007/s12035-016-9939-6; Ma YX, 2015, CURR MED CHEM, V22, P1239, DOI 10.2174/0929867322666150209154420; Parker TM, 2017, BRAIN INJURY, V31, P2, DOI 10.1080/02699052.2016.1217045; Polito F, 2016, INT J IMMUNOPATH PH, V29, P504, DOI 10.1177/0394632016656187; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Qiu YY, 2016, CELL BIOL INT, V40, P1152, DOI 10.1002/cbin.10616; Schuliga M, 2015, BIOMOLECULES, V5, P1266, DOI 10.3390/biom5031266; Serini S, 2016, CURR ALZHEIMER RES, V13, P123, DOI 10.2174/1567205012666150921101147; Takizawa T, 2017, J CEREBR BLOOD F MET, V37, P890, DOI 10.1177/0271678X16647398; Villalba JM, 2012, BIOFACTORS, V38, P349, DOI 10.1002/biof.1032; Wang B, 2016, WORLD J GASTROENTERO, V22, P9784, DOI 10.3748/wjg.v22.i44.9784; Wang DL, 2017, SCI REP-UK, V7, DOI 10.1038/srep46243; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Wang TJ, 2017, FISH SHELLFISH IMMUN, V71, P76, DOI 10.1016/j.fsi.2017.09.064; Wang TH, 2017, MOL NEUROBIOL, V54, P7746, DOI 10.1007/s12035-016-0259-7; Xie XQ, 2017, MOL NEUROBIOL, V54, P7251, DOI 10.1007/s12035-016-0173-z; Xu HZ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/5405104; Yang XY, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00131; Yao XL, 2017, J NEUROIMMUNOL, V310, P38, DOI 10.1016/j.jneuroim.2017.06.006; Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292; Zou JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087915	47	56	62	5	21	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 20	2018	15								116	10.1186/s12974-018-1151-3			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	GE1JK	WOS:000430972400002	29678169	DOAJ Gold, Green Published			2021-06-18	
J	Wright, DK; O'Brien, TJ; Shultz, SR; Mychasiuk, R				Wright, David K.; O'Brien, Terence J.; Shultz, Sandy R.; Mychasiuk, Richelle			Sex matters: repetitive mild traumatic brain injury in adolescent rats	ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY			English	Article							MYELIN BASIC-PROTEIN; HYPERPHOSPHORYLATED TAU; PROFESSIONAL FOOTBALL; CONCUSSION SYMPTOMS; EXECUTIVE FUNCTION; CORPUS-CALLOSUM; SODIUM SELENATE; WHITE-MATTER; ANIMAL-MODEL; NEUROINFLAMMATION	Objective: Whether sex differences contribute to the heterogeneity of mild traumatic brain injury (mTBI) and repeated mTBI (RmTBI) outcomes in adolescents is unknown. Therefore, this study examined changes in, and differences between, male and female rats following single mTBI and RmTBI. Methods: Rats were given a single mTBI, RmTBI (i.e., 3x), or sham injuries. Injuries were administered using a lateral impact model that mimics forces common in human mTBI. After the final injury, rats underwent extensive behavioral testing to examine cognition, motor function, and anxiety- and depressive-like behavior. Postmortem analyses investigated gene expression and structural changes in the brain. Results: Many of the outcomes exhibited a sex-dependent response to RmTBI. While all rats given RmTBI had deficits in balance, motor coordination, locomotion, and anxiety- like behavior, only male rats given RmTBI had short-term working memory deficits, whereas only females given RmTBI had increased depressive-like behavior. Volumetric and diffusion weighted MRI analyses found that while RmTBI-induced atrophy of the prefrontal cortex was greater in female rats, only the male rats exhibited worse white matter integrity in the corpus callosum following RmTBI. Sex-dependent changes in brain expression of mRNA for glial fibrillary acidic protein, myelin basic protein, and tau protein were also observed following injury. Interpretation: These findings suggest that in adolescent mTBI, sex matters; and future studies incorporating both male and females are warranted to provide a greater understanding of injury prognosis and better inform clinical practice.	[Wright, David K.] Univ Melbourne, Anat & Neurosci, Parkville, Vic 3010, Australia; [Wright, David K.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3052, Australia; [O'Brien, Terence J.; Shultz, Sandy R.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; [Mychasiuk, Richelle] Univ Calgary, Alberta Childrens Hosp Res Inst, Dept Psychol, Calgary, AB, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Dept Psychol, Alberta Childrens Hosp Res Inst, Hotchkiss Brain Inst, 3330 Hosp Dr NW, Calgary, AB, Canada.	rmmychas@ucalgary.ca		O'Brien, Terence/0000-0002-7198-8621; Wright, David/0000-0002-7535-8651	Alberta Children's Hospital Research Foundation; Integrated Concussion Research Program; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	The authors thank the Alberta Children's Hospital Research Foundation, the Integrated Concussion Research Program and the National Health and Medical Research Council for funding. We acknowledge the animal MRI facility at the Florey Institute of Neuroscience and Mental Health, a node of the National Imaging Facility.	Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Casey BJ, 2000, BIOL PSYCHOL, V54, P241, DOI 10.1016/S0301-0511(00)00058-2; Chamard E, 2016, J NEUROTRAUM, V33, P1220, DOI 10.1089/neu.2015.3948; Chisholm NC, 2016, NEUROBIOL DIS, V85, P245, DOI 10.1016/j.nbd.2015.03.028; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cordeau P, 2008, STROKE, V39, P935, DOI 10.1161/STROKEAHA.107.501460; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; Elder GA, 1999, J CELL BIOL, V146, P181; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gabbita SP, 2005, J NEUROTRAUM, V22, P83, DOI 10.1089/neu.2005.22.83; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Gerbeding J, 2003, C MILD TRAUM BRAIN I; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gur RC, 1999, J NEUROSCI, V19, P4065; Gyengesi E, 2014, BRAIN STRUCT FUNCT, V219, P539, DOI 10.1007/s00429-013-0516-8; Hehar H, 2016, NEUROBIOL DIS, V87, P11, DOI 10.1016/j.nbd.2015.12.007; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Kamphuis W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042823; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Kooy RF, 2001, EUR J HUM GENET, V9, P153, DOI 10.1038/sj.ejhg.5200606; Lenroot RK, 2006, NEUROSCI BIOBEHAV R, V30, P718, DOI 10.1016/j.neubiorev.2006.06.001; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Mayer C, 2010, P NATL ACAD SCI USA, V107, P22693, DOI 10.1073/pnas.1012406108; McCarthy MM, 2009, J NEUROSCI, V29, P12815, DOI 10.1523/JNEUROSCI.3331-09.2009; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28203; Mychasiuk R, 2014, BEHAV BRAIN RES, V259, P284, DOI 10.1016/j.bbr.2013.10.048; Mychasiuk R, 2016, NEUROSCI BIOBEHAV R, V70, P189, DOI 10.1016/j.neubiorev.2016.07.013; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Neselius S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081249; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Romeo RD, 2002, NEUROSCI BIOBEHAV R, V26, P381, DOI 10.1016/S0149-7634(02)00009-X; Rose SC, 2015, PEDIATR NEUROL, V53, P108, DOI 10.1016/j.pediatrneurol.2015.04.003; Rowe RK, 2016, DEV NEUROSCI-BASEL, V38, P195, DOI 10.1159/000446773; Russell KL, 2011, J NEUROSCI METH, V199, P214, DOI 10.1016/j.jneumeth.2011.05.008; Rzeczkowska PA, 2014, NEUROENDOCRINOLOGY, V99, P139, DOI 10.1159/000362559; Semple BD, 2017, BEHAV BRAIN RES, V319, P48, DOI 10.1016/j.bbr.2016.10.045; Semple BD, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00069; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sharma P, 2017, NEUROBIOL DIS, V104, P33, DOI 10.1016/j.nbd.2017.04.022; Shultz SR, 2017, NEUROSCI BIOBEHAV R, V76, P396, DOI 10.1016/j.neubiorev.2016.09.014; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Tan XL, 2016, NEUROPHARMACOLOGY, V108, P382, DOI 10.1016/j.neuropharm.2016.05.001; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Villapol S, 2017, GLIA, V65, P1423, DOI 10.1002/glia.23171; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wright D, 2017, J NEUROTRAUM, DOI DOI 10.1089/neu.2017.5204; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Wright DK, 2016, SCI REP-UK, V6, DOI 10.1038/srep28713; Wu QZ, 2008, J MAGN RESON IMAGING, V27, P446, DOI 10.1002/jmri.21111; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	74	56	56	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2328-9503			ANN CLIN TRANSL NEUR	Ann. Clin. Transl. Neurol.	SEP	2017	4	9					640	654		10.1002/acn3.441			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FG2IX	WOS:000409921800004	28904986	DOAJ Gold, Green Published			2021-06-18	
J	Spaite, DW; Hu, CC; Bobrow, BJ; Chikani, V; Sherrill, D; Barnhart, B; Gaither, JB; Denninghoff, KR; Viscusi, C; Mullins, T; Adelson, PD				Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Sherrill, Duane; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Viscusi, Chad; Mullins, Terry; Adelson, P. David			Mortality and Prehospital Blood Pressure in Patients With Major Traumatic Brain Injury Implications for the Hypotension Threshold	JAMA SURGERY			English	Article							SEVERE HEAD-INJURY; SEVERITY SCORE TRISS; INTERNATIONAL CLASSIFICATION; REDEFINING HYPOTENSION; PROGNOSTIC VALUE; 110 MMHG; INSULTS; HYPOXIA; PREDICTORS; MANAGEMENT	IMPORTANCE Current prehospital traumatic brain injury guidelines use a systolic blood pressure threshold of less than 90 mm Hg for treating hypotension for individuals 10 years and older based on studies showing higher mortality when blood pressure drops below this level. However, the guidelines also acknowledge the weakness of the supporting evidence. OBJECTIVE To evaluate whether any statistically supportable threshold between systolic pressure and mortality emerges from the data a priori, without assuming that a cut point exists. DESIGN, SETTING, AND PARTICIPANTS Observational evaluation of a large prehospital database established as a part of the Excellence in Prehospital Injury Care Traumatic Brain Injury Study. Patients from the preimplementation cohort (January 2007 to March 2014) 10 years and older with moderate or severe traumatic brain injury (Barell Matrix Type 1 classification, International Classification of Diseases, Ninth Revision head region severity score of 3 or greater, and/or Abbreviated Injury Scale head-region severity score of 3 or greater) and a prehospital systolic pressure between 40 and 119 mm Hg were included. The generalized additive model and logistic regression were used to determine the association between systolic pressure and probability of death, adjusting for significant/important confounders. MAIN OUTCOMES AND MEASURES The main outcome measure was in-hospital mortality. RESULTS Among the 3844 included patients, 2565 (66.7%) were male, and the median (range) age was 35 (10-99) years. The model revealed a monotonically decreasing association between systolic pressure and adjusted probability of death across the entire range (ie, from 40 to 119 mm Hg). Each 10-point increase of systolic pressure was associated with a decrease in the adjusted odds of death of 18.8% (adjusted odds ratio, 0.812; 95% CI, 0.748-0.883). Thus, the adjusted odds of mortality increased as much for a drop from 110 to 100 mm Hg as for a drop from 90 to 80 mm Hg, and so on throughout the range. CONCLUSIONS AND RELEVANCE We found a linear association between lowest prehospital systolic blood pressure and severity-adjusted probability of mortality across an exceptionally wide range. There is no identifiable threshold or inflection point between 40 and 119 mm Hg. Thus, in patients with traumatic brain injury, the concept that 90 mm Hg represents a unique or important physiological cut point may be wrong. Furthermore, clinically meaningful hypotension may not be as low as current guidelines suggest. Randomized trials evaluating treatment levels significantly above 90 mm Hg are needed.	[Spaite, Daniel W.; Bobrow, Bentley J.; Gaither, Joshua B.; Denninghoff, Kurt R.; Viscusi, Chad] Univ Arizona, Coll Med, Dept Emergency Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA; [Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Viscusi, Chad] Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ USA; [Hu, Chengcheng; Sherrill, Duane] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA; [Bobrow, Bentley J.; Chikani, Vatsal; Mullins, Terry] Arizona Dept Hlth Serv, Bur Emergency Med Serv, Phoenix, AZ 85007 USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ USA; [Adelson, P. David] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA	Spaite, DW (corresponding author), Univ Arizona, Coll Med, Dept Emergency Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	Dan@aemrc.arizona.edu	Adelson, David/W-2083-2019	Chikani, Vatsal/0000-0003-0904-7887	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049] Funding Source: NIH RePORTER	Research reported in this article was supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award R01NS071049.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bell JM, 2014, REPORT C TRAUMATIC B; Bernard SA, 2010, ANN SURG, V252, P959, DOI 10.1097/SLA.0b013e3181efc15f; Berry C, 2012, INJURY, V43, P1833, DOI 10.1016/j.injury.2011.08.014; Bruns B, 2008, J TRAUMA, V65, P1217, DOI 10.1097/TA.0b013e318184ee63; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Edelman DA, 2007, SHOCK, V27, P134, DOI 10.1097/01.shk.0000239772.18151.18; Edwards M, 2010, AM SURGEON, V76, P1035; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENTLEMAN D, 1992, INT SURG, V77, P297; Glance LG, 2009, ANN SURG, V249, P1032, DOI 10.1097/SLA.0b013e3181a38f28; GRAHAM DI, 1971, LANCET, V1, P265; Hannan EL, 1999, J TRAUMA, V47, P8, DOI 10.1097/00005373-199907000-00003; Hasler RM, 2012, RESUSCITATION, V83, P476, DOI 10.1016/j.resuscitation.2011.10.018; Hasler RM, 2011, RESUSCITATION, V82, P1202, DOI 10.1016/j.resuscitation.2011.04.021; HILL DA, 1993, AUST NZ J SURG, V63, P604, DOI 10.1111/j.1445-2197.1993.tb00466.x; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MacKenzie EJ, 1983, AM ASS AUTO MED QJ, V5, P25; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Osler TM, 1997, J TRAUMA, V43, P253, DOI 10.1097/00005373-199708000-00008; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; Rutledge R, 1997, J TRAUMA, V42, P477, DOI 10.1097/00005373-199703000-00016; Rutledge R, 1998, J TRAUMA, V44, P41, DOI 10.1097/00005373-199801000-00003; Seifert J., 2007, J EPIDEMIOL COMMUNIT, V61, P926, DOI DOI 10.1136/JECH.2007.059717; Shutter LA, 2008, ANN EMERG MED, V51, pS37, DOI 10.1016/j.annemergmed.2007.11.013; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Spaite DW, 2014, ACAD EMERG MED, V21, P818, DOI 10.1111/acem.12411; Spaite DW, 1993, PREHOSP DISASTER MED, V8, pS35; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Wood S., 2017, GEN ADDITIVE MODELS, V2nd ed.; Wood SN, 2013, BIOMETRIKA, V100, P221, DOI 10.1093/biomet/ass048; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x	57	56	57	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	APR	2017	152	4					360	368		10.1001/jamasurg.2016.4686			9	Surgery	Surgery	ES7WP	WOS:000399762400015	27926759	Green Accepted			2021-06-18	
J	Henderson, FC; Austin, C; Benzel, E; Bolognese, P; Ellenbogen, R; Francomano, CA; Ireton, C; Klinge, P; Koby, M; Long, DL; Patel, S; Singman, EL; Voermans, NC				Henderson, Fraser C., Sr.; Austin, Claudiu; Benzel, Edward; Bolognese, Paolo; Ellenbogen, Richard; Francomano, Clair A.; Ireton, Candace; Klinge, Petra; Koby, Myles; Long, Donlin; Patel, Sunil; Singman, Eric L.; Voermans, Nicol C.			Neurological and Spinal Manifestations of the Ehlers-Danlos Syndromes	AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS			English	Article						Ehlers-Danlos syndrome; headache; craniocervical instability; atlantoaxial instability; tethered cord syndrome	MALFORMATION TYPE-I; JOINT HYPERMOBILITY SYNDROME; TETHERED CORD SYNDROME; IDIOPATHIC INTRACRANIAL HYPERTENSION; PSYCHOGENIC MOVEMENT-DISORDERS; TRAUMATIC AXONAL INJURY; UPPER CERVICAL-SPINE; CRANIOVERTEBRAL JUNCTION; BRAIN-STEM; CONSERVATIVE TREATMENT	The Ehlers-Danlos syndromes (EDS) are a heterogeneous group of heritable connective tissue disorders characterized by joint hypermobility, skin extensibility, and tissue fragility. This communication briefly reports upon the neurological manifestations that arise including the weakness of the ligaments of the craniocervical junction and spine, early disc degeneration, and the weakness of the epineurium and perineurium surrounding peripheral nerves. Entrapment, deformation, and biophysical deformative stresses exerted upon the nervous system may alter gene expression, neuronal function and phenotypic expression. This report also discusses increased prevalence of migraine, idiopathic intracranial hypertension, Tarlov cysts, tethered cord syndrome, and dystonia, where associations with EDS have been anecdotally reported, but where epidemiological evidence is not yet available. Chiari Malformation Type I (CMI) has been reported to be a comorbid condition to EDS, and may be complicated by craniocervical instability or basilar invagination. Motor delay, headache, and quadriparesis have been attributed to ligamentous laxity and instability at the atlanto-occipital and atlantoaxial joints, which may complicate all forms of EDS. Discopathy and early degenerative spondylotic disease manifest by spinal segmental instability and kyphosis, rendering EDS patients prone to mechanical pain, and myelopathy. Musculoskeletal pain starts early, is chronic and debilitating, and the neuromuscular disease of EDS manifests symptomatically with weakness, myalgia, easy fatigability, limited walking, reduction of vibration sense, and mild impairment of mobility and daily activities. Consensus criteria and clinical practice guidelines, based upon stronger epidemiological and pathophysiological evidence, are needed to refine diagnosis and treatment of the various neurological and spinal manifestations of EDS. (C) 2017 Wiley Periodicals, Inc.	[Henderson, Fraser C., Sr.] Natl Hosp Neurol & Neurosurg, Disorders Craniocerv Junct, Queens Sq London, London, England; [Henderson, Fraser C., Sr.] Georgetown Univ, Neurosurg Spine & Craniocerv Junct, Washington, DC 20057 USA; [Henderson, Fraser C., Sr.] Ehlers Danlos Soc, Execut Board, Mclean, VA USA; [Henderson, Fraser C., Sr.] Chiari Syringomyelia Fdn, Execut Board, Staten Isl, NY USA; [Henderson, Fraser C., Sr.] ILC, Execut Board, Toronto, ON, Canada; [Henderson, Fraser C., Sr.] TCAPP Fdn, Execut Board, Chicago, IL USA; [Koby, Myles] NIH, Bldg 10, Bethesda, MD 20892 USA; [Austin, Claudiu; Koby, Myles] Doctors Community Hosp, Lanham, MD USA; [Francomano, Clair A.] Harvey Inst Human Genet, Adult Genet, London, England; [Francomano, Clair A.] Harvey Inst Human Genet, Ehlers Danlos Soc, Ctr Clin Care & Res, London, England; [Francomano, Clair A.] Johns Hopkins Univ, Sch Med, Med, Baltimore, MD USA; [Francomano, Clair A.] Ehlers Danlos Soc, Execut Board, Mclean, VA USA; [Francomano, Clair A.] Ehlers Danlos Soc, Med & Sci Board, Mclean, VA USA; [Bolognese, Paolo] North Shore Univ Hosp, Manhasset, NY USA; [Ellenbogen, Richard] Dept Neurol Adult Brain Tumors Trauma Surg Cranio, Mclean, VA USA; [Ireton, Candace] Grp Visit Program Primary Care EDS Patients, Asheville, NC USA; [Klinge, Petra] Brown Univ, Sch Med, Neurosurg, Providence, RI 02912 USA; [Patel, Sunil] Med Univ South Carolina, Neurosurg, Charleston, SC USA; [Singman, Eric L.] Johns Hopkins Univ Hosp, Ophthalmol, Baltimore, MD 21287 USA; [Singman, Eric L.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Baltimore, MD 21287 USA; [Voermans, Nicol C.] Radboud Univ Nijmegen, Neuromuscular Ctr, Med Ctr, Nijmegen, Netherlands	Henderson, FC (corresponding author), Greater Baltimore Med Ctr, Metropolitan Neurosurg Grp, Ehlers Danlos Soc, Ctr Clin Care & Res, 8401 Connecticut Ave,Suite 220, Baltimore, MD 20815 USA.	henderson@fraserhendersonMD.com	Voermans, N.C./L-4724-2015				Adib N, 2005, RHEUMATOLOGY, V44, P744, DOI 10.1093/rheumatology/keh557; ARNASSON O, 1987, ACTA NEUROCHIR, V84, P48, DOI 10.1007/BF01456351; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Aufschnaiter K, 2008, NEUROSURG REV, V31, P371, DOI 10.1007/s10143-008-0140-x; Bademci G, 2006, PEDIATR NEUROSURG, V42, P4, DOI 10.1159/000089503; Ball AK, 2006, LANCET NEUROL, V5, P433, DOI 10.1016/S1474-4422(06)70442-2; BANERJEE G, 1988, POSTGRAD MED J, V64, P126, DOI 10.1136/pgmj.64.748.126; Bathen T, 2013, AM J MED GENET A, V161, P3005, DOI 10.1002/ajmg.a.36060; Batzdorf U, 2015, COMORBIDITIES COMPLI; Bendik EM, 2011, CEPHALALGIA, V31, P603, DOI 10.1177/0333102410392606; Bui CJ, 2007, NEUROSURG FOCUS, V23, pE2, DOI [10.3171/FOC-07/08/E2, DOI 10.3171/FOC-07/08/E2, 10.3171/foc.2007.23.2.2, DOI 10.3171/FOC.2007.23.2.2]; Burstein R, 2015, J NEUROSCI, V35, P6619, DOI 10.1523/JNEUROSCI.0373-15.2015; CASTILLO M, 1995, AM J NEURORADIOL, V16, P1158; Castori M, 2014, IRAN J NEUROL, V13, P195; Castori M, 2015, AM J MED GENET C, V169, P84, DOI 10.1002/ajmg.c.31426; Casucci G, 2012, NEUROL SCI, V33, pS81, DOI 10.1007/s10072-012-1047-4; Celletti C, 2012, RES DEV DISABIL, V33, P1914, DOI 10.1016/j.ridd.2012.06.018; CORBETT JJ, 1982, ARCH NEUROL-CHICAGO, V39, P461, DOI 10.1001/archneur.1982.00510200003001; CUSICK JF, 1977, J NEUROSURG, V46, P767, DOI 10.3171/jns.1977.46.6.0767; DEBARROS MC, 1968, J NEUROL NEUROSUR PS, V31, P596; Donkervoort S, 2015, AM J MED GENET C, V169, P23, DOI 10.1002/ajmg.c.31433; DVORAK J, 1987, SPINE, V12, P726, DOI 10.1097/00007632-198710000-00002; Ellenbogen RG, 2000, NEUROSURG FOCUS, V8, P1; Estemalik E, 2013, NEUROPSYCH DIS TREAT, V9, P709, DOI 10.2147/NDT.S33769; Fabiano AJ, 2009, PEDIATR NEUROSURG, V45, P256, DOI 10.1159/000228983; Farb RI, 2003, NEUROLOGY, V60, P1418, DOI 10.1212/01.WNL.0000066683.34093.E2; Feigenbaum F, 2006, SEMIN SPINE SURG, V18, P154; Ferrari MD, 2015, LANCET NEUROL, V14, P65, DOI 10.1016/S1474-4422(14)70220-0; FIELDING JW, 1978, J BONE JOINT SURG AM, V60, P1102, DOI 10.2106/00004623-197860080-00015; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Gelfanda AA, 2013, MULT SCLER RELAT DIS, V2, P73, DOI 10.1016/j.msard.2012.10.003; Goel A, 2005, NEUROL MED-CHIR, V45, P512, DOI 10.2176/nmc.45.512; Grabb PA, 1999, NEUROSURGERY, V44, P520, DOI 10.1097/00006123-199903000-00050; Granata G, 2013, CLIN NEUROPHYSIOL, V124, P1689, DOI 10.1016/j.clinph.2012.12.051; HALKO GJ, 1995, J RHEUMATOL, V22, P2152; Hallett M, 2016, PARKINSONISM RELAT D, V22, pS149, DOI 10.1016/j.parkreldis.2015.08.036; Hankinson TC, 2010, NEUROSURGERY, V66, pA32, DOI 10.1227/01.NEU.0000365803.22786.F0; HARRIS JH, 1994, AM J ROENTGENOL, V162, P881, DOI 10.2214/ajr.162.4.8141012; HENDERSON FC, 1993, ANN RHEUM DIS, V52, P629, DOI 10.1136/ard.52.9.629; Henderson FC, 2005, NEUROSURGERY, V56, P1101, DOI 10.1227/01.NEU.0000157929.85251.7C; Henderson Fraser C, 2010, Surg Neurol Int, V1, DOI 10.4103/2152-7806.66461; HOFFMAN HJ, 1976, CHILD BRAIN, V2, P145; Huijing PA, 2010, J APPL PHYSIOL, V109, P986, DOI 10.1152/japplphysiol.00723.2009; Jacome DE, 1999, CEPHALALGIA, V19, P791, DOI 10.1046/j.1468-2982.1999.1909791.x; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jang HS, 2016, PEDIATR NEUROSURG, V51, P9, DOI 10.1159/000439284; Jelsma LD, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-35; Kahn EN, 2015, NEUROSURG CLIN N AM, V26, P501, DOI 10.1016/j.nec.2015.06.006; Kassavetis P, 2012, MOVEMENT DISORD, V27, P1070, DOI 10.1002/mds.25004; Klekamp J, 2012, J NEUROSURG-PEDIATR, V10, P538, DOI 10.3171/2012.9.PEDS12110; Klimo P, 2008, J NEUROSURG-SPINE, V9, P332, DOI 10.3171/SPI.2008.9.10.332; Klinge PM, 2015, CSF RES COLL C P SEP; Kothari P, 2000, J BONE JOINT SURG BR, V82B, P1034, DOI 10.1302/0301-620X.82B7.10641; Kress HG, 2015, CURR MED RES OPIN, V31, P1743, DOI 10.1185/03007995.2015.1072088; Lang AE, 2006, NEUROL REF SER, P35; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; Liu XZ, 1997, J NEUROSCI, V17, P5395; MacKenzie JM, 2003, AM J FOREN MED PATH, V24, P369, DOI 10.1097/01.paf.0000097853.26115.bb; Martin MD, 2010, NEUROSURGERY, V66, pA2, DOI 10.1227/01.NEU.0000365830.10052.87; Martin VT, 2014, HEADACHE, V54, P1403, DOI 10.1111/head.12417; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Menendez JA, 2007, NEUROSURGERY, V60, P103, DOI 10.1227/01.NEU.0000249220.50085.E4; Menezes AH, 2008, CHILD NERV SYST, V24, P1091, DOI 10.1007/s00381-008-0606-8; Menezes AH, 2012, J NEUROSURG, V116, P301, DOI 10.3171/2011.9.JNS11386; Merrison A F A, 2009, Pract Neurol, V9, P54, DOI 10.1136/jnnp.2008.167171; Milhorat TH, 1999, NEUROSURGERY, V44, P1005, DOI 10.1097/00006123-199905000-00042; Milhorat TH, 2007, J NEUROSURG-SPINE, V7, P601, DOI 10.3171/SPI-07/12/601; Milhorat TH, 2010, ACTA NEUROCHIR, V152, P1117, DOI 10.1007/s00701-010-0636-3; Milhorat TH, 2009, SURG NEUROL, V72, P20, DOI 10.1016/j.surneu.2009.03.008; Muellbacher W, 1998, MUSCLE NERVE, V21, P972, DOI 10.1002/(SICI)1097-4598(199807)21:7<972::AID-MUS25>3.0.CO;2-R; Muhle C, 1998, INVEST RADIOL, V33, P444, DOI 10.1097/00004424-199808000-00004; NABORS MW, 1988, J NEUROSURG, V68, P366, DOI 10.3171/jns.1988.68.3.0366; NAGASHIMA C, 1981, Neurological Surgery, V9, P601; Nappi RE, 2012, GYNECOL ENDOCRINOL, V28, P37, DOI 10.3109/09513590.2012.651931; NINDS Common Data Elements, 2016, CLIN RES COMM DAT EL; Novegno F, 2008, J NEUROSURG-PEDIATR, V2, P179, DOI 10.3171/PED/2008/2/9/179; Palmer S, 2016, PHYSIOTHERAPY, V102, P93, DOI 10.1016/j.physio.2015.05.001; Palmeri S, 2003, CLIN GENET, V63, P510, DOI 10.1034/j.1399-0004.2003.00075.x; PANG D, 1982, J NEUROSURG, V57, P32, DOI 10.3171/jns.1982.57.1.0032; Patel MR, 1997, AM J ROENTGENOL, V168, P367, DOI 10.2214/ajr.168.2.9016209; Penisson-Besnier I, 2013, NEUROMUSCULAR DISORD, V23, P664, DOI 10.1016/j.nmd.2013.04.009; Pierangeli G, 2012, NEUROL SCI, V33, pS47, DOI 10.1007/s10072-012-1040-y; RADHAKRISHNAN K, 1993, J NEUROL SCI, V116, P18, DOI 10.1016/0022-510X(93)90084-C; Ripa P, 2015, INT J WOMENS HEALTH, V7, P773, DOI 10.2147/IJWH.S70073; Rombaut L, 2012, ARTHRIT CARE RES, V64, P1584, DOI 10.1002/acr.21726; Rombaut L, 2011, ARCH PHYS MED REHAB, V92, P1106, DOI 10.1016/j.apmr.2011.01.016; Royo-Salvador M B, 1996, Rev Neurol, V24, P937; Rubio-Agusti I, 2012, MOVEMENT DISORD, V27, P203, DOI 10.1002/mds.24013; Satti SR, 2015, AM J NEURORADIOL, V36, P1899, DOI 10.3174/ajnr.A4377; Savasta S, 2011, CHILD NERV SYST, V27, P365, DOI 10.1007/s00381-010-1256-1; Schurks M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3914; SELECKI BR, 1969, MED J AUSTRALIA, V1, P1012, DOI 10.5694/j.1326-5377.1969.tb49865.x; Shedid D, 2007, NEUROSURGERY, V60, P7, DOI 10.1227/01.NEU.0000215430.86569.C4; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Steilen Danielle, 2014, Open Orthop J, V8, P326, DOI 10.2174/1874325001408010326; STERN WE, 1988, J NEUROSURG, V69, P221, DOI 10.3171/jns.1988.69.2.0221; Strahle J, 2011, J NEUROSURG-PEDIATR, V8, P214, DOI 10.3171/2011.5.PEDS1122; Syx D, 2015, HUM MUTAT, V36, P535, DOI 10.1002/humu.22774; Taniguchi D, 2008, CLIN RHEUMATOL, V27, P851, DOI 10.1007/s10067-007-0809-5; Thompson EM, 2014, J NEUROSURG-PEDIATR, V13, P255, DOI 10.3171/2013.12.PEDS13370; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; TREDWELL SJ, 1990, J PEDIATR ORTHOPED, V10, P602, DOI 10.1097/01241398-199009000-00006; Tu A, 2013, CHILD NERV SYST, V29, P1635, DOI 10.1007/s00381-013-2129-1; Tubbs RS, 2011, J NEUROSURG-SPINE, V14, P697, DOI 10.3171/2011.1.SPINE10612; Tubbs RS, 2011, J NEUROSURG-PEDIATR, V7, P248, DOI 10.3171/2010.12.PEDS10379; van Hemert S, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00241; van Rooijen DE, 2011, J NEUROL NEUROSUR PS, V82, P892, DOI 10.1136/jnnp.2010.232504; Voermans NC, 2008, NEUROMUSCULAR DISORD, V18, P843, DOI 10.1016/j.nmd.2008.05.017; Voermans NC, 2012, AM J MED GENET A, V158A, P850, DOI 10.1002/ajmg.a.35232; Voermans NC, 2011, CONNECT TISSUE RES, V52, P422, DOI 10.3109/03008207.2010.551616; Voermans NC, 2009, AM J MED GENET A, V149A, P2311, DOI 10.1002/ajmg.a.32997; Voermans NC, 2006, J NEUROL, V253, P670, DOI 10.1007/s00415-005-0056-0; Voermans NC, 2010, J PAIN SYMPTOM MANAG, V40, P370, DOI 10.1016/j.jpainsymman.2009.12.026; Voermans NC, 2009, ANN NEUROL, V65, P687, DOI 10.1002/ana.21643; Volman M, 2013, CATHETER CARDIO INTE, V81, P643, DOI 10.1002/ccd.24635; Voyadzis JM, 2001, J NEUROSURG, V95, P25, DOI 10.3171/spi.2001.95.1.0025; White AA, 1990, CLIN BIOMECHANICS SP, V2nd; WIESEL S W, 1979, Spine, V4, P187, DOI 10.1097/00007632-197905000-00001; Wilson WA, 2010, SPINE SURG TECHNIQUE, V1; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yamada S, 2007, NEUROSURG FOCUS, V23, P1, DOI DOI 10.3171/FOC-07/08/E6; Yarbrough CK, 2011, J NEUROSURG-PEDIATR, V7, P244, DOI 10.3171/2010.11.PEDS1097; Yoshizumi T, 2014, NEUROSURG REV, V37, P519, DOI 10.1007/s10143-014-0531-0; Zhang H, 2007, SPINE, V32, P968, DOI 10.1097/01.brs.0000261036.04919.91	124	56	56	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4868	1552-4876		AM J MED GENET C	Am. J. Med. Genet. C	MAR	2017	175	1			SI		195	211		10.1002/ajmg.c.31549			17	Genetics & Heredity	Genetics & Heredity	EV2RP	WOS:000401603100014	28220607	Bronze			2021-06-18	
J	Ljungqvist, J; Zetterberg, H; Mitsis, M; Blennow, K; Skoglund, T				Ljungqvist, Johan; Zetterberg, Henrik; Mitsis, Marios; Blennow, Kaj; Skoglund, Thomas			Serum Neurofilament Light Protein as a Marker for Diffuse Axonal Injury: Results from a Case Series Study	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; biomarkers; DTI; MRI; TBI	TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; SCALE; GUIDELINES; DAMAGE	Diffuse axonal injury (DAI) is an important cause of morbidity in patients with traumatic brain injury (TBI). There is currently no simple and reliable technique for early identification of patients with DAI, or to prognosticate long-term outcome in this patient group. In the present study, we examined acute serum concentrations of neurofilament light (NFL) in nine patients with severe TBI and DAI using a novel ultrasensitive single molecule array (Simoa) assay. The relationships between the NFL concentrations and MRI in the acute stage as well as clinical outcome and magnetic resonance diffusion tensor imaging (MR-DTI) parameters at 12 months were analyzed. We found that the mean NFL concentrations among the patients displayed a 30-fold increase compared with controls, and that NFL completely discriminated between the patients and controls. We also found a relationship between serum NFL and MR-DTI parameters, with higher NFL concentrations in patients with higher trace (R-2=0.79) and lower fractional anisotropy (FA) (R (2)=0.83). These results suggest that serum NFL may be a valuable blood biomarker for TBI, reflecting the severity of DAI.	[Ljungqvist, Johan; Skoglund, Thomas] Univ Gothenburg, Sahlgrenska Acad, Dept Neurosurg, Inst Neurosci & Physiol, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Gothenburg, Sweden; [Mitsis, Marios] Univ Gothenburg, Sahlgrenska Acad, Dept Neuroradiol, Inst Clin Sci, Gothenburg, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England	Ljungqvist, J (corresponding author), Sahlgrens Univ Hosp, SE-41345 Gothenburg, Sweden.	johan.ljungqvist@vgregion.se			Health and Medical Care Committee of Vastra Gotaland; Foundation for Medical Imaging in Memory of Erik Lysholm; Swedish Research CouncilSwedish Research CouncilEuropean Commission; European Research CouncilEuropean Research Council (ERC)European Commission; Knut and Alice Wallenberg FoundationKnut & Alice Wallenberg Foundation; Torsten Soderberg Foundation	This work was supported by grants from the Health and Medical Care Committee of Vastra Gotaland, the Foundation for Medical Imaging in Memory of Erik Lysholm, the Swedish Research Council, the European Research Council, the Knut and Alice Wallenberg Foundation, and the Torsten Soderberg Foundation. We thank Dr. Asgeir Jakola for his support with the statistical analysis.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Bettermann K, 2012, RSC DRUG DISCOV, V24, P1, DOI 10.1039/9781849734745-00001; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Gisslen M, 2016, EBIOMEDICINE, V3, P135, DOI 10.1016/j.ebiom.2015.11.036; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Magnoni S, 2015, BRAIN, V138, P2263, DOI 10.1093/brain/awv152; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Oliver J., 2016, J NEUROTRAUMA; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Studerus-Germann AM, 2016, INT J NEUROSCI, V126, P289, DOI 10.3109/00207454.2015.1033620; Van Geel WJA, 2005, J IMMUNOL METHODS, V296, P179, DOI 10.1016/j.jim.2004.11.015; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	20	56	57	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 1	2017	34	5					1124	1127		10.1089/neu.2016.4496			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EM6EI	WOS:000395405200016	27539721				2021-06-18	
J	Vestberg, T; Reinebo, G; Maurex, L; Ingvar, M; Petrovic, P				Vestberg, Torbjorn; Reinebo, Gustaf; Maurex, Liselotte; Ingvar, Martin; Petrovic, Predrag			Core executive functions are associated with success in young elite soccer players	PLOS ONE			English	Article							LATENT VARIABLE ANALYSIS; WORKING-MEMORY; PROGRESSIVE MATRICES; COGNITIVE CONTROL; FUNCTION SYSTEM; LATE CHILDHOOD; SKILLS; ANTICIPATION; INFORMATION; ACQUISITION	Physical capacity and coordination cannot alone predict success in team sports such as soccer. Instead, more focus has been directed towards the importance of cognitive abilities, and it has been suggested that executive functions (EF) are fundamentally important for success in soccer. However, executive functions are going through a steep development from adolescence to adulthood. Moreover, more complex EF involving manipulation of information (higher level EF) develop later than simple executive functions such as those linked to simple working memory capacity (Core EF). The link between EF and success in young soccer players is therefore not obvious. In the present study we investigated whether EF are associated with success in soccer in young elite soccer players. We performed tests measuring core EF (a demanding working memory task involving a variable n-back task; dWM) and higher level EF (Design Fluency test; DF). Color-Word Interference Test and Trail Making Test were performed on an exploratory level as they contain a linguistic element. The lower level EF test (dWM) was taken from CogStateSport computerized concussion testing and the higher level EF test (DF) was from Delis-Kaplan Executive Function System test battery (D-KEFS). In a group of young elite soccer players (n = 30; aged 12-19 years) we show that they perform better than the norm in both the dWM (+0.49 SD) and DF (+0.86 SD). Moreover, we could show that both dWM and DF correlate with the number of goals the players perform during the season. The effect was more prominent for dWM (r=0.437) than for DF (r=0.349), but strongest for a combined measurement (r= 0.550). The effect was still present when we controlled for intelligence, length and age in a partial correlation analysis. Thus, our study suggests that both core and higher level EF may predict success in soccer also in young players.	[Vestberg, Torbjorn; Reinebo, Gustaf; Maurex, Liselotte; Ingvar, Martin; Petrovic, Predrag] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden	Vestberg, T (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.	Torbjorn.vestberg@ki.se	Petrovic, Predrag/AAS-6736-2020	Petrovic, Predrag/0000-0002-5536-945X; Vestberg, Torbjorn/0000-0003-0523-6621; Reinebo, Gustaf/0000-0001-8444-8686; Ingvar, Martin/0000-0002-9041-5714	PRIMA Barnoch Vuxenpsykiatri AB; Karolinska InstitutetKarolinska Institutet	TV received funding from PRIMA Barnoch Vuxenpsykiatri AB [http://primapsykiatn.sen page td=237]. PP received funding from the Karolinska Institutet [http://ki.seistart]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABERNETHY B, 1989, CAN J SPORT SCI, V14, P27; Abernethy B, 2001, PERCEPTION, V30, P233, DOI 10.1068/p2872; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Barkley R, 2012, EXECUTIVE FUNCTIONS; Best JR, 2010, CHILD DEV, V81, P1641, DOI 10.1111/j.1467-8624.2010.01499.x; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Cieslik EC, 2015, NEUROSCI BIOBEHAV R, V48, P22, DOI 10.1016/j.neubiorev.2014.11.003; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Constantinidis C, 2016, NAT REV NEUROSCI, V17, P438, DOI 10.1038/nrn.2016.43; Court JH, 1998, MANUAL RAVENS PROGR; Crone EA, 2006, P NATL ACAD SCI USA, V103, P9315, DOI 10.1073/pnas.0510088103; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; De Luca CR, 2003, J CLIN EXP NEUROPSYC, V25, P242, DOI 10.1076/jcen.25.2.242.13639; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Farrow D, 2002, J SPORT SCI, V20, P471, DOI 10.1080/02640410252925143; Faubert J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01154; Faubert J, 2012, J CLIN SPORT PSYCHOL, V6, P85, DOI 10.1123/jcsp.6.1.85; Friedman NP, 2008, J EXP PSYCHOL GEN, V137, P201, DOI 10.1037/0096-3445.137.2.201; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldstein S., 2014, HDB EXECUTIVE FUNCTI; Homack S, 2005, J CLIN EXP NEUROPSYC, V27, P599, DOI 10.1080/13803390490918444; Hopwood MJ, 2011, INT J SPORTS SCI COA, V6, P523, DOI 10.1260/1747-9541.6.4.523; Huijgen BCH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144580; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Karbach J, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00390; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Luciana M, 2005, CHILD DEV, V76, P697, DOI 10.1111/j.1467-8624.2005.00872.x; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; Lundgren T, 2016, J CLIN SPOR IN PRESS; Mackintosh NJ, 2005, INTELLIGENCE, V33, P663, DOI 10.1016/j.intell.2005.03.004; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Murgia M, 2014, PSYCHOL SPORT EXERC, V15, P642, DOI 10.1016/j.psychsport.2014.07.009; Parsons B, 2016, CLIN EEG NEUROSCI, V47, P37, DOI 10.1177/1550059414563746; Petrovic P, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00070; Pind J, 2003, PERS INDIV DIFFER, V34, P375, DOI 10.1016/S0191-8869(02)00058-2; Raven J, 2000, COGNITIVE PSYCHOL, V41, P1, DOI 10.1006/cogp.1999.0735; Ryu D, 2013, RES Q EXERCISE SPORT, V84, P252, DOI 10.1080/02701367.2013.784843; Savelsbergh GJP, 2010, INT J SPORT PSYCHOL, V41, P24; Shim J, 2005, J MOTOR BEHAV, V37, P164, DOI 10.3200/JMBR.37.2.164-175; Shipstead Z, 2012, PSYCHOL BULL, V138, P628, DOI 10.1037/a0027473; Shunk A.W., 2006, APPL NEUROPSYCHOL, V13, P275, DOI [10.1207/s15324826an1304_9, DOI 10.1207/S15324826AN1304_9, DOI 10.1207/S15324826AN1304_]; Stratton G., 2004, YOUTH SOCCER SCI PER; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Swanson J, 2005, CAN J SCH PSYCHOL, V20, P117, DOI 10.1177/0829573506295469; Toga AW, 2006, TRENDS NEUROSCI, V29, P148, DOI 10.1016/j.tins.2006.01.007; Verburgh L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091254; Vestberg T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034731; Williams AM, 2005, J SPORT SCI, V23, P637, DOI 10.1080/02640410400021328	53	56	56	3	31	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 8	2017	12	2							e0170845	10.1371/journal.pone.0170845			13	Multidisciplinary Sciences	Science & Technology - Other Topics	EK1UY	WOS:000393712500016	28178738	DOAJ Gold, Green Published			2021-06-18	
J	Daverey, A; Agrawal, SK				Daverey, Amita; Agrawal, Sandeep K.			CURCUMIN ALLEVIATES OXIDATIVE STRESS AND MITOCHONDRIAL DYSFUNCTION IN ASTROCYTES	NEUROSCIENCE			English	Article						oxidative stress; curcumin; astrocytes; GFAP; neurodegenerative diseases	TRAUMATIC BRAIN-INJURY; PEROXIREDOXIN 6; EXPRESSION; NEURONS; GFAP; AGE	Oxidative stress plays a critical role in various neurodegenerative diseases, thus alleviating oxidative stress is a potential strategy for therapeutic intervention and/or prevention of neurodegenerative diseases. In the present study, alleviation of oxidative stress through curcumin is investigated in A172 (human glioblastoma cell line) and HA-sp (human astrocytes cell line derived from the spinal cord) astrocytes. H2O2 was used to induce oxidative stress in astrocytes (A172 and HA-sp). Data show that H2O2 induces activation of astrocytes in dose-and time-dependent manner as evident by increased expression of GFAP in A172 and HA-sp cells after 24 and 12 h respectively. An upregulation of Prdx6 was also observed in A172 and HA-sp cells after 24 h of H2O2 treatment as compared to untreated control. Our data also showed that curcumin inhibits oxidative stress-induced cytoskeleton disarrangement, and impedes the activation of astrocytes by inhibiting upregulation of GFAP, vimentin and Prdx6. In addition, we observed an inhibition of oxidative stress-induced inflammation, apoptosis and mitochondria fragmentation after curcumin treatment. Therefore, our results suggest that curcumin not only protects astrocytes from H2O2-induced oxidative stress but also reverses the mitochondrial damage and dysfunction induced by oxidative stress. This study also provides evidence for protective role of curcumin on astrocytes by showing its effects on attenuating reactive astrogliosis and inhibiting apoptosis. Published by Elsevier Ltd on behalf of IBRO.	[Daverey, Amita; Agrawal, Sandeep K.] Univ Nebraska Med Ctr, Div Neurosurg, Dept Surg, Omaha, NE USA	Agrawal, SK (corresponding author), Univ Nebraska Med Ctr, Div Neurosurg, Dept Surg, Omaha, NE 68198 USA.	agrawals@unmc.edu	Daverey, Amita/S-1718-2019		Division of Neurosurgery	The authors would like to acknowledge James R. Talaska and Janice Taylor for providing training to use the confocal microscope available at UNMC's core facility. Authors are thankful to the Division of Neurosurgery for providing funding for this study.	Ambegaokar SS, 2003, NEUROENDOCRINOL LETT, V24, P469; Bachetti T, 2012, EXP CELL RES, V318, P1844, DOI 10.1016/j.yexcr.2012.06.008; Bae MK, 2006, BBA-MOL CELL RES, V1763, P282, DOI 10.1016/j.bbamcr.2006.01.005; Ben Haim Lucile, 2015, Front Cell Neurosci, V9, P278, DOI 10.3389/fncel.2015.00278; Bezprozvanny I, 2009, TRENDS MOL MED, V15, P89, DOI 10.1016/j.molmed.2009.01.001; Bisht K, 2010, TOXICOLOGY, V278, P88, DOI 10.1016/j.tox.2009.11.008; Buonora JE, 2015, J NEUROTRAUM, V32, P1805, DOI 10.1089/neu.2014.3736; Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940-6207.CAPR-10-0098; Chen XP, 2012, NEURAL REGEN RES, V7, P376, DOI 10.3969/j.issn.1673-5374.2012.05.009; Cole GM, 2007, ADV EXP MED BIOL, V595, P197; Dinkova-Kostova AT, 2008, MOL NUTR FOOD RES, V52, pS128, DOI 10.1002/mnfr.200700195; Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030; Gonzalez-Reyes S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/801418; Gurd BJ, 2011, APPL PHYSIOL NUTR ME, V36, P589, DOI [10.1139/h11-070, 10.1139/H11-070]; Kim GH, 2015, EXP NEUROBIOL, V24, P325, DOI 10.5607/en.2015.24.4.325; Kim SY, 2011, CELL DEATH DIFFER, V18, P1573, DOI 10.1038/cdd.2011.21; Kimelberg HK, 2010, NEUROTHERAPEUTICS, V7, P338, DOI 10.1016/j.nurt.2010.07.006; Kumar A, 2011, J ASIAN NAT PROD RES, V13, P42, DOI 10.1080/10286020.2010.544253; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lin MS, 2011, J SURG RES, V166, P280, DOI 10.1016/j.jss.2009.07.001; Liu L, 2014, NEUROCHEM RES, V39, P1322, DOI 10.1007/s11064-014-1315-1; Lone J, 2016, J NUTR BIOCHEM, V27, P193, DOI 10.1016/j.jnutbio.2015.09.006; Manevich Y, 2014, FREE RADICAL BIO MED, V72, P210, DOI 10.1016/j.freeradbiomed.2014.04.002; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Metzler M, 2013, BIOFACTORS, V39, P14, DOI 10.1002/biof.1042; Monroy A, 2013, BIOFACTORS, V39, P122, DOI 10.1002/biof.1063; Morgan TE, 1997, FREE RADICAL BIO MED, V23, P524, DOI 10.1016/S0891-5849(97)00120-2; Nishinaka T, 2007, TOXICOL LETT, V170, P238, DOI 10.1016/j.toxlet.2007.03.011; Park SJ, 2012, J IMMUNOL, V188, P5132, DOI 10.4049/jimmunol.1101600; Phatnani H., 2015, COLD SPRING HARB PER, V7; Rastogi M, 2014, BIOGERONTOLOGY, V15, P21, DOI 10.1007/s10522-013-9466-z; Raza H, 2008, TOXICOL APPL PHARM, V226, P161, DOI 10.1016/j.taap.2007.09.002; Rodriguez-Arellano JJ, 2016, NEUROSCIENCE, V323, P170, DOI 10.1016/j.neuroscience.2015.01.007; Scapagnini G, 2006, ANTIOXID REDOX SIGN, V8, P395, DOI 10.1089/ars.2006.8.395; Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019; Seyedzadeh MH, 2014, INT IMMUNOPHARMACOL, V22, P230, DOI 10.1016/j.intimp.2014.06.035; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Wang YJ, 1997, J PHARMACEUT BIOMED, V15, P1867, DOI 10.1016/S0731-7085(96)02024-9; Wu JX, 2015, NEURAL REGEN RES, V10, P481, DOI 10.4103/1673-5374.153700; Yang YS, 2014, PHYTOTHER RES, V28, P1770, DOI 10.1002/ptr.5197; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507	44	56	59	2	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 1	2016	333						92	103		10.1016/j.neuroscience.2016.07.012			12	Neurosciences	Neurosciences & Neurology	DU1BU	WOS:000381942000009	27423629				2021-06-18	
J	Clausen, M; Pendergast, DR; Willer, B; Leddy, J				Clausen, Mary; Pendergast, David R.; Willer, Barry; Leddy, John			Cerebral Blood Flow During Treadmill Exercise Is a Marker of Physiological Postconcussion Syndrome in Female Athletes	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						carbon dioxide sensitivity; cerebral blood flow; exercise; postconcussion syndrome; ventilation	HEART-RATE-VARIABILITY; SPORTS-RELATED CONCUSSION; DYNAMIC EXERCISE; CARBON-DIOXIDE; VENTILATORY RESPONSE; BRAIN-INJURY; VELOCITY; AUTOREGULATION; HUMANS; CO2	Objective: Some patients with postconcussion syndrome (PCS) have reduced exercise capacity that may reflect altered central cardiorespiratory control. The purpose of this study was to evaluate control of cerebral blood flow (CBF) during exercise in females with PCS. Setting: University Concussion Clinic. Participants: Nine female Division 1 collegiate team athletes with PCS (23 +/- 6 years) and a reference group of 13 healthy female recreational aerobic athletes (21 +/- 3 years). Design: A prospective experimental study. All PCS athletes were compared with the reference group at the beginning of the study. Six of the PCS athletes were subsequently measured before and after a subsymptom threshold aerobic exercise treatment program. Main Measures: Exercise treadmill test during which blood pressure (BP), minute ventilation ((V)over dotE), end-tidal CO2 (PETCO2), and CBF velocity (CBFV, by transcranial Doppler) were measured. Results: Participants with PCS had significantly lower. (V)over dot (by 18%) and greater PETCO2 (5%) and CBFV (14%) versus the reference group at similar workloads in association with appearance of symptoms and premature exercise cessation. Subthreshold exercise normalized. VE, PETCO2, CBFV and exercise tolerance. Before treatment, PCS had low CO2 sensitivity that blunted their exercise ventilation. CO2 sensitivity and ventilation improved after exercise treatment. Conclusion: Some PCS patients have exercise intolerance due to abnormal CBF regulation that may be the result of concussion-induced altered sensitivity to CO2. Return of normal CBF control and exercise tolerance may be physiological markers of recovery from concussion.	[Clausen, Mary; Pendergast, David R.] SUNY Buffalo, Ctr Res & Educ Special Environm, Dept Physiol, Buffalo, NY USA; [Leddy, John] SUNY Buffalo, Univ Sports Med, Orthopaed, 160 Farber Hall, Buffalo, NY 14214 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA	Leddy, J (corresponding author), SUNY Buffalo, Univ Sports Med, Orthopaed, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu					[Anonymous], 2006, ACSMS GUID EX TEST P; Brys M, 2003, AM J PHYSIOL-HEART C, V285, pH1048, DOI 10.1152/ajpheart.00062.2003; Carter JB, 2003, MED SCI SPORT EXER, V35, P1333, DOI 10.1249/01.MSS.0000079046.01763.8F; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doering TJ, 1998, AM J PHYS MED REHAB, V77, P490, DOI 10.1097/00002060-199811000-00006; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Fisher JP, 2008, J APPL PHYSIOL, V105, P266, DOI 10.1152/japplphysiol.00118.2008; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giller CA, 2000, J APPL PHYSIOL, V88, P2205; GOFF LG, 1957, J APPL PHYSIOL, V10, P203; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heckmann JG, 2003, CEREBROVASC DIS, V16, P423, DOI 10.1159/000072567; HELLSTROM G, 1993, NEUROSURG REV, V16, P151, DOI 10.1007/BF00258249; Hellstrom G, 1996, J APPL PHYSIOL, V81, P413; Hetzel A, 1999, STROKE, V30, P398, DOI 10.1161/01.STR.30.2.398; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Ide K, 1998, ACTA PHYSIOL SCAND, V162, P13; Ide K, 1999, J APPL PHYSIOL, V87, P1604; Imray CHE, 2005, J APPL PHYSIOL, V99, P699, DOI 10.1152/japplphysiol.00973.2004; Imray CHE, 2003, CLIN SCI, V104, P203, DOI 10.1042/CS20020102; JORGENSEN LG, 1992, J APPL PHYSIOL, V73, P1825; JORGENSEN LG, 1992, J APPL PHYSIOL, V72, P1123; Katayama K, 1999, J APPL PHYSIOL, V86, P1805; KELLEY MA, 1984, RESP PHYSIOL, V55, P393, DOI 10.1016/0034-5687(84)90060-4; KEREM D, 1980, UNDERSEA BIOMED RES, V7, P17; King ML, 1997, BRAIN INJURY, V11, P445; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; LALLY DA, 1974, RESP PHYSIOL, V20, P117, DOI 10.1016/0034-5687(74)90101-7; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Levy M. N., 2006, BERNE LEVY PRINCIPLE; LINKIS P, 1995, J APPL PHYSIOL, V78, P12; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McConnell AK, 1996, MED SCI SPORT EXER, V28, P685, DOI 10.1097/00005768-199606000-00007; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Miyamoto T, 2012, EUR J APPL PHYSIOL, V112, P237, DOI 10.1007/s00421-011-1968-2; MIYAMURA M, 1990, EUR J APPL PHYSIOL O, V60, P353, DOI 10.1007/BF00713498; MIYAMURA M, 1988, Tohoku Journal of Experimental Medicine, V156, P125; MORAINE JJ, 1993, EUR J APPL PHYSIOL O, V67, P35, DOI 10.1007/BF00377701; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Nattie E, 1999, PROG NEUROBIOL, V59, P299, DOI 10.1016/S0301-0082(99)00008-8; Nybo L, 2001, J PHYSIOL-LONDON, V534, P279, DOI 10.1111/j.1469-7793.2001.t01-1-00279.x; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1526, DOI 10.1152/ajpheart.00979.2004; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1461, DOI 10.1152/ajpheart.00948.2004; Ogoh S, 2009, EXERC SPORT SCI REV, V37, P123, DOI 10.1097/JES.0b013e3181aa64d7; Ogoh S, 2009, J APPL PHYSIOL, V106, P880, DOI 10.1152/japplphysiol.91292.2008; Pendergast DR, 2006, UNDERSEA HYPERBAR M, V33, P447; Polak P, 2015, J HEAD TRAUMA REHAB, V30, pE32, DOI 10.1097/HTR.0000000000000037; Pott F, 1997, ACTA PHYSIOL SCAND, V160, P251, DOI 10.1046/j.1365-201X.1997.00144.x; Pott F, 1997, ACTA PHYSIOL SCAND, V160, P43, DOI 10.1046/j.1365-201X.1997.00126.x; Querido JS, 2007, SPORTS MED, V37, P765, DOI 10.2165/00007256-200737090-00002; Querido JS, 2009, EUR J APPL PHYSIOL, V105, P403, DOI 10.1007/s00421-008-0917-1; READ DJC, 1967, J APPL PHYSIOL, V23, P53; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Tarasow Eugeniusz, 2007, Med Sci Monit, V13 Suppl 1, P65; Ter Minassian A, 2002, CRIT CARE MED, V30, P1616, DOI 10.1097/00003246-200207000-00036; THOMAS SN, 1989, J APPL PHYSIOL, V67, P744; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Whaley M., 2005, ACSMS GUID EX TEST P; WHO, 1992, INT STAT CLASS DIS R; Yosefy C, 2004, EMERG MED J, V21, P557, DOI 10.1136/emj.2003.005819	72	56	57	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2016	31	3					215	224		10.1097/HTR.0000000000000145			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DR3FK	WOS:000379787800013	26098254				2021-06-18	
J	Leddy, JJ; Baker, JG; Willer, B				Leddy, John J.; Baker, John G.; Willer, Barry			Active Rehabilitation of Concussion and Post-concussion Syndrome	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Rehabilitation; Concussion; Post-concussion syndrome; Active; Physiology; Treatment	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; SYMPTOMATIC CONVERGENCE INSUFFICIENCY; COGNITIVE-BEHAVIORAL PREVENTION; MILD HEAD-INJURY; POSTCONCUSSION SYNDROME; EARLY INTERVENTION; VOLUNTARY EXERCISE; BALANCE DISORDERS; VESTIBULAR SYSTEM	Concussion is a physiological brain injury with physical, cognitive, and emotional sequelae. The macrophysiological insult to the brain affects the autonomic nervous system and its control of cerebral blood flow. Most patients recover within 2-4 weeks, but some do not. Persistence of symptoms beyond the generally accepted time frame for recovery is called post-concussion syndrome (PCS). PCS is not a single entity; it is a group of disorders that requires specific forms of therapy. Rest has been the mainstay of the treatment for concussion and PCS. This article discusses the rationale for the active treatment of concussion and PCS.	[Leddy, John J.] SUNY Buffalo, UBMD Dept Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA; [Baker, John G.] Univ Buffalo, Jacobs Sch Med & Biomed Sci, UBMD Dept Orthopaed & Sports Med & Nucl Med, Sch Social Work, Buffalo, NY USA; [Willer, Barry] Univ Buffalo, Jacobs Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY USA	Leddy, JJ (corresponding author), SUNY Buffalo, UBMD Dept Orthopaed & Sports Med, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu					Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Alla S, 2010, J SCI MED SPORT, V13, P24, DOI 10.1016/j.jsams.2008.12.629; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Barth JT, 2001, J ATHL TRAINING, V36, P253; Bazarian JJ, 2010, J HEAD TRAUMA REHAB, V25, P225, DOI 10.1097/HTR.0b013e3181e7f784; Berlin AA, 2006, PSYCHOSOM MED, V68, P224, DOI 10.1097/01.psy.0000204628.73273.23; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; Buckley TA, 2015, J HEAD TRAUMA REHABI; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Clausen M, 2015, J HEAD TRAUMA REHABI; Conder R, 2015, BRAIN INJURY, V29, P249, DOI 10.3109/02699052.2014.965209; Cullen KE, 2012, TRENDS NEUROSCI, V35, P185, DOI 10.1016/j.tins.2011.12.001; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Dimberg EL, 2005, CLIN SPORT MED, V24, P637, DOI 10.1016/j.csm.2005.04.002; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Endo K, 2006, EUR SPINE J, V15, P886, DOI 10.1007/s00586-005-0970-y; Friedman Jules M, 2004, Med Health R I, V87, P296; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2013, J NEUROTRAUM, V30, P281, DOI 10.1089/neu.2012.2616; Griesbach GS, 2012, J NEUROTRAUM, V29, P1426, DOI 10.1089/neu.2011.2229; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guiney H, 2015, NEUROPSYCHOLOGY, V29, P1, DOI 10.1037/neu0000124; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamilton MT, 2004, EXERC SPORT SCI REV, V32, P161; Helmick K, 2010, NEUROREHABILITATION, V26, P239, DOI 10.3233/NRE-2010-0560; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Itoh T, 2011, J NEURAL TRANSM, V118, P1263, DOI 10.1007/s00702-011-0629-2; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jacotte-Simancas A, 2015, J NEUROTRAUM, V32, P739, DOI 10.1089/neu.2014.3502; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Khan S, 2013, NEUROREHABILITATION, V32, P437, DOI 10.3233/NRE-130866; Kjeldgaard D, 2014, J HEADACHE PAIN, V15, DOI 10.1186/1129-2377-15-81; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; Kristjansson E, 2009, J ORTHOP SPORT PHYS, V39, P364, DOI 10.2519/jospt.2009.2834; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2015, CLIN J SPORT MED, V25, P237, DOI 10.1097/JSM.0000000000000128; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Leslie O, 2013, CLIN J SPORT MED, V23, P331, DOI 10.1097/JSM.0b013e318295bbb1; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2015, CLIN PEDIATR, P1; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; Meier TB, 2015, JAMA NEUROL, V72, P530, DOI 10.1001/jamaneurol.2014.4778; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Naguib MB, 2012, J LARYNGOL OTOL, V126, P26, DOI 10.1017/S002221511100291X; Palmese CA, 2000, BRAIN INJURY, V14, P535; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Potter S, 2012, NEUROPSYCHOL REHABIL, V22, P1, DOI 10.1080/09602011.2011.630883; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Satterthwaite TD, 2014, P NATL ACAD SCI USA, V111, P8643, DOI 10.1073/pnas.1400178111; Scheiman M, 2005, BRIT J OPHTHALMOL, V89, P1318, DOI 10.1136/bjo.2005.068197; Scheiman M, 2011, OPTOMETRY VISION SCI, V88, P1343, DOI 10.1097/OPX.0b013e31822f4d7c; Scheiman M, 2011, J AAPOS, V15, P123, DOI 10.1016/j.jaapos.2011.03.001; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Seo TB, 2010, NEUROSCI LETT, V481, P178, DOI 10.1016/j.neulet.2010.06.087; Silver JM, 2014, PSYCHIAT CLIN N AM, V37, P91, DOI 10.1016/j.psc.2013.11.001; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P313, DOI 10.1097/HTR.0b013e3182915cb5; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; Sturzenegger M, 2008, ACTA NEUROL SCAND, V117, P49, DOI 10.1111/j.1600-0404.2007.00939.x; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Treleaven J, 2011, SPINE, V36, pS211, DOI 10.1097/BRS.0b013e3182387f78; Twamley EW, 2014, J REHABIL RES DEV, V51, P59, DOI 10.1682/JRRD.2013.01.0020; Ventura RE, 2015, J NEURO-OPHTHALMOL, V35, P73, DOI 10.1097/WNO.0000000000000223; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Zhang R, 1997, J APPL PHYSIOL, V83, P2139	102	56	58	2	83	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2016	27	2					437	+		10.1016/j.pmr.2015.12.003			19	Rehabilitation	Rehabilitation	DN4RU	WOS:000377055700007	27154855				2021-06-18	
J	Wickwire, EM; Williams, SG; Roth, T; Capaldi, VF; Jaffe, M; Moline, M; Motamedi, GK; Morgan, GW; Mysliwiec, V; Germain, A; Pazdan, RM; Ferziger, R; Balkin, TJ; MacDonald, ME; Macek, TA; Yochelson, MR; Scharf, SM; Lettieri, CJ				Wickwire, Emerson M.; Williams, Scott G.; Roth, Thomas; Capaldi, Vincent F.; Jaffe, Michael; Moline, Margaret; Motamedi, Gholam K.; Morgan, Gregory W.; Mysliwiec, Vincent; Germain, Anne; Pazdan, Renee M.; Ferziger, Reuven; Balkin, Thomas J.; MacDonald, Margaret E.; Macek, Thomas A.; Yochelson, Michael R.; Scharf, Steven M.; Lettieri, Christopher J.			Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group	NEUROTHERAPEUTICS			English	Article						Sleep; Sleep disorders; Traumatic brain injury; Concussion; Insomnia; Sleep apnea	COGNITIVE-BEHAVIORAL THERAPY; EXCESSIVE DAYTIME SLEEPINESS; WAKE DISTURBANCES; CEREBRAL-ISCHEMIA; CLINICAL-SIGNIFICANCE; BLAST EXPOSURE; QUALITY INDEX; HEAD-INJURY; REM-SLEEP; INSOMNIA	Disturbed sleep is one of the most common complaints following traumatic brain injury (TBI) and worsens morbidity and long-term sequelae. Further, sleep and TBI share neurophysiologic underpinnings with direct relevance to recovery from TBI. As such, disturbed sleep and clinical sleep disorders represent modifiable treatment targets to improve outcomes in TBI. This paper presents key findings from a national working group on sleep and TBI, with a specific focus on the testing and development of sleep-related therapeutic interventions for mild TBI (mTBI). First, mTBI and sleep physiology are briefly reviewed. Next, essential empirical and clinical questions and knowledge gaps are addressed. Finally, actionable recommendations are offered to guide active and efficient collaboration between academic, industry, and governmental stakeholders.	[Wickwire, Emerson M.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA; [Wickwire, Emerson M.; Scharf, Steven M.] Univ Maryland, Sch Med, Dept Med, Sleep Disorders Ctr,Div Pulm & Crit Care, Baltimore, MD 21201 USA; [Williams, Scott G.] Walter Reed Natl Mil Med Ctr, Dept Med, Bethesda, MD USA; [Williams, Scott G.; Mysliwiec, Vincent; Lettieri, Christopher J.] Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA; [Roth, Thomas] Henry Ford Hosp, Sleep Disorders & Res Ctr, Detroit, MI 48202 USA; [Capaldi, Vincent F.; Balkin, Thomas J.] Ctr Mil Psychiat & Neurosci Res, Walter Reed Army Inst Res, Dept Behav Biol, Silver Spring, MD USA; [Jaffe, Michael] Univ Florida, Dept Neurol, Gainesville, FL USA; [Jaffe, Michael] Univ Florida Trauma, Concuss & Sports Program, Gainesville, FL USA; [Jaffe, Michael] UF Hlth Sleep Disorders Ctr, Gainesville, FL USA; [Moline, Margaret] Eisai Inc, Woodcliff Lake, NJ USA; [Motamedi, Gholam K.] Georgetown Univ Hosp, Dept Neurol, Washington, DC 20007 USA; [Morgan, Gregory W.] Natl Intrepid Ctr Excellence, Sleep Disorders Ctr, Bethesda, MD USA; [Mysliwiec, Vincent] San Antonio Mil Med Ctr, Dept Sleep Med, San Antonio, TX USA; [Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Pazdan, Renee M.] US PHS, Ft Carson, CO USA; [Ferziger, Reuven] Merck & Co Inc, Kenilworth, NJ USA; [MacDonald, Margaret E.] Evans Army Community Hosp, Def & Vet Brain Injury Ctr, Gen Dynam Hlth Solut, Ft Carson, CO USA; [Macek, Thomas A.] Takeda Dev Ctr Amer, CNS, Dept Clin Sci, Deerfield, IL USA; [Yochelson, Michael R.] Medstar Natl Rehabil Network, Washington, DC USA; [Yochelson, Michael R.] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA; [Yochelson, Michael R.] Georgetown Univ, Sch Med, Dept Rehabil Med, Washington, DC USA	Wickwire, EM (corresponding author), Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA.; Wickwire, EM (corresponding author), Univ Maryland, Sch Med, Dept Med, Sleep Disorders Ctr,Div Pulm & Crit Care, Baltimore, MD 21201 USA.	ewickwire@medicine.umaryland.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146			Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; [Anonymous], 2005, J Clin Sleep Med, V1, P412; Assefa SZ, 2015, AIMS NEUROSCI, V2, P155, DOI 10.3934/Neuroscience.2015.3.155; Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Barr T, 2015, ANNU REV NURS RES-SE, V33, P249, DOI 10.1891/0739-6686.33.249; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Berry RB, 2012, AASM MANUAL SCORING, P47; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Bruce ED, 2015, MOL CELL NEUROSCI, V66, P103, DOI 10.1016/j.mcn.2015.03.017; Buysse DJ, 2006, SLEEP, V29, P1155, DOI 10.1093/sleep/29.9.1155; Buysse DJ, 2010, SLEEP MED, V11, P56, DOI 10.1016/j.sleep.2009.02.010; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cam E, 2013, EXP NEUROL, V247, P673, DOI 10.1016/j.expneurol.2013.03.003; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Centers for Disease Control and Prevention, WHAT AR SIGNS SYMPT; Cheng OM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125877; Chiu HY, 2015, EUR NEUROPSYCHOPHARM, V25, P2271, DOI 10.1016/j.euroneuro.2015.09.011; Chiu HY, 2014, INT J NURS STUD, V51, P892, DOI 10.1016/j.ijnurstu.2013.10.020; Chong CD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0485-0; Cirelli C, 2012, GERONTOLOGY, V58, P441, DOI 10.1159/000336149; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Collen JF, 2012, J CLIN SLEEP MED, V8, P667, DOI 10.5664/jcsm.2260; Colorado Division of Workers' Compensation, 2012, TRAUM BRAIN INJ MED, P1; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cote KA, 2015, AIMS NEUROSCI, V2, P203, DOI 10.3934/Neuroscience.2015.4.203; Currie S, 2016, POSTGRAD MED J, V92, P41, DOI 10.1136/postgradmedj-2014-133211; Dash MB, 2009, J NEUROSCI, V29, P580, DOI 10.1523/JNEUROSCI.5486-08.2009; De La Rue-Evans L, 2013, REHABIL NURS, V38, P2, DOI 10.1002/rnj.66; Dean PJ, 2015, BRAIN INJ; Delouche A, 2016, EUR J RADIOL, V85, P25, DOI 10.1016/j.ejrad.2015.11.004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Farrell-Carnahan L, 2013, MIL MED, V178, P951, DOI 10.7205/MILMED-D-13-00037; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; FRANKEN P, 1991, AM J PHYSIOL, V261, pR198; Gagner C, 2015, J NEUROTRAUM, V32, P1539, DOI 10.1089/neu.2014.3753; Gao B, 2010, SLEEP, V33, P879, DOI 10.1093/sleep/33.7.879; Gerberding JL, 2003, REP C MILD TRAUM BRA; Gerdes L, 2013, BRAIN BEHAV, V3, P193, DOI 10.1002/brb3.116; Germain A, 2013, PSYCHIAT RES-NEUROIM, V211, P176, DOI 10.1016/j.pscychresns.2012.05.007; Gilbert KS, 2015, CLIN PSYCHOL REV, V40, P195, DOI 10.1016/j.cpr.2015.05.008; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Hasler BP, 2013, BIOL PSYCHOL, V94, P255, DOI 10.1016/j.biopsycho.2013.06.007; Hodor A, 2014, ANN CLIN TRANSL NEUR, V1, P765, DOI 10.1002/acn3.115; Hsu JC, 2003, BRAIN RES, V984, P170, DOI 10.1016/S0006-8993(03)03128-7; Jacobs GD, 2004, ARCH INTERN MED, V164, P1888, DOI 10.1001/archinte.164.17.1888; Jaffee MS, 2015, BRAIN INJURY, V29, P221, DOI 10.3109/02699052.2014.983978; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Kong JM, 2002, J NEUROSCI, V22, P5581; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laakso ML, 2004, SLEEP MED, V5, P541, DOI 10.1016/j.sleep.2004.05.002; Lam JC, 2011, BEHAV SLEEP MED, V9, P184, DOI 10.1080/15402002.2011.583906; Lavigne G, 2015, PAIN, V156, pS75, DOI 10.1097/j.pain.0000000000000111; Lee SW, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00843; Leo P., 2016, TRANSLATIONAL RES TR; Lequerica A, 2015, ARCH PHYS MED REHAB, V96, P1802, DOI 10.1016/j.apmr.2015.05.011; Lequerica A, 2014, NEUROREHABILITATION, V35, P485, DOI 10.3233/NRE-141141; Lettieri CJ, 2015, CHEST; Lu W, 2014, NEUROREHABILITATION, V35, P245, DOI 10.3233/NRE-141117; Lucke-Wold BP, 2015, NEUROSCI BIOBEHAV R, V55, P68, DOI 10.1016/j.neubiorev.2015.04.010; Lusardi TA, 2012, EXP NEUROL, V234, P161, DOI 10.1016/j.expneurol.2011.12.026; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Martinez-Vargas M, 2012, NEUROSCI LETT, V529, P118, DOI 10.1016/j.neulet.2012.09.037; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Menn SJ, 2014, J CLIN SLEEP MED, V10, P1181, DOI 10.5664/jcsm.4196; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moldovan M, 2010, EXP NEUROL, V222, P135, DOI 10.1016/j.expneurol.2009.12.023; Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Morries LD, 2015, NEUROPSYCH DIS TREAT, V11, P2159, DOI 10.2147/NDT.S65809; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Newell J, 2012, PSYCHIAT RES, V200, P795, DOI 10.1016/j.psychres.2012.07.045; Nofzinger EA, 2005, SLEEP MED REV, V9, P157, DOI 10.1016/j.smrv.2004.07.003; Okun ML, 2011, PSYCHOSOM MED, V73, P142, DOI 10.1097/PSY.0b013e3182020d08; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pace M, 2015, SLEEP, V38, P1707, DOI 10.5665/sleep.5148; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pisarenco I, 2014, INT J PSYCHOPHYSIOL; Plante DT, 2016, CLIN NEUROPHYSIOL, V127, P1436, DOI 10.1016/j.clinph.2015.10.040; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Poryazova R, 2015, J SLEEP RES, V24, P54, DOI 10.1111/jsr.12208; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Rye DB, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004685; Sanchez-Ortuno MM, 2012, J SLEEP RES, V21, P527, DOI 10.1111/j.1365-2869.2012.01010.x; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Seifman MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00237; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P165, DOI 10.1067/mai.2001.112270; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Sinclair KL, 2014, BEHAV SLEEP MED, V12, P13, DOI 10.1080/15402002.2012.726203; Sivertsen B, 2006, JAMA-J AM MED ASSOC, V295, P2851, DOI 10.1001/jama.295.24.2851; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Suh S, 2012, SLEEP MED, V13, P469, DOI 10.1016/j.sleep.2011.10.034; Tan G, 2009, PAIN MED, V10, P1237, DOI 10.1111/j.1526-4637.2009.00712.x; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tham SW, 2015, J NEUROTRAUM, V32, P847, DOI 10.1089/neu.2014.3559; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562; Weil ZM, 2009, EXP NEUROL, V218, P129, DOI 10.1016/j.expneurol.2009.04.018; Wickwire EM, 2016, SLEEP MED REV, V30, P72, DOI 10.1016/j.smrv.2015.11.004; Wickwire EM, 2013, CHEST, V144, P680, DOI 10.1378/chest.12-2681; Wickwire EM, 2010, SLEEP MED, V11, P772, DOI 10.1016/j.sleep.2010.03.012; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Zollman FS, 2010, BRAIN INJURY, V24, P748, DOI 10.3109/02699051003692167; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	136	56	56	1	23	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	APR	2016	13	2					403	417		10.1007/s13311-016-0429-3			15	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	DI6WY	WOS:000373642100013	27002812	Green Published, Bronze			2021-06-18	
J	Harvey, LD; Yin, Y; Attarwala, IY; Begum, G; Deng, J; Yan, HQ; Dixon, CE; Sun, DD				Harvey, Lloyd D.; Yin, Yan; Attarwala, Insiya Y.; Begum, Gulnaz; Deng, Julia; Yan, Hong Q.; Dixon, C. Edward; Sun, Dandan			Administration of DHA Reduces Endoplasmic Reticulum Stress-Associated Inflammation and Alters Microglial or Macrophage Activation in Traumatic Brain Injury	ASN NEURO			English	Article						cortical contusion injury; docosahexaenoic acid; microglial polarization; neuroinflammation; nuclear factor kappa-light-chain-enhancer of activated B cells; secondary injury	MICROGLIA/MACROPHAGE POLARIZATION DYNAMICS; DOCOSAHEXAENOIC ACID; ER STRESS; RESPONSES; IMPACT; EXPRESSION; MODEL	We investigated the effects of the administration of docosahexaenoic acid (DHA) post-traumatic brain injury (TBI) on reducing neuroinflammation. TBI was induced by cortical contusion injury in Sprague Dawley rats. Either DHA (16mg/kg in dimethyl sulfoxide) or vehicle dimethyl sulfoxide (1ml/kg) was administered intraperitonially at 5min after TBI, followed by a daily dose for 3 to 21 days. TBI triggered activation of microglia or macrophages, detected by an increase of Iba1 positively stained microglia or macrophages in peri-lesion cortical tissues at 3, 7, and 21 days post-TBI. The inflammatory response was further characterized by expression of the proinflammatory marker CD16/32 and the anti-inflammatory marker CD206 in Iba1(+) microglia or macrophages. DHA-treated brains showed significantly fewer CD16/32(+) microglia or macrophages, but an increased CD206(+) phagocytic microglial or macrophage population. Additionally, DHA treatment revealed a shift in microglial or macrophage morphology from the activated, amoeboid-like state into the more permissive, surveillant state. Furthermore, activated Iba1(+) microglial or macrophages were associated with neurons expressing the endoplasmic reticulum (ER) stress marker CHOP at 3 days post-TBI, and the administration of DHA post-TBI concurrently reduced ER stress and the associated activation of Iba1(+) microglial or macrophages. There was a decrease in nuclear translocation of activated nuclear factor kappa-light-chain-enhancer of activated B cells protein at 3 days in DHA-treated tissue and reduced neuronal degeneration in DHA-treated brains at 3, 7, and 21 days after TBI. In summary, our study demonstrated that TBI mediated inflammatory responses are associated with increased neuronal ER stress and subsequent activation of microglia or macrophages. DHA administration reduced neuronal ER stress and subsequent association with microglial or macrophage polarization after TBI, demonstrating its therapeutic potential to ameliorate TBI-induced cellular pathology.	[Harvey, Lloyd D.; Attarwala, Insiya Y.; Begum, Gulnaz; Deng, Julia; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Yin, Yan] Dalian Med Univ, Hosp 2, Dept Neurol, Dalian, Peoples R China; [Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Yan, Hong Q.; Dixon, C. Edward; Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA	Sun, DD (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol, S-598 South Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15213 USA.	sund@upmc.edu		Harvey, Lloyd/0000-0001-5934-9934; Yin, Yan/0000-0002-5982-7462	University of Pittsburgh Neurology Departmental start-up funds; UPMC Endowed Chair Professorship on Brain Disorder Research; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS089051]; United States Department of Veterans Aairs VA [RRD#B6761R]; Brackenridge Summer and Fall Research Fellowships; Chancellor's Undergraduate Research Fellowship; Honors College-Health Sciences Research Fellowship; James V. Kunkel, M.D. Translational Research Fellowship; Chinese Dalian Municipal Bureau Study Abroad Research Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089051] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by University of Pittsburgh Neurology Departmental start-up funds, a UPMC Endowed Chair Professorship on Brain Disorder Research, and the National Institutes of Health [R01NS089051] (DS) and the United States Department of Veterans Aairs VA [RR&D#B6761R] (CED). LDH was supported by the Brackenridge Summer and Fall Research Fellowships, the Chancellor's Undergraduate Research Fellowship, the Honors College-Health Sciences Research Fellowship, and the James V. Kunkel, M.D. Translational Research Fellowship. YY was supported by the Chinese Dalian Municipal Bureau Study Abroad Research Award.	Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Ajmone-Cat MA, 2012, J NEUROSCI RES, V90, P575, DOI 10.1002/jnr.22783; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fedorova I, 2007, PROSTAG LEUKOTR ESS, V77, P269, DOI 10.1016/j.plefa.2007.10.013; Harrison JL, 2015, BRAIN BEHAV IMMUN, V47, P131, DOI 10.1016/j.bbi.2015.01.001; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kaur P, 2008, NEUROTOXICOLOGY, V29, P978, DOI 10.1016/j.neuro.2008.06.004; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lalancette-Hebert M, 2011, STROKE, V42, P2903, DOI 10.1161/STROKEAHA.111.620856; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenz KM, 2015, NEUROSCIENTIST, V21, P306, DOI 10.1177/1073858414536468; Liu Y, 2010, J NEUROSCI, V30, P15210, DOI 10.1523/JNEUROSCI.3950-10.2010; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Morrison HW, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-4; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Shi YJ, 2011, J NEUROCHEM, V119, P124, DOI 10.1111/j.1471-4159.2011.07403.x; Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	37	56	57	0	6	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1759-0914			ASN NEURO	ASN Neuro	NOV-DEC	2015	7	6								10.1177/1759091415618969			15	Neurosciences	Neurosciences & Neurology	DA2EH	WOS:000367607600003	26685193	DOAJ Gold, Green Published			2021-06-18	
J	Bernick, C; Banks, SJ; Shin, W; Obuchowski, N; Butler, S; Noback, M; Phillips, M; Lowe, M; Jones, S; Modic, M				Bernick, Charles; Banks, Sarah J.; Shin, Wanyong; Obuchowski, Nancy; Butler, Sam; Noback, Michael; Phillips, Michael; Lowe, Mark; Jones, Stephen; Modic, Michael			Repeated head trauma is associated with smaller thalamic volumes and slower processing speed: the Professional Fighters' Brain Health Study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							ENCEPHALOPATHY; CONCUSSION; SPORTS; CONSEQUENCES; CONNECTIONS; INJURY	Objectives Cumulative head trauma may alter brain structure and function. We explored the relationship between exposure variables, cognition and MRI brain structural measures in a cohort of professional combatants. Methods 224 fighters (131 mixed martial arts fighters and 93 boxers) participating in the Professional Fighters Brain Health Study, a longitudinal cohort study of licensed professional combatants, were recruited, as were 22 controls. Each participant underwent computerised cognitive testing and volumetric brain MRI. Fighting history including years of fighting and fights per year was obtained from self-report and published records. Statistical analyses of the baseline evaluations were applied cross-sectionally to determine the relationship between fight exposure variables and volumes of the hippocampus, amygdala, thalamus, caudate, putamen. Moreover, the relationship between exposure and brain volumes with cognitive function was assessed. Results Increasing exposure to repetitive head trauma measured by number of professional fights, years of fighting, or a Fight Exposure Score (FES) was associated with lower brain volumes, particularly the thalamus and caudate. In addition, speed of processing decreased with decreased thalamic volumes and with increasing fight exposure. Higher scores on a FES used to reflect exposure to repetitive head trauma were associated with greater likelihood of having cognitive impairment. Conclusions Greater exposure to repetitive head trauma is associated with lower brain volumes and lower processing speed in active professional fighters.	[Bernick, Charles; Banks, Sarah J.; Noback, Michael] Cleveland Clin, Lou Ruvo Ctr Brain Hlth, Las Vegas, NV 89106 USA; [Shin, Wanyong; Phillips, Michael; Lowe, Mark; Jones, Stephen; Modic, Michael] Cleveland Clin, Dept Radiol, Cleveland, OH 44106 USA; [Obuchowski, Nancy; Butler, Sam] Cleveland Clin, Dept Qualitat Hlth Sci, Cleveland, OH 44106 USA	Banks, SJ (corresponding author), Cleveland Clin, Lou Ruvo Ctr Brain Hlth, 888 W Bonneville Ave, Las Vegas, NV 89106 USA.	bankss2@ccf.org		Banks, Sarah/0000-0001-7536-2370			Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Forstl H, 2010, DTSCH ARZTEBL INT, V107, P835, DOI 10.3238/arztebl.2010.0835; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Heilbronner RL, 2009, ARCH CLIN NEUROPSYCH, V24, P11, DOI 10.1093/arclin/acp005; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Minagar A, 2013, NEUROLOGY, V80, P210, DOI 10.1212/WNL.0b013e31827b910b; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; YETERIAN EH, 1978, BRAIN RES, V139, P43, DOI 10.1016/0006-8993(78)90059-8; Zazryn T, 2007, SPORTS MED, V37, P467	24	56	56	0	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2015	49	15					1007	U74		10.1136/bjsports-2014-093877			6	Sport Sciences	Sport Sciences	CM9IR	WOS:000358022600013	25633832	Other Gold, Green Published			2021-06-18	
J	Kroshus, E; Kubzansky, LD; Goldman, RE; Austin, SB				Kroshus, Emily; Kubzansky, Laura D.; Goldman, Roberta E.; Austin, S. Bryn			Norms, Athletic Identity, and Concussion Symptom Under-Reporting Among Male Collegiate Ice Hockey Players: A Prospective Cohort Study	ANNALS OF BEHAVIORAL MEDICINE			English	Article						Concussion; Norms; Sports medicine; Symptom reporting	PHYSICIAN-OBSERVED CONCUSSION; TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; WHITE-MATTER; SPORT; KNOWLEDGE; EPIDEMIOLOGY; TRANSLATION; EDUCATION; COHESION	Many athletes fail to report concussion symptoms to coaches or medical personnel, putting them at risk for potentially catastrophic neurologic consequences if additional brain trauma is sustained prior to full recovery. The purpose of this study was to determine whether concussion reporting norms prior to the start of the athletic season predicted reporting symptoms of a possible concussion during the season, and whether this association was moderated by athletic identity. Members of six National Collegiate Athletic Association Division 1 men's ice hockey teams (n = 116) completed written surveys before and after the 2012-2013 collegiate ice hockey season. Participants who at pre-season perceived that "most athletes" were likely to report symptoms of a concussion were themselves more likely to report symptoms during the season. Athletic identity weakly moderated this association. Perceived reporting norms may be an important target of interventions aimed at reducing symptom under-reporting among athletes.	[Kroshus, Emily; Kubzansky, Laura D.; Goldman, Roberta E.; Austin, S. Bryn] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02115 USA; [Goldman, Roberta E.] Brown Univ, Alpert Sch Med, Providence, RI 02912 USA; [Austin, S. Bryn] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Austin, S. Bryn] Boston Childrens Hosp, Div Adolescent Young Adult Med, Boston, MA USA	Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 677 Huntington Ave, Boston, MA 02115 USA.	emk329@mail.harvard.edu		Goldman, Roberta/0000-0001-7801-0530	National Collegiate Athletic Association	This research was partially supported by the National Collegiate Athletic Association's 2012-2013 Graduate Student Research Grant.	Agel J, 2007, J ATHL TRAINING, V42, P241; Aronson E., 2007, SOCIAL PSYCHOL, V6th; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Borden BP, 2007, AM J SPORTS MED, V35, P1075; Bramley H, 2012, CLIN PEDIATR, V51, P332, DOI 10.1177/0009922811425233; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Brewer B., 2001, ACAD ATHLETIC J, V15, P103; BREWER BW, 1993, INT J SPORT PSYCHOL, V24, P237; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chan DKC, 2012, SPORTS MED, V42, P725, DOI 10.2165/11633040-000000000-00000; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; Finch CF, 2011, BRIT J SPORT MED, V45, P1253, DOI 10.1136/bjsports-2011-090230; Gielen AC, 2003, EPIDEMIOL REV, V25, P65, DOI 10.1093/epirev/mxg004; Grossbard JR, 2009, ADDICT BEHAV, V34, P352, DOI 10.1016/j.addbeh.2008.11.011; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Keats MR, 2012, SPORTS MED, V42, P175, DOI 10.2165/11597050-000000000-00000; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; LaBrie JW, 2010, ADDICT BEHAV, V35, P1094, DOI 10.1016/j.addbeh.2010.08.003; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lindzey, 1998, HDB SOCIAL PSYCHOL; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Marar M, 2012, AM J SPORTS MED, V20, P1; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moreira MT, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006748.pub2; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; National Collegiate Athletic Association, 2012, 2012 2013 NCAA SPORT; National Collegiate Athletic Association, 2012, 2011 2012 NCAA SPORT; Neighbors C, 2010, PSYCHOL ADDICT BEHAV, V24, P522, DOI 10.1037/a0019944; Pescosolido AT, 2012, SMALL GR RES, V43, P744, DOI 10.1177/1046496412465020; Povlishock JT, 2013, J NEUROTRAUM, V30, P1, DOI 10.1089/neu.2013.9942; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Rovio E, 2009, SMALL GR RES, V40, P421, DOI 10.1177/1046496409334359; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; U. S. Department of Health and Human Services Centers for Disease Control and Prevention, 2012, YOUTH RISK BEH SURV; Verhagen EALM, 2010, SPORTS MED, V40, P899, DOI 10.2165/11536890-000000000-00000; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Wiechman S. A., 1997, Journal of Sport Behavior, V20, P199; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Winston FK, 2010, INJURY PREV, V16, P107, DOI 10.1136/ip.2009.021972	60	56	57	0	22	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0883-6612	1532-4796		ANN BEHAV MED	Ann. Behav. Med.	FEB	2015	49	1					95	103		10.1007/s12160-014-9636-5			9	Psychology, Multidisciplinary	Psychology	CC0TX	WOS:000350050800013	25236670				2021-06-18	
J	Schache, AG; Dorn, TW; Williams, GP; Brown, NAT; Pandy, MG				Schache, Anthony G.; Dorn, Tim W.; Williams, Gavin P.; Brown, Nicholas A. T.; Pandy, Marcus G.			Lower-Limb Muscular Strategies for Increasing Running Speed	JOURNAL OF ORTHOPAEDIC & SPORTS PHYSICAL THERAPY			English	Article						joint power; sprinting; traumatic brain injury; work	TRAUMATIC BRAIN-INJURY; TO-RUN TRANSITION; HUMAN LOCOMOTION; MUSCLE-ACTIVITY; LOWER-EXTREMITY; JOINT KINETICS; LEG MOVEMENTS; ACCELERATION PHASE; WILD TURKEYS; SWING PHASE	SYNOPSIS: This clinical commentary discusses the mechanisms used by the lower-limb musculature to achieve faster running speeds. A variety of methodological approaches have been taken to evaluate lower-limb muscle function during running, including direct recordings of muscle electromyographic signal, inverse dynamics based analyses, and computational musculoskeletal modeling. Progressing running speed from jogging to sprinting is mostly dependent on ankle and hip muscle performance. For speeds up to approximately 7.0 m/s, the dominant strategy is to push on the ground forcefully to increase stride length, and the major ankle plantar flexors (soleus and gastrocnemius) have a particularly important role in this regard. At speeds beyond approximately 7.0 m/s, the force-generating capacity of these muscles becomes less effective. Therefore, as running speed is progressed toward sprinting, the dominant strategy shifts toward the-goal of increasing stride frequency and pushing on the ground more frequently. This strategy is achieved by generating substantially more power at the hip joint, thereby increasing the biomechanical demand on proximal lower-limb muscles such as the iliopsoas, gluteus maximus, rectus femoris, and hamstrings. Basic science knowledge regarding lower-limb muscle function during running has implications for understanding why sprinting performance declines with age. It is also of great value to the clinician for designing rehabilitation programs to restore running ability in young, previously active adults who have sustained a traumatic brain injury and have severe impairments of muscle function (eg, weakness, spasticity, poor motor control) that limit their capacity to run at any speed.	[Schache, Anthony G.; Pandy, Marcus G.] Univ Melbourne, Dept Mech Engn, Melbourne, Vic 3010, Australia; [Dorn, Tim W.] Stanford Univ, Neuromuscular Biomech Lab, Stanford, CA 94305 USA; [Williams, Gavin P.] Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic, Australia; [Williams, Gavin P.] Univ Melbourne, Dept Physiotherapy, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Brown, Nicholas A. T.] Australian Inst Sport, Belconnen, ACT, Australia	Schache, AG (corresponding author), Univ Melbourne, Dept Mech Engn, Melbourne, Vic 3010, Australia.	anthonys@unimelb.edu.au	Schache, Anthony G/F-4482-2016	Schache, Anthony G/0000-0002-1041-5213; Pandy, Marcus/0000-0001-9234-1782; Brown, Nicholas/0000-0003-2747-6634; Williams, Gavin/0000-0003-2758-7473	Australian Research CouncilAustralian Research Council [LP110100262]; Victorian Neurotrauma Initiative; Australian Physiotherapy Association	Part of the research contained in this clinical commentary was funded by the Australian Research Council (LP110100262), the Victorian Neurotrauma Initiative, and the Australian Physiotherapy Association. The authors certify that they have no affiliations with or financial involvement in any organization or entity with a direct financial interest in the subject matter or materials discussed in the article.	Ae M., 1987, BIOMECHANICS X B, V6B, P895; Alexander RM, 2002, COMP BIOCHEM PHYS A, V133, P1001; Alexander RM, 1992, HUMAN MACHINE, P74; Arampatzis A, 1999, J BIOMECH, V32, P1349, DOI 10.1016/S0021-9290(99)00133-5; Arampatzis A, 2011, EXERC SPORT SCI REV, V39, P18, DOI 10.1097/JES.0b013e318201efe0; Arnold EM, 2013, J EXP BIOL, V216, P2150, DOI 10.1242/jeb.075697; Belli A, 2002, INT J SPORTS MED, V23, P136, DOI 10.1055/s-2002-20136; Bezodis NE, 2014, J SPORT SCI, V32, P738, DOI 10.1080/02640414.2013.849000; Brughelli M, 2011, J STRENGTH COND RES, V25, P933, DOI 10.1519/JSC.0b013e3181c64308; Bus SA, 2003, MED SCI SPORT EXER, V35, P1167, DOI 10.1249/01.MSS.0000074441.55707.D1; CAVAGNA GA, 1971, J PHYSIOL-LONDON, V217, P709, DOI 10.1113/jphysiol.1971.sp009595; Chumanov ES, 2007, J BIOMECH, V40, P3555, DOI 10.1016/j.jbiomech.2007.05.026; Chumanov ES, 2012, BRIT J SPORT MED, V46, P90, DOI 10.1136/bjsports-2011-090176; Chumanov ES, 2011, MED SCI SPORT EXER, V43, P525, DOI 10.1249/MSS.0b013e3181f23fe8; Debaere S, 2013, J SPORT SCI, V31, P137, DOI 10.1080/02640414.2012.722225; Debaere S, 2013, J STRENGTH COND RES, V27, P116, DOI 10.1519/JSC.0b013e31825183ef; Denny MW, 2008, J EXP BIOL, V211, P3836, DOI 10.1242/jeb.024968; Dorn TW, 2012, J EXP BIOL, V215, P1944, DOI 10.1242/jeb.064527; Farley CT, 1998, EXERCISE SPORT SCI R, V26, P253; Farris DJ, 2012, P NATL ACAD SCI USA, V109, P977, DOI 10.1073/pnas.1107972109; Farris DJ, 2012, J R SOC INTERFACE, V9, P110, DOI 10.1098/rsif.2011.0182; Fukuchi R, 2008, J SPORT SCI, V26, P1447, DOI 10.1080/02640410802209018; Fukuchi RK, 2014, CLIN BIOMECH, V29, P304, DOI 10.1016/j.clinbiomech.2013.12.007; HAMILTON N, 1993, J APPL BIOMECH, V9, P15, DOI 10.1123/jab.9.1.15; Hamner SR, 2013, J BIOMECH, V46, P780, DOI 10.1016/j.jbiomech.2012.11.024; Hamner SR, 2010, J BIOMECH, V43, P2709, DOI 10.1016/j.jbiomech.2010.06.025; Hof AL, 2002, ACTA PHYSIOL SCAND, V174, P17, DOI 10.1046/j.1365-201x.2002.00917.x; HOSHIKAWA T, 1973, BIOMECHANICS 3, VIII, P342; HRELJAC A, 1993, MED SCI SPORT EXER, V25, P1158; Hunter JP, 2005, J APPL BIOMECH, V21, P31, DOI 10.1123/jab.21.1.31; Hunter JP, 2004, J BIOMECH, V37, P1439, DOI 10.1016/j.jbiomech.2003.12.018; Ishikawa M, 2007, GAIT POSTURE, V25, P380, DOI 10.1016/j.gaitpost.2006.05.002; JACOBS R, 1992, J BIOMECH, V25, P953, DOI 10.1016/0021-9290(92)90031-U; Johnson MD, 2001, J SPORT SCI, V19, P263; Karamanidis K, 2005, J EXP BIOL, V208, P3907, DOI 10.1242/jeb.01830; KER RF, 1981, J EXP BIOL, V93, P283; KOMI PV, 1990, J BIOMECH, V23, P23, DOI 10.1016/0021-9290(90)90038-5; KOMI PV, 1992, CLIN SPORT MED, V11, P521; Korhonen MT, 2009, MED SCI SPORT EXER, V41, P844, DOI 10.1249/MSS.0b013e3181998366; Korhonen MT, 2003, MED SCI SPORT EXER, V35, P1419, DOI 10.1249/01.MSS.0000079080.15333.CA; Kugler F, 2010, J BIOMECH, V43, P343, DOI 10.1016/j.jbiomech.2009.07.041; Kuitunen S, 2002, MED SCI SPORT EXER, V34, P166, DOI 10.1097/00005768-200201000-00025; Kyrolainen H, 2005, J SPORT SCI, V23, P1101, DOI 10.1080/02640410400021575; Kyrolainen H, 2001, MED SCI SPORT EXER, V33, P1330; Kyrolainen H, 1999, J STRENGTH COND RES, V13, P400; Lai A, 2014, J EXP BIOL, V217, P3159, DOI 10.1242/jeb.100826; Lichtwark GA, 2007, J BIOMECH, V40, P157, DOI 10.1016/j.jbiomech.2005.10.035; MANN RA, 1986, AM J SPORT MED, V14, P501, DOI 10.1177/036354658601400614; Mann RA., 1982, AM AC ORTH SURG S FO, P1; Mero A, 2006, J SPORT SCI, V24, P165, DOI 10.1080/02640410500131753; MERO A, 1992, SPORTS MED, V13, P376, DOI 10.2165/00007256-199213060-00002; MERO A, 1990, EUR J APPL PHYSIOL O, V61, P73, DOI 10.1007/BF00236697; MERO A, 1988, RES Q EXERCISE SPORT, V59, P94, DOI 10.1080/02701367.1988.10605484; Mero A., 1983, SCANDINAVIAN J SPORT, V5, P20; Miller RH, 2012, J BIOMECH, V45, P1092, DOI 10.1016/j.jbiomech.2011.04.040; MOORE DH, 1975, NATURE, V253, P264, DOI 10.1038/253264a0; Morin JB, 2012, EUR J APPL PHYSIOL, V112, P3921, DOI 10.1007/s00421-012-2379-8; Morin JB, 2011, MED SCI SPORT EXER, V43, P1680, DOI 10.1249/MSS.0b013e318216ea37; Nagahara R, 2014, INT J SPORTS MED, V35, P755, DOI 10.1055/s-0033-1363252; Nagahara R, 2014, BIOL OPEN, V3, P689, DOI 10.1242/bio.20148284; Neptune RR, 2005, J EXP BIOL, V208, P799, DOI 10.1242/jeb.01435; NILSSON J, 1985, ACTA PHYSIOL SCAND, V123, P457, DOI 10.1111/j.1748-1716.1985.tb07612.x; NILSSON J, 1987, ACTA PHYSIOL SCAND, V129, P107, DOI 10.1111/j.1748-1716.1987.tb08045.x; Novacheck TF, 1998, GAIT POSTURE, V7, P77, DOI 10.1016/S0966-6362(97)00038-6; Nummela A, 2007, INT J SPORTS MED, V28, P655, DOI 10.1055/s-2007-964896; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pandy MG, 2010, ANNU REV BIOMED ENG, V12, P401, DOI 10.1146/annurev-bioeng-070909-105259; Putnam CA, 1989, BIOMECHANICS SPORT, P1; Roberts TJ, 2004, J EXP BIOL, V207, P4165, DOI 10.1242/jeb.01253; Roberts TJ, 2002, J EXP BIOL, V205, P1485; Rubenson J, 2012, J EXP BIOL, V215, P3539, DOI 10.1242/jeb.070466; Saito M., 1974, BIOMECHANICS 4; Sasaki K, 2006, GAIT POSTURE, V23, P383, DOI 10.1016/j.gaitpost.2005.05.002; Sasaki K, 2006, J BIOMECH, V39, P2005, DOI 10.1016/j.jbiomech.2005.06.019; Schache AG, 2012, MED SCI SPORT EXER, V44, P647, DOI 10.1249/MSS.0b013e318236a3d2; Schache AG, 2011, MED SCI SPORT EXER, V43, P1260, DOI 10.1249/MSS.0b013e3182084929; Segers V, 2013, J EXP BIOL, V216, P3047, DOI 10.1242/jeb.087015; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Swanson SC, 2000, MED SCI SPORT EXER, V32, P1146, DOI 10.1097/00005768-200006000-00018; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Van Caekenberghe I, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0222; Weyand PG, 2010, J APPL PHYSIOL, V108, P950, DOI 10.1152/japplphysiol.00947.2009; Weyand PG, 2000, J APPL PHYSIOL, V89, P1991; Williams G, 2014, AM J PHYS MED REHAB, V93, P511, DOI 10.1097/PHM.0000000000000058; Williams G, 2013, J HEAD TRAUMA REHAB, V28, P379, DOI 10.1097/HTR.0b013e3182575f80; Williams G, 2013, BRAIN INJURY, V27, P434, DOI 10.3109/02699052.2012.750754; Williams GP, 2013, J HEAD TRAUMA REHAB, V28, P371, DOI 10.1097/HTR.0b013e31824a1d40; Williams GP, 2010, J HEAD TRAUMA REHAB, V25, P164, DOI 10.1097/HTR.0b013e3181dc120b; Williams K R, 1985, Exerc Sport Sci Rev, V13, P389; Winter D. A., 2009, BIOMECHANICS MOTOR C, V4th	90	56	56	0	54	J O S P T	ALEXANDRIA	1111 NORTH FAIRFAX ST, STE 100, ALEXANDRIA, VA 22314-1436 USA	0190-6011	1938-1344		J ORTHOP SPORT PHYS	J. Orthop. Sports Phys. Ther.	OCT	2014	44	10			SI		813	824		10.2519/jospt.2014.5433			12	Orthopedics; Rehabilitation; Sport Sciences	Orthopedics; Rehabilitation; Sport Sciences	AQ0OP	WOS:000342482900013	25103134	Bronze			2021-06-18	
J	Weil, ZM; Gaier, KR; Karelina, K				Weil, Zachary M.; Gaier, Kristopher R.; Karelina, Kate			Injury timing alters metabolic, inflammatory and functional outcomes following repeated mild traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Traumatic brain injury; Glucose metabolism; Repeated injury; Learning and memory; Functional outcomes; Inflammation	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; TEMPORAL WINDOW; COGNITIVE DEFICITS; DYNAMIC CHANGES; IMPACT; VULNERABILITY; CONCUSSION; MICE	Repeated head injuries are a major public health concern both for athletes, and members of the police and armed forces. There is ample experimental and clinical evidence that there is a period of enhanced vulnerability to subsequent injury following head trauma. Injuries that occur close together in time produce greater cognitive, histological, and behavioral impairments than do injuries separated by a longer period. Traumatic brain injuries alter cerebral glucose metabolism and the resolution of altered glucose metabolism may signal the end of the period of greater vulnerability. Here, we injured mice either once or twice separated by three or 20 days. Repeated injuries that were separated by three days were associated with greater axonal degeneration, enhanced inflammatory responses, and poorer performance in a spatial learning and memory task. A single injury induced a transient but marked increase in local cerebral glucose utilization in the injured hippocampus and sensorimotor cortex, whereas a second injury, three days after the first, failed to induce an increase in glucose utilization at the same time point. In contrast when the second injury occurred substantially later (20 days after the first injury), an increase in glucose utilization occurred that paralleled the increase observed following a single injury. The increased glucose utilization observed after a single injury appears to be an adaptive component of recovery, while mice with 2 injuries separated by three days were not able to mount this response, thus this second injury may have produced a significant energetic crisis such that energetic demands outstripped the ability of the damaged cells to utilize energy. These data strongly reinforce the idea that too rapid return to activity after a traumatic brain injury can induce permanent damage and disability, and that monitoring cerebral energy utilization may be a tool to determine when it is safe to return to the activity that caused the initial injury. (C) 2014 Elsevier Inc. All rights reserved.	[Weil, Zachary M.; Gaier, Kristopher R.; Karelina, Kate] Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA	Weil, ZM (corresponding author), Biomed Res Tower 618,460 W 12th Ave, Columbus, OH USA.	Zachary.weil@osumc.edu	Weil, Zachary M/B-5003-2008; Weil, Zachary M/A-2439-2008	Weil, Zachary M/0000-0003-3758-1809; Weil, Zachary M/0000-0003-3758-1809; Karelina Weil, Kate/0000-0002-6628-0768			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Babikian T, 2010, DEV NEUROSCI-BASEL, V32, P431, DOI 10.1159/000320667; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Darrah SD, 2013, EPILEPSY RES, V103, P180, DOI 10.1016/j.eplepsyres.2012.07.006; Demeurisse G, 2000, ACTA NEUROL BELG, V100, P77; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Fogal B, 2005, J NEUROIMMUNOL, V161, P93, DOI 10.1016/j.jneuroim.2004.12.007; Fogal B, 2008, J NEUROCHEM, V106, P1, DOI 10.1111/j.1471-4159.2008.05315.x; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Harris NG, 2012, J NEUROTRAUM, V29, P1469, DOI 10.1089/neu.2011.2161; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HOVDA DA, 1990, ACT NEUR S, V51, P331; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; LIMBRICK DD, 1995, BRAIN RES, V690, P145, DOI 10.1016/0006-8993(95)00552-2; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Navarro RR, 2011, CURR SPORT MED REP, V10, P27, DOI 10.1249/JSR.0b013e318205e072; Neigh GN, 2009, STROKE, V40, P3601, DOI 10.1161/STROKEAHA.109.564146; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Robertson CS, 2011, J NEUROTRAUM, V28, P727, DOI 10.1089/neu.2010.1476; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Silverberg ND, 2013, J NEUROTRAUM, V30, P1398, DOI 10.1089/neu.2012.2827; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	62	56	56	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	OCT	2014	70						108	116		10.1016/j.nbd.2014.06.016			9	Neurosciences	Neurosciences & Neurology	AN6FW	WOS:000340691400011	24983210				2021-06-18	
J	Moen, KG; Brezova, V; Skandsen, T; Haberg, AK; Folvik, M; Vik, A				Moen, Kent G.; Brezova, Veronika; Skandsen, Toril; Haberg, Asta K.; Folvik, Mari; Vik, Anne			Traumatic Axonal Injury: The Prognostic Value of Lesion Load in Corpus Callosum, Brain Stem, and Thalamus in Different Magnetic Resonance Imaging Sequences	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; brain stem; corpus callosum; diffuse axonal injury; Glasgow Outcome Scale; prospective studies	SEVERE HEAD-INJURY; OUTCOME PREDICTION; MRI FINDINGS; DIAGNOSIS; MODERATE; SEVERITY; SCALE	The aim of this study was to explore the prognostic value of visible traumatic axonal injury (TAI) loads in different MRI sequences from the early phase after adjusting for established prognostic factors. Likewise, we sought to explore the prognostic role of early apparent diffusion coefficient (ADC) values in normal-appearing corpus callosum. In this prospective study, 128 patients (mean age, 33.9 years; range, 11-69) with moderate (n = 64) and severe traumatic brain injury (TBI) were examined with MRI at a median of 8 days (range, 0-28) postinjury. TAI lesions in fluid-attenuated inversion recovery (FLAIR), diffusion-weighted imaging (DWI), and T2*-weighted gradient echo (T2*GRE) sequences were counted and FLAIR lesion volumes estimated. In patients and 47 healthy controls, mean ADC values were computed in 10 regions of interests in the normal-appearing corpus callosum. Outcome measure was the Glasgow Outcome Scale-Extended (GOS-E) at 12 months. In patients with severe TBI, number of DWI lesions and volume of FLAIR lesions in the corpus callosum, brain stem, and thalamus predicted outcome in analyses with adjustment for age, Glasgow Coma Scale score, and pupillary dilation (odds ratio, 1.3-6.9; p = <0.001-0.017). The addition of Rotterdam CT score and DWI lesions in the corpus callosum yielded the highest R-2 (0.24), compared to all other MRI variables, including brain stem lesions. For patients with moderate TBI only the number of cortical contusions (p = 0.089) and Rotterdam CT score (p = 0.065) tended to predict outcome. Numbers of T2*GRE lesions did not affect outcome. Mean ADC values in the normal-appearing corpus callosum did not differ from controls. In conclusion, the loads of visible TAI lesions in the corpus callosum, brain stem, and thalamus in DWI and FLAIR were independent prognostic factors in patients with severe TBI. DWI lesions in the corpus callosum were the most important predictive MRI variable. Interestingly, number of cortical contusions in MRI and CT findings seemed more important for patients with moderate TBI.	[Moen, Kent G.; Brezova, Veronika; Skandsen, Toril; Haberg, Asta K.; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neurosci, N-7491 Trondheim, Norway; [Moen, Kent G.; Vik, Anne] St Olavs Univ Hosp, Dept Neurosurg, Trondheim, Norway; [Brezova, Veronika; Haberg, Asta K.; Folvik, Mari] St Olavs Univ Hosp, Dept Med Imaging, Trondheim, Norway; [Skandsen, Toril] St Olavs Univ Hosp, Dept Phys Med & Rehabil, Trondheim, Norway	Moen, KG (corresponding author), Norwegian Univ Sci & Technol, Dept Neurosci, Postboks 8905, N-7491 Trondheim, Norway.	kent.g.moen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Liaison Committee; National Resource Center for fMRI, Department of Medical Imaging, St. Olav University Hospital	Kent Goran Moen (K. G. M.) and Toril Skandsen (T. S.) have, during the study period, received a research grant from the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology. Veronika Brezova (V. B.) has, during the study period, received a research grant from the National Resource Center for fMRI, Department of Medical Imaging, St. Olav University Hospital. The authors thank Kjell Arne Kvistad (K. A. K.) and Jana Rydland (J.R.) for their help in MRI analyses, Ingrid Haavde Strand (I. H. S.) for her help in computing the Rotterdam CT score, and Stine Borgen Lund, Otto Aarhaug, and Beate Holmqvist Karlsen for their management of the patient database and performing the GOS-E interviews.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Brandstack N, 2011, CLIN NEURORADIOL, V21, P75, DOI 10.1007/s00062-011-0058-5; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chew BG, 2012, J NEUROSURG, V117, P722, DOI 10.3171/2012.6.JNS111736; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Gasparetto EL, 2011, NEUROIMAG CLIN N AM, V21, P115, DOI 10.1016/j.nic.2011.02.003; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Hou DJ, 2007, J NEUROTRAUM, V24, P1558, DOI 10.1089/neu.2007.0339; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lovstad M., 2014, J HEAD TRAUMA R 0109; Matsusue Eiji, 2006, Magn Reson Med Sci, V5, P99, DOI 10.2463/mrms.5.99; Moen KG, 2014, J NEUROTRAUM, V31, P56, DOI 10.1089/neu.2013.3000; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff Nicholas D, 2010, Cleve Clin J Med, V77 Suppl 3, pS27, DOI 10.3949/ccjm.77.s3.05; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	39	56	60	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2014	31	17					1486	1496		10.1089/neu.2013.3258			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AO7GO	WOS:000341520700003	24773587				2021-06-18	
J	Bedard, M; Felteau, M; Marshall, S; Cullen, N; Gibbons, C; Dubois, S; Maxwell, H; Mazmanian, D; Weaver, B; Rees, L; Gainer, R; Klein, R; Moustgaard, A				Bedard, Michel; Felteau, Melissa; Marshall, Shawn; Cullen, Nora; Gibbons, Carrie; Dubois, Sacha; Maxwell, Hillary; Mazmanian, Dwight; Weaver, Bruce; Rees, Laura; Gainer, Rolf; Klein, Rupert; Moustgaard, Amy			Mindfulness-Based Cognitive Therapy Reduces Symptoms of Depression in People With a Traumatic Brain Injury: Results From a Randomized Controlled Trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; mindfulness; randomized controlled trial; traumatic brain injury	INDIVIDUALS; PREVENTION; GUIDELINES; AWARENESS; SCALE; PHQ-9	Objective: We sought to determine if we could reduce symptoms of depression in individuals with a traumatic brain injury using mindfulness-based cognitive therapy. Setting: The study was conducted in a community setting. Participants: We enrolled adults with symptoms of depression after a traumatic brain injury. Design: We conducted a randomized controlled trial; participants were randomized to the 10-week mindfulness-based cognitive therapy intervention arm or to the wait-list control arm. Main Measures: The primary outcome measure was symptoms of depression using the Beck Depression Inventory-II. Results: The parallel group analysis revealed a greater reduction in Beck Depression Inventory-II scores for the intervention group (6.63, n = 38,) than the control group (2.13, n = 38, P =.029). A medium effect size was observed (Cohen d = 0.56). The improvement in Beck Depression Inventory-II scores was maintained at the 3-month follow-up. Conclusion: These results are consistent with those of other researchers that use mindfulness-based cognitive therapy to reduce symptoms of depression and suggest that further work to replicate these findings and improve upon the efficacy of the intervention is warranted.	[Bedard, Michel; Dubois, Sacha] Lakehead Univ, Dept Hlth Sci, Thunder Bay, ON P7B 5E1, Canada; [Bedard, Michel; Dubois, Sacha; Weaver, Bruce] Northern Ontario Sch Med, Thunder Bay, ON, Canada; [Bedard, Michel; Gibbons, Carrie; Dubois, Sacha; Maxwell, Hillary] St Josephs Care Grp, Res Dept, Thunder Bay, ON, Canada; [Felteau, Melissa] St Francis Xavier Univ, Antigonish, NS B2G 1C0, Canada; [Marshall, Shawn] Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Marshall, Shawn] Univ Ottawa, Inst Rehabil Res & Dev, Ottawa, ON, Canada; [Marshall, Shawn] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Marshall, Shawn] Ottawa Hosp Rehabil Ctr, Electromyog Lab, Ottawa, ON, Canada; [Marshall, Shawn] Ottawa Hosp Rehabil Ctr, Acquired Brain Injury Rehabil Program, Ottawa, ON, Canada; [Cullen, Nora] West Pk Healthcare Ctr, Toronto, ON, Canada; [Cullen, Nora] Toronto Rehab, NeuroRehabil, Toronto, ON, Canada; [Cullen, Nora] Univ Toronto, Div Physiatry, Toronto, ON, Canada; [Mazmanian, Dwight; Klein, Rupert] Lakehead Univ, Dept Psychol, Thunder Bay, ON P7B 5E1, Canada; [Rees, Laura] Ottawa Hosp, Dept Psychol, Ottawa, ON, Canada; [Gainer, Rolf] Brookhaven Hosp, Tulsa, OK USA; [Gainer, Rolf] Neurol Rehabil Inst Ontario, Etobicoke, ON, Canada; [Moustgaard, Amy] Royal Ottawa Mental Hlth Ctr, Ottawa, ON, Canada	Bedard, M (corresponding author), Lakehead Univ, Dept Hlth Sci, 955 Oliver Rd, Thunder Bay, ON P7B 5E1, Canada.	mbedard@lakeheadu.ca		Cullen, Nora/0000-0001-6359-9418; Dubois, Sacha/0000-0003-3579-6072	Ontario Neurotrauma Foundation [ABI-MIND2-476]; Canada Research Chair ProgramCanada Research Chairs	This study was funded by the Ontario Neurotrauma Foundation (grant ABI-MIND2-476). Michel Bedard was a Canada Research Chair in Aging and Health at the time this study was conducted (www.chairs.gc.ca); he acknowledges the support of the Canada Research Chair Program.	Beck A. T., 1996, BECK DEPRESSION INVE, VII; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bedard M, 2005, J COGNITIVE REHABILI, P2, DOI DOI 10.1080/0963828031000090489; Bedard Michel, 2012, Adv Mind Body Med, V26, P14; Cardaciotto L, 2008, ASSESSMENT, V15, P204, DOI 10.1177/1073191107311467; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CONZEN M, 1992, Brain Injury, V6, P45, DOI 10.3109/02699059209008121; D'Amico EJ, 2001, BEHAV RES METH INS C, V33, P479, DOI 10.3758/BF03195405; Derogatis L.R., 1994, SCL 90 R ADM SCORING, V3rd; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Foley E, 2010, J CONSULT CLIN PSYCH, V78, P72, DOI 10.1037/a0017566; Gibbons C, 2014, MINDFULNESS, V5, P232, DOI 10.1007/s12671-012-0170-x; Gracey F., 2002, ADV CLIN NEUROSCI RE, V2, P18; Grossman P, 2011, CONTEMP BUDDHISM, V12, P219, DOI 10.1080/14639947.2011.564841; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hofmann SG, 2010, J CONSULT CLIN PSYCH, V78, P169, DOI 10.1037/a0018555; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Kabat-Zinn J., 2009, FULL CATASTROPHE LIV; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lau MA, 2006, J CLIN PSYCHOL, V62, P1445, DOI 10.1002/jclp.20326; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Ma SH, 2004, J CONSULT CLIN PSYCH, V72, P31, DOI 10.1037/0022-006X.72.1.31; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; National Collaborating Centre for Mental Health, 2009, NICE CLIN GUID 90 DE, V23; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schulz KF, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-32; Segal Z.V., 2002, MINDFULNESS BASED CO; Segal ZV, 2010, ARCH GEN PSYCHIAT, V67, P1256, DOI 10.1001/archgenpsychiatry.2010.168; Teasdale JD, 2000, J CONSULT CLIN PSYCH, V68, P615, DOI 10.1037/0022-006X.68.4.615; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Williams M, 2007, MINDFULWAY DEPRESSIO	38	56	56	1	44	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					E13	E22		10.1097/HTR.0b013e3182a615a0			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300002	24052092				2021-06-18	
J	Salottolo, K; Levy, AS; Slone, DS; Mains, CW; Bar-Or, D				Salottolo, Kristin; Levy, A. Stewart; Slone, Denetta S.; Mains, Charles W.; Bar-Or, David			The Effect of Age on Glasgow Coma Scale Score in Patients With Traumatic Brain Injury	JAMA SURGERY			English	Article							SUBDURAL-HEMATOMA; ELDERLY-PATIENTS; SEVERITY SCORE; MORTALITY; PERFORMANCE; PREDICTION; IMPACT; RISK	IMPORTANCE The Glasgow Coma Scale (GCS) is used frequently to define the extent of neurologic injury in patients with a traumatic brain injury (TBI). Whether age affects the predictive ability of the GCS for severity of TBI (determined by the Abbreviated Injury Scale [AIS] score) remains unknown. OBJECTIVE To investigate the effect of age on the association between the GCS and anatomic TBI severity. DESIGN, SETTING, AND PARTICIPANTS We examined all patients with a TBI, defined by diagnostic codes 850 to 854 from the International Classification of Diseases, Ninth Revision, Clinical Modification, who were admitted to 2 level I trauma centers from January 1, 2008, through December 31, 2012. EXPOSURES We compared elderly (-65 years) and younger (18-64 years) adults with TBI. MAIN OUTCOMES AND MEASURES We examined differences by age in GCS category (defined by emergency department GCS as severe [3-8], moderate [9-12], or mild [13-15]) at each level of TBI severity (head AIS score, 1 [minor] to 5 [critical]). Cochran-Armitage X-2 trend tests and stepwise multivariate linear and logistic regression models were used. RESULTS During the study period, 6710 patients had a TBI (aged <65 years, 73.17%). Significant differences in GCS category by age occurred at each AIS score (P <= .01 for all). In particular, among patients with an AIS score of 5, most of the elderly patients (56.33%) had a mild neurologic deficit (GCS score, 13-15), whereas most of the younger patients (63.28%) had a severe neurologic deficit (GCS score, 3-8). After adjustment, the younger adults had increased odds of presenting with a severe neurologic deficit (GCS score, 3-8) at each of the following AIS scores: 1, 4.2 (95% CI, 1.0-17.6; P = .05); 2, 2.0 (1.0-3.7; P = .04); 3, 2.0 (1.2-3.5; P = .01); 4, 4.6 (2.8-7.5; P < .001); and 5, 3.1 (2.1-4.6; P < .001). The interaction between age and GCS for anatomic TBI severity remained significant after adjustment (estimate, -0.11; P = .005). CONCLUSIONS AND RELEVANCE Age affects the relationship between the GCS score and anatomic TBI severity. Elderly TBI patients have better GCS scores than younger TBI patients with similar TBI severity. These findings have implications for TBI outcomes research and for protocols and research selection criteria that use the GCS.	[Salottolo, Kristin; Slone, Denetta S.; Bar-Or, David] Swedish Med Ctr, Dept Trauma Res, Englewood, CO 80113 USA; [Salottolo, Kristin; Mains, Charles W.; Bar-Or, David] St Anthony Hosp, Dept Trauma Res, Lakewood, CO USA; [Levy, A. Stewart] St Anthony Hosp, Lakewood, CO USA; [Slone, Denetta S.; Mains, Charles W.; Bar-Or, David] Rocky Vista Univ, Dept Biomed Sci, Aurora, CO USA	Bar-Or, D (corresponding author), Swedish Med Ctr, Dept Trauma Res, 501 E Hampden Ave,Room 4-454, Englewood, CO 80113 USA.	dbaror@ampiopharma.com	Bar-Or, David/AAE-9328-2020		St Anthony Hospital;  [Swedish Medical Center]	This study was supported by St Anthony Hospital and Swedish Medical Center.	Adam Williams Initiative, EST HIGH STAND CAR T; Adhiyaman V, 2002, POSTGRAD MED J, V78, P71, DOI 10.1136/pmj.78.916.71; American College of Surgeons Committee on Trauma, 2008, ATLS STUD COURS MAN; [Anonymous], 1971, JAMA, V215, P277; Association for the Advancement of Automotive Medicine, 2007, ABBR INJ SCAL 2005 R; Association for the Advancement of Automotive Medicine, 2011, AIS; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruno MA, 2011, NEUROCRIT CARE, V15, P447, DOI 10.1007/s12028-011-9547-2; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; Chieregato A, 2010, ACTA ANAESTH SCAND, V54, P696, DOI 10.1111/j.1399-6576.2010.02234.x; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Dhandapani SS, 2012, J NEUROSCI RURAL PRA, V3, P131, DOI 10.4103/0976-3147.98208; Emergency Medical and Trauma Services Section, 2011, COL TRAUM REG INCL E; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Horikawa E, 2005, INTERNAL MED, V44, P717, DOI 10.2169/internalmedicine.44.717; Karnath B, 2004, GERIATRICS, V59, P18; Kim HJ, 2012, J KOREAN NEUROSURG S, V51, P24, DOI 10.3340/jkns.2012.51.1.24; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Lesko MM, 2013, J NEUROTRAUM, V30, P17, DOI 10.1089/neu.2012.2438; Linn S, 2007, ANN EPIDEMIOL, V17, P142, DOI 10.1016/j.annepidem.2006.08.004; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; McNett Molly, 2007, J Neurosci Nurs, V39, P68; Mohindra S, 2008, SURG NEUROL, V69, P474, DOI 10.1016/j.surneu.2007.02.031; Moore L, 2006, J TRAUMA, V60, P1238, DOI 10.1097/01.ta.0000195593.60245.80; Moore MM, 2012, J TRAUMA ACUTE CARE, V73, P126, DOI 10.1097/TA.0b013e31824b01af; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Potts MB, 2008, ACTA NEUROCHIR SUPPL, V102, P109, DOI 10.1007/978-3-211-85578-2_22; Renner C, 2012, BRAIN INJURY, V26, P1360, DOI 10.3109/02699052.2012.667592; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sheridan PL, 2007, DEMENT GERIATR COGN, V24, P125, DOI 10.1159/000105126; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stuke L, 2007, ANN SURG, V245, P651, DOI 10.1097/01.sla.0000250413.41265.d3; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; TEASDALE G, 1974, LANCET, V2, P81; Timiras P., 2003, PHYSL BASIS AGING GE, P99, DOI DOI 10.1161/01.ATV.0000173418.42264.19; Timmons SD, 2011, J TRAUMA, V71, P1172, DOI 10.1097/TA.0b013e31822b0f4b	46	56	57	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6254	2168-6262		JAMA SURG	JAMA Surg.	JUL	2014	149	7					727	734		10.1001/jamasurg.2014.13			8	Surgery	Surgery	AN8DV	WOS:000340833800020	24899145	Bronze			2021-06-18	
J	Velikonja, D; Tate, R; Ponsford, J; McIntyre, A; Janzen, S; Bayley, M				Velikonja, Diana; Tate, Robyn; Ponsford, Jennie; McIntyre, Amanda; Janzen, Shannon; Bayley, Mark		INCOG Expert Panel	INCOG Recommendations for Management of Cognition Following Traumatic Brain Injury, Part V: Memory	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; guidelines; knowledge translation; memory; neuropsychology; rehabilitation; therapeutic approaches for the treatment of central nervous system injury; traumatic brain injury	CLOSED-HEAD INJURY; RANDOMIZED CONTROLLED-TRIAL; FACE-NAME ASSOCIATIONS; OF-THE-LITERATURE; IMPAIRED PATIENTS; VANISHING CUES; ACUTE REHABILITATION; TRAINING-PROGRAM; EVERYDAY MEMORY; PAGING SYSTEM	Introduction: Traumatic brain injury results in complex cognitive sequelae. Impairments in memory are among the most common sequelae resulting in significant functional problems. An international team of researchers and clinicians (known as INCOG) was formed to develop recommendations for the management of impairments in memory. Methods: The experts met to select appropriate recommendations and then reviewed available literature to ensure recommendations were current. Decision algorithms incorporating the recommendations based on inclusion and exclusion criteria of published trials were developed. The team then prioritized recommendations for implementation and developed audit criteria to evaluate adherence to the best practice recommendations. Results: The recommendations for rehabilitation of memory impairments support the integration of internal and external compensatory strategies implemented using appropriate instructional techniques that consider functional relevance and important patient characteristics. Restorative strategies have regained significant popularity, given broader access to computer technology; however, evidence for efficacy of these techniques remains weak and the choice in using these should be guided by special considerations. Conclusion: There is good evidence for the integration of internal and external compensatory memory strategies that are implemented using instructional procedures for rehabilitation for memory impairments. The evidence for the efficacy of restorative strategies currently remains weak.	[Velikonja, Diana] Hamilton Hlth Sci, Acquired Brain Injury Program, Neuropsychol, Hamilton, ON L8L 0A4, Canada; [Velikonja, Diana] McMaster Univ, DeGroote Sch Med, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada; [Tate, Robyn; Ponsford, Jennie] NHMRC Ctr Res Excellence Traumat Brain Injury Psy, Sydney, NSW, Australia; [Tate, Robyn] Royal Rehabil Ctr, Sydney, NSW, Australia; [Tate, Robyn] Univ Sydney, Sydney Med Sch Northern, Kolling Inst, Rehabil Res Ctr, Sydney, NSW 2006, Australia; [Ponsford, Jennie] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Epworth Med Fdn, Melbourne, Vic, Australia; [Ponsford, Jennie] Monash Univ, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ponsford, Jennie] Alfred Hosp, Melbourne, Vic, Australia; [McIntyre, Amanda; Janzen, Shannon] St Josephs Parkwood Hosp, Lawson Hlth Res Inst, London, ON, Canada; [Bayley, Mark] Univ Toronto, Toronto Rehabil Inst, Neuro Rehabil Program, Toronto, ON, Canada	Velikonja, D (corresponding author), Hamilton Hlth Sci, Reg Rehabil Ctr, Acquired Brain Injury Program, 300 Wellington St North, Hamilton, ON L8L 0A4, Canada.	dvelikonja@svapsych.ca		Bayley, Mark/0000-0001-7860-9463	Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University; Ontario Neurotrauma Foundation	The authors gratefully acknowledge the support of the Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University, and the Ontario Neurotrauma Foundation for their support of this project.	[Anonymous], 2003, J NEUROPSYCH CLIN N, V15, P383, DOI 10.1176/appi.neuropsych.15.3.383; [Anonymous], 2006, TRAUM BRAIN INJ DIAG; [Anonymous], AGREE ADV SCI PRACT; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Bentley P, 2003, NEUROIMAGE, V20, P58, DOI 10.1016/S1053-8119(03)00302-1; Bergman M M, 2000, Appl Neuropsychol, V7, P76, DOI 10.1207/S15324826AN0702_2; Bergquist T, 2008, BRAIN INJURY, V22, P891, DOI 10.1080/02699050802405487; Boman IL, 2004, BRAIN INJURY, V18, P985, DOI 10.1080/02699050410001672396; Bourgeois JA, 2002, J NEUROPSYCH CLIN N, V14, P463, DOI 10.1176/appi.neuropsych.14.4.463; Bourgeois MS, 2007, BRAIN INJURY, V21, P1245, DOI 10.1080/02699050701727452; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; CONSTANTINIDOU F, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199508000-00009; DILLER L, 1976, CLINICAL PSYCHOLOGIS, V29, P13; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Dowds MM, 2011, J HEAD TRAUMA REHAB, V26, P339, DOI 10.1097/HTR.0b013e3181f2bf1d; Eakman AM, 2001, OCCUP THER J RES, V21, P109, DOI 10.1177/153944920102100205; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Fernandez E, 2012, MEDICC REV, V14, P32, DOI 10.1590/S1555-79602012000400007; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fleming J, 2008, J INT NEUROPSYCH SOC, V14, P823, DOI 10.1017/S1355617708080971; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; FREEMAN M R, 1992, Brain Injury, V6, P65, DOI 10.3109/02699059209008124; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; Glisky EL, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P137; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GLISKY EL, 1992, NEUROPSYCHOLOGIA, V30, P899, DOI 10.1016/0028-3932(92)90034-J; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; GODFREY HPD, 1988, ARCH PHYS MED REHAB, V69, P458; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Goldstein G, 1996, CLIN NEUROPSYCHOL, V10, P66, DOI 10.1080/13854049608406664; Gontkovsky ST, 2002, NEUROREHABILITATION, V17, P195; Goverover Y, 2009, AM J OCCUP THER, V63, P543, DOI 10.5014/ajot.63.5.543; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Grilli MD, 2011, NEUROPSYCHOL REHABIL, V21, P847, DOI 10.1080/09602011.2011.627263; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Haslam C, 2011, J CLIN EXP NEUROPSYC, V33, P432, DOI 10.1080/13803395.2010.533155; HAYMAN CAG, 1993, J COGNITIVE NEUROSCI, V5, P375, DOI 10.1162/jocn.1993.5.4.375; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P49, DOI 10.1076/jcen.25.1.49.13631; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P1255, DOI 10.1016/0028-3932(95)00061-7; Hux K, 2000, BRAIN INJURY, V14, P907; Jennett S M, 1991, Int Disabil Stud, V13, P83; Johansson B, 2012, SCAND J OCCUP THER, V19, P176, DOI 10.3109/11038128.2011.603352; Kalla T, 2001, NEUROPSYCHOL REHABIL, V11, P1; Kapur N, 1994, MEMORY DISORDERS CLI; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Kessler RC, 2010, INT J METH PSYCH RES, V19, P4, DOI 10.1002/mpr.310; Khateb A, 2005, EUR NEUROL, V54, P39, DOI 10.1159/000087718; Kim YW, 2009, CLIN NEUROPHARMACOL, V32, P63, DOI 10.1097/WNF.0b013e31816f1bc1; Kolb B, 2004, BRAIN COGNITION, V55, P104, DOI 10.1016/s0278-2626(03)00278-1; Lebowitz MS, 2012, J REHABIL RES DEV, V49, P1547, DOI 10.1682/JRRD.2011.07.0133; Lemoncello R, 2011, NEUROPSYCHOL REHABIL, V21, P825, DOI 10.1080/09602011.2011.618661; Lindsay P, 2008, CAN MED ASSOC J, V179, pS1, DOI 10.1503/cmaj.081148.R2; Lloyd J, 2009, NEUROPSYCHOL REHABIL, V19, P98, DOI 10.1080/09602010802117392; Loranye H, 1974, MEMORY BOOK CLASSIC; Luria AR, 1982, LANGUAGE COGNITION; Lynch B, 2002, J HEAD TRAUMA REHAB, V17, P446, DOI 10.1097/00001199-200210000-00006; Manasse NJ, 2005, BRAIN INJURY, V19, P633, DOI 10.1080/02699050400013667; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; McDonald A, 2011, NEUROPSYCHOL REHABIL, V21, P784, DOI 10.1080/09602011.2011.598405; McKerracher G, 2005, NEUROPSYCHOL REHABIL, V15, P115, DOI 10.1080/09602010443000056; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; MOLLOY M, 1984, AUST OCCUP THER J, V31, P20; Morey CE, 2003, BRAIN INJURY, V17, P809, DOI 10.1080/0269905031000088586; O'Neil-Pirozzi TM, 2010, J HEAD TRAUMA REHAB, V25, P43, DOI 10.1097/HTR.0b013e3181bf24b1; Owen AM, 2010, NATURE, V465, P775, DOI 10.1038/nature09042; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Page M, 2006, NEUROPSYCHOLOGIA, V44, P90, DOI 10.1016/j.neuropsychologia.2005.04.004; Parkin AJ, 1998, COGNITIVE NEUROPSYCH, V15, P361, DOI 10.1080/026432998381131; PATTEN BM, 1972, ARCH NEUROL-CHICAGO, V26, P25, DOI 10.1001/archneur.1972.00490070043006; Pitel AL, 2006, BRAIN INJURY, V20, P1099, DOI 10.1080/02699050600909961; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Potvin MJ, 2011, NEUROPSYCHOL REHABIL, V21, P899, DOI 10.1080/09602011.2011.630882; Powell LE, 2012, NEUROPSYCHOL REHABIL, V22, P85, DOI 10.1080/09602011.2011.640466; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Raskin SA, 2009, BRAIN IMPAIR, V10, P76, DOI 10.1375/brim.10.1.76; Riley GA, 2004, NEUROPSYCHOL REHABIL, V14, P257, DOI 10.1080/09602010343000057; Riley GA, 2000, NEUROPSYCHOL REHABIL, V10, P133, DOI 10.1080/096020100389219; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Schefft BK, 2008, APPL NEUROPSYCHOL, V15, P61, DOI 10.1080/09084280801917806; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Shum D, 2011, J REHABIL MED, V43, P216, DOI 10.2340/16501977-0647; Silver JM, 2009, BRAIN INJURY, V23, P123, DOI 10.1080/02699050802649696; Sohlberg M. M., 2006, REV NEUROPSICOLOGIA, V1, P14; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Sumowski JF, 2010, J INT NEUROPSYCH SOC, V16, P1147, DOI 10.1017/S1355617710001128; Svoboda E, 2010, NEUROPSYCHOL REHABIL, V20, P562, DOI 10.1080/09602011003669918; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Taverni JP, 1998, BRAIN INJURY, V12, P77; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Tenovuo O, 2009, BRAIN INJURY, V23, P548, DOI 10.1080/02699050902926275; The ADAPTE Collaboration, 2009, ADAPTE PROC RES TOOL; Thickpenny-Davis KL, 2007, J HEAD TRAUMA REHAB, V22, P303, DOI 10.1097/01.HTR.0000290975.09496.93; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Walker W, 2004, BRAIN INJURY, V18, P739, DOI 10.1080/02699050310001646224; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Wilson B.A., 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI [https://doi.org/10.1080/09602019108401386, DOI 10.1080/09602019108401386]; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wilson BA, 1997, NEUROPSYCHOL REHABIL, V7, P43, DOI 10.1080/713755518; Wilson Barbara A., 2009, MEMORY REHABILITATIO; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; ZENCIUS A, 1991, Brain Injury, V5, P321, DOI 10.3109/02699059109008102; ZENCIUS A, 1990, Brain Injury, V4, P33, DOI 10.3109/02699059009026146; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	124	56	57	1	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					369	386		10.1097/HTR.0000000000000069			18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300012	24984098				2021-06-18	
J	Zatzick, D; Russo, J; Lord, SP; Varley, C; Wang, J; Berliner, L; Jurkovich, G; Whiteside, LK; O'Connor, S; Rivara, FP				Zatzick, Douglas; Russo, Joan; Lord, Sarah Peregrine; Varley, Christopher; Wang, Jin; Berliner, Lucy; Jurkovich, Gregory; Whiteside, Lauren K.; O'Connor, Stephen; Rivara, Frederick P.			Collaborative Care Intervention Targeting Violence Risk Behaviors, Substance Use, and Posttraumatic Stress and Depressive Symptoms in Injured Adolescents A Randomized Clinical Trial	JAMA PEDIATRICS			English	Article							TRAUMA-CENTER; EMERGENCY-DEPARTMENTS; ANXIETY DISORDERS; ALCOHOL MISUSE; ASSOCIATION; CHILDREN; HEALTH; IMPACT; PREVALENCE; OUTCOMES	IMPORTANCE Violence and injury risk behaviors, alcohol and drug use problems, and posttraumatic stress disorder (PTSD) and depressive symptoms occur frequently among adolescents presenting to acute care medical settings after traumatic physical injury. OBJECTIVE To test the effectiveness of a stepped collaborative care intervention targeting this constellation of risk behaviors and symptoms in randomly sampled hospitalized adolescents with and without traumatic brain injury. DESIGN, SETTING, AND PARTICIPANTS A pragmatic randomized clinical trial was conducted at a single US level I trauma center. Participants included 120 adolescents aged 12 to 18 years randomized to intervention (n = 59) and control (n = 61) conditions. INTERVENTIONS Stepped collaborative care intervention included motivational interviewing elements targeting risk behaviors and substance use as well as medication and cognitive behavioral therapy elements targeting PTSD and depressive symptoms. MAIN OUTCOMES AND MEASURES Adolescents were assessed at baseline before randomization and 2, 5, and 12 months after injury hospitalization. Standardized instruments were used to assess violence risk behaviors, alcohol and drug use, and PTSD and depressive symptoms. RESULTS The investigation attained more than 95% adolescent follow-up at each assessment point. At baseline, approximately one-third of the participants endorsed the violence risk behavior of carrying a weapon. Regression analyses demonstrated that intervention patients experienced significant reductions in weapon carrying compared with controls during the year after injury (group x time effect, F-3,F-344 = 3.0; P =.03). At 12 months after the injury, 4 (7.3%) intervention patients vs 13 (21.3%) control patients reported currently carrying a weapon (relative risk, 0.31; 95% CI, 0.11-0.90). The intervention was equally effective in reducing the risk of weapon carrying among injured adolescents with and without traumatic brain injury. Other treatment targets, including alcohol and drug use problems and high levels of PTSD and depressive symptoms, occurred less frequently in the cohort relative to weapon carrying and were not significantly affected by the intervention. CONCLUSIONS AND RELEVANCE Collaborative care intervention reduced the risk of adolescent weapon carrying during the year after the injury hospitalization. Future investigation should replicate this preliminary observation. If the finding is replicated, orchestrated investigative and policy efforts could systematically implement and evaluate screening and intervention procedures targeting youth violence prevention at US trauma centers.	[Zatzick, Douglas; Wang, Jin] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Russo, Joan; Lord, Sarah Peregrine; Varley, Christopher; O'Connor, Stephen] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Berliner, Lucy] Univ Washington, Sch Med, Harborview Ctr Sexual Assault & Traumat Stress, Seattle, WA USA; [Jurkovich, Gregory] Denver Hlth Med Ctr, Trauma & Surg Serv, Denver, CO USA; [Whiteside, Lauren K.] Univ Washington, Sch Med, Div Emergency Med, Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA	Zatzick, D (corresponding author), Harborview Injury Prevent & Res Ctr, Dept Psychiat & Behav Sci, 325 Ninth Ave,POB 359960, Seattle, WA 98104 USA.	dzatzick@u.washington.edu		Whiteside, Lauren/0000-0002-0284-5336	Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [H34/MC08508-01-00]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24/MH086814]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K24MH086814] Funding Source: NIH RePORTER	This work was supported by the Health Resources and Services Administration grant H34/MC08508-01-00 and the National Institute of Mental Health grant K24/MH086814 (Dr Zatzick).	Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; American College of Surgeons Committee on Trauma, 2006, RES OPT CAR INJ PAT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bogenschutz MP, 2011, AM J DRUG ALCOHOL AB, V37, P417, DOI 10.3109/00952990.2011.596971; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Cook PJ, 1999, JAMA-J AM MED ASSOC, V282, P447, DOI 10.1001/jama.282.5.447; Cunningham RM, 2009, ACAD EMERG MED, V16, P1078, DOI 10.1111/j.1553-2712.2009.00552.x; Curran GM, 2012, MED CARE, V50, P217, DOI 10.1097/MLR.0b013e3182408812; D'Onofrio G, 2010, ANN EMERG MED, V56, P551, DOI 10.1016/j.annemergmed.2010.06.562; Dunn Chris, 2003, Semin Clin Neuropsychiatry, V8, P188, DOI 10.1016/S1084-3612(03)00025-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Gilbody S, 2006, ARCH INTERN MED, V166, P2314, DOI 10.1001/archinte.166.21.2314; Glasgow RE, 2012, AM J PUBLIC HEALTH, V102, P1274, DOI 10.2105/AJPH.2012.300755; Holbrook TL, 2005, J TRAUMA, V59, P1126, DOI 10.1097/01.ta.0000196433.61423.f2; Huemer J, 2010, CHILD PSYCHIAT HUM D, V41, P624, DOI 10.1007/s10578-010-0192-3; Institute of Medicine, 2006, EM CAR CHILDR GROW P; Johns Hopkins Health Services Research and Development Center, 1989, DET INJ SEV HOS DISC; Kassam-Adams N, 2011, J TRAUMA STRESS, V24, P252, DOI 10.1002/jts.20640; Katon WJ, 2010, NEW ENGL J MED, V363, P2611, DOI 10.1056/NEJMoa1003955; Kearns MC, 2012, DEPRESS ANXIETY, V29, P833, DOI 10.1002/da.21997; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koepsell TD, 2011, AM J PREV MED, V40, P191, DOI 10.1016/j.amepre.2010.10.022; Kolko DJ, 2012, ARCH PEDIAT ADOL MED, V166, P224, DOI 10.1001/archpediatrics.2011.201; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mahajan P, 2009, PEDIATR EMERG CARE, V25, P715, DOI 10.1097/PEC.0b013e3181bec82f; McCaig Linda F, 2006, Adv Data, P1; Miller TR, 1994, MMWR-MORBID MORTAL W, V43, P581; Monti PM, 1999, J CONSULT CLIN PSYCH, V67, P989, DOI 10.1037/0022-006X.67.6.989; MURRAY CJ, 1996, GLOB BURD DIS COMPR; National Center for Injury Prevention and Control, 2006, CDC INJ FACT BOOK; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; O'Donnell ML, 2012, J TRAUMA STRESS, V25, P125, DOI 10.1002/jts.21677; Pickett W, 2005, PEDIATRICS, V116, pE855, DOI 10.1542/peds.2005-0607; Ranney ML, 2012, ANN EMERG MED, V60, P218, DOI 10.1016/j.annemergmed.2012.02.026; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Richardson L, 2009, GEN HOSP PSYCHIAT, V31, P36, DOI 10.1016/j.genhosppsych.2008.09.019; Richardson LP, 2010, PEDIATRICS, V126, P1117, DOI 10.1542/peds.2010-0852; Roy-Byrne P, 2010, JAMA-J AM MED ASSOC, V303, P1921, DOI 10.1001/jama.2010.608; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Shafii T, 2007, AM J PUBLIC HEALTH, V97, P1090, DOI 10.2105/AJPH.2005.068437; Steinberg AM, 2013, J TRAUMA STRESS, V26, P1, DOI 10.1002/jts.21780; Strawn JR, 2010, J CLIN PSYCHIAT, V71, P932, DOI 10.4088/JCP.09r05446blu; TEASDALE G, 1974, LANCET, V2, P81; Terrell F, 2008, J AM COLL SURGEONS, V207, P630, DOI 10.1016/j.jamcollsurg.2008.05.021; Thorpe KE, 2009, J CLIN EPIDEMIOL, V62, P464, DOI 10.1016/j.jclinepi.2008.12.011; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Trusz SG, 2011, PSYCHIATRY, V74, P207, DOI 10.1521/psyc.2011.74.3.207; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; Villaveces A, 2000, JAMA-J AM MED ASSOC, V283, P1205, DOI 10.1001/jama.283.9.1205; Wagner Amy W, 2003, Semin Clin Neuropsychiatry, V8, P175, DOI 10.1016/S1084-3612(03)00018-2; Walton MA, 2010, JAMA-J AM MED ASSOC, V304, P527, DOI 10.1001/jama.2010.1066; Wells KB, 2000, JAMA-J AM MED ASSOC, V283, P212, DOI 10.1001/jama.283.2.212; Winston FK, 2003, JAMA-J AM MED ASSOC, V290, P643, DOI 10.1001/jama.290.5.643; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2001, MED CARE, V39, P327, DOI 10.1097/00005650-200104000-00004; Zatzick Douglas, 2003, Semin Clin Neuropsychiatry, V8, P168, DOI 10.1016/S1084-3612(03)00015-7; Zatzick D, 2013, ANN SURG, V257, P390, DOI 10.1097/SLA.0b013e31826bc313; Zatzick D, 2012, J SUBST ABUSE TREAT, V43, P410, DOI 10.1016/j.jsat.2012.08.009; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	68	56	56	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	JUN	2014	168	6					532	539		10.1001/jamapediatrics.2013.4784			8	Pediatrics	Pediatrics	AI4MZ	WOS:000336840800011	24733515	Bronze			2021-06-18	
J	Huang, XL; Zhang, F; Wang, Y; Sun, XL; Choi, KY; Liu, DB; Choi, JS; Shin, TH; Cheon, J; Niu, G; Chen, XY				Huang, Xinglu; Zhang, Fan; Wang, Yu; Sun, Xiaolian; Choi, Ki Young; Liu, Dingbin; Choi, Jin-sil; Shin, Tae-Hyun; Cheon, Jinwoo; Niu, Gang; Chen, Xiaoyuan			Design Considerations of Iron-Based Nanoclusters for Noninvasive Tracking of Mesenchymal Stem Cell Homing	ACS NANO			English	Article						mesenchymal stem cell; homing; iron oxide nanoparticle; magnetic resonance imaging; CXCR4/SDF-1 alpha	INFARCTED MYOCARDIUM; CXCR4 EXPRESSION; MRI CONTRAST; IN-VITRO; MIGRATION; NANOPARTICLES; ENGRAFTMENT; CHEMOKINE; RECEPTOR; MICE	Stem-cell-based therapies have attracted considerable interest in regenerative medicine and ontological research. However, a major limitation of systemic delivery of stem cells is the low homing efficiency to the target site. Here, we report a serendipitous finding that various iron-based magnetic nanoparticles (MNPs) actively augment chemokine receptor CXCR4 expression of bone-marrow-derived mesenchymal stem cells (MSCs). On the basis of this observation, we designed an iron-based nanocluster that can effectively label MSCs, improve cell homing efficiency, and track the fate of the cells in vivo. Using this nanocluster, the labeled MSCs were accurately monitored by magnetic resonance imaging and improved the homing to both traumatic brain Injury and glioblastoma models as compared to unlabeled MSCs. Our findings provide a simple and safe method for imaging and targeted delivery of stem cells and extend the potential applications of iron-based MNPs in regenerative medicine and oncology.	[Huang, Xinglu; Zhang, Fan; Wang, Yu; Sun, Xiaolian; Choi, Ki Young; Liu, Dingbin; Niu, Gang; Chen, Xiaoyuan] NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA; [Zhang, Fan] Xiamen Univ, Ctr Mol Imaging & Translat Med, State Key Lab Mol Vaccinol & Mol Diagnost, Sch Publ Hlth, Xiamen, Peoples R China; [Choi, Jin-sil; Shin, Tae-Hyun; Cheon, Jinwoo] Yonsei Univ, Dept Chem, Seoul 120749, South Korea	Chen, XY (corresponding author), NIBIB, LOMIN, NIH, Bethesda, MD 20892 USA.	shawn.chen@nih.gov	Choi, Jin-sil/AAD-1076-2021; CHOI, KI YOUNG/Q-7177-2016; Chen, Xiaoyuan/D-1860-2014	CHOI, KI YOUNG/0000-0002-4207-2665; Chen, Xiaoyuan/0000-0002-9622-0870	National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); Department of Defense (DOD) Center for Neuroscience and Regenerative Medicine (CNRM); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000073] Funding Source: NIH RePORTER	This work was supported, in part, by the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), and by the Department of Defense (DOD) Center for Neuroscience and Regenerative Medicine (CNRM).	Andrews M, 2012, BIOMETALS, V25, P749, DOI 10.1007/s10534-012-9543-9; Azab AK, 2012, BLOOD, V119, P5782, DOI 10.1182/blood-2011-09-380410; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chen M, 2004, J AM CHEM SOC, V126, P8394, DOI 10.1021/ja047648m; Cheng ZK, 2008, MOL THER, V16, P571, DOI 10.1038/sj.mt.6300374; Cho MH, 2012, NAT MATER, V11, P1038, DOI [10.1038/NMAT3430, 10.1038/nmat3430]; Choi KY, 2012, BIOMATERIALS, V33, P6186, DOI 10.1016/j.biomaterials.2012.05.029; Choi KY, 2010, BIOMATERIALS, V31, P106, DOI 10.1016/j.biomaterials.2009.09.030; Chung TH, 2011, ACS NANO, V5, P9807, DOI 10.1021/nn2033902; Dong F, 2012, CIRCULATION, V126, P314, DOI 10.1161/CIRCULATIONAHA.111.082453; Fleming RE, 2012, NEW ENGL J MED, V366, P348, DOI 10.1056/NEJMra1004967; Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260; Hinds KA, 2003, BLOOD, V102, P867, DOI 10.1182/blood-2002-12-3669; Huang XL, 2014, BIOMATERIALS, V35, P856, DOI 10.1016/j.biomaterials.2013.10.027; Huang XL, 2013, BIOMATERIALS, V34, P1772, DOI 10.1016/j.biomaterials.2012.11.032; Huang XL, 2012, ANGEW CHEM INT EDIT, V51, P1625, DOI 10.1002/anie.201107795; Jang JT, 2009, ANGEW CHEM INT EDIT, V48, P1234, DOI 10.1002/anie.200805149; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Karp JM, 2009, CELL STEM CELL, V4, P206, DOI 10.1016/j.stem.2009.02.001; Khan Wasim S, 2012, J Stem Cells, V7, P87; Kim HS, 2010, NMR BIOMED, V23, P514, DOI 10.1002/nbm.1487; Kircher MF, 2011, NAT REV CLIN ONCOL, V8, P677, DOI 10.1038/nrclinonc.2011.141; Li F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064771; Liu G, 2011, SMALL, V7, P2742, DOI 10.1002/smll.201100825; Loebinger MR, 2009, CANCER RES, V69, P8862, DOI 10.1158/0008-5472.CAN-09-1912; Ponte AL, 2007, STEM CELLS, V25, P1737, DOI 10.1634/stemcells.2007-0054; Matsumoto Y, 2008, MAGN RESON IMAGING, V26, P994, DOI 10.1016/j.mri.2008.01.039; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Mooney DJ, 2008, CELL STEM CELL, V2, P205, DOI 10.1016/j.stem.2008.02.005; Pantopoulos K, 2012, BIOCHEMISTRY-US, V51, P5705, DOI 10.1021/bi300752r; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Ruster B, 2006, BLOOD, V108, P3938, DOI 10.1182/blood-2006-05-025098; Sarkar D, 2011, BLOOD, V118, pE184, DOI 10.1182/blood-2010-10-311464; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852; Takeuchi H, 2007, NEUROSCI LETT, V426, P69, DOI 10.1016/j.neulet.2007.08.048; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Voswinkel J, 2013, CLIN REV ALLERG IMMU, V45, P180, DOI 10.1007/s12016-012-8347-6; Wang H, 2009, STEM CELLS, V27, P1548, DOI 10.1002/stem.81; Xie J, 2013, CELL IMMUNOL, V281, P68, DOI 10.1016/j.cellimm.2013.02.001; Zhang DS, 2008, J MOL CELL CARDIOL, V44, P281, DOI 10.1016/j.yjmcc.2007.11.010; Zhang F, 2012, BIOMATERIALS, V33, P5414, DOI 10.1016/j.biomaterials.2012.04.032; Zhang M, 2007, FASEB J, V21, P3197, DOI 10.1096/fj.06-6558com; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	46	56	59	3	87	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	MAY	2014	8	5					4403	4414		10.1021/nn4062726			12	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	AI1UM	WOS:000336640600031	24754735	Bronze, Green Published			2021-06-18	
J	Donovan, V; Kim, C; Anugerah, AK; Coats, JS; Oyoyo, U; Pardo, AC; Obenaus, A				Donovan, Virginia; Kim, Claudia; Anugerah, Ariana K.; Coats, Jacqueline S.; Oyoyo, Udochuwku; Pardo, Andrea C.; Obenaus, Andre			Repeated mild traumatic brain injury results in long-term white-matter disruption	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						axon caliber; bilateral injury; corpus callosum; diffusion tensor imaging; myelin	FLUID PERCUSSION INJURY; AXONAL INJURY; TEMPORAL WINDOW; MOUSE MODEL; IN-VIVO; DIFFUSION; VULNERABILITY; MICE; DEMYELINATION; SENSITIVITY	Mild traumatic brain injury (mTBI) is an increasing public health concern as repetitive injuries can exacerbate existing neuropathology and result in increased neurologic deficits. In contrast to other models of repeated mTBI (rmTBI), our study focused on long-term white-matter abnormalities after bilateral mTBIs induced 7 days apart. A controlled cortical impact (CCI) was used to induce an initial mTBI to the right cortex of Single and rmTBI Sprague Dawley rats, followed by a second injury to the left cortex of rmTBI animals. Shams received only a craniectomy. Ex vivo diffusion tensor imaging (DTI), transmission electron microscopy (TEM), and histology were performed on the anterior corpus callosum at 60 days after injury. The rmTBI animals showed a significant bilateral increase in radial diffusivity (myelin), while only modest changes in axial diffusivity (axonal) were seen between the groups. Further, the rmTBI group showed an increased g-ratio and axon caliber in addition to myelin sheath abnormalities using TEM. Our DTI results indicate ongoing myelin changes, while the TEM data show continuing axonal changes at 60 days after rmTBI. These data suggest that bilateral rmTBI induced 7 days apart leads to progressive alterations in white matter that are not observed after a single mTBI.	[Donovan, Virginia; Obenaus, Andre] Univ Calif Riverside, Cell Mol & Dev Biol Program, Riverside, CA 92521 USA; [Kim, Claudia; Anugerah, Ariana K.] Loma Linda Univ, Sch Med, Loma Linda, CA 92354 USA; [Coats, Jacqueline S.; Pardo, Andrea C.; Obenaus, Andre] Loma Linda Univ, Dept Pediat, Loma Linda, CA 92354 USA; [Oyoyo, Udochuwku] Loma Linda Univ, Dept Radiol, Loma Linda, CA 92354 USA	Obenaus, A (corresponding author), Loma Linda Univ, Dept Pediat, 11175 Campus St,Room A1120, Loma Linda, CA 92354 USA.	aobenaus@llu.edu	Pardo, Andrea/B-4836-2017	Pardo, Andrea/0000-0001-7767-8539	NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA014089]	The authors wish to acknowledge Douglas Hauser, Ernesto Barron, and the USC/Norris Cancer Center's Cell and Tissue Imaging Core facility (supported by NCI grant P30CA014089) for assistance with TEM tissue preparation and imaging. Additionally, the authors would like to thank Dr Monica J Carson and Bethann Martinez for helpful suggestions and Faisal Rashid for assistance with manual segmentation of regional DTI ROIs. We also thank Dr Richard Sun for use of the DTI software and helpful discussions.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klawiter EC, 2011, NEUROIMAGE, V55, P1454, DOI 10.1016/j.neuroimage.2011.01.007; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leigland LA, 2013, NEUROIMAGE, V83, P1081, DOI 10.1016/j.neuroimage.2013.07.068; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mnatsakanyan L, 2011, J NEURO-OPHTHALMOL, V31, P6, DOI 10.1097/WNO.0b013e3181fab1b4; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Payne SC, 2011, J NEUROTRAUM, V28, P1077, DOI 10.1089/neu.2010.1665; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schnaar RL, 2009, J NEUROSCI RES, V87, P3267, DOI 10.1002/jnr.21992; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Sun SW, 2006, NEUROIMAGE, V32, P1195, DOI 10.1016/j.neuroimage.2006.04.212; Sun SW, 2009, NEUROIMAGE, V44, P611, DOI 10.1016/j.neuroimage.2008.10.032; Sun SW, 2003, MAGN RESON MED, V50, P743, DOI 10.1002/mrm.10605; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Zhang JY, 2012, MAGN RESON MED, V67, P750, DOI 10.1002/mrm.23032	45	56	56	0	9	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2014	34	4					715	723		10.1038/jcbfm.2014.6			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AE2AE	WOS:000333774900022	24473478	Green Published, Bronze			2021-06-18	
J	Wisco, BE; Marx, BP; Holowka, DW; Vasterling, JJ; Han, SC; Chen, MS; Gradus, JL; Nock, MK; Rosen, RC; Keane, TM				Wisco, Blair E.; Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Han, Sohyun C.; Chen, May S.; Gradus, Jaimie L.; Nock, Matthew K.; Rosen, Raymond C.; Keane, Terence M.			Traumatic Brain Injury, PTSD, and Current Suicidal Ideation Among Iraq and Afghanistan U.S. Veterans	JOURNAL OF TRAUMATIC STRESS			English	Article							MILITARY PERSONNEL; RISK; DEPLOYMENT; INTERVIEW; PROJECT; HISTORY	Suicide is a prevalent problem among veterans deployed to Iraq and Afghanistan. Traumatic brain injury (TBI) and psychiatric conditions, such as posttraumatic stress disorder (PTSD), are potentially important risk factors for suicide in this population, but the literature is limited by a dearth of research on female veterans and imprecise assessment of TBI and suicidal behavior. This study examined 824 male and 825 female U.S. veterans who were enrolled in the baseline assessment of the Veterans After-Discharge Longitudinal Registry (Project VALOR), an observational registry of veterans with and without PTSD who deployed in support of the wars in Iraq and Afghanistan and were enrolled in the Veterans Affairs healthcare system. Results indicated that current depressive symptoms, PTSD, and history of prior TBI were all significantly associated with current suicidal ideation (Cohen's d = 0.91, Cramers' Vs = .19 and .08, respectively). After adding a number of variables to the model, including psychiatric comorbidity, TBI history was associated with increased risk of current suicidal ideation among male veterans only (RR = 1.55). TBI is an important variable to consider in future research on suicide among veterans of the wars in Iraq and Afghanistan, particularly among male veterans.	[Wisco, Blair E.; Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Han, Sohyun C.; Chen, May S.; Gradus, Jaimie L.; Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Wisco, Blair E.; Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Gradus, Jaimie L.; Keane, Terence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Gradus, Jaimie L.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; [Nock, Matthew K.] Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA; [Rosen, Raymond C.] New England Res Inst, Watertown, MA 02172 USA	Marx, BP (corresponding author), VA Boston Healthcare Syst, Natl Ctr PTSD, 150 South Huntington Ave,116B-4, Boston, MA 02130 USA.	brian.marx@va.gov	Nock, Matthew/AAE-8330-2019; Marx, Brian/AAK-5072-2020; Keane, Terence/I-8253-2014	Gradus, Jaimie/0000-0003-1459-5327; Keane, Terence/0000-0002-0482-3149	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019836] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019836] Funding Source: NIH RePORTER		American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Barnes SM, 2012, REHABIL PSYCHOL, V57, P18, DOI 10.1037/a0027007; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; Pietrzak RH, 2010, J AFFECT DISORDERS, V123, P102, DOI 10.1016/j.jad.2009.08.001; Rosen RC, 2012, INT J METH PSYCH RES, V21, P5, DOI 10.1002/mpr.355; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wells TS, 2013, J AFFECT DISORDERS, V148, P77, DOI 10.1016/j.jad.2012.11.052	14	56	56	0	17	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	APR	2014	27	2					244	248		10.1002/jts.21900			5	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	AF2II	WOS:000334535400017	24639101				2021-06-18	
J	Leong, DF; Balcer, LJ; Galetta, SL; Liu, Z; Master, CL				Leong, D. F.; Balcer, L. J.; Galetta, S. L.; Liu, Z.; Master, C. L.			The King-Devick test as a concussion screening tool administered by sports parents	JOURNAL OF SPORTS MEDICINE AND PHYSICAL FITNESS			English	Article						Eye movements; Sports; Boxing	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; ON-FIELD; RECURRENT CONCUSSION; EARLY ADULTHOOD; EPIDEMIOLOGY; RISK; ENCEPHALOPATHY; SYMPTOMS	Background. Sports-related concussion has received increasing awareness due to short- and long-term neurologic seguelae seen among athletes. The King-Devick (K-D) test captures impairment of eye movements and other correlates of suboptimal brain function. We investigated the K-D test as a screening for concussion when administered by layperson sports parents in a cohort of amateur boxers. Methods. The K-D test was administered pre-fight and post-fight by laypersons masked to the head trauma status of each athlete. Matches were watched over by a ringside physician and boxing trainer. Athletes with suspected head trauma received testing with the Military Acute Concussion Evaluation (MACE) by the ringside physician to determine concussion status. Athletes sustaining concussion were compared to the athletes screened using the K-D test. Results. Post-fight K-D scores were lower (better) than the best baseline score (41 vs. 39.3 s, P=0.34, Wilcoxon signe-drank test), in the absence of concussion. One boxer sustained a concussion as determined by the ringside physician. This boxer was accurately identified by the layperson K-D testers due to a worsening in K-D test compared to baseline (3.2 seconds) and an increased number of errors. High levels of test-retest reliability were observed (intraclass correlation coefficient 0.90 [95% CI 0.84-0.97]). Additionally, 6 boxers who participated in multiple bouts showed no worsening of their K-D times further supporting that scores are not affected by the fatigue associated with sparring. Conclusion. The K-D test is a rapid sideline screening tool for concussion that can be effectively administered by nonmedically trained laypersons.	[Leong, D. F.] King Devick Test LLC, Oak Brook Terrace, IL 60181 USA; [Balcer, L. J.] NYU, Langone Med Ctr, New York, NY 10003 USA; [Galetta, S. L.] Beverly Hosp, Dept Internal Med, Danvers, MA USA; [Liu, Z.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Master, C. L.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Sports Med, Philadelphia, PA 19104 USA	Leong, DF (corresponding author), King Devick Test LLC, 2 Mid America Pl Ste 110, Oak Brook Terrace, IL 60181 USA.	dleong@kingdevicktest.com		Master, Christina/0000-0002-6717-4270	NIH/NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI); National MS SocietyNational Multiple Sclerosis Society	Dr. Leong is employed at King-Devick Test, LLC as a Director of Research; Dr. Balcer has served as a consultant for Biogen Idec, Questcor, and Novartis; and has received research support from the NIH/NEI and the National MS Society; Dr. Galetta has served as a consultant for Biogen Idec, Questcor, and Teva Pharmaceutical Industries Ltd.	Alla S, 2009, BR J SPORTS MED S1, V43, pi13; Bay E, 2011, ADV EMERG NURS J, V33, P71, DOI 10.1097/TME.0b013e318207e851; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Defense and Veterans Brain Injury Center, MIL AC CONC EV; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2011, PHYS MED REH CLIN N, V22, P603, DOI 10.1016/j.pmr.2011.08.003; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2002, PROG BRAIN RES, V140, P433; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hunt T, 2010, CLIN SPORT MED, V29, P5, DOI 10.1016/j.csm.2009.09.002; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Krumholtz I, 2000, OPTOMETRY, V71, P489; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Reilly R., 2011, COMMUNICATION; Ridgway GR, 2012, NEUROLOGY, V79, P80, DOI 10.1212/WNL.0b013e31825dce28; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Talavage T. M., 2010, J NEUROTRAUMA; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; White OB, 2012, J NEURO-OPHTHALMOL, V32, P266, DOI 10.1097/WNO.0b013e3182688230; Zazryn TR, 2009, CLIN J SPORT MED, V19, P20, DOI 10.1097/JSM.0b013e31818f1582	47	56	56	3	18	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0022-4707	1827-1928		J SPORT MED PHYS FIT	J. Sports Med. Phys. Fit.	FEB	2014	54	1					70	77					8	Sport Sciences	Sport Sciences	AB8PG	WOS:000332051900010	24445547				2021-06-18	
J	Merrifield, C; Danckert, J				Merrifield, Colleen; Danckert, James			Characterizing the psychophysiological signature of boredom	EXPERIMENTAL BRAIN RESEARCH			English	Article						Boredom; Depression; Heart rate; Skin conductance levels; Attention	TRAUMATIC BRAIN-INJURY; AUTONOMIC AROUSAL; PRONENESS; CORTISOL; DISTINCT; ADULTS; LAPSES	Research on the experience and expression of boredom is underdeveloped. The purpose of the present study was to explore the psychophysiological signature of the subjective experience of boredom. Healthy undergraduates (n = 72) viewed previously validated and standardized video clips to induce boredom, sadness, and a neutral affective state, while their heart rate (HR), skin conductance levels (SCL), and cortisol levels were measured. Boredom yielded dynamic psychophysiological responses that differed from the other emotional states. Of particular interest, the physiological signature of boredom relative to sadness was characterized by rising HR, decreased SCL, and increased cortisol levels. This pattern of results suggests that boredom may be associated with both increased arousal and difficulties with sustained attention. These findings may help to resolve divergent conceptualizations of boredom in the extant literature and, ultimately, to enhance our understanding and treatment of clinical syndromes in which self-reported boredom is a prominent symptom.	[Merrifield, Colleen; Danckert, James] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada	Danckert, J (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.	jdancker@uwaterloo.ca			Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); NSERC Canada Graduate Scholarship (CGS)Natural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by the Natural Sciences and Engineering Research Council of Canada (NSERC) Canada Research Chair and Discovery Grants to J. D. and NSERC Canada Graduate Scholarship (CGS)-Masters and Vanier CGS awards to C. M. We would like to thank Dr. David Moscovitch for his assistance with data collection, design and analysis, and comments on earlier drafts of this work.	Barmack JE, 1939, AM J PSYCHOL, V52, P467; Beck AT., 1996, BECK DEPRESSION INVE, V2; Berlyne D.E., 1960, CONFLICT AROUSAL CUR; BLASZCZYNSKI A, 1990, PSYCHOL REP, V67, P35, DOI 10.2466/PR0.67.5.35-42; Carriere JSA, 2008, CONSCIOUS COGN, V17, P835, DOI 10.1016/j.concog.2007.04.008; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; COLES MGH, 1972, J EXP PSYCHOL, V96, P371, DOI 10.1037/h0033603; de Weerth C, 2003, CLIN CHEM, V49, P658, DOI 10.1373/49.4.658; Eastwood JD, 2012, PERSPECT PSYCHOL SCI, V7, P482, DOI 10.1177/1745691612456044; EKMAN P, 1980, J PERS SOC PSYCHOL, V38, P270, DOI 10.1037/0022-3514.38.2.270; Fahlman SA, 2013, ASSESSMENT, V20, P68, DOI 10.1177/1073191111421303; Fahlman SA, 2009, J SOC CLIN PSYCHOL, V28, P307, DOI 10.1521/jscp.2009.28.3.307; FARMER R, 1986, J PERS ASSESS, V50, P4, DOI 10.1207/s15327752jpa5001_2; Fothergill A, 2007, PLANET EARTH; FRITH CD, 1983, BIOL PSYCHOL, V17, P27, DOI 10.1016/0301-0511(83)90064-9; GEIWITZ PJ, 1966, J PERS SOC PSYCHOL, V3, P592, DOI 10.1037/h0023202; Goldberg Y, 2013, BEHAV SCI-BASEL, V3, P434, DOI 10.3390/bs3030434; Goldberg YK, 2011, J SOC CLIN PSYCHOL, V30, P647, DOI 10.1521/jscp.2011.30.6.647; GROSS JJ, 1995, COGNITION EMOTION, V9, P87, DOI 10.1080/02699939508408966; HEBB DO, 1955, PSYCHOL REV, V62, P243, DOI 10.1037/h0041823; Hermens DF, 2004, BIOL PSYCHOL, V66, P221, DOI 10.1016/j.biopsycho.2003.10.006; Hofmann SG, 2006, INT J PSYCHOPHYSIOL, V61, P134, DOI 10.1016/j.ijpsycho.2005.09.003; KIRSCHBAUM C, 1989, NEUROPSYCHOBIOLOGY, V22, P150, DOI 10.1159/000118611; Lacey J. I., 1970, PHYSL CORRELATES EMO, P205, DOI DOI 10.1016/B978-0-12-102850-3.50016-5; Lacey JI, 1959, RES PSYCHOTHERAPY; Lackschewitz H, 2008, PSYCHONEUROENDOCRINO, V33, P612, DOI 10.1016/j.psyneuen.2008.01.016; LEDOUX I, 1996, EMOTIONAL BRAIN MYST; Lee CM, 2007, ADDICT BEHAV, V32, P1384, DOI 10.1016/j.addbeh.2006.09.010; LePera N., 2011, NEW SCH PSYCHOL B, V8, P15; LONDON H, 1972, J ABNORM PSYCHOL, V80, P29, DOI 10.1037/h0033311; Lovell D. P., 1979, CHAMP; LUNDBERG U, 1993, ERGONOMICS, V36, P601, DOI 10.1080/00140139308967923; Malkovsky E, 2012, EXP BRAIN RES, V221, P59, DOI 10.1007/s00221-012-3147-z; Martin M., 2006, QUAL RES PSYCHOL, V3, P193, DOI [DOI 10.1191/1478088706QRP0660A, 10.1191/1478088706qrp066oa, DOI 10.1191/1478088706QRP066OA]; Mercer KB., 2010, INT GAMBL STUD, V10, P91, DOI [10.1080/1445979100 3754414, DOI 10.1080/14459791003754414, 10.1080/14459791003754414]; MIKULAS WL, 1993, PSYCHOL REC, V43, P3; O'Connell RG, 2008, NEUROPSYCHOLOGIA, V46, P1379, DOI 10.1016/j.neuropsychologia.2007.12.018; OBRIST PA, 1970, PSYCHOPHYSIOLOGY, V6, P695, DOI 10.1111/j.1469-8986.1970.tb02257.x; Ohman A, 2000, HDB PSYCHOPHYSIOLOGY; Ohsuga M, 2001, INT J PSYCHOPHYSIOL, V40, P211, DOI 10.1016/S0167-8760(00)00189-6; Papillo JF., 1990, PRINCIPLES PSYCHOPHY, P456; Passik SD, 2003, PSYCHO-ONCOL, V12, pS227; Passik Steven D, 2003, Palliat Support Care, V1, P41; Pattyn N, 2008, PHYSIOL BEHAV, V93, P369, DOI 10.1016/j.physbeh.2007.09.016; PHILIPPOT P, 1993, COGNITION EMOTION, V7, P171, DOI 10.1080/02699939308409183; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Sommers J, 2000, J CLIN PSYCHOL, V56, P149, DOI 10.1002/(SICI)1097-4679(200001)56:1<149::AID-JCLP14>3.0.CO;2-Y; Strahler J, 2010, PSYCHOPHYSIOLOGY, V47, P587, DOI 10.1111/j.1469-8986.2009.00957.x; Theobald Dale E, 2003, Palliat Support Care, V1, P71; van Tilburg WAP, 2012, MOTIV EMOTION, V36, P181, DOI 10.1007/s11031-011-9234-9; Vodanovich SJ, 2003, J PSYCHOL, V137, P569, DOI 10.1080/00223980309600636; VODANOVICH SJ, 1991, PSYCHOL REP, V69, P1139, DOI 10.2466/PR0.69.8.1139-1146; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WATT JD, 1992, PSYCHOL REP, V70, P688, DOI 10.2466/PR0.70.3.688-690	54	56	58	3	34	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	FEB	2014	232	2					481	491		10.1007/s00221-013-3755-2			11	Neurosciences	Neurosciences & Neurology	AA0GG	WOS:000330773000012	24202238				2021-06-18	
J	Tavender, EJ; Bosch, M; Gruen, RL; Green, SE; Knott, J; Francis, JJ; Michie, S; O'Connor, DA				Tavender, Emma J.; Bosch, Marije; Gruen, Russell L.; Green, Sally E.; Knott, Jonathan; Francis, Jill J.; Michie, Susan; O'Connor, Denise A.			Understanding practice: the factors that influence management of mild traumatic brain injury in the emergency department-a qualitative study using the Theoretical Domains Framework	IMPLEMENTATION SCIENCE			English	Article						Emergency department management; Mild traumatic brain injury; Theoretical Domains Framework; Semi-structured interviews	BEHAVIOR-CHANGE INTERVENTIONS; HEAD-INJURY; IMPLEMENTATION; INFORMATION; PERCEPTIONS; GUIDELINES; PHYSICIANS; DISCHARGE	Background: Mild traumatic brain injury is a frequent cause of presentation to emergency departments. Despite the availability of clinical practice guidelines in this area, there is variation in practice. One of the aims of the Neurotrauma Evidence Translation program is to develop and evaluate a targeted, theory-and evidence-informed intervention to improve the management of mild traumatic brain injury in Australian emergency departments. This study is the first step in the intervention development process and uses the Theoretical Domains Framework to explore the factors perceived to influence the uptake of four key evidence-based recommended practices for managing mild traumatic brain injury. Methods: Semi-structured interviews were conducted with emergency staff in the Australian state of Victoria. The interview guide was developed using the Theoretical Domains Framework to explore current practice and to identify the factors perceived to influence practice. Two researchers coded the interview transcripts using thematic content analysis. Results: A total of 42 participants (9 Directors, 20 doctors and 13 nurses) were interviewed over a seven-month period. The results suggested that (i) the prospective assessment of post-traumatic amnesia was influenced by: knowledge; beliefs about consequences; environmental context and resources; skills; social/professional role and identity; and beliefs about capabilities; (ii) the use of guideline-developed criteria or decision rules to inform the appropriate use of a CT scan was influenced by: knowledge; beliefs about consequences; environmental context and resources; memory, attention and decision processes; beliefs about capabilities; social influences; skills and behavioral regulation; (iii) providing verbal and written patient information on discharge was influenced by: beliefs about consequences; environmental context and resources; memory, attention and decision processes; social/professional role and identity; and knowledge; (iv) the practice of providing brief, routine follow-up on discharge was influenced by: environmental context and resources; social/professional role and identity; knowledge; beliefs about consequences; and motivation and goals. Conclusions: Using the Theoretical Domains Framework, factors thought to influence the management of mild traumatic brain injury in the emergency department were identified. These factors present theoretically based targets for a future intervention.	[Tavender, Emma J.; Bosch, Marije] Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia; [Gruen, Russell L.] Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst,Dept Trauma, Melbourne, Vic 3181, Australia; [Green, Sally E.; O'Connor, Denise A.] Monash Univ, Sch Publ Hlth & Preventat Med, Melbourne, Vic 3181, Australia; [Knott, Jonathan] Royal Melbourne Hosp, Melbourne Med Sch, Melbourne, Vic, Australia; [Knott, Jonathan] Royal Melbourne Hosp, Dept Emergency Med, Melbourne, Vic, Australia; [Francis, Jill J.] City Univ London, Sch Hlth Sci, London EC1V 0HB, England; [Michie, Susan] UCL, Dept Clin Educ & Hlth Psychol, London, England	Tavender, EJ (corresponding author), Monash Univ, Alfred Hosp, Dept Surg, Natl Trauma Res Inst, Melbourne, Vic 3181, Australia.	emma.tavender@monash.edu	O'Connor, Denise/ABC-6655-2020; Michie, Susan/A-1745-2010	O'Connor, Denise/0000-0002-6836-122X; Francis, Jill/0000-0001-5784-8895; Green, Sally Elizabeth/0000-0002-9564-9050; Michie, Susan/0000-0003-0063-6378; Tavender, Emma/0000-0002-7230-712X	Transport Accident Commission, Australia; Australian Postgraduate AwardAustralian Government; Australian National Health and Medical Research Council Public Health FellowshipNational Health and Medical Research Council of Australia [606726]	The NET Program is funded by the Transport Accident Commission, Australia. EJT is supported by an Australian Postgraduate Award. DOC is supported by an Australian National Health and Medical Research Council Public Health Fellowship (606726).	Abelson-Mitchell N, 2008, J CLIN NURS, V17, P46, DOI 10.1111/j.1365-2702.2007.01941.x; Angus D, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-4; Australian Bureau of Statistics, 2011, 1216 0 AUSTR STAND G; Baker R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005470.pub2; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Berben SAA, 2012, INJURY, V43, P1397, DOI 10.1016/j.injury.2011.01.029; Bessen T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3056; Bosch M, 2013, J EVAL CLIN PRACT, V19, P763, DOI 10.1111/j.1365-2753.2012.01835.x; Buetow S, 2010, J HEALTH SERV RES PO, V15, P123, DOI 10.1258/jhsrp.2009.009081; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Davies P, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-14; Dayawansa MK, 2010, THESIS MONASH U; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015; Francis JJ, 2009, BRIT J HEALTH PSYCH, V14, P625, DOI 10.1348/135910708X397025; French SD, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-38; Green SE, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-74; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Grol R., 2005, IMPROVING PATIENT CA; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Ingebrigtsen T, 1997, ACTA NEUROL SCAND, V95, P51, DOI 10.1111/j.1600-0404.1997.tb00068.x; Kerr J, 2005, EMERG MED J, V22, P850, DOI 10.1136/emj.2004.022673; Kerr J, 2007, EMERG MED J, V24, P330, DOI 10.1136/emj.2006.044230; Kuper A, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1035; Meurer WJ, 2011, BMC EMERG MED, V11, DOI 10.1186/1471-227X-11-5; Michie S, 2005, QUAL SAF HEALTH CARE, V14, P26, DOI 10.1136/qshc.2004.011155; Michie S, 2008, APPL PSYCHOL-INT REV, V57, P660, DOI 10.1111/j.1464-0597.2008.00341.x; Patey AM, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-52; Peachey T, 2011, EMERG MED J, V28, P707, DOI 10.1136/emj.2010.093872; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P42, DOI 10.1017/S0317167100006296; Sandelowski M, 2000, RES NURS HEALTH, V23, P246, DOI 10.1002/1098-240X(200006)23:3<246::AID-NUR9>3.0.CO;2-H; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stuart B, 2012, J EMERG NURS, V38, P435, DOI 10.1016/j.jen.2011.04.006; Tavender EJ, 2011, ACAD EMERG MED, V18, P880, DOI 10.1111/j.1553-2712.2011.01134.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587	39	56	56	1	31	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1748-5908			IMPLEMENT SCI	Implement. Sci.	JAN 13	2014	9								8	10.1186/1748-5908-9-8			10	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	290YB	WOS:000329793400001	24418161	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Davis, GA; Purcell, LK				Davis, Gavin A.; Purcell, Laura K.			The evaluation and management of acute concussion differs in young children	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Children; Children's injuries; Head injuries	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; BASE-LINE VALUES; POSTCONCUSSIVE SYMPTOMS; HEAD-INJURY; HIGH-SCHOOL; STANDARDIZED ASSESSMENT; FOOTBALL PLAYERS; YOUTH SPORTS; MILD	Background There are many reasons why concussion in children needs to be considered different from adults. The Zurich (2008) recommendations on the management of concussion in children are restricted to children less than to 10years of age. It does not include recommendations for children aged 5-10years. The aim of this study is to review the current literature on (1) concussion assessment at the sideline and during recovery stages, especially in the age group 5-15years, and (2) the management of concussion in children and adolescents. Methods A literature review using the MEDLINE database was undertaken. Articles were selected that included evaluation and/or management in children aged 5-15years. Results There are no sideline assessment tools validated for use in this age group. There are a number of different symptom scales that have been validated during different stages of the follow-up assessment in children. No single paediatric concussion assessment tool has been validated for use from sideline through to all stages of recovery. Reliability studies have been published on Balance Error Scoring System in children, but validity studies in this age group have not been published. The management of concussion includes withdrawal from play on the day and cognitive and physical rest. The priority of concussion management in children is to return to learn; while this is usually rapid, there are some children in whom a graduated return to school is required, which should include a number of accommodations. Conclusions A young child is physically, cognitively and emotionally very different from adults, and requires the use of a different set of tools for the diagnosis, recovery-assessment and management of concussion. Age-specific, validated diagnostic tools are required, and management of concussion in children should focus attention on return to learn before considering return to play.	[Davis, Gavin A.] Austin Hlth, Dept Neurosurg, Cabrini Hlth, Melbourne, Vic, Australia; [Davis, Gavin A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Purcell, Laura K.] McMaster Univ, Dept Pediat, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Purcell, Laura K.] Elliott Sports Med Clin, Burlington, ON, Canada	Davis, GA (corresponding author), Cabrini Hlth, Dept Neurosurg, Cabrini Med Ctr, Suite 53, Malvern, Vic 3144, Australia.	gadavis@netspace.net.au	Meijer, Anna/K-5118-2016				Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Casey BJ, 2005, TRENDS COGN SCI, V9, P104, DOI 10.1016/j.tics.2005.01.011; Davis GA., 2012, MILD TRAUMATIC BRAIN, P99; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Eckner JT, 2013, BR J SPORTS MED, DOI 10.1136/bjsports-2012-091579; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Holbourn AHS, 1943, LANCET, V2, P438; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Janusz J.A., 2012, MILD TRAUMATIC BRAIN, P241; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Jinguji TM, 2011, PHYS MED REH CLIN N, V22, P565, DOI 10.1016/j.pmr.2011.08.001; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mailer BJ, 2008, J SPORT REHABIL, V17, P11, DOI 10.1123/jsr.17.1.11; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Munoz-Sanchez M, 2005, CHILD NERV SYST, V21, P128, DOI 10.1007/s00381-004-1036-x; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Purcell LK, 2012, PAED CHILD HEALT-CAN, V17, P36; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	53	56	56	1	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					98	U102		10.1136/bjsports-2012-092132			5	Sport Sciences	Sport Sciences	276KK	WOS:000328749000009	23613516				2021-06-18	
J	Purushothuman, S; Johnstone, DM; Nandasena, C; Mitrofanis, J; Stone, J				Purushothuman, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Mitrofanis, John; Stone, Jonathan			Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex - evidence from two transgenic mouse models	ALZHEIMERS RESEARCH & THERAPY			English	Article							LOW-LEVEL LASER; MIDBRAIN DOPAMINERGIC CELLS; TERM NEUROLOGICAL DEFICITS; MESENCHYMAL STEM-CELLS; OXIDATIVE STRESS; BONE-MARROW; RAT-HEART; THERAPY; MICE; PARKINSONISM	Introduction: Previous work has demonstrated the efficacy of irradiating tissue with red to infrared light in mitigating cerebral pathology and degeneration in animal models of stroke, traumatic brain injury, parkinsonism and Alzheimer's disease (AD). Using mouse models, we explored the neuroprotective effect of near infrared light (NIr) treatment, delivered at an age when substantial pathology is already present in the cerebral cortex. Methods: We studied two mouse models with AD-related pathologies: the K369I tau transgenic model (K3), engineered to develop neurofibrillary tangles, and the APPswe/PSEN1dE9 transgenic model (APP/PS1), engineered to develop amyloid plaques. Mice were treated with NIr 20 times over a four-week period and histochemistry was used to quantify AD-related pathological hallmarks and other markers of cell damage in the neocortex and hippocampus. Results: In the K3 mice, NIr treatment was associated with a reduction in hyperphosphorylated tau, neurofibrillary tangles and oxidative stress markers (4-hydroxynonenal and 8-hydroxy-2'-deoxyguanosine) to near wildtype levels in the neocortex and hippocampus, and with a restoration of expression of the mitochondrial marker cytochrome c oxidase in surviving neurons. In the APP/PS1 mice, NIr treatment was associated with a reduction in the size and number of amyloid-beta plaques in the neocortex and hippocampus. Conclusions: Our results, in two transgenic mouse models, suggest that NIr may have potential as an effective, minimally-invasive intervention for mitigating, and even reversing, progressive cerebral degenerations.	[Purushothuman, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Mitrofanis, John; Stone, Jonathan] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Purushothuman, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Stone, Jonathan] Univ Sydney, Discipline Physiol, Sydney, NSW 2006, Australia; [Mitrofanis, John] Univ Sydney, Discipline Anat & Histol, Sydney, NSW 2006, Australia	Johnstone, DM (corresponding author), Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia.	Daniel.Johnstone@sydney.edu.au	Johnstone, Daniel/E-9929-2013	Johnstone, Daniel/0000-0003-2876-3299; Purushothuman, Sivaraman/0000-0002-0880-5060	Tenix Corporation; Sir Zelman Cowen Universities Fund; Bluesand Foundation; National Health and Medical Research Council of Australia (NHMRC)National Health and Medical Research Council of Australia	The authors thank Tenix Corporation, Sir Zelman Cowen Universities Fund and Bluesand Foundation for funding. They are grateful to Prof. Lars Ittner for providing the breeding litter for K369I mice, and to Dr Louise Cole and the Bosch Advanced Microscopy facility for the help with MetaMorph. Sharon Spana was splendid for her technical help. DMJ is supported by a National Health and Medical Research Council of Australia (NHMRC) Early Career Fellowship.	Aliev G, 2002, BRAIN PATHOL, V12, P21; Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; Blanchard V, 2003, EXP NEUROL, V184, P247, DOI 10.1016/S0014-4886(03)00252-8; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Bruck W, 1997, ANN NEUROL, V42, P783, DOI 10.1002/ana.410420515; Calabrese V, 2007, NEUROCHEM RES, V32, P757, DOI 10.1007/s11064-006-9203-y; Cao DF, 2007, J BIOL CHEM, V282, P36275, DOI 10.1074/jbc.M703561200; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; Grillo SL, 2013, J PHOTOCH PHOTOBIO B, V123, P13, DOI 10.1016/j.jphotobiol.2013.02.015; Hamel E, 2008, EXP PHYSIOL, V93, P116, DOI 10.1113/expphysiol.2007.038729; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hou JF, 2008, LASER SURG MED, V40, P726, DOI 10.1002/lsm.20709; Ittner LM, 2008, P NATL ACAD SCI USA, V105, P15997, DOI 10.1073/pnas.0808084105; Jankowsky JL, 2004, HUM MOL GENET, V13, P159, DOI 10.1093/hmg/ddh019; Karu T, 2010, PHOTOMED LASER SURG, V28, P159, DOI 10.1089/pho.2010.2789; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; MECOCCI P, 1994, ANN NEUROL, V36, P747, DOI 10.1002/ana.410360510; Moro C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-40; Natoli R, 2010, MOL VIS, V16, P1801; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; Purushothuman S, 2013, BRAIN RES, V1535, P61, DOI 10.1016/j.brainres.2013.08.047; Purushothuman S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059740; Sayre LM, 1997, J NEUROCHEM, V68, P2092; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Stamer K, 2002, J CELL BIOL, V156, P1051, DOI 10.1083/jcb.200108057; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Truett GE, 2000, BIOTECHNIQUES, V29, P52, DOI 10.2144/00291bm09; Tuby H, 2006, LASER SURG MED, V38, P682, DOI 10.1002/lsm.20377; Tuby H, 2013, PHOTOMED LASER SURG, V31, P269, DOI 10.1089/pho.2012.3395; Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Wen Y, 2004, J BIOL CHEM, V279, P22684, DOI 10.1074/jbc.M311768200; Whelan HT, 2001, J CLIN LASER MED SUR, V19, P305, DOI 10.1089/104454701753342758; Wilcock DM, 2006, NAT PROTOC, V1, P1591, DOI 10.1038/nprot.2006.277; Wilden L, 1998, J CLIN LASER MED SUR, V16, P159, DOI 10.1089/clm.1998.16.159; Wong-Riley MTT, 2001, NEUROREPORT, V12, P3033, DOI 10.1097/00001756-200110080-00011; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yan Q, 2003, J NEUROSCI, V23, P7504; Yao J, 2009, P NATL ACAD SCI USA, V106, P14670, DOI 10.1073/pnas.0903563106; Zhang X, 2010, EXP NEUROL, V223, P299, DOI 10.1016/j.expneurol.2009.07.033; Zhu XW, 2006, J ALZHEIMERS DIS, V9, P147	50	56	57	2	10	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1758-9193			ALZHEIMERS RES THER	Alzheimers Res. Ther.		2014	6	1							2	10.1186/alzrt232			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AM4DB	WOS:000339801600002	24387311	DOAJ Gold, Green Published			2021-06-18	
J	Tajiri, N; Kaneko, Y; Shinozuka, K; Ishikawa, H; Yankee, E; McGrogan, M; Case, C; Borlongan, CV				Tajiri, Naoki; Kaneko, Yuji; Shinozuka, Kazutaka; Ishikawa, Hiroto; Yankee, Ernest; McGrogan, Michael; Case, Casey; Borlongan, Cesar V.			Stem Cell Recruitment of Newly Formed Host Cells via a Successful Seduction? Filling the Gap between Neurogenic Niche and Injured Brain Site	PLOS ONE			English	Article							MARROW STROMAL CELLS; PROGENITOR CELLS; SB623 CELLS; MODEL; ISCHEMIA; NEUROPROTECTION; DIFFERENTIATION; PLASTICITY; NEURONS; STROKE	Here, we report that a unique mechanism of action exerted by stem cells in the repair of the traumatically injured brain involves their ability to harness a biobridge between neurogenic niche and injured brain site. This biobridge, visualized immunohistochemically and laser captured, corresponded to an area between the neurogenic subventricular zone and the injured cortex. That the biobridge expressed high levels of extracellular matrix metalloproteinases characterized initially by a stream of transplanted stem cells, but subsequently contained only few to non-detectable grafts and overgrown by newly formed host cells, implicates a novel property of stem cells. The transplanted stem cells manifest themselves as pathways for trafficking the migration of host neurogenic cells, but once this biobridge is formed between the neurogenic site and the injured brain site, the grafted cells disappear and relinquish their task to the host neurogenic cells. Our findings reveal that long-distance migration of host cells from the neurogenic niche to the injured brain site can be achieved through transplanted stem cells serving as biobridges for initiation of endogenous repair mechanisms. This is the first report of a stem cell-paved "biobridge". Indeed, to date the two major schools of discipline in stem cell repair mechanism primarily support the concept of "cell replacement" and bystander effects of "trophic factor secretion". The present novel observations of a stem cell seducing a host cell to engage in brain repair advances basic science concepts on stem cell biology and extracellular matrix, as well as provokes translational research on propagating this stem cell-paved biobridge beyond cell replacement and trophic factor secretion for the treatment of traumatic brain injury and other neurological disorders.	[Tajiri, Naoki; Kaneko, Yuji; Shinozuka, Kazutaka; Ishikawa, Hiroto; Borlongan, Cesar V.] Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA; [Yankee, Ernest; McGrogan, Michael; Case, Casey] Sanbio Inc, Mountain View, CA USA	Borlongan, CV (corresponding author), Univ S Florida, Morsani Coll Med, Ctr Excellence Aging & Brain Repair, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Kaneko, Yuji/J-6447-2012; Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782; Shinozuka, Kazutaka/0000-0002-6435-4460; Ishikawa, Hiroto/0000-0003-0760-7203	Sanbio Inc.; James and Esther King Biomedical Research Foundation [1KG01-33966]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5U01NS055914-04, 1R01NS071956-01A1]; Celgene Cellular TherapeuticsCelgene Corporation; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS055914, R01NS071956] Funding Source: NIH RePORTER	Financial support for this study was through Sanbio Inc. CVB is additionally funded by the James and Esther King Biomedical Research Foundation 1KG01-33966, NIH 5U01NS055914-04 and NIH 1R01NS071956-01A1, Celgene Cellular Therapeutics, KMPHC and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aizman I, 2009, J NEUROSCI RES, V87, P3198, DOI 10.1002/jnr.22146; Andres RH, 2011, BRAIN, V134, P1777, DOI 10.1093/brain/awr094; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Chen JL, 2011, STROKE, V42, P445, DOI 10.1161/STROKEAHA.110.596486; Dao M, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-81; del Zoppo GJ, 2012, J CEREBR BLOOD F MET, V32, P919, DOI 10.1038/jcbfm.2012.11; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Ducruet AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038664; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Hargus G, 2010, P NATL ACAD SCI USA, V107, P15921, DOI 10.1073/pnas.1010209107; Hassani Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050444; Hawkes SP, 2010, METHODS MOL BIOL, V622, P257, DOI 10.1007/978-1-60327-299-5_16; Hong SH, 2011, CELL STEM CELL, V9, P24, DOI 10.1016/j.stem.2011.06.002; Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603; JOYNER AL, 1989, NATURE, V338, P153, DOI 10.1038/338153a0; Kim Y, 2011, SCIENCE, V334, P1706, DOI 10.1126/science.1211222; Lee HS, 2010, STEM CELLS, V28, P501, DOI 10.1002/stem.294; Lee JP, 2007, NAT MED, V13, P439, DOI 10.1038/nm1548; Lin CH, 2013, NEUROBIOL DIS, V58, P76, DOI 10.1016/j.nbd.2013.05.006; Liu ZW, 2011, STROKE, V42, P740, DOI 10.1161/STROKEAHA.110.607226; Ma DKK, 2010, NAT NEUROSCI, V13, P1338, DOI 10.1038/nn.2672; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Mazzocchi-Jones D, 2009, EUR J NEUROSCI, V30, P2134, DOI 10.1111/j.1460-9568.2009.07006.x; Mezey E, 2011, J CELL BIOCHEM, V112, P2683, DOI 10.1002/jcb.23216; Park KP, 2009, STROKE, V40, P2836, DOI 10.1161/STROKEAHA.109.554824; Pastori C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002754; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Pollock K, 2006, EXP NEUROL, V199, P143, DOI 10.1016/j.expneurol.2005.12.011; Redmond DE, 2007, P NATL ACAD SCI USA, V104, P12175, DOI 10.1073/pnas.0704091104; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Seol HJ, 2011, CANCER LETT, V311, P152, DOI 10.1016/j.canlet.2011.07.001; Sobrino T, 2012, J NEUROSCI RES, V90, P1788, DOI 10.1002/jnr.23068; Tate CC, 2010, CELL TRANSPLANT, V19, P973, DOI 10.3727/096368910X494885; Tejima E, 2009, J NEUROTRAUM, V26, P1935, DOI 10.1089/neu.2009.0959; Trueman R C, 2013, Curr Top Behav Neurosci, V15, P357, DOI 10.1007/7854_2012_223; Wang L, 2011, J CEREBR BLOOD F MET, V31, P640, DOI 10.1038/jcbfm.2010.138; Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036663; Yasuda A, 2011, STEM CELLS, V29, P1983, DOI 10.1002/stem.767; Yasuhara T, 2008, J CEREBR BLOOD F MET, V28, P1804, DOI 10.1038/jcbfm.2008.68; Yasuhara T, 2006, J NEUROSCI, V26, P12497, DOI 10.1523/JNEUROSCI.3719-06.2006; Yasuhara T, 2009, STEM CELLS DEV, V18, P1501, DOI 10.1089/scd.2009.0011; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	48	56	59	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2013	8	9							e74857	10.1371/journal.pone.0074857			12	Multidisciplinary Sciences	Science & Technology - Other Topics	219OE	WOS:000324515600159	24023965	DOAJ Gold, Green Published			2021-06-18	
J	Day, NL; Floyd, CL; D'Alessandro, TL; Hubbard, WJ; Chaudry, IH				Day, Nicole L.; Floyd, Candace L.; D'Alessandro, Tracy L.; Hubbard, William J.; Chaudry, Irshad H.			17 beta-Estradiol Confers Protection after Traumatic Brain Injury in the Rat and Involves Activation of G Protein-Coupled Estrogen Receptor 1	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; estrogen; lateral fluid percussion; neuronal degeneration; neuroprotection	SPINAL-CORD-INJURY; SEX STEROID-HORMONES; CORTICAL PERICONTUSIONAL ZONE; FLUID-PERCUSSION MODEL; PROGRAMMED CELL-DEATH; FEMALE RATS; REACTIVE ASTROGLIA; UP-REGULATION; HEMORRHAGE; NEUROPROTECTION	Traumatic brain injury (TBI) is a significant public health problem in the United States. Despite preclinical success of various drugs, to date all clinical trials investigating potential therapeutics have failed. Recently, sex steroid hormones have sparked interest as possible neuroprotective agents after traumatic injury. One of these is 17 beta-estradiol (E2), the most abundant and potent endogenous vertebrate estrogen. The goal of our study was to investigate the acute potential protective effects of E2 or the specific G protein-coupled estrogen receptor 1 (GPER) agonist G-1 when administered in an intravenous bolus dose 1 hour post-injury in the lateral fluid percussion (LFP) rodent model of TBI. The results of this study show that, when assessed at 24 hours post-injury, E2 or G-1 confers protection in adult male rats subjected to LFP brain injury. Specifically, we found that an acute bolus dose of E2 or G-1 administered intravenously 1 hour post-TBI significantly increases neuronal survival in the ipsilateral CA 2/3 region of the hippocampus and decreases neuronal degeneration and apoptotic cell death in both the ipsilateral cortex and CA 2/3 region of the hippocampus. We also report a significant reduction in astrogliosis in the ipsilateral cortex, hilus, and CA 2/3 region of the hippocampus. Finally, these effects were observed to be chiefly dose-dependent for E2, with the 5 mg/kg dose generating a more robust level of protection. Our findings further elucidate estrogenic compounds as a clinically relevant pharmacotherapeutic strategy for treatment of secondary injury following TBI, and intriguingly, reveal a novel potential therapeutic target in GPER.	[Day, Nicole L.; Floyd, Candace L.; D'Alessandro, Tracy L.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Spain Rehabil Ctr, Birmingham, AL 35294 USA; [Hubbard, William J.; Chaudry, Irshad H.] Univ Alabama Birmingham, Dept Surg, Spain Rehabil Ctr, Birmingham, AL 35294 USA	Floyd, CL (corresponding author), Univ Alabama Birmingham, Dept Phys Med & Rehabil, Spain Rehabil Ctr 506, 1717 6th Ave South, Birmingham, AL 35294 USA.	clfloyd@uab.edu		Day, Nicole/0000-0003-3490-4908	Department of Defense Congressionally Directed Medical Research Programs (CDMRP)United States Department of Defense [W81XWH-08-2-0153]	This work was supported by funding from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), W81XWH-08-2-0153.	Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Ba ZF, 2008, SHOCK, V30, P585, DOI 10.1097/SHK.0b013e31816f1a45; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; Barreto G, 2007, EUR J NEUROSCI, V25, P3039, DOI 10.1111/j.1460-9568.2007.05563.x; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Bourque M, 2013, NEUROBIOL AGING, V34, P887, DOI 10.1016/j.neurobiolaging.2012.05.022; Brailoiu E, 2007, J ENDOCRINOL, V193, P311, DOI 10.1677/JOE-07-0017; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Carson F.L., 1990, HISTOTECHNOLOGY SELF; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Choudhry MA, 2008, J LEUKOCYTE BIOL, V83, P518, DOI 10.1189/jlb.0607369; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duckles SP, 2007, CLIN EXP PHARMACOL P, V34, P801, DOI 10.1111/j.1440-1681.2007.04683.x; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Faul X. L., 2010, TRAUMATIC BRAIN INJU; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Gingerich S, 2010, NEUROSCIENCE, V170, P54, DOI 10.1016/j.neuroscience.2010.06.076; Hammes SR, 2007, ENDOCR REV, V28, P726, DOI 10.1210/er.2007-0022; Hammond R, 2011, PSYCHONEUROENDOCRINO, V36, P182, DOI 10.1016/j.psyneuen.2010.07.007; Hammond R, 2009, HORM BEHAV, V56, P309, DOI 10.1016/j.yhbeh.2009.06.008; Hazell GGJ, 2009, J ENDOCRINOL, V202, P223, DOI 10.1677/JOE-09-0066; Honda K, 2000, J NEUROSCI RES, V60, P321, DOI 10.1002/(SICI)1097-4547(20000501)60:3<321::AID-JNR6>3.3.CO;2-K; Hsieh YC, 2007, CRIT CARE MED, V35, pS621, DOI 10.1097/01.CCM.0000278603.18687.4F; Hsieh YC, 2007, AM J PATHOL, V170, P1210, DOI 10.2353/ajpath.2007.060883; Hsieh YC, 2006, J MOL CELL CARDIOL, V41, P511, DOI 10.1016/j.yjmcc.2006.06.001; Kachadroka S, 2010, J NEUROTRAUM, V27, P611, DOI 10.1089/neu.2009.1069; Lapanantasin S, 2006, SYNAPSE, V60, P406, DOI 10.1002/syn.20308; Lebesgue D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008642; Lebesgue D, 2006, J NEUROTRAUM, V23, P1814, DOI 10.1089/neu.2006.23.1814; Lee E, 2012, J BIOL CHEM, V287, P26817, DOI 10.1074/jbc.M112.341867; Li LZ, 2011, NEUROCHEM INT, V58, P126, DOI 10.1016/j.neuint.2010.11.006; Liu SB, 2012, J NEUROSCI, V32, P4887, DOI 10.1523/JNEUROSCI.5828-11.2012; Liu SB, 2011, CLIN EXP PHARMACOL P, V38, P577, DOI 10.1111/j.1440-1681.2011.05549.x; Liverman CS, 2009, CEPHALALGIA, V29, P520, DOI [10.1111/j.1468-2982.2008.01755.x, 10.1111/j.1468-2982.2008.01789.x]; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Prossnitz ER, 2011, NAT REV ENDOCRINOL, V7, P715, DOI 10.1038/nrendo.2011.122; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Simpkins JW, 2010, BBA-GEN SUBJECTS, V1800, P1113, DOI 10.1016/j.bbagen.2009.11.013; Siriphorn A, 2012, J COMP NEUROL, V520, P2630, DOI 10.1002/cne.23056; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu H, 2009, NEUROSCIENCE, V158, P1599, DOI 10.1016/j.neuroscience.2008.11.028; Yu HP, 2007, ANN SURG, V245, P971, DOI 10.1097/01.sla.0000254417.15591.88; Yu HP, 2009, SHOCK, V31, P227, DOI 10.1097/SHK.0b013e31818347e7; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544	70	56	56	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2013	30	17					1531	1541		10.1089/neu.2013.2854			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202HX	WOS:000323205800009	23659385	Green Published			2021-06-18	
J	Yu, FS; Wang, ZF; Tanaka, M; Chiu, CT; Leeds, P; Zhang, YM; Chuang, DM				Yu, Fengshan; Wang, Zhifei; Tanaka, Mikiei; Chiu, Chi-Tso; Leeds, Peter; Zhang, Yumin; Chuang, De-Maw			Posttrauma cotreatment with lithium and valproate: reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; lithium; valproate; neuroprotection; acetylhistone H3; mouse	MOOD STABILIZERS LITHIUM; BIPOLAR DISORDER; MOUSE MODEL; ACID; INHIBITION; NEURODEGENERATION; DEFICITS; DISEASE; ROLES; HDAC	Object. Although traumatic brain injury (TBI) is the leading cause of death and morbidity in young adults, no effective pharmaceutical treatment is available. By inhibiting glycogen synthase kinase-3 (GSK-3) and histone deacetylases (HDACs), respectively, lithium and valproate (VPA) have beneficial effects in diverse neurodegenerative diseases. Furthermore, in an excitotoxic neuronal model and in animal models of amyotrophic lateral sclerosis, Huntington disease, and stroke, combined treatment with lithium and VPA produces more robust neuroprotective effects than treatment with either agent alone. Building on previous work that establishes that therapeutic doses of either lithium or VPA have beneficial effects in mouse models of TBI, this study evaluated the effects of combined treatment with subeffective doses of lithium and VPA in a mouse model of TBI. Methods. Male C57BL/6 mice underwent TBI and were subsequently treated with lithium, VPA, or a combination of lithium and VPA 15 minutes post-TBI and once daily thereafter for up to 3 weeks; all doses were subeffective (1 mEq/kg of lithium and 200 mg/kg of VPA). Assessed parameters included lesion volume via H & E staining; blood-brain bather (BBB) integrity via immunoglobulin G extravasation; neurodegeneration via Fluoro-Jade B staining; motor coordination via a beam-walk test; and protein levels of acetylhistone H3, phospho-GSK-3 beta, and beta-catenin via Western blotting. Results. Posttrauma treatment with combined subeffective doses of lithium and VPA significantly reduced lesion volume, attenuated BBB disruption, and mitigated hippocampal neurodegeneration 3 days after TBI. As expected, subeffective doses of lithium or VPA alone did not have these beneficial effects. Combined treatment also improved motor coordination starting from Day 7 and persisting at least 21 days after TBI. Acetylation of histone H3, an index of HDAC inhibition, was robustly increased by the combined treatment 3 days after TBI. Conclusions. Cotreatment with subeffective doses of lithium and VPA significantly attenuated TBI-induced brain lesion, BBB disruption, and neurodegeneration, and robustly improved long-term functional recovery. These findings suggest that potentiating histone acetylation by HDAC inhibition is probably part of the mechanism underlying the beneficial effects associated with this combined treatment for TBI. Because both lithium and VPA have a long history of safe clinical use, the results suggest that using a combination of these 2 agents at subtherapeutic doses to treat patients with TBI may also reduce side effects and enhance tolerability.	[Yu, Fengshan; Wang, Zhifei; Chiu, Chi-Tso; Leeds, Peter; Chuang, De-Maw] NIMH, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA; [Yu, Fengshan; Zhang, Yumin; Chuang, De-Maw] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Yu, Fengshan; Tanaka, Mikiei; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Chuang, DM (corresponding author), NIMH, Mol Neurobiol Sect, NIH, 10 Ctr Dr,MSC 1363, Bethesda, MD 20892 USA.	chuang@mail.nih.gov		Yu, Fengshan/0000-0001-8620-3084	Center for Neuroscience and Regenerative Medicine of the Department of Defense; Blast Lethality Injury and Research Program; Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002468] Funding Source: NIH RePORTER	This work was funded in part by the Center for Neuroscience and Regenerative Medicine of the Department of Defense, the Blast Lethality Injury and Research Program, and the Intramural Research Program of the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH). The authors have no conflicts of interest to disclose, financial or otherwise.	Autry AE, 2012, PHARMACOL REV, V64, P238, DOI 10.1124/pr.111.005108; Chiu CT, 2013, PHARMACOL REV, V65, P105, DOI 10.1124/pr.111.005512; Chiu CT, 2011, NEUROPSYCHOPHARMACOL, V36, P2406, DOI 10.1038/npp.2011.128; Chiu CT, 2010, PHARMACOL THERAPEUT, V128, P281, DOI 10.1016/j.pharmthera.2010.07.006; Chuang DM, 2009, TRENDS NEUROSCI, V32, P591, DOI 10.1016/j.tins.2009.06.002; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feng HL, 2008, NEUROSCIENCE, V155, P567, DOI 10.1016/j.neuroscience.2008.06.040; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Leng Y, 2008, J NEUROSCI, V28, P2576, DOI 10.1523/JNEUROSCI.5467-07.2008; Lin D, 2006, CNS DRUGS, V20, P29, DOI 10.2165/00023210-200620010-00003; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Tsai LK, 2011, STROKE, V42, P2932, DOI 10.1161/STROKEAHA.110.612788; Tsai LK, 2010, NEUROPSYCHOPHARMACOL, V35, P2225, DOI 10.1038/npp.2010.97; Wang ZF, 2011, ACTA PHARMACOL SIN, V32, P1433, DOI 10.1038/aps.2011.140; Wang ZF, 2011, J CEREBR BLOOD F MET, V31, P52, DOI 10.1038/jcbfm.2010.195; Yu F, 2012, J NEUROTRAUM, V29, P2342; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	28	56	56	0	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2013	119	3					766	773		10.3171/2013.6.JNS13135			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	204IJ	WOS:000323358700029	23848820	Green Accepted			2021-06-18	
J	Togher, L; McDonald, S; Tate, R; Power, E; Rietdijk, R				Togher, Leanne; McDonald, Skye; Tate, Robyn; Power, Emma; Rietdijk, Rachael			TRAINING COMMUNICATION PARTNERS OF PEOPLE WITH SEVERE TRAUMATIC BRAIN INJURY IMPROVES EVERYDAY CONVERSATIONS: A MULTICENTER SINGLE BLIND CLINICAL TRIAL	JOURNAL OF REHABILITATION MEDICINE			English	Article						communication; communication partner; traumatic brain injury; clinical; rehabilitation	HEAD-INJURY; REHABILITATION; EXPERIENCE; APHASIA; INDIVIDUALS; POPULATION; ADULTS	Objective: To determine effectiveness of communication training for partners of people with severe traumatic brain injury. Design: Three arm non-randomized controlled trial comparing communication partner training (JOINT) with individual treatment (TBI SOLO) and a waitlist control group with 6 month follow-up. Participants: Forty-four outpatients with severe chronic traumatic brain injuries were recruited. Intervention: Ten-week conversational skills treatment program encompassing weekly group and individual sessions for both treatment groups. The JOINT condition focused on both the partner and the person with traumatic brain injury while the TBI SOLO condition focused on the individual with TBI only. Main outcome measures: Primary outcomes were blind ratings of the person with traumatic brain injury's level of participation during conversation on the Measure of Participation in Communication Adapted Kagan scales. Results: Communication partner training improved conversational performance relative to training the person with traumatic brain injury alone and a waitlist control group on the primary outcome measures. Results were maintained at six months post-training. Conclusion: Training communication partners of people with chronic severe traumatic brain injury was more efficacious than training the person with traumatic brain injury alone. The Adapted Kagan scales proved to be a robust and sensitive outcome measure for a conversational skills training program.	[Togher, Leanne; Power, Emma; Rietdijk, Rachael] Univ Sydney, Fac Hlth Sci, Lidcombe, NSW 1825, Australia; [McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; [Tate, Robyn] Univ Sydney, Fac Med, Northern Clin Sch, Rehabil Studies Unit, Lidcombe, NSW 1825, Australia; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia	Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, POB 170, Lidcombe, NSW 1825, Australia.	leanne.togher@sydney.edu.au	Togher, Leanne/AAC-7083-2019; McDonald, Skye/G-4118-2014; Power, Emma/A-9263-2015; Rietdijk, Rachael/J-6573-2012	McDonald, Skye/0000-0003-0723-6094; Power, Emma/0000-0002-2638-0406; Rietdijk, Rachael/0000-0003-4343-4039; Togher, Leanne/0000-0002-4518-6748	NHMRCNational Health and Medical Research Council of Australia [402687]	We would like to acknowledge the contributions of the study participants, Dr Rob Heard for statistical advice, and Gaye Murrills, and the staff of the Brain Injury Rehabilitation Units at Liverpool Hospital, Royal Rehabilitation Centre Sydney and Westmead Hospital for their assistance with participant recruitment. The first author was supported by an NHMRC Senior Research Fellowship during the writing of this paper, and this project was funded by NHMRC Project Grant 402687.	Behn N, 2012, BRAIN INJURY, V26, P1702, DOI 10.3109/02699052.2012.722258; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Douglas Jacinta M., 2010, Seminars in Speech and Language, V31, P197, DOI 10.1055/s-0030-1257536; Eggins S., 1997, ANAL CASUAL CONVERSA; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Kagan Aura, 2004, Top Stroke Rehabil, V11, P67; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; Lefebvre H, 2012, BRAIN INJURY, V26, P1084, DOI 10.3109/02699052.2012.666364; Legg C, 2005, APHASIOLOGY, V19, P559, DOI 10.1080/02687030544000029; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Rebecca K, 2011, COGNITIVE REHABILITA; Saldert C, 2012, J INTERACT RES COM D, V3, P141, DOI 10.1558/jircd.v3i2.141; TATE RL, 1987, SCAND J REHABIL MED, V19, P19; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Togher L, 2012, DISABIL REHABIL, V34, P1562, DOI 10.3109/09638288.2012.656788; Togher L, 2010, APHASIOLOGY, V24, P914, DOI 10.1080/02687030903422478; Turner S, 2006, APHASIOLOGY, V20, P483, DOI 10.1080/02687030600589991; World Health Organization, 2001, INT CLASS FUNCT DIS; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; Ylvisaker M., 1993, STAFF DEV CLIN INTER, P57; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P303; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	32	56	57	0	30	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	JUL	2013	45	7					637	645		10.2340/16501977-1173			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	189TA	WOS:000322290000005	23803687	DOAJ Gold			2021-06-18	
J	Lu, J; Frerich, JM; Turtzo, LC; Li, SQ; Chiang, J; Yang, CZ; Wang, XP; Zhang, C; Wu, CX; Sun, ZC; Niu, G; Zhuang, ZP; Brady, RO; Chen, XY				Lu, Jie; Frerich, Jason M.; Turtzo, L. Christine; Li, Siqi; Chiang, Jeffrey; Yang, Chunzhang; Wang, Xiaoping; Zhang, Chao; Wu, Chenxi; Sun, Zhongchan; Niu, Gang; Zhuang, Zhengping; Brady, Roscoe O.; Chen, Xiaoyuan			Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							NERVE GROWTH-FACTOR; H3 ACETYLATION; UP-REGULATION; HEAD-INJURY; EXPRESSION; RATS; MICE; ASTROCYTES; ACTIVATION; MECHANISMS	Acute traumatic brain injury (TBI) is associated with long-term cognitive and behavioral dysfunction. In vivo studies have shown histone deacetylase inhibitors (HDACis) to be neuroprotective following TBI in rodent models. HDACis are intriguing candidates because they are capable of provoking widespread genetic changes and modulation of protein function. By using known HDACis and a unique small-molecule pan-HDACi (LB-205), we investigated the effects and mechanisms associated with HDACi-induced neuroprotection following CNS injury in an astrocyte scratch assay in vitro and a rat TBI model in vivo. We demonstrate the preservation of sufficient expression of nerve growth factor (NGF) and activation of the neurotrophic tyrosine kinase receptor type 1 (TrkA) pathway following HDACi treatment to be crucial in stimulating the survival of CNS cells after TBI. HDACi treatment up-regulated the expression of NGF, phospho-TrkA, phospho-protein kinase B (p-AKT), NF-kappa B, and B-cell lymphoma 2 (Bcl-2) cell survival factors while down-regulating the expression of p75 neurotrophin receptor (NTR), phospho-JNK, and Bcl-2-associated X protein apoptosis factors. HDACi treatment also increased the expression of the stem cell biomarker nestin, and decreased the expression of reactive astrocyte biomarker GFAP within damaged tissue following TBI. These findings provide further insight into the mechanisms by which HDACi treatment after TBI is neuroprotective and support the continued study of HDACis following acute TBI.	[Lu, Jie; Turtzo, L. Christine; Wu, Chenxi; Sun, Zhongchan; Niu, Gang; Chen, Xiaoyuan] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, Bethesda, MD 20892 USA; [Frerich, Jason M.; Li, Siqi; Yang, Chunzhang; Wang, Xiaoping; Zhang, Chao; Zhuang, Zhengping; Brady, Roscoe O.] NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA; [Chiang, Jeffrey] NCI, NIH, Bethesda, MD 20892 USA; [Lu, Jie; Turtzo, L. Christine; Chen, Xiaoyuan] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Zhuang, ZP (corresponding author), NINDS, Surg Neurol Branch, Bethesda, MD 20892 USA.	zhuangp@ninds.nih.gov; bradyr@ninds.nih.gov; shawn.chen@nih.gov	Chen, Xiaoyuan/D-1860-2014	Chen, Xiaoyuan/0000-0002-9622-0870; Yang, Chunzhang/0000-0001-6433-0867	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Intramural Research Programs of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NINDS; Imaging Sciences Training Program (sponsored by Radiology and Imaging Sciences in the Clinical Center and Intramural Research Programs of the NIBIB); Howard Hughes Medical Institute-NIH Medical Research Scholars Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003052] Funding Source: NIH RePORTER	We thank Dr. Paul E. Gallant [National Institute of Neurological Disorders and Stroke (NINDS) Light Microscopy Facility] for assistance with confocal microscopy, Dr. Dragan Maric (NINDS Flow Cytometry Core Facility) for assistance with flow cytometry, and Lixte Biotechnology Holdings for providing LB-205. This work was supported by the Department of Defense in the Center for Neuroscience and Regenerative Medicine, Intramural Research Programs of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NINDS, Imaging Sciences Training Program (sponsored by Radiology and Imaging Sciences in the Clinical Center and Intramural Research Programs of the NIBIB) (J.L.), and Howard Hughes Medical Institute-NIH Medical Research Scholars Program (J.M.F.).	Aloe L, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-239; Barr TL, 2011, BIOL RES NURS, V13, P140, DOI 10.1177/1099800410385671; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen LW, 2006, J COMP NEUROL, V497, P898, DOI 10.1002/cne.21014; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Fischer A, 2010, TRENDS PHARMACOL SCI, V31, P605, DOI 10.1016/j.tips.2010.09.003; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Holtzman DM, 1996, ANN NEUROL, V39, P114, DOI 10.1002/ana.410390117; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; Kim HJ, 2007, J PHARMACOL EXP THER, V321, P892, DOI 10.1124/jpet.107.120188; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Levenson JM, 2004, J BIOL CHEM, V279, P40545, DOI 10.1074/jbc.M402229200; Liu Y, 2011, MOL CANCER RES, V9, P1668, DOI 10.1158/1541-7786.MCR-10-0563; Lu J, 2011, P NATL ACAD SCI USA, V108, P21200, DOI 10.1073/pnas.1119181109; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Peleg S, 2010, SCIENCE, V328, P753, DOI 10.1126/science.1186088; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rietze RL, 2001, NATURE, V412, P736, DOI 10.1038/35089085; Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x; Shein NA, 2011, MOL MED, V17, P448, DOI 10.2119/molmed.2011.00038; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Yang CZ, 2013, CELL REP, V3, P52, DOI 10.1016/j.celrep.2012.12.007; Yang CZ, 2012, P NATL ACAD SCI USA, V109, P6963, DOI 10.1073/pnas.1118754109; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; Zhang Y, 2013, J NEUROSURG, V2013, P12	39	56	60	1	14	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 25	2013	110	26					10747	10752		10.1073/pnas.1308950110			6	Multidisciplinary Sciences	Science & Technology - Other Topics	179EY	WOS:000321503700067	23754423	Green Published, Bronze			2021-06-18	
J	Farrer, TJ; Frost, RB; Hedges, DW				Farrer, Thomas J.; Frost, R. Brock; Hedges, Dawson W.			Prevalence of traumatic brain injury in juvenile offenders: A meta-analysis	CHILD NEUROPSYCHOLOGY			English	Article						Traumatic brain injury; Juvenile offense; Delinquency	PROBLEM-SOLVING SKILLS; MILD HEAD-INJURY; AGGRESSIVE-BEHAVIOR; CHILDREN; DELINQUENCY; ADOLESCENTS	Studies of traumatic brain injury (TBI) among adult populations demonstrate that such injuries can lead to aggressive behaviors. Related findings suggest that incarcerated individuals have high rates of brain injuries. Such studies suggest that traumatic brain injury may be related to the etiology and recidivism of criminal behavior. Relatively few studies have examined the prevalence of TBI using a delinquent juvenile sample. In order to assess the relationship between TBI and juvenile offender status, the current study used meta-analytic techniques to examine the odds of having a TBI among juvenile offenders. Across 9 studies, we found that approximately 30% of juvenile offenders have sustained a previous brain injury. Across 5 studies that used a control group, a calculated summary odds ratio of 3.37 suggests that juvenile offenders are significantly more likely to have a TBI compared to controls. Results suggest that the rate of TBIs within the juvenile offender population is significant and that there may be a relationship between TBIs and juvenile criminal behavior.	[Farrer, Thomas J.; Frost, R. Brock; Hedges, Dawson W.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Hedges, Dawson W.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA	Farrer, TJ (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT,POB 25543, Provo, UT 84602 USA.	thomasfarrer@yahoo.com		Farrer, Thomas J./0000-0001-8092-6214			Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Carswell K, 2004, J ADOLESCENCE, V27, P415, DOI 10.1016/j.adolescence.2004.04.003; Center for Disease Control, 2011, TRAUM BRAIN INJ; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Forrest CB, 2000, PEDIATRICS, V105, P286; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hux D, 1998, BRAIN INJURY, V12, P667; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KELDGORD RE, 1968, ACAD THER, V4, P93, DOI 10.1177/105345126800400203; Kenny DT, 2007, COMTEMPORARY ISSUES, V107, P1; KRYNICKI VE, 1978, J NERV MENT DIS, V166, P59, DOI 10.1097/00005053-197801000-00009; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; LEVINE MD, 1985, AM J DIS CHILD, V139, P50, DOI 10.1001/archpedi.1985.02140030052028; LEWIS DO, 1985, AM J PSYCHIAT, V142, P1161; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; McCrea MA, 2007, MILD TRAUMATIC BRAIN; MOFFITT TE, 1988, J AM ACAD CHILD PSY, V27, P233, DOI 10.1097/00004583-198803000-00017; PALFREY JS, 1983, PUBLIC HEALTH REP, V98, P449; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Poggi G, 2003, BRAIN INJURY, V17, P835, DOI 10.1080/0269905031000088612; Riley A W, 1996, Inj Prev, V2, P266, DOI 10.1136/ip.2.4.266; Rockhill CM, 2010, BRAIN INJURY, V24, P1051, DOI 10.3109/02699052.2010.494586; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; YEUDALL LT, 1982, J NERV MENT DIS, V170, P257, DOI 10.1097/00005053-198205000-00001	39	56	56	0	24	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	MAY 1	2013	19	3					225	234		10.1080/09297049.2011.647901			10	Clinical Neurology	Neurosciences & Neurology	122BS	WOS:000317290900001	22372420				2021-06-18	
J	Achim, AM; Guitton, M; Jackson, PL; Boutin, A; Monetta, L				Achim, Amelie M.; Guitton, Matthieu; Jackson, Philip L.; Boutin, Andree; Monetta, Laura			On What Ground Do We Mentalize? Characteristics of Current Tasks and Sources of Information That Contribute to Mentalizing Judgments	PSYCHOLOGICAL ASSESSMENT			English	Article						theory of mind; mentalizing; attributions; social cognition; ecological validity	HIGH-FUNCTIONING AUTISM; TEMPORO-PARIETAL JUNCTION; TRAUMATIC BRAIN-INJURY; SOCIAL COGNITION; ASPERGER-SYNDROME; EMOTION RECOGNITION; SPECTRUM CONDITIONS; EMPATHIC ACCURACY; MIND IMPAIRMENTS; DAMAGED PATIENTS	Mentalizing is an aspect of social cognition that is garnering increased interest. Although a wide variety of experimental tasks are available to measure mentalizing abilities in adults, the most widely used tasks typically focus on specific aspects of mentalizing, and mentalizing judgments are performed based on a limited set of information about the agent and the context. Here, we present the Eight Sources of Information Framework (8-SIF), a model that describes the sources of information that can contribute to mentalizing judgments both in real life and in the context of mentalizing tasks. This model is then used to systematically review and analyze the most classical mentalizing tasks, with a particular focus on the sources of information provided as a basis for mentalizing judgments in these tasks. Next, mentalizing tasks with improved ecological validity are also examined, highlighting the greater richness and diversity of the sources of information provided in such tasks relative to the most classical tasks. We believe that the 8-SIP is an important first step to increase awareness of the sources of information that can contribute to mentalizing judgments and to favor investigations of the potential impact of these sources of information on mentalizing performance in different populations.	[Achim, Amelie M.; Guitton, Matthieu; Jackson, Philip L.; Boutin, Andree; Monetta, Laura] Univ Laval, Inst Univ Sante Mentale Quebec, Ctr Rech, Quebec City, PQ, Canada; [Achim, Amelie M.] Univ Laval, Dept Psychiat & Neurosci, Quebec City, PQ, Canada; [Guitton, Matthieu] Univ Laval, Dept Otorhinolaryngol & Ophtalmol, Quebec City, PQ, Canada; [Jackson, Philip L.] Univ Laval, Ecole Psychol, Quebec City, PQ, Canada; [Boutin, Andree; Monetta, Laura] Univ Laval, Dept Readapt, Quebec City, PQ, Canada	Achim, AM (corresponding author), Inst Univ Sante Mentale Quebec, Ctr Rech, Quebec F-4500 2601 Canardiere, Quebec City, PQ, Canada.	amelie.achim@crulrg.ulaval.ca	Monetta, Laura/AAK-7657-2020	Jackson, Philip/0000-0001-8991-3217			Anderson M. C., 2009, MEMORY; Barnes JL, 2009, AUTISM RES, V2, P148, DOI 10.1002/aur.79; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; BARONCOHEN S, 1989, J CHILD PSYCHOL PSYC, V30, P285, DOI 10.1111/j.1469-7610.1989.tb00241.x; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bazin N, 2009, PSYCHIAT RES, V167, P28, DOI 10.1016/j.psychres.2007.12.010; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beaumont R, 2006, AUTISM, V10, P365, DOI 10.1177/1362361306064416; Bless H., 2004, SOCIAL COGNITION IND; Brunet-Gouet E, 2011, PSYCHIAT RES, V190, P23, DOI 10.1016/j.psychres.2010.11.029; Castelli F, 2000, NEUROIMAGE, V12, P314, DOI 10.1006/nimg.2000.0612; Champagne-Lavau Maud, 2009, Cogn Neuropsychiatry, V14, P217, DOI 10.1080/13546800903004114; CHANDLER M, 1989, CHILD DEV, V60, P1263, DOI 10.2307/1130919; Corcoran R, 1997, SCHIZOPHR RES, V24, P319, DOI 10.1016/S0920-9964(96)00117-X; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; Couture SM, 2006, SCHIZOPHRENIA BULL, V32, pS44, DOI 10.1093/schbul/sbl029; Cutting AL, 1999, CHILD DEV, V70, P853, DOI 10.1111/1467-8624.00061; Dziobek I, 2006, J AUTISM DEV DISORD, V36, P623, DOI 10.1007/s10803-006-0107-0; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; FONAGY P, 1991, INFANT MENT HEALTH J, V12, P201, DOI 10.1002/1097-0355(199123)12:3<201::AID-IMHJ2280120307>3.0.CO;2-7; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Frith U, 2003, PHILOS T R SOC B, V358, P459, DOI 10.1098/rstb.2002.1218; Gallagher HL, 2000, NEUROPSYCHOLOGIA, V38, P11, DOI 10.1016/S0028-3932(99)00053-6; Giora R, 1999, HUMOR, V12, P425, DOI 10.1515/humr.1999.12.4.425; Golan O, 2006, SOC NEUROSCI-UK, V1, P111, DOI 10.1080/17470910600980986; GOPNIK A, 1988, CHILD DEV, V59, P26, DOI 10.2307/1130386; Green MF, 2008, SCHIZOPHRENIA BULL, V34, P1211, DOI 10.1093/schbul/sbm145; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Harrington Leigh, 2005, Cogn Neuropsychiatry, V10, P249, DOI 10.1080/13546800444000056; Hasson U, 2008, NEURON, V57, P452, DOI 10.1016/j.neuron.2007.12.009; Heavey L, 2000, J AUTISM DEV DISORD, V30, P225, DOI 10.1023/A:1005544518785; ICKES W, 1990, J PERS SOC PSYCHOL, V59, P730, DOI 10.1037/0022-3514.59.4.730; Keysar B, 2000, PSYCHOL SCI, V11, P32, DOI 10.1111/1467-9280.00211; Keysers Christian, 2009, P3, DOI 10.1007/978-1-59745-479-7_1; Klin A, 2000, J CHILD PSYCHOL PSYC, V41, P831, DOI 10.1111/1469-7610.00671; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Meins E, 2002, CHILD DEV, V73, P1715, DOI 10.1111/1467-8624.00501; Mendelsohn A, 2009, LEARN MEMORY, V16, P142, DOI 10.1101/lm.1157709; Mitchell JP, 2006, BRAIN RES, V1079, P66, DOI 10.1016/j.brainres.2005.12.113; Nili U, 2010, NEURON, V66, P949, DOI 10.1016/j.neuron.2010.06.009; Ouellet J, 2010, J INT NEUROPSYCH SOC, V16, P287, DOI 10.1017/S1355617709991329; Pell MD, 2009, J NONVERBAL BEHAV, V33, P107, DOI 10.1007/s10919-008-0065-7; PERNER J, 1989, CHILD DEV, V60, P689, DOI 10.1111/j.1467-8624.1989.tb02749.x; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Pijnenborg GHM, 2009, J INT NEUROPSYCH SOC, V15, P239, DOI 10.1017/S1355617709090341; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Rowe AD, 2001, BRAIN, V124, P600, DOI 10.1093/brain/124.3.600; Saxe R, 2003, NEUROIMAGE, V19, P1835, DOI 10.1016/S1053-8119(03)00230-1; Saxe R, 2005, NEUROPSYCHOLOGIA, V43, P1391, DOI 10.1016/j.neuropsychologia.2005.02.013; Spiers HJ, 2006, NEUROPSYCHOLOGIA, V44, P1674, DOI 10.1016/j.neuropsychologia.2006.03.028; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; TULVING E, 1984, BEHAV BRAIN SCI, V7, P223, DOI 10.1017/S0140525X0004440X; Vanhalle C, 2000, APHASIOLOGY, V14, P1127, DOI 10.1080/02687030050174665; Vollm BA, 2006, NEUROIMAGE, V29, P90, DOI 10.1016/j.neuroimage.2005.07.022; Wellman HM, 2004, CHILD DEV, V75, P523, DOI 10.1111/j.1467-8624.2004.00691.x; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	63	56	56	3	37	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590			PSYCHOL ASSESSMENT	Psychol. Assess.	MAR	2013	25	1					117	126		10.1037/a0029137			10	Psychology, Clinical	Psychology	104EH	WOS:000315974000011	22731676				2021-06-18	
J	Loane, DJ; Stoica, BA; Byrnes, KR; Jeong, W; Faden, AI				Loane, David J.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Jeong, William; Faden, Alan I.			Activation of mGluR5 and Inhibition of NADPH Oxidase Improves Functional Recovery after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional recovery; microglia; metabotropic glutamate receptor 5; NADPH oxidase; neuroprotection; traumatic brain injury	METABOTROPIC GLUTAMATE RECEPTORS; CELL-DEATH; NEURONAL APOPTOSIS; OXIDATIVE STRESS; MICROGLIA; LIPOPOLYSACCHARIDE; NEUROTOXICITY; EXPRESSION; NEUROINFLAMMATION; NEUROPROTECTION	Traumatic brain injury (TBI) induces microglial activation, which can contribute to secondary tissue loss. Activation of mGluR5 reduces microglial activation and inhibits microglial-mediated neurodegeneration in vitro, and is neuroprotective in experimental models of CNS injury. In vitro studies also suggest that the beneficial effects of mGluR5 activation involve nicotinamide adenine dinucleotide phosphate (NADPH) oxidase inhibition in activated microglia. We hypothesized that activation of mGluR5 by the selective agonist CHPG after TBI in mice is neuroprotective and that its therapeutic actions are mediated by NADPH oxidase inhibition. Vehicle, CHPG, or CHPG plus the mGluR5 antagonist (MPEP), were administered centrally, 30 minutes post-TBI, and functional recovery and lesion volume was assessed. CHPG significantly attenuated post-traumatic sensorimotor and cognitive deficits, and reduced lesion volumes; these effects were blocked by MPEP, thereby indicating neuroprotection involved selective activation of mGluR5. CHPG treatment also reduced NF kappa B activity and nitrite production in lipopolysaccharide-stimulated microglia and the protective effects of CHPG treatment were abrogated in NADPH oxidase deficient microglial cultures (gp91(phox-/-)). To address whether the neuroprotective effects of CHPG are mediated via the inhibition of NADPH oxidase, we administered the NADPH oxidase inhibitor apocynin with or without CHPG treatment after TBI. Both apocynin or CHPG treatment alone improved sensorimotor deficits and reduced lesion volumes when compared with vehicle-treated mice; however, the combined CHPG + apocynin treatment was not superior to CHPG alone. These data suggest that the neuroprotective effects of activating mGluR5 receptors after TBI are mediated, in part, via the inhibition of NADPH oxidase.	[Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Natl Study Ctr Trauma & EMS, Baltimore, MD 21201 USA; [Loane, David J.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Jeong, William; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Faden, AI (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Hlth Sci Facil 2, S247,20 Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734; Loane, David/0000-0003-0393-3503; Faden, Alan I./0000-0003-0128-2348	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS037313]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS052568] Funding Source: NIH RePORTER	We thank Dr. Mian Xie, Dr. Chun-shu Piao, and Ms. Titilola Akintola for expert technical support, and Dr. Shruti Kabadi for helpful discussion. This work was supported by a grant from the NIH/NINDS to A.I.F. (5R01NS037313).	Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bao WL, 2001, BRAIN RES, V922, P173, DOI 10.1016/S0006-8993(01)03062-1; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2009, ANN NEUROL, V66, P63, DOI 10.1002/ana.21673; Byrnes KR, 2009, NEUROTHERAPEUTICS, V6, P94, DOI 10.1016/j.nurt.2008.10.038; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Chen T, 2012, NEUROCHEM RES, V37, P983, DOI 10.1007/s11064-011-0691-z; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Drouin-Ouellet J, 2011, GLIA, V59, P188, DOI 10.1002/glia.21086; Farso MC, 2009, NEUROCHEM RES, V34, P1721, DOI 10.1007/s11064-009-9999-3; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gasparini F, 1999, NEUROPHARMACOLOGY, V38, P1493, DOI 10.1016/S0028-3908(99)00082-9; Lea PM, 2002, PHARMACOL BIOCHEM BE, V73, P287, DOI 10.1016/S0091-3057(02)00825-0; Loane David J, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P136; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lull ME, 2010, NEUROTHERAPEUTICS, V7, P354, DOI 10.1016/j.nurt.2010.05.014; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Nicoletti E, 2011, NEUROPHARMACOLOGY, V60, P1017, DOI 10.1016/j.neuropharm.2010.10.022; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Vincent AM, 1999, EXP NEUROL, V155, P79, DOI 10.1006/exnr.1998.6966; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang JW, 2012, BRAIN RES, V1464, P73, DOI 10.1016/j.brainres.2012.05.014; Wang Q, 2006, BRAIN RES, V1090, P182, DOI 10.1016/j.brainres.2006.03.060; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhu PM, 2004, J NEUROSCI RES, V77, P525, DOI 10.1002/jnr.20175	36	56	56	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2013	30	5					403	412		10.1089/neu.2012.2589			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	103CI	WOS:000315891600010	23199080	Green Published			2021-06-18	
J	Gatson, JW; Liu, MM; Abdelfattah, K; Wigginton, JG; Smith, S; Wolf, S; Minei, JP				Gatson, Joshua W.; Liu, Ming-Mei; Abdelfattah, Kareem; Wigginton, Jane G.; Smith, Scott; Wolf, Steven; Minei, Joseph P.			Resveratrol decreases inflammation in the brain of mice with mild traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						TBI; Resveratrol; microglia; IL-6; IL-12; mice	COGNITIVE DEFICITS; LIPID-PEROXIDATION; AXONAL INJURY; ADULT-RAT; NEUROGENESIS; ACTIVATION; CELLS; MODEL	BACKGROUND: Following a mild traumatic brain injury (TBI) event, the secondary brain injury that persists after the initial blow to the head consists of excitotoxicity, decreased cerebral glucose levels, oxidant injury, mitochondrial dysfunction, inflammation, and neuronal cell death. To date, there are no effective interventions used at decreasing secondary brain injury after mild TBI. METHODS: In this study, male mice were treated with either placebo or resveratrol (100 mg/kg) at 5 minutes and 12 hours after mild TBI. The mice were injured using the controlled cortical impact device. In this closed-head model, a midline incision was made to access the skull and the impactor tip was aligned on the sagittal suture midway between the bregma and lambda sutures. The mice were injured at a depth of 2.0 mm, velocity of 4 m/s, and a delay time of 100 milliseconds. At 72 hours following injury, the animals were intracardially perfused with 0.9% saline followed by 10% phosphate-buffered formalin. The whole brain was removed, sliced, and stained for microglial activation (Iba1). In addition, using the enzyme-linked immunosorbent assay, tissue levels of interleukin 6 (IL-6) and IL-12 were measured in the cerebral cortex and hippocampus. RESULTS: In this study, we found that in the placebo treatment group, there was a significant increase in Iba1 staining in the brain. The levels of microglial activation was reduced by resveratrol in the cerebral cortex (p < 0.001), corpus callosum (p < 0.001), and dentate gyrus (p < 0.005) brain regions after mild TBI. In addition to Iba1, resveratrol decreased the brain levels of IL-6 (p < 0.0001) and IL-12 (p < 0.004), which were observed in the hippocampus of the placebo group. In our model, no increase of IL-6 or IL-12 was observed in the cerebral cortex following TBI. CONCLUSION: Resveratrol given acutely after TBI results in a decrease in neuroinflammation. These results suggest that resveratrol may be beneficial in reducing secondary brain injury after experiencing a mild TBI. (J Trauma Acute Care Surg. 2013; 74: 470-475. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Gatson, Joshua W.; Liu, Ming-Mei; Abdelfattah, Kareem; Wigginton, Jane G.; Smith, Scott; Wolf, Steven; Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn Trauma Crit Care, Dallas, TX 75390 USA	Gatson, JW (corresponding author), Dept Surg, Div Burn Trauma Crit Care, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	joshua.gatson@utsouthwestern.edu		Wolf, Steven/0000-0003-2972-3440; Wigginton, Jane/0000-0002-8561-3492	Department Of Surgery, Division of Burn/Trauma/Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas	This study was supported by the Department Of Surgery, Division of Burn/Trauma/Critical Care, University of Texas Southwestern Medical Center, Dallas, Texas.	Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giza CC, 2001, J ATHL TRAINING, V36, P228; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hao HD, 2004, J MED FOOD, V7, P290, DOI 10.1089/jmf.2004.7.290; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Kasdallah-Grissa A, 2006, ALCOHOL ALCOHOLISM, V41, P236, DOI 10.1093/alcalc/agh256; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mannix Rebekah C, 2012, Int J Alzheimers Dis, V2012, P608732, DOI 10.1155/2012/608732; MAYEVSKY A, 1974, BRAIN RES, V65, P529, DOI 10.1016/0006-8993(74)90243-1; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Redell JB, 2012, J NEUROTRAUM, V29, P2283; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Washington PM, 2012, J NEUROTRAUMA; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; ZALESKA MM, 1985, NEUROCHEM RES, V10, P397, DOI 10.1007/BF00964608; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x; Zhuang H, 2003, ANN NY ACAD SCI, V993, P287, DOI DOI 10.1111/J.1749-6632.2003.TB07531.X	32	56	59	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					470	474		10.1097/TA.0b013e31827e1f51			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	108UH	WOS:000316321200033	23354240				2021-06-18	
J	Legrand, A; Jeanjean, P; Delanghe, F; Peltier, J; Lecat, B; Dupont, H				Legrand, Aurelien; Jeanjean, Patrick; Delanghe, Fanny; Peltier, Johann; Lecat, Benoit; Dupont, Herve			Estimation of optic nerve sheath diameter on an initial brain computed tomography scan can contribute prognostic information in traumatic brain injury patients	CRITICAL CARE			English	Article							RAISED INTRACRANIAL-PRESSURE; OCULAR SONOGRAPHY; ULTRASOUND; HYPERTENSION; ULTRASONOGRAPHY; VALIDATION; ACCURACY	Introduction: The aim of this study was to evaluate the prognostic value of optic nerve sheath diameter (ONSD) measured on the initial brain computed tomography (CT) scan for intensive care unit (ICU) mortality in severe traumatic brain injury (TBI) patients. Methods: A prospective observational study of all severe TBI patients admitted to a neurosurgical ICU (over a 10-month period). Demographic and clinical data and brain CT scan results were recorded. ONSD for each eye was measured on the initial CT scan. The group of ICU survivors was compared to non-survivors. Glasgow Outcome Scale (GOS) was evaluated six months after ICU discharge. Results: Seventy-seven patients were included (age: 43 +/- 18; 81% males; mean Injury Severity Score: 35 +/- 15; ICU mortality: 28.5% (n = 22)). Mean ONSD on the initial brain CT scan was 7.8 +/- 0.1 mm in non-survivors vs. 6.8 +/- 0.1 mm in survivors (P < 0.001). The operative value of ONSD was a good predictor of mortality (area under the curve: 0.805). An ONSD cutoff >= 7.3 had a sensitivity of 86.4% and a specificity of 74.6% and was independently associated with mortality in this population (adjusted odds ratio 95% confidence interval: 22.7 (3.2 to 159.6), P = 0.002). There was a relationship between initial ONSD values and six-month GOS (P = 0.03). Conclusions: ONSD measured on the initial brain CT scan is independently associated with ICU mortality rate (when >= 7.3 mm) in severe TBI patients.	[Legrand, Aurelien; Jeanjean, Patrick; Delanghe, Fanny; Lecat, Benoit; Dupont, Herve] Amiens Univ Hosp, Dept Anaesthesiol & Crit Care Med, Neurosurg Intens Care Unit, F-80054 Amiens, France; [Peltier, Johann] Amiens Univ Hosp, Dept Neurosurg, F-80054 Amiens, France; [Dupont, Herve] Jules Verne Univ Picardy, INSERM U 1088, F-80036 Amiens, France	Dupont, H (corresponding author), Amiens Univ Hosp, Dept Anaesthesiol & Crit Care Med, Neurosurg Intens Care Unit, Pl Victor Pauchet, F-80054 Amiens, France.	dupont.herve@chu-amiens.fr	Dupont, Herve/D-1259-2010				BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Cammarata G, 2011, J TRAUMA, V71, P779, DOI 10.1097/TA.0b013e3182220673; Carenini BB, 2002, ACTA OPHTHALMOL SCAN, V80, P40; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Clavier N, 2000, PRISE CHARGE TRAUMAT; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Ditillo M, 2011, J TRAUMA, V71, P373; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc6893; Geeraerts T, 2008, CRIT CARE, V12, DOI 10.1186/cc7006; GIBBY WA, 1993, AM J ROENTGENOL, V160, P143, DOI 10.2214/ajr.160.1.8416612; Hansen HC, 2011, ACTA OPHTHALMOL, V89, pE528, DOI 10.1111/j.1755-3768.2011.02159.x; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Jaggi GP, 2012, BRIT J OPHTHALMOL, V96, P53, DOI 10.1136/bjo.2010.199224; JENNETT B, 1975, LANCET, V1, P480; Kimberly HH, 2008, CRIT CARE, V12, DOI 10.1186/cc7008; Klein Y, 2010, J TRAUMA, V69, P544, DOI 10.1097/TA.0b013e3181c99936; Kramer LA, 2012, RADIOLOGY, V263, P819, DOI 10.1148/radiol.12111986; Lagreze WA, 2007, INVEST OPHTH VIS SCI, V48, P1913, DOI 10.1167/iovs.06-1075; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Ozgen A, 1998, AM J ROENTGENOL, V170, P1093, DOI 10.2214/ajr.170.4.9530066; Peng CYJ, 2002, J EDUC RES, V96, P3, DOI 10.1080/00220670209598786; Rajajee V, 2012, CRIT CARE, V16, DOI [10.1186/cc11336, 10.1186/CC11336]; Rajajee V, 2011, NEUROCRIT CARE, V15, P506, DOI 10.1007/s12028-011-9606-8; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tayal VS, 2007, ANN EMERG MED, V49, P508, DOI 10.1016/j.annemergmed.2006.06.040; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Watanabe A, 2008, J NEUROSURG, V109, P255, DOI 10.3171/JNS/2008/109/8/0255; Watanabe Y, 2006, J NEUROSURG, V105, P190, DOI 10.3171/sup.2006.105.7.190	43	56	57	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	2							R61	10.1186/cc12589			7	Critical Care Medicine	General & Internal Medicine	264OG	WOS:000327887300026	23536993	DOAJ Gold, Green Published			2021-06-18	
J	Thal, SC; Luh, C; Schaible, EV; Timaru-Kast, R; Hedrich, J; Luhmann, HJ; Engelhard, K; Zehendner, CM				Thal, Serge C.; Luh, Clara; Schaible, Eva-Verena; Timaru-Kast, Ralph; Hedrich, Jana; Luhmann, Heiko J.; Engelhard, Kristin; Zehendner, Christoph M.			Volatile Anesthetics Influence Blood-Brain Barrier Integrity by Modulation of Tight Junction Protein Expression in Traumatic Brain Injury	PLOS ONE			English	Article							ISOFLURANE ANESTHESIA; OCCLUDIN EXPRESSION; NEUROVASCULAR UNIT; CEREBRAL VESSELS; EDEMA FORMATION; SEVOFLURANE; FLOW; GLUTAMATE; ISCHEMIA; WATER	Disruption of the blood-brain barrier (BBB) results in cerebral edema formation, which is a major cause for high mortality after traumatic brain injury (TBI). As anesthetic care is mandatory in patients suffering from severe TBI it may be important to elucidate the effect of different anesthetics on cerebral edema formation. Tight junction proteins (TJ) such as zonula occludens-1 (ZO-1) and claudin-5 (cl5) play a central role for BBB stability. First, the influence of the volatile anesthetics sevoflurane and isoflurane on in-vitro BBB integrity was investigated by quantification of the electrical resistance (TEER) in murine brain endothelial monolayers and neurovascular co-cultures of the BBB. Secondly brain edema and TJ expression of ZO-1 and cl5 were measured in-vivo after exposure towards volatile anesthetics in native mice and after controlled cortical impact (CCI). In in-vitro endothelial monocultures, both anesthetics significantly reduced TEER within 24 hours after exposure. In BBB co-cultures mimicking the neurovascular unit (NVU) volatile anesthetics had no impact on TEER. In healthy mice, anesthesia did not influence brain water content and TJ expression, while 24 hours after CCI brain water content increased significantly stronger with isoflurane compared to sevoflurane. In line with the brain edema data, ZO-1 expression was significantly higher in sevoflurane compared to isoflurane exposed CCI animals. Immunohistochemical analyses revealed disruption of ZO-1 at the cerebrovascular level, while cl5 was less affected in the pericontusional area. The study demonstrates that anesthetics influence brain edema formation after experimental TBI. This effect may be attributed to modulation of BBB permeability by differential TJ protein expression. Therefore, selection of anesthetics may influence the barrier function and introduce a strong bias in experimental research on pathophysiology of BBB dysfunction. Future research is required to investigate adverse or beneficial effects of volatile anesthetics on patients at risk for cerebral edema.	[Thal, Serge C.; Luh, Clara; Schaible, Eva-Verena; Timaru-Kast, Ralph; Engelhard, Kristin] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Univ Med Ctr, Mainz, Germany; [Hedrich, Jana; Luhmann, Heiko J.; Zehendner, Christoph M.] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Univ Med Ctr, D-6500 Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Univ Med Ctr, Mainz, Germany.	thal@uni-mainz.de; zehendner@uni-mainz.de	Luhmann, Heiko J./N-8797-2019; Thal, Serge/D-6593-2011	Luhmann, Heiko J./0000-0002-7934-8661; Thal, Serge/0000-0002-1222-8729	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [TH1430/3-1]; Focus Program Translational Neurosciences (FTN); University Medical Center of the Johannes Gutenberg-University; University Medical Center of the Johannes Gutenberg-University Mainz; IMB Core Facility Microscopy of the Institute of Molecular Biology (IMB), Mainz	This work was supported by grants of the Deutsche Forschungsgemeinschaft (TH1430/3-1), the Focus Program Translational Neurosciences (FTN) and a stage 1 grant of the University Medical Center of the Johannes Gutenberg-University to SCT. CMZ is supported by a stage 1 grant of the University Medical Center of the Johannes Gutenberg-University Mainz. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors have no conflicting financial interest to declare.; The authors want to thank Dana Pieter, Tobias Hirnet, Sabine Rickheim-Lowack, Beate Kohler and Beate Krumm for her excellent technical assistance. Support by the IMB Core Facility Microscopy of the Institute of Molecular Biology (IMB), Mainz is gratefully acknowledged.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Antonetti DA, 2002, J NEUROCHEM, V80, P667, DOI 10.1046/j.0022-3042.2001.00740.x; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; D'Atri F, 2002, MOL MEMBR BIOL, V19, P103, DOI 10.1080/09687680210129236; Dittmar MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038260; Eberspacher E, 2009, ACTA ANAESTH SCAND, V53, P774, DOI 10.1111/j.1399-6576.2009.01954.x; FISCHER S, 1995, ANESTHESIOLOGY, V82, P451, DOI 10.1097/00000542-199502000-00015; Fischer S, 1996, BRAIN RES, V707, P47, DOI 10.1016/0006-8993(95)01219-2; Fukui K, 2010, J CLIN NEUROPHYSIOL, V27, P110, DOI 10.1097/WNP.0b013e3181d64da1; Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007; Hoffmann U, 2013, ACTA NEUROCHIR SUPPL, V115, P161, DOI 10.1007/978-3-7091-1192-5_31; Holmstrom A, 2004, J NEUROSURG ANESTH, V16, P136, DOI 10.1097/00008506-200404000-00005; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Iida H, 1998, ANESTHESIOLOGY, V89, P954, DOI 10.1097/00000542-199810000-00020; Jiang WG, 1998, BIOCHEM BIOPH RES CO, V244, P414, DOI 10.1006/bbrc.1998.8288; Kandatsu N, 2005, ANESTHESIOLOGY, V102, P1182, DOI 10.1097/00000542-200506000-00018; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Lu H, 1998, ANESTH ANALG, V87, P854, DOI 10.1097/00000539-199810000-00020; Luh C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019948; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; LUNDEEN G, 1983, ANESTH ANALG, V62, P499; MANOHAR M, 1984, J PHARMACOL EXP THER, V231, P640; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; Mills CD, 1997, J NEUROTRAUM, V14, P943, DOI 10.1089/neu.1997.14.943; Ritz MF, 2006, INT J NEUROSCI, V116, P191, DOI 10.1080/00207450500341555; Sandoval KE, 2008, NEUROBIOL DIS, V32, P200, DOI 10.1016/j.nbd.2008.08.005; SCHETTINI A, 1979, BRIT J ANAESTH, V51, P1117, DOI 10.1093/bja/51.12.1117; Seo JH, 2012, CURRENT PHARM DESIGN; Shulga A, 2012, J NEUROSCI, V32, P1757, DOI 10.1523/JNEUROSCI.3282-11.2012; SMITH AL, 1976, ANESTHESIOLOGY, V45, P64, DOI 10.1097/00000542-197607000-00012; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Stover JF, 2005, ACTA NEUROCHIR, V147, P847, DOI 10.1007/s00701-005-0562-y; Stover JF, 2004, ACTA NEUROCHIR, V146, P819, DOI 10.1007/s00701-004-0281-9; Tetrault S, 2008, EUR J NEUROSCI, V28, P1330, DOI 10.1111/j.1460-9568.2008.06443.x; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wachtel M, 2001, J NEUROCHEM, V78, P155, DOI 10.1046/j.1471-4159.2001.00399.x; Werner C, 2009, CAN J ANAESTH, V56, P883, DOI 10.1007/s12630-009-9166-y; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Zehendner CM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016760; Zehendner CM, 2009, J CEREBR BLOOD F MET, V29, P1879, DOI 10.1038/jcbfm.2009.103; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	48	56	60	1	33	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 10	2012	7	12							e50752	10.1371/journal.pone.0050752			12	Multidisciplinary Sciences	Science & Technology - Other Topics	052ML	WOS:000312201900015	23251381	DOAJ Gold, Green Published			2021-06-18	
J	Ghosh, M; Garcia-Castillo, D; Aguirre, V; Golshani, R; Atkins, CM; Bramlett, HM; Dietrich, WD; Pearse, DD				Ghosh, Mousumi; Garcia-Castillo, Daniela; Aguirre, Vladimir; Golshani, Roozbeh; Atkins, Coleen M.; Bramlett, Helen M.; Dietrich, W. Dalton; Pearse, Damien D.			Proinflammatory cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury	GLIA			English	Article						cyclic AMP; phosphodiesterase; Rolipram; TNF-a; IL-1 ss; inflammation; CNS	TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; FACTOR-ALPHA PRODUCTION; MESSENGER-RNA; FUNCTIONAL RECOVERY; INTERFERON-GAMMA; GENE-EXPRESSION; PROTEIN-LEVELS; SCHWANN-CELLS; UP-REGULATION	Cyclic AMP suppresses immune cell activation and inflammation. The positive feedback loop of proinflammatory cytokine production and immune activation implies that cytokines may not only be regulated by cyclic AMP but also conversely regulate cyclic AMP. This study examined the effects of tumor necrosis factor (TNF)-a and interleukin (IL)-1 beta on cyclic AMP-phosphodiesterase (PDE) signaling in microglia in vitro and after spinal cord injury (SCI) or traumatic brain injury (TBI). TNF-a or IL-1 beta stimulation produced a profound reduction (>90%) of cyclic AMP within EOC2 microglia from 30 min that then recovered after IL-1 beta but remained suppressed with TNF-a through 24 h. Cyclic AMP was also reduced in TNF-a-stimulated primary microglia, albeit to a lesser extent. Accompanying TNF-a-induced cyclic AMP reductions, but not IL-1 beta, was increased cyclic AMP-PDE activity. The role of PDE4 activity in cyclic AMP reductions was confirmed by using Rolipram. Examination of pde4 mRNA revealed an immediate, persistent increase in pde4b with TNF-a; IL-1 beta increased all pde4 mRNAs. Immunoblotting for PDE4 showed that both cytokines increased PDE4A1, but only TNF-a increased PDE4B2. Immunocytochemistry revealed PDE4B nuclear translocation with TNF-a but not IL-1 beta. Acutely after SCI/TBI, where cyclic AMP levels are reduced, PDE4B was localized to activated OX-42+ microglia; PDE4B was absent in OX-42+ cells in uninjured spinal cord/cortex or inactive microglia. Immunoblotting showed PDE4B2 up-regulation from 24 h to 1 wk post-SCI, the peak of microglia activation. These studies show that TNF-a and IL-1 beta differentially affect cyclic AMP-PDE signaling in microglia. Targeting PDE4B2 may be a putative therapeutic direction for reducing microglia activation in CNS injury and neurodegenerative diseases. (c) 2012 Wiley Periodicals, Inc.	[Pearse, Damien D.] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Lois Pope Life Ctr, Miami, FL 33101 USA; [Atkins, Coleen M.; Bramlett, Helen M.; Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Neurosci Program, Miami, FL 33101 USA; [Atkins, Coleen M.; Bramlett, Helen M.; Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33101 USA; [Dietrich, W. Dalton; Pearse, Damien D.] Univ Miami, Miller Sch Med, Interdisciplinary Stem Cell Inst, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33101 USA; [Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Dept Vet Affairs Med Ctr, Miami, FL 33101 USA	Pearse, DD (corresponding author), Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Lois Pope Life Ctr, Locator Code R-48,POB 016960, Miami, FL 33101 USA.	DPearse@miamiproject.med.miami.edu	Pearse, Damien D/D-3176-2011	Pearse, Damien D/0000-0003-1783-221X; Atkins, Coleen/0000-0003-4718-7493	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [056281, 056072]; Miami Project to Cure Paralysis; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056281, R01NS056072] Funding Source: NIH RePORTER	Grant sponsor: NINDS; Grant numbers: 056281 and 056072; Grant sponsor: Miami Project to Cure Paralysis.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Aronoff DM, 2004, J IMMUNOL, V173, P559, DOI 10.4049/jimmunol.173.1.559; Arp J, 2003, MOL CELL BIOL, V23, P8042, DOI 10.1128/MCB.23.22.8042-8057.2003; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Baillie GS, 2000, BRIT J PHARMACOL, V131, P811, DOI 10.1038/sj.bjp.0703636; Bao F, 2011, J NEUROTRAUM, V28, P1035, DOI 10.1089/neu.2010.1575; Barakat DJ, 2005, CELL TRANSPLANT, V14, P225, DOI 10.3727/000000005783983106; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; Caggiano AO, 1999, J NEUROCHEM, V72, P565, DOI 10.1046/j.1471-4159.1999.0720565.x; Chandrasekaran A, 2008, CELL SIGNAL, V20, P139, DOI 10.1016/j.cellsig.2007.10.003; D'Sa C, 2002, J NEUROCHEM, V81, P745, DOI 10.1046/j.1471-4159.2002.00878.x; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; Dunne A, 2003, SCI STKE, V25, P171; Ghosh M, 2012, GLIA, V60, P979, DOI 10.1002/glia.22330; Ghosh M, 2010, TRANSL NEUROSCI, V1, P101, DOI 10.2478/v10134-010-0012-0; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Hannibal J, 1999, NEUROENDOCRINOLOGY, V70, P73, DOI 10.1159/000054461; Hurley SD, 1999, GLIA, V25, P304, DOI 10.1002/(SICI)1098-1136(19990201)25:3<304::AID-GLIA10>3.0.CO;2-W; Huston E, 2008, P NATL ACAD SCI USA, V105, P12791, DOI 10.1073/pnas.0805167105; Jin SLC, 2005, J IMMUNOL, V175, P1523, DOI 10.4049/jimmunol.175.3.1523; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Jones LL, 1997, J NEUROCYTOL, V26, P755, DOI 10.1023/A:1018514415073; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Kleppisch Thomas, 2009, V191, P71, DOI 10.1007/978-3-540-68964-5_5; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Le Jeune IR, 2002, J BIOL CHEM, V277, P35980, DOI 10.1074/jbc.M204832200; Levi G, 1998, BIOCHIMIE, V80, P899, DOI 10.1016/S0300-9084(00)88886-0; LONDESBOROUGH J, 1982, MOL CELL BIOCHEM, V46, P65; Lucin KM, 2009, NEURON, V64, P110, DOI 10.1016/j.neuron.2009.08.039; Lugnier C, 1999, BBA-GEN SUBJECTS, V1472, P431, DOI 10.1016/S0304-4165(99)00145-2; LUPIDI G, 1990, ITAL J BIOCHEM, V39, P30; Ma DM, 1999, MOL PHARMACOL, V55, P50; MacKenzie SJ, 2000, BIOCHEM J, V347, P571, DOI 10.1042/0264-6021:3470571; McCahill A, 2008, CELL SIGNAL, V20, P2071, DOI 10.1016/j.cellsig.2008.07.017; Mecha M, 2011, EASY FAST WAY OBTAIN, DOI [10.1038/protex.2011.218, DOI 10.1038/PROTEX.2011.218]; Minguet S, 2005, EUR J IMMUNOL, V35, P31, DOI 10.1002/eji.200425524; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Ortis F, 2010, DIABETES, V59, P358, DOI 10.2337/db09-1159; PANG XP, 1992, J BIOL CHEM, V267, P12826; Patel V, 2010, J NEUROTRAUM, V27, P789, DOI 10.1089/neu.2008.0809; Patrizio M, 2004, GLIA, V48, P241, DOI 10.1002/glia.20074; PATRIZIO M, 1995, GLIA, V14, P94, DOI 10.1002/glia.440140204; Pearse D, 2010, CURR OPIN INVEST DR, V11, P1207; Pearse DD, 2004, EUR J NEUROSCI, V20, P3387, DOI 10.1111/j.1460-9568.2004.03799.x; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pearse DD, 2001, NEUROSCIENCE, V107, P143, DOI 10.1016/S0306-4522(01)00320-7; Pineau I, 2007, J COMP NEUROL, V500, P267, DOI 10.1002/cne.21149; Reyes-Irisarri E, 2007, J NEUROPATH EXP NEUR, V66, P923, DOI 10.1097/nen.0b013e3181567c31; Rice T, 2007, J NEUROPATH EXP NEUR, V66, P184, DOI 10.1097/01.jnen.0000248552.07338.7f; Schaal SM, 2007, CELL TRANSPLANT, V16, P207, DOI 10.3727/000000007783464768; Sebastiani G, 2006, NEUROBIOL AGING, V27, P691, DOI 10.1016/j.neurobiolaging.2005.03.024; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SEMMLER J, 1993, INT J IMMUNOPHARMACO, V15, P409, DOI 10.1016/0192-0561(93)90052-Z; Serezani CH, 2008, AM J RESP CELL MOL, V39, P127, DOI 10.1165/rcmb.2008-0091TR; SHARIF SF, 1993, NEUROL RES, V15, P109; Steininger TS, 2011, BRAIN RES, V1407, P1, DOI 10.1016/j.brainres.2011.06.050; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Walker WS, 1995, J NEUROIMMUNOL, V63, P163, DOI 10.1016/0165-5728(95)00146-8; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wang P, 1999, MOL PHARMACOL, V56, P170; Wang XF, 2006, ACTA NEUROPATHOL, V111, P220, DOI 10.1007/s00401-005-0016-x; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm2; Wen AY, 2010, J IMMUNOL, V185, P6413, DOI 10.4049/jimmunol.1001829; Whitaker CM, 2008, NEUROSCI LETT, V438, P200, DOI 10.1016/j.neulet.2008.03.087; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410	74	56	57	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	DEC	2012	60	12					1839	1859		10.1002/glia.22401			21	Neurosciences	Neurosciences & Neurology	026GM	WOS:000310262600003	22865690	Green Accepted			2021-06-18	
J	Moen, KG; Skandsen, T; Folvik, M; Brezova, V; Kvistad, KA; Rydland, J; Manley, GT; Vik, A				Moen, Kent Goran; Skandsen, Toril; Folvik, Mari; Brezova, Veronika; Kvistad, Kjell Arne; Rydland, Jana; Manley, Geoffrey T.; Vik, Anne			A longitudinal MRI study of traumatic axonal injury in patients with moderate and severe traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							WHITE-MATTER LESIONS; SEVERE HEAD-INJURY; PROGNOSTIC VALUE; CLASSIFICATION; HEMOSIDERIN; DIAGNOSIS; ATROPHY; SCALE; MILD	Objective To study the evolution of traumatic axonal injury (TAI) detected by structural MRI in patients with moderate and severe traumatic brain injury (TBI) during the first year and relate findings to outcome. Methods 58 patients with TBI (Glasgow Coma Scale score 3-13) were examined with MRI at a median of 7 days, 3 months and 12 months post injury. TAI lesions were evaluated blinded and categorised into three stages based on location: hemispheres, corpus callosum and brainstem. Lesions in T2* weighted gradient echo (GRE), fluid attenuated inversion recovery (FLAIR) and diffusion weighted imaging (DWI) were counted and FLAIR lesion volumes were estimated. Inter-rater reliability score was calculated. Outcome was assessed 12 months post injury using the Glasgow Outcome Scale Extended. Results In the initial MRI, 31% had brainstem lesions compared with 17% at 3 months (p=0.008). In the FLAIR sequences, number and volumes of lesions were reduced from early to 3 months (p<0.001). In T2* GRE sequences, the number of lesions persisted at 3 months but was reduced at 12 months (p=0.007). The number of lesions in DWI and volume of FLAIR lesions on early MRI predicted worse clinical outcome in adjusted analyses (p<0.05). Conclusion This is the first study to demonstrate and quantify attenuation of non-haemorrhagic TAI lesions on structural MRI during the first 3 months after TBI; most importantly, the disappearance of brainstem lesions. Haemorrhagic TAI lesions attenuate first after 3 months. Only early MRI findings predicted clinical outcome after adjustment for other prognostic factors. Hence valuable clinical information may be missed if MRI is performed too late after TBI.	[Moen, Kent Goran; Skandsen, Toril; Vik, Anne] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, N-7489 Trondheim, Norway; [Moen, Kent Goran; Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Trondheim, Norway; [Skandsen, Toril] Univ Trondheim Hosp, Dept Phys Med & Rehabil, St Olavs Hosp, Trondheim, Norway; [Folvik, Mari; Kvistad, Kjell Arne; Rydland, Jana] Univ Trondheim Hosp, Dept Diagnost Imaging, St Olavs Hosp, Trondheim, Norway; [Brezova, Veronika; Kvistad, Kjell Arne] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Diagnost Imaging, N-7489 Trondheim, Norway; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, Brain & Spinal Injury Ctr, San Francisco, CA USA	Moen, KG (corresponding author), Norwegian Univ Sci & Technol NTNU, Dept Neurosci, N-7489 Trondheim, Norway.	kent.g.moen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Central Norway Regional Health Authority (RHA); Norwegian University of Science and Technology (NTNU); National Resource Center for fMRI, Department of Diagnostic Imaging, St Olav University Hospital	KGM and TS have, during the study period, received a research grant from the liaison committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU). VB has, during the study period, received a research grant from the National Resource Center for fMRI, Department of Diagnostic Imaging, St Olav University Hospital.	Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Fleiss J., 1986, DESIGN ANAL CLIN EXP; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Goebel R, 2006, HUM BRAIN MAPP, V27, P392, DOI 10.1002/hbm.20249; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liang LX, 1999, AM J NEURORADIOL, V20, P1527; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Matsusue Eiji, 2006, Magn Reson Med Sci, V5, P99, DOI 10.2463/mrms.5.99; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Murray JG, 1996, SEMIN ULTRASOUND CT, V17, P185, DOI 10.1016/S0887-2171(96)90035-9; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Rosner B., 2006, FUNDAMENTALS BIOSTAT; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; SCHELTENS P, 1992, BRAIN, V115, P735, DOI 10.1093/brain/115.3.735; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Yanagawa Y, 2009, J TRAUMA, V66, P162, DOI 10.1097/TA.0b013e3181469857	37	56	58	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2012	83	12					1193	1200		10.1136/jnnp-2012-302644			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	037IU	WOS:000311097700016	22933813				2021-06-18	
J	Zhao, W; Varghese, M; Vempati, P; Dzhun, A; Cheng, A; Wang, J; Lange, D; Bilski, A; Faravelli, I; Pasinetti, GM				Zhao, Wei; Varghese, Merina; Vempati, Prashant; Dzhun, Anastasiya; Cheng, Alice; Wang, Jun; Lange, Dale; Bilski, Amanda; Faravelli, Irene; Pasinetti, Giulio Maria			Caprylic Triglyceride as a Novel Therapeutic Approach to Effectively Improve the Performance and Attenuate the Symptoms Due to the Motor Neuron Loss in ALS Disease	PLOS ONE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MEDIUM-CHAIN TRIGLYCERIDES; SUPEROXIDE-DISMUTASE GENE; TRAUMATIC BRAIN-INJURY; KETOGENIC DIET; MOUSE MODEL; MITOCHONDRIAL DYSFUNCTION; SKELETAL-MUSCLE; TRANSGENIC MICE; SPINAL-CORD	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of motor neurons causing progressive muscle weakness, paralysis, and finally death. ALS patients suffer from asthenia and their progressive weakness negatively impacts quality of life, limiting their daily activities. They have impaired energy balance linked to lower activity of mitochondrial electron transport chain enzymes in ALS spinal cord, suggesting that improving mitochondrial function may present a therapeutic approach for ALS. When fed a ketogenic diet, the G93A ALS mouse shows a significant increase in serum ketones as well as a significantly slower progression of weakness and lower mortality rate. In this study, we treated SOD1-G93A mice with caprylic triglyceride, a medium chain triglyceride that is metabolized into ketone bodies and can serve as an alternate energy substrate for neuronal metabolism. Treatment with caprylic triglyceride attenuated progression of weakness and protected spinal cord motor neuron loss in SOD1-G93A transgenic animals, significantly improving their performance even though there was no significant benefit regarding the survival of the ALS transgenic animals. We found that caprylic triglyceride significantly promoted the mitochondrial oxygen consumption rate in vivo. Our results demonstrated that caprylic triglyceride alleviates ALS-type motor impairment through restoration of energy metabolism in SOD1-G93A ALS mice, especially during the overt stage of the disease. These data indicate the feasibility of using caprylic acid as an easily administered treatment with a high impact on the quality of life of ALS patients.	[Zhao, Wei; Varghese, Merina; Vempati, Prashant; Dzhun, Anastasiya; Cheng, Alice; Wang, Jun; Bilski, Amanda; Faravelli, Irene; Pasinetti, Giulio Maria] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; [Zhao, Wei; Wang, Jun; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, GRECC, New York, NY USA; [Lange, Dale] Hosp Special Surg, New York, NY 10021 USA	Pasinetti, GM (corresponding author), Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.	Giulio.Pasinetti@mssm.edu	Zhao, Wei/A-2206-2010; Varghese, Merina/H-5472-2019; Faravelli, Irene/AAP-6300-2020	Varghese, Merina/0000-0002-1517-3903; Faravelli, Irene/0000-0001-8126-7353; Pasinetti, Giulio/0000-0002-1524-5196; Zhao, Wei/0000-0002-3449-2395	NIH-NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5R24 CA095823-04]; NSF Major Research InstrumentationNational Science Foundation (NSF) [DBI-9724504]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 S10 RR0 9145-01]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R24CA095823] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR009145] Funding Source: NIH RePORTER	This work was supported by funding from: NIH-NCI shared resources grant (5R24 CA095823-04), http://www.nih.gov/; NSF Major Research Instrumentation grant (DBI-9724504), http://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5260; and NIH shared instrumentation grant (1 S10 RR0 9145-01); http://www.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alavian KN, 2012, BRAIN RES, V1446, P1, DOI 10.1016/j.brainres.2012.01.046; Andreassen OA, 2001, J NEUROCHEM, V77, P383, DOI 10.1046/j.1471-4159.2001.00188.x; BACH AC, 1982, AM J CLIN NUTR, V36, P950; Beal MF, 2002, FREE RADICAL RES, V36, P455, DOI 10.1080/10715760290021315; BJUGN R, 1993, BRAIN RES, V627, P25, DOI 10.1016/0006-8993(93)90744-8; Browne SE, 1998, J NEUROCHEM, V71, P281; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cheng BH, 2009, BRAIN RES, V1286, P25, DOI 10.1016/j.brainres.2009.06.060; CHIU AY, 1995, MOL CELL NEUROSCI, V6, P349, DOI 10.1006/mcne.1995.1027; Ciavarro GL, 2003, J NEUROSCI METH, V129, P61, DOI 10.1016/S0165-0270(03)00201-2; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crugnola V, 2010, ARCH NEUROL-CHICAGO, V67, P849, DOI 10.1001/archneurol.2010.128; Cudkowicz M, 2011, NAT MED, V17, P1652, DOI 10.1038/nm.2579; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Dorst J, 2011, J NEUROL, V258, P613, DOI 10.1007/s00415-010-5805-z; Douglas RM, 2010, AM J PHYSIOL-CELL PH, V298, pC1594, DOI 10.1152/ajpcell.00298.2009; Fidler JA, 2011, FASEB J, V25, P4369, DOI 10.1096/fj.11-190819; Fujita K, 1996, J NEUROSCI RES, V45, P276, DOI 10.1002/(SICI)1097-4547(19960801)45:3<276::AID-JNR9>3.0.CO;2-A; Genton L, 2011, CLIN NUTR, V30, P553, DOI 10.1016/j.clnu.2011.06.004; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Henderson ST, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-31; Ho L, 2012, NUTR NEUROSCI, V15, P37, DOI 10.1179/1476830511Y.0000000027; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; HUTTENLOCHER PR, 1971, NEUROLOGY, V21, P1097, DOI 10.1212/WNL.21.11.1097; Jung CW, 2002, J NEUROSCI METH, V114, P165, DOI 10.1016/S0165-0270(01)00524-6; Kaal ECA, 2000, J NEUROCHEM, V74, P1158; Kong JM, 1998, J NEUROSCI, V18, P3241; Laffel L, 1999, DIABETES-METAB RES, V15, P412, DOI 10.1002/(SICI)1520-7560(199911/12)15:6<412::AID-DMRR72>3.0.CO;2-8; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Menzies FM, 2002, BRAIN, V125, P1522, DOI 10.1093/brain/awf167; PERLMAN BJ, 1984, MOL PHARMACOL, V26, P83; Pradat PF, 2010, AMYOTROPH LATERAL SC, V11, P166, DOI 10.3109/17482960902822960; PRAMATAROVA A, 1995, AM J HUM GENET, V56, P592; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Roman Marian W, 2010, Issues Ment Health Nurs, V31, P435, DOI 10.3109/01612841003768231; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Rothstein JD, 2003, ANN NEUROL, V53, P423, DOI 10.1002/ana.10561; Ruskin DN, 2011, PHYSIOL BEHAV, V103, P501, DOI 10.1016/j.physbeh.2011.04.001; Ruskin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008349; Sasaki S, 1996, NEUROSCI LETT, V204, P53, DOI 10.1016/0304-3940(96)12314-4; SILLS MA, 1986, ARCH DIS CHILD, V61, P1168, DOI 10.1136/adc.61.12.1168; SPECTOR R, 1988, J NEUROCHEM, V50, P639, DOI 10.1111/j.1471-4159.1988.tb02958.x; Stafstrom CE, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00059; Strong M, 2003, AMYOTROPH LATERAL SC, V4, P136, DOI 10.1080/14660820310011250; Tu PH, 1997, LAB INVEST, V76, P441; Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339; Vining EPG, 1998, ARCH NEUROL-CHICAGO, V55, P1433, DOI 10.1001/archneur.55.11.1433; Wiedemann FR, 1998, J NEUROL SCI, V156, P65, DOI 10.1016/S0022-510X(98)00008-2; Wlaz P, 2012, NEUROPHARMACOLOGY, V62, P1882, DOI 10.1016/j.neuropharm.2011.12.015; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Zhao W, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-51; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	53	56	58	1	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 7	2012	7	11							e49191	10.1371/journal.pone.0049191			8	Multidisciplinary Sciences	Science & Technology - Other Topics	048TK	WOS:000311935800228	23145119	DOAJ Gold, Green Published			2021-06-18	
J	Ahmad, A; Crupi, R; Impellizzeri, D; Campolo, M; Marino, A; Esposito, E; Cuzzocrea, S				Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Campolo, Michela; Marino, Angela; Esposito, Emanuela; Cuzzocrea, Salvatore			Administration of palmitoylethanolamide (PEA) protects the neurovascular unit and reduces secondary injury after traumatic brain injury in mice	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Inflammation; PEA; Mast cells; GFAP	SPINAL-CORD-INJURY; NITRIC-OXIDE SYNTHASE; KAPPA-B ACTIVATION; MAST-CELLS; BEHAVIORAL RECOVERY; CEREBRAL-ISCHEMIA; HYPERALGESIA; INFLAMMATION; RAT; ENDOCANNABINOIDS	Traumatic brain injury (TBI) is a major Cause of preventable death and morbidity in young adults. This complex condition is characterized by significant blood brain barrier leakage that stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain. Recovery of function after TBI is partly through neuronal plasticity. In order to test whether treatments that enhance plasticity might improve functional recovery, a controlled cortical impact (CCI) in adult mice, as a model of TBI, in which a controlled cortical impactor produced full thickness lesions of the forelimb region of the sensorimotor cortex, was performed. Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. The endogenous fatty acid palmitoylethanolamide (PEA) is one of the members of N-acyl-ethanolamines family that maintain not only redox balance but also inhibit the mechanisms of secondary injury. Therefore, we tested whether PEA shows efficacy in a mice model of experimental TBI. PEA treatment is able to reduced edema and brain infractions as evidenced by decreased 2,3,5-triphenyltetrazolium chloride staining across brain sections. PEA-mediated improvements in tissues histology shown by reduction of lesion size and improvement in apoptosis level further support the efficacy of PEA therapy. The PEA treatment blocked infiltration of astrocytes and restored CCI-mediated reduced expression of PAR, nitrotyrosine, iNOS, chymase, tryptase, CD11b and GFAP. PEA inhibited the TBI-mediated decrease in the expression of RINK and NF-kappa B. PEA-treated injured animals improved neurobehavioral functions as evaluated by behavioral tests. (C) 2012 Elsevier Inc. All rights reserved.	[Ahmad, Akbar; Crupi, Rosalia; Impellizzeri, Daniela; Campolo, Michela; Esposito, Emanuela; Cuzzocrea, Salvatore] Univ Messina, Dept Clin & Expt Med & Pharmacol, Sch Med, I-98100 Messina, Italy; [Marino, Angela] Univ Messina, Sect Gen Physiol & Pharmacol, Dept Life Sci M Malpighi, I-98100 Messina, Italy; [Cuzzocrea, Salvatore] Univ Manchester, Sch Med, Manchester Royal Infirm, Manchester Biomed Res Ctr, Manchester M13 9PL, Lancs, England	Cuzzocrea, S (corresponding author), Univ Messina, Dept Clin & Expt Med & Pharmacol, Sch Med, Policlin Univ Via C, I-98100 Messina, Italy.	salvator@unime.it	Crupi, Rosalia/U-4364-2019; Campolo, Michela/K-6432-2016	Crupi, Rosalia/0000-0002-7629-3132; Cuzzocrea, Salvatore/0000-0001-6131-3690; Ahmad, Akbar/0000-0003-1841-9670; Impellizzeri, Daniela/0000-0001-9492-3161	European CommunityEuropean Commission [PON01-02512]	This study was supported by a grant from European Community (National Operative Programme "Research and Competitiveness 2007-2013", PON01-02512). The authors thank Carmelo La Spada for their excellent technical assistance during this study.	Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Avila MA, 2008, J CEREBR BLOOD F MET, V28, P1733, DOI 10.1038/jcbfm.2008.66; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Berdyshev E, 1998, LIFE SCI, V63, pPL125, DOI 10.1016/S0024-3205(98)00324-5; Bethea JR, 1998, J NEUROSCI, V18, P3251; Botteri M, 2008, CRIT CARE MED, V36, P3089, DOI 10.1097/CCM.0b013e31818bd7df; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Calignano A, 1998, NATURE, V394, P277, DOI 10.1038/28393; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Esposito E, 2011, BRAIN BEHAV IMMUN, V25, P1099, DOI 10.1016/j.bbi.2011.02.006; Farquhar-Smith WP, 2001, ANESTHESIOLOGY, V94, P507, DOI 10.1097/00000542-200103000-00023; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gursoy-Ozdemir Y, 2004, STROKE, V35, P1449, DOI 10.1161/01.STR.0000126044.83777.f4; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; KOWNATZKI E, 1982, MOL IMMUNOL, V19, P1297, DOI 10.1016/0161-5890(82)90296-6; Lambert DM, 2001, EPILEPSIA, V42, P321, DOI 10.1046/j.1528-1157.2001.41499.x; Mackie K, 2006, AAPS J, V8, pE298, DOI 10.1007/BF02854900; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Mazzari S, 1996, EUR J PHARMACOL, V300, P227, DOI 10.1016/0014-2999(96)00015-5; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Michaloudi HC, 1999, J ANAT, V195, P577, DOI 10.1046/j.1469-7580.1999.19540577.x; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Parathath SR, 2006, J CELL SCI, V119, P339, DOI 10.1242/jcs.02734; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Raposo G, 1997, MOL BIOL CELL, V8, P2631, DOI 10.1091/mbc.8.12.2631; Rice ASC, 2002, PROSTAG LEUKOTR ESS, V66, P243, DOI 10.1054/plef.2001.0362; Ross RA, 2000, EUR J PHARMACOL, V401, P121, DOI 10.1016/S0014-2999(00)00437-4; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Theodosiou M, 1999, PAIN, V81, P245, DOI 10.1016/S0304-3959(99)00018-4; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36; Zuo YX, 2003, PAIN, V105, P467, DOI 10.1016/S0304-3959(03)00261-6	48	56	59	0	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591			BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2012	26	8					1310	1321		10.1016/j.bbi.2012.07.021			12	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	025JV	WOS:000310186000016	22884901				2021-06-18	
J	Cantor, JB; Bushnik, T; Cicerone, K; Dijkers, MP; Gordon, W; Hammond, FM; Kolakowsky-Hayner, SA; Lequerica, A; Nguyen, M; Spielman, LA				Cantor, Joshua B.; Bushnik, Tamara; Cicerone, Keith; Dijkers, Marcel P.; Gordon, Wayne; Hammond, Flora M.; Kolakowsky-Hayner, Stephanie A.; Lequerica, Anthony; Michael Nguyen; Spielman, Lisa A.			Insomnia, Fatigue, and Sleepiness in the First 2 Years After Traumatic Brain Injury: An NIDRR TBI Model System Module Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic brain injury; comorbidity; fatigue; insomnia; sleep; traumatic brain injury	LATENCY TEST MSLT; DAYTIME SLEEPINESS; RISK-FACTORS; GENERAL-POPULATION; OBJECTIVE MEASURES; HYGIENE PRACTICES; HEAD-INJURY; QUALITY; SCALE; SAMPLE	Objective: To determine the prevalence of insomnia and posttraumatic brain injury (TBI) fatigue (PTBIF) in individuals with moderate to severe TBI, to explore the relationship between PTBIF and insomnia and their association with outcomes. Design: Cross-sectional study. Setting: Five National Institute of Disability and Rehabilitation Research TBI Model Systems. Participants: Three hundred thirty-four individuals with TBI who completed 1-year (n = 213) or 2-year (n = 121) follow-up interviews between 2008 and 2012. Main Outcome Results: Insomnia occurred in 11% to 24% and PTBIF in 33% to 44% of the individuals. Insomnia and fatigue were both related to sleep disturbance, sleep hygiene, satisfaction with life, anxiety, and depression. PTBIF was associated with greater disability and sleepiness. Insomnia without fatigue was rare (2%-3%) but PTBIF without insomnia occurred in 21% to 23% of the individuals. Comorbidity occurred in 9% to 22% of the individuals. Conclusions: Although PTBIF and insomnia are closely related and both associated with poorer quality of life, they are affected independently by a variety of factors, especially psychopathology and sleep quality. A majority of individuals with PTBIF do not have insomnia; and PTBIF appears to be related to disability severity and daytime sleepiness, where insomnia is not. Demographic and injury variables are not strong predictors of insomnia or PTBIF.	[Cantor, Joshua B.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Bushnik, Tamara] NYU Langone Sch Med, Rusk Inst Rehabil Med, New York, NY USA; [Cicerone, Keith] Johnson Rehabil Inst, Edison, NJ USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN USA; [Bushnik, Tamara; Kolakowsky-Hayner, Stephanie A.] Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; [Lequerica, Anthony] Kessler Fdn Res Ctr, W Orange, NJ USA; [Lequerica, Anthony] Univ Med & Dent New Jersey, Newwark, NJ USA	Cantor, JB (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	joshua.cantor@mountsinai.org	Heinemann, Allen W/K-6283-2012; Kolakowsky-Hayner, Stephanie A./I-9858-2019	Heinemann, Allen W/0000-0003-2782-7326; Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Dijkers, Marcel/0000-0002-8362-5596; Bushnik, Tamara/0000-0003-3328-257X	National Institute on Disability and Rehabilitation Research [H133A070033, H133A070038, H133A070042, H133A070037, H133A070030]	This research was funded by National Institute on Disability and Rehabilitation Research grants H133A070033, H133A070038, H133A070042, H133A070037, and H133A070030 and carried out by Traumatic Brain Injury Model Systems Centers. The authors thank all the data collectors and participants in this research for their time and effort.	American Academy of Sleep Medicine, 2001, INT CLASS SLEEP DIS, P208; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bastien CH, 2000, J SLEEP RES, V9, P49, DOI 10.1046/j.1365-2869.2000.00182.x; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beaulieu-Bonneau S, 2012, SLEEP MED, V13, P598, DOI 10.1016/j.sleep.2012.02.010; Belanger L, 2004, J ANXIETY DISORD, V18, P561, DOI 10.1016/S0887-6185(03)00031-8; BELZA BL, 1995, J RHEUMATOL, V22, P639; Bormann J, 2001, J Assoc Nurses AIDS Care, V12, P75, DOI 10.1016/S1055-3290(06)60146-5; Brown FC, 2002, BEHAV MED, V28, P33, DOI 10.1080/08964280209596396; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Buysse DJ, 2008, J CLIN SLEEP MED, V4, P563; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chan-Chee C, 2011, REV EPIDEMIOL SANTE, V59, P409, DOI 10.1016/j.respe.2011.05.005; Collen J, 2012, CHEST; Cook KF, 2011, ARCH PHYS MED REHAB, V92, P1126, DOI 10.1016/j.apmr.2011.02.017; Corrigan J., 2000, CTR OUTCOME MEASUREM; de Groot MH, 2003, ARCH PHYS MED REHAB, V84, P1714, DOI 10.1053/S0003-9993(03)00346-0; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Jansson-Frojmark M, 2008, SLEEP, V31, P881, DOI 10.1093/sleep/31.6.881; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kohl AD, 2009, BRAIN INJURY, V23, P420, DOI 10.1080/02699050902788519; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LeBlanc M, 2009, SLEEP, V32, P1027, DOI 10.1093/sleep/32.8.1027; Leger D, 2011, SLEEP MED, V12, P454, DOI 10.1016/j.sleep.2010.12.012; LICHSTEIN KL, 1994, SLEEP, V17, P693, DOI 10.1093/sleep/17.8.693; Mastin DF, 2006, J BEHAV MED, V29, P223, DOI 10.1007/s10865-006-9047-6; Morin CM, 2012, LANCET, V379, P1129, DOI 10.1016/S0140-6736(11)60750-2; MORIN CM, 1989, PSYCHOL AGING, V4, P290, DOI 10.1037/0882-7974.4.3.290; Morin CM., 1993, INSOMNIA PSYCHOL ASS; ntroduction to the Disability Rating Scale, 2000, CTR OUTCOME MEASUREM, P2000; Ohayon MM, 2012, J PSYCHIATR RES, V46, P422, DOI 10.1016/j.jpsychires.2011.06.008; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Schepers VP, 2006, ARCH PHYS MED REHAB, V87, P184, DOI 10.1016/j.apmr.2005.10.005; Seicean S, 2011, SLEEP, V34, P1021, DOI 10.5665/SLEEP.1154; Singareddy R, 2012, SLEEP MED, V13, P346, DOI 10.1016/j.sleep.2011.10.033; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Sundstrom A, 2007, BRAIN INJURY, V21, P1049, DOI 10.1080/02699050701630367; Taylor DJ, 2011, BEHAV SLEEP MED, V9, P107, DOI 10.1080/15402002.2011.557992; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Yang CM, 2010, J HEALTH PSYCHOL, V15, P147, DOI 10.1177/1359105309346342; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	63	56	56	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2012	27	6					E1	E14		10.1097/HTR.0b013e318270f91e			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	039CU	WOS:000311221200001	23131966				2021-06-18	
J	von Steinbuechel, N; Wilson, L; Gibbons, H; Muehlan, H; Schmidt, H; Schmidt, S; Sasse, N; Koskinen, S; Sarajuuri, J; Hofer, S; Bullinger, M; Maas, A; Neugebauer, E; Powell, J; von Wild, K; Zitnay, G; Bakx, W; Christensen, AL; Formisano, R; Hawthorne, G; Truelle, JL				von Steinbuechel, Nicole; Wilson, Lindsay; Gibbons, Henning; Muehlan, Holger; Schmidt, Holger; Schmidt, Silke; Sasse, Nadine; Koskinen, Sanna; Sarajuuri, Jaana; Hoefer, Stefan; Bullinger, Monika; Maas, Andrew; Neugebauer, Edmund; Powell, Jane; von Wild, Klaus; Zitnay, George; Bakx, Wilbert; Christensen, Anne-Lise; Formisano, Rita; Hawthorne, Graeme; Truelle, Jean-Luc			QOLIBRI Overall Scale: a brief index of health-related quality of life after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SATISFACTION	Background The Quality of Life after Brain Injury (QOLIBRI) scale is a recently developed instrument that provides a profile of health-related quality of life (HRQoL) in domains typically affected by brain injury. However, for global assessment it is desirable to have a brief summary measure. This study examined a 6-item QOLIBRI Overall Scale (QOLIBRI-OS), and considered whether it could provide an index of HRQoL after traumatic brain injury (TBI). Methods The properties of the QOLIBRI-OS were studied in a sample of 792 participants with TBI recruited from centres in nine countries covering six languages. An examination of construct validity was undertaken on a subsample of 153 participants recruited in Germany who had been assessed on two relevant brief quality of life measures, the Satisfaction With Life Scale and the Quality of Life Visual Analogue Scale. Results The reliability of the QOLIBRI-OS was good (Cronbach's a 0.86, test-retest reliability =0.81) and similar in participants with higher and lower cognitive performance. Factor analysis indicated that the scale is unidimensional. Rasch analysis also showed a satisfactory fit with this model. The QOLIBRI-OS correlates highly with the total score from the full QOLIBRI scale (r=0.87). Moderate to strong relationships were found among the QOLIBRI-OS and the Extended Glasgow Outcome Scale, Short-Form-36, and Hospital Anxiety and Depression scale (r=0.54 to -0.76). The QOLIBRI-OS showed good construct validity in the TBI group. Conclusions The QOLIBRI-OS assesses a similar construct to the QOLIBRI total score and can be used as a brief index of HRQoL for TBI.	[Wilson, Lindsay] Univ Stirling, Dept Psychol, Div Psychol, Stirling FK9 4LA, Scotland; [von Steinbuechel, Nicole; Gibbons, Henning; Sasse, Nadine] Univ Gottingen, Dept Med Psychol & Med Sociol, Gottingen, Germany; [Muehlan, Holger] Ernst Moritz Arndt Univ Greifswald, Dept Hlth & Prevent, Greifswald, Germany; [Schmidt, Holger; Schmidt, Silke] Univ Med Ctr, Dept Neurol, Gottingen, Germany; [Koskinen, Sanna; Sarajuuri, Jaana] Kapyla Rehabil Ctr, Unit Clin Neuropsychol & Psychol, Helsinki, Finland; [Hoefer, Stefan] Innsbruck Med Univ, Dept Med Psychol, Innsbruck, Austria; [Bullinger, Monika] Univ Hamburg, Inst & Poliklin Med Psychol, Hamburg, Germany; [Maas, Andrew] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium; [Neugebauer, Edmund] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany; [Powell, Jane] Univ London, Dept Psychol, London, England; [von Wild, Klaus] Univ Munster, Munster, Germany; [Zitnay, George] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Bakx, Wilbert] Maastricht Univ, Adelante Adult Rehabil Ctr, Maastricht, Netherlands; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Rehabil Brain Injury, Copenhagen, Denmark; [Christensen, Anne-Lise] Univ Copenhagen, Ctr Cognit & Memory, Copenhagen, Denmark; [Formisano, Rita] IRCCS Fdn Santa Lucia, Rome, Italy; [Hawthorne, Graeme] Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia; [Truelle, Jean-Luc] Univ Hosp Garches, Rehabil Dept, Garches, France	Wilson, L (corresponding author), Univ Stirling, Dept Psychol, Div Psychol, Stirling FK9 4LA, Scotland.	jtlw1@stir.ac.uk	Maas, Andrew IR/C-5584-2013; Hofer, Stefan/B-8393-2008; Hofer, Stefan/N-8253-2019; Wilson, Lindsay/O-8883-2019; Sarajuuri, Jaana/AAD-8665-2019; Wilson, Lindsay/A-3659-2009	Maas, Andrew IR/0000-0003-1612-1264; Hofer, Stefan/0000-0002-6128-3687; Hofer, Stefan/0000-0002-6128-3687; Wilson, Lindsay/0000-0003-4113-2328; Sarajuuri, Jaana/0000-0002-6432-0295; Wilson, Lindsay/0000-0003-4113-2328; Koskinen, Sanna/0000-0002-3453-5084	ZNS-Hannelore Kohl Foundation, Germany [2008014]; Victorian Transport Accident Commission [D114]; Italian Ministry of HealthMinistry of Health, Italy [RF08.31]	This work was supported by research grant 2008014 from the ZNS-Hannelore Kohl Foundation, Germany. The Australian data were collected under grant D114 from the Victorian Transport Accident Commission. Italian data were collected under grant RF08.31 from the Italian Ministry of Health.	Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Bland JM, 1997, BRIT MED J, V314, P572, DOI 10.1136/bmj.314.7080.572; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111, DOI DOI 10.1159/000264678; Brown M, 2004, ARCH PHYS MED REHAB, V85, pS13, DOI 10.1016/j.apmr.2003.08.110; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; de Boer AGEM, 2004, QUAL LIFE RES, V13, P311, DOI 10.1023/B:QURE.0000018499.64574.1f; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Fleiss J., 1986, DESIGN ANAL CLIN EXP; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gregg PM, 2001, SOC INDIC RES, V54, P1, DOI 10.1023/A:1007221030609; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Heinemann AW, 2004, REHABIL PSYCHOL, V49, P156, DOI 10.1037/0090-5550.49.2.156; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Moosbrugger H., 2007, TESTTHEORIE FRAGEBOG; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Power M, 1998, SOC SCI MED, V46, P1569, DOI 10.1016/s0277-9536(98)00009-4; Riemsma R P, 2001, Health Technol Assess, V5, P1; Smith AB, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-33; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; STEIGER JH, 1980, PSYCHOL BULL, V87, P245, DOI 10.1037/0033-2909.87.2.245; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; US Food and Drug Administration, 2009, GUID IND PAT REP OUT; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Ware JE., 1993, SF 36 HLTH SURVEY MA; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	56	56	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2012	83	11					1041	1047		10.1136/jnnp-2012-302361			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	020MG	WOS:000309813600005	22851609				2021-06-18	
J	Yi, JH; Katagiri, Y; Susarla, B; Figge, D; Symes, AJ; Geller, HM				Yi, Jae-Hyuk; Katagiri, Yasuhiro; Susarla, Bala; Figge, David; Symes, Aviva J.; Geller, Herbert M.			Alterations in sulfated chondroitin glycosaminoglycans following controlled cortical impact injury in mice	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						chondroitin sulfate proteoglycan; traumatic brain injury; extracellular ma-trix; perineuronal nets	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; MONOCLONAL-ANTIBODY; GLIAL SCAR; PROTEOGLYCAN EXPRESSION; REACTIVE ASTROCYTES; PERINEURONAL NETS; NG2 PROTEOGLYCAN; ADULT-RAT; ARTICULAR-CARTILAGE	Chondroitin sulfate proteoglycans (CSPGs) play a pivotal role in many neuronal growth mechanisms including axon guidance and the modulation of repair processes following injury to the spinal cord or brain. Many actions of CSPGs in the central nervous system (CNS) are governed by the specific sulfation pattern on the glycosaminoglycan (GAG) chains attached to CSPG core proteins. To elucidate the role of CSPGs and sulfated GAG chains following traumatic brain injury (TBI), controlled cortical impact injury of mild to moderate severity was performed over the left sensory motor cortex in mice. Using immunoblotting and immunostaining, we found that TBI resulted in an increase in the CSPGs neurocan and NG2 expression in a tight band surrounding the injury core, which overlapped with the presence of 4-sulfated CS GAGs but not with 6-sulfated GAGs. This increase was observed as early as 7 days post injury (dpi), and persisted for up to 28 dpi. Labeling with markers against microglia/macrophages, NG2+ cells, fibroblasts, and astrocytes showed that these cells were all localized in the area, suggesting multiple origins of chondroitin-4-sulfate increase. TBI also caused a decrease in the expression of aggrecan and phosphacan in the pericontusional cortex with a concomitant reduction in the number of perineuronal nets. In summary, we describe a dual response in CSPGs whereby they may be actively involved in complex repair processes following TBI. J. Comp. Neurol. 520:32953313, 2012. (C) 2012 Wiley Periodicals, Inc.	[Yi, Jae-Hyuk; Katagiri, Yasuhiro; Figge, David; Geller, Herbert M.] NHLBI, Dev Neurobiol Sect, Cell Biol & Physiol Ctr, NIH, Bethesda, MD 20892 USA; [Yi, Jae-Hyuk; Susarla, Bala; Symes, Aviva J.; Geller, Herbert M.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Susarla, Bala; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	Geller, HM (corresponding author), NHLBI, Dev Neurobiol Sect, Cell Biol & Physiol Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	geller@helix.nih.gov	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Geller, Herbert/0000-0002-7048-6144	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G175PD, G1709B]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [ZIAHL006135, ZICHL006019] Funding Source: NIH RePORTER	Grant sponsor: Center for Neuroscience and Regenerative Medicine; Grant numbers: G175PD (to H.M.G. and A.J.S.) and G1709B (postdoctoral fellowship to J.-H.Y.).	Andrews EM, 2012, EXP NEUROL, V235, P174, DOI 10.1016/j.expneurol.2011.09.008; Asher RA, 2000, J NEUROSCI, V20, P2427; Asher RA, 2002, J NEUROSCI, V22, P2225, DOI 10.1523/JNEUROSCI.22-06-02225.2002; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; Bao XF, 2005, J BIOL CHEM, V280, P23184, DOI 10.1074/jbc.M503036200; Bartus K, 2012, EXP NEUROL, V235, P5, DOI 10.1016/j.expneurol.2011.08.008; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; BRAUER K, 1993, BRAIN RES, V631, P167, DOI 10.1016/0006-8993(93)91205-7; Brennand KJ, 2011, NATURE, V473, P221, DOI 10.1038/nature09915; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Bukhari N, 2011, J NEUROSCI, V31, P14931, DOI 10.1523/JNEUROSCI.3339-11.2011; Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.0.CO;2-5; Carulli D, 2006, J COMP NEUROL, V494, P559, DOI 10.1002/cne.20822; Corvetti L, 2005, J NEUROSCI, V25, P7150, DOI 10.1523/JNEUROSCI.0683-05.2005; Coulson-Thomas YA, 2008, J NEUROSCI METH, V171, P19, DOI 10.1016/j.jneumeth.2008.01.030; CSSZABO G, 1995, ARTHRITIS RHEUM, V38, P660, DOI 10.1002/art.1780380514; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Gama CI, 2006, NAT CHEM BIOL, V2, P467, DOI 10.1038/nchembio810; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Giamanco KA, 2010, NEUROSCIENCE, V170, P1314, DOI 10.1016/j.neuroscience.2010.08.032; Gilbert RJ, 2005, MOL CELL NEUROSCI, V29, P545, DOI 10.1016/j.mcn.2005.04.006; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Horii-Hayashi N, 2008, CELL TISSUE RES, V334, P163, DOI 10.1007/s00441-008-0698-1; Horii-Hayashi N, 2010, NEUROSCI LETT, V483, P67, DOI 10.1016/j.neulet.2010.07.064; Hu HY, 2011, J COMP NEUROL, V519, P1320, DOI 10.1002/cne.22572; Iida J, 2001, J BIOL CHEM, V276, P18786, DOI 10.1074/jbc.M010053200; Imagama S, 2011, J NEUROSCI, V31, P17091, DOI 10.1523/JNEUROSCI.5120-10.2011; Ishii M, 2008, GLYCOBIOLOGY, V18, P602, DOI 10.1093/glycob/cwn040; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200; Kim KK, 2009, J BIOL CHEM, V284, P31052, DOI 10.1074/jbc.M109.052969; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Komitova M, 2011, GLIA, V59, P800, DOI 10.1002/glia.21152; Kwok JCF, 2011, DEV NEUROBIOL, V71, P1073, DOI 10.1002/dneu.20974; Laabs TL, 2007, J NEUROSCI, V27, P14494, DOI 10.1523/JNEUROSCI.2807-07.2007; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; LEVINE JM, 1994, J NEUROSCI, V14, P4716; LEVINE JM, 1987, J NEUROSCI, V7, P2721; Lin R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021499; Lyck L, 2008, J HISTOCHEM CYTOCHEM, V56, P201, DOI 10.1369/jhc.7A7187.2007; MAEDA N, 1992, DEV BIOL, V151, P564, DOI 10.1016/0012-1606(92)90194-L; Maeda N, 2003, J BIOL CHEM, V278, P35805, DOI 10.1074/jbc.M305530200; MARK MP, 1989, DEV BIOL, V133, P475, DOI 10.1016/0012-1606(89)90051-1; Massey JM, 2008, EXP NEUROL, V209, P426, DOI 10.1016/j.expneurol.2007.03.029; McKeon RJ, 1999, J NEUROSCI, V19, P10778; Miyata S, 2004, BRAIN RES, V1017, P163, DOI 10.1016/j.brainres.2004.05.034; Morgenstern DA, 2003, MOL CELL NEUROSCI, V24, P787, DOI 10.1016/S1044-7431(03)00245-8; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nakamura M, 2009, BRAIN RES, V1252, P117, DOI 10.1016/j.brainres.2008.11.022; Ohsawa K, 2000, J CELL SCI, V113, P3073; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; POOLE CA, 1991, J HISTOCHEM CYTOCHEM, V39, P1175, DOI 10.1177/39.9.1717545; Pratta MA, 2000, J BIOL CHEM, V275, P39096, DOI 10.1074/jbc.M006201200; Properzi F, 2005, EUR J NEUROSCI, V21, P378, DOI 10.1111/j.1460-9568.2005.03876.x; Sajad M, 2011, J MOL NEUROSCI, V43, P531, DOI 10.1007/s12031-010-9476-0; Sato Y, 2009, CURR STEM CELL RES T, V4, P200, DOI 10.2174/157488809789057419; SATOYOSHITAKE R, 1989, NEURON, V3, P229, DOI 10.1016/0896-6273(89)90036-6; Shearer MC, 2003, MOL CELL NEUROSCI, V24, P913, DOI 10.1016/j.mcn.2003.09.004; Shimada IS, 2011, STROKE, V42, P3231, DOI 10.1161/STROKEAHA.111.623280; Shimazaki Y, 2005, J NEUROSCI RES, V82, P172, DOI 10.1002/jnr.20639; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Stallcup WB, 2001, J CELL SCI, V114, P2315; Takahashi H, 2011, MOL CELL NEUROSCI, V47, P119, DOI 10.1016/j.mcn.2011.03.006; Velasco J, 2011, J BIOL CHEM, V286, P26016, DOI 10.1074/jbc.M110.208694; Wang DF, 2011, J NEUROSCI, V31, P9332, DOI 10.1523/JNEUROSCI.0983-11.2011; Wang H, 2008, J CELL SCI, V121, P3083, DOI 10.1242/jcs.032649; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; Yamamoto Y, 1995, EUR J HISTOCHEM, V39, P265; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang HQ, 2006, GLYCOBIOLOGY, V16, P702, DOI 10.1093/glycob/cwj115	77	56	56	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	OCT 15	2012	520	15					3295	3313		10.1002/cne.23156			19	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	993HV	WOS:000307849400001	22628090	Green Accepted			2021-06-18	
J	Tomura, S; Vaccari, JPD; Keane, RW; Bramlett, HM; Dietrich, WD				Tomura, Satoshi; Vaccari, Juan Pablo de Rivero; Keane, Robert W.; Bramlett, Helen M.; Dietrich, W. Dalton			Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						caspase-1; hypothermia; IL-1; inflammasome; innate immunity; traumatic brain injury	INNATE IMMUNE-RESPONSE; POSTTRAUMATIC HYPOTHERMIA; CEREBROSPINAL-FLUID; PROTEIN-LEVELS; INTERLEUKIN-1-BETA; DAMAGE; MODEL; ACTIVATION; EXPRESSION; SUPPRESSION	Traumatic brain injury (TBI) activates the NALP1/NLRP1 inflammasome, which is an important component of the early innate inflammatory response to injury. We investigated the influence of therapeutic hypothermia on inflammasome activation after TBI. Adult male Sprague-Dawley rats were subjected to moderate fluid percussion brain injury. Temperature manipulation (33 degrees C or 37 degrees C) was initiated 30 minutes after TBI and maintained for 4 hours. At 4 or 24 hours after TBI, traumatized cortex and hippocampus were prepared for immunoblot or immunohistochemical analysis. In the normothermic groups, caspase-1, caspase-11 and expression of the purinergic receptor P2X7 increased at 24 hours after TBI. Posttraumatic hypothermia lead to decreased expression of these proteins at 24 hours compared with normothermic levels. Immunocytochemical studies showed that posttraumatic hypothermia also decreased caspase-1 staining in cerebral cortical neurons compared with normothermic TBI. Cultured cortical neurons subjected to stretch injury demonstrated significant secretion of caspase-1 into the culture medium and caspase-3 activation, both results reduced by hypothermic treatment. Posttraumatic hypothermia decreases inflammasome signaling in neurons and reduces the innate immune response to TBI at 24 hours after injury. Therapeutic hypothermia may protect the injured central nervous system by targeting the detrimental consequences of the innate immune response to injury. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 1939-1947; doi:10.1038/jcbfm.2012.99; published online 11 July 2012	[Tomura, Satoshi; Vaccari, Juan Pablo de Rivero; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Tomura, Satoshi; Vaccari, Juan Pablo de Rivero; Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu	de Rivero Vaccari, Juan Pablo/H-5718-2019; de Rivero Vaccari, Juan Pablo/ABE-3248-2020	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, NS 042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER	This work was supported by NIH NS030291 and NS 042133.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; Vaccari JPD, 2012, GLIA, V60, P414, DOI 10.1002/glia.22275; Dietrich WD, 2010, NEUROTHERAPEUTICS, V7, P43, DOI 10.1016/j.nurt.2009.10.015; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dinarello CA, 2005, CRIT CARE MED, V33, pS460, DOI 10.1097/01.CCM.0000185500.11080.91; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Finsen B, 2011, FEBS LETT, V585, P3806, DOI 10.1016/j.febslet.2011.05.030; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mawhinney LJ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-123; Mirzoyev SA, 2010, RESUSCITATION, V81, P1632, DOI 10.1016/j.resuscitation.2010.08.007; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	40	56	62	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2012	32	10					1939	1947		10.1038/jcbfm.2012.99			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	014KY	WOS:000309375800012	22781337	Green Published, Bronze			2021-06-18	
J	Li, LM; Kolias, AG; Guilfoyle, MR; Timofeev, I; Corteen, EA; Pickard, JD; Menon, DK; Kirkpatrick, PJ; Hutchinson, PJ				Li, Lucia M.; Kolias, Angelos G.; Guilfoyle, Mathew R.; Timofeev, Ivan; Corteen, Elizabeth A.; Pickard, John D.; Menon, David K.; Kirkpatrick, Peter J.; Hutchinson, Peter J.			Outcome following evacuation of acute subdural haematomas: a comparison of craniotomy with decompressive craniectomy	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Craniotomy; Decompressive craniectomy; Acute subdural hematoma	TRAUMATIC BRAIN-INJURY; HEAD-INJURIES; MANAGEMENT; MORTALITY; COMPLICATIONS; EPIDEMIOLOGY	Acute subdural haematomas (ASDH) occur commonly following traumatic brain injury and may be evacuated by either craniotomy (CR) or decompressive craniectomy (DC). We reviewed a series of consecutive patients undergoing evacuation of a traumatic ASDH at a regional centre, comparing observed clinical outcomes (assessed by Glasgow Outcome Scale at six months) with those predicted by the CRASH-CT prognostic model. Retrospective review of prospectively collected data. Ninety-one patients were identified (51 DC and 40 CR ). Eighty-five had available admission data sets from which predicted outcome could be calculated. The DC group were younger than the CR group (p = 0.015). The DC group also had a greater proportion of patients whose pre-intubation GCS was a parts per thousand currency sign8 (p = 0.001), with significant extracranial injuries (p = 0.001) and obliterated basal cisterns (p = 0.001) on their pre-operative CT scan. Bone flaps in the DC group (n = 45) were longer (mean 11.6 cm; 95 % CI: 11.1-12.1) in comparison to bone flaps in the CR (n = 34) group [(mean 10.2 cm; 95 % CI: 9.35 - 10.9); p = 0.0024] The mean CRASH-CT predicted risk of 14-day mortality and of unfavourable outcome at six months was significantly higher in the DC group compared with the CR group. Eighty-eight patients had available 6-month Glasgow Outcome Scale scores. Favourable outcomes were observed in 42 % of DC versus 45 % of CR (p = 0.83). The overall mortality rate was 38 % in DC versus 32 % in CR (p = 0.65). The standardised morbidity ratio (observed/expected unfavourable outcomes) was 0.75 (95 % CI: 0.51-1.07) for DC and 0.90 (95 % CI: 0.57-1.35) for CR. CR and DC for traumatic ASDH are both commonly used for primary evacuation of ASDH. Primary DC may be more effective than CR for selected patients with ASDH. Class I evidence is required in order to refine the indications for DC following evacuation of ASDH.	[Li, Lucia M.; Kolias, Angelos G.; Guilfoyle, Mathew R.; Timofeev, Ivan; Corteen, Elizabeth A.; Pickard, John D.; Kirkpatrick, Peter J.; Hutchinson, Peter J.] Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Li, Lucia M.; Kolias, Angelos G.; Guilfoyle, Mathew R.; Timofeev, Ivan; Corteen, Elizabeth A.; Pickard, John D.; Menon, David K.; Kirkpatrick, Peter J.; Hutchinson, Peter J.] Univ Cambridge, Cambridge CB2 0QQ, England; [Menon, David K.] Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 0QQ, England	Kolias, AG (corresponding author), Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Hills Rd, Cambridge CB2 0QQ, England.	angeloskolias@gmail.com	Timofeev, Ivan/AAE-7019-2019	Kolias, Angelos/0000-0003-3992-0587; Li, Lucia/0000-0001-7339-4854; Corteen, Elizabeth/0000-0002-3069-9655; Timofeev, Ivan/0000-0002-1168-0393	Academic Foundation Programme, East of England Deanery; Royal College of Surgeons of England Research Fellowship; Freemasons; Rosetrees TrustRosetrees Trust; National Institute for Health Research Academic Clinical Fellowship; Raymond and Beverly Sackler Studentship; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0601025, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327, ACF-2011-14-003] Funding Source: researchfish	We thank Anne Manktelow for her assistance. LML is supported by an Academic Foundation Programme, East of England Deanery. AGK is supported by a Royal College of Surgeons of England Research Fellowship (funded by the Freemasons and the Rosetrees Trust), a National Institute for Health Research Academic Clinical Fellowship and a Raymond and Beverly Sackler Studentship. JDP and DKM are National Institute for Health Research Senior Investigators. PJH is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship.	Bullock M, 2006, NEUROSURGERY, V58, P61; Chen SH, 2011, J TRAUMA; Compagnone C, 2005, NEUROSURGERY, V57, P1183; d'Avella D, 2003, ACTA NEUROCHIR, V145, P1037, DOI 10.1007/s00701-003-0150-y; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hanif S, 2009, Ir Med J, V102, P255; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Hlatky R, 2007, NEUROSURGERY, V61, P249, DOI [10.1227/01.NEU.0000143029.42638.2c, 10.1227/01.neu.0000279220.30633.45]; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kolias AG, 2012, ACTA NEUROCHIR WIEN; Leitgeb J, 2007, WIEN KLIN WOCHENSCHR, V119, P56, DOI 10.1007/s00508-006-0764-1; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rothman KJ, 1979, EPIDEMIOLOGIC ANAL P; Sawauchi S, 2008, ACTA NEUROCHIR, V150, P531, DOI 10.1007/s00701-007-1497-2; Sawauchi S, 2007, NEUROL SURG TOKYO, V35, P665; Sawauchi S, 2007, NEUROL SURG TOKYO, V35, P43; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Senft C, 2009, NEUROL RES, V31, P1012, DOI 10.1179/174313209X409034; SHIGEMORI M, 1991, Neurologia Medico-Chirurgica, V31, P390, DOI 10.2176/nmc.31.390; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; Statistics OfN, 2008, REG TRENDS LOC AUTH; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tagliaferri F, 2012, ACTA NEUROCHIR, V154, P919, DOI 10.1007/s00701-012-1318-0; Tallon JM, 2008, CAN J SURG, V51, P339; Taussky P, 2008, SWISS MED WKLY, V138, P281, DOI 2008/19/smw-12056; Timofeev I, 2012, Adv Tech Stand Neurosurg, V38, P115, DOI 10.1007/978-3-7091-0676-1_6; Tomita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P213; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; van Leeuwen N, 2011, NEUROSURGERY; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Wong GKC, 2010, ACTA NEUROCHIR SUPPL, V106, P235, DOI 10.1007/978-3-211-98811-4_44; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	40	56	57	0	5	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	SEP	2012	154	9					1555	1561		10.1007/s00701-012-1428-8			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	994UF	WOS:000307957500003	22752713				2021-06-18	
J	Villamar, MF; Portilla, AS; Fregni, F; Zafonte, R				Villamar, Mauricio Fernando; Portilla, Andrea Santos; Fregni, Felipe; Zafonte, Ross			Noninvasive Brain Stimulation to Modulate Neuroplasticity in Traumatic Brain Injury	NEUROMODULATION			English	Article						Diffuse axonal injury; neuroplasticity; transcranial direct current stimulation; transcranial magnetic stimulation; traumatic brain injury	TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; LONG-TERM POTENTIATION; THETA-BURST-STIMULATION; LOW-FREQUENCY RTMS; ADULT HUMAN BRAIN; SYNAPTIC PLASTICITY; STROKE PATIENTS; WORKING-MEMORY; CORTICAL EXCITABILITY	Objective: To review the use of noninvasive brain stimulation (NBS) as a therapeutic tool to enhance neuroplasticity following traumatic brain injury (TBI). Materials and Methods: Based on a literature search, we describe the pathophysiological events following TBI and the rationale for the use of transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) in this setting. Results: The pathophysiological mechanisms occurring after TBI vary across time and therefore require differential interventions. Theoretically, given the neurophysiological effects of both TMS and tDCS, these tools may: 1) decrease cortical hyperexcitability acutely after TBI; 2) modulate long-term synaptic plasticity as to avoid maladaptive consequences; and 3) combined with physical and behavioral therapy, facilitate cortical reorganization and consolidation of learning in specific neural networks. All of these interventions may help decrease the burden of disabling sequelae after brain injury. Conclusions: Evidence from animal and human studies reveals the potential benefit of NBS in decreasing the extent of injury and enhancing plastic changes to facilitate learning and recovery of function in lesioned neural tissue. However, this evidence is mainly theoretical at this point. Given safety constraints, studies in TBI patients are necessary to address the role of NBS in this condition as well as to further elucidate its therapeutic effects and define optimal stimulation parameters.	[Villamar, Mauricio Fernando; Portilla, Andrea Santos; Fregni, Felipe; Zafonte, Ross] Harvard Univ, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Lab Neuromodulat,Med Sch, Boston, MA 02114 USA; [Villamar, Mauricio Fernando; Portilla, Andrea Santos; Fregni, Felipe; Zafonte, Ross] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA	Zafonte, R (corresponding author), Harvard Univ, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Lab Neuromodulat,Med Sch, 125 Nashua St 706, Boston, MA 02114 USA.	rzafonte@partners.org		Edwards, Dylan/0000-0001-7346-3100; Fregni, Felipe/0000-0001-9359-8643; Villamar, Mauricio/0000-0003-4503-8152			Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013; Adkins DL, 2006, J APPL PHYSIOL, V101, P1776, DOI 10.1152/japplphysiol.00515.2006; Adkins-Muir DL, 2003, NEUROL RES, V25, P780, DOI 10.1179/016164103771953853; Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; [Anonymous], 1999, JAMA, V282, P974; [Anonymous], 2011, PLASTICITY INFLAMMAT; Antal A, 2004, INVEST OPHTH VIS SCI, V45, P702, DOI 10.1167/iovs.03-0688; Antal A, 2001, NEUROREPORT, V12, P3553, DOI 10.1097/00001756-200111160-00036; Ardolino G, 2005, J PHYSIOL-LONDON, V568, P653, DOI 10.1113/jphysiol.2005.088310; ARONIADOU VA, 1995, CEREB CORTEX, V5, P353, DOI 10.1093/cercor/5.4.353; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Bach-y-Rita P, 2003, BRAIN INJURY, V17, P643, DOI 10.1080/0269905031000107133; Bae EH, 2007, EPILEPSY BEHAV, V10, P521, DOI 10.1016/j.yebeh.2007.03.004; BARKER AT, 1985, LANCET, V1, P1106; BINDMAN LJ, 1964, J PHYSIOL-LONDON, V172, P369, DOI 10.1113/jphysiol.1964.sp007425; Black JE, 2004, AM J PSYCHIAT, V161, P742, DOI 10.1176/appi.ajp.161.4.742; Bliss TVP, 2011, CLINICS, V66, P3, DOI 10.1590/S1807-59322011001300002; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Blitz DM, 2004, NAT REV NEUROSCI, V5, P630, DOI 10.1038/nrn1475; Boggio PS, 2007, RESTOR NEUROL NEUROS, V25, P123; Boggio PS, 2006, NEUROSCI LETT, V404, P232, DOI 10.1016/j.neulet.2006.05.051; Bolognini N, 2011, NEUROREHAB NEURAL RE, V25, P819, DOI 10.1177/1545968311411056; Bolognini N, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-8; Bortolomasi M, 2007, PSYCHIAT RES, V150, P181, DOI 10.1016/j.psychres.2006.04.010; Braunewell KH, 2001, REV NEUROSCIENCE, V12, P121; Brough D, 2011, TRENDS PHARMACOL SCI, V32, P617, DOI 10.1016/j.tips.2011.06.002; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Brunoni AR, 2011, INT J NEUROPSYCHOPH, V14, P1133, DOI 10.1017/S1461145710001690; Bueno VF, 2011, NEUROCASE, V17, P318, DOI 10.1080/13554794.2010.509319; Buki A, 2000, J NEUROSCI, V20, P2825; BURNS BD, 1954, J PHYSIOL-LONDON, V125, P427, DOI 10.1113/jphysiol.1954.sp005170; Bushnik T, 2004, J HEAD TRAUMA REHAB, V19, P296, DOI 10.1097/00001199-200407000-00004; Cao Y, 1999, STROKE, V30, P2331, DOI 10.1161/01.STR.30.11.2331; Carey JR, 2006, RESTOR NEUROL NEUROS, V24, P191; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; CHOI DW, 1987, J NEUROSCI, V7, P369; Clarkson AN, 2010, NATURE, V468, P305, DOI 10.1038/nature09511; Collingridge GL, 2003, PHILOS T R SOC B, V358, P635, DOI 10.1098/rstb.2002.1241; Connors BW, 2004, ANNU REV NEUROSCI, V27, P393, DOI 10.1146/annurev.neuro.26.041002.131128; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; CREUTZFELDT O, 1962, EXP NEUROL, V5, P436, DOI 10.1016/0014-4886(62)90056-0; Datta A, 2010, NEUROIMAGE, V52, P1268, DOI 10.1016/j.neuroimage.2010.04.252; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; Deng ZD, 2010, IEEE ENG MED BIO, P6821, DOI 10.1109/IEMBS.2010.5625958; Desai NS, 1999, NAT NEUROSCI, V2, P515; Destexhe A, 2004, NATURE, V431, P789, DOI 10.1038/nature03011; Devine JM, 2009, PM&R, V1, P560, DOI 10.1016/j.pmrj.2009.03.015; Di Lazzaro V, 2008, J PHYSIOL-LONDON, V586, P3871, DOI 10.1113/jphysiol.2008.152736; Di Lazzaro V, 2008, CLIN NEUROPHYSIOL, V119, P715, DOI 10.1016/j.clinph.2007.11.049; Ding YC, 2002, NEUROL RES, V24, P829, DOI 10.1179/016164102101200816; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; Fawcett J, 2009, PROG BRAIN RES, V175, P501, DOI 10.1016/S0079-6123(09)17534-9; Fecteau S, 2007, J NEUROSCI, V27, P12500, DOI 10.1523/JNEUROSCI.3283-07.2007; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Fregni F, 2006, CLIN NEUROPHYSIOL, V117, P1217, DOI 10.1016/j.clinph.2006.02.015; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Fregni F, 2006, STROKE, V37, P2115, DOI 10.1161/01.STR.0000231390.58967.6b; Garcia AN, 2011, PM&R, V3, pS18, DOI 10.1016/j.pmrj.2011.03.017; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; GENTRY LR, 1994, RADIOLOGY, V191, P1; George MS, 2010, EXPERT REV NEUROTHER, V10, P1761, DOI 10.1586/ERN.10.95; George MS, 2010, NEUROPSYCHOPHARMACOL, V35, P301, DOI 10.1038/npp.2009.87; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; Gilio F, 2003, J PHYSIOL-LONDON, V551, P563, DOI 10.1113/jphysiol.2003.044313; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GOLDRING S, 1951, J NEUROPHYSIOL, V14, P275; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gulledge AT, 2005, J NEUROBIOL, V64, P75, DOI 10.1002/neu.20144; Hallett M, 2005, J REHABIL RES DEV, V42, pXVII, DOI 10.1682/JRRD.2005.07.0126; Hallett M, 2007, NEURON, V55, P187, DOI 10.1016/j.neuron.2007.06.026; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hasan A, 2011, BEHAV BRAIN RES, V224, P15, DOI 10.1016/j.bbr.2011.05.017; Hausmann A, 2000, MOL BRAIN RES, V76, P355, DOI 10.1016/S0169-328X(00)00024-3; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Heiss WD, 1999, ANN NEUROL, V45, P430, DOI 10.1002/1531-8249(199904)45:4<430::AID-ANA3>3.0.CO;2-P; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hesse S, 2011, NEUROREHAB NEURAL RE, V25, P838, DOI 10.1177/1545968311413906; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Holderbach R, 2007, BIOL PSYCHIAT, V62, P92, DOI 10.1016/j.biopsych.2006.07.007; Holscher C, 1999, J NEUROSCI RES, V58, P62; Hua Y, 2007, STROKE, V38, P759, DOI 10.1161/01.STR.0000247868.97078.10; Huang YZ, 2007, CLIN NEUROPHYSIOL, V118, P1028, DOI 10.1016/j.clinph.2007.01.021; Hummel F, 2005, NEUROREHAB NEURAL RE, V19, P14, DOI 10.1177/1545968304272698; Iyer MB, 2003, J NEUROSCI, V23, P10867; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; Jain KK, 2008, DRUG DISCOV TODAY, V13, P1082, DOI 10.1016/j.drudis.2008.09.006; Ji RR, 1998, P NATL ACAD SCI USA, V95, P15635, DOI 10.1073/pnas.95.26.15635; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kim YH, 2006, STROKE, V37, P1471, DOI 10.1161/01.STR.0000221233.55497.51; Kim YH, 2004, NEUROSCI LETT, V367, P181, DOI 10.1016/j.neulet.2004.05.113; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kohler S, 2004, J COGNITIVE NEUROSCI, V16, P178, DOI 10.1162/089892904322984490; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231; Lamprecht R, 2004, NAT REV NEUROSCI, V5, P45, DOI 10.1038/nrn1301; Laurer H.L., 2002, ENCY HUMAN BRAIN, P93; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; Liebetanz D, 2006, EPILEPSIA, V47, P1216, DOI 10.1111/j.1528-1167.2006.00539.x; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Linden DJ, 1999, NEURON, V22, P661, DOI 10.1016/S0896-6273(00)80726-6; Lippman J, 2005, J NEUROBIOL, V64, P47, DOI 10.1002/neu.20149; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luber B, 2007, BRAIN RES, V1128, P120, DOI 10.1016/j.brainres.2006.10.011; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Maeda F, 2000, EXP BRAIN RES, V133, P425, DOI 10.1007/s002210000432; Maldonado MA, 2008, NEUROREHAB NEURAL RE, V22, P250, DOI 10.1177/1545968307308551; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mesulam MM, 2000, ANN NY ACAD SCI, V924, P42; Miniussi C, 2008, BRAIN STIMUL, V1, P326, DOI 10.1016/j.brs.2008.07.002; Miotto EC, 2010, ARQ NEURO-PSIQUIAT, V68, P862, DOI 10.1590/S0004-282X2010000600006; Muller MB, 2000, NEUROPSYCHOPHARMACOL, V23, P205, DOI 10.1016/S0893-133X(00)00099-3; NICHOLLS DG, 1985, PROG BRAIN RES, V63, P97; Nitsche MA, 2003, SUPPL CLIN NEUROPHYS, V56, P255; Nitsche MA, 2004, CEREB CORTEX, V14, P1240, DOI 10.1093/cercor/bhh085; Nitsche MA, 2004, NEUROPSYCHOPHARMACOL, V29, P1573, DOI 10.1038/sj.npp.1300517; Nitsche MA, 2004, EUR J NEUROSCI, V19, P2720, DOI 10.1111/j.0953-816X.2004.03398.x; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Nitsche MA, 2005, J PHYSIOL-LONDON, V568, P291, DOI 10.1113/jphysiol.2005.092429; Nitsche MA, 2009, EXP NEUROL, V219, P14, DOI 10.1016/j.expneurol.2009.03.038; Nitsche MA, 2008, BRAIN STIMUL, V1, P206, DOI 10.1016/j.brs.2008.06.004; Nudo RJ, 2007, STROKE, V38, P840, DOI 10.1161/01.STR.0000247943.12887.d2; Nudo RJ, 2011, J COMMUN DISORD, V44, P515, DOI 10.1016/j.jcomdis.2011.04.004; O'Callaghan RM, 2007, BEHAV BRAIN RES, V176, P362, DOI 10.1016/j.bbr.2006.10.018; Oliveri M, 2001, NEUROLOGY, V57, P1338, DOI 10.1212/WNL.57.7.1338; Pannasch U, 2011, P NATL ACAD SCI USA, V108, P8467, DOI 10.1073/pnas.1016650108; Pape TLB, 2009, BRAIN STIMUL, V2, P22, DOI 10.1016/j.brs.2008.09.004; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pascual-Leone A, 2005, ANNU REV NEUROSCI, V28, P377, DOI 10.1146/annurev.neuro.27.070203.144216; PASCUALLEONE A, 1994, BRAIN, V117, P847, DOI 10.1093/brain/117.4.847; Paulus W, 2003, SUPPL CLIN NEUROPHYS, V56, P249; de la Ossa NP, 2010, STROKE, V41, P810, DOI 10.1161/STROKEAHA.109.570168; Philip S, 2009, J TRAUMA, V67, pS128, DOI 10.1097/TA.0b013e3181ad32c7; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Preston G, 2010, J COGNITIVE NEUROSCI, V22, P447, DOI 10.1162/jocn.2009.21209; PRINCE DA, 1984, ANN NEUROL, V16, pS59, DOI 10.1002/ana.410160710; PURPURA DP, 1965, J NEUROPHYSIOL, V28, P166; Quartarone A, 2008, CURR OPIN NEUROL, V21, P484, DOI 10.1097/WCO.0b013e328307bf07; Reinecke S, 2003, EUR J NEUROSCI, V17, P623, DOI 10.1046/j.1460-9568.2003.02459.x; Reis J, 2008, BRAIN STIMUL, V1, P363, DOI 10.1016/j.brs.2008.08.001; Reithler J, 2011, PROG NEUROBIOL, V94, P149, DOI 10.1016/j.pneurobio.2011.04.004; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; Rioult-Pedotti MS, 2000, SCIENCE, V290, P533, DOI 10.1126/science.290.5491.533; Romero JR, 2002, CLIN NEUROPHYSIOL, V113, P101, DOI 10.1016/S1388-2457(01)00693-9; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rotenberg A, 2007, CLIN NEUROPHYSIOL, V118, P2536, DOI 10.1016/j.clinph.2007.08.003; Rotenberg A, 2009, CLIN NEUROPHYSIOL, V120, P1417, DOI 10.1016/j.clinph.2009.05.004; Rothwell JC, 2010, FOLIA PHONIATR LOGO, V62, P153, DOI 10.1159/000314030; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Schambra HM, 2003, CLIN NEUROPHYSIOL, V114, P130, DOI 10.1016/S1388-2457(02)00342-5; Schatz DS, 2000, SYNAPSE, V36, P75, DOI 10.1002/(SICI)1098-2396(200004)36:1<75::AID-SYN8>3.3.CO;2-9; Sczesny-Kaiser M, 2009, NEUROSCI LETT, V457, P71, DOI 10.1016/j.neulet.2009.04.015; Shindo K, 2006, J REHABIL MED, V38, P65, DOI 10.1080/16501970500441807; Shors TJ, 1997, BEHAV BRAIN SCI, V20, P597, DOI 10.1017/S0140525X97001593; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Speer AM, 2000, BIOL PSYCHIAT, V48, P1133, DOI 10.1016/S0006-3223(00)01065-9; Stagg CJ, 2009, J NEUROPHYSIOL, V101, P2872, DOI 10.1152/jn.91060.2008; Stagg CJ, 2011, NEUROSCIENTIST, V17, P37, DOI 10.1177/1073858410386614; Stagg CJ, 2009, J NEUROSCI, V29, P5202, DOI 10.1523/JNEUROSCI.4432-08.2009; Stanton PK, 1996, HIPPOCAMPUS, V6, P35, DOI 10.1002/(SICI)1098-1063(1996)6:1<35::AID-HIPO7>3.3.CO;2-Z; Stefan K, 2002, J PHYSIOL-LONDON, V543, P699, DOI 10.1113/jphysiol.2002.023317; Steindler DA, 2002, LANCET, V359, P1047, DOI 10.1016/S0140-6736(02)08096-0; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Takeuchi N, 2005, STROKE, V36, P2681, DOI 10.1161/01.STR.0000189658.51972.34; Takeuchi N, 2008, J REHABIL MED, V40, P298, DOI 10.2340/16501977-0181; Talelli P, 2007, CLIN NEUROPHYSIOL, V118, P333, DOI 10.1016/j.clinph.2006.10.014; Tasset I, 2010, NEUROCHEM RES, V35, P1182, DOI 10.1007/s11064-010-0172-9; Teo F, 2011, FRONT PSYCHIATRY, V2, P1; Teyler TJ, 2001, INT REV NEUROBIOL, V45, P253; Thickbroom GW, 2007, EXP BRAIN RES, V180, P583, DOI 10.1007/s00221-007-0991-3; Thickbroom GW, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-4; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vines BW, 2006, NEUROREPORT, V17, P671, DOI 10.1097/00001756-200604240-00023; Wagner T, 2006, NEUROIMAGE, V30, P857, DOI 10.1016/j.neuroimage.2005.04.046; Wagner T, 2007, NEUROIMAGE, V35, P1113, DOI 10.1016/j.neuroimage.2007.01.027; Wagner T, 2009, CORTEX, V45, P1025, DOI 10.1016/j.cortex.2008.10.002; Ward NS, 2005, PROG BRAIN RES, V150, P527, DOI 10.1016/S0079-6123(05)50036-0; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yablon SA, 2007, BRAIN INJURY MED PRI, V1, P452; Yamashima T, 2003, HIPPOCAMPUS, V13, P791, DOI 10.1002/hipo.10127; Yue L, 2009, BRAIN RES, V1260, P94, DOI 10.1016/j.brainres.2009.01.009; Zago S, 2008, NEUROSCIENTIST, V14, P521, DOI 10.1177/1073858407311101; Zhang XQ, 2007, J HUAZHONG U SCI-MED, V27, P415, DOI 10.1007/s11596-007-0416-3; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zink BJ, 2010, PSYCHIAT CLIN N AM, V33, P741, DOI 10.1016/j.psc.2010.08.005	209	56	58	0	48	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1094-7159	1525-1403		NEUROMODULATION	Neuromodulation	JUL-AUG	2012	15	4					326	338		10.1111/j.1525-1403.2012.00474.x			13	Medicine, Research & Experimental; Clinical Neurology	Research & Experimental Medicine; Neurosciences & Neurology	984VG	WOS:000307219900008	22882244				2021-06-18	
J	Elliott, MB; Oshinsky, ML; Amenta, PS; Awe, OO; Jallo, JI				Elliott, Melanie B.; Oshinsky, Michael L.; Amenta, Peter S.; Awe, Olatilewa O.; Jallo, Jack I.			Nociceptive Neuropeptide Increases and Periorbital Allodynia in a Model of Traumatic Brain Injury	HEADACHE			English	Article						post-traumatic headache; traumatic brain injury; calcitonin gene-related peptide; trigeminal; allodynia; central sensitization	POSTTRAUMATIC-STRESS-DISORDER; US SOLDIERS; HEADACHE; COMBAT; IRAQ; VETERANS; FREEDOM; AFGHANISTAN; PREVALENCE; HEALTH	Objective.-This study tests the hypothesis that injury to the somatosensory cortex is associated with periorbital allodynia and increases in nociceptive neuropeptides in the brainstem in a mouse model of controlled cortical impact (CCI) injury. Methods.-Male C57BL/6 mice received either CCI or craniotomy-only followed by weekly periorbital von Frey (mechanical) sensory testing for up to 28 days post-injury. Mice receiving an incision only and na ve mice were included as control groups. Changes in calcitonin gene-related peptide (CGRP) and substance P (SP) within the brainstem were determined using enzyme-linked immunosorbent assay and immunohistochemistry, respectively. Activation of ionized calcium-binding adaptor molecule-1-labeled macrophages/microglia and glial fibrillary acidic protein (GFAP)-positive astrocytes were evaluated using immunohistochemistry because of their potential involvement in nociceptor sensitization. Results.-Incision-only control mice showed no changes from baseline periorbital von Frey mechanical thresholds. CCI significantly reduced mean periorbital von Frey thresholds (periorbital allodynia) compared with baseline and craniotomy-only at each endpoint, analysis of variance P <.0001. Craniotomy significantly reduced periorbital threshold at 14 days but not 7, 21, or 28 days compared with baseline threshold, P <.01. CCI significantly increased SP immunoreactivity in the brainstem at 7 and 14 days but not 28 days compared with craniotomy-only and controls, P <.001. CGRP levels in brainstem tissues were significantly increased in CCI groups compared with controls (incision-only and na ve mice) or craniotomy-only mice at each endpoint examined, P <.0001. There was a significant correlation between CGRP and periorbital allodynia (P <.0001, r = -0.65) but not for SP (r = 0.20). CCI significantly increased the number of macrophage/microglia in the injured cortex at each endpoint up to 28 days, although cell numbers declined over weeks post-injury, P <.001. GFAP+ immunoreactivity was significantly increased at 7 but not 14 or 28 days after CCI, P <.001. Craniotomy resulted in transient periorbital allodynia accompanied by transient increases in SP, CGRP, and GFAP immunoreactivity compared with control mice. There was no increase in the number of macrophage/microglia cells compared with controls after craniotomy. Conclusion.-Injury to the somatosensory cortex results in persistent periorbital allodynia and increases in brainstem nociceptive neuropeptides. Findings suggest that persistent allodynia and increased neuropeptides are maintained by mechanisms other than activation of macrophage/microglia or astrocyte in the injured somatosensory cortex.	[Elliott, Melanie B.; Amenta, Peter S.; Awe, Olatilewa O.; Jallo, Jack I.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Oshinsky, Michael L.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA	Elliott, MB (corresponding author), Thomas Jefferson Univ, Dept Neurosurg, 1025Walnut St,Suite 516 Coll, Philadelphia, PA 19107 USA.	Melanie.elliott@jefferson.edu		Oshinsky, Michael/0000-0002-0976-1047; Jallo, Jack/0000-0002-5512-1729	 [R01-NS061571]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS058695, R01NS061571] Funding Source: NIH RePORTER	Experiments were conducted by Dr. Melanie B. Elliott, Dr. Peter S. Amenta, Olatilewa O. Awe, and Karena Browne. Data interpretation and manuscript preparation were done by Drs. Melanie Elliott, Michael L. Oshinsky (support by R01-NS061571), and Jack I. Jallo. Thank you to Dr. Elisabeth Van Bockstaele for contributing microscopy equipment for our histological analyses and Karena Browne for contributing to the behavioral testing. We would also like to thank Dr. Mary Barbe for reviewing and providing valuable feedback on this manuscript.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; Amin MM, 2010, MIL MED, V175, P155; Baandrup L, 2005, CEPHALALGIA, V25, P132, DOI 10.1111/j.1468-2982.2004.00818.x; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2011, CLIN NEUROPSYCHOL, V1, P1; Bryan CJ, 2011, HEADACHE, V51, P945, DOI 10.1111/j.1526-4610.2011.01887.x; Couch JR, 2007, NEUROLOGY, V69, P1169, DOI 10.1212/01.wnl.0000276985.07981.0a; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; Finkel A, 2009, 24 INT HEAD C PHIL P; Ford S, 2008, HEADACHE, V48, P523, DOI 10.1111/j.1526-4610.2008.00859.x; Gladstone J, 2009, HEADACHE, V49, P1097, DOI 10.1111/j.1526-4610.2009.01461.x; Grosberg Brian M, 2007, Curr Pain Headache Rep, V11, P310, DOI 10.1007/s11916-007-0209-1; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2010, ARCH PHYS MED REHAB, V91, P963, DOI 10.1016/j.apmr.2010.02.005; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Neely ET, 2009, HEADACHE, V49, P1089, DOI 10.1111/j.1526-4610.2009.001460.x; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Scher AI, 2011, 63 ANN M AM AC NEUR; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2010, HEADACHE, V50, P790, DOI 10.1111/j.1526-4610.2009.01571.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Vargas BB, 2009, CURR PAIN HEADACHE R, V13, P64, DOI 10.1007/s11916-009-0013-1; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	32	56	57	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	JUN	2012	52	6					966	984		10.1111/j.1526-4610.2012.02160.x			19	Clinical Neurology	Neurosciences & Neurology	952OA	WOS:000304800600005	22568499	Green Published, Green Accepted			2021-06-18	
J	Max, JE; Keatley, E; Wilde, EA; Bigler, ED; Schachar, RJ; Saunders, AE; Ewing-Cobbs, L; Chapman, SB; Dennis, M; Yang, TT; Levin, HS				Max, Jeffrey E.; Keatley, Eva; Wilde, Elisabeth A.; Bigler, Erin D.; Schachar, Russell J.; Saunders, Ann E.; Ewing-Cobbs, Linda; Chapman, Sandra B.; Dennis, Maureen; Yang, Tony T.; Levin, Harvey S.			Depression in children and adolescents in the first 6 months after traumatic brain injury	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Depression; Anxiety; Traumatic brain injury; Children; Adolescents; Frontal lobe	PSYCHIATRIC-DISORDERS; PERSONALITY-CHANGE; HEAD-INJURY; RELIABILITY; VALIDITY; PREDICTORS; SCHEDULE; SEQUELAE	The objective was to assess the nature, rate, predictive factors, and neuroimaging correlates of novel (new-onset) depressive disorders, both definite and subclinical, after traumatic brain injury (TBI). Children with TBI from consecutive admissions were enrolled and studied with psychiatric interviews soon after injury (baseline), and again 6 months post-injury. Novel definite/subclinical depressive disorders at 6-month follow up occurred in 11% (n = 15) of the children and subsets of children with non-anxious depression (n = 9) and anxious depression (n = 6) were identified. Novel definite/subclinical depressive disorder was significantly associated with older age at the time of injury, family history of anxiety disorder, left inferior frontal gyrus (IFG) lesions, and right frontal white matter lesions. Non-anxious depressions were associated with older age at injury, left IFG and left temporal pole lesions. Anxious depressions were associated with family history of anxiety disorder, Personality Change due to TBI, right frontal white matter lesions, and left parietal lesions. These findings, which are similar to those reported after adult TBI, identify both similarities and differences in non-anxious and anxious depression following childhood TBI with respect to lesion laterality, genetic factors (in the form of family psychiatric history of anxiety disorder), age at injury, and more generalized affective dysregulation. (C) 2012 ISDN. Published by Elsevier Ltd. All rights reserved.	[Max, Jeffrey E.; Yang, Tony T.] Rady Childrens Hosp, San Diego, CA 92123 USA; [Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Cognit Neurosci Lab, Dept Radiol, Houston, TX 77030 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Ctr Neurosci, Provo, UT 84602 USA; [Schachar, Russell J.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Saunders, Ann E.] Univ Texas Houston, UT Harris Cty Psychiat Ctr, Dept Psychiat, Houston, TX 77021 USA; [Ewing-Cobbs, Linda] Univ Texas Houston, Dept Pediat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75235 USA; [Dennis, Maureen] Hosp Sick Children, Program Neurosci & Mental Hlth, Toronto, ON M5G 1X8, Canada; [Max, Jeffrey E.; Yang, Tony T.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92123 USA	Max, JE (corresponding author), Rady Childrens Hosp, 3020 Childrens Way,MC 5018, San Diego, CA 92123 USA.	jmax@ucsd.edu; ekeatley@gmail.com; ewilde@bcm.edu; erinb@cortex.byu.edu; russell.schachar@sickkids.ca; Ann.E.Saunders@uth.tmc.edu; Linda.Ewing-Cobbs@uth.tmc.edu; schapman@utdallas.edu; maureen.dennis@sickkids.ca; tyang@ucsd.edu; hlevin@bcm.tmc.edu		Schachar, Russell/0000-0002-2015-4395	National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K-08 MH01800]; National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH085734, K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This study was supported by National Institute of Mental Health (NIMH) Grant K-08 MH01800 (Dr. Max) and National Institute of Neurological Disorders and Stroke (NINDS) Grant NS-21889 (Dr. Levin).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Beesdo K, 2009, ARCH GEN PSYCHIAT, V66, P275, DOI 10.1001/archgenpsychiatry.2008.545; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Birmaher B, 1996, J AM ACAD CHILD PSY, V35, P1427, DOI 10.1097/00004583-199611000-00011; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Capizzano AA, 2010, J NEUROPSYCH CLIN N, V22, P370, DOI 10.1176/appi.neuropsych.22.4.370; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Klein DN, 2009, J AM ACAD CHILD PSY, V48, P703, DOI 10.1097/CHI.0b013e3181a56606; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Max J.E., 2011, TXB TRAUMATIC BRAIN, P438; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moffitt TE, 2007, ARCH GEN PSYCHIAT, V64, P651, DOI 10.1001/archpsyc.64.6.651; Pine D S, 2001, CNS Spectr, V6, P27; Shankman SA, 2009, J CHILD PSYCHOL PSYC, V50, P1485, DOI 10.1111/j.1469-7610.2009.02117.x; Sparrow S., 1984, VINELAND ADAPTIVE BE; TEASDALE G, 1974, LANCET, V2, P81	34	56	56	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748			INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		239	245		10.1016/j.ijdevneu.2011.12.005			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800010	22197971	Green Accepted			2021-06-18	
J	Lethaus, B; Safi, Y; ter Laak-Poort, M; Kloss-Brandstatter, A; Banki, F; Robbenmenke, C; Steinseifer, U; Kessler, P				Lethaus, Bernd; Safi, Yara; ter Laak-Poort, Mariel; Kloss-Brandstaetter, Anita; Banki, Frans; Robbenmenke, Christian; Steinseifer, Ulrich; Kessler, Peter			Cranioplasty with Customized Titanium and PEEK Implants in a Mechanical Stress Model	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; in vivo studies; surgery; traumatic brain injury	DECOMPRESSIVE CRANIECTOMY; BONE FLAP; POLYETHERETHERKETONE; HYDROXYAPATITE; BIOCOMPATIBILITY; RECONSTRUCTION; BIOMECHANICS; PHOSPHATE; ALPHA	Large skull defects as a result of craniectomies due to cerebral insults, trauma, or tumors create functional and aesthetic disturbances for the patient. Cranioplasty with implants in these cases are an alternative to autogenous bone transplantation. In our clinic, customized titanium or optima poly-ether-ether ketone (PEEK) implants are used to reconstruct craniectomy defects. To compare the two materials we investigated the structural changes of the implants fixed to a sintered polyamide skull model under mechanical stress in four simplified models. In a standard testing machine, the models were subjected to a load under a quasi-static loading rate of 1.925 mm/min. Fractures of the PEEK implants occurred at a force of 24.2 and 24.5kN with a displacement of 8.4 and 8 mm. The titanium implants showed no deformation, but extensive damage was seen in the polyamide skull models. The highest pressures achieved were 45.8 and 50.9 kN. In a simplified model with quasi-static loading, both implants withstood forces that were higher than those capable of causing skull fractures. It seems that the mechanical properties of PEEK could provide better protection when used for cranioplasty in patients after craniectomy if reconstruction with autogenous bone is not possible.	[Lethaus, Bernd; Banki, Frans; Kessler, Peter] Maastricht Univ Med Ctr, Dept Craniomaxillofacial Surg, NL-3202 AZ Maastricht, Netherlands; [Safi, Yara; Robbenmenke, Christian; Steinseifer, Ulrich] Rhein Westfal TH Aachen, Dept Cardiovasc Engn, Inst Appl Med Engn, Helmholtz Inst, Aachen, Germany; [ter Laak-Poort, Mariel] Maastricht Univ Med Ctr, Dept Neurosurg, NL-3202 AZ Maastricht, Netherlands; [Kloss-Brandstaetter, Anita] Innsbruck Med Univ, Div Genet Epidemiol, Innsbruck, Austria	Lethaus, B (corresponding author), Maastricht Univ Med Ctr, Dept Craniomaxillofacial Surg, Postbus 5800, NL-3202 AZ Maastricht, Netherlands.	bernd.lethaus@mumc.nl	Lethaus, Bernd/AAC-3091-2021	Lethaus, Bernd/0000-0002-9619-9362			Abu Bakar MS, 2003, BIOMATERIALS, V24, P2245, DOI 10.1016/S0142-9612(03)00028-0; ALBREKTSSON T, 1981, ACTA ORTHOP SCAND, V52, P155, DOI 10.3109/17453678108991776; Baldo S, 2010, WORLD NEUROSURG, V73, P552, DOI 10.1016/j.wneu.2010.02.018; Baumeister S, 2008, PLAST RECONSTR SURG, V122, p195E, DOI 10.1097/PRS.0b013e3181858eee; Cabraja M, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS091; Eschbach L, 2000, Injury, V31 Suppl 4, P22; Got C., 1983, P 27 STAPP CAR CRASH; HAMPSON D, 1995, J BIOMECH, V28, P1; Hanasono MM, 2009, ANN PLAS SURG, V62, P653, DOI 10.1097/SAP.0b013e318184abc7; Hodgson V.R., 1971, P 16 STAPP CAR CRASH, P292; Inamasu J, 2010, J TRAUMA, V68, P183, DOI 10.1097/TA.0b013e3181c45384; Jagur-Grodzinski J, 1999, REACT FUNCT POLYM, V39, P99, DOI 10.1016/S1381-5148(98)00054-6; Kamyszek T, 2001, Mund Kiefer Gesichtschir, V5, P233, DOI 10.1007/s100060100317; Katzer A, 2002, BIOMATERIALS, V23, P1749, DOI 10.1016/S0142-9612(01)00300-3; KLEIN CPAT, 1994, BIOMATERIALS, V15, P146, DOI 10.1016/0142-9612(94)90264-X; Kurtz SM, 2007, BIOMATERIALS, V28, P4845, DOI 10.1016/j.biomaterials.2007.07.013; Lethaus B., 2010, J CRANIOMAXILLOFAC S; Li LH, 2005, J BIOMED MATER RES A, V73A, P48, DOI 10.1002/jbm.a.30244; McElhaney J., 1972, HUMAN IMPACT TOLERAN, P85; MORRISON C, 1995, BIOMATERIALS, V16, P987, DOI 10.1016/0142-9612(95)94906-2; NAHUM A, 1980, P 24 STAPP CAR CRASH; SAE, 1994, HUM MECH RESP CHAR, pJ1460; Schmidt M, 2007, CIRP ANN-MANUF TECHN, V56, P205, DOI 10.1016/j.cirp.2007.05.097; Schneider DC, 1972, P 16 STAPP CAR CRASH, P186; Scolozzi P, 2007, J CRANIOFAC SURG, V18, P224, DOI 10.1097/01.scs.0000249359.56417.7e; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Takano Y, 1999, J ORTHOP RES, V17, P59, DOI 10.1002/jor.1100170110; Toth JM, 2006, BIOMATERIALS, V27, P324, DOI 10.1016/j.biomaterials.2005.07.011; Turner CH, 1999, J BIOMECH, V32, P437, DOI 10.1016/S0021-9290(98)00177-8; Wiltfang J, 2002, J BIOMED MATER RES, V63, P115, DOI 10.1002/jbm.10084; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014	32	56	59	4	40	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1077	1083		10.1089/neu.2011.1794			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100006	22017579				2021-06-18	
J	Murphy, PR; Robertson, IH; Allen, D; Hester, R; O'Connell, RG				Murphy, Peter R.; Robertson, Ian H.; Allen, Darren; Hester, Robert; O'Connell, Redmond G.			An electrophysiological signal that precisely tracks the emergence of error awareness	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						error positivity; EEG; error awareness; error processing; performance monitoring	ANTERIOR CINGULATE CORTEX; TRAUMATIC BRAIN-INJURY; FUNCTIONAL-SIGNIFICANCE; ERP COMPONENTS; NEURAL BASIS; DYNAMICS; MECHANISMS; ATTENTION; DISCRIMINATION; POTENTIALS	Recent electrophysiological research has sought to elucidate the neural mechanisms necessary for the conscious awareness of action errors. Much of this work has focused on the error positivity (Pe), a neural signal that is specifically elicited by errors that have been consciously perceived. While awareness appears to be an essential prerequisite for eliciting the Pe, the precise functional role of this component has not been identified. Twenty-nine participants performed a novel variant of the Go/No-go Error Awareness Task (EAT) in which awareness of commission errors was indicated via a separate speeded manual response. Independent component analysis (ICA) was used to isolate the Pe from other stimulus- and response-evoked signals. Single-trial analysis revealed that Pe peak latency was highly correlated with the latency at which awareness was indicated. Furthermore, the Pe was more closely related to the timing of awareness than it was to the initial erroneous response. This finding was confirmed in a separate study which derived IC weights from a control condition in which no indication of awareness was required, thus ruling out motor confounds. A receiver-operating-characteristic (ROC) curve analysis showed that the Pe could reliably predict whether an error would be consciously perceived up to 400 ms before the average awareness response. Finally, Pe latency and amplitude were found to be significantly correlated with overall error awareness levels between subjects. Our data show for the first time that the temporal dynamics of the Pe trace the emergence of error awareness. These findings have important implications for interpreting the results of clinical EEG studies of error processing.	[Murphy, Peter R.; Robertson, Ian H.; Allen, Darren; O'Connell, Redmond G.] Univ Dublin Trinity Coll, Inst Neurosci, Dublin 2, Ireland; [Murphy, Peter R.; Robertson, Ian H.; Allen, Darren; O'Connell, Redmond G.] Univ Dublin Trinity Coll, Sch Psychol, Dublin 2, Ireland; [Hester, Robert] Univ Melbourne, Dept Psychol Sci, Melbourne, Vic, Australia	Murphy, PR (corresponding author), Univ Dublin Trinity Coll, Inst Neurosci, Lloyd Bldg, Dublin 2, Ireland.	murphyp7@tcd.ie	Hester, Robert/F-2097-2011	Hester, Robert/0000-0003-0982-8026; Murphy, Peter R/0000-0003-1963-185X; O'Connell, Redmond/0000-0001-6949-2793; Robertson, Ian H/0000-0001-8637-561X	Irish Research Council for Science, Engineering, and Technology (IRCSET)Irish Research Council for Science, Engineering and Technology; ARCAustralian Research Council [FT110100088]; EUEuropean Commission; Irish Government	This research was supported by an Irish Research Council for Science, Engineering, and Technology (IRCSET) "Embark Initiative" grant awarded to Peter R. Murphy, an ARC Fellowship to Robert Hester (FT110100088), and an IRCSET "Empower" Fellowship to Redmond G. O'Connell. The authors also acknowledge funding support via the HEA PRTLI Cycle 3 program of the EU Structural Funds and the Irish Government's National Development Plan 2002-2006. We thank Hugh Nolan and Simon Kelly for their assistance with aspects of data analysis and Misha Byrne for assistance with figure design.	Althaus M, 2010, BIOL PSYCHOL, V85, P19, DOI 10.1016/j.biopsycho.2010.04.007; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Bartholow BD, 2012, J ABNORM PSYCHOL, V121, P173, DOI 10.1037/a0023664; BELL AJ, 1995, NEURAL COMPUT, V7, P1129, DOI 10.1162/neco.1995.7.6.1129; Biehl SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028396; Bland AR, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00080; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Brazil IA, 2009, BIOL PSYCHIAT, V65, P137, DOI 10.1016/j.biopsych.2008.08.011; Cavanagh JF, 2011, NAT NEUROSCI, V14, P1462, DOI 10.1038/nn.2925; Cavanagh JF, 2009, J NEUROSCI, V29, P98, DOI 10.1523/JNEUROSCI.4137-08.2009; Cohen MX, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00030; Cohen MX, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.054.2009; Colebatch JG, 2007, MOVEMENT DISORD, V22, P601, DOI 10.1002/mds.21323; Debener S, 2006, TRENDS COGN SCI, V10, P558, DOI 10.1016/j.tics.2006.09.010; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Dhar M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019578; Eichele H, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00065; Eichele T, 2008, P NATL ACAD SCI USA, V105, P6173, DOI 10.1073/pnas.0708965105; Einhauser Wolfgang, 2010, Front Hum Neurosci, V4, P18, DOI 10.3389/fnhum.2010.00018; Endrass T, 2005, J PSYCHOPHYSIOL, V19, P275, DOI 10.1027/0269-8803.19.4.275; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 1995, EEG CL N SU, P287; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Falkenstein M., 1990, PSYCHOPHYSIOLOGICAL, P192; Frank MJ, 2007, COGN AFFECT BEHAV NE, V7, P297, DOI 10.3758/CABN.7.4.297; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gold JI, 2007, ANNU REV NEUROSCI, V30, P535, DOI 10.1146/annurev.neuro.29.051605.113038; Herrmann MJ, 2004, COGNITIVE BRAIN RES, V20, P294, DOI 10.1016/j.cogbrainres.2004.02.013; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hester R, 2012, J NEUROSCI, V32, P2619, DOI 10.1523/JNEUROSCI.4052-11.2012; Holroyd C.B., 2004, COGNITIVE NEUROSCIEN, P219; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Hughes G, 2011, NEUROPSYCHOLOGIA, V49, P405, DOI 10.1016/j.neuropsychologia.2010.11.036; Klein TA, 2007, NEUROIMAGE, V34, P1774, DOI 10.1016/j.neuroimage.2006.11.014; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P61, DOI 10.1016/j.ijpsycho.2011.02.001; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Leuthold H, 1999, CLIN NEUROPHYSIOL, V110, P342, DOI 10.1016/S1388-2457(98)00058-3; Luijten M, 2011, PHARMACOL BIOCHEM BE, V97, P514, DOI 10.1016/j.pbb.2010.10.012; Luu P, 2004, CLIN NEUROPHYSIOL, V115, P1821, DOI 10.1016/j.clinph.2004.03.031; Macdonald JSP, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00082; Makeig S, 2004, TRENDS COGN SCI, V8, P204, DOI 10.1016/j.tics.2004.03.008; Mintz AR, 2004, SCHIZOPHR RES, V67, P213, DOI 10.1016/S0920-9964(03)00047-1; Murphy PR, 2011, PSYCHOPHYSIOLOGY, V48, P1531, DOI 10.1111/j.1469-8986.2011.01226.x; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Nolan H, 2010, J NEUROSCI METH, V192, P152, DOI 10.1016/j.jneumeth.2010.07.015; O'Connell RG, 2007, EUR J NEUROSCI, V25, P2571, DOI 10.1111/j.1460-9568.2007.05477.x; O'Connell RG, 2009, J COGNITIVE NEUROSCI, V21, P93, DOI 10.1162/jocn.2009.21008; O'Connell RG, 2009, J NEUROSCI, V29, P8604, DOI 10.1523/JNEUROSCI.5967-08.2009; O'Connell RG, 2009, NEUROPSYCHOLOGIA, V47, P1149, DOI 10.1016/j.neuropsychologia.2009.01.011; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Olvet DM, 2010, PSYCHIAT RES, V179, P30, DOI 10.1016/j.psychres.2010.06.008; Onton J, 2006, NEUROSCI BIOBEHAV R, V30, P808, DOI 10.1016/j.neubiorev.2006.06.007; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Perez VB, 2012, J ABNORM PSYCHOL, V121, P372, DOI 10.1037/a0025487; Peterburs J, 2012, NEUROPSYCHOLOGIA, V50, P379, DOI 10.1016/j.neuropsychologia.2011.12.009; Quiroga RQ, 2005, NATURE, V435, P1102, DOI 10.1038/nature03687; Rabbitt P, 2002, Q J EXP PSYCHOL-A, V55, P1081, DOI 10.1080/02724980244000080; RABBITT P, 1990, ERGONOMICS, V33, P1291, DOI 10.1080/00140139008925333; RABBITT P, 1981, Q J EXP PSYCHOL-A, V33, P223, DOI 10.1080/14640748108400790; RABBITT P, 1978, Q J EXP PSYCHOL, V30, P319, DOI 10.1080/14640747808400679; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; RABBITT PMA, 1966, NATURE, V212, P438, DOI 10.1038/212438a0; Ratcliff R, 2010, J EXP PSYCHOL GEN, V139, P70, DOI 10.1037/a0018128; Ridderinkhof KR, 2009, PSYCHOPHYSIOLOGY, V46, P531, DOI 10.1111/j.1469-8986.2009.00790.x; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Roitman JD, 2002, J NEUROSCI, V22, P9475; Shalgi S, 2007, EXP BRAIN RES, V182, P119, DOI 10.1007/s00221-007-1054-5; Shalgi S, 2009, EUR J NEUROSCI, V29, P1522, DOI 10.1111/j.1460-9568.2009.06690.x; SPENCER KM, 2004, EVENT RELATED POTENT, P209; Steinhauser M, 2008, J EXP PSYCHOL HUMAN, V34, P158, DOI 10.1037/0096-1523.34.1.158; Steinhauser M, 2010, J NEUROSCI, V30, P15643, DOI 10.1523/JNEUROSCI.1899-10.2010; Ullsperger M, 2006, BRAIN RES, V1105, P102, DOI 10.1016/j.brainres.2006.01.007; Ullsperger M, 2010, BRAIN STRUCT FUNCT, V214, P629, DOI 10.1007/s00429-010-0261-1; van Boxtel GJM, 2005, J PSYCHOPHYSIOL, V19, P1, DOI 10.1027/0269-8803.19.1.1; van Veen V, 2002, J COGNITIVE NEUROSCI, V14, P593, DOI 10.1162/08989290260045837; Viola FC, 2009, CLIN NEUROPHYSIOL, V120, P868, DOI 10.1016/j.clinph.2009.01.015; Wessel JR, 2011, J COGNITIVE NEUROSCI, V23, P3021, DOI 10.1162/jocn.2011.21635; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	78	56	56	0	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAR 28	2012	6								65	10.3389/fnhum.2012.00065			16	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	924ST	WOS:000302712300001	22470332	DOAJ Gold, Green Published			2021-06-18	
J	Ewert, DL; Lu, JZ; Li, W; Du, XP; Floyd, R; Kopke, R				Ewert, Donald L.; Lu, Jianzhong; Li, Wei; Du, Xiaoping; Floyd, Robert; Kopke, Richard			Antioxidant treatment reduces blast-induced cochlear damage and hearing loss	HEARING RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; IMPULSE NOISE BLAST; OXIDATIVE STRESS; TYMPANIC-MEMBRANE; N-ACETYLCYSTEINE; OVERPRESSURE; NXY-059; MODEL	Exposure to blast overpressure has become one of the hazards of both military and civilian life in many parts of the world due to war and terrorist activity. Auditory damage is one of the primary sequela of blast trauma, affecting immediate situational awareness and causing permanent hearing loss. Protecting against blast exposure is limited by the inability to anticipate the timing of these exposures, particularly those caused by terrorists. Therefore a therapeutic regimen is desirable that is able to ameliorate auditory damage when administered after a blast exposure has occurred. The purpose of this study was to determine if administration of a combination of antioxidants 2,4-disulfonyl alpha-phenyl tertiary butyl nitrone (HPN-07) and N-acetylcysteine (NAC) beginning 1 h after blast exposure could reduce both temporary and permanent hearing loss. To this end, a blast simulator was developed and the operational conditions established for exposing rats to blast overpressures comparable to those encountered in an open-field blast of 14 pounds per square inch (psi). This blast model produced reproducible blast overpressures that resulted in physiological and physical damage to the auditory system that was proportional to the number and amplitude of the blasts. After exposure to 3 consecutive 14 psi blasts 100% of anesthetized rats had permanent hearing loss as determined at 21 days post exposure by auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) testing. Animals treated with HPN-07 and NAC after blast exposure showed a significant reduction in ABR threshold shifts and DPOAE level shifts at 2-16 kHz with significant reduction in inner hair cell (IHC) and outer hair cell (OHC) loss across the 5-36 kHz region of the cochlea compared with control animals. The time course of changes in the auditory system was documented at 3 h, 24 h, 7 day and 21 day after blast exposure. At 3 h after blast exposure the auditory brainstem response (ABR) threshold shifts were elevated by 60 dB in both treated and control groups. A partial recovery of to 35 dB was observed at 24 h in the controls, indicative of a temporary threshold shift (ITS) and there was essentially no further recovery by 21 days representing a permanent threshold shift (PTS) of about 30 dB. Antioxidant treatment increased the amount of both us and PTS recovery relative to controls by 10 and 20 dB respectively. Distortion product otoacoustic emission (DPOAE) reached a maximum level shift of 25-30 dB measured in both control and treated groups at 3 h after blast exposure. These levels did not change by day 21 in the control group but in the treatment group the level shifts began to decline at 24 h until by day 21 they were 10-20 dB below that of the controls. Loss of cochlear hair cells measured at 21 day after blast exposure was mostly in the outer hair cells (OHC) and broadly distributed across the basilar membrane, consistent with the distribution of loss of frequency responses as measured by ABR and DPOAE analysis and typical of blast-induced damage. OHC loss progressively increased after blast exposure reaching an average loss of 32% in the control group and 10% in the treated group at 21 days. These findings provide the first evidence that a combination of antioxidants, HPN-07 and NAC, can both enhance ITS recovery and prevent PTS by reducing damage to the mechanical and neural components of the auditory system when administered shortly after blast exposure. (C) 2012 Elsevier B.V. All rights reserved.	[Ewert, Donald L.; Lu, Jianzhong; Li, Wei; Du, Xiaoping; Kopke, Richard] Hough Ear Inst, Oklahoma City, OK 73112 USA; [Floyd, Robert; Kopke, Richard] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; [Kopke, Richard] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK 73014 USA; [Kopke, Richard] Univ Oklahoma, Hlth Sci Ctr, Dept Otolaryngol, Oklahoma City, OK 73014 USA	Kopke, R (corresponding author), Hough Ear Inst, 3400 NW 56th St, Oklahoma City, OK 73112 USA.	dewert@houghear.org; jlu@houghear.org; weili@houghear.org; Xiaoping.du@houghear.org; robert-floyd@omrf.org; rkopke@houghear.org			US Department of Navy, Office of Naval Research [N00014-09-1-0999]	The authors appreciate the efforts of Joel Young in the design and construction of the blast simulator and of Dr. Ning Hu and Dr. Charles Stewart and Weihua Cheng for their outstanding technical assistance. This research was supported by grant N00014-09-1-0999 from the US Department of Navy, Office of Naval Research.	Abi-Hachem Ralph N, 2010, Recent Pat CNS Drug Discov, V5, P147; Cave KM, 2007, MIL MED, V172, P726, DOI 10.7205/MILMED.172.7.726; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chait R H, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P9; Chavko M, 2009, SHOCK, V32, P325, DOI 10.1097/SHK.0b013e31819c38f1; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Choi CH, 2008, FREE RADICAL BIO MED, V44, P1772, DOI 10.1016/j.freeradbiomed.2008.02.005; Clausen F, 2008, J NEUROTRAUM, V25, P1449, DOI 10.1089/neu.2008.0585; Elsayed NM, 2003, TOXICOLOGY, V189, P63, DOI 10.1016/S0300-483X(03)00153-7; Elsayed NM, 2000, TOXICOLOGY, V155, P91, DOI 10.1016/S0300-483X(00)00281-X; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Floyd RA, 2008, FREE RADICAL BIO MED, V45, P1361, DOI 10.1016/j.freeradbiomed.2008.08.017; GARTH RJN, 1994, J LARYNGOL OTOL, V108, P925, DOI 10.1017/S0022215100128555; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Haase GM, 2011, AM J OTOLARYNG, V32, P55, DOI 10.1016/j.amjoto.2009.09.002; HAMERNIK RP, 1991, J ACOUST SOC AM, V90, P197, DOI 10.1121/1.402344; HAMERNIK RP, 1987, J ACOUST SOC AM, V81, P1118, DOI 10.1121/1.394632; Henderson D, 2006, EAR HEARING, V27, P1, DOI 10.1097/01.aud.0000191942.36672.f3; HENRY WR, 1995, HEARING RES, V84, P81, DOI 10.1016/0378-5955(95)00014-U; Hoffer M.E., 2010, NEUROTRAUMA LETT; JAFFIN JH, 1987, J TRAUMA, V27, P349, DOI 10.1097/00005373-198704000-00002; JENSEN JH, 1993, ACTA OTO-LARYNGOL, V113, P62, DOI 10.3109/00016489309135768; Kopke R, 2005, ACTA OTO-LARYNGOL, V125, P235, DOI 10.1080/00016480410023038; Kopke RD, 2007, HEARING RES, V226, P114, DOI 10.1016/j.heares.2006.10.008; Kujawa SG, 2009, J NEUROSCI, V29, P14077, DOI 10.1523/JNEUROSCI.2845-09.2009; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lyden PD, 2007, STROKE, V38, P2262, DOI 10.1161/STROKEAHA.106.472746; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Nilsson D, 2007, J CLIN PHARMACOL, V47, P264, DOI 10.1177/0091270006293752; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P229, DOI 10.1159/000013846; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; PRICE GR, 1989, J ACOUST SOC AM, V85, P1245, DOI 10.1121/1.397455; Richmond D R, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P35; Roberto M, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P23; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; YLIKOSKI J, 1987, ACTA OTO-LARYNGOL, V103, P415	40	56	60	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0378-5955	1878-5891		HEARING RES	Hear. Res.	MAR	2012	285	1-2					29	39		10.1016/j.heares.2012.01.013			11	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	920WN	WOS:000302439600004	22326291				2021-06-18	
J	Palacios, EM; Sala-Llonch, R; Junque, C; Roig, T; Tormos, JM; Bargallo, N; Vendrell, P				Palacios, E. M.; Sala-Llonch, R.; Junque, C.; Roig, T.; Tormos, J. M.; Bargallo, N.; Vendrell, P.			White matter integrity related to functional working memory networks in traumatic brain injury	NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; CLOSED-HEAD-INJURY; DEFAULT-MODE; CORPUS-CALLOSUM; STRUCTURAL CONNECTIVITY; COGNITIVE IMPAIRMENT; MULTIPLE-SCLEROSIS; NEUROPATHOLOGY; ACTIVATION; INFERENCE	Objective: This study explores the functional and structural patterns of connectivity underlying working memory impairment after severe traumatic axonal injury. Methods: We performed an fMRI n-back task and acquired diffusion tensor images (DTI) in a group of 19 chronic-stage patients with severe traumatic brain injury (TBI) and evidence of traumatic axonal injury and 19 matched healthy controls. We performed image analyses with FSL software and fMRI data were analyzed using probabilistic independent component analysis. Fractional anisotropy (FA) maps from DTI images were analyzed with FMRIB's Diffusion Toolbox. Results: We identified working memory and default mode networks. Global FA values correlated with both networks and FA whole-brain analysis revealed correlations in several tracts associated with the functional activation. Furthermore, working memory performance in the patient group correlated with the functional activation patterns and with the FA values of the associative fasciculi. Conclusion: Combining structural and functional neuroimaging data, we were able to describe structural white matter changes related to functional network alterations and to lower performance in working memory in chronic TBI. Neurology (R) 2012;78:852-860	[Palacios, E. M.; Sala-Llonch, R.; Junque, C.; Vendrell, P.] Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain; [Palacios, E. M.; Sala-Llonch, R.; Junque, C.; Vendrell, P.] Inst Biomed Res August Pi i Sunyer IDIBAPS, Barcelona, Spain; [Roig, T.; Tormos, J. M.] Inst Univ Neurorehabil Guttmann, Badalona, Spain; [Bargallo, N.] Hosp Clin Barcelona, Ctr Diagnost Imatge Hosp Clin Barcelona CDIC, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona, Spain.	cjunque@ub.edu	Bargallo, Nuria/G-6854-2016; Sala-Llonch, Roser/L-4135-2015; Vendrell, Pere/B-4392-2011; Sala-Llonch, Roser/E-7882-2012; Junque, Carme/B-4400-2011	Bargallo, Nuria/0000-0001-6284-5402; Sala-Llonch, Roser/0000-0003-3576-0475; Vendrell, Pere/0000-0001-8918-5440; Sala-Llonch, Roser/0000-0003-3576-0475; Junque, Carme/0000-0002-6381-3063; Tormos Munoz, Jose Maria/0000-0002-8764-2289	Institute of Biomedical Research August Pi i Sunyer (IDIBAPS); MAPFRE Foundation	E.M. Palacios was supported by a fellowship from the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS) and research support from the MAPFRE Foundation. R. Sala-Llonch was supported by a fellowship from the Institute of Biomedical Research August Pi i Sunyer (IDIBAPS). Dr. Junque, Dr. Vendrell, Dr. Tormos, Dr. Roig, and Dr. Bargallo report no disclosures.	Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; Biswal BB, 2010, P NATL ACAD SCI USA, V107, P4734, DOI 10.1073/pnas.0911855107; Bonzano L, 2009, NEUROIMAGE, V44, P9, DOI 10.1016/j.neuroimage.2008.08.015; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; Hillary FG, 2007, CLIN NEUROPSYCHOL, V21, P58, DOI 10.1080/13854040601064542; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Kanwisher N, 2010, P NATL ACAD SCI USA, V107, P11163, DOI 10.1073/pnas.1005062107; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Minear M, 2004, BEHAV RES METH INS C, V36, P630, DOI 10.3758/BF03206543; Nakamura T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008220; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Penke L, 2010, J NEUROSCI, V30, P7569, DOI 10.1523/JNEUROSCI.1553-10.2010; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rocca MA, 2010, NEUROLOGY, V74, P1252, DOI 10.1212/WNL.0b013e3181d9ed91; Sanchez-Carrion R, 2008, J NEUROTRAUM, V25, P479, DOI 10.1089/neu.2007.0417; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sumowski JF, 2010, BRAIN, V133, P362, DOI 10.1093/brain/awp307; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; van den Heuvel MP, 2010, EUR NEUROPSYCHOPHARM, V20, P519, DOI 10.1016/j.euroneuro.2010.03.008; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Wechsler D., 1999, ESCALA INTELIGENCIA, V3; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412	38	56	56	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAR	2012	78	12					852	860		10.1212/WNL.0b013e31824c465a			9	Clinical Neurology	Neurosciences & Neurology	914GO	WOS:000301937700007	22345222	Green Published			2021-06-18	
J	Crowe, LM; Catroppa, C; Babl, FE; Anderson, V				Crowe, Louise M.; Catroppa, Cathy; Babl, Franz E.; Anderson, Vicki			Intellectual, Behavioral, and Social Outcomes of Accidental Traumatic Brain Injury in Early Childhood	PEDIATRICS			English	Article						traumatic brain injury; children; infants; intellectual functioning	YOUNG-CHILDREN; FUNCTIONAL RECOVERY; HEAD-INJURIES; FOLLOW-UP; INFANTS; ADOLESCENTS; PREDICTORS; AGE	OBJECTIVE: The intellectual, behavioral, and social function of children who sustained traumatic brain injury (TBI) before 3 years of age were compared with a group of uninjured children. The role of injury and environmental factors in recovery was examined. METHODS: A group of 53 children who sustained a TBI before 3 years of age (20 mild and 33 moderate/severe) and 27 uninjured children (control group) were assessed on an IQ measure and parent measures of behavior and social skills. Children were aged 4 to 6 years and were an average of 40 months since sustaining their injury. RESULTS: There were no demographic differences between the groups. Although all group scores were in the average range, children with moderate/severe TBI performed significantly below uninjured children on an IQ measure. No significant differences were found on parent behavior ratings, although effect sizes between groups were medium to large. No differences were found for social skills. All outcomes were significantly influenced by environmental but not injury factors. CONCLUSIONS: Moderate/severe TBI at an early age appears to be associated with lowered intellectual function and possibly behavior problems. A child's environment influences cognitive and behavior function after TBI. Pediatrics 2012;129:e262-e268	[Babl, Franz E.; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia; [Crowe, Louise M.; Catroppa, Cathy; Babl, Franz E.; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Crowe, Louise M.; Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia	Crowe, LM (corresponding author), Royal Childrens Hosp, Australian Ctr Child Neuropsychol Studies, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	louise.crowe@mcri.edu.au		Crowe, Louise/0000-0003-4619-9708	Foundation for Children; Victorian Government	This work was supported by a grant from the Foundation for Children and by the Victorian Government's Operational Infrastructure Support Program.	Achenbach T. M., 2000, CHILD BEHAV CHECKLIS; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Case ME, 2008, BRAIN PATHOL, V18, P562, DOI 10.1111/j.1750-3639.2008.00202.x; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Ennis Elaine, 2004, Pediatr Rehabil, V7, P205, DOI 10.1080/13638490410001703316; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; Falk AC, 2007, DEV NEUROREHABIL, V10, P267; Falk Ann-Charlotte, 2007, Dev Neurorehabil, V10, P49, DOI 10.1080/13638490600864066; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Gresham FM, 1995, SOCIAL SKILLS RATING; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Lalloo R, 2003, INJURY, V34, P261, DOI 10.1016/S0020-1383(02)00277-2; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Noller P, 1988, ICPS FAMILY FUNCTION; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Sonnenberg LK, 2010, BRAIN INJURY, V24, P1003, DOI 10.3109/02699052.2010.489033; Spady DW, 2004, PEDIATRICS, V113, P522, DOI 10.1542/peds.113.3.522; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Trewin D, 2009, AUSTR NZ STANDARD CL; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wechsler, 2002, WECHSLER PRESCHOOL P; Wetherington CE, 2010, J PEDIATR PSYCHOL, V35, P662, DOI 10.1093/jpepsy/jsp081; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387	45	56	56	0	24	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2012	129	2					E262	E268		10.1542/peds.2011-0438			7	Pediatrics	Pediatrics	893YZ	WOS:000300395100002	22271692	Bronze			2021-06-18	
J	Chen, CC; Hung, TH; Wang, YH; Lin, CW; Wang, PY; Lee, CY; Chen, SF				Chen, Chien-Cheng; Hung, Tai-Ho; Wang, Yen-Ho; Lin, Chii-Wann; Wang, Pei-Yi; Lee, Chun-Yen; Chen, Szu-Fu			Wogonin Improves Histological and Functional Outcomes, and Reduces Activation of TLR4/NF-kappa B Signaling after Experimental Traumatic Brain Injury	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; TOLL-LIKE RECEPTORS; SCUTELLARIA-BAICALENSIS GEORGI; FLUORO-JADE-B; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; ENDOTHELIAL-CELLS; FLAVONOID WOGONIN; RAT MODEL; IN-VIVO	Background: Traumatic brain injury (TBI) initiates a neuroinflammatory cascade that contributes to neuronal damage and behavioral impairment. This study was undertaken to investigate the effects of wogonin, a flavonoid with potent antiinflammatory properties, on functional and histological outcomes, brain edema, and toll-like receptor 4 (TLR4)- and nuclear factor kappa B (NF-kappa B)-related signaling pathways in mice following TBI. Methodology/Principal Findings: Mice subjected to controlled cortical impact injury were injected with wogonin (20, 40, or 50 mg.kg(-1)) or vehicle 10 min after injury. Behavioral studies, histology analysis, and measurement of blood-brain barrier (BBB) permeability and brain water content were carried out to assess the effects of wogonin. Levels of TLR4/NF-kappa B-related inflammatory mediators were also examined. Treatment with 40 mg.kg(-1) wogonin significantly improved functional recovery and reduced contusion volumes up to post-injury day 28. Wogonin also significantly reduced neuronal death, BBB permeability, and brain edema beginning at day 1. These changes were associated with a marked reduction in leukocyte infiltration, microglial activation, TLR4 expression, NF-kappa B translocation to nucleus and its DNA binding activity, matrix metalloproteinase-9 activity, and expression of inflammatory mediators, including interleukin-1 beta, interleukin-6, macrophage inflammatory protein-2, and cyclooxygenase-2. Conclusions/Significance: Our results show that post-injury wogonin treatment improved long-term functional and histological outcomes, reduced brain edema, and attenuated the TLR4/NF-kappa B-mediated inflammatory response in mouse TBI. The neuroprotective effects of wogonin may be related to modulation of the TLR4/NF-kappa B signaling pathway.	[Chen, Chien-Cheng; Wang, Pei-Yi; Lee, Chun-Yen; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chen, Chien-Cheng; Lin, Chii-Wann] Natl Taiwan Univ, Inst Biomed Engn, Taipei 10764, Taiwan; [Hung, Tai-Ho] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taipei, Taiwan; [Wang, Yen-Ho] Natl Taiwan Univ Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Wang, Yen-Ho] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan	Chen, CC (corresponding author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Lin, Chii-Wann/B-5527-2009; Hung, Tai-Ho/C-7584-2011; Chen, Szu-Fu/K-5040-2012; Hung, Tai-Ho/ABD-1800-2020	Lin, Chii-Wann/0000-0002-8721-3441; Hung, Tai-Ho/0000-0003-2354-7060	National Science Council of Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [98-2314-B-350-001-MY3]; Cheng Hsin General Hospital	This work was supported by the National Science Council of Taiwan, R.O.C. (98-2314-B-350-001-MY3 to S.-F.C.) and the Cheng Hsin General Hospital (C.-C.C., S.-F.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Caso JR, 2007, CIRCULATION, V115, P1599, DOI 10.1161/CIRCULATIONAHA.106.603431; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chang YL, 2001, MOL PHARMACOL, V60, P507; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chi YS, 2003, BIOCHEM PHARMACOL, V66, P1271, DOI 10.1016/S0006-2952(03)00463-5; Cho J, 2004, BIOL PHARM BULL, V27, P1561, DOI 10.1248/bpb.27.1561; Cho JS, 2004, EUR J PHARMACOL, V485, P105, DOI 10.1016/j.ejphar.2003.11.064; Conti AC, 1998, J NEUROSCI, V18, P5663; Dong XQ, 2011, INFLAMM RES, V60, P533, DOI 10.1007/s00011-010-0300-7; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Gao ZH, 1999, BBA-GEN SUBJECTS, V1472, P643, DOI 10.1016/S0304-4165(99)00152-X; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Huang GC, 2007, INT IMMUNOPHARMACOL, V7, P1054, DOI 10.1016/j.intimp.2007.04.001; Huang WH, 2006, BIOSCI BIOTECH BIOCH, V70, P2371, DOI 10.1271/bbb.50698; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kim H, 2001, NEUROSCI LETT, V309, P67, DOI 10.1016/S0304-3940(01)02028-6; Lee H, 2003, FASEB J, V17, P1943, DOI 10.1096/fj.03-0057fje; Lee SO, 2006, BIOCHEM BIOPH RES CO, V351, P118, DOI 10.1016/j.bbrc.2006.10.006; Lee YM, 2011, J CARDIOVASC PHARM, V58, P133, DOI 10.1097/FJC.0b013e31821a5078; LIU XF, 1990, MOL PHARMACOL, V37, P911; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Peng J, 2009, J ETHNOPHARMACOL, V124, P257, DOI 10.1016/j.jep.2009.04.031; Piao HZ, 2008, INT IMMUNOPHARMACOL, V8, P1658, DOI 10.1016/j.intimp.2008.07.018; Piao HZ, 2004, ARCH PHARM RES, V27, P930, DOI 10.1007/BF02975846; Qi Q, 2009, PHYTOTHER RES, V23, P417, DOI 10.1002/ptr.2645; Racke MK, 2009, CURR TOP MICROBIOL, V336, P155, DOI 10.1007/978-3-642-00549-7_9; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shen SC, 2006, NEUROSCIENCE, V140, P477, DOI 10.1016/j.neuroscience.2006.02.028; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Son D, 2004, EUR J PHARMACOL, V493, P99, DOI 10.1016/j.ejphar.2004.04.017; Strauss KI, 2008, BRAIN BEHAV IMMUN, V22, P285, DOI 10.1016/j.bbi.2007.09.011; Tai MC, 2005, CNS DRUG REV, V11, P141; Tang SC, 2007, P NATL ACAD SCI USA, V104, P13798, DOI 10.1073/pnas.0702553104; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Wakabayashi I, 2000, EUR J PHARMACOL, V406, P477, DOI 10.1016/S0014-2999(00)00695-6; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	49	56	63	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2012	7	1							e30294	10.1371/journal.pone.0030294			14	Multidisciplinary Sciences	Science & Technology - Other Topics	907XU	WOS:000301454400106	22272328	DOAJ Gold, Green Published			2021-06-18	
J	Foster, AM; Armstrong, J; Buckley, A; Sherry, J; Young, T; Foliaki, S; James-Hohaia, T; Theadom, A; McPherson, KM				Foster, Allison M.; Armstrong, Jonathan; Buckley, Ann; Sherry, Joanne; Young, Tony; Foliaki, Soana; James-Hohaia, Te Miria; Theadom, Alice; McPherson, Kathryn M.			Encouraging family engagement in the rehabilitation process: a rehabilitation provider's development of support strategies for family members of people with traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Acquired brain injury; adult; family needs; interdisciplinary rehabilitation services; neurorehabilitation; program evaluation and quality improvement; TBI	PARTICIPATORY ACTION RESEARCH; SOCIAL SUPPORT; CAREGIVERS; DISTRESS; QUALITY; IMPACT; INTERVENTION; ADOLESCENTS; PREDICTORS; EXPERIENCE	Purpose: After a moderate to severe traumatic brain injury, it is widely recommended that family members be actively engaged in the client's rehabilitation journey because evidence suggests that this is associated with better outcomes. The ability of family members to fully engage in rehabilitation may be hindered by the barriers (logistical and psychological) they encounter. However, rehabilitation services can facilitate family engagement through a person-centred approach that provides support to remove barriers. Limited published guidance exists regarding practical and effective methods for delivering such support. This paper describes how one rehabilitation service has developed an eight-tiered approach. Key messages and implications: Family support is provided by explicit structuring of services to include (i) early engagement, (ii) meeting cultural needs, (iii) keeping families together, (iv) actively listening, (v) active involvement, (vi) education, (vii) skills training, and (viii) support for community re-integration. Implementation of these support strategies are individualised based on the expressed needs of each family. Families report a high level of satisfaction with the service. Conclusion: A practice-based quality improvement model identified challenges, implemented changes, and observed/evaluated the results to successfully develop a multifaceted strategy for supporting families, thereby encouraging their engagement in rehabilitation. Ongoing refinements and evaluation are planned.	[Armstrong, Jonathan; Theadom, Alice; McPherson, Kathryn M.] Auckland Univ Technol, Auckland, New Zealand	Foster, AM (corresponding author), 180 Metcalfe Rd, Auckland 0612, New Zealand.	allison.foster@abi-rehab.co.nz		Theadom, Alice/0000-0003-0351-6216; McPherson, Kath/0000-0003-0487-8497; McPherson, Kathryn/0000-0003-1240-8882			Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P32, DOI 10.1159/000170090; Bernat JL, 2009, ANN NY ACAD SCI, V1157, P117, DOI 10.1111/j.1749-6632.2008.04124.x; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Campbell C H, 1988, Rehabil Nurs, V13, P320; Charles N, 2007, NEUROREHABILITATION, V22, P61; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Cloninger CR, 2011, J EVAL CLIN PRACT, V17, P371, DOI 10.1111/j.1365-2753.2010.01583.x; Das-Gupta R, 2002, DISABIL REHABIL, V24, P654, DOI 10.1080/09638280110109282; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Esselman PC, 2002, J HEAD TRAUMA REHAB, V17, P257, DOI 10.1097/00001199-200206000-00007; Faleafa Monique, 2009, Pac Health Dialog, V15, P28; Gan C, 2010, BRAIN INJURY, V24, P651, DOI 10.3109/02699051003692142; Gauld S, 2011, DISABIL REHABIL, V33, P1901, DOI 10.3109/09638288.2010.550382; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Giuliano K K, 2000, Dimens Crit Care Nurs, V19, P30, DOI 10.1097/00003465-200019010-00008; Gzil F, 2007, DISABIL REHABIL, V29, P1616, DOI 10.1080/09638280701618620; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Harwood M, 2010, DISABIL REHABIL, V32, P972, DOI 10.3109/09638281003775378; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jayadevappa R., 2011, OPEN HLTH SERVICES P, V4, P15, DOI DOI 10.2174/1874924001104010015; Kayes NM, HUMAN TECHNOLOGIES R; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Laroi F, 2003, BRAIN INJURY, V17, P175, DOI 10.1080/0269905021000010140; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Minkler M, 2000, PUBLIC HEALTH REP, V115, P191, DOI 10.1093/phr/115.2.191; Minnes P, 2000, BRAIN INJURY, V14, P737; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; Panting A., 1972, REHABILITATION, V38, P33; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Shaw LR, 1997, BRAIN INJURY, V11, P219; Sherer M, 2007, BRAIN INJURY, V21, P663, DOI 10.1080/02699050701481589; Siegert RJ, 2007, DISABIL REHABIL, V29, P1604, DOI 10.1080/09638280701618794; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Turner-Stokes L, ENGAGING HEARTS MIND; White GW, 2004, ARCH PHYS MED REHAB, V85, pS3, DOI 10.1016/j.apmr.2003.08.109	44	56	57	3	27	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.		2012	34	22					1855	1862		10.3109/09638288.2012.670028			8	Rehabilitation	Rehabilitation	013FG	WOS:000309290700002	22489631				2021-06-18	
J	Rapoport, MJ				Rapoport, Mark J.			Depression Following Traumatic Brain Injury Epidemiology, Risk Factors and Management	CNS DRUGS			English	Article							RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; HEAD-INJURY; EMOTIONAL DISTRESS; 1ST YEAR; MILD; MODERATE; SYMPTOMS	It is important for clinicians to recognize major depression following traumatic brain injury (TBI) because of its association with poor global and psychosocial outcome, postconcussive symptoms and cognitive deficits. The purpose of this review is to provide an up-to-date selective review of the current understanding of epidemiology, risk factors and management of major depression following TBI. Many studies of prevalence of depression following TBI have not used accepted structured criteria for the diagnoses, but those that did found wide ranges of rates, from 17% to 61%. The risk factors for development of depression following TBI are poorly understood, but past psychiatric history, frontal lesions and atrophy, and family dysfunction have been shown in more than one study to play important roles. There are few controlled trials of the treatment of major depression in patients with TBI using accepted diagnostic criteria for major depression, as well as defined criteria for response and remission. As such, it is important for clinicians to use best practice guidelines for the treatment of major depression in the absence of TBI.	[Rapoport, Mark J.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Geriatr Traumat Brain Injury Clin, Dept Psychiat, Toronto, ON, Canada	Rapoport, MJ (corresponding author), FG37-2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	mark.rapoport@sunnybrook.ca	Rapoport, Mark/AAD-8581-2020		Ontario Neurotrauma Foundation; Physician's Services Inc. Foundation; Canadian Institute of Health ResearchCanadian Institutes of Health Research (CIHR); Alzheimer's Society of Canada; Transport Canada	Speaker's honoraria: Janssen-Ortho (April 2008); Alzheimer's Society of Toronto (February 2009). Grant funding: Ontario Neurotrauma Foundation, Physician's Services Inc. Foundation, Canadian Institute of Health Research, Alzheimer's Society of Canada and Transport Canada.	Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chan F, 2008, BRAIN INJURY, V22, P471, DOI 10.1080/02699050802084886; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Demakis GJ, 2010, APPL NEUROPSYCHOL, V17, P183, DOI 10.1080/09084282.2010.499752; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Driver S, 2009, BRAIN INJURY, V23, P203, DOI 10.1080/02699050802695574; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hoffman JM, 2010, PM&R, V2, P911, DOI 10.1016/j.pmrj.2010.06.008; Hudak A, 2011, PSYCHIAT RES-NEUROIM, V191, P160, DOI 10.1016/j.pscychresns.2010.10.003; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kant R, 1999, J NEUROPSYCH CLIN N, V11, P32, DOI 10.1176/jnp.11.1.32; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lanctot KL, 2010, BRAIN INJURY, V24, P959, DOI 10.3109/02699051003789229; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Mainio A, 2007, BRAIN INJURY, V21, P851, DOI 10.1080/02699050701504265; Maric NP, 2010, J ENDOCRINOL INVEST, V33, P770, DOI [10.1007/BF03350340, 10.3275/7045]; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895; Rao V, J NEUROPSYCHIATRY CL, V22, P231; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2010, J CLIN PSYCHIAT, V71, P1125, DOI 10.4088/JCP.09m05086blu; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Ruttan LA, 2003, J CLIN EXP NEUROPSYC, V25, P407, DOI 10.1076/jcen.25.3.407.13812; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Schonberger M, 2011, BRAIN INJURY, V25, P543, DOI 10.3109/02699052.2011.565013; Schonberger M, 2010, NEUROPSYCHOL REHABIL, V20, P813, DOI 10.1080/09602011003620077; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Senathi-Raja D, 2010, J HEAD TRAUMA REHAB, V25, P330, DOI 10.1097/HTR.0b013e3181ccc893; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Silver JM, 2008, NEUROPSYCHIATRY BEHA; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Weddell RA, 2010, ARCH PHYS MED REHAB, V91, P897, DOI 10.1016/j.apmr.2010.01.020; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RLL, 2010, J INT NEUROPSYCH SOC, V16, P1108, DOI 10.1017/S1355617710001013; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206	75	56	57	0	23	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1172-7047	1179-1934		CNS DRUGS	CNS Drugs		2012	26	2					111	121		10.2165/11599560-000000000-00000			11	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	898OA	WOS:000300750500003	22296315				2021-06-18	
J	Sekhon, MS; McLean, N; Henderson, WR; Chittock, DR; Griesdale, DEG				Sekhon, Mypinder S.; McLean, Nielson; Henderson, William R.; Chittock, Dean R.; Griesdale, Donald E. G.			Association of hemoglobin concentration and mortality in critically ill patients with severe traumatic brain injury	CRITICAL CARE			English	Article							BLOOD-CELL TRANSFUSION; HEAD-INJURY; ANEMIA; INCREASES; INFECTIONS; METABOLISM; IMPACT	Introduction: The critical care management of traumatic brain injury focuses on preventing secondary ischemic injury. Cerebral oxygen delivery is dependent upon the cerebral perfusion pressure and the oxygen content of blood, which is principally determined by hemoglobin. Despite its importance to the cerebral oxygen delivery, the precise hemoglobin concentration to provide adequate oxygen delivery to injured neuronal tissue in TBI patients is controversial with limited evidence to provide transfusion thresholds. Methods: We conducted a retrospective cohort study of severe TBI patients, investigating the association between mean 7-day hemoglobin concentration and hospital mortality. Demographic, physiologic, intensive care interventions, clinical outcomes and daily hemoglobin concentrations were recorded for all patients. Patients were all cared for at a tertiary, level 1 trauma center in a mixed medical and surgical intensive unit. Patients were divided into quartiles based on their mean 7-day hemoglobin concentration: < 90 g/L, 90 -99 g/L, 100 -109 g/L and > 110 g/L. Multivariable log-binomial regression was used to model the association between mean daily hemoglobin concentration and hospital mortality. Results: Two hundred seventy-three patients with traumatic brain injury were identified and 169 were included in the analysis based on inclusion/exclusion criteria. Of these, 77% of the patients were male, with a mean age of 38 (SD 17) years and a median best GCS of 6 (IQR 5 - 7). One hundred fifteen patients (68%) received a red blood cell (RBC) transfusion. In RBCs administered in the ICU, the median pre-transfusion hemoglobin was 79 g/L (IQR 73 85). Thirty-seven patients (22%) died in hospital. Multivariable analysis revealed that mean 7-day hemoglobin concentration < 90 g/L was independently associated with an increased risk of hospital mortality (RR 3.1, 95% CI 1.5 - 6.3, p = 0.03). Other variables associated with increased mortality on multivariable regression were insertion of external ventricular drain, age and decreased GCS. Red blood cell transfusion was not associated with mortality following multivariable adjustment. Conclusions: A mean 7-day hemoglobin concentration of < 90g/L is associated with increased hospital mortality in patients with severe traumatic brain injury.	[Sekhon, Mypinder S.; McLean, Nielson; Henderson, William R.; Chittock, Dean R.; Griesdale, Donald E. G.] Univ British Columbia, Vancouver Gen Hosp, Div Crit Care Med, Dept Med, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.] Univ British Columbia, Vancouver Gen Hosp, Dept Anesthesia Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E. G.] Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 1M9, Canada	Griesdale, DEG (corresponding author), Univ British Columbia, Vancouver Gen Hosp, Div Crit Care Med, Dept Med, 855 W 12th Ave, Vancouver, BC V5Z 1M9, Canada.	donald.griesdale@vch.ca		Griesdale, Donald/0000-0001-5985-8624			Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Claridge JA, 2002, AM SURGEON, V68, P566; Corwin HL, 2004, CRIT CARE MED, V32, P39, DOI 10.1097/01.CCM.0000104112.34142.79; Desjardins P, 2012, CRIT CARE, V16, DOI 10.1186/cc11293; Duane TM, 2008, J SURG RES, V147, P163, DOI 10.1016/j.jss.2008.02.044; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hill GE, 2003, J TRAUMA, V54, P908, DOI 10.1097/01.TA.0000022460.21283.53; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kramer AH, 2009, CRIT CARE, V13, DOI 10.1186/cc7916; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Malone D, 2003, J TRAUMA, V54, P666; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Oddo M, 2012, INTENSIVE CARE MED; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; RONCO JJ, 1993, JAMA-J AM MED ASSOC, V270, P1724, DOI 10.1001/jama.270.14.1724; Salas M, 1999, AM J EPIDEMIOL, V149, P981; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Taylor RW, 2006, CRIT CARE MED, V34, P2302, DOI 10.1097/01.CCM.0000234034.51040.7F; Taylor RW, 2002, CRIT CARE MED, V30, P2249, DOI 10.1097/00003246-200210000-00012; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	32	56	60	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2012	16	4							R128	10.1186/cc11431			7	Critical Care Medicine	General & Internal Medicine	066CP	WOS:000313197800015	22817913	DOAJ Gold, Green Published			2021-06-18	
J	Snell, DL; Siegert, RJ; Hay-Smith, EJC; Surgenor, LJ				Snell, Deborah L.; Siegert, Richard J.; Hay-Smith, E. Jean C.; Surgenor, Lois J.			Associations between illness perceptions, coping styles and outcome after mild traumatic brain injury: Preliminary results from a cohort study	BRAIN INJURY			English	Article						Mild traumatic brain injury; MTBI; illness perceptions; outcome	POST-CONCUSSION SYMPTOMS; HEAD-INJURY; HEALTH PSYCHOLOGY; HOSPITAL ANXIETY; CLUSTER-ANALYSIS; NECK-CANCER; QUESTIONNAIRE; RECOVERY; DEPRESSION; PREDICTION	Purpose: The objective of this study was to examine associations between injury perceptions, coping, distress and outcome after mild traumatic brain injury (MTBI). Design: A prospective observational study with repeated measures. This study reports results from the first of two study visits. Participants: Participants (n = 147) were recruited within 3 months following presentation to a concussion clinic or an emergency department setting. Methods: Clinical and demographic information was collected and participants completed a range of questionnaires (Revised Illness Perceptions Questionnaire, Brief COPE, Rivermead Post-Concussion Symptoms Questionnaire, Rivermead Follow-Up Questionnaire and HADS). Associations between independent variables and outcome were examined using odds ratios and 95% confidence intervals. Results: Preliminary results suggested participants endorsing stronger beliefs about the injury identity (p < 0.05) and emotional impact (p < 0.01) had significantly greater odds of poor outcome at 3 months. There were also associations between higher educational attainment (p < 0.05), using active coping strategies (p < 0.06) and poor outcome. Conclusions: These variables appeared important determinants of outcome early after MTBI and may help identify those at risk for slow recovery. Current reassurance-based interventions may be improved by targeting such variables.	[Snell, Deborah L.] Burwood Hosp, Brain Injury Rehabil Serv, Canterbury Dist Hlth Board, Concuss Clin, Christchurch, New Zealand; [Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Siegert, Richard J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Sch Med Guys, London WC2R 2LS, England; [Siegert, Richard J.] St Thomas Hosp, London, England; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand	Snell, DL (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Canterbury Dist Hlth Board, Concuss Clin, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929	Neurological Foundation of New Zealand [0728-SPG]	This research has been supported by a Small Project Grant from the Neurological Foundation of New Zealand (Grant no: 0728-SPG).	American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cicerone KD, 2004, J HEAD TRAUMA REHAB, V19, P494, DOI 10.1097/00001199-200411000-00006; Clatworthy J, 2005, BRIT J HEALTH PSYCH, V10, P329, DOI 10.1348/135910705X25697; Clatworthy J, 2007, PSYCHOL HEALTH, V22, P123, DOI 10.1080/14768320600774496; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Foster NE, 2008, PAIN, V136, P177, DOI 10.1016/j.pain.2007.12.007; French DP, 2006, J PSYCHOSOM RES, V61, P757, DOI 10.1016/j.jpsychores.2006.07.029; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Leventhal H, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P19; Leventhal H, 2008, ANNU REV PSYCHOL, V59, P477, DOI 10.1146/annurev.psych.59.103006.093643; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Llewellyn CD, 2008, J PSYCHOSOM RES, V65, P525, DOI 10.1016/j.jpsychores.2008.03.014; Llewellyn CD, 2007, J PSYCHOSOM RES, V63, P17, DOI 10.1016/j.jpsychores.2007.01.013; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; New Zealand Guidelines Group, 2006, TRAUM BRAIN INJ DIAG; PETRIE K, 1995, J PSYCHOSOM RES, V39, P31, DOI 10.1016/0022-3999(94)00071-C; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Ptacek JT, 2008, ANXIETY STRESS COPIN, V21, P155, DOI 10.1080/10615800701466467; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rose JM, 2005, BRAIN INJURY, V19, P29, DOI 10.1080/02699050310001617361; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; SNELL D, 2011, PREDICTING IN PRESS; SNELL D, 2011, J HEAD TRAUMA REHABI; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; SNELL DL, 2006, NZ MED J, V119, P1231; Stanton AL, 2007, ANNU REV PSYCHOL, V58, P565, DOI 10.1146/annurev.psych.58.110405.085615; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Taylor SE, 2007, ANNU REV CLIN PSYCHO, V3, P377, DOI 10.1146/annurev.clinpsy.3.022806.091520; TEASDALE G, 1974, LANCET, V2, P81; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Van Ittersum MW, 2009, PATIENT EDUC COUNS, V74, P53, DOI 10.1016/j.pec.2008.07.041; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 1992, ICD 10 CLASS MENT BE; World Health Organization, 2001, INT CLASS FUNCT DIS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	64	56	56	0	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2011	25	11					1126	1138		10.3109/02699052.2011.607786			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	829WC	WOS:000295614900011	21870903				2021-06-18	
J	Strumwasser, A; Kwan, RO; Yeung, L; Miraflor, E; Ereso, A; Castro-Moure, F; Patel, A; Sadjadi, J; Victorino, GP				Strumwasser, Aaron; Kwan, Rita O.; Yeung, Louise; Miraflor, Emily; Ereso, Alex; Castro-Moure, Frederico; Patel, Atul; Sadjadi, Javid; Victorino, Gregory P.			Sonographic Optic Nerve Sheath Diameter as an Estimate of Intracranial Pressure in Adult Trauma	JOURNAL OF SURGICAL RESEARCH			English	Article						trauma ultrasound; optic nerve sheath diameter; ONSD; traumatic brain injury; intracranial pressure; ICP; sonographic technique	SEVERE HEAD-INJURY; BRAIN-INJURY; CLINICAL-EVALUATION; CODMAN MICROSENSOR; ULTRASOUND; AUTOREGULATION; COMPLICATIONS	Background. Intracranial pressure (ICP) is currently measured with invasive monitoring. Sonographic optic nerve sheath diameter (ONSD) may provide a noninvasive estimate of ICP. Our hypothesis was that bedside ONSD accurately estimates ICP in acutely injured patients. The specific aims were (1) to determine the accuracy of ONSD in estimating elevated ICP, (2) to correlate ONSD and ICP in unilateral and bilateral head injuries, and (3) to determine the effect of ICP monitor placement on ONSD measurements. Materials and Methods. A blinded prospective study of adult trauma patients requiring ICP monitoring was performed at a University-based urban trauma center. The ONSD was measured by ultrasound pre- and post-placement of an ICP monitor (Camino Bolt or Ventriculostomy). Results. One-hundred fourteen measurements were obtained in 10 trauma patients requiring ICP monitoring. Pre- and post-ONSD were compared with side of injury in the presence of an ICP monitor. ROC analysis demonstrated ONSD poorly estimates elevated ICP (AUC = 0.36). Overall sensitivity, specificity, PPV, NPV, and accuracy for estimating ICP with ONSD were 36%, 38%, 40%, 16%, and 37%. Poor correlation of ONSD to ICP was observed with unilateral (R-2 = 0.45, P < 0.01) and bilateral (R-2 = 0.21, P = 0.01) injuries. ICP monitor placement did not affect ONSD measurements on the right (P = 0.5), left (P = 0.4), or right and left sides combined (P = 0.3). Conclusions. Sonographic ONSD as a surrogate for elevated ICP in lieu of invasive monitoring is not reliable due to poor accuracy and correlation. (C) 2011 Elsevier Inc. All rights reserved.	[Strumwasser, Aaron; Kwan, Rita O.; Yeung, Louise; Miraflor, Emily; Ereso, Alex; Castro-Moure, Frederico; Patel, Atul; Sadjadi, Javid; Victorino, Gregory P.] UCSF E Bay, Dept Surg, Oakland, CA 94602 USA	Victorino, GP (corresponding author), UCSF E Bay, Dept Surg, 1411 E 31st St, Oakland, CA 94602 USA.	gregory.victorino@ucsfmedctr.org					Ball CG, 2009, CAN J SURG, V52, pE173; Banister K, 2000, PHYSIOL MEAS, V21, P473, DOI 10.1088/0967-3334/21/4/304; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; BRAIN TRAUM FD, 2000, J NEUROTRAUM, V17, P457; Chambers IR, 1998, ACT NEUR S, V71, P42; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; Cowley NJ, 2008, TRAUMA, V10, P35, DOI 10.1177/1460408608089322; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Demetriades D, 2003, ANNU REV MED, V54, P1, DOI 10.1146/annurev.med.54.101601.152512; Fernandes HM, 1998, ACT NEUR S, V71, P44; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Grathwohl KW, 2008, ANESTHESIOLOGY, V109, P44, DOI 10.1097/ALN.0b013e31817c02e3; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; Hashimoto Beverly E, 2008, Ultrasound Q, V24, P31, DOI 10.1097/RUQ.0b013e31816b8cdf; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; McGahan JP, 2002, J ULTRAS MED, V21, P789, DOI 10.7863/jum.2002.21.7.789; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; POPLE IK, 1995, PEDIATR NEUROSURG, V23, P64, DOI 10.1159/000120938; Rose JS, 2004, EMERG MED CLIN N AM, V22, P581, DOI 10.1016/j.emc.2004.04.007; Rozycki GS, 1998, SURG CLIN N AM, V78, P295, DOI 10.1016/S0039-6109(05)70314-5; SCHICKNER DJ, 1992, SURG NEUROL, V37, P251, DOI 10.1016/0090-3019(92)90147-F; Schmidt EA, 2003, J NEUROSURG, V99, P991, DOI 10.3171/jns.2003.99.6.0991; Signorini DF, 1998, BRIT J NEUROSURG, V12, P223; Smith J, 2010, POSTGRAD MED J, V86, P285, DOI 10.1136/pgmj.2008.076711; Soldatos T, 2009, EMERG MED J, V26, P630, DOI 10.1136/emj.2008.058453; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Soundappan SVS, 2005, INJURY, V36, P970, DOI 10.1016/j.injury.2005.02.026; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STENAGER E, 1986, ACTA NEUROCHIR, V83, P20, DOI 10.1007/BF01420503; Valentino M, 2007, SEMIN ULTRASOUND CT, V28, P130, DOI 10.1053/j.sult.2007.01.008; Wang M, 2008, ULTRASOUND MED BIOL, V34, P1944, DOI 10.1016/j.ultrasmedbio.2008.06.001; Yatsushige H, 2010, ACTA NEUROCHIR SUPPL, V106, P265, DOI 10.1007/978-3-211-98811-4_50	38	56	59	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2011	170	2					265	271		10.1016/j.jss.2011.03.009			7	Surgery	Surgery	823NH	WOS:000295128600026	21550065				2021-06-18	
J	Matter, AM; Folweiler, KA; Curatolo, LM; Kline, AE				Matter, Ashley M.; Folweiler, Kaitlin A.; Curatolo, Lauren M.; Kline, Anthony E.			Temporal Effects of Environmental Enrichment-Mediated Functional Improvement After Experimental Traumatic Brain Injury in Rats	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						beam-walking; controlled cortical impact; functional recovery; learning and memory; Morris water maze; neurobehavior; traumatic brain injury	CONTROLLED CORTICAL IMPACT; COGNITIVE DEFICITS; RECOVERY; HISTOPATHOLOGY; HIPPOCAMPUS; COMPLEXITY; EXPERIENCE; 8-OH-DPAT; SURVIVAL; EXERCISE	Background. Environmental enrichment (EE) enhances motor and cognitive performance after traumatic brain injury (TBI). However, whether the EE-mediated benefits are time dependent and task specific is unclear. A preliminary study, in which only half of the possible temporal manipulations were evaluated, revealed that the beneficial effects of enrichment were only observed when provided concurrently with specific training (ie, motor or cognitive), suggesting task-specific dependence. Objective. To further assess the effects of time of initiation and duration of EE on neurobehavioral recovery after TBI by evaluating and directly comparing all the temporal permutations. Methods. Anesthetized adult male rats received either a cortical impact or sham injury and were then randomly assigned to 8 groups receiving continuous or early and delayed EE with either 1 or 2 weeks of exposure. Functional outcome was assessed with established motor (beam-balance/walk) and cognitive (Morris water maze) tests on postinjury days 1 to 5 and 14 to 18, respectively. Results. Motor ability was enhanced in the TBI groups that received early EE (ie, during testing) versus standard housing. In contrast, acquisition of spatial learning was facilitated in the groups receiving delayed EE (ie, during training). Conclusions. These data support the conclusion from the previous study that EE-mediated functional improvement after TBI is contingent on task-specific neurobehavioral experience and extends those preliminary findings by demonstrating that the duration of enriched exposure is also important for functional recovery.	[Matter, Ashley M.; Folweiler, Kaitlin A.; Curatolo, Lauren M.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA 15213 USA	Kline, AE (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3471 5th Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD046700, NS060005]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD046700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060005] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research and/or authorship of this article: This work was supported, in part, by National Institutes of Health grants HD046700 and NS060005 awarded to AEK.	Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Gaulke LJ, 2005, MOL BRAIN RES, V141, P138, DOI 10.1016/j.molbrainres.2005.08.011; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hoffman AN, 2008, NEUROSCI LETT, V431, P226, DOI 10.1016/j.neulet.2007.11.042; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kokiko ON, 2007, BRAIN INJURY, V21, P259, DOI 10.1080/02699050701209964; KRECH D, 1960, J COMP PHYSIOL PSYCH, V53, P509, DOI 10.1037/h0045402; Leggio MG, 2005, BEHAV BRAIN RES, V163, P78, DOI 10.1016/j.bbr.2005.04.009; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Olson AK, 2006, HIPPOCAMPUS, V16, P250, DOI 10.1002/hipo.20157; Parton A, 2005, CURR OPIN NEUROL, V18, P675, DOI 10.1097/01.wco.0000189872.54245.13; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Reid WM, 2008, J NEUROTRAUM, V25, P248, DOI 10.1089/neu.2007.0389; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Torasdotter M, 1998, BEHAV BRAIN RES, V93, P83, DOI 10.1016/S0166-4328(97)00142-3; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318	32	56	56	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUL-AUG	2011	25	6					558	564		10.1177/1545968310397206			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	774KL	WOS:000291384200008	21436387	Green Accepted			2021-06-18	
J	Yurgelun-Todd, DA; Bueler, CE; McGlade, EC; Churchwell, JC; Brenner, LA; Lopez-Larson, MP				Yurgelun-Todd, Deborah A.; Bueler, C. Elliott; McGlade, Erin C.; Churchwell, John C.; Brenner, Lisa A.; Lopez-Larson, Melissa P.			Neuroimaging Correlates of Traumatic Brain Injury and Suicidal Behavior	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						diffusion tensor imaging; magnetic resonance imaging; suicide; TBI	WHITE-MATTER ABNORMALITIES; LATE-LIFE DEPRESSION; HUMAN CEREBRAL-CORTEX; DIFFUSION-TENSOR; CORPUS-CALLOSUM; MICROSTRUCTURAL ABNORMALITIES; GEOMETRICALLY ACCURATE; DEPENDENT SUBJECTS; BIPOLAR DISORDER; MRI	Introduction: There is an urgent need to define the neurobiological and cognitive underpinnings of suicidal ideation and behavior in veterans with traumatic brain injury (TBI). Separate studies implicate frontal white matter systems in the pathophysiology of TBI, suicidality, and impulsivity. We examined the relationship between the integrity of major frontal white matter (WM) systems on measures of impulsivity and suicidality in veterans with TBI. Methods: Fifteen male veterans with TBI and 17 matched healthy controls (HC) received clinical ratings, measures of impulsivity and MRI scans on a 3T magnet. Diffusion tensor imaging (DTI) data for the genu and cingulum were analyzed using Freesurfer and FSL. Correlations were performed for fractional anisotropy (FA) (DTI) values and measures of suicidality and impulsivity for veterans with TBI. Results: Significantly decreased in FA values in the left cingulum (P = 0.02), and left (P = 0.02) and total genu (P = 0.01) were observed in the TBI group relative to controls. Measures of impulsivity were significantly greater for the TBI group and total and right cingulum FA positively correlated with current suicidal ideation and measures of impulsivity (P < 0.03). Conclusion: These data demonstrate a significant reduction in FA in frontal WM tracts in veterans with mild TBI that was associated with both impulsivity and suicidality. These findings may reflect a neurobiological vulnerability to suicidal risk related to white matter microstructure.	[Yurgelun-Todd, Deborah A.; Bueler, C. Elliott; McGlade, Erin C.; Churchwell, John C.; Lopez-Larson, Melissa P.] Univ Utah, Inst Brain, Salt Lake City, UT 84108 USA; [Yurgelun-Todd, Deborah A.; Lopez-Larson, Melissa P.] Univ Utah, Sch Med, Salt Lake City, UT 84108 USA; [Yurgelun-Todd, Deborah A.; McGlade, Erin C.; Lopez-Larson, Melissa P.] VA VISN 19 Mental Illness Res Educ & Clin Ctr MIR, Salt Lake City, UT USA; [Brenner, Lisa A.] VA VISN 19 MIRECC, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Psychiat, Denver, CO 80262 USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Dept Neurol, Denver, CO USA	Yurgelun-Todd, DA (corresponding author), Univ Utah, Inst Brain, 383 Colorow Dr, Salt Lake City, UT 84108 USA.	deborah.yurgelun-todd@hsc.utah.edu	McGlade, Erin C/K-1157-2016; Brenner, Lisa A./AAG-2442-2019	McGlade, Erin C/0000-0003-2234-1984; 	VISN 19 MIRECC;  [5I01CX000253-02]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH087831] Funding Source: NIH RePORTER	This work was supported by research grants from Merit review 5I01CX000253-02 and VISN 19 MIRECC.	Abe O, 2004, J COMPUT ASSIST TOMO, V28, P533, DOI 10.1097/00004728-200407000-00016; Aguilar EJ, 2008, PROG NEURO-PSYCHOPH, V32, P1673, DOI 10.1016/j.pnpbp.2008.06.016; Ahearn EP, 2001, BIOL PSYCHIAT, V50, P266, DOI 10.1016/S0006-3223(01)01098-8; Alexopoulos GS, 2008, AM J PSYCHIAT, V165, P238, DOI 10.1176/appi.ajp.2007.07050744; Alexopoulos GS, 2002, AM J PSYCHIAT, V159, P1929, DOI 10.1176/appi.ajp.159.11.1929; Andersson J.L.R., 2007, TR07JA1 FMRIB; ANDERSSON JLR, 2011, TR07JA2 FMRIB; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Avants B, 2008, ACAD RADIOL, V15, P1360, DOI 10.1016/j.acra.2008.07.007; Barnea-Goraly N, 2009, BIOL PSYCHIAT, V66, P238, DOI 10.1016/j.biopsych.2009.02.025; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Bender TW, 2011, J AFFECT DISORDERS, V129, P301, DOI 10.1016/j.jad.2010.07.023; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Briere J., 1995, TRAUMA SYMPTOM INVEN; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cirino PT, 2002, ASSESSMENT, V9, P145, DOI 10.1177/10791102009002005; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; First M.B., 1996, STRUCTURED CLIN INTE; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gorlyn Marianne, 2005, Int J Adolesc Med Health, V17, P205; HAMILTON A, 1969, BRIT J PSYCHIAT, P76; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Horesh N, 2001, Crisis, V22, P27, DOI 10.1027//0227-5910.22.1.27; Hwang JP, 2010, J GERIATR PSYCH NEUR, V23, P171, DOI 10.1177/0891988710363713; Jia ZY, 2010, AM J PSYCHIAT, V167, P1381, DOI 10.1176/appi.ajp.2010.09101513; KAROL RL, 2003, NEUROPSYCHOLOGICAL I; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Konrad A, 2010, EUR J NEUROSCI, V31, P912, DOI 10.1111/j.1460-9568.2010.07110.x; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Li LJ, 2007, BRAIN RES, V1168, P124, DOI 10.1016/j.brainres.2007.06.094; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Maller JJ, 2010, BRAIN RES REV, V64, P213, DOI 10.1016/j.brainresrev.2010.04.003; Maser JD, 2002, SUICIDE LIFE-THREAT, V32, P10, DOI 10.1521/suli.32.1.10.22183; Matsuo K, 2010, NEUROSCI LETT, V469, P75, DOI 10.1016/j.neulet.2009.11.047; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAuliffe C, 2008, BRIT J CLIN PSYCHOL, V47, P43, DOI 10.1348/014466507X230958; McNair D., 1992, REVISED MANUAL PROFI; Minami T, 2003, NEUROPSYCHOBIOLOGY, V47, P141, DOI 10.1159/000070583; Moeller FG, 2005, NEUROPSYCHOPHARMACOL, V30, P610, DOI 10.1038/sj.npp.1300617; Monkul ES, 2007, MOL PSYCHIATR, V12, P360, DOI 10.1038/sj.mp.4001919; Mori S., 2005, MRI ATLAS HUMAN WHIT; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Nobuhara K, 2006, J NEUROL NEUROSUR PS, V77, P120, DOI 10.1136/jnnp.2004.055129; Oquendo MA, 2003, STANDARDIZED EVALUAT, P103; Parker RS, 2002, NEUROREHABILITATION, V17, P131; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Paulus MP, 2007, SCIENCE, V318, P602, DOI 10.1126/science.1142997; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Robertson IH, 2008, ARCH PHYS MED REHAB, V89, pS1, DOI 10.1016/j.apmr.2008.10.001; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salo R, 2009, BIOL PSYCHIAT, V65, P122, DOI 10.1016/j.biopsych.2008.08.004; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Taber K. H., 2007, J NEUROPSYCHIATRY CL, V19; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Taylor WD, 2004, AM J PSYCHIAT, V161, P1293, DOI 10.1176/appi.ajp.161.7.1293; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Versace A, 2008, ARCH GEN PSYCHIAT, V65, P1041, DOI 10.1001/archpsyc.65.9.1041; Versace A, 2010, BIOL PSYCHIAT, V68, P560, DOI 10.1016/j.biopsych.2010.04.036; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wei CW, 2008, ARCH PHYS MED REHAB, V89, pS85, DOI 10.1016/j.apmr.2008.07.005; Wessa M, 2009, BIPOLAR DISORD, V11, P504, DOI 10.1111/j.1399-5618.2009.00718.x; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yang Q, 2007, INT PSYCHOGERIATR, V19, P757, DOI 10.1017/S1041610207004875; Yoo SY, 2007, ACTA PSYCHIAT SCAND, V116, P211, DOI 10.1111/j.1600-0447.2007.01046.x; Yurgelun-Todd DA, 2007, BIPOLAR DISORD, V9, P504, DOI 10.1111/j.1399-5618.2007.00395.x; Zanetti MV, 2009, EUR ARCH PSY CLIN N, V259, P316, DOI 10.1007/s00406-009-0002-8	98	56	56	1	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2011	26	4					276	289		10.1097/HTR.0b013e31822251dc			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	789FZ	WOS:000292501700005	21734511				2021-06-18	
J	Newcombe, V; Chatfield, D; Outtrim, J; Vowler, S; Manktelow, A; Cross, J; Scoffings, D; Coleman, M; Hutchinson, P; Coles, J; Carpenter, TA; Pickard, J; Williams, G; Menon, D				Newcombe, Virginia; Chatfield, Doris; Outtrim, Joanne; Vowler, Sarah; Manktelow, Anne; Cross, Justin; Scoffings, Daniel; Coleman, Martin; Hutchinson, Peter; Coles, Jonathan; Carpenter, T. Adrian; Pickard, John; Williams, Guy; Menon, David			Mapping Traumatic Axonal Injury Using Diffusion Tensor Imaging: Correlations with Functional Outcome	PLOS ONE			English	Article							SEVERE HEAD-INJURY; BRAIN-INJURY; MR-IMAGES; SCALE; DISEASE; LESIONS; BURDEN; STATE	Background: Traumatic brain injury is a major cause of morbidity and mortality worldwide. Ameliorating the neurocognitive and physical deficits that accompany traumatic brain injury would be of substantial benefit, but the mechanisms that underlie them are poorly characterized. This study aimed to use diffusion tensor imaging to relate clinical outcome to the burden of white matter injury. Methodology/Principal Findings: Sixty-eight patients, categorized by the Glasgow Outcome Score, underwent magnetic resonance imaging at a median of 11.8 months (range 6.6 months to 3.7 years) years post injury. Control data were obtained from 36 age-matched healthy volunteers. Mean fractional anisotropy, apparent diffusion coefficient (ADC), and eigenvalues were obtained for regions of interest commonly affected in traumatic brain injury. In a subset of patients where conventional magnetic resonance imaging was completely normal, diffusion tensor imaging was able to detect clear abnormalities. Significant trends of increasing ADC with worse outcome were noted in all regions of interest. In the white matter regions of interest worse clinical outcome corresponded with significant trends of decreasing fractional anisotropy. Conclusions/Significance: This study found that clinical outcome was related to the burden of white matter injury, quantified by diffusivity parameters late after traumatic brain injury. These differences were seen even in patients with the best outcomes and patients in whom conventional magnetic resonance imaging was normal, suggesting that diffusion tensor imaging can detect subtle injury missed by other techniques. An improved in vivo understanding of the pathology of traumatic brain injury, including its distribution and extent, may enhance outcome evaluation and help to provide a mechanistic basis for deficits that remain unexplained by other approaches.	[Newcombe, Virginia; Chatfield, Doris; Outtrim, Joanne; Manktelow, Anne; Coles, Jonathan; Menon, David] Univ Cambridge, Univ Div Anaesthesia, Cambridge, England; [Newcombe, Virginia; Chatfield, Doris; Outtrim, Joanne; Manktelow, Anne; Coleman, Martin; Hutchinson, Peter; Coles, Jonathan; Carpenter, T. Adrian; Pickard, John; Williams, Guy; Menon, David] Univ Cambridge, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge, England; [Vowler, Sarah] Univ Cambridge, Ctr Appl Med Stat, Dept Publ Hlth & Primary Care, Cambridge, England; [Cross, Justin; Scoffings, Daniel] Univ Cambridge, Addenbrookes Hosp, Dept Radiol, Cambridge CB2 2QQ, England; [Hutchinson, Peter; Pickard, John] Univ Cambridge, Acad Neurosurg Unit, Dept Clin Neurosci, Cambridge, England	Newcombe, V (corresponding author), Univ Cambridge, Univ Div Anaesthesia, Cambridge, England.	vfjn2@wbic.cam.ac.uk		Newcombe, Virginia/0000-0001-6044-9035; Outtrim, Joanne/0000-0001-8118-6430	Medical Research Council (UK)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390 ID 65883]; UK National Institute of Health Research Biomedical Research Centre at CambridgeNational Institute for Health Research (NIHR); UK Department of Health; Gates Cambridge Trust; Overseas Research Studentship; NIHR Cambridge Biomedical Research CentreNational Institute for Health Research (NIHR); Academy of Medical Sciences/Health Foundation; Royal College of Anaesthetists; Evelyn Trust; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B, G0001237, G1000183B, G0001354, G0600986, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2009-14-007, NF-SI-0508-10327] Funding Source: researchfish	This work was supported by a Medical Research Council (UK) Program Grant (Acute brain injury: heterogeneity of mechanisms, therapeutic targets and outcome effects [G9439390 ID 65883]), the UK National Institute of Health Research Biomedical Research Centre at Cambridge, and the Technology Platform funding provided by the UK Department of Health. VN was supported by the Gates Cambridge Trust and an Overseas Research Studentship. JC and DS are supported by the NIHR Cambridge Biomedical Research Centre. PJH is supported by an Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. JPC is supported by a Clinician Scientist Award from the Academy of Medical Sciences/Health Foundation. DKM is supported by the BOC Professorship of the Royal College of Anaesthetists and the Evelyn Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; NIOGI SN, 2008, AJNR AM J NEURORADIO; Patrick PD, 2007, BRAIN INJURY, V21, P63, DOI 10.1080/02699050601111401; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; SIDAROS A, 2007, BRAIN; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424	28	56	60	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2011	6	5							e19214	10.1371/journal.pone.0019214			11	Multidisciplinary Sciences	Science & Technology - Other Topics	759EZ	WOS:000290224800017	21573228	DOAJ Gold, Green Published			2021-06-18	
J	Czlonkowska, A; Kurkowska-Jastrzebska, I				Czlonkowska, Anna; Kurkowska-Jastrzebska, Iwona			Inflammation and gliosis in neurological diseases - clinical implications	JOURNAL OF NEUROIMMUNOLOGY			English	Article						Neurodegeneration; Multiple sclerosis; Parkinson's disease; Alzheimer's disease; Stroke	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; APPEARING WHITE-MATTER; AMYLOID-BETA PEPTIDE; PARKINSONS-DISEASE; MULTIPLE-SCLEROSIS; MOUSE MODEL; MICROGLIAL ACTIVATION; T-CELLS; DOPAMINERGIC-NEURONS; ALZHEIMER-DISEASE	The inflammatory reaction accompany all acute processes in the central nervous system (CNS), (as stroke or traumatic brain injury) and chronic neurodegenerative processes (as Parkinson's or Alzheimer's disease), and through the stage of cleaning of damage tissue, contribute to recovery and regeneration and eventually to restoration of the function. However many studies showed that inflammation in the CNS may be harmful because of an excessive vulnerability of the nervous tissue or impaired regulation. Manipulation of the inflammation is now one of the approaches in the treatment of the various diseases of the CNS. (C) 2010 Elsevier B.V. All rights reserved.	[Czlonkowska, Anna; Kurkowska-Jastrzebska, Iwona] Inst Psychiat & Neurol, Dept Neurol 2, Warsaw, Poland; [Czlonkowska, Anna] Med Univ Warsaw, Dept Clin & Expt Pharmacol, Warsaw, Poland	Czlonkowska, A (corresponding author), Sobieskiego 9, PL-02957 Warsaw, Poland.	czlonkow@ipin.edu.pl		Kurkowska-Jastrzebska, Iwona/0000-0001-6553-9080; Czlonkowska, Anna/0000-0002-1956-1866			Aharoni R, 2010, J NEUROIMMUNOL, V225, P100, DOI 10.1016/j.jneuroim.2010.04.022; Aisen PS, 2008, CURR ALZHEIMER RES, V5, P73, DOI 10.2174/156720508783884602; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Aktas O, 2010, NAT REV NEUROL, V6, P373, DOI 10.1038/nrneurol.2010.76; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; Barouch R, 2002, FASEB J, V16, P1304, DOI 10.1096/fj.01-0467fje; Bartels AL, 2007, MOVEMENT DISORD, V22, P1852, DOI 10.1002/mds.21552; Benner EJ, 2004, P NATL ACAD SCI USA, V101, P9435, DOI 10.1073/pnas.0400569101; Bjartmar C, 2001, NEUROLOGY, V57, P1248, DOI 10.1212/WNL.57.7.1248; Bjartmar C, 2001, CURR OPIN NEUROL, V14, P271, DOI 10.1097/00019052-200106000-00003; BlumDegen D, 1995, NEUROSCI LETT, V202, P17, DOI 10.1016/0304-3940(95)12192-7; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Carvey PM, 2001, EXP NEUROL, V171, P98, DOI 10.1006/exnr.2001.7735; Castellani ML, 2007, INT J IMMUNOPATH PH, V20, P447, DOI 10.1177/039463200702000303; Chen HL, 2005, ANN NEUROL, V58, P963, DOI 10.1002/ana.20682; Chen HL, 2003, ARCH NEUROL-CHICAGO, V60, P1059, DOI 10.1001/archneur.60.8.1059; Ciesielska A, 2003, ACTA NEUROBIOL EXP, V63, P117; Compston A, 1996, Mult Scler, V1, P388; Danilov AI, 2006, EUR J NEUROSCI, V23, P394, DOI 10.1111/j.1460-9568.2005.04563.x; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dodel R, 2002, ANN NEUROL, V52, P253, DOI 10.1002/ana.10253; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.3.CO;2-A; Flugel A, 2001, IMMUNITY, V14, P547, DOI 10.1016/s1074-7613(01)00143-1; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002; Gilman S, 2005, NEUROLOGY, V64, P1553, DOI 10.1212/01.WNL.0000159740.16984.3C; Gimsa U, 2000, BRAIN PATHOL, V10, P365; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; Gromadzka G, 2007, J NEUROL NEUROSUR PS, V78, P183, DOI 10.1136/jnnp.2006.093104; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Hernan MA, 2006, NEUROLOGY, V66, P1097, DOI 10.1212/01.wnl.0000204446.82823.28; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Johansson S, 2002, J COMP NEUROL, V443, P237, DOI 10.1002/cne.10119; Joniec I, 2009, BRAIN RES, V1261, P7, DOI 10.1016/j.brainres.2008.12.081; Kokjohn TA, 2009, CNS NEUROL DISORD-DR, V8, P88, DOI 10.2174/187152709787847315; Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559; Kurkowska-Jastrzebska I, 2007, PARKINSONISM RELAT D, V13, pS141, DOI 10.1016/S1353-8020(08)70772-7; Kurkowska-Jastrzebska I, 2006, ANN NEUROL, V59, P988, DOI 10.1002/ana.20860; Kurkowska-Jastrzebska I, 1999, EXP NEUROL, V156, P50, DOI 10.1006/exnr.1998.6993; Kurkowska-Jastrzebska I, 2005, NEUROSCIENCE, V131, P247, DOI 10.1016/j.neuroscience.2004.10.027; Kurkowska-Jastrzebska I, 2004, INT IMMUNOPHARMACOL, V4, P1307, DOI 10.1016/j.intimp.2004.05.006; Kurkowska-Jastrzebska I, 2002, INT IMMUNOPHARMACOL, V2, P1213, DOI 10.1016/S1567-5769(02)00078-4; Kurkowska-Jastrzebska I, 2009, INT IMMUNOPHARMACOL, V9, P781, DOI 10.1016/j.intimp.2009.03.003; Kurkowska-Jastrzebska I, 2007, NEUROREPORT, V18, P425, DOI 10.1097/WNR.0b013e3280586777; Kurkowska-Jastrzebska I, 2008, J NEUROIMMUNOL, V203, P233; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; Lassmann H, 2007, BRAIN PATHOL, V17, P210, DOI 10.1111/j.1750-3639.2007.00064.x; Lisak RP, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-30; Lisak RP, 2006, MULT SCLER J, V12, P149, DOI 10.1191/135248506ms1251oa; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Lyketsos CG, 2007, NEUROLOGY, V68, P1800; McCombe PA, 2008, INT J STROKE, V3, P254, DOI 10.1111/j.1747-4949.2008.00222.x; McGeer PL, 2007, NEUROBIOL AGING, V28, P639, DOI 10.1016/j.neurobiolaging.2006.03.013; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; MOGI M, 1995, J NEURAL TRANSM-PARK, V9, P87, DOI 10.1007/BF02252965; Naismith RT, 2010, NEUROLOGY, V74, P1860, DOI 10.1212/WNL.0b013e3181e24373; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Noto ATW, 2006, THROMB HAEMOSTASIS, V96, P53, DOI 10.1160/TH05-11-0772; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Przedborski S, 2010, MOVEMENT DISORD, V25, pS55, DOI 10.1002/mds.22638; Przybylkowski A, 2004, BRAIN RES, V1019, P144, DOI 10.1016/j.brainres.2004.05.095; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Reines SA, 2004, NEUROLOGY, V62, P66, DOI 10.1212/WNL.62.1.66; Relkin NR, 2009, NEUROBIOL AGING, V30, P1728, DOI 10.1016/j.neurobiolaging.2007.12.021; Samii A, 2009, DRUG AGING, V26, P769, DOI 10.2165/11316780-000000000-00000; Sawada M, 2008, NEURODEGENER DIS, V5, P254, DOI 10.1159/000113717; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; Schwartz M, 2005, J NEUROL SCI, V233, P163, DOI 10.1016/j.jns.2005.03.014; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Schwartz M, 2006, J NEUROIMMUNE PHARM, V1, P4, DOI 10.1007/s11481-005-9010-2; Schwartz M, 2008, TRENDS PHARMACOL SCI, V29, P287, DOI 10.1016/j.tips.2008.03.006; Serrano-Pozo A, 2010, BRAIN, V133, P1312, DOI 10.1093/brain/awq056; Streit WJ, 2009, ACTA NEUROPATHOL, V118, P475, DOI 10.1007/s00401-009-0556-6; STRIJBOS PJLM, 1995, J NEUROSCI, V15, P3468; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Tsutsui S, 2009, ANN NEUROL, V66, P711, DOI 10.1002/ana.21845; Um JY, 2003, MOL BRAIN RES, V115, P50, DOI 10.1016/S0169-328X(03)00179-7; Van der Walt A, 2010, PHARMACOL THERAPEUT, V126, P82, DOI 10.1016/j.pharmthera.2010.01.006; Villoslada P, 2008, CLIN IMMUNOL, V128, P294, DOI 10.1016/j.clim.2008.04.003; Wang XJ, 2007, NEUROCHEM INT, V50, P39, DOI 10.1016/j.neuint.2006.07.014; Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004; Willenborg DO, 1999, J NEUROIMMUNOL, V100, P21, DOI 10.1016/S0165-5728(99)00212-X; Worrall BB, 2007, STROKE, V38, P1189, DOI 10.1161/01.STR.0000260099.42744.b0; Zhang SC, 2003, GLIA, V41, P191, DOI 10.1002/glia.10172	93	56	57	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	FEB	2011	231	1-2			SI		78	85		10.1016/j.jneuroim.2010.09.020			8	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	744YT	WOS:000289131800012	20943275				2021-06-18	
J	Genet, F; Jourdan, C; Schnitzler, A; Lautridou, C; Guillemot, D; Judet, T; Poiraudeau, S; Denormandie, P				Genet, Francois; Jourdan, Claire; Schnitzler, Alexis; Lautridou, Christine; Guillemot, Didier; Judet, Thierry; Poiraudeau, Serge; Denormandie, Philippe			Troublesome Heterotopic Ossification after Central Nervous System Damage: A Survey of 570 Surgeries	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; HUMORAL-FACTORS; EARLY EXCISION; BONE-FORMATION; RISK-FACTORS; HEAD-TRAUMA; RESECTION; CLASSIFICATION; ELBOW	Background: Heterotopic ossification (HO) is a frequent complication after central nervous system (CNS) damage but has seldom been studied. We aimed to investigate features of HO for the first time in a large sample and the rate of early recurrence of HO in terms of the time of surgery. Methodology/Principal Findings: We retrospectively analyzed data from an anonymous prospective survey of patients undergoing surgery between May 1993 and November 2009 in our institution for troublesome HO related to acquired neurological disease. Demographic and HO characteristics and neurological etiologies were recorded. For 357 consecutive patients, we collected data on 539 first surgeries for HO (129 surgeries for multiple sites). During the follow-up, recurrences requiring another surgery appeared in 31 cases (5.8% [31/539]; 95% confidence interval [CI]: 3.8%-7.8%; 27 patients). Most HO requiring surgery occurred after traumatic brain injury (199 patients [55.7%]), then spinal cord injury (86 [24.0%]), stroke (42 [11.8%]) and cerebral anoxia (30 [8.6%]). The hip was the primary site of HO (328 [60.9%]), then the elbow (115 [21.3%]), knee (77 [14.3%]) and shoulder (19 [3.5%]). For all patients, 181 of the surgeries were performed within the first year after the CNS damage, without recurrence of HO. Recurrence was not associated with etiology (p = 0.46), sex (p = 1.00), age at CNS damage (p = 0.2), multisite localization (p = 0.34), or delay to surgery (p = 0.7). Conclusions/Significance: In patients with CNS damage, troublesome HO and recurrence occurs most frequently after traumatic brain injury and appears frequently in the hip and elbow. Early surgery for HO is not a factor of recurrence.	[Genet, Francois; Jourdan, Claire; Schnitzler, Alexis] Hop Raymond Poincare, Serv Med Phys & Readaptat, Garches, France; [Lautridou, Christine; Judet, Thierry; Denormandie, Philippe] Hop Raymond Poincare, Serv Chirurg Orthoped & Traumatol, Garches, France; [Guillemot, Didier] Hop Raymond Poincare, Unite Fonct Sante Publ, Garches, France; [Poiraudeau, Serge] Hop Cochin, Serv Med Phys & Readaptat, F-75674 Paris, France	Genet, F (corresponding author), Hop Raymond Poincare, Serv Med Phys & Readaptat, Garches, France.	francois.genet@rpc.aphp.fr	POIRAUDEAU, SERGE/P-5301-2016; Guillemot, Didier/AAN-3051-2020	Poiraudeau, Serge/0000-0002-1988-9124; Guillemot, Didier/0000-0002-8497-1765			Balboni TA, 2006, INT J RADIAT ONCOL, V65, P1289, DOI 10.1016/j.ijrobp.2006.03.053; Beingessner DM, 2000, J HAND SURG-AM, V25A, P483, DOI 10.1053/jhsu.2000.6922; BRAVOPAYNO P, 1992, PARAPLEGIA, V30, P740, DOI 10.1038/sc.1992.142; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; Cadosch D, 2010, J BONE JOINT SURG AM, V92A, P645, DOI 10.2106/JBJS.I.00097; Cadosch D, 2009, J BONE JOINT SURG AM, V91A, P282, DOI 10.2106/JBJS.G.01613; Chalidis B, 2007, J NEUROTRAUM, V24, P1675, DOI 10.1089/neu.2007.0342; Charnley G, 1996, INJURY, V27, P125, DOI 10.1016/0020-1383(95)00180-8; Cipriano C, 2009, ORTHOPEDICS, V32; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; Cullen N, 2007, BRAIN INJURY, V21, P215, DOI 10.1080/02699050701202027; da Paz AC, 2007, MED HYPOTHESES, V68, P67, DOI 10.1016/j.mehy.2006.06.035; de Palma L, 2002, ORTHOPEDICS, V25, P665; Denys P, 1996, BRAIN INJURY, V10, P149, DOI 10.1080/026990596124656; DITUNNO JF, 1994, PARAPLEGIA, V32, P70, DOI 10.1038/sc.1994.13; Fuller DA, 2005, CLIN ORTHOP RELAT R, P197, DOI 10.1097/01.blo.0000170718.86747.da; GARLAND DE, 1989, CLIN ORTHOP RELAT R, P169; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Genet F, 2009, J BONE JOINT SURG BR, V91B, P1493, DOI 10.1302/0301-620X.91B11.22305; HARAN M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003321.PUB3; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Lazarus MD, 1999, NEUROREHABILITATION, V12, P145; Melamed E, 2002, AM J PHYS MED REHAB, V81, P670, DOI 10.1097/00002060-200209000-00006; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; Pelissier J., 2002, Annales de Readaptation et de Medecine Physique, V45, P188, DOI 10.1016/S0168-6054(02)00202-7; Riklin C, 2003, SPINAL CORD, V41, P192, DOI 10.1038/sj.sc.3101421; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; Shehab D, 2002, J NUCL MED, V43, P346; Silver J R, 1969, Paraplegia, V7, P220; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; STOVER SL, 1991, CLIN ORTHOP RELAT R, P71; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Toffoli AM, 2008, BRAIN INJURY, V22, P511, DOI 10.1080/02699050802158235; Vanden Bossche L, 2005, J REHABIL MED, V37, P129, DOI 10.1080/16501970510027628	37	56	58	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e16632	10.1371/journal.pone.0016632			7	Multidisciplinary Sciences	Science & Technology - Other Topics	714UK	WOS:000286834300104	21304993	DOAJ Gold, Green Published			2021-06-18	
J	Krajewska, M; Xu, L; Xu, WJ; Krajewski, S; Kress, CL; Cui, JK; Yang, L; Irie, F; Yamaguchi, Y; Lipton, SA; Reed, JC				Krajewska, Maryla; Xu, Lucy; Xu, Wenjie; Krajewski, Stan; Kress, Christina L.; Cui, Jiankun; Yang, Li; Irie, Fumitoshi; Yamaguchi, Yu; Lipton, Stuart A.; Reed, John C.			Endoplasmic reticulum protein BI-1 modulates unfolded protein response signaling and protects against stroke and traumatic brain injury	BRAIN RESEARCH			English	Article						Neuroprotection; Unfolded protein response; Brain injury	BAX-DEPENDENT APOPTOSIS; NEURONAL CELL-DEATH; ER STRESS; NITRIC-OXIDE; PHOSPHORYLATION; INHIBITOR-1; MICE; ACTIVATION; JNK; IRE1-ALPHA	Bax-Inhibitor-1 (BI-1) is an evolutionarily conserved cytoprotective protein that resides in membranes of the endoplasmic reticulum (ER). BI-1's cytoprotective activity is manifested in the context of ER stress, with previous studies showing that BI-1 modulates several ER-associated functions, including Unfolded Protein Response (UPR) signaling. Here we investigated the role of BM in neuroprotection by generating transgenic mice in which BI-1 was constitutively expressed from a neuronal-specific promoter. Cultured primary cortical neurons from BI-1 transgenic mouse embryos exhibited greater resistance to cell death induced by agents known to cause ER stress compared to their non-transgenic counterparts. While brain morphology and vasculature of BI-1 mice appeared to be unchanged from normal non-transgenic mice, BI-1 transgenic mice showed reduced brain lesion volumes and better performance in motoric tests, compared with non-transgenic littermates, in two models of acute brain injury: stroke caused by middle cerebral artery occlusion (MCAO) and traumatic brain injury (TBI) caused by controlled cortical impact. Furthermore, brain tissue from BI-1 transgenic mice showed reduced levels of apoptotic cells and reduced induction of markers of ER stress after brain injury, including CHOP protein expression. In summary, our findings demonstrate that enforced neuronal expression of BI-1 reduces ER stress and provides protection from acute brain injury, suggesting that strategies for enhancing BI-1 expression or activity should be considered for development of new therapies for counteracting the consequences of stroke and acute brain trauma. (C) 2010 Elsevier B.V. All rights reserved.	[Krajewska, Maryla; Xu, Lucy; Xu, Wenjie; Krajewski, Stan; Kress, Christina L.; Cui, Jiankun; Yang, Li; Irie, Fumitoshi; Yamaguchi, Yu; Lipton, Stuart A.; Reed, John C.] Sanford Burnham Med Res Inst, La Jolla, CA 92037 USA	Reed, JC (corresponding author), Sanford Burnham Med Res Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	reedoffice@burnham.org			NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG015393] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG015393-10, AG-15393, R01 AG015393] Funding Source: Medline		Ahlemeyer B, 2005, J NEUROSCI METH, V149, P110, DOI 10.1016/j.jneumeth.2005.05.022; Bailly-Maitre B, 2006, P NATL ACAD SCI USA, V103, P2809, DOI 10.1073/pnas.0506854103; Bailly-Maitre B, 2010, J BIOL CHEM, V285, P6198, DOI 10.1074/jbc.M109.056648; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bredesen DE, 2006, NATURE, V443, P796, DOI 10.1038/nature05293; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; Gotoh T, 2006, ARTERIOSCL THROM VAS, V26, P1439, DOI 10.1161/01.ATV.0000223900.67024.15; Habelhah H, 2004, EMBO J, V23, P322, DOI 10.1038/sj.emboj.7600044; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Iadecola C, 1997, J NEUROSCI, V17, P9157; Kadoya K, 2008, J HISTOCHEM CYTOCHEM, V56, P295, DOI 10.1369/jhc.7A7349.2007; Kang KW, 2005, ANTIOXID REDOX SIGN, V7, P1664, DOI 10.1089/ars.2005.7.1664; Kermer P, 2003, BRAIN PATHOL, V13, P495; Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755; Krajewska M, 2009, J HISTOCHEM CYTOCHEM, V57, P649, DOI 10.1369/jhc.2009.952812; Lee GH, 2007, J BIOL CHEM, V282, P21618, DOI 10.1074/jbc.M700053200; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lisbona F, 2009, MOL CELL, V33, P679, DOI 10.1016/j.molcel.2009.02.017; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Nakanishi N, 2009, J NEUROSCI, V29, P5260, DOI 10.1523/JNEUROSCI.1067-09.2009; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Paxinos A, 2001, SPORTS MED, V31, P819, DOI 10.2165/00007256-200131110-00004; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Rao RV, 2004, CURR OPIN CELL BIOL, V16, P653, DOI 10.1016/j.ceb.2004.09.012; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Rong YP, 2008, MOL CELL, V31, P255, DOI 10.1016/j.molcel.2008.06.014; ROSEN GD, 1990, J NEUROSCI METH, V35, P115, DOI 10.1016/0165-0270(90)90101-K; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Shen XH, 2004, J CHEM NEUROANAT, V28, P79, DOI 10.1016/j.jchemneu.2004.02.006; Srivastava RK, 1998, MOL CELL BIOL, V18, P3509, DOI 10.1128/MCB.18.6.3509; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tajiri S, 2004, CELL DEATH DIFFER, V11, P403, DOI 10.1038/sj.cdd.4401365; Uehara T, 2006, NATURE, V441, P513, DOI 10.1038/nature04782; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wei YJ, 2008, AUTOPHAGY, V4, P949, DOI 10.4161/auto.6788; Westphalen BC, 2005, CELL DEATH DIFFER, V12, P304, DOI 10.1038/sj.cdd.4401547; Xu CY, 2008, J BIOL CHEM, V283, P11477, DOI 10.1074/jbc.M708385200; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu QL, 2000, METHOD ENZYMOL, V322, P283; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zou W, 2008, CANCER RES, V68, P7484, DOI 10.1158/0008-5472.CAN-08-1318	49	56	66	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 25	2011	1370						227	237		10.1016/j.brainres.2010.11.015			11	Neurosciences	Neurosciences & Neurology	717RU	WOS:000287065900022	21075086	Green Accepted			2021-06-18	
J	Beauchamp, M; Catroppa, C; Godfrey, C; Morse, S; Rosenfeld, JV; Anderson, V				Beauchamp, Miriam; Catroppa, Cathy; Godfrey, Celia; Morse, Sue; Rosenfeld, Jeffrey V.; Anderson, Vicki			Selective Changes in Executive Functioning Ten Years After Severe Childhood Traumatic Brain Injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							LATENT VARIABLE ANALYSIS; PROBLEM-SOLVING SKILLS; ATTENTIONAL SKILLS; PRESCHOOL-CHILDREN; MEMORY FUNCTION; YOUNG-CHILDREN; FOLLOW-UP; RECOVERY; TBI; PERFORMANCE	Pediatric traumatic brain injury (TBI) impacts on children's executive functions, but little is known of how such deficits evolve in the long term. Forty adolescents with TBI were assessed ten years post-injury and compared to 19 typically developing participants on a range of executive measures (attentional control, cognitive flexibility, goal setting, information processing). Children with mild or moderate TBI performed within age expectations on all tests; however, those with severe injuries had poorer performance on goal setting and processing speed tasks. Childhood TBI may result in subtle lasting changes in complex executive skills, which could require ongoing support into adulthood.	[Beauchamp, Miriam] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Catroppa, Cathy; Godfrey, Celia; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Morse, Sue] Royal Childrens Hosp, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia	Beauchamp, M (corresponding author), CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca	Rosenfeld, Jeffrey V/B-7249-2011				Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson P., 2008, EXECUTIVE FUNCTIONS, P4; Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2001, Pediatr Rehabil, V4, P119, DOI 10.1080/13638490110091347; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Asikainen I, 1996, BRAIN INJURY, V10, P883, DOI 10.1080/026990596123864; Best JR, 2009, DEV REV, V29, P180, DOI 10.1016/j.dr.2009.05.002; Bull R, 2008, DEV NEUROPSYCHOL, V33, P205, DOI 10.1080/87565640801982312; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Catroppa C, 2006, Pediatr Rehabil, V9, P89, DOI 10.1080/13638490500155458; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Daniel A. E., 1983, POWER PRIVILEGE PRES; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dennis M, 2009, J INT NEUROPSYCH SOC, V15, P331, DOI 10.1017/S1355617709090481; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2004, BEHAV RATING INVENTO; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldberg E, 2005, PSYCHIAT CLIN N AM, V28, P567, DOI 10.1016/j.psc.2005.05.005; Hebb DO., 1949, ORG BEHAV NEUROPSYCH; HOLM S, 1979, SCAND J STAT, V6, P65; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Jacobs R, 2002, CHILD NEUROPSYCHOL, V8, P93, DOI 10.1076/chin.8.2.93.8726; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kelly T., 2000, CLIN NEUROPSYCHOL, V1, P38; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Levin HS, 2001, NEUROPSYCHOLOGY, V15, P557, DOI 10.1037//0894-4105.15.4.557; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Luria A. R., 1966, HIGHER CORTICAL FUNC; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; MUSCARA F, 2008, NEUROPSYCHOL REHABIL, V19, P541; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Noller P, 1988, ICPS FAMILY FU UNPUB; Nybo T, 2004, J INT NEUROPSYCH SOC, V10, P719, DOI 10.1017/S1355617704105109; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; PARKER DM, 1992, HDB NEUROPSYCHOLOGIC, P267; Prigatano GP, 2008, CLIN NEUROPSYCHOL, V22, P603, DOI 10.1080/13854040701440501; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Senn TE, 2004, DEV NEUROPSYCHOL, V26, P445, DOI 10.1207/s15326942dn2601_5; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Smidts DP, 2004, DEV NEUROPSYCHOL, V26, P385, DOI 10.1207/s15326942dn2601_2; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O., 1985, DEV NEUROPSYCHOLOGY; Stuss D.T., 1986, FRONTAL LOBES; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; TEASDALE G, 1974, LANCET, V2, P81; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; WALSH KW, 1998, NEUROPSYCHOLOGY CLIN; Wechsler D., 1997, WECHSLER ADULTS INTE; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64	82	56	56	0	15	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2011	36	5					578	595	PII 938567966	10.1080/87565641.2011.555572			18	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	776NK	WOS:000291542000004	21667362				2021-06-18	
J	Bellander, BM; Olafsson, IH; Ghatan, PH; Skejo, HPB; Hansson, LO; Wanecek, M; Svensson, MA				Bellander, Bo-Michael; Olafsson, Ingvar Hakon; Ghatan, Per Hamid; Skejo, Hanne Pernille Bro; Hansson, Lars-Olof; Wanecek, Mikael; Svensson, Mikael A.			Secondary insults following traumatic brain injury enhance complement activation in the human brain and release of the tissue damage marker S100B	ACTA NEUROCHIRURGICA			English	Article						Traumatic brain injury; Complement; C5b9; S-100B; NSE; Human; Secondary insults	SEVERE HEAD-INJURY; NEUROBIOCHEMICAL MARKERS; NEUROLOGICAL DISORDERS; BARRIER DYSFUNCTION; INTENSIVE-CARE; IGG ANALYSES; ADULT-RAT; SERUM; CYTOKINES; IMPACT	Complement activation has been suggested to play a role in the development of secondary injuries following traumatic brain injury (TBI). The present study was initiated in order to analyze complement activation in relation to the primary brain injury and to secondary insults, frequently occurring following TBI. Twenty patients suffering from severe TBI (Glasgow coma score a parts per thousand currency sign8) were included in the study. The "membrane attack complex," C5b9, which is the cytolytic end product of the complement system was analyzed in cerebrospinal fluid (CSF). The degree of brain tissue damage was assessed using the release of S100B and neuron-specific enolase (NSE) to the CSF and blood. The blood-brain barrier was assessed using the CSF/serum quotient of albumin (Q (A)). Following impact, initial peaks (0-48 h) of C5b9, S100B, and NSE with a concomitant loss of integrity of the blood-brain barrier were observed. Secondary insults at the intensive care unit were monitored. Severe secondary insults were paralleled by a more pronounced complement activation (C5b9 in CSF) as well as increased levels of S100B (measured in CSF), but not with NSE. This human study indicates that complement activation in the brain is triggered not only by the impact of trauma per se but also by the amount of secondary insults that frequently occur at the scene of accident as well as during treatment in the neurointensive care unit. Complement activation and in particular the end product C5b9 may in turn contribute to additional secondary brain injuries by its membrane destructive properties.	[Bellander, Bo-Michael; Olafsson, Ingvar Hakon; Svensson, Mikael A.] Karolinska Univ Hosp Solna, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Ghatan, Per Hamid] Karolinska Univ Hosp Solna, Sect Cognit Neurophysiol, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Skejo, Hanne Pernille Bro] Karolinska Univ Hosp Solna, Neuroradiol Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Wanecek, Mikael] Karolinska Univ Hosp Solna, Sect Anesthesiol & Intens Care Med, Dept Clin Neurosci, S-17176 Stockholm, Sweden; [Hansson, Lars-Olof] Karolinska Univ Hosp Solna, Karolinska Univ Lab, S-17176 Stockholm, Sweden	Bellander, BM (corresponding author), Karolinska Univ Hosp Solna, Neurosurg Sect, Dept Clin Neurosci, S-17176 Stockholm, Sweden.	bo-michael.bellander@karolinska.se	Wanecek, Michael/AAE-7998-2021; Svensson, Mikael/F-8662-2012	Svensson, Mikael/0000-0003-1179-7003	Stockholm countyStockholm County Council; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission	The study was approved by the local ethical committee (01-297; 03-540). The staff at NICU, especially Pia Svensson, R.N., and Birgitta Ohlgren, R.N., are gratefully acknowledged for their everlasting enthusiasm and help concerning the present project. Mrs. Rumjana Dijlai-Merzoug is greatly acknowledged for excellent laboratory technical assistance. Magnus Backheden and Margaretha Krook are acknowledged for their help and guidance concerning the statistical analysis. This study was funded by the Stockholm county and the Swedish Medical Research Council.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; BARNUM SR, 1993, GLIA, V7, P225, DOI 10.1002/glia.440070306; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DICK JPR, 1984, J NEUROL NEUROSUR PS, V47, P496, DOI 10.1136/jnnp.47.5.496; Edwards P, 2005, LANCET, V365, P1957; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FREEMAN BA, 1982, LAB INVEST, V47, P412; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; Graham D.I., 1993, HEAD INJURY, P91; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; LINK H, 1977, SCAND J CLIN LAB INV, V37, P391, DOI 10.3109/00365517709091497; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MILLER JD, 1995, NEUROTRAUMA, P61; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Olney J W, 1986, Adv Exp Med Biol, V203, P631; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rudehill A, 2002, J NEUROTRAUM, V19, P855, DOI 10.1089/08977150260190447; RUS HG, 1992, J IMMUNOL, V148, P928; Sandelin M, 2004, J COMP NEUROL, V473, P233, DOI 10.1002/cne.20115; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Suarez JI, 2004, CRIT CARE MED, V32, P2311, DOI 10.1097/01.CCM.0000146132.29042.4c; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; TODD NV, 1990, ACT NEUR S, V51, P296; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Varelas PN, 2004, CRIT CARE MED, V32, P2191, DOI 10.1097/01.CCM.0000146131.03578.21; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91	46	56	61	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	JAN	2011	153	1					90	100		10.1007/s00701-010-0737-z			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	700YD	WOS:000285780600015	20686797	Other Gold, Green Published			2021-06-18	
J	Douglas-Escobar, M; Yang, C; Bennett, J; Shuster, J; Theriaque, D; Leibovici, A; Kays, D; Zheng, T; Rossignol, C; Shaw, G; Weiss, MD				Douglas-Escobar, Martha; Yang, Cui; Bennett, Jeffrey; Shuster, Jonathan; Theriaque, Douglas; Leibovici, Avital; Kays, David; Zheng, Tong; Rossignol, Candace; Shaw, Gerry; Weiss, Michael D.			A Pilot Study of Novel Biomarkers in Neonates With Hypoxic-Ischemic Encephalopathy	PEDIATRIC RESEARCH			English	Article							ANEURYSMAL SUBARACHNOID HEMORRHAGE; TRAUMATIC BRAIN-INJURY; NF-H; TERMINAL HYDROLASE; PNF-H; MARKER; BLOOD; EXPRESSION; PROTEINS; SERUM	Severe hypoxic-ischemic encephalopathy (HIE) is a devastating condition that can lead to mortality and long-term disabilities in term newborns. No rapid and reliable laboratory test exists to assess the degree of neuronal injury in these patients. We propose two possible biomarkers: 1) phosphorylated axonal neurofilament heavy chain (pNF-H) protein, one of the major subunits of neuro-filaments, found only in axonal cytoskeleton of neurons and 2) Ubiquitin C-terminal hydrolase 1 (UCHL1 protein) that is heavily and specifically concentrated in neuronal perikarya and dendrites. High-serum pNF-H and UCHL1 levels are reported in subarachnoid hemorrhage and traumatic brain injury, suggesting that they are released into blood following neuronal injury. We hypothesized that serum pNF-H and UCHL1 were higher in neonates with moderate-to-severe HIE than in healthy neonates. A time-limited enrollment of 14 consecutive patients with HIE and 14 healthy controls was performed. UCHL1 and pNF-H were correlated with clinical data and brain MRI. UCHL1 and pNF-H serum levels were higher in HIE versus controls. UCHL1 showed correlation with the 10-min Apgar score, and pNF-H showed correlation with abnormal brain MRI. Our findings suggest that serum UCHL1 and pNF-H could be explored as diagnostic and prognostic tools in neonatal HIE. (Pediatr Res 68: 531-536, 2010)	[Douglas-Escobar, Martha] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Yang, Cui; Zheng, Tong; Shaw, Gerry] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA; [Bennett, Jeffrey] Univ Florida, Dept Neuroradiol, Gainesville, FL 32611 USA; [Shuster, Jonathan] Univ Florida, Dept Epidemiol & Hlth Policy Res, Gainesville, FL 32611 USA; [Leibovici, Avital; Rossignol, Candace; Weiss, Michael D.] Univ Florida, Dept Pediat, Gainesville, FL 32611 USA; [Kays, David] Univ Florida, Dept Pediat Surg, Gainesville, FL 32611 USA; [Shuster, Jonathan; Theriaque, Douglas] Univ Florida, Clin & Translat Sci Inst, Gainesville, FL 32610 USA	Douglas-Escobar, M (corresponding author), Baylor Coll Med, Dept Pediat, 6621 Fannin MC WT 6-145, Houston, TX 77030 USA.	douglase@bcm.edu	, Gerry/X-2377-2019		National Institute of Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR00082, U54RR025208]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA;  [NS02198]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002198] Funding Source: NIH RePORTER	Supported, in part, by Grants M01RR00082 and U54RR025208 from the National Institute of Research Resources and National Institutes of Health and by Grant NS02198 [M.D.W.].	Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Boylan K, 2009, J NEUROCHEM, V111, P1182, DOI 10.1111/j.1471-4159.2009.06386.x; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Gunn AJ, 1998, PEDIATRICS, V102, P1098, DOI 10.1542/peds.102.5.1098; Guy J, 2008, MOL VIS, V14, P2443; HARRIS J, 1991, J NEUROSCI RES, V30, P47, DOI 10.1002/jnr.490300107; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Ramaswamy V, 2009, PEDIATR NEUROL, V40, P215, DOI 10.1016/j.pediatrneurol.2008.09.026; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; SHAW G, 1982, NATURE, V298, P277, DOI 10.1038/298277a0; Shaw G, 1998, NEUROFILAMENTS; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, pA61; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Thorngren-Jerneck K, 2004, PEDIATR RES, V55, P406, DOI 10.1203/01.PDR.0000106806.75086.D3; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630	19	56	59	0	11	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 W CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	DEC	2010	68	6					531	536		10.1203/PDR.0b013e3181f85a03			6	Pediatrics	Pediatrics	683YY	WOS:000284515400014	20736881	Green Accepted, Bronze			2021-06-18	
J	Green, DM; O'Phelan, KH; Bassin, SL; Chang, CWJ; Stern, TS; Asai, SM				Green, Deborah M.; O'Phelan, Kristine H.; Bassin, Sarice L.; Chang, Cherylee W. J.; Stern, Tracy S.; Asai, Susan M.			Intensive Versus Conventional Insulin Therapy in Critically Ill Neurologic Patients	NEUROCRITICAL CARE			English	Article						Insulin; Glucose; Intensive care unit; Mortality; Stroke; Traumatic brain injury; Intensive insulin therapy; ICU	GLUCOSE LEVEL; BRAIN-INJURY; HYPERGLYCEMIA; THROMBOLYSIS; METABOLISM; STROKE; IMPACT	Previous studies of glycemic control in non-neurologic ICU patients have shown conflicting results. The purpose was to investigate whether intensive insulin therapy (IIT) to keep blood glucose levels from 80 to 110 mg/dl or conventional treatment to keep levels less than 151 mg/dl was associated with a reduction of mortality and improved functional outcome in critically ill neurologic patients. Within 24 h of ICU admission, mechanically ventilated adult neurologic patients were enrolled after written informed consent and randomized to intensive or conventional control of blood glucose levels with insulin. Primary outcome measure was death within 3 months. Secondary outcome measures included 90-day modified Rankin scale (mRS) score, ICU, and hospital LOS. 81 patients were enrolled. The proportion of deaths was higher among IIT patients but this was not statistically significant (36 vs. 25%, P = 0.34). When good versus poor outcome at 3 months was dichotomized to mRS score 0-2 versus 3-6, respectively, there was no difference in outcome between the two groups (76.2 vs. 75% had a poor 3-month outcome, P = 1.0). There was also no difference in ICU or hospital LOS. Hypoglycemia (< 60 mg/dl) and severe hypoglycemia (< 40 mg/dl) were more common in the intensive arm (48 vs. 11%, P = 0.0006; and 4 vs. 0%, P = 0.5, respectively). There was no benefit to IIT in this small critically ill neurologic population. This is the first glycemic control study to specifically examine both critically ill stroke and traumatic brain injury (TBI) patients and functional outcome. Given these results, IIT cannot be recommended over conventional control.	[Green, Deborah M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [O'Phelan, Kristine H.] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Bassin, Sarice L.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Chang, Cherylee W. J.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA; [Stern, Tracy S.; Asai, Susan M.] Queens Med Ctr, Honolulu, HI USA	Green, DM (corresponding author), Boston Univ, Sch Med, Boston, MA 02118 USA.	deborah.green@bmc.org	Chang, Cherylee/Y-8450-2019; Chang, Cherylee/ABG-2080-2020	Green-LaRoche, MD, Deborah/0000-0001-8158-0788	American Heart AssociationAmerican Heart Association; HMSA Foundation; Abbott LaboratoriesAbbott Laboratories; Queen Emma Foundation	This research was supported by grants from the American Heart Association, HMSA Foundation, Abbott Laboratories, and The Queen Emma Foundation. The Glucommander software was provided by American Healthways for a several month trial period though not specifically for the study, and was later purchased by the medical center. The findings and conclusions of this study do not necessarily represent the views of The Queen's Medical Center. Special thanks to the following people who contributed to the data collection, statistical analysis and advice regarding the study: Gheorghe Doros, PhD, Harlan Meyer, MD, PhD, Johnna Delcastillo, Lyle Oshita, RN, Edward Helekahi, RN, Eileen Cacal, RN, and Lisa Wagner, RN.	Baird TA, 2003, STROKE, V34, P2208, DOI 10.1161/01.STR.0000085087.41330.FF; Bruno A, 1999, NEUROLOGY, V52, P280, DOI 10.1212/WNL.52.2.280; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Davidson PC, 2005, DIABETES CARE, V28, P2418, DOI 10.2337/diacare.28.10.2418; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Els T, 2002, CEREBROVASC DIS, V13, P89, DOI 10.1159/000047756; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Kase CS, 2001, NEUROLOGY, V57, P1603, DOI 10.1212/WNL.57.9.1603; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Van den Berghe G, 2003, CRIT CARE MED, V31, P359, DOI 10.1097/01.CCM.0000045568.12881.10; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F	20	56	62	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2010	13	3					299	306		10.1007/s12028-010-9417-3			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	685UO	WOS:000284653800002	20697836				2021-06-18	
J	Rao, V; Bertrand, M; Rosenberg, P; Makley, M; Schretlen, DJ; Brandt, J; Mielke, MM				Rao, Vani; Bertrand, Melaine; Rosenberg, Paul; Makley, Michael; Schretlen, David J.; Brandt, Jason; Mielke, Michelle M.			Predictors of New-Onset Depression After Mild Traumatic Brain Injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MAJOR DEPRESSION; CONCUSSION; LIFE	Mild traumatic brain injury (TBI) is the most common form of TBI. Most people recover after mild TBI, but a small percentage continues to have persistent problems, predominantly depression. There is, however, minimal literature on the risk factors associated with mild TBI depression. In a sample of 43 mild TBI patients, followed longitudinally for 1 year, the prevalence of new-onset depression was found to be 18%. Older age and presence of frontal subdural hemorrhage were the only two significant findings noted in the depressed group compared with the nondepressed group. Identifying risk factors for mild TBI depression can aid in early diagnosis and treatment. (The Journal of Neuropsychiatry and Clinical Neurosciences 2010; 22:100-104)	[Rao, Vani; Bertrand, Melaine; Rosenberg, Paul; Mielke, Michelle M.] Johns Hopkins Univ, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Johns Hopkins Sch Med, Baltimore, MD 21224 USA; [Makley, Michael] Univ Maryland, Dept Neurol, Baltimore, MD 21201 USA; [Schretlen, David J.; Brandt, Jason] Johns Hopkins Sch Med, Div Med Psychol, Dept Psychiat, Baltimore, MD USA; [Brandt, Jason] Johns Hopkins Sch Med, Div Med Psychol, Dept Neurol, Baltimore, MD USA	Rao, V (corresponding author), Johns Hopkins Univ, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Johns Hopkins Sch Med, 5300 Alpha Commons Dr,4th Floor,444, Baltimore, MD 21224 USA.	vrao@jhmi.edu		Brandt, Jason/0000-0001-7381-6244; Mielke, Michelle/0000-0001-7177-1185	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 066894]; Forest; PfizerPfizer; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894] Funding Source: NIH RePORTER	This study was supported by grant K23 MH 066894 from the NIMH. The abstract was presented at the 2008 annual neuropsychiatry conference in Savannah, Ga. Dr. Rao has a grant from Forest to conduct a clinical trial in post-TBI depression and a grant from Pfizer to conduct a clinical trial in poststroke anxiety. Dr. Jason Brandt receives royalties from Psychological Assessment Resources, Inc., on sales of Hopkins Verbal Learning Test and Dr. David Schretlen on sales of Brief Test of Attention. There are no conflicts of interest to declare by other authors on this paper.	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Beekman ATF, 1997, PSYCHOL MED, V27, P1397, DOI 10.1017/S0033291797005734; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	15	56	56	0	8	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2010	22	1					100	104		10.1176/jnp.2010.22.1.100			5	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	555VO	WOS:000274544500013	20160216	Green Accepted			2021-06-18	
J	Witt, ST; Lovejoy, DW; Pearlson, GD; Stevens, MC				Witt, Suzanne T.; Lovejoy, David W.; Pearlson, Godfrey D.; Stevens, Michael C.			Decreased prefrontal cortex activity in mild traumatic brain injury during performance of an auditory oddball task	BRAIN IMAGING AND BEHAVIOR			English	Article						fMRI; Mild TBI; Auditory oddball; Working memory; Executive function	CLOSED-HEAD-INJURY; WORKING-MEMORY CAPACITY; EVENT-RELATED POTENTIALS; NEUROPSYCHOLOGICAL DEFICITS; INDIVIDUAL-DIFFERENCES; TARGET DETECTION; FMRI; ATTENTION; P300; CONCUSSION	Up to one-third of patients with mild traumatic brain injury (TBI) demonstrate persistent cognitive deficits in the 'executive' function domain. Mild TBI patients have shown prefrontal cortex activity deficits during the performance of executive tasks requiring active information maintenance and manipulation. However, it is unclear whether these deficits are related to the executive processes themselves, or to the degree of mental effort. To determine whether prefrontal deficits also would be found during less effortful forms of executive ability, fMRI images were obtained on 31 mild TBI patients and 31 control participants during three-stimulus auditory oddball task performance. Although patients and controls had similar topographical patterns of brain activity, region-of-interest analysis revealed significantly decreased activity in right dorsolateral prefrontal cortex for mild TBI patients during target stimulus detection. Between-group analyses found evidence for potential compensatory brain activity during target detection and default-mode network dysfunction only during the detection of novel stimuli.	[Witt, Suzanne T.; Pearlson, Godfrey D.; Stevens, Michael C.] Hartford Hosp, Olin Neuropsychiat Res Ctr, Inst Living, Hartford, CT 06106 USA; [Lovejoy, David W.] Hartford Hosp, Dept Neurosurg, Hartford, CT 06106 USA; [Lovejoy, David W.] Univ Connecticut, Sch Med, Dept Traumatol & Emergency Med, Farmington, CT USA; [Pearlson, Godfrey D.; Stevens, Michael C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA; [Pearlson, Godfrey D.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA	Witt, ST (corresponding author), Hartford Hosp, Olin Neuropsychiat Res Ctr, Inst Living, 200 Retreat Ave,Whitehall Bldg, Hartford, CT 06106 USA.	stwitt@harthosp.org	Stevens, Michael/M-7678-2017	Stevens, Michael/0000-0002-3799-5465; Witt, Suzanne/0000-0002-5530-0807			Alvarez-Nunez F, 2006, THYROID, V16, P17, DOI 10.1089/thy.2006.16.17; ALVES W, 1993, J HEAD TRAUMA REHAB, V8, P60; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bleckley MK, 2003, PSYCHON B REV, V10, P884, DOI 10.3758/BF03196548; Brett M, 2002, NAT REV NEUROSCI, V3, P243, DOI 10.1038/nrn756; Calhoun VD, 2004, NEUROIMAGE, V22, P252, DOI 10.1016/j.neuroimage.2003.12.029; Calhoun VD, 2006, NEUROIMAGE, V30, P544, DOI 10.1016/j.neuroimage.2005.08.060; Campbell K., 1986, ELECTROENCEPHALOGR S, V38, P486; CAMPBELL KB, 1990, ELECTROEN CLIN NEURO, P202; Carpenter PA, 2000, CURR OPIN NEUROBIOL, V10, P195, DOI 10.1016/S0959-4388(00)00074-X; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Colflesh GJH, 2007, PSYCHON B REV, V14, P699, DOI 10.3758/BF03196824; Conway A.R.A., 2007, VARIATION WORKING ME; Cripe LI, 1987, COGNITIVE REHABILITA, V5, P18; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Duncan CC, 2005, INT J PSYCHOPHYSIOL, V58, P133, DOI 10.1016/j.ijpsycho.2005.05.011; Duncan CC, 2003, PSYCHOPHYSIOLOGY, V40, P45, DOI 10.1111/1469-8986.00006; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Elliott EM, 2006, EUR J COGN PSYCHOL, V18, P90, DOI 10.1080/09541440500216044; First M.B., 1996, STRUCTURED CLIN INTE; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Freire L, 2002, IEEE T MED IMAGING, V21, P470, DOI 10.1109/TMI.2002.1009383; Freire L, 2001, NEUROIMAGE, V14, P709, DOI 10.1006/nimg.2001.0869; FRIEDMAN D, 1993, PSYCHOL AGING, V8, P120, DOI 10.1037/0882-7974.8.1.120; Friedman D, 2009, HUM BRAIN MAPP, V30, P1144, DOI 10.1002/hbm.20587; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; GENTILINI M, 1989, MILD HEAD INJURY, P163; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Josephs O, 1999, PHILOS T R SOC B, V354, P1215, DOI 10.1098/rstb.1999.0475; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kiehl KA, 2005, NEUROIMAGE, V25, P899, DOI 10.1016/j.neuroimage.2004.12.035; Kiehl KA, 2001, PSYCHOPHYSIOLOGY, V38, P133, DOI 10.1111/1469-8986.3810133; Kirino E, 2000, J NEUROSCI, V20, P6612, DOI 10.1523/JNEUROSCI.20-17-06612.2000; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; Lancaster JL, 1997, HUM BRAIN MAPP, V5, P238, DOI 10.1002/(SICI)1097-0193(1997)5:4<238::AID-HBM6>3.0.CO;2-4; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Linden DEJ, 2005, NEUROSCIENTIST, V11, P563, DOI 10.1177/1073858405280524; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCarthy G, 1997, J NEUROPHYSIOL, V77, P1630; McCrea M, 2008, MILD TRAUMATIC BRAIN; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Naatanen R, 1986, Electroencephalogr Clin Neurophysiol Suppl, V38, P169; Naatanen R, 2004, CLIN NEUROPHYSIOL, V115, P140, DOI 10.1016/j.clinph.2003.04.001; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Poole BJ, 2009, Q J EXP PSYCHOL, V62, P1430, DOI 10.1080/17470210802479329; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Redick TS, 2006, APPL COGNITIVE PSYCH, V20, P713, DOI 10.1002/acp.1224; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; SMITH ME, 1990, ELECTROEN CLIN NEURO, V76, P235, DOI 10.1016/0013-4694(90)90018-F; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stevens MC, 2005, PSYCHOPHYSIOLOGY, V42, P636, DOI 10.1111/j.1469-8986.2005.00368.x; Stevens MC, 2005, NEUROIMAGE, V26, P782, DOI 10.1016/j.neuroimage.2005.02.044; Stevens MC, 2007, AM J PSYCHIAT, V164, P1737, DOI 10.1176/appi.ajp.2007.06050876; Stranjalis G, 2008, J TRAUMA, V65, P789, DOI 10.1097/TA.0b013e3181469e26; Strobel A, 2008, NEUROIMAGE, V40, P869, DOI 10.1016/j.neuroimage.2007.10.065; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; von Wild KRH, 2008, ACT NEUR S, V101, P55; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255	109	56	57	0	13	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	DEC	2010	4	3-4					232	247		10.1007/s11682-010-9102-3			16	Neuroimaging	Neurosciences & Neurology	658SB	WOS:000282508600004	20703959				2021-06-18	
J	Colantonio, A; Harris, JE; Ratcliff, G; Chase, S; Ellis, K				Colantonio, Angela; Harris, Jocelyn E.; Ratcliff, Graham; Chase, Susan; Ellis, Kristina			Gender differences in self reported long term outcomes following moderate to severe traumatic brain injury	BMC NEUROLOGY			English	Article							SEX-DIFFERENCES; SLEEP DISTURBANCE; HEAD-INJURY; HEALTH; POPULATION; HOSPITALIZATION; REHABILITATION; EPIDEMIOLOGY; ADJUSTMENT; ANXIETY	Background: The majority of research on health outcomes after a traumatic brain injury is focused on male participants. Information examining gender differences in health outcomes post traumatic brain injury is limited. The purpose of this study was to investigate gender differences in symptoms reported after a traumatic brain injury and to examine the degree to which these symptoms are problematic in daily functioning. Methods: This is a secondary data analysis of a retrospective cohort study of 306 individuals who sustained a moderate to severe traumatic brain injury 8 to 24 years ago. Data were collected using the Problem Checklist (PCL) from the Head Injury Family Interview (HIFI). Using Bonferroni correction, group differences between women and men were explored using Chi-square and Wilcoxon analysis. Results: Chi-square analysis by gender revealed that significantly more men reported difficulty setting realistic goals and restlessness whereas significantly more women reported headaches, dizziness and loss of confidence. Wilcoxon analysis by gender revealed that men reported sensitivity to noise and sleep disturbances as significantly more problematic than women, whereas for women, lack of initiative and needing supervision were significantly more problematic in daily functioning. Conclusion: This study provides insight into gender differences on outcomes after traumatic brain injury. There are significant differences between problems reported by men compared to women. This insight may facilitate health service planners and clinicians when developing programs for individuals with brain injury.	[Colantonio, Angela; Harris, Jocelyn E.] Toronto Rehabil Inst, Toronto, ON, Canada; [Colantonio, Angela; Ellis, Kristina] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Chase, Susan] Working Order, Sharpsburg, PA USA	Colantonio, A (corresponding author), Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34740-2]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [F33 AGO5856-01A1]; Washington County Brain Injury Association; Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Toronto Rehabilitation InstituteUniversity of Toronto; CIHR Fellowship AwardCanadian Institutes of Health Research (CIHR); Strategic Training Fellowship in Health Care, Technology and Place [FRN: STP 53911]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034740] Funding Source: NIH RePORTER	Funding for this study was obtained from NINDS (NS34740-2), NIA (F33 AGO5856-01A1), Washington County Brain Injury Association, the Canadian Institutes for Health Research and the Toronto Rehabilitation Institute. Support for this study was given to JEH in a CIHR Fellowship Award and a Strategic Training Fellowship in Health Care, Technology and Place (FRN: STP 53911).	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Attias J., 2005, Journal of Basic and Clinical Physiology and Pharmacology, V16, P117; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Bay E, 2009, J NEUROSCI NURS, V41, P298, DOI 10.1097/JNN.0b013e3181b6be81; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; LANGELY RL, 2003, SEX GENDER DIFFERENC; MacIntyre S, 1996, SOC SCI MED, V42, P617, DOI 10.1016/0277-9536(95)00335-5; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PAVUR R, 1988, AM STAT, V42, P171, DOI 10.2307/2684994; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sankoh AJ, 1997, STAT MED, V16, P2529, DOI 10.1002/(SICI)1097-0258(19971130)16:22<2529::AID-SIM692>3.0.CO;2-J; Schopp LH, 2001, J CLIN PSYCHOL MED S, V8, P181, DOI 10.1023/A:1011369620254; Slewa-Younan S, 2008, J NEUROL NEUROSUR PS, V79, P1197, DOI 10.1136/jnnp.2008.147983; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; Tate D G, 2001, Phys Med Rehabil Clin N Am, V12, P23; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; VERBRUGGE LM, 1989, J HEALTH SOC BEHAV, V30, P282, DOI 10.2307/2136961; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	51	56	57	1	20	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1471-2377		BMC NEUROL	BMC Neurol.	OCT 28	2010	10								102	10.1186/1471-2377-10-102			7	Clinical Neurology	Neurosciences & Neurology	697ZB	WOS:000285557200001	21029463	DOAJ Gold, Green Published			2021-06-18	
J	Ban, SP; Son, YJ; Yang, HJ; Chung, YS; Lee, SH; Han, DH				Ban, Seung Pil; Son, Young-Je; Yang, Hee-Jin; Chung, Yeong Seob; Lee, Sang Hyung; Han, Dae Hee			Analysis of Complications Following Decompressive Craniectomy for Traumatic Brain Injury	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						Decompressive craniectomy; Traumatic brain injury; Complication	INTRACRANIAL HYPERTENSION; HEAD-INJURY; PRESSURE; HEMICRANIECTOMY; MANAGEMENT; MORTALITY	Objective : Adequate management of increased intracranial pressure (ICP) is critical in patients with traumatic brain injury (TBI), and decompressive craniectomy is widely used to treat refractory increased ICP. The authors reviewed and analyzed complications following decompressive craniectomy for the management of TBI. Methods : A total of 89 consecutive patients who underwent decompressive craniectomy for TBI between February 2004 and February 2009 were reviewed retrospectively. Incidence rates of complications secondary to decompressive craniectomy were determined, and analyses were performed to identify clinical factors associated with the development of complications and the poor outcome. Results : Complications secondary to decompressive craniectomy occurred in 48 of the 89 (53.9%) patients. Furthermore, these complications occurred in a sequential fashion at specific times after surgical intervention; cerebral contusion expansion (2.2 +/- 1.2 days), newly appearing subdural or epidural hematoma contralateral to the craniectomy defect (1.5 +/- 0.9 days), epilepsy (2.7 +/- 1.5 days), cerebrospinal fluid leakage through the scalp incision (7.0 +/- 4.2 days), and external cerebral herniation (5.5 +/- 3.3 days). Subdural effusion (10.8 +/- 5.2 days) and postoperative infection (9.8 +/- 3.1 days) developed between one and four weeks postoperatively. Trephined and post-traumatic hydrocephalus syndromes developed after one month postoperatively (at 79.5 +/- 23.6 and 49.2 +/- 14.1 days, respectively). Conclusion : A poor GCS score (<= 8) and an age of >= 65 were found to be related to the occurrence of one of the above-mentioned complications. These results should help neurosurgeons anticipate these complications, to adopt management strategies that reduce the risks of complications, and to improve clinical outcomes.	[Ban, Seung Pil; Son, Young-Je; Yang, Hee-Jin; Chung, Yeong Seob; Lee, Sang Hyung; Han, Dae Hee] Seoul Natl Univ, Dept Neurosurg, Boramae Med Ctr, Seoul 156707, South Korea	Son, YJ (corresponding author), Seoul Natl Univ, Dept Neurosurg, Boramae Med Ctr, 39 Boramae Gil, Seoul 156707, South Korea.	petitprince1024@hanmail.net	Chung, Young Seob/J-5644-2012; Lee, Sang Hyung/J-5581-2012				Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Boret H, 2006, ACTA ANAESTH SCAND, V50, P252, DOI 10.1111/j.1399-6576.2005.00862.x; CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; Chen JWY, 2009, J REHABIL RES DEV, V46, P685, DOI 10.1682/JRRD.2008.09.0130; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; Cooper P R, 1976, Surg Neurol, V5, P25; Danish SF, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS945; DeWitt D S, 1995, New Horiz, V3, P376; Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442; GAAB MR, 1990, ACT NEUR S, V51, P326; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Huang APH, 2008, J NEUROTRAUM, V25, P1347, DOI 10.1089/neu.2008.0625; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; Makino H, 1979, Acta Neurochir Suppl (Wien), V28, P193; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99; Zunt Joseph R, 2010, Handb Clin Neurol, V96, P125, DOI 10.1016/S0072-9752(09)96009-2	31	56	64	0	4	KOREAN NEUROSURGICAL SOC	SEOUL	BLDG B, #402, 27, CHILPAE-RO, JUNG-GU, SEOUL, 04511, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	SEP	2010	48	3					244	250		10.3340/jkns.2010.48.3.244			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	670DY	WOS:000283402600010	21082053	DOAJ Gold, Green Published			2021-06-18	
J	Mannix, R; Bourgeois, FT; Schutzman, SA; Bernstein, A; Lee, LK				Mannix, Rebekah; Bourgeois, Florence T.; Schutzman, Sara A.; Bernstein, Ari; Lee, Lois K.			Neuroimaging for Pediatric Head Trauma: Do Patient and Hospital Characteristics Influence Who Gets Imaged?	ACADEMIC EMERGENCY MEDICINE			English	Article						craniocerebral trauma; diagnostic imaging; emergency service; hospital	EMERGENCY-DEPARTMENT; COMPUTED-TOMOGRAPHY; UNITED-STATES; INTRACRANIAL INJURY; RACIAL DISPARITIES; SPLENIC INJURIES; DECISION RULE; CHILDREN; RACE/ETHNICITY; CARE	P>Objectives: The objective was to identify patient, provider, and hospital characteristics associated with the use of neuroimaging in the evaluation of head trauma in children. Methods: This was a cross-sectional study of children (< 19 years of age) with head injuries from the National Hospital Ambulatory Medical Care Survey (NHAMCS) collected by the National Center for Health Statistics. NHAMCS collects data on approximately 25,000 visits annually to 600 randomly selected hospital emergency and outpatient departments. This study examined visits to U.S. emergency departments (EDs) between 2002 and 2006. Multivariable logistic regression was used to analyze characteristics associated with neuroimaging in children with head injuries. Results: There were 50,835 pediatric visits in the 5-year sample, of which 1,256 (2.5%, 95% confidence interval [CI] = 2.2% to 2.7%) were for head injury. Among these, 39% (95% CI = 34% to 43%) underwent evaluation with neuroimaging. In multivariable analyses, factors associated with neuroimaging included white race (odds ratio [OR] = 1.5, 95% CI = 1.02 to 2.1), older age (OR = 1.3, 95% CI = 1.1 to 1.5), presentation to a general hospital (vs. a pediatric hospital, OR = 2.4, 95% CI = 1.1 to 5.3), more emergent triage status (OR = 1.4, 95% CI = 1.1 to 1.8), admission or transfer (OR = 2.7, 95% CI = 1.4 to 5.3), and treatment by an attending physician (OR = 2.0, 95% CI = 1.1 to 3.7). The effect of race was mitigated at the pediatric hospitals compared to at the general hospitals (p < 0.001). Conclusions: In this study, patient race, age, and hospital-specific characteristics were associated with the frequency of neuroimaging in the evaluation of children with closed head injuries. Based on these results, focusing quality improvement initiatives on physicians at general hospitals may be an effective approach to decreasing rates of neuroimaging after pediatric head trauma.	[Mannix, Rebekah; Bourgeois, Florence T.; Schutzman, Sara A.; Bernstein, Ari; Lee, Lois K.] Childrens Hosp Boston, Dept Med, Div Emergency Med, Boston, MA 02115 USA	Mannix, R (corresponding author), Childrens Hosp Boston, Dept Med, Div Emergency Med, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Bourgeois, Florence/H-6710-2016	Bourgeois, Florence/0000-0001-7798-4560	National Institutes of Health through the Harvard School of Public Health [T32 MH073122-04]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH073122] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health through the Harvard School of Public Health Interdisciplinary Training Program in Neurodevelopmental Toxicology Award to Dr. Mannix (T32 MH073122-04).	Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P287, DOI 10.1016/S0033-3549(04)50252-2; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Bourgeois FT, 2008, ANN EMERG MED, V52, P599, DOI 10.1016/j.annemergmed.2008.03.012; Bowman SM, 2005, JAMA-J AM MED ASSOC, V294, P2611, DOI 10.1001/jama.294.20.2611; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Chamberlain JM, 2007, PEDIATRICS, V119, pE1319, DOI 10.1542/peds.2006-2309; Conners GP, 1999, PEDIATR EMERG CARE, V15, P241; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Guagliardo MF, 2003, ACAD EMERG MED, V10, P1218, DOI 10.1197/S1069-6563(03)00492-5; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Hostetler MA, 2002, AM J EMERG MED, V20, P139, DOI 10.1053/ajem.2002.33002; James CA, 2005, PEDIATRICS, V115, pE310, DOI 10.1542/peds.2004-1541; Kalauokalani D, 2007, PAIN MED, V8, P17, DOI 10.1111/j.1526-4637.2007.00170.x; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mooney DP, 2006, J TRAUMA, V61, P330, DOI 10.1097/01.ta.0000226167.44892.1d; National Center for Health Statistics, 2009, AMB HLTH CAR DAT; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Pines JM, 2009, ACAD EMERG MED, V16, P403, DOI 10.1111/j.1553-2712.2009.00381.x; Pletcher MJ, 2008, JAMA-J AM MED ASSOC, V299, P70, DOI 10.1001/jama.2007.64; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Tamayo-Sarver JH, 2003, ACAD EMERG MED, V10, P1239, DOI 10.1197/S1069-6563903)00494-9	27	56	56	0	4	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JUL 10	2010	17	7					694	700		10.1111/j.1553-2712.2010.00797.x			7	Emergency Medicine	Emergency Medicine	621VO	WOS:000279613400010	20653582	Green Accepted			2021-06-18	
J	Hinton-Bayre, AD				Hinton-Bayre, Anton D.			Deriving Reliable Change Statistics from Test-Retest Normative Data: Comparison of Models and Mathematical Expressions	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Assessment; Norms; normative studies; Practice effects; reliable change; Statistical methods	SPORT CONCUSSION RESEARCH; CHANGE FORMULA QUERY; NEUROPSYCHOLOGICAL CHANGE; CLINICAL-SIGNIFICANCE; REGRESSION EQUATIONS; CLASSICAL APPROACH; EPILEPSY SURGERY; STANDARD ERROR; TEST-SCORES; JACOBSON	The use of reliable change (RC) statistics to determine whether an individual has significantly improved or deteriorated on retesting is growing rapidly in clinical neuropsychology. This paper demonstrates how with only basic test-retest data and a series of simple expressions, the clinician/researcher can implement the majority of contemporary RC model(s). Though sharing a fundamental structure, RC models vary in how they derive predicted retest scores and standard error terms. Published test-retest normative data and a simple case study are presented to demonstrate how to calculate several well-known RC scores. The paper highlights the circumstances under which models will diverge in the estimation of RC. Most importantly variations in individual's performance relative to controls at initial testing, practice effects, inequality of control variability from test to retest, and degree of reliability will see systematic and predictable disagreement among models. More generally, the limitations and opportunities of RC methodology were discussed. Although a consensus on preferred model continues to be debated, the comparison of RC models in clinical samples is encouraged.	[Hinton-Bayre, Anton D.] Univ Queensland, Sch Med, Princess Alexandra Hosp, Dept Surg, Brisbane, Qld, Australia	Hinton-Bayre, AD (corresponding author), Univ Queensland, Princess Alexandra Hosp, Sch Med, Dept Surg, 199 Ipswich Rd, Woolloongabba, Qld 4102, Australia.	anton.hb@hotmail.com					Abramson IS, 2000, J INT NEUROPSYCH SOC, V6, P365, DOI 10.1017/S1355617700633131; BOYKO EJ, 1990, J CLIN EPIDEMIOL, V43, P851, DOI 10.1016/0895-4356(90)90068-Z; Charter RA, 1996, PERCEPT MOTOR SKILL, V82, P1139, DOI 10.2466/pms.1996.82.3c.1139; Charter RA, 2000, J PSYCHOEDUC ASSESS, V18, P125, DOI 10.1177/073428290001800203; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; CHRISTENSEN L, 1986, BEHAV THER, V17, P305, DOI 10.1016/S0005-7894(86)80060-0; Crawford JR, 2006, NEUROPSYCHOLOGY, V20, P259, DOI 10.1037/0894-4105.20.3.259; Crawford JR, 1998, J CLIN EXP NEUROPSYC, V20, P755, DOI 10.1076/jcen.20.5.755.1132; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; Hinton-Bayre A, 2000, J INT NEUROPSYCH SOC, V6, P362, DOI 10.1017/S1355617700633118; Hinton-Bayre AD, 2005, J INT NEUROPSYCH SOC, V11, P788, DOI 10.1017/S1355617705050940; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Maassen GH, 2006, BRIT J SPORT MED, V40, P829, DOI 10.1136/bjsm.2005.023713; Maassen GH, 2009, J CLIN EXP NEUROPSYC, V31, P339, DOI 10.1080/13803390802169059; Maassen GH, 2005, BRIT J SPORT MED, V39, P483, DOI 10.1136/bjsm.2004.015594; Maassen GH, 2004, J INT NEUROPSYCH SOC, V10, P888, DOI 10.1017/S1355617704106097; McCaffrey RJ, 1995, NEUROPSYCHOL REV, V5, P203, DOI 10.1007/BF02214762; Pepe MS, 2004, AM J EPIDEMIOL, V159, P882, DOI 10.1093/aje/kwh101; Salinsky MC, 2001, J INT NEUROPSYCH SOC, V7, P597, DOI 10.1017/S1355617701755075; Sherman EMS, 2003, J INT NEUROPSYCH SOC, V9, P879, DOI 10.1017/S1355617703960085; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Temkin NR, 2004, J INT NEUROPSYCH SOC, V10, P899, DOI 10.1017/S1355617704106115; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P83, DOI 10.1016/j.acn.2005.07.008	28	56	56	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2010	25	3					244	256		10.1093/arclin/acq008			13	Psychology, Clinical; Psychology	Psychology	587MC	WOS:000276995600010	20197293	Green Published, Bronze			2021-06-18	
J	Caeyenberghs, K; Leemans, A; Geurts, M; Taymans, T; Linden, CV; Smits-Engelsman, BCM; Sunaert, S; Swinnen, SP				Caeyenberghs, K.; Leemans, A.; Geurts, M.; Taymans, T.; Linden, C. Vander; Smits-Engelsman, B. C. M.; Sunaert, S.; Swinnen, S. P.			Brain-behavior relationships in young traumatic brain injury patients: Fractional anisotropy measures are highly correlated with dynamic visuomotor tracking performance	NEUROPSYCHOLOGIA			English	Article						Traumatic brain injury; Diffusion tensor imaging; Children; Manual pursuit; Eye-hand coordination; Motor control	MOVEMENT ASSESSMENT BATTERY; DIFFUSION TENSOR IMAGES; WHITE-MATTER INJURY; PERIVENTRICULAR LEUKOMALACIA; CEREBRAL-PALSY; MOTOR DEFICITS; AXONAL INJURY; CHILDREN; RELIABILITY; MODERATE	Traumatic brain injury (TBI) patients have a high incidence of eye-hand coordination deficits. Diffuse axonal injury is common in TBI and is presumed to contribute to persistent motor problems. Using Diffusion Tensor Imaging (DTI), this study sought to identify changes in (sensori)motor white matter (WM) pathways/regions in a TBI group during the chronic recovery stage. A secondary objective was to examine the relationship between WM integrity and upper-limb visuomotor tracking performance. A young TBI (n = 17) and control (n = 14) group performed a dynamic tracking task, characterized by increasing information processing speed and predictive movement control. DTI scans were administered along with standard anatomical scans. The TBI group was found to perform inferior to the control group on the tracking task. Decreased fractional anisotropy was found in the TBI group in dedicated pathways involved in transmission of afferent and efferent information, i.e., corticospinal tract, posterior thalamic radiation, and optic radiation, due to increased diffusivity parallel and perpendicular to axonal fibre direction. This decrease in WM integrity was associated with inferior visuomotor tracking performance. Moreover, discriminant function analysis demonstrated that the model, based on the combined application of DTI and behavioral measures, was the most effective in distinguishing between TBI patients and controls. This study shows that specific eye-hand coordination deficits in a young TBI group are related to microstructural abnormalities in task-specific cerebral WM structures. Measures of white matter integrity are potentially important biomarkers for TBI that may support prognosis of motor deficits. (C) 2010 Elsevier Ltd. All rights reserved.	[Swinnen, S. P.] Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, B-3001 Heverlee, Belgium; [Leemans, A.] Univ Med Ctr Utrecht, Dept Radiol, Image Sci Inst, Utrecht, Netherlands; [Leemans, A.] Cardiff Univ, Sch Psychol, CUBRIC, Cardiff, S Glam, Wales; [Linden, C. Vander] Ghent Univ Hosp, Dept Phys Med & Rehabil, Child Rehabil Ctr, Ghent, Belgium; [Smits-Engelsman, B. C. M.] Univ Profess, Avans, Breda, Netherlands; [Sunaert, S.] Katholieke Univ Leuven, Univ Hosp, Dept Radiol, B-3001 Heverlee, Belgium	Swinnen, SP (corresponding author), Katholieke Univ Leuven, Lab Motor Control, Res Ctr Motor Control & Neuroplast, Grp Biomed Sci, Tervuursevest 101, B-3001 Heverlee, Belgium.	Karen.Caeyenberghs@faber.kuleuven.be; Stephan.Swinnen@faber.kuleuven.be	Leemans, Alexander/A-1784-2011; Sunaert, Stefan/E-8031-2011	Leemans, Alexander/0000-0002-9306-6126; Sunaert, Stefan/0000-0002-1177-4680; Caeyenberghs, Karen/0000-0001-7009-6843	Research Foundation-Flanders (FWO)FWO [7.0004.05]; Belgian federal government [P6/29]	Support for this study was provided through a grant from the Research Programme of the Research Foundation-Flanders (FWO) (Levenslijn # 7.0004.05), as well as Grant P6/29 from the Interuniversity Attraction Poles program of the Belgian federal government. Caeyenberghs K. is funded by a PhD fellowship of the Research Foundation-Flanders (FWO).	Aralasmak A, 2006, J COMPUT ASSIST TOMO, V30, P695, DOI 10.1097/01.rct.0000226397.43235.8b; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Basser PJ, 2000, MAGNET RESON MED, V44, P625, DOI 10.1002/1522-2594(200010)44:4<625::AID-MRM17>3.0.CO;2-O; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bleyenheuft Y, 2007, PEDIATRICS, V120, pE1502, DOI 10.1542/peds.2007-0394; Bookheimer SY, 2000, MENT RETARD DEV D R, V6, P161, DOI 10.1002/1098-2779(2000)6:3<161::AID-MRDD2>3.3.CO;2-N; Byars AW, 2002, J CHILD NEUROL, V17, P885, DOI 10.1177/08830738020170122201; Caeyenberghs K, 2009, BRAIN, V132, P684, DOI 10.1093/brain/awn344; Caeyenberghs K, 2009, J HEAD TRAUMA REHAB, V24, P363, DOI 10.1097/HTR.0b013e3181af0810; Concha L, 2006, NEUROIMAGE, V32, P1090, DOI 10.1016/j.neuroimage.2006.04.187; Croce RV, 2001, PERCEPT MOTOR SKILL, V93, P275, DOI 10.2466/pms.2001.93.1.275; DAVIDOFF RA, 1990, NEUROLOGY, V40, P332; DeJong WP, 1996, HANDWRITING AND DRAWING RESEARCH, P429; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Foulder-Hughes L., 2003, BRIT J OCCUPATIONAL, V66, P9; Gaillard WD, 2001, NEUROIMAGE, V13, P239, DOI 10.1006/nimg.2000.0681; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Galea MP, 1997, J COMP NEUROL, V381, P307; Heitger MH, 2007, J NEUROL SCI, V253, P34, DOI 10.1016/j.jns.2006.11.007; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Henderson S. E., 1992, MOVEMENT ASSESSMENT; Hong JH, 2009, BRAIN RES BULL, V80, P30, DOI 10.1016/j.brainresbull.2009.05.021; Hoon AH, 2002, NEUROLOGY, V59, P752, DOI 10.1212/WNL.59.5.752; Hoon AH, 2009, DEV MED CHILD NEUROL, V51, P697, DOI 10.1111/j.1469-8749.2009.03306.x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 2004, MAGN RESON MED, V52, P979, DOI 10.1002/mrm.20283; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; KAMALI A, 2001, EUROPEAN RADIOLOGY, V19, P1480; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lancaster JL, 2007, HUM BRAIN MAPP, V28, P1194, DOI 10.1002/hbm.20345; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Leemans A, 2005, LECT NOTES COMPUT SC, V3708, P523; Leemans A., 2009, 17 ANN M INT SOC MAG, P3537; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Lemon RN, 1997, NEUROSCIENTIST, V3, P389, DOI 10.1177/107385849700300612; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Miall RC, 2001, NAT NEUROSCI, V4, P638, DOI 10.1038/88465; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S., 2005, MRI ATLAS HUMAN WHIT; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nagae LM, 2007, AM J NEURORADIOL, V28, P1213, DOI 10.3174/ajnr.A0534; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rivkin MJ, 2000, MENT RETARD DEV D R, V6, P68, DOI 10.1002/(SICI)1098-2779(2000)6:1<68::AID-MRDD9>3.0.CO;2-9; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schaechter JD, 2009, HUM BRAIN MAPP, V30, P3461, DOI 10.1002/hbm.20770; Schneider KA, 2004, J NEUROSCI, V24, P8975, DOI 10.1523/JNEUROSCI.2413-04.2004; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smits-Engelsman BC, 1998, MOVEMENT ASSESSMENT; Smits-Engelsman BCM, 1998, HUM MOVEMENT SCI, V17, P699, DOI 10.1016/S0167-9457(98)00019-0; Smits-Engelsman BCM, 2008, PHYS THER, V88, P286, DOI 10.2522/ptj.20070068; Stamatakis EA, 2002, J NUCL MED, V43, P476; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; TERAYAMA Y, 1991, J CEREBR BLOOD F MET, V11, P852, DOI 10.1038/jcbfm.1991.145; Thomas B, 2005, BRAIN, V128, P2562, DOI 10.1093/brain/awh600; van Hartingsveldt Margo J, 2005, Occup Ther Int, V12, P1, DOI 10.1002/oti.11; Van Hecke W, 2008, NEUROIMAGE, V43, P69, DOI 10.1016/j.neuroimage.2008.07.006; Van Hecke W, 2007, IEEE T MED IMAGING, V26, P1598, DOI 10.1109/TMI.2007.906786; van Roon D, 2008, CHILD DEV, V79, P852, DOI 10.1111/j.1467-8624.2008.01163.x; Van Waelvelde H, 2007, CLIN REHABIL, V21, P465, DOI 10.1177/0269215507074052; Wechsler D., 1991, WECHSLER INTELLIGENC; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilke M, 2003, NEUROPEDIATRICS, V34, P225; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	77	56	57	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	APR	2010	48	5					1472	1482		10.1016/j.neuropsychologia.2010.01.017			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	584RR	WOS:000276770800032	20117121				2021-06-18	
J	Stuart, RM; Schmidt, M; Kurtz, P; Waziri, A; Helbok, R; Mayer, SA; Lee, K; Badjatia, N; Hirsch, LJ; Connolly, ES; Claassen, J				Stuart, R. Morgan; Schmidt, Michael; Kurtz, Pedro; Waziri, Allen; Helbok, Raimund; Mayer, Stephan A.; Lee, Kiwon; Badjatia, Neeraj; Hirsch, Lawrence J.; Connolly, E. Sander; Claassen, Jan			Intracranial Multimodal Monitoring for Acute Brain Injury: A Single Institution Review of Current Practices	NEUROCRITICAL CARE			English	Article						Intracranial monitoring; Multimodality brain monitoring; Acute brain injury; Microdialysis; Brain oxygen; Neurological intensive care unit; Subarachnoid hemorrhage; Intracerebral hemorrhage; Traumatic brain injury; Stroke; Depth electrode; Neurocritical care; EEG; Nonconvulsive seizures; Intracortical EEG (ICE)	CEREBRAL PERFUSION-PRESSURE; PROVINCIAL TRAUMA CENTER; FRESH-FROZEN PLASMA; WAVE-FORM ANALYSIS; DELIVERY 1 YEAR; HEAD-INJURY; TISSUE OXYGEN; SUBARACHNOID HEMORRHAGE; RESOURCE UTILIZATION; CLINICAL-EXPERIENCE	Critical care management of patients with severe acute brain injury has undergone tremendous advances. Neurosurgeons and neurointensivists have a large armamentarium of invasive monitoring devices available to help detect secondary brain injury and guide therapy. No consensus exists regarding patient specific selection of monitoring devices, the placement of devices in relation to injured brain tissue, or the preferred insertion technique. Here we review our experience in a consecutive series of acutely brain injured patients who underwent multimodality monitoring. Sixty-one patients admitted to the Neurological Intensive Care Unit underwent multimodality intracranial monitoring between January 2005 and October 2008. Patient demographics, hospital length of stay, types of monitoring devices and modalities monitored, insertion techniques, device placement location relative to injury, and complications are reported. Monitored modalities included brain tissue oxygen (PbtO(2)) in 97% (N = 59), microdialysis (MD) in 79% (N = 48), intracranial electroencephalography in 31% (N = 19), brain temperature in 18% (N = 11), and cerebral blood flow in 11% (N = 7). On average, monitoring started within 2 days (0-8) of admission and was continued for 7 days (1-17). The majority of probes (56%; N = 35) were placed into patients with focal brain injuries, while in 43% N = 26 the injury was diffuse. Among those with focal injury, probe placement was categorized as peri-lesional in 46% (N = 16), and within a clot or infarct in 17% (N = 6). The most frequent complication of multimodality brain monitoring was device malfunction or dislodgement (43%; N = 26). Rates of hematoma and infection were 3 and 5%, respectively. Average NICU length of stay was 17 days (3-48) and 26% (N = 16) of patients were dead at discharge. Collaboration among institutions is necessary to establish practice guidelines for the choice and placement of multimodal monitors. Further advancement in device technology is needed to improve insertion techniques, inter-device compatibility, and device durability. Multimodality data needs to be analyzed to determine the preferable device location.	[Schmidt, Michael; Kurtz, Pedro; Helbok, Raimund; Mayer, Stephan A.; Lee, Kiwon; Badjatia, Neeraj; Claassen, Jan] Columbia Univ, Div Crit Care Neurol, Dept Neurol, Coll Phys & Surg, New York, NY 10032 USA; [Stuart, R. Morgan; Waziri, Allen; Mayer, Stephan A.; Lee, Kiwon; Badjatia, Neeraj; Connolly, E. Sander; Claassen, Jan] Columbia Univ, Dept Neurol Surg, Coll Phys & Surg, New York, NY 10032 USA; [Hirsch, Lawrence J.; Claassen, Jan] Columbia Univ, Dept Neurol, Coll Phys & Surg, Comprehens Epilepsy Ctr, New York, NY 10032 USA	Claassen, J (corresponding author), Columbia Univ, Div Crit Care Neurol, Dept Neurol, Coll Phys & Surg, 177 Ft Washington Ave,Milstein 8 Ctr Room 300, New York, NY 10032 USA.	jclaassen@neuro.columbia.edu	Claassen, Jan/AAA-5451-2020; Helbok, Raimund/AAA-8361-2021	Hirsch, Lawrence/0000-0002-6333-832X			[Anonymous], 1994, JAMA, V271, P777; Bardt TF, 1998, ACTA NEUROCHIR, V140, P357, DOI 10.1007/s007010050109; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P551; Birch AA, 2006, NEUROCRIT CARE, V5, P51, DOI 10.1385/NCC:5:1:51; Czosnyka M, 1996, CEREBROVAS BRAIN MET, V8, P273; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; CZOSNYKA M, 1992, ACTA NEUROCHIR, V115, P90, DOI 10.1007/BF01406364; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Dings J, 1998, NEUROL RES, V20, pS71; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Engstrom M, 2005, J NEUROSURG, V102, P460, DOI 10.3171/jns.2005.102.3.0460; Frontera JA, 2008, NEUROSURGERY, V62, P80, DOI 10.1227/01.NEU.0000311064.18368.EA; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Hlatky R, 2001, SEMIN RESP CRIT CARE, V22, P3, DOI 10.1055/s-2001-13835; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Kirkpatrick PJ, 1996, J NEUROL NEUROSUR PS, V60, P131, DOI 10.1136/jnnp.60.2.131; Lozier AP, 2008, NEUROSURGERY, V62, P688, DOI [10.1227/01.NEU.0000017465.78245.6C, 10.1227/01.neu.0000316273.35833.7c]; Mack William J, 2003, Neurosurg Focus, V14, pe3; Meixensberger J, 1998, ACT NEUR S, V71, P260; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Radolovich DK, 2009, NEUROCRIT CARE, V10, P274, DOI 10.1007/s12028-009-9190-3; Rumana CS, 1998, CRIT CARE MED, V26, P562, DOI 10.1097/00003246-199803000-00032; Simons R, 1999, J TRAUMA, V46, P811, DOI 10.1097/00005373-199905000-00008; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; Springborg JB, 2005, BRIT J ANAESTH, V94, P259, DOI 10.1093/bja/aei004; Steiner T, 2001, STROKE, V32, P2500, DOI 10.1161/hs1101.097400; Stewart C, 2008, NEUROSURGERY, V63, P1159, DOI 10.1227/01.NEU.0000333265.19131.7C; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Waziri AE, 2007, EPILEPSIA, V48, P208; Winchell RJ, 1998, J TRAUMA, V45, P104	33	56	57	1	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2010	12	2					188	198		10.1007/s12028-010-9330-9			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	573IL	WOS:000275905800008	20107926				2021-06-18	
J	Koutures, CG; Gregory, AJM				Koutures, Chris G.; Gregory, Andrew J. M.		Council Sports Med Fitness	Clinical Report-Injuries in Youth Soccer	PEDIATRICS			English	Article						soccer; concussion; knee injury; anterior cruciate ligament tear	CRUCIATE LIGAMENT INJURIES; FOOTBALL SOCCER; HEAD-INJURIES; CONSENSUS STATEMENT; BRAIN-INJURY; RISK-FACTORS; FEMALE; CONCUSSIONS; PLAYERS	Injury rates in youth soccer, known as football outside the United States, are higher than in many other contact/collision sports and have greater relative numbers in younger, preadolescent players. With regard to musculoskeletal injuries, young females tend to suffer more knee injuries, and young males suffer more ankle injuries. Concussions are fairly prevalent in soccer as a result of contact/collision rather than purposeful attempts at heading the ball. Appropriate rule enforcement and emphasis on safe play can reduce the risk of soccer-related injuries. This report serves as a basis for encouraging safe participation in soccer for children and adolescents. Pediatrics 2010; 125:410-414								*AM YOUTH SOCC ORG, AB AYSO; Arendt EA, 1999, J ATHL TRAINING, V34, P86; Bergeron Michael F, 2007, New Dir Youth Dev, P27; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; *CDCP, HEADS CONC HIGH SCH; *CINC CHILDR HOSP, ACL INJ TREATM PREV; Collins CL, 2008, INJURY PREV, V14, P34, DOI 10.1136/ip.2007.017277; Crichlow R, 2006, CLIN J SPORT MED, V16, P352, DOI 10.1097/00042752-200607000-00012; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Delaney JS, 2005, CLIN J SPORT MED, V15, P212; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Emery CA, 2006, AM J SPORT MED, V34, P1636, DOI 10.1177/0363546506288018; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Gilchrist J, 2008, AM J SPORT MED, V36, P1476, DOI 10.1177/0363546508318188; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Hewett TE, 2006, AM J SPORT MED, V34, P490, DOI 10.1177/0363546505282619; Hewett TE, 2006, AM J SPORT MED, V34, P299, DOI 10.1177/0363546505284183; Houshian S, 2000, BRIT J SPORT MED, V34, P218, DOI 10.1136/bjsm.34.3.218; Ireland ML, 2002, ORTHOP CLIN N AM, V33, P637, DOI 10.1016/S0030-5898(02)00028-7; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; Kakavelakis KN, 2003, SCAND J MED SCI SPOR, V13, P175, DOI 10.1034/j.1600-0838.2003.00294.x; Kirkendall D. T., 2002, Medicine & Science in Sports & Exercise, V34, pS101; Le Gall F, 2008, AM J SPORT MED, V36, P276, DOI 10.1177/0363546507307866; Leininger RE, 2007, AM J SPORT MED, V35, P288, DOI 10.1177/0363546506294060; Mandelbaum BR, 2005, AM J SPORT MED, V33, P1003, DOI 10.1177/0363546504272261; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; *NAT FED HIGH SCH, 2008, HIGH SCH ATHL PART S; *NAT SPORT GOODS A, PART RANK ALPH; PATLAK M, 2002, SOCCER BAD CHILDRENS; Pickett W, 2005, BRIT J SPORT MED, V39, P226, DOI 10.1136/bjsm.2004.013169; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian Margot, 2004, Curr Sports Med Rep, V3, P9; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; *SANT MON ORTHP SP, ACL PREV PROJ; Soderman K, 2001, SCAND J MED SCI SPOR, V11, P299, DOI 10.1034/j.1600-0838.2001.110508.x; SULLIVAN JA, 2000, CARE YOUNG ATHLETE; *US CONS PROD SAF, 2007, NAT EL INJ SURV SYST; *US CONS PROD SAF, 1995, GUID MOV SOCC GOAL S; US Youth Soccer Association, HIST US SOCC; Vinger PF, 2000, PHYSICIAN SPORTSMED, V28, P49, DOI 10.3810/psm.2000.06.961; Washington RL, 2004, PEDIATRICS, V113, P619; Wong P, 2005, BRIT J SPORT MED, V39, P473, DOI 10.1136/bjsm.2004.015511; Youn J, 2008, MED SCI SPORT EXER, V40, P428, DOI [10.1249/mss.0b013e31815e7263, 10.1249/MSS.0b013e31815e7263]	49	56	56	2	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	FEB	2010	125	2					410	414		10.1542/peds.2009-3009			5	Pediatrics	Pediatrics	573VH	WOS:000275942900028	20100755	Bronze			2021-06-18	
J	Rockswold, GL; Solid, CA; Paredes-Andrade, E; Rockswold, SB; Jancik, JT; Quickel, RR				Rockswold, Gaylan L.; Solid, Craig A.; Paredes-Andrade, Eduardo; Rockswold, Sarah B.; Jancik, Jon T.; Quickel, Robert R.			HYPERTONIC SALINE AND ITS EFFECT ON INTRACRANIAL PRESSURE, CEREBRAL PERFUSION PRESSURE, AND BRAIN TISSUE OXYGEN	NEUROSURGERY			English	Article						Brain tissue oxygen; Cerebral perfusion pressure; Hypertonic saline; Intracranial pressure; Mean arterial pressure	HEAD-INJURED PATIENTS; CRITICAL-CARE MANAGEMENT; BLOOD-FLOW; 7.5-PERCENT SALINE; MANNITOL SOLUTION; SODIUM-CHLORIDE; HYPERTENSION; RESUSCITATION; DEXTRAN; EDEMA	OBJECTIVE: Hypertonic saline is emerging as a potentially effective single osmotic agent for control of acute elevations in intracranial pressure (ICP) caused by severe traumatic brain injury. This study examines its effect on ICP, cerebral perfusion pressure (CPP) and brain tissue oxygen tension (PbtO(2)). METHODS: Twenty-five consecutive patients with severe traumatic brain injury who were treated with 23.4% NaCl for elevated ICP were evaluated. Bolt catheter probes were placed in the noninjured hemisphere, and hourly ICP, mean arterial pressure, CPP, and PbtO(2) values were recorded. Thirty milliliters of 23.40% NaCl was infused over 15 minutes for intracranial hypertension, defined as ICP greater than 20 mm Hg. Twenty-one male patients and 4 female patients aged 16 to 64 years were included. The mean presenting Glasgow Coma Scale score was 5.7. RESULTS: Mean pretreatment values included an ICP level of 25.9 mm Hg and a PbtO(2) value of 32 mm Hg. The posttreatment ICP level was decreased by a mean of 8.3 mm Hg (P < 0.0001), and there was an improvement in PbtO(2) of 3.1 mm Hg (P < 0,01). ICP of more than 31 mm Hg decreased by 14.2 mm Hg. Pretreatment CPP values of less than 70 mm Hg increased by a mean of 6 mm Hg (P < 0.0001). No complications occurred from this treatment, with the exception of electrolyte and chemistry abnormalities. At 6 months postinjury, the mortality rate was 28%, with 48% of patients achieving a favorable outcome by the dichotomized Glasgow Outcome Scale. CONCLUSION: Hypertonic saline as a single osmotic agent decreased ICP while improving CPP and PbtO(2) in patients with severe traumatic brain injury. Patients with higher baseline ICP and lower CPP levels responded to hypertonic saline more significantly.	[Rockswold, Gaylan L.; Paredes-Andrade, Eduardo; Rockswold, Sarah B.] Hennepin Cty Med Ctr, Dept Surg, Div Neurosurg, Minneapolis, MN 55415 USA; [Rockswold, Gaylan L.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA; [Solid, Craig A.] Minneapolis Med Res Fdn Inc, Chron Dis Res Grp, Analyt Serv, Minneapolis, MN USA; [Rockswold, Sarah B.] Hennepin Cty Med Ctr, Dept Phys Med & Rehabil, Minneapolis, MN 55415 USA; [Jancik, Jon T.] Hennepin Cty Med Ctr, Dept Pharm, Minneapolis, MN 55415 USA	Rockswold, GL (corresponding author), Hennepin Cty Med Ctr, Dept Surg, Div Neurosurg, 701 Pk Ave, Minneapolis, MN 55415 USA.	gaylan.rockswold@hcmed.org					Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Becker DP, 1972, INTRACRANIAL PRESSUR, P309; Bhardwaj, 1999, Curr Treat Options Neurol, V1, P179, DOI 10.1007/s11940-999-0002-z; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; DUBICK MA, 1995, SHOCK, V3, P137, DOI 10.1097/00024382-199503020-00009; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FISHMAN RA, 1992, CEREBROSPINAL FLUID, P43; Gasco J, 2005, ACTA NEUROCHIR SUPPL, V95, P73; Georgiadis Alexandros L, 2003, Curr Neurol Neurosci Rep, V3, P524, DOI 10.1007/s11910-003-0058-1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hartl R, 1997, ACT NEUR S, V70, P40; Harukuni Izumi, 2002, J Anesth, V16, P229, DOI 10.1007/s005400200030; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Kempski O, 1997, J TRAUMA, V42, pS38, DOI 10.1097/00005373-199705001-00007; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kramer GC, 2003, J TRAUMA, V54, pS89, DOI 10.1097/01.TA.0000065609.82142.F1; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; Mayer SA, 2002, J INTENSIVE CARE MED, V17, P55, DOI 10.1046/j.1525-1489.2002.17201.x; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Pascual JL, 2008, AM SURGEON, V74, P253; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Polderman KH, 2003, CRIT CARE MED, V31, P584, DOI 10.1097/01.CCM.0000050287.68977.84; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; RAMIRES JAF, 1992, CIRC SHOCK, V37, P220; Raslan Ahmed, 2007, Neurosurg Focus, V22, pE12; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; Saltarini M, 2002, Eur J Emerg Med, V9, P262, DOI 10.1097/00063110-200209000-00011; SCHMALL LM, 1990, EQUINE VET J, V22, P273, DOI 10.1111/j.2042-3306.1990.tb04266.x; Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Swanson PD, 1976, HDB CLIN NEUROLOGY, V28, P443; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; WALSH JC, 1991, CIRC SHOCK, V34, P336; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; Zornow M H, 1995, New Horiz, V3, P488	53	56	60	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2009	65	6					1035	1041		10.1227/01.NEU.0000359533.16214.04			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	522SQ	WOS:000272019400014	19934962				2021-06-18	
J	Atif, F; Sayeed, I; Ishrat, T; Stein, DG				Atif, Fahim; Sayeed, Iqbal; Ishrat, Tauheed; Stein, Donald G.			Progesterone with Vitamin D Affords Better Neuroprotection against Excitotoxicity in Cultured Cortical Neurons than Progesterone Alone	MOLECULAR MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; 1,25-DIHYDROXYVITAMIN D-3; 1-ALPHA,25(OH)(2)-VITAMIN D-3; MEDROXYPROGESTERONE ACETATE; MULTIPLE-SCLEROSIS; GLUTAMATE RELEASE; INDUCED APOPTOSIS; NERVOUS-SYSTEM; D HORMONE; EXPRESSION	Because the complex heterogeneity of traumatic brain injury (TBI) is believed by many to be a major reason for the failed clinical trials of monotherapies, combining two (or more) drugs with some potentially different mechanisms of action may produce better effects than administering those agents individually. In this study, we investigated whether combinatorial treatment with progesterone (PROG) and 1,25-dihydroxyvitamin D-3 hormone (VDH) would produce better neuroprotection than PROG alone following excitotoxic neuronal injury in vitro. E18 rat primary cortical neurons were pretreated with various concentrations of PROG and VDH separately or in combination for 24 h and then exposed to glutamate (0.5 mu mol/L) for the next 24 h. Lactate dehydrogenase (LDH) release and 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide (MTT) reduction assays were used to measure cell death. Both PROG and VDH significantly (P < 0.001) reduced neuronal loss when tested independently. Primary cortical cultures treated with VDH exhibited a U-shaped concentration-response curve. PROG at 20 mu mol/L and VDH at 100 nmol/L concentrations were the most neuroprotective. When the drugs were combined, the "best" doses of PROG (20 mu mol/L) and VDH (100 nmol/L), used individually, did not show substantial efficacy; rather, the lower dose of VDH (20 nmol/L) was most effective when used in combination with PROG (P < 0.01). We also examined the effect of combinatorial treatment on mitogen-activated protein kinase (MAPK) activation as a potential neuroprotective mechanism and observed that PROG and VDH activated MAPK alone and in combination. Interestingly, the best combination dose of PROG and VDH (20 mu mol/L and 20 nmol/L, respectively), as observed in cell death assays (LDH and MU), resulted in increased MAPK activation compared with either the most neuroprotective concentration of individual PROG (20 mu mol/L) and VDH (100 nmol/L) or the combination of these individual best doses. Such interactions must be considered in planning individualized combinatorial therapies. In conclusion, the findings of the present study can be taken to suggest that VDH warrants study as a potential partner for combination therapy with PROG. (C) 2009 The Feinstein Institute for Medical Research, www.feinsteininstitute.org Online address: http://www.molmed.org doi: 10.2119/molmed.2009.00016	[Atif, Fahim; Sayeed, Iqbal; Ishrat, Tauheed; Stein, Donald G.] Emory Univ, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Brain Res Lab, 1365 B Clifton Rd NE,Suite 5100, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01SO4851]	This research was supported by NIH grant R01SO4851. The authors would like to thank Leslie McCann for invaluable editorial assistance.	Alexianu ME, 1998, J NEUROSCI RES, V51, P58, DOI 10.1002/(SICI)1097-4547(19980101)51:1<58::AID-JNR6>3.0.CO;2-K; Asakura H, 2001, THROMB HAEMOSTASIS, V85, P287; Barrera D, 2007, J STEROID BIOCHEM, V103, P529, DOI 10.1016/j.jsbmb.2006.12.097; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Buitrago CG, 2006, J CELL BIOCHEM, V97, P698, DOI 10.1002/jcb.20639; CEKIC M, 2009, NEUROBIOL AGING 0529; Cekic M, 2009, FRONT NEUROENDOCRIN, V30, P158, DOI 10.1016/j.yfrne.2009.04.002; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Garcion E, 1999, J NEUROCHEM, V73, P859, DOI 10.1046/j.1471-4159.1999.0730859.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Hayes CE, 1997, P SOC EXP BIOL MED, V216, P21, DOI 10.3181/00379727-216-44153A; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kong J, 2003, AM J PHYSIOL-REG I, V285, pR255, DOI 10.1152/ajpregu.00517.2002; Kutuzova GD, 2004, ARCH BIOCHEM BIOPHYS, V432, P152, DOI 10.1016/j.abb.2004.09.004; Li YC, 2002, J CLIN INVEST, V110, P229, DOI [10.1172/JCI200215219, 10.1172/JCI0215219]; Lin AMY, 2003, FREE RADICAL BIO MED, V34, P1416, DOI 10.1016/S0891-5849(03)00105-9; Losem-Heinrichs E, 2005, ARCH BIOCHEM BIOPHYS, V439, P70, DOI 10.1016/j.abb.2005.04.021; Losem-Heinrichs E, 2004, J STEROID BIOCHEM, V89-90, P371, DOI 10.1016/j.jsbmb.2004.03.001; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McCann JC, 2008, FASEB J, V22, P982, DOI 10.1096/fj.07-9326rev; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Mills CD, 2000, NEUROREPORT, V11, P3067, DOI 10.1097/00001756-200009280-00007; Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; Oermann E, 2004, J CHEM NEUROANAT, V28, P225, DOI 10.1016/j.jchemneu.2004.07.003; Pardo VG, 2006, INT J BIOCHEM CELL B, V38, P1181, DOI 10.1016/j.biocel.2005.12.018; Pardo VG, 2004, INT J BIOCHEM CELL B, V36, P489, DOI 10.1016/j.biocel.2003.08.005; Riaz SS, 2000, MOL BRAIN RES, V85, P179; Ronda AC, 2007, J STEROID BIOCHEM, V103, P462, DOI 10.1016/j.jsbmb.2006.11.005; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Sanchez B, 2002, MOL BRAIN RES, V108, P143, DOI 10.1016/S0169-328X(02)00545-4; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shinpo K, 2000, J NEUROSCI RES, V62, P374, DOI 10.1002/1097-4547(20001101)62:3<374::AID-JNR7>3.0.CO;2-7; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; Wang Y, 2000, NEUROPHARMACOLOGY, V39, P873, DOI 10.1016/S0028-3908(99)00255-5; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiang W, 2005, AM J PHYSIOL-ENDOC M, V288, pE125, DOI 10.1152/ajpendo.00224.2004; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu Y, 2006, MOL PHARMACOL, V69, P56, DOI 10.1124/mol.105.017392	45	56	57	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1076-1551	1528-3658		MOL MED	Mol. Med.	SEP-OCT	2009	15	9-10					328	336		10.2119/molmed.2009.00016			9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	575CW	WOS:000276043900006	19603099	DOAJ Gold, Green Published			2021-06-18	
J	Wei, HH; Lu, XCM; Shear, DA; Waghray, A; Yao, CP; Tortella, FC; Dave, JR				Wei, Hans H.; Lu, Xi-Chun M.; Shear, Deborah A.; Waghray, Anu; Yao, Changping; Tortella, Frank C.; Dave, Jitendra R.			NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats	JOURNAL OF NEUROINFLAMMATION			English	Article							GROWTH-FACTOR-I; GLYCINE-PROLINE-GLUTAMATE; N-TERMINAL TRIPEPTIDE; NECROSIS-FACTOR-ALPHA; CLOSED-HEAD INJURY; GENE-EXPRESSION; IGF-I; TISSUE-DAMAGE; ANIMAL-MODEL; CELL-DEATH	Background: Inflammatory cytokines play a crucial role in the pathophysiology of traumatic brain injury (TBI), exerting either deleterious effects on the progression of tissue damage or beneficial roles during recovery and repair. NNZ-2566, a synthetic analogue of the neuroprotective tripeptide Glypromate (R), has been shown to be neuroprotective in animal models of brain injury. The goal of this study was to determine the effects of NNZ-2566 on inflammatory cytokine expression and neuroinflammation induced by penetrating ballistic-like brain injury (PBBI) in rats. Methods: NNZ-2566 or vehicle (saline) was administered intravenously as a bolus injection (10 mg/kg) at 30 min post-injury, immediately followed by a continuous infusion of NNZ-2566 (3 mg/kg/h), or equal volume of vehicle, for various durations. Inflammatory cytokine gene expression from the brain tissue of rats exposed to PBBI was evaluated using microarray, quantitative real time PCR (QRT-PCR), and enzyme-linked immunosorbent assay (ELISA) array. Histopathology of the injured brains was examined using hematoxylin and eosin (H&E) and immunocytochemistry of inflammatory cytokine IL-1 beta. Results: NNZ-2566 treatment significantly reduced injury-mediated up-regulation of IL-1 beta, TNF-alpha, E-selectin and IL-6 mRNA during the acute injury phase. ELISA cytokine array showed that NZ-2566 treatment significantly reduced levels of the pro-inflammatory cytokines IL-1 beta, TNF-alpha and IFN-gamma in the injured brain, but did not affect anti-inflammatory cytokine IL- 6 levels. Conclusion: Collectively, these results suggest that the neuroprotective effects of NNZ-2566 may, in part, be functionally attributed to the compound's ability to modulate expression of multiple neuroinflammatory mediators in the injured brain.	[Wei, Hans H.; Lu, Xi-Chun M.; Shear, Deborah A.; Waghray, Anu; Yao, Changping; Tortella, Frank C.; Dave, Jitendra R.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA	Wei, HH (corresponding author), Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD 20910 USA.	hans.wei@us.army.mil; may.lu@amedd.army.mil; deborah.shear@amedd.army.mil; anu.waghray@amedd.army.mi; changping.yao@amedd.army.mil; frank.tortella@amedd.army.mil; jit.dave@amedd.army.mil	Dave, Jitendra R/A-8940-2011; Shear, Deborah/B-3607-2011		Neuren Pharmaceuticals Ltd. [W81XWH-05-0074]	We would like to thank SPC. Monika Torres and SPC. Katie Phillips for their excellent technical assistance and Ms. Christine Gallo for her help in manuscript preparation. These studies were supported in part by a cooperative research and development agreement with Neuren Pharmaceuticals Ltd. (W81XWH-05-0074).	Alexi T, 1999, EXP NEUROL, V159, P84, DOI 10.1006/exnr.1999.7168; Amantea D, 2009, FEBS J, V276, P13, DOI 10.1111/j.1742-4658.2008.06766.x; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Asirvatham AJ, 2009, CYTOKINE, V45, P58, DOI 10.1016/j.cyto.2008.11.010; Balasingam V, 1996, J NEUROSCI, V16, P2945; Batchelor DC, 2003, ANAL BIOCHEM, V323, P156, DOI 10.1016/j.ab.2003.08.032; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Berti R, 2003, NEUROTOX RES, V5, P505, DOI 10.1007/BF03033160; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019; Bourguignon JP, 1999, BRAIN RES, V847, P247, DOI 10.1016/S0006-8993(99)02051-X; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CARLSSONSKWIRUT C, 1989, BIOCHIM BIOPHYS ACTA, V1011, P192, DOI 10.1016/0167-4889(89)90209-7; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; ELNER SG, 1991, LAB INVEST, V64, P819; ELNER VM, 1990, AM J PATHOL, V136, P745; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Guan J, 2004, NEUROPHARMACOLOGY, V47, P892, DOI 10.1016/j.neuropharm.2004.07.002; Guan Jian, 2008, Recent Pat CNS Drug Discov, V3, P112, DOI 10.2174/157488908784534630; Haraldsen G, 1996, J IMMUNOL, V156, P2558; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koprich JB, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-8; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; LU XC, J NEUROTRAUMA, V26, P141; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Ray KP, 1997, BIOCHEM J, V328, P707; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Romano M, 1997, IMMUNITY, V6, P315, DOI 10.1016/S1074-7613(00)80334-9; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SARA VR, 1993, ANN NY ACAD SCI, V692, P183; SARA VR, 1989, BIOCHEM BIOPH RES CO, V165, P766, DOI 10.1016/S0006-291X(89)80032-4; Saura J, 1999, NEUROREPORT, V10, P161, DOI 10.1097/00001756-199901180-00031; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018; Williams AJ, 2005, J NEUROTRAUM, V22, P313, DOI 10.1089/neu.2005.22.313; Williams AJ, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-17; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; YAMAMOTO H, 1995, J ENDOCRINOL, V146, P141, DOI 10.1677/joe.0.1460141; YAMAMOTO H, 1994, ENDOCRINOLOGY, V135, P2432, DOI 10.1210/en.135.6.2432	62	56	56	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	AUG 5	2009	6								19	10.1186/1742-2094-6-19			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	495DB	WOS:000269869000001	19656406	DOAJ Gold, Green Published			2021-06-18	
J	Linares, G; Mayer, SA				Linares, Guillermo; Mayer, Stephan A.			Hypothermia for the treatment of ischemic and hemorrhagic stroke	CRITICAL CARE MEDICINE			English	Article						therapeutic hypothermia; stroke; ischemia; hypothermia; temperature control; neuroprotection	TRANSIENT CEREBRAL-ISCHEMIA; DAMAGE COOL AID; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; MODERATE HYPOTHERMIA; CARDIAC-ARREST; CLINICAL-TRIAL; AWAKE PATIENTS; FOCAL MODEL; FEASIBILITY	Hypothermia is considered nature's "gold standard" for neuroprotection, and its efficacy for improving outcome in patients with hypoxic-ischemic brain injury as a result of cardiac arrest is well-established. Hypothermia reduces brain edema and intracranial pressure in patients with traumatic brain injury. By contrast, only a few small pilot studies have evaluated hypothermia as a treatment for acute ischemic stroke, and no controlled trials of hypothermia for hemorrhagic stroke have been performed. Logistic challenges present an important barrier to the widespread application of hypothermia for stroke, most importantly the need for high-quality critical care to start immediately in the emergency department. Rapid induction of hypothermia within 3 to 6 hrs of onset has been hampered by slow cooling rates, but is feasible. Delayed cooling for the treatment of cytotoxic brain edema does not provide definitive or lasting treatment for intra-cranial mass effect, and should not be used as an alternative to hemicraniectomy. Sustained fever control is feasible in patients with intracerebral and subarachnoid hemorrhage, but has yet to be tested in a phase III study. Important observations from studies investigating the use of hypothermia for stroke to date include the necessity for proactive antishivering therapy for successful cooling, the importance of slow controlled rewarming to avoid rebound brain edema, and the high risk for infectious and cardiovascular complications in this patient population. More research is clearly needed to bring us closer to the successful application of hypothermia in the treatment for stroke. (Crit Care Med 2009; 37[Suppl.]:S243-S249)	[Linares, Guillermo; Mayer, Stephan A.] Columbia Univ, Coll Phys & Surg, Dept Neurol, Div Neurocrit Care, New York, NY 10027 USA; [Linares, Guillermo] Columbia Univ, Coll Phys & Surg, Dept Neurol, Div Stroke, New York, NY USA; [Mayer, Stephan A.] Columbia Univ, Coll Phys & Surg, Dept Neurol Surg, New York, NY USA	Mayer, SA (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Neurol, Div Neurocrit Care, New York, NY 10027 USA.	sam14@columbia.edu					Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Bath P, 2002, STROKE, V33, P639; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; CAMARATA PJ, 1994, NEUROSURGERY, V34, P144, DOI 10.1227/00006123-199401000-00021; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; Corbett D, 2000, BRAIN PATHOL, V10, P145; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; Feigin VL, 2002, J CLIN NEUROSCI, V9, P502, DOI 10.1054/jocn.2001.1072; Feng Honglin, 2002, Zhonghua Yi Xue Za Zhi, V82, P1622; Fingas M, 2007, EXP NEUROL, V208, P277, DOI 10.1016/j.expneurol.2007.08.018; Gasser S, 2003, J NEUROSURG ANESTH, V15, P240, DOI 10.1097/00008506-200307000-00012; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GINSBERG MD, 2004, THERAPEUTIC HYPOTHER; Guluma KZ, 2008, NEUROCRIT CARE, V8, P42, DOI 10.1007/s12028-007-9009-z; Guluma KZ, 2006, ACAD EMERG MED, V13, P820, DOI 10.1197/j.aem.2006.03.559; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; HOWELL D A, 1956, Can Med Assoc J, V75, P388; Ji XM, 2007, FRONT BIOSCI, V12, P1737, DOI 10.2741/2185; Jiang JY, 2006, J NEUROTRAUM, V23, P1847, DOI 10.1089/neu.2006.23.1847; Kammersgaard LP, 2000, STROKE, V31, P2251, DOI 10.1161/01.STR.31.9.2251; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; Kliegel A, 2005, RESUSCITATION, V64, P347, DOI 10.1016/j.resuscitation.2004.09.002; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; Komotar RJ, 2008, NEUROSURGERY, V62, P396, DOI 10.1227/01.neu.0000316006.26635.b0; Krieger DW, 2004, STROKE, V35, P1482, DOI 10.1161/01.STR.0000126118.44249.5c; Krieger DW, 2001, STROKE, V32, P1847, DOI 10.1161/01.STR.32.8.1847; KURZ M, 1993, ANESTHESIOLOGY, V79, P1193, DOI 10.1097/00000542-199312000-00009; Lyden Patrick D, 2005, J Stroke Cerebrovasc Dis, V14, P107, DOI 10.1016/j.jstrokecerebrovasdis.2005.01.001; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Moran JL, 2007, CRIT CARE MED, V35, P155, DOI 10.1097/01.CCM.0000250318.31453.CB; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; Steiner T, 2001, STROKE, V32, P2833, DOI 10.1161/hs1201.99511; Theard MA, 1997, J NEUROSURG ANESTH, V9, P250; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; Yanamoto H, 1999, STROKE, V30, P2720, DOI 10.1161/01.STR.30.12.2720; YOUNG RSK, 1980, JAMA-J AM MED ASSOC, V244, P1233, DOI 10.1001/jama.244.11.1233; Zweifler Richard M, 2003, J Stroke Cerebrovasc Dis, V12, P237, DOI 10.1016/j.jstrokecerebrovasdis.2003.09.006	48	56	62	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2009	37	7		S			S243	S249		10.1097/CCM.0b013e3181aa5de1			7	Critical Care Medicine	General & Internal Medicine	461DT	WOS:000267245500009	19535954				2021-06-18	
J	Giorgi, RG; Woods, RL; Peli, E				Giorgi, Robert G.; Woods, Russell L.; Peli, Eli			Clinical and Laboratory Evaluation of Peripheral Prism Glasses for Hemianopia	OPTOMETRY AND VISION SCIENCE			English	Article						low vision; prism adaptation; rehabilitation; prism treatment; visual impairment; traumatic brain injury; stroke	UNILATERAL VISUAL NEGLECT; LOW-VISION REHABILITATION; HOMONYMOUS HEMIANOPIA; FIELD EXPANSION; SUCCESS; STROKE; SPECTACLES; ADAPTATION; BLINDNESS; SCOTOMAS	Purpose. Homonymous hemianopia (the loss of vision on the same side in each eye) impairs the ability to navigate and walk safely. We evaluated peripheral prism glasses as a low vision optical device for hemianopia in an extended wearing trial. Methods. Twenty-three patients with complete hemianopia (13 right) with neither visual neglect nor cognitive deficit enrolled in the 5-visit study. To expand the horizontal visual field, patients' spectacles were fitted with both upper and lower Press-On Fresnel prism segments (each 40 prism diopters) across the upper and lower portions of the lens on the hemianopic ("blind") side. Patients were asked to wear these spectacles as much as possible for the duration of the study, which averaged 9 (range: 5 to 13) weeks. Clinical success (continued wear, indicating perceived overall benefit), visual field expansion, perceived direction, and perceived quality of life were measured. Results. Clinical success: 14 of 21 (67%) patients chose to continue to wear the peripheral prism glasses at the end of the study (two patients did not complete the study for non-vision reasons). At long-term follow-up (8 to 51 months), 5 of 12 (42%) patients reported still wearing the device. Visual field expansion: expansion of about 220 in both the upper and lower quadrants was demonstrated for all patients (binocular perimetry, Goldmann V4e). Perceived direction: two patients demonstrated a transient adaptation to the change in visual direction produced by the peripheral prism glasses. Quality of life: at study end, reduced difficulty noticing obstacles on the hemianopic side was reported. Conclusions. The peripheral prism glasses provided reported benefits (usually in obstacle avoidance) to 2/3 of the patients completing the study, a very good success rate for a vision rehabilitation device. Possible reasons for long-term discontinuation and limited adaptation of perceived direction are discussed. (Optom Vis Sci 2009;86:492-502)	[Giorgi, Robert G.; Woods, Russell L.; Peli, Eli] Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02114 USA	Peli, E (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA.	eli.peli@schepens.harvard.edu	Woods, Russell L/O-2600-2015	Woods, Russell L/0000-0002-7193-1211; Peli, Eli/0000-0002-1340-9257	NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R24 EY012890, R01 EY012890-08, EY12890, R24 EY012890-05, R01 EY012890] Funding Source: Medline; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R24EY012890, R01EY012890] Funding Source: NIH RePORTER		BACK A, 1992, OPTOMETRY VISION SCI, V69, P474, DOI 10.1097/00006324-199206000-00011; BACK AP, 1989, OPTOMETRY VISION SCI, V66, P518, DOI 10.1097/00006324-198908000-00005; Bowers AR, 2008, ARCH OPHTHALMOL-CHIC, V126, P657, DOI 10.1001/archopht.126.5.657; Cohen JM, 1996, REMEDIATION MANAGEME, P1; DEMER JL, 1991, INVEST OPHTH VIS SCI, V32, P2826; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GAUTHIER CA, 1992, OPTOMETRY VISION SCI, V69, P858, DOI 10.1097/00006324-199211000-00004; Gottlieb DD, 1998, NEUROREHABILITATION, V11, P175, DOI 10.3233/NRE-1998-11303; Gottlieb DD, 1996, LIVING VISION LOSS; Greene HA, 2001, OPTOMETRY VISION SCI, V78, P297, DOI 10.1097/00006324-200105000-00013; HALLIGAN PW, 1993, UNILATERAL NEGLECT C, P3; Hamalainen H, 2000, SCAND J REHABIL MED, V32, P180, DOI 10.1080/003655000750060931; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Jamara RJ, 2003, OPTOMETRY VISION SCI, V80, P495, DOI 10.1097/00006324-200307000-00011; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; KERKHOFF G, 1992, RESTOR NEUROL NEUROS, V4, P245, DOI 10.3233/RNN-1992-4402; KERKHOFF G, 1994, ARCH NEUROL-CHICAGO, V51, P474, DOI 10.1001/archneur.1994.00540170050016; Kohler I, 1964, PSYCHOL ISSUES, V3, P1; Korner-Bitensky NA, 1998, AM J OCCUP THER, V52, P916, DOI 10.5014/ajot.52.10.916; LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009; Lowe JB, 2000, OPTOMETRY VISION SCI, V77, P260, DOI 10.1097/00006324-200005000-00013; Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050; Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1; Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025; Pambakian ALM, 1997, BRIT J OPHTHALMOL, V81, P324, DOI 10.1136/bjo.81.4.324; Peli E, 2000, OPTOMETRY VISION SCI, V77, P453, DOI 10.1097/00006324-200009000-00006; PICK HL, 1969, J EXP PSYCHOL, V80, P125, DOI 10.1037/h0027111; ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597; SCHENKENBERG T, 1980, NEUROLOGY, V30, P509, DOI 10.1212/WNL.30.5.509; Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859; Szlyk JP, 2005, OPHTHAL PHYSL OPT, V25, P128, DOI 10.1111/j.1475-1313.2004.00265.x; Turano KA, 1999, INVEST OPHTH VIS SCI, V40, P865; VANDEUSEN J, 1984, PHYSICAL OCCUPATIONA, V3, P49; Vanier M, 1990, NEUROPSYCHOLOGY, V4, P87, DOI 10.1037/0894-4105.4.2.87; Verezen CA, 2006, OPTOMETRY VISION SCI, V83, P88, DOI 10.1097/01.opx.0000200679.81892.d4; WELCH RB, 1993, PERCEPT PSYCHOPHYS, V54, P195, DOI 10.3758/BF03211756; Williams GR, 1999, STROKE, V30, P2523, DOI 10.1161/01.STR.30.12.2523; Zhang X, 2006, NEUROLOGY, V66, P906, DOI 10.1212/01.wnl.0000203913.12088.93; Zhang X, 2006, NEUROLOGY, V66, P901, DOI 10.1212/01.wnl.0000203338.54323.22; Zhu SH, 2002, NEW ENGL J MED, V347, P1087, DOI 10.1056/NEJMsa020660; ZIHL J, 1995, BRAIN, V118, P891, DOI 10.1093/brain/118.4.891	41	56	58	1	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	MAY	2009	86	5					492	502		10.1097/OPX.0b013e31819f9e4d			11	Ophthalmology	Ophthalmology	442AA	WOS:000265810800010	19357552	Green Accepted			2021-06-18	
J	Bowman, SM; Aitken, ME; Helmkamp, JC; Maham, SA; Graham, CJ				Bowman, S. M.; Aitken, M. E.; Helmkamp, J. C.; Maham, S. A.; Graham, C. J.			Impact of helmets on injuries to riders of all-terrain vehicles	INJURY PREVENTION			English	Article							UNITED-STATES; DEATH RATES; TRAUMA; CHILDREN; SEVERITY; CRASHES; KIDS	Background: Although helmet use has been shown to be effective in reducing traumatic brain injuries (TBIs) due to motorcycle and bicycle crashes, it is unknown whether helmet use is associated with different injury patterns and severity for users of all-terrain vehicles (ATVs). Objectives: To compare likelihood of injury and death between helmeted and unhelmeted riders of ATVs. Methods: The National Trauma Data Bank for years 2002-2006 was used to examine the records of 11 589 patients hospitalized for injuries resulting from ATV use. The likelihood of receiving a TBI diagnosis or a significant injury to other body regions and differences in injury severity and in-hospital mortality between helmeted and unhelmeted ATV riders were compared. Results: After multivariable adjustment, compared with helmeted riders, unhelmeted riders were significantly more likely to sustain any TBI (OR 1.62, 95% CI 1.49 to 1.76, p, 0.001) and major/severe TBI (OR 3.19, 95% CI 2.39 to 4.25, p, 0.001). Unhelmeted riders were significantly more likely to die while in hospital than were helmeted riders (OR 2.58, 95% CI 1.79 to 3.71, p, 0.001). Significant injuries to the neck and face regions were also significantly more likely in unhelmeted riders (OR 3.53, 95% CI 1.28 to 9.71, p = 0.015, and OR 1.94, 95% CI 1.32 to 2.84, p = 0.001, respectively). Conclusions: ATV riders who do not wear helmets are more likely to receive significant injuries to the head, face, and neck. Prevention strategies and enforceable policy interventions to increase helmet use among ATV riders appear warranted.	[Bowman, S. M.; Aitken, M. E.; Maham, S. A.; Graham, C. J.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Helmkamp, J. C.] W Virginia Univ, Morgantown, WV 26506 USA	Bowman, SM (corresponding author), Arkansas Childrens Hosp, 800 Marshall St,Slot 512-26, Little Rock, AR 72202 USA.	bowmanstephenm@uams.edu	Bowman, Stephen/AAF-2154-2019	Aitken, Mary/0000-0002-8318-9755			Acosta JA, 2003, J TRAUMA, V55, P282, DOI 10.1097/01.TA.0000080525.77566.ED; Aitken ME, 2004, INJURY PREV, V10, P303, DOI 10.1136/ip.2003.004176; American College of Surgeons, NAT TRAUM DAT BANK 2; *AR LEG FUND CONC, 2007, DEATH INJ RES ATV BI; Balthrop PM, 2007, J TRAUMA, V62, P1163, DOI 10.1097/01.ta.0000229814.08289.9a; BALTHROP PM, 2007, J EMERG MED     1012; Brandenburg Mark A, 2005, J Okla State Med Assoc, V98, P194; Brown RL, 2002, J PEDIATR SURG, V37, P375, DOI 10.1053/jpsu.2002.30826; Carr AM, 2004, NEUROSURGERY, V54, P861, DOI 10.1227/01.NEU.0000114922.46342.38; Charles A, 2007, AM SURGEON, V73, P1; Clark DE, 2007, J TRAUMA, V62, P592, DOI 10.1097/01.ta.0000257239.15436.29; Fonseca AH, 2005, AM SURGEON, V71, P937; Gennarelli T. A, 2007, ABBREVIATED INJURY S; Gittelman MA, 2006, PEDIATRICS, V117, P2190, DOI 10.1542/peds.2005-2603; Helmkamp JC, 2008, AM J PREV MED, V34, P39, DOI 10.1016/j.amepre.2007.09.016; Helmkamp JC, 2001, AM J PUBLIC HEALTH, V91, P1792, DOI 10.2105/AJPH.91.11.1792; Helmkamp J, 2007, PEDIATRICS, V119, P223, DOI 10.1542/peds.2006-2890; *J HOPK U TRI AN, 1997, ICDMAP 90 INJ SEV CO; Jones CS, 2005, J RURAL HEALTH, V21, P70, DOI 10.1111/j.1748-0361.2005.tb00064.x; Keenan HT, 2004, PEDIATRICS, V113, pE330, DOI 10.1542/peds.113.4.e330; Kelleher CM, 2005, J PEDIATR SURG, V40, P929, DOI 10.1016/j.jpedsurg.2005.03.007; Killingsworth JB, 2005, PEDIATRICS, V115, pE316, DOI 10.1542/peds.2004-1585; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; Mullins RJ, 2007, J AM COLL SURGEONS, V204, P216, DOI 10.1016/j.jamcollsurg.2006.10.025; Murphy N, 2004, J TRAUMA, V56, P1185, DOI 10.1097/01.TA.0000123038.94864.E2; RODGERS GB, 1990, ACCIDENT ANAL PREV, V22, P47, DOI 10.1016/0001-4575(90)90006-7; Rodgers GB, 1999, ACCIDENT ANAL PREV, V31, P409, DOI 10.1016/S0001-4575(98)00080-3; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; *SPEC VEH I AM, 2005, STAT ALL TERR VEH RE; *US CONS PROD SAF, 2008, 2006 ANN REP ATV REL; *US CONS PROD SAF, ATV STAT LEG	32	56	56	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047			INJURY PREV	Inj. Prev.	FEB	2009	15	1					3	7		10.1136/ip.2008.019372			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	403GO	WOS:000263071300003	19190268				2021-06-18	
J	Eriksson, G; Kottorp, A; Borg, J; Tham, K				Eriksson, Gunilla; Kottorp, Anders; Borg, Jorgen; Tham, Kerstin			RELATIONSHIP BETWEEN OCCUPATIONAL GAPS IN EVERYDAY LIFE, DEPRESSIVE MOOD AND LIFE SATISFACTION AFTER ACQUIRED BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article; Proceedings Paper	COTEC Conference 2008	MAY 20-21, 2008	Hamburg, GERMANY			brain injuries; activities of daily living; adaptation psychological; quality of life	18-TO 64-YEAR-OLD SWEDES; SCALE; ANXIETY; STROKE	Objective: To explore the relationship between occupational gaps, depressive mood and life satisfaction in persons who have acquired a brain injury during the past 1-4 years and to test the Occupational Gaps Questionnaire. Design: A cross-sectional study. Subjects: A total of 116 persons with traumatic brain injury or subarachnoid haemorrhage acquired 1-4 years previously. Methods: A postal survey with questions on occupational gaps, focusing on the domains instrumental activities of daily living, social life, leisure and work (Occupational Gaps Questionnaire), life satisfaction (LiSat-11 checklist) and depressive mood (Hospital Anxiety and Depression Scale). Rasch analyses and principal component analyses were performed to ensure that data from the LiSat-11 and Occupational Gaps Questionnaire could be used subsequently as valid unidimensional measures in regression and correlational analyses. Results: Calibration of the Occupational Gaps Questionnaire and the LiSat-11 revealed that the items and persons demonstrated acceptable goodness-of-fit to the Rasch models respectively, supporting internal scale validity and person-response validity. In addition, principal component analyses revealed that the measures could be used as valid uni-dimensional estimations of occupational gaps and life satisfaction. There was a strong relationship between the extent of occupational gaps and perceived life satisfaction, a weaker relationship with depressive mood and a non-significant relationship with the aetiological diagnoses and life satisfaction. The factors explained 32% (occupational gaps), 6% (depressive mood), and 2% (diagnosis), respectively, of the total explained variance (40%). Conclusion: There was a strong correlation between participation in desired everyday occupations and life satisfaction 1-4 years after an acquired brain injury. This indicates that individually perceived occupational gaps, as recorded by the for tailored interventions in order to improve life satisfaction among clients with acquired brain injuries.	[Eriksson, Gunilla; Kottorp, Anders; Tham, Kerstin] Karolinska Inst, Caring Sci & Soc, Dept Neurobiol, Div Occupat Therapy, Stockholm, Sweden; [Eriksson, Gunilla; Borg, Jorgen] Uppsala Univ, Dept Neurosci, Uppsala, Sweden; [Eriksson, Gunilla] Univ Uppsala Hosp, Dept Occupat Therapy, Uppsala, Sweden	Eriksson, G (corresponding author), Karolinska Inst, Caring Sci & Soc, Dept Neurobiol, Div Occupat Therapy, Alfred Nobels Alle 23,4th Floor, SE-14183 Huddinge, Sweden.	gunilla.eriksson@ki.se	; Tham, Kerstin/T-3964-2018	Borg, Jorgen/0000-0002-2372-7478; Kottorp, Anders/0000-0002-8976-2612; Tham, Kerstin/0000-0001-7025-5226			Atchley R. C., 1999, CONTINUITY ADAPTATIO; BAUM CM, 1993, EFFECTS OCCUPATION B; BECKER G, 1993, GERONTOLOGIST, V33, P148, DOI 10.1093/geront/33.2.148; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bodlund O, 1999, SCAND J PRIM HEALTH, V17, P153; BRANHOLM IB, 1994, DISABIL REHABIL, V16, P205; Carlsson GE, 2003, CEREBROVASC DIS, V16, P383, DOI 10.1159/000072561; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; Fisher WP., 1992, RASCH MEASUREMENT T, V6, P238; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; Fugl-Meyer AR, 2002, J REHABIL MED, V34, P239, DOI 10.1080/165019702760279242; Gaete Jorge Moncayo, 2008, Expert Rev Neurother, V8, P75, DOI 10.1586/14737175.8.1.75; Gordon WA, 1997, ARCH PHYS MED REHAB, V78, P658, DOI 10.1016/S0003-9993(97)90433-0; Hoofien D, 2001, BRAIN INJURY, V15, P189; Johnston MV, 2002, ARCH PHYS MED REHAB, V83, pS26, DOI 10.1053/apmr.2002.37100; JOHNSTONE AJ, 1993, BRAIN INJURY, V7, P501, DOI 10.3109/02699059309008177; Kielhofner G, 2002, MODEL HUMAN OCCUPATI; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Linacre J. M., 1991, USERS GUIDE WINSTEPS; Linacre J.M, 2006, WINSTEPS RASCH MEASU; Linacre John M, 2002, J Appl Meas, V3, P85; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Melin R, 2003, J REHABIL MED, V35, P84, DOI 10.1080/16501970306119; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PAKARINEN S, 1967, ACTA NEUROL SCAND, VS 43, P9; Prigatano GP, 1991, AWARENESS DEFICIT BR, P11; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Stone MH., 1979, BEST TEST DESIGN; TEASDALE G, 1974, LANCET, V2, P81; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Tham K, 2000, AM J OCCUP THER, V54, P398, DOI 10.5014/ajot.54.4.398; Townsend E, 2002, ENABLING OCCUPATION; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wilcock A., 1998, OCCUPATIONAL PERSPEC; Wilson M., 2005, CONSTRUCTING MEASURE; World Health Organization, 2001, INT CLASS FUNCT DIS; Wright B.D., 1982, RATING SCALE ANAL; Wright BD., 1994, RASCH MEASUREMENT T, V8, P370, DOI DOI 10.1177/01461672012710004	41	56	58	0	18	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2009	41	3					187	194		10.2340/16501977-0307			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	416PD	WOS:000264017100013	19229453	DOAJ Gold, Green Published			2021-06-18	
J	Diaz-Arrastia, R; Agostini, MA; Madden, CJ; Van Ness, PC				Diaz-Arrastia, Ramon; Agostini, Mark A.; Madden, Christopher J.; Van Ness, Paul C.			Posttraumatic epilepsy: The endophenotypes of a human model of epileptogenesis	EPILEPSIA			English	Article						Magnetic resonance imaging; Diffusion tensor imaging; Video-EEG monitoring; Neuropathology of epilepsy	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; HEAD-INJURY; RANDOMIZED-TRIAL; SEIZURES; PREVENTION; NEUROPROTECTION; RAT; ANTIEPILEPTOGENESIS; LESSONS	Posttraumatic epilepsy is a common complication of traumatic brain injury (TBI), occurring in up to 15-20% of patients with severe brain trauma. Trauma accounts for approximately 5% of chronic epilepsy in the community. Because it is a common condition, and because of the relatively short latency period between injury and onset of chronic seizures, posttraumatic epilepsy represents a good model to test antiepileptogenic therapies. However, several well-conducted clinical trials have failed to demonstrate antiepileptogenic efficacy for several common anticonvulsants. Posttraumatic epilepsy can arise through a number of mechanisms, which often coexist within a single patient. Penetrating brain injury produces a cicatrix in the cortex and is associated with a risk of posttraumatic epilepsy of approximately 50%, whereas nonpenetrating head injury may produce focal contusions and intracranial hemorrhages, and is associated with a risk of posttraumatic epilepsy of up to 30%. Furthermore, closed head injury often produces diffuse concussive injury, with shearing of axons and selective damage to vulnerable brain regions, such as the hippocampus. The clinical, neurophysiologic, imaging, and neuropathologic features or epileptogenicity differ between these alternate mechanisms. It is likely that better understanding of the subtypes of epilepsy resulting from brain trauma will be required to successfully identify antiepileptogenic therapies.	[Diaz-Arrastia, Ramon; Agostini, Mark A.; Van Ness, Paul C.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Comprehens Epilepsy Ctr, Parkland Mem Hosp, Dallas, TX 75390 USA; [Madden, Christopher J.] Univ Texas SW Med Ctr Dallas, Dept Neurol Surg, Comprehens Epilepsy Ctr, Parkland Mem Hosp, Dallas, TX 75390 USA	Diaz-Arrastia, R (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ramon.Diaz-Arrastia@UTSouthwestern.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NIH-NICDHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD48179, U01 HD42652]; U.S. Dept. of Education [H133 A020526]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER	This work was supported by grants from NIH-NICDH (R01 HD48179, U01 HD42652), and U.S. Dept. of Education Grant (H133 A020526) (to RD-A).	Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers J.F., 1996, TREATMENT EPILEPSY P, P165; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arrowsmith JE, 1998, STROKE, V29, P2357, DOI 10.1161/01.STR.29.11.2357; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cascino GD, 2002, MAYO CLIN PROC, V77, P1111, DOI 10.4065/77.10.1111; Cohen-Gadol AA, 2006, J NEUROSURG, V104, P513, DOI 10.3171/jns.2006.104.4.513; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; GOTTESMAN II, 1973, BRIT J PSYCHIAT, V122, P15, DOI 10.1192/bjp.122.1.15; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Klitgaard H, 2003, EPILEPTIC DISORD, V5, pS9; KNAKE S, 2006, TREATMENT EPILEPSY P, P1009; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; MARKS DA, 1995, NEUROLOGY, V45, P2051, DOI 10.1212/WNL.45.11.2051; MATHERN GW, 1994, EPILEPSY RES, V19, P129, DOI 10.1016/0920-1211(94)90023-X; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCNAMARA JO, 1989, EPILEPSIA, V30, pS13, DOI 10.1111/j.1528-1157.1989.tb05809.x; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pitkanen A, 1999, EPILEPSY RES, V33, P67, DOI 10.1016/S0920-1211(98)00074-6; Prince D A, 1999, Adv Neurol, V79, P665; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schuh LA, 1998, ARCH NEUROL-CHICAGO, V55, P1325, DOI 10.1001/archneur.55.10.1325; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Wang J.Y., 2008, ARCH NEUROL-CHICAGO, V65, P1; WILLMORE LJ, 1990, NEUROLOGY S3, V31, pS67; Yang Y, 1998, BRAIN RES, V804, P169, DOI 10.1016/S0006-8993(98)00410-7	45	56	59	0	10	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia		2009	50						14	20		10.1111/j.1528-1167.2008.02006.x			7	Clinical Neurology	Neurosciences & Neurology	399VN	WOS:000262827500004	19187290	Bronze			2021-06-18	
J	Driver, S; Ede, A				Driver, Simon; Ede, Alison			Impact of physical activity on mood after TBI	BRAIN INJURY			English	Article						physical activity; exercise; rehabilitation; brain injury; aquatics	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; ACUTE REHABILITATION; COPING STRATEGIES; SOCIAL SUPPORT; FOLLOW-UP; ACTIVITY BEHAVIORS; HEAD TRAUMA; EXERCISE; INDIVIDUALS	Primary objective: To examine the effect of a physical activity programme on the mood states of individual's with a traumatic brain injury. Research design: Participants were randomly assigned to an experimental (aquatic physical activity intervention) (n = 8) or control group (n = 8). Methods and procedures: The intervention group completed an 8-week aquatic programme consisting of 24 sessions. The control group completed a vocational rehabilitation class for the same number of weeks and sessions. Participants within the physical activity and control group completed the Profile of Mood States (POMS) pre- and post-programme. The POMS measures six dimensions of mood including tension, depression, anger, vigour, fatigue and confusion. An ANOVA was completed to examine between and within group differences pre- and post-programme. Main outcomes and results: Results for the experimental group indicated significant differences and large effect sizes for tension, depression, anger, vigour, fatigue and confusion. No significant differences were found for the control group across all variables. Conclusions: As research has shown increased disturbances in psychosocial states following a brain injury as well as higher rates of depression, results have important implications for individuals involved in rehabilitation, as physical activity can positively influence mood.	[Driver, Simon] Univ N Texas, Dept Kinesiol Hlth Promot & Recreat, Denton, TX 76203 USA	Driver, S (corresponding author), Univ N Texas, Dept Kinesiol Hlth Promot & Recreat, POB 310769, Denton, TX 76203 USA.	simon.driver@unt.edu		driver, simon/0000-0003-2356-432X			Alderson AL, 2002, J HEAD TRAUMA REHAB, V17, P210, DOI 10.1097/00001199-200206000-00003; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arenth PM, 2006, BRAIN INJURY, V20, P253, DOI 10.1080/02699050500487662; ARMSTRONG C, 1991, J REHABIL, V17, P15; Baker CW, 2003, HEALTH PSYCHOL, V22, P189, DOI 10.1037/0278-6133.22.2.189; BAKERROTH S, 1995, THERAPEUTIC RECREATI, V25, P316; BANDURA A, 1977, J PERS SOC PSYCHOL, V35, P125, DOI 10.1037/0022-3514.35.3.125; Bandura A., 1986, SOCIAL FDN THOUGHT A, P544; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; Bowen A, 1999, BRAIN INJURY, V13, P547; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bullock C. C., 1991, Therapeutic Recreation Journal, V25, P7; BYRNE A, 1993, J PSYCHOSOM RES, V37, P565, DOI 10.1016/0022-3999(93)90050-P; Callaghan P, 2004, J Psychiatr Ment Health Nurs, V11, P476, DOI 10.1111/j.1365-2850.2004.00751.x; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Cohen J, 1988, STAT ANAL BEHAV SCI; Cullen N, 2007, BRAIN INJURY, V21, P113, DOI 10.1080/02699050701201540; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dawes H, 2006, DISABIL REHABIL, V28, P1243, DOI 10.1080/09638280600554595; Deb S, 1999, AM J PSYCHIAT, V156, P374; DiLorenzo TM, 1999, PREV MED, V28, P75, DOI 10.1006/pmed.1998.0385; Driver S, 2006, ADAPT PHYS ACT Q, V23, P148, DOI 10.1123/apaq.23.2.148; Driver S, 2006, BRAIN INJURY, V20, P133, DOI 10.1080/02699050500443822; Driver S, 2005, BRAIN INJURY, V19, P1067, DOI 10.1080/02699050500149338; Driver S, 2004, BRAIN INJURY, V18, P847, DOI 10.1080/02699050410001671856; DRIVER S, 2003, J PHYS ED RECREATION, V74, P41; DRIVER S, 2003, J COGNITIVE REHABILI, V21, P26; Driver S, 2003, J COGNITIVE REHABILI, V21, P22; DRYOVAGE J, 1992, COGNITIVE REHABILITA, V4, P12; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Fazio S M, 1988, Ther Recreation J, V22, P46; Fines L., 1994, J COGNITIVE REHABILI, V12, P10; Finset A, 2000, BRAIN INJURY, V14, P887; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gemmell C, 2006, BRAIN INJURY, V20, P151, DOI 10.1080/02699050500442998; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Gouick J, 2004, TRAUMA, V6, P285, DOI DOI 10.1191/1460408604TA3230A; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greenwood C.M., 1990, ADAPT PHYS ACT Q, V7, P12, DOI [10.1123/apaq.7.1.12, DOI 10.1123/APAQ.7.1.12]; Henschen K., 1984, ADAPTED PHYSICAL ACT, V1, P118; HORVAT M, 1986, PARAPLEGIA, V24, P115, DOI 10.1038/sc.1986.15; Israelian MK, 2000, REHABIL PSYCHOL, V45, P284, DOI 10.1037/0090-5550.45.3.284; Johnson CC, 2000, J HLTH ED, V31, P2, DOI DOI 10.1080/10556699.2000.10608640; KALPAKJIAN C, 2001, DISS ABSTR INT B, V61, P6709; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lane AM, 2000, J APPL SPORT PSYCHOL, V12, P16, DOI 10.1080/10413200008404211; Lane AM, 2002, PERCEPT MOTOR SKILL, V94, P732, DOI 10.2466/PMS.94.3.732-734; Lane AM, 2001, J SPORT MED PHYS FIT, V41, P539; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Levin H. S., 1997, SEMINARS CLIN NEUROP, V2, P207; Lox CL, 1999, REHABIL PSYCHOL, V44, P1; LOX CL, 1996, J HEALTH PSYCHOL, V2, P235; LOX CL, 2003, PSYCHOL EXERCISE THE; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Martin JJ, 2002, SPORT PSYCHOL, V16, P384, DOI 10.1123/tsp.16.4.384; MCAULEY E, 1993, J BEHAV MED, V16, P103, DOI 10.1007/BF00844757; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; McGrath JC, 2008, CLIN REHABIL, V22, P635, DOI 10.1177/0269215507086432; McNair D.M., 1971, MANUAL PROFILE MOOD; Mutrie N., 1995, European perspectives on exercise and sport psychology., P50; North T C, 1990, Exerc Sport Sci Rev, V18, P379; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; PETRUZZELLO SJ, 1991, SPORTS MED, V11, P143, DOI 10.2165/00007256-199111030-00002; Riley GA, 2004, BRAIN INJURY, V18, P871, DOI 10.1080/02699050410001671829; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SLOAN S, 2007, BRAIN IMPAIRMENT, V12, P251; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Stern RA, 1997, APHASIOLOGY, V11, P59, DOI 10.1080/02687039708248455; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; STUMBO NJ, 1990, THERAPEUTIC RECREATI, V24, P64; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Taylor-Piliae RE, 2007, TOP STROKE REHABIL, V14, P9, DOI 10.1310/tsr1404-9; Terry PC, 2000, J APPL SPORT PSYCHOL, V12, P93, DOI 10.1080/10413200008404215; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Zoerink D. A., 1991, Therapeutic Recreation Journal, V25, P19	91	56	57	0	21	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	3					203	212	PII 908612884	10.1080/02699050802695574			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	406AJ	WOS:000263267100003	19205956				2021-06-18	
J	Flierl, MA; Stahel, PF; Rittirsch, D; Huber-Lang, M; Niederbichler, AD; Hoesel, LM; Touban, BM; Morgan, SJ; Smith, WR; Ward, PA; Ipaktchi, K				Flierl, Michael A.; Stahel, Philip F.; Rittirsch, Daniel; Huber-Lang, Markus; Niederbichler, Andreas D.; Hoesel, L. Marco; Touban, Basel M.; Morgan, Steven J.; Smith, Wade R.; Ward, Peter A.; Ipaktchi, Kyros			Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis	CRITICAL CARE			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; CENTRAL-NERVOUS-SYSTEM; MELANOCYTE-STIMULATING HORMONE; CLOSED-HEAD INJURY; SEPTIC ENCEPHALOPATHY; ANAPHYLATOXIN C5A; RECEPTOR EXPRESSION; ADHESION MOLECULE-1; INNATE IMMUNITY; ANIMAL-MODELS	Introduction Septic encephalopathy secondary to a breakdown of the blood-brain barrier (BBB) is a known complication of sepsis. However, its pathophysiology remains unclear. The present study investigated the effect of complement C5a blockade in preventing BBB damage and pituitary dysfunction during experimental sepsis. Methods Using the standardised caecal ligation and puncture (CLP) model, Sprague-Dawley rats were treated with either neutralising anti-C5a antibody or pre-immune immunoglobulin (Ig) G as a placebo. Sham-operated animals served as internal controls. Results Placebo-treated septic rats showed severe BBB dysfunction within 24 hours, accompanied by a significant upregulation of pituitary C5a receptor and pro-inflammatory cytokine expression, although gene levels of growth hormone were significantly attenuated. The pathophysiological changes in placebo-treated septic rats were restored by administration of neutralising anti-C5a antibody to the normal levels of BBB and pituitary function seen in the sham-operated group. Conclusions Collectively, the neutralisation of C5a greatly ameliorated pathophysiological changes associated with septic encephalopathy, implying a further rationale for the concept of pharmacological C5a inhibition in sepsis.	[Flierl, Michael A.; Stahel, Philip F.; Touban, Basel M.; Morgan, Steven J.; Smith, Wade R.; Ipaktchi, Kyros] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, Denver, CO 80204 USA; [Rittirsch, Daniel] Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland; [Huber-Lang, Markus] Univ Hosp Ulm, Dept Trauma Hand Plast & Reconstruct Surg, D-89075 Ulm, Germany; [Niederbichler, Andreas D.] Univ Med Ctr Hannover MHH, Dept Plast Hand & Reconstruct Surg, D-30625 Hannover, Germany; [Rittirsch, Daniel; Hoesel, L. Marco; Ward, Peter A.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	Stahel, PF (corresponding author), Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Orthopaed Surg, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org	Huber-Lang, Markus/AAJ-2209-2020	Rittirsch, Daniel/0000-0002-1185-2431			Albrecht EA, 2004, AM J PATHOL, V164, P849, DOI 10.1016/S0002-9440(10)63173-2; Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; BAKER CC, 1983, SURGERY, V94, P331; Boos L, 2004, J IMMUNOL, V173, P4708, DOI 10.4049/jimmunol.173.7.4708; BREDER CD, 1994, P NATL ACAD SCI USA, V91, P11393, DOI 10.1073/pnas.91.24.11393; Brzoska T, 2008, ENDOCR REV, V29, P581, DOI 10.1210/er.2007-0027; Catania A, 2000, CRIT CARE MED, V28, P1403, DOI 10.1097/00003246-200005000-00024; Crane JW, 2007, NEUROSCI LETT, V424, P10, DOI 10.1016/j.neulet.2007.07.012; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; Davoust N, 1999, GLIA, V26, P201, DOI 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9; ERNST JD, 1984, INFECT IMMUN, V46, P81, DOI 10.1128/IAI.46.1.81-86.1984; Esmon CT, 2004, CRIT CARE MED, V32, pS219, DOI 10.1097/01.CCM.0000127036.27343.48; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; FAUSTUMANN PM, 1995, ACTA NEUROPATHOL, V89, P239; Flierl MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002560; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; Francis K, 2003, FASEB J, V17, P2266, DOI 10.1096/fj.02-1103fje; Francis Karen, 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403006252; Gasque P, 1997, AM J PATHOL, V150, P31; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Gerard C, 2003, NEW ENGL J MED, V348, P167, DOI 10.1056/NEJMcibr022995; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Guo RF, 2000, J CLIN INVEST, V106, P1271, DOI 10.1172/JCI10793; HACK CE, 1989, AM J MED, V86, P20, DOI 10.1016/0002-9343(89)90224-6; Handa O, 2008, AM J PHYSIOL-HEART C, V295, pH1712, DOI 10.1152/ajpheart.00476.2008; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hess DC, 1996, NEUROSCI LETT, V213, P37, DOI 10.1016/0304-3940(96)12837-8; HESS DC, 1994, NEUROSCI LETT, V168, P201, DOI 10.1016/0304-3940(94)90450-2; Hofer S, 2008, J SURG RES, V146, P276, DOI 10.1016/j.jss.2007.07.021; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Huber-Lang MS, 2002, J IMMUNOL, V169, P3223, DOI 10.4049/jimmunol.169.6.3223; Huber-Lang MS, 2001, FASEB J, V15, P568; Jacob A, 2007, LAB INVEST, V87, P1186, DOI 10.1038/labinvest.3700686; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; Laudes IJ, 2002, J IMMUNOL, V169, P5962, DOI 10.4049/jimmunol.169.10.5962; Laudes IJ, 2002, AM J PATHOL, V160, P1867, DOI 10.1016/S0002-9440(10)61133-9; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; LEWIS BM, 2006, END ABSTR, V11, pP602; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; Maxime V, 2007, CRIT CARE MED, V35, pS596, DOI 10.1097/01.CCM.0000279097.67263.52; Mulligan MS, 1997, J IMMUNOL, V158, P1857; Mulligan MS, 1996, J CLIN INVEST, V98, P503, DOI 10.1172/JCI118818; NAKAE H, 1994, RES COMMUN CHEM PATH, V84, P189; Nakae H, 1996, SURG TODAY, V26, P225, DOI 10.1007/BF00311579; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; Niederbichler AD, 2006, J EXP MED, V203, P53, DOI 10.1084/jem.20051207; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Papadopoulos MC, 2000, CRIT CARE MED, V28, P3019, DOI 10.1097/00003246-200008000-00057; Piazza O, 2007, BRIT J ANAESTH, V99, P518, DOI 10.1093/bja/aem201; Poli-De-Figueiredo LF, 2008, SHOCK, V30, P53, DOI 10.1097/SHK.0b013e318181a343; PORTER JC, 1983, VITAM HORM, V40, P145, DOI 10.1016/S0083-6729(08)60434-3; Raffin-Sanson ML, 2003, EUR J ENDOCRINOL, V149, P79, DOI 10.1530/eje.0.1490079; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Reyes TM, 1999, BRAIN RES, V851, P215, DOI 10.1016/S0006-8993(99)02189-7; RIECKMANN P, 1995, NEUROSCI LETT, V186, P61, DOI 10.1016/0304-3940(95)11282-2; Riedemann NC, 2003, J IMMUNOL, V170, P503, DOI 10.4049/jimmunol.170.1.503; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Rittirsch D, 2008, NAT REV IMMUNOL, V8, P776, DOI 10.1038/nri2402; Rittirsch D, 2008, NAT MED, V14, P551, DOI 10.1038/nm1753; Rittirsch D, 2007, J LEUKOCYTE BIOL, V81, P137, DOI 10.1189/jlb.0806542; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; Schmid E, 1997, SHOCK, V8, P119, DOI 10.1097/00024382-199708000-00010; Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38; Sharshar T, 2005, CRIT CARE, V9, P37, DOI 10.1186/cc2951; Sharshar T, 2007, INTENS CARE MED, V33, P798, DOI 10.1007/s00134-007-0598-y; Stahel PF, 1997, J IMMUNOL, V159, P861; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Stove S, 1996, CLIN DIAGN LAB IMMUN, V3, P175; TOKLU HZ, 2008, J SURG RES; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; WILLIAMS CA, 1985, J NEUROIMMUNOL, V9, P29, DOI 10.1016/S0165-5728(85)80004-7; WONG D, 1995, MICROVASC RES, V49, P325, DOI 10.1006/mvre.1995.1028; Wratten ML, 2008, EUR J ANAESTH, V25, P1, DOI 10.1017/S0265021507003444	81	56	62	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2009	13	1							R12	10.1186/cc7710			9	Critical Care Medicine	General & Internal Medicine	421IC	WOS:000264351600012	19196477	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Patel, SP; Sullivan, PG; Pandya, JD; Rabchevsky, AG				Patel, Samir P.; Sullivan, Patrick G.; Pandya, Jignesh D.; Rabchevsky, Alexander G.			Differential Effects of the Mitochondrial Uncoupling Agent, 2,4-Dinitrophenol, or the Nitroxide Antioxidant, Tempol, on Synaptic or Nonsynaptic Mitochondria After Spinal Cord Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						electron transport system; excitotoxicity; mitochondrial bioenergetics; mitochondrial membrane potential (Delta Psi); mitochondrial permeability transition; oxidative damage	TRAUMATIC BRAIN-INJURY; PERMEABILITY TRANSITION; THERAPEUTIC TARGET; CALCIUM-UPTAKE; IMPROVES; NEURONS; DEATH; EXCITOTOXICITY; BIOENERGETICS; REDUCTION	We recently documented the progressive nature of mitochondrial dysfunction over 24 hr after contusion spinal cord injury (SCI), but the underlying mechanism has not been elucidated. We investigated the effects of targeting two distinct possible mechanisms of mitochondrial dysfunction by using the mitochondrial uncoupler 2,4-dinitrophenol (2,4-DNP) or the nitroxide antioxidant Tempol after contusion SCI in rats. A novel aspect of this study was that all assessments were made in both synaptosomal (neuronal)- and nonsynaptosomal (glial and neuronal soma)-derived mitochondria 24 hr after injury. Mitochondrial uncouplers target Ca2+ cycling and subsequent reactive oxygen species production in mitochondria after injury. When 2,4-DNP was injected 15 and 30 min after injury, mitochondrial function was preserved in both populations compared with vehicle-treated rats, whereas 1 hr postinjury treatment was ineffective. Conversely, targeting peroxynitrite with Tempol failed to maintain normal bioenergetics in synaptic mitochondria, but was effective in nonsynaptic mitochondria when administered 15 min after injury. When administered at 15 and 30 min after injury, increased hydroxynonenal, 3-NT, and protein carbonyl levels were significantly reduced by 2,4-DNP, whereas Tempol only reduced 3-NT and protein carbonyls after SCI. Despite such antioxidant effects, only 2,4-DNP was effective in preventing mitochondrial dysfunction, indicating that mitochondrial Ca2+ overload may be the key mechanism involved in acute mitochondrial damage after SCI. Collectively, our observations demonstrate the significant role that mitochondrial dysfunction plays in SCI neuropathology. Moreover, they indicate that combinatorial therapeutic approaches targeting different populations of mitochondria holds great potential in fostering neuroprotection after acute SCI. (C) 2008 Wiley-Liss,Inc.	[Patel, Samir P.; Sullivan, Patrick G.; Pandya, Jignesh D.; Rabchevsky, Alexander G.] Univ Kentucky, SCoBIRC, Lexington, KY 40536 USA; [Patel, Samir P.; Rabchevsky, Alexander G.] Univ Kentucky, Dept Physiol, Lexington, KY USA; [Sullivan, Patrick G.; Pandya, Jignesh D.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Rabchevsky, AG (corresponding author), Univ Kentucky, SCoBIRC, B471 Biomed & Biol Sci Res Bldg,741 S Limestone, Lexington, KY 40536 USA.	agrab@uky.edu	Rabchevsky, Alexander/AAQ-2451-2021	Rabchevsky, Alexander/0000-0002-1991-0915	Kentucky Spinal Cord and Head Injury Research Trust [3-11, NS 048191]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191] Funding Source: NIH RePORTER	Kentucky Spinal Cord and Head Injury Research Trust; Contract grant number: 3-11 (to A.G.R.); Contract grant number: NS 048191 (to P.G.S.).	ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Bambrick LL, 2006, J BIOENERG BIOMEMBR, V38, P43, DOI 10.1007/s10863-006-9004-7; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Bonini MG, 2002, CHEM RES TOXICOL, V15, P506, DOI 10.1021/tx015571z; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Brustovetsky N, 2002, NEUROSCI LETT, V332, P91, DOI 10.1016/S0304-3940(02)00948-5; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; CHEN KY, 1985, BIOCHIM BIOPHYS ACTA, V845, P189, DOI 10.1016/0167-4889(85)90176-4; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1993, RES P ARNMD, V71, P81; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; Jin Y, 2004, J NEUROTRAUM, V21, P1396, DOI 10.1089/neu.2004.21.1396; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Ljubkovic M, 2007, AM J PHYSIOL-CELL PH, V292, pC1583, DOI 10.1152/ajpcell.00221.2006; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Profyris C, 2004, NEUROBIOL DIS, V15, P415, DOI 10.1016/j.nbd.2003.11.015; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Sengpiel B, 1998, EUR J NEUROSCI, V10, P1903, DOI 10.1046/j.1460-9568.1998.00202.x; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SMITH L, 1955, Methods Biochem Anal, V2, P427, DOI 10.1002/9780470110188.ch13; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Ueda A, 2003, MOL CELL BIOCHEM, V244, P119, DOI 10.1023/A:1022477530291; Wharton D., 1967, METHODS ENZYMOL, V10, P245, DOI [10.1016/0076-6879(67)10048-7, DOI 10.1016/0076-6879(67)10048-7]; White RJ, 1996, J NEUROSCI, V16, P5688; ZIENGLER D, 1967, METHOD ENZYMOL, V10, P231	37	56	60	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN	2009	87	1					130	140		10.1002/jnr.21814			11	Neurosciences	Neurosciences & Neurology	397QX	WOS:000262678300014	18709657	Green Accepted			2021-06-18	
J	Tokutomi, T; Miyagi, T; Ogawa, T; Ono, J; Kawamata, T; Sakamoto, T; Shigemori, M; Nakamura, N				Tokutomi, Takashi; Miyagi, Tomoya; Ogawa, Takeki; Ono, Jun-ichi; Kawamata, Tatsuro; Sakamoto, Tetsuya; Shigemori, Minoru; Nakamura, Norio			Age-Associated Increases in Poor Outcomes after Traumatic Brain Injury: A Report from the Japan Neurotrauma Data Bank	JOURNAL OF NEUROTRAUMA			English	Article						age; outcome; traumatic brain injury	CLOSED-HEAD INJURY; COMPUTERIZED-TOMOGRAPHY; ADULT PATIENTS; FARE WORSE; MORTALITY; DEATH; COMA; DETERIORATE; PREDICTOR; CYTOKINES	Age is an important factor influencing outcome after severe traumatic brain injury (TBI). In general, the older the victim, the higher the probability of a poor Outcome. To investigate the mechanism underlying the link between age and Outcome, the data for 797 patients enrolled in the Japan Neurotrauma Data Bank (JNTDB), aged 6 years or older, with Glasgow Coma Scale (GCS) scores of 8 or less on admission or deterioration to that level within 48 h of impact were analyzed. Thirty-eight percent of the patients were between the ages of 40 and 69 years, and 24%, of the patients were older than 69 years. Older patients had higher rates of mortality and lower rates of favorable outcome. The frequency of mass lesions which were associated with poorer outcomes significantly increased with age, but regardless of the intracranial lesion type, older patients had poorer outcomes. The GCS score and the occurrence of systemic complications did not differ significantly according to age. Multiple systemic injury was less frequent in older patients. The varied Occurrence of intracranial lesion types according to age is likely caused by the disparity between the young and aged brain in the progression of secondary brain injury. Alteration in the pathophysiological response, which is related to the development of secondary brain injury in the aging brain, probably contributes to more severe and irreversible brain damage in older patients, and is thus associated with poor outcomes.	[Tokutomi, Takashi; Miyagi, Tomoya; Shigemori, Minoru] Kurume Univ, Sch Med, Dept Neurosurg, Kurume, Fukuoka 8300011, Japan; [Tokutomi, Takashi; Ogawa, Takeki; Ono, Jun-ichi; Kawamata, Tatsuro; Sakamoto, Tetsuya; Shigemori, Minoru; Nakamura, Norio] Japanese Council Traff Sci, Japan Soc Neurotraumatol, Japan Neurotrauma Data Bank Comm, Tokyo, Japan	Tokutomi, T (corresponding author), Kurume Univ, Sch Med, Dept Neurosurg, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	toku@med.kurume-u.ac.jp			General Insurance Association of Japan; Mitsui Sumitomo Insurance Welfare FoundationMitsui Sumitomo Insurance Welfare Foundation; Japan Brain Foundation; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591617] Funding Source: KAKEN	This work was Supported by a grant from The General Insurance Association of Japan, Mitsui Sumitomo Insurance Welfare Foundation, and the Japan Brain Foundation.	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; *DEP EC SOC AFF PO, 2007, WORLD POP PROSP 2006; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakamura N, 2006, NEUROL MED-CHIR, V46, P567, DOI 10.2176/nmc.46.567; Nijboer JMM, 2007, J TRAUMA, V63, P670, DOI 10.1097/01.ta.0000228890.65522.53; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wagner AK, 2005, CRIT CARE MED, V33, P407, DOI 10.1097/01.CCM.0000153931.23488.DD; Xue MZ, 2001, STROKE, V32, P2164, DOI 10.1161/hs0901.095408; Yokota H, 2007, NEUROL MED-CHIR, V47, P383, DOI 10.2176/nmc.47.383	38	56	57	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1407	1414		10.1089/neu.2008.0577			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500002	19086809				2021-06-18	
J	Wasserman, JK; Schlichter, LC				Wasserman, Jason K.; Schlichter, Lyanne C.			White matter injury in young and aged rats after intracerebral hemorrhage	EXPERIMENTAL NEUROLOGY			English	Article						Stroke; Traumatic brain injury; Axonal injury; Demyelination; Microglial activation; Amyloid precursor protein	AMYLOID PRECURSOR PROTEIN; MIDDLE CEREBRAL-ARTERY; DELAYED MINOCYCLINE TREATMENT; TRAUMATIC BRAIN-INJURY; AXONAL-TRANSPORT; DAMAGED AXONS; NEURON DEATH; BETA-APP; STROKE; EDEMA	Experimental studies of intracerebral hemorrhage (ICH) have focused on neuron death, with little or no information on axonal and myelin damage outside the hematoma. Because development of effective therapies will require an understanding of white matter injury, we examined white matter injury and its spatial and temporal relationship with microglial/macrophage activation in a collagenase model of rat striatal ICH. The hematoma and parenchyma surrounding the hematoma were assessed in young and aged animals at 6 h, 1, 3 and 28 days after ICH onset. Demyelination occurred inside and at the edge of the hematoma; regions where we have shown substantial neuron death. In contrast, there was axonal damage without demyelination at the edge of the hematoma, and by 3 days this damage had spread to the surrounding parenchyma, a region where we have shown there is no neuron death. Because the axonal damage preceded infiltration of activated microglia into the white matter tracts (seen at 3 days), our results support the hypothesis that these cells respond to, rather than perpetrate the damage. Importantly, axonal damage was worse in aged animals, which provides a plausible explanation for the poorer functional recovery of older animals after ICH, despite a similar loss of grey matter. Our findings support strategies that target white matter injury to reduce neurological impairment after ICH. (C) 2008 Elsevier Inc. All rights reserved.	[Schlichter, Lyanne C.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; Univ Hlth Network, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A1, Canada	Schlichter, LC (corresponding author), Toronto Western Hosp, 399 Bathurst St,MC 9-415, Toronto, ON M5T 2S8, Canada.	schliclit@uhnres.utoronto.ca		Wasserman, Jason/0000-0003-3821-8956	Heart & Stroke Foundation, OntarioHeart & Stroke Foundation of CanadaHeart & Stroke Foundation of Ontario [T5546, T6279]; Peterborough KM Hunter Foundation; Heart & Stroke Foundation, OntarioHeart & Stroke Foundation of CanadaHeart & Stroke Foundation of Ontario	Excellent technical assistance was provided by Helen Wang. JKW's work would not have been accomplished without support from Talea Coghlin. Supported by operating grants to LCS from the Heart & Stroke Foundation, Ontario Chapter (HSFO; T5546; T6279), and scholarships to JKW from the Peterborough KM Hunter Foundation, and the Heart & Stroke Foundation, Ontario Chapter.	Badan I, 2004, EUR J NEUROSCI, V19, P2270, DOI 10.1111/j.0953-816X.2004.03323.x; Baltan S, 2008, J NEUROSCI, V28, P1479, DOI 10.1523/JNEUROSCI.5137-07.2008; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Coleman MP, 2002, TRENDS NEUROSCI, V25, P532, DOI 10.1016/S0166-2236(02)02255-5; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Felberg RA, 2002, ANN NEUROL, V51, P517, DOI 10.1002/ana.10160; Fordyce CB, 2005, J NEUROSCI, V25, P7139, DOI 10.1523/JNEUROSCI.1251-05.2005; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Gong Y, 2004, STROKE, V35, P2571, DOI 10.1161/01.STR.0000145485.67827.d0; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Justicia C, 2003, J CEREBR BLOOD F MET, V23, P1430, DOI 10.1097/01.WCB.0000090680.07515.C8; Kaushal V, 2008, J NEUROSCI, V28, P2221, DOI 10.1523/JNEUROSCI.5643-07.2008; Kaushal V, 2007, J NEUROSCI, V27, P234, DOI 10.1523/JNEUROSCI.3593-06.2007; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; MacLellan CL, 2006, J CEREBR BLOOD F MET, V26, P1031, DOI 10.1038/sj.jcbfm.9600255; Marik C, 2007, BRAIN, V130, P2800, DOI 10.1093/brain/awm236; Matsuo A, 1997, AM J PATHOL, V150, P1253; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; MORIOKA T, 1993, J COMP NEUROL, V327, P123, DOI 10.1002/cne.903270110; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Popa-Wagner A, 1998, STROKE, V29, P2196, DOI 10.1161/01.STR.29.10.2196; Qureshi AI, 2003, CRIT CARE MED, V31, P1482, DOI 10.1097/01.CCM.0000063047.63862.99; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; Rincon Fred, 2004, Curr Opin Crit Care, V10, P94, DOI 10.1097/00075198-200404000-00003; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; SCHMUED LC, 1990, J HISTOCHEM CYTOCHEM, V38, P717, DOI 10.1177/38.5.1692056; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Tepper JM, 2007, PROG BRAIN RES, V160, P3, DOI 10.1016/S0079-6123(06)60001-0; Wagner KR, 2005, CURR NEUROVASC RES, V2, P149, DOI 10.2174/1567202053586785; Wang J, 2007, J CEREBR BLOOD F MET, V27, P894, DOI 10.1038/sj.jcbfm.9600403; Wasserman JK, 2008, EUR J NEUROSCI, V28, P1316, DOI 10.1111/j.1460-9568.2008.06442.x; Wasserman JK, 2007, BRAIN RES, V1180, P140, DOI 10.1016/j.brainres.2007.08.058; Wasserman JK, 2007, EXP NEUROL, V207, P227, DOI 10.1016/j.expneurol.2007.06.025; Wasserman JK, 2007, BRAIN RES, V1136, P208, DOI 10.1016/j.brainres.2006.12.035; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4	45	56	65	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2008	214	2					266	275		10.1016/j.expneurol.2008.08.010			10	Neurosciences	Neurosciences & Neurology	380RW	WOS:000261483900014	18848934				2021-06-18	
J	Stravitz, RT				Stravitz, R. Todd			Critical Management Decisions in Patients With Acute Liver Failure	CHEST			English	Article						hepatitis; liver; liver failure	FULMINANT HEPATIC-FAILURE; TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; CONTROLLED-TRIAL; MODERATE HYPOTHERMIA; CEREBRAL PERFUSION; N-ACETYLCYSTEINE; GASTROINTESTINAL HEMORRHAGE; THERAPEUTIC HYPOTHERMIA; ARTERIAL AMMONIA	Few admissions to the ICU present a greater clinical challenge than the patient with acute liver failure (ALF), the syndrome of abrupt loss of liver function in a previously unaffected individual. Although advances in the intensive care management of patients with ALF have improved survival, the prognosis of ALF remains poor, with a 33% mortality rate and a 25% liver transplant rate in the United States. ALF adversely affects nearly every organ system, with most deaths occurring from sepsis and subsequent multiorgan system failure, and cerebral edema, resulting in intracranial hypertension (ICH) and brainstem herniation. Unfortunately, the optimal management of ALF remains poorly defined, and practices are often based on local experience and case reports rather than on randomized, controlled clinical trials. The paramount question in any patient presenting with ALF remains defining an etiology, since specific antidotes can save lives and spare the liver. This article will consider recent advances in the assignment of an etiology, the administration of etiology-specific treatment to abate the liver injury, and the management of complications (eg, infection, cerebral edema, and the bleeding diathesis) in patients with ALF. New data on the administration of N-acetylcysteine to patients with non-acetaminophen ALF, the treatment of ICH, and assessment of the need for liver transplantation will also be presented. (CHEST 2008; 134:1092-1102)	[Stravitz, R. Todd] Virginia Commonwealth Univ, Hume Lee Transplant Ctr, Sect Hepatol, Richmond, VA 23298 USA	Stravitz, RT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Sect Hepatol, POB 980341, Richmond, VA 23298 USA.	rstravit@hsc.vcu.edu					Bernal W, 2003, SEMIN LIVER DIS, V23, P227; Bernal W, 2002, LANCET, V359, P558, DOI 10.1016/S0140-6736(02)07743-7; Bernal W, 2007, HEPATOLOGY, V46, P1844, DOI 10.1002/hep.21838; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417; BERNUAU J, 1991, HEPATOLOGY, V14, pA49; Bernuau J, 1999, OXFORD TXB CLIN HEPA, P1341; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; Blei AT, 2005, NEUROCHEM INT, V47, P71, DOI 10.1016/j.neuint.2005.04.009; CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; Clemmesen JO, 1997, HEPATOLOGY, V26, P1423; Clemmesen JO, 1999, HEPATOLOGY, V29, P648, DOI 10.1002/hep.510290309; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Daas M, 1995, Liver Transpl Surg, V1, P210, DOI 10.1002/lt.500010403; Davern TJ, 2006, GASTROENTEROLOGY, V130, P687, DOI 10.1053/j.gastro.2006.01.033; DAVIES MH, 1994, LANCET, V343, P1329, DOI 10.1016/S0140-6736(94)92471-6; Demetriou AA, 2004, ANN SURG, V239, P660, DOI 10.1097/01.sla.0000124298.74199.e5; FORBES A, 1989, HEPATOLOGY, V10, P306, DOI 10.1002/hep.1840100309; GAZZARD BG, 1974, GUT, V15, P89, DOI 10.1136/gut.15.2.89; GAZZARD BG, 1975, GUT, V16, P617, DOI 10.1136/gut.16.8.617; GAZZARD BG, 1975, Q J MED, V44, P615; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; HANID MA, 1980, GUT, V21, P866, DOI 10.1136/gut.21.10.866; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HARRISON PM, 1990, BMJ-BRIT MED J, V301, P964, DOI 10.1136/bmj.301.6758.964; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Ichai P, 2007, LIVER TRANSPLANT, V13, P996, DOI 10.1002/lt.21036; Ilan Y, 2007, ALIMENT PHARM THER, V26, P1293, DOI 10.1111/j.1365-2036.2007.03519.x; Jalan R, 2004, GASTROENTEROLOGY, V127, P1338, DOI 10.1053/j.gastro.2004.08.005; Jalan R, 2003, TRANSPLANTATION, V75, P2034, DOI 10.1097/01.TP.0000066240.42113.FF; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Jalan R, 2001, HEPATOLOGY, V34, P50, DOI 10.1053/jhep.2001.25386; James LP, 2006, PEDIATRICS, V118, pE676, DOI 10.1542/peds.2006-0069; KEAYS R, 1991, Q J MED, V79, P425; Kortsalioudaki C, 2008, LIVER TRANSPLANT, V14, P25, DOI 10.1002/lt.21246; Kumar M, 2007, HEPATOLOGY, V45, P97, DOI 10.1002/hep.21486; LANGLEY PG, 1990, EUR J CLIN INVEST, V20, P627, DOI 10.1111/j.1365-2362.1990.tb01911.x; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Lee WM, 2007, HEPATOLOGY, V46, p268A; Lee WM, 2003, SEMIN LIVER DIS, V23, P217; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; Lisman T, 2002, HEPATOLOGY, V35, P616, DOI 10.1053/jhep.2002.31771; Lisman T, 2007, DIGEST SURG, V24, P250, DOI 10.1159/000103655; MACDOUGALL BRD, 1978, GASTROENTEROLOGY, V74, P464; MACDOUGALL BRD, 1977, LANCET, V1, P617; MacQuillan GC, 2005, LIVER TRANSPLANT, V11, P1073, DOI 10.1002/lt.20427; MAKIN AJ, 1997, ACUTE LIVER FAILURE, P32; McKenzie TJ, 2008, SEMIN LIVER DIS, V28, P210, DOI 10.1055/s-2008-1073120; Mitchell I, 1998, CRIT CARE MED, V26, P279, DOI 10.1097/00003246-199802000-00026; MUNOZ S, 2009, CLIN LIVER IN PRESS; MUNOZ SJ, 1989, TRANSPLANT P, V21, P3535; Murphy N, 2004, HEPATOLOGY, V39, P464, DOI 10.1002/hep.20056; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; Pavese P, 2005, CAN J ANAESTH, V52, P26, DOI 10.1007/BF03018576; PEREIRA LMMB, 1992, GUT, V33, P98, DOI 10.1136/gut.33.1.98; Pereira SP, 2005, J HEPATOL, V42, P365, DOI 10.1016/j.jhep.2004.11.030; PERNAMBUCO JRB, 1993, HEPATOLOGY, V18, P1350, DOI 10.1016/0270-9139(93)90223-A; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Polson J, 2008, CLIN CHIM ACTA, V391, P24, DOI 10.1016/j.cca.2008.01.018; Polson J, 2008, SEMIN LIVER DIS, V28, P218, DOI 10.1055/s-2008-1073121; Rana R, 2006, TRANSFUSION, V46, P1478, DOI 10.1111/j.1537-2995.2006.00930.x; Riordan SM, 2008, SEMIN LIVER DIS, V28, P137, DOI 10.1055/s-2008-1073113; Roberts MS, 2004, LIVER TRANSPLANT, V10, P886, DOI 10.1002/lt.20137; Rolando N, 1996, Liver Transpl Surg, V2, P8, DOI 10.1002/lt.500020103; ROLANDO N, 1991, J HEPATOL, V12, P1, DOI 10.1016/0168-8278(91)90900-V; Rolando N, 2000, HEPATOLOGY, V32, P734, DOI 10.1053/jhep.2000.17687; Rolando N, 1996, SEMIN LIVER DIS, V16, P389, DOI 10.1055/s-2007-1007252; ROLANDO N, 1990, HEPATOLOGY, V11, P49, DOI 10.1002/hep.1840110110; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1002/hep.1840170206; Schmidt LE, 2007, HEPATOLOGY, V45, P789, DOI 10.1002/hep.21503; Schmidt LE, 2004, CLIN GASTROENTEROL H, V2, P418, DOI 10.1016/S1542-3565(04)00128-4; Schmidt LE, 2005, HEPATOLOGY, V41, P26, DOI 10.1002/hep.20511; Schmidt LE, 2002, HEPATOLOGY, V36, P659, DOI 10.1053/jhep.2002.35069; Shami VM, 2003, LIVER TRANSPLANT, V9, P138, DOI 10.1053/jlts.2003.50017; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SMILKSTEIN MJ, 1988, NEW ENGL J MED, V319, P1557, DOI 10.1056/NEJM198812153192401; Stadbauer V, 2007, CURR OPIN CRIT CARE, V13, P215, DOI 10.1097/MCC.0b013e328052c4cc; Stravitz RT, 2008, NEUROCRIT CARE, V9, P90, DOI 10.1007/s12028-008-9090-y; Stravitz RT, 2007, CRIT CARE MED, V35, P2498, DOI 10.1097/01.CCM.0000287592.94554.5F; Tillmann HL, 2006, J VIRAL HEPATITIS, V13, P256, DOI 10.1111/j.1365-2893.2005.00695.x; Tofteng F, 2004, J CEREBR BLOOD F MET, V24, P798, DOI 10.1097/01.WCB.0000125648.03213.1D; TREY C, 1970, Progress in Liver Diseases, P282; Vaquero J, 2005, LIVER TRANSPLANT, V11, P1581, DOI 10.1002/lt.20625; Vaquero J, 2005, J CLIN GASTROENTEROL, V39, pS147, DOI 10.1097/01.mcg.0000155515.94843.55; Vaquero J, 2003, GASTROENTEROLOGY, V125, P755, DOI 10.1016/S0016-5085(03)01051-5; Vaquero J, 2007, GASTROENTEROLOGY, V132, P372, DOI 10.1053/j.gastro.2006.11.025; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wijdicks EFM, 2002, TRANSPLANT P, V34, P1220, DOI 10.1016/S0041-1345(02)02804-X; Zimmerman HJ., 1999, HEPATOTOXICITY ADVER	91	56	62	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0012-3692	1931-3543		CHEST	Chest	NOV	2008	134	5					1092	1102		10.1378/chest.08-1071			11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	372RF	WOS:000260918500034	18988787				2021-06-18	
J	Mazzeo, AT; Alves, OL; Gilman, CB; Hayes, RL; Tolias, C; Kunene, KN; Bullock, MR				Mazzeo, Anna Teresa; Alves, Oscar Luis; Gilman, Charlotte B.; Hayes, Ronald L.; Tolias, Christos; Kunene, K. Niki; Bullock, M. Ross			Brain metabolic and hemodynamic effects of cyclosporin A after human severe traumatic brain injury: a microdialysis study	ACTA NEUROCHIRURGICA			English	Article						Cyclosporin A; Neuroprotection; Traumatic brain injury; Cerebral microdialysis; Cerebral hemodynamics	MITOCHONDRIAL PERMEABILITY TRANSITION; POSITRON-EMISSION-TOMOGRAPHY; HUMAN HEAD-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; CEREBRAL PERFUSION-PRESSURE; NITRIC-OXIDE SYNTHASE; INDUCED AXONAL DAMAGE; AMINO-ACID RELEASE; INTRACEREBRAL MICRODIALYSIS; CELL-DEATH	Background Mitochondrial dysfunction is a major limiting factor in neuronal recovery following traumatic brain injury. Cyclosporin A (CsA) has been recently proposed for use in the early phase after severe head injury, for its ability to preserve mitochondrial bioenergetic state, potentially exerting a neuroprotective effect. The aim of this study was, therefore, to evaluate the effect of CsA on brain energy metabolism, as measured by cerebral microdialysis, and on cerebral hemodynamics, in a group of severely head injured patients. Methods Fifty adult patients with a severe head injury were enrolled in this randomized, double-blind, placebo-controlled study. Patients received 5 mg/kg of CsA over 24 h, or placebo, within 12 h of the injury. A microdialysis probe was placed in all patients, who were managed according to standard protocols for the treatment of severe head injury. Findings The most robust result of this study was that, over most of the monitoring period, brain dialysate glucose was significantly higher in the CsA treated patients than in placebo. Both lactate and pyruvate were also significantly higher in the CsA group. Glutamate concentration and lactate/pyruvate ratio were significantly higher in the placebo group than in CsA treated patients, respectively 1 to 2 days, and 2 to 3 days after the end of the 24-h drug infusion. The administration of CsA was also associated with a significant increase in mean arterial pressure (MAP) and cerebral perfusion pressure (CPP). Conclusions The administration of CsA in the early phase after head injury resulted in significantly higher extracellular fluid glucose and pyruvate, which may be evidence of a beneficial effect. The early administration of CsA was also associated with a significant increase in MAP and CPP and such a potentially beneficial hemodynamic effect might contribute to a neuroprotective effect.	[Mazzeo, Anna Teresa] Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, I-98121 Messina, Italy; [Mazzeo, Anna Teresa; Gilman, Charlotte B.] Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA; [Alves, Oscar Luis] Univ Porto, Fac Med, Ctr Hosp Vila Nova Gaia, Serv Neurocirurgia, P-4100 Oporto, Portugal; [Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Innovat Res, Alachua, FL USA; [Tolias, Christos] Kings Coll Hosp London, Dept Neurosurg, London, England; [Kunene, K. Niki] Univ Louisville, Dept Comp Informat Syst, Louisville, KY 40292 USA; [Bullock, M. Ross] Univ Miami, Miller Sch Med, Lois Pope LIFE Ctr, Dept Neurosurg, Miami, FL 33136 USA	Mazzeo, AT (corresponding author), Univ Messina, Dept Neurosci Psychiat & Anesthesiol Sci, Viale Regina Margherita 59, I-98121 Messina, Italy.	annateresamazzeo@unime.it; oscar.luis.alves@clix.pt; cbgilman@vcu.edu; rhayes@banyanbio.com; Christos.Tolias@kch.nhs.uk; niki.kunene@gmail.com; rbullock@med.miami.edu		Mazzeo, Anna Teresa/0000-0002-8454-7243	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS 12587-27]; Reynolds; Lind-Lawrence Foundations; Fundacao para a Ciencia e TecnologiaPortuguese Foundation for Science and TechnologyEuropean Commission [SFRH/BD/3421/2000]; Fulbright Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587] Funding Source: NIH RePORTER	Funding for this study was provided by NIH NINDS grant N. P50 NS 12587-27, and Ross Bullock was supported by the Reynolds, and Lind-Lawrence Foundations.; Oscar L Alves was supported by grant no. SFRH/BD/3421/2000 from Fundacao para a Ciencia e Tecnologia, and by a Fulbright Fellowship.	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Alves OL, 2003, ANN NY ACAD SCI, V993, P25, DOI 10.1111/j.1749-6632.2003.tb07508.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Chaurasia CS, 1999, BIOMED CHROMATOGR, V13, P317, DOI 10.1002/(SICI)1099-0801(199908)13:5<317::AID-BMC891>3.0.CO;2-I; Christians U, 2004, BRIT J PHARMACOL, V143, P388, DOI 10.1038/sj.bjp.0705939; Danovitch GM, 2005, HDB KIDNEY TRANSPLAN, P72; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Dusick JR, 2007, J CEREBR BLOOD F MET, V27, P1593, DOI 10.1038/sj.jcbfm.9600458; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Friberg H, 1998, J NEUROSCI, V18, P5151; Gardiner SM, 2004, BRIT J PHARMACOL, V141, P634, DOI 10.1038/sj.bjp.0705659; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; KATSURA K, 1992, J CEREBR BLOOD F MET, V12, P270, DOI 10.1038/jcbfm.1992.37; Kett-White R, 2002, NEUROSURGERY, V50, P1213, DOI 10.1097/00006123-200206000-00008; Kosch M, 2003, TRANSPLANTATION, V76, P1516, DOI 10.1097/01.TP.0000092521.57633.BD; Koura SS, 1998, ACT NEUR S, V71, P244; LANGEMANN H, 1995, CLIN NEUROL NEUROSUR, V97, P149, DOI 10.1016/0303-8467(94)00067-G; Langemann H, 2001, NEUROL RES, V23, P531, DOI 10.1179/016164101101198785; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lungu AO, 2004, J BIOL CHEM, V279, P48794, DOI 10.1074/jbc.M313897200; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Marrif H, 1999, J NEUROSCI RES, V57, P255; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MEYERSON BA, 1990, LIFE SCI, V46, P301, DOI 10.1016/0024-3205(90)90037-R; Nishiyama A, 2003, HYPERTENSION, V42, P754, DOI 10.1161/01.HYP.0000085195.38870.44; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1996, ACT NEUR S, V66, P81; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; ROULLET JB, 1994, J CLIN INVEST, V93, P2244, DOI 10.1172/JCI117222; Sanchez-Lozada LG, 2000, HYPERTENSION, V36, P642, DOI 10.1161/01.HYP.36.4.642; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schneweis S, 2001, STROKE, V32, P1863, DOI 10.1161/01.STR.32.8.1863; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Shaltout HA, 2003, J PHARMACOL EXP THER, V305, P966, DOI 10.1124/jpet.102.048447; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Starkov AA, 2004, CELL CALCIUM, V36, P257, DOI 10.1016/j.ceca.2004.02.012; Staub F, 2000, NEUROSURGERY, V47, P1106, DOI 10.1097/00006123-200011000-00016; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2007, J NEUROTRAUMA S1, V24, pS59, DOI DOI 10.1089/NEU.2007.9987; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Ungerstedt U, 2004, CURR PHARM DESIGN, V10, P2145, DOI 10.2174/1381612043384105; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valtysson J, 1998, ACTA NEUROCHIR, V140, P387, DOI 10.1007/s007010050113; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wang XD, 2001, GENE DEV, V15, P2922; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Yu GL, 2004, BRAIN RES, V1018, P32, DOI 10.1016/j.brainres.2004.05.056; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	83	56	58	0	7	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	OCT	2008	150	10					1019	1031		10.1007/s00701-008-0021-7			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	363ZP	WOS:000260306300001	18781275				2021-06-18	
J	Jehle, T; Dimitriu, C; Auer, S; Knoth, R; Vidal-Sanz, M; Gozes, I; Lagreze, WA				Jehle, T.; Dimitriu, C.; Auer, S.; Knoth, R.; Vidal-Sanz, M.; Gozes, I.; Lagreze, W. A.			The neuropeptide NAP provides neuroprotection against retinal ganglion cell damage after retinal ischemia and optic nerve crush	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						neuropeptide; NAP; optic nerve crush; retinal ischemia; neuroprotection	VASOACTIVE-INTESTINAL-PEPTIDE; CLOSED-HEAD INJURY; IN-VIVO; NEUROTROPHIC FACTOR; AXONAL REGENERATION; NEURONAL SURVIVAL; RAT MODEL; ACTIVATED MICROGLIA; DEATH; DEGENERATION	Background NAP, an 8-amino acid peptide (NAPVSIPQ=Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln) derived from activity-dependent neuroprotective protein (ADNP), plays an important role in neuronal differentiation and the survival of neurons in different pathological situations. We already discovered that NAP increases the survival of retinal ganglion cells (RGC) in vitro, and supports neurite outgrowth in retinal explants at femtomolar concentrations. The aim of this study was to investigate the effects of NAP on RGC survival after transient retinal ischemia and optic nerve crush. Methods RGC of male Wistar rats were labelled retrogradely with 6 l FluoroGold injected stereotactically into both superior colliculi. Seven days later, retinal ischemia was induced by elevating the intraocular pressure to 120 mm Hg for 60 minutes or by crushing one optic nerve for 10 s after a partial orbitotomy. NAP was either injected intraperitoneally in the concentration of 100 mg/kg 1 day before, directly after, and on the first and the second days after damage, or intravitreally (0.05 or 0.5 mu g/eye) directly after the optic nerve crush. Controls received the same concentrations of a control peptide. Densities of surviving RGC and activated microglial cells (AMC) were quantified in a masked fashion 10 days after damage by counting FluoroGold-labelled cells. Results After retinal ischemia, intraperitoneal injections of NAP increased the number of surviving RGC by 40% (p<0.005) compared to the control group. After optic nerve crush, NAP raised the number of surviving RGC by 31% (p=0.07) when injected intraperitoneally and by 54% (p<0.05) when administered intravitreally. Conclusions NAP acts neuroprotectively in vivo after retinal ischemia and optic nerve crush, and may have potential in treating optic nerve diseases.	[Jehle, T.; Dimitriu, C.; Auer, S.; Lagreze, W. A.] Univ Eye Hosp Freiburg, D-79106 Freiburg, Germany; [Knoth, R.] Univ Freiburg, Freiburg, Germany; [Vidal-Sanz, M.] Univ Murcia, Fac Med, Dept Ophthalmol, Murcia, Spain; [Gozes, I.] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, IL-69978 Tel Aviv, Israel	Jehle, T (corresponding author), Univ Eye Hosp Freiburg, Killianstr 5, D-79106 Freiburg, Germany.	thomas.jehle@uniklinik-freiburg.de	Vidal-Sanz, Manuel/J-6989-2016	Vidal-Sanz, Manuel/0000-0002-9216-1615			Ashur-Fabian O, 2003, PEPTIDES, V24, P1413, DOI 10.1016/j.peptides.2003.08.005; Ashur-Fabian O, 2001, NEUROSCI LETT, V307, P167, DOI 10.1016/S0304-3940(01)01954-1; Bakalash S, 2002, INVEST OPHTH VIS SCI, V43, P2648; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; BELOKOPYTOV M, 2006, INVEST OPHTHALMOL VI, V47; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bodeutsch N, 2000, GLIA, V32, P91, DOI 10.1002/1098-1136(200010)32:1<91::AID-GLIA90>3.0.CO;2-X; Braun, 1999, Expert Opin Investig Drugs, V8, P1599, DOI 10.1517/13543784.8.10.1599; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; Brenneman DE, 1998, ANN NY ACAD SCI, V865, P207, DOI 10.1111/j.1749-6632.1998.tb11180.x; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Cellerino A, 2003, J COMP NEUROL, V467, P97, DOI 10.1002/cne.10908; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Divinski I, 2004, J BIOL CHEM, V279, P28531, DOI 10.1074/jbc.M403197200; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Fischer D, 2000, INVEST OPHTH VIS SCI, V41, P3943; Gellrich NC, 2002, J CRANIO MAXILL SURG, V30, P230, DOI 10.1054/jcms.2002.0312; Glazner GW, 1999, J NEUROCHEM, V73, P2341, DOI 10.1046/j.1471-4159.1999.0732341.x; Gozes I, 2004, J MOL NEUROSCI, V24, P67, DOI 10.1385/JMN:24:1:067; GOZES I, 1987, HUM GENET, V75, P41; Heiduschka P, 2000, NEUROPHARMACOLOGY, V39, P889, DOI 10.1016/S0028-3908(99)00245-2; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; Jehle T, 2001, OPHTHALMOLOGE, V98, P237, DOI 10.1007/s003470170155; Jehle T, 2000, N-S ARCH PHARMACOL, V362, P74, DOI 10.1007/s002100000265; JEHLE T, 2007, INVEST OPHTHALMOL VI, V48; Kacza J, 2001, J NEUROCYTOL, V30, P801, DOI 10.1023/A:1019641404940; Kacza J, 1997, INFLAMM RES, V46, P430, DOI 10.1007/s000110050219; Kaplan DR, 2006, CELL, V125, P224, DOI 10.1016/j.cell.2006.03.031; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lafuente MP, 2002, EXP EYE RES, V74, P181, DOI 10.1006/exer.2001.1122; Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074; Lagreze WA, 2005, INVEST OPHTH VIS SCI, V46, P933, DOI 10.1167/iovs.04-0766; Lagreze WA, 1998, INVEST OPHTH VIS SCI, V39, P1063; Leahy KM, 2004, EXP EYE RES, V79, P131, DOI 10.1016/j.exer.2004.02.007; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; Leker RR, 2002, STROKE, V33, P1085, DOI 10.1161/01.STR.0000014207.05597.D7; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534; Levkovitch-Verbin H, 2003, INVEST OPHTH VIS SCI, V44, P3388, DOI 10.1167/iovs.02-0646; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; Midorikawa R, 2006, CELL, V125, P371, DOI 10.1016/j.cell.2006.02.039; Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962; Nickells RW, 2004, BRAIN RES BULL, V62, P439, DOI 10.1016/j.brainresbull.2003.07.007; Osborne NN, 2004, EYE, V18, P1075, DOI 10.1038/sj.eye.6701588; Pinhasov A, 2003, DEV BRAIN RES, V144, P83, DOI 10.1016/S0165-3806(03)00162-7; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; Sobrado-Calvo P, 2007, J COMP NEUROL, V501, P866, DOI 10.1002/cne.21279; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; THANOS S, 1993, J NEUROSCI, V13, P455; THANOS S, 1994, TRENDS NEUROSCI, V17, P177, DOI 10.1016/0166-2236(94)90098-1; THANOS S, 1992, BRAIN RES, V588, P21, DOI 10.1016/0006-8993(92)91340-K; Visochek L, 2005, J NEUROSCI, V25, P7420, DOI 10.1523/JNEUROSCI.0333-05.2005; Vorwerk CK, 1996, INVEST OPHTH VIS SCI, V37, P1618; Watanabe M, 2002, PROG RETIN EYE RES, V21, P529, DOI 10.1016/S1350-9462(02)00037-X; Yoles E, 1999, INVEST OPHTH VIS SCI, V40, P65; Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104; Zaltzman R, 2005, PEPTIDES, V26, P1520, DOI 10.1016/j.peptides.2005.03.014; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1; Zeng XX, 2000, VISUAL NEUROSCI, V17, P463, DOI 10.1017/S0952523800173122	59	56	60	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	SEP	2008	246	9					1255	1263		10.1007/s00417-007-0746-7			9	Ophthalmology	Ophthalmology	330HV	WOS:000257932500007	18414890				2021-06-18	
J	Stancin, T; Wade, SL; Walz, NC; Yeates, KO; Taylor, HG				Stancin, Terry; Wade, Shari L.; Walz, Nicolay C.; Yeates, Keith O.; Taylor, H. Gerry			Traumatic brain injuries in early childhood: Initial impact on the family	JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS			English	Article						traumatic brain injury; family impact; parent coping; early childhood	ASSESSMENT DEVICE; SEVERITY SCALE; SHORT-TERM; CHILDREN; OUTCOMES; RELIABILITY; ADAPTATION; VALIDITY; HEALTH; PREDICTORS	Objective: The purpose of this study was to examine factors that affect parental burden and distress during the first few months following a traumatic brain injury (TBI) in young children. Methods: Participants were consecutively enrolled children ages 3 through 6 years with either a TBI (n = 89; 21 severe, 22 moderate, and 45 complicated mild) or orthopedic injury (OI; n = 119) requiring hospitalization. During the post-acute period, parents provided information regarding the preinjury family environment and current caregiver functioning and injury-related burden. Results: Compared with parents of young children with OI, parents of children with TBI reported greater overall caregiver burden and greater burden related to the injury. Parents of children with severe TBI also reported more stress with spouses and siblings and higher levels of parental depression and global distress relative to the OI comparison group. Parents of 5- to 6-year-old children reported significantly higher levels of both injury-related burden and distress than parents of 3- to 4-year-old children. Parents of children with mild TBI based on the Glasgow Coma Scale (GCS) who also had positive neuroimaging findings reported greater injury-related burden than parents of children with moderate TBI. Parents reported using a variety of coping strategies, with higher levels of denial and disengagement corresponding with greater injury-related burden and distress. Conclusions: Consistent with previous research on family adaptation to TBI in school-age children, chronic life stresses and interpersonal resources accounted for significant variance in measures of acute injury-related burden and parental distress in parents of younger children, although differences were small. TBI severity defined by GCS scores alone may not be sufficient to identify families at risk of increased burden. Findings suggest that services aimed at facilitating family adjustment following TBI in young children may need to consider a broader definition of risk factors when identifying families who would benefit from interventions.	[Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH 44109 USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp, Dept Rehabil, Med Ctr, Cincinnati, OH USA; [Walz, Nicolay C.] Cincinnati Childrens Hosp, Dept Pediat, Med Ctr, Div Pediat Psychol, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus Childrens Hosp, Div Pediat, Columbus, OH 43210 USA; [Yeates, Keith O.] Childrens Res Inst, Columbus, OH USA; [Taylor, H. Gerry] Rainbow Babies & Childrens Hosp, Dept Pediat, Div Dev & Behav Pediat & Pediat Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Cleveland, OH 44106 USA	Stancin, T (corresponding author), Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH 44109 USA.	tstancin@metrohealth.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR026315, M01RR008084] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 08084, KL2 RR026315, M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042729, R01 HD42729] Funding Source: Medline		ALDWIN CM, 1987, J PERS SOC PSYCHOL, V53, P337, DOI 10.1037/0022-3514.53.2.337; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRAIN INJURY, V14, P679; Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV EX; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Derogatis L., 1982, BRIEF SYMPTOM INVENT; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; HOLAHAN CJ, 1987, J ABNORM PSYCHOL, V96, P3, DOI 10.1037/0021-843X.96.1.3; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lazurus RichardS., 1984, STRESS APPRAISAL COP; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MAYER T, 1984, J TRAUMA, V24, P31, DOI 10.1097/00005373-198401000-00004; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Moos R, 1994, LIFE STRESSORS SOCIA; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Stancin T, 1998, J TRAUMA, V45, P1031, DOI 10.1097/00005373-199812000-00010; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; WADE SL, 2006, TREATING NEURODEVELO, P170; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Youngblut JM, 2006, J PEDIATR PSYCHOL, V31, P608, DOI 10.1093/jpepsy/jsj066	36	56	57	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0196-206X			J DEV BEHAV PEDIATR	J. Dev. Behav. Pediatr.	AUG	2008	29	4					253	261		10.1097/DBP.0b013e31816b6b0f			9	Behavioral Sciences; Psychology, Developmental; Pediatrics	Behavioral Sciences; Psychology; Pediatrics	337CA	WOS:000258411900003	18454041				2021-06-18	
J	Demakis, GJ; Gervais, RO; Rohling, ML				Demakis, George J.; Gervais, Roger O.; Rohling, Martin L.			The effect of failure on cognitive and psychological symptom validity tests in litigants with symptoms of post-traumatic stress disorder	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN-INJURY; FAKE BAD SCALE; COMBAT VETERANS; COMPENSATION SEEKING; INTERPRETIVE METHOD; FORENSIC ASSESSMENT; BASE RATES; PTSD; MEMORY; SCORES	This study examined the influence of performance on cognitive and psychological symptom validity tests on neuropsychological and psychological test performance in claimants evaluated in a medico-legal context (N = 301) with symptoms of PTSD. A second purpose of this study was to examine the influence of the severity of PTSD symptoms on cognitive test performance after excluding patients who failed to put forth adequate best effort and who exaggerated psychiatric symptoms. Patients were administered a battery of neuropsychological measures that were aggregated into a composite measure, the Cognitive-Test Battery Mean (C-TBM). Patients were also administered a battery of psychological tests that were aggregated into another composite measure, the Psychological-Test Battery Mean (P-TBM). We found that failure on cognitive symptom validity tests was associated with significantly poorer neuropsychological functioning, but there was not a significant effect on psychological symptoms. Conversely, failure on psychological symptom validity tests was associated with higher levels of psychopathology, but there was not a significant effect on cognitive ability. Finally, once patients were screened for adequate effort and genuine symptom reporting, the severity of PTSD symptoms did not appear to influence cognitive ability. This is the first study that assessed both types of symptom validity testing in PTSD claimants, which is important given that previous literature has demonstrated cognitive impairment in PTSD and that individuals with PTSD tend to claim cognitive impairment. Implications of these findings are discussed with regard to the existing literature and the relationship between these two types of symptom validity tests.	[Demakis, George J.] Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA; [Rohling, Martin L.] Univ S Alabama, Mobile, AL 36688 USA	Demakis, GJ (corresponding author), Univ N Carolina, Dept Psychol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	gdemakis@uncc.edu					Allen L.M., 1997, CARB 97 MANUAL COMPU; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Beck A. T., 1996, BECK DEPRESSION INVE; Beck A.T., 1993; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Briere J., 2001, DETAILED ASSESSMENT; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; Daly OE, 2002, J TRAUMA STRESS, V15, P461, DOI 10.1023/A:1020913821272; Davidson J, 1996, DAVIDSON TRAUMA SCAL; Delis DC, 1987, CALIFORNIA VERBAL LE; Demakis GJ, 2001, PSYCHOL ASSESSMENT, V13, P240, DOI 10.1037//1040-3590.13.2.240; Elhai JD, 2004, ASSESSMENT, V11, P139, DOI 10.1177/1073191104264965; Frueh BC, 2000, CLIN PSYCHOL REV, V20, P853, DOI 10.1016/S0272-7358(99)00015-X; Frueh BC, 1996, J TRAUMA STRESS, V9, P427, DOI 10.1002/jts.2490090303; Frueh BC, 2003, PSYCHIATR SERV, V54, P84, DOI 10.1176/appi.ps.54.1.84; Golier JA, 2002, AM J PSYCHIAT, V159, P1682, DOI 10.1176/appi.ajp.159.10.1682; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; GREEN P, 2003, STORY RECALL TEST; Green P., 1996, WORD MEMORY TEST USE; Green P., 2003, WORD MEMORY TEST MAN; Greiffenstein MF, 2004, CLIN NEUROPSYCHOL, V18, P573, DOI 10.1080/13854040490888512; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GREIFFENSTEIN MF, CLIN NEUROP IN PRESS; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Guriel Jennifer, 2003, Clin Psychol Rev, V23, P881; Heaton R., 1993, WISCONSIN CARD SORTI; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JACKSON DN, 1998, MULTIDIMENSIONAL APT, V2; Kaemmer B, 2001, MMPI-2: Manual for Administration and Scoring; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Millis S. R., 2004, PRINCIPLES PRACTICE, P1077; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; *OFF INSP GEN, 2005, REV STAT VAR VA DIS; Resnick P.J., 1988, CLIN ASSESSMENT MALI; Rohling ML, 2004, NEUROPSYCHOL REV, V14, P155, DOI 10.1023/B:NERV.0000048182.55980.4b; Rosen GM, 2006, J ANXIETY DISORD, V20, P530, DOI 10.1016/j.janxdis.2005.03.004; Rosen GM, 2003, J ANXIETY DISORD, V17, P361, DOI 10.1016/S0887-6185(02)00200-1; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; SWEET JJ, 1999, FORENSIC NEUROPSYCHO; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Yehuda R, 2005, J CLIN EXP NEUROPSYC, V27, P504, DOI 10.1080/138033990520223	55	56	56	1	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	5					879	895		10.1080/13854040701564482			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	342HP	WOS:000258775500009	18756390				2021-06-18	
J	Fernandez-Espejo, D; Junque, C; Vendrell, P; Bernabeu, M; Roig, T; Bargallo, N; Mercader, JM				Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere; Bernabeu, Montserrat; Roig, Teresa; Bargallo, Nuria; Mercader, Jose Maria			Cerebral response to speech in vegetative and minimally conscious states after traumatic brain injury	BRAIN INJURY			English	Article						Functional magnetic resonance imaging; minimally conscious state; traumatic brain injury; vegetative state	OWN NAME; PERSISTENT; ACTIVATION; AWARENESS; SCALE; COMA; PET	Primary objective: To study cerebral response in a functional magnetic resonance imaging (fMRI) task of speech perception in a sample of patients in vegetative state (VS) and minimally conscious state (MCS) after traumatic brain injury. Methods: Three patients in VS, four patients in MCS and 19 healthy volunteers were enrolled for the study. All subjects underwent an fMRI task of passive listening of narratives played forward and backward, alternated with periods of silence. This study analysed cerebral response to language and to complex sound processing in the healthy subjects' group and in each patient, using SPM5. Results: One patient in VS and one in MCS showed cerebral responses to language and to complex sound very similar to those shown by the healthy volunteers. Two more patients, one in VS and one in MCS, showed significant responses to complex sound only. Finally, one patient in VS and one patient in MCS failed to show significant activation in response to either stimulus. Conclusions: Some patients in VS and MCS can preserve cerebral responses to language and auditory stimuli. fMRI may be useful to identify these responses, which may pass unnoticed in a bedside examination.	[Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere] Univ Barcelona, IDIBAPS, Dept Psychiat & Clin Psychobiol, E-08036 Barcelona, Spain; [Fernandez-Espejo, Davinia; Junque, Carme; Vendrell, Pere; Bargallo, Nuria; Mercader, Jose Maria] IDIBAPS, Inst Biomed Res August Pi & Sunyer, Barcelona, Spain; [Bernabeu, Montserrat; Roig, Teresa] Inst Univ Neurorehabil Guttmann, Dept Neuropsychol, Badalona, Spain; [Bernabeu, Montserrat] Inst Univ Neurorehabil Guttmann, Head Injury Unit, Badalona, Spain; [Bargallo, Nuria; Mercader, Jose Maria] Hosp Clin Barcelona, CDI, Dept Radiol, Neuroradiol Sect, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, IDIBAPS, Dept Psychiat & Clin Psychobiol, Casanova 143, E-08036 Barcelona, Spain.	cjunque@ub.edu	Bargallo, Nuria/G-6854-2016; Junque, Carme/B-4400-2011; Vendrell, Pere/B-4392-2011	Bargallo, Nuria/0000-0001-6284-5402; Junque, Carme/0000-0002-6381-3063; Vendrell, Pere/0000-0001-8918-5440; Fernandez-Espejo, Davinia/0000-0001-5941-7546	Spanish Ministry of Education and ScienceSpanish Government [SAF2007-66077, AP2006-00862]	This study was supported by grant SAF2007-66077 and fellowship AP2006-00862, from the Spanish Ministry of Education and Science. Part of this research work was presented at the Seventh World Congress on Brain Injury (Lisbon, 2008).	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Anton, 2002, 8 INT C FUNCT MAPP H, V16; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Bernat JL, 2007, NEUROLOGY, V68, P885, DOI 10.1212/01.wnl.0000258973.95355.68; Binder JR, 2000, CEREB CORTEX, V10, P512, DOI 10.1093/cercor/10.5.512; Black D, 1996, J ROY COLL PHYS LOND, V30, P119; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Coleman MR, 2007, BRAIN, V130, P2494, DOI 10.1093/brain/awm170; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066; Di HB, 2007, NEUROLOGY, V68, P895, DOI 10.1212/01.wnl.0000258544.79024.d0; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hagen C, 1979, REHABILITATION HEAD, P87; HAGEN C, 1984, LANGUAGE DISORDERS A, P247; JENNETT B, 1972, LANCET, V1, P734; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rousseau MC, 2008, BRAIN INJURY, V22, P123, DOI 10.1080/02699050801895415; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Shiel A, 2004, BRIT J NEUROSURG, V18, P5, DOI 10.1080/02688690410001660625; Staffen W, 2006, J NEUROL NEUROSUR PS, V77, P1383, DOI 10.1136/jnnp.2006.095166	32	56	56	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	11					882	890		10.1080/02699050802403573			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700007	18850346				2021-06-18	
J	Hlatky, R; Valadka, AB; Gopinath, SP; Robertson, CS				Hlatky, Roman; Valadka, Alex B.; Gopinath, Shankar P.; Robertson, Claudia S.			Brain tissue oxygen tension response to induced hyperoxia reduced in hypoperfused brain	JOURNAL OF NEUROSURGERY			English	Article						brain tissue oxygenation; brain trauma; cerebral blood flow; hyperoxia	SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; TOMOGRAPHY; METABOLISM; THERAPY; HYPOXIA; PO2	Object. Increasing PaO2 can increase brain tissue PO2 (PbtO(2)). Nevertheless, the small increase in arterial O-2 content induced by hyperoxia does not increase O-2 delivery much, especially when cerebral blood flow (CBF) is low, and the effectiveness of hyperoxia as a therapeutic intervention remains controversial. The purpose of this study was to examine the role of regional (r)CBF at the site of the PO2 probe in determining the response of PbtO(2) to induced hyperoxia. Methods. The authors measured PaO2 and PbtO(2) at baseline normoxic conditions and after increasing inspired O-2 concentration to 100% on I I I occasion. in 83 patients with severe traumatic brain injury in whom a stable xenon-enhanced computed tomography measurement of CBF was available. The 0, reactivity was calculated as the change in PbtO(2) X 100/change in PaO2. Results. The O-2 reactivity was significantly different (p < 0.001) at the 5 levels of rCBF (< 10, 11-15, 16-20, 21-40, and > 40 ml/100 g/min). When rCBF was < 20 ml/100 g/min, the increase in PNO2 induced by hyperoxia was very small compared with the increase that occurred when rCBF was > 20 ml/100 g/min. Conclusions. Although the level of CBF is probably only one of the factors that determines the PbtO(2) response to hyperoxia, it is apparent from these results that the areas of the brain that would most likely benefit from improved oxygenation are the areas that are the least likely to have increased PbtO(2).	[Hlatky, Roman; Gopinath, Shankar P.; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Hlatky, Roman] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Valadka, Alex B.] Univ Texas Houston, Hlth Sci Ctr, Houston, TX USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		Ahn Edward S, 2005, Clin Neurosurg, V52, P348; Bardt TF, 1998, ACT NEUR S, V71, P153; Dings J, 1998, NEUROL RES, V20, pS71; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Kiening KL, 1998, ACT NEUR S, V71, P172; LAMBERTSEN CJ, 1953, J APPL PHYSIOL, V5, P471; Longhi L, 2002, ACT NEUR S, V81, P315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McLeod AD, 2003, ANESTH ANALG, V97, P851, DOI 10.1213/01.ANE.0000072541.57132.BA; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; ROSTRUP E, 1995, NMR BIOMED, V8, P41, DOI 10.1002/nbm.1940080109; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Watson NA, 2000, EUR J ANAESTH, V17, P152, DOI 10.1046/j.1365-2346.2000.00640.x	25	56	58	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2008	108	1					53	58		10.3171/JNS/2008/108/01/0053			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	248AI	WOS:000252123300007	18173310				2021-06-18	
J	Chibbaro, S; Tacconi, L				Chibbaro, Salvatore; Tacconi, Leonello			Role of decompressive craniectomy in the management of severe head injury with refractory cerebral edema and intractable intracranial pressure. Our experience with 48 cases	SURGICAL NEUROLOGY			English	Article						decompressive craniectomy; malignant brain edema; diffuse brain injury; refractory ICP; cranioplasty	TRAUMATIC BRAIN-INJURY; HYPERTENSION	Background: The effects of decompressive craniectomy in the treatment of severe head injury remain unclear. Only very few randomized studies relating to this topic exist in the literature, including a very small number of patients with no class I evidence. Methods: We rretrospectively reviewed a series of 221 patients operated on for a head injury during a 25-month period. Of these, 48 patients underwent a decompressive craniectomy. All data available on patients' Glasgow Coma Scale score, pupil size and reaction, and intracranial pressure were collected and analyzed. The patients' outcome was evaluated by the Glasgow Outcome Scale (GOS) and the results compared with the data available in the Traumatic Coma Data Bank. Furthermore, the results were analyzed in respect of the time of surgical intervention (early or late), age, and the preoperative Glasgow Coma Score. Results: Decompressive craniectomy reduced the midline shift in all patients with monolateral diffuse brain edema and contusions having a median value of 7 mm; in the remaining, it ameliorated the basal cisterns effacement. At a mean follow-up of 14 months, 6 (12.5%) patients died, 7 (15%) were discharged home with a GOS of 5, 18 (40%) showed a favorable outcome after rehabilitation with a GOS of 4 and 5, 6 (12.5%) had a severe disability (GOS 3), 9 (20%) were in a vegetative state (GOS 2), and 2 were lost to follow-up. The younger age, earlier surgery, and higher preoperative Glasgow Coma Scale score were related to better outcome (P < .001, P < .05, and P < .034, respectively). Conclusion: Our results seem to support the idea that decompressive craniectomy coupled with neurointensive care may be an effective way to reduce intractable raised intracranial pressure, and probably to improve patient outcome. However, it should be obvious that our results and those available in the literature can not be considered conclusive. (c) 2007 Published by Elsevier Inc.	[Chibbaro, Salvatore; Tacconi, Leonello] Univ Hosp, Dept Neurosurg, I-34100 Trieste, Italy	Chibbaro, S (corresponding author), Univ Hosp, Dept Neurosurg, I-34100 Trieste, Italy.	leonello.tacconi@aots.sanita.fvg.it	Chibbaro, Salvatore/AAI-6368-2020	chibbaro, salvatore/0000-0003-1318-1245; tacconi, leonello/0000-0003-3915-5635			Bostrom S, 2005, ACTA NEUROCHIR, V147, P279, DOI 10.1007/s00701-004-0480-4; Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; DeWitt D S, 1995, New Horiz, V3, P376; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAAB MR, ACTA NEUROCHIR S51, P326; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hutchinson PJ, 2005, ACTA NEUROCHIR, V147, P1, DOI 10.1007/s00701-004-0400-7; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; KLEISTWELCH GW, 1999, J NEUROSURG, V90, P157; Koh MS, 2000, SURG NEUROL, V53, P225, DOI 10.1016/S0090-3019(00)00163-4; KUNZE E, ACTA NEUROCHIR S71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1976, INTRACRANIAL PRESSUR, V3, P67; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, V7, P598; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 2001, NEW ENGL J MED, V344, P602, DOI 10.1056/NEJM200102223440810; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Safar P, 2001, NEW ENGL J MED, V345, P66; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stefini R, 1999, NEUROSURGERY, V45, P626, DOI 10.1097/00006123-199909000-00038; WHITFIELD PC, 2000, BRIT J NEUROSURG, V14, P292	32	56	60	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	DEC	2007	68	6					632	638		10.1016/j.surneu.2006.12.046			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	245NU	WOS:000251943000010	17765952				2021-06-18	
J	Corrigan, JD; Lineberry, LA; Komaroff, E; Langlois, JA; Selassie, AW; Wood, KD				Corrigan, John D.; Lineberry, Lee A.; Komaroff, Eugene; Langlois, Jean A.; Selassie, Anbesaw W.; Wood, Kenneth D.			Employment after traumatic brain injury: Differences between men and women	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; rehabilitation; sex	VOCATIONAL-REHABILITATION CLIENTS; POSTTRAUMATIC-STRESS-DISORDER; COMMUNITY INTEGRATION; GENDER-DIFFERENCES; FOLLOW-UP; OUTCOME MEASURES; ACUTE PREDICTORS; SYSTEMATIC BIAS; MAJOR TRAUMA; RETURN	Corrigan JD, Lineberry LA, Komaroff E, Langlois JA, Selassie AW, Wood KD. Employment after traumatic brain injury: differences between men and women. Arch Phys Med Rehabil 2007;88:1400-9. Objective: To determine whether there are sex differences in employment 1 year after traumatic brain injury. Design: Prospective cohort. Setting: Acute care hospitals in South Carolina and Traumatic Brain Injury Model Systems TBIMS) rehabilitation centers. Participants: Subjects in the TBIMS national dataset and the South Carolina Traumatic Brain Injury Follow-up Registry who were expected to be working before injury and followed at 1 year postinjury. Interventions: Not applicable. Main Outcome Measure: Change in employment from preinjury to 1 year postinjury. Results: When other measured influences on change in hours worked were held constant, there were significant interactions for sex by age and sex by marital status. Compared with men, women were more likely to decrease hours or stop working, except in the oldest age group (55-64y) in which men were more likely to stop working. For women, there was a pattern showing better employment outcomes as age increased. Decreased employment for women was most evident for married women, who were much more likely to reduce hours or stop working. There was also a tendency for divorced women to be more likely to stop working when compared with divorced men. Conclusions: These findings run counter to the current literature. Although definitive explanations must await future studies, causal factors arising from differential societal behavior toward women as well as discriminatory attitudes about women and employment deserve further study.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Med Univ S Carolina, Dept Biostat, Charleston, SC 29425 USA; Kessler Med Rehabil Res & Educ Ctr, W Orange, NJ USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Corrigan, JD (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, 480 Med Ctr Dr, Columbus, OH 43210 USA.	corrigan.l@osu.edu	Corrigan, John D./E-2921-2011		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU421926] Funding Source: Medline		Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bounds TA, 2003, NEUROREHABILITATION, V18, P189; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; *CDCP DIV AC CAR R, 1999, TRAUM BRAIN INJ US R; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; CREPEAU F, 1993, NEUROPSYCHOL REHABIL, V3, P5; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Fleming J, 1999, BRAIN INJURY, V13, P417; FRASER RT, 1995, NEUROREHABILITATION, V5, P39, DOI 10.3233/NRE-1995-5104; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Holbrook TL, 2002, J TRAUMA, V53, P882, DOI 10.1097/00005373-200211000-00012; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; *J HOPK U TRIAN IN, 1997, X ICDMAP 90 SOFTW US; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MCMAHON B, 2002, EVALUATION PROGRESSI; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; NOSEK MA, 2006, BRAIN INJ PROF, V3, P28; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P25; Rennison C. M., 2003, INTIMATE PARTNER VIO; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SELASSIE A, 2004, S CAROLINA TRAUMATIC, P118; Slewa-Younan S, 2004, ARCH PHYS MED REHAB, V85, P376, DOI 10.1016/j.apmr.2003.05.007; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; TJADEN P, 2000, FUL REPORT PREVALENC; *TRAUM BRAIN INJ N, TBI MOD SYST NAT DAT; *US BUR LAB STAT, EMPL CHAR FAM 2006; *US BUR LAB STAT, 2005, WOM LAB FORC DAT; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	58	56	56	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2007	88	11					1400	1409		10.1016/j.apmr.2007.08.006			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	229AT	WOS:000250774400005	17964879				2021-06-18	
J	Sigmund, GA; Tong, KA; Nickerson, JP; Wall, CJ; Oyoyo, U; Ashwal, S				Sigmund, Geoffrey A.; Tong, Karen A.; Nickerson, Joshua P.; Wall, Christopher J.; Oyoyo, Udo; Ashwal, Stephen			Multimodality comparison of neuroimaging in pediatric traumatic brain injury	PEDIATRIC NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; HEAD-INJURY; MAGNETIC-RESONANCE; INTENSIVE-CARE; FIELD MR; CT; LESIONS; CHILDREN; TOMOGRAPHY; IMAGES	Traumatic brain injury is a common cause of death and disability in children; early neuroimaging has assumed an increasingly important role in evaluating the extent and severity of injury. Several imaging methods were assessed in a study of 40 children with traumatic brain injury: computed tomography (CT), T-2-weighted magnetic resonance imaging (MRI), fluid-attenuated inversion recovery (FLAIR) MRI, and susceptibility-weighted imaging (SWI) MRI to determine which were most valuable in predicting 6-12 month outcomes as classified by the Pediatric Cerebral Performance Category Scale score. Patients were subdivided into three groups: (1) normal, (2) mild disability, and (3) moderate/severe disability/persistent vegetative state. T-2, FLAIR, and SWI showed no significant difference in lesion volume between normal and mild outcome groups, but did indicate significant differences between normal and poor and between mild and poor outcome groups. Computed tomography revealed no significant differences in lesion volume between any groups. The findings suggest that T-2, FLAIR, and SWI MRI sequences provide a more accurate assessment of injury severity and detection of outcome-influencing lesions than does CT in pediatric traumatic brain injury patients. Although CT was inconsistent at lesion detection/outcome prediction, it remains an essential part of the acute traumatic brain injury work-up to assess the need for neurosurgic intervention. (C) 2007 by Elsevier Inc. All rights reserved.	Loma Linda Univ, Med Ctr, Dept Radiol, Sch Med, Loma Linda, CA 92354 USA; Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; Univ Vermont, Fletcher Allen Healthcare, Burlington, VT USA; Univ Saskatchewan, Dept Med Imaging, Saskatoon, SK, Canada	Tong, KA (corresponding author), Loma Linda Univ, Med Ctr, Dept Radiol, Sch Med, Schuman Pavil,Rm B623,11234 Anderson St, Loma Linda, CA 92354 USA.	ktong@ahs.llumc.edu					Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; Eder HG, 2000, CHILD NERV SYST, V16, P21, DOI 10.1007/s003810050005; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Meyer P G, 2001, Curr Opin Crit Care, V7, P81, DOI 10.1097/00075198-200104000-00005; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Ogawa T, 1992, Acta Neurochir Suppl (Wien), V55, P8; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; SMITH AS, 1985, AM J ROENTGENOL, V145, P949, DOI 10.2214/ajr.145.5.949; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tsuchiya T, 1996, AM J NEURORADIOL, V17, P1081; Tsurushima H, 1996, NEUROL SURG TOKYO, V24, P891; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215	27	56	69	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0887-8994	1873-5150		PEDIATR NEUROL	Pediatr. Neurol.	APR	2007	36	4					217	226		10.1016/j.pediatrneurol.2007.01.003			10	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	161QV	WOS:000246031400002	17437903				2021-06-18	
J	Maruishi, M; Miyatani, M; Nakao, T; Muranaka, H				Maruishi, M.; Miyatani, M.; Nakao, T.; Muranaka, H.			Compensatory cortical activation during performance of an attention task by patients with diffuse axonal injury: a functional magnetic resonance imaging study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; MULTIPLE-SCLEROSIS; EARLIEST STAGE; HEAD-INJURY; FMRI; MS; REORGANIZATION; IMPAIRMENT; SEQUELAE	Objective: To determine how cortical compensation occurs in higher cognitive systems during the recovery phase of diffuse axonal injury (DAI). Design: 12 right-handed patients with a magnetic resonance imaging (MRI) lesion pattern compatible with pure DAI were identified. Pure DAI was defined as finding of traumatic microbleeds on T2*-weighted gradient-echo images in the absence of otherwise traumatic or non-traumatic MRI abnormalities. 12 matched healthy controls were also enrolled. Functional magnetic resonance imaging (fMRI) was used to assess brain activation during a working memory test (Paced Visual Serial Attention Test (PVSAT)). Results: No significant group differences were observed in reaction times for the PVSAT. Although patients with pure DAI committed a few errors during the PVSAT, controls respond correctly to each probe. Controls showed activations in the left frontal gyrus, left parietal gyrus and right inferior parietal gyrus. Patients with pure DAI showed activations in the left inferior frontal gyrus, right inferior frontal gyrus and right middle frontal gyrus. Between-group analysis of the PVSAT task showed significantly greater activation of the right inferior frontal gyrus (BA 45) and right middle frontal gyrus (BA 9) in patient with pure DAI versus controls. Conclusions: Patients with pure DAI require compensatory activation of the contralateral (right) prefrontal region to carry out activities similar to healthy controls. These findings provide further evidence for the adaptive capacity of neuronal systems and brain plasticity during the recovery stages of DAI.	Hiroshima Prefectural Rehabil Ctr, Higher Brain Funct Ctr, Higashihiroshima 7390036, Japan; Hiroshima Univ, Grad Sch Educ, Psychol Lab, Higashihiroshima 724, Japan	Maruishi, M (corresponding author), Hiroshima Prefectural Rehabil Ctr, Higher Brain Funct Ctr, 295-3 Taguchi, Higashihiroshima 7390036, Japan.	maruishi@rehab-hiroshima.gr.jp	nakao, takashi/U-7188-2017	nakao, takashi/0000-0002-2227-4526			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ashburner J, 1997, NEUROIMAGE, V6, P209, DOI 10.1006/nimg.1997.0290; Audoin B, 2005, HUM BRAIN MAPP, V24, P216, DOI 10.1002/hbm.20083; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chang L, 2001, NEUROLOGY, V57, P1001, DOI 10.1212/WNL.57.6.1001; Chein J. M., 2003, HDB NEUROPSYCHOLOGY, V9, P299; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; D'Esposito M, 2000, EXP BRAIN RES, V133, P3, DOI 10.1007/s002210000395; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; Ernst T, 2002, NEUROLOGY, V59, P1343, DOI 10.1212/01.WNL.0000031811.45569.B0; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; FOS LA, 2000, APPL NEUROPSYCHOL, V9, P97; FRISTON KJ, 1995, NEUROIMAGE, V2, P166, DOI 10.1006/nimg.1995.1019; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P965, DOI 10.1076/jcen.25.7.965.16490; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; JENKINS IH, 1994, J NEUROSCI, V14, P3775; Mainero C, 2004, NEUROIMAGE, V21, P858, DOI 10.1016/j.neuroimage.2003.10.004; Maruishi M, 2004, NEUROIMAGE, V21, P1604, DOI 10.1016/j.neuroimage.2003.12.001; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Nagels G, 2005, CLIN NEUROL NEUROSUR, V107, P218, DOI 10.1016/j.clineuro.2004.11.016; Olfield R. C., 1971, NEUROPSYCHOLOGIA, V9, P97; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Penner IK, 2003, J NEUROL, V250, P461, DOI 10.1007/s00415-003-1025-0; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Staffen W, 2002, BRAIN, V125, P1275, DOI 10.1093/brain/awf125; TALAIRACH J, 1998, CO PLANAR STEREOTAXI; Wishart HA, 2004, NEUROLOGY, V62, P234, DOI 10.1212/01.WNL.0000103238.91536.5F; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010	36	56	56	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2007	78	2					168	173		10.1136/jnnp.2006.097345			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	126NY	WOS:000243520800015	16952916	Green Published			2021-06-18	
J	Shen, YM; Kou, ZF; Kreipke, CW; Petrov, T; Hu, JN; Haacke, EM				Shen, Yimin; Kou, Zhifeng; Kreipke, Christian W.; Petrov, Theodor; Hu, Jiani; Haacke, E. Mark			In vivo measurement of tissue damage, oxygen saturation changes and blood flow changes after experimental traumatic brain injury in rats using susceptibility weighted imaging	MAGNETIC RESONANCE IMAGING			English	Article						cerebral blood flow; susceptibility weighted imaging; traumatic brain injury; experimental model; blood oxygen saturation	CONTROLLED CORTICAL IMPACT; SPIN-LABELED MRI; PERFUSION; ENDOTHELIN-1; HIPPOCAMPUS; EXPRESSION; MODEL; HYPERVENTILATION; CORTEX	Traumatic brain injury (TBI) is a prevalent disease, and many TBI patients experience disturbed cerebral blood flow (CBF) after injury. Moreover, TBI is difficult to quantify with conventional imaging modalities. In this paper, we utilized susceptibility weighted imaging (SWI) as a means to monitor functional blood oxygenation changes and to quantify CBF changes in animals after trauma. In this study using six rats, brain trauma was induced by a weight drop model and the brain was scanned over four time points: pre trauma, and 4 h, 24 h and 48 h post trauma. Five rats survived and one died after trauma. A blood phase analysis using filtered SWI phase images suggested that three rats recovered after 48 h and two rats deteriorated. SWI also suggested that CBF decreased by up to 26%. The CBF change is in agreement with the results of arterial spin labeling methods conducted in this study and with previously published results. Furthermore, SWI revealed an enlargement of the major venous vasculature in deep brain structures, in accordance with the location of diffuse axonal injury. Compared with the traditional, invasive, clinical monitoring of cerebral vascular damage and reduction in blood flow, this method offers a novel, safe and noninvasive approach to quantify changes in oxygen saturation and CBF and to visualize structural changes in blood vasculature after TBI. (c) 2007 Elsevier Inc. All rights reserved.	Magnet Resonance Imaging Inst Biomed Res, Detroit, MI 48202 USA; Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA; Wayne State Univ, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Haacke, EM (corresponding author), Magnet Resonance Imaging Inst Biomed Res, Detroit, MI 48202 USA.	nmrimaging@aol.com			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39860] Funding Source: Medline		Abu-Judeh HH, 1999, NUCL MED COMMUN, V20, P505, DOI 10.1097/00006231-199906000-00003; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; Bouma G J, 1995, New Horiz, V3, P384; *BRAIN TRAUM FDN, 2000, GUID PERH MAN TRAUM; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Calamante F, 1999, J CEREBR BLOOD F MET, V19, P701, DOI 10.1097/00004647-199907000-00001; CDC, 2003, REP C MILD TRAUM BRA; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; DETRE JA, 1994, NMR BIOMED, V7, P75, DOI 10.1002/nbm.1940070112; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Haacke E M, 1999, MAGNETIC RESONANCE I, P741; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haacke EM, 1997, HUM BRAIN MAPP, V5, P341, DOI 10.1002/(SICI)1097-0193(1997)5:5<341::AID-HBM2>3.0.CO;2-3; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Hyder F, 2001, NMR BIOMED, V14, P413, DOI 10.1002/nbm.733; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McBeth BD, 2005, ACAD EMERG MED, V12, P483, DOI 10.1197/j.aem.2004.11.028; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Mulvey JM, 2004, NEUROCRIT CARE, V1, P391, DOI 10.1385/NCC:1:3:391; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Reichenbach JR, 2000, J COMPUT ASSIST TOMO, V24, P949, DOI 10.1097/00004728-200011000-00023; Ritter A M, 1994, Neurosurg Clin N Am, V5, P633; Robertson CL, 2000, ACT NEUR S, V76, P187; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; SCHIERHOUT G, 2000, COCHRANE DB SYST REV, V2; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; WEISSKOFF RM, 1992, MAGNET RESON MED, V24, P375, DOI 10.1002/mrm.1910240219; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; ZAUNER A, 1997, HEAD INJURY PATHOLOG, P1; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505; 2000, J NEUROTRAUMA, V17, P513	42	56	71	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	FEB	2007	25	2					219	227		10.1016/j.mri.2006.09.018			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	136YZ	WOS:000244261300010	17275617				2021-06-18	
J	Ettelt, S; Ruhrmann, S; Barnow, S; Buthz, F; Hochrein, A; Meyer, K; Kraft, S; Reck, C; Pukrop, R; Klosterkotter, J; Falkai, P; Maier, W; Wagner, M; Freyberger, HJ; Grabe, HJ				Ettelt, S.; Ruhrmann, S.; Barnow, S.; Buthz, F.; Hochrein, A.; Meyer, K.; Kraft, S.; Reck, C.; Pukrop, R.; Klosterkoetter, J.; Falkai, P.; Maier, W.; Wagner, M.; Freyberger, H. J.; Grabe, H. J.			Impulsiveness in obsessive-compulsive disorder: results from a family study	ACTA PSYCHIATRICA SCANDINAVICA			English	Article						obsessive-compulsive disorder; impulsiveness; cognitive impulsiveness; neuropsychological disinhibition	TRAUMATIC BRAIN-INJURY; EPIDEMIOLOGY; PERSONALITY; INVENTORY; SYMPTOMS	Objective: Although obsessive-compulsive disorder (OCD) is usually conceptualized as an anxiety disorder some studies suggested it to be a deficit of impulse control. The purpose of this study was to assess impulsiveness in OCD families and compare it to control families. Method: Seventy cases and their 139 relatives were compared with 70 controls and their 134 relatives from a German family study on OCD (German Epidemiologic Network for OCD Studies). All subjects were interviewed and diagnosed according DSM-IV criteria and were administered the Barratt Impulsiveness Scale (BIS) and PADUA-Inventory to assess obsessive-compulsive symptoms. Results: OCD subjects had significantly higher scores of cognitive impulsiveness. However, first-degree relatives of OCD cases and of controls had comparable BIS-11 scores. Significant associations of aggressive obsessions and checking with cognitive impulsiveness were found. Conclusion: OCD is a severe mental disorder that is characterized by a lack of cognitive inhibition. However, impulsiveness does not represent a familial trait in families of OCD subjects.	Ernst Moritz Arndt Univ Greifswald, Dept Psychiat & Psychotherapy, D-18437 Stralsund, Germany; Univ Cologne, Dept Psychiat & Psychotherapy, Cologne, Germany; Univ Bonn, Dept Psychiat & Psychotherapy, D-5300 Bonn, Germany; Univ Homburg, Dept Psychiat & Psychotherapy, D-6650 Homburg, Germany	Ettelt, S (corresponding author), Ernst Moritz Arndt Univ Greifswald, Klinikum Hansestadt Stralsund, Rostocker Chaussee 70, D-18437 Stralsund, Germany.	ettelt@uni-greifswald.de	Wagner, Michael/E-2325-2011; Falkai, Peter/E-3273-2017; Ruhrmann, Stephan/AAG-9470-2020	Wagner, Michael/0000-0003-2589-6440; Falkai, Peter/0000-0003-2873-8667; Ruhrmann, Stephan/0000-0002-6022-2364			Barratt ES, 1985, MOTIVATION EMOTION P, P137; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Buss A. H., 1975, TEMPERAMENT THEORY P; Caci H, 2003, ACTA PSYCHIAT SCAND, V107, P34, DOI 10.1034/j.1600-0447.2003.01464.x; Chamberlain SR, 2005, NEUROSCI BIOBEHAV R, V29, P399, DOI 10.1016/j.neubiorev.2004.11.006; Denys D, 2004, J CLIN PSYCHIAT, V65, P11; DONOVAN NJ, 1994, AM J PSYCHIAT, V151, P618; Eysenck S. B. G., 1975, MANUAL EYSENCK PERSO; Fontenelle LE, 2005, PSYCHIAT CLIN NEUROS, V59, P30, DOI 10.1111/j.1440-1819.2005.01328.x; GOODMAN WK, 1989, ARCH GEN PSYCHIAT, V46, P1006; Grabe HJ, 2000, EUR ARCH PSY CLIN N, V250, P262, DOI 10.1007/s004060070017; GRABE HJ, 2006, IN PRESS J PSYCHIAT; Grados MA, 2003, INT REV PSYCHIATR, V15, P350, DOI 10.1080/09540260310001606737; Hand I, 1991, VERHALTENSTHERAPIE, V1, P223, DOI DOI 10.1159/000257972; HEATH AC, 1994, J PERS SOC PSYCHOL, V66, P762, DOI 10.1037/0022-3514.66.4.762; Herpertz S, 1997, NERVENARZT, V68, P171, DOI 10.1007/s001150050112; HOLLANDER E, HDB PSYCHIAQT MEASUR, P691; John U, 2001, SOZ PRAVENTIV MED, V46, P186, DOI 10.1007/BF01324255; KARNO M, 1988, ARCH GEN PSYCHIAT, V45, P1094, DOI 10.1001/archpsyc.1988.01800360042006; Ketzenberger KE, 1998, PSYCHOL REP, V83, P303, DOI 10.2466/PR0.83.5.303-306; Kochman F, 2001, PRESSE MED, V30, P1747; KOLADA JL, 1994, ACTA PSYCHIAT SCAND, V89, P24, DOI 10.1111/j.1600-0447.1994.tb05788.x; Lyoo IK, 2003, ACTA PSYCHIAT SCAND, V107, P298, DOI 10.1034/j.1600-0447.2003.00054.x; MANNUZZA S, 1986, J PSYCHIAT RES, V20, P317, DOI 10.1016/0022-3956(86)90034-8; Mannuzza S, 1985, FAMILY INFORMANT SCH; Mataix-Cols D, 2004, ARCH GEN PSYCHIAT, V61, P564, DOI 10.1001/archpsyc.61.6.564; MAX JE, 1995, J AM ACAD CHILD PSY, V34, P45, DOI 10.1097/00004583-199501000-00012; Mohammadi MR, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-2; PFOHL B, 1990, BIOL PSYCHIAT, V28, P41, DOI 10.1016/0006-3223(90)90430-A; SANAVIO E, 1988, BEHAV RES THER, V26, P169, DOI 10.1016/0005-7967(88)90116-7; Schruers K, 2005, ACTA PSYCHIAT SCAND, V111, P261, DOI 10.1111/j.1600-0447.2004.00502.x; Sieg J, 2003, VERHALTENSTHERAPIE, V13, P96, DOI 10.1159/000072182; Snider LA, 2004, MOL PSYCHIATR, V9, P900, DOI 10.1038/sj.mp.4001542; STEIN DJ, 1994, J NERV MENT DIS, V182, P240, DOI 10.1097/00005053-199404000-00009; WEISSMAN MM, 1994, J CLIN PSYCHIAT, V55, P5; ZIMMERMANN P, 2002, TESTBATTERIE AUFME 1	36	56	56	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-690X	1600-0447		ACTA PSYCHIAT SCAND	Acta Psychiatr. Scand.	JAN	2007	115	1					41	47		10.1111/j.1600-0447.2006.00835.x			7	Psychiatry	Psychiatry	117GO	WOS:000242861300007	17201865				2021-06-18	
J	Ho, J; Kleiven, S				Ho, Johnson; Kleiven, Svein			Dynamic response of the brain with vasculature: A three-dimensional computational study	JOURNAL OF BIOMECHANICS			English	Article						human head model; finite element analysis; cerebral blood vessels; traumatic brain injury	HUMAN HEAD; INJURY; IMPACT; SIZE	To date, the influence of the vasculature on the dynamic response of the brain has not been studied with a complete three-dimensional (3D) finite element head model. In this study, short duration rotational (10,000 rad/s(2) with a duration of 5 ms) and translational (100 G with a duration of 5 ms) acceleration impulses were applied to the 3D finite element models to study the dynamic response of the brain. The hypothesis of this study was that due to the convoluted organization and non-linear material properties of cerebral vasculature, the difference in maximum principle strain between models with and without vasculature should be minimal. The effects of non-linear material properties and the convoluted structure of the vasculature were examined by comparing the results from the 3D finite element models. The peak average strain reduction in a model with non-linear elastic vasculature and a model with linear elastic vasculature compared to a model without vasculature was 2% and 5%, respectively, indicating that the influence of the vasculature on the dynamic response of the brain is minimal. (c) 2007 Elsevier Ltd. All rights reserved.	Royal Inst Technol, Sch Technol Hlth, Div Neuron Engn, Stockholm, Sweden	Ho, J (corresponding author), Royal Inst Technol, Sch Technol Hlth, Div Neuron Engn, Stockholm, Sweden.	johnsonh@kth.se; sveink@kth.se	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Ho, Johnson/0000-0001-9785-2071			ALDMAN B, 1981, P HEAD NECK INJ CRIT; ARBOGAST KB, 1997, P 41 STAPP CAR CRASH, P293; BAIN BC, 2000, J BIOMECH ENG, V16, P615; CHALUPNIK JD, 1971, 7111 ME U WASH; DONNELLY BR, 1998, P 26 INT WORKSH, P47; ESTES MS, 1970, 70BHF13 ASME; Fung Y. C, 1981, BIOMECHANICS MECH PR; HOLBOURN AHS, 1943, MECH HEAD INJURIES, P438; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; *LIV SOFTW TECHN C, 2003, LSDYNA KEYWORD USERS; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; *MATH WORKS INC, 1994, MATH WORKS MATLAB RE; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Monson K. L., 2001, THESIS U CALIFORNIA; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; OMORI K, 2000, P 2000 ASME INT MECH; Parnaik Yednesh, 2004, Stapp Car Crash J, V48, P259; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; ZHOU C, 1994, 942314 SAE	30	56	58	0	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.		2007	40	13					3006	3012		10.1016/j.jbiomech.2007.02.011			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	222EB	WOS:000250277800023	17433331				2021-06-18	
J	O'Bryant, SE; Engel, LR; Kleiner, JS; Vasterling, JJ; Black, FW				O'Bryant, Sid E.; Engel, Lisa R.; Kleiner, Jennifer S.; Vasterling, Jennifer J.; Black, F. William			Test of memory malingering (TOMM) trial 1 as a screening measure for insufficient effort	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE DYSFUNCTION; COGNITIVELY INTACT; NORMATIVE DATA; PERFORMANCE; VALIDATION; RATES; EXAGGERATION; DEPRESSION; CRITERIA	The identification of insufficient effort is critical to neuropsychological evaluation, and several existing instruments assess effort on neuropsychological tasks. Yet instruments designed to detect insufficient effort are underutilized in standard neuropsychological assessments, perhaps in part because they typically require significant administration time and are, therefore, not ideally suited to screening contexts. The Test of Memory Malingering (TOMM) is a commonly administered, well-validated symptom validity test. This study evaluates the utility of TOMM Trial 1 as a relatively brief screening measure of insufficient effort. Results suggest that TOMM Trial 1 demonstrates high diagnostic accuracy and is a viable option for screening insufficient effort. Diagnostic accuracy estimates are presented for a range of base rates. The need for more comprehensive SVT assessment in most clinical and forensic situation is discussed.	New Orleans VA Med Ctr, New Orleans, LA USA; Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA	O'Bryant, SE (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Neuropsychiat & Behav Sci, 3601 4th St STOP 8321, Lubbock, TX 79430 USA.	sid.obryant@ttuhsc.edu		O'Bryant, Sid/0000-0003-0582-5266			Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini KJ, 2003, J OCCUP ENVIRON MED, V45, P1087, DOI 10.1097/01.jom.0000085886.18136.7d; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Camara WJ, 2000, PROF PSYCHOL-RES PR, V31, P141, DOI 10.1037/0735-7028.31.2.141; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Green P., 1996, WORD MEMORY TEST USE; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Lynch W, 2004, J HEAD TRAUMA REHAB, V19, P277, DOI 10.1097/00001199-200405000-00008; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; MCCAFFREY RJ, 2003, PRACTITIONERS GUIDE; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; O'Bryant SE, 2004, ARCH CLIN NEUROPSYCH, V19, P489, DOI 10.1016/j.acn.2003.07.001; O'Bryant SE, 2006, CLIN NEUROPSYCHOL, V20, P533, DOI 10.1080/13854040590967568; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481	29	56	56	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2007	21	3					511	521		10.1080/13854040600611368			11	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	158HA	WOS:000245781200088	17455034				2021-06-18	
J	Serino, A; Ciaramelli, E; Di Santantonio, A; Malagu, S; Servadei, F; Ladavas, E				Serino, Andrea; Ciaramelli, Elisa; Di Santantonio, Anna; Malagu, Susanna; Servadei, Franco; Ladavas, Elisabetta			A pilot study for rehabilitation of central executive deficits after traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; working memory; working memory training; central executive system; Glasgow Coma Scale	WORKING-MEMORY; COGNITIVE REHABILITATION; DIVIDED ATTENTION; HEAD-INJURY; IMPAIRMENTS; RECALL	Primary objective: An impairment of the central executive system (CES) of working memory (WM) is a common consequence of traumatic brain injury (TBI), and may also explain deficits in divided attention, long-term memory and executive functions. Here we investigated the efficacy of a rehabilitative program (working memory training: WMT) targeting the CES in improving WM and other cognitive functions dependent on this system. Methods and procedures: Nine TBI patients with severe WM deficits underwent the WMT (experimental training). The WMT was preceded by a general stimulation training (GST, control training). Patients' cognitive performance was evaluated at the admission, after the GST and at the end of the WMT. Main outcomes and results: Whereas the GST had no effect on patients' performance, after the WMT patients improved in all the cognitive functions dependent on the CES, but not in those functions not thought to tap this system. Importantly, a beneficial WMT effect was found on patients' everyday life functioning. Conclusions: The results support the efficacy of the WMT in recovering CES impairments.	Univ Bologna, Dipartimento Psicol, I-40127 Bologna, Italy; Ctr Studi & Ric Neurosci Cognit, Cesena, Italy; Osped Bufalini, Cesena, Italy	Ladavas, E (corresponding author), Univ Bologna, Dipartimento Psicol, Viale Berti Pichat 5, I-40127 Bologna, Italy.	elisabetta.ladavas@unibo.it		Servadei, Franco/0000-0002-3595-3464; LADAVAS, ELISABETTA/0000-0001-8930-725X			Baddeley A, 2003, NAT REV NEUROSCI, V4, P829, DOI 10.1038/nrn1201; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A, 2002, NEUROPSYCHOLOGIA, V40, P1737, DOI 10.1016/S0028-3932(01)00146-4; Baddeley A. D., 1986, WORKING MEMORY; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Cappa SF, 2005, EUR J NEUROL, V12, P665; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CIARAMELLI E, 2006, GIORNALE I PSICOLOGI, V3, P607; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; CULBERTSON WC, 2001, TOWER LONDON; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Davidson PSR, 2006, J INT NEUROPSYCH SOC, V12, P210, DOI 10.1017/S1355617706060334; Diehr MC, 1998, ASSESSMENT, V5, P375, DOI 10.1177/107319119800500407; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATEER CA, 1990, COGNITIVE REHABILITA, P68; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; Robertson IH, 1996, GOAL MANAGEMENT TRAI; Serino A, 2006, BRAIN INJURY, V20, P23, DOI 10.1080/02699050500309627; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; SPINNLER H, 1987, ITAL J NEUROL SCI S6, V8, P7; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; Sturm W, 1997, NEUROPSYCHOL REHABIL, V7, P81, DOI 10.1080/713755526; TEASDALE G, 1974, LANCET, V2, P81; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110; ZOCCOLOTTI P, 1994, BATTERIA TEST ESAME	48	56	58	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2007	21	1					11	19		10.1080/02699050601151811			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141FQ	WOS:000244564600002	17364515				2021-06-18	
J	Beffert, U; Farsian, FN; Masiulis, I; Hammer, RE; Yoon, SO; Giehl, KM; Herz, J				Beffert, Uwe; Farsian, Farnas Nematollah; Masiulis, Irene; Hammer, Robert E.; Yoon, Sung Ok; Giehl, Klaus M.; Herz, Joachim			ApoE receptor 2 controls neuronal survival in the adult brain	CURRENT BIOLOGY			English	Article							LIPOPROTEIN RECEPTORS; SYNAPTIC PLASTICITY; INDUCED APOPTOSIS; CORTICAL-NEURONS; PROTEIN-KINASE; MICE LACKING; REELIN; DEATH; DISRUPTION; MODULATION	A central pathogenic feature of neurodegenerative diseases and neurotrauma is the death of neurons. A mechanistic understanding of the factors and conditions that induce the dysfunction and death of neurons is essential for devising effective treatment strategies against neuronal loss after trauma or during aging. Because Apolipoprotein E (ApoE) is a major risk factor for several neurodegenerative diseases, including Alzheimer's disease [1], a direct or indirect role of ApoE receptors in the disease process is likely. Here we have used gene targeting in mice to investigate possible roles of ApoE receptors in the regulation of neuronal survival. We demonstrate that a differentially spliced isoform of an ApoE receptor, ApoE receptor 2 (Apoer2), is essential for protection against neuronal cell loss during normal aging. Furthermore, the same splice form selectively promotes neuronal cell death after injury through mechanisms that may involve serine/threonine kinases of the Jun N-terminal kinase (JNK) family. These findings raise the possibility that ApoE and its receptors cooperatively regulate common mechanisms that are essential to neuronal survival in the adult brain.	Univ Texas, Southwestern Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, Southwestern Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, Southwestern Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Ohio State Univ, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Ohio State Univ, Dept Cellular & Mol Biochem, Columbus, OH 43210 USA; Univ Freiburg, Zentrum Neurowissenschaft, D-79104 Freiburg, Germany	Giehl, KM (corresponding author), Univ Texas, Southwestern Med Ctr, Dept Mol Genet, 5323 Harry Hines blvd, Dallas, TX 75390 USA.	klausgiehl@web.de; joachim.herz@utsouthwestern.edu	Yoon, Sung Ok/C-5992-2012		NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37 HL063762] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL063762] Funding Source: NIH RePORTER		Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Ballif BA, 2003, MOL BRAIN RES, V117, P152, DOI 10.1016/S0169-328X(03)00295-X; Beffert U, 2006, J NEUROSCI, V26, P2041, DOI 10.1523/JNEUROSCI.4566-05.2006; Beffert U, 2005, NEURON, V47, P567, DOI 10.1016/j.neuron.2005.07.007; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Bonatz H, 2000, J NEUROSCI METH, V100, P105, DOI 10.1016/S0165-0270(00)00238-7; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Chen Y, 2005, J NEUROSCI, V25, P8209, DOI 10.1523/JNEUROSCI.1951-05.2005; GIEHL K, 1995, EXP BRAIN RES, V103, P344; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Hoe HS, 2006, J BIOL CHEM, V281, P3425, DOI 10.1074/jbc.M509380200; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; Lo EH, 2002, J NEUROSCI RES, V69, P1, DOI 10.1002/jnr.10270; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; May P, 2003, J BIOL CHEM, V278, P37386, DOI 10.1074/jbc.M305858200; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; OLEARY DDM, 1993, NEURON, V10, P991, DOI 10.1016/0896-6273(93)90049-W; OUDEGA M, 1994, J COMP NEUROL, V347, P115, DOI 10.1002/cne.903470109; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Stockman RH, 2000, RES HUMAN SOCI CONFL, V2, P1; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	26	56	59	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0960-9822	1879-0445		CURR BIOL	Curr. Biol.	DEC 19	2006	16	24					2446	2452		10.1016/j.cub.2006.10.029			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	119UP	WOS:000243039800028	17174920	Bronze			2021-06-18	
J	Qiu, WS; Shen, H; Zhang, Y; Wang, WM; Liu, WG; Jiang, QZ; Luo, M; Manou, M				Qiu, Wusi; Shen, Hong; Zhang, Ying; Wang, Weimin; Liu, Weiguo; Jiang, Qizhou; Luo, Ming; Manou, Merriem			Noninvasive selective brain cooling by head and neck cooling is protective in severe traumatic brain injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						traumatic brain injury; hypothermia; selective brain cooling; intracranial pressure; prognosis	PROMISING TREATMENT MODALITY; THERAPEUTIC HYPOTHERMIA; SYSTEMIC HYPOTHERMIA; CLINICAL-TRIAL; TEMPERATURE; OPPORTUNITIES; PITFALLS; RATS	Therapeutic hypothermia is a promising treatment for patients with severe traumatic brain injury (TBI). We present here the results of a study in which noninvasive selective brain cooling (SBC) was achieved using a head cap and neckband. Ninety patients with severe TBI were divided into a normothermia control group (n = 45) and a SBC group (n = 45), whose brain temperature was maintained at 33-35 degrees C for 3 days using a combination of head and neck cooling. At 24, 48 and 72 h after injury, the mean intracranial pressure (ICP) values of the patients who underwent SBC were lower than those of the normothermia controls (19.14 +/- 2.33, 19.72 +/- 1.73 and 17.29 +/- 2.07 mmHg, versus 23.41 +/- 2.51, 20.97 +/- 1.86, and 20.13 +/- 1.87 mmHg, respectively, P < 0.01). There was a significant difference in the neurological recovery of the two groups at the 6-month follow-up after TBI. Good neurological outcome (Glasgow Outcome Scale score of 4 to 5) rates 6 months after injury were 68.9% for the SBC group, and 46.7% for the control group (P < 0.05). There were no complications resulting in severe sequelae. In conclusion, the noninvasive SBC described here is a safe method of administering therapeutic hypothermia, which can reduce ICP and improve prognosis without severe complications in patients with severe TBI. (c) 2006 Elsevier Ltd. All rights reserved.	Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg,Brain Ctr, Hangzhou 310009, Peoples R China; Hangzhou Normal Coll, Hangzhou Hosp Affiliated 2, Dept Neurosurg, Sch Med, Hangzhou, Peoples R China	Qiu, WS (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg,Brain Ctr, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.	sh-2nd@126.com					Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Andrews PJD, 2005, BRIT J ANAESTH, V94, P330, DOI 10.1093/bja/aei025; Azzaroni A, 1999, BRAIN RES, V844, P206, DOI 10.1016/S0006-8993(99)01903-4; Bell Scott E, 2006, Curr Treat Options Neurol, V8, P167, DOI 10.1007/s11940-006-0007-9; Clifton Guy L, 2004, Curr Opin Crit Care, V10, P116, DOI 10.1097/00075198-200404000-00007; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Hagioka S, 2003, CRIT CARE MED, V31, P2502, DOI 10.1097/01.CCM.0000084845.76762.F4; Irmak MK, 2004, MED HYPOTHESES, V63, P974, DOI 10.1016/j.mehy.2004.05.003; Iwata O, 2003, PEDIATR INT, V45, P163, DOI 10.1046/j.1442-200X.2003.01682.x; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Liu Wei-guo, 2004, Chin J Traumatol, V7, P175; Maxwell WL, 2005, J NEUROTRAUM, V22, P873, DOI 10.1089/neu.2005.22.873; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Michael DB, 2005, J CLIN NEUROSCI, V12, P284, DOI 10.1016/j.jocn.2004.11.003; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Steinberg GK, 2004, NEUROSURGERY, V55, P307, DOI 10.1227/01.NEU.0000129683.99430.8C; Thompson HJ, 2005, J CEREBR BLOOD F MET, V25, P163, DOI 10.1038/sj.jcbfm.9600008; Tooley JR, 2005, ARCH DIS CHILD-FETAL, V90, P262, DOI 10.1136/adc.2003.044305; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Wright JE, 2005, CRIT CARE NURS Q, V28, P150, DOI 10.1097/00002727-200504000-00007	21	56	60	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	DEC	2006	13	10					995	1000		10.1016/j.jocn.2006.02.027			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	119TZ	WOS:000243037900004	17113984				2021-06-18	
J	Lotocki, G; Vaccari, JPD; Perez, ER; Alonso, OF; Curbelo, K; Keane, RW; Dietrich, WD				Lotocki, George; de Rivero Vaccari, Juan Pablo; Perez, Enrique R.; Alonso, Ofelia F.; Curbelo, Karell; Keane, Robert W.; Dietrich, W. Dalton			Therapeutic hypothermia modulates TNFR1 signaling in the traumatized brain via early transient activation of the JNK pathway and suppression of XIAP cleavage	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; inflammation; intracellular signaling; preconditioning; traumatic brain injury; tumor necrosis factor	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; FACTOR-ALPHA; ISCHEMIC TOLERANCE; CASPASE-3 ACTIVATION; MODERATE HYPOTHERMIA; FACTOR RECEPTOR-1; GENE-EXPRESSION	Tumor necrosis factor (TNF) plays a critical role in pathomechanisms associated with secondary damage after traumatic brain injury (TBI). The TNF ligand-receptor system stimulates inflammation by activation of gene transcription through the I kappa B kinase (IKK)-NF-kappa B and c-Jun NH2-terminal kinase (JNK)-AP-1 signaling cascades. TNF signaling following TBI involves both cell survival and apoptotic pathways, but the mechanism that accounts for the dual role of TNF remains unclear. Multiple studies have reported hypothermia to be protective following TBI, but the precise mechanism has not been clearly defined. Here, TNFR1 signaling pathways were investigated in the cerebral cortex of adult male Sprague-Dawley rats subjected to moderate fluid-percussion TBI and of naive controls. Another group was subjected to moderate TBI with 30 min of pre- and post-traumatic hypothermia (33 degrees C). Rapid and marked increases in protein expression of TNFR1 and signaling intermediates in both the IKK-NF-kappa B and JNK pathways were induced in traumatized cortices. Hypothermia decreased TNFR1 protein expression acutely in traumatized cortices and stimulated early activation of signaling intermediates in the JNK, but not the IKK-NF-kappa B, signaling pathways. Hypothermia promoted a rapid activation of caspase-3 acutely after injury but suppressed caspase-3 activation at later time points. Moreover, hypothermia treatment suppressed cleavage of X-linked inhibitor of apoptosis protein (XIAP) into fragments induced by TBI. These data suggest that hypothermia may regulate both the JNK signaling cascade via XIAP and the preconditioning pathways that activate caspases. Thus, hypothermia mediates TNFR1 responses via early activation of the JNK signaling pathway and caspase-3, leading to endogenous neuroprotective events.	Univ Miami, Miller Sch Med, Dept Neurol Sci, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Sci, 1095 NW 14th Terrace, Miami, FL 33136 USA.	ddietrich@miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS42133, NS30291] Funding Source: Medline		Bozyczko-Coyne D, 2002, CNS NEUROL DISORD-DR, V1, P31, DOI 10.2174/1568007023339472; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clark WM, 2001, EXPERT OPIN BIOL TH, V1, P227, DOI 10.1517/14712598.1.2.227; Clem RJ, 2001, CELL DEATH DIFFER, V8, P137, DOI 10.1038/sj.cdd.4400821; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Conte D, 2001, P NATL ACAD SCI USA, V98, P5049, DOI 10.1073/pnas.081547998; Dawson VL, 2000, TRENDS PHARMACOL SCI, V21, P423, DOI 10.1016/S0165-6147(00)01560-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1996, ADV NEUROL, V71, P177; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Javelaud D, 2001, ONCOGENE, V20, P4365, DOI 10.1038/sj.onc.1204570; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kogel D, 2005, CELL DEATH DIFFER, V12, P1, DOI 10.1038/sj.cdd.4401495; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Luo JJ, 2001, J NEUROSCI RES, V63, P410, DOI 10.1002/1097-4547(20010301)63:5<410::AID-JNR1036>3.0.CO;2-B; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1038/nrd1132; Matsuda S, 2001, J NEUROSCI, V21, P6597; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Noguchi K, 2001, BIOCHEM BIOPH RES CO, V281, P1313, DOI 10.1006/bbrc.2001.4498; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Perez-Pinzon MA, 1999, NEUROREPORT, V10, P2951, DOI 10.1097/00001756-199909290-00014; Perez-Pinzon MA, 1997, ADV EXP MED BIOL, V428, P155; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Probert L, 2001, GLIA, V36, P212, DOI 10.1002/glia.1110; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Schermanz K, 2002, CATALY SCI, V2, P1, DOI 10.1142/9781860949654_0001; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tanaka H, 2004, J NEUROSCI, V24, P2750, DOI 10.1523/JNEUROSCI.5475-03.2004; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Taru H, 2002, J BIOL CHEM, V277, P27567, DOI 10.1074/jbc.M203713200; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Ventura JJ, 2006, MOL CELL, V21, P701, DOI 10.1016/j.molcel.2006.01.018; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Yamaguchi K, 1999, EMBO J, V18, P179, DOI 10.1093/emboj/18.1.179; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuan HB, 2004, ANESTHESIOLOGY, V100, P331, DOI 10.1097/00000542-200402000-00023; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005	65	56	58	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	OCT	2006	24	8					2283	2290		10.1111/j.1460-9568.2006.05123.x			8	Neurosciences	Neurosciences & Neurology	098FL	WOS:000241506300018	17074049				2021-06-18	
J	Ganesalingam, K; Sanson, A; Anderson, V; Yeates, KO				Ganesalingam, Kalaichelvi; Sanson, Ann; Anderson, Vicki; Yeates, Keith Owen			Self-regulation and social and behavioral functioning following childhood traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc		traumatic brain injury; children; self-regulation; social and behavioral functioning; injury severity; postinjury outcomes	CLOSED-HEAD-INJURY; DEFICIT HYPERACTIVITY DISORDER; LONGITUDINAL STABILITY; EXTERNALIZING PROBLEMS; INHIBITORY CONTROL; MIDDLE CHILDHOOD; RATING-SCALE; CHILDREN; ATTENTION; IMPULSIVITY	This study examined the impact of childhood traumatic brain injury (TBI) on self-regulation and social and behavioral functioning, and the role of self-regulation as a predictor of children's social and behavioral functioning. Participants included 65 children with moderate to severe TBI and 65 children without TBI, all between 6 and 11 years of age. Self-regulation and social and behavioral functioning were assessed 2 to 5 years following injury. Children with TBI displayed deficits in self-regulation and social and behavioral functioning, after controlling for socioeconomic status (SES), although the magnitude of the deficits was not related to injury severity. Self-regulation accounted for significant variance in children's social and behavioral functioning, after controlling for SES and group membership. Self-regulation may be an important determinant of children's social and behavioral functioning following TBI.	Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Childrens Res Inst, Columbus, OH USA	Ganesalingam, K (corresponding author), Columbus Childrens Hosp, Childrens Res Inst, Childrens Dr, Columbus, OH 43205 USA.	GanesaKa@chi.osu.edu	Yeates, Keith/AAJ-4223-2020	Sanson, Ann/0000-0003-4910-3310; Yeates, Keith/0000-0001-7680-2892			Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; *AUSTR BUR STAT, 2001, POP AUSTR NZ COMP; Banerjee M., 1997, DEV SOCIAL COGNITION, P241; Barkley R. A., 1997, ADHD NATURE SELF CON; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bradley S.J., 2000, AFFECT REGULATION DE; CAMPBELL SB, 1995, J CHILD PSYCHOL PSYC, V36, P113, DOI 10.1111/j.1469-7610.1995.tb01657.x; CASPI A, 1995, CHILD DEV, V66, P55, DOI 10.1111/j.1467-8624.1995.tb00855.x; CASPI A, 1995, DEV PSYCHOPATHOL, V2, P472; CICCHETTI D, 1994, MONOGRAPHS SOC RES C, V59, P228; Dagenbach D., 1994, INHIBITORY PROCESSES; Daniel A. E., 1983, POWER PRIVILEGE PRES; Davis P., 1997, NZ SOCIOECONOMIC IND; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dodge K. A., 1998, HDB CHILD PSYCHOL, V3, P779, DOI DOI 10.1002/9780470147658; Dodge KA, 1997, J ABNORM PSYCHOL, V106, P37, DOI 10.1037/0021-843X.106.1.37; Eisenberg N, 2000, CHILD DEV, V71, P1367, DOI 10.1111/1467-8624.00233; Eisenberg N, 1997, CHILD DEV, V68, P642, DOI 10.2307/1132116; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; EYBERG SM, 1983, J CLIN CHILD PSYCHOL, V12, P347, DOI 10.1207/s15374424jccp1203_19; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FUNDERBURK BW, 1989, BEHAV ASSESS, V11, P297; Ganzeboom HBG, 1996, SOC SCI RES, V25, P201, DOI 10.1006/ssre.1996.0010; Gresham F. M., 1990, SOCIAL SKILLS RATING; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KAGAN J, 1966, J ABNORM PSYCHOL, V71, P17, DOI 10.1037/h0022886; Kehle TJ, 1996, J LEARN DISABIL, V29, P633, DOI 10.1177/002221949602900607; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Krueger RF, 1996, J PERS, V64, P107, DOI 10.1111/j.1467-6494.1996.tb00816.x; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; Luria A. R, 1973, WORKING BRAIN; Manly T., 1999, TEST EVERYDAY ATTENT; Mariani MA, 1997, DEV NEUROPSYCHOL, V13, P111, DOI 10.1080/87565649709540671; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; MISCHEL W, 1970, J PERS SOC PSYCHOL, V16, P329, DOI 10.1037/h0029815; Moffitt TE, 2003, CAUSES OF CONDUCT DISORDER AND JUVENILE DELINQUENCY, P49; *NAT HLTH INF MAN, 2001, NAT HLTH PLAN AUSTR; Olson SL, 1999, J ABNORM CHILD PSYCH, V27, P151, DOI 10.1023/A:1021915615677; Olson SL, 2005, DEV PSYCHOPATHOL, V17, P25, DOI 10.1017/S0954579405050029; OLSON SL, 1989, J CLIN CHILD PSYCHOL, V18, P176, DOI 10.1207/s15374424jccp1802_9; OLSON SL, 1990, J ABNORM CHILD PSYCH, V18, P317, DOI 10.1007/BF00916568; Olson SL, 2000, J ABNORM CHILD PSYCH, V28, P119, DOI 10.1023/A:1005166629744; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RODRIGUEZ ML, 1989, J PERS SOC PSYCHOL, V57, P358, DOI 10.1037/0022-3514.57.2.358; Rothbart M.K., 2006, HDB CHILD PSYCHOL, P99, DOI DOI 10.1002/9780470147658.CHPSY0303; Saarni C., 1997, EMOTIONAL DEV EMOTIO; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; SCHACHAR RJ, 1993, CLIN PSYCHOL REV, V13, P721, DOI 10.1016/S0272-7358(05)80003-0; Schore AN, 1996, DEV PSYCHOPATHOL, V8, P59, DOI 10.1017/S0954579400006970; Sethi A, 2000, DEV PSYCHOL, V36, P767, DOI 10.1037//0012-1649.36.6.767; Shields A, 1998, J CLIN CHILD PSYCHOL, V27, P381, DOI 10.1207/s15374424jccp2704_2; Shields A, 2001, DEV PSYCHOL, V37, P321, DOI 10.1037//0012-1649.37.3.321; Shields A., 1998, EMOTION REGULATION C; SHIELDS AM, 1994, DEV PSYCHOPATHOL, V6, P57, DOI 10.1017/S0954579400005885; Stuss D.T., 1986, FRONTAL LOBES; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	67	56	56	0	24	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2006	12	5					609	621		10.1017/S1355617706060796			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	081ZE	WOS:000240355300003	16961942				2021-06-18	
J	Fakhry, SM; Scanlon, JM; Robinson, L; Askari, R; Watenpaugh, RL; Fata, P; Hauda, WE; Trask, A				Fakhry, SM; Scanlon, JM; Robinson, L; Askari, R; Watenpaugh, RL; Fata, P; Hauda, WE; Trask, A			Prehospital rapid sequence intubation for head trauma: Conditions for a successful program	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	18th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 11-15, 2005	Ft Lauderdale, FL	Eastern Assoc Surg Trauma		prehospital intubation; head trauma; complications; quality control	BRAIN-INJURY; ENDOTRACHEAL INTUBATION; LIFE-SUPPORT; FIELD; VENTILATION; HYPOTENSION	Background: Recent reports have questioned the safety and efficacy of prehospital rapid sequence intubation (RSI) for patients with head trauma. The purpose of this study is to determine the rate of successful prehospital RSI, associated complications, and delays in transport of critically injured trauma patients treated by a select, well-trained group of paramedics with frequent exposure to this procedure and a rigorous quality control system. Methods: A helicopter paramedic group's database of patient flight records (1999 to 2003) was merged with registry data of a suburban Level I trauma center. Both databases included comprehensive performance improvement data. After Institutional Review Board approval, data were analyzed to determine RSI success rate, impact. on oxygenation, delays in transport and complications associated with attempted RSI. Attempted RSI was defined as any insertion of the laryngoscope into the oropharynx. Results: In all, 1,117 trauma patients were transported. One hundred and seventy-five had attempted RSI (74% male, mean age 31.1 +/- 19.2 years, 91% blunt trauma, 88% with Head/Neck AIS >= 2, mean Injury Severity Score 25.6, mean scene Glasgow Coma Scale score 4.8 +/- 2.4). One hundred and sixty-nine patients (96.6%) had successful scene RSI. Seventy percent were intubated on the first attempt, 89% by the second attempt, and 96% by the third attempt. Of the six patients (3.4% overall) who failed RSI, (2.3% overall) had scene cricothyroidotomy and two (1.1% overall) were managed by bag-valve mask. Complications included five (2.9%) right mainstem intubations and 2 (1.2%) endotracheal tube dislodgments en route. There were no esophageal intubations. Four patients in extremis (2.3%) had arterial desaturations associated with RSL Arterial blood gas analyzed upon arrival revealed (mean pCO(2) 36.6 +/- 8, median 37). Attempted RSI was associated with a mean of 6 minutes of added scene time. Conclusion: Prehospital RSI for trauma patients can be safely and effectively performed with low rates of complication and without significant delay in transport. This study suggests that resources for prehospital airway management should be focused on training, regular experience, and close monitoring of a limited group of providers, thereby maximizing their exposure and experience with this procedure. This is particularly important given the high rates of traumatic brain injury encountered.	Inova Fairfax Hosp, Trauma Serv, Inova Reg Trauma Ctr, Falls Church, VA USA; George Washington Univ, Dept Surg, Med Ctr, Washington, DC 20052 USA; Fairfax Cty Police Helicopter Div, Fairfax, VA USA	Fakhry, SM (corresponding author), Inova Fairfax Hosp, Trauma Serv, Inova Reg Trauma Ctr, 3300 Gallos Rd, Falls Church, VA USA.	samir.fakhry@inova.com		Hauda II, William/0000-0003-1425-7715			Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis DP, 2003, J TRAUMA, V55, P713, DOI 10.1097/01.TA.0000037428.65987.12; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Helm M, 2003, BRIT J ANAESTH, V90, P327, DOI 10.1093/bja/aeg069; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Ummenhofer Wolfgang, 2002, Curr Opin Crit Care, V8, P559, DOI 10.1097/00075198-200212000-00013; Wang HE, 2002, ANN EMERG MED, V40, P168, DOI 10.1067/mem.2002.126370; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	18	56	59	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2006	60	5					997	1001		10.1097/01.ta.0000217285.94057.5e			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	044NB	WOS:000237678100019	16688061				2021-06-18	
J	Byrnes, KR; Garay, J; Di Giovanni, S; De Biase, A; Knoblach, SM; Hoffman, EP; Movsesyan, V; Faden, AI				Byrnes, KR; Garay, J; Di Giovanni, S; De Biase, A; Knoblach, SM; Hoffman, EP; Movsesyan, V; Faden, AI			Expression of two temporally distinct microglia-related gene clusters after spinal cord injury	GLIA			English	Article						C1qB; chemokine; contusion; cytokine; Galectin-3; inflammation; microarray; p22(phox)	BLOOD-BRAIN-BARRIER; ACUTE INFLAMMATORY RESPONSE; CHEMOKINE MESSENGER-RNA; NITRIC-OXIDE SYNTHASE; NADPH OXIDASE; IN-VITRO; TRAUMATIC INJURY; BONE-MARROW; ADULT RATS; TNF-ALPHA	The dual role of microglia in cytotoxicity and neuroprotection is believed to depend on the specific, temporal expression of microglial-related genes. To better clarify this issue, we used high-density oligonucleotide microarrays to examine microglial gene expression after spinal cord injury (SCI) in rats. We compared expression changes at the lesion site, as well as in rostral and caudal regions after mild, moderate, or severe SCI. Using microglial-associated anchor genes, we identified two clusters with different temporal profiles. The first, induced by 4 h postinjury to peak between 4 and 24 h, included interieukin-1 beta, interleukin-6, osteopontin, and calgranulin, among others. The second was induced 24 h after SCI, and peaked between 72 h and 7 days; it included C1qB, Galectin-3, and p22(phox). These two clusters showed similar expression profiles regardless of injury severity, albeit with slight decreases in expression in mild or severe injury vs. moderate injury. Expression was also decreased rostral and caudal to the lesion site. We validated the expression of selected cluster members at the mRNA and protein levels. In addition, we demonstrated that stimulation of purified microglia in culture induces expression of C1qB, Galectin-3, and p22(phox). Finally, inhibition of P22(phox) activity within microglial cultures significantly suppressed proliferation in response to stimulation, confirming that this gene is involved in microglial activation. Because microglial-related factors have been implicated both in secondary injury and recovery, identification of temporally distinct clusters of genes related to microglial activation may suggest distinct roles for these groups of factors. (c) 2005 Wiley-Liss, Inc.	Georgetown Univ, Dept Neurosci, Med Ctr, Washington, DC 20057 USA; Childrens Natl Med Ctr, Ctr Genet Med, Washington, DC 20010 USA	Byrnes, KR (corresponding author), Georgetown Univ, Dept Neurosci, Med Ctr, Room EP16A,New Res Bldg,3790 Reservoir Rd NW, Washington, DC 20057 USA.	krb27@georgetown.edu		Byrnes, Kimberly/0000-0002-7501-7734; Hoffman, Eric/0000-0001-6470-5139	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS041218] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD40677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-1-2339, 5T32NS041218-04] Funding Source: Medline		Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; Albright AV, 2004, J NEUROIMMUNOL, V157, P27, DOI 10.1016/j.jneuroim.2004.09.007; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Bellander BM, 2004, J NEUROTRAUM, V21, P605, DOI 10.1089/089771504774129937; Blamire AM, 2000, J NEUROSCI, V20, P8153; Bonmann E, 1997, NEUROSCI LETT, V230, P109, DOI 10.1016/S0304-3940(97)00485-0; Brandes RP, 2001, THROMB HAEMOSTASIS, V85, P1104; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; De Biase A, 2005, PHYSIOL GENOMICS, V22, P368, DOI 10.1152/physiolgenomics.00081.2005; Dehghani F, 2004, EXP NEUROL, V189, P241, DOI 10.1016/j.expneurol.2004.06.010; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677; Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; Di Giovanni S, 2004, FASEB J, V18, P153, DOI 10.1096/fj.04-2694fje; Di Giovanni S, 2005, J BIOL CHEM, V280, P2084, DOI 10.1074/jbc.M411975200; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Enose Y, 2005, GLIA, V51, P161, DOI 10.1002/glia.20193; Fernandez GC, 2005, GLYCOBIOLOGY, V15, P519, DOI 10.1093/glycob/cwi026; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004; Gomes-Leal W, 2004, EXP NEUROL, V190, P456, DOI 10.1016/j.expneurol.2004.06.028; Grewal RP, 1999, NEUROSCI LETT, V271, P65, DOI 10.1016/S0304-3940(99)00496-6; Hashimoto M, 2005, ACTA NEUROPATHOL, V109, P165, DOI 10.1007/s00401-004-0926-z; HWANG S, 1994, J BIOL CHEM, V269, P711; Jiang H, 1996, CELL IMMUNOL, V167, P293, DOI 10.1006/cimm.1996.0038; Kim HRC, 1999, CANCER RES, V59, P4148; Kim TG, 1995, BIBL SHAMAN, V1, P1; Lin HM, 2002, ONCOGENE, V21, P8001, DOI 10.1038/sj.onc.1205820; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; Ma MH, 2002, J NEUROSCI RES, V68, P691, DOI 10.1002/jnr.10269; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Moran LB, 2004, NEUROGENETICS, V5, P95, DOI 10.1007/s10048-004-0172-5; Pan JZ, 2002, J NEUROSCI RES, V68, P315, DOI 10.1002/jnr.10215; Pawate S, 2004, J NEUROSCI RES, V77, P540, DOI 10.1002/jnr.20180; Peng TQ, 2004, FASEB J, V18, P293, DOI 10.1096/fj.04-2289fje; Pesheva P, 1998, J NEUROSCI RES, V51, P49, DOI 10.1002/(SICI)1097-4547(19980101)51:1<49::AID-JNR5>3.3.CO;2-2; Popovich PG, 2003, EXP NEUROL, V182, P275, DOI 10.1016/S0014-4886(03)00120-1; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Popovich PG, 2002, J NEUROPATH EXP NEUR, V61, P623, DOI 10.1093/jnen/61.7.623; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9; Reichert F, 1999, EXP NEUROL, V160, P508, DOI 10.1006/exnr.1999.7229; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Schwartz M, 1999, NEUROSURGERY, V44, P1041, DOI 10.1097/00006123-199905000-00057; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; Shin T, 2005, BRAIN RES, V1041, P95, DOI 10.1016/j.brainres.2005.02.019; Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Stern EL, 2000, J NEUROIMMUNOL, V106, P114, DOI 10.1016/S0165-5728(00)00194-6; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; Suh HS, 2005, J IMMUNOL, V174, P2712, DOI 10.4049/jimmunol.174.5.2712; Tachibana T, 2002, NEUROSCI LETT, V327, P133, DOI 10.1016/S0304-3940(02)00375-0; Tator C H, 1996, J Spinal Cord Med, V19, P206; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Watanabe T, 1999, J NEUROTRAUM, V16, P255, DOI 10.1089/neu.1999.16.255; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; YAO JB, 1992, BRAIN RES, V591, P88, DOI 10.1016/0006-8993(92)90981-E; Zhang KH, 2004, NEUROSCIENCE, V128, P375, DOI 10.1016/j.neuroscience.2004.07.008	76	56	60	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAR	2006	53	4					420	433		10.1002/glia.20295			14	Neurosciences	Neurosciences & Neurology	020CV	WOS:000235886400010	16345062				2021-06-18	
J	[Anonymous]				[Anonymous]			Concussion (mild traumatic brain injury) and the team physician: A consensus statement	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article							NEUROPSYCHOLOGICAL TEST-PERFORMANCE; PROFESSIONAL FOOTBALL; HEAD-INJURY; SPORT	This document provides an overview of select medical issues that are important to team physicians who are responsible for athletes with concussion. It is not intended as a standard of care. and should not be interpreted as such. This document is only a guide, and as such, is of a general nature, consistent with the reasonable, objective practice of the healthcare professional. Individual treatment will turn on the specific facts and circumstances presented to the physician. Adequate insurance should be in place to help protect the physician. the athlete. and the sponsoring organization. This statement was developed by a collaboration of six major professional associations concerned about clinical sports medicine issues: they have committed to forming an ongoing project-based alliance to bring together sports medicine organizations to best serve active people and athletes. The organizations are: American Academy of Family Physicians, American Academy of Orthopaedic Surgeons, American College of Sports Medicine. American Medical Society for Sports Medicine, American Orthopaedic Society for Sports Medicine, and the American Osteopathic Academy of Sports Medicine.								*AM COLL SPORTS ME, 2001, MED SCI SPORTS EXERC, V33, P846; Asplund CA, 2004, CLIN J SPORT MED, V14, P339, DOI 10.1097/00042752-200411000-00003; Barth JT., 1989, MILD HEAD INJURY, P257; Cantu R, 2004, LANCET NEUROL, V3, P437; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Herring SA, 2002, MED SCI SPORT EXER, V34, P1212; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JOHNSTON K, 2002, PHYSICIAN SPORTSMED, V30, P57; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; PUTUKIAN M, 2004, ORTHO KNOWLEDGE UPDA, P29	26	56	57	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2006	38	2					395	399		10.1249/01.mss.0000202025.48774.31			5	Sport Sciences	Sport Sciences	016SY	WOS:000235641900029	16531912				2021-06-18	
J	Hong, SB; Koh, Y; Lee, IC; Kim, MJ; Kim, WS; Kim, DS; Kim, WD; Lim, CM				Hong, SB; Koh, Y; Lee, IC; Kim, MJ; Kim, WS; Kim, DS; Kim, WD; Lim, CM			Induced hypothermia as a new approach to lung rest for the acutely injured lung	CRITICAL CARE MEDICINE			English	Article						acute lung injury; lung rest; mechanical ventilation; hypothermia; ventilator-induced lung injury; ventilatory frequency	RESPIRATORY-DISTRESS-SYNDROME; ISCHEMIA-REPERFUSION INJURY; EXTRACORPOREAL CO2 REMOVAL; TRAUMATIC BRAIN INJURY; NECROSIS-FACTOR-ALPHA; FACTOR-KAPPA-B; MECHANICAL VENTILATION; RNA EXPRESSION; RATS; ENDOTOXIN	Objective: To investigate whether low-frequency ventilation during hypothermia could attenuate lung injury associated with endotoxin and mechanical ventilation. Design: Experimental animal study. Setting. University-affiliated animal laboratory. Subjects. Forty-eight Sprague-Dawley rats. Interventions: Lipopolysaccharide was administered to rats intratracheally to induce acute lung injury. After 1 hr of this treatment, animals were assigned to normothermia-only (NO, rectal temperature 37 degrees C, ventilatory frequency 90/min), normothermia-lung rest (NR, 37 degrees C, 45/min), hypothermia -only (H0, 27 degrees C, 90/min), or hypothermia-lung rest (HR, 27 degrees C, 45/min). After 1 hr of injurious ventilation, the lungs of the rats were removed for bronchoalveolar lavage and histologic examination. Measurements and Main Results: Compared with the normothermia groups (NO, NR), the neutrophil counts (per milliliter) (NO, 7708 +/- 5704; NR, 10,479 +/- 11,152; HO, 1638 +/- 955; HR, 805 +/- 591) and interleukin-1 beta levels (pg/mL) (1180 +/- 439, 1081 +/- 652, 620 +/- 426, 420 +/- 182, respectively) in the bronchoalveolar lavage fluid, the wet-to-dry lung weight ratios (6.0 +/- 0.4, 5.7 +/- 0.4, 5.6 +/- 0.2, 5.2 +/- 0.2, respectively), and histologic acute lung injury scores (8.3 +/- 2.7, 10.4 +/- 3.1, 3.5 +/- 2.1, 3.1 +/- 2.2, respectively) of the hypothermia groups (HO, HR) were lower (all p <.001). Compared with the HO group, the neutrophil counts and protein content (HO, 1367 +/- 490 mu g/mL vs. HR, 831 +/- 369 mu g/mL) in the bronchoalveolar lavage fluid, the serum lactate dehydrogenase levels (units/mL) (9.1 +/- 3.6 vs. 5.3 +/- 1.5), and the wet-to-dry lung weight ratios of the HR group were lower (all p <.05). Conclusions: Reduction of ventilatory frequency in conjunction with hypothermia attenuated many variables of acute lung injury in rats. Use of hypothermia could be exploited as a new approach to lung rest for the ventilatory management of the acutely injured lung.	Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med,Div Pulm & Crit Care Med, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea	Hong, SB (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Internal Med,Div Pulm & Crit Care Med, Seoul, South Korea.						Bartlett RH, 2000, JAMA-J AM MED ASSOC, V283, P904, DOI 10.1001/jama.283.7.904; Behnia R, 1996, ANN CLIN LAB SCI, V26, P437; BELZER FO, 1988, TRANSPLANTATION, V45, P673, DOI 10.1097/00007890-198804000-00001; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; Boussarsar M, 2002, INTENS CARE MED, V28, P406, DOI 10.1007/s00134-001-1178-1; Broccard AF, 1998, AM J RESP CRIT CARE, V157, P1935, DOI 10.1164/ajrccm.157.6.9612006; Broccard AF, 2001, AM J RESP CRIT CARE, V164, P802, DOI 10.1164/ajrccm.164.5.2007060; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; BSHOUTY Z, 1992, AM REV RESPIR DIS, V145, P372, DOI 10.1164/ajrccm/145.2_Pt_1.372; Choudhury S, 2004, AM J PHYSIOL-LUNG C, V287, pL902, DOI 10.1152/ajplung.00187.2004; GATTINONI L, 1986, JAMA-J AM MED ASSOC, V256, P881, DOI 10.1001/jama.256.7.881; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; HARKNESS JE, 1995, BIOL MED RABBITS ROD, P84; HASHIN Z, 1978, MATER SCI ENG, V34, P147, DOI 10.1016/0025-5416(78)90045-9; HASINOFF I, 1988, J CRIT CARE, V3, P225, DOI 10.1016/0883-9441(88)90106-2; HIDA W, 1984, J APPL PHYSIOL, V57, P262; Hotchkiss JR, 2000, AM J RESP CRIT CARE, V161, P463, DOI 10.1164/ajrccm.161.2.9811008; HURST JM, 1985, CRIT CARE MED, V13, P771, DOI 10.1097/00003246-198509000-00019; Imai Y, 1999, J APPL PHYSIOL, V87, P510; Koay MA, 2002, AM J RESP CELL MOL, V26, P572, DOI 10.1165/ajrcmb.26.5.4748; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P399, DOI 10.1164/ajrccm.162.2.9911026; Lim CM, 2004, INTENS CARE MED, V30, P1638, DOI 10.1007/s00134-004-2336-z; Lim CM, 2003, LUNG, V181, P23, DOI 10.1007/s00408-002-0111-x; Lim CM, 2003, INTENS CARE MED, V29, P453, DOI 10.1007/s00134-002-1529-6; MEAD J, 1970, J APPL PHYSIOL, V28, P596; Moonka R, 1996, J TRAUMA, V40, P1026, DOI 10.1097/00005373-199606000-00031; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; Moshkovitz Y, 1998, ANN THORAC SURG, V66, P1179, DOI 10.1016/S0003-4975(98)00805-4; Mowlavi A, 2003, PLAST RECONSTR SURG, V111, P242, DOI 10.1097/01.PRS.0000034936.25458.98; Murphy DB, 2000, AM J RESP CRIT CARE, V162, P27, DOI 10.1164/ajrccm.162.1.9908110; Parsey MV, 1998, J IMMUNOL, V160, P1007; Pattin CA, 1996, J BIOMECH, V29, P69, DOI 10.1016/0021-9290(94)00156-1; Pugin J, 1996, AM J RESP CRIT CARE, V153, P1850, DOI 10.1164/ajrccm.153.6.8665045; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Rimensberger PC, 1998, CRIT CARE MED, V26, P548, DOI 10.1097/00003246-199803000-00030; RITTENHOUSE EA, 1974, ANN THORAC SURG, V17, P63, DOI 10.1016/S0003-4975(10)65062-X; Schechtman H, 1997, J BIOMECH, V30, P829, DOI 10.1016/S0021-9290(97)00033-X; Suzuki S, 2004, CRIT CARE MED, V32, P144, DOI 10.1097/01.CCM.0000098857.14923.44; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Torbati D, 2000, INTENS CARE MED, V26, P585, DOI 10.1007/s001340051208; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; VILLAR J, 1993, RESUSCITATION, V26, P183, DOI 10.1016/0300-9572(93)90178-S; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; Whalen MJ, 1997, ACT NEUR S, V70, P260; XING Z, 1994, AM J RESP CELL MOL, V10, P148, DOI 10.1165/ajrcmb.10.2.8110470	47	56	63	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	SEP	2005	33	9					2049	2055		10.1097/01.CCM.0000178186.37167.53			7	Critical Care Medicine	General & Internal Medicine	042CG	WOS:000237504200022	16148479				2021-06-18	
J	Sherer, M; Nakase-Thompson, R; Yablon, SA; Gontkovsky, ST				Sherer, M; Nakase-Thompson, R; Yablon, SA; Gontkovsky, ST			Multidimensional assessment of acute confusion after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						amnesia; brain injuries; confusion; delirium; rehabilitation	MEDICINE-AND-REHABILITATION; POSTTRAUMATIC AMNESIA; COGNITIVE TEST; HEAD-INJURIES; RATING-SCALE; PRACTICAL SCALE; DELIRIUM; VALIDATION; ORIENTATION; DEFINITION	Objectives: To describe the phenomenology of posttraumatic confusional state (PTCS) and to provide preliminary validation of a new procedure, the Confusion Assessment Protocol (CAP), for assessing PTCS. Design: Criterion standard investigation. Setting: Inpatient traumatic brain injury (TBI) rehabilitation program. Participants: Two consecutive series of patients (n = 62, n = 93) with TBI admitted for inpatient rehabilitation. Interventions: Not applicable. Main Outcome Measures: Clinical diagnosis of delirium based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria, classification of posttraumatic amnesia (PTA) based on the Galveston Orientation and Amnesia Test (GOAT), and Disability Rating Scale score at time of rehabilitation hospital discharge. Results: Agreement between the diagnosis of PTCS with the CAP and DSM-IV classification of delirium was 87%, and agreement between PTCS and PTA using GOAT criteria was 90%. Patients classified as in PTCS sustained more severe injuries and required longer rehabilitation stays. Confusion status was associated with poorer functional status at rehabilitation discharge. Conclusions: The CAP is a brief, structured, repeatable measure of multiple neurobehavioral aspects of PTCS. Confusion status as determined by CAP assessment contributed to prediction of outcome at rehabilitation discharge after adjustment for other potential predictors.	Methodist Rehabil Ctr, Neuropsychol Dept, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA	Sherer, M (corresponding author), Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goodglass H., 1983, ASSESSMENT APHASIA R; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kennedy RE, 2003, PSYCHOSOMATICS, V44, P283, DOI 10.1176/appi.psy.44.4.283; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCEVOY JP, 1981, ANN INTERN MED, V95, P212, DOI 10.7326/0003-4819-95-2-212; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Neelon VJ, 1996, NURS RES, V45, P324, DOI 10.1097/00006199-199611000-00002; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Russell WR, 1935, LANCET, V2, P762; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds C P, 1937, Proc R Soc Med, V30, P1081; TEASDALE G, 1974, LANCET, V2, P81; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; TRZEPACZ PT, 1994, AM PSYCHIATRIC PR, P189; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	31	56	57	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2005	86	5					896	904		10.1016/j.apmr.2004.09.029			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	928NM	WOS:000229278500008	15895334				2021-06-18	
J	Lotocki, G; Alonso, OF; Dietrich, WD; Keane, RW				Lotocki, G; Alonso, OF; Dietrich, WD; Keane, RW			Tumor necrosis factor receptor 1 and its signaling intermediates are recruited to lipid rafts in the traumatized brain	JOURNAL OF NEUROSCIENCE			English	Article						tumor necrosis factor; apoptosis; traumatic brain injury; lipid rafts; intracellular signaling; inflammation	NF-KAPPA-B; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; CELL-DEATH; TRANSDUCTION PATHWAYS; MEDIATED APOPTOSIS; TNF RECEPTOR-1; RAT-BRAIN; ACTIVATION; EXPRESSION	The tumor necrosis factor (TNF) ligand-receptor system plays an essential role in apoptosis that contributes to secondary damage after traumatic brain injury (TBI). TNF also stimulates inflammation by activation of gene transcription through the IkappaB kinase (IKK)/NF-kappaB and JNK (c-Jun N-terminal protein kinase)/AP-1 signaling cascades. The mechanism by which TNF signals between cell death and survival and the role of receptor localization in the activation of downstream signaling events are not fully understood. Here, TNF receptor 1 (TNFR1) signaling complexes in lipid rafts were investigated in the cerebral cortex of adult male Sprague Dawley rats subjected to moderate (1.8-2.2 atmospheres) fluid-percussion TBI and naive controls. In the normal rat cortex, a portion of TNFR1 was present in lipid raft microdomains, where it associated with the adaptor proteins TRADD ( TNF receptor-associated death domain), TNF receptor-associated factor-2 (TRAF-2), the Ser/Thr kinase RIP (receptor-interacting protein), TRAF1, and cIAP-1 ( cellular inhibitor of apoptosis protein-1), forming a survival signaling complex. Moderate TBI resulted in rapid recruitment of TNFR1, but not TNFR2 or Fas, to lipid rafts and induced alterations in the composition of signaling intermediates. TNFR1 and TRAF1 were polyubiquitinated in lipid rafts after TBI. Subsequently, the signaling complex contained activated caspase-8, thus initiating apoptosis. In addition, TBI caused a transient activation of NF-kappaB, but receptor signaling interacting proteins IKKalpha and IKKbeta were not detected in raft-containing fractions. Thus, redistribution of TNFR1 in lipid rafts and nonraft regions of the plasma membrane may regulate the diversity of signaling responses initiated by these receptors in the normal brain and after TBI.	Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.	rkeane@miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, R01 NS042133, NS42133, P50 NS030291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, R01NS042133] Funding Source: NIH RePORTER		Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Choi C, 2004, BRAIN RES REV, V44, P65, DOI 10.1016/j.brainresrev.2003.08.007; Clark WM, 2001, EXPERT OPIN BIOL TH, V1, P227, DOI 10.1517/14712598.1.2.227; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Doan JES, 2004, J IMMUNOL, V172, P7654, DOI 10.4049/jimmunol.172.12.7654; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; EKLLIHER MA, 1998, IMMUNITY, V8, P297; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Keane RW, 1997, J NEUROSCI RES, V48, P168, DOI 10.1002/(SICI)1097-4547(19970415)48:2<168::AID-JNR9>3.0.CO;2-A; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; Kim GM, 2001, J NEUROSCI, V21, P6617; Ko YG, 1999, J IMMUNOL, V162, P7217; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Muppidi JR, 2004, NAT IMMUNOL, V5, P182, DOI 10.1038/ni1024; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Perry RT, 2001, NEUROBIOL AGING, V22, P873, DOI 10.1016/S0197-4580(01)00291-3; Probert L, 2001, GLIA, V36, P212, DOI 10.1002/glia.1110; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shinoda S, 2003, EUR J NEUROSCI, V17, P2065, DOI 10.1046/j.1460-9568.2003.02655.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yan P, 2003, EXP NEUROL, V183, P286, DOI 10.1016/S0014-4886(03)00135-3; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002	48	56	61	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC 8	2004	24	49					11010	11016		10.1523/JNEUROSCI.3823-04.2004			7	Neurosciences	Neurosciences & Neurology	878AI	WOS:000225618300002	15590916	Green Published, Bronze			2021-06-18	
J	Georgeadis, AC; Brennan, DM; Barker, LM; Baron, CR				Georgeadis, AC; Brennan, DM; Barker, LM; Baron, CR			Telerehabilitation and its effect on story retelling by adults with neurogenic communication disorders	APHASIOLOGY			English	Article; Proceedings Paper	33rd Annual Clinical Aphasiology Conference	MAY, 2003	Orcas Isl, WA				TRAUMATIC BRAIN INJURY; COGNITIVE FUNCTION; SPEECH; TELEHEALTH; ATTENTION; PATHOLOGY	Background: Telerehabilitation (telerehab) is the method of using technology to provide rehabilitation services at a distance. The concept of delivering remote speech-language pathology (SLP) services using telerehab tools and techniques has been acknowledged for more than 25 years. While research has demonstrated videoconference-based telerehab to be a feasible, effective, and appropriate method for providing SLP services to a broad range of clients, studies have been primarily limited to technical feasibility or demonstration projects with relatively small sample sizes. There is an expressed need in the literature for controlled, randomised studies that track both quantitative outcomes of services delivered via telerehab as well as qualitative measures of satisfaction. Aims: The purpose of the study was to measure performance of adults with acquired brain injury on a standardised SLP assessment conducted in both face-to-face (FF) and videoconference-based telerehab (T) settings. The objective was to determine if performance on the assessment, or subjective feedback from the participants, differed between settings. Methods & Procedures: A total of 40 participants with a recent onset of brain injury--12 with traumatic brain injury (TBI), 14 with a left cerebrovascular accident (LCVA), and 14 with a right cerebrovascular accident (RCVA)--were enrolled in the study. Participants were asked to retell stories from the Story Retell Procedure (Doyle, McNeil, Spencer, Goda, Cotrell, & Lustig, 1998) in both FF and T settings. Responses from the stories were scored by the clinician using the percent information unit scoring metric (McNeil, Doyle, Fossett, Park, & Goda, 2001). Additionally, a survey tool was used to probe each participant's level of satisfaction and willingness to use telerehab services in the future. Outcomes & Results: Across all participants, and within the TBI, LCVA, and RCVA groups, no significant difference in performance between the FF and T settings was found. Feedback from survey data demonstrated a high level of acceptance of the T setting. When compared to participants with LCVA or RCVA, however, participants with TBI were significantly more likely to show a lack of interest in future videoconferencing use. Conclusions: Story-retelling performance by brain-injured adults was not affected by setting. Additionally, participants expressed a high level of interest in using videoconferencing in the future. These findings offer additional support for telerehab as a viable alternative mode of SLP treatment for survivors of stroke and TBI. Further research is needed to investigate the utility of telerehab for delivering services to clients with attention impairments as well as those with severe cognitive-communicative impairment, dysarthria, or aphasia.	Natl Rehabil Hosp, Speech Language Pathol Serv, Washington, DC 20010 USA	Georgeadis, AC (corresponding author), Natl Rehabil Hosp, Speech Language Pathol Serv, 102 Irving St NW, Washington, DC 20010 USA.	amy.c.georgeadis@medstar.net					APPEL PR, 2002, P STAT SCI C TEL APP, P23; Ball C, 1997, J Telemed Telecare, V3, P126, DOI 10.1258/1357633971931020; Ball C, 1998, J TELEMED TELECARE, V4, P36, DOI 10.1258/1357633981931362; BRENNAN D, IN PRESS TELEMEDICIN; Brennan David, 2002, Top Stroke Rehabil, V8, P71; Brookshire RH, 1993, DISCOURSE COMPREHENS; BUCKLEY KM, 2002, P STAT SCI C TEL APP, P35; Burnham AK, 1999, ENERG FUEL, V13, P1, DOI 10.1021/ef9800765; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Doyle PJ, 1998, APHASIOLOGY, V12, P561, DOI 10.1080/02687039808249558; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; Goodglass H., 1983, ASSESSMENT APHASIA R; Halstead Lauro S, 2003, Adv Skin Wound Care, V16, P91, DOI 10.1097/00129334-200303000-00010; Hill A, 2002, J TELEMED TELECARE, V8, P187, DOI 10.1258/135763302320272158; Kully D, 2000, J TELEMED TELECARE, V6, P39, DOI 10.1258/1357633001935509; Mashima P A, 1999, J Healthc Inf Manag, V13, P71; Mateer CA, 1996, J HEAD TRAUMA REHAB, V11, P1; McCullough A, 2001, INT J LANG COMM DIS, V36, P321, DOI 10.3109/13682820109177905; McNeil MR, 2001, APHASIOLOGY, V15, P991, DOI 10.1080/02687040143000348; Menon AS, 2001, J NERV MENT DIS, V189, P399, DOI 10.1097/00005053-200106000-00009; Savard L, 2003, NEUROREHABILITATION, V18, P93; SAVARD L, 2002, COMB SECT M AM PHYS; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; TRAN BQ, 2003, COMB SECT M AM PHYS; TREPAGNIER C, 2002, P STAT SCI C TEL APP, P42; Vaughn G R, 1976, ASHA, V18, P13; Vesmarovich S, 1999, Adv Wound Care, V12, P264; Wertz R. T., 1987, CLIN APHASIOLOGY, V17, P117; WERTZ RT, 1992, APHASIOLOGY, V6, P195, DOI 10.1080/02687039208248591; WHITE MW, 2003, ANN C AM OCC THER AS	30	56	56	1	28	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	MAY-JUL	2004	18	5-7					639	652		10.1080/02687030444000075			14	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	817NC	WOS:000221183200017					2021-06-18	
J	Young, KD; Okada, PJ; Sokolove, PE; Palchak, MJ; Panacek, EA; Baren, JM; Huff, KR; McBride, DQ; Inkelis, SH; Lewis, RJ				Young, KD; Okada, PJ; Sokolove, PE; Palchak, MJ; Panacek, EA; Baren, JM; Huff, KR; McBride, DQ; Inkelis, SH; Lewis, RJ			A randomized, double-blinded, placebo-controlled trial of phenytoin for the prevention of early posttraumatic seizures in children with moderate to severe blunt head injury	ANNALS OF EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; EMERGENCY RESEARCH; INFORMED-CONSENT; CLINICAL-TRIALS; EPILEPSY; COMA; PROPHYLAXIS; PREDICTORS; INFANTS	Study objective: We determine the efficacy of prophylactic phenytoin in preventing early posttraumatic seizures in children with moderate to severe blunt head injury. Methods: Children younger than 16 years and experiencing moderate to severe blunt head injury were randomized to receive phenytoin or placebo within 60 minutes of presentation at 3 pediatric trauma centers. The primary endpoint was posttraumatic seizures within 48 hours; secondary endpoints were survival and neurologic outcome 30 days after injury. A Bayesian decision-theoretic clinical trial design was used to determine the probability of remaining posttraumatic seizure free for each treatment group. Results: One hundred two patients were enrolled, with a median age of 6.1 years. Sixty-eight percent were boys. The 2 treatment groups were well matched. During the 48-hour observation period, 3 (7%) of 46 patients given phenytoin and 3 (5%) of 56 patients given placebo experienced a posttraumatic seizure. There were no significant differences between the treatment groups in survival or neurologic outcome after 30 days. According to these results, the probability that phenytoin has the originally hypothesized effect of reducing the rate of early posttraurnatic seizures by 12.5% is 0.0053. The probability that phenytoin has any prophylactic efficacy is 0.383. The median effect size in this trial was -0.015 (seizure rate increased by 1.5% in the phenytoin group), 95% probability interval -0.127 to 0.091 (12.7% higher rate of posttraumatic seizures to a 9.1% lower rate of posttraumatic seizures with phenytoin). Conclusion: The rate of early posttraumatic seizures in children may be much lower than previously reported. Phenytoin did not substantially reduce that rate.	Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA; Harbor UCLA Med Ctr, Dept Pediat, Torrance, CA 90509 USA; Harbor UCLA Med Ctr, Dept Neurosurg, Torrance, CA 90509 USA; Univ Texas, SW Childrens Med Ctr, Dept Pediat, Dallas, TX 75230 USA; Univ Calif Davis, Ctr Med, Dept Emergency Med, Sacramento, CA 95817 USA; Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA	Lewis, RJ (corresponding author), Harbor UCLA Med Ctr, Dept Emergency Med, 1000 W Carson St,Box 21, Torrance, CA 90509 USA.	roger@emedharbor.edu					Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; BERRY DA, 1987, AM STAT, V41, P117, DOI 10.2307/2684222; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; Biros MH, 1998, ACAD EMERG MED, V5, P359, DOI 10.1111/j.1553-2712.1998.tb02722.x; BRAILOWSKY S, 1986, BRAIN RES, V376, P71, DOI 10.1016/0006-8993(86)90900-5; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P549, DOI DOI 10.1089/NEU.2000.17.549; Bruce D A, 1990, Curr Probl Pediatr, V20, P61; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; ELLIS G, 2004, 933 OPRR; Fost Norman, 1980, IRB, V2, P5, DOI 10.2307/3564363; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HAUSER WA, 1990, NEW ENGL J MED, V323, P540, DOI 10.1056/NEJM199008233230809; HENDRICK EB, 1968, J TRAUM, V8, P547; Hunt EA, 2002, ARCH DIS CHILD, V86, P62, DOI 10.1136/adc.86.1.62; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVINE RJ, 1991, CONTROL CLIN TRIALS, V12, P546, DOI 10.1016/0197-2456(91)90012-B; LEWIS RJ, 1994, J AM STAT ASSOC, V89, P1528, DOI 10.2307/2291016; Lewis RJ, 2001, ACAD EMERG MED, V8, P1179, DOI 10.1111/j.1553-2712.2001.tb01137.x; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Lewis RJ, 1996, BAYESIAN BIOSTATISTI, P279; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Marion DW, 2000, CRIT CARE MED, V28, P16, DOI 10.1097/00003246-200001000-00003; MORI A, 1990, PAVLOVIAN J BIOL SCI, V25, P54; Okada PJ, 2003, ACAD EMERG MED, V10, P1034, DOI 10.1197/S1069-6563(03)00364-6; OKADA PJ, 1995, ARCH PEDIAT ADOLESC, V149, pP65; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; *US FDA, 1995, EX SUMM PUBL FOR INF; US Food and Drug Administration, 1995, FED REGISTER, V60, P49085; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	44	56	59	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	APR	2004	43	4					435	446		10.1016/j.annemergmed.2003.09.016			12	Emergency Medicine	Emergency Medicine	807KV	WOS:000220501300001	15039684				2021-06-18	
J	Fabbri, A; Servadei, F; Marchesini, G; Morselli-Labate, AM; Dente, M; Iervese, T; Spada, M; Vandelli, A				Fabbri, A; Servadei, F; Marchesini, G; Morselli-Labate, AM; Dente, M; Iervese, T; Spada, M; Vandelli, A			Prospective validation of a proposal for diagnosis and management of patients attending the emergency department for mild head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; PROGNOSIS; ADULTS; RULES; SCALE	Background: In mild head injury, predictors to select patients for computed tomography (CT) and/or to plan proper management are needed. The strength of evidence of published recommendations is insufficient for current use. We assessed the diagnostic accuracy and the clinical validity of the proposal of the Neurotraumatology Committee of the World Federation of Neurosurgical Societies on mild head injury from an emergency department perspective. Methods: In a three year period, 5578 adolescent and adult subjects were prospectively recruited and managed according to the proposed protocol. Outcome measures were: ( a) any post-traumatic lesion; (b) need for neurosurgical intervention; ( c) unfavourable outcome ( death, permanent vegetative state or severe disability) after six months. The predictive value of a model based on five variables ( Glasgow coma score, clinical findings, risk factors, neurological deficits, and skull fracture) was tested by logistic regression analysis. Findings: At first CT evaluation 327 patients (5.9%) had intracranial post-traumatic lesions. In 16 cases (0.3%) previously undiagnosed lesions were detected after re-evaluation within seven days. Neurosurgical intervention was needed in 71 patients (1.3%) and an unfavourable outcome occurred in 39 cases (0.7%). The area under the ROC curve of the variables in predicting post-traumatic lesions was 0.906 (0.009) ( sensitivity 70.0%, specificity 94.1% at best cut off), neurosurgical intervention was 0.926 (0.016) ( sensitivity 81.7%, specificity 94.1%), and unfavourable outcome was 0.953 (0.014) ( sensitivity 88.1%, specificity 95.1%). Interpretation: The variables prove highly accurate in the prediction of clinically meaningful outcomes, when applied to a consecutive set of patients with mild head injury in the clinical setting of a 1st level emergency department.	Osped GB Morgagni, Azienda USL Forli, Dipartimento Emergenza Urgenza Accettaz, I-47100 Forli, Italy; Osped Gen Provinciale M Bufalini, Azienda Unita Sanitaria Locale Cesena, Div Neurochirurg Traumatol, Cesena, Italy; Univ Bologna, Dipartimento Med Interna & Gastroenterol, I-40126 Bologna, Italy	Fabbri, A (corresponding author), Osped GB Morgagni, Azienda USL Forli, Dipartimento Emergenza Urgenza Accettaz, 1 Ple Solieri 1, I-47100 Forli, Italy.	andfabbri@libero.it		Fabbri, Andrea/0000-0002-9837-4638; Servadei, Franco/0000-0002-3595-3464; Marchesini, Giulio/0000-0003-2407-9860; Morselli/Labate, Antonio Maria/0000-0001-9318-8564			BELL RS, 1987, NEW ENGL J MED, V316, P84; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; GALBRAITH S, 1976, BMJ-BRIT MED J, V1, P1438, DOI 10.1136/bmj.1.6023.1438; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; National Institute for Clinical Excellence, HEAD INJ INF CHILDR; NORUSIS MJ, 1992, SPSS PC BASE SYSTEM; Pezzilli R, 1999, CLIN CHEM, V45, P1762; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, ANN EMERG MED, V38, P160, DOI 10.1067/mem.2001.116796; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; ZWEIG MH, 1993, CLIN CHEM, V39, P561	23	56	56	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR 1	2004	75	3					410	416		10.1136/jnnp.2003.016113			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	774FW	WOS:000188970000015	14966157	Green Published, Bronze			2021-06-18	
J	Brown, M; Gordon, WA; Spielman, L				Brown, M; Gordon, WA; Spielman, L			Participation in social and recreational activity in the community by individuals with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							SPINAL-CORD-INJURY; QUALITY-OF-LIFE; CLOSED HEAD-INJURY; REHABILITATION; SATISFACTION; OUTCOMES; SUPPORT; INTEGRATION; HANDICAP; HEALTH	Objective: To compare the extent of engagement in social-recreational activity in individuals with traumatic brain injury (TBI) and with no disability (ND). Study Design: Between- and within-group comparisons. Participants: Samples (TBI, N = 279; ND, N = 224) recruited from community sources. Outcome Measures: A social-recreational measure based on items drawn from 3 measures of community integration. Results: The ND group was more active than the TBI group. For the latter, greater social-recreational activity was associated with being single, higher income, less depression, more vocational hours, and greater time since injury. Conclusions: Addressing depression, fatigue, and vocational engagement may promote entree to a fuller social-recreational life for individuals with TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Gordon, WA (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.						Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Bassuk SS, 1999, ANN INTERN MED, V131, P165, DOI 10.7326/0003-4819-131-3-199908030-00002; Baum FE, 2000, J EPIDEMIOL COMMUN H, V54, P414, DOI 10.1136/jech.54.6.414; Beck A.T., 1987, BECK DEPRESSION INVE; BIGELOW D, 1992, PSYCHOL REHABIL J, V14, P94; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; BROWN M, 1998, UNPUB FLANAGAN QUALI; BROWN MM, 1983, DISS ABSTR INT B, V43, P2314; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Crespo CJ, 1999, MED SCI SPORT EXER, V31, P1821, DOI 10.1097/00005768-199912000-00019; Dalgard OS, 1998, J EPIDEMIOL COMMUN H, V52, P476, DOI 10.1136/jech.52.8.476; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers M., 2002, QUAL LIFE RES, V11, P672; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Eckert JK, 1999, MED CLIN N AM, V83, P1151, DOI 10.1016/S0025-7125(05)70156-5; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; GORDON WA, 1998, J HEAD TRAUMA REHAB, V13, P17; GOTTLIEB BH, 1985, HEALTH EDUC QUART, V12, P5, DOI 10.1177/109019818501200102; Hall KM, 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; Harlow RE, 1996, J PERS SOC PSYCHOL, V71, P1235, DOI 10.1037/0022-3514.71.6.1235; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Helminen A, 1997, J BIOSOC SCI, V29, P129, DOI 10.1017/S0021932097001296; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; HUGHES C, 1996, QUALITY LIFE, V1, P51; Kannisto M, 1997, SPINAL CORD, V35, P747, DOI 10.1038/sj.sc.3100542; Lawton MP, 1999, J AGING HEALTH, V11, P169, DOI 10.1177/089826439901100203; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; Lin N, 1999, J HEALTH SOC BEHAV, V40, P344, DOI 10.2307/2676330; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; *MED OUTC TRUST, 1992, SF 36 HLTH SURV; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Noreau L, 2000, DISABIL REHABIL, V22, P170; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prince MJ, 1998, PSYCHOL MED, V28, P337, DOI 10.1017/S0033291797006478; Ren XS, 1999, SOC SCI MED, V48, P1721, DOI 10.1016/S0277-9536(99)00069-6; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; *SPSS INC, 1999, SPSS WIND REL 10 0 0; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Steptoe A, 1996, LANCET, V347, P1789, DOI 10.1016/S0140-6736(96)91616-5; Veenstra G, 2000, SOC SCI MED, V50, P619, DOI 10.1016/S0277-9536(99)00307-X; Vogel LC, 1998, ARCH PHYS MED REHAB, V79, P1496, DOI 10.1016/S0003-9993(98)90409-9; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Whiteneck G, 1999, ARCH PHYS MED REHAB, V80, P1485, DOI 10.1016/S0003-9993(99)90262-9; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WHITENECK GG, 1992, UNPUB COMMUNITY REEN; *WHO, 1997, ICIDH 2 INT CLASS IM; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; Zencius AH, 1999, BRAIN INJURY, V13, P723	57	56	56	0	10	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2003	48	4					266	274		10.1037/0090-5550.48.4.266			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	741ER	WOS:000186446200006					2021-06-18	
J	Gottshall, K; Drake, A; Gray, N; McDonald, E; Hoffer, ME				Gottshall, K; Drake, A; Gray, N; McDonald, E; Hoffer, ME			Objective vestibular tests as outcome measures in head injury patients	LARYNGOSCOPE			English	Article						traumatic brain injury; dynamic visual acuity; vestibular dysfunction	TRAUMATIC BRAIN-INJURY; DYNAMIC VISUAL-ACUITY; POSTCONCUSSION SYNDROME; DEPRESSION; CONCUSSION; MANAGEMENT; INVENTORY; DEFICITS; SCALE; COMA	Hypothesis: Dynamic visual acuity testing (DVAT) and the Dizziness Handicap Index (DHI) can be used as reliable outcome measures in patients after head injury. Background: Balance disorders are a significant disability after mild traumatic brain injury (TBI). Assessing when individuals can perform activities of daily living, return to work, and begin to play sports can be difficult to determine. Objective outcome measures that correlate with successful life skills can be useful in managing these patients. Methods. Fifty-three active duty individuals who suffered mild TBI underwent weekly DVAT testing and were administered a weekly DHI. Results in this group were compared with 46 control subjects who had not experienced TBI. In addition, weekly scores were compared with the patient's functional level, time to return to work, and time to perform all job related activities. Results. Individuals with TBI showed an overall increase of 42% in DVAT function over the first 4 weeks of testing, whereas controls showed an 8% increase. Concurrently, individuals with TBI averaged a 18-point improvement in DHI function, whereas control subjects showed no significant change in this score. Improvement in DVAT and DHI function correlated closely at the 1-week time point. Improvement in the patient's cognitive function, ability to return to activities of daily living, and ability to return to work gradually improved continuously. Conclusion: DVAT and the DHI can be used as reliable outcome measures in evaluating the progress of patients with balance disorders associated with TBI. These measures allow providers to make more reliable recommendations regarding such activities as returning to work.	US Dept Def, Spatial Orientat Ctr, Dept Otolaryngol, Naval Med Ctr San Diego, San Diego, CA 92134 USA; Def Vet Head Injury Program, San Diego, CA USA	Gottshall, K (corresponding author), US Dept Def, Spatial Orientat Ctr, Dept Otolaryngol, Naval Med Ctr San Diego, San Diego, CA 92134 USA.	krgottshall@nmcsd.med.navy.mil					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; *AM C REH MED, 1993, HEAD TRAUMA REHABIL, V8, P86; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; *CDCP, 1999, TRAUM BRAIN INJ US; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Clark WD, 1998, HEALTH CARE FINANC R, V20, P1; Clendaniel RA, 2000, OTOLARYNG CLIN N AM, V33, P519, DOI 10.1016/S0030-6665(05)70225-5; Demer JL, 2001, ANN NY ACAD SCI, V942, P428; Demer JL, 1998, OTOLARYNG HEAD NECK, V119, P78, DOI 10.1016/S0194-5998(98)70176-7; EVANS RW, 1992, NEUROL CLIN, V10, P815; Flanagan S, 1999, MT SINAI J MED, V66, P152; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; GRONWALL D, 1975, LANCET, V2, P995; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; Herdman SJ, 2001, ARCH OTOLARYNGOL, V127, P1205, DOI 10.1001/archotol.127.10.1205; Herdman SJ, 1998, AM J OTOL, V19, P790; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; KIRTANE MV, 1982, J LARYNGOL OTOL, V96, P521, DOI 10.1017/S0022215100092793; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Lee MH, 1997, AVIAT SPACE ENVIR MD, V68, P111; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; *MICR TECHN, 1999, DVA TEST VERS 12 US, P1; Nell V, 2000, ARCH PHYS MED REHAB, V81, P614, DOI 10.1053/mr.2000.3877; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Schubert MC, 2001, ANN NY ACAD SCI, V942, P490; TEASDALE G, 1974, LANCET, V2, P81; TUOHIMAA P, 1978, ACTA OTO-LARYNGOL, P7; Wallace CA, 2000, BRAIN INJURY, V14, P549; Whitney SL, 2000, OTOLARYNG CLIN N AM, V33, P659, DOI 10.1016/S0030-6665(05)70232-2; WRIGHT JH, 1983, HOSP COMMUNITY PSYCH, V34, P1119; Wright SC, 1998, AVIAT SPACE ENVIR MD, V69, P999	34	56	58	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0023-852X	1531-4995		LARYNGOSCOPE	Laryngoscope	OCT	2003	113	10					1746	1750		10.1097/00005537-200310000-00016			5	Medicine, Research & Experimental; Otorhinolaryngology	Research & Experimental Medicine; Otorhinolaryngology	731EL	WOS:000185871500015	14520100				2021-06-18	
J	Hellal, F; Pruneau, D; Palmier, B; Faye, P; Croci, N; Plotkine, M; Marchand-Verrecchia, C				Hellal, F; Pruneau, D; Palmier, B; Faye, P; Croci, N; Plotkine, M; Marchand-Verrecchia, C			Detrimental role of bradykinin B-2 receptor in a murine model of diffuse brain injury	JOURNAL OF NEUROTRAUMA			English	Article						B-2 receptor null mice; bradykinin B-2 receptor antagonist; brain edema; closed head injury; inflammation; neuroprotection	NITRIC-OXIDE SYNTHASE; CLOSED-HEAD TRAUMA; KININ RECEPTORS; NEUTROPHIL ACCUMULATION; CEREBRAL-ISCHEMIA; SMOOTH-MUSCLE; AXONAL INJURY; LF 16-0687MS; RAT MODEL; ANTAGONIST	Inhibition of the bradykinin B-2 receptor type (B2R) has been shown to improve neurological outcome in models of focal traumatic brain injury. However, the involvement of B2R in trauma-induced diffuse injury has not yet been explored. This is an important point, since in humans a pattern of diffuse injury is commonly found in severely injured patients and has been associated with a poor neurological outcome and prognosis. Using the non-peptide BY antagonist LF 16-0687 Ms and B2R null (B2R-/-) mice, we investigated the role of B2R in a model of closed head trauma (CHT). LF 16-0687 Ms given 30 min after injury reduced the neurological deficit by 26% and the cerebral edema by 22% when evaluated 4 h after CHT. Neurological function after CHT was improved in B2R-/- mice compared to B2R+/+ mice, although there was no difference in the development of brain edema. Treatment with LF 16-0687 Ms and B2R gene deletion decreased the accumulation of neutrophils at 24 h after CHT (50% and 36%, respectively). In addition, the inducible NO synthase (iNOS) mRNA level increased markedly, and this was reduced by LF 16-0687 Ms. Taken together, these data support a detrimental role of B2R in the development of the neurological deficit and of the inflammatory secondary damage resulting from diffuse traumatic brain injury. Therefore, blockade of bradykinin B-2 receptors might represent an attractive therapeutic approach in the pharmacological treatment of traumatic brain injury.	Univ Paris 05, Pharmacol Lab, UPRESEA 2510, F-75270 Paris 06, France; Ctr Rech Labs Fournier, Daix, France	Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Pharmacol Lab, UPRESEA 2510, F-75270 Paris 06, France.	Verrecchia@pharmacie.univ-paris5.fr	Hellal, Farida/E-8533-2013; Hellal, Farida/D-1834-2015; MARCHAND-LEROUX, Catherine/L-7453-2017	Hellal, Farida/0000-0002-9344-1846; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348			Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; BORKOWSKI JA, 1995, J BIOL CHEM, V270, P13706, DOI 10.1074/jbc.270.23.13706; Campos MM, 1998, PEPTIDES, V19, P1269, DOI 10.1016/S0196-9781(98)00087-4; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; Charriaut-Marlangue C, 1999, DEV BRAIN RES, V116, P133, DOI 10.1016/S0165-3806(99)00084-X; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; CHRISTOPHER TA, 1994, AM J PHYSIOL, V266, pH867; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Costa SKP, 2002, NEUROSCI LETT, V318, P158, DOI 10.1016/S0304-3940(01)02498-3; Couture R, 2000, HAND CHEM N, V16, P241; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; DRAY A, 1997, KININ SYSTEM, P157; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; FIGUEROA CD, 1989, BRIT J HAEMATOL, V72, P321, DOI 10.1111/j.1365-2141.1989.tb07711.x; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Gorlach C, 2001, J NEUROTRAUM, V18, P833, DOI 10.1089/089771501316919193; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Kaplanski J, 2002, J NEUROTRAUM, V19, P953, DOI 10.1089/089771502320317104; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Levy D, 2000, PAIN, V86, P265, DOI 10.1016/S0304-3959(00)00256-6; Lo EJ, 1999, NEUROREPORT, V10, P3821, DOI 10.1097/00001756-199912160-00018; Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Milia AF, 2001, HYPERTENSION, V37, P1473, DOI 10.1161/01.HYP.37.6.1473; Niess C, 2002, ACTA NEUROPATHOL, V104, P79, DOI 10.1007/s00401-002-0525-9; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PERKINS MN, 1993, PAIN, V53, P191, DOI 10.1016/0304-3959(93)90080-9; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Relton JK, 1997, STROKE, V28, P1430, DOI 10.1161/01.STR.28.7.1430; Rodell TC, 1996, IMMUNOPHARMACOLOGY, V33, P279, DOI 10.1016/0162-3109(96)00071-9; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Schilling L, 1997, KIDNEY INT, pS69; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; Tomita M, 1996, ACT NEUR S, V66, P32; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; WALKER K, 1995, NEUROCHEM INT, V26, P1, DOI 10.1016/0197-0186(94)00114-A; WHITTLE IR, 1992, ACTA NEUROCHIR, V115, P53, DOI 10.1007/BF01400591; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067	53	56	56	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2003	20	9					841	851		10.1089/089771503322385773			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	725BB	WOS:000185521800003	14577862				2021-06-18	
J	Amirjamshidi, A; Abbassioun, K; Rahmat, H; Hunt, CD				Amirjamshidi, A; Abbassioun, K; Rahmat, H; Hunt, CD			Minimal debridement or simple wound closure as the only surgical treatment in war victims with low-velocity penetrating head injuries - Indications and management protocol based upon more than 8 years follow-up of 99 cases from Iran-Iraq conflict	SURGICAL NEUROLOGY			English	Article						bone fragment; epilepsy; head injury; missile wound; surgical infection; war wound	MISSILE WOUNDS; BRAIN-ABSCESS; CRANIOCEREBRAL INJURIES; BONE FRAGMENTS; INFECTIONS; FISTULAS	BACKGROUND During military conflicts, surviving victims traditionally underwent large enough craniectomy or craniotomy to achieve extensive debridement of the in-driven bone, shell fragments, and debris. Meanwhile, the completely as well as the partially devitalized adjacent brain tissue would also be debrided. This might have led to additional neurologic deficit or lesser degree of recovery of functions. METHOD We studied the efficacy and safety of much more limited or even absence of surgical intervention in a selected group of wartime head-wounded patients. Among 1,150 war victims with penetrating head wounds referred to two major centers affiliated with Tehran University of Medical Sciences during the 8-year period spanning the Iran-Iraq conflict, there were 191 head-wounded patients who underwent either no surgical intervention or a very limited debridement. We have attempted to follow up as closely as possible for more than 8 years. Ninety-nine of them fulfilled the criteria to be included in this series. Close follow-up for development of cerebral infections, functional recovery, or development of new neurologic deficits and epilepsy were performed. At least 3 contrast-enhanced CT scans were taken for each patient. All patients were victims of the battle-field areas with low- to moderate-velocity missile or shell fragment injury. The Glasgow Coma Scale (GCS) scores of the patients were between 8-14 when visited by the first attending neurosurgery staff. The factors considered to be effective in the outcome analysis were the entry point, the number of the in-driven bone fragments, the retained shell fragments, the brain compartments affected, and the paranasal sinus or skull base involvement with or without cerebrospinal fluid (CSF) fistula. RESULTS There were 13 unilobar, 44 bilobar, 4 trilobar, 38 transventricular, and 3 skull base lesions. The number of retained metal fragments varied between 1 to 6. The number of retained bone fragments varied between 1 to 5 in 73 victims and more than five chips in other cases. The outcome was good (back to work) in 90 patients and poor (severely disabled) in 4. Five patients died because of severity of brain damage and meningitis. The effect of the different enumerated variables upon the outcome was measured using chi(2) and Fisher exact test, which was nonsignificant for all of the variables except for the orbitofacial entry point of injury (p = 0.00006). CONCLUSION This study seems to indicate that not only is reoperation for retained bone or shell fragments unnecessary, but surgeons having modern neuroradiological instruments available to detect the proper explanation for changes in GCS of the patients may decide not to proceed with any surgical intervention in a good number of patients. As a result of the "no surgical treatment protocol," one can preserve cerebral tissue without exposing the patient to undue risk of seizures, infection, or death by leaving behind some or all the in-driven bone and shell fragments. (C) 2003 Elsevier Inc. All rights reserved.	Sina Hosp, Dept Neurosurg, Tehran, Iran; Univ Tehran Med Sci, Tehran, Iran; Dr Shariati Hosp, Dept Neurosurg, Tehran, Iran; UMDNY, Sch Med, Dept Neurosurg, Newark, NJ USA	Amirjamshidi, A (corresponding author), POB 19585-678, Tehran 678, Iran.						Aarabi B, 1998, NEUROSURGERY, V42, P500, DOI 10.1097/00006123-199803000-00014; ABBOTT K H, 1946, Mil Surg, V98, P469; Abou Nader M, 2000, SURG NEUROL, V54, P397, DOI 10.1016/S0090-3019(00)00279-2; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Amirjamshidi A, 1996, J NEUROSURG, V84, P769, DOI 10.3171/jns.1996.84.5.0769; Ascroft PB, 1943, LANCET, V2, P211; BARATHAM G, 1972, J NEUROL NEUROSUR PS, V35, P698, DOI 10.1136/jnnp.35.5.698; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; CAIRNS H, 1947, BR J SURG WAR SURG S, V1, P198; CAREY ME, 1972, SURG GYNECOL OBSTETR, V135, P386; CAREY ME, 1974, J NEUROSURG, V41, P542, DOI 10.3171/jns.1974.41.5.0542; Cushing H, 1918, BRIT J SURG, V5, P558; DREW JH, 1954, J NEUROSURG, V11, P386, DOI 10.3171/jns.1954.11.4.0386; DZENITIS AJ, 1965, J NEUROSURG, V22, P169, DOI 10.3171/jns.1965.22.2.0169; ECKLUND JM, 2000, CLIN NEUROSURG, V48, pCH47; GEORGE ED, 1999, MISSILE WOUNDS HEAD, V1, pCH10; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HAYNES WG, 1945, J NEUROSURG, V2, P463, DOI 10.3171/jns.1945.2.6.0463; HAYNES WG, 1945, J NEUROSURG, V2, P365, DOI 10.3171/jns.1945.2.5.0365; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; Lee JH, 2000, J NEUROSURG, V93, P477, DOI 10.3171/jns.2000.93.3.0477; MALTBY GL, 1946, J NEUROSURG, V3, P239, DOI 10.3171/jns.1946.3.3.0239; Marquardt G, 2000, BRIT J NEUROSURG, V14, P246; MATSON DD, 1958, SURGERY WORLD WAR 2, V1, P123; MEIROWSKY AM, 1982, J NEUROSURG, V57, P617, DOI 10.3171/jns.1982.57.5.0617; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; MYERS PW, 1989, J NEUROSURG, V70, pA319; PENECK TL, 1986, J NEUROSURG, V64, P813; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; RISH BL, 1980, J NEUROSURG, V53, P772, DOI 10.3171/jns.1980.53.6.0772; SOLOMON RA, 1988, SURG NEUROL, V30, P321, DOI 10.1016/0090-3019(88)90307-2; Splavski B, 1998, SURG NEUROL, V50, P194, DOI 10.1016/S0090-3019(98)00047-0; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; TAHA JM, 1991, NEUROSURGERY, V29, P864, DOI 10.1227/00006123-199112000-00010; WANNAMAKER GT, 1958, J NEUROSURG, V15, P512, DOI 10.3171/jns.1958.15.5.0512	38	56	61	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	AUG	2003	60	2					105	111		10.1016/S0090-3019(03)00358-6			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	707WB	WOS:000184531900003	12900110				2021-06-18	
J	Tinius, TP				Tinius, TP			The Integrated Visual and Auditory Continuous Performance Test as a neuropsychological measure	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mTBI; attention; brain injury; ADHD; head injury	CLOSED-HEAD-INJURY; REACTION-TIME; SUSTAINED ATTENTION	The Integrated Visual and Auditory (IVA) Continuous Performance Test (CPT) and Neuropsychological Impairment Scale (NIS) were completed by adults diagnosed with mild traumatic brain injury (mTBI), adults diagnosed with attention deficit hyperactivity disorder (ADHD), and controls. On the IVA CPT, the mTBI and ADHD groups performed significantly lower on the full and secondary scales for attention and response accuracy. For individual scales, the mTBI and ADHD groups showed lower performance on measures of reaction time, inattention, impulsivity, and variability of RT. The mTBI and ADHD groups showed similar patterns of performance on the IVA. On the NIS, the mTBI and ADHD groups reported more neuropsychological symptoms than the control group, and the mTBI group reported more neuropsychological symptoms than the ADHD group. The results are discussed in regard to changes in cognitive processing and sustained attention in individuals diagnosed with mTBI and ADHD. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd. All rights reserved.	St Cloud State Univ, Dept Psychol, St Cloud, MN 56301 USA	Tinius, TP (corresponding author), St Cloud State Univ, Dept Psychol, 420 7th Ave S, St Cloud, MN 56301 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Beck A. T., 1967, DEPRESSION CLIN EXPT; BURG JS, 1995, BRAIN INJURY, V9, P395, DOI 10.3109/02699059509005779; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; Conners C.K., 1999, CONNERS ADULT ADHD R; ERRICO AL, 1990, J CONSULT CLIN PSYCH, V1, P45; GENTILINI M, 1989, MILD HEAD INJURY, P163; Gordon M, 1988, INSTRUCTION MANUAL G; Gronwall D, 1989, MILD HEAD INJURY, P153; KLENSCH H, 1973, FORTSCHR NEUROL PSYC, V41, P575; LARRABEE GJ, 1996, ECOLOGICAL VALIDITY; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; Miller E, 1970, Cortex, V6, P121; O'Donnell W., 1994, NEUROPSYCHOLOGICAL I; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Rimel R. W., 1981, NEUROSURGERY, V9, P35; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; SANDFORD JA, 1995, MANUAL INTEGRATED VI; SOLHBERG MM, 1989, INTRO COGNITIVE REHA; Spielberger CD, 1970, TEST MANUAL STATE TR; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; VANZOMENEN AH, 1990, NEUROBEHAVORIAL RECO; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Wechsler D., 1981, WAIS R MANUAL WECHSL; Western SL, 1996, ARCH CLIN NEUROPSYCH, V11, P557, DOI 10.1016/0887-6177(95)00043-7	30	56	65	7	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2003	18	5					439	454	PII S0887-6177(02)00144-0	10.1016/S0887-6177(02)00144-0			16	Psychology, Clinical; Psychology	Psychology	689CB	WOS:000183473100001	14591441				2021-06-18	
J	Dimopoulou, I; Korfias, S; Dafni, U; Anthi, A; Psachoulia, C; Jullien, G; Sakas, DE; Roussos, C				Dimopoulou, I; Korfias, S; Dafni, U; Anthi, A; Psachoulia, C; Jullien, G; Sakas, DE; Roussos, C			Protein S-100b serum levels in trauma-induced brain death	NEUROLOGY			English	Article							SEVERE HEAD-INJURY; MARKERS; DAMAGE; TOMOGRAPHY; S-100-BETA; PATHOLOGY; ENOLASE	Objective: To analyze the time course of serum protein S-100b in patients with traumatic brain injury deteriorating to brain death and to investigate the predictive value of initial S-100b levels in relation to clinical and radiologic measures of injury severity with regard to brain death. Methods: Forty-seven patients who sustained severe head injury were studied. Blood samples for measurement of S-100b were drawn on admission in the intensive care unit and every 24 hours thereafter for a maximum of 6 consecutive days or until brain death occurred. Variables related to outcome were recorded, including age, sex, Glasgow Coma Scale (GCS), and brain CT findings on admission. Outcome was defined as deterioration to brain death or not. Results: Of the 47 patients studied, 17 deteriorated to brain death and 30 did not. On admission, patients who became brain dead had higher median serum S-100b levels compared with those who did not (2.32 mug/L vs 1.04 mug/L, p = 0.0028). Logistic regression analysis showed that initial S-100b was an independent predictor of brain death (p = 0.041), in the presence of advanced age (p = 0.043) and low GCS score (p = 0.013). The odds ratio of 2.09 (95% CI, 1.03 to 4.25) indicates a more than doubling of the probability of deteriorating to brain death per 1-mug/L increase in S-100b on admission. At clinical brain death, median S-100b was higher in patients with brain death compared with the peak S-100b value obtained over a 6-day period in those who did not become brain dead (6.58 mug/L vs 1.49 mug/L, p < 0.0001). Conclusions: Prediction of brain death after severe head injury can be improved by combining clinical and S-100b data; thus, serum S-100b determination deserves to be included in the neuromonitoring of patients with severe traumatic brain injury.	Natl & Kapodistrian Univ, Dept Crit Care Med, Athens, Greece; Natl & Kapodistrian Univ, Dept Neurosurg, Athens, Greece; Natl & Kapodistrian Univ, Dept Neurosurg, Athens, Greece; Natl & Kapodistrian Univ, Dept Biostat, Athens, Greece; Natl & Kapodistrian Univ, Dept Biochem, Athens, Greece; Natl & Kapodistrian Univ, Evangelismos Hosp, Med & Nursing Sch, Athens, Greece	Dimopoulou, I (corresponding author), 2 Pesmazoglou St, Athens 14561, Greece.		Dafni, Ourania/AAH-4453-2019	Dafni, Ourania/0000-0003-4367-4497			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ikeda Y, 2001, NEUROSURG QUART, V11, P173, DOI 10.1097/00013414-200109000-00001; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Marshall SB, 1991, J NEUROSURG S, V75, P14; McKeating EG, 1998, ACT NEUR S, V71, P117; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, J NEUROSURG, V91, P875, DOI 10.3171/jns.1999.91.5.0875; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rothoerl RD, 2000, ACT NEUR S, V76, P97; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Wiesmann M, 1998, CLIN CHEM, V44, P1056; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	26	56	56	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	MAR 25	2003	60	6					947	951		10.1212/01.WNL.0000049931.77887.7F			5	Clinical Neurology	Neurosciences & Neurology	679YB	WOS:000182948600012	12654958				2021-06-18	
J	Pan, WH; Kastin, AJ; Rigai, T; McLay, R; Pick, CG				Pan, WH; Kastin, AJ; Rigai, T; McLay, R; Pick, CG			Increased hippocampal uptake of tumor necrosis factor alpha and behavioral changes in mice	EXPERIMENTAL BRAIN RESEARCH			English	Article						traumatic brain injury; staircase test; blood-brain barrier; transport; TNF alpha; IL1 beta; behavior; hippocampus	BLOOD-BRAIN-BARRIER; SPINAL-CORD-INJURY; STAIRCASE TEST; MESSENGER-RNA; TNF-ALPHA; HEAD-INJURY; EXPRESSION; MOUSE; PERMEABILITY; TRANSPORT	Brain trauma may alter the function of the blood-brain barrier (BBB) and affect psychornotor activity. We have shown that the transport system for tumor necrosis factor a (TNFalpha) at the BBB undergoes regulatory changes after spinal cord injury. In this study, we show in CD I mice that mild trauma by weight-drop to the right temporal region specifically increases the uptake of blood-borne TNFalpha. This increase, measured by use of radiolabeled murine TNFalpha, occurred only in the right hippocampus 24 h after injury and returned to normal at 1 week. There was no increase in the uptake of the vascular marker albumin at I h, 24 h, or I week postinjury, indicating that the BBB remained relatively intact. Human interleukin-1beta, which does not cross the BBB by saturable transport, showed no significant changes in brain uptake after trauma. Therefore, the selective entry of TNFa in the injured right hippocampus may be explained by enhanced transport across the BBB. To explore the functional relevance of this transport regulation, we measured mouse behavior by the staircase test. The number of rearings, mainly reflective of exploratory behavior, decreased at I h and I day after injury but increased at 1 week after a 30-g weight-drop injury. The number of stairs ascended, mainly indicative of locomotor activity, was unchanged at all times tested. We conclude that mild, blunt brain trauma involving the hippocampus causes specific upregulation of TNFalpha transport and a selective change in exploratory behavior. Although no causal relationship can be established at this time, the behavioral changes might be related to the increased TNFalpha transport after trauma.	Tulane Univ, Sch Med, New Orleans, LA 70112 USA; VAMC, New Orleans, LA 70112 USA; Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; USN, Ctr Med, Dept Mental Hlth, San Diego, CA USA	Pan, WH (corresponding author), Tulane Univ, Sch Med, 1430 Tulane Ave, New Orleans, LA 70112 USA.	wpan@tulane.edu	Pick, Chaim/D-4789-2009				BANKS WA, 1992, PEPTIDES, V13, P1289, DOI 10.1016/0196-9781(92)90037-4; Banks WA, 2001, J PHARMACOL EXP THER, V299, P536; BANKS WA, 1991, J PHARMACOL EXP THER, V259, P988; BANKS WA, 1990, AM J PHYSIOL, V259, P1; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; EMMANOUIL DE, 1990, PSYCHOPHARMACOLOGY, V102, P95, DOI 10.1007/BF02245750; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Gabellec MM, 1999, NEUROSCI RES, V33, P251, DOI 10.1016/S0168-0102(99)00014-0; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Pan WH, 1996, AM J PHYSIOL-ENDOC M, V271, pE636; Pan WH, 1999, J NEUROSCI, V19, P3649; Pan WH, 1997, EXP NEUROL, V146, P367, DOI 10.1006/exnr.1997.6533; Pan WH, 1997, J NEUROIMMUNOL, V76, P105, DOI 10.1016/S0165-5728(97)00034-9; Pan WH, 2000, EXP NEUROL, V170, P357, DOI 10.1006/exnr.2001.7702; Pick CG, 1996, PSYCHOPHARMACOLOGY, V128, P61, DOI 10.1007/s002130050110; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SIMIAND J, 1984, PSYCHOPHARMACOLOGY, V84, P48, DOI 10.1007/BF00432023; SMITH RA, 1987, J BIOL CHEM, V262, P6951; Weizman R, 2001, PHARMACOL BIOCHEM BE, V68, P491, DOI 10.1016/S0091-3057(01)00450-6	25	56	57	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	MAR	2003	149	2					195	199		10.1007/s00221-002-1355-7			5	Neurosciences	Neurosciences & Neurology	660BH	WOS:000181813700008	12610687				2021-06-18	
J	Wehman, P; Kregel, J; Keyser-Marcus, L; Sherron-Targett, P; Campbell, L; West, M; Cifu, DX				Wehman, P; Kregel, J; Keyser-Marcus, L; Sherron-Targett, P; Campbell, L; West, M; Cifu, DX			Supported employment for persons with traumatic brain injury: A preliminary investigation of long-term follow-up costs and program efficiency	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; employment; supported; rehabilitation	RETURN; WORK; REHABILITATION; BENEFIT; DISABILITIES	Objective: To investigate the long-term follow-up costs of supported employment as well as the wage and employment characteristics for individuals with moderate to severe traumatic brain injury (TBI) who participated in supported employment services over a 14-year time period. Design: Longitudinal design with prospectively collected data. Setting: A university-based supported employment program that uses the individual placement model of supported employment. Participants: Fifty-nine individuals with moderate to severe TBI who were consecutively referred for supported employment services. The sample was restricted to individuals who were placed into a least 1 supported employment position during the study period. Interventions: Not applicable. Main Outcome Measures: Data. were collected on clients placed into at least 1 competitive supported employment position from 1985 to 1999. Analyses were performed to examine the costs of supported employment, employment characteristics (eg, wages, length of employment), and benefit-cost ratios of supported employment for individuals with TBI. Results: The average length of employment for the current sample was 42.58 months. Average gross earnings were $26,129.74 for individuals during their entire duration of employment. Billing charges accrued for employment services averaged $10,349.37. Individuals with TBI earned an average of $17,515 more than the costs associated with their supported employment. Conclusions: Our investigation provides additional support for the conclusion that supported employment is cost effective for individuals with disabilities, including individuals with TBI, and that the costs of supported employment decrease over time.	Virginia Commonwealth Univ, Med Coll Virginia, Rehabil Res & Training Ctr, Dept Phys Med & Rehabil, Richmond, VA 23284 USA; Virginia Commonwealth Univ, Sch Educ, Richmond, VA 23284 USA	Wehman, P (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Rehabil Res & Training Ctr, Dept Phys Med & Rehabil, Box 842011, Richmond, VA 23284 USA.	pwehman@atlas.vcu.edu		Cifu, David/0000-0003-1600-9387			Anthes M, 1999, LIBR COLLECT ACQUIS, V23, P1, DOI 10.1016/S1464-9055(98)00103-1; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS21, DOI 10.1016/S0003-9993(98)90116-2; BOND GR, 1995, J VOCATIONAL REHABIL, V5, P75; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cimera RE, 1998, MENT RETARD, V36, P280, DOI 10.1352/0047-6765(1998)036<0280:AIWSMR>2.0.CO;2; Clark RE, 1996, ADM POLICY MENT HLTH, V24, P63, DOI 10.1007/BF02106484; CRISP R, 1992, J REHABIL, V58, P27; Curl RM, 1996, J HEAD TRAUMA REHAB, V11, P75, DOI 10.1097/00001199-199602000-00009; DANLEY KS, 1994, REHABIL PSYCHOL, V39, P269, DOI 10.1037/0090-5550.39.4.269; HILL ML, 1987, RES DEV DISABIL, V8, P71, DOI 10.1016/0891-4222(87)90041-2; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kregel J., 2000, J VOCATIONAL REHABIL, V14, P153; KREUTZER JS, 1988, VOCATIONAL REHABILIT, P291; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MCCAUGHRIN WB, 1993, MENT RETARD, V31, P41; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Rogers ES, 1997, PSYCHIATR REHABIL J, V20, P25, DOI 10.1037/h0095367; ROGERS ES, 1995, EVAL PROGRAM PLANN, V18, P105, DOI 10.1016/0149-7189(95)00002-S; SHAFER MS, 1990, AM J MENT RETARD, V95, P316; Shearn J, 2000, J APPL RES INTELLECT, V13, P29, DOI 10.1046/j.1468-3148.2000.00005.x; THOMPSON L, 1992, J ASSOC PERS SEVERE, V17, P87, DOI 10.1177/154079699201700203; Wall JR, 1998, NEUROREHABILITATION, V10, P39, DOI 10.3233/NRE-1998-10105; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WEHMAN P, 1998, AM REHABIL       SPR, P31; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; WEHMAN PH, 1990, ARCH PHYS MED REHAB, V71, P1047; WEST M, 1991, ARCH PHYS MED REHAB, V72, P127	31	56	57	1	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					192	196		10.1053/apmr.2003.50027			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700007	12601649	Green Published			2021-06-18	
J	Trombly, CA; Radomski, MV; Trexel, C; Burnett-Smith, SE				Trombly, CA; Radomski, MV; Trexel, C; Burnett-Smith, SE			Occupational therapy and achievement of self-identified goals by adults with acquired brain injury: Phase II	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article; Proceedings Paper	Annual Conference of the American-Occupational-Therapy-Association	2000	WASHINGTON, D.C.	Amer Occupat Therapy Assoc		Canadian Occupational Performance Measure; Community Integration Questionnaire; goal attainment scaling; goal-specific therapy	COMMUNITY INTEGRATION QUESTIONNAIRE; COGNITIVE REHABILITATION; POSTTRAUMATIC AMNESIA; OUTCOMES EVALUATION; TBI REHABILITATION; HEAD-INJURY; REINTEGRATION	OBJECTIVE The purpose of this study was to investigate the association between participation in goal-specific outpatient occupational therapy and improvement in self-identified goals in adults with acquired brain injury. METHOD Thirty-one persons with traumatic brain injury of mixed chronicity participated at three sites located in different regions of the United States. Using a repeated-measures design, therapy that usually was offered at each site to achieve specific goals was followed by a no-treatment period Participants completed the Canadian Occupational Performance Measure Performance subscale (COPM-P) and Satisfaction subscale (COPM-S), and the Community Integration Questionnaire (CIQ) at admission, discharge, and 1 to 18 weeks after discharge Goal attainment scales were developed at admission and scored at discharge; the differences for each site were tested, using dependent t tests. Gains for the treatment period (admission to discharge) in COPM subscales and the CIQ were compared with gains during the no-treatment period (discharge to follow-up) for each site, using dependent Nests. The results were synthesized meta-analytically across the sites. RESULTS The participants identified a total of 149 goals, 81 % of which were achieved Goal attainment T scores improved significantly (Z=7.52, p<.001), and the combined effect size was large (r=94) The COPM-P (Z=4 13, p<001) and COPM-S (Z=4 25, p<001) showed significantly greater gains during the treatment (average 15.3 weeks) versus the no-treatment (average 9.9 weeks) period Effect size estimates were large 71 and .76, respectively Gain scores of the CIQ did not differ significantly (Z=.75, p=22, r=29) between periods CONCLUSION. Participation in goal-specific outpatient occupational therapy that focused on teaching compensatory strategies was strongly associated with achievement of self-identified goals and reduction of disability in adults with mild to moderate brain injury.	Boston Univ, Dept Occupat Therapy, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA; Sister Kenny Rehabil Serv, Outpatient Brain Injury Clin, Minneapolis, MN USA; Progress Rehabil Associates, Brain Injury Rehabil Ctr, Portland, OR USA; Community Reentry Program Legacy Hlth Syst, Portland, OR USA; Santa Monica Coll, Acquired Brain Injury Program, Disabled Student Serv, Santa Monica, CA USA	Trombly, CA (corresponding author), Boston Univ, Dept Occupat Therapy, Sargent Coll Hlth & Rehabil Sci, 635 Commonwealth Ave, Boston, MA 02215 USA.	ctrombly@bu.edu					Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BANJA J, 1994, ARCH PHYS MED REHAB, V75, pSC19; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Clark M S, 1983, Int Rehabil Med, V5, P41; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; *CTR EV BAS MED, 2001, LEV EVID GRAD REC; Cusick CP, 2000, J HEAD TRAUMA REHAB, V15, P739, DOI 10.1097/00001199-200002000-00012; Dirette DK, 1999, OCCUP THER J RES, V19, P223, DOI 10.1177/153944929901900401; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Giles GM, 1999, AM J OCCUP THER, V53, P406, DOI 10.5014/ajot.53.4.406b; Giles GM, 1997, AM J OCCUP THER, V51, P256, DOI 10.5014/ajot.51.4.256; Gutman SA, 1999, AM J OCCUP THER, V53, P101, DOI 10.5014/ajot.53.1.101; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; JOHNSTONE EC, 1980, BRIT J CLIN PHARMACO, V10, P5, DOI 10.1111/j.1365-2125.1980.tb00497.x; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Law M, 1990, Can J Occup Ther, V57, P82; Law M., 1994, CANADIAN OCCUPATIONA; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALKMUS D, 1980, REHABILITATION HEAD; McColl M A, 2000, Can J Occup Ther, V67, P22; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; NEISTADT ME, 1994, AM J OCCUP THER, V48, P877, DOI 10.5014/ajot.48.10.877; Nelson DL, 1996, AM J OCCUP THER, V50, P223, DOI 10.5014/ajot.50.3.223; OTTENBACHER KJ, 1990, AM J OCCUP THER, V44, P519, DOI 10.5014/ajot.44.6.519; OTTENBACHER KJ, 1993, AM J OCCUP THER, V47, P349, DOI 10.5014/ajot.47.4.349; POLLOCK N, 1993, AM J OCCUP THER, V47, P298, DOI 10.5014/ajot.47.4.298; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; *RANCH LOS AM HOSP, 1985, MEAS COGN FUNCT REH; Rockwood K, 1996, NEUROEPIDEMIOLOGY, V15, P330, DOI 10.1159/000109923; Rockwood K, 1997, J CLIN EPIDEMIOL, V50, P581, DOI 10.1016/S0895-4356(97)00014-0; ROCKWOOD K, 1990, J CLIN EPIDEMIOL, V46, P1113; ROSENTHAL R, 1984, METAANALYTIC PROCEDU; ROSNOW RL, 1988, J COUNS PSYCHOL, V35, P203, DOI 10.1037/0022-0167.35.2.203; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCHWARTZ SM, 1995, AM J OCCUP THER, V49, P655, DOI 10.5014/ajot.49.7.655; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; SIETSEMA JM, 1993, AM J OCCUP THER, V47, P19, DOI 10.5014/ajot.47.1.19; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Trombly C, 1999, AM J OCCUP THER, V53, P407, DOI 10.5014/ajot.53.4.407; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WOODDAUPHINEE SL, 1988, ARCH PHYS MED REHAB, V69, P583; ZWEBER B, 1990, Occupational Therapy in Health Care, V7, P45, DOI 10.1080/J003v07n01_05	57	56	57	0	10	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2002	56	5					489	498		10.5014/ajot.56.5.489			10	Rehabilitation	Rehabilitation	594UT	WOS:000178070000002	12269503				2021-06-18	
J	Yamada, H; Sakai, A; Yamada, E; Nishimura, T; Matsumura, M				Yamada, H; Sakai, A; Yamada, E; Nishimura, T; Matsumura, M			Spontaneous closure of traumatic macular hole	AMERICAN JOURNAL OF OPHTHALMOLOGY			English	Article							OPTICAL COHERENCE TOMOGRAPHY; DISAPPEARANCE; VITRECTOMY; SURGERY	PURPOSE: To investigate the mechanism by which traumatic macular hole closes spontaneously. DESIGN: Consecutive observational case series of three patients with unilateral traumatic macular hole who consulted medical staff at the Kansai Medical University between 1997 and 2000. METHODS: Three patients who sustained unilateral blunt trauma to the eye and developed traumatic macular hole were followed with ophthalmic examination, fundus photography, fluorescein angiography, and optical coherence tomography (OCT). RESULTS: Case 1 was an 11-year-old boy. He had neither a macular hole nor prominent macular edema at his first consultation, but a macular hole opened 3 weeks later. OCT showed macular edema and a full,thickness macular hole. The tissue around the edge of the macular hole protruded inward toward the center and finally closed spontaneously 18 weeks later. Case 2 was a 19,year,old man. He had a tiny rough-edged macular hole at his first consultation with a local ophthalmologist. OCT showed macular hole enlargement and worsening of the macular edema during follow up. The macular hole finally closed 4 months after injury. Case 3 was a 15-year-old boy. He had a tiny rough,edged macular hole at his first consultation with a local ophthalmologist. The macular hole finally closed 6 months after injury. CONCLUSION: Macular hole can be a result of severe damage from ocular concussion or damage to the retina. For 6 months following injury, traumatic macular hole should probably be observed rather than surgically re, paired, because of the possibility that the macular hole may close spontaneously. (C) 2002 by Elsevier Science Inc. All rights reserved.		Yamada, H (corresponding author), Kansai Med Univ, Dept Ophthalmol, 10-15 Fumizonocho, Moriguchi, Osaka 5708507, Japan.						Amari F, 1999, RETINA-J RET VIT DIS, V19, P410, DOI 10.1097/00006982-199909000-00007; COATS G, 1907, ROYAL LONDON OPHTHAL, V17, P69; deBustros S, 1996, RETINA-J RET VIT DIS, V16, P451, DOI 10.1097/00006982-199616050-00018; DELORI F, 1969, INVEST OPHTH VISUAL, V8, P290; Frangieh G T, 1981, Retina, V1, P311, DOI 10.1097/00006982-198101040-00008; Freeman WR, 1997, ARCH OPHTHALMOL-CHIC, V115, P11, DOI 10.1001/archopht.1997.01100150013002; GarciaArumi J, 1997, RETINA-J RET VIT DIS, V17, P372; GASS JDM, 1995, AM J OPHTHALMOL, V119, P752, DOI 10.1016/S0002-9394(14)72781-3; Imai M, 1999, AM J OPHTHALMOL, V128, P621, DOI 10.1016/S0002-9394(99)00200-7; KELLY NE, 1991, ARCH OPHTHALMOL-CHIC, V109, P654, DOI 10.1001/archopht.1991.01080050068031; Knapp H., 1869, ARCH AUGENHEILKD, V1, P6; Kusaka S, 1997, AM J OPHTHALMOL, V123, P837, DOI 10.1016/S0002-9394(14)71136-5; LEWIS H, 1986, AM J OPHTHALMOL, V102, P172, DOI 10.1016/0002-9394(86)90139-X; Mikajiri K, 1999, AM J OPHTHALMOL, V128, P655, DOI 10.1016/S0002-9394(99)00203-2; MIZUSAWA Y, 1996, JPN REV CLIN OPHTHAL, V90, P790; MURAKAMI T, 1998, JPN J CLIN OPHTHAL, V52, P473; OGLIVIE F, 1900, T OPHTHAL SOC UK, V20, P202; Parmar DN, 1999, RETINA-J RET VIT DIS, V19, P470, DOI 10.1097/00006982-199919050-00026; RYAN EH, 1994, ARCH OPHTHALMOL-CHIC, V112, P1545, DOI 10.1001/archopht.1994.01090240051025; SCHEPENS CL, 1955, AM J OPHTHALMOL, P631; Takahashi H, 1999, AM J OPHTHALMOL, V128, P519, DOI 10.1016/S0002-9394(99)00173-7; TAKAHASHI R, 1992, ACTA OPHTHALMOL JPN, V39, P327; WENDEL RT, 1993, OPHTHALMOLOGY, V100, P1607; YOKOZUKA K, 1991, JPN J CLIN OPHTHAL, V45, P1121	24	56	70	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9394			AM J OPHTHALMOL	Am. J. Ophthalmol.	SEP	2002	134	3					340	347	PII S0002-9394(02)01535-0	10.1016/S0002-9394(02)01535-0			8	Ophthalmology	Ophthalmology	587TY	WOS:000177660300004	12208244				2021-06-18	
J	Hansen, HS; Moesgaard, B; Petersen, G; Hansen, HH				Hansen, HS; Moesgaard, B; Petersen, G; Hansen, HH			Putative neuroprotective actions of N-acyl-ethanolamines	PHARMACOLOGY & THERAPEUTICS			English	Article; Proceedings Paper	International Symposium on Endocannabinoids	OCT, 2000	MADRID, SPAIN			N-acyl-ethanolamine phospholipids; anandamide; neurodegeneration; ischemia; brain; necrosis	CANNABINOID-RECEPTOR-LIGAND; FREE FATTY-ACIDS; PROTEIN-KINASE-C; ANANDAMIDE INDUCES APOPTOSIS; PLATELET-ACTIVATING-FACTOR; TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; RAT CEREBRAL-CORTEX; ARACHIDONIC-ACID; ACYLETHANOLAMINE PHOSPHOLIPIDS	N-Acyl-ethanotamines (NAEs) and their precursors, N-acyl-ethanolamine phospholipids (NAPEs), are present in the mammalian brain at levels of a few hundred picomoles/gram tissue and a few nanomoles/gram tissue, respectively. NAE-containing arachidonic acid is called anandamide, and it has attracted particular attention since it is a partial agonist for the cannabinoid receptors, for which 2-arachidonoylglycerol is the full agonist. In addition, anandamide may also activate the vanilloid receptor. Anandamide usually amounts to 1-10% of NAEs, as the vast majority of N-acyl groups are saturated and monounsaturated fatty acids. Formation of NAPE and NAE is catalyzed by an N-acyltransferase and an NAPE-hydrolyzing phospholipase D. respectively, two enzymes that have been characterized only preliminary. Interestingly, NAPEs and NAEs accumulate in the brain in response to neurodegenerative insults at a time when other phospholipids are subjected to rapid degradation. This is an important biosynthetic aspect of NAPE and NAE, as NAEs may be neuroprotective by a number of different mechanisms involving both receptor activation and non-receptor-mediated effects, e.g. by binding to cannabinoid receptors and interfering with ceramide turnover, respectively. (C) 2002 Elsevier Science Inc. All rights reserved.	Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark	Hansen, HS (corresponding author), Royal Danish Sch Pharm, Dept Pharmacol, Univ Pk 2, DK-2100 Copenhagen, Denmark.			Hansen, Harald S./0000-0001-7360-7418			Agranoff Bernard W., 1999, P47; AKOKA S, 1988, CHEM PHYS LIPIDS, V46, P43, DOI 10.1016/0009-3084(88)90112-0; Ameri A, 1999, BRIT J PHARMACOL, V126, P1831, DOI 10.1038/sj.bjp.0702478; Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Ben-Shabat S, 1998, EUR J PHARMACOL, V353, P23, DOI 10.1016/S0014-2999(98)00392-6; Berdyshev EV, 2000, BIOCHEM J, V346, P369, DOI 10.1042/0264-6021:3460369; Berdyshev EV, 1997, EUR J PHARMACOL, V330, P231, DOI 10.1016/S0014-2999(97)01007-8; Berdyshev EV, 2001, WORLD REV NUTR DIET, V88, P207; Bertrand N, 1996, NEUROCHEM INT, V28, P293, DOI 10.1016/0197-0186(95)00086-0; Blazquez C, 1999, J NEUROCHEM, V72, P1759, DOI 10.1046/j.1471-4159.1999.721759.x; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Braida D, 2000, NEUROSCI LETT, V296, P69, DOI 10.1016/S0304-3940(00)01634-7; Cadas H, 1997, J NEUROSCI, V17, P1226; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Contos JJA, 2000, MOL PHARMACOL, V58, P1188; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; de Urquiza AM, 2000, SCIENCE, V290, P2140; Dekker LV, 2000, SCIENCE, V287, P982, DOI 10.1126/science.287.5455.982; Deutsch J, 1997, NEUROCHEM RES, V22, P759, DOI 10.1023/A:1022030306359; DEVANE WA, 1988, MOL PHARMACOL, V34, P605; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; DOMINGO JC, 1994, CHEM PHYS LIPIDS, V69, P229, DOI 10.1016/0009-3084(94)90004-3; EIKELENBOOM P, 1994, TRENDS PHARMACOL SCI, V15, P447, DOI 10.1016/0165-6147(94)90057-4; EPPS DE, 1982, J BIOL CHEM, V257, P1383; FACCI L, 1995, P NATL ACAD SCI USA, V92, P3376, DOI 10.1073/pnas.92.8.3376; Geddes JW, 1997, NEUROBIOL AGING, V18, P305, DOI 10.1016/S0197-4580(97)80312-0; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; Gulaya NM, 1998, CHEM PHYS LIPIDS, V97, P49, DOI 10.1016/S0009-3084(98)00093-0; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HH, 2001, J NEUROCHEM, V76, P39, DOI 10.1046/j.1471-4159.2001.00006.x; HANSEN HS, 1995, BBA-LIPID LIPID MET, V1258, P303, DOI 10.1016/0005-2760(95)00134-X; Hansen HS, 1998, BIOCHEM PHARMACOL, V55, P719, DOI 10.1016/S0006-2952(97)00396-1; Hansen HS, 1997, J NEUROCHEM, V69, P753; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Hillard CJ, 1997, J LIPID RES, V38, P2383; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; KATSUKI H, 1995, PROG NEUROBIOL, V46, P607, DOI 10.1016/0301-0082(95)00016-O; Katsura K, 2000, J NEUROCHEM, V75, P2521, DOI 10.1046/j.1471-4159.2000.0752521.x; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; KISHIRO K, 1988, ANAL BIOCHEM, V175, P516, DOI 10.1016/0003-2697(88)90576-3; KLEIN J, 1993, BRAIN RES, V630, P337, DOI 10.1016/0006-8993(93)90674-C; Klein J, 2000, J NEURAL TRANSM, V107, P1027, DOI 10.1007/s007020070051; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; Kondo S, 1998, ARCH BIOCHEM BIOPHYS, V354, P303, DOI 10.1006/abbi.1998.0688; KOZUKA M, 1995, NEUROCHEM RES, V20, P23, DOI 10.1007/BF00995148; Kubota M, 1996, NEUROL RES, V18, P337; KUEHL FA, 1957, J AM CHEM SOC, V79, P5577, DOI 10.1021/ja01577a066; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Lauritzen L, 2001, PROG LIPID RES, V40, P1, DOI 10.1016/S0163-7827(00)00017-5; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Maccarrone M, 2000, J BIOL CHEM, V275, P31938, DOI 10.1074/jbc.M005722200; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Moesgaard B, 1999, J LIPID RES, V40, P515; Moesgaard B, 2000, J LIPID RES, V41, P985; Moesgaard B, 2002, COMP BIOCHEM PHYS B, V131, P475, DOI 10.1016/S1096-4959(02)00003-9; Molina-Holgado F, 1998, FEBS LETT, V433, P139, DOI 10.1016/S0014-5793(98)00851-5; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Nagayama T, 1999, J NEUROSCI, V19, P2987; Nakane M, 2000, NEUROSCI LETT, V296, P89, DOI 10.1016/S0304-3940(00)01655-4; Narita K, 2000, NEUROL RES, V22, P393, DOI 10.1080/01616412.2000.11740689; NATARAJAN V, 1981, BIOCHIM BIOPHYS ACTA, V664, P445, DOI 10.1016/0005-2760(81)90067-9; NATARAJAN V, 1986, BIOCHIM BIOPHYS ACTA, V878, P32, DOI 10.1016/0005-2760(86)90341-3; NATARAJAN V, 1982, BIOCHIM BIOPHYS ACTA, V712, P342, DOI 10.1016/0005-2760(82)90352-6; NEWMAN JL, 1986, CHEM PHYS LIPIDS, V42, P249, DOI 10.1016/0009-3084(86)90084-8; Nishida K, 1996, STROKE, V27, P514, DOI 10.1161/01.STR.27.3.514; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PARINANDI NL, 1988, FEBS LETT, V237, P49, DOI 10.1016/0014-5793(88)80169-8; PERLIK F, 1971, ACTA PHYSIOL HUNG, V39, P395; Petersen G, 1999, FEBS LETT, V455, P41, DOI 10.1016/S0014-5793(99)00861-3; Phillis JW, 2000, BRAIN RES, V884, P155, DOI 10.1016/S0006-8993(00)02938-3; Ping SE, 1998, J NEUROSCI RES, V54, P206, DOI 10.1002/(SICI)1097-4547(19981015)54:2<206::AID-JNR8>3.3.CO;2-O; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Rao AM, 2000, J NEUROCHEM, V75, P2528, DOI 10.1046/j.1471-4159.2000.0752528.x; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Ross RA, 2000, EUR J PHARMACOL, V401, P121, DOI 10.1016/S0014-2999(00)00437-4; Sarker KP, 2000, FEBS LETT, V472, P39, DOI 10.1016/S0014-5793(00)01425-3; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SCHMID PC, 1983, J BIOL CHEM, V258, P9302; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Shen MX, 1998, MOL PHARMACOL, V54, P459; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Skaper SD, 1996, P NATL ACAD SCI USA, V93, P3984, DOI 10.1073/pnas.93.9.3984; Skaper SD, 1996, J NEUROCHEM, V66, P1157; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Sugimoto Y, 2000, PROG LIPID RES, V39, P289, DOI 10.1016/S0163-7827(00)00008-4; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Sugiura T, 2000, J BIOL CHEM, V275, P605, DOI 10.1074/jbc.275.1.605; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sugiura T, 1999, J BIOL CHEM, V274, P2794, DOI 10.1074/jbc.274.5.2794; Sugiura T, 1996, EUR J BIOCHEM, V240, P53, DOI 10.1111/j.1432-1033.1996.0053h.x; Sugiura T, 1996, BIOCHEM BIOPH RES CO, V218, P113, DOI 10.1006/bbrc.1996.0020; Sugiura T, 2001, NEUROSCI LETT, V297, P175, DOI 10.1016/S0304-3940(00)01691-8; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Wiesner DA, 1996, GLYCOCONJUGATE J, V13, P327, DOI 10.1007/BF00731508; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; Wiesner DA, 1997, J BIOL CHEM, V272, P9868	109	56	57	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0163-7258			PHARMACOL THERAPEUT	Pharmacol. Ther.	AUG	2002	95	2					119	126	PII S0163-7258(02)00251-6	10.1016/S0163-7258(02)00251-6			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	592XE	WOS:000177961500003	12182959				2021-06-18	
J	Mangels, JA; Craik, FIM; Levine, B; Schwartz, ML; Stuss, DT				Mangels, JA; Craik, FIM; Levine, B; Schwartz, ML; Stuss, DT			Effects of divided attention on episodic memory in chronic traumatic brain injury: A function of severity and strategy	NEUROPSYCHOLOGIA			English	Article; Proceedings Paper	Rotman-Research-Institute Conference on Traumatic Brain Injury	1999	TORONTO, CANADA	Rotman Res Inst		executive control; frontal-lobe; outcome; neuropsychology	CLOSED-HEAD-INJURY; DUAL-TASK PERFORMANCE; FRONTAL-LOBE LESIONS; TECHNETIUM-99M-HMPAO SPECT; AMNESIC PATIENTS; EXPLICIT MEMORY; PRACTICAL SCALE; FALSE RECALL; OLDER-ADULTS; MILD	Eleven patients with mild traumatic brain injury (MTBI) and 13 patients with moderate-to-severe TBI (STBI) were compared to 10 matched controls on episodic memory for pictorial scene-object associations (e.g. kitchen-bread) and a range of standardized neuropsychological tests of memory and frontal-lobe functions. We tested the hypothesis that deficits in episodic memory result from impaired attentional resources and/or strategic control by manipulating attentional load at encoding (focused versus divided attention) and environmental support at retrieval (free recall and recalled cued by scene versus recognition of object and scene). Patients with TBI were disproportionately affected by the divided attention manipulation, but this effect was modulated by injury severity and encoding strategy. Overall, MTBI patients were impaired only when items were encoded under divided attention, indicating memory deficits that were secondary to deficits in the executive control. STBI patients could be differentiated into two distinct functional subgroups based on whether they favored a strategy of attending to the encoding or digit-monitoring task. The subgroup favoring the digit-monitoring task demonstrated deficits in the focused attention condition, and disproportionate memory deficits in the divided attention condition. In contrast, the subgroup favoring the encoding task demonstrated intact performance across all memory Measures, regardless of attentional load, and despite remarkable similarity to the other STBI subgroup on demographic, neuropsychological, and acute injury severity measures. We discuss these outcome differences in terms of the relationship between strategy and executive control and highlight the need for more sensitive anatomical and behavioral measurement at both acute and chronic stages of injury. (C) 2002 Elsevier Science Ltd. All rights reserved.	Columbia Univ, Dept Psychol, New York, NY 10027 USA; Univ Toronto, Rotman Res Inst, Baycrest Ctr Geriatr Care, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Neurosurg, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol, Toronto, ON, Canada; Univ Toronto, Dept Surg, Toronto, ON, Canada; Univ Toronto, Dept Med Neurol Rehabil Med, Toronto, ON, Canada	Mangels, JA (corresponding author), Columbia Univ, Dept Psychol, Schermerhorn Hall,1190 Amsterdam Ave, New York, NY 10027 USA.	mangels@psych.columbia.edu	Levine, Brian/G-4328-2010; Levine, Brian/O-2725-2019	Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X; Craik, Fergus/0000-0001-8073-3236			Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Anderson ND, 2000, J COGNITIVE NEUROSCI, V12, P775, DOI 10.1162/089892900562598; Anderson ND, 1998, PSYCHOL AGING, V13, P405, DOI 10.1037/0882-7974.13.3.405; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A. D., 1986, WORKING MEMORY; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Campbell K. B., 1995, HDB NEUROPSYCHOLOGY, V10, P269; Craik FIM, 1996, J EXP PSYCHOL GEN, V125, P159, DOI 10.1037/0096-3445.125.2.159; DELIS DC, 1992, NEUROPSYCHOLOGIA, V30, P683, DOI 10.1016/0028-3932(92)90039-O; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Eslinger P. J., 1996, ATTENTION MEMORY EXE, P367; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V33, P1305, DOI 10.1016/0028-3932(95)00103-A; GRAY BG, 1992, J NUCL MED, V33, P52; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HARTMAN A, 1992, CLIN REHABIL, V6, P133; Iidaka T, 2000, J COGNITIVE NEUROSCI, V12, P267, DOI 10.1162/089892900562093; JACOBS A, 1994, J NUCL MED, V35, P942; JANOWSKY JS, 1989, NEUROPSYCHOLOGIA, V27, P1043, DOI 10.1016/0028-3932(89)90184-X; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; LEVINE B, IN PRESS NEUROSURGER; Mangels JA, 1997, NEUROPSYCHOLOGY, V11, P207, DOI 10.1037/0894-4105.11.2.207; Mangels JA, 2001, COGNITIVE BRAIN RES, V11, P77, DOI 10.1016/S0926-6410(00)00066-5; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Melo B, 1999, COGNITIVE NEUROPSYCH, V16, P343, DOI 10.1080/026432999380825; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Niemann H, 1996, NEUROPSYCHOL REV, V6, P11, DOI 10.1007/BF01875418; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; ROENKER DL, 1971, PSYCHOL BULL, V76, P45, DOI 10.1037/h0031355; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Santos ME, 1998, BRAIN INJURY, V12, P759, DOI 10.1080/026990598122151; SCHACTER DL, 1984, J VERB LEARN VERB BE, V23, P593, DOI 10.1016/S0022-5371(84)90373-6; Schacter DL, 1996, J MEM LANG, V35, P319, DOI 10.1006/jmla.1996.0018; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHIMAMURA AP, 1987, J EXP PSYCHOL LEARN, V13, P464, DOI 10.1037/0278-7393.13.3.464; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STERN Y, 2002, J CLIN EXPT NEURPSYC, V58, P1182; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Stuss DT, 2000, NEUROLOGY, V54, P1337, DOI 10.1212/WNL.54.6.1337; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81; Troyer AK, 1999, NEUROPSYCHOLOGY, V13, P467, DOI 10.1037/0894-4105.13.4.467; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Watt S, 1999, NEUROPSYCHOLOGY, V13, P338, DOI 10.1037/0894-4105.13.3.338; Wheeler M A, 1995, J Int Neuropsychol Soc, V1, P525; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013	69	56	57	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2002	40	13					2369	2385	PII S0028-3932(02)00084-2	10.1016/S0028-3932(02)00084-2			17	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	623RH	WOS:000179716300016	12417466				2021-06-18	
J	McCauley, SR; Levin, HS; Vanier, M; Mazaux, JM; Boake, C; Goldfader, PR; Rockers, D; Butters, M; Kareken, DA; Lambert, J; Clifton, GL; Butters, M; Lambert, J				McCauley, SR; Levin, HS; Vanier, M; Mazaux, JM; Boake, C; Goldfader, PR; Rockers, D; Butters, M; Kareken, DA; Lambert, J; Clifton, GL; Butters, M; Lambert, J			The neurobehavioural rating scale-revised: sensitivity and validity in closed head injury assessment	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						outcome measures; head injury; randomised clinical trials; neurobehavioural sequelae	TRAUMATIC BRAIN INJURY; BEHAVIORAL DISTURBANCES; PSYCHIATRIC-SYMPTOMS; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; TEST-PERFORMANCE; FOLLOW-UP; RECOVERY; SEQUELAE; RELIABILITY	Objectives-To investigate the factor structure and psychometric properties of the neurobehavioural rating scale-revised (NRS-R) and to determine its usefulness in clinical trials. Methods-A consecutive series of patients sustaining severe closed head injury were evacuated to one of 11 large regional North American trauma centres and entered into a randomised, phase III, multicentre clinical trial investigating the therapeutic use of moderate hypothermia. Acute care personnel were blinded to outcome and outcome personnel were blinded to treatment condition. The Glasgow outcome scale (GOS) was the primary outcome measure. Secondary outcome measures included the disability rating scale (DRS) and the NRS-R. Results-Exploratory factor analysis of NRS-R data collected at 6 months after injury (n=210) resulted in a five factor model including: (1) executive/cognition, (2) positive symptoms, (3) negative symptoms, (4) mood/affect, and (5) oral/motor. These factors showed acceptable internal consistency (0.62 to 0.88), low to moderate interfactor correlations (0.19 to 0.61), and discriminated well between GOS defined groups. Factor validity was demonstrated by significant correlations with specific neuropsychological domains. Significant change was measured from 3 to 6 months after injury for the total score (sum of all 29 item ratings) and all factor scores except mood/affect and positive symptoms. The total score and all factor scores correlated significantly with concurrent GOS and DRS scores. Conclusions-The NRS-R is weld suited as a secondary outcome measure for clinical trials as its completion rate exceeds that of neuropsychological assessment and it provides important neurobehavioural information complementary to that provided by global outcome and neuropsychological measures.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Univ Montreal, Ecole Readapt, Montreal, PQ, Canada; CHU Bordeaux, Bordeaux, France; Univ Texas, Hlth Sci Ctr, Dept Phys Med & Rehabil, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Neurosurg, Houston, TX USA; St Louis Univ, Sch Med, Dept Neurol, St Louis, MO 63103 USA; St Louis Univ, Sch Med, Dept Neurosurg, St Louis, MO 63103 USA; Univ Calif Davis, Dept Neurol Surg, Sacramento, CA 95817 USA; Indiana Univ, Sch Med, Dept Neurol, Indianapolis, IN 46202 USA	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 6560 Fannin,Ste 1144, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu	Butters, Meryl/AAR-2863-2021; Kareken, David/Z-1960-2019	Kareken, David/0000-0003-0855-8300	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS032786, R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-32786, NS-21889] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [49CCR612707-01] Funding Source: Medline		ACHTE K, 1991, PSYCHOPATHOLOGY, V24, P309, DOI 10.1159/000284731; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; BENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285; BENNETT B, 1979, NEUROSURGERY, V4, P283; BENNETT B, 1976, LANCET, V1, P1031; Benton A, 1989, MULTILINGUAL APHASIA; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; CORRIGAN J D, 1990, Brain Injury, V4, P215, DOI 10.3109/02699059009026170; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Foglia JP, 1997, PSYCHOPHARMACOL BULL, V33, P109; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; GASS CS, 1990, PSYCHOL REP, V67, P435, DOI 10.2466/PR0.67.6.435-438; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GUALTIERI CT, 1991, J CLIN PSYCHOPHARM, V11, P280, DOI 10.1097/00004714-199108000-00027; HART RP, 1987, J CONSULT CLIN PSYCH, V55, P101, DOI 10.1037/0022-006X.55.1.101; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HILLBOM E, 1951, ACTA PSYCHIAT NEUROL, V60, P36; Hilton G, 1990, J Neurosci Nurs, V22, P36; Jane J, 1996, NEUROTRAUMA, P793; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KARLSSON C, 1968, J NEUROSURG, V29, P242; Kaszniak A. W., 1986, HDB CLIN MEMORY ASSE, P168, DOI 10.1037/10057-014; KAY T, 1988, J HEAD TRAUMA REHAB, V3, P65; KING DA, 1990, SUBCORTICAL DEMENTIA, P218; KIRK C, 1975, LANCET, V1, P1180; KLOVE H, 1973, MED CLIN N AM; Larrabee GJ, 1988, NEUROPSYCHOLOGY, V2, P173, DOI 10.1037//0894-4105.2.3-4.173; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A. R, 1973, WORKING BRAIN; MATTHEWS CG, 1974, INSTRUCTION MANUAL A; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P336; Mulsant BH, 1997, INT J GERIATR PSYCH, V12, P537, DOI 10.1002/(SICI)1099-1166(199705)12:5<537::AID-GPS542>3.0.CO;2-Z; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; OVERALL JE, 1962, PSYCHOL REP, V10, P799; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Silver Jonathan M., 1994, P313; Smeltzer Donald J., 1994, P251; Smith A., 1968, LEARNING DISORDERS, P83; Smith A., 1982, SYMBOL DIGIT MODALIT; Stevens J., 1996, APPL MULTIVARIATE ST; SULTZER DL, 1995, J NEUROPSYCH CLIN N, V7, P476; SULTZER DL, 1995, ARCH NEUROL-CHICAGO, V52, P773, DOI 10.1001/archneur.1995.00540320049012; SULTZER DL, 1993, AM J PSYCHIAT, V150, P1806; SULTZER DL, 1995, J PSYCHIATR RES, V29, P185, DOI 10.1016/0022-3956(95)00018-Z; SULTZER DL, 1992, J AM GERIATR SOC, V40, P549, DOI 10.1111/j.1532-5415.1992.tb02101.x; Tabachnick B.G., 1989, USING MULTIVARIATE S; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1053/apmr.2000.4436; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; VIOLON A, 1987, ACTA NEUROCHIR, V85, P96, DOI 10.1007/BF01456104; WEINGARTNER H, 1986, HDB CLIN MEMORY ASSE, P218	69	56	59	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2001	71	5					643	651		10.1136/jnnp.71.5.643			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	486BM	WOS:000171798600017	11606677	Bronze, Green Published			2021-06-18	
J	Wright, P; Rogers, N; Hall, C; Wilson, B; Evans, J; Emslie, H; Bartram, C				Wright, P; Rogers, N; Hall, C; Wilson, B; Evans, J; Emslie, H; Bartram, C			Comparison of pocket-computer memory aids for people with brain injury	BRAIN INJURY			English	Article								Two styles of pocket computer memory aid were compared as support for people who had sustained non-progressive, closed-head brain injury. A purpose-designed interface provided a diary with auditory alarms, a notebook and links between diary entries and specific notepages. One computer had a physical keyboard, the other did not. Twelve adult volunteers were loaned each computer for 2 months, with a 1 month gap between, in counterbalanced order. It was found that all participants could use the memory aids, and most (83%) found them useful. Little customizing was needed, but amount of use varied widely. Predictors of usage included use of other reminding systems before joining the project, and speed in calculator addition which may reflect working memory. High users preferred the computer with a physical keyboard; low users made more entries with the palm-size computer. These data highlight the need to distinguish ability to use from willingness to use.	Cardiff Univ, Sch Psychol, Cardiff CF10 3YG, S Glam, Wales; Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge, England; Oliver Zangwill Ctr, Ely, Cambs, England	Wright, P (corresponding author), Cardiff Univ, Sch Psychol, POB 901, Cardiff CF10 3YG, S Glam, Wales.	WrightP1@cardiff.ac.uk					Baddeley A.D., 1992, SPEED CAPACITY LANGU; Einstein G., 1996, PROSPECTIVE MEMORY T, P115; EVANS JJ, 1999, ANN C SOC COGN REH B; Herrmann D., 1999, HDB APPL COGNITION, P377; KAPUR N, 1995, HDB MEMORY DISORDERS; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; *LIGHTH LOW VIS PR, LIGHTH NEAR VIS AC T; MASUI T, 1998, P ACM C HUM FACT COM, P328; Smith AD, 1996, PERSPECTIVES COGNITI, P192; Wilson, 1991, NATL ADULT READING T; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wright P, 2000, J EXP PSYCHOL-APPL, V6, P158; Wright P, 2000, ERGONOMICS, V43, P702, DOI 10.1080/001401300404689	16	56	56	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2001	15	9					787	800		10.1080/02699050110045161			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400004	11516347				2021-06-18	
J	Hammond, FM; Grattan, KD; Sasser, H; Corrigan, JD; Bushnik, T; Zafonte, RD				Hammond, FM; Grattan, KD; Sasser, H; Corrigan, JD; Bushnik, T; Zafonte, RD			Long-term recovery course after traumatic brain injury: A comparison of the functional independence measure and disability rating scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; Disability Rating Scale; Functional Independence Measure; outcome	SPINAL-CORD INJURY; GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; REHABILITATION; VALIDITY; DYSFUNCTION; RELIABILITY; PREDICTION; RETURN; TESTS	Objectives: To study group changes over time after traumatic brain injury (TBI). Design: Prospective cohort. Setting and Participants: TBI Model System Database with 1160 subjects using cohort with complete data. Main Outcome Measures: Functional Independence Measure (FIM (TM)) and Disability Rating Scale (DRS) at rehabilitation discharge and annually after injury. Results: Statistically significant differences existed between FIM (TM) -Total, FIM (TM) -Motor. FIM (TM) -Cognitive subscales, and DRS at rehabilitation discharge and year 1. Comparisons of year-to-year intervals. years I and 3, 1 and 5, and 3 and 5, revealed no statistically significant differences except between years I and 3 and I and 5 with DRS. and years I and 5 with FIM (TM). Including only those more dependent at year I revealed statistically significant differences between years 1 and 2 and I and 5 on FIM (TM) -Cognitive and DRS, but not the FIM (TM) -Motor. The proportion of change for FIM (TM) and DRS items from year I to years 2 and 5 revealed DRS Level of Functioning and Employability items accounted for most DRS change, whereas FIM (TM) change was more spread across its components. Conclusions: DRS is more sensitive to changes during a shorter time period than FIM (TM) and seems to he more appropriate for detecting long-term deficits. However, research studies aimed at detecting meaningful changes year to year after TBI may need to use other tools or consider changes among individuals instead of group changes, DRS Level of Function and Employability Items represent complex functions expected to recover later than the more basic DRS items. Sole use of these two DRS items might provide an efficient means of measuring long-term recovery when resources are limited. whereas expansion of these two items might allow greater sensitivity and detail.	Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Carolinas Healthcare Syst, Charlotte, NC 28203 USA; R Stuart Dickson Inst Hlth Stat, Carolinas Healthcare Syst, Charlotte, NC USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Univ Pittsburgh, Coll Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA	Hammond, FM (corresponding author), Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Carolinas Healthcare Syst, 1100 Blythe Blvd, Charlotte, NC 28203 USA.		Corrigan, John D./E-2921-2011	Bushnik, Tamara/0000-0003-3328-257X			Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DITUNNO JF, 1995, SPINAL CORD INJURY C; ELIASON MR, 1984, PHYS THER, V64, P1357, DOI 10.1093/ptj/64.9.1357; Fiedler R.C., 1996, FUNCTIONAL EVALUATIO, P75; FRYER LJ, 1987, J HEAD TRAUMA REHAB, V2, P51, DOI DOI 10.1097/00001199-198709000-00007; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM, 1999, ARCH PHYS MED REHAB, V80, P1471, DOI 10.1016/S0003-9993(99)90260-5; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Heinemann AW, 1997, ARCH PHYS MED REHAB, V78, P143, DOI 10.1016/S0003-9993(97)90255-0; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; Stineman MG, 1996, AM J PHYS MED REHAB, V75, P68, DOI 10.1097/00002060-199601000-00018; Stineman MG, 1996, ARCH PHYS MED REHAB, V77, P1101, DOI 10.1016/S0003-9993(96)90130-6; STINEMAN MG, 1994, TOP STROKE REHABIL, V1, P40; TEASDALE G, 1974, LANCET, V2, P81; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; World Health Organization, 1980, INT CLASS IMP DIS HA	41	56	58	0	4	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2001	16	4					318	329		10.1097/00001199-200108000-00003			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	459YA	WOS:000170278000003	11461655				2021-06-18	
J	Hanna-Pladdy, B; Berry, ZM; Bennett, T; Phillips, HL; Gouvier, WD				Hanna-Pladdy, B; Berry, ZM; Bennett, T; Phillips, HL; Gouvier, WD			Stress as a diagnostic challenge for postconcussive symptoms: Sequelae of mild traumatic brain injury or physiological stress response	CLINICAL NEUROPSYCHOLOGIST			English	Article; Proceedings Paper	Annual Meeting of the American-Psychological-Association	AUG 14-18, 1998	SAN FRANCISCO, CA	Amer Psychol Assoc			MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; RECOVERY; REHABILITATION; CONCUSSION; TASK	There is considerable controversy regarding whether persistent postconcussive symptoms (PCS) are injury-specific, in a subgroup of individuals after mild traumatic brain injury (TBI). The following findings have contributed to this controversy: (1) The base rate of PCS in mild TBI is comparable to uninjured controls; and (2) The severity of PCS covary with daily stress levels (Gouvier, Cubic, Jones, Brantley, & Cutlip, 1992). We examined this relationship further by evaluating the effects of experimental conditions of stress or relaxation on individuals with TBI and uninjured control subjects, with low and high PCS endorsement. We evaluated psychophysiological parameters, neuropsychological performance, and changes in PCS and stress perception. In our study, subjects with TBI increased PCS after engaging in cognitively challenging tasks, and demonstrated significant autonomic changes in the stress condition. Symptomatic TBI subjects exposed to high stress had increases in PCS complaints, decreased speed of information processing, and subtle memory deficits. Our results suggest that PCS are injury-specific and that individuals with a history of TBI are susceptible to the effects of stress. Relaxation training including breathing retraining may be an effective means of decreasing PCS and cognitive complaints in subjects with mild TBI.	Univ Florida, Hlth Sci Ctr, Dept Neurol, Gainesville, FL 32610 USA; Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA	Hanna-Pladdy, B (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Neurol, 100 S Newell Dr Room L3-100 Box 100236 UFBI, Gainesville, FL 32610 USA.	pladdybh@neurology.ufl.edu		Hanna-Pladdy, Brenda/0000-0001-7806-3843			ALBUS M, 1987, STRESS MEDICINE, V3, P233, DOI 10.1002/smi.2460030314; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 1942, Proc R Soc Med, V35, P601; BARTEL PL, 1993, CLONTECHNIQUES, V8, P1; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1989, FRONTIERS CLIN NEURO, P37; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 1992, Brain Inj, V6, P477, DOI 10.3109/02699059209008143; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; Galea LAM, 1997, NEUROSCIENCE, V81, P689, DOI 10.1016/S0306-4522(97)00233-9; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; LEGEWIEPERTZBORN H, 1977, PSYCHIAT PRAX, V4, P223; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1984, J REHABIL, V50, P39; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; Lupien SJ, 1997, BRAIN RES REV, V24, P1, DOI 10.1016/S0165-0173(97)00004-0; LYSAGHT R, 1990, AM J OCCUP THER, V44, P797, DOI 10.5014/ajot.44.9.797; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; McEwen BS, 2000, NEUROCHEM RES, V25, P1219, DOI 10.1023/A:1007687911139; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; NOVACK TA, 1988, REHABIL COUNS BULL, V31, P313; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P205; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raber J, 2000, J NEUROSCI, V20, P2064; RAO SL, 1985, NIMHANS J, V2, P141; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Shohami E, 1995, J NEUROTRAUM, V12, P1069, DOI 10.1089/neu.1995.12.1069; Smith A., 1991, SYMBOL DIGIT MODALIT; STOZ P, 1998, BRAIN INJURY, V12, P537; STRICH SJ, 1969, LATE EFFECTS HEAD IN, P501; TREMONT G, 1994, 14 M NAT AC NEUR ORL; UNO T, 1989, J NEUROSCI, V9, P1709; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wetzel L., 1987, SHORT CATEGORY TEST; Wilken JA, 2000, INT J PSYCHOPHYSIOL, V37, P233, DOI 10.1016/S0167-8760(00)00082-9; Zachary R., 1986, SHIPLEY I LIVING SCA	76	56	56	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2001	15	3					289	304		10.1076/clin.15.3.289.10272			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	482NA	WOS:000171581200001	11778766				2021-06-18	
J	Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, IJ; Gurka, JA				Bryant, RA; Marosszeky, JE; Crooks, J; Baguley, IJ; Gurka, JA			Posttraumatic stress disorder and psychosocial functioning after severe traumatic brain injury	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article							CLOSED-HEAD INJURY; PSYCHIATRIC-DISORDERS; SCALE; PSEUDOMEMORIES; DEFICITS	The aim of this study was to investigate the influence of posttraumatic stress disorder (PTSD) on rehabilitation after severe traumatic brain injury (TBI). Ninety-six patients with severe TBI patients were assessed 6 months after hospital discharge with the Posttraumatic Stress Disorder Interview, the Functional Assessment Measure (FAM), the Community Integration Questionnaire (CIQ), the Overt Aggression Scale (OAS), the General Health Questionnaire (GHQ), the Beck Depression inventory (BDI), and the Satisfaction with Life Scale (SWL). PTSD was diagnosed in 27% of patients. Patients with PTSD reported higher scores on the GHQ and BDI, and lower scores on the FAM, CIQ, GAS, and SWLS than those without PTSD. Effective rehabilitation after severe TBI may be enhanced by management of PTSD.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Westmead Hosp, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Baguley, Ian J/K-6878-2013; Bryant, Richard/AAA-6479-2019; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Bryant, Richard/0000-0002-9607-819X; 			Barrett DH, 1996, J ABNORM PSYCHOL, V105, P575, DOI 10.1037/0021-843X.105.4.575; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; BRYAN S, 1995, HEALTH POLICY, V33, P31, DOI 10.1016/0168-8510(94)00699-F; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; BRYANT RA, IN PRESS CLIN PSYCHO; Chemtob CM, 1997, J TRAUMA STRESS, V10, P17, DOI 10.1023/A:1024852228908; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Hall K. M., 1992, NEUROREHABILITATION, V2, DOI [10.3233/NRE-1992-2410, DOI 10.3233/NRE-1992-2410]; Henderson S, 1981, NEUROSIS SOCIAL ENV; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; Norris Fran H., 1997, P7; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P318; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Silver J M, 1991, J Neuropsychiatry Clin Neurosci, V3, pS22; Valentiner DP, 1996, J ABNORM PSYCHOL, V105, P455, DOI 10.1037/0021-843X.105.3.455; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Warda G, 1998, BEHAV RES THER, V36, P1177, DOI 10.1016/S0005-7967(98)00071-0; WATSON CG, 1991, J CLIN PSYCHOL, V47, P179, DOI 10.1002/1097-4679(199103)47:2<179::AID-JCLP2270470202>3.0.CO;2-P; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	36	56	57	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	FEB	2001	189	2					109	113		10.1097/00005053-200102000-00006			5	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	402YK	WOS:000167015600006	11225683				2021-06-18	
J	Arciniegas, D; Olincy, A; Topkoff, J; McRae, K; Cawthra, E; Filley, CM; Reite, M; Adler, LE				Arciniegas, D; Olincy, A; Topkoff, J; McRae, K; Cawthra, E; Filley, CM; Reite, M; Adler, LE			Impaired auditory gating and P50 nonsuppression following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							MINOR HEAD-INJURIES; NICOTINIC RECEPTORS; ALZHEIMERS-DISEASE; EVOKED-POTENTIALS; MENTAL-STATE; SCHIZOPHRENIA; HIPPOCAMPAL; ACETYLCHOLINE; RATS; CONCUSSION	Traumatic brain injury (TBI) can produce persistent attention and memory impairment that may in part be produced by impaired auditory sensory getting. The P50 evoked waveform response to paired auditory stimuli appears to be a useful measure of auditory gating. The first controlled measurement of the P50 ratio in TBI patients is described: when 20 patients with persistently symptomatic TBI were compared with 20 control subjects, the P50 ratio was significantly greater in the TBI group. The potential neurophysiologic and therapeutic implications of this finding in TBI patients who report symptoms consistent with impaired auditory gating are discussed.	Univ Colorado, Hlth Sci Ctr, Dept Psychiat & Neurol, Denver, CO 80262 USA; Vet Affairs Med Ctr, Res Serv, Denver, CO USA; Vet Affairs Med Ctr, Psychiat Serv, Denver, CO USA; Vet Affairs Med Ctr, Serv Neurol, Denver, CO USA	Arciniegas, D (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Psychiat & Neurol, Campus Box C268-28,4200 E 9th Ave, Denver, CO 80262 USA.		Arciniegas, David/A-3792-2009		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH15442, MH47476, MH56601] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH047476, R03MH056601] Funding Source: NIH RePORTER		Adler LE, 1998, SCHIZOPHRENIA BULL, V24, P189, DOI 10.1093/oxfordjournals.schbul.a033320; ADLER LE, 1992, BIOL PSYCHIAT, V32, P607, DOI 10.1016/0006-3223(92)90073-9; ADLER LE, 1993, AM J PSYCHIAT, V150, P1856; ADLER LE, IN PRESS BIOL PSYCHI; ALEXANDER MP, 1982, TRAUMATIC BRAIN INJU, P219; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; BICKFORDWIMER PC, 1990, BIOL PSYCHIAT, V27, P183, DOI 10.1016/0006-3223(90)90648-L; BOUTROS N, 1995, PSYCHIAT RES, V57, P57, DOI 10.1016/0165-1781(95)02597-P; BOUTROS NN, 1991, CLIN ELECTROENCEPHAL, V22, P40, DOI 10.1177/155005949102200109; Breese CR, 1997, J COMP NEUROL, V387, P385, DOI 10.1002/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X; BUCHWALD JS, 1989, ELECTROEN CLIN NEURO, V74, P378, DOI 10.1016/0168-5597(89)90005-1; Cassidy John W., 1994, P43; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Clementz BA, 1998, AM J PSYCHIAT, V155, P1691, DOI 10.1176/ajp.155.12.1691; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; Fenton GW, 1996, CLIN ELECTROENCEPHAL, V27, P174; Filley C., 1995, NEUROBEHAVIORAL ANAT; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FREEDMAN R, 1994, HARVARD REV PSYCHIAT, V2, P179, DOI 10.3109/10673229409017136; Frith CD, 1996, NEUROIMAGE, V4, P210, DOI 10.1006/nimg.1996.0072; GARCIARILL E, 1995, NEUROSCIENCE, V66, P321, DOI 10.1016/0306-4522(94)00564-L; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; GUALTIERI CT, 1988, CLIN NEUROPHARMACOL, V12, P273; Guillery RW, 1998, TRENDS NEUROSCI, V21, P28, DOI 10.1016/S0166-2236(97)01157-0; GUPTA NK, 1986, NEUROLOGY, V36, P578, DOI 10.1212/WNL.36.4.578; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; Harris JG, 1996, SCHIZOPHR RES, V20, P253, DOI 10.1016/0920-9964(96)00009-6; JABBARI B, 1987, ELECTROEN CLIN NEURO, V67, P289, DOI 10.1016/0013-4694(87)90115-5; JENNETT B, 1975, LANCET, V1, P480; JOHNSON MR, 1993, BIOL PSYCHIAT, V33, P380, DOI 10.1016/0006-3223(93)90328-B; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; KRAUS JF, 1994, EPIDEMIOLOGY NEUROPS, P3; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; Lovell Mark R., 1994, P133; LUNTZLEYBMAN V, 1992, BRAIN RES, V587, P130, DOI 10.1016/0006-8993(92)91437-J; McAllister Thomas W., 1994, P357; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nagamoto HT, 1996, BIOL PSYCHIAT, V40, P181, DOI 10.1016/0006-3223(95)00371-1; NAGAMOTO HT, 1989, BIOL PSYCHIAT, V25, P549, DOI 10.1016/0006-3223(89)90215-1; OLBRICH HM, 1986, ACTA NEUROCHIR, V80, P116, DOI 10.1007/BF01812285; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; PAPANICOLAOU AC, 1984, NEUROSURGERY, V14, P676, DOI 10.1227/00006123-198406000-00005; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RANDOLPH C, 1988, NEUROPSYCHOBIOLOGY, V20, P43, DOI 10.1159/000118471; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIZZO PA, 1983, NEUROPSYCHOBIOLOGY, V9, P78, DOI 10.1159/000117941; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rund BR, 1998, SCAND J PSYCHOL, V39, P101, DOI 10.1111/1467-9450.00062; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; Seidman LJ, 1998, BIOL PSYCHIAT, V44, P260, DOI 10.1016/S0006-3223(97)00392-2; Silver JM., 1994, NEUROPSYCHIATRY TRAU; Stevens KE, 1997, PHARMACOL BIOCHEM BE, V57, P869, DOI 10.1016/S0091-3057(96)00466-2; Stevens KE, 1998, NEUROSCIENCE, V82, P701; STRUB RL, 1988, NEUROBEHAVIORAL DISO; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1984, PATHOPHYSIOLOGY HEAD, P4; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Venables PH, 1964, INPUT DYSFUNCTION SC, P1; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514	71	56	56	0	2	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2000	12	1					77	85		10.1176/jnp.12.1.77			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	280JY	WOS:000085100700013	10678517				2021-06-18	
J	Gray, DS; Burnham, RS				Gray, DS; Burnham, RS			Preliminary outcome analysis of a long-term rehabilitation program for severe acquired brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; length of stay; outcome assessment (health care); rehabilitation	SEVERE HEAD-INJURY; FUNCTIONAL INDEPENDENCE MEASURE; DISABILITY RATING-SCALE; FOLLOW-UP; EARLY INTERVENTION; OLDER ADULTS; RECOVERY; TRAUMA; COMA; RELIABILITY	Objectives: To describe the general characteristics and functional outcomes of individuals treated in a publicly funded, long-term, acquired brain injury rehabilitation program and investigate variables affecting functional outcomes in this patient population. Design: Retrospective database review of demographic, descriptive, and functional outcome assessment data. Setting: Publicly funded, comprehensive, multidisciplinary, long-term, residential brain injury rehabilitation program in Alberta, Canada (64 beds). Patients: All rehabilitation patients admitted to and discharged from the brain injury program from February 1991 to March 1999 (n = 349). Interventions: Multidisciplinary rehabilitation program. Main Outcome Measures: Demographic and descriptive information included sex, age at admission, type and severity of injury, time from injury to long-term program admission, and length of stay (LOS). Functional outcome information included level of care required at admission and discharge, admission and discharge Rappaport disability rating scale scores, and admission and discharge FIM(TM) instrument and Functional Assessment Measure scores for a subset of patients. Results: Fifty-nine percent of the subjects had severe traumatic brain injuries (TBI) and 41% had severe nontraumatic brain injuries (NTBI) of various causes. Mean age at admission was older and LOS was longer for NTBI compared with TBI; there were no other differences between the groups in demographic or descriptive measures. The TBI group had significantly lower admission motor subscale scores than the NTBI group, but the groups did not differ on cognitive scores. All functional assessment measures showed statistically significant improvement from admission to discharge, and 85.6% of patients were discharged to community living after a mean LOS of 359.5 days. Functional status at admission, age at admission, length of time between injury and admission, and LOS in the rehabilitation program significantly correlated with functional improvement. Conclusions: Patients with severe TBI and NTBI who were not candidates for other more conventional forms of rehabilitation showed significant improvement in functional outcomes after extended program admissions. Consideration was also given to the potential insensitivity of commonly used outcome assessment measures in this population.	Univ Alberta, Div Phys Med & Rehabil, Edmonton, AB, Canada; Alberta Hosp Ponoka, Brain Injury Rehabil Program, Alberta Mental Hlth Board, Edmonton, AB, Canada	Gray, DS (corresponding author), Univ Alberta, Glenrose Rehabil Hosp, Div Phys Med & Rehabil, 10230 111 Ave, Edmonton, AB T5G 0B7, Canada.	gray@telusplanet.net					ANDIEL C, 1995, CAN J REHABIL, V9, P17; BATES D, 1991, J NEUROL NEUROSUR PS, V54, P569, DOI 10.1136/jnnp.54.7.569; BELL KR, 1995, BRAIN INJURY, V9, P315, DOI 10.3109/02699059509008201; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; BURKE DC, 1995, BRAIN INJURY, V9, P735, DOI 10.3109/02699059509008229; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Clinchot DM, 1997, ARCH PHYS MED REHAB, V78, P346, DOI 10.1016/S0003-9993(97)90223-9; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; FINSET A, 1992, SCAND J REHABIL MED, P25; FLEMING JM, 1994, ARCH PHYS MED REHAB, V75, P156; GOLDSTEIN FC, 1995, J HEAD TRAUMA REHAB, V10, P57, DOI 10.1097/00001199-199502000-00007; Good DC, 1998, J NEUROL REHABIL, V12, P153; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; HALL K, 1997, J REHABIL OUTCOMES M, V1, P63; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; HEDRICK WP, 1995, BRAIN INJURY, V9, P563, DOI 10.3109/02699059509008215; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P399, DOI 10.1016/S0003-9993(95)80567-2; KRAUS JF, 1987, HEAD INJURY, P1; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Marks I, 1996, PSYCHIAT SERV, V47, P811; Ogden JA, 1997, NEUROSURGERY, V41, P25, DOI 10.1097/00006123-199707000-00008; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; SILVERSTEIN B, 1992, ARCH PHYS MED REHAB, V73, P507; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; SPIVACK G, 1992, Brain Injury, V6, P419, DOI 10.3109/02699059209008138; Stewart DG, 1998, NEUROREHABILITATION, V10, P13, DOI 10.3233/NRE-1998-10103; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Walker WC, 1996, BRAIN INJURY, V10, P65; Walpoth BH, 1997, NEW ENGL J MED, V337, P1500, DOI 10.1056/NEJM199711203372103; WHITENECK GG, 1994, ARCH PHYS MED REHAB, V75, P1073, DOI 10.1016/0003-9993(94)90080-9; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; Willer B, 1999, ARCH PHYS MED REHAB, V80, P399, DOI 10.1016/S0003-9993(99)90276-9; WILSON BA, 1997, J REHABILITATION OUT, V1, P60	64	56	57	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2000	81	11					1447	1456		10.1053/apmr.2000.16343			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	369YT	WOS:000165095900001	11083347				2021-06-18	
J	Smith, FM; Raghupathi, R; MacKinnon, MA; McIntosh, TK; Saatman, KE; Meaney, DF; Graham, DI				Smith, FM; Raghupathi, R; MacKinnon, MA; McIntosh, TK; Saatman, KE; Meaney, DF; Graham, DI			TUNEL-positive staining of surface contusions after fatal head injury in man	ACTA NEUROPATHOLOGICA			English	Article						human traumatic brain injury; TUNEL staining	TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; GLUTATHIONE-S-TRANSFERASE; SELECTIVE NEURONAL DEATH; PROGRAMMED CELL-DEATH; ALZHEIMERS-DISEASE; DNA FRAGMENTATION; CORTICAL IMPACT; APOPTOSIS; RATS	In frontal lobe contusions obtained post mortem from 18 patients who survived between 6 h and 10 days after head injury, DNA fragmentation associated with either apoptotic and/or necrotic cell death was identified by the terminal deoxynucleotidyl transferase-mediated biotinylated deoxyuridine triphosphate nick end labelling (TUNEL) histochemical technique. Additional histological techniques were also used to identify regional and temporal patterns of tissue damage. TUNEL-positive cells were present in both the grey and white matter of the contusion, where they peaked in number between 25 and 48 h, and were still identifiable at 10 days post injury. Fewer TUNEL-positive cells were observed in grey than in white matter; and most TUNEL-positive neurons in the grey matter demonstrated the morphological features of necrosis. However, the morphology of some TUNEL stained neurons, and of TUNEL-stained oligodendroglia and macrophages in white matter was suggestive of apoptosis. Apoptosis was not seen in age- and sex-matched controls, none of whom had died from intracranial pathology or had pre-existing neurological disease. These findings suggest that multiple cell types in frontal lobe contusions exhibit DNA fragmentation and that both necrosis and apoptosis are likely to contribute to post-traumatic pathology. These findings provide further evidence that the observations made in animal models of traumatic brain injury have fidelity with clinical head injury.	Univ Glasgow, So Gen Hosp NHS Trust, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Bioengn, Philadelphia, PA 19104 USA	Graham, DI (corresponding author), Univ Glasgow, So Gen Hosp NHS Trust, Inst Neurol Sci, Dept Neuropathol, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.			Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0I-NS26818, P50-NS08803] Funding Source: Medline		ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BURKE MJ, 1996, BRAIN PATHOL, V6, P427; CAMMER W, 1992, J COMP NEUROL, V321, P40, DOI 10.1002/cne.903210105; CharriautMarlangue C, 1996, TRENDS NEUROSCI, V19, P109, DOI 10.1016/S0166-2236(96)80039-7; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; FUNG KM, 1995, AM J PATHOL, V146, P1376; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEHRMANN J, 1991, ACTA NEUROPATHOL, V82, P442, DOI 10.1007/BF00293378; GEHRMANN J, 1992, LAB INVEST, V67, P100; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1979, P 23 STAPP CAR CRASH, P561; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Johnson EM, 1996, BRAIN PATHOL, V6, P397, DOI 10.1111/j.1750-3639.1996.tb00872.x; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Lipton SA, 1996, BRAIN PATHOL, V6, P507, DOI 10.1111/j.1750-3639.1996.tb00879.x; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; NAMASHIMA K, 1999, J NEUROTRAUM, V16, P143; PETITO CK, 1995, J NEUROPATH EXP NEUR, V54, P761, DOI 10.1097/00005072-199511000-00002; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Probst-Cousin S, 1998, J NEUROPATH EXP NEUR, V57, P814, DOI 10.1097/00005072-199809000-00002; Raine CS, 1997, J NEUROIMMUNOL, V77, P135, DOI 10.1016/S0165-5728(97)00073-8; RINK A, 1995, AM J PATHOL, V147, P1575; Sheng JG, 1998, J NEUROPATH EXP NEUR, V57, P714, DOI 10.1097/00005072-199807000-00008; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.3.CO;2-#; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH FM, 1997, J NEUROTRAUM, V15, P54; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; TANSEY FA, 1991, J NEUROCHEM, V57, P95, DOI 10.1111/j.1471-4159.1991.tb02104.x; THOMAS LB, 1995, EXP NEUROL, V133, P265, DOI 10.1006/exnr.1995.1029; Troncoso JC, 1996, J NEUROPATH EXP NEUR, V55, P1134, DOI 10.1097/00005072-199611000-00004; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; YOSHIKAWA N, 1994, DERMATOLOGY, V188, P207, DOI 10.1159/000247141	53	56	58	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	NOV	2000	100	5					537	545		10.1007/s004010000222			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	352GK	WOS:000089206800012	11045676				2021-06-18	
J	Weinstock, M; Goren, T; Youdim, MBH				Weinstock, M; Goren, T; Youdim, MBH			Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities	DRUG DEVELOPMENT RESEARCH			English	Article						propargylamine; selective brain MAO inhibition; antidepressant; neuroprotection	CLOSED-HEAD INJURY; B INHIBITOR; LONG-TERM; MEMORY; RATS; RASAGILINE; R(-)-DEPRENYL; RIVASTIGMINE; DEPRESSION; DEMENTIA	TV3326 [(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate] is a novel aminoindan derivative possessing both cholinesterase (ChE) and monoamine oxidase (MAO)-inhibitory activity. In doses of 35-100 mu mol/kg administered orally to rats, it inhibits ChE by 25%-40% and antagonises scopolamine-induced impairments in spatial memory. After daily oral administration of 75 mu mol/kg for 2 weeks, TV3326 inhibits MAO-A and -B in the brain by similar to 80% but has little or no effect on the enzymes in the intestine or liver. This reduces the likelihood of it producing the "cheese effect" if administered with tyramine-containing foods or beverages. TV3326 has activity in the forced-swim test, consistent with that of known antidepressants. Both TV3326 and its S- isomer, TV3279, which inhibits ChE but lacks MAO-inhibitory activity, have neuroprotective effects against a variety of insults in PC12 cells and in vivo. TV3326 significantly reduces hippocampal cell damage caused by global ischaemia in gerbils and the cerebral oedema induced by closed head injury in mice and speeds recovery of their motor and memory deficits. These pharmacological actions of TV3326 could clearly be of clinical importance for the treatment of Alzheimer's disease, and the drug is currently in development for this purpose. Drug Dev. Res. 50:216-222, 2000. (C) 2000 Wiley-Liss, Inc.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91120 Jerusalem, Israel; Teva Pharmaceut Ind Ltd, Netanya, Israel; Technion Israel Inst Technol, Fac Med, Eve Topf Neurodegenerat Dis Ctr Res & Teaching, Haifa, Israel	Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91120 Jerusalem, Israel.	martar@cc.huji.ac.il					Abu-Raya S, 1999, J NEUROSCI RES, V58, P456, DOI 10.1002/(SICI)1097-4547(19991101)58:3<456::AID-JNR12>3.0.CO;2-S; ANISMAN H, 1982, BEHAV BRAIN SCI, V5, P89, DOI 10.1017/S0140525X00010633; ANSARI KS, 1993, J NEUROSCI, V13, P4042; BEATTY WW, 1986, BEHAV NEURAL BIOL, V45, P196, DOI 10.1016/S0163-1047(86)90772-7; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Braida D, 1996, EUR J PHARMACOL, V302, P13, DOI 10.1016/0014-2999(96)00072-6; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; DAWSON GR, 1991, PHARMACOL BIOCHEM BE, V39, P865, DOI 10.1016/0091-3057(91)90045-4; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; EDWARDS JG, 1995, CNS DRUGS, V4, P141, DOI 10.2165/00023210-199504020-00006; Filip V, 1999, J PSYCHIATR NEUROSCI, V24, P234; Finberg JPM, 1996, J NEURAL TRANSM-SUPP, P95; Finberg JPM, 1998, NEUROREPORT, V9, P703; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Giacobini E, 1997, JPN J PHARMACOL, V74, P225, DOI 10.1254/jjp.74.225; Good PF, 1996, AM J PATHOL, V149, P21; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; KOPELMAN MD, 1988, BRAIN, V111, P1079, DOI 10.1093/brain/111.5.1079; Kragten E, 1998, J BIOL CHEM, V273, P5821, DOI 10.1074/jbc.273.10.5821; Lahtinen H, 1997, BRAIN RES, V757, P260, DOI 10.1016/S0006-8993(97)00227-8; Magyar K, 1998, J NEURAL TRANSM-SUPP, P109; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MCGEER PL, 1994, ALZ DIS ASSOC DIS, V8, P149, DOI 10.1097/00002093-199408030-00001; PALMER AM, 1988, ANN NEUROL, V23, P616, DOI 10.1002/ana.410230616; PORSOLT RD, 1978, EUR J PHARMACOL, V47, P379, DOI 10.1016/0014-2999(78)90118-8; SANO M, 1909, NEW ENGL J MED, V336, P1216; SAURA J, 1994, NEUROSCIENCE, V62, P15, DOI 10.1016/0306-4522(94)90311-5; SPEIZER Z, 1998, PHARM BIOCH BEHAV, V60, P1; STROLINBENEDETT.M, 1983, BIOCHEM PHARMACOL, V32, P47; Tatton WG, 1996, NEUROLOGY, V47, pS171, DOI 10.1212/WNL.47.6_Suppl_3.171S; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; WEINSTOCK M, 1999, NEUROSCI LETT S, V54, pS44; YOUDIM MBH, 1999, NEUROSCI LETT, V54, pS45; Zhang X, 1996, J NEUROSCI RES, V43, P482, DOI 10.1002/(SICI)1097-4547(19960215)43:4<482::AID-JNR9>3.0.CO;2-B	37	56	58	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0272-4391	1098-2299		DRUG DEVELOP RES	Drug Dev. Res.	JUL-AUG	2000	50	3-4					216	222		10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.0.CO;2-Z			7	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	359TK	WOS:000089628000004					2021-06-18	
J	Morris, MW; Smith, S; Cressman, J; Ancheta, J				Morris, MW; Smith, S; Cressman, J; Ancheta, J			Evaluation of infants with subdural hematoma who lack external evidence of abuse	PEDIATRICS			English	Article						subdural hematoma; intracranial hemorrhage; traumatic brain injury; child abuse; child protection	PERMANENT BRAIN-DAMAGE; SHAKEN BABY SYNDROME; MENTAL-RETARDATION; YOUNG-CHILDREN; HEAD-INJURY; SHAKING; TRAUMA	Objective. Advances in radiologic technique have increased the recognition of subdural hematoma. No study to date has addressed the role of child protective investigation into the cause and management of subdural hematoma in children who lack other indicators of abuse. Methods. Medical records, radiology studies, and social service notes for all infants and children referred for child abuse investigation who had any form of intracranial hemorrhage were reviewed. The study covered the 12 months of 1997. All referrals were to the Suncoast Child Protection Team (St Petersburg, FL). Results. There were 19 investigations because of subdural hematoma. Eight children had retinal hemorrhage as well as other major findings of trauma, such as bruises and/or fractures; all 8 were victims of child abuse. Two infants had tiny subdurals adjacent to accidental linear skull fractures. Nine infants were investigated for the possibility of abuse that had no findings of trauma apart from the subdural hematoma. These 9 cases form the basis for this study. The age range was 11 days to 15 months. Inflicted cerebral trauma was the medical diagnosis in 8 of the 9 cases; 1 case had a final diagnosis of possible inflicted injury in a high-risk setting. Conclusions. Infants with subdural hematoma but no other findings of abuse present a difficult challenge to child protection workers. Investigation by a medically oriented team can uncover the circumstances of the trauma in most instances and can usefully direct protective efforts. The high incidence of severe sequelae in infants with inflicted cerebral trauma warrants a vigorous approach.	Suncoast Child Protect Team Inc, Pinellas Pk, FL 33782 USA; Univ S Florida, All Childrens Hosp, Dept Pediat Med, St Petersburg, FL 33701 USA; Univ S Florida, All Childrens Hosp, Dept Pediat Radiol, St Petersburg, FL 33701 USA; Univ S Florida, Sch Med, Dept Pediat, Tampa, FL 33620 USA	Morris, MW (corresponding author), Suncoast Child Protect Team Inc, 8800 49th St N,Suite 410, Pinellas Pk, FL 33782 USA.	markmorris@prodigy.net					ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; AOKI N, 1990, J NEUROSURG, V73, P201, DOI 10.3171/jns.1990.73.2.0201; BARKOVICH AJ, 1992, PEDIATR NEUROSURG, V18, P65; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; EWINGCOBBS L, 1995, J HEAD TRAUMA REHAB, V10, P13, DOI 10.1097/00001199-199510000-00004; FELDMAN KW, 1977, BATTERED CHILD, P194; HANIGAN WC, 1987, PEDIATRICS, V80, P618; HANSEN KK, 1994, ARCH PEDIAT ADOL MED, V148, P1345, DOI 10.1001/archpedi.1994.02170120107021; HARWOODNASH DC, 1992, AM J NEURORADIOL, V13, P569; HELFER RE, 1977, PEDIATRICS, V60, P533; HOBBS CJ, 1984, ARCH DIS CHILD, V59, P246, DOI 10.1136/adc.59.3.246; KLEIN M, 1971, AM J DIS CHILD, V122, P15, DOI 10.1001/archpedi.1971.02110010051005; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P312; KRUGMAN RD, 1993, PEDIATRICS, V92, P872; PARENT AD, 1992, PEDIATR NEUROSURG, V18, P266, DOI 10.1159/000120674; REECE RM, 1994, CHILD ABUSE MED DIAG, P8	22	56	58	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2000	105	3					549	553		10.1542/peds.105.3.549			5	Pediatrics	Pediatrics	290MZ	WOS:000085681100027	10699108				2021-06-18	
J	Achiron, A; Miron, S; Lavie, V; Margalit, R; Biegon, A				Achiron, A; Miron, S; Lavie, V; Margalit, R; Biegon, A			Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis	JOURNAL OF NEUROIMMUNOLOGY			English	Article						EAE; multiple sclerosis; TNF-alpha inhibition; relapse; animal model	CLOSED-HEAD INJURY; NONCOMPETITIVE NMDA ANTAGONIST; NECROSIS-FACTOR-ALPHA; RAT; METHYLPREDNISOLONE; NEUROPROTECTANT; CANNABINOIDS; SUPPRESSION; ISCHEMIA; TERM	Dexanabinol (HU-211) is a synthetic non-psychotropic cannabinoid which suppresses TNF-a production in the brain and peripheral blood. The effects of dexanabinol in rat experimental autoimmune encephalomyelitis (EAE) were studied using different doses, modes of administration and time regimes. Dexanabinol, 5 mg/kg i.v. given once after disease onset (day 10), significantly reduced maximal EAE score. Increasing the dose or treatment duration resulted in further suppression of EAE. Drug administration at earlier phases during disease induction was not effective. Histological studies supported the clinical findings demonstrating reduction in the inflammatory response in the brain and spinal cord in animals treated with dexanabinol. The results suggest that dexanabinol may provide an alternative mode of treatment for acute exacerbations of multiple sclerosis (MS). (C) 2000 Elsevier Science B.V. All rights reserved.	Chaim Sheba Med Ctr, Multiple Sclerosis Ctr, IL-52621 Tel Hashomer, Ramat Gan, Israel; Kiryat Weizmann, Pharmos, Rehovot, Israel; Weizmann Inst Sci, Dept Cell Biol, IL-76100 Rehovot, Israel	Achiron, A (corresponding author), Chaim Sheba Med Ctr, Multiple Sclerosis Ctr, IL-52621 Tel Hashomer, Ramat Gan, Israel.						BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; Bass R, 1996, J INFECT DIS, V173, P735, DOI 10.1093/infdis/173.3.735; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BIEGON A, 1993, AM SOC NEUR ABSTR, V19, P1485; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; BURNETTECURLEY D, 1995, P SOC EXP BIOL MED, V210, P64, DOI 10.3181/00379727-210-43926; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; FREQUIN STFM, 1994, ACTA NEUROL SCAND, V90, P105; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; Hautecoeur P, 1997, ACTA NEUROL BELG, V97, P240; LYMAN WD, 1989, J NEUROIMMUNOL, V23, P73, DOI 10.1016/0165-5728(89)90075-1; MARTIN R, 1995, CRIT REV CLIN LAB SC, V32, P82; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; NADLER V, 1993, NEUROSCI LETT, V159, P1; OLSSON T, 1995, NEUROLOGY, V45, pS11, DOI 10.1212/WNL.45.6_Suppl_6.S11; Philippe J, 1996, CLIN NEUROL NEUROSUR, V98, P286, DOI 10.1016/0303-8467(96)00041-8; RAINE CS, 1994, ANN NEUROL S, V36, P61; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; van Oosten BW, 1998, ARCH NEUROL-CHICAGO, V55, P793, DOI 10.1001/archneur.55.6.793; WIRGUIN I, 1994, IMMUNOPHARMACOLOGY, V28, P209, DOI 10.1016/0162-3109(94)90056-6; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49	27	56	56	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	JAN 3	2000	102	1					26	31		10.1016/S0165-5728(99)00149-6			6	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	270PV	WOS:000084545400004	10626663				2021-06-18	
J	Barone, FC; Ohlstein, EH; Hunter, AJ; Campbell, CA; Hadingham, SH; Parsons, AA; Yang, Y; Shohami, E				Barone, FC; Ohlstein, EH; Hunter, AJ; Campbell, CA; Hadingham, SH; Parsons, AA; Yang, Y; Shohami, E			Selective antagonism of endothelin-A-receptors improves outcome in both head trauma and focal stroke in rat	JOURNAL OF CARDIOVASCULAR PHARMACOLOGY			English	Article; Proceedings Paper	6th International Symposium on Endothelin	OCT 10-14, 1999	MONTREAL, CANADA			closed head injury (CHI); focal stroke; neuroprotection; neurological deficits; brain edema; brain injury; endothelin antagonists; SE 234551; SE 209670	CEREBRAL-ARTERY OCCLUSION; BRAIN-BARRIER PERMEABILITY; PHARMACOLOGICAL CHARACTERIZATION; ISCHEMIA; INJURY; MODEL; IMMUNOREACTIVITY; SB-209670; DAMAGE; MOTOR	Increased levels of endothelin (ET) have been demonstrated in the ischemic brain, and ET receptor antagonism has been shown to improve outcome in cerebral ischemia. However, no previous work has been carried out evaluating the role of ET and its antagonism in brain trauma as compared to experimental stroke. In this study, we evaluated changes in brain ET levels following closed head injury (CHI) and the effects of SB 234551, an endothelin-A- (ETA) selective antagonist, and SE 209670, a mixed endothelin-A and -B- (ETA/ETB) antagonist, on outcome in CHI and focal stroke. Male Sabra rats were subjected to CHI (weight drop model). Male Sprague Dawley rats were subjected to focal stroke (intraluminal suture model). Motor function(s) were assessed and immunoreactive ET (irET) and the degree of cerebral edema were measured for 24 h after CHI. Brain swelling (edema), neurological deficits and forebrain infarct volumes were measured 24 h after focal stroke. Antagonists (total doses of 7.5, 15, 30 or 60 mg/kg) were administered intravenously fur 6-24 h (beginning 15 min after injury). Control rats were infused with vehicle. CHI resulted in increased ET levels in the directly contused hemisphere at 12 and 24 h. In addition, SB 234551 significantly reduced neurological deficits (decreased 30%) and brain edema (decreased 40%) following CHI (p < 0.05 at 60 mg/kg dose). SE 209670 had no effects on CHI outcome. Focal stroke studies yielded similar results. SE 234551 reduced focal stroke-induced neurological deficits by 50%, brain swelling by 54% and the degree of infarction by 36% (p < 0.05 at 30 mg/kg). SE 209670 did not provide any neuroprotection in focal stroke. These data indicate that ET plays a significant role in the pathophysiology of CHI, and that selectively targeting ETA-receptors similarly in both CHI and stroke might be a therapeutic opportunity.	SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Neurosci Res, Harlow CM19 5AD, Essex, England; Hebrew Univ Jerusalem, Sch Pharm, IL-91120 Jerusalem, Israel	Barone, FC (corresponding author), SmithKline Beecham Pharmaceut, Dept Cardiovasc Pharmacol, 709 Swedeland Rd,POB 1539, King Of Prussia, PA 19406 USA.						BALAYEV L, 1995, STROKE, V26, P2313; BARONE FC, 1995, J CARDIOVASC PHARM, V26, pS404; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; BARONE FC, 1992, NEUROSCI BIOBEHAV R, V16, P219, DOI 10.1016/S0149-7634(05)80182-4; BARONE FC, 1995, NEUROL RES, V17, P259, DOI 10.1080/01616412.1995.11740323; BIAN LG, 1994, NEUROSCI LETT, V174, P47, DOI 10.1016/0304-3940(94)90115-5; CINTRA A, 1989, ACTA PHYSIOL SCAND, V137, P557, DOI 10.1111/j.1748-1716.1989.tb08799.x; Gartshore G, 1997, EXP NEUROL, V147, P353, DOI 10.1006/exnr.1997.6635; Hama H, 1997, J NEUROSCI RES, V47, P590, DOI 10.1002/(SICI)1097-4547(19970315)47:6<590::AID-JNR4>3.0.CO;2-8; JIANG MH, 1993, NEUROREPORT, V4, P935, DOI 10.1097/00001756-199307000-00024; LONGA ZZ, 1980, STROKE, V20, P84; Mackay KB, 1996, NEURODEGENERATION, V5, P319, DOI 10.1006/neur.1996.0043; McAuley MA, 1996, EUR J PHARMACOL, V307, P171, DOI 10.1016/0014-2999(96)00251-8; OHLSTEIN EH, 1994, J PHARMACOL EXP THER, V271, P762; Ohlstein EH, 1998, J PHARMACOL EXP THER, V286, P650; OHLSTEIN EH, 1994, P NATL ACAD SCI USA, V91, P8052, DOI 10.1073/pnas.91.17.8052; OSBORNE KA, 1987, J NEUROL NEUROSUR PS, V50, P402, DOI 10.1136/jnnp.50.4.402; PATEL TR, 1995, J CARDIOVASC PHARM, V26, pS412; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; SALOM JB, 1995, CEREBROVAS BRAIN MET, V7, P131; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; VIOSSAT I, 1993, J CARDIOVASC PHARM, V22, pS306, DOI 10.1097/00005344-199322008-00080; Willette RN, 1998, J CARDIOVASC PHARM, V31, pS149, DOI 10.1097/00005344-199800001-00044; Wu W, 1996, Chin Med Sci J, V11, P228; YAMASHITA K, 1994, J NEUROCHEM, V63, P1042; YAMASHITA K, 1995, CLIN EXP PHARM PHYSL, V1, pS277	29	56	58	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0160-2446			J CARDIOVASC PHARM	J. Cardiovasc. Pharmacol.		2000	36			1			S357	S361		10.1097/00005344-200036001-00104			5	Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy	Cardiovascular System & Cardiology; Pharmacology & Pharmacy	368RF	WOS:000090130800103	11078420				2021-06-18	
J	Marion, DW; Spiegel, TP				Marion, DW; Spiegel, TP			Changes in the management of severe traumatic brain injury: 1991-1997	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; acute care; intracranial hypertension; guidelines; survey	SEVERE HEAD-INJURY	Objective: To survey the management of head-injured patients in 1997 and to identify differences compared with a survey conducted in 1991, Design: A two-page questionnaire was mailed to all neurosurgeons in North America certified by the American Board of Neurologic Surgeons, asking their views regarding the most appropriate acute care of patients with severe traumatic brain injury (TBI), Setting: North American neurosurgical practices. Patients: Not applicable, Interventions: None. Measurements and Main Results: Compared with a 1991 survey, there was a significant increase in the proportion of neuro-surgeons who felt these patients should have intracranial pressure monitoring (28% vs, 83%) and a decrease in the proportion who used prophylactic hyperventilation therapy (83% vs, 36%) and steroids (64% vs, 19%). Ninety-seven percent of respondents felt that the cerebral perfusion pressure should be maintained at >70 mm Hg, and 44% indicated that patients with severe TBI should be treated at Level I trauma centers, Conclusions: There have been significant changes in the acute management of patients with severe TBI since 1991, Current practices more closely reflect the recommendations of evidence based guidelines.	Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA	Marion, DW (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Brain Trauma Res Ctr, 200 Lothrop St,Suite B400, Pittsburgh, PA 15213 USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-30318-5] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER		BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; KRAUS JF, 1987, HEAD INJURY, P1; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020	8	56	63	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2000	28	1					16	18		10.1097/00003246-200001000-00003			3	Critical Care Medicine	General & Internal Medicine	279QV	WOS:000085057400003	10667493				2021-06-18	
J	Graber, KD; Prince, DA				Graber, KD; Prince, DA			Tetrodotoxin prevents posttraumatic epileptogenesis in rats	ANNALS OF NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC SEIZURES; DENTATE GRANULE; KINDLING MODEL; GROWTH-FACTOR; BRAIN INJURY; IN-VITRO; SYNAPTIC TRANSMISSION; NEUROTROPHIC FACTOR	Severe cortical trauma frequently causes epilepsy that develops after a long latency. We hypothesized that plastic changes in excitability during this latent period might be initiated or sustained by the level of neuronal activity in the injured cortex. We therefore studied effects of action potential blockade by application of tetrodotoxin (TTX) to areas of cortical injury in a model of chronic epileptogenesis. Partially isolated islands of sensorimotor cortex were made in 28- to 30-day-old male Sprague-Dawley rats and thin sheets of Elvax polymer containing TTX or control vehicle were implanted over lesions. Ten to 15 days later neocortical slices were obtained through isolates for electrophysiological studies. Slices from all animals (n = 12) with lesions contacted by control-Elvax (58% of 36 slices) exhibited evoked epileptiform field potentials, and those hom 4 rats had spontaneous epileptiform events. Only 2 of 11 lesioned animals and 6% of slices from cortex exposed to TTX in vivo exhibited evoked epileptiform potentials, and no spontaneous epileptiform events were observed. There was no evidence of residual TTX during recordings. TTX-Elvax was ineffective in reversing epileptogenesis when implanted 11 days after cortical injury. These data suggest that development of anti-epileptogenic drugs for humans may be possible.	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Prince, DA (corresponding author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Room M016, Stanford, CA 94305 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12151, NS 06477] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012151, P01NS012151] Funding Source: NIH RePORTER		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ASPRODINI EK, 1992, J PHARMACOL EXP THER, V262, P1011; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; Burack MA, 1995, EPILEPSY RES, V22, P115, DOI 10.1016/0920-1211(95)00030-5; BUSH PC, 1999, IN PRESS J NEUROPHYS; Carmignoto G, 1997, J PHYSIOL-LONDON, V498, P153, DOI 10.1113/jphysiol.1997.sp021848; CHIAIA NL, 1994, DEV BRAIN RES, V79, P301, DOI 10.1016/0165-3806(94)90136-8; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; DRAGUNOW M, 1992, MOL BRAIN RES, V13, P119, DOI 10.1016/0169-328X(92)90051-C; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARIELLO RG, 1989, EPILEPSY RES, V3, P206, DOI 10.1016/0920-1211(89)90025-9; GALL CM, 1993, EXP NEUROL, V124, P150, DOI 10.1006/exnr.1993.1186; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GODDARD GV, 1983, TRENDS NEUROSCI, V6, P275, DOI 10.1016/0166-2236(83)90118-2; Gold SJ, 1996, J COMP NEUROL, V365, P541; GOLDENSOHN ES, 1984, EPILEPSIA, V25, pS156, DOI 10.1111/j.1528-1157.1984.tb05648.x; GRIGONIS AM, 1994, DEV BRAIN RES, V77, P251, DOI 10.1016/0165-3806(94)90200-3; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P197; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; HOFFMAN WH, 1989, J NEUROSCI, V9, P206; HOLTZMAN DM, 1995, J NEUROSCI, V15, P7062; INNOCENTI G M, 1991, Journal of Neural Transplantation and Plasticity, V2, P29; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; Jacobs KM, 1999, J NEUROPHYSIOL, V81, P159; KRNJEVIC K, 1970, ELECTROEN CLIN NEURO, V29, P269, DOI 10.1016/0013-4694(70)90139-2; Liang FY, 1997, J NEUROSCI, V17, P2168; Lowenstein DH, 1996, NEUROSCIENCE, V74, P1197, DOI 10.1016/S0306-4522(96)00226-6; LYNCH JJ, 1995, J PHARMACOL EXP THER, V273, P554; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; McNamara J O, 1992, Adv Neurol, V57, P555; MCNAMARA JO, 1980, PROG NEUROBIOL, V15, P139, DOI 10.1016/0301-0082(80)90006-4; MCNAMARA RK, 1995, MOL BRAIN RES, V33, P22, DOI 10.1016/0169-328X(95)00083-5; MIKATI MA, 1994, ANN NEUROL, V36, P425, DOI 10.1002/ana.410360314; MODY I, 1987, NATURE, V326, P701, DOI 10.1038/326701a0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; Niessen C. E., 1997, Society for Neuroscience Abstracts, V23, P1687; PATEL MN, 1995, NEUROSCIENCE, V69, P763, DOI 10.1016/0306-4522(95)00281-M; POLLARD H, 1994, NEUROSCIENCE, V61, P773, DOI 10.1016/0306-4522(94)90401-4; Prince D A, 1965, Epilepsia, V6, P226, DOI 10.1111/j.1528-1157.1965.tb03791.x; Prince D A, 1986, Adv Neurol, V44, P275; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; PRINCE DA, IN PRESS BASIC MECHA; Prince David A., 1995, P3; Purpura DP, 1972, EXPT MODELS EPILEPSY; Rice A, 1996, P NATL ACAD SCI USA, V93, P9665, DOI 10.1073/pnas.93.18.9665; Rice AC, 1998, BRAIN RES, V782, P240, DOI 10.1016/S0006-8993(97)01285-7; RUTLEDGE LT, 1967, ELECTROEN CLIN NEURO, V23, P256, DOI 10.1016/0013-4694(67)90122-8; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; SATO M, 1990, ELECTROEN CLIN NEURO, V76, P459, DOI 10.1016/0013-4694(90)90099-6; Schwartzkroin Philip A., 1995, P276; Sharpless SK, 1969, BASIC MECH EPILEPSIE, P329; Shatz CJ, 1996, P NATL ACAD SCI USA, V93, P602, DOI 10.1073/pnas.93.2.602; SILBERSTEIN GB, 1982, DEV BIOL, V93, P272, DOI 10.1016/0012-1606(82)90259-7; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; STASHEFF SF, 1989, SCIENCE, V245, P648, DOI 10.1126/science.2569762; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Sutula T, 1996, J NEUROSCI, V16, P7398; SUZUKI H, 1964, ELECTROEN CLIN NEURO, V17, P405, DOI 10.1016/0013-4694(64)90164-6; Temkin N R, 1998, Adv Neurol, V76, P179; Temkin Nancy R., 1997, Epilepsia, V38, P102; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; VANDERZEE CEE, 1995, J NEUROSCI, V15, P5316; WADA JA, 1976, ARCH NEUROL-CHICAGO, V33, P426, DOI 10.1001/archneur.1976.00500060032008; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, CHILD BRAIN, V10, P185	70	56	56	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0364-5134			ANN NEUROL	Ann. Neurol.	AUG	1999	46	2					234	242		10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	224BU	WOS:000081876900013	10443889				2021-06-18	
J	Marketos, SG; Skiadas, P				Marketos, SG; Skiadas, P			Hippocrates - The father of spine surgery	SPINE			English	Article						history of ancient medicine; Hippocrates; spine; spinal curvatures		Hippocrates (5th-4th century B.C.), the founder of scientific medicine, left a valuable heritage of knowledge and methodology, which extends to almost all branches of modern medicine. Among the many fields of medicine he explored, he devoted much of his scientific interest to the study of orthopedics In fact, some of the principles found in the Hippocratic treatises On Fractures and On Joints are still valid today. This great physician also was the first to deal with the anatomy and the pathology of human spine. In his books, he provides a precise description of the segments and the normal curves of the spine, the structure of the vertebrae, the tendons attached to them, the blood supply to the spine, and even its anatomic relations to adjacent vessels. The Hippocratic list of spinal diseases includes tuberculous spondylitis, post-traumatic kyphosis, scoliosis, concussion, dislocations of the vertebrae, and fractures of the spinous processes. Hippocrates devised two apparatuses, known as the Hippocratic ladder and the Hippocratic board, to reduce displaced vertebrae. Those pioneer methods are deemed to be the precursors to the sophisticated techniques used in spine surgery today. Because of his thorough study of spinal diseases and their management, which was the first such study in orthopedics in the history of medicine, Hippocrates should be regarded as the father of spine surgery.	Univ Athens, Sch Med, Dept Hist Med, GR-11527 Athens, Greece	Marketos, SG (corresponding author), 20 Patriarchou Ioakim St, Athens 10675, Greece.						Adams F, 1849, GENUINE WORKS HIPPOC; BURY RG, 1929, PLATO LONDON CLASSIC, P1; CAPPS E, 1927, HIPPOCRATES LOEB CLA, V3, P200; CAPPS E, 1923, HIPPOCRATES LOEB CLA, V2, P127; CAPPS E, 1927, HIPPOCRATES LOEB CLA, V3, P398; CAPPS E, 1923, HIPPOCRATES LOEB CLA, V2, P185; EDELSTEIN L, 1967, ANCIENT MED SELECTED, P247; GOOLD GP, 1994, HIPPOCRATES LOEB CLA, V7, P18; GOOLD GP, 1995, HIPPOCRATES LOEB CLA, V8, P13; HANEVELD GT, 1980, NETH J SURG, V32, P2; HARTOFIL.G, 1972, CLIN ORTHOP RELAT R, P308; KOLLESCH J, 1965, CORPUS MEDICORUM GRA, V11, P1; KUHN CG, 1965, C GALENI OPERA OMN 1, V18, P300; Kumar K, 1996, SPINE, V21, P653, DOI 10.1097/00007632-199603010-00024; LITTRE PE, 1982, OEUVRES COMPLETES HI, V9, P162; MARKETOS SG, 1996, P 1 INT MED OL KOS I, P59; MARKETOS SG, 1993, ILLUSTRATED HIST MED, P53; Michler M, 1968, Bull Hist Med, V42, P297; PAGE TE, 1937, ARISTOTLE LOEB CLASS, P1; PETREQUIN JE, 1877, CHIRURGIE HIPPOCRATE; Sigerist HE, 1961, HIST MED, VII, P260	21	56	59	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	JUL 1	1999	24	13					1381	1387		10.1097/00007632-199907010-00018			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	211QH	WOS:000081171300021	10404583				2021-06-18	
J	Knerlich, F; Schilling, L; Gorlach, C; Wahl, M; Ehrenreich, H; Siren, AL				Knerlich, F; Schilling, L; Gorlach, C; Wahl, M; Ehrenreich, H; Siren, AL			Temporal profile of expression and cellular localization of inducible nitric oxide synthase, interleukin-1 beta and interleukin converting enzyme after cryogenic lesion of the rat parietal cortex	MOLECULAR BRAIN RESEARCH			English	Article						neurotrauma; iNOS; ICE; IL-1 beta; mRNA expression; immunoreactivity	ISCHEMIC BRAIN INJURY; NECROSIS-FACTOR-ALPHA; CEREBRAL-ARTERY OCCLUSION; GENE-EXPRESSION; MESSENGER-RNA; RECEPTOR ANTAGONIST; NEURONAL DAMAGE; HEAD-INJURY; EDEMA; ACTIVATION	We used in situ hybridization, RT PCR and immunohistochemistry to study the time course of expression and the cellular localization of inducible nitric oxide synthase (iNOS) and interleukin-1 beta (IL-1 beta) during the first 7 days after induction of a standardized cryogenic lesion on the right parietal cortex in male rats. Cryogenic lesion induced iNOS mRNA in the lesioned hemisphere after 6 to 72 h with a maximum (15 +/- 2 cells/mm(2), n = 4, p < 0.01 vs. sham) at 24 h. Microglia, invading monocytes and granulocytes in and around the lesion expressed iNOS immunoreactivity starting at 12 h and peaking (29 +/- 10 cells/mm(2), n = 4, p < 0.05 vs. sham) at 24 h after lesion. Induction of IL-1 beta mRNA expression was immediate with a peak (29 +/- 1 cells/mm2, It = 4, p < 0.01 vs. sham) at 24 h after cryogenic lesion. The number of round cells with IL-1 beta immunoreactivity around the lesion was maximal (8 +/- 2 cells/0.1 mm(2), n = 3, p < 0.01 vs, sham) at 24 h. A weak astrocytic expression of IL-lp-immunoreactivity was seen in sham animal brains. Astrocytic IL-lp-expression was significantly increased in the lesion hemisphere and both hippocampi. Interleukin converting enzyme (ICE) was expressed in astrocytes and microglia around the lesion 6 h after injury. The number of ICE immunoreactive cells (8 +/- 2 cells/0.1 mm2, n = 3, p < 0.05 vs, sham) peaked at 72 h after lesion. Neuronal expression of ICE and IL-1 beta was seen in the lesion periphery 72 h and 7 days after injury. At this time, morphological features of apoptosis were evident in cells in the lesion periphery. The data indicate an early activation of microglia and monocyte invasion into the lesion hemisphere leading to multicellular expression of iNOS, ICE, and IL-1 beta. These events may contribute to the expansion of neuronal damage after brain injury. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Gottingen, Dept Psychiat, D-3400 Gottingen, Germany; Univ Gottingen, Dept Neurol, D-3400 Gottingen, Germany; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Hosp Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; Univ Munich, Dept Physiol, D-80366 Munich, Germany	Siren, AL (corresponding author), Univ Gottingen, Dept Psychiat, D-3400 Gottingen, Germany.	siren@exmax1.mpiem.gwdg.de	Siren, Anna-Leena/AAE-1374-2019; Knerlich-Lukoschus, Friederike/A-3233-2011; Knerlich-Lukoschus, Friederike F/J-2895-2016	Siren, Anna-Leena/0000-0002-2217-0081; Knerlich-Lukoschus, Friederike F/0000-0002-6284-0449; Ehrenreich, Hannelore/0000-0001-8371-5711			BERGER SL, 1989, METHOD ENZYMOL, V180, P3; Berker E, 1996, INT J NEUROSCI, V85, P195, DOI 10.3109/00207459608986683; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cook JL, 1998, BRAIN RES PROTOC, V3, P1, DOI 10.1016/S1385-299X(98)00012-9; EHRENREICH H, 1993, BRAIN RES, V600, P201, DOI 10.1016/0006-8993(93)91374-2; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; ERISKAT J, 1994, ACTA NEUROCHIR, P425; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Gorlach C, 1998, J CEREBR BLOOD F MET, V18, P1357; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Hallenbeck JM, 1997, NEUROLOGY, V49, pS5, DOI 10.1212/WNL.49.5_Suppl_4.S5; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hayashi T, 1998, STROKE, V29, P1007, DOI 10.1161/01.STR.29.5.1007; Hermann DM, 1998, NEUROREPORT, V9, P1249, DOI 10.1097/00001756-199804200-00053; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Kitagawa H, 1998, STROKE, V29, P1417, DOI 10.1161/01.STR.29.7.1417; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Loddick SA, 1997, BIOCHEM BIOPH RES CO, V234, P211, DOI 10.1006/bbrc.1997.6436; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; Murakami K, 1998, J NEUROTRAUM, V15, P825, DOI 10.1089/neu.1998.15.825; Murakami K, 1997, NEUROSCIENCE, V81, P231, DOI 10.1016/S0306-4522(97)00197-8; Murakami K, 1997, ACT NEUR S, V70, P234; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; Sairanen TR, 1997, J CEREBR BLOOD F MET, V17, P1107, DOI 10.1097/00004647-199710000-00013; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; SCHILLING L, 1994, ACTA NEUROCHIR, P79; Stoffel M, 1997, J NEUROTRAUM, V14, P339, DOI 10.1089/neu.1997.14.339; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317	47	56	56	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	MAY 7	1999	68	1-2					73	87		10.1016/S0169-328X(99)00064-9			15	Neurosciences	Neurosciences & Neurology	197JB	WOS:000080360700008	10320785				2021-06-18	
J	Levine, JM; Enquist, LW; Card, JP				Levine, JM; Enquist, LW; Card, JP			Reactions of oligodendrocyte precursor cells to alpha herpesvirus infection of the central nervous system	GLIA			English	Article						O-2A progenitor cell; reactive glia; neuropathology; pseudorabies virus; vagus nerve	CHONDROITIN-SULFATE PROTEOGLYCAN; O-2A PROGENITOR CELLS; RAT OPTIC-NERVE; PSEUDORABIES VIRUS; NG2 PROTEOGLYCAN; BRAIN INJURY; ASTROCYTES; EXPRESSION; DIFFERENTIATION; PROLIFERATION	Adult animals harbor an abundant population of oligodendrocyte precursor cells (OPCs) whose functions, other than providing a pool of precursors for oligodendrocytes, are unknown. Previous studies have demonstrated that these unusual glial cells, which can be identified by virtue of their expression of the NG2 chondroitin sulfate proteoglycan, react to traumatic brain injury. To determine the generality of the ability of OPCs to react to neuropathological insults, we have examined the reactions of OPCs to infection of the brainstem with virulent and attenuated strains pseudorabies virus (PRV). When motor neurons within the dorsal vagal complex are infected with PRV, OPCs immediately adjacent to the infected neurons display dramatic reactive changes. These changes are characterized by (1) cell bodies that stain more heavily with antibodies against NG2 than do non-reactive OPCs, (2) an increased density of processes, and (3) the appearance of fine filopodia on the cell body and processes. The onset of these morphological changes was rapid, and they occurred simultaneously with the appearance of viral antigens in motor neurons. At late stages of infection, the soma of OPCs elaborated fewer processes. A small number of the reactive OPCs contain viral antigens. These findings extend the range of neuropathological situations to which OPCs react indicating that this cell population is extremely dynamic. They also suggest that the reaction of OPCs and the consequences of these reactions to brain function must be considered in any procedure, either experimental or clinical, in which viruses are introduced into the central nervous system. (C) 1998 Wiley-Liss, Inc.	SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15260 USA	Levine, JM (corresponding author), SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA.	jlevine@neurobio.sunysb.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Card, John/0000-0002-6148-7364	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021198] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH53574] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21198] Funding Source: Medline; DS NIH HHS [NINDS33506] Funding Source: Medline		Bartha A., 1961, Magyar Allatorvosok Lapja, V16, P42; BECKER CH, 1967, EXPERIENTIA, V23, P209, DOI 10.1007/BF02136291; BIRDSALL HH, 1992, J IMMUNOL, V148, P2717; CALDER VL, 1988, EUR J IMMUNOL, V18, P1195, DOI 10.1002/eji.1830180808; Card J. Patrick, 1995, P319, DOI 10.1016/B978-012397570-6/50020-4; CARD JP, 1995, CRIT REV NEUROBIOL, V9, P137; CARD JP, 1990, J NEUROSCI, V10, P1974; CARD JP, 1993, J NEUROSCI, V13, P2515; CARD JP, 1994, METH MOL G, V4, P363; CAVANAGH JB, 1970, J ANAT, V106, P471; DOU CL, 1994, J NEUROSCI, V14, P7616; Enquist L.W., 1996, PROTOCOLS GENE TRANS, P333; FULTON BP, 1992, J NEUROSCI, V12, P4816; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRAKO KA, 1995, EXP CELL RES, V221, P231, DOI 10.1006/excr.1995.1371; Ho Dora Y., 1995, P133, DOI 10.1016/B978-012397570-6/50011-3; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEVINE JM, 1987, J NEUROSCI, V7, P2711; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 1996, PERSPECT DEV NEUROBI, V3, P245; LEVINE JM, 1993, GLIA, V7, P307, DOI 10.1002/glia.440070406; LEVINE JM, 1987, J NEUROSCI, V7, P2721; Loewy Arthur D., 1995, P349, DOI 10.1016/B978-012397570-6/50021-6; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; METTENLEITER TC, 1995, VIRAL VECTORS GENE T, P333; MILNER R, 1994, DEVELOPMENT, V120, P3497; MIYAKE T, 1988, BRAIN RES, V451, P133, DOI 10.1016/0006-8993(88)90757-3; NISHIYAMA A, 1995, MOL BIOL CELL, V6, P1819; NISHIYAMA A, 1991, J CELL BIOL, V114, P359, DOI 10.1083/jcb.114.2.359; Nishiyama A, 1997, J NEUROSCI RES, V48, P299, DOI 10.1002/(SICI)1097-4547(19970515)48:4<299::AID-JNR2>3.0.CO;2-6; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; OKAMOTO M, 1994, BRAIN RES, V637, P57, DOI 10.1016/0006-8993(94)91217-3; OKAMOTO M, 1994, NEUROSCI LETT, V172, P51, DOI 10.1016/0304-3940(94)90660-2; ONG WY, 1997, NEUR ABS, V23, P64; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; RINAMAN L, 1993, J NEUROSCI, V13, P685; ROIZMAN B, 1990, VIROLOGY, P1787; STALLCUP WB, 1983, COLD SPRING HARB SYM, V48, P761, DOI 10.1101/SQB.1983.048.01.078; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; SUGIURA M, 1994, DEV BIOL, V164, P102, DOI 10.1006/dbio.1994.1183; SUR M, 1988, J NEUROSCI, V8, P874; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ugolini Gabriella, 1995, P293, DOI 10.1016/B978-012397570-6/50019-8; WILSON SS, 1981, DEV BIOL, V83, P146, DOI 10.1016/S0012-1606(81)80017-6; Wittmann G., 1989, DEV VET VIROL, V9, P230, DOI [10.1007/978-1-4613-1587-2_7, DOI 10.1007/978-1-4613-1587-2_7, DOI 10.1007/978-1-4613-1587-2]	53	56	56	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	AUG	1998	23	4					316	328		10.1002/(SICI)1098-1136(199808)23:4<316::AID-GLIA4>3.0.CO;2-0			13	Neurosciences	Neurosciences & Neurology	ZX335	WOS:000074505200004	9671962				2021-06-18	
J	Oehmichen, M; Meissner, C; Schmidt, V; Pedal, I; Konig, HG; Saternus, KS				Oehmichen, M; Meissner, C; Schmidt, V; Pedal, I; Konig, HG; Saternus, KS			Axonal injury - a diagnostic tool in forensic neuropathology? A review	FORENSIC SCIENCE INTERNATIONAL			English	Article; Proceedings Paper	76th Congress of the German-Society-of-Legal-Medicine	SEP, 1997	JENA, GERMANY	German Soc Legal Med		axonal injury; traumatic brain injury; vitality; survival time; biomechanics; diffuse; axonal injury	AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; TRAUMATIC BRAIN INJURY; BETA-APP; HUMANS; MARKER	We used beta-amyloid precursor protein (beta-APP) to investigate our own forensic neuropathological case material (n=252) in light of the current literature on the phenomenon "axonal injury" (AI) to determine the incidence, specificity and biomechanical significance of AI and its significance for determining vitality and survival time. The case material consisted of cases of fatal nonmissile closed-head injury (n=119), gunshot injury (n=30), fatal cerebral ischemia/hypoxia (n=51), brain death caused by mechanical trauma (n=14) or nonmechanical injury (n=18), and acute hemorrhagic shock (n=20). AI was observed in 65% to 100% of cases of closed-head injury, fatal cerebral ischemia/hypoxia, and brain death with a survival time of more than 3 h; AI could not be detected in the cases of acute hemorrhagic shock. A statistically significant difference between traumatically and nontraumatically induced (nondisruptive) AI was not found. There was no statistical evidence of a correlation between AI and the different types of external force, since AI could be demonstrated after both acceleration/deceleration injuries and traumatic impact. Therefore, biomechanical inferences for reconstruction purposes are not possible. On the other hand, beta-APP was found to be a definite marker of vitality. In our material, cases with a posttraumatic interval of under 180 min did not express beta-APP. Moreover, the literature shows that the posttraumatic interval can be determined by other methods for demonstration of AI such as by ubiquitin immunostaining (360 min), silver staining (15-18 h), hematoxylin and eosin staining (about 24 h), or by demonstration of a microglial reaction (about 4 to 10 days) or of a few remaining isolated bulbs, without accompanying fibers, which can be detected after a survival time of up to 17 months. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.	Univ Lubeck, Dept Legal Med, D-23562 Lubeck, Germany; Univ Halle, Dept Legal Med, Halle, Germany; Univ Heidelberg, Dept Legal Med, D-6900 Heidelberg, Germany; Univ Tubingen, Dept Legal Med, D-72074 Tubingen, Germany; Univ Gottingen, Dept Legal Med, D-3400 Gottingen, Germany	Oehmichen, M (corresponding author), Univ Lubeck, Dept Legal Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.						ADAMS JH, 1986, ARCH PATHOL LAB MED, V110, P485; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; GEAN AD, 1995, IMAGING HEAD TRAUMA; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1996, NEUROPATHOL APPL S1, V22, P44; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Graham DI, 1996, NEUROPATH APPL NEURO, V22, P505, DOI 10.1111/j.1365-2990.1996.tb01125.x; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; JAFARI SS, 1997, NEUROCYTOL, V26, P207; Jellinger KA, 1977, APALLIC SYNDROME, P88; KATZ DI, 1994, HDB NEUROREHABILITAT, P493; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; McLellan D, 1986, COMA TRAUMATIQUE, P165; MILLER JD, 1978, NEURAL TRAUMA, P173; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; Oehmichen M, 1997, RES LEG MED, V17, P203; Oehmichen M, 1981, Beitr Gerichtl Med, V39, P57; OEHMICHEN M, 1997, NEUROTRAUMATOLOGY BI; OEHMICHEN M, 1992, KOPFSCHUSS SPANNUNGS, P37; OEHMICHEN M, 1998, IN PRESS INT J LEGAL; OEHMICHEN M, 1998, IN PRESS INT J FOREN; OEHMICHEN M, 1995, NEUROPATHOLOGIE, P197; Olsson Y, 1996, NEUROPATH APPL NEURO, V22, P518, DOI 10.1111/j.1365-2990.1996.tb01129.x; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Povlishock JT, 1997, RES LEG MED, V17, P175; SCHWEITZER JB, 1993, ACTA NEUROPATHOL, V85, P503; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SIKAL RR, 1969, BIOMETRY, P607; STRICH SJ, 1968, J NEUROL NEUROSUR PS, V31, P110, DOI 10.1136/jnnp.31.2.110; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; VANEZIS P, 1997, FORENS SCI INT, V35, P1; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	44	56	63	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738			FORENSIC SCI INT	Forensic Sci.Int.	JUL 6	1998	95	1					67	83		10.1016/S0379-0738(98)00075-9			17	Medicine, Legal	Legal Medicine	106TN	WOS:000075166700008	9718672				2021-06-18	
J	Harvey, AG; Bryant, RA				Harvey, AG; Bryant, RA			Predictors of acute stress following mild traumatic brain injury	BRAIN INJURY			English	Article							MOTOR-VEHICLE ACCIDENTS; MINOR HEAD-INJURY; DISORDER; SURVIVORS; RESPONSES; EVENTS	The aim of this study was to investigate the predictors of acute stress disorder (ASD) following mild traumatic brain injury (MTBI). Patients who sustained MTBI following a motor vehicle accident (n = 48) were assessed with a structured interview within 18 days of the trauma for the presence of ASD and administered the Beck Depression Inventory (BDI), Coping Style Questionnaire, Dissociative Experiences Scale, and the Eysenck Personality Inventory. ASD was diagnosed in 14.6% of patients and 4.2% were diagnosed with sub-syndromal ASD. BDI scores and avoidant coping were significant predictors of ASD and acute stress severity. This study provides further evidence that traumatic stress reactions occur following MTBI and highlights the possibility of identifying those who may benefit from early intervention.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BECK AT, 1979, COGNITIVE THERAPY DE; Billings A G, 1981, J Behav Med, V4, P139, DOI 10.1007/BF00844267; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; BRYANT RA, 1995, BEHAV RES THER, V33, P631, DOI 10.1016/0005-7967(94)00093-Y; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BRYANT RA, 1997, UNPUB PSYCHOMETRIC P; CARLSON EB, 1992, UNPUB MANUAL DISSOCI; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; DAVIDOFF DA, 1988, COGNITIVE REHABILITA, V2, P8; DUNCANJONES P, 1983, UNPUB SHORT MEASURES; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRIGSBY JP, 1986, INT J CLIN NEUROPSYC, V8, P65; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MIDDELBOE T, 1991, Acta Neurologica Scandinavica, V85, P5; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; NORTH CS, 1994, AM J PSYCHIAT, V151, P82; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; RATTOCK J, 1993, J CLIN EXPT NEUROPSY, V6, P243; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHWARZ ED, 1992, J NERV MENT DIS, V180, P767, DOI 10.1097/00005053-199212000-00005; SHORE JH, 1989, J NERV MENT DIS, V177, P681, DOI 10.1097/00005053-198911000-00004; SOLOMON Z, 1988, J ABNORM PSYCHOL, V97, P302, DOI 10.1037/0021-843X.97.3.302; Tabachnick B.G., 1989, USING MULTIVARIATE S; Waller NG, 1996, PSYCHOL METHODS, V1, P300, DOI 10.1037/1082-989X.1.3.300	35	56	57	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	1998	12	2					147	154		10.1080/026990598122773			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YV073	WOS:000071786900005	9492962				2021-06-18	
J	Soblosky, JS; Colgin, LL; Chorney-Lane, D; Davidson, JF; Carey, ME				Soblosky, JS; Colgin, LL; Chorney-Lane, D; Davidson, JF; Carey, ME			Ladder beam and camera video recording system for evaluating forelimb and hindlimb deficits after sensorimotor cortex injury in rats	JOURNAL OF NEUROSCIENCE METHODS			English	Article						sensorimotor cortex; brain lesion; hindlimb; forelimb; motor recovery; beam-walking; wire-grid test; rat	TRAUMATIC BRAIN INJURY; CORTICAL DAMAGE; MOTOR CORTEX; RECOVERY; ORGANIZATION; AMPHETAMINE; LESIONS; MEMORY; MODEL	Hindlimb and forelimb deficits in rats caused by sensorimotor cortex lesions are frequently tested by using the narrow flat beam (hindlimb), the narrow pegged beam (hindlimb and forelimb) or the grid-walking (forelimb) tests. Although these are excellent tests, the narrow flat beam generates non-parametric data so that using more powerful parametric statistical analyses are prohibited. All these tests can be difficult to score if the rat is moving rapidly. Foot misplacements, especially on the grid-walking test, are indicative of an ongoing deficit, but have not been reliably and accurately described and quantified previously. In this paper we present an easy to construct and use horizontal ladder-beam with a camera system on rails which can be used to evaluate both hindlimb and forelimb deficits in a single test. By slow motion videotape playback we were able to quantify and demonstrate foot misplacements which go beyond the recovery period usually seen using more conventional measures (i.e. footslips and footfaults). This convenient system provides a rapid and reliable method for recording and evaluating rat performance on any type of beam and may be useful for measuring sensorimotor recovery following brain injury. (C) 1997 Elsevier Science B.V.	Louisiana State Univ, Med Ctr, Dept Neurosurg, Neurotrauma Res Lab, New Orleans, LA 70112 USA	Soblosky, JS (corresponding author), Louisiana State Univ, Med Ctr, Dept Neurosurg, Neurotrauma Res Lab, 1542 Tulane Ave, New Orleans, LA 70112 USA.			Colgin, Laura/0000-0002-4853-8913; Lane, Diane/0000-0001-7313-557X			BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; BOYESON MG, 1992, BRAIN RES BULL, V29, P435, DOI 10.1016/0361-9230(92)90080-H; BOYESON MG, 1993, PHARMACOL BIOCHEM BE, V44, P297, DOI 10.1016/0091-3057(93)90465-6; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GENTILE AM, 1978, BEHAV BIOL, V22, P417, DOI 10.1016/S0091-6773(78)92547-6; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; GOLDSTEIN LB, 1993, NEUROSCI PROTOCOLS, P1; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; PELLEGRINO I, 1979, STEREOTAXIC ATLAS RA; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Soblosky J. S., 1994, Society for Neuroscience Abstracts, V20, P194; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Soblosky JS, 1996, BEHAV BRAIN RES, V80, P185, DOI 10.1016/0166-4328(96)00034-4; SOBLOSKY JS, IN PRESS BEHAV BRAIN	22	56	56	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	DEC 30	1997	78	1-2					75	83		10.1016/S0165-0270(97)00131-3			9	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	YV689	WOS:000071852900008	9497003				2021-06-18	
J	Clark, RSB; Carcillo, JA; Kochanek, PM; Obrist, WD; Jackson, EK; Mi, ZC; Wisneiwski, SR; Bell, MJ; Marion, DW				Clark, RSB; Carcillo, JA; Kochanek, PM; Obrist, WD; Jackson, EK; Mi, ZC; Wisneiwski, SR; Bell, MJ; Marion, DW			Cerebrospinal fluid adenosine concentration and uncoupling of cerebral blood flow and oxidative metabolism after severe head injury in humans	NEUROSURGERY			English	Article; Proceedings Paper	10th International Symposium on Brain Edema	OCT 20-23, 1996	SAN DIEGO, CA			adenosine; cerebral blood flow; cerebral metabolism; cerebrospinal fluid; head injury; oxidative metabolism	INTRACRANIAL HYPERTENSION; GLUCOSE-UTILIZATION; AUTO-REGULATION; BRAIN TRAUMA; RAT-BRAIN; RECEPTORS; ISCHEMIA; CHILDREN; PRESSURE; HYPOXIA	OBJECTIVE: Uncoupling of cerebral blood flow (CBF) and oxidative metabolism is observed after severe head injury in comatose patients; however, the mechanism(s) involved remain undefined. Adenosine can produce cerebral vasodilation and reduce neuronal activity and is a possible mediator of uncoupling. We hypothesized that cerebrospinal fluid (CSF) adenosine concentrations would be increased during uncoupling of CBF and oxidative metabolism, defined as a narrow arterio-jugular venous oxygen difference [D(a-v)O-2 4 vol%] after head injury. METHODS: Adenosine concentrations were measured using fluorescent-based high-pressure liquid chromatography in 67 CSF samples obtained from 13 comatose (Glasgow Coma Scale score 7) adult patients who sustained a severe closed head injury. At the time each sample was obtained, CBF was measured by the xenon-133 method, and blood samples were obtained for determination of D(a-v)O-2. RESULTS: CSF adenosine concentration was negatively associated with D(a-v)O-2 (P < 0.05, generalized multivariate linear regression model), In addition, CSF adenosine concentration was increased when D(a-v)O-2 was 4 versus >4 vol% (38.5 [3.2-306.3] versus 14.0 [2.7-795.5] nmol/L, respectively, median [range]; P < 0.025) and in patients who died versus survivors (40.1 [6.9-306.3] versus 12.9 [2.7-795.5] nmol/L, respectively, median [range]; P < 0.001). CONCLUSION: The association between increased CSF adenosine concentration and a reduction in global cross-brain extraction of oxygen supports a regulatory role for adenosine in the complex balance between CBF and oxidative and nonoxidative metabolism after severe head injury in humans.	UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT PEDIAT,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT NEUROSURG,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT PHARMACOL,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT EPIDEMIOL,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA 15260			Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS30318-04A1] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARIE PS, 1993, J TRAUMA, V35, P88, DOI 10.1097/00005373-199307000-00015; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERNE RM, 1974, CIRC RES, V35, P262, DOI 10.1161/01.RES.35.2.262; BERNINI JC, 1995, LANCET, V345, P544, DOI 10.1016/S0140-6736(95)90464-6; BORN GVR, 1963, J PHYSIOL-LONDON, V168, P178, DOI 10.1113/jphysiol.1963.sp007185; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BRAUN JS, 1994, J NEUROCYTOL, V23, P193, DOI 10.1007/BF01181560; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; CRONSTEIN BN, 1994, J APPL PHYSIOL, V176, P5; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DIRNAGL U, 1994, AM J PHYSIOL, V267, pH296; EDVINSSON L, 1993, CEREBRAL BLOOD FLOW, P325; FLEISCHER AS, 1977, J NEUROSURG, V47, P517, DOI 10.3171/jns.1977.47.4.0517; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; GINSBERG MD, 1987, NEUROLOGY, V37, P11, DOI 10.1212/WNL.37.1.11; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; JACKSON EK, 1997, J PHARMACOL EXP THER, V279, P1250; JACOBSON KA, 1993, FEBS LETT, V336, P57, DOI 10.1016/0014-5793(93)81608-3; JENNETT B, 1985, LANCET, V1, P480; KO KR, 1990, AM J PHYSIOL, V259, pH1703; Lam JMK, 1996, BRIT J NEUROSURG, V10, P357; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LAUDIGNON N, 1991, J CEREBR BLOOD F MET, V11, P424, DOI 10.1038/jcbfm.1991.83; LEE KS, 1986, BRAIN RES, V380, P155, DOI 10.1016/0006-8993(86)91440-X; LONDOS C, 1980, P NATL ACAD SCI-BIOL, V77, P2551, DOI 10.1073/pnas.77.5.2551; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARMAROU A, 1997, P 10 INT S BRAIN ED, P90; MASS AIR, 1977, CEREBROSPINAL FLUID, P17; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; MILLER LP, 1992, J NEUROTRAUM, V9, pS563; MORII S, 1987, AM J PHYSIOL, V253, pH165; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; ONODERA H, 1987, BRAIN RES, V415, P309, DOI 10.1016/0006-8993(87)90213-7; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PHILLIS J W, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P26; PHILLIS JW, 1984, J CEREBR BLOOD F MET, V4, P586, DOI 10.1038/jcbfm.1984.83; PHILLIS JW, 1975, EUR J PHARMACOL, V30, P125, DOI 10.1016/0014-2999(75)90214-9; RAICHLE ME, 1976, ARCH NEUROL-CHICAGO, V33, P523, DOI 10.1001/archneur.1976.00500080001001; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; RUBIO R, 1975, AM J PHYSIOL, V228, P1896; RUDOLPHI KA, 1992, CEREBROVAS BRAIN MET, V4, P346; RUTH VJ, 1993, AM J PHYSIOL, V265, pH1762; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; SCHRODER ML, 1994, XENON CT CBF CLIN DE, P275; SHALMON E, 1996, J NEUROSURG, V84, pA344; SOLLEVI A, 1986, PROG NEUROBIOL, V27, P319, DOI 10.1016/0301-0082(86)90005-5; STEFANOVICH V, 1988, ROLE ADENOSINE CEREB, P2; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TEASDALE G, 1974, LANCET, V2, P81; VANCALKER D, 1979, J NEUROCHEM, V33, P999, DOI 10.1111/j.1471-4159.1979.tb05236.x; VILLRINGER A, 1995, CEREBROVAS BRAIN MET, V7, P240; WINN HR, 1981, AM J PHYSIOL, V241, pH235; WINN HR, 1980, AM J PHYSIOL, V239, pH636; WINN HR, 1981, J CEREBR BLOOD F MET, V1, P239, DOI 10.1038/jcbfm.1981.29; WINN HR, 1985, ANN BIOMED ENG, V13, P321, DOI 10.1007/BF02584250; ZUPPING R, 1970, J NEUROSURG, V33, P498, DOI 10.3171/jns.1970.33.5.0498	64	56	58	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	DEC	1997	41	6					1284	1292		10.1097/00006123-199712000-00010			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	YH863	WOS:A1997YH86300034	9402580				2021-06-18	
J	Dixon, CE; Ma, XC; Marion, DW				Dixon, CE; Ma, XC; Marion, DW			Reduced evoked release of acetylcholine in the rodent neocortex following traumatic brain injury	BRAIN RESEARCH			English	Article						brain injury; neocortex; acetylcholine; microdialysis; rat	NERVE GROWTH-FACTOR; NUCLEUS BASALIS MAGNOCELLULARIS; CONTROLLED CORTICAL IMPACT; FOREBRAIN CHOLINERGIC NEURONS; FIMBRIA-FORNIX TRANSECTION; FLUID-PERCUSSION INJURY; HEAD-INJURY; RAT; MEMORY; ACETYLTRANSFERASE	Neocortical acetylcholine (ACh) release was examined in awake, freely-moving rats at 14 days following lateral controlled cortical impact. Extracellular ACh was measured prior to and after an intraperitoneal administration of scopolamine, which evokes ACh release by blocking autoreceptors. At 14 days post-injury there was a significant reduction in scopolamine-evoked ACh release. The data suggest that neocortical cholinergic neurotransmission is chronically compromised, and may contribute to post-traumatic memory deficits.		Dixon, CE (corresponding author), UNIV PITTSBURGH,DEPT NEUROSURG,3434 5TH AVE,SUITE 201,PITTSBURGH,PA 15260, USA.		Marion, Donald/AAR-5749-2021	Marion, Donald/0000-0003-4627-7702	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P01NS031998] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS31998] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49-CCR303547] Funding Source: Medline		ARMSTRONG DM, 1987, J COMP NEUROL, V264, P421, DOI 10.1002/cne.902640309; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BLAKER SN, 1988, J COMP NEUROL, V272, P127, DOI 10.1002/cne.902720109; CARROLL PT, 1980, SCIENCE, V210, P641, DOI 10.1126/science.7433989; COLLERTON D, 1986, NEUROSCIENCE, V19, P1, DOI 10.1016/0306-4522(86)90002-3; DEKKER AJ, 1992, NEUROSCIENCE, V48, P111, DOI 10.1016/0306-4522(92)90342-Y; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon C. E., 1995, Journal of Neurotrauma, V12, P491; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GAGE FH, 1988, J COMP NEUROL, V269, P147, DOI 10.1002/cne.902690112; GAGE FH, 1986, NEUROSCIENCE, V19, P241, DOI 10.1016/0306-4522(86)90018-7; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAROUTUNIAN V, 1989, BRAIN RES, V487, P200, DOI 10.1016/0006-8993(89)90960-8; HASSELMO ME, 1993, TRENDS NEUROSCI, V16, P218, DOI 10.1016/0166-2236(93)90159-J; JIANG JY, 1994, BRAIN RES, V640, P240; JOHNSTON MV, 1981, EXP BRAIN RES, V43, P159; JOHNSTON MV, 1987, NEUROCHEM RES, V12, P985, DOI 10.1007/BF00970927; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MANDEL RJ, 1989, EXP NEUROL, V104, P208, DOI 10.1016/0014-4886(89)90031-9; MARKOWSKA AL, 1990, BEHAV NEURAL BIOL, V54, P13, DOI 10.1016/0163-1047(90)91211-S; MESULAM MM, 1983, NEUROSCIENCE, V10, P1185, DOI 10.1016/0306-4522(83)90108-2; POSMANTUR R, 1996, J NEUROPATHOL EXP NE, V55, P65; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SONFRONIEW M, 1987, BRAIN RES, V411, P310; SONFRONIEW MV, 1983, BRAIN RES, V289, P370; SPENCER DG, 1983, DRUG DEVELOP RES, V3, P489, DOI 10.1002/ddr.430030602; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0	34	56	60	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 21	1997	749	1					127	130		10.1016/S0006-8993(96)01310-8			4	Neurosciences	Neurosciences & Neurology	WL911	WOS:A1997WL91100016	9070636				2021-06-18	
J	Heinemann, AW; Kirk, P; Hastie, BA; Semik, P; Hamilton, BB; Linacre, JM; Wright, BD; Granger, C				Heinemann, AW; Kirk, P; Hastie, BA; Semik, P; Hamilton, BB; Linacre, JM; Wright, BD; Granger, C			Relationships between disability measures and nursing effort during medical rehabilitation for patients with traumatic brain and spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; CLASSIFICATION-SYSTEM; LIFE SATISFACTION; ASSESSMENT SCALES; FOLLOW-UP; IMPAIRMENT; HANDICAP; HEAD; STROKE	Objective: The increasing use of disability measures requires that the validity of these instruments be adequately demonstrated. This study sought to evaluate the concurrent validity of one disability measure, the Functional Independence Measure (FIM(SM)) using minutes of care reported by nursing staff. Study Design: Correlational, cohort design. Setting: Eight inpatient medical rehabilitation hospitals that subscribe to the Uniform Data System for Medical Rehabilitation. Patients or Other Participants: 129 patients with traumatic brain injury (TBI) and 53 patients with traumatic spinal cord injury (SCI). Interventions: Routine rehabilitation care. Main Outcome Measures: Patient-nurse contact times were recorded with a stop watch for a 24-hour period during the first and last weeks of inpatient rehabilitation. The FIM was also completed during the first and last weeks of rehabilitation. Results: Contact times declined from the first to last weeks of rehabilitation, concurrent with improving scores on motor and cognitive measures derived from the FIM. Statistically significant correlations between contact times and FIM measures were observed for medication dispensing, treatment provision, and teaching/activities of daily living at admission and discharge. Smaller and usually nonsignificant correlations were observed in activities that did not involve direct patient contact. Contact times increased exponentially as disability increased. Conclusions: These results support the construct validity of the FIM by demonstrating strong relationships (r values in the range of .40 to .60) between burden of care and a measure of disability. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	NORTHWESTERN UNIV,SCH MED,DEPT PHYS MED & REHABIL,EVANSTON,IL 60208; UNIV CHICAGO,DEPT EDUC,MESA PSYCHOMETR LAB,CHICAGO,IL 60637; VET AFFAIRS MED CTR,DURHAM,NC 27705; SUNY BUFFALO,CTR FUNCT ASSESSMENT RES,BUFFALO,NY 14260	Heinemann, AW (corresponding author), REHABIL INST CHICAGO,ROOM 1374,345 E SUPERIOR ST,CHICAGO,IL 60611, USA.		Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR503609] Funding Source: Medline		BROWN SC, 1993, J DISABIL POLICY STU, V4, P57; DEGROOT HA, 1989, J NURS ADMIN, V19, P24; DeVivo M, 1995, SPINAL CORD INJURY C, P234; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; DISLER PB, 1993, ARCH PHYS MED REHAB, V74, P139; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; GIOVANETTI P, 1978, HRA7827 DHEW; GIOVANETTI P, 1984, NURS MANAGE, V15, P35; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; HAMILITON BB, 1994, PHYS THER, V74, P494, DOI 10.1093/ptj/74.5.494; Hamilton B., 1987, REHABILITATION OUTCO; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; HEINEMANN AW, 1995, 103 ANN CONV AM PSYC; JOHNSTON MV, 1992, ARCH PHYS MED REHAB, V73, pS3; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kelleher C, 1992, Nurs Econ, V10, P31; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEWIS NL, 1984, NURSING STAFFING PAT; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MENTER RR, 1991, PARAPLEGIA, V29, P613, DOI 10.1038/sc.1991.90; OBRIENPALLAS L, 1992, J NURS ADMIN, V22, P17; PARDUE S, 1986, J PSYCHOSOC NURS, V2, P23; PHILLIPS CY, 1992, J NURS ADMIN, V22, P46, DOI 10.1097/00005110-199204000-00012; RINTALA DH, 1993, AM SPIN INJ ASS M SA; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; *SUNY, 1993, GUID UN DAT SET MED; *U AL, 1994, SPIN CORD INJ FACTS; UNGER J, 1985, J NURS ADMIN, V15, P18; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; Wrona-Sexton S, 1992, Nurs Manage, V23, P38, DOI 10.1097/00006247-199212000-00010	36	56	57	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1997	78	2					143	149		10.1016/S0003-9993(97)90255-0			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	WH072	WOS:A1997WH07200006	9041894				2021-06-18	
J	Day, LB; Schallert, T				Day, LB; Schallert, T			Anticholinergic effects on acquisition of place learning in the Morris water task: Spatial mapping deficit or inability to inhibit nonplace strategies?	BEHAVIORAL NEUROSCIENCE			English	Article							CHOLINERGIC RECEPTOR BLOCKADE; TRAUMATIC BRAIN INJURY; HIPPOCAMPAL-LESIONS; SWIMMING POOL; AGED RATS; NAVIGATION; LOCALIZATION; HYPOTHERMIA; IMPAIRMENT; CUES	The role of central cholinergic blockage in spatial learning was examined by testing atropine sulfate-treated (50 mg/kg) rats and saline-injected controls in the Morris water task using training procedures designed to promote the use of a spatial search strategy. First, constraints used in early trials deterred thigmotaxis. Second, an originally oversized hidden platform that nearly occupied the entire pool was effectively ''shrunk'' into the southwest quadrant of the pool by substituting smaller platforms over trials, a procedure intended to focus attention on the hidden platform in relation to extramaze cues. Task acquisition did not differ between groups, and on the probe trial both groups increased distance and latency and swam preferentially in the previously correct quadrant. Impairments caused by atropine sulfate may be the result of deficits in ability to inhibit nonefficient escape strategies.	UNIV TEXAS,DEPT PSYCHOL,AUSTIN,TX 78712; UNIV TEXAS,INST NEUROSCI,AUSTIN,TX 78712				Day, Lainy/0000-0002-9122-3044			AMSEL A, 1993, HIPPOCAMPUS, V3, P251, DOI 10.1002/hipo.450030302; BAXTER MG, 1995, BEHAV NEUROSCI, V109, P714, DOI 10.1037/0735-7044.109.4.714; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; BLODGETT HC, 1949, J EXP PSYCHOL, V39, P800, DOI 10.1037/h0058978; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; DEVIETTI TL, 1985, BEHAV NEUROSCI, V99, P1128, DOI 10.1037/0735-7044.99.6.1128; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DOUGLAS RJ, 1967, PSYCHOL BULL, V67, P416, DOI 10.1037/h0024599; GABRIEL M, 1987, EXP BRAIN RES, V67, P131, DOI 10.1007/BF00269462; GAGE FH, 1984, NEUROBIOL AGING, V5, P43, DOI 10.1016/0197-4580(84)90084-8; GALLAGHER M, 1993, BEHAV NEUROSCI, V107, P618, DOI 10.1037/0735-7044.107.4.618; GRAY JA, 1983, NEUROSCI BIOBEHAV R, V7, P119, DOI 10.1016/0149-7634(83)90014-3; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; KIMBLE DP, 1968, PSYCHOL BULL, V70, P285, DOI 10.1037/h0026470; KOLB B, 1983, BEHAV NEUROSCI, V97, P12; LINDNER MD, 1988, BEHAV NEUROSCI, V102, P621, DOI 10.1037/0735-7044.102.5.621; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NILSSON OG, 1992, NEUROREPORT, V3, P1005, DOI 10.1097/00001756-199211000-00015; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; RAPP PR, 1987, BEHAV NEUROSCI, V101, P3, DOI 10.1037/0735-7044.101.1.3; Saucier D, 1996, BEHAV NEUROSCI, V110, P103, DOI 10.1037/0735-7044.110.1.103; SCHALLERT T, 1980, J COMP PHYSIOL PSYCH, V94, P1, DOI 10.1037/h0077656; SUTHERLAND RJ, 1982, J COMP PHYSIOL PSYCH, V96, P563, DOI 10.1037/h0077914; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; WHISHAW IQ, 1985, BEHAV NEUROSCI, V99, P979, DOI 10.1037/0735-7044.99.5.979; WHISHAW IQ, 1995, J NEUROSCI, V15, P5779; YAMAMURA HI, 1974, BRAIN RES, V80, P170, DOI 10.1016/0006-8993(74)90738-0	31	56	56	0	3	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0735-7044			BEHAV NEUROSCI	Behav. Neurosci.	OCT	1996	110	5					998	1005					8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	VQ506	WOS:A1996VQ50600013	8919002				2021-06-18	
J	Hertel, R; Pisan, M; Lambert, S; Ballmer, FT				Hertel, R; Pisan, M; Lambert, S; Ballmer, FT			Plate osteosynthesis of diaphyseal fractures of the radius and ulna	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article							BONE	Between January 1980 and December 1989, 133 consecutive patients were treated for a fracture of the shaft of one or both forearm bones (134 forearms in total). All fractures were stabilized with AO/ASIF 3.5 mm stainless-steel dynamic compression plates. The 1 year follow-up rate was 99 per cent; the long-term follow-up rate was 92 per cent (the mean long-term follow-up was 10.2 years (range, 2.7-15.2)) so there were 96 men and 35 women, with an average age of 37.5 years (range, 16-63). Twenty-two per cent of the forearms had open fractures, 26 per cent of patients had sustained multiple injuries and 19 per cent had a head injury. One hundred and twenty-seven of 132 forearms (96.2 per cent) underwent problem-free consolidation before 6 months. Two delayed unions and two non-unions required reoperation. There was one superficial infection in a patient with a closed fracture. Plates were removed from 70 patients (53 percent) at a mean of 33.1 months (range, 8-122) after the first operation. In this group, there were three refractures (4.3 per cent) occurring at a mean of 8.7 months (range, 0-14) after plate removal. This study confirms the safety and efficacy of plate osteosynthesis in forearm shaft fractures: a high union rate and low complication rate can be anticipated. The data presented form the most reliable information on this subject currently available with the longest and highest rate of follow up of a sufficient number of patients using a single implant system in a single institution. Copyright (C) 1996 Elsevier Science Ltd.		Hertel, R (corresponding author), UNIV BERN,INSELSPITAL,DEPT ORTHOPAED SURG,CH-3010 BERN,SWITZERLAND.						ANDERSON LD, 1975, J BONE JOINT SURG AM, VA 57, P287, DOI 10.2106/00004623-197557030-00001; CHAPMAN MW, 1989, J BONE JOINT SURG AM, V71A, P159, DOI 10.2106/00004623-198971020-00001; DELUCA PA, 1988, J BONE JOINT SURG AM, V70A, P1372, DOI 10.2106/00004623-198870090-00015; DODGE HS, 1972, J BONE JOINT SURG AM, V54, P1167, DOI 10.2106/00004623-197254060-00003; GRACE TG, 1980, J BONE JOINT SURG AM, V62, P433, DOI 10.2106/00004623-198062030-00013; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HIDAKA S, 1984, J BONE JOINT SURG AM, V66A, P1241, DOI 10.2106/00004623-198466080-00012; MOED BR, 1986, J BONE JOINT SURG AM, V68A, P1008, DOI 10.2106/00004623-198668070-00007; Muller M, 1991, MANUAL INTERNAL FIXA, VThird; Muller ME, 1990, COMPREHENSIVE CLASSI; PAAVOLAINEN P, 1978, CLIN ORTHOP RELAT R, V136, P287; PERREN SM, 1988, CLIN ORTHOP RELAT R, V232, P139; ROSSON JW, 1991, J BONE JOINT SURG BR, V73, P65; Rumball K, 1990, J Orthop Trauma, V4, P124, DOI 10.1097/00005131-199004020-00004; UHTHOFF HK, 1983, J BONE JOINT SURG BR, V65, P66	15	56	59	0	0	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0020-1383			INJURY	Injury-Int. J. Care Inj.	OCT	1996	27	8					545	548		10.1016/S0020-1383(96)00091-5			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	VV305	WOS:A1996VV30500004	8994558				2021-06-18	
J	Kreutzer, JS; Witol, AD; Sander, AM; Cifu, DX; Marwitz, JH; Delmonico, R				Kreutzer, JS; Witol, AD; Sander, AM; Cifu, DX; Marwitz, JH; Delmonico, R			A prospective longitudinal multicenter analysis of alcohol use patterns among persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alcohol use; substance abuse	HEAD-INJURY; SUBSTANCE-ABUSE; FOLLOW-UP; REHABILITATION	Objective: To characterize long-term post injury drinking patterns of persons with traumatic brain injury and to identify injury-related and sociodemographic factors related to post injury consumption, Design: A cross-sectional design (n=322) was first used to characterize drinking patterns at three time intervals. A longitudinal design (n=73) nas then used to examine changes in consumption patterns. chi(2) analyses and Wilcoxon matched-pairs signed-ranks test (t-tests) were conducted to investigate the relationship between patients' reported alcohol use and time post injury. Spearman rank-order correlations, chi(2) analyses. and Fisher's exact probability tests were used to examine relationships among drinking classifications and injury-related and sociodemographic characteristics. Setting: Rehabilitation center outpatient clinics affiliated with the four brain injury model Systems programs. Patients: Patients with moderate and severe brain injury who received acute medical care and inpatient rehabilitation. Inclusion criteria were: patient >16 years old, participation in follow-up medical and psychologic evaluations, and willingness to provide information regarding alcohol consumption Main Outcome. Measures: Quantity Frequency Variability index, Disability Rating Scale, and Functional Independence Measure scores. Results: At each follow up interval, the proportion of persons classified as moderate or heavy drinkers was generally comparable to that in the general population, Abstention rates, however, were markedly higher than those within the general population. For the cross-sectional sample, chi(2) analyses revealed no significant differences in the distribution of drinking classifications across follow-up intervals. For the longitudinal group however, Wilcoxon matched-pairs signed-ranks tests revealed substantial differences in drinking ratings for individuals over time. A pattern of increasing consumption was indicated. Correlational analyses revealed higher consumption levels for younger persons and those with higher admission blood alcohol levels. Furthermore. relationships were observed between injury severity and consumption levels, Higher levels of disability were associated with loner consumption rates. Conclusions: These data suggest that alcohol use patterns are dynamic during the first 4 years after injury. Also, long-term monitoring of alcohol use patterns may be cost-effective. particularly for younger persons and those with a preinjury history of problem drinking.	SANTA CLARA VALLEY MED CTR,PSYCHOL SERV,SAN JOSE,CA	Kreutzer, JS (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,MCV BOX 980542,RICHMOND,VA 23298, USA.			Cifu, David/0000-0003-1600-9387			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; Glow B., 1989, ALCOHOLISM SUBSTANCE; GOLD MA, 1993, J ADOLESCENT HEALTH, V14, P80, DOI 10.1016/1054-139X(93)90089-8; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HILTON ME, 1987, ALCOHOL CLIN EXP RES, V11, P167, DOI 10.1111/j.1530-0277.1987.tb01283.x; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAISTO SA, 1979, J CONSULT CLIN PSYCH, V47, P106, DOI 10.1037/0022-006X.47.1.106; MOORE D, 1991, INT J ADDICT, V26, P65, DOI 10.3109/10826089109056240; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PORKORNY AD, 1972, AM J PSYCHIAT, V129, P342; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SANDER A, 1996, 20 ANN POSTGR COURS; SIEGEL D, 1956, NONPARAMETRIC STAT B; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; *WI DEP HLTH SOC S, 1985, ALC US PERS DIS PREL	33	56	56	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					58	69		10.1097/00001199-199610000-00006			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300006					2021-06-18	
J	Sandel, ME; Williams, KS; Dellapietra, L; Derogatis, LR				Sandel, ME; Williams, KS; Dellapietra, L; Derogatis, LR			Sexual functioning following traumatic brain injury	BRAIN INJURY			English	Article							STROKE; HEMISPHERE; HEMIPLEGIA	In this study we investigated sexual functioning in 52 outpatients with a history of traumatic brain injury to determine: (1) the prevalence of reported sexual dysfunction; and (2) the relationship between sexual functioning and age, severity and locus of injury, time since injury, and physical and cognitive function. Reports of sexual functioning indicated a reduction below levels within non-injured populations, but only to statistically significant levels on two scales of the Derogatis Interview of Sexual Function (DISF): Orgasm and Drive/Desire. Location of injury was related to sexuality in that patients with frontal lobe lesions reported an overall higher level of sexual satisfaction and functioning than those individuals without frontal lobe lesions. Time since injury was inversely related to reports of levels of sexual arousal; that is, patients with more recent injuries reported greater levels of arousal than those not recently injured. Right hemisphere injuries also correlated with higher scores on reports of sexual arousal and sexual experiences.	MAGEE MEM REHABILITAT CTR,PHILADELPHIA,PA; MED COLL PENN & HAHNEMANN UNIV,PHILADELPHIA,PA 19102	Sandel, ME (corresponding author), HOSP UNIV PENN,DEPT REHABIL MED,5 W GATES,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.						BERROL S, 1989, SEX DISABIL, P203; COSLETT HB, 1986, ARCH NEUROL-CHICAGO, V43, P1036, DOI 10.1001/archneur.1986.00520100048013; DAVIS DL, 1990, J HEAD TRAUMA REHAB, V5, P31, DOI DOI 10.1097/00001199-199005020-00006; Derogatis L, 1987, DEROGATIS INTERVIEW; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Goddess E, 1979, MED ASPECTS HUMAN SE, V13, P6; Griffith ER, 1990, REHABILITATION ADULT, P206; Horn LJ, 1990, J HEAD TRAUMA REHAB, V5, P1; KALLIOMAKI JL, 1961, FERTIL STERIL, V12, P156; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; MEYER J, 1971, J NEUROVISCERAL RE S, V10, P519; MONGA TN, 1986, ARCH PHYS MED REHAB, V67, P415; MORRIS PLP, 1992, NEUROPSY NEUROPSY BE, V5, P75; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SANDEL ME, 1996, MED REHABILITATION T, P557; SATZ P, 1962, J CLIN PSYCHOL, V18, P7; SJOGREN K, 1983, SCAND J REHABIL MED, V15, P63; SJOGREN K, 1983, SCAND J REHABIL MED, V15, P55; Spreen O., 1977, NEUROSENSORY CTR COM; WALKER AE, 1959, J NEUROSURG, V16, P600, DOI 10.3171/jns.1959.16.6.0600; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Williams JM, 1991, MEMORY ASSESSMENT SC; ZINREICH ES, 1990, INT J RADIAT ONCOL, V19, P729, DOI 10.1016/0360-3016(90)90503-C	25	56	56	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1996	10	10					719	728		10.1080/026990596123981			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VH730	WOS:A1996VH73000002	8879662				2021-06-18	
J	Wallis, RA; Panizzon, KL; Girard, JM				Wallis, RA; Panizzon, KL; Girard, JM			Traumatic neuroprotection with inhibitors of nitric oxide and ADP-ribosylation	BRAIN RESEARCH			English	Article						ADP-ribosylation; mono-ADP-ribosylation; poly-ADP-ribosylation; nitric oxide; N-methyl-D-aspartate; traumatic brain injury; CA1; hippocampus	HEAD-INJURY; POLY(ADP-RIBOSE) SYNTHETASE; RAT-LIVER; ARGININE; RIBOSYLTRANSFERASE; IDENTIFICATION	N-Methyl-D-aspartate (NMDA) receptor activation is known to contribute to neuronal damage from head trauma. Additionally, NMDA neurotoxicity occurs in part through the generation of nitric oxide (NO), and injury from NO has been shown to be mediated by ADP-ribosylation. Therefore, we investigated whether inhibitors of NO and ADP-ribosylation would protect against acute CA1 traumatic neuronal injury in hippocampal slices subjected to fluid percussion. Treatment with the nitric oxide synthase (NOS) inhibitor, methyl-L-arginine 170 mu M for 35 min after trauma injury, improved CA1 antidromic population spike (PS) recovery to 91 +/- 2%, compared to unmediated slices which recovered to only a mean of 20 +/- 4%, 90 min after trauma. Similarly, hemoglobin 50 mu M, which directly binds NO, protected against traumatic neuronal injury and yielded a mean CA1 PS recovery of 92 +/- 1%. Treatment with inhibitors of poly-ADP-ribosylation was also strongly protective, with the vitamin nicotinamide 10 mM and 3-aminobenzamide 1 mM yielding PS recoveries of 98 +/- 2% and 90 +/- 3%, respectively. Protection was also seen with inhibitors of mono-ADP-ribosylation, including novobiocin 500 mu M and meta-iodobenzylguanidine 20 mu M which yielded recoveries of 89 +/- 6% and 96 +/- 26%. Novobiocin also protected against direct application of NO and NMDA. These findings suggest that NO and ADP-ribosylation are mediators of acute traumatic neuronal injury.	VET AFFAIRS MED CTR 111N1,SEPULVEDA,CA 91343	Wallis, RA (corresponding author), UNIV CALIF LOS ANGELES,DEPT NEUROL,16111 PLUMMER,SEPULVEDA,CA 91343, USA.						ADAMS RD, 1989, PRINCIPLES NEUROLOGY; BANASIK M, 1992, J BIOL CHEM, V267, P1569; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DIMMELER S, 1991, BIOCHEM BIOPH RES CO, V178, P848, DOI 10.1016/0006-291X(91)90968-D; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GENNARELLI TA, 1993, J EMERG MED S1, V11, pS5; GIRARD JM, 1993, SOC NEUR ABSTR, V23, P1876; Ikonomidou C., 1994, Society for Neuroscience Abstracts, V20, P1677; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MOSS J, 1981, J BIOL CHEM, V256, P7830; OBRIEN P, 1994, COMMUNICATION   1007; Olney J, 1978, KAINIC ACID TOOL NEU, P95; SAKUMA I, 1988, P NATL ACAD SCI USA, V85, P8664, DOI 10.1073/pnas.85.22.8664; SCAIFE RM, 1992, BIOCHEMISTRY-US, V31, P310, DOI 10.1021/bi00116a042; SCHURR A, 1984, BRAIN RES, V297, P357, DOI 10.1016/0006-8993(84)90576-6; SMETS LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P49, DOI 10.1016/0167-4889(90)90204-Q; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P770; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.bi.54.070185.000445; VOLPE BT, 1992, BEHAV NEUROSCI, V106, P457, DOI 10.1037/0735-7044.106.3.457; WALLIS RA, 1992, NEUROREPORT, V3, P645, DOI 10.1097/00001756-199207000-00026; WALLIS RA, 1993, NEUROREPORT, V5, P245; WALLIS RA, 1994, BRAIN RES, V664, P115, DOI 10.1016/0006-8993(94)91961-5; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	30	56	57	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 26	1996	710	1-2					169	177		10.1016/0006-8993(95)01278-8			9	Neurosciences	Neurosciences & Neurology	UA126	WOS:A1996UA12600020	8963656				2021-06-18	
J	BAVARIA, JE; WOO, YJ; HALL, RA; CARPENTER, JP; GARDNER, TJ				BAVARIA, JE; WOO, YJ; HALL, RA; CARPENTER, JP; GARDNER, TJ			RETROGRADE CEREBRAL AND DISTAL AORTIC PERFUSION DURING ASCENDING AND THORACOABDOMINAL AORTIC OPERATIONS	ANNALS OF THORACIC SURGERY			English	Article							CIRCULATORY ARREST; SURGICAL-TREATMENT; ARCH ANEURYSM; REPLACEMENT; EXPERIENCE; DISSECTION; PREVENTION; SURGERY; BYPASS; BRAIN	Background. Several alternative circulatory management techniques during thoracic aortic reconstruction have been implemented at this institution. This study was performed to assess whether retrograde cerebral perfusion during proximal aortic operations and distal aortic perfusion during thoracoabdominal aortic operations have improved outcomes. Methods. A retrospective review of 156 patients undergoing elective and emergent operations of the thoracic aorta over the past 7 years was performed. Seventy-five patients underwent proximal aortic procedures: 22 with ascending aneurysms, 45 with type A dissections, and 8 with arch reconstructions. Eighty-one patients underwent descending thoracic or thoracoabdominal procedures: 26 with Crawford type I aneurysms, 18 with type II, 8 with type III, 8 with type IV, 11 with traumatic transections, and 10 with type B dissections. Outcomes measured were neurologic injury, renal failure, and mortality. Results. For proximal aortic procedures, the stroke rate was 12% using cardiopulmonary bypass and 48% using hypothermic circulatory arrest. The addition of retrograde cerebral perfusion decreased the stroke rate to 0% (p < 0.01) and the mortality rate to 7.1% compared with 37% for hypothermic circulatory arrest (p < 0.05). For thoracic and thoracoabdominal aortic operations, straight cross-clamping resulted in a 27% rate of spinal cord injury and a 24% rate of renal failure, whereas the addition of distal aortic bypass resulted in a statistically significant reduction (p < 0.01) in neurologic injury to 7% and a notable, but not statistically significant, decrease in renal failure to 13%. Distal aortic bypass also reduced the mortality rate from 22% to 7% (p < 0.05). Conclusions. Retrograde cerebral perfusion decreases the stroke rate and mortality rate in proximal aortic operations and distal aortic perfusion decreases the rates of neurologic injury, renal failure, and mortality in thoracoabdominal aortic operations.		BAVARIA, JE (corresponding author), HOSP UNIV PENN,DEPT SURG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.						BORST HG, 1994, J THORAC CARDIOV SUR, V107, P126; BORST HG, 1991, SEMIN THORAC CARDIOV, V3, P334; CABROL CE, 1990, SEMIN THORAC CARDIOV, V3, P177; COOLEY DA, 1981, ANN THORAC SURG, V32, P260, DOI 10.1016/S0003-4975(10)61048-X; CRAWFORD ES, 1989, J THORAC CARDIOV SUR, V98, P659; CRAWFORD ES, 1981, ANN SURG, V194, P180, DOI 10.1097/00000658-198108000-00012; CRAWFORD ES, 1990, SEMIN TTHORAC CARDIO, V3, P194; DAVIS EA, 1992, ANN THORAC SURG, V53, P402, DOI 10.1016/0003-4975(92)90258-6; FEHRENBACHER JW, 1993, J VASC SURG, V18, P366, DOI 10.1016/0741-5214(93)90253-I; GRIEPP RB, 1975, J THORAC CARDIOV SUR, V70, P1051; GRIEPP RB, 1990, SEMIN THORAC CARDIOV, V3, P188; HIGGINS RSD, 1992, ARCH SURG-CHICAGO, V127, P516; HOLLIER LH, 1992, AM J SURG, V164, P210, DOI 10.1016/S0002-9610(05)81072-4; KAZUI T, 1992, ANN THORAC SURG, V53, P190; LIVESAY JJ, 1982, CIRCULATION, V66, P122; MASSIMO CG, 1993, ANN THORAC SURG, V56, P1110, DOI 10.1016/0003-4975(95)90026-8; MILLS NL, 1980, J THORAC CARDIOV SUR, V80, P708; NOJIMA T, 1994, AORTIC SURGERY S, V4; SAFI HJ, 1993, ANN THORAC SURG, V56, P270, DOI 10.1016/0003-4975(93)91158-J; SAFI HJ, 1994, AORTIC SURGERY S, V4; SVENSSON LG, 1993, J THORAC CARDIOV SUR, V106, P19, DOI 10.1016/S0022-5223(19)33737-7; UEDA U, 1988, J JPN ASS THOR SURG, V36, P161; UEDA Y, 1992, EUR J CARDIO-THORAC, V6, P36, DOI 10.1016/1010-7940(92)90096-G; USUI A, 1994, J THORAC CARDIOV SUR, V107, P1228, DOI 10.1016/S0022-5223(94)70042-7; USUI A, 1994, J THORAC CARDIOV SUR, V107, P300; USUI A, 1992, ANN THORAC SURG, V53, P47, DOI 10.1016/0003-4975(92)90756-T; VERDANT A, 1992, CAN J SURG, V35, P493; WADOUH F, 1992, THORAC CARDIOV SURG, V40, P26, DOI 10.1055/s-2007-1020106; YASUURA K, 1992, ANN THORAC SURG, V53, P655, DOI 10.1016/0003-4975(92)90328-2; YASUURA K, 1994, J THORAC CARDIOV SUR, V107, P1237, DOI 10.1016/S0022-5223(94)70043-5	30	56	57	1	2	ELSEVIER SCIENCE PUBL CO INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	AUG	1995	60	2					345	353		10.1016/0003-4975(95)00447-S			9	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	RQ583	WOS:A1995RQ58300018	7646094				2021-06-18	
J	BOHNEN, NI; JOLLES, J; TWIJNSTRA, A; MELLINK, R; WIJNEN, G				BOHNEN, NI; JOLLES, J; TWIJNSTRA, A; MELLINK, R; WIJNEN, G			LATE NEUROBEHAVIORAL SYMPTOMS AFTER MILD HEAD-INJURY	BRAIN INJURY			English	Article							CONCUSSION	The present study examined whether patients (n = 11) with post-concussional symptoms (PCS) 12-34 months after mild head injury (MHI) performed less well on selected neuropsychological tests than patients with MHI without PCS (n = 11) and healthy controls (n = 11). Patients with PCS were individually matched with controls for the time elapsed after the injury, age, sex, education and IQ. There were no overall gross differences between the groups in cognitive functioning, except for an isolated deficit on a sustained attention task. Post-hoc analysis of results obtained with two behavioural rating scales showed that patients with higher ratings on a post-concussive/cognitive complaints scale performed less well on a sustained attention task than subjects with lower ratings.	UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS							BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BRAND N, 1985, J GEN PSYCHOL, V112, P201, DOI 10.1080/00221309.1985.9711004; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GENTILINI M, 1989, MILD HEAD INJURY, P163; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luteijn F., 1983, Handleiding Groninger Intelligentie Test [Manual Groningen Intelligence Test]; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; NOVICK MR, 1966, J MATH PSYCHOL, V3, P1, DOI 10.1016/0022-2496(66)90002-2; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Verhage R, 1964, THESIS ASSEN; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 1985, SAS USERS GUIDE STAT	23	56	56	0	0	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1995	9	1					27	33		10.3109/02699059509004568			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QB052	WOS:A1995QB05200004	7874093				2021-06-18	
J	FAKHOURY, T; ABOUKHALIL, B; PEGUERO, E				FAKHOURY, T; ABOUKHALIL, B; PEGUERO, E			DIFFERENTIATING CLINICAL-FEATURES OF RIGHT AND LEFT TEMPORAL-LOBE SEIZURES	EPILEPSIA			English	Article						TEMPORAL LOBE EPILEPSY; SEIZURE SEMIOLOGY; COMPLEX PARTIAL SEIZURES; ELECTROENCEPHALOGRAPHY CLOSED-CIRCUIT VIDEO MONITORING	COMPLEX PARTIAL SEIZURES; EPILEPTIC SEIZURES; LOCALIZING VALUE; HEAD-INJURY; LATERALIZATION; CONSCIOUSNESS; SPEECH; AURAS	We reviewed 127 seizures in 19 consecutive patients with temporal lobe epilepsy (TLE) documented by EEG/closed-circuit TV (EEG-CCTV) monitoring. Ten patients had seizure onset in the right temporal lobe (RTL, 54 seizures), and 9 had seizure onset in the left temporal lobe (LTL, 73 seizures). We compared the clinical characteristics in the two groups and analyzed the seizures for frequency of auras, seizures secondarily generalized, automatisms, tonic head deviation, focal posturing and jerking, ictal speech, and postical manifestations. Automatisms overall were more common in the RTL group, but individual categories (extremity, head and trunk, oroalimentary) were comparable among the two groups. Contralateral focal jerking and tonic head deviation were more common in LTL lobe seizures, as were secondarily generalized seizures. In addition to focal motor symptoms, three features were most statistically significant in distinguishing the two groups: Postictal aphasia occurred exclusively in the LTL group, whereas well-formed ictal speech and rapid return to baseline postictally were noted only in RTL seizures.	VANDERBILT UNIV,MED CTR,DEPT NEUROL,NASHVILLE,TN 37212							ALBERT ML, 1976, ARCH NEUROL-CHICAGO, V33, P453, DOI 10.1001/archneur.1976.00500060059013; BERKOVIC SF, 1991, ANN NEUROL, V29, P175, DOI 10.1002/ana.410290210; CURRIE S, 1971, BRAIN, V94, P173, DOI 10.1093/brain/94.1.173; ENGEL J, 1987, SURGICAL TREATMENT E, P75; Engel Jr J, 1987, SURG TREATMENT EPILE, P553; GABR M, 1989, ANN NEUROL, V25, P82, DOI 10.1002/ana.410250113; GUPTA AK, 1983, J NEUROL NEUROSUR PS, V46, P1079, DOI 10.1136/jnnp.46.12.1079; JACKSON JH, 1931, SELECTED WRITINGS J, V1, P464; KING DW, 1977, ANN NEUROL, V2, P138, DOI 10.1002/ana.410020209; KOERNER M, 1988, NEUROLOGY, V38, P634, DOI 10.1212/WNL.38.4.634; KOTAGAL P, 1992, EPILEPSY SURGERY, P143; KOTAGAL P, 1989, NEUROLOGY, V39, P196, DOI 10.1212/WNL.39.2.196; KRAMER RE, 1988, NEUROLOGY, V38, P1048, DOI 10.1212/WNL.38.7.1048; LEVIN HS, 1989, LANCET, V1, P1001; LUDERS H, 1991, BRAIN, V114, P743, DOI 10.1093/brain/114.2.743; MALDONADO HM, 1988, EPILEPSIA, V29, P420, DOI 10.1111/j.1528-1157.1988.tb03741.x; MCLACHLAN RS, 1987, NEUROLOGY, V37, P1617, DOI 10.1212/WNL.37.10.1617; MITCHELL WG, 1983, ARCH NEUROL-CHICAGO, V40, P251, DOI 10.1001/archneur.1983.04050040081017; OCHS R, 1984, NEUROLOGY, V34, P884, DOI 10.1212/WNL.34.7.884; PALMINI A, 1992, NEUROLOGY, V42, P801, DOI 10.1212/WNL.42.4.801; PRIVITERA MD, 1991, ANN NEUROL, V30, P391, DOI 10.1002/ana.410300311; QUESNEY LF, 1986, EPILEPSIA, V27, pS27, DOI 10.1111/j.1528-1157.1986.tb05738.x; ROBILLARD A, 1983, NEUROLOGY, V33, P1241, DOI 10.1212/WNL.33.9.1241; ROSADINI G, 1967, BRAIN, V90, P101, DOI 10.1093/brain/90.1.101; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SCHWARTZ B, 1967, ACTA NEUROL SCAND, V43, P513, DOI 10.1111/j.1600-0404.1967.tb05757.x; SERAFETINIDES EA, 1963, BRAIN, V86, P333, DOI 10.1093/brain/86.2.333; SERAFETINIDES EA, 1965, BRAIN, V88, P107, DOI 10.1093/brain/88.1.107; TAYLOR DC, 1987, J NEUROL NEUROSUR PS, V50, P673, DOI 10.1136/jnnp.50.6.673; THEODORE WH, 1983, NEUROLOGY, V53, P1115; WADA JA, 1982, ADV EPILEPTOL, P365; Wieser HG, 1986, RECENT ADV EPILEPSY, P57; WYLLIE E, 1986, NEUROLOGY, V36, P606, DOI 10.1212/WNL.36.5.606	33	56	57	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0013-9580			EPILEPSIA	Epilepsia	SEP-OCT	1994	35	5					1038	1044		10.1111/j.1528-1157.1994.tb02552.x			7	Clinical Neurology	Neurosciences & Neurology	PP612	WOS:A1994PP61200020	7925149				2021-06-18	
J	TANIGUCHI, MH; MOYER, RS				TANIGUCHI, MH; MOYER, RS			ASSESSMENT OF RISK-FACTORS FOR PNEUMONIA IN DYSPHAGIC CHILDREN - SIGNIFICANCE OF VIDEOFLUOROSCOPIC SWALLOWING EVALUATION	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							ASPIRATION PNEUMONIA; ACID ASPIRATION; GASTROESOPHAGEAL REFLUX; PULMONARY ASPIRATION; NOSOCOMIAL PNEUMONIA; DISORDERS; TUBES; GASTROSTOMY; DISEASE; VOLUME	The purpose of this study was to investigate the relationship between aspiration, as identified by videofluoroscopic swallowing (VFS) study, and pneumonia in children with suspected dysphagia. Data were retrospectively collected and analysed from 142 children referred for VFS over a one-year period. The median age was 33 months. Aspiration was identified in 44 per cent of the children studied. A history of pneumonia within one year of the VFS was found in 35 per cent. Aspiration, gastro-oesophageal reflux, and age one year or less were significant risk factors for pneumonia. Children with traumatic brain-injury were at less risk for pneumonia than all other children with suspected dysphagia. These results lend objective support to the previously suspected relationship between aspiration and pneumonia in this patient population.	OHIO STATE UNIV,SCH MED,COLUMBUS,OH	TANIGUCHI, MH (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PHYS MED & REHABIL,500 BOYNTON HLTH SERV SKYWAY,420 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.						ALESSI DM, 1986, OTOLARYNG HEAD NECK, V94, P486, DOI 10.1177/019459988609400414; BARISH CF, 1985, ARCH INTERN MED, V145, P1882, DOI 10.1001/archinte.145.10.1882; BOSCOE MJ, 1984, BRIT MED J, V289, P1421, DOI 10.1136/bmj.289.6456.1421; BROWNING DH, 1983, J PEDIATR-US, V102, P582, DOI 10.1016/S0022-3476(83)80191-7; BUI HD, 1989, AM J MENT RETARD, V94, P16; CHEN MYM, 1990, RADIOLOGY, V176, P641, DOI 10.1148/radiology.176.3.2389021; CHOKSHI SK, 1986, AM FAM PHYSICIAN, V33, P195; COGEN R, 1989, AM J GASTROENTEROL, V84, P1509; DEMEESTER TR, 1990, ANN SURG, V211, P337, DOI 10.1097/00000658-199003000-00005; GILBERT RW, 1987, ANN OTO RHINOL LARYN, V96, P561, DOI 10.1177/000348948709600516; GOITEIN KJ, 1984, CRIT CARE MED, V12, P19, DOI 10.1097/00003246-198401000-00005; GRIGGS CA, 1989, DEV MED CHILD NEUROL, V31, P303; HARKNESS GA, 1990, AM J MED, V89, P457, DOI 10.1016/0002-9343(90)90376-O; HORNER J, 1988, NEUROLOGY, V38, P1359; HORNER J, 1988, NEUROLOGY, V38, P317, DOI 10.1212/WNL.38.2.317; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JAMES CF, 1984, ANESTH ANALG, V63, P665; KENNEDY TP, 1989, ANESTH ANALG, V69, P87; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; LINDEN T, 1989, Biotechnology Techniques, V3, P189, DOI 10.1007/BF01875618; Logemann J. A., 1983, EVALUATION TREATMENT; MACFADYEN UM, 1983, ARCH DIS CHILD, V58, P87, DOI 10.1136/adc.58.2.87; MANCHIKANTI L, 1985, ANESTH ANALG, V64, P11; METHENY NA, 1986, HEART LUNG, V15, P256; NASH M, 1988, OTOLARYNG CLIN N AM, V21, P701; RAIDOO DM, 1990, BRIT J ANAESTH, V65, P248, DOI 10.1093/bja/65.2.248; RUSSIN SJ, 1989, POSTGRAD MED, V85, P159; SHAPIRO MS, 1989, CLIN CHEST MED, V10, P617; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; Terry P B, 1989, Dysphagia, V3, P179, DOI 10.1007/BF02407220; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; VEIS SL, 1985, ARCH PHYS MED REHAB, V66, P372	32	56	57	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUN	1994	36	6					495	502					8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	NM358	WOS:A1994NM35800005	8005360				2021-06-18	
J	LEVIN, LA; JOSEPH, MP; RIZZO, JF; LESSELL, S				LEVIN, LA; JOSEPH, MP; RIZZO, JF; LESSELL, S			OPTIC CANAL DECOMPRESSION IN INDIRECT OPTIC-NERVE TRAUMA	OPHTHALMOLOGY			English	Article								Background: The proper management of neurogenic visual loss after blunt head trauma is controversial. Non-treatment, corticosteroids, and surgical decompression of the optic canal are all currently considered to be reasonable alternatives. The goal of this study was to identify factors affecting improvement in patients treated with canal decompression. Methods: A retrospective analysis of 31 cases in which transethmoidal decompression of the optic canal had been performed for neurogenic visual loss after closed head trauma was conducted. Each patient was alert and free of injury to the globe when evaluated before surgery. Surgery was performed within 6 days of injury, and all were given perioperative steroids. Results: Visual acuity improved in 22 (71%) patients, with 6 (19%) regaining visual acuity of 20/40 or better. The mean improvement from preoperative visual deficit was 42.0% +/- 6.6%, with a median improvement of 45.2%. Both univariate and multivariate analysis suggested that vision improved more in patients who were younger than 40 years of age than in patients who were 40 years of age or older. Interval between injury and surgery, preoperative visual acuity, and the presence of optic canal fracture did not affect outcome. Conclusion: Any future randomized trials of therapy should stratify patients based on age. Enrollment of patients with no light perception or who experienced delay between injury and treatment may be reasonably considered.	MASSACHUSETTS EYE & EAR INFIRM, DEPT OPHTHALMOL, NEUROOPHTHALMOL UNIT, BOSTON, MA 02114 USA							ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; COSTA VP, 1993, OPHTHALMOLOGY, V100, P599; Gottlob I, 1990, J Pediatr Ophthalmol Strabismus, V27, P40; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; JOSEPH MP, 1990, ARCH OPHTHALMOL-CHIC, V108, P1091, DOI 10.1001/archopht.1990.01070100047032; Kertesz A, 1984, Adv Neurol, V42, P23; KLINE LB, 1984, NEUROSURGERY, V14, P756, DOI 10.1227/00006123-198406000-00021; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; LUDWIN SK, 1980, LAB INVEST, V43, P382; Reinvang I, 1984, Adv Neurol, V42, P13; SPOOR TC, 1990, AM J OPHTHALMOL, V110, P665, DOI 10.1016/S0002-9394(14)77065-5; Walsh F, 1969, CLIN NEUROOPHTHALMOL; Winer BJ., 1971, STAT PRINCIPLES EXPT	13	56	62	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0161-6420	1549-4713		OPHTHALMOLOGY	Ophthalmology	MAR	1994	101	3					566	569					4	Ophthalmology	Ophthalmology	NB220	WOS:A1994NB22000032	8127578				2021-06-18	
J	BORGENS, RB; TOOMBS, JP; BLIGHT, AR; MCGINNIS, ME; BAUER, MS; WIDMER, WR; COOK, JR				BORGENS, RB; TOOMBS, JP; BLIGHT, AR; MCGINNIS, ME; BAUER, MS; WIDMER, WR; COOK, JR			EFFECTS OF APPLIED ELECTRIC-FIELDS ON CLINICAL CASES OF COMPLETE PARAPLEGIA IN DOGS	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						SPINAL CORD; REGENERATION; ELECTRIC FIELD; PARAPLEGIA; BEHAVIORAL RECOVERY; NEUROTRAUMA	SPINAL-CORD INJURY; IMPROVES NEUROLOGIC RECOVERY; DIRECT-CURRENT STIMULATION; MOTOR-EVOKED-POTENTIALS; GUINEA-PIG; CONTROLLED TRIAL; CHICK-EMBRYO; METHYLPREDNISOLONE; NALOXONE; TRAUMA	A clinical trial of applied, slowly oscillating, weak electric fields was performed in dogs with naturally occurring spinal cord injuries due to intervertebral disc herniation. Criteria for admission to the study were: complete paraplegia, defined by neurological examination and electrophysiological testing; intact segmental reflexes; radiologic and myelographic evidence of spinal cord compression due to disc herniation and a focal lesion, without appreciable rostrocaudal spread of necrosis; weight less than 16 kg; onset of paralysis less than 1 month before surgery. The injured cord was exposed by laminectomy, and decompressed by aspiration of disc material. Active (n = 13) or sham (n = 11) stimulators were implanted subcutaneously, with platinum/iridium electrodes sutured to muscle several millimeters above the cord surface, at either end of the laminectomy site. Active stimulators delivered 200 muA of direct current, switching polarity every 15 min, for 3, 6, or 15 weeks. Neurological and electrophysiological examinations were repeated approximately 6 weeks and 6 months after implantation. Few complications were noted. None were attributable to current application. The group of dogs with active stimulators showed greater improvement in function than the group with sham implants, with a trend towards greater recovery in all neurological measures, and evoked potentials. The combined neurological score derived from these separate tests was significantly different from controls at 6 weeks and 6 months (P < 0.05). Application of slowly oscillating electric fields thus appears to be beneficial in the treatment of paraplegia in dogs.	PURDUE UNIV,SCH VET MED,DEPT VET CLIN SCI,W LAFAYETTE,IN 47907	BORGENS, RB (corresponding author), PURDUE UNIV,SCH VET MED,DEPT ANAT,1244 CTR PARALYSIS RES,W LAFAYETTE,IN 47907, USA.						ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; Anderson S.M., 1991, CALIFORNIA VET, V45, P24; BLACK P, 1971, Surgical Forum (Chicago), V22, P409; Blight AR, 1991, J NEUROTRAUM, V8, P103, DOI 10.1089/neu.1991.8.103; BLIGHT AR, 1990, J COMP NEUROL, V296, P614, DOI 10.1002/cne.902960408; Borgens R.B., 1989, ELECTRIC FIELDS VERT, P77; BORGENS RB, 1981, SCIENCE, V213, P611, DOI 10.1126/science.7256258; BORGENS RB, 1986, J COMP NEUROL, V250, P168, DOI 10.1002/cne.902500204; BORGENS RB, 1987, SCIENCE, V238, P366, DOI 10.1126/science.3659920; BORGENS RB, 1990, J COMP NEUROL, V296, P634, DOI 10.1002/cne.902960409; Borgens RB, 1989, ELECTRIC FIELDS VERT, P117; BORGENS RB, 1992, SPINAL CORD DYSFUNCT, V3, P110; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BREZILE JE, 1968, J COMP NEUROL, V133, P373; BRIGHTON CT, 1984, ORTHOP CLIN N AM, V15, P1; BROWN NO, 1977, J AM ANIM HOSP ASSOC, V13, P665; COOK JR, 1990, AM J VET RES, V51, P1340; DWYER AF, 1974, MED J AUSTRALIA, V1, P73; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FEHLINGS MG, 1988, J NEUROSURG, V68, P781, DOI 10.3171/jns.1988.68.5.0781; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FUNKQUIST B., 1962, ACTA VET SCAND, V3, P344; GAMBARDELLA PC, 1980, VET SURG, V9, P24, DOI 10.1111/j.1532-950X.1980.tb01647.x; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; Hansebout R R, 1975, Surg Neurol, V4, P531; HANSEBOUT RR, 1982, EARLY MANAGEMENT ACU, P181; HANSEN H J, 1952, Acta Orthop Scand Suppl, V11, P1; Henry W B, 1975, J AM ANIM HOSP ASSOC, V11, P627; HINKLE L, 1981, J PHYSIOL-LONDON, V314, P121, DOI 10.1113/jphysiol.1981.sp013695; HOERLEIN BF, 1979, J AM ANIM HOSP ASSOC, V15, P535; HOERLEIN BF, 1978, J AM ANIM HOSP ASSOC, V14, P563; HOERLEIN BF, 1985, JAAHA, V21, P68; HOTARY KB, 1992, DEVELOPMENT, V114, P985; HOTARY KB, 1990, DEV BIOL, V140, P149, DOI 10.1016/0012-1606(90)90062-N; HURLBERT R J, 1990, Society for Neuroscience Abstracts, V16, P1115; JAFFE LF, 1977, ANNU REV BIOPHYS BIO, V6, P445, DOI 10.1146/annurev.bb.06.060177.002305; JAFFE LF, 1981, PHILOS T ROY SOC B, V295, P553, DOI 10.1098/rstb.1981.0160; KENNARD MA, 1954, J COMP NEUROL, V100, P511, DOI 10.1002/cne.901000304; LAVINE LS, 1987, J BONE JOINT SURG AM, V69A, P626, DOI 10.2106/00004623-198769040-00024; LEVY WJ, 1984, NEUROSURGERY, V15, P214, DOI 10.1227/00006123-198408000-00011; MCCAIG CD, 1986, J PHYSIOL-LONDON, V375, P55, DOI 10.1113/jphysiol.1986.sp016105; MCCAIG CD, 1987, DEVELOPMENT, V100, P31; MCCAIG CD, 1986, J EMBRYOL EXP MORPH, V94, P245; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; NUCCITELLI R, 1988, ADV CELL BIOL, V2, P213, DOI DOI 10.1016/S1569-2558(08)60435-X; PATEL N, 1982, J NEUROSCI, V2, P483; PRATA RG, 1981, J AM ANIM HOSP ASSOC, V17, P17; ROEDERER E, 1983, J NEUROSCI, V3, P153; SALZMAN SK, 1990, BRAIN RES, V521, P33, DOI 10.1016/0006-8993(90)91521-H; SHORES A, 1987, AM J VET RES, V48, P1525; STRAUTMAN AF, 1990, J NEUROSCI, V10, P3564; TARLOV IM, 1957, SPINAL CORD COMPRESS, P1; TATOR CH, 1973, J NEUROSURG, V39, P52, DOI 10.3171/jns.1973.39.1.0052; WALLACE MC, 1987, NEUROSURGERY, V20, P878; Young W, 1988, Clin Neurosurg, V34, P675; YOUNG W, 1985, CENTRAL NERVOUS SYST, P463	59	56	58	3	7	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.	SEP	1993	5	5-6					305	322					18	Neurosciences	Neurosciences & Neurology	MB152	WOS:A1993MB15200001	21551717				2021-06-18	
J	CLIFTON, GL; KREUTZER, JS; CHOI, SC; DEVANY, CW; EISENBERG, HM; FOULKES, MA; JANE, JA; MARMAROU, A; MARSHALL, LF				CLIFTON, GL; KREUTZER, JS; CHOI, SC; DEVANY, CW; EISENBERG, HM; FOULKES, MA; JANE, JA; MARMAROU, A; MARSHALL, LF			RELATIONSHIP BETWEEN GLASGOW OUTCOME SCALE AND NEUROPSYCHOLOGICAL MEASURES AFTER BRAIN INJURY	NEUROSURGERY			English	Article						BRAIN INJURY; GLASGOW OUTCOME SCALE; NEUROPSYCHOLOGICAL EXAMINATION	SEVERE HEAD-INJURY; REHABILITATION; RECOVERY; PREDICTION	THE PRESENT STUDY was conducted to further our understanding of the relationship between performance on neuropsychological tests and functional status after head injury and to provide information on the relative usefulness of neuropsychological tests as outcome measures in clinical trials of brain injury. We sought to select the fewest number of 19 neuropsychological tests administered to 110 patients that, in combination, were most closely related to outcome (as measured by the Glasgow Outcome Scale (GOS) and to the remaining neuropsychological measures. The relationship of memory and intellectual deficits to functional status was also considered. To address these questions, we analyzed 19 neuropsychological measures and GOS scores of 110 severely brain injured patients from the Traumatic Coma Data Bank. Of 19 neuropsychological measures compared with GOS at 3 and 6 months, four tests (Controlled Oral Word Association, Grooved Pegboard, Trailmaking Part B, and Rey-Osterrieth Complex Figure Delayed Recall) provided the closest relationship to GOS and to the remaining 15 tests. Similar analyses were performed on 30 moderately injured patients to test the generality of our findings across different levels of patient severity. The same four tests were found to be highly predictive of GOS. Grooved Pegboard, a test of fine motor coordination, accounted for 80% of the variation in GOS. Fifteen percent of 116 patients with severe brain injury could not complete a neuropsychological battery and 39% were excluded because of previous brain injury or known substance abuse.	UNIV CALIF SAN DIEGO,SAN DIEGO HEAD INJURY CTR,SAN DIEGO,CA 92103; UNIV VIRGINIA,DEPT NEUROSURG,CHARLOTTESVILLE,VA 22903; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT REHABIL MED,DIV NEUROL SURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOSTAT,RICHMOND,VA 23298; UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550; NINCDS,BETHESDA,MD 20892	CLIFTON, GL (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT NEUROSURG,6431 FANNIN ST,SUITE 7-148,HOUSTON,TX 77030, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032341, N01NS032339, N01NS032340] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS-3-2340, N01-NS-3-2339, N01-NS-3-2341] Funding Source: Medline		ANDERSON TP, 1974, ARCH PHYS MED REHAB, V55, P544; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BENYISHA.Y, 1970, J CONSULT CLIN PSYCH, V34, P436, DOI 10.1037/h0029366; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; GILBERSTADT H, 1968, J GERONTOL, V23, P483, DOI 10.1093/geronj/23.4.483; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; LEHMANN JF, 1975, ARCH PHYS MED REHAB, V56, P383; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P63; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LORENZE EJ, 1963, ARCH PHYS MED REHAB, V43, P514; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MCSWEENY AJ, 1985, J CLIN EXP NEUROPSYC, V7, P281, DOI 10.1080/01688638508401260; REITAN RM, 1985, HALSTEAD REITAN NEUR, P10; SUNDET K, 1988, J CLIN EXP NEUROPSYC, V10, P363, DOI 10.1080/01688638808408245; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; THOMAS RL, 1988, TOXIC CONTAMINATION, V3, P1	20	56	57	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUL	1993	33	1					34	39					6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LK123	WOS:A1993LK12300005	8355845				2021-06-18	
J	CHAPLIN, D; DEITZ, J; JAFFE, KM				CHAPLIN, D; DEITZ, J; JAFFE, KM			MOTOR-PERFORMANCE IN CHILDREN AFTER TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; MOTOR PERFORMANCE; PEDIATRIC REHABILITATION	HEAD-INJURY		UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT NEUROL SURG,SEATTLE,WA 98195	CHAPLIN, D (corresponding author), CHILDRENS HOSP & MED CTR,DIV OCCUPAT THERAPY,4800 SAND POINT WAY NE,POB C5371,SEATTLE,WA 98105, USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [2S07RR05655-17] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S07RR005655] Funding Source: NIH RePORTER		BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BROWN BW, 1977, STATISTICS BIOMEDICA, P232; BRUININKS RH, 1977, BRUININKS OSERETSKY; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; CRATTY B, 1975, REMEDIAL MOTOR ACTIV, P12; ESPENSCHADE A, 1980, MOTOR DEV, P210; GODFREY K, 1985, NEW ENGL J MED, V313, P1450, DOI 10.1056/NEJM198512053132305; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; OAKLAND T, 1985, 9TH MENTAL MEASUREME, P1142; TEASDALE G, 1974, LANCET, V2, P81; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218	14	56	56	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1993	74	2					161	164					4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	KL171	WOS:A1993KL17100009	8431100				2021-06-18	
J	LEVIN, HS				LEVIN, HS			TREATMENT OF POSTCONCUSSIONAL SYMPTOMS WITH CDP-CHOLINE	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	MEETING ON PHARMACOLOGY OF TRAUMATIC BRAIN INJURY	JUN 22-23, 1990	TOLEDO, SPAIN	WORLD FEDERAT NEUROL				To evaluate the efficacy of cytidine diphosphoryl choline (CDP-choline) in treating postconcussional symptoms for one month after mild to moderate closed head injury (CHI), we completed a preliminary double blind placebo-controlled study. Fourteen young men admitted to the neurosurgery service after sustaining mild to moderate CHI were randomized to oral CDP-choline (1 g) and placebo control groupswhich were matched for age, education and severity of impaired consciousness. Baseline (prior to discharge) and one month examinations consisted of a structured postconcussional symptom interview and neuropsychological tests. Results (Wilcoxon test) showed that CDP-choline produced a greater reduction of postconcussional symptoms than placebo (P < 0.005). Analysis of the neuropsychological findings revealed a significantly greater improvement in recognition memory for designs in the CDP-choline treated patients (P < 0.02) whereas other changes in test performance did not differ for the two groups. Pending replication in a larger series of patients, our findings suggest that CDP-choline may be effective in treating sequelae of mild to moderate CHI.		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.							0	56	58	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUL	1991	103			S			S39	S42					4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GF379	WOS:A1991GF37900007	1940965				2021-06-18	
J	Mamik, MK; Power, C				Mamik, Manmeet K.; Power, Christopher			Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts	BRAIN			English	Article						inflammasome; interleukin-1beta; caspase-1; ASC; pyroptosis	CENTRAL-NERVOUS-SYSTEM; INHIBITS NLRP3 INFLAMMASOME; SMALL-MOLECULE INHIBITOR; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; MULTIPLE-SCLEROSIS; INTERLEUKIN-1-BETA PRODUCTION; RECEPTOR ANTAGONIST; ALZHEIMERS-DISEASE; PERIPHERAL-BLOOD	Inflammasome activation in the central nervous system occurs in both health and disease. Inflammasomes are cytosolic protein complexes that sense specific infectious or host stimuli and initiate inflammatory responses through caspase activation. Assembly of inflammasomes results in caspase-1-mediated proteolytic cleavage and release of the pro-inflammatory cytokines, interleukin-1 beta and interleukin-18, with initiation of pyroptosis, an inflammatory programmed cell death. Recent developments in the inflammasome field have uncovered novel molecular mechanisms that contribute to a broad range of neurological disorders including those associated with specific mutations in inflammasome genes as well as diseases modulated by inflammasome activation. This update focuses on recent developments in the field of inflammasome biology highlighting different inflammasome activators and pathways discovered in the nervous system. We also discuss targeted therapies that regulate inflammasomes and improve neurological outcomes.	[Mamik, Manmeet K.; Power, Christopher] Univ Alberta, Dept Med, Div Nephrol, Edmonton, AB, Canada; [Power, Christopher] Univ Alberta, Neurosci & Mental Hlth Inst, Edmonton, AB, Canada	Power, C (corresponding author), Univ Alberta, Heritage Med Res Ctr 611, Dept Med, Edmonton, AB T6G 2S2, Canada.; Power, C (corresponding author), Univ Alberta, Heritage Med Res Ctr 611, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada.	chris.power@ualberta.ca			Alberta Innovates-Health Solution; Campus Alberta Neuroscience; Canada Research Chair in Neurological Infection and ImmunityCanada Research Chairs; Alberta Innovates [201400453] Funding Source: researchfish	M.K.M. is supported by fellowships from Alberta Innovates-Health Solution and Campus Alberta Neuroscience. C.P. is supported by a Canada Research Chair in Neurological Infection and Immunity.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alcocer-Gomez E, 2014, BRAIN BEHAV IMMUN, V36, P111, DOI 10.1016/j.bbi.2013.10.017; Ayna G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040069; Bandyopadhyay S, 2013, BIOCHEM BIOPH RES CO, V439, P407, DOI 10.1016/j.bbrc.2013.08.056; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Bartlett R, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/271813; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Biragyn A, 2008, J LEUKOCYTE BIOL, V83, P998, DOI 10.1189/jlb.1007700; Blok DC, 2014, J INNATE IMMUN, V6, P542, DOI 10.1159/000358239; Branton WG, 2016, SCI REP-UK, V6, DOI 10.1038/srep37344; Bryant C, 2009, TRENDS CELL BIOL, V19, P455, DOI 10.1016/j.tcb.2009.06.002; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Bulau AM, 2014, P NATL ACAD SCI USA, V111, P2650, DOI 10.1073/pnas.1324140111; Burm SM, 2015, J NEUROSCI, V35, P678, DOI 10.1523/JNEUROSCI.2510-14.2015; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; Chakraborty A, 2013, J CLIN PHARMACOL, V53, P1240, DOI 10.1002/jcph.162; Chen LZ, 2014, BRAIN RES, V1566, P1, DOI 10.1016/j.brainres.2014.04.019; Cho MH, 2014, AUTOPHAGY, V10, P1761, DOI 10.4161/auto.29647; Claxton A, 2015, J ALZHEIMERS DIS, V44, P897, DOI 10.3233/JAD-141791; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Coll RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029539; Couturier J, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0477-y; Curto-Reyes V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133707; Dagenais M, 2012, CELL DEATH DIFFER, V19, P5, DOI 10.1038/cdd.2011.159; Debye B, 2018, BRAIN PATHOL, V28, P14, DOI 10.1111/bpa.12467; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Dinarello CA, 2007, EUR J IMMUNOL, V37, pS34, DOI 10.1002/eji.200737772; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dong LP, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/370804; Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Fann DYW, 2013, AGEING RES REV, V12, P941, DOI 10.1016/j.arr.2013.09.004; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Festoff BW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0670-z; Frank MG, 2015, BRAIN BEHAV IMMUN, V48, P1, DOI 10.1016/j.bbi.2015.03.010; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Furlan R, 1999, J NEUROL NEUROSUR PS, V67, P785, DOI 10.1136/jnnp.67.6.785; Galea J, 2018, J NEUROSURG, V128, P515, DOI 10.3171/2016.9.JNS16615; Geldhoff M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-358; Geng FY, 2016, NEUROIMMUNOMODULAT, V23, P122, DOI 10.1159/000445689; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Gong YN, 2010, CELL RES, V20, P1289, DOI 10.1038/cr.2010.135; Gougeon ML, 2017, J INTERN MED, V281, P433, DOI 10.1111/joim.12570; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Gustot A, 2015, BIOCHEM J, V471, P323, DOI 10.1042/BJ20150617; Hafner-Bratkovic I, 2012, CELL MOL LIFE SCI, V69, P4215, DOI 10.1007/s00018-012-1140-0; Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15; Han S, 2008, ARCH PHARM RES, V31, P67, DOI 10.1007/s12272-008-1122-9; Hanamsagar R, 2014, J NEUROCHEM, V129, P704, DOI 10.1111/jnc.12669; HAUSER SL, 1990, NEUROLOGY, V40, P1735, DOI 10.1212/WNL.40.11.1735; He Y, 2014, J BIOL CHEM, V289, P1142, DOI 10.1074/jbc.M113.515080; Heidary M, 2014, J NEUROL SCI, V343, P41, DOI 10.1016/j.jns.2014.05.013; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Hoogman M, 2007, J NEUROL NEUROSUR PS, V78, P1092, DOI 10.1136/jnnp.2006.110023; Howard C, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-94; Huang WX, 2004, MULT SCLER J, V10, P482, DOI 10.1191/1352458504ms1071oa; Inoue M, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002767; Italiani P, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-94; Jesus AA, 2014, ANNU REV MED, V65, P223, DOI 10.1146/annurev-med-061512-150641; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jones G, 2005, VIROLOGY, V334, P178, DOI 10.1016/j.virol.2005.01.027; Juliana C, 2010, J BIOL CHEM, V285, P9792, DOI 10.1074/jbc.M109.082305; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Kappos L, 2006, NEUROLOGY, V67, P944, DOI 10.1212/01.wnl.0000237994.95410.ce; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Kaushal V, 2015, CELL DEATH DIFFER, V22, P1676, DOI 10.1038/cdd.2015.16; Keystone EC, 2012, ANN RHEUM DIS, V71, P1630, DOI 10.1136/annrheumdis-2011-143578; Kim HK, 2016, J PSYCHIATR RES, V72, P43, DOI 10.1016/j.jpsychires.2015.10.015; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; Kita T, 2009, INT REV NEUROBIOL, V88, P43, DOI 10.1016/S0074-7742(09)88003-3; Kitley JL, 2010, NEUROLOGY, V74, P1267, DOI 10.1212/WNL.0b013e3181d9ed69; Kong XX, 2017, J NEUROSCI RES, V95, P1565, DOI 10.1002/jnr.24004; Kumar M, 2013, J VIROL, V87, P3655, DOI 10.1128/JVI.02667-12; Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Li Q, 2013, NEUROSCIENCE, V254, P230, DOI 10.1016/j.neuroscience.2013.09.028; Liao KC, 2013, INFECT IMMUN, V81, P570, DOI 10.1128/IAI.01003-12; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu L, 2014, NEUROBIOL AGING, V35, P309, DOI 10.1016/j.neurobiolaging.2013.08.016; Liu W, 2013, BIOCHEM PHARMACOL, V85, P1504, DOI 10.1016/j.bcp.2013.03.008; Lu M, 2014, NEUROBIOL AGING, V35, P421, DOI 10.1016/j.neurobiolaging.2013.08.015; Maier NK, 2015, J IMMUNOL, V194, P2776, DOI 10.4049/jimmunol.1401611; Maier NK, 2014, J IMMUNOL, V192, P763, DOI 10.4049/jimmunol.1301434; Malhotra S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0269-9; Mamik MK, 2017, J NEUROIMMUNE PHARM, V12, P233, DOI 10.1007/s11481-016-9708-3; Marchetti C, 2014, J CARDIOVASC PHARM, V63, P316, DOI 10.1097/FJC.0000000000000053; Maroso M, 2011, NEUROTHERAPEUTICS, V8, P304, DOI 10.1007/s13311-011-0039-z; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; Meng XF, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0212-5; Ming X, 2002, J NEUROL SCI, V197, P9, DOI 10.1016/S0022-510X(02)00030-8; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Momeni M, 2016, NORD J PSYCHIAT, V70, P280, DOI 10.3109/08039488.2015.1100328; Moretti S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004462; Mortimer L, 2016, NAT IMMUNOL, V17, P1176, DOI 10.1038/ni.3538; Munoz LS, 2016, SEMIN REPROD MED, V34, P273, DOI 10.1055/s-0036-1592066; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415; Netea MG, 2015, ANNU REV IMMUNOL, V33, P49, DOI 10.1146/annurev-immunol-032414-112306; Nomura J, 2015, J IMMUNOL, V195, P5718, DOI 10.4049/jimmunol.1402512; Nowakowski TJ, 2016, CELL STEM CELL, V18, P591, DOI 10.1016/j.stem.2016.03.012; Pan Y, 2014, BRAIN BEHAV IMMUN, V41, P90, DOI 10.1016/j.bbi.2014.04.007; Qu Y, 2009, J IMMUNOL, V182, P5052, DOI 10.4049/jimmunol.0802968; Rajamaki K, 2013, J BIOL CHEM, V288, P13410, DOI 10.1074/jbc.M112.426254; Ramaswamy V, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-152; Ramos HJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003039; Robaeys G, 2007, WORLD J GASTROENTERO, V13, P5736, DOI 10.3748/wjg.v13.i43.5736; Rogliani P, 2015, PULM PHARMACOL THER, V31, P15, DOI 10.1016/j.pupt.2015.01.005; Santoni G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0239-2; Saresella M, 2016, BRAIN BEHAV IMMUN, V57, P125, DOI 10.1016/j.bbi.2016.03.009; Saresella M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0088-1; Schrijver IA, 2001, BRAIN, V124, P1544, DOI 10.1093/brain/124.8.1544; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Sokolowska M, 2015, J IMMUNOL, V194, P5472, DOI 10.4049/jimmunol.1401343; Son MY, 2015, J PATHOL, V237, P98, DOI 10.1002/path.4551; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Steptoe A, 2007, BRAIN BEHAV IMMUN, V21, P901, DOI 10.1016/j.bbi.2007.03.011; Tan CC, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0233-0; Tan MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.348; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432; Tricarico PM, 2017, BIOCHEM BIOPH RES CO, V492, P597, DOI 10.1016/j.bbrc.2017.01.158; TYOR WR, 1993, NEUROLOGY, V43, P1002, DOI 10.1212/WNL.43.5.1002; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2012, J NEUROSCI, V32, P3058, DOI 10.1523/JNEUROSCI.4930-11.2012; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; van de Veerdonk FL, 2010, P NATL ACAD SCI USA, V107, P3030, DOI 10.1073/pnas.0914795107; Vasudeva K, 2015, J NEUROIMMUNOL, V283, P43, DOI 10.1016/j.jneuroim.2015.04.012; Vigano E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9761; Walsh JG, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-35; Wannamaker W, 2007, J PHARMACOL EXP THER, V321, P509, DOI 10.1124/jpet.106.111344; Weber MD, 2015, J NEUROSCI, V35, P316, DOI 10.1523/JNEUROSCI.3561-14.2015; Weber MD, 2013, BRAIN BEHAV IMMUN, V32, P112, DOI 10.1016/j.bbi.2013.03.004; Wesselingh SL, 1997, J NEUROIMMUNOL, V74, P1, DOI 10.1016/S0165-5728(96)00160-9; Wong ML, 2016, MOL PSYCHIATR, V21, P797, DOI 10.1038/mp.2016.46; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu PJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32405; Xing HQ, 2009, NEUROPATHOLOGY, V29, P433, DOI 10.1111/j.1440-1789.2008.00996.x; Xiong XY, 2015, TRANSL STROKE RES, V6, P339, DOI 10.1007/s12975-015-0402-1; Yang Z, 2015, MOL IMMUNOL, V65, P267, DOI 10.1016/j.molimm.2014.12.018; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zhou Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0094-3; Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695; Zwijnenburg PJG, 2003, J IMMUNOL, V170, P4724, DOI 10.4049/jimmunol.170.9.4724; Zwijnenburg RJG, 2001, J INFECT DIS, V183, P1143, DOI 10.1086/319271	155	55	61	1	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP	2017	140		9				2273	2285		10.1093/brain/awx133			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FF0PB	WOS:000408602500012	29050380	Bronze			2021-06-18	
J	Dreha-Kulaczewski, S; Joseph, AA; Merboldt, KD; Ludwig, HC; Gartner, J; Frahm, J				Dreha-Kulaczewski, Steffi; Joseph, Arun A.; Merboldt, Klaus-Dietmar; Ludwig, Hans-Christoph; Gaertner, Jutta; Frahm, Jens			Identification of the Upward Movement of Human CSF In Vivo and its Relation to the Brain Venous System	JOURNAL OF NEUROSCIENCE			English	Article						CSF; human; in vivo flow; phase-contrast real-time MRI; respiration	CEREBROSPINAL-FLUID MOVEMENT; FLOW MRI; RESPIRATION; DYNAMICS; RESOLUTION; PULSATION; CLEARANCE; TRANSPORT	CSF flux is involved in the pathophysiology of neurodegenerative diseases and cognitive impairment after traumatic brain injury, all hallmarked by the accumulation of cellular metabolic waste. Its effective disposal via various CSF routes has been demonstrated in animal models. In contrast, the CSF dynamics in humans are still poorly understood. Using novel real-time MRI, forced inspiration has been identified recently as a main driving force of CSF flow in the human brain. Exploiting technical advances toward real-time phase-contrast MRI, the current work analyzed directions, velocities, and volumes of human CSF flow within the brain aqueduct as part of the internal ventricular system and in the spinal canal during respiratory cycles. A consistent upward CSF movement toward the brain in response to forced inspiration was seen in all subjects at the aqueduct, in 11/12 subjects at thoracic level 2, and in 4/12 subjects at thoracic level 5. Concomitant analyses of CSF dynamics and cerebral venous blood flow, that is, in epidural veins at cervical level 3, uniquely demonstrated CSF and venous flow to be closely communicating cerebral fluid systems in which inspiration-induced downward flow of venous blood due to reduced intrathoracic pressure is counterbalanced by an upward movement of CSF. The results extend our understanding of human CSF flux and open important clinical implications, including concepts for drug delivery and new classifications and therapeutic options for various forms of hydrocephalus and idiopathic intracranial hypertension.	[Dreha-Kulaczewski, Steffi; Gaertner, Jutta] Univ Med Ctr Gottingen, Dept Pediat & Adolescent Med, Div Pediat Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany; [Ludwig, Hans-Christoph] Univ Med Ctr Gottingen, Dept Neurosurg, Div Pediat Neurosurg, D-37075 Gottingen, Germany; [Joseph, Arun A.; Merboldt, Klaus-Dietmar; Frahm, Jens] Biomed NMR Forsch GmbH, Max Planck Inst Biophys, D-37077 Gottingen, Germany; [Frahm, Jens] German Ctr Cardiovasc Res, Partner Site, Gottingen, Germany	Dreha-Kulaczewski, S (corresponding author), Univ Med Ctr Gottingen, Dept Pediat & Adolescent Med, Div Pediat Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.	sdreha@gwdg.de		Frahm, Jens/0000-0002-8279-884X; Ludwig, Hans/0000-0001-8744-9510	Dorothea Schloezer Program of the Georg-August-University Gottingen, Germany	The work was supported by the Dorothea Schloezer Program of the Georg-August-University Gottingen, Germany (S.D.-K.).	Baledent O, 2004, INVEST RADIOL, V39, P45, DOI 10.1097/01.rli.0000100892.87214.49; Chen LY, 2015, NEUROIMAGE, V122, P281, DOI 10.1016/j.neuroimage.2015.07.073; Chitiboi T, 2014, I S BIOMED IMAGING, P943, DOI 10.1109/ISBI.2014.6868027; Dreha-Kulaczewski S, 2015, J NEUROSCI, V35, P2485, DOI 10.1523/JNEUROSCI.3246-14.2015; DUBOULAY GH, 1966, BRIT J RADIOL, V39, P255, DOI 10.1259/0007-1285-39-460-255; Friese S, 2004, INVEST RADIOL, V39, P120, DOI 10.1097/01.rli.0000112089.66448.bd; Fu X, 2014, TOXICOL SCI, V139, P432, DOI 10.1093/toxsci/kfu048; GIDEON P, 1994, NEURORADIOLOGY, V36, P350, DOI 10.1007/BF00612116; GREITZ D, 1993, ACTA RADIOL, V34, P321; GREITZ D, 1992, NEURORADIOLOGY, V34, P370, DOI 10.1007/BF00596493; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Joseph A, 2014, J MAGN RESON IMAGING, V40, P206, DOI 10.1002/jmri.24328; Joseph AA, 2012, NMR BIOMED, V25, P917, DOI 10.1002/nbm.1812; Klose U, 2000, JMRI-J MAGN RESON IM, V11, P438, DOI 10.1002/(SICI)1522-2586(200004)11:4<438::AID-JMRI12>3.0.CO;2-O; Reitan H, 1941, ACTA RADIOL, V22, P762, DOI 10.3109/00016924109136456; Schaetz Sebastian, 2012, Algorithms and Architectures for Parallel Processing. Proceedings of the 12th International Conference, ICA3PP 2012, P114, DOI 10.1007/978-3-642-33078-0_9; Schwartz M, 2012, HUM VACC IMMUNOTHER, V8, P1465, DOI 10.4161/hv.21649; Spector R, 2007, J NEUROCHEM, V103, P425, DOI 10.1111/j.1471-4159.2007.04773.x; Stadlbauer A, 2010, NEUROIMAGE, V51, P42, DOI 10.1016/j.neuroimage.2010.01.110; Stringer MD, 2012, CLIN ANAT, V25, P609, DOI 10.1002/ca.21281; Uecker M, 2010, NMR BIOMED, V23, P986, DOI 10.1002/nbm.1585; Untenberger M, 2016, MAGN RESON MED, V75, P1901, DOI 10.1002/mrm.25696; WILLIAMS B, 1981, ACTA NEUROCHIR, V58, P167, DOI 10.1007/BF01407124; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xu Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep31787; Yamada S, 2008, RADIOLOGY, V249, P644, DOI 10.1148/radiol.2492071985; Yamada S, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-36; Zenker W, 1996, ANAT EMBRYOL, V193, P1	29	55	55	3	14	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	MAR 1	2017	37	9					2395	2402		10.1523/JNEUROSCI.2754-16.2017			8	Neurosciences	Neurosciences & Neurology	EP2BX	WOS:000397189100015	28137972	Bronze, Green Published			2021-06-18	
J	Fischer, M; Kehrberger, E; Marung, H; Moecke, H; Pruckner, S; Trentzsch, H; Urban, B				Fischer, M.; Kehrberger, E.; Marung, H.; Moecke, H.; Prueckner, S.; Trentzsch, H.; Urban, B.		Fachexperten Eckpunktepapier	The 2016 consensus document on emergency care for the general public during the pre-hospital phase and at the hospital	NOTFALL & RETTUNGSMEDIZIN			German	Article						Tracer diagnosis; Pre-hospital time; Structural planning; Quality management; Adequate Hospital	ACUTE MEDICINE; MAIN POINTS; POPULATION; PROJECT; DRAFT	The 2007 consensus document for emergency medical care (Eckpunktepapier) has defined a framework for structure and planning. The increasing demands for emergency medical care for the general public require the 2007 consensus document for to be updated and expanded. The results of the revision are presented in this article. The draft of the new Eckpunktepapier was developed at a symposium with representatives of the associations, institutions, and organisations involved in emergency medical care and was presented at a plenary session. In order to define the exact terminology of technical terms, a glossary was issued. In a two-tiered consencus process the documents were circulated for revision and finally approved. Thirty specialist associations, institutions and organisations participated in the consensus, and the approval rate of 96.7 % mirrors a strong consensus. The Eckpunktepapier 2016 contains recommendations for structural planning and emergency medical procedures in accordance with the applicable guidelines, and the need for a adequate hospital. In addition to the current tracer diagnoses severe traumatic brain injury, stroke, severely injured multiple trauma, and ST- elevation myocardial infarction, additional recommendations have been included for sudden cardiac death and sepsis. The process quality of the dispatch centre, requirements for diagnosis and therapy by emergency physician/paramedics, tactical approaches and time management, initial emergency medical treatment in the field and at the adequate hospital, as well as quality management instruments have in turn been taken into consideration. Also, the special requirements of paediatric patients are presented. Furthermore, the paper includes essential recommendations for the first link in the rescue chain (risk assessment, first aid and the emergency call). The 2016 Consensus Paper takes into account the entire emergency medical process chain from the occurrence of the emergency and when the emergency call is received, the care of the emergency physician/paramedics, through to the continuation of treatment in hospital, and serves as a guideline for the integrated planning of access-oriented emergency medical care.	[Fischer, M.; Kehrberger, E.] Arbeitsgemeinschaft Sudwestdeutscher Notarzte eV, Filderstadt, Germany; [Fischer, M.] Klin Eichert, Klin Anasthesiol Operat Intens Med Notfallmed & S, Goppingen, Germany; [Kehrberger, E.] Kreiskliniken Esslingen Paracelsus Krankenhaus, Klin Anasthesiol & Operat Intens Med, Ruit, Germany; [Marung, H.] Univ Klinikum Schleswig Holstein, Inst Rettungs & Notfallmed, Kiel, Germany; [Marung, H.; Moecke, H.] Asklepios Kliniken Harburg, Inst Notfallmed IfN, Hamburg, Germany; [Prueckner, S.; Trentzsch, H.; Urban, B.] Univ Munich, Klinikum Univ Munchen, INM, Schillerstr 53, D-80336 Munich, Germany	Pruckner, S (corresponding author), Univ Munich, Klinikum Univ Munchen, INM, Schillerstr 53, D-80336 Munich, Germany.	stephan.prueckner@med.uni-muenchen.de	Prueckner, Stephan/AAB-2280-2021; Trentzsch, Heiko/I-7679-2014; Trentzsch, Heiko/ABF-3979-2020	Prueckner, Stephan/0000-0002-5128-7625; Trentzsch, Heiko/0000-0002-6395-6873; 			Ahnefeld FW, 2008, NOTFALL RETTUNGSMED, V11, P421; Altemeyer KH, 2008, NOTFALL RETTUNGSMED, V11, P419, DOI 10.1007/s10049-008-1105-x; Landesarztekammer Bayerische, 2013, BAYERISCHES ARZTEBL, V68, P564	3	55	57	0	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1434-6222	1436-0578		NOTFALL RETTUNGSMED	Notfall Rettungsmed.	AUG	2016	19	5					387	395		10.1007/s10049-016-0187-0			9	Emergency Medicine	Emergency Medicine	DS3UE	WOS:000380707400013					2021-06-18	
J	Bhomia, M; Balakathiresan, NS; Wang, KK; Papa, L; Maheshwari, RK				Bhomia, Manish; Balakathiresan, Nagaraja S.; Wang, Kevin K.; Papa, Linda; Maheshwari, Radha K.			A Panel of Serum MiRNA Biomarkers for the Diagnosis of Severe to Mild Traumatic Brain Injury in Humans	SCIENTIFIC REPORTS			English	Article							FIBRILLARY ACIDIC PROTEIN; INTRACRANIAL LESIONS; NEUROSURGICAL INTERVENTION; POTENTIAL BIOMARKERS; MICRORNAS; DISEASES; MODERATE; PLASMA	MicroRNAs (MiRNAs) are small endogenous RNA molecules and have emerged as novel serum diagnostic biomarkers for several diseases due to their stability and detection at minute quantities. In this study, we have identified a serum miRNA signature in human serum samples of mild to severe TBI, which can be used for diagnosis of mild and moderate TBI (MMTBI). Human serum samples of MMTBI, severe TBI (STBI), orthopedic injury and healthy controls were used and miRNA profiling was done using taqman real time PCR. The real time PCR data for the MMTBI, STBI and orthopedic injury was normalized to the control samples which showed upregulation of 39, 37 and 33 miRNAs in MMTBI, STBI and orthopedic injury groups respectively. TBI groups were compared to orthopedic injury group and an up-regulation of 18 and 20 miRNAs in MMTBI and STBI groups was observed. Among these, a signature of 10 miRNAs was found to be present in both MMTBI and STBI groups. These 10 miRNAs were validated in cerebrospinal fluid (CSF) from STBI and four miRNAs were found to be upregulated in CSF. In conclusion, we identified a subset of 10 unique miRNAs which can be used for diagnosis of MMTBI and STBI.	[Bhomia, Manish; Balakathiresan, Nagaraja S.; Maheshwari, Radha K.] Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Wang, Kevin K.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL 32611 USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA	Bhomia, M (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	manish.bhomia.ctr@usuhs.edu	Balakathiresan, Nagaraja Sethuraman/O-3213-2019; Bhomia, Manish/C-7683-2015	Bhomia, Manish/0000-0003-2808-9927; Balakathiresan, Nagaraja Sethuraman/0000-0001-5756-6070; Wang, Kevin/0000-0002-9343-6473	defense medical research and development program (DMRDP)	The authors will like to thank Dr Claudia S. Robertson for her help in providing the STBI serum samples for this study. The authors also acknowledge Dr. Barbara Knollmann-Ritschel for her input into this study and careful review of the manuscript. The study was supported by a grant from defense medical research and development program (DMRDP) to Radha K. Maheshwari (Principal Investigator). The opinions expressed herein are those of authors and are not necessarily representative of those of the Uniformed Services University of the Health Sciences, Department of Defense or, the United States Army, Navy, or Air Force and DMRDP. The authors wish to dedicate this manuscript to Dr Radha K. Maheshwari, who passed away after the manuscript was submitted for review. He read and approved the initial version of the manuscript which was submitted for review.	Alevizos I, 2010, NAT REV RHEUMATOL, V6, P391, DOI 10.1038/nrrheum.2010.81; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Balakathiresan NS, 2014, J PSYCHIATR RES, V57, P65, DOI 10.1016/j.jpsychires.2014.05.020; Blondal T, 2013, METHODS, V59, pS1, DOI 10.1016/j.ymeth.2012.09.015; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Centers for Disease Control and Prevention, 2014, C TRAUM BRAIN INJ US; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jin XF, 2013, CELL MOL NEUROBIOL, V33, P601, DOI 10.1007/s10571-013-9940-9; Kelly JP, 1997, NEUROLOGY, V48, P581; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Nam JW, 2014, MOL CELL, V53, P1031, DOI 10.1016/j.molcel.2014.02.013; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Powers CJ, 2016, PHYSIOL GENOMICS, V48, P361, DOI 10.1152/physiolgenomics.00052.2015; Rao V, 2013, PSYCHOSOMATICS, V54, P403, DOI 10.1016/j.psym.2013.01.001; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Siddeek B, 2014, MUTAT RES-GEN TOX EN, V764, P46, DOI 10.1016/j.mrgentox.2014.01.010; Wang WX, 2015, EXP NEUROL, V265, P84, DOI 10.1016/j.expneurol.2014.12.018	30	55	58	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 24	2016	6								28148	10.1038/srep28148			12	Multidisciplinary Sciences	Science & Technology - Other Topics	DP4RK	WOS:000378483300001	27338832	DOAJ Gold, Green Published			2021-06-18	
J	Wang, YC; Reis, C; Applegate, R; Stier, G; Martin, R; Zhang, JH				Wang, Yuechun; Reis, Cesar; Applegate, Richard, II; Stier, Gary; Martin, Robert; Zhang, John H.			Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-stroke	EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	3rd Pangu Stroke Conference	OCT 10-12, 2014	Beijing, PEOPLES R CHINA			Innate cerebroprotection; Stroke; Ischemia; Preconditioning; Postconditioning; Perconditioning	ENDOPLASMIC-RETICULUM STRESS; FOCAL CEREBRAL-ISCHEMIA; GLIAL GLUTAMATE TRANSPORTER-1; ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; GERBIL HIPPOCAMPUS; GLOBAL-ISCHEMIA; RAT-BRAIN; TNF-ALPHA; BEHAVIORAL DEFICITS	In the area of brain injury and neurodegenerative diseases, a plethora of experimental and clinical evidence strongly indicates the promise of therapeutically exploiting the endogenous adaptive system at various levels like triggers, mediators and the end-effectors to stimulate and mobilize intrinsic protective capacities against brain injuries. It is believed that ischemic pre-conditioning and post-conditioning are actually the strongest known interventions to stimulate the innate neuroprotective mechanism to prevent or reverse neurodegenerative diseases including stroke and traumatic brain injury. Recently, studies showed the effectiveness of ischemic per-conditioning in some organs. Therefore the term ischemic conditioning, including all interventions applied pre-, per- and post-ischemia, which spans therapeutic windows in 3 time periods, has recently been broadly accepted by scientific communities. In addition, it is extensively acknowledged that ischemia-mediated protection not only affects the neurons but also all the components of the neurovascular network (consisting of neurons, glial cells, vascular endothelial cells, pericytes, smooth muscle cells, and venule/veins). The concept of cerebroprotection has been widely used in place of neuroprotection. Intensive studies on the cellular signaling pathways involved in ischemic conditioning have improved the mechanistic understanding of tolerance to cerebral ischemia. This has added impetus to exploration for potential pharmacologic mimetics, which could possibly induce and maximize inherent protective capacities. However, most of these studies were performed in rodents, and the efficacy of these mimetics remains to be evaluated in human patients. Several classical signaling pathways involving apoptosis, inflammation, or oxidation have been elaborated in the past decades. Newly characterized mechanisms are emerging with the advances in biotechnology and conceptual renewal. In this review we are going to focus on those recently reported methodological and mechanistic discoveries in the realm of ischemic conditioning. Due to the varied time differences of ischemic conditioning in different animal models and clinical trials, it is important to define optimal timing to achieve the best conditioning induced neuroprotection. This brings not only an opportunity in the treatment of stroke, but challenges as well, as data is just becoming available and the procedures are not yet optimized. The purpose of this review is to shed light on exploiting these ischemic conditioning modalities to protect the cerebrovascular system against diverse injuries and neurodegenerative disorders. (C) 2015 Elsevier Inc. All rights reserved.	[Wang, Yuechun; Zhang, John H.] Loma Linda Univ, Sch Med, Dept Physiol & Pharmacol, Loma Linda, CA 92354 USA; [Zhang, John H.] Loma Linda Univ, Sch Med, Dept Neurosurg, Loma Linda, CA 92354 USA; [Reis, Cesar; Applegate, Richard, II; Stier, Gary; Martin, Robert; Zhang, John H.] Loma Linda Univ, Med Ctr, Dept Anesthesiol, Loma Linda, CA 92354 USA; [Wang, Yuechun] Jinan Univ, Sch Med, Dept Physiol, Guangzhou, Guangdong, Peoples R China	Zhang, JH (corresponding author), Loma Linda Univ, Sch Med, Dept Anesthesiol, 11041 Campus St,Risley Hall,Room 219, Loma Linda, CA 92354 USA.	johnzhang3910@Yahoo.com		Applegate II, Richard/0000-0002-1454-4549	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043338, P01NS082184] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS082184, R01 NS043338] Funding Source: Medline		Abete P, 1997, J AM COLL CARDIOL, V30, P947, DOI 10.1016/S0735-1097(97)00256-8; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Andjelkovic AV, 2003, J CEREBR BLOOD F MET, V23, P1348, DOI 10.1097/01.WCB.0000091762.61714.FE; Ates E, 2002, TRANSPLANTATION, V74, P1247, DOI 10.1097/01.TP.0000032752.61372.36; AUCHAMPACH JA, 1992, CARDIOVASC RES, V26, P1054, DOI 10.1093/cvr/26.11.1054; Bacigaluppi Marco, 2010, Open Neurol J, V4, P34, DOI 10.2174/1874205X01004020034; Bahjat FR, 2013, TRANSL STROKE RES, V4, P89, DOI 10.1007/s12975-012-0223-4; Balduini W, 2009, AUTOPHAGY, V5, P221, DOI 10.4161/auto.5.2.7363; Bastide M, 2003, J CEREBR BLOOD F MET, V23, P399, DOI 10.1097/01.WCB.0000050064.57184.F2; Bell KFS, 2011, OXID MED CELL LONGEV, V2011, DOI 10.1155/2011/689524; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Bi Qi, 2011, Zhonghua Nei Ke Za Zhi, V50, P140; Bickler PE, 2009, NEUROSCIENCE, V160, P51, DOI 10.1016/j.neuroscience.2009.02.013; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bu QX, 2014, BRAIN RES, V1558, P100, DOI 10.1016/j.brainres.2014.02.034; Burda J, 2003, NEUROCHEM RES, V28, P1213, DOI 10.1023/A:1024232513106; Carloni S, 2008, NEUROBIOL DIS, V32, P329, DOI 10.1016/j.nbd.2008.07.022; Castillo J, 2003, ANN NEUROL, V54, P811, DOI 10.1002/ana.10765; Chen DD, 2014, TRANSL STROKE RES, V5, P156, DOI 10.1007/s12975-013-0320-z; Chen F, 2014, PROG NEUROBIOL, V115, P246, DOI 10.1016/j.pneurobio.2013.12.007; Chen Jiao-Jiao, 2008, Neurosci Bull, V24, P183, DOI 10.1007/s12264-008-0183-6; CHOI DW, 1987, J NEUROSCI, V7, P357; Connolly M, 2013, CLIN NEUROL NEUROSUR, V115, P2124, DOI 10.1016/j.clineuro.2013.07.038; Danielisova V, 2005, NEUROCHEM RES, V30, P559, DOI 10.1007/s11064-005-2690-4; Dave KR, 2005, J NEUROSCI RES, V82, P665, DOI 10.1002/jnr.20674; DeFazio RA, 2009, J CEREBR BLOOD F MET, V29, P375, DOI 10.1038/jcbfm.2008.126; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; del Zoppo GJ, 2000, THROMB RES, V98, pV73; Della-Morte D, 2009, NEUROSCIENCE, V159, P993, DOI 10.1016/j.neuroscience.2009.01.017; Della-Morte D, 2012, PHARMACOGENOMICS, V13, P1741, DOI [10.2217/PGS.12.157, 10.2217/pgs.12.157]; Deng J, 2014, PROG NEUROBIOL, V115, P210, DOI 10.1016/j.pneurobio.2014.01.001; Dezfulian C, 2013, TRANSL STROKE RES, V4, P19, DOI 10.1007/s12975-012-0224-3; Dhodda VK, 2004, J NEUROCHEM, V89, P73, DOI 10.1111/j.1471-4159.2004.02316.x; Ding YH, 2005, ACTA NEUROPATHOL, V109, P237, DOI 10.1007/s00401-004-0943-y; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Douen AG, 2000, J NEUROCHEM, V75, P812, DOI 10.1046/j.1471-4159.2000.0750812.x; Durukan Aysan, 2010, Exp Transl Stroke Med, V2, P2, DOI 10.1186/2040-7378-2-2; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Frassdorf J, 2009, J THORAC CARDIOV SUR, V137, P1436, DOI 10.1016/j.jtcvs.2008.04.034; Furuya K, 2005, J NEUROSURG, V103, P715, DOI 10.3171/jns.2005.103.4.0715; Gao B, 2013, ACTA PHARMACOL SIN, V34, P657, DOI 10.1038/aps.2013.34; Gao L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046092; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Ghiardi GJ, 1999, VISION RES, V39, P2519, DOI 10.1016/S0042-6989(99)00038-3; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Ginis I, 2002, J CEREBR BLOOD F MET, V22, P142, DOI 10.1097/00004647-200202000-00002; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P39, DOI 10.1016/0304-3940(91)90889-2; Go AS, 2013, CIRCULATION, V127, P143, DOI 10.1161/CIR.0b013e318282ab8f; Gong SJ, 2012, NEUROCHEM RES, V37, P527, DOI 10.1007/s11064-011-0639-3; Gonzalez NR, 2013, ACTA NEUROCHIR SUPPL, V115, P193, DOI 10.1007/978-3-7091-1192-5_36; Hahn CD, 2011, STROKE, V42, P2960, DOI 10.1161/STROKEAHA.111.622340; Halkos ME, 2004, ANN THORAC SURG, V78, P961, DOI 10.1016/j.athoracsur.2004.03.033; Hao L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/468748; Hashiguchi A, 2004, J CEREBR BLOOD F MET, V24, P271, DOI 10.1097/01.WCB.0000110539.96047.FC; Hayakawa K, 2010, J CEREBR BLOOD F MET, V30, P871, DOI 10.1038/jcbfm.2009.257; Hayes K, 2008, ACTA NEUROPATHOL, V115, P289, DOI 10.1007/s00401-008-0340-z; He Z, 2005, CURR NEUROVASC RES, V2, P365, DOI 10.2174/156720205774962674; Hebert DN, 2007, PHYSIOL REV, V87, P1377, DOI 10.1152/physrev.00050.2006; Hepponstall M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048284; Hoda MN, 2014, TRANSL STROKE RES, V5, P484, DOI 10.1007/s12975-013-0318-6; Hong YK, 2004, FASEB J, V18, P1111, DOI 10.1096/fj.03-1179fje; Hu BR, 1999, NEUROSCIENCE, V89, P437, DOI 10.1016/S0306-4522(98)00352-2; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Huber R, 1999, NEUROREPORT, V10, P1543, DOI 10.1097/00001756-199905140-00027; Igarashi Y, 1999, BIOCHEM BIOPH RES CO, V261, P108, DOI 10.1006/bbrc.1999.0992; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jiang T, 2015, MOL NEUROBIOL, V51, P220, DOI 10.1007/s12035-014-8725-6; Jneid H, 2005, CARDIOVASC DRUG THER, V19, P211, DOI 10.1007/s10557-005-2466-8; Johnson WD, 2011, FOOD CHEM TOXICOL, V49, P3319, DOI 10.1016/j.fct.2011.08.023; Kariko K, 2004, J CEREBR BLOOD F MET, V24, P1288, DOI 10.1097/01.WCB.0000145666.68576.71; KATO H, 1992, BRAIN RES BULL, V29, P395, DOI 10.1016/0361-9230(92)90074-8; KATO H, 1992, BRAIN RES BULL, V29, P559, DOI 10.1016/0361-9230(92)90123-F; KATO H, 1992, NEUROSCI LETT, V139, P118, DOI 10.1016/0304-3940(92)90871-4; Keep RF, 2014, TRANSL STROKE RES, V5, P535, DOI 10.1007/s12975-014-0363-9; Kharbanda RK, 2002, CIRCULATION, V106, P2881, DOI 10.1161/01.CIR.0000043806.51912.9B; Kim EJ, 2008, J CEREBR BLOOD F MET, V28, P1329, DOI 10.1038/jcbfm.2008.26; KITAGAWA K, 1991, BRAIN RES, V561, P203, DOI 10.1016/0006-8993(91)91596-S; Koch S, 2014, J CEREBR BLOOD F MET, V34, P933, DOI 10.1038/jcbfm.2014.42; Koch S, 2013, TRANSL STROKE RES, V4, P15, DOI 10.1007/s12975-012-0220-7; Koch S, 2013, TRANSL STROKE RES, V4, P1, DOI 10.1007/s12975-012-0252-z; Koch S, 2012, STROKE, V43, P1455, DOI 10.1161/STROKEAHA.111.646919; Koch S, 2011, STROKE, V42, P1387, DOI 10.1161/STROKEAHA.110.605840; Koch S, 2010, TRANSL STROKE RES, V1, P161, DOI 10.1007/s12975-010-0025-5; Koch Sebastian, 2007, J Stroke Cerebrovasc Dis, V16, P114, DOI 10.1016/j.jstrokecerebrovasdis.2007.01.002; Koike M, 2008, AM J PATHOL, V172, P454, DOI 10.2353/ajpath.2008.070876; Kondo T, 1996, NEUROSCI LETT, V208, P101, DOI 10.1016/0304-3940(96)12555-6; Konstantinov IE, 2004, PHYSIOL GENOMICS, V19, P143, DOI 10.1152/physiolgenomics.00046.2004; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kunze A, 2014, TRANSL STROKE RES, V5, P569, DOI 10.1007/s12975-014-0337-y; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Lalancette-Hebert M, 2012, J NEUROSCI, V32, P10383, DOI 10.1523/JNEUROSCI.1498-12.2012; Lange-Asschenfeldt C, 2004, J CEREBR BLOOD F MET, V24, P636, DOI 10.1097/01.WCB.0000121235.42748.BF; Lavignon M, 1992, Antisense Res Dev, V2, P315; Lee S. R., 2014, TRANSL STROKE RES; Lehotsky J, 2004, GEN PHYSIOL BIOPHYS, V23, P401; Lehotsky J, 2002, FRONT BIOSCI-LANDMRK, V7, pD53, DOI 10.2741/lehotsky; Lehotsky J, 2002, GEN PHYSIOL BIOPHYS, V21, P31; Lehotsky J, 2009, ANAT REC, V292, P2002, DOI 10.1002/ar.20970; Leng TD, 2014, PROG NEUROBIOL, V115, P189, DOI 10.1016/j.pneurobio.2013.12.008; Li WJ, 2006, J CEREBR BLOOD F MET, V26, P181, DOI 10.1038/sj.jcbfm.9600180; Lin HW, 2011, ANTIOXID REDOX SIGN, V14, P1853, DOI 10.1089/ars.2010.3467; Lipton P, 1999, PHYSIOL REV, V79, P1431; Liu AJ, 2011, J NEUROCHEM, V119, P202, DOI 10.1111/j.1471-4159.2011.07396.x; Liu C, 2005, NEUROSCIENCE, V134, P69, DOI 10.1016/j.neuroscience.2005.03.036; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144; Liu JL, 2014, PROG NEUROBIOL, V115, P138, DOI 10.1016/j.pneurobio.2013.11.004; Liu XR, 2014, TRANSL STROKE RES, V5, P692, DOI 10.1007/s12975-014-0359-5; Liu XQ, 2009, ACTA PHARMACOL SIN, V30, P1071, DOI 10.1038/aps.2009.105; Liu XH, 2007, BIOCHEM BIOPH RES CO, V359, P628, DOI 10.1016/j.bbrc.2007.05.129; Liu YH, 2006, CAN J ANAESTH, V53, P194, DOI 10.1007/BF03021827; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Lorgis L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048513; Luo TF, 2013, TRANSL STROKE RES, V4, P581, DOI 10.1007/s12975-013-0299-5; Ma J., 2012, COCHRANE DB SYST REV, V9; Maag RS, 2003, CURR OPIN CELL BIOL, V15, P456, DOI 10.1016/S0955-0674(03)00075-9; Mangoni AA, 2010, PHARMACOEPIDEM DR S, V19, P490, DOI 10.1002/pds.1945; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Meller R, 2013, TRANSL STROKE RES, V4, P40, DOI 10.1007/s12975-012-0246-x; Meng R, 2012, NEUROLOGY, V79, P1853, DOI 10.1212/WNL.0b013e318271f76a; Mergenthaler P, 2011, J PHYSIOL-LONDON, V589, P4147, DOI 10.1113/jphysiol.2011.209718; Moncayo J, 2000, NEUROLOGY, V54, P2089, DOI 10.1212/WNL.54.11.2089; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nakajima T, 2002, NEUROSCI LETT, V331, P13, DOI 10.1016/S0304-3940(02)00752-8; Nakajima T, 2004, J VET MED SCI, V66, P521, DOI 10.1292/jvms.66.521; Nakamura H, 2006, LIFE SCI, V78, P1713, DOI 10.1016/j.lfs.2005.08.008; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Narayanan SV, 2013, CURR OPIN NEUROL, V26, P1, DOI 10.1097/WCO.0b013e32835bf200; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Nepal S, 2013, BBA-MOL CELL RES, V1833, P2111, DOI 10.1016/j.bbamcr.2013.05.013; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; Obrenovitch TP, 2008, PHYSIOL REV, V88, P211, DOI 10.1152/physrev.00039.2006; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; Otani H, 2008, ANTIOXID REDOX SIGN, V10, P207, DOI 10.1089/ars.2007.1679; Ovbiagele B, 2013, STROKE, V44, P2361, DOI 10.1161/STR.0b013e31829734f2; Park JA, 2003, BIOCHEM BIOPH RES CO, V311, P247, DOI 10.1016/j.bbrc.2003.09.129; Pauly M, 2012, AM J PATHOL, V181, P583, DOI 10.1016/j.ajpath.2012.04.004; Pavlikova M, 2009, CELL MOL NEUROBIOL, V29, P909, DOI 10.1007/s10571-009-9374-6; Perez-Pinzon MA, 1999, NEUROSCIENCE, V89, P453, DOI 10.1016/S0306-4522(98)00560-0; Perez-Pinzon MA, 2007, COMP BIOCHEM PHYS A, V147, P291, DOI 10.1016/j.cbpa.2006.08.032; Perez-Pinzon MA, 2012, J CEREBR BLOOD F MET, V32, P1362, DOI 10.1038/jcbfm.2012.32; PerezPinzon MA, 1996, NEUROSCIENCE, V75, P687; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; Petcu EB, 2008, CURR NEUROVASC RES, V5, P214, DOI 10.2174/156720208786413424; Petegnief V, 2013, TRANSL STROKE RES, V4, P663, DOI 10.1007/s12975-013-0277-y; Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4; Pignataro G, 2008, J CEREBR BLOOD F MET, V28, P232, DOI 10.1038/sj.jcbfm.9600559; Pignataro G, 2014, TRANSL STROKE RES, V5, P145, DOI 10.1007/s12975-013-0308-8; Plamondon H, 1999, J CEREBR BLOOD F MET, V19, P1296, DOI 10.1097/00004647-199912000-00002; Puisieux F, 2000, EUR J PHARMACOL, V389, P71, DOI 10.1016/S0014-2999(99)00893-6; Quinn R, 2005, NUTRITION, V21, P775, DOI 10.1016/j.nut.2005.04.002; Rabinovich GA, 2009, NAT REV IMMUNOL, V9, P338, DOI 10.1038/nri2536; Racay P, 2007, NEUROCHEM RES, V32, P1823, DOI 10.1007/s11064-007-9437-3; Racay P, 2009, CELL MOL NEUROBIOL, V29, P901, DOI 10.1007/s10571-009-9373-7; Rami A, 2008, NEUROBIOL DIS, V29, P132, DOI 10.1016/j.nbd.2007.08.005; Ramzy D, 2006, CARDIOVASC RES, V70, P174, DOI 10.1016/j.cardiores.2006.01.020; Raval AP, 2003, J NEUROSCI, V23, P384; Rehni AK, 2007, PHARMACOL REP, V59, P192; Reshef A, 1996, BRAIN RES, V741, P252, DOI 10.1016/S0006-8993(96)00939-0; Riepe MW, 1997, STROKE, V28, P2006, DOI 10.1161/01.STR.28.10.2006; Romera C, 2007, J CEREBR BLOOD F MET, V27, P1327, DOI 10.1038/sj.jcbfm.9600438; Rosenzweig HL, 2004, STROKE, V35, P2576, DOI 10.1161/01.STR.0000143450.04438.ae; Rotshenker S, 2003, J MOL NEUROSCI, V21, P65, DOI 10.1385/JMN:21:1:65; Satoh K, 2011, BRAIN RES, V1382, P266, DOI 10.1016/j.brainres.2011.01.049; Schultz JE, 1997, J MOL CELL CARDIOL, V29, P1055, DOI 10.1006/jmcc.1996.0358; SCHURR A, 1986, BRAIN RES, V374, P244, DOI 10.1016/0006-8993(86)90418-X; Schwartz Longacre L, 2011, CIRCULATION, V124, P1172, DOI 10.1161/CIRCULATIONAHA.111.032698; Seifert HA, 2014, TRANSL STROKE RES, V5, P543, DOI 10.1007/s12975-014-0349-7; Sepulveda MR, 2008, MOL CELL NEUROSCI, V38, P461, DOI 10.1016/j.mcn.2008.02.012; Shah NH, 2014, TRANSL STROKE RES, V5, P38, DOI 10.1007/s12975-013-0297-7; Shao B, 2012, CURR DRUG TARGETS, V13, P188, DOI 10.2174/138945012799201702; Sheng R, 2012, AUTOPHAGY, V8, P310, DOI 10.4161/auto.18673; Sheng R, 2010, AUTOPHAGY, V6, P482, DOI 10.4161/auto.6.4.11737; SOMMER C, 1995, BRAIN PATHOL, V5, P135, DOI 10.1111/j.1750-3639.1995.tb00587.x; Sommer C, 2003, ACTA NEUROPATHOL, V105, P197, DOI 10.1007/s00401-002-0632-7; Sommer C, 2002, STROKE, V33, P1698, DOI 10.1161/01.STR.0000016404.14407.77; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Stenzel-Poore MP, 2003, LANCET, V362, P1028, DOI 10.1016/S0140-6736(03)14412-1; Stroev S A, 2009, Neurosci Behav Physiol, V39, P1, DOI 10.1007/s11055-008-9091-5; Stroev SA, 2004, J NEUROSCI RES, V78, P563, DOI 10.1002/jnr.20282; Sun HS, 2013, ACTA PHARMACOL SIN, V34, P24, DOI 10.1038/aps.2012.138; Tanaka K, 2003, ANESTHESIOLOGY, V98, P935, DOI 10.1097/00000542-200304000-00021; Tang LH, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/107091; Tewari Anurag, 2014, J Anaesthesiol Clin Pharmacol, V30, P160, DOI 10.4103/0970-9185.130001; Urban P, 2009, CELL MOL NEUROBIOL, V29, P181, DOI 10.1007/s10571-008-9309-7; Urikova A, 2006, CELL MOL NEUROBIOL, V26, P1343, DOI 10.1007/s10571-006-9030-3; Vinten-Johansen J, 2011, J CARDIOVASC PHARM T, V16, P260, DOI 10.1177/1074248411415270; Voellmy R, 2004, PROG NUCLEIC ACID RE, V78, P143, DOI 10.1016/S0079-6603(04)78004-6; Wali B, 2014, BRAIN, V137, P486, DOI 10.1093/brain/awt319; Wang LT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079814; Wang MM, 2013, TRANSL STROKE RES, V4, P3, DOI 10.1007/s12975-012-0219-0; Wang X, 2014, NEUROSCIENCE, V274, P393, DOI 10.1016/j.neuroscience.2014.05.053; Warzecha Z, 2007, J PHYSIOL PHARMACOL, V58, P303; Wegener S, 2004, STROKE, V35, P616, DOI 10.1161/01.STR.0000115767.17923.6A; Wei K, 2012, CNS NEUROSCI THER, V18, P879, DOI 10.1111/cns.12005; Wei N, 2013, CNS NEUROSCI THER, V19, P753, DOI 10.1111/cns.12123; Wen YD, 2008, AUTOPHAGY, V4, P762, DOI 10.4161/auto.6412; Wick A, 2002, J NEUROSCI, V22, P6401; Willis CL, 2004, GLIA, V45, P325, DOI 10.1002/glia.10333; Wootton LL, 2004, BBA-BIOMEMBRANES, V1664, P189, DOI 10.1016/j.bbamem.2004.05.009; Wu JC, 2006, ACTA BIOCH BIOPH SIN, V38, P219, DOI 10.1111/j.1745-7270.2006.00156.x; Xie ZL, 2011, DIABETES, V60, P1770, DOI 10.2337/db10-0351; Yokobori S, 2013, TRANSL STROKE RES, V4, P25, DOI 10.1007/s12975-012-0226-1; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zaouali MA, 2013, J PINEAL RES, V55, P65, DOI 10.1111/jpi.12051; Zemke D, 2004, NEUROTOXICOLOGY, V25, P895, DOI 10.1016/j.neuro.2004.03.009; Zhang J, 2012, COCHRANE DB SYST REV, V5; Zhang Y, 2001, LIFE SCI, V68, P1013, DOI 10.1016/S0024-3205(00)01004-3; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhao L, 2006, J CEREBR BLOOD F MET, V26, P1128, DOI 10.1038/sj.jcbfm.9600269; Zheng S, 2003, NEUROSCIENCE, V118, P99, DOI 10.1016/S0306-4522(02)00767-4; Zheng SQ, 2004, MOL PHARMACOL, V65, P1172, DOI 10.1124/mol.65.5.1172; Zhou AM, 2004, NEUROSCI RES, V48, P397, DOI 10.1016/j.neures.2003.12.010; Zhou YL, 2011, STROKE, V42, P439, DOI 10.1161/STROKEAHA.110.592162	218	55	59	0	20	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2015	272				SI		26	40		10.1016/j.expneurol.2015.04.009			15	Neurosciences	Neurosciences & Neurology	CV6AS	WOS:000364353700005	25900056	Green Accepted			2021-06-18	
J	Junge, A; Dvorak, J				Junge, Astrid; Dvorak, Jiri			Football injuries during the 2014 FIFA World Cup	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PRECOMPETITION MEDICAL ASSESSMENT; DATA-COLLECTION PROCEDURES; SPORTS INJURIES; CONSENSUS STATEMENT; ATHLETICS CHAMPIONSHIPS; ELITE FOOTBALL; SURVEILLANCE; ILLNESSES; DEFINITIONS; PLAYERS	Background FIFA has surveyed match injuries in its tournaments since 1998. Aim To analyse the incidence and characteristics of match injuries incurred during the 2014 FIFA World Cup in comparison to previous FIFA World Cups. Methods The chief physicians of the participating teams reported all newly incurred injuries of their players after the match on a standardised report form. 124 (97%) forms were returned. Results A total of 104 injuries were reported, equivalent to an incidence of 1.68 injuries per match (95% CI 1.36 to 2.00). 64 (63.4%) injuries were caused by contact with another player. Thigh (26; 25%) and head (19; 18%) were the most frequently injured body parts. The most frequent diagnosis was thigh strain (n=18). Five concussions and three fractures to the head were reported. While most thigh strains (15/17; 88.2%) occurred without contact, almost all head injuries (18/19; 94.7%) were caused by contact. 0.97 injuries per match (95% CI 0.72 to 1.22) were expected to result in absence from training or match. Eight injuries were classified as severe. The incidence of match injuries in the 2014 FIFA World Cup was significantly lower than the average of the four preceding FIFA World Cups, both for all injuries (2.34; 95% CI 2.15 to 2.53) and time-loss injuries (1.51; 95% CI 1.37 to 1.65). Conclusions The overall incidence of injury during the FIFA World Cups decreased from 2002 to 2014 by 37%. A detailed analysis of the injury mechanism is recommended to further improve prevention strategies.	[Junge, Astrid; Dvorak, Jiri] FIFA Med Assessment & Res Ctr F MARC, Zurich, Switzerland; [Junge, Astrid; Dvorak, Jiri] Schulthess Klin, Zurich, Switzerland; [Junge, Astrid] MSH, Hamburg, Germany; [Dvorak, Jiri] FIFA, Zurich, Switzerland	Dvorak, J (corresponding author), F MARC, Schulthess Klin, Lengghalde 2, CH-8008 Zurich, Switzerland.	Medical@FIFA.org		Junge, Astrid/0000-0002-6815-9793	FIFA	This study was funded by FIFA.	Arnason A, 2008, SCAND J MED SCI SPOR, V18, P40, DOI 10.1111/j.1600-0838.2006.00634.x; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2006.034579; Dvorak J, 2013, BRIT J SPORT MED, V47, P1199, DOI 10.1136/bjsports-2013-092767; Dvorak J, 2012, BRIT J SPORT MED, V46, P1132, DOI 10.1136/bjsports-2011-090374; Dvorak J, 2011, BRIT J SPORT MED, V45, P626, DOI 10.1136/bjsm.2010.079905; Dvorak J, 2009, CLIN J SPORT MED, V19, P316, DOI 10.1097/JSM.0b013e3181b21b6e; Eirale C, 2013, J SCI MED SPORT, V16, P113, DOI 10.1016/j.jsams.2012.07.001; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Engebretsen L, 2013, BRIT J SPORT MED, V47, P407, DOI 10.1136/bjsports-2013-092380; Engebretsen L, 2010, BRIT J SPORT MED, V44, P772, DOI 10.1136/bjsm.2010.076992; Feddermann-Demont N, 2014, BRIT J SPORT MED, V48, P513, DOI 10.1136/bjsports-2013-093087; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2004, AM J SPORT MED, V32, p43S, DOI 10.1177/0363546503261248; Fuller CW, 2004, AM J SPORT MED, V32, p28S, DOI 10.1177/0363546503261247; Fuller CW, 2013, BRIT J SPORT MED, V47, P1184, DOI 10.1136/bjsports-2012-091155; Fuller CW, 2012, BRIT J SPORT MED, V46, P11, DOI 10.1136/bjsports-2011-090634; Fuller CW, 2006, BRIT J SPORT MED, V40, P193, DOI 10.1136/bjsm.2005.025270; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Goldman EF, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006782.pub2; Junge A, 2008, BRIT J SPORT MED, V42, P413, DOI 10.1136/bjsm.2008.046631; Junge A, 2004, AM J SPORT MED, V32, p80S, DOI 10.1177/0363546503261245; Junge A, 2004, AM J SPORT MED, V32, p23S, DOI 10.1177/0363546503261246; Junge A, 2013, BRIT J SPORT MED, V47, P782, DOI 10.1136/bjsports-2013-092205; Junge A, 2009, AM J SPORT MED, V37, P2165, DOI 10.1177/0363546509339357; Langevoort G, 2007, SCAND J MED SCI SPOR, V17, P400, DOI 10.1111/j.1600-0838.2006.00587.x; Alonso JM, 2009, CLIN J SPORT MED, V19, P26, DOI 10.1097/JSM.0b013e318191c8e7; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mountjoy M, 2010, BRIT J SPORT MED, V44, P522, DOI 10.1136/bjsm.2010.071720; Nichols Andrew W, 2013, Clin J Sport Med, V23, P85, DOI 10.1097/JSM.0b013e31827e9f40; Petersen J, 2011, AM J SPORT MED, V39, P2296, DOI 10.1177/0363546511419277; Timpka T, 2014, BRIT J SPORT MED, V48, P483, DOI 10.1136/bjsports-2013-093241; Tscholl P, 2007, BRIT J SPORT MED, V41, pI8, DOI 10.1136/bjsm.2007.036871; Tscholl P, 2007, BRIT J SPORT MED, V41, pI15, DOI 10.1136/bjsm.2007.036889; Walden M, 2005, SCAND J MED SCI SPOR, V15, P118, DOI 10.1111/j.1600-0838.2004.00393.x; Walden M, 2007, KNEE SURG SPORT TR A, V15, P1155, DOI 10.1007/s00167-007-0290-3; Yeung SS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001256.pub2, 10.1002/14651858.CD001256]	36	55	59	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2015	49	9					599	U58		10.1136/bjsports-2014-094469			5	Sport Sciences	Sport Sciences	CG0TZ	WOS:000352985700010	25878077	Green Published, Other Gold			2021-06-18	
J	Sugarman, MA; Axelrod, BN				Sugarman, Michael A.; Axelrod, Bradley N.			Embedded Measures of Performance Validity Using Verbal Fluency Tests in a Clinical Sample	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						logistic regression; malingering; COWAT; effort	TRAUMATIC BRAIN-INJURY; PATTERNS	The objective of this study was to determine to what extent verbal fluency measures can be used as performance validity indicators during neuropsychological evaluation. Participants were clinically referred for neuropsychological evaluation in an urban-based Veteran's Affairs hospital. Participants were placed into 2 groups based on their objectively evaluated effort on performance validity tests (PVTs). Individuals who exhibited credible performance (n=431) failed 0 PVTs, and those with poor effort (n=192) failed 2 or more PVTs. All participants completed the Controlled Oral Word Association Test (COWAT) and Animals verbal fluency measures. We evaluated how well verbal fluency scores could discriminate between the 2 groups. Raw scores and T scores for Animals discriminated between the credible performance and poor-effort groups with 90% specificity and greater than 40% sensitivity. COWAT scores had lower sensitivity for detecting poor effort. A combination of FAS and Animals scores into logistic regression models yielded acceptable group classification, with 90% specificity and greater than 44% sensitivity. Verbal fluency measures can yield adequate detection of poor effort during neuropsychological evaluation. We provide suggested cut points and logistic regression models for predicting the probability of poor effort in our clinical setting and offer suggested cutoff scores to optimize sensitivity and specificity.	[Sugarman, Michael A.; Axelrod, Bradley N.] John D Dingell Vet Affairs Med Hosp, Dept Psychol, Detroit, MI USA; [Sugarman, Michael A.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA	Sugarman, MA (corresponding author), Wayne State Univ, Dept Psychol, 7th Floor,5057 Woodward Ave, Detroit, MI 48202 USA.	Mike.Sugarman@wayne.edu					Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Backhaus SL, 2004, CLIN NEUROPSYCHOL, V18, P591, DOI 10.1080/13854040490888558; Benton AL, 1978, MULTILINGUAL APHASIA; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; Green, 2004, GREENS MED SYMPTOM V; Heaton RK, 2004, REVISED COMPREHENSIV; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Millis S. R., 2009, NEUROPSYCHOLOGY MALI, P21; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Schutte C, 2012, MILD TRAUMATIC BRAIN, P159; Silverberg ND, 2008, CLIN NEUROPSYCHOL, V22, P140, DOI 10.1080/13854040601160597; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tombaugh TN, 1996, TEST MEMORY MALINGER; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Wechsler, 1997, WAIS 3 WMS 3 TECHNIC; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed	23	55	56	1	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	2327-9095	2327-9109		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult	MAR 4	2015	22	2					141	146		10.1080/23279095.2013.873439			6	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	CC5DR	WOS:000350379400009	25153155				2021-06-18	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Adolescents Demonstrate Greater Gait Balance Control Deficits After Concussion Than Young Adults	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						cerebral concussion; postural balance; development; adolescence	SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; RECOVERY; ATTENTION; STABILITY; AGE; PERFORMANCE; STATEMENT; SYMPTOMS	Background: Age has been described as a factor that affects recovery after concussion. The recommended management protocol is to treat adolescents in a more cautious manner than adults. However, few studies have prospectively and longitudinally assessed the way these age groups perform on motor tasks after concussion. Purpose: To examine dual-task gait balance control deficits after concussion in a group of adolescents and young adults in reference to matched control subjects within 72 hours of injury and throughout 2 months after injury. Study Design: Cohort study; Level of evidence, 2. Methods: Adolescents and young adults who sustained a concussion and individually matched controls completed a whole-body motion gait analysis while simultaneously performing a cognitive task. Subjects with concussion reported to the laboratory within 72 hours after injury and at the following time points: 1 week, 2 weeks, 1 month, and 2 months after injury. Control subjects completed the same protocol at similar time points. Gait balance control measurements included whole-body center-of-mass (COM) medial-lateral displacement/velocity and anterior velocity. Results: A total of 38 subjects with concussion, 19 young adults (mean SD age, 20.3 +/- 2.4 years) and 19 adolescents (mean +/- SD age, 15.1 +/- 1.1 years), and 38 individually matched control subjects were tested. Within 72 hours of injury, adolescents displayed significantly greater COM medial-lateral displacement (P = .001) and peak velocity (P = .001) relative to their control group, and the young adult concussion group displayed significantly less peak COM anterior velocity than their control group (P = .01). Across the 2 months of testing, adolescents with concussion displayed significantly greater total COM medial-lateral displacement than did adolescent controls (P = .001), while young adults with concussion did not significantly differ from their matched controls (P = .07). Conclusion: An examination of gait balance control during dual-task walking revealed that after concussion, in reference to matched controls, adolescents demonstrated greater gait balance control deficits than did young adults initially and throughout the 2-month postinjury period, supporting the recommendation of conservative management for adolescents after concussion.	[Howell, David R.; Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA.	chou@uoregon.edu	Meijer, Anna/K-5118-2016	Howell, David/0000-0002-2955-0191	Veterans AdministrationUS Department of Veterans Affairs [A4842C8, A4843C]; Translational Research Award from the University of Oregon and Peace Health Oregon Region; Department of Defense-TATRC Award [W81XWH-11-1-0717]	This work was supported by Veterans Administration subcontract awards (A4842C8 and A4843C), the Translational Research Award from the University of Oregon and Peace Health Oregon Region, and the Department of Defense-TATRC Award (W81XWH-11-1-0717).	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Catena RD, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-8; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lee YM, 2013, J NEUROSURG-PEDIATR, V12, P537, DOI 10.3171/2013.7.PEDS12572; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; WOLTRING HJ, 1986, ADV ENG SOFTW WORKST, V8, P104, DOI 10.1016/0141-1195(86)90098-7	29	55	55	0	17	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2015	43	3					625	632		10.1177/0363546514560994			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CC6JP	WOS:000350471500015	25540297				2021-06-18	
J	Olenick, M; Flowers, M; Diaz, VJ				Olenick, Maria; Flowers, Monica; Diaz, Valerie J.			US veterans and their unique issues: enhancing health care professional awareness	ADVANCES IN MEDICAL EDUCATION AND PRACTICE			English	Article						veterans; veteran health care; veteran health issues; veteran content		United States veterans are a multifaceted population with a distinct culture that includes, but is not limited to, values, customs, ethos, selfless duty, codes of conduct, implicit patterns of communication, and obedience to command. Veterans experience mental health disorders, substance use disorders, post-traumatic stress, and traumatic brain injury at disproportionate rates compared to their civilian counterparts. Eighteen to 22 American veterans commit suicide daily and young veterans aged 18-44 are most at risk. Health care professionals must be aware of patients' military history and be able to recognize suicide-risk factors, regardless of age. Advancement in medical technology has allowed servicemen to survive their injuries but, for many, at the cost of a traumatic limb amputation and associated mental scarring. Health care professionals must be able to address physical safety concerns, as well as, emotional health of veterans. Approximately 49,933 American veterans are homeless and face the same difficulties as non-veterans in addition to service-related matters. Separation from military service and issues related to complex multiple deployments are among specifically identified veteran issues. Successful veteran reintegration into civilian life rests upon providing veterans with training that builds on their military knowledge and skill, employment post-separation from service, homelessness prevention, and mental health programs that promote civilian transition. Preparing health care providers to meet the complex needs of a vast veteran population can be facilitated by implementing veteran content into curricula that includes veteran patient simulations and case studies, and utilizes veteran clinical faculty.	[Olenick, Maria; Flowers, Monica; Diaz, Valerie J.] Florida Int Univ, Nicole Wertheim Coll Nursing & Hlth Sci, 11200 8th St,AHC3-329, Miami, FL 33199 USA; [Diaz, Valerie J.] US Navy, Nurse Corps, Operat Hlth Support Unit Jacksonville, Jacksonville, FL USA	Olenick, M (corresponding author), Florida Int Univ, Nicole Wertheim Coll Nursing & Hlth Sci, 11200 8th St,AHC3-329, Miami, FL 33199 USA.	molenick@fiu.edu	Olenick, maria/AAM-9991-2020		Division of Nursing and Public Health, Bureau of Health Workforce, Health Resources and Services Administration; Department of Health and Human Services, Veterans' Bachelor of Science Degree in Nursing Program (VBSN) [UF1HP26980]	This project was supported by funds from the Division of Nursing and Public Health, Bureau of Health Workforce, Health Resources and Services Administration. Department of Health and Human Services Grant UF1HP26980, Veterans' Bachelor of Science Degree in Nursing Program (VBSN).	American Academy of Colleges of Nursing (AACN) [homepage on the Internet], JOIN FORC ENH VET CA; [Anonymous], 2005, THERAPY PRACTICE; APA American Psychiatric Association, 2013, POSTTR STRESS DIS; Federation of American Scientists, 2015, GUID MIL CAS STAT OP; Fontana A, 2008, J NERV MENT DIS, V196, P513, DOI 10.1097/NMD.0b013e31817cf6e6; Institute of Medicine, 2014, VET AG OR UPD 2012; Johnson BS, 2013, AM J NURS, V113, P24, DOI 10.1097/01.NAJ.0000431913.50226.83; Kemp J, 2012, SUICIDE DATA REPORT; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; National Alliance on Mental Illness (NAMI), 2009, DEPR VET FACT SHEET; National Coalition for Homeless Veterans (NCHV), FAQ HOM VET; United States Department of Veterans Affairs, SEL VET HLTH ADM CHA; US Department of Veteran Affairs, UND TRAUM BRAIN INJ; US Department of Veteran Affairs, MIL EXP; US Department of Veteran Affairs [homepage on the Internet], VA HLTH CAR UT REC V; Veterans Health Administration, 2008, COLL CAR DEPR PRIM C	16	55	55	1	8	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1179-7258			ADV MED EDUC PRACT	Adv. Med. Educ. Pract.		2015	6						635	639		10.2147/AMEP.S89479			5	Education, Scientific Disciplines	Education & Educational Research	DA6BB	WOS:000367885600003	26664252	DOAJ Gold, Green Published			2021-06-18	
J	Assis, LC; Straliotto, MR; Engel, D; Hort, MA; Dutra, RC; De Bem, AF				Assis, L. C.; Straliotto, M. R.; Engel, D.; Hort, M. A.; Dutra, R. C.; De Bem, A. F.			beta-CARYOPHYLLENE PROTECTS THE C6 GLIOMA CELLS AGAINST GLUTAMATE-INDUCED EXCITOTOXICITY THROUGH THE NRF2 PATHWAY	NEUROSCIENCE			English	Article						beta-caryophyllene; C6 cell line; glutamate; Nrf2 pathway; CB2R	MITOCHONDRIAL PERMEABILITY TRANSITION; AMYOTROPHIC-LATERAL-SCLEROSIS; DEXTRAN SULFATE SODIUM; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; IN-VITRO; NEUROLOGICAL DISEASES; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; INDUCED APOPTOSIS	beta-Caryophyllene (BCP), a natural bicyclic sesquiterpene present in several essential oils, displays analgesic and anti-inflammatory properties in vitro and in vivo. Astrocytes are a major class of glial cells that regulate extracellular ion balance, repair and scarring processes in the CNS following neuroinflammatory conditions and traumatic injuries. This study sought to determine the protective effect of BCP against glutamate (Glu)-induced cytotoxicity in the C6 glioma cell line on neurochemical parameters as well as their biochemical mechanism. Glu increases intracellular reactive oxygen species (ROS) production and induces mitochondrial dysfunction as well as decreasing antioxidant defenses such as glutathione (GSH) and glutathione peroxidase activity. BCP prevented C6 cells from Glu-induced cytotoxicity by modulating the cellular antioxidant response, mainly by inhibiting ROS production and reestablishing the mitochondrial membrane potential (Delta Psi(m)). Moreover, BCP per se induced the nuclear translocation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) which was reflected by improvement in the cellular GSH antioxidant system. Taken together, our results suggest that cytoprotective effects of BCP were mediated by the amelioration of cellular antioxidant responses via Nrf2 activation, which is, in part, dependent on cannabinoid receptor type 2 (CB2R) activation. This functional nonpsychoactive CB2R ligand, could represent an important molecule for protection of glial cells against oxidative stress induced by glutamate. (c) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Assis, L. C.; Straliotto, M. R.; Engel, D.; Hort, M. A.; De Bem, A. F.] Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Bioquim, Florianopolis, SC, Brazil; [Dutra, R. C.] Univ Fed Santa Catarina, Lab Autoimunidade & Imunofarmacol, BR-88900000 Ararangua, SC, Brazil; [Dutra, R. C.] Univ Fed Santa Catarina, Ctr Ciencias Biol, Dept Farmacol, BR-88900000 Ararangua, SC, Brazil	Dutra, RC (corresponding author), Univ Fed Santa Catarina, Lab Autoimunidade & Imunofarmacol, Campus Ararangua, BR-88900000 Ararangua, SC, Brazil.	rafaelcdutra@gmail.com	de, Andreza/AAA-1523-2019; Dutra, Rafael C/F-8452-2012; Hort, Mariana/T-7377-2019; Engel, Daiane F./AAN-9044-2020	de, Andreza/0000-0003-1090-5244; Dutra, Rafael C/0000-0002-6938-2161; Hort, Mariana/0000-0001-5877-3506; Engel, Daiane F./0000-0002-1950-196X	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) in BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) in BrazilCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC)/PRONEX in Brazil; CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This work was supported by grants from the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), and the Fundacao de Apoio a Pesquisa do Estado de Santa Catarina (FAPESC)/PRONEX, all in Brazil. LCA and MRS are PhD students in neuroscience and biochemistry, respectively, receiving grants from CAPES. AFB is supported by a research fellowship from CNPq.	Akerboom T P, 1981, Methods Enzymol, V77, P373; Alonso-Alconada D, 2012, NEUROCHEM RES, V37, P161, DOI 10.1007/s11064-011-0594-z; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Astani A, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep187; Bai G, 2001, J NEUROSCI RES, V66, P981, DOI 10.1002/jnr.10056; Barbeito LH, 2004, BRAIN RES REV, V47, P263, DOI 10.1016/j.brainresrev.2004.05.003; Batkai S, 2007, FASEB J, V21, P1788, DOI 10.1096/fj.06-7451com; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Bento AF, 2011, AM J PATHOL, V178, P1153, DOI 10.1016/j.ajpath.2010.11.052; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bhaskaran MD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010683; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Chen J, 2005, NEUROSCI LETT, V389, P99, DOI 10.1016/j.neulet.2005.07.028; Choi IY, 2000, GLIA, V31, P155, DOI 10.1002/1098-1136(200008)31:2<155::AID-GLIA70>3.0.CO;2-1; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; Contartese A, 2012, PHARMACOL RES, V66, P555, DOI 10.1016/j.phrs.2012.08.003; Dasgupta A, 2007, FREE RADICAL BIO MED, V42, P617, DOI 10.1016/j.freeradbiomed.2006.11.030; Dingledine R, 1999, PHARMACOL REV, V51, P7; Downer EJ, 2011, THESCIENTIFICWORLDJO, V11, P855, DOI 10.1100/tsw.2011.84; Elmann A, 2009, J AGR FOOD CHEM, V57, P6636, DOI 10.1021/jf901162f; Farber NB, 1998, PROG BRAIN RES, V116, P421, DOI 10.1016/S0079-6123(08)60453-7; Farooqui T, 2009, MECH AGEING DEV, V130, P203, DOI 10.1016/j.mad.2008.11.006; Fernandez-Checa JC, 2010, SIGNALING PATHWAYS IN LIVER DISEASES, SECOND EDITION, P439, DOI 10.1007/978-3-642-00150-5_29; Fernandez-Fernandez S, 2012, BIOCHEM J, V443, P3, DOI 10.1042/BJ20111943; Fernandez-Lopez D, 2006, PEDIATR RES, V60, P169, DOI 10.1203/01.pdr.0000228839.00122.6c; Fischedick JT, 2012, PLANTA MED, V78, P1725, DOI 10.1055/s-0032-1315241; Fujimura M, 2014, ARCH TOXICOL, V88, P109, DOI 10.1007/s00204-013-1089-2; Gautier CA, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-22; Gertsch J, 2008, P NATL ACAD SCI USA, V105, P9099, DOI 10.1073/pnas.0803601105; Ghelardini C, 2001, FARMACO, V56, P387, DOI 10.1016/S0014-827X(01)01092-8; GREENAMYRE JT, 1994, NEUROLOGY, V44, P7; Heales SJR, 2002, NEUROCHEM INT, V40, P469, DOI 10.1016/S0197-0186(01)00117-6; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Hybertson BM, 2011, MOL ASPECTS MED, V32, P234, DOI 10.1016/j.mam.2011.10.006; Ibrahim SM, 2001, BRAIN, V124, P1927, DOI 10.1093/brain/124.10.1927; Ichiyama K, 2008, J BIOL CHEM, V283, P17003, DOI 10.1074/jbc.M801286200; Iwamura H, 2001, J PHARMACOL EXP THER, V296, P420; Jing X, 2013, TOXICOL APPL PHARM, V273, P672, DOI 10.1016/j.taap.2013.10.018; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Jou MJ, 2008, ADV DRUG DELIVER REV, V60, P1512, DOI 10.1016/j.addr.2008.06.004; Kataria H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037080; Kawakami N, 2005, J IMMUNOL, V175, P69, DOI 10.4049/jimmunol.175.1.69; Keum YS, 2003, PHARM RES-DORDR, V20, P1351, DOI 10.1023/A:1025737622815; Kim C, 2013, MOL CARCINOG; Kimball ES, 2006, AM J PHYSIOL-GASTR L, V291, pG364, DOI 10.1152/ajpgi.00407.2005; Kulawiak B, 2012, MITOCHONDRION, V12, P169, DOI 10.1016/j.mito.2011.12.001; Lee HG, 2009, BRAIN RES, V1249, P244, DOI 10.1016/j.brainres.2008.10.055; Lee M, 2010, FASEB J, V24, P2533, DOI 10.1096/fj.09-149997; Li Q, 2013, CELL PHYSIOL BIOCHEM, V31, P693, DOI 10.1159/000350088; Lin SX, 2011, ASN NEURO, V3, DOI 10.1042/AN20100033; Lipton SA, 2008, NAT NEUROSCI, V11, P381, DOI 10.1038/nn0408-381; Mates JM, 2002, INT J BIOCHEM CELL B, V34, P439, DOI 10.1016/S1357-2725(01)00143-1; McElnea EM, 2011, MOL VIS, V17, P1182; Mockute D, 2001, PHYTOCHEMISTRY, V57, P65, DOI 10.1016/S0031-9422(00)00474-X; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Niciu MJ, 2012, PHARMACOL BIOCHEM BE, V100, P656, DOI 10.1016/j.pbb.2011.08.008; Olney JW, 1990, CAN DIS WKLY REP, V16, P57; Onyango Isaac G., 2006, Current Alzheimer Research, V3, P339, DOI 10.2174/156720506778249489; Palazuelos J, 2008, J BIOL CHEM, V283, P13320, DOI 10.1074/jbc.M707960200; Paquet M, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-9; Prat A, 2005, ARCH NEUROL-CHICAGO, V62, P795, DOI 10.1001/archneur.62.5.795; Quincozes-Santos A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064372; Quincozes-Santos A, 2009, NEUROTOX RES, V16, P30, DOI 10.1007/s12640-009-9042-0; Rae MG, 2004, NEUROPHARMACOLOGY, V46, P1057, DOI 10.1016/j.neuropharm.2004.02.002; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rossi DJ, 2007, NAT NEUROSCI, V10, P1377, DOI 10.1038/nn2004; Sevcik MA, 2005, J PAIN, V6, P771, DOI 10.1016/j.jpain.2005.06.010; Sheng WS, 2013, NEUROCHEM RES, V38, P2148, DOI 10.1007/s11064-013-1123-z; Sibbald B, 2005, CAN MED ASSOC J, V172, P1672, DOI 10.1503/cmaj.050628; SINGH M, 2013, BIOMED RES INT, V2013, DOI DOI 10.1155/2013/569206; Siqueira JM, 2009, CANCER CHEMOTH PHARM, V64, P529, DOI 10.1007/s00280-008-0901-9; Sohn JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026625; Sun R, 2012, FOLIA NEUROPATHOL, V50, P270, DOI 10.5114/fn.2012.30527; Szydlowska K, 2006, J NEUROCHEM, V99, P965, DOI 10.1111/j.1471-4159.2006.04136.x; Van Damme P, 2007, P NATL ACAD SCI USA, V104, P14825, DOI 10.1073/pnas.0705046104; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Wang Y, 2008, AUTOPHAGY, V4, P214, DOI 10.4161/auto.5369; Weiss N, 2009, BBA-BIOMEMBRANES, V1788, P842, DOI 10.1016/j.bbamem.2008.10.022; Weng CJ, 2011, NEW BIOTECHNOL, V28, P767, DOI 10.1016/j.nbt.2011.05.003; Yamanaka K, 2008, NAT NEUROSCI, V11, P251, DOI 10.1038/nn2047; Yang L, 2008, NATURE, V454, P350, DOI 10.1038/nature07021; Yeh CT, 2006, J NUTR, V136, P11; Yokote H, 2008, AM J PATHOL, V173, P1714, DOI 10.2353/ajpath.2008.080622; Zhang YC, 2013, FOOD CHEM TOXICOL, V59, P272, DOI 10.1016/j.fct.2013.05.058	84	55	55	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	OCT 24	2014	279						220	231		10.1016/j.neuroscience.2014.08.043			12	Neurosciences	Neurosciences & Neurology	AR5ON	WOS:000343633800017	25194788				2021-06-18	
J	Tchantchou, F; Tucker, LB; Fu, AH; Bluett, RJ; McCabe, JT; Patel, S; Zhang, YM				Tchantchou, Flaubert; Tucker, Laura B.; Fu, Amanda H.; Bluett, Rebecca J.; McCabe, Joseph T.; Patel, Sachin; Zhang, Yumin			The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury	NEUROPHARMACOLOGY			English	Article						TBI; FAAH inhibition; AEA; Inflammation; Neuroprotection	ISCHEMIA-REPERFUSION INJURY; AMYLOID PRECURSOR PROTEIN; RAT MODEL; MONOACYLGLYCEROL LIPASE; MOUSE MODEL; EXPRESSION; ANANDAMIDE; ANXIETY; FAAH; NEUROPROTECTION	Traumatic brain injury (TBI) is the leading cause of death in young adults in the United States, but there is still no effective agent for treatment. N-arachidonoylethanolamine (anandamide, AEA) is a major endocannabinoid in the brain. Its increase after brain injury is believed to be protective. However, the compensatory role of AEA is transient due to its rapid hydrolysis by the fatty acid amide hydrolase (FAAH). Thus, inhibition of FAAH can boost the endogenous levels of AEA and prolong its protective effect. Using a TBI mouse model, we found that post-injury chronic treatment with PF3845, a selective and potent FAAH inhibitor, reversed TBI-induced impairments in fine motor movement, hippocampus dependent working memory and anxiety-like behavior. Treatment with PF3845 inactivated FAAH activity and enhanced the AEA levels in the brain. It reduced neurodegeneration in the dentate gyrus, and up-regulated the expression of Bcl-2 and Hsp70/72 in both cortex and hippocampus. PF3845 also suppressed the increased production of amyloid precursor protein, prevented dendritic loss and restored the levels of synaptophysin in the ipsilateral dentate gyrus. Furthermore, PF3845 suppressed the expression of inducible nitric oxide synthase and cyclooxygenase-2 and enhanced the expression of arginase-1 post-TBI, suggesting a shift of microglia/macrophages from M1 to M2 phenotype. The effects of PF3845 on TBI-induced behavioral deficits and neurodegeneration were mediated by activation of cannabinoid type 1 and 2 receptors and might be attributable to the phosphorylation of ERK1/2 and AKT. These results suggest that selective inhibition of FAAH is likely to be beneficial for TBI treatment. Published by Elsevier Ltd.	[Tchantchou, Flaubert; Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Tucker, Laura B.; Fu, Amanda H.; McCabe, Joseph T.; Zhang, Yumin] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Bluett, Rebecca J.; Patel, Sachin] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN 37232 USA; [Bluett, Rebecca J.; Patel, Sachin] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Zhang, YM (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	yumin.zhang@usuhs.edu	B, Rebecca/W-4528-2019; Patel, Sachin/E-5608-2012; McCabe, Joseph/J-6293-2014	B, Rebecca/0000-0003-2156-3497; McCabe, Joseph/0000-0002-1159-7442; Tucker, Laura/0000-0002-5984-6399	Blast Lethality Injury and Research Program [R600-070-00000-00-106109]; Defense Medical Research and Development Program [0130-10-00003-00002]; Military Center of Excellence Research Award [306514-1.00-63671]; Center for Neuroscience and Regenerative Medicine Surgical and Behavioral Core, Department of DefenseUnited States Department of Defense [300600-7.01-60855]; National Institutes and Health [MH100096, MH090412]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH090412, R01MH100096] Funding Source: NIH RePORTER	This work was supported by grants from the Blast Lethality Injury and Research Program (R600-070-00000-00-106109 to Y.Z.), the Defense Medical Research and Development Program (0130-10-00003-00002 to Y.Z.), the Military Center of Excellence Research Award (306514-1.00-63671 to Y.Z.), the Center for Neuroscience and Regenerative Medicine Surgical and Behavioral Core, Department of Defense (300600-7.01-60855 to J.T.M) and National Institutes and Health (MH100096 and MH090412 to S.P.). The authors wish to thank Dr. Fengshan Yu for his technical assistance. The opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army, Department of Defense, the U.S. government, or the Uniformed Services University of the Health Sciences. The use of trade names does not constitute an official endorsement or approval of the use of such reagents or commercial hardware or software. All the authors declare no conflict of interest.	Ahn K, 2008, CHEM REV, V108, P1687, DOI 10.1021/cr0782067; Ahn K, 2009, CHEM BIOL, V16, P411, DOI 10.1016/j.chembiol.2009.02.013; Amdekar S, 2012, INT J INFLAMM, V2012, DOI 10.1155/2012/752015; Bisogno T, 1997, ADV EXP MED BIOL, V433, P201; Booker L, 2012, BRIT J PHARMACOL, V165, P2485, DOI 10.1111/j.1476-5381.2011.01445.x; Busquets-Garcia A, 2011, BIOL PSYCHIAT, V70, P479, DOI 10.1016/j.biopsych.2011.04.022; Chen RQ, 2012, CELL REP, V2, P1329, DOI 10.1016/j.celrep.2012.09.030; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Di Filippo C, 2004, J LEUKOCYTE BIOL, V75, P453, DOI 10.1189/jlb.0703303; Duggan KC, 2011, NAT CHEM BIOL, V7, P803, DOI 10.1038/nchembio.663; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Galve-Roperh I, 2008, CURR PHARM DESIGN, V14, P2279, DOI 10.2174/138161208785740117; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Goonawardena AV, 2011, NEUROPHARMACOLOGY, V61, P1016, DOI 10.1016/j.neuropharm.2011.07.003; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Gunduz-Cinar O, 2013, MOL PSYCHIATR, V18, P813, DOI 10.1038/mp.2012.72; Hermanson DJ, 2013, NAT NEUROSCI, V16, P1291, DOI 10.1038/nn.3480; Hwang J, 2010, LIFE SCI, V86, P615, DOI 10.1016/j.lfs.2009.06.003; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kinsey SG, 2009, J PHARMACOL EXP THER, V330, P902, DOI 10.1124/jpet.109.155465; Lehmann ML, 2011, J NEUROSCI, V31, P6159, DOI 10.1523/JNEUROSCI.0577-11.2011; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li Q, 2013, J PHYSIOL SCI, V63, P47, DOI 10.1007/s12576-012-0228-5; Lichtman AH, 2004, J PHARMACOL EXP THER, V311, P441, DOI 10.1124/jpet.104.069401; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lourbopoulos A, 2011, BRAIN RES, V1390, P126, DOI 10.1016/j.brainres.2011.03.020; Marrs WR, 2010, NAT NEUROSCI, V13, P951, DOI 10.1038/nn.2601; Mazzola C, 2009, LEARN MEMORY, V16, P332, DOI 10.1101/lm.1145209; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Molina-Holgado F, 2007, EUR J NEUROSCI, V25, P629, DOI 10.1111/j.1460-9568.2007.05322.x; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Moreira FA, 2008, NEUROPHARMACOLOGY, V54, P141, DOI 10.1016/j.neuropharm.2007.07.005; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Naidoo V, 2012, NEUROTHERAPEUTICS, V9, P801, DOI 10.1007/s13311-011-0100-y; Oddi S, 2012, J MOL MED, V90, P371, DOI 10.1007/s00109-011-0846-z; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Panlilio LV, 2013, PHARMACOL THERAPEUT, V138, P84, DOI 10.1016/j.pharmthera.2013.01.003; Patel S, 2009, NEUROPSYCHOPHARMACOL, V34, P2699, DOI 10.1038/npp.2009.101; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Sagar DR, 2008, BRIT J PHARMACOL, V155, P1297, DOI 10.1038/bjp.2008.335; Savinainen JR, 2012, ACTA PHYSIOL, V204, P267, DOI 10.1111/j.1748-1716.2011.02280.x; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Tanaka K, 2009, NEUROSCI LETT, V462, P235, DOI 10.1016/j.neulet.2009.07.024; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Thau-Zuchman O, 2012, J NEUROTRAUM, V29, P375, DOI 10.1089/neu.2010.1673; van der Stelt M, 2001, J NEUROSCI, V21, P8765, DOI 10.1523/JNEUROSCI.21-22-08765.2001; Varvel SA, 2007, NEUROPSYCHOPHARMACOL, V32, P1032, DOI 10.1038/sj.npp.1301224; Vizcaychipi MP, 2011, ANESTHESIOLOGY, V114, P891, DOI 10.1097/ALN.0b013e31820ad3ce; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wise LE, 2009, NEUROBIOL LEARN MEM, V92, P597, DOI 10.1016/j.nlm.2009.06.001; Yu FS, 2012, J NEUROTRAUM, V29, P362, DOI 10.1089/neu.2011.1942; Zhang D, 2007, NEUROPHARMACOLOGY, V52, P1095, DOI 10.1016/j.neuropharm.2006.11.009	58	55	56	0	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	OCT	2014	85						427	439		10.1016/j.neuropharm.2014.06.006			13	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AN8KR	WOS:000340853600045	24937045	Green Accepted			2021-06-18	
J	Dal Monte, O; Schintu, S; Pardini, M; Berti, A; Wassermann, EM; Grafman, J; Krueger, F				Dal Monte, Olga; Schintu, Selene; Pardini, Matteo; Berti, Anna; Wassermann, Eric M.; Grafman, Jordan; Krueger, Frank			The left inferior frontal gyrus is crucial for reading the mind in the eyes: Brain lesion evidence	CORTEX			English	Article						RMET; Mental states; Voxel-based lesion symptom mapping; Traumatic brain injury; Semantic working memory	PREFRONTAL CORTEX; ARCUATE FASCICULUS; EMOTION RECOGNITION; COGNITIVE IMPAIRMENT; ASPERGER-SYNDROME; SOCIAL COGNITION; LOBE DAMAGE; INJURY; FMRI; LANGUAGE	Deficit in the ability to understand and predict the mental states of others is one of the central features of traumatic brain injury (TBI), leading to problems in social-daily life such as social withdrawal and the inability to maintain work or family relationships. Although several functional neuroimaging studies have identified a widely distributed brain network involved in the Reading the Mind in the Eyes Test (RMET), the necessary brain regions engaged in this capacity are still heavily debated. In this study, we combined the RMET with a whole-brain voxel-based lesion symptom mapping (VLSM) approach to identify brain regions necessary for adequate RMET performance in a large sample of patients with penetrating TBI (pTBI). Our results revealed that pTBI patients performed worse on the RMET compared to non-head injured controls, and impaired RMET performance was associated with lesions in the left inferior frontal gyms (IFG). Our findings suggest that the left IFG is a key region in reading the mind in the eyes, probably involved in a more general impairment of a semantic working memory system that facilitates reasoning about what others are feeling and thinking as expressed by the eyes. (C) 2014 Elsevier Ltd. All rights reserved.	[Dal Monte, Olga; Berti, Anna] Univ Turin, Dept Neuropsychol, Turin, Italy; [Schintu, Selene] Lyon Neurosci Res Ctr, CNRS, INSERM, ImpAct Team,UMR5292,U1028, Lyon, France; [Schintu, Selene] Univ UCBL Lyon 1, Lyon, France; [Pardini, Matteo] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet & Mat & Ch, Genoa, Italy; [Wassermann, Eric M.] Natl Inst Neurol Disorders & Stroke, Behav Neurol Unit, NIH, Bethesda, MD USA; [Grafman, Jordan] Rehabil Inst Chicago, Cognit Neurosci Lab, Chicago, IL 60611 USA; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA USA	Krueger, F (corresponding author), George Mason Univ, Dept Psychol, Mol Neurosci Dept, 4400 Univ Dr,Mail Stop 2A1, Fairfax, VA 22030 USA.	fkrueger@gmu.edu	Dal Monte, Olga/P-3759-2018; Schintu, Selene/ABF-7032-2020; Wassermann, Eric M./AAC-9064-2020; Pardini, Matteo/F-8414-2010	Dal Monte, Olga/0000-0002-7823-4769; Schintu, Selene/0000-0002-6362-3905; Wassermann, Eric M./0000-0003-0628-0210; Pardini, Matteo/0000-0002-4740-1982; Berti, Anna/0000-0001-9972-5543	U.S. National Institute of Neurological Disorders and Stroke Intramural Research ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)	This study was conducted and supported by the U.S. National Institute of Neurological Disorders and Stroke Intramural Research Program and took place at the National Institutes of Health Clinical Research Center. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the U.S. Government. For further information about the Vietnam Head Injury Study, contact J.G. at jgrafman@northwestern.edu. We thank the NIH Clinical Center for the provision of their facilities and for their supportive services. We thank Sandra Bonifant, Michael Tiemey, Leila Glass, Lyanne Yozawitz, Carolee Noury, Vivien YJ Tsen, and Anne Leopold who worked tirelessly to test subjects and organize the study. As always, the authors are grateful to all of the Vietnam veterans and caregivers who participated in this study. Their unending commitment to improving the health care of veterans is the reason this study could be completed.	Adams RB, 2010, J COGNITIVE NEUROSCI, V22, P97, DOI 10.1162/jocn.2009.21187; Baglio F, 2012, J ALZHEIMERS DIS, V29, P25, DOI 10.3233/JAD-2011-111256; Baldo JV, 1998, NEUROPSYCHOLOGY, V12, P259, DOI 10.1037/0894-4105.12.2.259; Baron-Cohen S, 1999, EUR J NEUROSCI, V11, P1891, DOI 10.1046/j.1460-9568.1999.00621.x; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Baron-Cohen S., 1995, MINDBLINDNESS ESSAY; Baron-Cohen S, 2006, BRAIN COGNITION, V61, P122, DOI 10.1016/j.bandc.2005.12.011; BECK AT, 1978, BECK DEPRESSION INVE; Brauer J, 2011, CEREB CORTEX, V21, P459, DOI 10.1093/cercor/bhq108; Castelli I, 2010, NEUROPSYCHOLOGIA, V48, P2586, DOI 10.1016/j.neuropsychologia.2010.05.005; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Dal Monte O, 2013, SOC COGN AFFECT NEUR, V8, P632, DOI 10.1093/scan/nss041; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Dick AS, 2012, BRAIN, V135, P3529, DOI 10.1093/brain/aws222; Friederici AD, 2009, TRENDS COGN SCI, V13, P175, DOI 10.1016/j.tics.2009.01.001; Gabrieli JDE, 1998, P NATL ACAD SCI USA, V95, P906, DOI 10.1073/pnas.95.3.906; Glascher J, 2009, NEURON, V61, P681, DOI 10.1016/j.neuron.2009.01.026; Glasser MF, 2008, CEREB CORTEX, V18, P2471, DOI 10.1093/cercor/bhn011; Goodglass H, 1997, J Int Neuropsychol Soc, V3, P128; Goodkind MS, 2012, HUM BRAIN MAPP, V33, P753, DOI 10.1002/hbm.21251; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Gross JJ, 1997, PSYCHOL AGING, V12, P590, DOI 10.1037/0882-7974.12.4.590; Havet-Thomassin V, 2006, BRAIN INJURY, V20, P83, DOI 10.1080/02699050500340655; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Hirao K, 2008, SCHIZOPHR RES, V105, P165, DOI 10.1016/j.schres.2008.07.021; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Jang SH, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00749; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; KAPLAN E, 1976, BOSTON NAMING TEST; Kawashima R, 1999, BRAIN, V122, P779, DOI 10.1093/brain/122.4.779; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kemp J, 2012, AGEING RES REV, V11, P199, DOI 10.1016/j.arr.2011.12.001; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; Marchina S, 2011, STROKE, V42, P2251, DOI 10.1161/STROKEAHA.110.606103; Martin PI, 2009, BRAIN LANG, V111, P20, DOI 10.1016/j.bandl.2009.07.007; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P231, DOI 10.1017/S1355617712001506; McNeil M. M., 1994, REVISED TOKEN TEST; Moor BG, 2012, SOC COGN AFFECT NEUR, V7, P44, DOI 10.1093/scan/nsr020; Mori S., 2005, MRI ATLAS HUMAN WHIT; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; Obler LK, 2010, BRAIN LANG, V113, P113, DOI [10.1016/j.band1.2010.03.001, 10.1016/j.bandl.2010.03.001]; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; Paulesu E, 1997, NEUROREPORT, V8, P2011, DOI 10.1097/00001756-199705260-00042; Poldrack RA, 1999, NEUROIMAGE, V10, P15, DOI 10.1006/nimg.1999.0441; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Rilling JK, 2008, NAT NEUROSCI, V11, P426, DOI 10.1038/nn2072; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1982; Russell TA, 2000, AM J PSYCHIAT, V157, P2040, DOI 10.1176/appi.ajp.157.12.2040; Sabbagh MA, 2004, J COGNITIVE NEUROSCI, V16, P415, DOI 10.1162/089892904322926755; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Thompson-Schill SL, 1997, P NATL ACAD SCI USA, V94, P14792, DOI 10.1073/pnas.94.26.14792; Tsuchida A, 2012, CEREB CORTEX, V22, P2904, DOI 10.1093/cercor/bhr370; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; United States Department of Defense, 1960, ARM FORC QUAL TEST A; Wagner AD, 1998, BRAIN, V121, P1985, DOI 10.1093/brain/121.10.1985; Warrington E., 1991, VISUAL OBJECT SPACE; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004	64	55	55	0	38	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	SEP	2014	58						9	17		10.1016/j.cortex.2014.05.002			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	AO6OA	WOS:000341470200002	24946302				2021-06-18	
J	Lange, S; Rocha-Ferreira, E; Thei, L; Mawjee, P; Bennett, K; Thompson, PR; Subramanian, V; Nicholas, AP; Peebles, D; Hristova, M; Raivich, G				Lange, Sigrun; Rocha-Ferreira, Eridan; Thei, Laura; Mawjee, Priyanka; Bennett, Kate; Thompson, Paul R.; Subramanian, Venkataraman; Nicholas, Anthony P.; Peebles, Donald; Hristova, Mariya; Raivich, Gennadij			Peptidylariginine deiminases: novel drug targets for prevention of neuronal damage following hypoxic ischemic insult (HI) in neonates	JOURNAL OF NEUROCHEMISTRY			English	Article						hypoxic ischaemic encephalopathy; lipopolysaccharide; microglia; neonatal; peptidylarginine deiminases; protein deimination/citrullination	WHITE-MATTER INJURY; PEPTIDYLARGININE DEIMINASE; POSTTRANSLATIONAL MODIFICATION; CELL-DEATH; BRAIN; CITRULLINATION; EXPRESSION; ASPHYXIA; ENZYMES; MODELS	Neonatal hypoxic ischaemic (HI) injury frequently causes neural impairment in surviving infants. Our knowledge of the underlying molecular mechanisms is still limited. Protein deimination is a post-translational modification caused by Ca+2-regulated peptidylarginine deiminases (PADs), a group of five isozymes that display tissue-specific expression and different preference for target proteins. Protein deimination results in altered protein conformation and function of target proteins, and is associated with neurodegenerative diseases, gene regulation and autoimmunity. In this study, we used the neonatal HI and HI/infection [lipopolysaccharide (LPS) stimulation] murine models to investigate changes in protein deimination. Brains showed increases in deiminated proteins, cell death, activated microglia and neuronal loss in affected brain areas at 48 h after hypoxic ischaemic insult. Upon treatment with the pan-PAD inhibitor Cl-amidine, a significant reduction was seen in microglial activation, cell death and infarct size compared with control saline or LPS-treated animals. Deimination of histone 3, a target protein of the PAD4 isozyme, was increased in hippocampus and cortex specifically upon LPS stimulation and markedly reduced following Cl-amidine treatment. Here, we demonstrate a novel role for PAD enzymes in neural impairment in neonatal HI Encephalopathy, highlighting their role as promising new candidates for drug-directed intervention in neurotrauma.	[Lange, Sigrun; Rocha-Ferreira, Eridan; Thei, Laura; Mawjee, Priyanka; Hristova, Mariya; Raivich, Gennadij] UCL Inst Womens Hlth Maternal & Fetal Med, Perinatal Brain Repair Grp, London WC1E 6HX, England; [Lange, Sigrun] UCL Sch Pharm, London, England; [Bennett, Kate] UCL Inst Womens Hlth, London, England; [Thompson, Paul R.; Subramanian, Venkataraman] Scripps Res Inst, Dept Chem, Jupiter, FL USA; [Nicholas, Anthony P.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA; [Nicholas, Anthony P.] Birmingham VA, Med Ctr, Birmingham, AL 35294 USA; [Peebles, Donald] UCL Med Sch, London, England	Lange, S (corresponding author), UCL Inst Womens Hlth Maternal & Fetal Med, Perinatal Brain Repair Grp, London WC1E 6HX, England.	sigrun.lange@ucl.ac.uk	Raivich, Gennadij/AAL-7229-2021	Rocha Ferreira, Eridan/0000-0002-9342-4691	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM079357] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM079357] Funding Source: Medline; Wellbeing of WomenWellbeing of Women (WoW) [RG1266] Funding Source: researchfish		Adhami F, 2007, AUTOPHAGY, V3, P42, DOI 10.4161/auto.3412; Culman J, 2007, TRENDS PHARMACOL SCI, V28, P244, DOI 10.1016/j.tips.2007.03.004; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; Faulkner S, 2011, ANN NEUROL, V70, P133, DOI 10.1002/ana.22387; Gyorgy B, 2006, INT J BIOCHEM CELL B, V38, P1662, DOI 10.1016/j.biocel.2006.03.008; Hagberg H, 2002, MENT RETARD DEV D R, V8, P30, DOI 10.1002/mrdd.10007; Hagiwara T, 2002, BIOCHEM BIOPH RES CO, V290, P979, DOI 10.1006/bbrc.2001.6303; Horibata S, 2012, J REPROD DEVELOP, V58, P274, DOI 10.1262/jrd.2011-040; Hristova M, 2010, GLIA, V58, P11, DOI 10.1002/glia.20896; Keilhoff G, 2008, DEV NEUROBIOL, V68, P101, DOI 10.1002/dneu.20578; Kendall GS, 2011, DEV NEUROSCI-BASEL, V33, P505, DOI 10.1159/000333850; Kendall GS, 2011, LAB INVEST, V91, P328, DOI 10.1038/labinvest.2010.192; Kendall GS, 2006, PEDIATR RES, V59, P227, DOI 10.1203/01.pdr.0000196805.68082.22; Kumral A, 2013, EARLY HUM DEV, V89, P165, DOI 10.1016/j.earlhumdev.2012.09.016; Lange S, 2011, DEV BIOL, V355, P205, DOI 10.1016/j.ydbio.2011.04.015; Li PX, 2008, MOL CELL BIOL, V28, P4745, DOI 10.1128/MCB.01747-07; Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239; Loos T, 2008, BLOOD, V112, P2648, DOI 10.1182/blood-2008-04-149039; Loos T, 2009, METHOD ENZYMOL, V461, P3, DOI 10.1016/S0076-6879(09)05401-9; Luo Y, 2006, BIOCHEMISTRY-US, V45, P11727, DOI 10.1021/bi061180d; Mallard C, 2003, NEUROCHEM RES, V28, P215, DOI 10.1023/A:1022368915400; Mastronardi FG, 2006, J NEUROSCI, V26, P11387, DOI 10.1523/JNEUROSCI.3349-06.2006; Moelants EAV, 2013, CYTOKINE, V61, P161, DOI 10.1016/j.cyto.2012.09.011; Moelants EAV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028976; Moller JC, 1996, GLIA, V17, P121; Nicholas AP, 2002, GLIA, V37, P328, DOI 10.1002/glia.10039; Perlman JM, 2006, CLIN THER, V28, P1353, DOI 10.1016/j.clinthera.2006.09.005; Pirianov G, 2007, J CEREBR BLOOD F MET, V27, P1022, DOI 10.1038/sj.jcbfm.9600413; Proost P, 2008, J EXP MED, V205, P2085, DOI 10.1084/jem.20080305; Robertson NJ, 2013, BRAIN, V136, P90, DOI 10.1093/brain/aws285; Robertson NJ, 2004, NEUROPEDIATRICS, V35, P20, DOI 10.1055/s-2004-815787; Stys PK, 1998, J CEREBR BLOOD F MET, V18, P2, DOI 10.1097/00004647-199801000-00002; Vossenaar ER, 2003, BIOESSAYS, V25, P1106, DOI 10.1002/bies.10357; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Wu Y. W, 2000, JAMA-J AM MED ASSOC, V28, P2996; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; WYATT JS, 1989, ARCH DIS CHILD-FETAL, V64, P953, DOI 10.1136/adc.64.7_Spec_No.953; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019	38	55	55	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2014	130	4					555	562		10.1111/jnc.12744			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	AN3ZN	WOS:000340527500009	24762056	Other Gold, Green Published, Green Accepted			2021-06-18	
J	Alvarez, Z; Castano, O; Castells, AA; Mateos-Timoneda, MA; Planell, JA; Engel, E; Alcantara, S				Alvarez, Zaida; Castano, Oscar; Castells, Alba A.; Mateos-Timoneda, Miguel A.; Planell, Josep A.; Engel, Elisabeth; Alcantara, Soledad			Neurogenesis and vascularization of the damaged brain using a lactate-releasing biomimetic scaffold	BIOMATERIALS			English	Article						Nanofibers; Lactate; Regeneration; Neural stem cells; Vascularization; Neurogenesis	NEURAL STEM-CELLS; RADIAL GLIA; EXTRACELLULAR-MATRIX; MIGRATING NEURONS; SPINAL-CORD; ASTROCYTES; SYSTEM; ANGIOGENESIS; REGENERATION; PROGENITORS	Regenerative medicine strategies to promote recovery following traumatic brain injuries are currently focused on the use of biomaterials as delivery systems for cells or bioactive molecules. This study shows that cell-free biomimetic scaffolds consisting of radially aligned electrospun poly-L/DL. lactic acid (PLA70/30) nanofibers release L-lactate and reproduce the 3D organization and supportive function of radial glia embryonic neural stem cells. The topology of PLA nanofibers supports neuronal migration while L-lactate released during PLA degradation acts as an alternative fuel for neurons and is required for progenitor maintenance. Radial scaffolds implanted into cavities made in the postnatal mouse brain fostered complete implant vascularization, sustained neurogenesis, and allowed the long-term survival and integration of the newly generated neurons. Our results suggest that the endogenous central nervous system is capable of regeneration through the in vivo dedifferentiation induced by biophysical and metabolic cues, with no need for exogenous cells, growth factors, or genetic manipulation. (C) 2014 Elsevier Ltd. All rights reserved.	[Alvarez, Zaida; Castano, Oscar; Mateos-Timoneda, Miguel A.; Planell, Josep A.; Engel, Elisabeth] Inst Bioengn Catalonia IBEC, Barcelona, Spain; [Alvarez, Zaida; Castells, Alba A.; Alcantara, Soledad] Univ Barcelona, Dpt Pathol & Expt Therapeut, Sch Med, Barcelona, Spain; [Castano, Oscar; Engel, Elisabeth] Tech Univ Catalonia UPC, Dpt Mat Sci & Met Engn, Barcelona, Spain; [Alvarez, Zaida; Castano, Oscar; Mateos-Timoneda, Miguel A.; Engel, Elisabeth] CIBER BBN, Barcelona, Spain	Alcantara, S (corresponding author), Univ Barcelona, Cell Biol Unit, Dept Expt Pathol & Therapeut, Sch Med, Bellvitge Campus, Barcelona 08907, Spain.	salcantara@ub.edu	Castells, Alba Aina/AAB-2200-2020; Alcantara, Soledad/K-3648-2014; Engel, Elisabeth/D-4365-2014; Timoneda, Miguel Angel Mateos/D-4666-2014; alvarez, zaida/AAA-3132-2020; Castano, Oscar/F-6725-2012	Castells, Alba Aina/0000-0002-3508-8562; Alcantara, Soledad/0000-0003-3313-2715; Engel, Elisabeth/0000-0003-4855-8874; Timoneda, Miguel Angel Mateos/0000-0001-7657-1414; Castano, Oscar/0000-0001-9212-784X; Alvarez, Zaida/0000-0001-5104-1388	Spain's Ministerio de Economia y Competitividad (MINECO) [MAT2011-29778-C02-02, MAT2011-29778-C02-01]; European Regional Development FundEuropean Commission; fellowship IBEC [10-2009-01]; Spanish MINECO for the Ramon y Cajal contract;  [SGR 719]	This study was supported by grants from Spain's Ministerio de Economia y Competitividad (MINECO) [MAT2011-29778-C02-02] and [MAT2011-29778-C02-01], co-financed by the European Regional Development Fund, to S.A. and O.C., respectively; from 2009 SGR 719 to S.A.; and from fellowship IBEC 10-2009-01 to Z.A. O.C. acknowledges the Spanish MINECO for the Ramon y Cajal contract. We are grateful to Wendy Ran for editorial assistance, to P. Hyrossova for helping with lactate degradation studies, to J.C. Perales and J. Domingo for critical reading of the manuscript, to J.A. Ortega for the drawing in Figure 6, to B. Torrejon from the UB's Scientific-Technical Services (Bellvitge Campus) for technical support in confocal microscopy, to X. Ramis for DSC measurements and technical support, to the Experimental 7T MRI Unit (IDIBAPS) and to F. Artigas and M.P. Celada for electrophysiological studies.	Alvarez Z, 2013, BIOMATERIALS, V34, P2221, DOI 10.1016/j.biomaterials.2012.12.001; Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0; Anton ES, 1997, DEVELOPMENT, V124, P3501; Baud O, 2003, J COMP NEUROL, V465, P445, DOI 10.1002/cne.10853; Belvindrah R, 2007, J NEUROSCI, V27, P13854, DOI 10.1523/JNEUROSCI.4494-07.2007; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Bible E, 2009, BIOMATERIALS, V30, P2985, DOI 10.1016/j.biomaterials.2009.02.012; Bigler ED, 2013, BRAIN, V136, P9, DOI 10.1093/brain/aws342; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Christensen K, 2008, J NEURO-ONCOL, V90, P157, DOI 10.1007/s11060-008-9648-8; Conte WL, 2009, NAT PROTOC, V4, P1157, DOI 10.1038/nprot.2009.93; Covey MV, 2010, DEV NEUROSCI-BASEL, V32, P488, DOI 10.1159/000321607; Englund C, 2005, J NEUROSCI, V25, P247, DOI 10.1523/JNEUROSCI.2899-04.2005; Fame RM, 2011, TRENDS NEUROSCI, V34, P41, DOI 10.1016/j.tins.2010.10.002; Fan HJ, 2007, NANO LETT, V7, P993, DOI 10.1021/nl070026p; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Forraz N, 2013, J TISSUE ENG REGEN M, V7, P523, DOI 10.1002/term.552; Freire E, 2004, J CELL SCI, V117, P4067, DOI 10.1242/jcs.01276; Frontczak-Baniewicz M, 2011, FOLIA NEUROPATHOL, V49, P204; Hisaoka T, 2010, NEUROSCIENCE, V166, P551, DOI 10.1016/j.neuroscience.2009.12.055; Hsieh J, 2012, GENE DEV, V26, P1010, DOI 10.1101/gad.187336.112; Hurtado A, 2011, BIOMATERIALS, V32, P6068, DOI 10.1016/j.biomaterials.2011.05.006; Kazanis I, 2010, J NEUROSCI, V30, P9771, DOI 10.1523/JNEUROSCI.0700-10.2010; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Lathia JD, 2007, DEV DYNAM, V236, P3267, DOI 10.1002/dvdy.21319; Li YW, 2008, NAT PROTOC, V3, P1703, DOI 10.1038/nprot.2008.172; Loulier K, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000176; Ma S, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001469; Magavi SS, 2000, NATURE, V405, P951; Mattotti M, 2012, BIOMATERIALS, V33, P1759, DOI 10.1016/j.biomaterials.2011.10.086; Miller FD, 2007, NEURON, V54, P357, DOI 10.1016/j.neuron.2007.04.019; Niu WZ, 2013, NAT CELL BIOL, V15, P1164, DOI 10.1038/ncb2843; Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685; Ovens MJ, BIOCH J; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Rakic P, 2003, CEREB CORTEX, V13, P541, DOI 10.1093/cercor/13.6.541; Robel S, 2011, NAT REV NEUROSCI, V12, P88, DOI 10.1038/nrn2978; Saha B, 2013, STEM CELL RES, V11, P965, DOI 10.1016/j.scr.2013.06.006; Saha B, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00014; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Simon-Assmann P, 2011, INT J DEV BIOL, V55, P455, DOI 10.1387/ijdb.103223ps; Speder P, 2011, CURR OPIN CELL BIOL, V23, P724, DOI 10.1016/j.ceb.2011.08.004; Stubbs D, 2009, CEREB CORTEX, V19, pI32, DOI 10.1093/cercor/bhp040; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Tam SJ, 2010, ANNU REV NEUROSCI, V33, P379, DOI 10.1146/annurev-neuro-060909-152829; Tanaka EM, 2009, NAT REV NEUROSCI, V10, P713, DOI 10.1038/nrn2707; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Volpato FZ, 2013, BIOMATERIALS, V34, P4945, DOI 10.1016/j.biomaterials.2013.03.057; Weissman T, 2003, CEREB CORTEX, V13, P550, DOI 10.1093/cercor/13.6.550	50	55	57	4	82	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	JUN	2014	35	17					4769	4781		10.1016/j.biomaterials.2014.02.051			13	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	AG4ZT	WOS:000335429600005	24636215				2021-06-18	
J	Claassen, J; Albers, D; Schmidt, JM; De Marchis, GM; Pugin, D; Falo, CM; Mayer, SA; Cremers, S; Agarwal, S; Elkind, MSV; Connolly, ES; Dukic, V; Hripcsak, G; Badjatia, N				Claassen, Jan; Albers, David; Schmidt, J. Michael; De Marchis, Gian Marco; Pugin, Deborah; Falo, Christina Maria; Mayer, Stephan A.; Cremers, Serge; Agarwal, Sachin; Elkind, Mitchell S. V.; Connolly, E. Sander; Dukic, Vanja; Hripcsak, George; Badjatia, Neeraj			Nonconvulsive Seizures in Subarachnoid Hemorrhage Link Inflammation and Outcome	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; C-REACTIVE PROTEIN; STATUS EPILEPTICUS; INTRACEREBRAL HEMORRHAGE; RESPONSE SYNDROME; TNF-ALPHA; RECEPTOR; STROKE; MECHANISMS; MANAGEMENT	Objective: Nonconvulsive seizures (NCSz) are frequent following acute brain injury and have been implicated as a cause of secondary brain injury, but mechanisms that cause NCSz are controversial. Proinflammatory states are common after many brain injuries, and inflammation-mediated changes in blood-brain barrier permeability have been experimentally linked to seizures. Methods: In this prospective observational study of aneurysmal subarachnoid hemorrhage (SAH) patients, we explored the link between the inflammatory response following SAH and in-hospital NCSz studying clinical (systemic inflammatory response syndrome [SIRS]) and laboratory (tumor necrosis factor receptor 1 [TNF-R1], high-sensitivity C-reactive protein [hsCRP]) markers of inflammation. Logistic regression, Cox proportional hazards regression, and mediation analyses were performed to investigate temporal and causal relationships. Results: Among 479 SAH patients, 53 (11%) had in-hospital NCSz. Patients with in-hospital NCSz had a more pronounced SIRS response (odds ratio [OR]=1.9 per point increase in SIRS, 95% confidence interval [CI]=1.3-2.9), inflammatory surges were more likely immediately preceding NCSz onset, and the negative impact of SIRS on functional outcome at 3 months was mediated in part through in-hospital NCSz. In a subset with inflammatory serum biomarkers, we confirmed these findings linking higher serum TNF-R1 and hsCRP to in-hospital NCSz (OR=1.2 per 20-point hsCRP increase, 95% CI=1.1-1.4; OR=2.5 per 100-point TNF-R1 increase, 95% CI=2.1-2.9). The association of inflammatory biomarkers with poor outcome was mediated in part through NCSz. Interpretation: In-hospital NCSz were independently associated with a proinflammatory state following SAH as reflected in clinical symptoms and serum biomarkers of inflammation. Our findings suggest that inflammation following SAH is associated with poor outcome and that this effect is at least in part mediated through in-hospital NCSz.	[Claassen, Jan; Schmidt, J. Michael; De Marchis, Gian Marco; Pugin, Deborah; Falo, Christina Maria; Mayer, Stephan A.; Agarwal, Sachin; Badjatia, Neeraj] Columbia Univ, Coll Phys & Surg, Dept Neurol, Div Crit Care Neurol, New York, NY 10032 USA; [Claassen, Jan] Columbia Univ, Coll Phys & Surg, Dept Neurol, Comprehens Epilepsy Ctr, New York, NY 10032 USA; [Claassen, Jan; Mayer, Stephan A.; Agarwal, Sachin; Connolly, E. Sander; Badjatia, Neeraj] Columbia Univ, Coll Phys & Surg, Dept Neurosurg, New York, NY 10032 USA; [Albers, David; Hripcsak, George] Columbia Univ, Coll Phys & Surg, Dept Biomed Informat, New York, NY 10032 USA; [Cremers, Serge] Columbia Univ, Coll Phys & Surg, Irving Inst, Biomarkers Core Lab, New York, NY 10032 USA; [Elkind, Mitchell S. V.] Columbia Univ, Coll Phys & Surg, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA; [Elkind, Mitchell S. V.] Columbia Univ, Coll Phys & Surg, Div Stroke, Dept Neurol, New York, NY 10032 USA; [Dukic, Vanja] Univ Colorado, Dept Appl Math, Boulder, CO 80309 USA	Claassen, J (corresponding author), Columbia Univ, Div Crit Care Neurol, 177 Ft Washington Ave,MHB 8 Ctr,Room 300, New York, NY 10032 USA.	jc1439@columbia.edu	Dukic, Vanja/AAI-1494-2020; Claassen, Jan/AAA-5451-2020; De Marchis, Gian Marco/J-5414-2019	Dukic, Vanja/0000-0002-0348-0834; De Marchis, Gian Marco/0000-0002-0342-9780; Schmidt, J. Michael/0000-0001-8141-2944	NIH National Center for Advancing Translational Sciences [UL1 TR000040, UL1 RR024156]; National Library of Medicine, "Discovering and Applying Knowledge in Clinical Databases" [R01 LM006910]; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBBEP3_139388]; Swisslife Jubilaumsstiftung for Medical Research; Swiss Neurological Society; Fondazione Dr. Ettore Balli; De Quervain Research Grant; Dana Foundation; National Science FoundationNational Science Foundation (NSF) [1211668]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000040] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [R01LM006910] Funding Source: NIH RePORTER	This publication was supported by the NIH National Center for Advancing Translational Sciences through grant number UL1 TR000040 (formerly the National Center for Research Resources, grant number UL1 RR024156). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Both J.C. and N.B. received grants through this funding mechanism. Additional support for this work included a grant from the National Library of Medicine, "Discovering and Applying Knowledge in Clinical Databases" (R01 LM006910; G. H., D. A.). G. M. D. M. received grants from the Swiss National Science Foundation (PBBEP3_139388), Swisslife Jubilaumsstiftung for Medical Research, Swiss Neurological Society, and Fondazione Dr. Ettore Balli, and a De Quervain Research Grant. J.M.S. received a grant from the Dana Foundation. V. D. received grants from National Science Foundation (#1211668) and the NIH.	Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Badjatia N, 2011, STROKE, V42, P2436, DOI 10.1161/STROKEAHA.111.614685; Bernstein LH, 2007, CLIN CHEM LAB MED, V45, P1566, DOI 10.1515/CCLM.2007.334; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2013, ANN NEUROL, V74, P53, DOI 10.1002/ana.23859; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; DUNCOMBE AS, 1988, NEW ENGL J MED, V319, P1227; Elkind MS, 2002, STROKE, V33, P31, DOI 10.1161/hs0102.100531; Frigerio F, 2012, EPILEPSIA, V53, P1887, DOI 10.1111/j.1528-1167.2012.03666.x; Furuya K, 2001, STROKE, V32, P2665, DOI 10.1161/hs3211.098535; Greenhalgh AD, 2012, DIS MODEL MECH, V5, P823, DOI 10.1242/dmm.008557; Haley EC, 2005, STROKE, V36, P1006, DOI 10.1161/01.STR.0000163053.77982.8d; Hanafy KA, 2010, J NEUROL SCI, V291, P69, DOI 10.1016/j.jns.2009.12.023; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Komotar RJ, 2009, NEUROSURGERY, V64, P397, DOI 10.1227/01.NEU.0000338946.42939.C7; KOMOTAR RJ, 2009, NEUROSURGERY, V64, P411; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Librizzi L, 2012, ANN NEUROL, V72, P82, DOI 10.1002/ana.23567; Loscher W., 2012, JASPERS BASIC MECH E; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Marchi N, 2012, EPILEPSIA, V53, P1877, DOI 10.1111/j.1528-1167.2012.03637.x; Marchi N, 2011, EPILEPSIA, V52, P1627, DOI 10.1111/j.1528-1167.2011.03080.x; Marchi N, 2009, NEUROBIOL DIS, V33, P171, DOI 10.1016/j.nbd.2008.10.002; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Meierkord H, 2010, EUR J NEUROL, V17, P348, DOI 10.1111/j.1468-1331.2009.02917.x; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pearl J., 2009, CAUSALITY MODELS REA; Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395; Pinilla JC, 1998, SURGERY, V124, P799, DOI 10.1067/msy.1998.91365; Preacher KJ, 2004, BEHAV RES METH INS C, V36, P717, DOI 10.3758/BF03206553; Riazi K, 2008, P NATL ACAD SCI USA, V105, P17151, DOI 10.1073/pnas.0806682105; Rossato M, 2012, P NATL ACAD SCI USA, V109, pE3101, DOI 10.1073/pnas.1209100109; Rossetti AO, 2011, NEUROCRIT CARE, V14, P4, DOI 10.1007/s12028-010-9445-z; Rossetti AO, 2005, ARCH NEUROL-CHICAGO, V62, P1698, DOI 10.1001/archneur.62.11.1698; Sarrafzadeh A, 2010, NEUROCRIT CARE, V13, P339, DOI 10.1007/s12028-010-9432-4; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Sutter R, 2013, CRIT CARE MED, V41, P1526, DOI 10.1097/CCM.0b013e318287f2ac; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646; Zhang SH, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006778.pub2; Ziv Y, 2007, STROKE, V38, P774, DOI 10.1161/01.STR.0000255784.27298.23	50	55	55	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	MAY	2014	75	5					771	781		10.1002/ana.24166			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AJ5EV	WOS:000337706100017	24771589	Green Accepted			2021-06-18	
J	Pandit, V; Rhee, P; Hashmi, A; Kulvatunyou, N; Tang, A; Khalil, M; O'Keeffe, T; Green, D; Friese, RS; Joseph, B				Pandit, Viraj; Rhee, Peter; Hashmi, Ammar; Kulvatunyou, Narong; Tang, Andrew; Khalil, Mazhar; O'Keeffe, Terence; Green, Donald; Friese, Randall S.; Joseph, Bellal			Shock index predicts mortality in geriatric trauma patients: An analysis of the National Trauma Data Bank	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Geriatric; shock index; vitals on presentation; mortality; blood transfusion	110 MM HG; REDEFINING HYPOTENSION; VITAL SIGNS; HEART-RATE; CORRELATE; UTILITY; BEGINS	BACKGROUND Heart rate and systolic blood pressure are unreliable in geriatric trauma patients. Shock index (SI) (heart rate/systolic blood pressure) is a simple marker of worse outcomes after injury. The aim of this study was to assess the utility of SI in predicting outcomes. We hypothesized that SI predicts mortality in geriatric trauma patients. METHODS We performed a 4-year (2007-2010) retrospective analysis using the National Trauma Data Bank. Patients 65 years or older were included. Transferred patients, patients dead on arrival, missing vitals on presentation, and patients with burns and traumatic brain injury were excluded. A cutoff value of SI greater than or equal to 1 (sensitivity, 81%; specificity, 79%) was used to define hemodynamic instability. The primary outcome measure was mortality. Secondary outcome measures were need for blood transfusion, need for exploratory laparotomy, and development of in-hospital complications. Multiple logistic regressions were performed. RESULTS A total of 485,595 geriatric patients were reviewed, of whom 217,190 were included. The mean (SD) age was 77.7 (7.1) years, 60% were males, median Glasgow Coma Scale (GCS) score was 14 (range, 3-15), median Injury Severity Score (ISS) was 9 (range, 4-18), and mean (SD) SI was 0.58 (0.18). Three percent (n = 6,585) had an SI greater than or equal to 1. Patients with SI greater than or equal to 1 were more likely to require blood product requirement (p = 0.001), require an exploratory laparotomy (p = 0.01), and have in-hospital complications (p = 0.02). The overall mortality rate was 4.1% (n = 8,952). SI greater than or equal to 1 was the strongest predictor for mortality (odds ratio, 3.1; 95% confidence interval, 2.6-3.3; p = 0.001) in geriatric trauma patients. Systolic blood pressure (p = 0.09) and heart rate (p = 0.2) were not predictive of mortality. CONCLUSION SI is an accurate and specific predictor of morbidity and mortality in geriatric trauma patients. SI is superior to heart rate and systolic blood pressure for predicting mortality in geriatric trauma patients. Geriatric trauma patients with SI greater than or equal to 1 should be transferred to a Level 1 trauma center. LEVEL OF EVIDENCE Prognostic/epidemiologic study, level III.	[Pandit, Viraj; Rhee, Peter; Hashmi, Ammar; Kulvatunyou, Narong; Tang, Andrew; Khalil, Mazhar; O'Keeffe, Terence; Green, Donald; Friese, Randall S.; Joseph, Bellal] Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Allgower M, 1968, Ger Med Mon, V13, P14; ALLGOWER M, 1967, DEUT MED WOCHENSCHR, V92, P1947, DOI 10.1055/s-0028-1106070; Birkhahn RH, 2005, AM J EMERG MED, V23, P323, DOI 10.1016/j.ajem.2005.02.029; Birkhahn RH, 2003, AM J OBSTET GYNECOL, V189, P1293, DOI 10.1067/S0002-9378(03)00663-X; BROOS PLO, 1993, INJURY, V24, P365, DOI 10.1016/0020-1383(93)90096-O; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Cancio LC, 2008, J TRAUMA, V65, P813, DOI 10.1097/TA.0b013e3181848241; Cannon CM, 2009, J TRAUMA, V67, P1426, DOI 10.1097/TA.0b013e3181bbf728; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Franklin GA, 2007, J TRAUMA, V63, P297; Hashmi A, 2014, PREDICTORS MORTALITY; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P196, DOI 10.1097/TA.0b013e3182a833ac; King RW, 1996, ACAD EMERG MED, V3, P1041, DOI 10.1111/j.1553-2712.1996.tb03351.x; Mcnab A, 2013, SURGERY, V154, P384, DOI 10.1016/j.surg.2013.05.007; Oyetunji TA, 2011, ARCH SURG-CHICAGO, V146, P865, DOI 10.1001/archsurg.2011.154; RADY MY, 1992, RESUSCITATION, V23, P227, DOI 10.1016/0300-9572(92)90006-X; RADY MY, 1994, ANN EMERG MED, V24, P685, DOI 10.1016/S0196-0644(94)70279-9; Rady MY, 1996, AM J EMERG MED, V14, P218, DOI 10.1016/S0735-6757(96)90136-9; Rogers A, 2012, AM SURGEON, V78, P711; Summers RL, 2009, RESUSCITATION, V80, P1405, DOI 10.1016/j.resuscitation.2009.09.001; Vandromme MJ, 2011, J TRAUMA, V70, P384, DOI 10.1097/TA.0b013e3182095a0a; Victorino GP, 2003, J AM COLL SURGEONS, V196, P679, DOI 10.1016/S1072-7515(03)00128-5; Zarzaur BL, 2010, J TRAUMA, V68, P1134, DOI 10.1097/TA.0b013e3181d87488	23	55	57	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2014	76	4					1111	1115		10.1097/TA.0000000000000160			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	AE7FF	WOS:000334161500037	24662879				2021-06-18	
J	French, LM; Lange, RT; Brickell, TA				French, Louis M.; Lange, Rael T.; Brickell, Tracey A.			Subjective cognitive complaints and neuropsychological test performance following military-related traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cognitive complaints; military; Neurobehavioral Symptom Inventory; neurocognitive measures; Personality Assessment Inventory; psychological distress; PTSD Checklist; self-reported symptoms; servicemembers; traumatic brain injury.	MILD HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; POSTCONCUSSION-LIKE SYMPTOMS; SELF-REPORT; BASE RATES; LITIGATION STATUS; OIF/OEF VETERANS; RESPONSE BIAS; CHRONIC PAIN	This study examined the relation between neuropsychological test performance and self-reported cognitive complaints following traumatic brain injury (TBI). Participants were 109 servicemembers from the U. S. military who completed a neuropsychological evaluation within the first 2 yr following mild-severe TBI. Measures included the Personality Assessment Inventory (PAI), Posttraumatic Stress Disorder Symptom Checklist-Civilian version (PCL-C), Neurobehavioral Symptom Inventory (NSI), and 17 select measures from a larger neurocognitive test battery that corresponded to three self-reported cognitive complaints from the NSI (i.e., memory, attention/concentration, and processing speed/organization). Self-reported cognitive complaints were significantly correlated with psychological distress (PCL-C total: r = 0.50-0.58; half the PAI clinical scales: r = 0.40-0.58). In contrast, self-reported cognitive complaints were not significantly correlated with overall neurocognitive functioning (with the exception of five measures). There was a low rate of agreement between neurocognitive test scores and self-reported cognitive complaints. For the large minority of the sample (38.5%-45.9%), self-reported cognitive complaints were reported in the presence of neurocognitive test scores that fell within normal limits. In sum, self-reported cognitive complaints were not associated with neurocognitive test performance, but rather were associated with psychological distress. These results provide information to contextualize cognitive complaints following TBI.	[French, Louis M.; Lange, Rael T.; Brickell, Tracey A.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [French, Louis M.; Lange, Rael T.; Brickell, Tracey A.] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA; [French, Louis M.; Lange, Rael T.; Brickell, Tracey A.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [French, Louis M.; Brickell, Tracey A.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 8,Room 2264,8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.lange@gmail.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conners K., 2002, CONNERS CONTINUOUS P; Delis DC, 2000, CALIFORNIA VERBAL LE; Donovan NJ, 2011, BRAIN INJURY, V25, P348, DOI 10.3109/02699052.2011.556105; Dujardin K, 2010, J NEUROL, V257, P79, DOI 10.1007/s00415-009-5268-2; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gass CS, 1997, J CLIN EXP NEUROPSYC, V19, P290, DOI 10.1080/01688639708403858; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gervais RO, 2008, CLIN NEUROPSYCHOL, V22, P1061, DOI 10.1080/13854040701756930; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Green P., 2003, GREENS WORD MEMORY T; Greve KW, 2013, CLIN NEUROPSYCHOL, V27, P108, DOI 10.1080/13854046.2012.739646; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry GK, 2009, CLIN NEUROPSYCHOL, V23, P153, DOI 10.1080/13854040801969524; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howard L, 2005, J NEUROL NEUROSUR PS, V76, P1558, DOI 10.1136/jnnp.2004.057851; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2007, BRAIN INJURY MED PRI, P333; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Johnson I, 2011, COMPR PSYCHIAT, V52, P688, DOI 10.1016/j.comppsych.2010.12.008; Keane T., 1994, PTSD CHECKLIST CIVIL; King EG, 2013, REHABIL PSYCHOL, V58, P272, DOI 10.1037/a0033116; Kinsinger SW, 2010, NEUROPSYCHOLOGY, V24, P573, DOI 10.1037/a0019222; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, ARCH CLIN NEUROPSYCH, V27, P480, DOI 10.1093/arclin/acs059; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P395, DOI 10.1076/clin.17.3.395.18087; Larson EB, 2013, J INT NEUROPSYCH SOC, V19, P88, DOI 10.1017/S1355617712000999; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Liik M, 2009, EPILEPSY RES, V84, P194, DOI 10.1016/j.eplepsyres.2009.02.006; Logan BW, 2013, BEHAV SCI LAW, V31, P803, DOI 10.1002/bsl.2092; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Marino SE, 2009, EPILEPSY BEHAV, V14, P459, DOI 10.1016/j.yebeh.2008.12.007; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meyers J., 1995, REY COMPLEX FIGURE T; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Miller L J, 1998, Appl Neuropsychol, V5, P172, DOI 10.1207/s15324826an0504_2; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morey L. C., 1991, PERSONALITY ASSESSME; Poppelreuter M, 2004, EUR J CANCER, V40, P43, DOI 10.1016/j.ejca.2003.08.001; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Reitan R. M., 1992, TRAIL MAKING TEST MA; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scholten J, 2013, J HEAD TRAUMA REHAB, V28, P219, DOI 10.1097/HTR.0b013e318291daca; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spencer RJ, 2013, J REHABIL RES DEV, V50, P1, DOI 10.1682/JRRD.2012.01.0018; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr J, 2008, ARCH CLIN NEUROPSYCH, V23, P521, DOI 10.1016/j.acn.2008.05.003; TAYLOR R, 1990, J DIAGN MED SONOG, V6, P35, DOI 10.1177/875647939000600106; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Tsanadis J, 2007, J INT NEUROPSYCH SOC, V13, P196; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Vogel A, 2011, LUPUS, V20, P35, DOI 10.1177/0961203310382430; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Wechsler D, 1997, WAIS 3 ADM SCORING M; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Worthen MD, 2011, PSYCHOL INJ LAW, V4, P187, DOI 10.1007/s12207-011-9115-2; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027	80	55	55	0	6	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2014	51	6					933	949		10.1682/JRRD.2013.10.0226			17	Rehabilitation	Rehabilitation	AT0OT	WOS:000344635900011	25479042	Bronze			2021-06-18	
J	Hundza, SR; Hook, WR; Harris, CR; Mahajan, SV; Leslie, PA; Spani, CA; Spalteholz, LG; Birch, BJ; Commandeur, DT; Livingston, NJ				Hundza, Sandra R.; Hook, William R.; Harris, Christopher R.; Mahajan, Sunny V.; Leslie, Paul A.; Spani, Carl A.; Spalteholz, Leonhard G.; Birch, Benjamin J.; Commandeur, Drew T.; Livingston, Nigel J.			Accurate and Reliable Gait Cycle Detection in Parkinson's Disease	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Angular rate reversal; continuous walking gait analysis; gyroscope; medical instrumentation; Parkinsons; stride event detection; stride time validation; stride time variability	TRAUMATIC BRAIN-INJURY; AMBULATORY SYSTEM; WALKING SPEED; OLDER-ADULTS; RELIABILITY; PARAMETERS; FALLS; VARIABILITY; GYROSCOPES; VALIDITY	There is a growing interest in the use of Inertial Measurement Unit (IMU)-based systems that employ gyroscopes for gait analysis. We describe an improved IMU-based gait analysis processing method that uses gyroscope angular rate reversal to identify the start of each gait cycle during walking. In validation tests with six subjects with Parkinson disease (PD), including those with severe shuffling gait patterns, and seven controls, the probability of True-Positive event detection and False-Positive event detection was 100% and 0%, respectively. Stride time validation tests using high-speed cameras yielded a standard deviation of 6.6 ms for controls and 11.8 ms for those with PD. These data demonstrate that the use of our angular rate reversal algorithm leads to improvements over previous gyroscope-based gait analysis systems. Highly accurate and reliable stride time measurements enabled us to detect subtle changes in stride time variability following a Parkinson's exercise class. We found unacceptable measurement accuracy for stride length when using the Aminian et al. gyro-based biomechanical algorithm, with errors as high as 30% in PD subjects. An alternative method, using synchronized infrared timing gates to measure velocity, combined with accurate mean stride time from our angular rate reversal algorithm, more accurately calculates mean stride length.	[Hundza, Sandra R.; Commandeur, Drew T.] Univ Victoria, Sch Exercise Sci Phys & Hlth Educ, Victoria, BC V8W 2Y2, Canada; [Hook, William R.; Leslie, Paul A.; Spani, Carl A.; Spalteholz, Leonhard G.; Livingston, Nigel J.] Univ Victoria, CanAssist, Victoria, BC V8W 2Y2, Canada; [Harris, Christopher R.] Tantalus Syst Corp, Burnaby, BC V5G 4Y1, Canada; [Mahajan, Sunny V.] OMsignal, Montreal, PQ H2Y2M4, Canada; [Birch, Benjamin J.] Camosun Coll, Victoria, BC V9E 2C1, Canada	Hundza, SR (corresponding author), Univ Victoria, Sch Exercise Sci Phys & Hlth Educ, Victoria, BC V8W 2Y2, Canada.	shundza@uvic.ca; wrogershook@gmail.com; crh.iphone@gmail.com; sunnyvm@gmail.com; pleslie@uvic.ca; cspani@uvic.ca; leos@uvic.ca; benj.birch@gmail.com; dcommand@uvic.ca; njl@uvic.ca			Assistive Technology organization CanAssist, University of Victoria, Canada [BC V8W2Y2]	This work was carried out by the Assistive Technology organization CanAssist, University of Victoria, BC V8W2Y2 Canada.	Aminian K, 2002, J BIOMECH, V35, P689, DOI 10.1016/S0021-9290(02)00008-8; Begg R. K., 2009, INSTRUMENTATION USED; Bilney B, 2003, GAIT POSTURE, V17, P68, DOI 10.1016/S0966-6362(02)00053-X; Bloem BR, 2004, MOVEMENT DISORD, V19, P871, DOI 10.1002/mds.20115; Brach J., 2006, J GERIATR PHYS THER, V29, P118; Furuse N, 2007, IFMBE PROC, V16, P689; Hausdorff JM, 2007, HUM MOVEMENT SCI, V26, P555, DOI 10.1016/j.humov.2007.05.003; Hausdorff JM, 2009, CHAOS, V19, DOI 10.1063/1.3147408; Hausdorff JM, 2001, ARCH PHYS MED REHAB, V82, P1050, DOI 10.1053/apmr.2001.24893; Hausdorff JM, 1998, MOVEMENT DISORD, V13, P428, DOI 10.1002/mds.870130310; Herman T, 2010, J GERONTOL A-BIOL, V65, P1086, DOI 10.1093/gerona/glq077; Hetzler RK, 2008, J STRENGTH COND RES, V22, P1969, DOI 10.1519/JSC.0b013e318185f36c; Hollman JH, 2010, GAIT POSTURE, V32, P23, DOI 10.1016/j.gaitpost.2010.02.017; I. CIR Systems, 2010, GAITRITE EL WALKW TE, P1; Mansfield A, 2003, MED ENG PHYS, V25, P879, DOI 10.1016/S1350-4533(03)00116-4; Moore ST, 2007, GAIT POSTURE, V26, P200, DOI 10.1016/j.gaitpost.2006.09.011; MORRIS ME, 1994, BRAIN, V117, P1169, DOI 10.1093/brain/117.5.1169; Qutubuddin AA, 2005, ARCH PHYS MED REHAB, V86, P789, DOI 10.1016/j.apmr.2004.11.005; Rikli R. E., 2012, GERONTOLOGIST, P1; Rueterbories J, 2010, MED ENG PHYS, V32, P545, DOI 10.1016/j.medengphy.2010.03.007; Salarian A, 2004, IEEE T BIO-MED ENG, V51, P1434, DOI 10.1109/TBME.2004.827933; van Loo M, 2003, CLIN REHABIL, V17, P775, DOI 10.1191/0269215503cr677oa; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314; Verghese J, 2007, J NEUROL NEUROSUR PS, V78, P929, DOI 10.1136/jnnp.2006.106914; VONSCHROEDER HP, 1995, J REHABIL RES DEV, V32, P25; Wong WY, 2007, PROSTHET ORTHOT INT, V31, P62, DOI 10.1080/03093640600983949	26	55	56	1	33	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	JAN	2014	22	1					127	137		10.1109/TNSRE.2013.2282080			11	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	292BK	WOS:000329876500014	24158491				2021-06-18	
J	Huang, XT; Zhang, YQ; Li, SJ; Li, SH; Tang, Q; Wang, ZT; Dong, JF; Zhang, JN				Huang, Xin-Tao; Zhang, Yong-Qiang; Li, Sheng-Jie; Li, Sheng-Hui; Tang, Qing; Wang, Zhi-Tao; Dong, Jing-Fei; Zhang, Jian-Ning			Intracerebroventricular Transplantation of Ex Vivo Expanded Endothelial Colony-Forming Cells Restores Blood-Brain Barrier Integrity and Promotes Angiogenesis of Mice with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						endothelial colony-forming cells; endothelial progenitor cells; transplantation; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; UMBILICAL-CORD BLOOD; PROGENITOR CELLS; PRECURSOR CELLS; STROKE; NEOVASCULARIZATION; RATS; REGENERATION; MOBILIZATION; PATHOPHYSIOLOGY	Endothelial progenitor cells (EPCs) play a key role in tissue repair and regeneration. Previous studies have shown a positive correlation between the number of circulating EPCs and clinical outcomes of patients with traumatic brain injury (TBI). A recent study has further shown that intravenous infusion of human umbilical cord blood-derived endothelial colony-forming cells (ECFCs) improves outcomes of mice subjected to experimental TBI. This follow-up study was designed to determine whether intracerebroventricular (i.c.v.) infusion of ECFCs, which may reduce systemic effects of these cells, could repair the blood-brain barrier (BBB) and promote angiogenesis of mice with TBI. Adult nude mice were exposed to fluid percussion injury and transplanted i.c.v. with ECFCs on day 1 post-TBI. These ECFCs were detected at the TBI zone 3 days after transplantation by SP-DiIC(18)(3) and fluorescence in situ hybridization. Mice with ECFCs transplant had reduced Evans blue extravasation and brain water content, increased expression of ZO-1 and claudin-5, and showed a higher expression of angiopoietin 1. Consistent with the previous report, mice with ECFCs transplant had also increased microvascular density. Modified neurological severity score and Morris water maze test indicated significant improvements in motor ability, spatial acquisition and reference memory in mice receiving ECFCs, compared to those receiving saline. These data demonstrate the beneficial effects of ECFC transplant on BBB integrity and angiogenesis in mice with TBI.	[Huang, Xin-Tao; Zhang, Yong-Qiang; Li, Sheng-Jie; Li, Sheng-Hui; Wang, Zhi-Tao; Zhang, Jian-Ning] Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, Tianjin 300052, Peoples R China; [Huang, Xin-Tao] Shanxi Med Univ, Hosp 1, Dept Neurosurg, Taiyuan, Peoples R China; [Tang, Qing] Tianjin Med Univ, Dept Immunol, Tianjin, Peoples R China; [Dong, Jing-Fei] Puget Sound Blood Ctr, Seattle, WA 98104 USA; [Dong, Jing-Fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neurosurg, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com		Huang, Xintao/0000-0002-9683-9518	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271361]; Tianjin Health Bureau Technology Foundation [07KZ26]	The authors acknowledge Wei-yun Cui, Li Liu, and Lei Zhou for their excellent technical support. The work was supported by the National Natural Science Foundation of China (grant no.: 81271361) and the Tianjin Health Bureau Technology Foundation (grant no.: 07KZ26).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Baudin B, 2007, NAT PROTOC, V2, P481, DOI 10.1038/nprot.2007.54; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Gill M, 2001, CIRC RES, V88, P167; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hansen TM, 2008, CURR NEUROVASC RES, V5, P236, DOI 10.2174/156720208786413433; Hayward NMEA, 2010, J NEUROTRAUM, V27, P2203, DOI 10.1089/neu.2010.1448; Ingram DA, 2004, BLOOD, V104, P2752, DOI 10.1182/blood-2004-04-1396; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Jiao HX, 2011, J MOL NEUROSCI, V44, P130, DOI 10.1007/s12031-011-9496-4; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Khoo CP, 2008, REGEN MED, V3, P863, DOI 10.2217/17460751.3.6.863; Lev EI, 2005, J VASC RES, V42, P408, DOI 10.1159/000087370; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Lin Y, 2000, J CLIN INVEST, V105, P71, DOI 10.1172/JCI8071; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Liu L, 2011, CRIT CARE MED, V39, P1760, DOI 10.1097/CCM.0b013e3182186cee; Melero-Martin JM, 2007, BLOOD, V109, P4761, DOI 10.1182/blood-2006-12-062471; Mukai N, 2008, EXP CELL RES, V314, P430, DOI 10.1016/j.yexcr.2007.11.016; Murasawa S, 2005, PHYSIOLOGY, V20, P36, DOI 10.1152/physiol.00033.2004; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Pfaff D, 2006, J LEUKOCYTE BIOL, V80, P719, DOI 10.1189/jlb.1105652; Rehman J, 2003, CIRCULATION, V107, P1164, DOI 10.1161/01.CIR.0000058702.69484.A0; Richardson MR, 2011, J MOL CELL CARDIOL, V50, P266, DOI 10.1016/j.yjmcc.2010.07.009; Rouhl RPW, 2008, STROKE, V39, P2158, DOI 10.1161/STROKEAHA.107.507251; Shear DA, 2011, J NEUROTRAUM, V28, P2185, DOI 10.1089/neu.2011.1916; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Takahashi T, 1999, NAT MED, V5, P434; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Yoon YS, 2005, BIOL CELL, V97, P253, DOI 10.1042/BC20040099; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhao J, 2012, J NEUROTRAUM, V29, P1209, DOI 10.1089/neu.2011.1858	46	55	61	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2080	2088		10.1089/neu.2013.2996			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500010	23957220	Green Published			2021-06-18	
J	Rachmany, L; Tweedie, D; Li, YZ; Rubovitch, V; Holloway, HW; Miller, J; Hoffer, BJ; Greig, NH; Pick, CG				Rachmany, Lital; Tweedie, David; Li, Yazhou; Rubovitch, Vardit; Holloway, Harold W.; Miller, Jonathan; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice	AGE			English	Article						Mild traumatic brain injury; Glucagon-like peptide-1; Exendin-4; Liraglutide; Neuroprotection; Brain trauma; Incretin; Alzheimer's disease; Glutamate toxicity; Oxidative stress	CLINICAL-PRACTICE GUIDELINES; ANXIETY-LIKE BEHAVIOR; CLOSED-HEAD-INJURY; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; SOCIAL RECOVERY; SPATIAL MEMORY; RODENT MODELS; RISK-FACTOR; CELL-DEATH	Mild traumatic brain injury (mTBI) represents a major and increasing public health concern and is both the most frequent cause of mortality and disability in young adults and a chief cause of morbidity in the elderly. Albeit mTBI patients do not show clear structural brain defects and, generally, do not require hospitalization, they frequently suffer from long-lasting cognitive, behavioral, and emotional problems. No effective pharmaceutical therapy is available, and existing treatment chiefly involves intensive care management after injury. The diffuse neural cell death evident after mTBI is considered mediated by oxidative stress and glutamate-induced excitotoxicity. Prior studies of the long-acting GLP-1 receptor agonist, exendin-4 (Ex-4), an incretin mimetic approved for type 2 diabetes mellitus treatment, demonstrated its neurotrophic/protective activity in cellular and animal models of stroke, Alzheimer's and Parkinson's diseases, and, consequent to commonalities in mechanisms underpinning these disorders, Ex-4 was assessed in a mouse mTBI model. In neuronal cultures in this study, Ex-4 ameliorated H2O2-induced oxidative stress and glutamate toxicity. To evaluate in vivo translation, we administered steady-state Ex-4 (3.5 pM/kg/min) or saline to control and mTBI mice over 7 days starting 48 h prior to or 1 h post-sham or mTBI (30 g weight drop under anesthesia). Ex-4 proved well-tolerated and fully ameliorated mTBI-induced deficits in novel object recognition 7 and 30 days post-trauma. Less mTBI-induced impairment was evident in Y-maze, elevated plus maze, and passive avoidance paradigms, but when impairment was apparent Ex-4 induced amelioration. Together, these results suggest that Ex-4 may act as a neurotrophic/neuroprotective drug to minimize mTBI impairment.	[Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sagol Sch Neurosci, IL-69978 Tel Aviv, Israel; [Tweedie, David; Li, Yazhou; Holloway, Harold W.; Greig, Nigel H.] NIA, Lab Neurosci, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Miller, Jonathan; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA; [Greig, Nigel H.] NIA, Drug Design & Dev Sect, Lab Neurosci, Intramural Res Program,NIH, Baltimore, MD 21224 USA	Greig, NH (corresponding author), NIA, Drug Design & Dev Sect, Lab Neurosci, Intramural Res Program,NIH, BRC Room 05 C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	Greign@grc.nia.nih.gov		Miller, Jonathan/0000-0001-5441-1751	National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Sackler School of Medicine, Tel-Aviv University; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333] Funding Source: NIH RePORTER	This research was supported in part by the Intramural Research Program of both the National Institute on Aging, National Institutes of Health, and the Sackler School of Medicine, Tel-Aviv University.	Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Banks WA, 2004, J PHARMACOL EXP THER, V309, P469, DOI 10.1124/jpet.103.063222; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barnett AH, 2012, DIABETES OBES METAB, V14, P304, DOI 10.1111/j.1463-1326.2011.01523.x; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Belzung C, 2001, BEHAV BRAIN RES, V125, P141, DOI 10.1016/S0166-4328(01)00291-1; Berrigan L, 2011, BRAIN INJURY, V25, P742, DOI 10.3109/02699052.2011.580317; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Calara F, 2005, CLIN THER, V27, P210, DOI 10.1016/j.clinthera.2005.02.008; Chaudhuri A, 2012, J CLIN ENDOCR METAB, V97, P198, DOI 10.1210/jc.2011-1508; Dix SL, 1999, BEHAV BRAIN RES, V99, P191, DOI 10.1016/S0166-4328(98)00079-5; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Drucker DJ, 2008, LANCET, V372, P1240, DOI 10.1016/S0140-6736(08)61206-4; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Erreger K, 2012, PHYSIOL BEHAV, V106, P574, DOI 10.1016/j.physbeh.2012.03.014; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Gallwitz B, 2011, DRUGS, V71, P1675, DOI 10.2165/11592810-000000000-00000; Garber AJ, 2011, DIABETES CARE, V34, pS279, DOI 10.2337/dc11-s231; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Grant P, 2011, J DIABETES COMPLICAT, V25, P244, DOI 10.1016/j.jdiacomp.2011.03.002; Hamilton A, 2009, NEUROREPORT, V20, P1161, DOI 10.1097/WNR.0b013e32832fbf14; Harkavyi A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-19; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Hoare SRJ, 2005, DRUG DISCOV TODAY, V10, P417, DOI 10.1016/S1359-6446(05)03370-2; Holscher Christian, 2010, Recent Pat CNS Drug Discov, V5, P109; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; Howard PK, 2011, ADV EMERG NURS J, V33, P274, DOI 10.1097/TME.0b013e318233d43c; Hunter K, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-33; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Kastin AJ, 2003, INT J OBESITY, V27, P313, DOI 10.1038/sj.ijo.0802206; Kastin AJ, 2002, J MOL NEUROSCI, V18, P7, DOI 10.1385/JMN:18:1-2:07; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; Lovshin JA, 2009, NAT REV ENDOCRINOL, V5, P262, DOI 10.1038/nrendo.2009.48; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Magnoni S, 2010, ARCH NEUROL-CHICAGO, V67, P1068, DOI 10.1001/archneurol.2010.214; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Pawaskar M, 2012, CURR MED RES OPIN, V28, P991, DOI 10.1185/03007995.2012.686901; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V302, P881, DOI 10.1124/jpet.102.037481; Porter D, 2012, PEPTIDES, V35, P1, DOI 10.1016/j.peptides.2012.03.014; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; Sambamurti K, 2002, NEUROMOL MED, V1, P1, DOI 10.1385/NMM:1:1:1; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Sharma S, 2010, LIFE SCI, V87, P521, DOI 10.1016/j.lfs.2010.09.004; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SIESJO BK, 1995, ANN THORAC SURG, V59, P1316, DOI 10.1016/0003-4975(95)00077-X; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Strawn JR, 2008, J PSYCHIATR RES, V42, P787, DOI 10.1016/j.jpsychires.2007.08.007; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zipp F, 2006, TRENDS NEUROSCI, V29, P518, DOI 10.1016/j.tins.2006.07.006; Zitnay GA, 2005, ACT NEUR S, V93, P131; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	89	55	55	0	38	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0161-9152	1574-4647		AGE	Age	OCT	2013	35	5					1621	1636		10.1007/s11357-012-9464-0			16	Geriatrics & Gerontology	Geriatrics & Gerontology	219XO	WOS:000324545200008	22892942	Green Published			2021-06-18	
J	Dustrude, ET; Wilson, SM; Ju, WN; Xiao, YC; Khanna, R				Dustrude, Erik T.; Wilson, Sarah M.; Ju, Weina; Xiao, Yucheng; Khanna, Rajesh			CRMP2 Protein SUMOylation Modulates NaV1.7 Channel Trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED SODIUM-CHANNELS; RESPONSE MEDIATOR PROTEIN-2; TRAUMATIC BRAIN-INJURY; SPINAL SENSORY NEURONS; ROOT GANGLION NEURONS; GROWTH CONE COLLAPSE; SUMO MODIFICATION; SLOW INACTIVATION; NEUROPATHIC PAIN; ANTICONVULSANT LACOSAMIDE	Voltage-gated sodium channel (NaV) trafficking is incompletely understood. Post-translational modifications of NaVs and/or auxiliary subunits and protein-protein interactions have been posited as NaV-trafficking mechanisms. Here, we tested if modification of the axonal collapsin response mediator protein 2 (CRMP2) by a small ubiquitin-like modifier (SUMO) could affect NaV trafficking; CRMP2 alters the extent of NaV slow inactivation conferred by the anti-epileptic (R)-lacosamide, implying NaV-CRMP2 functional coupling. Expression of a CRMP2 SUMOylation-incompetent mutant (CRMP2-K374A) in neuronal model catecholamine A differentiated (CAD) cells did not alter lacosamide-induced NaV slow inactivation compared with CAD cells expressing wild type CRMP2. Like wild type CRMP2, CRMP2-K374A expressed robustly in CAD cells. Neurite outgrowth, a canonical CRMP2 function, was moderately reduced by the mutation but was still significantly higher than enhanced GFP-transfected cortical neurons. Notably, huwentoxin-IV-sensitive NaV1.7 currents, which predominate in CAD cells, were significantly reduced in CAD cells expressing CRMP2-K374A. Increasing deSUMOylation with sentrin/SUMO-specific protease SENP1 or SENP2 in wild type CRMP2-expressing CAD cells decreased NaV1.7 currents. Consistent with a reduction in current density, biotinylation revealed a significant reduction in surface NaV1.7 levels in CAD cells expressing CRMP2-K374A; surface NaV1.7 expression was also decreased by SENP1 + SENP2 overexpression. Currents in HEK293 cells stably expressing NaV1.7 were reduced by CRMP2-K374A in a manner dependent on the E2-conjugating enzyme Ubc9. No decrement in current density was observed in HEK293 cells co-expressing CRMP2-K374A and NaV1.1 or NaV1.3. Diminution of sodium currents, largely NaV1.7, was recapitulated in sensory neurons expressing CRMP2-K374A. Our study elucidates a novel regulatory mechanism that utilizes CRMP2 SUMOylation to choreograph NaV1.7 trafficking.	[Dustrude, Erik T.; Wilson, Sarah M.; Khanna, Rajesh] Indiana Univ Sch Med, Paul & Carole Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Ju, Weina; Xiao, Yucheng; Khanna, Rajesh] Indiana Univ Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA	Khanna, R (corresponding author), 950 West Walnut St,R2 Bldg,Rm 478, Indianapolis, IN 46202 USA.	khanna5@iu.edu		Khanna, Rajesh/0000-0002-9066-2969	National Institutes of Health Clinical and Translational Sciences Grant from the Indiana Clinical and Translational Sciences Institute [RR025761]; NCRR Project Development Team; Indiana State Department of Health-Spinal Cord and Brain Injury Fund [A70-9-079138]; National Scientist Development Grant from the American Heart Association [SDG5280023]; Neurofibromatosis New Investigator Award from the Department of Defense/Congressionally Directed Medical Research Program [NF1000099]; Stark fellowships; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Clinical and Translational Sciences Grant RR025761 from the Indiana Clinical and Translational Sciences Institute funded by NCRR Project Development Team. This work was also supported by the Indiana State Department of Health-Spinal Cord and Brain Injury Fund A70-9-079138 (to R. K.), National Scientist Development Grant SDG5280023 from the American Heart Association (to R. K.), and Neurofibromatosis New Investigator Award NF1000099 from the Department of Defense/Congressionally Directed Medical Research Program (to R. K.).; Supported in part by Stark fellowships.	Anckar J, 2007, BIOCHEM SOC T, V35, P1409, DOI 10.1042/BST0351409; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Arimura N, 2005, MOL CELL BIOL, V25, P9973, DOI 10.1128/MCB.25.22.9973-9984.2005; Benson M, 2009, SUMO REGULATION OF CELLULAR PROCESSES, P117, DOI 10.1007/978-90-481-2649-1_7; Benson MD, 2007, P NATL ACAD SCI USA, V104, P1805, DOI 10.1073/pnas.0606702104; Beyreuther BK, 2007, CNS DRUG REV, V13, P21, DOI 10.1111/j.1527-3458.2007.00001.x; Black JA, 2004, PAIN, V108, P237, DOI 10.1016/j.pain.2003.12.035; Bretin S, 2006, J NEUROCHEM, V98, P1252, DOI 10.1111/j.1471-4159.2006.03969.x; Brittain JM, 2012, FEBS LETT, V586, P3813, DOI 10.1016/j.febslet.2012.09.022; Brittain JM, 2011, J BIOL CHEM, V286, P37778, DOI 10.1074/jbc.M111.255455; Brittain JM, 2011, NAT MED, V17, P822, DOI 10.1038/nm.2345; Brittain JM, 2009, J BIOL CHEM, V284, P31375, DOI 10.1074/jbc.M109.009951; Casini S, 2010, CARDIOVASC RES, V85, P691, DOI 10.1093/cvr/cvp352; Catterall WA, 2010, J PHYSIOL-LONDON, V588, P1849, DOI 10.1113/jphysiol.2010.187484; Chan AW, 2007, CHANNELS, V1; Chi XX, 2007, J NEUROPHYSIOL, V98, P2683, DOI 10.1152/jn.00437.2007; Chi XX, 2009, J CELL SCI, V122, P4351, DOI 10.1242/jcs.053280; Cox JJ, 2006, NATURE, V444, P894, DOI 10.1038/nature05413; Cummins TR, 2001, J NEUROSCI, V21, P5952; Dib-Hajj SD, 2013, NAT REV NEUROSCI, V14, P49, DOI 10.1038/nrn3404; Duprez E, 1999, J CELL SCI, V112, P381; Errington AC, 2008, MOL PHARMACOL, V73, P157, DOI 10.1124/mol.107.039867; Errington AC, 2006, NEUROPHARMACOLOGY, V50, P1016, DOI 10.1016/j.neuropharm.2006.02.002; Escayg A, 2010, EPILEPSIA, V51, P1650, DOI 10.1111/j.1528-1167.2010.02640.x; Estacion M, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-92; Feliciangeli S, 2007, CELL, V130, P563, DOI 10.1016/j.cell.2007.06.012; Felts PA, 1997, MOL BRAIN RES, V45, P71, DOI 10.1016/S0169-328X(96)00241-0; Hodgdon KE, 2012, NEUROSCIENCE, V206, P237, DOI 10.1016/j.neuroscience.2011.12.045; Hong SS, 2004, J BIOL CHEM, V279, P29341, DOI 10.1074/jbc.M404167200; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; Ju WN, 2013, CHANNELS, V7, P153, DOI 10.4161/chan.24224; Khanna R, 2012, FUTUR NEUROL, V7, P749, DOI 10.2217/FNL.12.68; Kim CH, 2001, MOL BRAIN RES, V95, P153, DOI 10.1016/S0169-328X(01)00226-1; Kim DY, 2007, NAT CELL BIOL, V9, P755, DOI 10.1038/ncb1602; Kim DY, 2005, J BIOL CHEM, V280, P23251, DOI 10.1074/jbc.M412938200; King AM, 2012, ACS CHEM NEUROSCI, V3, P1037, DOI 10.1021/cn300129d; Konopacki FA, 2011, P NATL ACAD SCI USA, V108, P19772, DOI 10.1073/pnas.1111575108; Leclere PG, 2005, J NEUROSCI METH, V142, P137, DOI 10.1016/j.jneumeth.2004.08.012; Leterrier C, 2010, NEUROSCI LETT, V486, P92, DOI 10.1016/j.neulet.2010.08.079; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; Lopez-Santiago LF, 2006, J NEUROSCI, V26, P7984, DOI 10.1523/JNEUROSCI.2211-06.2006; Malhotra JD, 2000, J BIOL CHEM, V275, P11383, DOI 10.1074/jbc.275.15.11383; Martin S, 2007, NAT REV NEUROSCI, V8, P948, DOI 10.1038/nrn2276; Merrill JC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008794; Momin A, 2008, CURR OPIN NEUROBIOL, V18, P383, DOI 10.1016/j.conb.2008.08.017; Morinaka A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001127; Mukhopadhyay D, 2007, TRENDS BIOCHEM SCI, V32, P286, DOI 10.1016/j.tibs.2007.05.002; Okuse K, 2002, NATURE, V417, P653, DOI 10.1038/nature00781; Park KD, 2010, ORG BIOMOL CHEM, V8, P2803, DOI 10.1039/c000987c; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; Pertin M, 2005, J NEUROSCI, V25, P10970, DOI 10.1523/JNEUROSCI.3066-05.2005; Plant LD, 2011, J GEN PHYSIOL, V137, P441, DOI 10.1085/jgp.201110604; Plant LD, 2010, P NATL ACAD SCI USA, V107, P10743, DOI 10.1073/pnas.1004712107; Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019; Rusconi R, 2007, J NEUROSCI, V27, P11037, DOI 10.1523/JNEUROSCI.3515-07.2007; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Shao DM, 2009, INT J BIOCHEM CELL B, V41, P1471, DOI 10.1016/j.biocel.2009.01.016; Sheets PL, 2008, J PHARMACOL EXP THER, V326, P89, DOI 10.1124/jpet.107.133413; Stenmark P, 2007, J NEUROCHEM, V101, P906, DOI 10.1111/j.1471-4159.2006.04401.x; Takahashi N, 2003, NEUROSCIENCE, V121, P441, DOI 10.1016/S0306-4522(03)00432-9; Theile JW, 2011, MOL PHARMACOL, V80, P724, DOI 10.1124/mol.111.072751; Vacher H, 2012, EPILEPSIA, V53, P21, DOI 10.1111/epi.12032; Wang LH, 1997, J NEUROCHEM, V69, P2261; Wang YY, 2011, ACS CHEM NEUROSCI, V2, P317, DOI 10.1021/cn200024z; Wang YY, 2011, ACS CHEM NEUROSCI, V2, P90, DOI 10.1021/cn100089b; Wang YY, 2010, J BIOL CHEM, V285, P25296, DOI 10.1074/jbc.M110.128801; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466; Wilkinson KA, 2008, NEUROSCI LETT, V436, P239, DOI 10.1016/j.neulet.2008.03.029; Wilkinson KA, 2010, BRAIN RES REV, V64, P195, DOI 10.1016/j.brainresrev.2010.04.002; Wilkinson KA, 2010, BIOCHEM J, V428, P133, DOI 10.1042/BJ20100158; Wilson SM, 2012, NEUROSCIENCE, V210, P451, DOI 10.1016/j.neuroscience.2012.02.038; Wilson SM, 2012, J BIOL CHEM, V287, P35065, DOI 10.1074/jbc.M112.378695; WINTER J, 1988, NEURON, V1, P973, DOI 10.1016/0896-6273(88)90154-7; Wolff C, 2012, CNS NEUROSCI THER, V18, P493, DOI 10.1111/j.1755-5949.2012.00313.x; Xiao YC, 2008, J BIOL CHEM, V283, P27300, DOI 10.1074/jbc.M708447200; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078; Zhu JM, 2008, J BIOL CHEM, V283, P29405, DOI 10.1074/jbc.M803632200	80	55	55	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 23	2013	288	34					24316	24331		10.1074/jbc.M113.474924			16	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	302NW	WOS:000330612300004	23836888	Green Published, Other Gold			2021-06-18	
J	Harrison, DA; Prabhu, G; Grieve, R; Harvey, SE; Sadique, MZ; Gomes, M; Griggs, KA; Walmsley, E; Smith, M; Yeoman, P; Lecky, FE; Hutchinson, PJA; Menon, DK; Rowan, KM				Harrison, D. A.; Prabhu, G.; Grieve, R.; Harvey, S. E.; Sadique, M. Z.; Gomes, M.; Griggs, K. A.; Walmsley, E.; Smith, M.; Yeoman, P.; Lecky, F. E.; Hutchinson, P. J. A.; Menon, D. K.; Rowan, K. M.			Risk Adjustment In Neurocritical care (RAIN) - prospective validation of risk prediction models for adult patients with acute traumatic brain injury to use to evaluate the optimum location and comparative costs of neurocritical care: a cohort study	HEALTH TECHNOLOGY ASSESSMENT			English	Article							ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; CHRONIC HEALTH EVALUATION; LONG-TERM OUTCOMES; SOCIETY APACHE-II; INTENSIVE-CARE; MULTIPLE IMPUTATION; POSTAL QUESTIONNAIRES; FUNCTIONAL RECOVERY	Objectives: To validate risk prediction models for acute traumatic brain injury (TBI) and to use the best model to evaluate the optimum location and comparative costs of neurocritical care in the NHS. Design: Cohort study. Setting: Sixty-seven adult critical care units. Participants: Adult patients admitted to critical care following actual/suspected TBI with a Glasgow Coma Scale (GCS) score of < 15. Interventions: Critical care delivered in a dedicated neurocritical care unit, a combined neuro/general critical care unit within a neuroscience centre or a general critical care unit outside a neuroscience centre. Main outcome measures: Mortality, Glasgow Outcome Scale - Extended (GOSE) questionnaire and European Quality of Life-5 Dimensions, 3-level version (EQ-5D-3L) questionnaire at 6 months following TBI. Results: The final Risk Adjustment In Neurocritical care (RAIN) study data set contained 3626 admissions. After exclusions, 3210 patients with acute TBI were included. Overall follow-up rate at 6 months was 81%. Of 3210 patients, 101 (3.1%) had no GCS score recorded and 134 (4.2%) had a last pre-sedation GCS score of 15, resulting in 2975 patients for analysis. The most common causes of TBI were road traffic accidents (RTAs) (33%), falls (47%) and assault (12%). Patients were predominantly young (mean age 45 years overall) and male (76% overall). Six-month mortality was 22% for RTAs, 32% for falls and 17% for assault. Of survivors at 6 months with a known GOSE category, 44% had severe disability, 30% moderate disability and 26% made a good recovery. Overall, 61% of patients with known outcome had an unfavourable outcome (death or severe disability) at 6 months. Between 35% and 70% of survivors reported problems across the five domains of the EQ-5D-3L. Of the 10 risk models selected for validation, the best discrimination overall was from the International Mission for Prognosis and Analysis of Clinical Trials in TBI Lab model (IMPACT) (c-index 0.779 for mortality, 0.713 for unfavourable outcome). The model was well calibrated for 6-month mortality but substantially underpredicted the risk of unfavourable outcome at 6 months. Baseline patient characteristics were similar between dedicated neurocritical care units and combined neuro/general critical care units. In lifetime cost-effectiveness analysis, dedicated neurocritical care units had higher mean lifetime quality-adjusted life-years (QALYs) at small additional mean costs with an incremental cost-effectiveness ratio (ICER) of 14,000 pound per QALY and incremental net monetary benefit (INB) of 17,000 pound. The cost-effectiveness acceptability curve suggested that the probability that dedicated compared with combined neurocritical care units are cost-effective is around 60%. There were substantial differences in case mix between the 'early' (within 18 hours of presentation) and 'no or late' (after 24 hours) transfer groups. After adjustment, the 'early' transfer group reported higher lifetime QALYs at an additional cost with an ICER of 11,000 pound and INB of 17,000 pound. Conclusions: The risk models demonstrated sufficient statistical performance to support their use in research but fell below the level required to guide individual patient decision-making. The results suggest that management in a dedicated neurocritical care unit may be cost-effective compared with a combined neuro/general critical care unit (although there is considerable statistical uncertainty) and support current recommendations that all patients with severe TBI would benefit from transfer to a neurosciences centre, regardless of the need for surgery. We recommend further research to improve risk prediction models; consider alternative approaches for handling unobserved confounding; better understand long-term outcomes and alternative pathways of care; and explore equity of access to postcritical care support for patients following acute TBI.	[Harrison, D. A.; Prabhu, G.; Harvey, S. E.; Griggs, K. A.; Walmsley, E.; Rowan, K. M.] Intens Care Natl Audit & Res Ctr, London, England; [Grieve, R.; Sadique, M. Z.; Gomes, M.] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London WC1, England; [Smith, M.] Univ Coll London Hosp NHS Fdn Trust, Natl Hosp Neurol & Neurosurg, London, England; [Yeoman, P.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Nottingham, England; [Lecky, F. E.] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Hutchinson, P. J. A.; Menon, D. K.] Univ Cambridge, Cambridge, England	Harrison, DA (corresponding author), Intens Care Natl Audit & Res Ctr, London, England.		Harrison, David A/O-4355-2018	Harrison, David A/0000-0002-9002-9098; Harvey, Sheila/0000-0001-7604-8607; Gomes, Manuel/0000-0002-1428-1232; Grieve, Richard/0000-0001-8899-1301	National Institute for Health Research Health Technology Assessment programmeNational Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090, 07/37/29] Funding Source: researchfish	The National Institute for Health Research Health Technology Assessment programme.	Abadie A, 2011, J BUS ECON STAT, V29, P1, DOI 10.1198/jbes.2009.07333; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; ANDREWS PJD, 1990, LANCET, V335, P327, DOI 10.1016/0140-6736(90)90614-B; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Barber Julie, 2004, J Health Serv Res Policy, V9, P197, DOI 10.1258/1355819042250249; Barratt H, 2010, EMERG MED J, V27, P173, DOI 10.1136/emj.2009.075382; Black N, 1996, BRIT MED J, V312, P1215; Brier G.W., 1950, MONTHLY WEATHER REV, V78, P1, DOI 2.0.CO;2; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Carpenter JR, 2011, J STAT SOFTW, V45, P1; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Centers for Disease Control and Prevention, 2010, TRAUMATIC BRAIN INJU; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Curtis L., 2011, UNIT COSTS HLTH SOCI; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; Department for Communities and Local Government, 2011, ENGL IND DEPR 2010; Department of Health (DoH), 2011, NHS REF COSTS 2010 1; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dolan P, 1999, 138 CHE U YORK; DONNER A, 1992, STAT MED, V11, P1511, DOI 10.1002/sim.4780111109; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; Edwards P, 2005, LANCET, V365, P1957; Edwards P, 2002, BRIT MED J, V324, P1183, DOI 10.1136/bmj.324.7347.1183; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Feiz-Erfan I, 2007, J NEUROSURG, V107, P364, DOI 10.3171/JNS-07/08/0364; Field D, 2005, PEDIATRICS, V115, P926, DOI 10.1542/peds.2004-1209; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fuller G, 2011, BRIT J NEUROSURG, V25, P414, DOI 10.3109/02688697.2011.570882; Fuller G, 2011, J NEUROSURG ANESTH, V23, P198, DOI 10.1097/ANA.0b013e3182161816; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; GENTLEMAN D, 1981, LANCET, V2, P853; Gomes M, 2012, MED DECIS MAKING, V32, P350, DOI 10.1177/0272989X11418372; Greene W.H., 2003, ECONOMETRIC ANAL; Grieve R, 2010, MED DECIS MAKING, V30, P163, DOI 10.1177/0272989X09341752; HANLEY JA, 1988, MED DECIS MAKING, V8, P197, DOI 10.1177/0272989X8800800308; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrison DA, 2006, CRIT CARE MED, V34, P1378, DOI 10.1097/01.CCM.0000216702.94014.75; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hayes JA, 2000, HLTH TECHNOL ASSESS, V4; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; HOSMER DW, 1980, COMMUN STAT A-THEOR, V9, P1043, DOI 10.1080/03610928008827941; Hsiao KY, 2008, EMERG MED J, V25, P670, DOI 10.1136/emj.2007.053405; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Ibrahim MI, 2007, ASIAN J SURG, V30, P261, DOI 10.1016/S1015-9584(08)60036-6; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Johnson P, 2006, BRAIN COGNITION, V60, P205; Kenward MG, 2007, STAT METHODS MED RES, V16, P199, DOI 10.1177/0962280206075304; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Kochanek PM, 2001, CRIT CARE MED, V29, P692, DOI 10.1097/00003246-200103000-00053; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Latimer N, 2011, NICE DSU TECHNICAL S; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Liao CC, 2007, J TRAUMA, V63, P827, DOI 10.1097/TA.0b013e31814b9466; Livingston BM, 2000, CRIT CARE MED, V28, P389, DOI 10.1097/00003246-200002000-00017; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; McCullagh P., 1989, GEN LINEAR MODELS; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Menon D, 2008, BMJ-BRIT MED J, V336, P397, DOI 10.1136/bmj.39461.616991.80; Menon David, 2004, Curr Opin Crit Care, V10, P91, DOI 10.1097/00075198-200404000-00002; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Collaborating Centre for Acute Care (UK), 2007, HEAD INJ TRIAG ASS I; Neurocritical Care Stakeholder Group, 2006, NEUR CAR CAP DEM; NICE, 2008, GUID METH TECHN APPR; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Noah MA, 2011, JAMA-J AM MED ASSOC, V306, P1659, DOI 10.1001/jama.2011.1471; Office for National Statistics (ONS), 2011, INT LIF TABL 2008 20; Oh Hyun Soo, 2006, Taehan Kanho Hakhoe Chi, V36, P621; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Pang BC, 2007, J NEUROTRAUM, V24, P136, DOI 10.1089/neu.2006.0113; Pape TLB, 2006, BRAIN INJURY, V20, P743, DOI 10.1080/02699050600676933; Park CA, 2001, AM SURGEON, V67, P665; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Pirracchio R, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-132; Reichenheim ME, 2004, STATA J, V4, P421, DOI 10.1177/1536867X0400400404; Rocker GM, 2006, CAN J ANAESTH, V53, P814, DOI 10.1007/BF03022799; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Rosenbaum PR, 2002, STAT SCI, V17, P286; Rowan K, 2007, EVALUATION OUTREACH; ROWAN KM, 1993, BRIT MED J, V307, P977, DOI 10.1136/bmj.307.6910.977; ROWAN KM, 1993, BRIT MED J, V307, P972, DOI 10.1136/bmj.307.6910.972; Rubin DB., 1987, MULTIPLE IMPUTATION; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salorio CF, 2008, PEDIATR CRIT CARE ME, V9, P47, DOI 10.1097/01.PCC.0000298638.66240.0E; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI [10.1201/9781439821862, DOI 10.1201/9781439821862]; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Smith M, 2004, BRIT J ANAESTH, V93, P753, DOI 10.1093/bja/aeh275; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Statistics for Wales, 2011, WELSH IND MULT DEPR; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teig M, 2010, J NEUROSURG ANESTH, V22, P357, DOI 10.1097/ANA.0b013e3181f0dada; The CRASH trial management group, 2001, BMC Emerg Med, V1, P1; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; van Buuren S, 2011, J STAT SOFTW, V45, P1; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Xu XY, 2007, BRAIN INJURY, V21, P575, DOI 10.1080/02699050701426881; Yeoman P, 2011, J TRAUMA, V71, P387, DOI 10.1097/TA.0b013e31820ceadd; Zheng WB, 2007, NEURORADIOLOGY, V49, P271, DOI 10.1007/s00234-006-0187-8; Zou GY, 2004, BIOMETRICS, V60, P807, DOI 10.1111/j.0006-341X.2004.00232.x	153	55	57	0	9	NIHR JOURNALS LIBRARY	SOUTHAMPTON	UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE, ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND	1366-5278	2046-4924		HEALTH TECHNOL ASSES	Health Technol. Assess.	JUN	2013	17	23					1	+		10.3310/hta17230			351	Health Care Sciences & Services	Health Care Sciences & Services	164AG	WOS:000320380500001	23763763	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Pilla, AA				Pilla, Arthur A.			Nonthermal electromagnetic fields: From first messenger to therapeutic applications	ELECTROMAGNETIC BIOLOGY AND MEDICINE			English	Article						calmodulin; first messenger; nitric oxide; pulsed electromagnetic field; radio frequency; signaling; tissue repair	NITRIC-OXIDE SYNTHASE; POSTOPERATIVE PAIN; ALZHEIMERS-DISEASE; LORENTZ MODEL; THERMAL NOISE; DOUBLE-BLIND; IN-VITRO; CALMODULIN; NO; ANGIOGENESIS	Nonthermal pulsed electromagnetic fields, from low frequency to pulse-modulated radio frequency, have been successfully employed as adjunctive therapy for the treatment of delayed and non-union fractures, fresh fractures and chronic wounds. Recent increased understanding of the mechanism of action of electromagnetic fields (EMF) has permitted technologic advances allowing the development of EMF devices which are portable and disposable, can be incorporated into dressings, supports and casts, and can be used over clothing. This broadens the use of non-pharmacological, non-invasive EMF therapy to the treatment of postoperative pain and edema to enhance surgical recovery. EMF therapy is rapidly becoming a standard part of surgical care, and new, more significant, clinical applications for osteoarthritis, brain and cardiac ischemia and traumatic brain injury are in the pipeline. This study reviews recent evidence which suggests that calmodulin (CaM)-dependent nitric oxide signaling is involved in cell and tissue response to weak nonthermal EMF signals. There is abundant evidence that EMF signals can be configured a priori to increase the rate of CaM activation, which, in turn, can modulate the biochemical cascades living cells and tissues employ in response to external insult. Successful applications in pilot clinical trials, coupled with evidence at the cellular and animal levels, provide support that EMF is a first messenger that can modulate the response of challenged biological systems.	[Pilla, Arthur A.] Columbia Univ, Dept Biomed Engn, New York, NY USA; [Pilla, Arthur A.] Mt Sinai Sch Med, Dept Orthoped, New York, NY USA	Pilla, AA (corresponding author), 1 Winding Ridge, Oakland, NJ 07436 USA.	aap1@columbia.edu					Arendash GW, 2012, J ALZHEIMERS DIS, V32, P243, DOI 10.3233/JAD-2012-120943; Arendash GW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035751; Arendash GW, 2010, J ALZHEIMERS DIS, V19, P191, DOI 10.3233/JAD-2010-1228; Batchelor AM, 2010, P NATL ACAD SCI USA, V107, P22060, DOI 10.1073/pnas.1013147107; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; Bootman MD, 2001, J CELL SCI, V114, P2213; Borhade N, 2012, CHEM PHARM BULL, V60, P465, DOI 10.1248/cpb.60.465; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brighton CT, 2008, J BONE JOINT SURG AM, V90A, P833, DOI 10.2106/JBJS.F.01437; Callaghan MJ, 2008, PLAST RECONSTR SURG, V121, P130, DOI 10.1097/01.prs.0000293761.27219.84; Chang K, 2004, EXP MOL MED, V36, P311, DOI 10.1038/emm.2004.42; Chen Y, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-13; Cheng D. K., 1959, ANAL LINEAR SYSTEMS; CHIABRERA A, 1993, BIOELECTROCH BIOENER, V30, P35, DOI 10.1016/0302-4598(93)80060-8; Chiarini Anna, 2006, Italian Journal of Anatomy and Embryology, V111, P221; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Cooke JP, 2003, ATHEROSCLEROSIS SUPP, V4, P53, DOI 10.1016/S1567-5688(03)00034-5; Cury Y, 2011, NITRIC OXIDE-BIOL CH, V25, P243, DOI 10.1016/j.niox.2011.06.004; Daff S, 2003, BIOCHEM SOC T, V31, P502, DOI 10.1042/bst0310502; De Mattei M, 2009, OSTEOARTHR CARTILAGE, V17, P252, DOI 10.1016/j.joca.2008.06.002; DeFelice LJ, 1981, INTRO MEMBRANE NOISE, P243; Delle Monache S, 2008, BIOELECTROMAGNETICS, V29, P640, DOI 10.1002/bem.20430; Dragicevic N, 2011, NEUROSCIENCE, V185, P135, DOI 10.1016/j.neuroscience.2011.04.012; Duran WN, 2010, CARDIOVASC RES, V87, P254, DOI 10.1093/cvr/cvq139; EDMONDS DT, 1993, BIOELECTROCH BIOENER, V30, P3, DOI 10.1016/0302-4598(93)80057-2; Faas GC, 2011, NAT NEUROSCI, V14, P301, DOI 10.1038/nn.2746; Heden P, 2008, AESTHET PLAST SURG, V32, P660, DOI 10.1007/s00266-008-9169-z; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Janis JE, 2006, PLAST RECONSTR SUR S, V117, p12S; KAVALIERS M, 1991, BIOL BULL, V180, P301, DOI 10.2307/1542401; Konieczny V, 2012, SEMIN CELL DEV BIOL, V23, P172, DOI 10.1016/j.semcdb.2011.09.006; Kowalczuk C, 2010, BIOELECTROMAGNETICS, V31, P556, DOI 10.1002/bem.20597; Kwon MS, 2012, BIOELECTROMAGNETICS, V33, P247, DOI 10.1002/bem.20702; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P734, DOI 10.1097/00000542-199903000-00015; Lee RH, 2001, J SURG RES, V101, P104, DOI 10.1006/jsre.2001.6261; MARKOV MS, 1994, CHARGE FIELD EFFECTS, V4, P274; Mellstrom B, 2008, PHYSIOL REV, V88, P421, DOI 10.1152/physrev.00041.2005; Mo E, 2004, J BIOL CHEM, V279, P26149, DOI 10.1074/jbc.M400916200; Moffett J, 2010, J DIABET FOOT COMPLI, V2, P57; Moffett J., 2011, J DIABETES FOOT COMP, V2, P30; Moffett John, 2012, J Pain Res, V5, P347, DOI 10.2147/JPR.S35076; Muehsam DJ, 2009, BIOELECTROMAGNETICS, V30, P476, DOI 10.1002/bem.20493; Muehsam DJ, 2009, BIOELECTROMAGNETICS, V30, P462, DOI 10.1002/bem.20494; Nelson FR, 2012, RHEUMATOL INT; Palmi M, 2002, MOL NEUROBIOL, V25, P133, DOI 10.1385/MN:25:2:133; Parazzini M, 2007, RADIAT RES, V168, P608, DOI 10.1667/RR1020.1; Patel MK, 2006, J RECONSTR MICROSURG, V22, P611, DOI 10.1055/s-2006-956231; Pilla A., 2006, HDB BIOL EFFECTS ELE, P351; PILLA A A, 1974, Bioelectrochemistry and Bioenergetics, V1, P227, DOI 10.1016/0302-4598(74)85024-5; Pilla A. A., 1972, Proceedings of the 7th Intersociety Energy conversion Engineering conference, P761; PILLA AA, 1970, J ELECTROCHEM SOC, V117, P467, DOI 10.1149/1.2407544; PILLA AA, 1994, BIOELECTROCH BIOENER, V35, P63, DOI 10.1016/0302-4598(94)87013-6; Pilla AA, 1999, BIOELECTROCH BIOENER, V48, P27, DOI 10.1016/S0302-4598(98)00148-2; PILLA AA, 1974, ANN NY ACAD SCI, V238, P149, DOI 10.1111/j.1749-6632.1974.tb26785.x; Pilla AA, 2010, P 32 ANN M BIOEL SOC; Pilla A, 2011, BBA-GEN SUBJECTS, V1810, P1236, DOI 10.1016/j.bbagen.2011.10.001; Pilla AA, 2012, BIOCHEM BIOPH RES CO, V426, P330, DOI 10.1016/j.bbrc.2012.08.078; PRATO FS, 1995, FASEB J, V9, P807; Rawe IM, 2012, AESTHET PLAST SURG, V36, P458, DOI 10.1007/s00266-011-9828-3; Reale M, 2006, NITRIC OXIDE-BIOL CH, V15, P50, DOI 10.1016/j.niox.2005.11.010; Ren K, 2009, BRAIN RES REV, V60, P57, DOI 10.1016/j.brainresrev.2008.12.020; Rohde C, 2010, PLAST RECONSTR SURG, V125, P1620, DOI 10.1097/PRS.0b013e3181c9f6d3; Roland D, 2000, PLAST RECONSTR SURG, V105, P1371, DOI 10.1097/00006534-200004040-00016; Shen MYH, 2009, J AM COLL CARDIOL, V53, pA346; Sluka KA, 1999, J PHARMACOL EXP THER, V289, P840; Strauch B, 2006, P 28 ANN M BIOEL SOC; Strauch B, 2007, PLAST RECONSTR SURG, V120, P425, DOI 10.1097/01.prs.0000267700.15452.d0; Strauch B, 2006, J HAND SURG-AM, V31A, P1131, DOI 10.1016/j.jhsa.2006.03.024; Strauch B, 2009, AESTHET SURG J, V29, P135, DOI 10.1016/j.asj.2009.02.001; Tepper OM, 2004, FASEB J, V18, P1231, DOI 10.1096/fj.03-0847fje; Tsoukias N, 2008, MICROCIRCULATION, V15, P813, DOI 10.1080/10739680802010070; Varani K, 2011, BIOELECTROMAGNETICS, P276, DOI [10.1002/bem.20704.33, DOI 10.1002/BEM.20704.33:276-287]; Velazquez C, 2005, J MED CHEM, V48, P4061, DOI 10.1021/jm050211k; Vianale G, 2008, BRIT J DERMATOL, V158, P1189, DOI 10.1111/j.1365-2133.2008.08540.x; Wachten D., 2010, HDB CELL SIGNAL, V2, P937, DOI [10.1016/B978-0-12-374145-5.00117-0, DOI 10.1016/B978-0-12-374145-5.00117-0]; Wang ZY, 2006, J BONE JOINT SURG AM, V88A, P1053, DOI 10.2106/JBJS.E.00443; Weber RV, 2004, PLAST RECONSTR SURG, V114, P1185, DOI 10.1097/01.prs.0000135857.95310.13; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; YENPATTON GPA, 1988, J CELL PHYSIOL, V134, P37, DOI 10.1002/jcp.1041340105	79	55	59	0	14	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1536-8378	1536-8386		ELECTROMAGN BIOL MED	Electromagn. Biol. Med.	JUN	2013	32	2					123	136		10.3109/15368378.2013.776335			14	Biology; Biophysics	Life Sciences & Biomedicine - Other Topics; Biophysics	144LA	WOS:000318939500002	23675615				2021-06-18	
J	Rogers, ML; Feuerstein, D; Leong, CL; Takagaki, M; Niu, XZ; Graf, R; Boutelle, MG				Rogers, Michelle L.; Feuerstein, Delphine; Leong, Chi Leng; Takagaki, Masatoshi; Niu, Xize; Graf, Rudolf; Boutelle, Martyn G.			Continuous Online Microdialysis Using Microfluidic Sensors: Dynamic Neurometabolic Changes during Spreading Depolarization	ACS CHEMICAL NEUROSCIENCE			English	Article						Microfluidic; biosensor; microdialysis; real-time; spreading depolarization	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; LACTATE LEVELS; PERIINFARCT DEPOLARIZATIONS; BLOOD-FLOW; DEPRESSION; GLUCOSE; ANESTHETICS; DAMAGE	Microfluidic glucose biosensors and potassium ion selective electrodes were used in an in vivo study to measure the neurochemical effects of spreading depolarizations (SD), which have been shown to be detrimental to the injured human brain. A microdialysis probe implanted in the cortex of rats was connected to a microfluidic PDMS chip containing the sensors. The dialysate was also analyzed using our gold standard, rapid sampling microdialysis (rsMD). The glucose biosensor performance was validated against rsMD with excellent results. The glucose biosensors successfully monitored concentration changes, in response to SD wave induction, in the range of 10-400 mu M with a second time-resolution. The data show that during a SD wave, there is a time delay of 62 +/- 24.8 s (n = 4) between the onset of the increase in potassium and the decrease in glucose. This delay can be for the first time demonstrated, thanks to the high-temporal resolution of the microfluidic sensors sampling from a single tissue site (the microdialysis probe), and it indicates that the decrease in glucose is due to the high demand of energy required for repolarization.	[Rogers, Michelle L.; Leong, Chi Leng; Boutelle, Martyn G.] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England; [Feuerstein, Delphine; Takagaki, Masatoshi; Graf, Rudolf] Max Planck Inst Neurol Res, D-50931 Cologne, Germany; [Niu, Xize] Univ Southampton, Southampton, Hants, England	Boutelle, MG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England.	m.boutelle@imperial.ac.uk	Niu, Xize/D-4627-2013	Rogers, Michelle/0000-0002-1434-2322; Leong, Chi Leng/0000-0002-2654-1345	Wellcome Trust/DOH HICF fund; Alexander von Humboldt FoundationAlexander von Humboldt Foundation; BBSRCUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)	The authors thank the Wellcome Trust/DOH HICF fund, Alexander von Humboldt Foundation, and the BBSRC.	[Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; Caesar K, 2008, J PHYSIOL-LONDON, V586, P1337, DOI 10.1113/jphysiol.2007.144154; CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; Clough GF, 2002, J PHARMACOL EXP THER, V302, P681, DOI 10.1124/jpet.102.035634; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Dunn AK, 2001, J CEREBR BLOOD F MET, V21, P195, DOI 10.1097/00004647-200103000-00002; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Feuerstein D., 2013, CAPACITY RAISE UNPUB; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Feuerstein D, 2009, ANAL CHEM, V81, P4987, DOI 10.1021/ac900161x; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hashemi P, 2009, J CEREBR BLOOD F MET, V29, P166, DOI 10.1038/jcbfm.2008.108; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Horn T, 2010, NEUROCHEM INT, V57, P940, DOI 10.1016/j.neuint.2010.09.014; Hu YB, 1997, J NEUROCHEM, V69, P1484; Hutchens MP, 2006, NEUROCRIT CARE, V4, P54, DOI 10.1385/NCC:4:1:054; Kudo C, 2008, EXP NEUROL, V212, P201, DOI 10.1016/j.expneurol.2008.03.026; Kumagai T, 2011, J CEREBR BLOOD F MET, V31, P580, DOI 10.1038/jcbfm.2010.128; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Leong C., 2013, ON LINE POTASS UNPUB; Luckl J, 2009, J NEUROSCI RES, V87, P1219, DOI 10.1002/jnr.21933; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; MIES G, 1993, J NEUROCHEM, V60, P360, DOI 10.1111/j.1471-4159.1993.tb05860.x; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Oliver NS, 2009, DIABETIC MED, V26, P197, DOI 10.1111/j.1464-5491.2008.02642.x; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Patel BA, 2011, BIOSENS BIOELECTRON, V26, P2890, DOI 10.1016/j.bios.2010.11.033; Richter F, 2003, J NEUROPHYSIOL, V90, P2163, DOI 10.1152/jn.00388.2003; Richter F, 2002, NEUROSCI LETT, V334, P123, DOI 10.1016/S0304-3940(02)01120-5; Rogers M, 2011, PHYS CHEM CHEM PHYS, V13, P5298, DOI 10.1039/c0cp02810j; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; STRONG AJ, 2003, J CEREB BLOOD FLO S1, V23, P300; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392; Takagaki M., 2013, ISOFLURANE SUP UNPUB; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; VYSKOCIL F, 1972, BRAIN RES, V39, P255, DOI 10.1016/0006-8993(72)90802-5; Whitfield P., 2009, HEAD INJURY A MULTID, P309; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	46	55	56	2	49	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	MAY	2013	4	5					799	807		10.1021/cn400047x			9	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	148ND	WOS:000319250400017	23574576	Green Published, Other Gold			2021-06-18	
J	Freund, P; Curt, A; Friston, KJ; Thompson, A				Freund, Patrick; Curt, Armin; Friston, Karl J.; Thompson, Alan			Tracking Changes following Spinal Cord Injury: Insights from Neuroimaging	NEUROSCIENTIST			English	Article						neuroimaging; atrophy; cortical reorganization; disability	VOXEL-BASED MORPHOMETRY; MULTIPLE-SCLEROSIS; MOTOR CORTEX; FUNCTIONAL RECOVERY; CORTICAL THICKNESS; WHITE-MATTER; IN-VIVO; BRAIN; ATROPHY; REORGANIZATION	Traumatic spinal cord injury is often disabling and recovery of function is limited. As a consequence of damage, both spinal cord and brain undergo anatomical and functional changes. Besides clinical measures of recovery, biomarkers that can detect early anatomical and functional changes might be useful in determining clinical outcome-during the course of rehabilitation and recovery-as well as furnishing a tool to evaluate novel treatment interventions and their mechanisms of action. Recent evidence suggests an interesting three-way relationship between neurological deficit and changes in the spinal cord and of the brain and that, importantly, noninvasive magnetic resonance imaging techniques, both structural and functional, provide a sensitive tool to lay out these interactions. This review describes recent findings from multimodal imaging studies of remote anatomical changes (i.e., beyond the lesion site), cortical reorganization, and their relationship to clinical disability. These developments in this field may improve our understanding of effects on the nervous system that are attributable to the injury itself and will allow their distinction from changes that result from rehabilitation (i.e., functional retraining) and from interventions affecting the nervous system directly (i.e., neuroprotection or regeneration).	[Freund, Patrick; Thompson, Alan] UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, London WCN1 3BG, England; [Freund, Patrick; Curt, Armin] Univ Zurich, Univ Hosp Balgrist, Spinal Cord Injury Ctr, Zurich, Switzerland; [Freund, Patrick; Friston, Karl J.] UCL, UCL Inst Neurol, Wellcome Trust Ctr Neuroimaging, London WCN1 3BG, England	Freund, P (corresponding author), UCL, UCL Inst Neurol, Dept Brain Repair & Rehabil, Queens Sq, London WCN1 3BG, England.	p.freund@ucl.ac.uk	Friston, Karl/D-9230-2011; Thompson, Alan J/C-2654-2008; Freund, Patrick/D-4193-2013	Friston, Karl/0000-0001-7984-8909; Thompson, Alan J/0000-0002-4333-8496; Freund, Patrick/0000-0002-4851-2246	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBFR33-120920]; Schweizerische Stiftung fur medizinische und biologische Stipendien [PASMP3-124194]; Wellcome Trust in the United KingdomWellcome Trust	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Swiss National Science Foundation (Grant No. PBFR33-120920), Schweizerische Stiftung fur medizinische und biologische Stipendien (Grant No. PASMP3-124194), and the Wellcome Trust in the United Kingdom.	Aguilar J, 2010, J NEUROSCI, V30, P7528, DOI 10.1523/JNEUROSCI.0379-10.2010; Andre Jalal B, 2010, Top Magn Reson Imaging, V21, P367, DOI 10.1097/RMR.0b013e31823e65a1; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barkhof F, 2009, NAT REV NEUROL, V5, P256, DOI 10.1038/nrneurol.2009.41; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bodini B, 2009, HUM BRAIN MAPP, V30, P2852, DOI 10.1002/hbm.20713; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Budde MD, 2008, NMR BIOMED, V21, P589, DOI 10.1002/nbm.1229; Calancie B, 1996, ELECTROMYOGR MOTOR C, V101, P304, DOI 10.1016/0924-980X(96)95194-2; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; Cheran S, 2011, J NEUROTRAUM, V28, P1881, DOI 10.1089/neu.2010.1741; Ciccarelli O, 2008, LANCET NEUROL, V7, P715, DOI 10.1016/S1474-4422(08)70163-7; Cohen-Adad J, 2011, NEUROIMAGE, V55, P1024, DOI 10.1016/j.neuroimage.2010.11.089; Courtine G, 2008, NAT MED, V14, P69, DOI 10.1038/nm1682; Crawley AP, 2004, BRAIN RES, V1028, P19, DOI 10.1016/j.brainres.2004.08.060; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; Curt A, 2012, SPINAL CORD, V50, P352, DOI 10.1038/sc.2011.113; Curt A, 2002, BRAIN, V125, P2567, DOI 10.1093/brain/awf250; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Draganski B, 2011, NEUROIMAGE, V55, P1423, DOI 10.1016/j.neuroimage.2011.01.052; Draganski B, 2004, NATURE, V427, P311, DOI 10.1038/427311a; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Endo T, 2009, NEUROSCIENTIST, V15, P291, DOI 10.1177/1073858408329508; Fawcett JW, 2007, SPINAL CORD, V45, P190, DOI 10.1038/sj.sc.3102007; Fehlings MG, 2011, J NEUROTRAUM, V28, P1329, DOI 10.1089/neu.2011.1955; Felix MS, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00045; Fields RD, 2008, TRENDS NEUROSCI, V31, P361, DOI 10.1016/j.tins.2008.04.001; Freund P, 2006, NAT MED, V12, P790, DOI 10.1038/nm1436; Freund P, 2012, J NEUROL NEUROSUR PS, V83, P629, DOI 10.1136/jnnp-2011-301875; Freund P, 2011, EUR J NEUROSCI, V34, P1839, DOI 10.1111/j.1460-9568.2011.07895.x; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Freund P, 2010, MULT SCLER J, V16, P1193, DOI 10.1177/1352458510376180; Freund PAB, 2010, J MAGN RESON IMAGING, V32, P1242, DOI 10.1002/jmri.22340; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; Furkiewicz MT, 2007, NEUROREHAB NEURAL RE, V21, P527, DOI 10.1177/1545968307301872; Ghosh A, 2012, CEREB CORTEX, V22, P1309, DOI 10.1093/cercor/bhr191; Ghosh A, 2010, NAT NEUROSCI, V13, P97, DOI 10.1038/nn.2448; Guleria S, 2008, J NEUROSCI RES, V86, P2271, DOI 10.1002/jnr.21664; Hains BC, 2003, J COMP NEUROL, V462, P328, DOI 10.1002/cne.10733; Henderson LA, 2011, J NEUROSCI, V31, P2630, DOI 10.1523/JNEUROSCI.2717-10.2011; Horsfield MA, 2010, NEUROIMAGE, V50, P446, DOI 10.1016/j.neuroimage.2009.12.121; Hubli M, 2012, NEUROREHAB NEURAL RE, V26, P188, DOI 10.1177/1545968311420844; Hutton C, 2008, NEUROIMAGE, V40, P1701, DOI 10.1016/j.neuroimage.2008.01.027; Hutton C, 2009, NEUROIMAGE, V48, P371, DOI 10.1016/j.neuroimage.2009.06.043; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; Jones EG, 2000, ANNU REV NEUROSCI, V23, P1, DOI 10.1146/annurev.neuro.23.1.1; Jurkiewicz MT, 2010, NEUROREHAB NEURAL RE, V24, P136, DOI 10.1177/1545968309347680; Jurkiewicz MT, 2006, NEUROLOGY, V66, P762, DOI 10.1212/01.wnl.0000201276.28141.40; Kim BG, 2006, EXP NEUROL, V198, P401, DOI 10.1016/j.expneurol.2005.12.010; Kim JH, 2010, J NEUROTRAUM, V27, P587, DOI 10.1089/neu.2009.1063; Kokotilo KJ, 2009, J NEUROTRAUM, V26, P2113, DOI 10.1089/neu.2008.0688; Lang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030461; Langer N, 2012, NEUROLOGY, V78, P182, DOI 10.1212/WNL.0b013e31823fcd9c; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Lundell H, 2011, SPINAL CORD, V49, P70, DOI 10.1038/sc.2010.87; Lundell H, 2011, NEUROIMAGE, V54, P1254, DOI 10.1016/j.neuroimage.2010.09.009; Miller DH, 2002, BRAIN, V125, P1676, DOI 10.1093/brain/awf177; Mohammadi S, 2012, MAGN RESON MED, V68, P882, DOI 10.1002/mrm.23308; Mohammadi S, 2012, NEUROIMAGE, V60, P562, DOI 10.1016/j.neuroimage.2011.12.009; Morelli JN, 2010, INVEST RADIOL, V45, P29, DOI 10.1097/RLI.0b013e3181c65c11; Nicotra A, 2006, BRAIN, V129, P718, DOI 10.1093/brain/awh699; Nishimura Y, 2007, SCIENCE, V318, P1150, DOI 10.1126/science.1147243; Petersen JA, 2012, J NEUROTRAUM, V29, P1556, DOI 10.1089/neu.2011.2027; Ramer MS, 2000, NATURE, V403, P312, DOI 10.1038/35002084; Schmid MR, 2005, AM J ROENTGENOL, V184, P1744, DOI 10.2214/ajr.184.6.01841744; Schmierer K, 2004, ANN NEUROL, V56, P407, DOI 10.1002/ana.20202; Schmierer K, 2007, NEUROIMAGE, V35, P467, DOI 10.1016/j.neuroimage.2006.12.010; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Thurnher MM, 2009, MAGN RESON IMAGING C, V17, P225, DOI 10.1016/j.mric.2009.02.004; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248; Wang DF, 2011, J NEUROSCI, V31, P9332, DOI 10.1523/JNEUROSCI.0983-11.2011; Wannier T, 2005, J NEUROTRAUM, V22, P703, DOI 10.1089/neu.2005.22.703; Ward NS, 2004, ANN NEUROL, V55, P829, DOI 10.1002/ana.20099; Weiskopf N, 2011, NEUROIMAGE, V54, P2116, DOI 10.1016/j.neuroimage.2010.10.023; Wilm BJ, 2009, NMR BIOMED, V22, P174, DOI 10.1002/nbm.1298; Woollett K, 2011, CURR BIOL, V21, P2109, DOI 10.1016/j.cub.2011.11.018; Wrigley PJ, 2009, CEREB CORTEX, V19, P224, DOI 10.1093/cercor/bhn072; Wyndaele M, 2006, SPINAL CORD, V44, P523, DOI 10.1038/sj.sc.3101893; Yague JG, 2011, EXP NEUROL, V227, P252, DOI 10.1016/j.expneurol.2010.11.011	82	55	59	0	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	APR	2013	19	2					116	128		10.1177/1073858412449192			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	134YP	WOS:000318252000006	22730072	Green Published, Other Gold			2021-06-18	
J	Stansbury, LG; Hess, AS; Thompson, K; Kramer, B; Scalea, TM; Hess, JR				Stansbury, Lynn G.; Hess, Aaron S.; Thompson, Kwaku; Kramer, Betsy; Scalea, Thomas M.; Hess, John R.			The clinical significance of platelet counts in the first 24 hours after severe injury	TRANSFUSION			English	Article							TRAUMATIC BRAIN-INJURY; MASSIVE TRANSFUSION; MORTALITY; ADMISSION; COAGULATION; PROGRESSION; PATTERNS; RATIOS; IMPACT; TIME	BACKGROUND: Admission platelet (PLT) counts are known to be associated with all-cause mortality for seriously injured patients admitted to a trauma center. The course of subsequent PLT counts, their implications, and the effects of PLT therapy are less well known. STUDY DESIGN AND METHODS: Trauma center patients who were directly admitted from the scene of injury, received 1 or more units of uncrossmatched red blood cells in the first hour of care, survived for at least 15 minutes, and had a PLT count measured in the first hour were analyzed for the association of their admission and subsequent PLT counts in the first 24 hours with injury severity and hemorrhagic and central nervous system (CNS) causes of in-hospital mortality. RESULTS: Over an 8.25-year period, 1292 of 45,849 direct trauma admissions met entry criteria. Admission PLT counts averaged 228x109 +/- 90x109/L and decreased by 104x109/L by the second hour and 1x109/L each hour thereafter. The admission count was not related to time to admission. Each 1-point increase in the injury severity score was associated with a 1x109/L decrease in the PLT count at all times in the first 24 hours of care. Admission PLT counts were strongly associated with hemorrhagic and CNS injury mortality and subsequent PLT counts. Effects of PLT therapy could not be ascertained. DISCUSSION: Admission PLT counts in critically injured trauma patients are usually normal, decreasing after admission. Low PLT counts at admission and during the course of trauma care are strongly associated with mortality.	[Stansbury, Lynn G.; Hess, Aaron S.; Thompson, Kwaku; Kramer, Betsy; Scalea, Thomas M.; Hess, John R.] Univ Maryland, Program Trauma Epidemiol & Pathol, Sch Med, Baltimore, MD 20201 USA	Hess, JR (corresponding author), Univ Maryland, Blood Bank, Med Ctr, N2W50a,22 South Greene St, Baltimore, MD 20201 USA.	jhess@umm.edu	Hess, John R./K-4001-2013	Hess, John R./0000-0001-8596-4420			[Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; ATTAR S, 1969, J TRAUM, V9, P939, DOI 10.1097/00005373-196911000-00004; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Bizzozero J., 1982, VIRCHOWS ARCH PATHOL, V90, P261, DOI DOI 10.1007/BF01931360; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brown LM, 2011, J TRAUMA, V71, pS337, DOI 10.1097/TA.0b013e318227f67c; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; COUNTS RB, 1979, ANN SURG, V190, P91, DOI 10.1097/00000658-197907000-00020; CROSBY WH, 1954, BLOOD, V9, P439, DOI 10.1182/blood.V9.5.439.439; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; HARKER LA, 1972, NEW ENGL J MED, V287, P155, DOI 10.1056/NEJM197207272870401; Hess JR, 2009, TRANSFUSION, V49, P34, DOI 10.1111/j.1537-2995.2008.01944.x; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; Kautza BC, 2012, J TRAUMA ACUTE CARE, V72, P106, DOI 10.1097/TA.0b013e3182410a3c; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Patton GC, 2009, LANCET, V374, P881, DOI 10.1016/S0140-6736(09)60741-8; PEPPER H, 1960, SURG GYNECOL OBSTET, V110, P319; REED RL, 1986, ANN SURG, V203, P40, DOI 10.1097/00000658-198601000-00008; Rossaint R, 2010, CRIT CARE, V14, DOI 10.1186/cc8943; Sambasivan CN, 2011, J TRAUMA, V71, pS329, DOI 10.1097/TA.0b013e318227edd3; Saxena R, 1999, STROKE, V30, P993, DOI 10.1161/01.STR.30.5.993; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stainsby D, 2000, BRIT J ANAESTH, V85, P487, DOI 10.1093/bja/85.3.487; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034	27	55	58	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	APR	2013	53	4					783	789		10.1111/j.1537-2995.2012.03828.x			7	Hematology	Hematology	123DI	WOS:000317368200017	22882316				2021-06-18	
J	Thelin, EP; Johannesson, L; Nelson, D; Bellander, BM				Thelin, Eric Peter; Johannesson, Louise; Nelson, David; Bellander, Bo-Michael			S100B Is an Important Outcome Predictor in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; humans; outcome; S100B; TBI	SEVERE HEAD-INJURY; SERUM S-100B PROTEIN; COMPUTED-TOMOGRAPHY FINDINGS; NEURON-SPECIFIC ENOLASE; GLASGOW COMA SCALE; PROGNOSTIC VALUE; SUBARACHNOID HEMORRHAGE; NEUROBIOCHEMICAL MARKERS; EXTRACRANIAL INJURIES; CT FINDINGS	The objective of the study was to examine how S100B, a biomarker of traumatic brain injury (TBI), contributes to outcome prediction after adjusting for known parameters, including age, Glasgow Coma Scale (GCS), pupil reaction, and computed tomography (CT) variables; to examine which parameters have the best correlation to elevated serum levels of S100B; and to investigate when to sample S100B to achieve the strongest association to outcome. This retrospective study included 265 patients with TBI admitted to the neurointensive care unit, Karolinska University Hospital Solna, Stockholm, Sweden. Univariate and multivariate proportional odds regressions were performed to determine parameters most closely related to outcome, and how S100B adds to prediction accuracy. Age (p < 0.0001), pupil reaction (p < 0.0001), and levels of S100B (p < 0.0001) had the strongest statistical correlation to outcome. The area under curve of S100B, the first 48 h after trauma, yielded an additional explained variance of 6.6% in excess of known outcome parameters, including age, GCS, pupil reaction, and CT variables, themselves exhibiting an explained variance of 29.3%. S100B adds substantial information regarding patient outcome, in excess of that provided by known parameters. Only CT variables were found to be significant predictors of increased levels of S100B in uni- and multivariate analysis. Early samples of S100B, within 12 h after trauma, appear to have little prognostic value, and S100B should likely be sampled 12-36 h following trauma to best enhance TBI outcome prediction.	[Thelin, Eric Peter; Bellander, Bo-Michael] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, SE-17176 Stockholm, Sweden; [Nelson, David] Karolinska Univ Hosp Solna, Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, SE-17176 Stockholm, Sweden; [Johannesson, Louise] Stockholm Univ, Dept Econ, S-10691 Stockholm, Sweden	Thelin, EP (corresponding author), Karolinska Univ Hosp Solna, Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, R3 02, SE-17176 Stockholm, Sweden.	eric.thelin@ki.se	Thelin, Eric Peter/K-2144-2012	Thelin, Eric Peter/0000-0002-2338-4364	Stockholm County CouncilStockholm County Council; Karolinska Institutet (ALF)Karolinska Institutet	We thank the staff at our NICU, especially Vivian Hamback-Hellkvist and Birgitta Ohlgren; the Karolinska Univeristy Hospital, Department of Clinical Chemistry for analyzing the S100B samples; and Gunilla Malmborg-Bornhall for keeping track of the trauma database at the Karolinska NICU. The study was funded by grants from the regional agreement between Stockholm County Council and Karolinska Institutet (ALF).	Acker JE, 2004, ADV TRAUMA LIFE SUPP; Aminmansour B, 2009, J RES MED SCI, V14, P343; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Gonzalez-Mao MC, 2011, CLIN LAB, V57, P587; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Husson EC, 2010, J REHABIL MED, V42, P425, DOI 10.2340/16501977-0566; Jackson RGM, 2000, CLIN CHEM LAB MED, V38, P1165, DOI 10.1515/CCLM.2000.179; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Murillo-Cabezas F, 2010, BRAIN INJURY, V24, P609, DOI 10.3109/02699051003652823; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Mussack T, 2006, CLIN BIOCHEM, V39, P349, DOI 10.1016/j.clinbiochem.2005.12.007; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Olivecrona M, 2009, J NEUROL NEUROSUR PS, V80, P1241, DOI 10.1136/jnnp.2008.158196; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pham N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012691; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 2004, NEUROL RES, V26, P440, DOI 10.1179/016164104225015958; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Smit LHM, 2005, INT J BIOL MARKER, V20, P34; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vergouwen MDI, 2006, LANCET NEUROL, V5, P1029, DOI 10.1016/S1474-4422(06)70582-8; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	75	55	61	0	12	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					519	528		10.1089/neu.2012.2553			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300003	23297751				2021-06-18	
J	Yallampalli, R; Wilde, EA; Bigler, ED; McCauley, SR; Hanten, G; Troyanskaya, M; Hunter, JV; Chu, ZL; Li, XQ; Levin, HS				Yallampalli, Ragini; Wilde, Elisabeth A.; Bigler, Erin D.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Hunter, Jill V.; Chu, Zili; Li, Xiaoqi; Levin, Harvey S.			Acute White Matter Differences in the Fornix Following Mild Traumatic Brain Injury Using Diffusion Tensor Imaging	JOURNAL OF NEUROIMAGING			English	Article						Diffusion tensor imaging; mild traumatic brain injury; fornix	AXONAL INJURY; HIPPOCAMPAL; CONCUSSION; RESPONSES; ATROPHY; MEMORY	The integrity of the fornix using diffusion tensor imaging (DTI) in adolescent participants with acute mild traumatic brain injury (mTBI) compared to a demographically matched control group was examined. Fractional anisotropy (FA) in the fornix was elevated in the mild traumatic brain injured group. Performance on the Automated Neuropsychological Assessment Metrics (ANAM) was lower in the group with mTBI. A relation was found between lower performance on cognitive tasks and higher FA. The potential role of fornix injury as a basis of memory and processing speed deficits in mTBI is discussed.	[Yallampalli, Ragini; Wilde, Elisabeth A.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Li, Xiaoqi; Levin, Harvey S.] Baylor Coll Med, Phys Med & Rehabil Alliance, Houston, TX 77030 USA; [Yallampalli, Ragini; Wilde, Elisabeth A.; McCauley, Stephen R.; Hanten, Gerri; Troyanskaya, Maya; Li, Xiaoqi; Levin, Harvey S.] Univ Texas Houston, Sch Med, Houston, TX USA; [Wilde, Elisabeth A.; McCauley, Stephen R.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Hunter, Jill V.; Chu, Zili] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Troyanskaya, Maya; Levin, Harvey S.] Univ Houston, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA; [Yallampalli, Ragini] Univ Houston, Dept Psychol, Houston, TX USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA	Wilde, EA (corresponding author), Baylor Coll Med, 1709 Dryden Rd,Ste 1200, Houston, TX 77030 USA.	ewilde@bcm.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS056202-02]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This research was supported by Grant NS056202-02 awarded to Harvey S. Levin by the National Institutes of Health. We would also like to acknowledge the generous support by Mission Connect of the TIRR Foundation. We would also like to thank the patients and their families for involvement in this study. The information in this manuscript and the manuscript itself has never been published either electronically or in print. None of the authors have any financial or other relationship(s) that could be construed as a conflict of interest with respect to the content of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Bartnik BL, 2001, BRAIN RES, V915, P133, DOI 10.1016/S0006-8993(01)02805-0; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dikranian K, 2008, EXP NEUROL, V211, P551, DOI 10.1016/j.expneurol.2008.03.012; GAFFAN D, 1991, BRAIN, V114, P2611, DOI 10.1093/brain/114.6.2611; Griffiths PD, 2009, NEURORADIOLOGY, V51, P337, DOI 10.1007/s00234-009-0506-y; Jang SH, 2009, ARCH NEUROL-CHICAGO, V66, P1424, DOI 10.1001/archneurol.2009.242; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kirov I, 2007, BRAIN INJURY, V21, P1147, DOI 10.1080/02699050701630383; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; Loftus M, 2000, EXP NEUROL, V163, P180, DOI 10.1006/exnr.2000.7361; MacDonald CL, 2008, NEUROLOGY, V71, P1199, DOI 10.1212/01.wnl.0000327521.69520.7f; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; Pugliese L, 2009, NEUROIMAGE, V47, P427, DOI 10.1016/j.neuroimage.2009.05.014; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Saeki N, 2001, NEURORADIOLOGY, V43, P547, DOI 10.1007/s002340100549; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Singh M, MAGN RESON IMAGING, V28, P22; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54	30	55	56	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1051-2284			J NEUROIMAGING	J. Neuroimaging	APR	2013	23	2					224	227		10.1111/j.1552-6569.2010.00537.x			4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	126LN	WOS:000317617800016	21988147				2021-06-18	
J	Yeh, CC; Chen, TL; Hu, CJ; Chiu, WT; Liao, CC				Yeh, Chun-Chieh; Chen, Ta-Liang; Hu, Chaur-Jong; Chiu, Wen-Ta; Liao, Chien-Chang			Risk of epilepsy after traumatic brain injury: a retrospective population-based cohort study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							LATE POSTTRAUMATIC SEIZURES; OUTCOMES; CHILDREN	Objective To investigate the associated risk of epilepsy after traumatic brain injury (TBI) in a population-based retrospective cohort study. Methods Using Taiwan's National Health Insurance Research Database of reimbursement claims, we conducted a retrospective cohort study of 19 336 TBI patients and 540 322 non-TBI participants aged >= 15 years as reference group. Data on newly developed epilepsy after TBI with 5-8 years' follow-up during 2000 to 2008 were collected. HRs and 95% CIs for the risk of epilepsy associated with TBI were analysed with multivariate Cox proportional hazards regressions. Results Compared with the non-TBI cohort, the adjusted HRs of developing epilepsy among TBI patients with skull fracture, severe or mild brain injury were 10.6 (95% CI 7.14 to 15.8), 5.05 (95% CI 4.40 to 5.79) and 3.02 (95% CI 2.42 to 3.77), respectively. During follow-up, men exhibited higher risks of post-TBI epilepsy. Patients who had mixed types of cerebral haemorrhage were at the highest risk of epilepsy compared with the non-TBI cohort (HR 7.83, 95% CI 4.69 to 13.0). The risk of post-TBI epilepsy was highest within the first year after TBI (HR 38.2, 95% CI 21.7 to 67.0). Conclusions The risk of epilepsy after TBI varied by patient gender, age, latent interval and complexity of TBI. Integrated care for early identification and treatment of post-trauma epilepsy were crucial for TBI patients.	[Yeh, Chun-Chieh] China Med Univ Hosp, Dept Surg, Taichung, Taiwan; [Yeh, Chun-Chieh] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei 110, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ Hosp, Hlth Policy Res Ctr, Taipei 110, Taiwan; [Chen, Ta-Liang; Liao, Chien-Chang] Taipei Med Univ, Sch Med, Taipei, Taiwan; [Hu, Chaur-Jong] Taipei Med Univ, Dept Neurol, Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan	Liao, CC (corresponding author), Taipei Med Univ Hosp, Dept Anesthesiol, 252 Wuxing St, Taipei 110, Taiwan.	jacky48863027@yahoo.com.tw	Yeh, Chun Chieh/I-4893-2019	Yeh, Chun Chieh/0000-0001-6753-7564	Foundation for Anaesthesia Education and Research fellowship grant, Taipei Medical University, Taipei, Taiwan	This research was supported by a Foundation for Anaesthesia Education and Research fellowship grant, Taipei Medical University, Taipei, Taiwan.	Alldredge BK, 1999, NEUROLOGY, V53, pS68; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Camilo O, 2004, STROKE, V35, P1769, DOI 10.1161/01.STR.0000130989.17100.96; Chang CC, 2012, EPILEPSIA, V53, P987, DOI 10.1111/j.1528-1167.2012.03448.x; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chou YC, 2012, J REHABIL MED, V44, P319, DOI 10.2340/16501977-0935; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Eleftheriadis N, 2003, ACTA NEUROL SCAND, V107, P142, DOI 10.1034/j.1600-0404.2003.02092.x; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GLENN CM, 1992, PEDIATR NEPHROL, V6, P182, DOI 10.1007/BF00866310; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Haut SR, 2006, LANCET NEUROL, V5, P148, DOI 10.1016/S1474-4422(06)70348-9; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Liao CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031527; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MORRIS HH, 1993, EPILEPSIA, V34, P1038, DOI 10.1111/j.1528-1157.1993.tb02131.x; Neiman J, 1998, ALCOHOL CLIN EXP RES, V22, p346S, DOI 10.1111/j.1530-0277.1998.tb04389.x; Poole GV, 1997, J TRAUMA, V42, P711, DOI 10.1097/00005373-199704000-00022; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Shih CC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-191; Tokutomi T, 2008, J NEUROTRAUM, V25, P1407, DOI 10.1089/neu.2008.0577; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Wang IK, 2011, STROKE, V42, P716, DOI 10.1161/STROKEAHA.110.594523; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901	31	55	56	1	31	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2013	84	4					441	445		10.1136/jnnp-2012-302547			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	103XH	WOS:000315952300018	23117492				2021-06-18	
J	Logan, TT; Villapol, S; Symes, AJ				Logan, Trevor T.; Villapol, Sonia; Symes, Aviva J.			TGF-beta Superfamily Gene Expression and Induction of the Runx1 Transcription Factor in Adult Neurogenic Regions after Brain Injury	PLOS ONE			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NEURAL STEM-CELLS; ENHANCED HIPPOCAMPAL NEUROGENESIS; TRANSFORMING GROWTH-FACTOR-BETA-1; NEURONAL DIFFERENTIATION; INCREASES NEUROGENESIS; SUBVENTRICULAR ZONE; COGNITIVE RECOVERY; PROGENITOR CELLS; ANALYSIS REVEALS	Traumatic brain injury (TBI) increases neurogenesis in the forebrain subventricular zone (SVZ) and the hippocampal dentate gyrus (DG). Transforming growth factor-beta (TGF-beta) superfamily cytokines are important regulators of adult neurogenesis, but their involvement in the regulation of this process after brain injury is unclear. We subjected adult mice to controlled cortical impact (CCI) injury, and isolated RNA from the SVZ and DG at different post-injury time points. qPCR array analysis showed that cortical injury caused significant alterations in the mRNA expression of components and targets of the TGF-beta, BMP, and activin signaling pathways in the SVZ and DG after injury, suggesting that these pathways could regulate post-injury neurogenesis. In both neurogenic regions, the injury also induced expression of Runt-related transcription factor-1 (Runx1), which can interact with intracellular TGF-beta Smad signaling pathways. CCI injury strongly induced Runx1 expression in activated and proliferating microglial cells throughout the neurogenic regions. Runx1 protein was also expressed in a subset of Nestin-and GFAP-expressing putative neural stem or progenitor cells in the DG and SVZ after injury. In the DG only, these Runx1+ progenitors proliferated. Our data suggest potential roles for Runx1 in the processes of microglial cell activation and proliferation and in neural stem cell proliferation after TBI.	[Logan, Trevor T.; Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Logan, Trevor T.; Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aviva.symes@usuhs.edu	Villapol, Sonia/D-1949-2014; Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Villapol, Sonia/0000-0002-6174-4113	Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [300604 11.0 60855]	This project was funded by the Center for Neuroscience and Regenerative Medicine (grant no: 300604 11.0 60855), http://www.usuhs.mil/cnrm/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdipranoto-Cowley A, 2009, STEM CELLS, V27, P1330, DOI 10.1002/stem.80; Ageta H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001869; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Battista D, 2006, EUR J NEUROSCI, V23, P83, DOI 10.1111/j.1460-9568.2005.04539.x; Beck K, 2012, CELL TISSUE RES, V347, P187, DOI 10.1007/s00441-011-1228-0; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bonaguidi MA, 2008, J NEUROSCI, V28, P9194, DOI 10.1523/JNEUROSCI.3314-07.2008; Bonnert TP, 2006, EUR J NEUROSCI, V24, P661, DOI 10.1111/j.1460-9568.2006.04912.x; Buckwalter MS, 2006, AM J PATHOL, V169, P154, DOI 10.2353/ajpath.2006.051272; Cao WS, 1997, ONCOGENE, V15, P1315, DOI 10.1038/sj.onc.1201305; Challen GA, 2010, EXP HEMATOL, V38, P403, DOI 10.1016/j.exphem.2010.02.011; Chang CF, 2003, STROKE, V34, P558, DOI 10.1161/01.STR.0000051507.64423.00; Chen CL, 2006, NEURON, V49, P365, DOI 10.1016/j.neuron.2005.10.036; Cheng XX, 2007, STEM CELLS, V25, P3204, DOI 10.1634/stemcells.2007-0284; Curry Parichat, 2011, Int J Crit Illn Inj Sci, V1, P27, DOI 10.4103/2229-5151.79279; Dhaliwal J, 2011, EUR J NEUROSCI, V33, P1025, DOI 10.1111/j.1460-9568.2011.07600.x; Docagne F, 2002, MOL CELL NEUROSCI, V21, P634, DOI 10.1006/mcne.2002.1206; Ekdahl CT, 2009, NEUROSCIENCE, V158, P1021, DOI 10.1016/j.neuroscience.2008.06.052; Florio P, 2007, ADV CLIN CHEM, V43, P117, DOI 10.1016/S0065-2423(06)43004-3; Franklin KBJ, 2007, MOUSE BRAIN STEREOTA; Friedman AD, 2009, J CELL PHYSIOL, V219, P520, DOI 10.1002/jcp.21738; Fujita Y, 2001, BIOCHEM BIOPH RES CO, V281, P1248, DOI 10.1006/bbrc.2001.4513; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Ginhoux F, 2011, M S-MED SCI, V27, P719, DOI 10.1051/medsci/2011278013; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gobeske KT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007506; Goings GE, 2006, GLIA, V54, P329, DOI 10.1002/glia.20381; Graciarena M, 2010, BRAIN BEHAV IMMUN, V24, P1301, DOI 10.1016/j.bbi.2010.06.005; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Hultman K, 2010, J NEUROSCI RES, V88, P2441, DOI 10.1002/jnr.22412; Ihrie RA, 2011, NEURON, V70, P674, DOI 10.1016/j.neuron.2011.05.004; Jaffee MS, 2009, J REHABIL RES DEV, V46, P655, DOI 10.1682/JRRD.2008.09.0114; Jakubowiak A, 2000, J BIOL CHEM, V275, P40282, DOI 10.1074/jbc.C000485200; Jeon H, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-149; Kandasamy M, 2010, J NEUROPATH EXP NEUR, V69, P717, DOI 10.1097/NEN.0b013e3181e4f733; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Kobayashi A, 2012, MOL CELL NEUROSCI, V49, P23, DOI 10.1016/j.mcn.2011.08.009; Kovesdi E, 2007, PROG BRAIN RES, V161, P81, DOI 10.1016/S0079-6123(06)61006-6; KRIEGLSTEIN K, 1995, EMBO J, V14, P736, DOI 10.1002/j.1460-2075.1995.tb07052.x; Li LY, 2012, J MOL NEUROSCI; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Ma MM, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-117; Mahmood A, 2012, EXP NEUROL; Mathieu P, 2010, NEUROIMMUNOMODULAT, V17, P200, DOI 10.1159/000258723; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mira H, 2010, CELL STEM CELL, V7, P78, DOI 10.1016/j.stem.2010.04.016; Miyazono K, 2004, ONCOGENE, V23, P4232, DOI 10.1038/sj.onc.1207131; Nagai N, 2005, J THROMB HAEMOST, V3, P1379, DOI 10.1111/j.1538-7836.2005.01466.x; Nakagawa M, 2011, BLOOD, V118, P6626, DOI 10.1182/blood-2010-12-326710; Okuda T, 2000, MOL CELL BIOL, V20, P319, DOI 10.1128/MCB.20.1.319-328.2000; Park SW, 2004, EXP MOL MED, V36, P211, DOI 10.1038/emm.2004.29; Richardson RM, 2010, J NEUROSURG, V112, P1125, DOI 10.3171/2009.4.JNS081087; Russo I, 2011, J NEUROCHEM, V116, P947, DOI 10.1111/j.1471-4159.2010.07168.x; Sashindranath M, 2012, BRAIN, V135, P3251, DOI 10.1093/brain/aws178; Sohur US, 2006, PHILOS T R SOC B, V361, P1477, DOI 10.1098/rstb.2006.1887; Stifani N, 2008, P NATL ACAD SCI USA, V105, P6451, DOI 10.1073/pnas.0711299105; Strom DK, 2000, J BIOL CHEM, V275, P3438, DOI 10.1074/jbc.275.5.3438; Suh H, 2007, CELL STEM CELL, V1, P515, DOI 10.1016/j.stem.2007.09.002; Swiers G, 2010, INT J DEV BIOL, V54, P1151, DOI 10.1387/ijdb.103106gs; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Thapa N, 2007, INT J BIOCHEM CELL B, V39, P2183, DOI 10.1016/j.biocel.2007.06.004; Theriault FM, 2005, J NEUROSCI, V25, P2050, DOI 10.1523/JNEUROSCI.5108-04.2005; Tjarnlund-Wolf A, 2012, STROKE, V43, P2833, DOI 10.1161/STROKEAHA.111.622217; Wachs FP, 2006, J NEUROPATH EXP NEUR, V65, P358, DOI 10.1097/01.jnen.0000218444.53405.f0; Wang Y, 2001, STROKE, V32, P2170, DOI 10.1161/hs0901.095650; Wang YZ, 2011, STEM CELLS, V29, P907, DOI 10.1002/stem.644; Wang Y, 2010, J MOL NEUROSCI, V41, P383, DOI 10.1007/s12031-010-9329-x; Widera D, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-64; Xiong Y, 2010, DISCOV MED, V10, P434; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Yun SJ, 2002, MOL BRAIN RES, V107, P57, DOI 10.1016/S0169-328X(02)00447-3; Zagami CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013944; Zusso M, 2012, J NEUROSCI, V32, P11285, DOI 10.1523/JNEUROSCI.6182-11.2012	78	55	56	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2013	8	3							e59250	10.1371/journal.pone.0059250			14	Multidisciplinary Sciences	Science & Technology - Other Topics	111UM	WOS:000316546400027	23555640	DOAJ Gold, Green Published			2021-06-18	
J	Terpolilli, NA; Kim, SW; Thal, SC; Kuebler, WM; Plesnila, N				Terpolilli, Nicole A.; Kim, Seong-Woong; Thal, Serge C.; Kuebler, Wolfgang M.; Plesnila, Nikolaus			Inhaled nitric oxide reduces secondary brain damage after traumatic brain injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain edema; brain trauma; cerebral blood flow; microcirculation; nitric oxide	CONTROLLED CORTICAL IMPACT; CEREBRAL-BLOOD-FLOW; PERSISTENT PULMONARY-HYPERTENSION; RESPIRATORY-DISTRESS-SYNDROME; L-ARGININE; PLATELET-AGGREGATION; HEAD-INJURY; PERMEABILITY; RAT; ISCHEMIA	Ischemia, especially pericontusional ischemia, is one of the leading causes of secondary brain damage after traumatic brain injury (1131). So far efforts to improve cerebral blood flow (CBF) after TBI were not successful because of various reasons. We previously showed that nitric oxide (NO) applied by inhalation after experimental ischemic stroke is transported to the brain and induces vasodilatation in hypoxic brain regions, thus improving regional ischemia, thereby improving brain damage and neurological outcome. As regional ischemia in the traumatic penumbra is a key mechanism determining secondary posttraumatic brain damage, the aim of the current study was to evaluate the effect of NO inhalation after experimental TBI. NO inhalation significantly improved CBF and reduced intracranial pressure after TBI in male C57 BI/6 mice. Long-term application (24 hours NO inhalation) resulted in reduced lesion volume, reduced brain edema formation and less blood brain barrier disruption, as well as improved neurological function. No adverse effects, e.g., on cerebral auto-regulation, systemic blood pressure, or oxidative damage were observed. NO inhalation might therefore be a safe and effective treatment option for TBI patients. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 311-318; doi: 10.1038/jcbfm.2012.176; published online 28 November 2012	[Terpolilli, Nicole A.] Univ Munich, Med Ctr, Dept Neurosurg, D-81377 Munich, Germany; [Terpolilli, Nicole A.; Kim, Seong-Woong; Thal, Serge C.] Univ Munich, Med Ctr, Inst Surg Res, D-81377 Munich, Germany; [Plesnila, Nikolaus] Univ Munich, Med Ctr, Inst Stroke & Dementia Res, D-81377 Munich, Germany; [Kuebler, Wolfgang M.] Li Ka Shing Knowledge Inst St Michaels, Keenan Res Ctr, Toronto, ON, Canada	Plesnila, N (corresponding author), Univ Munich, Med Ctr, Inst Stroke & Dementia Res, Max Lebsche Pl 30, D-81377 Munich, Germany.	nikolaus.plesnila@med.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019; Terpolilli, Nicole/AAG-3598-2021; Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Kuebler, Wolfgang/0000-0003-4100-2961	GEMI Fund	This work was supported by the GEMI Fund (NP). Parts of the present study are part of the PhD thesis of NT.	Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bode-Boger SM, 2005, CELL MOL BIOL, V51, P307, DOI 10.1170/T632; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Cannon RO, 2001, J CLIN INVEST, V108, P279, DOI 10.1172/JCI200112761; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DIRNAGL U, 1993, NEUROL RES, V15, P128; El Kebir D, 2005, CHEST, V128, P2910, DOI 10.1378/chest.128.4.2910; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; FILEP JG, 1993, BRIT J PHARMACOL, V108, P323, DOI 10.1111/j.1476-5381.1993.tb12803.x; Fox-Robichaud A, 1998, J CLIN INVEST, V101, P2497, DOI 10.1172/JCI2736; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Guillen J, 2012, J AM ASSOC LAB ANIM, V51, P311; He P, 1997, AM J PHYSIOL-HEART C, V272, pH176; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hlatky R, 2002, ACT NEUR S, V81, P347; HOGMAN M, 1994, ACTA PHYSIOL SCAND, V151, P125, DOI 10.1111/j.1748-1716.1994.tb09728.x; Kermarrec N, 1998, AM J RESP CRIT CARE, V158, P833, DOI 10.1164/ajrccm.158.3.9709097; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; KINSELLA JP, 1993, J PEDIATR-US, V123, P103, DOI 10.1016/S0022-3476(05)81551-3; Liu H, 2002, J NEUROTRAUM, V19, P327, DOI 10.1089/089771502753594891; Lundblad C, 2007, MICROVASC RES, V74, P1, DOI 10.1016/j.mvr.2007.03.001; Mayhan WG, 2000, BRAIN RES, V866, P101, DOI 10.1016/S0006-8993(00)02254-X; Menon DK, 2003, ANESTHESIOLOGY, V98, P805, DOI 10.1097/00000542-200304000-00002; Neye N, 2012, INTENS CARE MED, V38, P1381, DOI 10.1007/s00134-012-2605-1; OLIVER JA, 1992, J CELL PHYSIOL, V151, P506, DOI 10.1002/jcp.1041510309; PARKER JO, 1990, EUR J CLIN PHARMACOL, V38, pS21, DOI 10.1007/BF01417561; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; SAMAMA CM, 1995, ANESTHESIOLOGY, V83, P56, DOI 10.1097/00000542-199507000-00007; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Sokol J, 2003, ANESTH ANALG, V97, P989, DOI 10.1213/01.ANE.0000078819.45523.26; Terpolilli NA, 2012, CIRC RES, V110, P727, DOI 10.1161/CIRCRESAHA.111.253419; Terpolilli NA, 2009, J NEUROTRAUM, V26, P1963, DOI 10.1089/neu.2008.0853; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vakili A, 2005, J CEREBR BLOOD F MET, V25, P1012, DOI 10.1038/sj.jcbfm.9600097; von Baumgarten L, 2008, J CEREBR BLOOD F MET, V28, P1353, DOI 10.1038/jcbfm.2008.30; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wong D, 2004, EXP NEUROL, V190, P446, DOI 10.1016/j.expneurol.2004.08.008; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	47	55	57	0	26	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2013	33	2					311	318		10.1038/jcbfm.2012.176			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	087CT	WOS:000314739600020	23188422	Bronze, Green Published			2021-06-18	
J	Budde, MD; Shah, A; McCrea, M; Cullinan, WE; Pintar, FA; Stemper, BD				Budde, Matthew D.; Shah, Alok; McCrea, Michael; Cullinan, William E.; Pintar, Frank A.; Stemper, Brian D.			Primary blast traumatic brain injury in the rat: relating diffusion tensor imaging and behavior	FRONTIERS IN NEUROLOGY			English	Article						traumatic brain injury; blast neurotrauma; memory dysfunction; diffusion tensor imaging; magnetic resonance imaging		The incidence of traumatic brain injury (TBI) among military personnel is at its highest point in U.S. history. Experimental animal models of blast have provided a wealth of insight into blast injury. The mechanisms of neurotrauma caused by blast, however, are still under debate. Specifically, it is unclear whether the blast shockwave in the absence of head motion is sufficient to induce brain trauma. In this study, the consequences of blast injury were investigated in a rat model of primary blastTBl. Animals were exposed to blast shock waves with peak reflected overpressures of either 100 or 450 kPa (39 and 110 kPa incident pressure, respectively) and subsequently underwent a battery of behavioral tests. Diffusion tensor imaging (DTI), a promising method to detect blast injury in humans, was performed on fixed brains to detect and visualize the spatial dependence of blast injury. Blast TBI caused significant deficits in memory function as evidenced by the Morris Water Maze, but limited emotional deficits as evidenced by the Open Field Test and Elevated Plus Maze. Fractional anisotropy, a metric derived from DTI, revealed significant brain abnormalities in blast-exposed animals. A significant relationship between memory deficits and brain microstructure was evident in the hippocampus, consistent with its role in memory function. The results provide fundamental insight into the neurological consequences of blast TBI, including the evolution of injury during the sub-acute phase and the spatially dependent pattern of injury. The relationship between memory dysfunction and microstructural brain abnormalities may provide insight into the persistent cognitive difficulties experienced by soldiers exposed to blast neurotrauma and may be important to guide therapeutic and rehabilitative efforts.	[Budde, Matthew D.; Shah, Alok; McCrea, Michael; Pintar, Frank A.; Stemper, Brian D.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53295 USA; [McCrea, Michael; Pintar, Frank A.; Stemper, Brian D.] Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA; [Cullinan, William E.] Marquette Univ, Dept Biomed Sci, Coll Hlth & Sci, Milwaukee, WI 53233 USA	Budde, MD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, VA Med Ctr Res 151, 5000 West Natl Ave, Milwaukee, WI 53295 USA.	mdbudde@mcw.edu	Stemper, Brian/AAX-7611-2020		Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; Department of Neurosurgery; Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin [5520207]	This project was partially funded through a grant from the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service, the Department of Neurosurgery, and the Research and Education Initiative Fund, a component of the Advancing a Healthier Wisconsin endowment at the Medical College of Wisconsin (5520207 to Matthew D. Budde).	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Bir C, 2012, MAGN RESON IMAGING, V30, P527, DOI 10.1016/j.mri.2011.12.003; Bolander R, 2011, ANN BIOMED ENG, V39, P2550, DOI 10.1007/s10439-011-0343-0; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cullen DK, 2011, J NEUROTRAUM, V28, P2307, DOI [10.1089/neu.2010.1718, 10.1089/neu.2011.1718]; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holdeman TC, 2009, PSYCHIAT SERV, V60, P273, DOI 10.1176/appi.ps.60.2.273; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kim JH, 2007, NMR BIOMED, V20, P352, DOI 10.1002/nbm.1138; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; LONG JB, 2009, NEUROTRAUMA, V26, P827, DOI DOI 10.1089/NEU.2008.0748; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mao JC, 2012, J NEUROTRAUM, V29, P430, DOI 10.1089/neu.2011.1934; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; Newlander SM, 2014, J MAGN RESON IMAGING, V39, P387, DOI 10.1002/jmri.24157; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Shah Ms Alok S, 2012, Biomed Sci Instrum, V48, P393; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wood GW, 2013, INJURY PREV, V19, P19, DOI 10.1136/injuryprev-2011-040277; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784	57	55	55	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								154	10.3389/fneur.2013.00154			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QT	WOS:000209629000151	24133481	DOAJ Gold, Green Published			2021-06-18	
J	Liu, X; An, CY; Jin, P; Liu, XS; Wang, LH				Liu, Xin; An, Chiying; Jin, Peng; Liu, Xuesong; Wang, Longhu			Protective effects of cationic bovine serum albumin-conjugated PEGylated tanshinone IIA nanoparticles on cerebral ischemia	BIOMATERIALS			English	Article						Tanshinone IIA; Cationic bovine serum albumin; PEGylated nanoparticles; Cerebral ischemia; Neuroprotection	TRAUMATIC BRAIN-INJURY; THERAPEUTIC TARGET; COPOLYMER NANOPARTICLES; MOLECULAR-MECHANISMS; REPERFUSION INJURY; PLA NANOPARTICLES; ARTERY OCCLUSION; PPAR-GAMMA; STROKE; INFLAMMATION	Tanshinone IIA is a good candidate for treating cerebral ischemia, but its short half-life and poor permeability across the blood brain-barrier (BBB) limit its curative efficacy. In this study, we successfully developed cationic bovine serum albumin-conjugated tanshinone IIA PEGylated nanoparticles (CBSA-PEG-TIIA-NPs). A cerebral ischemia rat model was established to evaluate the treatment efficacy and protective mechanism of CBSA-PEG-TIIA-NPs. CBSA-PEG-TIIA-NPs showed the mean particle size 118 +/- 14 nm with drug loaded ratio and encapsulation efficiency 5.69 +/- 0.6% and 83.2 +/- 2.6%, respectively. The pharmacokinetics demonstrated that CBSA-PEG-TIIA-NPs could significantly prolong circulation time and increase plasma concentration compared with intravenously administrated TIIA solution. The biodistribution and brain uptake study confirmed that CBSA-PEG-TIIA-NPs possessed better brain delivery efficacy with a high accumulation in brain. CBSA-PEG-TIIA-NPs obviously ameliorated infarct volume, neurological deficit and histopathological severity. Treatment with CBSA-PEG-TIIA-NPs markedly inhibited the levels of the MPO, TNF-alpha, IL-1 beta p and IL-6. Furthermore, CBSA-PEG-TIIA-NPs significantly decreased the mRNA expressions of iNOS and p38MAPK, upregulated PPAR gamma expression, and inhibited the protein levels of iNOS, GFAP and p38MAPK phosphorylation. These results demonstrated that CBSA-PEG-TIIA-NPs possessed remarkable neuroprotective effects on ischemic stroke through modulation of inflammatory cascades and neuronal signal pathways involved in cerebral ischemia. Crown Copyright (c) 2012 Published by Elsevier Ltd. All rights reserved.	[Liu, Xin; Liu, Xuesong; Wang, Longhu] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China; [An, Chiying] Harbin Med Univ, Affiliated Hosp 1, Harbin 150001, Peoples R China; [Jin, Peng] Harbin Med Univ, Affiliated Hosp 4, Harbin 150001, Peoples R China	Liu, X (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China.	xinliu98@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30902008]; Youth Scientific Innovation Special Program of Basic research Foundation of Zhejiang University, China [2010QNA7026]	This study was supported by grants from the National Natural Science Foundation of China (NO. 30902008) and the Youth Scientific Innovation Special Program of Basic research Foundation of Zhejiang University, China (NO. 2010QNA7026).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Barone FC, 1992, STROKE, V23, P1347; BAZILE D, 1995, J PHARM SCI, V84, P493, DOI 10.1002/jps.2600840420; BERGMANN P, 1984, CLIN SCI, V67, P35, DOI 10.1042/cs0670035; Bernardi A, 2010, NEUROCHEM INT, V57, P629, DOI 10.1016/j.neuint.2010.07.012; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; Calvo P, 2001, PHARMACEUT RES, V18, P1157, DOI 10.1023/A:1010931127745; Castellanos M, 2002, STROKE, V33, P982, DOI 10.1161/hs0402.105339; Chen J, 2009, HIPPOCAMPUS, V19, P79, DOI 10.1002/hipo.20479; Chen X, 2007, XENOBIOTICA, V37, P635, DOI 10.1080/00498250701411258; Cheyuo C, 2012, NEUROPHARMACOLOGY, V62, P890, DOI 10.1016/j.neuropharm.2011.09.018; Chio CC, 2010, J NEUROCHEM, V115, P921, DOI 10.1111/j.1471-4159.2010.06969.x; Cimini A, 2012, ACTA BIOMATER, V8, P2056, DOI 10.1016/j.actbio.2012.01.035; Collino Massimo, 2008, Ther Adv Cardiovasc Dis, V2, P179, DOI 10.1177/1753944708090924; Culman J, 2007, TRENDS PHARMACOL SCI, V28, P244, DOI 10.1016/j.tips.2007.03.004; Dong YC, 2004, BIOMATERIALS, V25, P2843, DOI 10.1016/j.biomaterials.2003.09.055; [杜玮 DU Wei], 2008, [中国药学杂志, Chinese Pharmaceutical Journal], V43, P786; Fu JJ, 2007, EUR J PHARMACOL, V568, P213, DOI 10.1016/j.ejphar.2007.04.031; Gabathuler R, 2010, NEUROBIOL DIS, V37, P48, DOI 10.1016/j.nbd.2009.07.028; Gao F, 2002, CARDIOVASC RES, V53, P414, DOI 10.1016/S0008-6363(01)00488-6; Han JY, 2008, PHARMACOL THERAPEUT, V117, P280, DOI 10.1016/j.pharmthera.2007.09.008; Huang J, 2006, SURG NEUROL, V66, P232, DOI 10.1016/j.surneu.2005.12.028; Huwyler J, 1996, P NATL ACAD SCI USA, V93, P14164, DOI 10.1073/pnas.93.24.14164; Jain AK, 2010, INT J PHARMACEUT, V387, P253, DOI 10.1016/j.ijpharm.2009.12.013; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; Jeong S, 2012, J NEUROSURG ANESTH, V24, P51, DOI 10.1097/ANA.0b013e3182368d70; Kaminska B, 2009, ANAT REC, V292, P1902, DOI 10.1002/ar.21047; Karakoti AS, 2011, ANGEW CHEM INT EDIT, V50, P1980, DOI 10.1002/anie.201002969; Kovalska M, 2012, NEUROCHEM RES, V37, P1568, DOI 10.1007/s11064-012-0752-y; Lerouet D, 2002, BRAIN RES, V958, P166, DOI 10.1016/S0006-8993(02)03685-5; Liu JP, 2005, DRUG DEV IND PHARM, V31, P551, DOI 10.1080/03639040500214761; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lou HY, 2004, CHINESE J PHYSIOL, V47, P197; Lu W, 2007, J CONTROL RELEASE, V118, P38, DOI 10.1016/j.jconrel.2006.11.015; Maddahi A, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-14; Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003; Nakka VP, 2008, MOL NEUROBIOL, V37, P7, DOI 10.1007/s12035-007-8013-9; Olivier JC, 2002, PHARMACEUT RES, V19, P1137, DOI 10.1023/A:1019842024814; Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006; Parikh T, 2010, EUR J PHARM BIOPHARM, V74, P442, DOI 10.1016/j.ejpb.2009.11.001; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Saito K, 1996, NEUROSCI LETT, V206, P149, DOI 10.1016/S0304-3940(96)12460-5; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Soo PL, 2008, EUR J PHARM BIOPHARM, V69, P149, DOI 10.1016/j.ejpb.2007.11.003; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Tang C, 2010, PHYTOMEDICINE, V17, P1145, DOI 10.1016/j.phymed.2010.03.017; Vila N, 2001, STROKE, V32, P1234, DOI 10.1161/01.STR.32.5.1234-a; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Walton KM, 1998, J NEUROCHEM, V70, P1764; Wang CX, 2009, J CEREBR BLOOD F MET, V29, P1683, DOI 10.1038/jcbfm.2009.87; Wang XL, 2007, APOPTOSIS, V12, P1209, DOI 10.1007/s10495-007-0055-y; Wei Q, 2008, J COLLOID INTERF SCI, V323, P267, DOI 10.1016/j.jcis.2008.04.058; Xiao RZ, 2010, INT J NANOMED, V5, P1057, DOI [10.2147/ijn.S14912, 10.2147/IJN.S14912]; Xie Z, 2004, GLIA, V45, P170, DOI 10.1002/glia.10314; Yu JH, 2008, INT J BIOCHEM CELL B, V40, P677, DOI 10.1016/j.biocel.2007.10.007; Zhang Y, 2004, COLLOID POLYM SCI, V282, P1323, DOI 10.1007/s00396-004-1068-5	59	55	56	5	80	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	JAN	2013	34	3					817	830		10.1016/j.biomaterials.2012.10.017			14	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	060ER	WOS:000312759800022	23111336				2021-06-18	
J	Alvarez, TL; Kim, EH; Vicci, VR; Dhar, SK; Biswal, BB; Barrett, AM				Alvarez, Tara L.; Kim, Eun H.; Vicci, Vincent R.; Dhar, Sunil K.; Biswal, Bharat B.; Barrett, A. M.			Concurrent Vision Dysfunctions in Convergence Insufficiency With Traumatic Brain Injury	OPTOMETRY AND VISION SCIENCE			English	Article						traumatic brain injury; oculomotor dysfunction; binocular vision; convergence insufficiency; visual dysfunction; visual impairment; visual acuity; mechanism of injury; vestibular dysfunction	FUNCTIONAL INDEPENDENCE MEASURE; DIFFUSE AXONAL INJURY; CRITICAL FLICKER FREQUENCY; POLYTRAUMA NETWORK SITE; VERGENCE EYE-MOVEMENTS; OCULOMOTOR NERVE PALSY; MINOR HEAD TRAUMA; VISUAL FUNCTION; AC/A RATIO; BINOCULAR DYSFUNCTIONS	Purpose. This study assessed the prevalence of convergence insufficiency (CI) with and without simultaneous vision dysfunctions within the traumatic brain injury (TBI) sample population because although CI is commonly reported with TBI, the prevalence of concurrent visual dysfunctions with CI in TBI is unknown. Methods. A retrospective analysis of 557 medical records from TBI civilian patients was conducted. Patients were all evaluated by a single optometrist. Visual acuity, oculomotor function, binocular vision function, accommodation, visual fields, ocular health, and vestibular function were assessed. Statistical comparisons between the CI and non-CI, as well as inpatient and outpatient subgroups, were conducted using chi(2) and Z tests. Results. Approximately 9% of the TBI sample had CI without the following simultaneous diagnoses: saccade or pursuit dysfunction; third, fourth, or sixth cranial nerve palsy; visual field deficit; visual spatial inattention/neglect; vestibular dysfunction; or nystagmus. Photophobia with CI was observed in 16.3% (21 of 130), and vestibular dysfunction with CI was observed in 18.5% (24 of 130) of the CI subgroup. Convergence insufficiency and cranial nerve palsies were common and yielded prevalence rates of 23.3% (130 of 557) and 26.9% (150 of 557), respectively, within the TBI sample. Accommodative dysfunction was common within the nonpresbyopic TBI sample, with a prevalence of 24.4% (76 of 314). Visual field deficits or unilateral visual spatial inattention/neglect was observed within 29.6% (80 of 270) of the TBI inpatient subgroup and was significantly more prevalent compared with that of the outpatient subgroup (p < 0.001). Most TBI patients had visual acuities of 20/60 or better in the TBI sample (85%; 473 of 557). Conclusions. Convergence insufficiency without simultaneous visual or vestibular dysfunctions was observed in about 9% of the visually symptomatic TBI civilian population studied. A thorough visual and vestibular examination is recommended for all TBI patients. (Optom Vis Sci 2012; 89: 1740-1751)	[Alvarez, Tara L.; Kim, Eun H.; Biswal, Bharat B.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA; [Vicci, Vincent R.] Kessler Inst Rehabil, W Orange, NJ USA; [Dhar, Sunil K.] New Jersey Inst Technol, Ctr Appl Math & Stat, Dept Math Sci, Newark, NJ 07102 USA; [Barrett, A. M.] Kessler Fdn, W Orange, NJ USA	Alvarez, TL (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	tara.l.alvarez@njit.edu		Alvarez, Tara/0000-0002-8797-1613; Barrett, A.M./0000-0002-0789-2887	NSF CAREERNational Science Foundation (NSF)NSF - Office of the Director (OD) [BES-044713]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS055808, 5R01NS049176]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055808, R01NS049176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG032088] Funding Source: NIH RePORTER	Supported in part by NSF CAREER BES-044713 to T. L. A., NIH R01NS055808 to A. M. B., and 5R01NS049176 to B. B. B. The authors thank John Semmlow, PhD, and Norbert Elliot, PhD, for comments on the article and writing style and Mooyeon Oh-Park, MD, for summarizing the Kessler Institute TBI FIM statistics.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALQURAINY IA, 1995, BRIT J ORAL MAX SURG, V33, P71, DOI 10.1016/0266-4356(95)90203-1; Alvarez TL, 2010, OPTOMETRY VISION SCI, V87, P985, DOI 10.1097/OPX.0b013e3181fef1aa; Barrett BT, 2009, OPHTHAL PHYSL OPT, V29, P4, DOI 10.1111/j.1475-1313.2008.00607.x; Ben-David BM, 2011, J INT NEUROPSYCH SOC, V17, P354, DOI 10.1017/S135561771000175X; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brautaset RL, 2006, INVEST OPHTH VIS SCI, V47, P2876, DOI 10.1167/iovs.04-1372; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Martinez PC, 2009, OPTOMETRY, V80, P702, DOI 10.1016/j.optm.2009.06.011; Chang TTL, 2007, BRAIN INJURY, V21, P1055, DOI 10.1080/02699050701591437; Chen CC, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.016311; Chen YF, 2010, J MED BIOL ENG, V30, P1; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda KJ, 2006, NEUROREHABILITATION, V21, P9; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Cooper JS, 2011, QUICK REFERENCE GUID; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dhaliwal A, 2006, J NEURO-OPHTHALMOL, V26, P4, DOI 10.1097/01.wno.0000204661.48806.1d; Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60; Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326; Fukushima K, 1996, NEUROSCI RES, V25, P391; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Granet DB, 2005, STRABISMUS, V13, P163, DOI 10.1080/09273970500455436; GRANGER CV, 1994, AM J PHYS MED REHAB, V73, P51, DOI 10.1097/00002060-199473010-00012; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hammond FM, 2010, EUR J PHYS REHAB MED, V46, P545; HOFFMAN LG, 1980, J AM OPTOM ASSOC, V51, P119; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HUGHES A, 1967, BRIT J OPHTHALMOL, V51, P786, DOI 10.1136/bjo.51.11.786; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Ivins BJ, 2010, NEUROREHABILITATION, V26, P199, DOI 10.3233/NRE-2010-0556; Kaas JH, 1989, CHANGING CONCEPTS VI; Kaas JH, 2008, BRAIN RES BULL, V75, P384, DOI 10.1016/j.brainresbull.2007.10.009; Kaido T, 2006, J CLIN NEUROSCI, V13, P852, DOI 10.1016/j.jocn.2005.08.020; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Kapoor Neera, 2002, Curr Treat Options Neurol, V4, P271, DOI 10.1007/s11940-002-0027-z; KOCHANEK PM, 2007, BRAIN INJURY MED PRI, P81; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Krishnan M, 2011, ARCH CLIN NEUROPSYCH, V26, P176, DOI 10.1093/arclin/acr010; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lara F, 2001, OPHTHAL PHYSL OPT, V21, P70, DOI 10.1046/j.1475-1313.2001.00540.x; Lavrich JB, 2010, CURR OPIN OPHTHALMOL, V21, P356, DOI 10.1097/ICU.0b013e32833cf03a; LEPORE FE, 1995, ARCH NEUROL-CHICAGO, V52, P924, DOI 10.1001/archneur.1995.00540330106022; LETOURNEAU JE, 1979, AM J OPTOM PHYS OPT, V56, P18; Levy RL, 2005, NEUROLOGY, V65, P169, DOI 10.1212/01.wnl.0000167288.10702.03; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mutti DO, 2000, INVEST OPHTH VIS SCI, V41, P2469; National Data and Statistical Center, 2012, TRAUM BRAIN INJ MOD; Numminen HJ, 2011, EUR J NEUROL, V18, P460, DOI 10.1111/j.1468-1331.2010.03179.x; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pankhania SR, 2011, STRABISMUS, V19, P52, DOI 10.3109/09273972.2011.578192; Pielmaier L, 2011, BRAIN INJURY, V25, P259, DOI 10.3109/02699052.2010.542429; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; Prigatano GP, 2011, CURR OPIN PSYCHIATR, V24, P243, DOI 10.1097/YCO.0b013e328344698b; Raymond MJ, 1996, NEUROREHABILITATION, V6, P229, DOI 10.3233/NRE-1996-6309; Rosenfield M, 2000, OPHTHAL PHYSL OPT, V20, P207, DOI 10.1016/S0275-5408(99)00051-4; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P1169, DOI 10.1097/OPX.0b013e3181baad13; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Rouse MW, 1999, OPTOMETRY VISION SCI, V76, P643, DOI 10.1097/00006324-199909000-00022; Rutner D, 2006, BRAIN INJURY, V20, P1079, DOI 10.1080/02699050600909904; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; Sandhaug M, 2011, J NEUROLOGICAL RES, V1, P48; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Scheiman M, 2005, OPTOMETRY VISION SCI, V82, P583, DOI 10.1097/01.opx.0000171331.36871.2f; Scheiman M, 2008, OPHTHAL EPIDEMIOL, V15, P24, DOI 10.1080/09286580701772037; Scheiman M, 2006, OPTOMETRY VISION SCI, V83, P857, DOI 10.1097/01.opx.0000245513.51878.26; Scheiman M, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006768.pub2; Scheiman M, 2009, OPTOMETRY VISION SCI, V86, P420, DOI 10.1097/OPX.0b013e31819fa712; SCHLAGETER K, 1993, BRAIN INJURY, V7, P439, DOI 10.3109/02699059309029687; Schrupp LE, 2009, OPTOMETRY, V80, P642, DOI 10.1016/j.optm.2009.04.097; Serra A, 2011, CURR OPIN NEUROL, V24, P32, DOI 10.1097/WCO.0b013e328341eebd; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suchoff Irwin B, 2008, Optometry, V79, P259, DOI 10.1016/j.optm.2007.10.012; Tanielian T, 2008, STOP LOSS NATION WEI; Taub MB, 2006, REV OPTOM, V3, P49; Thurman DJ, 2001, HEAD TRAUMA, P327; Warren M, 2009, AM J OCCUP THER, V63, P626, DOI 10.5014/ajot.63.5.626; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; West TD, 2007, REBUILDING TRUST IND; Zasler N. D., 2007, BRAIN INJURY MED PRI, P779	92	55	55	1	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-5488			OPTOMETRY VISION SCI	Optom. Vis. Sci.	DEC	2012	89	12					1740	1751		10.1097/OPX.0b013e3182772dce			12	Ophthalmology	Ophthalmology	049TJ	WOS:000312006000017	23190716	Green Accepted			2021-06-18	
J	Carroll, CP; Cochran, JA; Guse, CE; Wang, MC				Carroll, Christopher P.; Cochran, Joseph A.; Guse, Clare E.; Wang, Marjorie C.			Are We Underestimating the Burden of Traumatic Brain Injury? Surveillance of Severe Traumatic Brain Injury Using Centers for Disease Control International Classification of Disease, Ninth Revision, Clinical Modification, Traumatic Brain Injury Codes	NEUROSURGERY			English	Article						Accuracy; Centers for Disease Control; Epidemiology; Sensitivity; Traumatic brain injury: International Classification of Diseases; ninth revision; clinical modification	ACCURACY; TRENDS	BACKGROUND: The epidemiology of traumatic brain injury (TBI) is often studied through the use of International Classification of Disease, ninth revision, clinical modification (ICD-9-CM), diagnosis codes from the Centers for Disease Control and Prevention TBI Surveillance System. Recent studies suggest that these codes may underestimate the burden of TBI because of inaccuracies and low sensitivity. OBJECTIVE: To determine the sensitivity and specificity of ICD-9-CM codes in a severe TBI population. METHODS: We retrospectively reviewed medical records of all hospital admissions including computed tomography of the head at a single center to identify severe blunt TBI patients, their injuries, and the neurosurgical procedures performed. We calculated sensitivity and specificity by comparing ICD-9-CM diagnosis and procedure codes assigned by hospital coders with medical records, the gold standard. RESULTS: In 2008, there were 148 qualifying admissions. These codes were 89% sensitive for the presence of any severe TBI. However, one-fifth of these cases were identified only with a code defining a nonspecific head injury. Next, we studied types of TBI by categories defined by the Centers for Disease Control and Prevention (morbidity groups) and by ICD-9-CM codes for types of injury (any skull fracture, intracranial contusion, intracranial hemorrhage, concussion/loss of consciousness) and found widely varying sensitivity and specificity for both. In general, these codes had higher specificity than sensitivity. Both sensitivity and specificity were > 80% for only 2 categories: any skull fracture and intracranial hemorrhage. In contrast, we found high sensitivity and specificity for neurosurgical procedures (97% and 94%). CONCLUSION: ICD-9-CM codes were sensitive for the presence of any severe TBI, but further classification of specific types of TBI was limited by variable sensitivity/specificity. Use of these codes should be supplemented by other methodology.	[Cochran, Joseph A.; Wang, Marjorie C.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Guse, Clare E.] Med Coll Wisconsin, Injury Res Ctr, Dept Family & Community Med, Milwaukee, WI 53226 USA; [Carroll, Christopher P.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA	Wang, MC (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	mwang@mcw.edu	Carroll, Christopher P./AAK-5502-2020	Carroll, Christopher P./0000-0001-5833-7405	Department of Neurosurgery, Medical College of Wisconsin; Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE001175]	This project was supported by the Department of Neurosurgery, Medical College of Wisconsin. C.E. Guse is partially supported by Centers for Disease Control grant R49/CE001175. The other authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Ahmed S, 2000, BRAIN INJURY, V14, P765; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Buck CJ, 2008, 2008 ICD 9 CM, V2; Buck CJ, 2008, 2008 ICD 9 CM, V3; Buck CJ, 2008, 2008 ICD 9 CM, V1; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Centers for Disease Control and Prevention (CDC), 2004, CENTR NERV SYST INJ; Elkin PL, 2001, J AM MED INFORM ASSN, P159; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Golomb MR, 2006, NEUROLOGY, V67, P2053, DOI 10.1212/01.wnl.0000247281.98094.e2; Hagen EM, 2009, SPINAL CORD, V47, P367, DOI 10.1038/sc.2008.118; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lorence Daniel P, 2003, J Health Care Finance, V29, P29; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Trent R, 2001, 129 ANN M AM PUBL HL; Woodworth GF, 2009, NEUROSURGERY, V65, P251, DOI 10.1227/01.NEU.0000347003.35690.7A	27	55	55	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2012	71	6					1064	1070		10.1227/NEU.0b013e31826f7c16			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	040RC	WOS:000311339600017	22922677				2021-06-18	
J	Phelan, HA; Wolf, SE; Norwood, SH; Aldy, K; Brakenridge, SC; Eastman, AL; Madden, CJ; Nakonezny, PA; Yang, L; Chason, DP; Arbique, GM; Berne, J; Minei, JP				Phelan, Herb A.; Wolf, Steven E.; Norwood, Scott H.; Aldy, Kim; Brakenridge, Scott C.; Eastman, Alexander L.; Madden, Christopher J.; Nakonezny, Paul A.; Yang, Lisa; Chason, David P.; Arbique, Gary M.; Berne, John; Minei, Joseph P.			A randomized, double-blinded, placebo-controlled pilot trial of anticoagulation in low-risk traumatic brain injury: The Delayed Versus Early Enoxaparin Prophylaxis I (DEEP I) study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	42nd Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 03, 2012	Vail, CO	Western Trauma Assoc		Brain injury; venous thromboembolism; prophylaxis; enoxaparin; randomized trial	MOLECULAR-WEIGHT HEPARIN; VENOUS THROMBOEMBOLISM PROPHYLAXIS; INTRACRANIAL HEMORRHAGE; VEIN THROMBOSIS; SAFETY; AGREEMENT; HEAD; VARIANCE; EFFICACY	BACKGROUND: Our group has created an algorithm for venous thromboembolism prophylaxis after traumatic brain injury (TB!), which stratifies patients into low, moderate, and high risk for spontaneous injury progression and tailors a prophylaxis regimen to each arm. We present the results of the Delayed Versus Early Enoxaparin Prophylaxis I study, a double-blind, placebo-controlled, randomized pilot trial on the low-risk arm. METHODS: In this two-institution study, patients presenting within 6 hours of injury with prespecified small TBI patterns and stable scans at 24 hours after injury were randomized to receive enoxaparin 30 mg bid or placebo from 24 to 96 hours after injury in a double-blind fashion. An additional computed tomography scan was obtained on all subjects 24 hours after starting treatment (and therefore 48 hours after injury). The primary end point was the radiographic worsening of TBI; secondary end points were venous thromboembolism occurrence and extracranial hemorrhagic complications. RESULTS: A total of 683 consecutive patients with TBI were screened during the 28 center months. The most common exclusions were for injuries larger than the prespecified criteria (n = 199) and preinjury anticoagulant use (n = 138). Sixty-two patients were randomized to enoxaparin (n = 34) or placebo (n = 28). Subclinical, radiographic TBI progression rates on the scans performed 48 hours after injury and 24 hours after start of treatment were 5.9% (95% confidence interval [CI], 0.7-19.7%) for enoxaparin and 3.6% (95% CI, 0.1-18.3%) for placebo, a treatment effect difference of 2.3% (95% CI, -14.42-16.5%). No clinical TBI progressions occurred. One deep vein thrombosis occurred in the placebo arm. CONCLUSION: TBI progression rates after starting enoxaparin in small, stable injuries 24 hours after injury are similar to those of placebo and are subclinical. The next Delayed Versus Early Enoxaparin Prophylaxis studies will assess efficacy of this practice in a powered study on the low-risk arm and a pilot trial of safety of a 72-hour time point in the moderate-risk arm. (J Trauma Acute Care Surg. 2012;73: 1434-1441. Copyright (C) 2012 by Lippincott Williams & Wilkins) LEVEL OF EVIDENCE: Therapeutic study, level II.	[Phelan, Herb A.; Wolf, Steven E.; Aldy, Kim; Eastman, Alexander L.; Minei, Joseph P.] UT SW Med Ctr, Div Burns Trauma Crit Care, Dept Surg, Parkland Mem Hosp, Dallas, TX 75390 USA; [Norwood, Scott H.] Univ S Florida, Sch Med, Dept Surg, Hudson, FL USA; [Brakenridge, Scott C.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; [Madden, Christopher J.] UT SW Med Ctr, Parkland Mem Hosp, Dept Neurosurg, Dallas, TX 75390 USA; [Nakonezny, Paul A.] UT SW Med Ctr, Dept Clin Sci, Div Biostat, Dallas, TX 75390 USA; [Yang, Lisa; Chason, David P.] UT SW Med Ctr, Parkland Mem Hosp, Dept Radiol, Div Neuroradiol, Dallas, TX 75390 USA; [Arbique, Gary M.] UT SW Med Ctr, Dept Radiol, Dallas, TX 75390 USA; [Berne, John] E Texas Med Ctr, Dept Surg, Tyler, TX USA	Phelan, HA (corresponding author), UT SW Med Ctr, Div Burns Trauma Crit Care, Dept Surg, Parkland Mem Hosp, 5323 Harry Hines Blvd,E5-508A, Dallas, TX 75390 USA.	herb.phelan@utsouthwestern.edu	Brakenridge, Scott C/AAD-6691-2019	Brakenridge, Scott C/0000-0002-7327-3718; Wolf, Steven/0000-0003-2972-3440	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024983] Funding Source: NIH RePORTER		Chow SC, 2004, DESIGN ANAL CLIN TRI; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Depew AJ, 2008, AM SURGEON, V74, P906; Dudley RR, 2010, J NEUROTRAUM, V27, P2165, DOI 10.1089/neu.2010.1366; FLEISS JL, 1979, PSYCHOL BULL, V86, P974, DOI 10.1037/0033-2909.86.5.974; FLEISS JL, 1971, PSYCHOL BULL, V76, P378, DOI 10.1037/h0031619; Fleiss Joseph L., 2003, STAT METHODS RATES P; Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Gwet K., 2002, STAT METHODS INTERRA, V1, P1; Gwet KL, 2008, BRIT J MATH STAT PSY, V61, P29, DOI 10.1348/000711006X126600; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Minshall CT, 2011, J TRAUMA, V71, P396, DOI 10.1097/TA.0b013e31822734c9; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Phelan HA, 2012, J TRAUMA ACUTE CARE, V73, pS122, DOI 10.1097/TA.0b013e3182606327; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; US Department of Health and Human Services, 1998, ICH TOP E9 GUID IND	25	55	56	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2012	73	6					1434	1441		10.1097/TA.0b013e31825ac49e			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	058FV	WOS:000312620400013	22914079				2021-06-18	
J	McMillan, TM; Teasdale, GM; Stewart, E				McMillan, Thomas M.; Teasdale, Graham M.; Stewart, Elaine			Disability in young people and adults after head injury: 12-14 year follow-up of a prospective cohort	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; STRUCTURED INTERVIEWS; REHABILITATION; PREDICTORS; SEVERITY	Background There is a need to establish how long term outcome evolves after head injury (HI) and factors related to this, to inform opportunities for intervention. Objective To determine late outcome in adults 12-14 years after hospital admission for HI and to examine relationships between injury, early and late factors, and disability. Methods A prospective cohort with HI, whose outcome was reported previously at 1 and 5-7 years after injury, were followed up after 12-14 years. Participants were assessed using structured and validated measures of disability (Glasgow Outcome Scale-Extended), psychological well being, alcohol use and health status. Results Of 219 survivors followed-up at 5-7 years, 34 (15.5%) had died by 12-14 years. Disability remained common in survivors at 12-14 years (51%), as found at 1 and 5-7 years (53%). For those disabled at 1 year, outcome was poor, with 80% dead or disabled at 12-14 years. Older age at injury, a premorbid history of brain illness or physical disability and post-injury low self-esteem and stress were associated with disability at 12-14 years. Disability changed between 5-7 and 12-14 years in 55% of survivors, improving in 23%. Late changes in disability between 5-7 and 12-14 years were associated with self-perceptions of locus of control as being 'powerful others' at 5-7 years. Conclusions Disability is common 12-14 years after hospital admission with a HI. For some there is a dynamic process of change in disability over time that is associated with self-perceptions of control that could be a target for intervention based research.	[McMillan, Thomas M.; Teasdale, Graham M.; Stewart, Elaine] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Inst Hlth & Wellbeing, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	thomas.mcmillan@glasgow.ac.uk					Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Babor T.F., 1992, GUIDELINES USE PRIMA; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Judge TA, 2002, J PERS SOC PSYCHOL, V83, P693, DOI 10.1037//0022-3514.83.3.693; McMillan TM, 2007, BRAIN, V130, P2520, DOI 10.1093/brain/awm185; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Rosenberg M., 1989, SOC ADOLESCENT SELF; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; *SCOTT EX, 2000, FAIR SHAR ALL FIN RE; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TURNERSTOKES L, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1016/S0079-6123(09)17707-5; Walker J., 2001, CONTROL PSYCHOL HLTH; WALLSTON KA, 1978, RES LOCUS CONTROL CO, V1; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	28	55	55	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2012	83	11					1086	1091		10.1136/jnnp-2012-302746			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	020MG	WOS:000309813600011	22645256	Green Accepted, Bronze			2021-06-18	
J	Wang, YY; Adamson, C; Yuan, WH; Altaye, M; Rajagopal, A; Byars, AW; Holland, SK				Wang, Yingying; Adamson, Chris; Yuan, Weihong; Altaye, Mekibib; Rajagopal, Akila; Byars, Anna W.; Holland, Scott K.			Sex differences in white matter development during adolescence: A DTI study	BRAIN RESEARCH			English	Article						Adolescence; Diffusion tensor imaging; Sex differences; Tract based spatial statistics; White matter development	TRAUMATIC BRAIN-INJURY; COGNITIVE FUNCTIONS; RADIAL DIFFUSIVITY; MATURATION; CHILDHOOD; AGE; CHILDREN; MRI; MICROSTRUCTURE; CONNECTIVITY	Adolescence is a complex transitional period in human development, composing physical maturation, cognitive and social behavioral changes. The objective of this study is to investigate sex differences in white matter development and the associations between intelligence and white matter microstructure in the adolescent brain using diffusion tensor imaging (DTI) and tract-based spatial statistics (TBSS). In a cohort of 16 typically-developing adolescents aged 13 to 17 years, longitudinal DTI data were recorded from each subject at two time points that were one year apart. We used TBSS to analyze the diffusion indices including fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD). Our results suggest that boys (13-18 years) continued to demonstrate white matter maturation, whereas girls appeared to reach mature levels earlier. In addition, we identified significant positive correlations between FA and full-scale intelligence quotient (IQ) in the right inferior fronto-occipital fasciculus when both sexes were looked at together. Only girls showed significant positive correlations between FA and verbal IQ in the left cortico-spinal tract and superior longitudinal fasciculus. The preliminary evidence presented in this study supports that boys and girls have different developmental trajectories in white matter microstructure. (c) 2012 Elsevier B.V. All rights reserved.	[Wang, Yingying; Yuan, Weihong; Rajagopal, Akila; Holland, Scott K.] Cincinnati Childrens Hosp, Pediat Neuroimaging Res Consortium, Cincinnati, OH USA; [Yuan, Weihong; Holland, Scott K.] Cincinnati Childrens Hosp, Dept Radiol, Cincinnati, OH USA; [Altaye, Mekibib] Cincinnati Childrens Hosp, Dept Biostat & Epidemiol, Cincinnati, OH USA; [Wang, Yingying; Byars, Anna W.] Cincinnati Childrens Hosp, Div Neurol, Cincinnati, OH USA; [Wang, Yingying; Holland, Scott K.] Univ Cincinnati, Dept Biomed Engn, Cincinnati, OH USA; [Adamson, Chris] Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia	Wang, YY (corresponding author), Pediat Neuroimaging Res Ctr, MLC 5033,3333 Burnet Ave, Cincinnati, OH 45229 USA.	yingying.wang@cchmc.org	Altaye, Mekibib/N-5274-2015; Wang, Yingying/I-2705-2018	Holland, Scott/0000-0003-3719-0875; Wang, Yingying/0000-0001-6502-1388	U.S. National Institute of Health (NIH grant)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-HD38578]; Victorian Government's Operational Infrastructure Support Program; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD038578] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER	This study was supported in part by a grant from the U.S. National Institute of Health (NIH grant R01-HD38578, P.I. SK Holland). The study was also supported in part by the Victorian Government's Operational Infrastructure Support Program. The authors acknowledge the assistance of Ms. Amanda Huber, Ms. Sara Robertson and Ms. Julie Franks, for helping with recruitment and data collection, and Mr. Kendall O'Brien and Ms. Amanda Woods, for performing all the MRI scans.	Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Basser PJ, 1997, ANN NY ACAD SCI, V820, P123, DOI 10.1111/j.1749-6632.1997.tb46192.x; Bava S, 2011, BRAIN RES, V1375, P41, DOI 10.1016/j.brainres.2010.12.051; Bava S, 2010, BRAIN RES, V1327, P38, DOI 10.1016/j.brainres.2010.02.066; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; Bonekamp D, 2007, NEUROIMAGE, V34, P733, DOI 10.1016/j.neuroimage.2006.09.020; Brizendine L., 2006, FEMALE BRAIN; Casey BJ, 2008, ANN NY ACAD SCI, V1124, P111, DOI 10.1196/annals.1440.010; Clayden JD, 2012, CEREB CORTEX, V22, P1738, DOI 10.1093/cercor/bhr243; Cohen RZ, 1999, AM J PSYCHIAT, V156, P1059; Dahl RE, 2004, ANN NY ACAD SCI, V1021, P1, DOI 10.1196/annals.1308.001; De Bellis MD, 1999, BIOL PSYCHIAT, V45, P1271, DOI 10.1016/S0006-3223(99)00045-1; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; Eluvathingal TJ, 2007, CEREB CORTEX, V17, P2760, DOI 10.1093/cercor/bhm003; Focke NK, 2008, NEUROIMAGE, V40, P728, DOI 10.1016/j.neuroimage.2007.12.031; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1997, PROG NEURO-PSYCHOPH, V21, P1185, DOI 10.1016/S0278-5846(97)00158-9; Giorgio A, 2010, NEUROIMAGE, V49, P94, DOI 10.1016/j.neuroimage.2009.08.003; Hermoye L, 2006, NEUROIMAGE, V29, P493, DOI 10.1016/j.neuroimage.2005.08.017; Herting MM, 2012, CEREB CORTEX, V22, P1979, DOI 10.1093/cercor/bhr246; Holland SK, 2007, INT J AUDIOL, V46, P533, DOI 10.1080/14992020701448994; Ihaka R., 1996, J COMPUT GRAPH STAT, V5, P299, DOI [DOI 10.1080/10618600.1996.10474713, 10.1080/10618600.1996.10474713]; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Le Bihan D, 1991, Magn Reson Q, V7, P1; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Lebel C, 2011, J NEUROSCI, V31, P10937, DOI 10.1523/JNEUROSCI.5302-10.2011; Lenroot RK, 2010, BRAIN COGNITION, V72, P46, DOI 10.1016/j.bandc.2009.10.008; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Lobel U, 2009, NEURORADIOLOGY, V51, P253, DOI 10.1007/s00234-008-0488-1; Mabbott DJ, 2006, NEUROIMAGE, V33, P936, DOI 10.1016/j.neuroimage.2006.07.024; Mabbott DJ, 2009, BRAIN RES, V1294, P80, DOI 10.1016/j.brainres.2009.07.046; Metwalli NS, 2010, BRAIN RES, V1348, P156, DOI 10.1016/j.brainres.2010.05.067; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Nagy Z, 2004, J COGNITIVE NEUROSCI, V16, P1227, DOI 10.1162/0898929041920441; Nguyen D, 2011, EPILEPSY RES, V94, P189, DOI 10.1016/j.eplepsyres.2011.02.001; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; Paus T, 2010, BRAIN COGNITION, V72, P26, DOI 10.1016/j.bandc.2009.06.002; Perrin JS, 2009, NEUROIMAGE, V45, P1055, DOI 10.1016/j.neuroimage.2009.01.023; Rametti G, 2011, J PSYCHIATR RES, V45, P949, DOI 10.1016/j.jpsychires.2010.11.007; Ramsden S, 2011, NATURE, V479, P113, DOI 10.1038/nature10514; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schmithorst VJ, 2008, HUM BRAIN MAPP, V29, P696, DOI 10.1002/hbm.20431; Schmithorst VJ, 2007, NEUROIMAGE, V35, P406, DOI 10.1016/j.neuroimage.2006.11.046; Schmithorst VJ, 2010, BRAIN COGNITION, V72, P16, DOI 10.1016/j.bandc.2009.06.005; Schmithorst VJ, 2009, INTELLIGENCE, V37, P164, DOI 10.1016/j.intell.2008.07.001; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Schmithorst VJ, 2002, RADIOLOGY, V222, P212, DOI 10.1148/radiol.2221010626; Schneider JFL, 2004, NEURORADIOLOGY, V46, P258, DOI 10.1007/s00234-003-1154-2; Schneiderman JS, 2007, NEUROPSYCHOBIOLOGY, V55, P96, DOI 10.1159/000104277; Schwartz ED, 2005, NEUROREPORT, V16, P73, DOI 10.1097/00001756-200501190-00017; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Stice E, 2001, DEV PSYCHOL, V37, P608, DOI 10.1037//0012-1649.37.5.608; Tamnes CK, 2010, HUM BRAIN MAPP, V31, P1609, DOI 10.1002/hbm.20962; Wechsler D., 2011, WECHLSER ABBREVIATED; Wickham H., 2006, GGPLOT IMPLEMENTATIO; Yeh PH, 2009, PSYCHIAT RES-NEUROIM, V173, P22, DOI 10.1016/j.pscychresns.2008.07.012; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	69	55	56	0	40	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 10	2012	1478						1	15		10.1016/j.brainres.2012.08.038			15	Neurosciences	Neurosciences & Neurology	028HU	WOS:000310414200001	22954903	Green Accepted, Green Published			2021-06-18	
J	Bao, F; Shultz, SR; Hepburn, JD; Omana, V; Weaver, LC; Cain, DP; Brown, A				Bao, Feng; Shultz, Sandy R.; Hepburn, Jeff D.; Omana, Vanessa; Weaver, Lynne C.; Cain, Donald P.; Brown, Arthur			A CD11d Monoclonal Antibody Treatment Reduces Tissue Injury and Improves Neurological Outcome after Fluid Percussion Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; behavioral assessments; inflammation; oxidative stress; traumatic brain injury	SPINAL-CORD-INJURY; AMYLOID PRECURSOR PROTEIN; LONG-EVANS RAT; HEAD-INJURY; SYNAPTIC PLASTICITY; REACTIVE ASTROCYTES; ADHESION MOLECULES; LIPID-PEROXIDATION; DNA OXIDATION; INFLAMMATION	Traumatic brain injury (TBI) is an international health concern often resulting in chronic neurological abnormalities, including cognitive deficits, emotional disturbances, and motor impairments. An anti-CD11d monoclonal antibody that blocks the CD11d/CD18 integrin and vascular cell adhesion molecule (VCAM)-1 interaction following experimental spinal cord injury improves functional recovery, while reducing the intraspinal number of neutrophils and macrophages, oxidative activity, and tissue damage. Since the mechanisms of secondary injury in the brain and spinal cord are similar, we designed a study to evaluate fully the effects of anti-CD11d treatment after a moderate lateral fluid percussion TBI in the rat. Rats were treated at 2 h after TBI with either the anti-CD11d antibody or an isotype-matched control antibody 1B7, and both short (24- to 72-h) and long (4-week) recovery periods were examined. The anti-CD11d integrin treatment reduced neutrophil and macrophage levels in the injured brain, with concomitant reductions in lipid peroxidation, astrocyte activation, amyloid precursor protein accumulation, and neuronal loss. The reduced neuroinflammation seen in anti-CD11d-treated rats correlated with improved performance on a number of behavioral tests. At 24 h, the anti-CD11d group performed significantly better than the 1B7 controls on several water maze measures of spatial cognition. At 4 weeks post-injury the anti-CD11d-treated rats had better sensorimotor function as assessed by the beam task, and reduced anxiety-like behaviors, as evidenced by elevated-plus maze testing, compared to 1B7 controls. These findings suggest that neuroinflammation is associated with behavioral deficits after TBI, and that anti-CD11d antibody treatment is a viable strategy to improve neurological outcomes after TBI.	[Brown, Arthur] Univ Western Ontario, Robarts Res Inst, Schulich Sch Med, London, ON N6A 5K8, Canada; [Shultz, Sandy R.; Weaver, Lynne C.; Cain, Donald P.; Brown, Arthur] Univ Western Ontario, Dept Psychol, London, ON N6A 5K8, Canada; [Shultz, Sandy R.; Weaver, Lynne C.; Cain, Donald P.; Brown, Arthur] Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5K8, Canada; [Hepburn, Jeff D.; Brown, Arthur] Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5K8, Canada	Brown, A (corresponding author), Univ Western Ontario, Robarts Res Inst, Schulich Sch Med, 100 Perth Dr, London, ON N6A 5K8, Canada.	abrown@robarts.ca	Brown, Arthur/K-8328-2013; Weaver, Lynne C/K-8491-2013; Brown, Arthur/K-6837-2013	Brown, Arthur/0000-0002-8725-3195; Shultz, Sandy/0000-0002-2525-8775	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This work was supported the Canadian Institutes of Health Research (L.C.W. and A. B.), and the Natural Sciences and Engineering Research Council of Canada (D.P.C.).	Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bao F, 2004, J NEUROCHEM, V90, P1194, DOI 10.1111/j.1471-4159.2004.02580.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Cain P, 1993, Nurs Times, V89, P36; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Dringen R, 2005, ANTIOXID REDOX SIGN, V7, P1223, DOI 10.1089/ars.2005.7.1223; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fleming JC, 2008, EXP NEUROL, V214, P147, DOI 10.1016/j.expneurol.2008.04.024; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hall ED, 1995, J NEUROL SCI, V134, P79, DOI 10.1016/0022-510X(95)00211-J; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hogg N, 2001, J LEUKOCYTE BIOL, V69, P893; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kadhim Hazim J, 2008, J Intensive Care Med, V23, P236, DOI 10.1177/0885066608318458; Knoblach SM, 2002, J NEUROTRAUM, V19, P1039, DOI 10.1089/089771502760341956; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leski ML, 2001, FREE RADICAL BIO MED, V30, P613, DOI 10.1016/S0891-5849(00)00500-1; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; Oatway MA, 2005, J NEUROSCI, V25, P637, DOI 10.1523/JNEUROSCI.3960-04.2005; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Steimer T, 2003, STRESS, V6, P87, DOI 10.1080/1025389031000111320; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Whishaw IQ, 1995, HIPPOCAMPUS, V5, P595, DOI 10.1002/hipo.450050610; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Zhu SW, 2006, BEHAV BRAIN RES, V169, P10, DOI 10.1016/j.bbr.2005.11.024; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	67	55	55	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2012	29	14					2375	2392		10.1089/neu.2012.2408			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	004SM	WOS:000308701400002	22676851	Green Accepted			2021-06-18	
J	Ahmed, OH; Sullivan, SJ; Schneiders, AG; McCrory, PR				Ahmed, Osman H.; Sullivan, S. John; Schneiders, Anthony G.; McCrory, Paul R.			Concussion information online: evaluation of information quality, content and readability of concussion-related websites	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							KNOWLEDGE TRANSFER; SOCIAL NETWORKING; HEALTH; INTERNET; PATIENT; EDUCATION; LEAFLETS	Background The internet plays an important role in the dissemination of health information to the general public. Information on orthopaedic sports medicine websites has been shown to be of a varying standard, and to date there has been no evaluation of the overall quality of concussion-related websites. Methods A four-stage methodological sampling technique was used to identify concussion-related websites. Websites were assessed for the presence of a quality standard (the HONcode), their adherence to current expert concussion knowledge using a custom-developed concussion checklist ('CONcheck'), and their readability using the established Flesch Reading Ease (FRE) and Flesch-Kincaid Grade Level (FKGL). Results 43 Websites were identified from the search strategy with the majority (70%) not HONcode certified. A wide distribution of scores was seen for the CONcheck (0-22), FRE (16.3-77.4) and FKGL (6-17.8). Statistical analysis using independent t tests between websites with the HONcode and websites without the HONcode showed no significant differences between the two groups for CONcheck (t(41) = 0.571, p = 0.571), FRE (t(41) = 0.808, p = 0.424) and FKGL(t(41) = -0.964, p = 0.341) scores. Conclusions The variability in the standard of concussion-related websites highlights the need for sports medicine website providers to consider the delivery, content and readability of information to the public.	[Ahmed, Osman H.; Sullivan, S. John; Schneiders, Anthony G.] Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, Dunedin 9054, New Zealand; [McCrory, Paul R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia	Sullivan, SJ (corresponding author), Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, POB 56, Dunedin 9054, New Zealand.	sjohn.sullivan@otago.ac.nz	McCrory, Paul/Q-8688-2019; Schneiders, Anthony/F-4212-2015	McCrory, Paul/0000-0003-4850-0568; Schneiders, Anthony/0000-0002-1583-3879	International Rugby Board	This study was facilitated by funding from the International Rugby Board.	Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Alla S, 2011, BRIT J SPORT MED, V45, P132, DOI 10.1136/bjsm.2010.074088; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Burneo JG, 2006, EPILEPSY BEHAV, V8, P299, DOI 10.1016/j.yebeh.2005.09.008; Clauson KA, 2010, J ALTERN COMPLEM MED, V16, P119, DOI 10.1089/acm.2008.0611; D'Alessandro DM, 2001, ARCH PEDIAT ADOL MED, V155, P807, DOI 10.1001/archpedi.155.7.807; Eysenbach G, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.1030; Farr JN, 1951, J APPL PSYCHOL, V35, P333, DOI 10.1037/h0062427; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gustafson DH, 2004, BMJ-BRIT MED J, V328, P1150, DOI 10.1136/bmj.328.7449.1150; Hanif F, 2009, INFORM HEALTH SOC CA, V34, P231, DOI 10.3109/17538150903359030; Harland Juliet, 2007, Health Informatics J, V13, P207, DOI 10.1177/1460458207079837; Kunst H, 2002, BRIT MED J, V324, P581, DOI 10.1136/bmj.324.7337.581; Lewiecki EM, 2006, OSTEOPOROSIS INT, V17, P741, DOI 10.1007/s00198-005-0042-5; Macdonald S, 2010, EMERG MED J, V27, P279, DOI 10.1136/emj.2009.075424; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Moore C, 2004, NZ MED J, V117, P1; Pappano D, 2008, CLIN PEDIATR, V47, P930, DOI 10.1177/0009922808320600; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell GP, 2002, BMJ-BRIT MED J, V324, P557, DOI 10.1136/bmj.324.7337.557; Sambandam SN, 2007, ARTHROSCOPY, V23, P509, DOI 10.1016/j.arthro.2006.12.007; Starman JS, 2010, J BONE JOINT SURG AM, V92A, P1612, DOI 10.2106/JBJS.I.00821; Steininger K, 2010, INT J HEALTHC TECHNO, V11, P13, DOI 10.1504/IJHTM.2010.033272; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Vallance JK, 2008, PATIENT EDUC COUNS, V72, P342, DOI 10.1016/j.pec.2008.03.010; van der Marel S, 2009, INFLAMM BOWEL DIS, V15, P1891, DOI 10.1002/ibd.20976	28	55	55	1	33	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUL	2012	46	9					675	683		10.1136/bjsm.2010.081620			9	Sport Sciences	Sport Sciences	961QR	WOS:000305482800011	21504964				2021-06-18	
J	Drag, LL; Spencer, RJ; Walker, SJ; Pangilinan, PH; Bieliauskas, LA				Drag, Lauren L.; Spencer, Robert J.; Walker, Sara J.; Pangilinan, Percival H.; Bieliauskas, Linas A.			The Contributions of Self-reported Injury Characteristics and Psychiatric Symptoms to Cognitive Functioning in OEF/OIF Veterans with Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Neuropsychology; Head injuries; Anxiety; Depression; PTSD; Military	POSTTRAUMATIC-STRESS-DISORDER; CHRONIC PAIN PATIENTS; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; WAR VETERANS; DEPRESSION; COMPLAINTS; CONCUSSION; IRAQ; METAANALYSIS	Mild traumatic brain injury (mTBI) affects a significant number of combat veterans returning from Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF). Although resolution of mTBI symptoms is expected over time, some individuals continue to report lingering cognitive difficulties. This study examined the contributions of self-reported mTBI injury characteristics (e.g., loss of consciousness, post-traumatic amnesia) and psychiatric symptoms to both subjective and objective cognitive functioning in a sample of 167 OEF/OIF veterans seen in a TBI clinic. Injury characteristics were not associated with performance on neuropsychological tests but were variably related to subjective ratings of cognitive functioning. Psychiatric symptoms were highly prevalent and fully mediated most of the relationships between injury characteristics and cognitive ratings. This indicates that mTBI characteristics such as longer time since injury and loss of consciousness or post-traumatic amnesia can lead to increased perceived cognitive deficits despite having no objective effects on cognitive performance. Psychiatric symptoms were associated with both cognitive ratings and neuropsychological performance, illustrating the important role that psychiatric treatment can potentially play in optimizing functioning. Finally, subjective cognitive ratings were not predictive of neuropsychological performance once psychiatric functioning was statistically controlled, suggesting that neuropsychological assessment provides valuable information that cannot be gleaned from self-report alone. (JINS, 2012, 18, 576-584)	[Drag, Lauren L.] VA Palo Alto Healthcare Syst, Res Serv, Palo Alto, CA USA; [Spencer, Robert J.; Bieliauskas, Linas A.] VA Ann Arbor Healthcare Syst, Mental Hlth Serv, Ann Arbor, MI USA; [Walker, Sara J.; Bieliauskas, Linas A.] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI USA; [Pangilinan, Percival H.] VA Ann Arbor Healthcare Syst, Dept Phys Med & Rehabil, Ann Arbor, MI USA; [Pangilinan, Percival H.] Univ Michigan Hlth Syst, Dept Phys Med & Rehabil, Ann Arbor, MI USA	Drag, LL (corresponding author), 3801 Miranda Ave,118J, Palo Alto, CA 94304 USA.	lauren.drag@va.gov					Arnstein P, 1999, PAIN, V80, P483, DOI 10.1016/S0304-3959(98)00220-6; Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; COMUNIAN AL, 1989, PERCEPT MOTOR SKILL, V69, P755, DOI 10.2466/pms.1989.69.3.755; Defense and Veterans Brain Injury Center, 2011, DEP DEF NUMB TRAUM B; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Golier J, 2002, PSYCHIAT CLIN N AM, V25, P295, DOI 10.1016/S0193-953X(01)00004-1; Government Accountability Office, 2005, VA DIS BEN ROUT MON; Government Accountability Office, 2008, MILD TRAUM BRAIN INJ; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P313, DOI 10.1097/HTR.0b013e3181d6f9bd; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Langenecker S.A., 2009, NEUROPSYCHOLOGICAL A, P523; Lees-Haley PR, 2001, ARCH CLIN NEUROPSYCH, V16, P689, DOI 10.1016/S0887-6177(00)00092-5; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meyers J., 1995, REY COMPLEX FIGURE T; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Randolph C, 1998, REPEATABLE BATTERY A; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Southwick SM, 1997, AM J PSYCHIAT, V154, P173; SOUTHWICK SM, 1991, AM J PSYCHIAT, V148, P179; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; SULLIVAN MJL, 1990, J ABNORM PSYCHOL, V99, P260, DOI 10.1037/0021-843X.99.3.260; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Wearden AJ, 1996, J PSYCHOSOM RES, V41, P197, DOI 10.1016/0022-3999(96)00131-6; Wechsler D, 2008, WAIS 4 ADM SCORING M; ZACHARY RA, 2000, SHIPLEY I LIVING SCA; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	54	55	55	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2012	18	3					576	584		10.1017/S1355617712000203			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	937VG	WOS:000303690500019	22390876				2021-06-18	
J	Kalkonde, YV; Jawaid, A; Qureshi, SU; Shirani, P; Wheaton, M; Pinto-Patarroyo, GP; Schulz, PE				Kalkonde, Yogeshwar V.; Jawaid, Ali; Qureshi, Salah U.; Shirani, Peyman; Wheaton, Michael; Pinto-Patarroyo, Gineth P.; Schulz, Paul E.			Medical and environmental risk factors associated with frontotemporal dementia: A case-control study in a veteran population	ALZHEIMERS & DEMENTIA			English	Article						Frontotemporal dementia; Veterans; Risk factors; Traumatic brain injury; Heart disease; Cerebrovascular disease	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; LOBAR DEGENERATION; INTERNATIONAL WORKSHOP; PROPENSITY SCORE; PROGRANULIN; HEALTH; ENCEPHALOPATHY; PREVALENCE	Background: Compared with other major dementias, very little is known about the medical and environmental risk factors associated with frontotemporal dementia (FTD). In this study, we evaluated medical and environmental disorders associated with FTD in a veteran population. Methods: The medical records of 845 consecutive veterans who were evaluated for cognitive and/or behavioral complaints at a cognitive disorders clinic in an academic medical center between March 1, 2003, and June 30, 2008, were reviewed and 554 patients received a diagnosis of dementia. Medical disorders and environmental risk factors in 63 patients with behavioral variant of FTD were compared with 491 patients with non-FTD dementias. Results: The prevalence of traumatic brain injury (TBI) was significantly greater in patients with FTD versus those with non-FTD dementias (12.7% vs 3.5%; P < .05). The FTD group also had a lower prevalence of heart disease (19.0% vs 36.7%; P < .05) and cerebrovascular diseases (12.7% vs 26.1%; P < .05), although the prevalence of vascular risk factors was comparable between FTD and non-FTD dementia groups: hypertension (65.1% vs 68.2%), diabetes (31.7% vs 26.9%), hyperlipidemia (42.9% vs 48.9%), and tobacco use (7.9% vs 8.8%; P > .05 for all). In multivariate analysis, the risk for FTD was increased in patients with TBI (OR, 4.4; 95% CI, 1.6-11.8). The risk for FTD was marginally decreased in patients with heart disease (OR, 0.4; 95% CI, 0.3-0.96). Conclusions: In a clinical sample of veterans, risk of FTD was increased in patients with TBI and marginally decreased in patients with heart disease. Prospective studies are needed to confirm these associations temporally and to identify their underlying mechanisms. (C) 2012 The Alzheimer's Association. All rights reserved.	[Jawaid, Ali; Schulz, Paul E.] Univ Texas Hlth Sci Ctr, Dept Neurol, Houston, TX 77225 USA; [Kalkonde, Yogeshwar V.; Qureshi, Salah U.; Shirani, Peyman; Wheaton, Michael; Pinto-Patarroyo, Gineth P.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Kalkonde, Yogeshwar V.; Qureshi, Salah U.; Shirani, Peyman] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Qureshi, Salah U.] Vet Affairs S Cent Mental Illness Res Educ & Clin, Houston, TX USA	Schulz, PE (corresponding author), Univ Texas Hlth Sci Ctr, Dept Neurol, Houston, TX 77225 USA.	Paul.E.Schulz@uth.tmc.edu	Kalkonde, Yogeshwar/O-2926-2019	Kalkonde, Yogeshwar/0000-0003-3543-3618; Jawaid, Ali/0000-0002-5126-6744	Lou DeGeorge Foundation; Department of Veteran AffairsUS Department of Veterans Affairs	The authors thank the Lou DeGeorge family for continued invaluable support. The study was supported in part by the Lou DeGeorge Foundation and the Department of Veteran Affairs. Both of these sources did not have any role in the study design and implementation, data analysis and interpretation, or the preparation of this report.	Agosta F, 2009, P NATL ACAD SCI USA, V106, P2018, DOI 10.1073/pnas.0812697106; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Becker SO, 2002, STATA J, V2, P358, DOI 10.1177/1536867X0200200403; Benussi L, 2010, EUR J NEUROL, V17, P143, DOI 10.1111/j.1468-1331.2009.02767.x; Bernardi L, 2006, NEUROBIOL AGING, V27, P702, DOI 10.1016/j.neurobiolaging.2005.03.008; Bird T, 2003, ANN NEUROL, V54, pS29, DOI 10.1002/ana.10572; Brunnstrom H, 2009, ARCH GERONTOL GERIAT, V49, P146, DOI 10.1016/j.archger.2008.06.005; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Duckworth J, CURR OPIN C IN PRESS; Dupuis L, 2008, NEUROLOGY, V70, P1004, DOI 10.1212/01.wnl.0000285080.70324.27; Finch N, 2009, BRAIN, V132, P583, DOI 10.1093/brain/awn352; Fitzmaurice G, 2006, NUTRITION, V22, P1214, DOI 10.1016/j.nut.2006.08.015; GALES BJ, 1995, ANN PHARMACOTHER, V29, P354, DOI 10.1177/106002809502900402; Ghidoni R, 2008, NEUROLOGY, V71, P1235, DOI 10.1212/01.wnl.0000325058.10218.fc; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Jawaid A, 2010, EUR J NEUROL, V17, P733, DOI 10.1111/j.1468-1331.2009.02923.x; Jawaid A, 2009, NEURODEGENER DIS, V6, P219, DOI 10.1159/000258704; KNOPMAN DS, 1990, NEUROLOGY, V40, P251, DOI 10.1212/WNL.40.2.251; Lehmann DJ, 2000, J NEUROL NEUROSUR PS, V69, P404, DOI 10.1136/jnnp.69.3.404; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McKhann GM, 2001, ARCH NEUROL-CHICAGO, V58, P1803, DOI 10.1001/archneur.58.11.1803; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Newman AB, 2005, J AM GERIATR SOC, V53, P1101, DOI 10.1111/j.1532-5415.2005.53360.x; Passant U, 1997, INT J GERIATR PSYCH, V12, P395, DOI 10.1002/(SICI)1099-1166(199703)12:3<395::AID-GPS527>3.0.CO;2-#; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Riedijk SR, 2006, DEMENT GERIATR COGN, V22, P405, DOI 10.1159/000095750; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rosso SM, 2003, J NEUROL NEUROSUR PS, V74, P1574, DOI 10.1136/jnnp.74.11.1574; Rosso SM, 2002, J NEUROL NEUROSUR PS, V72, P820, DOI 10.1136/jnnp.72.6.820; Shelley BP, 2007, DEMENT GERIATR COGN, V24, P280, DOI 10.1159/000107494; Snowden JS, 2001, J NEUROL NEUROSUR PS, V70, P323, DOI 10.1136/jnnp.70.3.323; StataCorp, 2003, STAT STAT SOFTW REL; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; van Swieten JC, 2008, LANCET NEUROL, V7, P965, DOI 10.1016/S1474-4422(08)70194-7; Xydakis MS, 2008, NEW ENGL J MED, V358, P2177, DOI 10.1056/NEJMc086083	43	55	55	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	MAY	2012	8	3					204	210		10.1016/j.jalz.2011.03.011			7	Clinical Neurology	Neurosciences & Neurology	945NP	WOS:000304283500006	22465176				2021-06-18	
J	Bramley, H; Patrick, K; Lehman, E; Silvis, M				Bramley, Harry; Patrick, Katherine; Lehman, Erik; Silvis, Matthew			High School Soccer Players With Concussion Education Are More Likely to Notify Their Coach of a Suspected Concussion	CLINICAL PEDIATRICS			English	Article						concussion; traumatic brain injury; head injuries; pediatrics; soccer	TRAUMATIC BRAIN-INJURY; UNITED-STATES; SPORT; MANAGEMENT; LEAGUE	Previously published studies have found that concussion symptoms are underreported in youth athletics. This study evaluated the likelihood high school soccer players would identify themselves as having concussion related symptoms during game situations. A questionnaire inquiring about past concussion education and the likelihood of notifying their coach of concussion symptoms was administered to 183 high school soccer players. Of the 60 (33%) who completed the survey, 18 (72%) athletes who had acknowledged receiving concussion training responded that they would always notify their coach of concussion symptoms, as compared with 12 (36%) of the players who reported having no such training (P = .01). The results of this study suggest that athletes with past concussion training are more likely to notify their coach of concussion symptoms, potentially reducing their risk for further injury. Concussion education should be considered for all high school soccer players.	[Bramley, Harry; Lehman, Erik; Silvis, Matthew] Penn State Milton S Hershey Med Ctr, Dept Pediat, Hershey, PA 17033 USA; [Patrick, Katherine] Penn State Coll Med, Hershey, PA USA	Bramley, H (corresponding author), Penn State Milton S Hershey Med Ctr, Dept Pediat, Mail Code H085,500 Univ Dr, Hershey, PA 17033 USA.	hbramley@hmc.psu.edu		Patrick, Katherine/0000-0002-4293-5619			Bovard RS, 2008, CURR SPORT MED REP, V7, P359, DOI 10.1249/JSR.0b013e31818f0bed; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cantu Robert C, 2006, Neurosurg Focus, V21, pE3; *CDCP, HEADS CONC YOUTH SPO; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Melnick MJ, 2010, HEALTH EDUC BEHAV, V37, P23, DOI 10.1177/1090198107308377; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sulloway FJ, 2010, PERS SOC PSYCHOL REV, V14, P402, DOI 10.1177/1088868310361241; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Washington State Department of Health, CONC MAN SCH SPORTS; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	20	55	55	1	26	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228			CLIN PEDIATR	Clin. Pediatr.	APR	2012	51	4					332	336		10.1177/0009922811425233			5	Pediatrics	Pediatrics	915FF	WOS:000302008800004	22007039				2021-06-18	
J	van Leeuwen, N; Lingsma, HF; Perel, P; Lecky, F; Roozenbeek, B; Lu, J; Shakur, H; Weir, J; Steyerberg, EW; Maas, AIR				van Leeuwen, Nikki; Lingsma, Hester F.; Perel, Pablo; Lecky, Fiona; Roozenbeek, Bob; Lu, Juan; Shakur, Haleema; Weir, James; Steyerberg, Ewout W.; Maas, Andrew I. R.		Int Mission Prognosis Clinical; Corticosteroid Randomization; Trauma Audit Res Network	Prognostic Value of Major Extracranial Injury in Traumatic Brain Injury: An Individual Patient Data Meta-analysis in 39 274 Patients	NEUROSURGERY			English	Article						Acute care; Extracranial injury; Meta-analysis; Prognosis; Trauma; Traumatic brain injury	HEAD-INJURY; MISSING VALUES; IMPUTATION; MORTALITY; DESIGN; MODELS; TRENDS; CARE	BACKGROUND: Major extracranial injury (MEI) is common in traumatic brain injury (TBI) patients, but the effect on outcome is controversial. OBJECTIVE: To assess the prognostic value of MEI on mortality after TBI in an individual patient data meta-analysis of 3 observational TBI studies (International Mission on Prognosis and Clinical Trial Design in TBI [IMPACT]), a randomized controlled trial (Corticosteroid Randomization After Significant Head Injury [CRASH]), and a trauma registry (Trauma Audit and Research Network [TARN]). METHODS: MEI (extracranial injury with an Abbreviated Injury Scale >= 3 or requiring hospital admission) was related to mortality with logistic regression analysis, adjusted for age, Glasgow Coma Scale motor score, and pupil reactivity and stratified by TBI severity. We pooled odds ratios (ORs) with random-effects meta-analysis. RESULTS: We included 39 274 patients. Mortality was 25%, and 32% had MEI. MEI was a strong predictor for mortality in TARN, with adjusted odds ratios of 2.81 (95% confidence interval [CI], 2.44-3.23) in mild, 2.18 (95% CI, 1.80-2.65) in moderate, and 2.14 (95% CI, 1.95-2.35) in severe TBI patients. The prognostic effect was smaller in IMPACT and CRASH, with pooled adjusted odds ratios of 2.14 (95% CI, 0.93-4.91) in mild, 1.46 (95% CI, 1.14-1.85) in moderate, and 1.18 (95% CI, 1.03-1.55) in severe TBI. When patients who died within 6 hours after injury were excluded from TARN, the effect of MEI was comparable with IMPACT and CRASH. CONCLUSION: MEI is an important prognostic factor for mortality in TBI patients. However, the effect varies by population, which explains the controversy in the literature. The strength of the effect is smaller in patients with more severe brain injury and depends on time of inclusion in a study.	[van Leeuwen, Nikki; Lingsma, Hester F.; Roozenbeek, Bob; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Perel, Pablo; Shakur, Haleema] London Sch Hyg & Trop Med, Nutr & Publ Hlth Intervent Res Unit, London WC1, England; [Lecky, Fiona] Hope Hosp, Trauma Audit & Res Network, Manchester, Lancs, England; [Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Lu, Juan] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Weir, James] Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland	Lingsma, HF (corresponding author), POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl	IBIS, NEUROCRITICOS/C-1805-2016; Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; /0000-0002-2342-301X; Shakur-Still, Haleema/0000-0002-6511-109X; Lu, Juan/0000-0002-5389-7603; Steyerberg, Ewout/0000-0002-7787-0122	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-42691]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	Grant support was provided by National Institutes of Health NS-42691. The authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	Braet V, 2002, EMERG MED J, V19, P510; Donders ART, 2006, J CLIN EPIDEMIOL, V59, P1087, DOI 10.1016/j.jclinepi.2006.01.014; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Steyerberg EW, 2007, J CLIN EPIDEMIOL, V60, P979, DOI 10.1016/j.jclinepi.2007.03.003; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015	18	55	56	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	APR	2012	70	4					811	818		10.1227/NEU.0b013e318235d640			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	914FF	WOS:000301934000028	21904253	Bronze			2021-06-18	
J	Olson, SD; Pollock, K; Kambal, A; Cary, W; Mitchell, GM; Tempkin, J; Stewart, H; McGee, J; Bauer, G; Kim, HS; Tempkin, T; Wheelock, V; Annett, G; Dunbar, G; Nolta, JA				Olson, Scott D.; Pollock, Kari; Kambal, Amal; Cary, Whitney; Mitchell, Gaela-Marie; Tempkin, Jeremy; Stewart, Heather; McGee, Jeannine; Bauer, Gerhard; Kim, Hyun Sook; Tempkin, Teresa; Wheelock, Vicki; Annett, Geralyn; Dunbar, Gary; Nolta, Jan A.			Genetically Engineered Mesenchymal Stem Cells as a Proposed Therapeutic for Huntington's Disease	MOLECULAR NEUROBIOLOGY			English	Article						Human mesenchymal stem cells; Neurite outgrowth; Neurodegenerative diseases; Hypoxia; Tissue repair; Huntington's disease; Clinical trials; BDNF	AMYOTROPHIC-LATERAL-SCLEROSIS; SPONTANEOUS MALIGNANT-TRANSFORMATION; IMMUNE-DEFICIENT MICE; SPINAL-CORD-INJURY; BONE-MARROW; STROMAL CELLS; NEUROTROPHIC FACTOR; MULTIPLE-SCLEROSIS; MOUSE MODEL; PROGENITOR CELLS	There is much interest in the use of mesenchymal stem cells/marrow stromal cells (MSC) to treat neurodegenerative disorders, in particular those that are fatal and difficult to treat, such as Huntington's disease. MSC present a promising tool for cell therapy and are currently being tested in FDA-approved phase I-III clinical trials for many disorders. In preclinical studies of neurodegenerative disorders, MSC have demonstrated efficacy, when used as delivery vehicles for neural growth factors. A number of investigators have examined the potential benefits of innate MSC-secreted trophic support and augmented growth factors to support injured neurons. These include overexpression of brain-derived neurotrophic factor and glial-derived neurotrophic factor, using genetically engineered MSC as a vehicle to deliver the cytokines directly into the microenvironment. Proposed regenerative approaches to neurological diseases using MSC include cell therapies in which cells are delivered via intracerebral or intrathecal injection. Upon transplantation, MSC in the brain promote endogenous neuronal growth, encourage synaptic connection from damaged neurons, decrease apoptosis, reduce levels of free radicals, and regulate inflammation. These abilities are primarily modulated through paracrine actions. Clinical trials for MSC injection into the central nervous system to treat amyotrophic lateral sclerosis, traumatic brain injury, and stroke are currently ongoing. The current data in support of applying MSC-based cellular therapies to the treatment of Huntington's disease is discussed.	[Olson, Scott D.; Pollock, Kari; Kambal, Amal; Cary, Whitney; Mitchell, Gaela-Marie; Tempkin, Jeremy; Stewart, Heather; McGee, Jeannine; Bauer, Gerhard; Kim, Hyun Sook; Annett, Geralyn; Nolta, Jan A.] Univ Calif Davis Hlth Syst, Stem Cell Program, Sacramento, CA 95817 USA; [Olson, Scott D.; Pollock, Kari; Kambal, Amal; Cary, Whitney; Mitchell, Gaela-Marie; Tempkin, Jeremy; Stewart, Heather; McGee, Jeannine; Bauer, Gerhard; Kim, Hyun Sook; Annett, Geralyn; Nolta, Jan A.] Univ Calif Davis Hlth Syst, Inst Regenerat Cures, Sacramento, CA 95817 USA; [Tempkin, Teresa; Wheelock, Vicki] Univ Calif Davis Hlth Syst, Dept Neurol, Sacramento, CA 95817 USA; [Kim, Hyun Sook] CHA Univ Sch Med, Dept Neurol, Bundang, South Korea; [Dunbar, Gary] Cent Michigan Univ, Dept Psychol, Mt Pleasant, MI 48859 USA	Nolta, JA (corresponding author), Univ Calif Davis Hlth Syst, Stem Cell Program, 2921 Stockton Blvd,Room 1300, Sacramento, CA 95817 USA.	Jan.nolta@ucdmc.ucdavis.edu		Olson, Scott/0000-0001-8032-3755; Tempkin, Jeremy/0000-0002-1602-6649; Nolta, Jan/0000-0003-4576-8542	California Institute for Regenerative Medicine (CIRM)California Institute for Regenerative Medicine [TR1-01257, DR2-05415]; UC Davis CTSC [2P51RR000169-49]; NIH NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [1RO1 HL073256-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01GM099688, 5P30AG010129-19]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P51RR000169] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL073256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM099688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010129] Funding Source: NIH RePORTER	Our work on MSC therapy for Huntington's disease and other neurodegenerative disorders is funded by the California Institute for Regenerative Medicine (CIRM) grants no. TR1-01257 (Nolta) and DR2-05415 (Wheelock), UC Davis CTSC pilot project 2P51RR000169-49, CIRM Training Grant to UC Davis, CIRM Bridges to Stem Cell Training Grant to California State University, Sacramento, NIH NHLBI 1RO1 HL073256-01 (Nolta), NIH Director's transformative award 1R01GM099688 (Nolta), 5P30AG010129-19 (DeCarli PI: Olson-Pilot project PI), and philanthropic donors from the HD community including the Roberson family and TeamKJ. We thank the HD patients and their families who provide daily inspiration to our group.	Aizman I, 2009, J NEUROSCI RES, V87, P3198, DOI 10.1002/jnr.22146; Alberch J, 2004, PROG BRAIN RES, V146, P195, DOI 10.1016/S0079-6123(03)46014-7; Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Amin EM, 2008, NEUROL RES, V30, P1086, DOI 10.1179/174313208X327955; Arregui L, 2011, CELL MOL NEUROBIOL, V31, P1229, DOI 10.1007/s10571-011-9725-y; Bachoud-Levi AC, 2006, LANCET NEUROL, V5, P303, DOI 10.1016/S1474-4422(06)70381-7; Bantubungi K, 2008, MOL CELL NEUROSCI, V37, P454, DOI 10.1016/j.mcn.2007.11.001; Baquet ZC, 2004, J NEUROSCI, V24, P4250, DOI 10.1523/JNEUROSCI.3920-03.2004; Bauer G, 2008, MOL THER, V16, P1308, DOI 10.1038/mt.2008.93; Biglan KM, 2009, MOVEMENT DISORD, V24, P1763, DOI 10.1002/mds.22601; Bonab MM, 2010, IRAN J IMMUNOL, V4, P50; Boudreau RL, 2009, MOL THER, V17, P1053, DOI 10.1038/mt.2009.17; Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798; Busch SA, 2011, J NEUROSCI, V31, P944, DOI 10.1523/JNEUROSCI.3566-10.2011; Capoccia BJ, 2009, BLOOD, V113, P5340, DOI 10.1182/blood-2008-04-154567; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Choi YH, 2011, HUM GENE THER, V22, P3, DOI 10.1089/hum.2010.211; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Croft AP, 2009, EXP NEUROL, V216, P329, DOI 10.1016/j.expneurol.2008.12.010; Croll SD, 1999, NEUROSCIENCE, V93, P1491, DOI 10.1016/S0306-4522(99)00296-1; Danielyan L, 2009, EUR J CELL BIOL, V88, P315, DOI 10.1016/j.ejcb.2009.02.001; Dao MA, 1997, STEM CELLS, V15, P443, DOI 10.1002/stem.150443; Delcroix GJR, 2010, BIOMATERIALS, V31, P2105, DOI 10.1016/j.biomaterials.2009.11.084; Delcroix GJR, 2009, BRAIN RES, V1255, P18, DOI 10.1016/j.brainres.2008.12.013; Dey ND, 2010, BEHAV BRAIN RES, V214, P193, DOI 10.1016/j.bbr.2010.05.023; DiFiglia M, 2007, P NATL ACAD SCI USA, V104, P17204, DOI 10.1073/pnas.0708285104; Dryden GW, 2009, EXPERT OPIN BIOL TH, V9, P841, DOI 10.1517/14712590902956615; Edalatmanesh MA, 2010, NEUROL RES, V32, P166, DOI 10.1179/174313209X409025; Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Hardy SA, 2008, CURR STEM CELL RES T, V3, P43; Hare JM, 2009, J AM COLL CARDIOL, V54, P2277, DOI 10.1016/j.jacc.2009.06.055; Harper SQ, 2005, P NATL ACAD SCI USA, V102, P5820, DOI 10.1073/pnas.0501507102; Im W., 2010, PLOS CURR, V2; Jiang YF, 2011, NEUROL RES, V33, P331, DOI 10.1179/016164110X12816242542571; Josse C, 2010, STEM CELLS DEV, V19, P1167, DOI 10.1089/scd.2009.0264; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; KARUSSIS D, 2010, MULTIPLE SCLEROSIS A; Karussis D, 2008, J NEUROL SCI, V265, P131, DOI 10.1016/j.jns.2007.05.005; Karussis D, 2010, ARCH NEUROL-CHICAGO, V67, P1187, DOI 10.1001/archneurol.2010.248; Kassis I, 2008, ARCH NEUROL-CHICAGO, V65, P753, DOI 10.1001/archneur.65.6.753; Kebriaei P, 2011, CYTOTHERAPY, V13, P262, DOI 10.3109/14653249.2010.549688; Kidd S, 2008, CYTOTHERAPY, V10, P657, DOI 10.1080/14653240802486517; Kidd S, 2009, STEM CELLS, V27, P2614, DOI 10.1002/stem.187; Kim HJ, 2009, STEM CELLS, V27, P390, DOI 10.1634/stemcells.2007-1047; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Laflamme MA, 2005, NAT BIOTECHNOL, V23, P845, DOI 10.1038/nbt1117; Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399; Lee ST, 2009, ANN NEUROL, V66, P671, DOI 10.1002/ana.21788; Lescaudron L, 2003, INT J NEUROSCI, V113, P945, DOI 10.1080/00207450390207759; Liang J, 2009, MULT SCLER J, V15, P644, DOI 10.1177/1352458509104590; Lin YT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022924; Lombardi MS, 2009, EXP NEUROL, V217, P312, DOI 10.1016/j.expneurol.2009.03.004; Matthay MA, 2010, CHEST, V138, P965, DOI 10.1378/chest.10-0518; Mays RW, 2007, EXPERT OPIN BIOL TH, V7, P173, DOI 10.1517/14712598.7.2.173; Mazzini L, 2003, AMYOTROPH LATERAL SC, V4, P158, DOI 10.1080/14660820310014653; Mazzini L, 2010, EXP NEUROL, V223, P229, DOI 10.1016/j.expneurol.2009.08.007; Meyerrose T, 2006, ESTABLISHMENT TRANSD; Meyerrose T, 2010, ADV DRUG DELIVER REV, V62, P1167, DOI 10.1016/j.addr.2010.09.013; Meyerrose TE, 2008, STEM CELLS, V26, P1713, DOI 10.1634/stemcells.2008-0008; Meyerrose TE, 2007, STEM CELLS, V25, P220, DOI 10.1634/stemcells.2006-0243; Montzka K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-16; Morita E, 2008, EXP NEUROL, V213, P431, DOI 10.1016/j.expneurol.2008.07.011; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; Murphy JM, 2003, ARTHRITIS RHEUM-US, V48, P3464, DOI 10.1002/art.11365; Newman Robert E., 2009, Inflammation & Allergy Drug Targets, V8, P110; NOLTA JA, 1994, BLOOD, V83, P3041, DOI 10.1182/blood.V83.10.3041.3041; NOLTA JA, 1990, HUM GENE THER, V1, P257, DOI 10.1089/hum.1990.1.3-257; Nolta JA, 1996, P NATL ACAD SCI USA, V93, P2414, DOI 10.1073/pnas.93.6.2414; Nolta JA., 2006, GENETIC ENG MESENCHY; Olson SD, 2011, MOL NEUROLO IN PRESS; Paulsen JS, 2006, BIOL PSYCHIAT, V59, P57, DOI 10.1016/j.biopsych.2005.06.003; Pfister EL, 2009, CURR BIOL, V19, P774, DOI 10.1016/j.cub.2009.03.030; Quesenberry PJ, 2008, STEM CELL REV, V4, P137, DOI 10.1007/s12015-008-9036-y; Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132; Rosland GV, 2009, CANCER RES, V69, P5331, DOI 10.1158/0008-5472.CAN-08-4630; Rosova I, 2008, STEM CELLS, V26, P2173, DOI 10.1634/stemcells.2007-1104; Rossignol J, 2011, BEHAV BRAIN RES, V217, P369, DOI 10.1016/j.bbr.2010.11.006; Rossignol J, 2009, J CELL MOL MED, V13, P2547, DOI 10.1111/j.1582-4934.2009.00657.x; Saccardi R, 2006, MULT SCLER, V12, P814, DOI 10.1177/1352458506071301; Sadan O, 2008, STEM CELLS, V26, P2542, DOI 10.1634/stemcells.2008-0240; Sadan O, 2009, ISR MED ASSOC J, V11, P201; Satija NK, 2009, J CELL MOL MED, V13, P4385, DOI 10.1111/j.1582-4934.2009.00857.x; Sharp J, 2009, NEUROSCI LETT, V456, P107, DOI 10.1016/j.neulet.2008.04.106; Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007; Skinner AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006219; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; Spitkovsky D, 2008, MINIM INVASIV THER, V17, P79, DOI 10.1080/13645700801969758; Taylor DD, 2011, SEMIN IMMUNOPATHOL, V33, P441, DOI 10.1007/s00281-010-0234-8; Ting AE, 2008, CRIT REV ONCOL HEMAT, V65, P81, DOI 10.1016/j.critrevonc.2007.09.007; Torsvik A, 2010, CANCER RES, V70, P6393, DOI 10.1158/0008-5472.CAN-10-1305; Tsark EC, 2001, J IMMUNOL, V166, P170, DOI 10.4049/jimmunol.166.1.170; Venkataramana NK, 2010, TRANSL RES, V155, P62, DOI 10.1016/j.trsl.2009.07.006; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; Wang XL, 2003, BLOOD, V101, P4201, DOI 10.1182/blood-2002-05-1338; Wang YL, 2005, NEUROSCI RES, V53, P241, DOI 10.1016/j.neures.2005.06.021; Watts C, 2000, CELL TRANSPLANT, V9, P65, DOI 10.1177/096368970000900109; Wilkins A, 2011, STEM CELL RES; Wright KT, 2011, STEM CELLS, V29, P169, DOI 10.1002/stem.570; Wu GD, 2003, TRANSPLANTATION, V75, P679, DOI 10.1097/01.TP.0000048488.35010.95; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang Y, 2009, J NEUROCHEM, V108, P82, DOI 10.1111/j.1471-4159.2008.05734.x; Zhang ZX, 2008, CYTOTHERAPY, V10, P134, DOI 10.1080/14653240701883061; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581; Zuccato C, 2007, PROG NEUROBIOL, V81, P294, DOI 10.1016/j.pneurobio.2007.01.003; Zuccato C, 2010, PHYSIOL REV, V90, P905, DOI 10.1152/physrev.00041.2009; Zuccato C, 2009, NAT REV NEUROL, V5, P311, DOI 10.1038/nrneurol.2009.54	109	55	58	2	28	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	FEB	2012	45	1					87	98		10.1007/s12035-011-8219-8			12	Neurosciences	Neurosciences & Neurology	879YN	WOS:000299370800007	22161544	Green Published, Other Gold			2021-06-18	
J	Park, J; Zhang, J; Qiu, JH; Zhu, XX; Degterev, A; Lo, EH; Whalen, MJ				Park, Juyeon; Zhang, Jimmy; Qiu, Jianhua; Zhu, Xiaoxia; Degterev, Alexei; Lo, Eng H.; Whalen, Michael J.			Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Akt; cognition; mammalian target of rapamycin; mice; protein kinase B; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; NEURONAL SURVIVAL; ACTIVATION; KINASE; PHOSPHORYLATION; HISTOPATHOLOGY; DAMAGE; DEATH; CELLS	Akt and mammalian target of rapamycin (mTOR) are both activated after traumatic brain injury (TBI), however complex interplay between the two hampers deciphering their functional implications in vivo. We examined the effects of single and combination inhibitors of Akt/mTOR in a mouse controlled cortical impact (CCI) model. Following CCI, phospho-Akt-473 (p-Akt) and -S6 ribosomal protein (p-S6RP), a downstream substrate of mTOR, were increased in cortical and hippocampal brain homogenates (P<0.05 versus sham). At 24 hours, p-S6RP was detected in neurons and was robustly induced in microglia and astrocytes in injured hippocampus. In vivo activity of Akt and mTOR inhibitors administered separately was confirmed by reduced expression of p-GSK3 beta (P<0.01) or p-S6RP (P<0.05), respectively, after CCI. Importantly, administration of Akt and mTOR inhibitors together (but not of either alone) improved postinjury motor (P=0.02) and cognitive deficits (hidden platform trials, P=0.001; probe trials, P<0.05), decreased propidium iodide-positive cells in CA1 and CA3 (P<0.005), and unexpectedly increased p-GSK3 beta in hippocampus. Although the roles of Akt and mTOR in the pathogenesis of TBI remain to be fully elucidated, dual inhibition of Akt and mTOR may have therapeutic potential for TBI. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 330-340; doi:10.1038/jcbfm.2011.131; published online 21 September 2011	[Park, Juyeon; Zhang, Jimmy; Qiu, Jianhua; Zhu, Xiaoxia; Lo, Eng H.; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept PediatNeurosci Ctr, Charlestown, MA 02129 USA; [Zhu, Xiaoxia] Fudan Univ, Huashan Hosp, Dept Rheumatol, Shanghai 200433, Peoples R China; [Degterev, Alexei] Tufts Univ, Dept Biochem, Boston, MA 02111 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA; [Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA	Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept PediatNeurosci Ctr, Charlestown, MA 02129 USA.	mwhalen@partners.org			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5RO1NS047447, 5RO1NS064545]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047447, R01NS064545] Funding Source: NIH RePORTER	This work was supported by grants from NINDS 5RO1NS047447 and 5RO1NS064545 (MJW).	Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Carloni S, 2010, AUTOPHAGY, V6, P366, DOI 10.4161/auto.6.3.11261; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; DErcole AJ, 1996, MOL NEUROBIOL, V13, P227, DOI 10.1007/BF02740625; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Hooper C, 2008, J NEUROCHEM, V104, P1433, DOI 10.1111/j.1471-4159.2007.05194.x; Hu LY, 2010, NEUROSCIENCE, V169, P1046, DOI 10.1016/j.neuroscience.2010.05.046; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jo J, 2011, NAT NEUROSCI, V14, P545, DOI 10.1038/nn.2785; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Komandirov MA, 2011, J MOL NEURO IN PRESS; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Li J, 2008, J NEUROL SCI, V269, P105, DOI 10.1016/j.jns.2007.12.034; Maddika S, 2008, J CELL SCI, V121, P979, DOI 10.1242/jcs.009530; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Namikawa K, 2000, J NEUROSCI, V20, P2875; Neary JT, 2005, IUBMB LIFE, V57, P711, DOI 10.1080/15216540500319143; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Pignataro G, 2011, J CEREBR BLOOD F MET, V31, P362, DOI 10.1038/jcbfm.2010.100; Qi SH, 2010, NEUROSCI RES, V68, P88, DOI 10.1016/j.neures.2010.06.008; Ropelle ER, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003856; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; Song YS, 2008, J CEREBR BLOOD F MET, V28, P1917, DOI 10.1038/jcbfm.2008.80; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Wu YT, 2009, AUTOPHAGY, V5, P824, DOI 10.4161/auto.9099; Wymann MP, 2003, BIOCHEM SOC T, V31, P275, DOI 10.1042/bst0310275; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhu ZF, 2010, BRAIN RES BULL, V83, P272, DOI 10.1016/j.brainresbull.2010.07.008	40	55	58	1	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2012	32	2					330	340		10.1038/jcbfm.2011.131			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	886LZ	WOS:000299857200013	21934697	Green Published, Bronze			2021-06-18	
J	Elkin, BS; Ilankovan, AI; Morrison, B				Elkin, Benjamin S.; Ilankovan, Ashok I.; Morrison, Barclay, III			A Detailed Viscoelastic Characterization of the P17 and Adult Rat Brain	JOURNAL OF NEUROTRAUMA			English	Article						age-dependence; constitutive modeling; heterogeneous mechanical properties; indentation; neurosurgery; rat brain; traumatic brain injury; viscoelasticity	TISSUE; INJURY; DEFORMATION; INDENTATION; STRESS; MODELS; TESTS	Brain is a morphologically and mechanically heterogeneous organ. Although rat brain is commonly used as an experimental neurophysiological model for various in vivo biomechanical studies, little is known about its regional viscoelastic properties. To address this issue, we have generated viscoelastic mechanical property data for specific anatomical regions of the P17 and adult rat brain. These ages are commonly used in rat experimental models. We measured mechanical properties of both white and gray matter regions in coronal slices with a custom-designed microindentation device performing stress-relaxation indentations to 10% effective strain. Shear moduli calculated for short (100 ms), intermediate (1 sec), and long (20 sec) time points, ranged from similar to 1 kPa for short term moduli to similar to 0.4 kPa for long term moduli. Both age and anatomic region were significant factors affecting the time-dependent shear modulus. White matter regions and regions of the cerebellum were much more compliant than those of the hippocampus, cortex, and thalamus. Linear viscoelastic models (Prony series, continuous phase lag, and a power law model) were fit to the time-dependent shear modulus data. All models fit the data equally with no significant differences between them (F-test; p > 0.05). The F-test was also used to statistically determine that a Prony series with three time-dependent parameters accurately fit the data with no added benefit from additional terms. The age-and region-dependent rat brain viscoelastic properties presented here will help inform future biomechanical models of the rat brain with specific and accurate regional mechanical property data.	[Elkin, Benjamin S.; Ilankovan, Ashok I.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,1210 Amsterdam Ave,MC 8904, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); National Highway Traffic Safety Administration	The authors thank Chris Puleo for help performing indentation tests and Dr. Ed X. Guo for use of laboratory space and equipment. This work was supported by a Natural Sciences and Engineering Research Council of Canada (NSERC) postgraduate scholarship (BSE) and the National Highway Traffic Safety Administration.	Allen MP, 1997, UNDERSTANDING REGRES, P113; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Bonferroni C.E., 1935, STUDI ONORE PROFESSO, P13; Cheng L, 2000, J POLYM SCI POL PHYS, V38, P10, DOI 10.1002/(SICI)1099-0488(20000101)38:1<10::AID-POLB2>3.0.CO;2-6; Cheng S, 2008, MED ENG PHYS, V30, P1318, DOI 10.1016/j.medengphy.2008.06.003; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Dong X Neil, 2005, Mech Chem Biosyst, V2, P63; Dutta-Roy T, 2008, J BIOMECH, V41, P2263, DOI 10.1016/j.jbiomech.2008.04.014; Elkin B.S., 2010, J BIOMECH ENG, V121; Elkin BS, 2007, J NEUROTRAUM, V24, P812, DOI 10.1089/neu.2006.0169; Gao CP, 2008, ACTA NEUROCHIR SUPPL, V102, P279, DOI 10.1007/978-3-211-85578-2_52; Garo A, 2007, BIORHEOLOGY, V44, P51; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; HARDING JW, 1945, P CAMB PHILOS SOC, V41, P16, DOI 10.1017/S0305004100022325; HILDEBRANDT J, 1969, B MATH BIOPHYS, V31, P651, DOI 10.1007/BF02477779; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Kalidindi SR, 2008, ACTA MATER, V56, P3523, DOI 10.1016/j.actamat.2008.03.036; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; MASSEY FJ, 1951, J AM STAT ASSOC, V46, P68, DOI 10.2307/2280095; NEUBERT HKP, 1963, AERONAUT QUART, V14, P187, DOI 10.1017/S0001925900002754; Papazoglou S, 2009, PHYS MED BIOL, V54, P2229, DOI 10.1088/0031-9155/54/7/025; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Schiessel H, 1995, J PHYS A-MATH GEN, V28, P6567, DOI 10.1088/0305-4470/28/23/012; Takhounts EG, 2008, STAPP CAR C, V52, P1; Tripathy S., 2009, J BIOMECH ENG, V131; Zamir EA, 2004, J BIOMECH ENG-T ASME, V126, P276, DOI 10.1115/1.1695573	31	55	55	2	24	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2011	28	11			SI		2235	2244		10.1089/neu.2010.1604			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	849VY	WOS:000297154600004	21341982				2021-06-18	
J	Yang, CP; Gilley, JA; Zhang, G; Kernie, SG				Yang, Cui-Ping; Gilley, Jennifer A.; Zhang, Gui; Kernie, Steven G.			ApoE is required for maintenance of the dentate gyrus neural progenitor pool	DEVELOPMENT			English	Article						Neurogenesis; Neural stem cell; Hippocampus; Mouse	CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN-INJURY; STEM-CELL NICHES; ADULT NEUROGENESIS; APOLIPOPROTEIN-E; HIPPOCAMPAL NEUROGENESIS; IN-VIVO; STEM/PROGENITOR CELLS; ALZHEIMERS-DISEASE; SONIC HEDGEHOG	Many genes regulating adult neurogenesis have been identified and are known to play similar roles during early neuronal development. We recently identified apolipoprotein E (ApoE) as a gene the expression of which is essentially absent in early brain progenitors but becomes markedly upregulated in adult dentate gyrus stem/progenitor cells. Here, we demonstrate that ApoE deficiency impairs adult dentate gyrus development by affecting the neural progenitor pool over time. We utilized ApoE-deficient mice crossed to a nestin-GFP reporter to demonstrate that dentate gyrus progenitor cells proliferate more rapidly at early ages, which is subsequently accompanied by an overall decrease in neural progenitor cell number at later time points. This appears to be secondary to over-proliferation early in life and ultimate depletion of the Type 1 nestin-and GFAP-expressing neural stem cells. We also rescue the proliferation phenotype with an ApoE-expressing retrovirus, demonstrating that ApoE works directly in this regard. These data provide novel insight into late hippocampal development and suggest a possible role for ApoE in neurodegenerative diseases.	[Yang, Cui-Ping; Gilley, Jennifer A.; Zhang, Gui; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Yang, Cui-Ping; Gilley, Jennifer A.; Zhang, Gui; Kernie, Steven G.] Univ Texas SW Med Ctr Dallas, Dept Dev Biol, Dallas, TX 75390 USA	Kernie, SG (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pediat, 3959 Broadway,CHN 10-24, New York, NY 10032 USA.	sk3516@columbia.edu	Kernie, Steven/AAT-9912-2020	Kernie, Steven/0000-0003-1371-0549	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS048192]; Sarah M. and Charles E. Seay Endowed Fund for Research on Brain and Spinal Cord Injuries in Children; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048192] Funding Source: NIH RePORTER	Financial support is from NIH grant R01 NS048192 (to S. G. K.) and the Sarah M. and Charles E. Seay Endowed Fund for Research on Brain and Spinal Cord Injuries in Children. Deposited in PMC for release after 12 months.	Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; Bersenev A, 2008, J CLIN INVEST, V118, P2832, DOI 10.1172/JCI35808; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bonaguidi MA, 2011, CELL, V145, P1142, DOI 10.1016/j.cell.2011.05.024; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chen J, 2009, GENESIS, V47, P122, DOI 10.1002/dvg.20465; Christie BR, 2006, HIPPOCAMPUS, V16, P199, DOI 10.1002/hipo.20151; Deguchi K, 2003, J NEUROPATH EXP NEUR, V62, P676, DOI 10.1093/jnen/62.6.676; Ding HK, 2008, LEARN MEMORY, V15, P290, DOI 10.1101/lm.905008; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Duan X, 2008, CURR OPIN NEUROBIOL, V18, P108, DOI 10.1016/j.conb.2008.04.001; Eidukevicius R, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-122; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Encinas JM, 2011, CELL STEM CELL, V8, P566, DOI 10.1016/j.stem.2011.03.010; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; Fujita SC, 1999, NEUROSCI RES, V35, P123, DOI 10.1016/S0168-0102(99)00075-9; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gilley JA, 2011, HIPPOCAMPUS, V21, P33, DOI 10.1002/hipo.20719; Gritti A, 2007, NEURON GLIA BIOL, V3, P309, DOI 10.1017/S1740925X0800001X; GUNDERSEN HJG, 1980, MICROSC ACTA, V83, P409; Guo Y, 2008, MICROSURG, V28, P54, DOI 10.1002/micr.20443; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; Huang Z, 2009, MOL CELL NEUROSCI, V42, P11, DOI 10.1016/j.mcn.2009.06.003; Joksimovic M, 2009, NAT NEUROSCI, V12, P125, DOI 10.1038/nn.2243; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054; Kriegstein A, 2009, ANNU REV NEUROSCI, V32, P149, DOI 10.1146/annurev.neuro.051508.135600; Lagace DC, 2007, J NEUROSCI, V27, P12623, DOI 10.1523/JNEUROSCI.3812-07.2007; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Li G, 2009, CELL STEM CELL, V5, P634, DOI 10.1016/j.stem.2009.10.015; Li Y, 2008, NEURON, V59, P399, DOI 10.1016/j.neuron.2008.06.023; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; Miles DK, 2008, HIPPOCAMPUS, V18, P793, DOI 10.1002/hipo.20439; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Peng Q, 2008, EXP NEUROL, V210, P154, DOI 10.1016/j.expneurol.2007.10.015; Pfrieger FW, 2003, CELL MOL LIFE SCI, V60, P1158, DOI 10.1007/s00018-003-3018-7; Pfrieger FW, 2003, BIOESSAYS, V25, P72, DOI 10.1002/bies.10195; Riquelme PA, 2008, PHILOS T R SOC B, V363, P123, DOI 10.1098/rstb.2006.2016; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Seki T, 2002, J NEUROSCI RES, V69, P772, DOI 10.1002/jnr.10366; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; SHAPIRO HM, 1981, CYTOMETRY, V2, P143, DOI 10.1002/cyto.990020302; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Slezak M, 2003, TRENDS NEUROSCI, V26, P531, DOI 10.1016/j.tins.2003.08.005; Suh H, 2009, ANNU REV CELL DEV BI, V25, P253, DOI 10.1146/annurev.cellbio.042308.113256; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; WEST MJ, 1993, NEUROBIOL AGING, V14, P275, DOI 10.1016/0197-4580(93)90112-O; Xu Q, 2006, J NEUROSCI, V26, P4985, DOI 10.1523/JNEUROSCI.5476-05.2006; Yu TS, 2005, GENESIS, V41, P147, DOI 10.1002/gene.20110; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	63	55	57	0	10	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	0950-1991			DEVELOPMENT	Development	OCT 15	2011	138	20					4351	4362		10.1242/dev.065540			12	Developmental Biology	Developmental Biology	822YD	WOS:000295085600003	21880781	Green Published, Bronze			2021-06-18	
J	Bachelani, AM; Bautz, JT; Sperry, JL; Corcos, A; Zenati, M; Billiar, TR; Peitzman, AB; Marshall, GT				Bachelani, Arshad M.; Bautz, Joshua T.; Sperry, Jason L.; Corcos, Alain; Zenati, Mazen; Billiar, Timothy R.; Peitzman, Andrew B.; Marshall, Gary T.			Assessment of platelet transfusion for reversal of aspirin after traumatic brain injury	SURGERY			English	Article							PREINJURY ANTICOAGULATION; ANTIPLATELET AGENTS; ELDERLY-PATIENTS; UNITED-STATES; HEAD-INJURY; RESISTANCE; IMPACT; PREVENTION; HEMORRHAGE; OUTCOMES	Background. Platelet transfusion is utilized increasingly for traumatic brain injury (TBI) for the reversal of aspirin (ASA) therapy. Assessment of platelet inhibition and reversal by platelet transfusion after TBI has not been adequately characterized. Methods. A retrospective cohort analysis of TBI patients at a level I trauma center (January 2008-December 2009) was performed. The Aspirin Response Test (ART; VerifyNow) was used to assess platelet inhibition in TBI patients and guide platelet transfusion in patients with ASA-induced suppression. A follow-up ART was obtained after platelet administration. Primary endpoints were progression of intracranial hemorrhage on computed tomography, need for craniotomy, and mortality. Results. We analyzed 84 patients (median age, 78 [interquartile range, 64-86)]; 54% male). ASA use was documented in 36 (42%) patients. Initial ART indicated platelet dysfunction in 54 (64%) patients, including 42% of patients without a documented history of ASA use. Of the patients with a documented history of ASA, 2.4% had a normal ART Of those with an initial ART of <550 ASA response units, 45 received platelets. Repeat ART demonstrated reversal of inhibition in 29 patients (64.4%). Initial responders to transfusion received a greater volume of platelets, suggesting a dose-response relationship. Logistic regression revealed a trend toward higher mortality in nonresponders to transfusion (P = .09). Receiver operating characteristic curve analysis revealed that ART results increased prediction of poor outcome compared with ASA history alone (area under the curve = 0.760 and 0.775, respectively). Conclusion. The ART should be used to better target and guide platelet transfusions in TBI patients with known or suspected ASA use history. Patients with occult platelet dysfunction can be identified, unnecessary platelet transfusions avoided, and the adequate volume of platelets administered to correct drug-induced dysfunction. A dose response relationship between quantity of platelets transfused and reversal of ASA inhibition was observed. (Surgery 2011;150:836-43.)	[Bachelani, Arshad M.; Bautz, Joshua T.; Sperry, Jason L.; Corcos, Alain; Zenati, Mazen; Billiar, Timothy R.; Peitzman, Andrew B.; Marshall, Gary T.] Univ Pittsburgh, Med Ctr, Div Gen Surg & Trauma, Dept Surg,Mercy & Presbyterian Hosp, Pittsburgh, PA 15213 USA	Marshall, GT (corresponding author), Univ Pittsburgh, Med Ctr, Div Gen Surg & Trauma, Dept Surg, 200 Lothrop St,F1266-2, Pittsburgh, PA 15213 USA.	marshallgt@upmc.edu	Zenati, Mazen S/C-2020-2012	Marshall, Gary/0000-0003-1398-5366			Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; Ajani UA, 2006, AM J PREV MED, V30, P74, DOI 10.1016/j.amepre.2005.08.042; Blais N, 2009, THROMB HAEMOSTASIS, V102, P404, DOI 10.1160/TH09-02-0126; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Downey DM, 2009, AM SURGEON, V75, P1100; Ducruet AF, 2010, NEUROL RES, V32, P706, DOI 10.1179/174313209X459129; Feher G, 2009, CLIN GENET, V75, P1, DOI 10.1111/j.1399-0004.2008.01105.x; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Gasparyan AY, 2008, J AM COLL CARDIOL, V51, P1829, DOI 10.1016/j.jacc.2007.11.080; Greer DM, 2010, CNS DRUGS, V24, P1027, DOI 10.2165/11539160-000000000-00000; Kinsella K, 2001, AGING WORLD 2001; MICHELSON AD, 2002, PLATELETS; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Moore L, 2006, J TRAUMA, V60, P305, DOI 10.1097/01.ta.0000200840.89685.b0; Norfolk DR, 1998, BRIT J HAEMATOL, V101, P609; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594; Siracuse JJ, 2010, SURGERY, V148, P724, DOI 10.1016/j.surg.2010.07.014; Smock KJ, 2010, AM J HEMATOL, V85, P358, DOI 10.1002/ajh.21674; Stead LG, 2010, CLIN NEUROL NEUROSUR, V112, P275, DOI 10.1016/j.clineuro.2009.12.002; Stroncek DF, 2007, LANCET, V370, P427, DOI 10.1016/S0140-6736(07)61198-2; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234; 2003, MMWR MORB MORTAL WKL, V52, P101	25	55	55	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0039-6060			SURGERY	Surgery	OCT	2011	150	4					836	842		10.1016/j.surg.2011.07.059			7	Surgery	Surgery	838SB	WOS:000296311400060	22000198				2021-06-18	
J	Deng-Bryant, Y; Prins, ML; Hovda, DA; Harris, NG				Deng-Bryant, Ying; Prins, Mayumi L.; Hovda, David A.; Harris, Neil G.			Ketogenic Diet Prevents Alterations in Brain Metabolism in Young but not Adult Rats after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						ketogenic diet; nuclear magnetic resonance spectroscopy; phosphorus; proton; TBI	PROTON-MAGNETIC-RESONANCE; CORTICAL IMPACT INJURY; CEREBRAL GLUCOSE-UTILIZATION; MITOCHONDRIAL DYSFUNCTION; N-ACETYLASPARTATE; MICROWAVE IRRADIATION; P-31-NMR SPECTROSCOPY; EMISSION-TOMOGRAPHY; NAD(+) DEPLETION; CONTUSION INJURY	Previous studies have shown that the change of cerebral metabolic rate of glucose (CMRglc) in response to traumatic brain injury (TBI) is different in young (PND35) and adult rats (PND70), and that prolonged ketogenic diet treatment results in histological and behavioral neuroprotection only in younger rat brains. However, the mechanism(s) through which ketones act in the injured brain and the biochemical markers of their action remain unknown. Therefore, the current study was initiated to: 1) determine the effect of injury on the neurochemical profile in PND35 compared to PND70 rats; and 2) test the effect of early post-injury administration of ketogenic diet on brain metabolism in PND35 versus PND70 rats. The data show that alterations in energy metabolites, amino acid, and membrane metabolites were not evident in PND35 rats on standard diet until 24 h after injury, when the concentration of most metabolites was reduced from sham-injured values. In contrast, acute, but transient deficits in energy metabolism were measured at 6 h in PND70 rats, together with deficits in N-acetylaspartate that endured until 24 h. Administration of a ketogenic diet resulted in significant increases in plasma beta-hydroxybutyrate (beta OHB) levels. Similarly, brain beta OHB levels were significantly elevated in all injured rats, but were elevated by 43% more in PND35 rats compared to PND70 rats. As a result, ATP, creatine, and phosphocreatine levels at 24 h after injury were significantly improved in the ketogenic PND35 rats, but not in the PND70 group. The improvement in energy metabolism in the PND35 brains was accompanied by the recovery of NAA and reduction of lactate levels, as well as amelioration of the deficits of other amino acids and membrane metabolites. These results indicate that the PND35 brains are more resistant to the injury, indicated by a delayed deficit in energy metabolism. Moreover, the younger brains revert to ketones metabolism more quickly than do the adult brains, resulting in better neurochemical and cerebral metabolic recovery after injury.	[Deng-Bryant, Ying; Prins, Mayumi L.; Hovda, David A.; Harris, Neil G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Hovda, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Deng-Bryant, Ying; Prins, Mayumi L.; Hovda, David A.; Harris, Neil G.] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Deng-Bryant, Y (corresponding author), Walter Reed Army Inst Res, Brain Trauma Neuroprotect & Neurorestorat Branch, Ctr Mil Psychiat & Neurosci, 503 Robert Grant Ave,Room 2W15, Silver Spring, MD 20910 USA.	ying.d.bryant@us.army.mil	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739; Harris, Neil/0000-0002-1965-6750	UCLA Brain Injury Research Center; National Institutes of Health, National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS055910, NS058489]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055910, P01NS058489] Funding Source: NIH RePORTER	We thank Dr. Brenda Bartnik-Olson for helpful comments on the manuscript and Dr. David McArthur for help with statistics. This work was supported by the UCLA Brain Injury Research Center and National Institutes of Health Award Numbers NS055910 and NS058489 from the National Institute of Neurological Disorders and Stroke (NINDS). The content is the sole responsibility of the authors and does not necessarily represent official views of the NINDS or the National Institutes of Health.	Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200; Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; Alfieri RR, 2006, J PHYSIOL-LONDON, V576, P391, DOI 10.1113/jphysiol.2006.115006; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Benton RL, 2000, NEUROSCI LETT, V291, P1, DOI 10.1016/S0304-3940(00)01362-8; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Briellmann RS, 2005, EPILEPSIA, V46, P760, DOI 10.1111/j.1528-1167.2005.47604.x; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Brooks WM, 1999, J RHEUMATOL, V26, P81; Caramanos Z, 2005, BRAIN, V128, P2483, DOI 10.1093/brain/awh640; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Clark JB, 1998, DEV NEUROSCI-BASEL, V20, P271, DOI 10.1159/000017321; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; GLONEK T, 1982, J NEUROCHEM, V39, P1210, DOI 10.1111/j.1471-4159.1982.tb12557.x; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; GUIDOTTI A, 1974, NEUROPHARMACOLOGY, V13, P1115, DOI 10.1016/0028-3908(74)90061-6; Haces ML, 2008, EXP NEUROL, V211, P85, DOI 10.1016/j.expneurol.2007.12.029; Harris NG, 1996, J NEUROCHEM, V67, P2030; Harris NG, 1997, J NEUROCHEM, V68, P305; HOVDA DA, 1990, ACT NEUR S, V51, P331; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KOCHER M, 1990, J CEREBR BLOOD F MET, V10, P564, DOI 10.1038/jcbfm.1990.99; Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Lehmann C, 2009, BRAIN RES, V1297, P1, DOI 10.1016/j.brainres.2009.08.070; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McKenna MC, 1996, J NEUROCHEM, V66, P386; MEDINA MA, 1975, J NEUROCHEM, V24, P223, DOI 10.1111/j.1471-4159.1975.tb11868.x; MICCHELI A, 1988, CELL MOL BIOL, V34, P591; Morell P, 1996, NEUROCHEM RES, V21, P463, DOI 10.1007/BF02527711; NEHLIG A, 1988, J NEUROSCI, V8, P2321; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Parsons MW, 2000, NEUROLOGY, V55, P498, DOI 10.1212/WNL.55.4.498; PETITO CK, 1992, BRAIN RES, V569, P275, DOI 10.1016/0006-8993(92)90639-Q; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins ML, 2008, J CEREBR BLOOD F MET, V28, P1, DOI 10.1038/sj.jcbfm.9600543; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Ramonet D, 2004, HIPPOCAMPUS, V14, P586, DOI 10.1002/hipo.10188; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Ruskin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008349; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Sestili P, 2006, FREE RADICAL BIO MED, V40, P837, DOI 10.1016/j.freeradbiomed.2005.10.035; SHARPLESS NS, 1978, BRAIN RES, V140, P171, DOI 10.1016/0006-8993(78)90248-2; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SWAAB DF, 1971, J NEUROCHEM, V18, P2085, DOI 10.1111/j.1471-4159.1971.tb05067.x; Thomale UW, 2007, NEUROL RES, V29, P594, DOI 10.1179/016164107X166272; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Trehout D, 2002, NMR BIOMED, V15, P393, DOI 10.1002/nbm.794; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	81	55	56	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1813	1825		10.1089/neu.2011.1822			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000013	21635175	Green Published			2021-06-18	
J	Itoh, T; Imano, M; Nishida, S; Tsubaki, M; Hashimoto, S; Ito, A; Satou, T				Itoh, Tatsuki; Imano, Motohiro; Nishida, Shozo; Tsubaki, Masahiro; Hashimoto, Shigeo; Ito, Akihiko; Satou, Takao			Exercise inhibits neuronal apoptosis and improves cerebral function following rat traumatic brain injury	JOURNAL OF NEURAL TRANSMISSION			English	Article						Cerebral dysfunction; Neuroprotection; Apoptotic cell death; Neuronal degeneration	CENTRAL-NERVOUS-SYSTEM; CELL-DEATH; GROWTH-FACTOR; ISCHEMIA; ACTIVATION; PROTECTS; MICE; NEUROPROTECTION; HIPPOCAMPUS; RECEPTOR	Exercise is reported to inhibit neuronal apoptotic cell death in the hippocampus and improve learning and memory. However, the effect of exercise on inhibition of neuronal apoptosis surrounding the area of damage after traumatic brain injury (TBI) and the improvement of cerebral dysfunction following TBI are unknown. Here, we investigate the effect of exercise on morphology and cerebral function following TBI in rats. Wistar rats received TBI by a pneumatic controlled injury device were randomly divided into two groups: (1) non-exercise group and (2) exercise group. The exercise group ran on a treadmill for 30 min/day at 22 m/min for seven consecutive days. Immunohistochemical and behavioral studies were performed following TBI. The number of single-stranded DNA (ssDNA)-positive cells around the damaged area early after TBI was significantly reduced in the exercise group compared with the non-exercise group (P < 0.05). Furthermore, most ssDNA-positive cells in the non-exercise group co-localized with neuronal cells. However, in the exercise group, a few ssDNA-positive cells co-localized with neurons. In addition, there was a significant increase in neuronal cell number and improvement in cerebral dysfunction after TBI in the exercise group compared with the non-exercise group (P < 0.05). These results indicate that exercise following TBI inhibits neuronal degeneration and apoptotic cell death around the damaged area, which results in improvement of cerebral dysfunction. In summary, treadmill running improved cerebral dysfunction following TBI, indicating its potential as an effective clinical therapy. Therefore, exercise therapy (rehabilitation) in the early phase following TBI is important for recuperation from cerebral dysfunction.	[Itoh, Tatsuki; Ito, Akihiko; Satou, Takao] Kinki Univ, Sch Med, Dept Pathol, Osaka 5898511, Japan; [Imano, Motohiro] Kinki Univ, Sch Med, Dept Surg, Osaka 5898511, Japan; [Nishida, Shozo; Tsubaki, Masahiro] Kinki Univ, Sch Pharmaceut Sci, Osaka 5898511, Japan; [Hashimoto, Shigeo] PL Hosp, Div Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ Hosp, Sch Med, Div Hosp Pathol, Osaka, Japan; [Satou, Takao] Kinki Univ, Inst Life Sci, Div Sports Med, Osaka 5898511, Japan	Itoh, T (corresponding author), Kinki Univ, Sch Med, Dept Pathol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	tatsuki@med.kindai.ac.jp		Itoh, Tatsuki/0000-0003-2015-7788	ZENRYOKEN;  [20500472];  [21500803]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [21500803] Funding Source: KAKEN	This work was supported by Grant-in-Aid for Scientific Research (20500472 and 21500803) and ZENRYOKEN. The authors thank Mari Yachi for technical assistance.	Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Blackmore DG, 2009, STEM CELLS, V27, P2044, DOI 10.1002/stem.120; Cechetti F, 2008, BRAIN RES, V1188, P182, DOI 10.1016/j.brainres.2007.10.012; Chae CH, 2009, NEUROCHEM INT, V55, P208, DOI 10.1016/j.neuint.2009.02.024; CHAN PH, 1985, PROG BRAIN RES, V63, P227; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Dressler Jan, 2009, Leg Med (Tokyo), V11 Suppl 1, pS54, DOI 10.1016/j.legalmed.2009.02.024; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Hayes K, 2008, ACTA NEUROPATHOL, V115, P289, DOI 10.1007/s00401-008-0340-z; Hennigan A, 2007, BIOCHEM SOC T, V35, P424, DOI 10.1042/BST0350424; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hsuan SL, 2006, J NEUROSCI, V26, P4481, DOI 10.1523/JNEUROSCI.4922-05.2006; Irving EA, 2002, J CEREBR BLOOD F MET, V22, P631, DOI 10.1097/00004647-200206000-00001; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Itoh T, 2007, NEUROL RES, V29, P734, DOI 10.1179/016164107X208086; Itoh T, 2011, J NEURAL TRANSM, V118, P193, DOI 10.1007/s00702-010-0495-3; Itoh T, 2010, NEUROCHEM RES, V35, P348, DOI 10.1007/s11064-009-0061-2; Itoh T, 2009, MOL CELL BIOCHEM, V324, P191, DOI 10.1007/s11010-008-0013-1; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kim DH, 2004, J NEUROSURG, V100, P79, DOI 10.3171/jns.2004.100.1.0079; Lee EJ, 2005, J PINEAL RES, V38, P42, DOI 10.1111/j.1600-079X.2004.00173.x; Liebelt B, 2010, NEUROSCIENCE, V166, P1091, DOI 10.1016/j.neuroscience.2009.12.067; LLorens-Martin M, 2010, MOL CELL NEUROSCI, V44, P109, DOI 10.1016/j.mcn.2010.02.006; Lyden P, 2000, J Stroke Cerebrovasc Dis, V9, P9; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Nguyen TLX, 2010, EXP MOL MED, V42, P583, DOI 10.3858/emm.2010.42.8.060; Ou-Yang W, 2000, ACTA PHARMACOL SIN, V21, P296; Radak Z, 2001, NEUROCHEM INT, V38, P17, DOI 10.1016/S0197-0186(00)00063-2; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rizk NN, 2007, ENDOCRINE, V31, P66, DOI 10.1007/s12020-007-0012-0; Sahin S, 2010, J CLIN NEUROSCI, V17, P227, DOI 10.1016/j.jocn.2009.05.016; Shin DH, 2004, NEUROSCI LETT, V354, P64, DOI 10.1016/j.neulet.2003.09.070; Sim YJ, 2005, PHYSIOL BEHAV, V84, P733, DOI 10.1016/j.physbeh.2005.02.019; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Sun X, 2010, TOXICOLOGY, V271, P5, DOI 10.1016/j.tox.2010.01.001; Uda M, 2006, BRAIN RES, V1104, P64, DOI 10.1016/j.brainres.2006.05.066; Uysal N, 2005, NEUROSCI LETT, V383, P241, DOI 10.1016/j.neulet.2005.04.054; Wine RN, 2009, NEUROTOX RES, V16, P280, DOI 10.1007/s12640-009-9060-y; Wu CW, 2007, J NEUROCHEM, V103, P2471, DOI 10.1111/j.1471-4159.2007.04987.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Zhang CY, 2002, NEUROSCI LETT, V328, P265, DOI 10.1016/S0304-3940(02)00543-8	45	55	56	0	18	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	SEP	2011	118	9					1263	1272		10.1007/s00702-011-0629-2			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	813HB	WOS:000294356300001	21442353				2021-06-18	
J	Elliott, MB; Tuma, RF; Amenta, PS; Barbe, MF; Jallo, JI				Elliott, Melanie B.; Tuma, Ronald F.; Amenta, Peter S.; Barbe, Mary F.; Jallo, Jack I.			Acute Effects of a Selective Cannabinoid-2 Receptor Agonist on Neuroinflammation in a Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact injury; glial response; inflammation; neurotransmitters; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SPINAL-CORD NEUROCHEMICALS; SUBSTANCE-P; CB2 RECEPTORS; FUNCTIONAL-CHARACTERIZATION; MURINE MACROPHAGES; CEREBRAL EDEMA; MICE; NEUROPROTECTION; INFLAMMATION	Proposed therapeutic strategies for attenuating secondary traumatic brain injury (TBI) include modulation of acute neuroimmune responses. The goal of this study was to examine the acute effects of cannabinoid-2 receptor (CB(2)R) modulation on behavioral deficits, cerebral edema, perivascular substance P, and macrophage/microglial activation in a murine model of TBI. Thirty male C57BL/6 mice underwent sham surgery, or cortical contusion impact injury (CCI). CCI mice received vehicle or the CB(2)R agonist 0-1966 at 1 and 24 h after injury. Performance on the rotarod, forelimb cylinder, and open-field tests were evaluated before and at 48 h after sham or CCI surgery. Cerebral edema was evaluated using the wet-dry weight technique. Immunohistochemical analysis was used to examine changes in substance P and macrophage/microglia-specific Iba1 protein immunoreactivity. Locomotor performance and exploratory behavior were significantly improved in mice receiving 0-1966 (CB(2)R agonist) compared to vehicle-treated mice. Significant reductions were found for cerebral edema, number of perivascular areas of substance P immunoreactivity, and number of activated macrophages/microglial cells in the injured brains of 0-1966-treated mice compared to vehicle-treated mice. The findings show that the effects of the CB(2)R agonist 0-1966 on edema, substance P immunoreactivity, and macrophage/microglial activation, were associated with recovery of acute motor and exploratory deficits. This study provides evidence of acute neuroprotective effects derived from selective CB(2)R activation that may represent an avenue for further development of novel therapeutic agents in the treatment of TBI.	[Elliott, Melanie B.; Amenta, Peter S.; Jallo, Jack I.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Tuma, Ronald F.] Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19122 USA; [Barbe, Mary F.] Temple Univ, Sch Med, Dept Anat & Cell Biol, Philadelphia, PA 19122 USA	Elliott, MB (corresponding author), Thomas Jefferson Univ, Dept Neurosurg, 1025 Walnut St, Philadelphia, PA 19107 USA.	melanie.elliott@jefferson.edu		Jallo, Jack/0000-0002-5512-1729; Barbe, Mary/0000-0002-5235-9803			Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Baty Darric E, 2008, Clin Neurosurg, V55, P172; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Black PH, 2002, BRAIN BEHAV IMMUN, V16, P622, DOI 10.1016/S0889-1591(02)00021-1; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cabral GA, 2008, BRIT J PHARMACOL, V153, P240, DOI 10.1038/sj.bjp.0707584; Cabral GA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000957; Carrier EJ, 2005, CNS NEUROL DISORD-DR, V4, P657, DOI 10.2174/156800705774933023; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Elliott MB, 2010, NEUROSCIENCE, V170, P929, DOI 10.1016/j.neuroscience.2010.07.041; Elliott MB, 2009, NEUROSCIENCE, V158, P922, DOI 10.1016/j.neuroscience.2008.10.050; Elliott MB, 2008, BRAIN RES, V1218, P103, DOI 10.1016/j.brainres.2008.04.029; Elliott MB, 2008, J NEUROSCI METH, V168, P320, DOI 10.1016/j.jneumeth.2007.10.019; Elliott MB, 2007, J NEUROTRAUM, V24, P195, DOI 10.1089/neu.2006.0094; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; Elliott MB, 2009, NEUROSCI LETT, V454, P34, DOI 10.1016/j.neulet.2009.01.037; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Gong JP, 2006, BRAIN RES, V1071, P10, DOI 10.1016/j.brainres.2005.11.035; Kawamata T, 2007, PROG BRAIN RES, V161, P235, DOI 10.1016/S0079-6123(06)61016-9; Kingery WS, 2003, BONE, V33, P927, DOI 10.1016/j.bone.2003.07.003; Klein TW, 2006, J NEUROIMMUNE PHARM, V1, P50, DOI 10.1007/s11481-005-9007-x; Lin RCS, 1995, NEUROREPORT, V7, P310, DOI 10.1097/00001756-199512290-00074; Lombard C, 2007, CLIN IMMUNOL, V122, P259, DOI 10.1016/j.clim.2006.11.002; Marriott I, 1998, CELL IMMUNOL, V183, P113, DOI 10.1006/cimm.1998.1248; Mechoulam R, 2007, MOL NEUROBIOL, V36, P68, DOI 10.1007/s12035-007-8008-6; MOUTON PR, 2002, PRINCIPLES PRACTICES; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Palma C, 1997, GLIA, V21, P183, DOI 10.1002/(SICI)1098-1136(199710)21:2<183::AID-GLIA2>3.0.CO;2-8; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Severini C, 2002, PHARMACOL REV, V54, P285, DOI 10.1124/pr.54.2.285; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; van der Stelt M, 2002, MOL NEUROBIOL, V26, P317, DOI 10.1385/MN:26:2-3:317; Van Sickle MD, 2005, SCIENCE, V310, P329, DOI 10.1126/science.1115740; Vink R, 2010, NEUROTHERAPEUTICS, V7, P74, DOI 10.1016/j.nurt.2009.10.018; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Walter L, 2004, BRIT J PHARMACOL, V141, P775, DOI 10.1038/sj.bjp.0705667; Wiley JL, 2002, J PHARMACOL EXP THER, V301, P679, DOI 10.1124/jpet.301.2.679; Zhang M, 2007, J CEREBR BLOOD F MET, V27, P1387, DOI 10.1038/sj.jcbfm.9600447; Zhang M, 2009, MICROVASC RES, V78, P86, DOI 10.1016/j.mvr.2009.03.005; Zhang M, 2009, J NEUROIMMUNE PHARM, V4, P249, DOI 10.1007/s11481-009-9148-4	48	55	55	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2011	28	6					973	981		10.1089/neu.2010.1672			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	788PT	WOS:000292457600011	21332427				2021-06-18	
J	Shi, XQ; Lim, TKY; Lee, S; Zhao, YQ; Zhang, J				Shi, Xiang Qun; Lim, Tony K. Y.; Lee, Seunghwan; Zhao, Yuan Qing; Zhang, Ji			Statins alleviate experimental nerve injury-induced neuropathic pain	PAIN			English	Article						HMG-CoA reductase; Peripheral inflammation; Central inflammation; Cytokines; Glia; Pain behavior	COA REDUCTASE INHIBITORS; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; RAT MODEL; IN-VIVO; ATORVASTATIN; SIMVASTATIN; ROSUVASTATIN; ACTIVATION; THERAPY	The statins are a well-established class of drugs that lower plasma cholesterol levels by inhibiting HMG-CoA (3-hydroxy-3-methyl-glutaryl-coenzyme A) reductase. They are widely used for the treatment of hypercholesterolemia and for the prevention of coronary heart disease. Recent studies suggest that statins have anti-inflammatory effects beyond their lipid-lowering properties. We sought to investigate whether statins could affect neuropathic pain by mediating nerve injury-associated inflammatory responses. The effects of hydrophilic rosuvastatin and lipophilic simvastatin were examined in the mouse partial sciatic nerve ligation model. Systemic daily administration of either statin from days 0 to 14 completely prevented the development of mechanical allodynia and thermal hyperalgesia. When administered from days 8 to 14 after injury, both statins dose-dependently reduced established hypersensitivity. After treatment, the effects of the statins were washed out within 2 to 7 days, depending on dose. Effects of both statins in alleviating mechanical allodynia were further confirmed in a different injury-associated neuropathic pain model, mental nerve chronic constriction, in rats. Both statins were able to abolish interleukin-1 beta expression in sciatic nerve triggered by nerve ligation. Additionally, quantitative analysis with Iba-1 and glial fibrillary acid protein immunoreactivity demonstrated that rosuvastatin and simvastatin significantly reduced the spinal microglial and astrocyte activation produced by sciatic nerve injury. The increase of interleukin-1 beta mRNA in the ipsilateral side of spinal cords was also reduced by the treatment of either statin. We identified a potential new application of statins in the treatment of neuropathic pain. The pain-alleviating effects of statins are likely attributable to their immunomodulatory effects. (C) 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Shi, Xiang Qun; Lim, Tony K. Y.; Lee, Seunghwan; Zhao, Yuan Qing; Zhang, Ji] McGill Univ, Alan Edwards Ctr Res Pain, Montreal, PQ, Canada	Zhang, J (corresponding author), McGill Univ, Alan Edwards Ctr Res Pain, 740 Dr Penfield Ave, Montreal, PQ, Canada.	Ji.Zhang@mcgill.ca	Zhang, Ji/L-5922-2019	Lim, Tony/0000-0003-1843-0060	Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [MOP-77624]	The study was supported by Canadian Institutes for Health Research (CIHR) Grant MOP-77624 to J.Z., and the CIHR neuroinflammation training program. T.L. holds a CIHR Frederick Banting and Charles Best Canada Graduate (doctoral) scholarship. J.Z. holds a CIHR new investigator award.	Azkue JJ, 1998, EUR J NEUROSCI, V10, P2204, DOI 10.1046/j.1460-9568.1998.00260.x; Barsante MM, 2005, EUR J PHARMACOL, V516, P282, DOI 10.1016/j.ejphar.2005.05.005; BOWSHER D, 1991, BRIT MED BULL, V47, P644, DOI 10.1093/oxfordjournals.bmb.a072498; Brass LM, 2006, AM J CARDIOL, V97, p86C, DOI 10.1016/j.amjcard.2005.12.017; Brown WV, 2008, CURR OPIN LIPIDOL, V19, P558, DOI 10.1097/MOL.0b013e328319baba; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chello M, 2006, CRIT CARE MED, V34, P660, DOI 10.1097/01.CCM.0000201407.89977.EA; Chong PH, 2004, PHARMACOTHERAPY, V24, P1194, DOI 10.1592/phco.24.13.1194.38084; Clarke RM, 2007, NEUROPHARMACOLOGY, V52, P136, DOI 10.1016/j.neuropharm.2006.07.031; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; Daglioglu E, 2010, FOLIA NEUROPATHOL, V48, P49; Davidson MH, 2002, EXPERT OPIN INV DRUG, V11, P125, DOI 10.1517/13543784.11.1.125; Davis TME, 2008, DIABETOLOGIA, V51, P562, DOI 10.1007/s00125-007-0919-2; DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301; Echeverry S., 2010, P 13 WORLD C PAIN AU; ENDO A, 1979, BIOCHIM BIOPHYS ACTA, V575, P266; Ferroni P, 2003, CIRCULATION, V108, P1673, DOI 10.1161/01.CIR.0000094732.02060.27; GABAY E, 2010, EUR J PAIN; Gordh T, 2006, PAIN, V124, P211, DOI 10.1016/j.pain.2006.05.020; Graham KL, 2008, ARTHRITIS RHEUM, V58, P2098, DOI 10.1002/art.23605; Grelik C, 2005, EUR J NEUROSCI, V21, P2475, DOI 10.1111/j.1460-9568.2005.04089.x; GRUNDY SM, 1988, NEW ENGL J MED, V319, P24; Han HC, 2000, PAIN, V84, P253; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hemandez-Romero MD, 2008, J NEUROCHEM, V105, P445, DOI 10.1111/j.1471-4159.2007.05148.x; Hu Y, 2009, DIABETES VASC DIS RE, V6, P262, DOI 10.1177/1479164109339966; Inoue K, 2009, GLIA, V57, P1469, DOI 10.1002/glia.20871; Jensen MP, 2007, NEUROLOGY, V68, P1178, DOI 10.1212/01.wnl.0000259085.61898.9e; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lin CS, 2007, REGION ANESTH PAIN M, V32, P209, DOI 10.1016/j.rapm.2007.01.005; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malmberg AB, 1998, PAIN, V76, P215, DOI 10.1016/S0304-3959(98)00045-1; Matthews EA, 2001, PAIN, V92, P235, DOI 10.1016/S0304-3959(01)00255-X; Mayanagi K, 2008, J CEREBR BLOOD F MET, V28, P1927, DOI 10.1038/jcbfm.2008.81; McDermott AM, 2006, EUR J PAIN, V10, P127, DOI 10.1016/j.ejpain.2005.01.014; McTaggart F, 2001, AM J CARDIOL, V87, p28B; MERSKEY H, 1994, CLASSIFICATION CHRON, pR11; Mika J, 2010, NEUROSCIENCE, V165, P1420, DOI 10.1016/j.neuroscience.2009.11.064; Mika J, 2007, EUR J PHARMACOL, V560, P142, DOI 10.1016/j.ejphar.2007.01.013; Mix E, 2006, J AUTOIMMUN, V27, P251, DOI 10.1016/j.jaut.2006.09.006; NEZASA K, 2000, ATHEROSCLEROSIS, V151, P39; O'Connor AB, 2009, PHARMACOECONOMICS, V27, P95, DOI 10.2165/00019053-200927020-00002; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pan HC, 2010, NEUROSURGERY, V67, P376, DOI 10.1227/01.NEU.0000371729.47895.A0; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Reichert F, 1996, EUR J NEUROSCI, V8, P530, DOI 10.1111/j.1460-9568.1996.tb01237.x; SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974; Santodomingo-Garzon T, 2006, BRIT J PHARMACOL, V149, P14, DOI 10.1038/sj.bjp.0706836; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Smith BH, 2007, CLIN J PAIN, V23, P143, DOI 10.1097/01.ajp.0000210956.31997.89; Torrance N, 2007, FAM PRACT, V24, P481, DOI 10.1093/fampra/cmm042; van der Most PJ, 2009, PROG NEUROBIOL, V88, P64, DOI 10.1016/j.pneurobio.2009.02.002; Waehre T, 2004, CIRCULATION, V109, P1966, DOI 10.1161/01.CIR.0000125700.33637.B1; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Warwick MJ, 2000, ATHEROSCLEROSIS, V151, P39; Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393; Wolf G, 2006, PAIN, V120, P315, DOI 10.1016/j.pain.2005.11.011; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Wu HT, 2010, J NEUROSURG, V113, P591, DOI 10.3171/2009.9.JNS09859; ZHANG J, 2009, FUNCTIONAL PAIN SYND, P319; Zhao SP, 2004, CLIN CHIM ACTA, V344, P195, DOI 10.1016/j.cccn.2004.03.003	63	55	59	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	MAY	2011	152	5					1033	1043		10.1016/j.pain.2011.01.006			11	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	749YI	WOS:000289507500015	21414721				2021-06-18	
J	Toien, K; Bredal, IS; Skogstad, L; Myhren, H; Ekeberg, O				Toien, Kirsti; Bredal, Inger S.; Skogstad, Laila; Myhren, Hilde; Ekeberg, Oivind			Health related quality of life in trauma patients. Data from a one-year follow up study compared with the general population	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article							INTENSIVE-CARE-UNIT; POSTTRAUMATIC-STRESS-DISORDER; MAJOR TRAUMA; MULTIPLE TRAUMA; FUNCTIONAL CONSEQUENCES; DEPRESSION SCALE; RECOVERY PROJECT; HOSPITAL ANXIETY; CRITICAL ILLNESS; BRAIN-INJURY	Background: Trauma patients have impaired health-related quality of life (HRQOL) after trauma. The aim of the study was to assess HRQOL during the first year after trauma and hospital stay in trauma patients admitted to an intensive-care unit (ICU) for > 24 hours compared with non-ICU trauma patients and the general population, and to identify predictors of HRQOL. Methods: A prospective one-year follow-up study of 242 trauma patients received by the trauma team of a trauma referral centre in Norway was performed. HRQOL was measured using the Medical Outcomes Study Short Form 36 (SF-36) at 3 and 12 months. Results: The mean age of the cohort was 42.3 years (95% CI, 40.4-44.3 years). The median Injury Severity Score (ISS) was 10, interquartile range 16. The HRQOL improved significantly from the 3 to the 12 months follow up in the trauma patients. However their scores were significantly lower for most subscales of SF-36 compared to the general population. Significant differences between ICU and non-ICU patients at 12 months were observed only for physical functioning and role physical subscales. Optimism was an independent predictor of good HRQOL at 12 months, in all dimensions (beta, 0.95-2.45). A higher depression score at baseline predicted lower HRQOL in four of eight dimensions (beta -1.1 to -1.70). In addition, better physical functioning was predicted by lower age (beta, -0.20), and having head injury (reference) as the most severe injury vs. spine or extremity injuries (beta, -9.49 and -10.85), and better mental health by higher age (beta, 0.21) and being employed or studying before the trauma (beta, 12.27). In addition to optimism good general health was predicted by lower score for post-traumatic stress (PTS) symptoms at baseline (beta, -0.27) and lower ISS score (beta -10.59). Conclusions: The HRQOL improved significantly from the 3 to the 12 months follow up in our sample. However their scores were significantly lower for most subscales of SF-36 compared to the general population. Significant differences between ICU and non-ICU patients were observed for only two subscales. Better HRQOL at 12 months was predicted mainly by optimism, low score for depression and PTS symptoms at baseline. High ISS predicted low general health exclusively.	[Toien, Kirsti; Skogstad, Laila] Ulleval Hosp, Oslo Univ Hosp, Div Crit Care, Dept Res & Dev, NO-0424 Oslo, Norway; [Toien, Kirsti] Ulleval Hosp, Oslo Univ Hosp, Div Crit Care, Dept Crit Care Nursing, NO-0424 Oslo, Norway; [Bredal, Inger S.] Ulleval Hosp, Oslo Univ Hosp, Unit Breast & Endocrine Surg, NO-0424 Oslo, Norway; [Bredal, Inger S.] Univ Oslo, Fac Med, Inst Hlth & Soc, NO-0315 Oslo, Norway; [Myhren, Hilde] Ulleval Hosp, Oslo Univ Hosp, Dept Cardiol, NO-0424 Oslo, Norway; [Ekeberg, Oivind] Ulleval Hosp, Oslo Univ Hosp, Dept Acute Med, NO-0424 Oslo, Norway; [Ekeberg, Oivind] Univ Oslo, Fac Med, Dept Behav Sci Med, NO-0317 Oslo, Norway	Toien, K (corresponding author), Ulleval Hosp, Oslo Univ Hosp, Div Crit Care, Dept Res & Dev, POB 4956, NO-0424 Oslo, Norway.	kirsti.toien@uus.no			Oslo University Hospital; Health region east; University of Oslo	KT was funded by Oslo University Hospital throughout the study. LS was funded by Health region east and Oslo University Hospital. ISB and OE were funded by Oslo University Hospital and University of Oslo. HM received her funding from Health region east.	Aitken LM, 2007, INJURY, V38, P19, DOI 10.1016/j.injury.2006.05.020; Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; [Anonymous], 1998, ABBREVIATED INJURY S; Baranyi A, 2010, PSYCHOSOMATICS, V51, P237, DOI 10.1176/appi.psy.51.3.237; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Borg T, 2010, INJURY, V41, P400, DOI 10.1016/j.injury.2009.11.006; BULL JP, 1985, ACCIDENT ANAL PREV, V17, P387, DOI 10.1016/0001-4575(85)90093-4; Crosby RD, 2003, J CLIN EPIDEMIOL, V56, P395, DOI 10.1016/S0895-4356(03)00044-1; Dimopoulou I, 2004, AM J PHYS MED REHAB, V83, P171, DOI 10.1097/01.PHM.0000107497.77487.C1; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; Gabbe BJ, 2010, J TRAUMA, V69, P532, DOI 10.1097/TA.0b013e3181e5125b; Granja C, 2008, CRIT CARE MED, V36, P2801, DOI 10.1097/CCM.0b013e318186a3e7; GREER S, 1992, BRIT MED J, V304, P675, DOI 10.1136/bmj.304.6828.675; Harris IA, 2008, J TRAUMA, V64, P969, DOI 10.1097/01.ta.0000245972.83948.1a; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holbrook TL, 2001, J TRAUMA, V50, P91, DOI 10.1097/00005373-200101000-00016; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; Kopjar B, 1996, Inj Prev, V2, P135, DOI 10.1136/ip.2.2.135; Loge JH, 1998, J CLIN EPIDEMIOL, V51, P1069, DOI 10.1016/S0895-4356(98)00098-5; Loge JH, 1998, SCAND J SOC MED, V26, P250; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Mata GV, 1996, J TRAUMA, V41, P326, DOI 10.1097/00005373-199608000-00022; Matsuoka Y, 2009, PSYCHIAT CLIN NEUROS, V63, P235, DOI 10.1111/j.1440-1819.2009.01928.x; McClure RJ, 1996, ACCIDENT ANAL PREV, V28, P443, DOI 10.1016/0001-4575(96)00012-7; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Miller RS, 2000, J TRAUMA, V48, P229, DOI 10.1097/00005373-200002000-00006; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Myhren H, 2010, CRIT CARE, V14, DOI 10.1186/cc8870; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Richmond TS, 2009, PSYCHOL MED, V39, P1709, DOI 10.1017/S0033291709005376; Ringdal M, 2009, J TRAUMA, V66, P1226, DOI 10.1097/TA.0b013e318181b8e3; Sampalis JS, 2006, J TRAUMA, V60, P806, DOI 10.1097/01.ta.0000215103.62783.4d; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SCHEIER MF, 1989, J PERS SOC PSYCHOL, V57, P1024, DOI 10.1037/0022-3514.57.6.1024; Schou I, 2005, PSYCHO-ONCOLOGY, V14, P718, DOI 10.1002/pon.896; Schou I, 2004, PSYCHO-ONCOLOGY, V13, P309, DOI 10.1002/pon.747; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Toien K, 2010, J TRAUMA, V69, P1552, DOI 10.1097/TA.0b013e3181e125f3; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Ware J.E., 1997, SF 36 HLTH SURVEY MA, V2nd ed; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 2000, SF 36 HLTH SURVEY MA; Watson WL, 2007, INJURY PREV, V13, P45, DOI 10.1136/ip.2005.010157; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	59	55	56	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	APR 8	2011	19								22	10.1186/1757-7241-19-22			12	Emergency Medicine	Emergency Medicine	760KH	WOS:000290322700001	21477280	DOAJ Gold, Green Published			2021-06-18	
J	Rao, KVR; Reddy, PVB; Curtis, KM; Norenberg, MD				Rao, Kakulavarapu V. Rama; Reddy, Pichili V. B.; Curtis, Kevin M.; Norenberg, Michael D.			Aquaporin-4 Expression in Cultured Astrocytes after Fluid Percussion Injury	JOURNAL OF NEUROTRAUMA			English	Article						aquaporin-4; astrocyte swelling; brain edema; Na+,K+,Cl- co-transporter; oxidative/nitrative stress; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NF-KAPPA-B; ACTIVATED PROTEIN-KINASES; FOCAL CEREBRAL-ISCHEMIA; V1A RECEPTOR ANTAGONIST; CORTICAL IMPACT INJURY; OXIDATIVE STRESS; WATER CHANNELS; CYCLOSPORINE-A; PERMEABILITY TRANSITION	The development of cytotoxic brain edema resulting in increased intracranial pressure is a major cause of death occurring in the early phase of traumatic brain injury (TBI). Such edema predominantly develops as a consequence of astrocyte swelling. We recently documented that fluid percussion injury (FPI) to cultured astrocytes causes cell swelling. Since aquaporin-4 (AQP4) has been strongly implicated in the development of brain edema/astrocyte swelling in various neurological conditions, this study examined the effect of in vitro trauma on AQP4 protein expression in cultured astrocytes. Exposure of astrocytes to FPI resulted in a significant upregulation of AQP4 protein in the plasma membrane due to neosynthesis, as cycloheximide blocked the trauma-induced AQP4 upregulation. Silencing the aqp4 gene by siRNA resulted in a significant reduction in trauma-induced astrocyte swelling, indicating a critical role of AQP4 in this process. We recently documented that oxidative/nitrative stress (ONS), the mitochondrial permeability transition (mPT), and activation of mitogen-activated protein kinases (MAPKs), contribute to trauma-induced astrocyte swelling in culture. We now show that inhibition of these factors reduces the upregulation of AQP4 following trauma. Since TBI has been shown to activate nuclear factor-kappa B (NF-kappa B), as well as the Na+, K+, Cl- co-transporter (NKCC), both of which are implicated in brain edema/astrocyte swelling in other conditions, we also examined the effect of BAY 11-7082 and bumetanide, inhibitors of NF-kappa B and NKCC, respectively, and found that these agents also significantly inhibited the trauma-induced-AQP4 upregulation. Our findings show that in vitro trauma upregulates AQP4, and that ONS, MAPKs, mPT, NF-kappa B, and NKCC are involved in its upregulation.	[Rao, Kakulavarapu V. Rama; Reddy, Pichili V. B.; Norenberg, Michael D.] Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL 33101 USA; [Norenberg, Michael D.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; [Curtis, Kevin M.; Norenberg, Michael D.] Vet Affairs Med Ctr, Miami, FL 33125 USA	Norenberg, MD (corresponding author), Univ Miami, Miller Sch Med, Dept Pathol, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu	Curtis, Kevin/B-8020-2011	Curtis, Kevin/0000-0002-7480-1818	Department of Veterans AffairsUS Department of Veterans Affairs	This work was supported by a Merit Review from the Department of Veterans Affairs. We are grateful to Alina Fernandez for preparation of astrocyte cultures.	Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Arima H, 2003, J BIOL CHEM, V278, P44525, DOI 10.1074/jbc.M304368200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bauer R, 1999, EXP TOXICOL PATHOL, V51, P143, DOI 10.1016/S0940-2993(99)80088-8; Bemeur C, 2005, NEUROCHEM INT, V46, P399, DOI 10.1016/j.neuint.2004.11.007; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Darwish RS, 2007, J TRAUMA, V63, P439, DOI 10.1097/TA.0b013e318069178a; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Gaitanaki C, 2003, J EXP BIOL, V206, P2759, DOI 10.1242/jeb.00483; Ghabriel MN, 2006, ACTA NEUROCHIR SUPPL, V96, P402; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hao W, 2009, BRAIN RES, V1282, P156, DOI 10.1016/j.brainres.2009.05.041; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Hu Hua, 2005, J Zhejiang Univ Sci B, V6, P33, DOI 10.1631/jzus.2005.B0033; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Ito H, 2006, J NEUROCHEM, V99, P107, DOI 10.1111/j.1471-4159.2006.04036.x; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; JAYAKUMAR AR, NEUROBIOL D IN PRESS; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; King LS, 1996, ANNU REV PHYSIOL, V58, P619, DOI 10.1146/annurev.physiol.58.1.619; King LS, 2000, MOL MED TODAY, V6, P60, DOI 10.1016/S1357-4310(99)01636-6; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lu KT, 2007, NEUROL RES, V29, P404, DOI 10.1179/016164107X204738; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nielsen S, 1997, J NEUROSCI, V17, P171; Norenberg MD, 2005, METAB BRAIN DIS, V20, P303, DOI 10.1007/s11011-005-7911-7; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; Nozaki K, 2001, MOL NEUROBIOL, V23, P1, DOI 10.1385/MN:23:1:01; Okuno K, 2008, ACTA NEUROCHIR SUPPL, V102, P431, DOI 10.1007/978-3-211-85578-2_84; Panickar KS, 2002, NEUROCHEM RES, V27, P161, DOI 10.1023/A:1014875210852; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pasantes-Morales H, 2010, NEUROSCIENCE, V168, P871, DOI 10.1016/j.neuroscience.2009.11.074; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2003, EXP NEUROL, V183, P438, DOI 10.1016/S0014-4886(03)00166-3; Rao KVR, 2010, GLIA, V58, P1490, DOI 10.1002/glia.21023; Rao KVR, 2010, AM J PATHOL, V176, P1400, DOI 10.2353/ajpath.2010.090756; Russell JM, 2000, PHYSIOL REV, V80, P211; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sharma V, 2007, BRAIN RES BULL, V73, P55, DOI 10.1016/j.brainresbull.2007.01.016; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Votyakova TV, 2005, J NEUROCHEM, V93, P526, DOI 10.1111/j.1471-4159.2005.03042.x; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	79	55	67	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2011	28	3					371	381		10.1089/neu.2010.1705			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734WD	WOS:000288370600004	21204635				2021-06-18	
J	Petzold, A; Tisdall, MM; Girbes, AR; Martinian, L; Thom, M; Kitchen, N; Smith, M				Petzold, Axel; Tisdall, Martin M.; Girbes, Armand R.; Martinian, Lillian; Thom, Maria; Kitchen, Neil; Smith, Martin			In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study	BRAIN			English	Article						extracellular fluid; interstitial fluid; neurocritical care; neurodegeneration; neurofilaments	DIFFUSE AXONAL INJURY; POSITRON-EMISSION-TOMOGRAPHY; NEUROFILAMENT HEAVY-CHAIN; CENTRAL-NERVOUS-SYSTEM; CEREBRAL-BLOOD-FLOW; PC12 CELLS; THERAPEUTIC HYPOTHERMIA; NORMOBARIC HYPEROXIA; OXYGEN-TOXICITY; PHOSPHORYLATION	Traumatic brain injury causes diffuse axonal injury and loss of cortical neurons. These features are well recognized histologically, but their in vivo monitoring remains challenging. In vivo cortical microdialysis samples the extracellular fluid adjacent to neurons and axons. Here, we describe a novel neuronal proteolytic pathway and demonstrate the exclusive neuro-axonal expression of Pavlov's enterokinase. Enterokinase is membrane bound and cleaves the neurofilament heavy chain at positions 476 and 986. Using a 100 kDa microdialysis cut-off membrane the two proteolytic breakdown products, extracellular fluid neurofilament heavy chains NfH(476-986) and NfH(476-1026), can be quantified with a relative recovery of 20%. In a prospective clinical in vivo study, we included 10 patients with traumatic brain injury with a median Glasgow Coma Score of 9, providing 640 cortical extracellular fluid samples for longitudinal data analysis. Following high-velocity impact traumatic brain injury, microdialysate extracellular fluid neurofilament heavy chain levels were significantly higher (6.18 +/- 2.94 ng/ml) and detectable for longer (> 4 days) compared with traumatic brain injury secondary to falls (0.84 +/- 1.77 ng/ml, < 2 days). During the initial 16 h following traumatic brain injury, strong correlations were found between extracellular fluid neurofilament heavy chain levels and physiological parameters (systemic blood pressure, anaerobic cerebral metabolism, excessive brain tissue oxygenation, elevated brain temperature). Finally, extracellular fluid neurofilament heavy chain levels were of prognostic value, predicting mortality with an odds ratio of 7.68 (confidence interval 2.15-27.46, P = 0.001). In conclusion, this study describes the discovery of Pavlov's enterokinase in the human brain, a novel neuronal proteolytic pathway that gives rise to specific protein biomarkers (NfH(476-986) and Nf(H476-1026)) applicable to in vivo monitoring of diffuse axonal injury and neuronal loss in traumatic brain injury.	[Petzold, Axel] Natl Hosp Neurol & Neurosurg, Dept Neuroimmunol, Tavistock Intens Care Unit, London WC1N 3BG, England; [Petzold, Axel; Tisdall, Martin M.] Natl Hosp Neurol & Neurosurg, Dept Neurosurg, London WC1N 3BG, England; [Petzold, Axel] UCL Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England; [Petzold, Axel; Girbes, Armand R.] Vrije Univ Amsterdam Med Ctr, Dept Intens Care, NL-1081 HV Amsterdam, Netherlands; [Martinian, Lillian; Thom, Maria] UCL Inst Neurol, Div Neuropathol, London WC1N 3BG, England; [Kitchen, Neil] Natl Hosp Neurol & Neurosurg, Dept Neurosurg, London WC1N 3BG, England; [Smith, Martin] Natl Hosp Neurol & Neurosurg, Ctr Neuroanaesthesia, London WC1N 3BG, England; [Smith, Martin] Natl Hosp Neurol & Neurosurg, Tavistock Intens Care Unit, London WC1N 3BG, England	Petzold, A (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Neuroimmunol, Tavistock Intens Care Unit, Queen Sq, London WC1N 3BG, England.	a.petzold@ion.ucl.ac.uk	Petzold, Axel/C-1090-2009; Smith, Martin/B-2616-2009	Petzold, Axel/0000-0002-0344-9749; Tisdall, Martin/0000-0001-8880-8386	Department of Health's National Institute for Health Research Centres, University College London Hospitals; Wellcome Clinical Research Fellow [075608]; Department of Health's NIHR Biomedical Research CentreNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0701458] Funding Source: researchfish	Wellcome Clinical Research Fellow (Grant No. 075608 to M. T.); Department of Health's National Institute for Health Research Centres funding scheme, University College London Hospitals (partial). This work was undertaken at UCLH/UCL, who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centre funding scheme.	Adekoya N, 2004, PUBLIC HEALTH REP, V119, P486, DOI 10.1016/j.phr.2004.07.006; Afinowi R, 2009, J NEUROSCI METH, V181, P95, DOI 10.1016/j.jneumeth.2009.02.021; Arieli R, 2008, EUR J APPL PHYSIOL, V104, P867, DOI 10.1007/s00421-008-0843-2; Arieli R, 2006, AVIAT SPACE ENVIR MD, V77, P1153; Bakir A, 2005, NEUROL MED-CHIR, V45, P281, DOI 10.2176/nmc.45.281; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Blaber SI, 2002, BIOCHEMISTRY-US, V41, P1165, DOI 10.1021/bi015781a; Boulware KT, 2006, P NATL ACAD SCI USA, V103, P7583, DOI 10.1073/pnas.0511108103; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Coles JP, 2009, J CEREBR BLOOD F MET, V29, P965, DOI 10.1038/jcbfm.2009.22; Corbo J, 2004, ANN EMERG MED, V44, P57, DOI 10.1016/j.annemergmed.2003.11.010; Dashiell SM, 2002, J NEUROCHEM, V81, P1263, DOI 10.1046/j.1471-4159.2002.00927.x; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; Enblad P, 2001, STROKE, V32, P1574, DOI 10.1161/01.STR.32.7.1574; Ericsson C, 2007, ACTA ONCOL, V46, P10, DOI 10.1080/02841860600847061; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gieron MA, 1998, PEDIATR NEUROL, V19, P382, DOI 10.1016/S0887-8994(98)00072-1; Graham DI, 2005, PROG BRAIN RES, V150, P445, DOI 10.1016/S0079-6123(05)50031-1; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; GREENWOOD JA, 1993, J NEUROCHEM, V61, P191, DOI 10.1111/j.1471-4159.1993.tb03555.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Kirkpatrick J B, 1983, Acta Neurochir Suppl (Wien), V32, P115; Kitson R, 2005, CRITICAL CARE, V9, pE28; Langbein John H., 2006, TRAUMATIC BRAIN INJU, P1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEE VMY, 1985, J NEUROSCI, V5, P3039; Leissring MA, 2008, J BIOL CHEM, V283, P29645, DOI 10.1074/jbc.R800022200; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; LIGHT A, 1989, TRENDS BIOCHEM SCI, V14, P110, DOI 10.1016/0968-0004(89)90133-3; LINDENBAUM MH, 1987, J BIOL CHEM, V262, P605; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Littell RC, 1998, J ANIM SCI, V76, P1216; Ma M, 2009, EXP NEUROL, V215, P119, DOI 10.1016/j.expneurol.2008.09.024; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Minino Arialdi M, 2006, Natl Vital Stat Rep, V54, P1; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Pavlov IP, 1910, WORK DIGESTIVE GLAND; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Petzold A, 2008, EXP NEUROL, V213, P326, DOI 10.1016/j.expneurol.2008.06.008; Petzold A, 2007, NEUROL RES, V29, P691, DOI 10.1179/016164107X240080; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; Poca MA, 2005, J NEUROTRAUM, V22, P1303, DOI 10.1089/neu.2005.22.1303; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Sairanen T, 2009, ACTA NEUROPATHOL, V118, P541, DOI 10.1007/s00401-009-0559-3; Schepowalnikow N, 1899, THESIS ST PETERSBURG; Schutze K, 2007, METHOD CELL BIOL, V82, P649, DOI 10.1016/S0091-679X(06)82023-6; Shaw G, 1998, NEUROFILAMENTS; Shin HK, 2007, BRAIN, V130, P1631, DOI 10.1093/brain/awm071; Smith M, 2003, TRAUMA, V5, P1; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiver SI, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E5; Sulejczak D, 2008, FOLIA NEUROPATHOL, V46, P213; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Umschwief G, 2010, J CEREBR BLOOD F MET, V30, P616, DOI 10.1038/jcbfm.2009.234; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vilen ST, 2008, EXP CELL RES, V314, P914, DOI 10.1016/j.yexcr.2007.10.025; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; WIEGAND U, 1993, GENE, V136, P167, DOI 10.1016/0378-1119(93)90460-K; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1	80	55	58	0	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	FEB	2011	134		2				464	483		10.1093/brain/awq360			20	Clinical Neurology; Neurosciences	Neurosciences & Neurology	716RI	WOS:000286990800014	21278408	Bronze, Green Published			2021-06-18	
J	Xiong, Y; Mahmood, A; Meng, YL; Zhang, YL; Zhang, ZG; Morris, DC; Chopp, M				Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu; Zhang, Zheng Gang; Morris, Daniel C.; Chopp, Michael			Treatment of traumatic brain injury with thymosin beta(4) in rats Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; neurogenesis; rat; oligodendrogenesis; thymosin beta(4); traumatic brain injury	FUNCTIONAL RECOVERY; CELL MIGRATION; SPATIAL MEMORY; MESSENGER-RNA; HAIR-GROWTH; NEUROGENESIS; STROKE; ERYTHROPOIETIN; BETA-4; ANGIOGENESIS	Object. This study was designed to investigate the efficacy of delayed thymosin beta(4) (T beta(4)) treatment of traumatic brain injury (TBI) in rats. Methods. Young adult male Wistar rats were divided into the following groups: 1) sham group (6 rats); 2) TBI + saline group (9 rats); 3) and TBI + T beta(4) group (10 rats). Traumatic brain injury was induced by controlled cortical impact over the left parietal cortex. Thymosin beta(4) (6 mg/kg) or saline was administered intraperitoneally starting at Day 1 and then every 3 days for an additional 4 doses. Neurological function was assessed using a modified neurological severity score (mNSS), foot fault, and Morris water maze tests. Animals were killed 35 days after injury, and brain sections were stained for immunohistochemistry to assess angiogenesis, neurogenesis, and oligodendrogenesis after T beta(4) treatment. Results. Compared with the saline treatment, delayed T beta(4) treatment did not affect lesion volume but significantly reduced hippocampal cell loss, enhanced angiogenesis and neurogenesis in the injured cortex and hippocampus, increased oligodendrogenesis in the CA3 region, and significantly improved sensorimotor functional recovery and spatial learning. Conclusions. These data for the first time demonstrate that delayed administration of T beta(4) significantly improves histological and functional outcomes in rats with TBI, indicating that T beta(4) has considerable therapeutic potential for patients with TBI. (DOI: 10.3171/2010.4.JNS10118)	[Xiong, Ye; Mahmood, Asim; Meng, Yuling; Zhang, Yanlu] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Morris, Daniel C.] Henry Ford Hlth Syst, Dept Emergency Med, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS62002, P01 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS062002] Funding Source: NIH RePORTER	This work was supported by NIH Grant Nos. R01 NS62002 (to Dr. Xiong) and P01 NS42345 (to Drs. Mahmood and Chopp). Drs. Z. G. Zhang, Morris, and Chopp have applied for a patent for the use of T beta<INF>4</INF> as a treatment of stroke, neurological disease, and injury.	BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bednarek R, 2008, J BIOL CHEM, V283, P1534, DOI 10.1074/jbc.M707539200; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Boncela J, 2006, J BIOL CHEM, V281, P1066, DOI 10.1074/jbc.M506303200; Cavasin Maria A, 2006, Am J Cardiovasc Drugs, V6, P305, DOI 10.2165/00129784-200606050-00003; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Choi SY, 2007, BIOCHEM BIOPH RES CO, V362, P587, DOI 10.1016/j.bbrc.2007.08.031; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; Crockford D, 2007, ANN NY ACAD SCI, V1112, P385, DOI 10.1196/annals.1415.051; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dong JH, 2005, NEUROREPORT, V16, P1629, DOI 10.1097/01.wnr.0000183326.21241.48; Fine JD, 2007, ANN NY ACAD SCI, V1112, P396, DOI 10.1196/annals.1415.017; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Guarnera G, 2007, ANN NY ACAD SCI, V1112, P407, DOI 10.1196/annals.1415.003; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Hinkel R, 2008, CIRCULATION, V117, P2232, DOI 10.1161/CIRCULATIONAHA.107.758904; Ho JHC, 2008, BRIT J OPHTHALMOL, V92, P992, DOI 10.1136/bjo.2007.136747; Ho JHC, 2007, INVEST OPHTH VIS SCI, V48, P27, DOI 10.1167/iovs.06-0826; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Kupatt C, 2008, TRENDS CARDIOVAS MED, V18, P205, DOI 10.1016/j.tcm.2008.10.002; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mora CA, 1997, INT J IMMUNOPHARMACO, V19, P1, DOI 10.1016/S0192-0561(97)00005-2; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Paulussen M, 2009, PEPTIDES, V30, P1822, DOI 10.1016/j.peptides.2009.07.010; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Philp D, 2003, FASEB J, V17, P385, DOI 10.1096/fj.03-0244fje; Philp D, 2004, MECH AGEING DEV, V125, P113, DOI 10.1016/j.mad.2003.11.005; Philp D, 2007, ANN NY ACAD SCI, V1112, P95, DOI 10.1196/annals.1415.009; Popoli P, 2007, ANN NY ACAD SCI, V1112, P219, DOI 10.1196/annals.1415.033; Qiu FY, 2009, J CARDIOVASC PHARM, V53, P209, DOI 10.1097/FJC.0b013e318199f326; Reti R, 2008, EUR J ORAL SCI, V116, P424, DOI 10.1111/j.1600-0722.2008.00569.x; Riley PR, 2009, BIOCHEM SOC T, V37, P1218, DOI 10.1042/BST0371218; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Smart Nicola, 2007, Angiogenesis, V10, P229, DOI 10.1007/s10456-007-9077-x; Smart N, 2007, ANN NY ACAD SCI, V1112, P171, DOI 10.1196/annals.1415.000; Smart N, 2007, NATURE, V445, P177, DOI 10.1038/nature05383; Sosne G, 2007, ANN NY ACAD SCI, V1112, P114, DOI 10.1196/annals.1415.004; Srivastava D, 2007, ANN NY ACAD SCI, V1112, P161, DOI 10.1196/annals.1415.048; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sun W, 2007, ANN NY ACAD SCI, V1112, P210, DOI 10.1196/annals.1415.013; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Vartiainen N, 1996, NEUROREPORT, V7, P1613, DOI 10.1097/00001756-199607080-00017; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yang H, 2008, NEUROCHEM RES, V33, P2269, DOI 10.1007/s11064-008-9712-y; Yarmola EG, 2007, ANN NY ACAD SCI, V1112, P76, DOI 10.1196/annals.1415.008; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhang RL, 2008, NEUROPHARMACOLOGY, V55, P345, DOI 10.1016/j.neuropharm.2008.05.027; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	70	55	56	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2011	114	1					102	115		10.3171/2010.4.JNS10118			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	699NG	WOS:000285669500022	20486893	Green Accepted			2021-06-18	
J	Zhu, ZF; Wang, QG; Han, BJ; William, CP				Zhu, Zu-Fu; Wang, Qing-Guang; Han, Bo-Jun; William, Callie P.			Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice	BRAIN RESEARCH BULLETIN			English	Article						Lithium; Traumatic brain injury; Neuroprotection; Learning and memory	LONG-TERM POTENTIATION; CONTROLLED CORTICAL IMPACT; RAT DENTATE GYRUS; SYNAPTIC PLASTICITY; CEREBRAL-ISCHEMIA; OXIDATIVE STRESS; NMDA RECEPTOR; FLUORO-JADE; MEMORY; EXCITOTOXICITY	In vitro and in vivo studies have demonstrated that lithium treatment can protect neurons against excitotoxic and ischemic damage Yet the possible beneficial effect of chronic low dose lithium on a model of traumatic brain injury (TBI) has not been intensively investigated In this study lithium (1 mmol/kg) was given daily intraperitonealy for 14 days before the onset of moderate controlled TBI and was continued until the mice were sacrificed The results showed that in brain injured animals chronic lithium treatment attenuated the loss of hemispheric tissue cerebral edema and the expression of pro-inflammatory cytokine interleukin-1 beta The neuronal degeneration in hippocampal CA3 and dentate gyrus sub-regions was also attenuated in the chronic lithium-treated mice as shown by Fluoro-Jade B staining Moreover chronic lithium treatment enhanced spatial learning and memory performance of injured mice in the Morns water maze Our current study extended the protective role of lithium in the model of TBI and suggested that chronic lithium treatment might be a helpful therapeutic strategy for brain injury with multiple beneficial effects (C) 2010 Elsevier Inc All rights reserved	[Zhu, Zu-Fu; Wang, Qing-Guang; Han, Bo-Jun; William, Callie P.] Southeast Univ, Coll Med, Affiliated Jiangyin Hosp, Dept Neurol, Jiangyin 214400, Jiangsu Prov, Peoples R China	Zhu, ZF (corresponding author), Southeast Univ, Coll Med, Affiliated Jiangyin Hosp, Dept Neurol, 163 Shoushan Rd, Jiangyin 214400, Jiangsu Prov, Peoples R China.				Educational Commission of Jiangsu Province of China [05KJD320229]	This work was supported by a grant from the Educational Commission of Jiangsu Province of China (No 05KJD320229)	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Ballanger F, 2008, ARCH DERMATOL RES, V300, P215, DOI 10.1007/s00403-007-0824-z; Basselin M, 2006, NEUROPSYCHOPHARMACOL, V31, P1659, DOI 10.1038/sj.npp.1300920; Bian QM, 2007, BRAIN RES, V1184, P270, DOI 10.1016/j.brainres.2007.09.054; Bielecka AM, 2008, PHARMACOL REP, V60, P771; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Cappuccio I, 2005, J NEUROSCI, V25, P2647, DOI 10.1523/JNEUROSCI.5230-04.2005; Chuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399-5618.2002.01179.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Goldstein BI, 2009, J CLIN PSYCHIAT, V70, P1078, DOI 10.4088/JCP.08r04505; Griebenow M, 2007, J NEUROTRAUM, V24, P1529, DOI 10.1089/neu.2007.0306; Hardingham GE, 2009, BIOCHEM SOC T, V37, P1147, DOI 10.1042/BST0371147; Hashimoto R, 2003, FEBS LETT, V538, P145, DOI 10.1016/S0014-5793(03)00167-4; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; Holscher C, 1999, J NEUROSCI RES, V58, P62; Hooper C, 2007, EUR J NEUROSCI, V25, P81, DOI 10.1111/j.1460-9568.2006.05245.x; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Liossi C, 2009, J NEUROPSYCH CLIN N, V21, P43, DOI 10.1176/appi.neuropsych.21.1.43; Mai L, 2002, J NEUROCHEM, V82, P75, DOI 10.1046/j.1471-4159.2002.00939.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nocjar C, 2007, NEUROSCIENCE, V150, P774, DOI 10.1016/j.neuroscience.2007.09.063; Nonaka S, 1998, P NATL ACAD SCI USA, V95, P2642, DOI 10.1073/pnas.95.5.2642; Nonaka S, 1998, NEUROREPORT, V9, P2081, DOI 10.1097/00001756-199806220-00031; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ren M, 2003, P NATL ACAD SCI USA, V100, P6210, DOI 10.1073/pnas.0937423100; Rockenstein E, 2007, J NEUROSCI, V27, P1981, DOI 10.1523/JNEUROSCI.4321-06.2007; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shao L, 2005, BIOL PSYCHIAT, V58, P879, DOI 10.1016/j.biopsych.2005.04.052; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shim SS, 2007, PROG NEURO-PSYCHOPH, V31, P343, DOI 10.1016/j.pnpbp.2006.09.008; Sinha D, 2005, AM J PHYSIOL-RENAL, V288, pF703, DOI 10.1152/ajprenal.00189.2004; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Son H, 2003, J NEUROCHEM, V85, P872, DOI 10.1046/j.1471-4159.2003.01725.x; Tsaltas E, 2007, BEHAV BRAIN RES, V180, P241, DOI 10.1016/j.bbr.2007.03.017; Tsaltas E, 2007, BEHAV BRAIN RES, V177, P51, DOI 10.1016/j.bbr.2006.11.003; Tsaltas E, 2009, PSYCHOPHARMACOLOGY, V202, P457, DOI 10.1007/s00213-008-1311-8; Vasconcellos APS, 2003, PHYSIOL BEHAV, V79, P143, DOI 10.1016/S0031-9384(03)00113-6; Wada A, 2005, J PHARMACOL SCI, V99, P307, DOI 10.1254/jphs.CRJ05009X; Wada A, 2009, J PHARMACOL SCI, V110, P14, DOI 10.1254/jphs.09R02CR; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xu JH, 2003, STROKE, V34, P1287, DOI 10.1161/01.STR.0000066308.25088.64; Yan XB, 2007, BEHAV BRAIN RES, V177, P282, DOI 10.1016/j.bbr.2006.11.021; Yu IT, 2003, BIOCHEM BIOPH RES CO, V303, P1193, DOI 10.1016/S0006-291X(03)00494-7; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhu LQ, 2007, J NEUROSCI, V27, P12211, DOI 10.1523/JNEUROSCI.3321-07.2007; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	57	55	57	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	OCT 30	2010	83	5					272	277		10.1016/j.brainresbull.2010.07.008			6	Neurosciences	Neurosciences & Neurology	683YN	WOS:000284514300015	20638460				2021-06-18	
J	Grubenhoff, JA; Kirkwood, M; Gao, DX; Deakyne, S; Wathen, J				Grubenhoff, Joseph A.; Kirkwood, Michael; Gao, Dexiang; Deakyne, Sara; Wathen, Joe			Evaluation of the Standardized Assessment of Concussion in a Pediatric Emergency Department	PEDIATRICS			English	Article						brain concussion; closed head injury; traumatic brain injury	TRAUMATIC BRAIN-INJURY; GLASGOW COMA SCALE; POSTCONCUSSION SYNDROME; COGNITIVE IMPAIRMENT; UNITED-STATES; SYMPTOMS	OBJECTIVE: The Standardized Assessment of Concussion (SAC) is a validated tool for identifying the effects of mild traumatic brain injury (mTBI). Previous research focused on sport-related sideline evaluation of adolescents and adults. Our goal was to evaluate performance of the SAC among subjects with and without head injury in a pediatric emergency department (ED). METHODS: This was an observational study of children 6 to 18 years of age who presented to an ED with blunt head injury (case-patients) or minor extremity injury (controls). SAC and graded-symptom-checklist scores were compared. American Academy of Neurology concussion grades, presence of loss of consciousness and posttraumatic amnesia were also compared with SAC and graded-symptom-checklist scores among case-patients. RESULTS: Three hundred forty-eight children were enrolled. SAC scores trended lower (greater cognitive deficits) for case-patients compared with controls but did not reach significance. Graded-symptom-checklist scores were significantly higher among case-patients. Presence of altered mental status magnified this effect. There was no correlation between SAC scores and other indicators of mTBI. There was a positive correlation between graded-symptom-checklist scores and posttraumatic amnesia and American Academy of Neurology concussion grade. CONCLUSIONS: The graded symptom checklist reliably identified mTBI symptoms for all children aged 6 years and older. SAC scores tended to be lower for case-patients compared with controls but did not reach significance. Patients with altered mental status at the time of injury manifest an increased number and severity of symptoms. Additional research into strategies to identify cognitive deficits related to mTBI and classify mTBI severity in children is needed. Pediatrics 2010;126:688-695	[Grubenhoff, Joseph A.; Deakyne, Sara; Wathen, Joe] Univ Colorado, Sch Med, Dept Pediat, Sect Emergency Med, Denver, CO USA; [Kirkwood, Michael] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA; [Gao, Dexiang] Childrens Hosp, Clin Translat Res Ctr, Denver, CO 80218 USA	Grubenhoff, JA (corresponding author), Childrens Hosp, 13123 16th Ave,B-251, Aurora, CO 80045 USA.	grubenhoff.joe@tchden.org	Gao, Dexiang/ABC-8930-2020; Grubenhoff, Joseph A/H-9994-2019	Grubenhoff, Joseph A/0000-0001-5072-4064			Ahmed S, 2000, BRAIN INJURY, V14, P765; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1999, BRAIN INJURY, V13, P151; Kelly JP, 1997, NEUROLOGY, V48, P581; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	26	55	55	0	9	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	OCT	2010	126	4					688	695		10.1542/peds.2009-2804			8	Pediatrics	Pediatrics	658WW	WOS:000282526100039	20819901				2021-06-18	
J	Robertson, CS; Zager, EL; Narayan, RK; Handly, N; Sharma, A; Hanley, DF; Garza, H; Maloney-Wilensky, E; Plaum, JM; Koenig, CH; Johnson, A; Morgan, T				Robertson, Claudia S.; Zager, Eric L.; Narayan, Raj K.; Handly, Neal; Sharma, Alok; Hanley, Daniel F.; Garza, Homero; Maloney-Wilensky, Eileen; Plaum, Justin M.; Koenig, Carolyn H.; Johnson, Anne; Morgan, Timothy			Clinical Evaluation of a Portable Near-Infrared Device for Detection of Traumatic Intracranial Hematomas	JOURNAL OF NEUROTRAUMA			English	Article						head injury; intracranial hematomas; near-infrared spectroscopy; traumatic brain injury	SPECTROSCOPY	The purpose of this multicenter observational clinical study was to evaluate the performance of a near-infrared (NIR)-based, non-invasive, portable device to screen for traumatic intracranial hematomas. Five trauma centers collected data using the portable NIR device at the time a computed tomography (CT) scan was performed to evaluate a suspected traumatic brain injury (TBI). The CT scans were read by an independent neuroradiologist who was blinded to the NIR measurements. Of 431 patients enrolled, 365 patients were included in the per-protocol population analyzed. Of the 365 patients, 96 were determined by CT scan to have intracranial hemorrhages of various sizes, depths, and anatomical locations. The NIR device demonstrated sensitivity of 88% (95% confidence interval [CI] 74.9,95.0%), and specificity of 90.7% (95% CI 86.4,93.7%), in detecting the 50 intracranial hematomas that were large enough to be clinically important (larger than 3.5mL in volume), and that were less than 2.5 cm from the surface of the brain. For all 96 cases with intracranial hemorrhage, regardless of size and type of hemorrhage, the sensitivity was 68.7% (CI 58.3,77.6%), and specificity was 90.7% (CI 86.4,93.7%). These results confirm the results of previous studies that indicate that a NIR-based portable device can reliably screen for intracranial hematomas that are superficial and of a size likely to be of clinical importance. The NIR device cannot replace CT scanning in the diagnosis of TBI, but the device might be useful to supplement clinical information used to triage TBI patients, and in situations in which CT scanning is not readily available.	[Robertson, Claudia S.; Garza, Homero] Baylor Univ, Dept Neurosurg, Houston, TX 77030 USA; [Zager, Eric L.] Dept Neurosurg, Philadelphia, PA USA; [Maloney-Wilensky, Eileen] Neurosurg Clin Res Div, Philadelphia, PA USA; [Narayan, Raj K.] N Shore Univ Hosp, Dept Neurosurg, Manhasset, NY USA; [Handly, Neal] Drexel Univ, Dept Emergency Med, Coll Med, Philadelphia, PA 19104 USA; [Johnson, Anne] Drexel Univ, Clin Res Grp, Coll Med, Philadelphia, PA 19104 USA; Hahnemann Hosp, Philadelphia, PA USA; [Sharma, Alok] Lokmanya Tilak Municipal Gen Hosp, Dept Neurosurg, Bombay, Maharashtra, India; [Hanley, Daniel F.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21218 USA; [Hanley, Daniel F.] Johns Hopkins Univ, Dept Neurosurg & Anesthesia Crit Med, Baltimore, MD 21218 USA; [Koenig, Carolyn H.] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; [Koenig, Carolyn H.] Univ Cincinnati, Coll Med, Mayfield Clin, Cincinnati, OH 45267 USA; [Morgan, Timothy] Johns Hopkins Univ, Div Brain Injury Outcomes, Clin Reading Ctr, Baltimore, MD USA; [Plaum, Justin M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA	Robertson, CS (corresponding author), Baylor Univ, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			InfraScan, Inc.	This study was supported by InfraScan, Inc. We thank Meltem Izzetoglu, Ph.D. from Drexel University, who provided statistical analysis for the study.	ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; Cope M., 1991, APPL NEAR INFRARED S; FLETCHER RH, 1997, CLIN EPIDEMIOLOGY; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Francis SV, 2005, J CLIN NEUROSCI, V12, P291, DOI 10.1016/j.jocn.2004.06.009; Kahraman S, 2006, J TRAUMA, V61, P1480, DOI 10.1097/01.ta.0000197616.10279.48; Kessel B, 2007, INJURY, V38, P1065, DOI 10.1016/j.injury.2007.05.009; Marion DW, 2006, NEUROSURGERY, V58, P655; Robertson C S, 1997, J Biomed Opt, V2, P31, DOI 10.1117/12.261680; Rolfe P, 2000, ANNU REV BIOMED ENG, V2, P715, DOI 10.1146/annurev.bioeng.2.1.715; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Silver JM, 2005, TXB TRAUMATIC BRAIN; Strangman G, 2002, BIOL PSYCHIAT, V52, P679, DOI 10.1016/S0006-3223(02)01550-0	13	55	57	2	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1597	1604		10.1089/neu.2010.1340			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500006	20568959				2021-06-18	
J	Santiago, PN; Wilk, JE; Milliken, CS; Castro, CA; Engel, CC; Hoge, CW				Santiago, Patcho N.; Wilk, Joshua E.; Milliken, Charles S.; Castro, Carl A.; Engel, Charles C.; Hoge, Charles W.			Screening for Alcohol Misuse and Alcohol-Related Behaviors Among Combat Veterans	PSYCHIATRIC SERVICES			English	Article							TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; PRIMARY-CARE; MILITARY; IRAQ; DISORDERS; PERSONNEL; PTSD; DUTY	Objective: The U.S. military conducts health screenings of service members three to six months after they return from combat deployments. This population health program includes a modified version of the Two-Item Conjoint Screen (TICS), which is widely used in primary care to screen for alcohol misuse. Rates of referral in the military for alcohol treatment are very low, and the utility of these screening questions in predicting serious alcohol-related behaviors is unknown. Methods: Anonymous surveys were collected from 6,527 U. S. Army soldiers who were screened three to four months after returning from deployment to Iraq. Positive responses on the TICS alcohol screen were correlated with alcohol-related behaviors. Odds ratios (ORs) were calculated using logistic regression, after adjusting for gender, rank, race, and military component (active or reserve). Results: Twenty-seven percent of soldiers screened positive for alcohol misuse. Compared with soldiers who screened negative, those who screened positive were more likely to have recently engaged in the following behaviors: drinking and driving (OR=4.99, 95% confidence interval [CI]=4.31-5.76), riding with a driver who had been drinking (OR=5.87, CI=4.99-6.91), reporting late or missing work because of a hangover (OR=9.24, CI=6.73-12.68), using illicit drugs (OR=4.97, CI=3.68-6.71), being referred to alcohol rehabilitation (OR=7.15, CI=4.84-10.58), and being convicted of driving under the influence (OR=4.84, CI=3.04-7.67). Conclusions: Positive responses to a two-item alcohol screening tool were strongly associated with serious alcohol-related behaviors. This study highlights the need to improve screening and access to care for alcohol-related problems among service members returning from combat deployments. (Psychiatric Services 61:575-581, 2010)	[Santiago, Patcho N.; Engel, Charles C.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Wilk, Joshua E.; Milliken, Charles S.; Castro, Carl A.; Hoge, Charles W.] Walter Reed Army Inst Res, Div Psychiat & Neurosci, Silver Spring, MD USA	Santiago, PN (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Psychiat, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	psantiago@usuhs.mil		Santiago, Patcho/0000-0003-0805-4313			Ames GM, 2007, J STUD ALCOHOL DRUGS, V68, P336, DOI 10.15288/jsad.2007.68.336; Bell N S, 2001, Inj Prev, V7, P4, DOI 10.1136/ip.7.1.4; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese P. D., 2005, POSTDEPLOYMENT PSYCH; Bray RM, 2007, ADDICTION, V102, P1092, DOI 10.1111/j.1360-0443.2007.01841.x; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Browne T, 2008, OCCUP ENVIRON MED, V65, P628, DOI 10.1136/oem.2007.036830; Day Andrew, 2003, Crim Behav Ment Health, V13, P45, DOI 10.1002/cbm.530; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Hosmer D, 1989, APPL LOGISTIC REGRES; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; MAXFIELD BD, 2005, ARMY PROFILE FY 05; McFarlane AC, 1998, ADDICT BEHAV, V23, P813, DOI 10.1016/S0306-4603(98)00098-7; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Solberg LI, 2008, AM J PREV MED, V34, P143, DOI 10.1016/j.amepre.2007.09.035; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Taft CT, 2007, J ABNORM PSYCHOL, V116, P498, DOI 10.1037/0021-843X.116.3.498; Wynd CA, 1998, MIL MED, V163, P283	21	55	55	1	13	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	1075-2730			PSYCHIAT SERV	Psychiatr. Serv.	JUN	2010	61	6					575	581					7	Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry	Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry	602UT	WOS:000278165100008	20513680				2021-06-18	
J	Yang, ZY; Duan, HM; Mo, LH; Qiao, H; Li, XG				Yang, Zhaoyang; Duan, Hongmei; Mo, Linhong; Qiao, Hui; Li, Xiaoguang			The effect of the dosage of NT-3/chitosan carriers on the proliferation and differentiation of neural stem cells	BIOMATERIALS			English	Article						Chitosan carriers; NT-3; Neural stem cells; Cell differentiation; Neuron	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NEURONAL DIFFERENTIATION; PROGENITOR CELLS; ADULT RATS; PARKINSONS-DISEASE; GENE-THERAPY; NEUROTROPHIN-3; TRANSPLANTATION	This study aimed to determine the optimal dosage range of NT-3 in the soluble form or loaded with chitosan carriers by using NT-3/chitosan carriers to support the survival and proliferation of neural stem cells (NSCs) and induce them to differentiate into desired phenotypes. NSCs were co-cultured with chitosan carriers loaded with different doses of NT-3. As the control, NSCs were cultured in the defined medium, into which were added different doses of NT-3 in the soluble form every day. The ELISA kit was used to study the NT-3 releasing kinetics, which showed that, in the initial co-culture stage from 1 h to 14 weeks, the chitosan carriers loaded with different doses of NT-3 released NT-3 stably and constantly. The 3-(4,5-dimethylthiazol-2-y1)-2, 5-diphenyltetrazolium bromide (MTT) assay was conducted to measure the cell viability, and the immunocytochemical methods were adopted to quantitatively analyze the phenotypes differentiating from the NSCs. Compared to the 100 ng NT-3 daily addition group (1400 ng over 14 days), the 25 ng, 50 ng and 200 ng NT-3 daily addition group showed dramatically shorter processes length and much lower differentiation percentage from NSCs into neurons. By contrast, the NT-3 (25 ng)-chitosan carriers group had not only higher cell viability, but also similar processes length and differentiation percentage from NSCs into neurons to the 100 ng NT-3 daily addition group. The method developed in this study significantly reduced the NT-3 amount required to support the survival, proliferation and differentiation of NSCs in vitro. Meanwhile, the chitosan carriers used here provided an ideal 3-dimensional scaffold for the adhesion, migration, proliferation and differentiation of NSC and the differentiated cells. Therefore, this method may open a new field for the large-scaled culture and amplification of NSCs in vitro to replace the lost neural cells, meanwhile lower the consumption of neurotrophic factors in the cell transplantation therapy of brain and spinal injury. (C) 2010 Elsevier Ltd. All rights reserved.	[Yang, Zhaoyang; Li, Xiaoguang] Beihang Univ, Sch Biol Sci & Med Engn, Beijing 100191, Peoples R China; [Duan, Hongmei; Mo, Linhong; Li, Xiaoguang] Capital Med Univ, Beijing Inst Neurosci, Beijing 100069, Peoples R China; [Qiao, Hui] Ningxia Med Univ, Publ Heath Sch, Ningxia 750004, Peoples R China	Li, XG (corresponding author), Beihang Univ, Sch Biol Sci & Med Engn, XueYuan Rd 37, Beijing 100191, Peoples R China.	lxgchina@sina.com		Duan, Hongmei/0000-0003-2261-2182	National 863 Project [2006AA02A129]; Department of Science and Technology, Beijing, ChinaDepartment of Science & Technology (India) [D09080703660902]	This work was supported by The National 863 Project (Grant No. 2006AA02A129), and Key Project of Department of Science and Technology (Grant No. D09080703660902), Beijing, China. The authors would like to express heartfelt thanks to Liwei Zhang for kind help and constructive comments.	Bithell A, 2005, CLIN SCI, V108, P13, DOI 10.1042/CS20040276; Burdick JA, 2006, BIOMATERIALS, V27, P452, DOI 10.1016/j.biomaterials.2005.06.034; Caldwell MA, 2001, NAT BIOTECHNOL, V19, P475, DOI 10.1038/88158; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; Cheng H, 2007, BIOCHEM BIOPH RES CO, V357, P938, DOI 10.1016/j.bbrc.2007.04.049; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Dutton R, 1999, J NEUROSCI, V19, P2601; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; GAO EJ, 2004, CHIN J REHABIL THEOR, V10, P28; Grill R, 1997, J NEUROSCI, V17, P5560; Guo JS, 2007, SPINAL CORD, V45, P15, DOI 10.1038/sj.sc.3101943; Hapner SJ, 2006, DEV BIOL, V297, P182, DOI 10.1016/j.ydbio.2006.05.007; Hung CH, 2006, BIOMATERIALS, V27, P4461, DOI 10.1016/j.biomaterials.2006.04.021; IIKHANIZADEH S, 2007, BIOMATERIALS, V28, P3936; Ito H, 2003, J NEUROSCI RES, V71, P648, DOI 10.1002/jnr.10532; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Lepore AC, 2004, NEURON GLIA BIOL, V1, P113, DOI 10.1017/S1740925X04000213; Li XG, 2006, PROG NAT SCI-MATER, V16, P1051; Li XG, 2006, CHINESE SCI BULL, V51, P918, DOI 10.1007/s11434-006-0918-6; Li XG, 2009, BIOMATERIALS, V30, P4978, DOI 10.1016/j.biomaterials.2009.05.047; Li XG, 2009, BIOMATERIALS, V30, P1121, DOI 10.1016/j.biomaterials.2008.10.063; Liu Y, 1999, EXP NEUROL, V158, P9, DOI 10.1006/exnr.1999.7079; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Lu HX, 2008, BRAIN RES BULL, V77, P158, DOI 10.1016/j.brainresbull.2008.02.037; Lundberg C, 1997, EXP NEUROL, V145, P342, DOI 10.1006/exnr.1997.6503; Park KI, 2006, EXP NEUROL, V199, P179, DOI 10.1016/j.expneurol.2006.03.016; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; Taylor SJ, 2006, J CONTROL RELEASE, V116, P204, DOI 10.1016/j.jconrel.2006.07.005; Tzeng SF, 2002, J BIOMED SCI, V9, P10, DOI 10.1007/BF02256573; Wang JH, 2006, BIOMATERIALS, V27, P3441, DOI 10.1016/j.biomaterials.2006.02.002; Wang Y, 2007, J NEUROIMMUNE PHARM, V2, P243, DOI 10.1007/s11481-007-9074-2; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Winkler C, 1998, MOL CELL NEUROSCI, V11, P99, DOI 10.1006/mcne.1998.0674; Yan J, 2004, J COMP NEUROL, V480, P101, DOI 10.1002/cne.20344; Young TH, 2005, BIOMATERIALS, V26, P4291, DOI 10.1016/j.biomaterials.2004.10.043; Zhao LX, 2004, EXP NEUROL, V190, P396, DOI 10.1016/j.expneurol.2004.06.025; ZHENG LH, 2002, THEORY PRACTICE NEUR, P195; ZIGMOND SH, J CELL BIOL, V88, P644	43	55	66	3	45	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	JUN	2010	31	18					4846	4854		10.1016/j.biomaterials.2010.02.015			9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	597SY	WOS:000277783100008	20346501				2021-06-18	
J	Ragel, BT; Klimo, P; Martin, JE; Teff, RJ; Bakken, HE; Armonda, RA				Ragel, Brian T.; Klimo, Paul, Jr.; Martin, Jonathan E.; Teff, Richard J.; Bakken, Hans E.; Armonda, Rocco A.			Wartime decompressive craniectomy: technique and lessons learned	NEUROSURGICAL FOCUS			English	Article						battlefield; decompressive craniectomy; military	PENETRATING CRANIOCEREBRAL INJURIES; MIDDLE CEREBRAL-ARTERY; SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; NEUROSURGICAL EXPERIENCE; TRAUMATIC BRAIN; BULLET VELOCITY; INFARCTION; LEBANON; WOUNDS	Object. Decompressive craniectomy (DC) with dural expansion is a life-saving neurosurgical procedure performed for recalcitrant intracranial hypertension due to trauma, stroke, and a multitude of other etiologies. Illustratively, we describe technique and lessons learned using DC for battlefield trauma. Methods. Neurosurgical operative logs from service (October 2007 to September 2009) in Afghanistan that detail DC cases for trauma were analyzed. Illustrative examples of frontotemporoparietal and bifrontal DC that depict battlefield experience performing these procedures are presented with attention drawn to the L. G. Kempe hemispherectomy incision, brainstem decompression techniques, and dural onlay substitutes. Results. Ninety craniotomies were performed for trauma over the time period analyzed. Of these, 28 (31%) were DCs. Of the 28 DCs, 24 (86%) were frontotemporoparietal DCs, 7 (25%) were bifrontal DCs, and 2 (7%) were suboccipital DCs. Decompressive craniectomies were performed for 19 penetrating head injuries (13 gunshot wounds and 6 explosions) and 9 severe closed head injuries (6 war-related explosions and 3 others). Conclusions. Thirty-one percent of craniotomies performed for trauma were DCs. Battlefield neurosurgeons use DC to allow for safe transfer of neurologically ill patients to tertiary military hospitals, which can be located 8-18 hours from a war zone. The authors recommend the L. G. Kempe incision for blood supply preservation, large craniectomies to prevent brain strangulation over bone edges, minimal brain debridement, adequate brainstem decompression, and dural onlay substitutes for dural closure. (DOI: 10.3171/2010.3.FOCUS1028)	[Ragel, Brian T.] Oregon Hlth & Sci Univ, Dept Neurol Surg, Portland, OR 97239 USA; [Klimo, Paul, Jr.] Neurosurg Serv, Wright Patterson AFB, OH USA; [Martin, Jonathan E.] Connecticut Childrens Med Ctr, Div Neurosurg, Hartford, CT USA; [Teff, Richard J.] Brooke Army Med Ctr, Dept Neurosurg, Ft Sam Houston, TX 78234 USA; [Bakken, Hans E.] Madigan Army Med Ctr, Dept Neurosurg, Ft Lewis, WA USA; [Armonda, Rocco A.] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA	Ragel, BT (corresponding author), Oregon Hlth & Sci Univ, Dept Neurol Surg, Mail Code CH8N,3303 SW Bond Ave, Portland, OR 97239 USA.	brian.ragel@gmail.com		Martin, Jonathan/0000-0003-3180-2084			Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; BATES M, 2008, AIRMAN OFFICAL MAGAZ, V42, P4; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; Chen CC, 2007, J CLIN NEUROSCI, V14, P317, DOI 10.1016/j.jocn.2005.05.024; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cushing H, 1918, BRIT J SURG, V5, P558; Cushing H, 1908, ANN SURG, V47, P641, DOI 10.1097/00000658-190805000-00001; Day JD, 1998, NEUROSURGERY, V42, P198, DOI 10.1097/00006123-199801000-00045; DEMUTH WE, 1969, J TRAUM, V9, P27, DOI 10.1097/00005373-196901000-00003; DEMUTH WE, 1966, J TRAUM, V6, P222, DOI 10.1097/00005373-196606020-00008; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Kempke LG, 1968, OPERATIVE NEUROSURGE, V1, P179; KLIMO PK, 2009, AANS YOUNG NEUROSURG, P2; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVI L, 1990, ISRAEL J MED SCI, V26, P555; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; MATSON DD, 1958, SURGERY WORLD WAR 2, V1, P123; MOORES L, 2008, C Q, V9, P31; Schirmer CM, 2008, NEUROCRIT CARE, V8, P456, DOI 10.1007/s12028-008-9082-y; TRUNKEY D, 1993, ARCH SURG-CHICAGO, V128, P261; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012	26	55	57	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	MAY	2010	28	5							E2	10.3171/2010.3.FOCUS1028			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	589ZU	WOS:000277193600002	20568936				2021-06-18	
J	Topolovec-Vranic, J; Cullen, N; Michalak, A; Ouchterlony, D; Bhalerao, S; Masanic, C; Cusimano, MD				Topolovec-Vranic, Jane; Cullen, Nora; Michalak, Alicja; Ouchterlony, Donna; Bhalerao, Shree; Masanic, Cheryl; Cusimano, Michael D.			Evaluation of an online cognitive behavioural therapy program by patients with traumatic brain injury and depression	BRAIN INJURY			English	Article						Cognitive behaviour therapy; depression; Internet; outcomes; traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; REHABILITATION RESEARCH; MAJOR DEPRESSION; PRIMARY-CARE; CES-D; INTERNET; DISTRESS; INTERVENTIONS; PREVALENCE; DISORDERS	Primary objective: The most frequently reported psychiatric symptom after traumatic brain injury (TBI) is depression. This study examined whether internet-delivered cognitive behaviour therapy (CBT) could be appropriate and effective for patients with mild or moderate TBI and depression. Methods and procedures: Patients were recruited for an at-home, 6-week internet-based CBT program (MoodGYM). Participants were assessed during this period by weekly telephone calls and at 12 months post-enrolment. Intervention completion rates, predictors of adherence, user feedback and changes in scores on validated depression scales were assessed. Main outcomes and results: Twenty-one patients were recruited: 64% and 43% completed the 6-week intervention and the 12-month follow-up, respectively. Adherence rates were not predicted by demographic or injury characteristics in this small sample. Patients identified reading, memory and comprehension requirements as limitations of the program. Scores on the depression scales were significantly decreased upon completion of the intervention and at the 12-month follow-up. Conclusions: The MoodGYM program may be effective for treating symptoms of depression in patients with TBI. While adherence rates were not predicted by age, education level or injury severity, demands upon memory and concentration which may already be compromised in these patients need to be considered.	[Topolovec-Vranic, Jane] St Michaels Hosp, Trauma & Neurosurg Program, Toronto, ON M5B 1W8, Canada; [Cullen, Nora; Masanic, Cheryl] Toronto Rehabil Inst, Neurol Serv, Toronto, ON, Canada; [Michalak, Alicja; Ouchterlony, Donna; Masanic, Cheryl] St Michaels Hosp, Head Injury Clin, Toronto, ON M5B 1W8, Canada; [Bhalerao, Shree] St Michaels Hosp, Dept Psychiat, Toronto, ON M5B 1W8, Canada; [Cusimano, Michael D.] St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada	Topolovec-Vranic, J (corresponding author), St Michaels Hosp, Trauma & Neurosurg Program, 30 Bond St,Bond 4-016, Toronto, ON M5B 1W8, Canada.	topolovec-vranicj@smh.ca	Topolovec-Vranic, Jane/A-5293-2013; Cusimano, Michael/X-4059-2019	Topolovec-Vranic, Jane/0000-0001-7695-4212; Cullen, Nora/0000-0001-6359-9418; Cusimano, Michael/0000-0002-9989-0650	Ontario Neurotrauma Foundation	We thank Helen Christensen and Kathy Griffiths for allowing use of the MoodGYM website and supporting collaboration on this study. We also wish to acknowledge research assistants Sarah Johnston, Mary Ann Pollmann-Mudryj, Tatiana Santini, Amanda White McFarlan and Michelle Williams for their assistance with patient recruitment and data collection, Valerie Gilmore and Martine Andrews for input into the study design and data conduct, Wei Xiong for assistance with data analysis and The Ontario Neurotrauma Foundation for financially supporting this project.	Andrews G, 2001, AUST NZ J PUBL HEAL, V25, P494, DOI 10.1111/j.1467-842X.2001.tb00310.x; Andrews GA, 1999, UNMET NEED PSYCHIAT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Batterham Philip J, 2008, Patient Prefer Adherence, V2, P97; Bebbington PE, 2000, PSYCHOL MED, V30, P1369, DOI 10.1017/S0033291799002974; Beck J.S., 1995, COGNITIVE THERAPY BA; Bell KR, 2008, AM J PHYS MED REHAB, V87, P330, DOI 10.1097/PHM.0b013e318168d092; Berger M, 2005, SOC SCI MED, V61, P1821, DOI 10.1016/j.socscimed.2005.03.025; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; Christensen H, 2006, PSYCHOL MED, V36, P1737, DOI 10.1017/S0033291706008695; Christensen H, 2002, MED J AUSTRALIA, V177, pS122; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Christensen H, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.1.e3; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Giuffrida A, 1997, BRIT MED J, V315, P703, DOI 10.1136/bmj.315.7110.703; Groves C., 2003, WORKING OUT MOODGYM; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kaltenthaler E, 2002, Health Technol Assess, V6, P1; Kessler RC, 2001, HEALTH SERV RES, V36, P987; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LINTVEDT OK, 2006, EVALUATING EFFECTIVE, V50; Mackinnon A, 2008, BRIT J PSYCHIAT, V192, P130, DOI 10.1192/bjp.bp.106.032078; Mason S, 2006, BRIT J CLIN PSYCHOL, V45, P217, DOI 10.1348/014466505X50158; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Nease DE, 2003, J FAM PRACTICE, V52, P118; Neil AL, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1050; O'Kearney Richard, 2006, Cognitive Behaviour Therapy, V35, P43, DOI 10.1080/16506070500303456; O'Kearney R, 2009, DEPRESS ANXIETY, V26, P65, DOI 10.1002/da.20507; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Proudfoot J, 2003, PSYCHOL MED, V33, P217, DOI 10.1017/S0033291702007225; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; ZICH JM, 1990, INT J PSYCHIAT MED, V20, P259, DOI 10.2190/LYKR-7VHP-YJEM-MKM2	44	55	55	0	21	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2010	24	5					762	772		10.3109/02699051003709599			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	592PJ	WOS:000277391300009	20370383				2021-06-18	
J	Lee, C; Agoston, DV				Lee, Cheol; Agoston, Denes V.			Vascular Endothelial Growth Factor Is Involved in Mediating Increased De Novo Hippocampal Neurogenesis in Response to Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						dentate gyrus; neurogenesis; traumatic brain injury; VEGF	CENTRAL-NERVOUS-SYSTEM; TRANSIENT FOREBRAIN ISCHEMIA; RECEPTOR TYROSINE KINASE; FOCAL CEREBRAL-ISCHEMIA; DENTATE GYRUS; ADULT-RAT; CELL-PROLIFERATION; NEUROTROPHIC FACTOR; COGNITIVE RECOVERY; FACTOR VEGF	Stimulating the endogenous repair process after traumatic brain injury (TBI) can be an important approach in neuroregenerative medicine. Vascular endothelial growth factor (VEGF) is one of the molecules that can increase de novo hippocampal neurogenesis. Here, we tested whether VEGF signaling through Flk1 (VEGF receptor 2) is involved in the neurogenic process after experimental TBI. We found that Flk1 is expressed both by neuroblasts in the subgranular layer (SGL) and by maturing granule neurons in the adult dentate gyrus (DG) of the hippocampus. After lateral fluid percussion TBI (LFP-TBI) in the rat, we detected elevated VEGF levels and also increased numbers of de novo neurons in the ipsilateral DG. To test the involvement of VEGF and Flk1 in the neurogenic process directly, we delivered recombinant VEGF or SU5416, an inhibitor to Flk1, into the ipsilateral cerebral ventricle of injured animals. We found that VEGF infusion significantly increased the number of BrdU+/Prox1+ new neurons, decreased the number of TUNEL+ cells, but did not change the number of BrdU+ newborn cells per se. Infusion with SU5416 caused no significant changes. Our results suggest that (a) VEGF is a part of the molecular signaling network that mediates de novo hippocampal neurogenesis after TBI; (b) VEGF predominantly mediates survival of de novo granule neurons rather than proliferation of neuroblasts in the injured brain; and (c) additional VEGF receptor(s) and/or other molecular mechanism(s) are also involved in mediating increased neurogenesis following injury.	[Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Sch Med, APG, Neurosci Program,Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, APG, Neurosci Program,Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu			Department of DefenseUnited States Department of Defense	We thank Drs. S. Juliano, S. Young, G. Ling, and T. Darling for their help with the project. We also thank Ms. E. Lee for her technical assistance; Dr. C. Olsen, USUHS Biostatistics Consulting Center, for statistical consultation; and Ms. A. Thorburn for her editorial assistance. C. L. was supported by the Translational Research Program of Defense Brain & Spinal Cord Injury Program of the Department of Defense. The views and statements expressed herein are the private opinions of the authors and do not reflect the official policy or position of the USUHS, the Department of Defense, or the United States Government.	Ahn MJ, 2004, J NEUROTRAUM, V21, P1431, DOI 10.1089/neu.2004.21.1431; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Choi JS, 2007, J NEUROTRAUM, V24, P521, DOI 10.1089/neu.2006.0139; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dobi A, 2000, J NEUROSCI, V20, P1073, DOI 10.1523/JNEUROSCI.20-03-01073.2000; Dombrowski SM, 2008, NEUROSCIENCE, V152, P346, DOI 10.1016/j.neuroscience.2007.11.049; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Fabel K, 2003, EUR J NEUROSCI, V18, P2803, DOI 10.1111/j.1460-9568.2003.03041.x; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Hashimoto T, 2006, DEVELOPMENT, V133, P2201, DOI 10.1242/dev.02385; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Kawai T, 2006, NEUROSCIENCE, V141, P1209, DOI 10.1016/j.neuroscience.2006.04.064; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 1997, P NATL ACAD SCI USA, V94, P10409, DOI 10.1073/pnas.94.19.10409; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Liu JL, 1998, J NEUROSCI, V18, P7768; Liu M, 2000, P NATL ACAD SCI USA, V97, P865, DOI 10.1073/pnas.97.2.865; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Marti HH, 1998, P NATL ACAD SCI USA, V95, P15809, DOI 10.1073/pnas.95.26.15809; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Ogunshola OO, 2002, J BIOL CHEM, V277, P11410, DOI 10.1074/jbc.M111085200; Okragly AJ, 1997, EXP NEUROL, V145, P592, DOI 10.1006/exnr.1997.6500; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 1997, J NEUROSCI, V17, P3727; Pencea V, 2001, J NEUROSCI, V21, P6706; Rosenstein JM, 2003, J NEUROSCI, V23, P11036; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shetty AK, 2005, GLIA, V51, P173, DOI 10.1002/glia.20187; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Smolich BD, 2001, BLOOD, V97, P1413, DOI 10.1182/blood.V97.5.1413; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Svensson B, 2002, J CEREBR BLOOD F MET, V22, P1170; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yee KWH, 2002, BLOOD, V100, P2941, DOI 10.1182/blood-2002-02-0531; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618	61	55	58	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					541	553		10.1089/neu.2009.0905			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100008	20001687				2021-06-18	
J	Seel, RT; Macciocchi, S; Kreutzer, JS				Seel, Ronald T.; Macciocchi, Stephen; Kreutzer, Jeffrey S.			Clinical Considerations for the Diagnosis of Major Depression After Moderate to Severe TBI	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; diagnosis; rehabilitation; traumatic brain injury; validity	TRAUMATIC BRAIN-INJURY; NEUROBEHAVIORAL FUNCTIONING INVENTORY; SELF-REPORTED ANXIETY; PSYCHIATRIC-DISORDERS; TRIPARTITE MODEL; SLEEP DISORDERS; RISK-FACTORS; PREVALENCE; PATIENT; APATHY	Major depression (MD) is the most common psychiatric disorder after traumatic brain injury (TBI). Yet, diagnosing MD is often challenging because of cognitive, emotional, and somatic symptoms that overlap with TBI and other psychiatric disorders. Best current evidence suggests that depressed mood is characterized more by irritability, anger, and aggression than by sadness and tearfulness in persons with TBI. Rumination, self-criticism, and guilt may best differentiate depressed persons from nondepressed persons. Anxiety, aggression, sleep problems, alcohol use, lower-income levels, and poor social functioning appear to be primary associated factors to MD. Objective levels of injury severity, impairment, and functioning do not appear to be related to developing MD. The presence of "organic" TBI sequelae that overlap with the Diagnostic and Statistical Manual of Mental Disorders-Version IV MD criteria does not appear to lead to false-positive MD diagnoses, and anosognosia does not appear to lead to false-negative MD diagnoses. Only the Patient Health Questionnaire-9 and Neurobehavioral Functioning Inventory-Depression demonstrated evidence of acceptably ruling out MD in persons with TBI; the Patient Health Questionnaire-9 had the best ability to rule in the presence of MD following TBI. Apathy, anxiety, dysregulation, and emotional lability require careful clinical consideration when making a differential diagnosis of MD in persons with TBI. Lastly, recommendations are provided on how clinicians can improve diagnostic accuracy and what future research is required to improve our understanding of MD in persons with TBI.	[Seel, Ronald T.; Macciocchi, Stephen] Shepherd Ctr, Atlanta, GA 30309 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Richmond, VA USA	Seel, RT (corresponding author), Shepherd Ctr, 2020 Peachtree Rd NW, Atlanta, GA 30309 USA.	ron_seel@shepherd.org					ALOIA MS, 1995, BRAIN INJURY, V9, P575, DOI 10.3109/02699059509008216; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Barnhart W Jason, 2004, J Psychiatr Pract, V10, P196, DOI 10.1097/00131746-200405000-00010; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Beck A., 1979, COGNITIVE THERAPY EM; Benca RM, 2008, SLEEP MED, V9, pS3, DOI 10.1016/S1389-9457(08)70010-8; Bessell AL, 2008, J INT NEUROPSYCH SOC, V14, P63, DOI 10.1017/S1355617708080065; Bond M. R., 1990, REHABILITATION ADULT, P179; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Caracciolo B, 2002, J REHABIL MED, V34, P221, DOI 10.1080/165019702760279215; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; CLARK DA, 1990, J ABNORM PSYCHOL, V99, P148, DOI 10.1037/0021-843X.99.2.148; CLARK DA, 1994, J ABNORM PSYCHOL, V103, P645, DOI 10.1037/0021-843X.103.4.645; CLARK LA, 1991, J ABNORM PSYCHOL, V100, P316, DOI 10.1037/0021-843X.100.3.316; Davidson RJ, 2002, BIOL PSYCHIAT, V52, P478, DOI 10.1016/S0006-3223(02)01458-0; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; Deb S, 1999, AM J PSYCHIAT, V156, P374; Demakis GJ, 2007, ARCH CLIN NEUROPSYCH, V22, P123, DOI 10.1016/j.acn.2006.09.004; DICESARE A, 1990, J COG REHABIL    MAR, P14; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Dow BM, 1996, BIOL PSYCHIAT, V39, P42, DOI 10.1016/0006-3223(95)00103-4; Drevets WC, 2000, BIOL PSYCHIAT, V48, P813, DOI 10.1016/S0006-3223(00)01020-9; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; Edlund W, 2004, CLIN PRACTICE GUIDEL; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Finset A, 2000, BRAIN INJURY, V14, P887; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gilbody S, 2007, J GEN INTERN MED, V22, P1596, DOI 10.1007/s11606-007-0333-y; Glenn MB, 2002, J HEAD TRAUMA REHAB, V17, P273, DOI 10.1097/00001199-200208000-00002; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Goodyer IM, 2003, PSYCHOL MED, V33, P601, DOI 10.1017/S0033291702007286; Goodyer IM, 1998, PSYCHOL MED, V28, P265, DOI 10.1017/S0033291797006314; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hawton K, 2009, LANCET, V373, P1372, DOI 10.1016/S0140-6736(09)60372-X; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Just N, 1997, J ABNORM PSYCHOL, V106, P221, DOI 10.1037/0021-843X.106.2.221; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Koenigs M, 2008, J NEUROSCI, V28, P12341, DOI 10.1523/JNEUROSCI.2324-08.2008; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; KREUTZER JS, 2001, BRAIN INJURY, V15, P543; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MCALLISTER TW, 2007, BRAIN INJURY MED PRI, P835; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Michael A, 2000, BIOL PSYCHIAT, V48, P989, DOI 10.1016/S0006-3223(00)00955-0; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nolen-Hoeksema S, 2000, J ABNORM PSYCHOL, V109, P504, DOI 10.1037/0021-843X.109.3.504; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; Posener JA, 2004, PSYCHONEUROENDOCRINO, V29, P1129, DOI 10.1016/j.psyneuen.2004.01.004; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Riemann D, 2007, SLEEP MED, V8, pS15, DOI 10.1016/S1389-9457(08)70004-2; Roberts JE, 1998, COGNITIVE THER RES, V22, P401, DOI 10.1023/A:1018713313894; ROSENBERGARSKA M, 1989, PHAGOCYTES DISEASE, P43; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; Salmond CH, 2006, J NEUROTRAUM, V23, P1049, DOI 10.1089/neu.2006.23.1049; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHERER M, 1996, J INT NEUROPSYCH SOC, V2, P17; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; STEER RA, 1995, J ABNORM PSYCHOL, V104, P542, DOI 10.1037/0021-843X.104.3.542; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Walker WC, 2005, ARCH PHYS MED REHAB, V86, P1793, DOI 10.1016/j.apmr.2004.12.042; Wasserman L, 2008, BRAIN INJURY, V22, P811, DOI 10.1080/02699050802372166; Watkins E, 2001, J ABNORM PSYCHOL, V110, P353, DOI 10.1037/0021-843X.110.2.333; Watkins E, 2004, J AFFECT DISORDERS, V82, P1, DOI 10.1016/j.jad.2003.10.006; WATSON D, 1995, J ABNORM PSYCHOL, V104, P3, DOI 10.1037/0021-843X.104.1.3; WATSON D, 1995, J ABNORM PSYCHOL, V104, P15, DOI 10.1037/0021-843X.104.1.15; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Williams JW, 2002, JAMA-J AM MED ASSOC, V287, P1160, DOI 10.1001/jama.287.9.1160; Young AH, 2002, AM J PSYCHIAT, V159, P1237, DOI 10.1176/appi.ajp.159.7.1237	118	55	57	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					99	112		10.1097/HTR.0b013e3181ce3966			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000005	20134332				2021-06-18	
J	Gerrard-Morris, A; Taylor, HG; Yeates, KO; Walz, NC; Stancin, T; Minich, N; Wade, SL				Gerrard-Morris, Aimee; Taylor, H. Gerry; Yeates, Keith Owen; Walz, Nicolay Chertkoff; Stancin, Terry; Minich, Nori; Wade, Shari L.			Cognitive development after traumatic brain injury in young children	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Head injuries; outcomes; Child development; Child; Preschool; Brain injuries; Neurobehavioral manifestations; Recovery of function	CLOSED-HEAD-INJURY; OUTCOME 30 MONTHS; EARLY-CHILDHOOD; LONGITUDINAL OUTCOMES; SOCIOECONOMIC-STATUS; EXECUTIVE FUNCTIONS; SOCIAL COMPETENCE; SHORT-TERM; FULL-TERM; RECOVERY	The primary aims of this study were to examine post-injury cognitive development in young Children with traumatic brain injury (TBI) and to investigate the role of the proximal family environment in predicting Cognitive Outcomes. Age at injury, was 3-6 years, and TBI was classified as severe (n = 23), moderate (n = 21), and complicated mild (n = 43). A comparison group of children who Sustained orthopedic injuries (OI, n = 117) was also recruited. Child cognitive assessments were administered at a post-acute baseline evaluation and repeated at 6, 12, and 18 months post-injury. Assessment of the family environment consisted of baseline measures of learning support and stimulation in the home and of parenting characteristics observed during videotaped parent-child interactions. Relative to the OI group, children with severe TBI group had generalized cognitive deficiencies and those with less severe TBI had weaknesses in Visual memory and executive function. Although deficits persisted or emerged across follow-up, more optimal family environments were associated with higher scores for all injury groups. The findings confirm other reports of poor recovery of cognitive skills following early childhood TBI and suggest environmental influences on outcomes. (JINS, 2010, 16, 157-168.)	[Gerrard-Morris, Aimee; Taylor, H. Gerry; Minich, Nori] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Gerrard-Morris, Aimee; Taylor, H. Gerry; Minich, Nori] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA; [Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Rehabil, Cincinnati, OH USA	Taylor, HG (corresponding author), Div Dev Behav Pediat & Psychol, WO Walker Bldg,Suite 3150,10524 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@case.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; USPHS NIHUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [M01 RR 08084]; State of Ohio Emergency Medical Services; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD039834, K02HD044099] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	Supported by grant R01 HD42729 to Dr. Wade from NICHD, in part by USPHS NIH grant no. M01 RR 08084, and by Trauma Research grants from the State of Ohio Emergency Medical Services. The authors wish to acknowledge the contributions of Christine Abraham. Andrea Beebe, Lori Bernard, Anne Birnbaum, Belli Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, and Elizabeth Shaver in data collection and coding. The Cincinnati Children's Medical Center Trauma Registry. Rainbow Pediatric Trauma Center at Rainbow Babies & Children's Hospital, Nationwide Children's Hospital Trauma Program, and MetroHealth Center Department of Pediatrics and Trauma Registry provided assistance with recruitment.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Barnes MA, 2001, BRAIN LANG, V76, P253, DOI 10.1006/brln.2000.2385; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blair C, 2006, BEHAV BRAIN SCI, V29, P109; Bradley RH, 2002, ANNU REV PSYCHOL, V53, P371, DOI 10.1146/annurev.psych.53.100901.135233; BRADLEY RH, 1989, DEV PSYCHOL, V25, P217, DOI 10.1037/0012-1649.25.2.217; Bradley RH, 2000, J RES ADOLESCENCE, V10, P247, DOI 10.1207/SJRA1003_1; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; Breslau N, 2001, AM J EPIDEMIOL, V154, P711, DOI 10.1093/aje/154.8.711; Burchinal MR, 2000, DEV PSYCHOL, V36, P793, DOI 10.1037//0012-1649.36.6.793; CALDWELL BM, 2000, HOME INVENTORY ADM M; Carrow-Woolfolk E, 2000, COMPREHENSIVE ASSESS; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins WA, 2000, AM PSYCHOL, V55, P218, DOI 10.1037/0003-066X.55.2.218; Conger RD, 2007, ANNU REV PSYCHOL, V58, P175, DOI 10.1146/annurev.psych.58.110405.085551; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DENNIS M, 1988, MASTER LECT SERIES C, P89; Donders J, 2005, J INT NEUROPSYCH SOC, V11, P386, DOI 10.1017/S1355617705050435; Elliott C.D., 1990, DIFFERENTIAL ABILITY; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 2001, MERRILL PALMER QUART, V47, P42, DOI 10.1353/mpq.2001.0001; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Eyberg S., 1988, CHILD FAM BEHAV THER, V10, P33, DOI [DOI 10.1300/J019V10N01_04, 10.1300/J019v10n01_04]; Farah MJ, 2006, BRAIN RES, V1110, P166, DOI 10.1016/j.brainres.2006.06.072; Fiese B. H., 2001, ENV EFFECTS COGNITIV, P39; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Korkman M, 1998, NEPSY DEV NEUROPSYCH; LANDRY SH, 1990, CHILD DEV, V61, P1605, DOI 10.2307/1130768; Landry SH, 1998, CHILD DEV, V69, P105, DOI 10.2307/1132074; Landry SH, 1997, DEV PSYCHOL, V33, P1040, DOI 10.1037/0012-1649.33.6.1040; Landry SH, 2006, DEV PSYCHOL, V42, P627, DOI 10.1037/0012-1649.42.4.627; Landry SH, 1996, MERRILL PALMER QUART, V42, P177; Landry SH, 2003, DEV NEUROPSYCHOL, V24, P559, DOI 10.1207/S15326942DN242&3_04; Landry SH, 2002, DEV NEUROPSYCHOL, V21, P15, DOI 10.1207/S15326942DN2101_2; Landry SH, 2001, DEV PSYCHOL, V37, P387, DOI 10.1037//0012-1649.37.3.387; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; McLoyd VC, 1998, AM PSYCHOL, V53, P185, DOI 10.1037/0003-066X.53.2.185; Murray AD, 1997, DEV PSYCHOPATHOL, V9, P507, DOI 10.1017/S0954579497001272; Noble KG, 2005, DEVELOPMENTAL SCI, V8, P74, DOI 10.1111/j.1467-7687.2005.00394.x; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Rutter M, 2001, PSYCHOL BULL, V127, P291, DOI 10.1037//0033-2909.127.3.291; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Smith KE, 2000, J SCHOOL PSYCHOL, V38, P27, DOI 10.1016/S0022-4405(99)00035-7; Stiles J, 2005, TRENDS COGN SCI, V9, P136, DOI 10.1016/j.tics.2005.01.002; Taylor HG, 2004, J INT NEUROPSYCH SOC, V10, P149, DOI 10.1017/S1355617704102038; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Taylor HG, 2000, NEUROPSYCHOLOGY, V14, P509, DOI 10.1037/0894-4105.14.4.509; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; Taylor JH, 2008, AFR J AGR RES, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Woodcock R.W., 2001, WOODCOCKJOHNSON 3 TE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	88	55	55	0	25	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2010	16	1					157	168		10.1017/S1355617709991135			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	543LR	WOS:000273579600017	19849883	Green Accepted			2021-06-18	
J	Rochat, L; Beni, C; Billieux, J; Azouvi, P; Annoni, JM; Van der Linden, M				Rochat, Lucien; Beni, Catia; Billieux, Joel; Azouvi, Philippe; Annoni, Jean-Marie; Van der Linden, Martial			Assessment of impulsivity after moderate to severe traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						TBI; Impulsivity; Executive functions; UPPS	BEHAVIOR SCALE; DECISION-MAKING; 4-FACTOR MODEL; PERSONALITY; FACETS; PERFORMANCE; ADAPTATION; DEFICITS	The aim of the study was to develop and validate a short questionnaire assessing four dimensions of impulsivity (urgency, lack of premeditation, lack of perseverance, sensation seeking) in patients with traumatic brain injury (TBI). To this end, 82 patients with TBI and their caregivers completed a short questionnaire adapted from the UPPS Impulsive Behavior Scale designed to assess impulsivity changes after TBI. Confirmatory factor analyses (CFAs) performed on the version of the scale completed by the relatives revealed that a hierarchical model holding that lack of premeditation and lack of perseverance are facets of a higher order construct (lack of conscientiousness), with urgency and sensation seeking as separate correlated factors, fit the data best. Urgency, lack of premeditation, and lack of perseverance increased after the TBI, whereas sensation seeking decreased. CFA failed to reveal a satisfactory model in the version of the scale completed by the patients. The psychological processes related to these impulsivity changes and the discrepancy observed between self-report and informant-report are discussed. This short questionnaire opens up interesting prospects for better comprehension and assessment of behavioural symptoms of TBI.	[Rochat, Lucien; Beni, Catia; Billieux, Joel; Van der Linden, Martial] Univ Geneva, Cognit Psychopathol & Neuropsychol Unit, CH-1205 Geneva, Switzerland; [Azouvi, Philippe] Versailles St Quentin Univ, Neurol Reeduc Ctr, Garches, France; [Annoni, Jean-Marie] Univ Hosp Geneva, Neuropsychol Unit, Geneva, Switzerland; [Van der Linden, Martial] Univ Liege, Cognit Psychopathol Unit, B-4000 Liege, Belgium	Rochat, L (corresponding author), Univ Geneva, Cognit Psychopathol & Neuropsychol Unit, 40 Blvd Pont dArve, CH-1205 Geneva, Switzerland.	Lucien.Rochat@unige.ch		Billieux, Joel/0000-0002-7388-6194; Rochat, Lucien/0000-0002-9992-2720			Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; Billieux J, 2007, ADDICT BEHAV, V32, P1189, DOI 10.1016/j.addbeh.2006.08.007; Billieux J, 2008, PERS INDIV DIFFER, V44, P1432, DOI 10.1016/j.paid.2007.12.011; Bivona U, 2008, J INT NEUROPSYCH SOC, V14, P862, DOI 10.1017/S1355617708081125; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Byrne B.M., 1994, STRUCTURAL EQUATION; Claes L, 2005, PERS INDIV DIFFER, V39, P739, DOI 10.1016/j.paid.2005.02.022; Costa P., 1992, REVISED NEO PERSONAL; d'Acremont M, 2005, J YOUTH ADOLESCENCE, V34, P427, DOI 10.1007/s10964-005-7260-1; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Evenden JL, 1999, PSYCHOPHARMACOLOGY, V146, P348, DOI 10.1007/PL00005481; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Gay P, 2008, ACTA PSYCHOL, V129, P332, DOI 10.1016/j.actpsy.2008.08.010; Greve KW, 2001, BRAIN INJURY, V15, P255; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Lecrubier Y, 1995, EUR PSYCHIAT, V10, P331, DOI 10.1016/0924-9338(96)80333-6; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; LEVY R, 2005, CEREB CORTEX, V5, P1; Marsh NV, 2006, NEUROPSYCHOL REHABIL, V16, P684, DOI 10.1080/09602010500220290; MAZAUX JM, 2000, TRAITE NEUROPSYCHOLO, V2, P31; McHugh L, 2008, BRAIN INJURY, V22, P715, DOI 10.1080/02699050802263027; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Miller J, 2003, PERS INDIV DIFFER, V34, P1403, DOI 10.1016/S0191-8869(02)00122-8; Muthen L., 2006, MPLUS USERS GUIDE; Patton JH, 1995, J CLIN PSYCHOL, V51, P768, DOI 10.1002/1097-4679(199511)51:6<768::AID-JCLP2270510607>3.0.CO;2-1; Rochat L, 2008, ALZ DIS ASSOC DIS, V22, P278, DOI 10.1097/WAD.0b013e318166d692; Rochat L, 2009, J NEUROPSYCHOL, V3, P213, DOI 10.1348/174866408X397656; Roche RAP, 2004, NEUROSCI LETT, V362, P1, DOI 10.1016/j.neulet.2003.11.064; Schermelleh-Engel K., 2003, METHODS PSYCHOL RES, V8, P23, DOI DOI 10.1002/0470010940; Schmidt RE, 2008, SWISS J PSYCHOL, V67, P107, DOI 10.1024/1421-0185.67.2.107; Schmidt RE, 2008, BEHAV SLEEP MED, V6, P178, DOI 10.1080/15402000802162570; Smith GT, 2007, ASSESSMENT, V14, P155, DOI 10.1177/1073191106295527; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Van der Linden M, 2006, EUR J PSYCHOL ASSESS, V22, P38, DOI 10.1027/1015-5759.22.1.38; Votruba KL, 2008, J HEAD TRAUMA REHAB, V23, P65, DOI 10.1097/01.HTR.0000314525.93381.69; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Whiteside SP, 2005, EUR J PERSONALITY, V19, P559, DOI 10.1002/per.556; Whiteside SP, 2003, EXP CLIN PSYCHOPHARM, V11, P210, DOI 10.1037/1064-1297.11.3.210; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Wood RL, 2008, BRAIN INJURY, V22, P905, DOI 10.1080/02699050802491271; Wood RL, 2001, BRAIN DAM B, P3; Zermatten A, 2005, J NERV MENT DIS, V193, P647, DOI 10.1097/01.nmd.0000180777.41295.65	46	55	57	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	5					778	797	PII 924372892	10.1080/09602011.2010.495245			20	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	648YB	WOS:000281730300008	20635306	Green Published			2021-06-18	
J	Schonberger, M; Ponsford, J; Olver, J; Ponsford, M				Schonberger, Michael; Ponsford, Jennie; Olver, John; Ponsford, Michael			A longitudinal study of family functioning after TBI and relatives' emotional status	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury (TBI); Family functioning; Relatives; Emotional status; Distress; Anxiety; Depression	TRAUMATIC BRAIN-INJURY; SOCIAL SUPPORT; CAREGIVER BURDEN; HEAD-INJURY; FOLLOW-UP; PSYCHOLOGICAL DISTRESS; REHABILITATION PROGRAM; ASSESSMENT DEVICE; DEPRESSION SCALE; HOSPITAL ANXIETY	The objectives of the study were to examine family functioning and relatives' emotional state after traumatic brain injury (TBI), and to test a model of the relationship between neurobehavioural status, family functioning and relatives' emotional status at two and five years post-injury. The relatives of 98 adult individuals who had sustained severe TBI were followed up 2 and 5 years post-injury and completed the Family Assessment Device, the Hospital Anxiety and Depression Scale, and rated the neurobehavioural status (cognitive, behavioural, emotional, social) of their injured relative, using the Structured Outcomes Questionnaire. A structural equation model, based on existing research, was developed and tested on 66 of the participants. The level of family functioning and the rates of clinically relevant levels of anxiety and depression did not change over time (p .05). The starting path model was revised. The final model had an excellent fit, 2(16) = 15.20, p = .51; CFI = 1.00, RMSEA .001, p for test of close fit = .66. In this model, poor family functioning and symptoms of anxiety and depression in the relatives were predicted by behavioural and mood changes in the injured individual. The relationship between family functioning and relatives' mood was reciprocal. The findings suggest the need for timely investigation and institution of interventions. Support is needed both for individual family members in dealing with their emotional distress as well as for the family as a whole, with the aim of maximising quality of life for those with TBI and their relatives.	[Schonberger, Michael; Ponsford, Jennie; Olver, John; Ponsford, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Schonberger, Michael; Ponsford, Jennie] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia	Schonberger, M (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Clayton Campus,Wellington Rd,Bldg 17, Clayton, Vic 3800, Australia.	michael.schoenberger@web.de		Olver, John/0000-0001-7069-1191	Victorian Neurotrauma Initiative; Transport Accident Commission	This study was supported by the Victorian Neurotrauma Initiative and the Transport Accident Commission.	ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bragg RM, 1992, J HEAD TRAUMA REHAB, V7, P94; Brooks D. N., 1987, J HEAD TRAUMA REHAB, V2, P1; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Burke L, 2003, INT REV PSYCHIATR, V15, P243, DOI 10.1080/0954026031000136866; Butterworth P, 2008, SOC PSYCH PSYCH EPID, V43, P758, DOI 10.1007/s00127-008-0366-5; CARNWATH CM, 1987, BRIT MED J, V294, P409; Chan J, 2007, INT J REHABIL RES, V30, P137, DOI 10.1097/MRR.0b013e32813a2f11; Charles N, 2007, NEUROREHABILITATION, V22, P61; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Ergh TC, 2001, CLIN NEUROPSYCHOL, V15, P271; Flora DB, 2004, PSYCHOL METHODS, V9, P466, DOI 10.1037/1082-989X.9.4.466; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hobfoll S.E., 1992, J FAM PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; J?reskog K.G., 1999, LARGE CAN STANDARDIZ; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Kessing LV, 1999, AM J EPIDEMIOL, V149, P404; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEIF L, 1993, BRAIN INJURY, V7, P543; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Marshall AJ, 2008, J FAM NURS, V14, P56, DOI 10.1177/1074840707312717; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Minnes P, 2000, BRAIN INJURY, V14, P737; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sinnakaruppan I, 2005, BRAIN INJURY, V19, P283, DOI 10.1080/02699050400003924; SNAITH RP, 1983, HOSP ANXIETY DEPRESS; TEASDALE G, 1974, LANCET, V2, P81; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; van Wijngaarden B, 2004, J AFFECT DISORDERS, V81, P211, DOI 10.1016/S0165-0327(03)00168-X; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; Weddell RA, 2006, BRAIN INJURY, V20, P1221, DOI 10.1080/02699050601049783; Wilson BA, 2009, NEUROPSYCHOLOGICAL REHABILITATION: THEORY, MODELS, THERAPY AND OUTCOME, P1, DOI 10.1017/CBO9780511581083; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; Yonkers KA, 2003, DEPRESS ANXIETY, V17, P173, DOI 10.1002/da.10106	60	55	55	0	18	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	6					813	829	PII 927100089	10.1080/09602011003620077			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	684GB	WOS:000284537300002	20859828				2021-06-18	
J	Kilbourne, M; Kuehn, R; Tosun, C; Caridi, J; Keledjian, K; Bochicchio, G; Scalea, T; Gerzanich, V; Simard, JM				Kilbourne, Michael; Kuehn, Reed; Tosun, Cigdem; Caridi, John; Keledjian, Kaspar; Bochicchio, Grant; Scalea, Thomas; Gerzanich, Volodymyr; Simard, J. Marc			Novel Model of Frontal Impact Closed Head Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						activated caspase-3; beta-amyloid precursor protein; diffuse axonal injury; frontal impact; impact acceleration; traumatic brain injury	TRAUMATIC BRAIN-INJURY; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; FLUID PERCUSSION INJURY; ACCELERATION; BIOMECHANICS; DEFICITS; PEPTIDE; DAMAGE; MILD	Frontal impact, closed head trauma is a frequent cause of traumatic brain injury (TBI) in motor vehicle and sports accidents. Diffuse axonal injury (DAI) is common in humans and experimental animals, and results from shearing forces that develop within the anisotropic brain. Because the specific anisotropic properties of the brain are axis-dependent, the anatomical site where force is applied as well as the resultant acceleration, be it linear, rotational, or some combination, are important determinants of the resulting pattern of brain injury. Available rodent models of closed head injury do not reproduce the frontal impact commonly encountered in humans. Here we describe a new rat model of closed head injury that is a modification of the impact-acceleration model of Marmarou. In our model (the Maryland model), the impact force is applied to the anterior part of the cranium and produces TBI by causing anterior-posterior plus sagittal rotational acceleration of the brain inside the intact cranium. Skull fractures, prolonged apnea, and mortality were absent. The animals exhibited petechial hemorrhages, DAI marked by a bead-like pattern of beta-amyloid precursor protein (beta-APP) in damaged axons, and widespread upregulation of beta-APP in neurons, with regions affected including the orbitofrontal cortex (coup), corpus callosum, caudate, putamen, thalamus, cerebellum, and brainstem. Activated caspase-3 was prominent in hippocampal neurons and Purkinje cells at the grey-white matter junction of the cerebellum. Neurobehavioral dysfunction, manifesting as reduced spontaneous exploration, lasted more than 1 week. We conclude that the Maryland model produces diffuse injuries that may be relevant to human brain injury.	[Tosun, Cigdem; Caridi, John; Gerzanich, Volodymyr; Simard, J. Marc] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Kilbourne, Michael; Kuehn, Reed] Walter Reed Army Med Ctr, Dept Surg, Washington, DC 20307 USA; [Keledjian, Kaspar; Bochicchio, Grant; Scalea, Thomas] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; [Simard, J. Marc] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Bochicchio, Grant; Scalea, Thomas; Simard, J. Marc] R Adams Cowley Shock Trauma Ctr, Baltimore, MD USA	Simard, JM (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S12D, Baltimore, MD 21201 USA.	msimard@smail.umaryland.edu	Tosun, Cigdem/AAG-4026-2020		Department of Veterans Affairs (Baltimore, MD)US Department of Veterans Affairs; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL082517]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS061808, NS060801, NS061934]; Christopher and Dana Reeve Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL082517] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061934, R01NS061808] Funding Source: NIH RePORTER	This work was supported by grants to J.M.S. from the Department of Veterans Affairs (Baltimore, MD), the National Heart, Lung, and Blood Institute (no. HL082517), the National Institute of Neurological Disorders and Stroke (no. NS061808 and NS060801), and the Christopher and Dana Reeve Foundation, and to V. G. from the National Institute of Neurological Disorders and Stroke (no. NS061934).	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ai JL, 2007, EXP BRAIN RES, V177, P95, DOI 10.1007/s00221-006-0654-9; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Ellingson Benjamin M., 2005, V41, P86; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Fijalkowski RJ, 2006, BIOMED SCI INSTRUM, V42, P108; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; He XS, 2000, J NEUROSURG, V93, P626, DOI 10.3171/jns.2000.93.4.0626; Itoh T, 2009, NEUROL RES, V31, P103, DOI 10.1179/016164108X323771; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; KOLB B, 1985, NEUROBEH TOXICOL TER, V7, P71; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Park E, 2007, PROG BRAIN RES, V161, P327, DOI 10.1016/S0079-6123(06)61023-6; Pierce JES, 1996, J NEUROSCI, V16, P1083; Prange M T, 2000, Stapp Car Crash J, V44, P205; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Xiao-Sheng H, 2004, J CLIN NEUROSCI, V11, P402, DOI 10.1016/j.jocn.2004.01.001	40	55	60	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2233	2243		10.1089/neu.2009.0968			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200011	19929375	Green Published			2021-06-18	
J	Broglio, SP; Zhu, WM; Sopiarz, K; Park, Y				Broglio, Steven P.; Zhu, Weimo; Sopiarz, Kay; Park, Youngsik			Generalizability Theory Analysis of Balance Error Scoring System Reliability in Healthy Young Adults	JOURNAL OF ATHLETIC TRAINING			English	Article						learning effects; concussions; postural control	COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; MILD HEAD-INJURY; HIGH-SCHOOL; POSTURAL STABILITY; RECOVERY; IMPACT; SEX; AGE	Context: An assessment of postural control is commonly included in the clinical concussion evaluation. Previous investigators have demonstrated learning effects that may mask concussion-induced balance decrements. Objective: To establish the test-retest reliability of the Balance Error Scoring System (BESS) and to provide recommendations that account for known learning effects. Design: Test-retest generalizability study. Setting: Balance research laboratory. Patients or Other Participants: Young adults (n = 48) free from injuries and illnesses known to affect balance. Intervention(s): Each participant completed 5 BESS trials on each of the assessment dates, which were separated by 50 days. Main Outcome Measure(s): Total score of the BESS was used in a generalizability theory analysis to estimate the overall reliability of the BESS and that of each facet. A decision study was completed to estimate the number of days and trials needed to establish clinical reliability. Results: The overall reliability of the BESS was G = 0.64. The test-retest reliability was improved when male (0.92) and female (0.91) participants were examined independently. Clinically acceptable reliability (greater than 0.80) was established when 3 BESS trials were administered in a single day or 2 trials were administered at different time points. Conclusions: Learning effects have been noted in individuals with no previous exposure to the BESS. Our findings indicate that clinicians should consider interpreting the mean score from 3 BESS administrations on a given occasion for both normative data comparison and pretest and posttest design. The multiple assessment technique yields clinically reliable scores and provides the sports medicine practitioner with accurate data for clinical decision making.	[Broglio, Steven P.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@illinois.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BRENNAN RL, 2001, GENERALIZABILITY THE, P1; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cronbach L.J., 1972, DEPENDABILITY BEHAV, P1; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Morrow J.R., 1989, MEASUREMENT CONCEPTS, P73; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; PORTNEY LG, 1993, FDN CLIN RES APPL PR, P63; Riemann BL, 2000, PROPRIOCEPTION AND NEUROMUSCULAR CONTROL IN JOINT STABILITY, P37; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Safrit MJ, 1995, INTRO MEASUREMENT PH, P159; Steindl R, 2006, DEV MED CHILD NEUROL, V48, P477, DOI 10.1017/S0012162206001022; Thompson B., 2002, SCORE RELIABILITY CO, P3; Tjernstrom F, 2002, GAIT POSTURE, V15, P75, DOI 10.1016/S0966-6362(01)00175-8; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wade MG, 1997, PHYS THER, V77, P619, DOI 10.1093/ptj/77.6.619	30	55	56	0	7	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2009	44	5					497	502		10.4085/1062-6050-44.5.497			6	Sport Sciences	Sport Sciences	499SP	WOS:000270246100008	19771288	Green Published, Bronze			2021-06-18	
J	Guo, XB; Liu, L; Zhang, M; Bergeron, A; Cui, Z; Dong, JF; Zhang, JN				Guo, Xinbin; Liu, Li; Zhang, Ming; Bergeron, Angela; Cui, Zhuang; Dong, Jing-Fei; Zhang, Jianning			Correlation of CD34(+) Cells with Tissue Angiogenesis after Traumatic Brain Injury in a Rat Model	JOURNAL OF NEUROTRAUMA			English	Article						angiogenesis; CD34(+) cells; endothelial progenitor cells; traumatic brain injury	ENDOTHELIAL PROGENITOR CELLS; FOCAL CEREBRAL-ISCHEMIA; ACUTE MYOCARDIAL-INFARCTION; PERIPHERAL-BLOOD; THERAPEUTIC NEOVASCULARIZATION; MONONUCLEAR-CELLS; MOUSE MODEL; STROKE; TRANSPLANTATION; NEUROGENESIS	Increasing evidence suggests that circulating endothelial progenitor cells, which are a subpopulation of hematopoietic progenitor CD34(+) cells, play a critical role in neovascularization and tissue repair. We have tested the hypothesis that traumatic brain injury (TBI) could mobilize CD34(+) cells to peripheral blood and brain tissue, a process critical for vascular repair, in a rat model of TBI. Male Wistar rats were subjected to controlled fluid percussion. Blood and brain tissue were collected before and after TBI to measure the levels of CD34(+) cells in peripheral blood and to detect their accumulation in the damaged cerebral tissue. Compared with surgery controls, CD34(+) cells significantly increased in the peripheral blood and accumulated in the brain tissue of TBI rats. Immunohistochemistry detected new vessels with incomplete CD34(+) endothelial-like cell lining and an increased number of microvessels in the injured and surrounding tissue. The results demonstrate a close correlation between an increase in circulating CD34(+) cells in response to traumatic injury and angiogenesis in TBI rat brain. They also suggest that transplantation of CD34(+) cells or augmentation of endogenous CD34(+) cells may be a novel therapeutic approach for patients with TBI.	[Guo, Xinbin; Liu, Li; Cui, Zhuang; Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Tianjin Neurol Inst, Lab TJIVR, Tianjin 300052, Peoples R China; [Zhang, Ming] Temple Univ, Dept Physiol, Sch Med, Philadelphia, PA 19122 USA; [Bergeron, Angela; Dong, Jing-Fei] Baylor Coll Med, Dept Med, Thrombosis Res Sect, Houston, TX 77030 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Tianjin Neurol Inst, Lab TJIVR, 154 Anshan Rd, Tianjin 300052, Peoples R China.	Jianning_zhang@sina.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30772229]; National 973 ProjectNational Basic Research Program of China [2005CB522600]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL71895]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071895] Funding Source: NIH RePORTER	This work was supported by the National Natural Science Foundation of China (30772229), the National 973 Project (2005CB522600), and an NIH grant (HL71895).	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Assmus B, 2006, NEW ENGL J MED, V355, P1222, DOI 10.1056/NEJMoa051779; Beck H, 2003, J CEREBR BLOOD F MET, V23, P709, DOI 10.1097/01.WCB.0000065940.18332.8D; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Cho SW, 2007, CIRCULATION, V116, P2409, DOI 10.1161/CIRCULATIONAHA.106.687038; del Zoppo GJ, 2006, NEW ENGL J MED, V354, P553, DOI 10.1056/NEJMp058312; Fujiyama S, 2003, CIRC RES, V93, P980, DOI 10.1161/01.RES.0000099245.08637.CE; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; Kawamoto A, 2006, CIRCULATION, V114, P2163, DOI 10.1161/CIRCULATIONAHA.106.644518; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Krupinski J, 2003, NEUROREPORT, V14, P1171, DOI 10.1097/00001756-200306110-00014; Ladeby R, 2005, GLIA, V50, P121, DOI 10.1002/glia.20159; Liu L, 2007, J NEUROTRAUM, V24, P936, DOI 10.1089/neu.2006.0250; Machalinski B, 2006, FOLIA HISTOCHEM CYTO, V44, P97; Morris DC, 2003, BRAIN RES, V972, P31, DOI 10.1016/S0006-8993(03)02433-8; Ohab JJ, 2006, J NEUROSCI, V26, P13007, DOI 10.1523/JNEUROSCI.4323-06.2006; Ohta T, 2006, NEUROSURGERY, V59, P679, DOI 10.1227/01.NEU.0000229058.08706.88; Okada S, 2008, DIABETES CARE, V31, P157, DOI 10.2337/dc07-1125; Paczkowska E, 2005, EUR J HAEMATOL, V75, P461, DOI 10.1111/j.1600-0609.2005.00536.x; Rookmaaker MB, 2005, ARTERIO THROMB VASC, V25, P1; Salven P, 2003, BLOOD, V101, P168, DOI 10.1182/blood-2002-03-0755; Shen FX, 2006, STROKE, V37, P2601, DOI 10.1161/01.STR.0000240407.14765.e8; Shyu WC, 2006, J NEUROSCI, V26, P3444, DOI 10.1523/JNEUROSCI.5165-05.2006; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tei K, 2008, STEM CELLS, V26, P819, DOI 10.1634/stemcells.2007-0671; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Wojakowski W, 2004, CIRCULATION, V110, P3213, DOI 10.1161/01.CIR.0000147609.39780.02; Xu Qing-Bo, 2005, Shengli Xuebao, V57, P1; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	30	55	63	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1337	1344		10.1089/neu.2008.0733			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900016	19226208	Green Published			2021-06-18	
J	Sribnick, EA; Del Re, AM; Ray, SK; Woodward, JJ; Banik, NL				Sribnick, Eric A.; Del Re, Angelo M.; Ray, Swapan K.; Woodward, John J.; Banik, Naren L.			Estrogen attenuates glutamate-induced cell death by inhibiting Ca2+ influx through L-type voltage-gated Ca2+ channels	BRAIN RESEARCH			English	Article						Apoptosis; Calpain; Ca2+ influx; Caspase-3; Glutamate; Motoneurons; Nifedipine	SPINAL-CORD-INJURY; NMDA RECEPTOR ACTIVATION; PRIMARY CORTICAL-NEURONS; PROTEIN-KINASE PATHWAY; C6 GLIOMA-CELLS; BRAIN-INJURY; INDUCED APOPTOSIS; HIPPOCAMPAL-NEURONS; OXIDATIVE STRESS; PLASMA-MEMBRANE	Estrogen-mediated neuroprotection is observed in neurodegenerative disease and neurotrauma models; however, deter-mining a mechanism for these effects has been difficult. We propose that estrogen may limit cell death in the nervous system tissue by inhibiting increases in intracellular free Ca2+. Here, we present data using VSC 4.1 cell line, a ventral spinal motoneuron and neuroblastoma hybrid cell line. Treatment with 1 mM glutamate for 24 h induced apoptosis. When cells were pre-treated with 100 nM 17 beta-estradiol (estrogen) for 1 h and then co-treated with glutamate, apoptotic death was significantly attenuated. Estrogen also prevented glutamate-mediated changes in resting membrane potential and membrane capacitance. Treatment with either 17 alpha-estradiol or cell impermeable estrogen did not mimic the findings seen with estrogen. Glutamate treatment significantly increased both intracellular free Ca2+ and the activities of downstream proteases such as calpain and caspase-3. Estrogen attenuated both the increases in intracellular free Ca2+ and protease activities, In order to determine the pathway responsible for estrogen-mediated inhibition of these increases in intracellular free Ca2+, cells were treated with several Ca2+ entry inhibitors, but only the L-type Ca2+ channel blocker nifedipine demonstrated cytoprotective effects comparable to estrogen. To expand these findings, cells were treated with the L-type Ca2+ channel agonist FPL 64176, which increased both cell death and intracellular free Ca2+ and estrogen inhibited both effects. From these observations, we conclude that estrogen limits glutamate-induced cell death in VSC 4.1 cells through effects on L-type Ca2+ channels, inhibiting Ca2+ influx as well as activation of the pro-apoptotic proteases calpain and caspase-3. (C) 2009 Elsevier B.V. All rights reserved.	[Sribnick, Eric A.; Del Re, Angelo M.; Woodward, John J.; Banik, Naren L.] Med Univ S Carolina, Div Neurol, Dept Neurosci, Charleston, SC 29425 USA; [Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29209 USA	Banik, NL (corresponding author), Med Univ S Carolina, Div Neurol, Dept Neurosci, 96 Jonathan Lucas St, Charleston, SC 29425 USA.	baniknl@musc.edu	Sribnick, Eric/AAH-6693-2020		Medical Scientist Training Program (MSTP) [GM08716]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Spinal Cord Injury Research Fund [SCIRF-0803]; state of South Carolina;  [NS-31622];  [NS-45967];  [NS-57811];  [CA-91460]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA091460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008716] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057811, R01NS045967, R01NS031622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R37AA009986] Funding Source: NIH RePORTER	This work was supported in part by R01 grants (NS-31622, NS-45967, NS-57811, and CA-91460) and a Medical Scientist Training Program (MSTP) grant (GM08716) from the National Institutes of Health (Bethesda, MD, USA), and also a Spinal Cord Injury Research Fund grant (SCIRF-0803) from the state of South Carolina.	Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Alkayed NJ, 2001, J NEUROSCI, V21, P7543; Ba F, 2004, NEUROCHEM INT, V45, P31, DOI 10.1016/j.neuint.2003.12.013; BARNEA A, 1970, BIOCHEMISTRY-US, V9, P1899, DOI 10.1021/bi00811a006; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bennett MVL, 1996, COLD SPRING HARB SYM, V61, P373; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Berman FW, 2000, J NEUROCHEM, V74, P1443, DOI 10.1046/j.1471-4159.2000.0741443.x; Bhatt A, 2002, J CELL SCI, V115, P3415; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; Cano-Abad MF, 2001, J BIOL CHEM, V276, P39695, DOI 10.1074/jbc.M102334200; Chaban VV, 2003, NEUROSCIENCE, V118, P941, DOI 10.1016/S0306-4522(02)00915-6; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Das A, 2008, BRAIN RES, V1227, P207, DOI 10.1016/j.brainres.2008.06.045; Das BP, 2005, J THEOR COMPUT CHEM, V4, P1, DOI 10.1142/S0219633605001441; Dhillon HS, 1999, NEUROCHEM RES, V24, P751, DOI 10.1023/A:1020779413122; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; FAVERO TG, 1995, J BIOL CHEM, V270, P25557, DOI 10.1074/jbc.270.43.25557; FINIELS F, 1995, J NEUROCHEM, V65, P1027; George J, 2009, NEUROCHEM RES, V34, P66, DOI 10.1007/s11064-008-9659-z; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; Green P S, 2000, Novartis Found Symp, V230, P202, DOI 10.1002/0470870818.ch15; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harms C, 2001, J NEUROSCI, V21, P2600, DOI 10.1523/JNEUROSCI.21-08-02600.2001; Honda K, 2001, J NEUROSCI RES, V64, P466, DOI 10.1002/jnr.1098; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; Ihionkhan CE, 2002, CIRC RES, V91, P814, DOI 10.1161/01.RES.0000038304.62046.4C; Karmakar S, 2007, NEUROSCI LETT, V415, P242, DOI 10.1016/j.neulet.2007.01.071; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P9870, DOI 10.1073/pnas.152336999; Kim YJ, 2000, J NEUROCHEM, V74, P2490, DOI 10.1046/j.1471-4159.2000.0742490.x; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Kurata K, 2001, EUR J PHARMACOL, V416, P203, DOI 10.1016/S0014-2999(01)00880-9; LaBella V, 1996, NEUROSCIENCE, V70, P1039, DOI 10.1016/0306-4522(95)00401-7; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Lee MO, 2002, MOL CELL ENDOCRINOL, V188, P47, DOI 10.1016/S0303-7207(01)00753-5; LEVITAN IB, 1997, NEURON CELL MOL BIOL; Linford NJ, 2002, STEROIDS, V67, P1029, DOI 10.1016/S0039-128X(02)00062-4; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Mitsumoto Y, 1998, BIOCHEM BIOPH RES CO, V248, P660, DOI 10.1006/bbrc.1998.8986; Monroe DG, 2002, MOL ENDOCRINOL, V16, P1322, DOI 10.1210/me.16.6.1322; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; Morales A, 2003, EUR J NEUROSCI, V18, P2505, DOI 10.1046/j.1460-9568.2003.02997.x; MURAYAMA A, 1984, J BIOCHEM-TOKYO, V95, P1697, DOI 10.1093/oxfordjournals.jbchem.a134783; Nakamizo T, 2000, NEUROREPORT, V11, P3493, DOI 10.1097/00001756-200011090-00019; Nash MS, 2001, J BIOL CHEM, V276, P19286, DOI 10.1074/jbc.M007600200; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Ray SK, 1999, BRAIN RES, V829, P18, DOI 10.1016/S0006-8993(99)01290-1; Ray SK, 2003, CNS NEUROL DISORD-DR, V2, P173, DOI 10.2174/1568007033482887; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Sharrow KM, 2002, NEUROSCIENCE, V113, P89, DOI 10.1016/S0306-4522(02)00151-3; Singer CA, 1999, J NEUROSCI, V19, P2455; SMITH RG, 1994, P NATL ACAD SCI USA, V91, P3393, DOI 10.1073/pnas.91.8.3393; Sribnick EA, 2006, NEUROSCIENCE, V137, P197, DOI 10.1016/j.neuroscience.2005.08.074; Sribnick EA, 2004, J NEUROSCI RES, V76, P688, DOI 10.1002/jnr.20124; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Stevis PE, 1999, ENDOCRINOLOGY, V140, P5455, DOI 10.1210/en.140.11.5455; Sur P, 2003, BRAIN RES, V971, P178, DOI 10.1016/S0006-8993(03)02349-7; Tiidus PM, 2001, CAN J PHYSIOL PHARM, V79, P400, DOI 10.1139/cjpp-79-5-400; Toran-Allerand CD, 2002, J NEUROSCI, V22, P8391; TOWLE AC, 1983, J STEROID BIOCHEM, V18, P135, DOI 10.1016/0022-4731(83)90079-1; Wang CN, 2001, J BIOL CHEM, V276, P5287, DOI 10.1074/jbc.M006406200; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Weaver CE, 1997, BRAIN RES, V761, P338, DOI 10.1016/S0006-8993(97)00449-6; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xue BJ, 2003, BRAIN RES, V976, P41, DOI 10.1016/S0006-8993(03)02629-5; YANASE M, 1995, J NEUROSURG, V83, P884, DOI 10.3171/jns.1995.83.5.0884	79	55	61	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUN 18	2009	1276						159	170		10.1016/j.brainres.2009.04.022			12	Neurosciences	Neurosciences & Neurology	464PD	WOS:000267516700018	19389388	Green Accepted			2021-06-18	
J	Aarabi, B; Chesler, D; Maulucci, C; Blacklock, T; Alexander, M				Aarabi, Bizhan; Chesler, David; Maulucci, Christopher; Blacklock, Tiffany; Alexander, Melvin			Dynamics of subdural hygroma following decompressive craniectomy: a comparative study	NEUROSURGICAL FOCUS			English	Article						decompressive craniectomy; subdural hygroma; head injury; intracranial pressure	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; ASSISTED VOLUMETRIC-ANALYSIS; CEREBROSPINAL-FLUID; CHOROID-PLEXUS; INTRACRANIAL HYPERTENSION; PRESSURE; HEMATOMA; MANAGEMENT; EFFUSION	Object. This retrospective comparative cohort study was aimed at discovering the risk factors associated with subdural hygroma (SDG) following decompressive craniectomy (DC) to relieve intracranial hypertension in severe head injury. Methods. Sixty-eight of 104 patients who had undergone DC during a 48-month period and survived > 30 days were eligible for this study. To assess the dynamics of subdural fluid collections, the authors compared CT scanning data from and the characteristics of 39 patients who had SDGs with the data in 29 patients who did not have hygromas. Variables significant in the appearance, evolution, and resolution of this complication were analyzed in a 36-week longitudinal study. Results. The earliest imaging evidence of SDG was seen during the 1st week after DC. The SDG volume peaked between Weeks 3 and 4 post-DC and was gradually resolved by the 17th week. Among the mechanisms of injury, motor vehicle accidents were most often linked to the development of an SDG after DC (p < 0.0007), and falls were least often associated (p < 0.005). Moreover, patients with diffuse brain injury were more prone to this complication (p < 0.0299) than those with an evacuated mass (p < 0.0001). There were no statistically significant differences between patients with and without hygromas in terms of age, sex, Glasgow Coma Scale score, intraventricular and subarachnoid hemorrhage, levels of intracranial pressure and cerebral perfusion pressure, timing of decompression, and the need for CSF diversion. More than 90% of the SDGs were ipsilateral to the side of the craniectomy, and 3 (8%) of 39 SDGs showed evidence of internal bleeding at similar to 8 weeks postinjury. Surgical evacuation was needed in 4 patients with SDGs. Conclusions. High dynamic accidents and patients with diffuse injury were more prone to SDGs. Close to 8% of SDGs converted themselves into subdural hematomas at similar to 2 months postinjury. Although SDGs developed in 39 (similar to 60%) of 68 post-DC patients, surgical evacuation was needed in only 4. (DOI: 10.3171/2009.3.FOCUS0947)	[Aarabi, Bizhan; Chesler, David; Maulucci, Christopher] Univ Maryland, Sch Med, Dept Neurosurg, Baltimore, MD 21201 USA; [Blacklock, Tiffany; Alexander, Melvin] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA	Aarabi, B (corresponding author), Univ Maryland, Sch Med, Dept Neurosurg, 22 S Greene St,Suite S-12-D, Baltimore, MD 21201 USA.	baarabi@smail.umaryland.edu		Andrews, Tiffany/0000-0002-2874-2298; Maulucci, Christopher/0000-0002-7777-3971			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AARABI B, 2008, 26 ANN NAT NEUR S HE; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; ARNASON O, 1983, ACTA NEUROCHIR, V67, P231, DOI 10.1007/BF01401424; BORN JD, 1984, ACTA NEUROL BELG, V84, P174; Borzone M, 1983, J Neurosurg Sci, V27, P161; Boulton M, 1997, AM J PHYSIOL-REG I, V272, pR1613; BROADWELL RD, 1993, EXP NEUROL, V120, P245, DOI 10.1006/exnr.1993.1059; Cohen I, 1927, ARCH NEURO PSYCHIATR, V18, P709, DOI 10.1001/archneurpsyc.1927.02210050041004; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; CSERR HF, 1974, EXP NEUROL, V45, P50, DOI 10.1016/0014-4886(74)90099-5; CSERR HF, 1977, EXP EYE RES, V25, P461, DOI 10.1016/S0014-4835(77)80041-9; da Costa DG, 1941, ARCH SURG-CHICAGO, V43, P559, DOI 10.1001/archsurg.1941.01210160020003; Dandy WE, 1955, PRACTICE SURG, P291; Dandy WE, 1932, PRACTICE SURG, P306; DAVELLA D, 1980, J NEUROSURG, V53, P656, DOI 10.3171/jns.1980.53.5.0656; Deltour P, 1999, JBR-BTR, V82, P155; DEROUGEMONT AA, 1960, J NEUROPHYSIOL, V23, P485; ENDTZ LJ, 1978, SURG NEUROL, V10, P305; Feng JF, 2008, MED HYPOTHESES, V70, P1147, DOI 10.1016/j.mehy.2007.11.014; FRENCH BN, 1978, SURG NEUROL, V9, P145; GAAB MR, 1990, ACT NEUR S, V51, P326; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Han CY, 2005, OTOLARYNG CLIN N AM, V38, P569, DOI 10.1016/j.otc.2005.01.005; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; HOFF J, 1973, J TRAUMA, V13, P870, DOI 10.1097/00005373-197313100-00005; Jiang JY, 2005, J NEUROTRAUM, V22, P623, DOI 10.1089/neu.2005.22.623; Johnston I, 2000, CHILD NERV SYST, V16, P776, DOI 10.1007/s003810000383; Johnston M, 2005, NEUROPATH APPL NEURO, V31, P632, DOI 10.1111/j.1365-2990.2005.00679.x; Kapoor KG, 2008, BRAIN RES BULL, V77, P327, DOI 10.1016/j.brainresbull.2008.08.009; KAUFMAN HH, 1984, ACTA NEUROCHIR, V72, P197, DOI 10.1007/BF01406870; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; Koh L, 2006, ANAT EMBRYOL, V211, P335, DOI 10.1007/s00429-006-0085-1; KOIZUMI H, 1981, Neurologia Medico-Chirurgica, V21, P397; KOIZUMI H, 1987, SURG NEUROL, V27, P147, DOI 10.1016/0090-3019(87)90286-2; Lang JK, 1999, SURG NEUROL, V52, P630, DOI 10.1016/S0090-3019(99)00144-5; Lee KS, 2000, J KOREAN MED SCI, V15, P560, DOI 10.3346/jkms.2000.15.5.560; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Li G, 2008, CHIN J TRAUMATOL, V11, P253, DOI 10.1016/S1008-1275(08)60052-8; LINDSEY AE, 1990, P NATL ACAD SCI USA, V87, P5278, DOI 10.1073/pnas.87.14.5278; Liu Yu-guang, 2004, Chin J Traumatol, V7, P188; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASUZAWA T, 1984, BRAIN RES, V302, P357, DOI 10.1016/0006-8993(84)90250-6; Mori K, 2000, SURG NEUROL, V53, P303, DOI 10.1016/S0090-3019(00)00199-3; Munch E, 2000, NEUROSURGERY, V47, P315; Murata Keiji, 1993, Neurologia Medico-Chirurgica, V33, P691, DOI 10.2176/nmc.33.691; NAFFZIGER HC, 1924, JAMA-J AM MED ASSOC, V82, P1751; Nagra G, 2006, AM J PHYSIOL-REG I, V291, pR1383, DOI 10.1152/ajpregu.00235.2006; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NILSSON C, 1992, AM J PHYSIOL, V262, pR20; OHNO K, 1987, J NEUROL NEUROSUR PS, V50, P1694, DOI 10.1136/jnnp.50.12.1694; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Papasian NC, 2000, PEDIATR NEUROSURG, V33, P188, DOI 10.1159/000055951; PARK CK, 1994, ACTA NEUROCHIR, V127, P41, DOI 10.1007/BF01808545; Park SH, 2008, J CLIN NEUROSCI, V15, P868, DOI 10.1016/j.jocn.2007.08.003; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Praetorius J, 2007, PFLUG ARCH EUR J PHY, V454, P1, DOI 10.1007/s00424-006-0170-6; Praetorius J, 2006, AM J PHYSIOL-CELL PH, V291, pC59, DOI 10.1152/ajpcell.00433.2005; RABE EF, 1968, NEUROLOGY, V18, P559, DOI 10.1212/WNL.18.6.559; RABE EF, 1962, NEUROLOGY, V12, P79, DOI 10.1212/WNL.12.2.79; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; STJOHN JN, 1981, NEUROSURGERY, V9, P621, DOI 10.1227/00006123-198112000-00002; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; Su FW, 2008, J CLIN NEUROSCI, V15, P305, DOI 10.1016/j.jocn.2006.08.019; Sucu HK, 2005, STROKE, V36, P998, DOI 10.1161/01.STR.0000162714.46038.0f; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; TRIPATHI BJ, 1974, J PHYSIOL-LONDON, V239, P195, DOI 10.1113/jphysiol.1974.sp010563; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; WEIR B, 1980, J NEUROSURG, V53, P512, DOI 10.3171/jns.1980.53.4.0512; WELCH K, 1963, AM J PHYSIOL, V205, P617; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Yang XF, 2009, MED PRIN PRACT, V18, P16, DOI 10.1159/000163040; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953; ZEUTHEN T, 1978, BIOCHIM BIOPHYS ACTA, V511, P517, DOI 10.1016/0005-2736(78)90287-0	78	55	64	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	JUN	2009	26	6							E8	10.3171/2009.3.FOCUS0947			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	451WK	WOS:000266501400008	19485721	Bronze			2021-06-18	
J	Chaiwat, O; Sharma, D; Udomphorn, Y; Armstead, WM; Vavilala, MS				Chaiwat, Onuma; Sharma, Deepak; Udomphorn, Yuthana; Armstead, William M.; Vavilala, Monica S.			Cerebral Hemodynamic Predictors of Poor 6-Month Glasgow Outcome Score in Severe Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral autoregulation; outcome; pediatric; traumatic brain injury	SEVERE HEAD-INJURIES; BLOOD-FLOW; PERFUSION-PRESSURE; CHILDREN; AUTOREGULATION; HYPOTENSION; METABOLISM; AGE; SURVIVAL; MODERATE	Little is known regarding the cerebral autoregulation in pediatric traumatic brain injury (TBI). We examined the relationship between cerebral hemodynamic predictors, including cerebral autoregulation, and long-term outcome after severe pediatric TBI. After Institutional Review Board (IRB) approval, a retrospective analysis of prospectively collected data (May 2002 to October 2007) for children age <= 16 years with severe TBI (admission Glasgow Coma Scale [GCS] score < 9) was performed. Cerebral autoregulation was assessed within 72 h after TBI. Cerebral hemodynamic predictors (intracranial pressure [ICP], systolic blood pressure [SBP], and cerebral perfusion pressure [CPP]) through the first 72 h after TBI were abstracted. Univariate and multivariate analyses examined the relationship between impaired cerebral autoregulation (autoregulatory index <0.4), intracranial hypertension (ICP >20mmHg), and hypotension (SBP <5(th) percentile and CPP < 40 mm Hg). Six-month Glasgow Outcome Scale (GOS) score of <4 defined poor outcome. Ten (28%) of the 36 children examined (9.1 +/- 5.3 [0.8-16] years; 74% male) had poor outcome. Univariate factors associated with poor outcome were impaired cerebral autoregulation (p = 0.005), SBP < 5(th) percentile for age and gender ( p = 0.02), and low middle cerebral artery flow velocity (< 2 SD for age and gender; p = 0.04). Independent risk factors for poor 6-month GOS were impaired cerebral autoregulation (adjusted odds ratio [aOR] 12.0; 95% confidence interval [CI] 1.4-99.4) and hypotension (SBP <5(th) percentile; aOR 8.8; 95% CI 1.1-70.5), respectively. Previous studies of TBI describing poor outcome with hemodynamics did not consider the status of cerebral autoregulation. In this study, both impaired cerebral autoregulation and SBP < 5(th) percentile were independent risk factors for poor 6-month GOS.	[Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Harborview Med Ctr, Seattle, WA 98104 USA; [Chaiwat, Onuma; Udomphorn, Yuthana] Univ Washington, Harborview Anesthesiol Res Ctr, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Dept Pediat, Seattle, WA 98104 USA; [Vavilala, Monica S.] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Vavilala, Monica S.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA; [Armstead, William M.] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA	Vavilala, MS (corresponding author), Univ Washington, Dept Anesthesiol, Harborview Med Ctr, 325 Ninth Ave,Box 359724,7EH-77, Seattle, WA 98104 USA.	vavilala@u.washington.edu					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; BODE H, 1988, APPL PEDIAT TRANSCRA; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JA, 2001, TRAUMATIC BRAIN INJU; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NAKAYAMA DK, 1991, J TRAUMA, V31, P1521, DOI 10.1097/00005373-199111000-00010; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Puppo C, 2007, ACTA NEUROCHIR, V149, P139, DOI 10.1007/s00701-006-1074-0; Samant UB, 2008, J NEUROTRAUM, V25, P495, DOI 10.1089/neu.2007.0491; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Tontisirin N, 2007, CHILD NERV SYST, V23, P1163, DOI 10.1007/s00381-007-0339-0; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2008, NEUROCRIT CARE, V9, P45, DOI 10.1007/s12028-007-9036-9; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P13, DOI 10.1097/00008506-200101000-00003	29	55	59	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2009	26	5					657	663		10.1089/neu.2008.0770			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	452XM	WOS:000266574500002	19292656	Green Published			2021-06-18	
J	Wester, BA; Lee, RH; LaPlaca, MC				Wester, B. A.; Lee, R. H.; LaPlaca, M. C.			Development and characterization of in vivo flexible electrodes compatible with large tissue displacements	JOURNAL OF NEURAL ENGINEERING			English	Article							TRAUMATIC BRAIN-INJURY; MICROELECTRODE ARRAYS; CORTEX; OSCILLATIONS; POTENTIALS; IMPLANT; EEG	Electrical activity is the ultimate functional measure of neuronal tissue and recording that activity remains a key technical challenge in neuroscience. The mechanical mismatch between rigid electrodes and compliant brain tissue is a critical limitation in applications where movement is an inherent component. An electrode that permits recording of neural activity, while minimizing tissue disruption, is beneficial for applications that encompass both normal physiological movements and those which require consistent recording during large tissue displacements. In order to test the extreme of this range of movement, flexible electrodes were developed to record activity during and immediately following cortical impact in the rat. Photolithography techniques were used to fabricate flexible electrodes that were readily insertable into the brain Using a parylene C base and gold conduction lines and contact pads, permitting custom geometry. We found that this electrode configuration retained mechanical and electrical integrity following both durability Studies and large movements within the cortex. This novel flexible electrode configuration provides a novel platform for experimentally examining neuronal activity during a range of brain movements.	[Wester, B. A.; Lee, R. H.; LaPlaca, M. C.] Georgia Inst Technol, Dept Biomed Engn, Atlanta, GA 30332 USA; [Wester, B. A.] Georgia Inst Technol, Sch Elect Engn, Microelect Res Ctr, Atlanta, GA 30332 USA	Wester, BA (corresponding author), Georgia Inst Technol, Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	brock@gitech.edu; rhlee@bme.gatech.edu; michelle.laplaca@bme.gatech.edu	Wester, Brock/H-2217-2013	Wester, Brock/0000-0002-1500-2143	NSFNational Science Foundation (NSF) [DGE-0333411]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NINDS/NIMH/NIBIB NS046851, NIBIB EB000786]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000786] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046851] Funding Source: NIH RePORTER	This work was supported by the NSF (DGE-0333411) and the NIH (NINDS/NIMH/NIBIB NS046851 and N113113 EB000786). The authors wish to thank Dr Yoonsu Choi for his guidance with fabrication processing, Mr Scott Kasprzak and Dr Ken Gall for support with mechanical testing, Dr George C McConnell for suraical trainino, Dr Jim Ross for help with impedance testing and Mr Ashish Patil for assistance with mechanical and electrical evaluation.	Chou SL, 2008, ELECTROCHEM COMMUN, V10, P1724, DOI 10.1016/j.elecom.2008.08.051; DI S, 1991, BRAIN RES, V546, P106, DOI 10.1016/0006-8993(91)91164-V; Fee MS, 2000, NEURON, V27, P461, DOI 10.1016/S0896-6273(00)00057-X; Fujimoto K, 2008, JPN J APPL PHYS, V47, P8644, DOI 10.1143/JJAP.47.8644; HOOGERWERF AC, 1994, IEEE T BIO-MED ENG, V41, P1136, DOI 10.1109/10.335862; Jensen W, 2006, IEEE T BIO-MED ENG, V53, P934, DOI 10.1109/TBME.2006.872824; Jones MS, 1999, J NEUROPHYSIOL, V82, P1599; Juergens E, 1999, EXP BRAIN RES, V129, P247, DOI 10.1007/s002210050895; Lawn B., 1993, FRACTURE BRITTLE SOL; Lee H, 2005, J NEURAL ENG, V2, P81, DOI 10.1088/1741-2560/2/4/003; Lee KK, 2004, J MICROMECH MICROENG, V14, P32, DOI 10.1088/0960-1317/14/1/305; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Myllymaa S, 2008, TISSUE ENG PT A, V14, P735; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OBRIEN DP, 2001, 14 IEEE INT C MICR M; ORTEGA A, 2006, COL I C; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Rousche PJ, 2001, IEEE T BIO-MED ENG, V48, P361, DOI 10.1109/10.914800; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; SUZUKI T, 2003, P 1 INT IEEE EMBS CA; Szarowski DH, 2003, BRAIN RES, V983, P23, DOI 10.1016/S0006-8993(03)03023-3; Takeuchi S, 2005, LAB CHIP, V5, P519, DOI 10.1039/b417497f; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; Yu HY, 2008, J MICROELECTROMECH S, V17, P1178, DOI 10.1109/JMEMS.2008.927749	24	55	56	1	14	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	1741-2560	1741-2552		J NEURAL ENG	J. Neural Eng.	APR	2009	6	2							024002	10.1088/1741-2560/6/2/024002			7	Engineering, Biomedical; Neurosciences	Engineering; Neurosciences & Neurology	438LF	WOS:000265556200002	19255461				2021-06-18	
J	Xiong, Y; Qu, CS; Mahmood, A; Liu, ZW; Ning, RZ; Li, Y; Kaplan, DL; Schallert, T; Chopp, M				Xiong, Ye; Qu, Changsheng; Mahmood, Asim; Liu, Zhongwu; Ning, Ruizhuo; Li, Yi; Kaplan, David L.; Schallert, Timothy; Chopp, Michael			Delayed transplantation of human marrow stromal cell-seeded scaffolds increases transcallosal neural fiber length, angiogenesis, and hippocampal neuronal survival and improves functional outcome after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Angiogenesis; Neural fiber length; Human bone marrow stromal cell; Scaffold; Sensorimotor; Spatial learning; Traumatic brain injury	SPINAL-CORD-INJURY; SPATIAL MEMORY; STEM-CELLS; STROKE; NEUROGENESIS; MICE; ERYTHROPOIETIN; RECOVERY; THERAPY; PROLIFERATION	Traumatic brain injury (TBI) is a major cause of death and disability worldwide; however, no effective treatment has been clinically identified. Our recent studies show that the combination of Collagen scaffolds with human bone morrow stromal cells (hMSCs) for treatment of TBI improves functional outcome and reduces the lesion volume when this combination was applied at day 4 after TBI in rats. The mechanisms underlying these benefits remain unclear. Whether further delayed treatment with this combination will provide benefits has not been investigated. In the present study, we investigated whether the delayed (7 days post injury) transplantation would have beneficial effects on functional and histological outcome and sought to elucidate underlying mechanisms of therapeutic action. Collagen scaffolds seeded with 3 x 106 hMSCs, scaffolds alone, 3 x 106 hMSCs alone, or saline were transplanted into the lesion cavity of the injured cortex 7 days after TBI. Sensorimotor function and spatial learning were measured. Corticocortical labeling with 1, 1 ''-dioleyl-3, 3, 3 '', 3 ''-tetramethylindocarbocyanine methanesulfonate (DiI) was performed at day 36 after TBI. The rats were sacrificed 43 days after TBI, and the brain tissue was processed for DiI-labeling fiber and immunohistochemical analyses. The present data show that delayed transplantation of hMSCs or scaffolds seeded with hMSCs improved spatial learning and sensorimotor function, enhanced angiogenesis in the injured cortex and the ipsilateral hippocampus and increased DiI-labeled neural fiber length in the injured cortex. hMSC-seeded scaffolds may be a new and effective way to improve neurological function after TBI. (C) 2009 Elsevier B.V. All rights reserved.	[Xiong, Ye; Qu, Changsheng; Mahmood, Asim; Ning, Ruizhuo] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Liu, Zhongwu; Li, Yi; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Kaplan, David L.] Tufts Univ, Dept Biomed Engn, Medford, MA 02155 USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, E&R Bldg,Room 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	ning, ruizhuo/E-6401-2012	Xiong, Ye/0000-0001-9770-6031	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS042259, RO1 NS 062002, PO1 NS42345, P41 EB002520]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS062002, R01NS042259] Funding Source: NIH RePORTER	This work was supported by NIH grants RO1 NS042259, RO1 NS 062002, PO1 NS42345 and P41 EB002520.	Bakshi A, 2004, J NEUROSURG-SPINE, V1, P322, DOI 10.3171/spi.2004.1.3.0322; Chen Jieli, 2006, NeuroRx, V3, P466, DOI 10.1016/j.nurx.2006.07.007; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Liu ZW, 2007, BRAIN RES, V1149, P172, DOI 10.1016/j.brainres.2007.02.047; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; PAXINOS G, 1986, RAT BRAIN STEREOTACT; Potter W, 2008, FRONT BIOSCI-LANDMRK, V13, P806, DOI 10.2741/2721; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Shen CF, 2007, IET OPTOELECTRON, V1, P27, DOI 10.1049/iet-opt:20060003; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; Wright KT, 2007, BIOCHEM BIOPH RES CO, V354, P559, DOI 10.1016/j.bbrc.2007.01.013; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang C, 2006, NEUROSCIENCE, V141, P687, DOI 10.1016/j.neuroscience.2006.04.054; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; NIH CONSENS STATEMEN, V16, P1	35	55	56	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 31	2009	1263						183	191		10.1016/j.brainres.2009.01.032			9	Neurosciences	Neurosciences & Neurology	431CV	WOS:000265039800020	19368838	Green Accepted			2021-06-18	
J	Stahel, PF; Flierl, MA; Morgan, BP; Persigehl, I; Stoll, C; Conrad, C; Touban, BM; Smith, WR; Beauchamp, K; Schmidt, OI; Ertel, W; Leinhase, I				Stahel, Philip F.; Flierl, Michael A.; Morgan, B. Paul; Persigehl, Ivonne; Stoll, Christiane; Conrad, Claudia; Touban, Basel M.; Smith, Wade R.; Beauchamp, Kathryn; Schmidt, Oliver I.; Ertel, Wolfgang; Leinhase, Iris			Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice	JOURNAL OF NEUROINFLAMMATION			English	Article							MEMBRANE ATTACK COMPLEX; CLOSED-HEAD INJURY; NEURONAL CELL-DEATH; NERVOUS-SYSTEM; ALTERNATIVE PATHWAY; BARRIER DYSFUNCTION; AXONAL INJURY; ACTIVATION; DEFICIENCY; INHIBITION	Background: Complement represents a crucial mediator of neuroinflammation and neurodegeneration after traumatic brain injury. The role of the terminal complement activation pathway, leading to generation of the membrane attack complex (MAC), has not been thoroughly investigated. CD59 is the major regulator of MAC formation and represents an essential protector from homologous cell injury after complement activation in the injured brain. Methods: Mice deleted in the Cd59a gene (CD59a(-/-)) and wild-type littermates (n = 60) were subjected to focal closed head injury. Sham-operated (n = 60) and normal untreated mice (n = 14) served as negative controls. The posttraumatic neurological impairment was assessed for up to one week after trauma, using a standardized Neurological Severity Score (NSS). The extent of neuronal cell death was determined by serum levels of neuron-specific enolase (NSE) and by staining of brain tissue sections in TUNEL technique. The expression profiles of pro-apoptotic (Fas, FasL, Bax) and anti-apoptotic (Bcl-2) mediators were determined at the gene and protein level by real-time RT-PCR and Western blot, respectively. Results: Clinically, the brain-injured CD59a(-/-) mice showed a significantly impaired neurological outcome within 7 days, as determined by a higher NSS, compared to wild-type controls. The NSE serum levels, an indirect marker of neuronal cell death, were significantly elevated in CD59a(-/-) mice at 4 h and 24 h after trauma, compared to wild-type littermates. At the tissue level, increased neuronal cell death and brain tissue destruction was detected by TUNEL histochemistry in CD59a(-/-) mice within 24 hours to 7 days after head trauma. The analysis of brain homogenates for potential mediators and regulators of cell death other than the complement MAC (Fas, FasL, Bax, Bcl-2) revealed no difference in gene expression and protein levels between CD59a(-/-) and wild-type mice. Conclusion: These data emphasize an important role of CD59 in mediating protection from secondary neuronal cell death and further underscore the key role of the terminal complement pathway in the pathophysiology of traumatic brain injury. The exact mechanisms of complement MAC-induced secondary neuronal cell death after head injury require further investigation.	[Stahel, Philip F.; Flierl, Michael A.; Touban, Basel M.; Smith, Wade R.] Univ Colorado, Sch Med, Dept Orthoped Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA; [Schmidt, Oliver I.] Dept Trauma Surg & Orthopaed, Trauma Ctr St Georg, D-04129 Leipzig, Germany; [Beauchamp, Kathryn] Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Surg,Div Neurosurg, Denver, CO 80204 USA; [Persigehl, Ivonne; Stoll, Christiane; Conrad, Claudia; Ertel, Wolfgang; Leinhase, Iris] Charite Univ Med Ctr, Dept Trauma & Reconstruct Surg, D-12207 Berlin, Germany; [Morgan, B. Paul] Cardiff Univ, Sch Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales	Stahel, PF (corresponding author), Univ Colorado, Sch Med, Dept Orthoped Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA.	philip.stahel@dhha.org; michael.flierl@dhha.org; morganbp@cardiff.ac.uk; ivonne.persigehl@charite.de; christiane.stoll@charite.de; claudia.conrad@charite.de; bmtouba@hotmail.com; wade.smith@dhha.org; kathryn.beauchamp@dhha.org; oliver.schmidt@sanktgeorg.de; wolfgang.ertel@charite.de; irisleinhase@freenet.de		Morgan, Paul/0000-0003-4075-7676	German Research FoundationGerman Research Foundation (DFG) [STA 635/2-1, STA 635/2-2]	This study was supported by the German Research Foundation (DFG) grants No. STA 635/2-1 and STA 635/2-2 to PFS, OIS, and WE. The project has been previously presented at the "11th European Meeting on Complement in Human Diseases" in Cardiff, Wales, UK, September 8-11, 2007. Parts of this work have been published in abstract form in the proceedings of this scientific meeting.	Baalasubramanian S, 2004, J IMMUNOL, V173, P3684, DOI 10.4049/jimmunol.173.6.3684; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Casarsa C, 2003, EUR J IMMUNOL, V33, P1260, DOI 10.1002/eji.200323574; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cole DS, 2006, MOL IMMUNOL, V43, P1953, DOI 10.1016/j.molimm.2005.11.015; Donev RM, 2008, MOL IMMUNOL, V45, P534, DOI 10.1016/j.molimm.2007.05.011; Farkas I, 1998, NEUROSCIENCE, V86, P903, DOI 10.1016/S0306-4522(98)00108-0; Holers VM, 2004, MOL IMMUNOL, V41, P147, DOI 10.1016/j.molimm.2004.03.012; Holt DS, 2001, BLOOD, V98, P442, DOI 10.1182/blood.V98.2.442; Huang YX, 2005, J BIOL CHEM, V280, P34073, DOI 10.1074/jbc.M504922200; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kimberley FC, 2007, MOL IMMUNOL, V44, P73, DOI 10.1016/j.molimm.2006.06.019; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408; Mead RJ, 2004, LAB INVEST, V84, P21, DOI 10.1038/labinvest.3700015; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Morgan BP, 1999, CRIT REV IMMUNOL, V19, P173; Morgan BP, 2003, MOL IMMUNOL, V40, P159, DOI 10.1016/S0161-5890(03)00111-1; Morgan BP, 1997, EXP CLIN IMMUNOGENET, V14, P19; MULLEREBERHARD HJ, 1985, J INVEST DERMATOL, V85, pS47; Niculescu T, 2003, ANN NY ACAD SCI, V1010, P530, DOI 10.1196/annals.1299.098; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Sahu A, 2000, IMMUNOPHARMACOLOGY, V49, P133, DOI 10.1016/S0162-3109(00)80299-4; Singhrao SK, 1999, LAB INVEST, V79, P1247; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Turnberg D, 2004, AM J PATHOL, V165, P825, DOI 10.1016/S0002-9440(10)63345-7; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Xiong ZQ, 2003, J NEUROSCI, V23, P955; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497	42	55	55	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 8	2009	6								2	10.1186/1742-2094-6-2			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	409WJ	WOS:000263536200001	19133139	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Immonen, RJ; Irina, KIB; Niskanen, JP; Heidi, GC; Pitkanen, A; Grohn, OHJ				Immonen, Riikka J.; Kharatishvili, Irina; Niskanen, Juha-Pekka; Grohn, Heidi; Pitkanen, Asla; Grohn, Olli H. J.			Distinct MRI pattern in lesional and perilesional area after traumatic brain injury in rat-11 month's follow-up	EXPERIMENTAL NEUROLOGY			English	Article							LATERAL FLUID-PERCUSSION; MAGNETIC-RESONANCE SPECTROSCOPY; APOPTOTIC CELL-DEATH; NEURONAL DEGENERATION; CEREBRAL-ISCHEMIA; ROTATING-FRAME; TIME-COURSE; RATS; MODEL; DIFFUSION	To understand the dynamics of progressive brain damage after lateral fluid-percussion induced traumatic brain injury (TBI) in rat, which is the most widely used animal model of closed head TBI in humans, MRI follow-up of 11 months was performed. The evolution Of tissue damage was quantified using MRI contrast parameters T-2, T-1 rho, diffusion (D-av), and tissue atrophy in the focal cortical lesion and adjacent areas: the perifocal and contralateral cortex, and the ipsilateral and contralateral hippocampus. In the primary cortical lesion area, which undergoes remarkable irreversible pathologic changes, MRI alterations start at 3 h post-injury and continue to progress for LIP to 6 months. Ill more mildly affected perifocal and hippocampal regions, the robust alterations in T-2, T-1 rho, and D-av at 3 h to 3 d post-injury normalize within the next 9-23 d, and thereafter, progressively increase for several weeks. The severity of damage in the perifocal and hippocampal areas 23 d post-injury appeared independent of the focal lesion Volume. Magnetic resonance spectroscopy (MRS) performed at 5 and 10 months post-injury detected metabolic alterations in the ipsilateral hippocampus, Suggesting ongoing neurodegeneration and inflammation. Our data show that TBI induced by lateral fluid-percussion injury triggers long-lasting alterations with region-dependent temporal profiles. Importantly, the temporal pattern in MRI parameters during the first 23 d post-injury call indicate the regions that will develop secondary damage. This information is Valuable for targeting and timing interventions ill Studies aiming at alleviating or reversing the molecular and/or cellular cascades Causing the delayed injury. (C) 2008 Elsevier Inc. All rights reserved.	[Immonen, Riikka J.; Niskanen, Juha-Pekka; Grohn, Olli H. J.] Univ Kuopio, AI Virtanen Inst Mol Sci, Biomed Imaging Unit, Biomed NMR Res Grp,Dept Neurobiol, FIN-70211 Kuopio, Finland; [Kharatishvili, Irina; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Grp, Dept Neurobiol, FIN-70211 Kuopio, Finland; [Grohn, Heidi] N Karelia Cent Hosp, Dept Clin Physiol Nucl Med & Neurophysiol, FIN-80120 Joensuu, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland	Grohn, OHJ (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Biomed Imaging Unit, Biomed NMR Res Grp,Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	olli.grohn@uku.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Emil Aaltonen Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; CURE (Citizens United for Research for Epilepsy); Finnish Epilepsy Research Foundation; Finnish Cultural FoundationFinnish Cultural Foundation	This work was Supported by the Academy of Finland, the Emil Aaltonen Foundation, the Sigrid Juselius Foundation, CURE (Citizens United for Research for Epilepsy), the Finnish Epilepsy Research Foundation, and the Finnish Cultural Foundation. We thank Mrs. Maarit Pulkkinen, Mr. Jarmo Hartikainen, Mrs. Merja Lukkari, and Jari Nissinen, Ph.D., for technical assistance, Nick Hayward, M.Sc., for revising the language of the Manuscript, and Ivan Tkac providing the short echo time STEAM pulse sequence.	Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Berry I, 1986, Acta Radiol Suppl, V369, P338; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Choi CB, 2005, EUR J RADIOL, V55, P96, DOI 10.1016/j.ejrad.2004.10.009; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dube C, 2001, EXP NEUROL, V167, P227, DOI 10.1006/exnr.2000.7561; Dubreuil CI, 2006, EXP NEUROL, V198, P361, DOI 10.1016/j.expneurol.2005.12.002; Duvvuri U, 2001, RADIOLOGY, V220, P822, DOI 10.1148/radiol.2203001662; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Grohn HI, 2005, MAGN RESON MED, V54, P14, DOI 10.1002/mrm.20536; Grohn OHJ, 2000, J CEREBR BLOOD F MET, V20, P1457; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Iwamoto Y, 1997, NEUROSURGERY, V40, P163, DOI 10.1097/00006123-199701000-00036; Karhunen H, 2005, NEUROCHEM RES, V30, P1529, DOI 10.1007/s11064-005-8831-y; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leon-Carrion Jose, 2005, Pituitary, V8, P197, DOI 10.1007/s11102-006-6041-5; Makela HI, 2001, BIOCHEM BIOPH RES CO, V289, P813, DOI 10.1006/bbrc.2001.6058; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Michaeli S, 2006, J MAGN RESON, V181, P135, DOI 10.1016/j.jmr.2006.04.002; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Onyszchuk G, 2008, J NEUROTRAUM, V25, P153, DOI 10.1089/neu.2007.0430; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; RINK A, 1995, AM J PATHOL, V147, P1575; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2002, ACT NEUR S, V81, P209; SEPPONEN RE, 1985, J COMPUT ASSIST TOMO, V9, P1007, DOI 10.1097/00004728-198511000-00002; Shutter L, 2006, J HEAD TRAUMA REHAB, V21, P334, DOI 10.1097/00001199-200607000-00005; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soares HD, 1995, J NEUROSCI, V15, P8223; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2006, RESTOR NEUROL NEUROS, V24, P109; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tkac I, 1999, MAGNET RESON MED, V41, P649, DOI 10.1002/(SICI)1522-2594(199904)41:4<649::AID-MRM2>3.0.CO;2-G; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201	53	55	57	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2009	215	1					29	40		10.1016/j.expneurol.2008.09.009			12	Neurosciences	Neurosciences & Neurology	394QM	WOS:000262462300004	18929562				2021-06-18	
J	Limond, J; Dorris, L; McMillan, TM				Limond, Jenny; Dorris, Liam; McMillan, Thomas M.			Quality of life in children with acquired brain injury: Parent perspectives 1-5 years after injury	BRAIN INJURY			English	Article						Acquired brain injury; Quality of life; child; rehabilitation	HEAD-INJURY; ADOLESCENTS; CHILDHOOD; HEALTH; RELIABILITY; VALIDITY; OUTCOMES; SCALE	Primary objective: To obtain parental ratings of children's quality of life, cognitive, emotional and behavioural functioning, as well as ratings of service provision, following traumatic brain injury (TBI). Research design: A retrospective, cross-sectional study. Methods and procedures: Parents of 47 children with mild or moderate-severe TBI completed standardized questionnaires evaluating quality of life (PedsQL 4.0) and cognitive, emotional and behavioural functioning (Strengths and Difficulties Questionnaire). Data collected was compared with published normative data for these scales. Views regarding parental experiences of care and their ratings of service provision were also obtained. Results: Quality of life was significantly lower in 13-times as many children with TBI than expected from the normative population. Parents reported that more than 43% of children with TBI had cognitive, emotional and behavioural difficulties that impacted on their daily life. Whilst high levels of social deprivation were found, this did not fully explain the significantly raised levels of difficulties. Another factor associated with this poor outcome was the absence of systematic, routine follow-up or intervention. Conclusions: Parents frequently reported poor quality of life and cognitive, emotional and behavioural problems in their children following TBI. These preliminary findings indicate that children, after TBI, are at risk of developing persistent clinical problems and require follow-up beyond the acute period of their recovery.	[Dorris, Liam] Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland; [Limond, Jenny; Dorris, Liam; McMillan, Thomas M.] Univ Glasgow, Fac Med, Glasgow, Lanark, Scotland	Dorris, L (corresponding author), Royal Hosp Sick Children, Fraser Allander Neurosci Unit, Glasgow G3 8SJ, Lanark, Scotland.	liam.dorris@ggc.scot.nhs.uk	Dorris, Liam/AAK-2273-2021	Dorris, Liam/0000-0002-9502-3154	NHS	This study was funded by NHS Greater Glasgow and Clyde. The authors would like to thank Shona Forsyth and Karen Mackenzie for help with administrative aspects of the study.	BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Goodman R, 1999, J CHILD PSYCHOL PSYC, V40, P791, DOI 10.1111/1469-7610.00494; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hysing M, 2007, J CHILD PSYCHOL PSYC, V48, P785, DOI 10.1111/j.1469-7610.2007.01755.x; JENNETT B, 1977, LANCET, V1, P878; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meltzer H., 2000, MENTAL HLTH CHILDREN; Middleton JA, 2001, J CHILD PSYCHOL PSYC, V42, P165, DOI 10.1017/S0021963001006667; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Scottish Executive National Statistics, 2006, SCOTT IND MULT DEPR; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Upton Penney, 2005, Health Qual Life Outcomes, V3, P22, DOI 10.1186/1477-7525-3-22; Varni JW, 2002, CANCER-AM CANCER SOC, V94, P2090, DOI 10.1002/cncr.10428; VARNI JW, 2005, PEDIAT QUALITY LIFE	20	55	55	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	7-8					617	622	PII 912684241	10.1080/02699050902997870			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462QL	WOS:000267370600005	19557564				2021-06-18	
J	Theriault, M; De Beaumont, L; Gosselin, N; Filipinni, M; Lassonde, M				Theriault, Martin; De Beaumont, Louis; Gosselin, Nadia; Filipinni, Melissa; Lassonde, Maryse			Electrophysiological abnormalities in well functioning multiple concussed athletes	BRAIN INJURY			English	Article						Event-related potentials; concussion; P3a; P3b; athletes	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SPORTS CONCUSSION; LONG-TERM; P300; RECOVERY; P3A; EPIDEMIOLOGY	Objective: The present study was aimed at characterizing the short- and long-term effects of multiple concussions using an electrophysiological approach. Method: Participants for this study were recruited from college football teams. They included athletes who never sustained concussions compared to two groups of asymptomatic multiple concussed athletes, one that sustained their last concussion within the year and the other more than 2 years prior to testing. All participants were submitted to an auditory three-tone Oddball paradigm while event-related potentials (ERP) were recorded. Results: Results from ERP recordings reveal significantly reduced P3a and P3b amplitudes in the recent concussed group in the three-tone task compared to control athletes. In contrast, athletes who sustained their concussions more than 2 years prior to testing had equivalent P3a and P3b amplitude to that of controls. Conclusion: These findings suggest that, despite functioning normally in their daily lives, concussed athletes still show subtle neuronal changes in information processing. Thus, the persistence of sub-clinical abnormalities on ERP components despite normal overt functioning may indicate sub-optimal compensation in multiple concussed athletes and leave them vulnerable to subsequent concussions.	[Lassonde, Maryse] Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, Montreal, PQ H3C 3J7, Canada	Lassonde, M (corresponding author), Univ Montreal, Dept Psychol, Ctr Rech Neuropsychol & Cognit, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	maryse.lassonde@umontreal.ca			Canadian Institutes of Health Research (CIHR: ML)Canadian Institutes of Health Research (CIHR); Reseau Provincial de Recherche en Adaptation Readaptation (REPAR: MT); Fonds de la Recherche en Sante du Quebec (FRSQ: MT) and the CIHR (LDB)Fonds de la Recherche en Sante du Quebec	This work was supported by a Canada Research Chair in Developmental Neuropsychology held by ML, research grants by the Canadian Institutes of Health Research (CIHR: ML), scholarships by the Reseau Provincial de Recherche en Adaptation Readaptation (REPAR: MT), the Fonds de la Recherche en Sante du Quebec (FRSQ: MT) and the CIHR (LDB). We also wish to thank GT, MD for his precious contribution to the recruitment process.	American Clinical Neurophysiology Society, 2006, J Clin Neurophysiol, V23, P107; [Anonymous], 1994, J Clin Neurophysiol, V11, P111; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BARTH J, 1989, J COGNITIVE NEUROREH, V26, P451; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Comerchero MD, 1999, CLIN NEUROPHYSIOL, V110, P24, DOI 10.1016/S0168-5597(98)00033-1; Comerchero MD, 1998, COGNITIVE BRAIN RES, V7, P41, DOI 10.1016/S0926-6410(98)00009-3; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Elting JW, 2005, CLIN NEUROPHYSIOL, V116, P2606, DOI 10.1016/j.clinph.2005.07.014; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hecht S, 2005, CLIN J SPORT MED, V15, P281, DOI DOI 10.1097/01.jsm.0000172669.85640.05; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JOHNSON R, 1978, ELECTROEN CLIN NEURO, V44, P424, DOI 10.1016/0013-4694(78)90027-5; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P581; Kopp B, 2006, J COGNITIVE NEUROSCI, V18, P949, DOI 10.1162/jocn.2006.18.6.949; KRAMER AF, 1988, BIOL PSYCHOL, V26, P231, DOI 10.1016/0301-0511(88)90022-1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; LEZAK MD, 1995, NEUROPSYCHYOLOGICAL; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nordby H, 1999, PERCEPT MOTOR SKILL, V88, P819, DOI 10.2466/PMS.88.3.819-830; Polich John, 2004, Phys Med Rehabil Clin N Am, V15, P133, DOI 10.1016/S1047-9651(03)00109-8; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	52	55	57	2	25	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					899	906	PII 915243219	10.1080/02699050903283189			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300006	20100126				2021-06-18	
J	Su, TM; Lee, TH; Chen, WF; Lee, TC; Cheng, CH				Su, Thung-Ming; Lee, Tsung-Han; Chen, Wu-Fu; Lee, Tao-Chen; Cheng, Ching-Hsiao			Contralateral Acute Epidural Hematoma After Decompressive Surgery of Acute Subdural Hematoma: Clinical Features and Outcome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Acute epidural hematoma; Acute subdural hematoma; Decompressive surgery	EXTRADURAL HEMATOMA; CT-SCAN; EVACUATION	Background. Delayed contralateral epidural hematoma (EDH) after decompressive surgery for acute subdural hematoma (SDH) is uncommon. If unrecognized, this delayed hematoma can cause devastating consequences. We present our experience with this group of patients and discuss the diagnosis and management of this dangerous condition. Methods: This study included 12 traumatic patients with acute SDH who developed delayed contralateral EDH after acute SDH evacuation. Clinical and radiographic information was obtained through a retrospective review of the medical records and the radiographs. Results: There were seven males and five females. Nine patients had severe head injury (Glasgow Coma Scale (GCS) score <= 8). Ten patients underwent acute SDH evacuation within 4 hours after the trauma. Intraoperative brain swelling during SDH evacuation was noted in 10 patients. A skull fracture at the site of the EDH on computed tomography (CT) was noted only in 10 patients. However, a skull fracture overlying the EDH was found during EDH evacuation in all patients. Only three patients with less severe head injury (GCS > 8) had good recovery. Other patients with severe bead injury (GCS <= 58) had poor outcome. Conclusions: Severe head injury, a skull fracture contralateral to the original hematoma, intraoperative brain protrusion, and a poor outcome are typical clinical findings in this disorder. In patients with acute SDH and a contralateral skull fracture, immediate postoperative CT scan is indicated to evaluate this rare but potentially lethal complication. According to the findings of the postoperative CT scan, the neurosurgeon can make an appropriate strategy of treatment promptly. Early detection and prompt treatment may improve the poor outcome in this group of patients.	[Su, Thung-Ming; Lee, Tsung-Han; Chen, Wu-Fu; Lee, Tao-Chen; Cheng, Ching-Hsiao] Chang Gung Univ Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Neurosurg, Niao Sung Hsiang, Kaohsiung Hsien, Taiwan	Cheng, CH (corresponding author), Chang Gung Univ Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Neurosurg, 123 Ta Pei Rd, Niao Sung Hsiang, Kaohsiung Hsien, Taiwan.	ma4200@adm.cgmh.org.tw					BOROVICH B, 1985, J NEUROSURG, V63, P30, DOI 10.3171/jns.1985.63.1.0030; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; FEUERMAN T, 1988, NEUROSURGERY, V23, P480, DOI 10.1227/00006123-198810000-00013; JENNETT B, 1975, LANCET, V1, P480; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; Matsuno A, 2003, SURG NEUROL, V60, P23, DOI 10.1016/S0090-3019(03)00023-5; MEGURO K, 1987, NEUROSURGERY, V20, P326, DOI 10.1227/00006123-198702000-00023; Mohindra S, 2005, BRIT J NEUROSURG, V19, P490, DOI 10.1080/02688690500495216; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; PIEPMEIER JM, 1982, J TRAUMA, V22, P455, DOI 10.1097/00005373-198206000-00003; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; THIBODEAU M, 1987, J CAN ASSOC RADIOL, V38, P52; Yague L G, 1991, J Neurosurg Sci, V35, P107	14	55	68	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2008	65	6					1298	1302		10.1097/TA.0b013e31815885d9			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	383WV	WOS:000261706000020	19077617				2021-06-18	
J	Mauritz, W; Steltzer, H; Bauer, P; Dolanski-Aghamanoukjan, L; Metnitz, P				Mauritz, Walter; Steltzer, Heinz; Bauer, Peter; Dolanski-Aghamanoukjan, Lorenz; Metnitz, Philipp			Monitoring of intracranial pressure in patients with severe traumatic brain injury: an Austrian prospective multicenter study	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; intracranial pressure; mortality; Glasgow Coma Scale; Abbreviated Injury Score	INTENSIVE-CARE; HEAD-INJURY; OUTCOMES; EPIDEMIOLOGY; MANAGEMENT; MORTALITY; EFFICACY; SYSTEM; SCORE; AGE	Objective: The goals of this study were to elucidate reasons why patients did or did not receive intracranial pressure (ICP) monitoring and to describe factors influencing hospital mortality after severe traumatic brain injury (TBI). Design: Prospective multicenter cohort study. Patients and participants: 88,274 patients consecutively admitted to 32 medical, surgical and mixed Austrian ICUs between 1998 and 2004. Interventions: None. Measurements and results: 1,856 patients (2.1% of all ICU admissions) exhibited severe TBI (GCS < 9); of these, 1,031 (56%) had ICP monitoring. The "worst" and the "best" cases were both less likely to receive ICP monitoring. Younger patients, female patients, and patients with isolated TBI were more likely to receive ICP monitoring. Compared with large centers ICP was monitored more frequently [odds ratio (OR) 3.09, CI 2.42-3.94] in medium-sized centers. The 20% of patients with the highest likelihood to receive ICP monitoring were monitored in 91% of cases, and had the lowest hospital mortality (31%, OR 0.78, CI 0.37-1.64). Multivariate analysis revealed that severity of illness, TBI severity, isolated TBI, and the number of cases treated per year were associated with hospital outcome. Compared with the large centers, ORs for hospital mortality were 1.85 (CI 1.42-2.40) for patients from medium-sized centers and 1.91 (CI 1.24-2.93) for patients from small centers. Conclusions: ICP monitoring may possibly have some beneficial effects, but this needs further evaluation. Patients with severe TBI should be admitted to experienced centers with high patient volumes since this might improve hospital mortality rates.	[Mauritz, Walter] Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, A-1200 Vienna, Austria; [Steltzer, Heinz] Trauma Hosp Meidling, Dept Anaesthesia & Crit Care Med, A-1120 Vienna, Austria; [Bauer, Peter; Dolanski-Aghamanoukjan, Lorenz] Med Univ Vienna, Dept Med Stat, A-1090 Vienna, Austria; [Metnitz, Philipp] Med Univ Vienna, Dept Anaesthesia & Gen Intens Care Med, A-1090 Vienna, Austria	Mauritz, W (corresponding author), Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, Donaueschingenstr 13, A-1200 Vienna, Austria.	walter.mauritz@auva.nt		Mauritz, Walter/0000-0001-9043-3712			*AM ASS SURG TRAUM, 2003, J TRAUMA S, V24, P235; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; Firsching R, 2001, WORLD J SURG, V25, P1221; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lane PL, 2000, CAN J SURG, V43, P442; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lu J, 2005, ACT NEUR S, V95, P281; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Metnitz PGH, 1999, CRIT CARE MED, V27, P1486, DOI 10.1097/00003246-199908000-00014; Metnitz PGH, 1997, WIEN KLIN WOCHENSCHR, V109, P132; Miranda DR, 1996, CRIT CARE MED, V24, P64, DOI 10.1097/00003246-199601000-00012; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Procaccio F, 2000, J Neurosurg Sci, V44, P1; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Thompson HJ, 2008, CRIT CARE MED, V36, P282, DOI 10.1097/01.CCM.0000297884.86058.8A	29	55	58	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	JUL	2008	34	7					1208	1215		10.1007/s00134-008-1079-7			8	Critical Care Medicine	General & Internal Medicine	318WL	WOS:000257123400007	18365169				2021-06-18	
J	Martin, EM; Lu, WC; Helmick, K; French, L; Warden, DL				Martin, Elisabeth Moy; Lu, Wei C.; Helmick, Katherine; French, Louis; Warden, Deborah L.			Traumatic brain injuries sustained in the Afghanistan and Iraq wars	AMERICAN JOURNAL OF NURSING			English	Article							REHABILITATION; CLIENTS	Overview: When traumatic brain injury (TBI) occurs simultaneously with more obviously life-threatening wounds, it may go unrecognized. Civilians and military personnel working in or near combat zones are at risk for this injury. Blast-related and closed-head injuries, rather than penetrating injuries, constitute the majority of TBIs in this population. The authors describe the experiences of the Defense and Veterans Brain Injury Center team at Walter Reed Army Medical Center in Washington, DC, and present a composite case to illustrate the nurse's role in the assessment and care of the TBI patient.	[Martin, Elisabeth Moy; Lu, Wei C.; Helmick, Katherine; French, Louis; Warden, Deborah L.] Walter Reed Army Med Ctr, DVBIC, Washington, DC 20307 USA	Martin, EM (corresponding author), Walter Reed Army Med Ctr, DVBIC, Washington, DC 20307 USA.	lisamoymartin@yaboo.com	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; GOLDBERG MS, 2007, DEPUTY ASSISTANT DIR; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keane T., 1994, PTSD CHECKLIST CIVIL; Martin EM, 2006, REHABIL NURS, V31, P54, DOI 10.1002/j.2048-7940.2006.tb00125.x; Martin EM, 2003, AM J NURS, V103, P75, DOI 10.1097/00000446-200310000-00036; MCCREA M, 2000, STANDARDIED ASSESSME; *NAT CTR INJ PREV, 2007, TRAUMATIC BRAIN INJU; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; SNYDER V, 2007, STATEMENT SUBCOMMITT; SUNSHINE RA, 2007, ASSISTANT DIRECTOR B; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; 2007, INT HERALD TRIB 1203	23	55	58	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0002-936X			AM J NURS	Am. J. Nurs.	APR	2008	108	4					40	47		10.1097/01.NAJ.0000315260.92070.3f			8	Nursing	Nursing	283SV	WOS:000254657700016	18367927				2021-06-18	
J	Schneider, M; Schneider, HJ; Yassouridis, A; Saller, B; von Rosen, F; Stalla, GK				Schneider, M.; Schneider, H. J.; Yassouridis, A.; Saller, B.; von Rosen, F.; Stalla, G. K.			Predictors of anterior pituitary insufficiency after traumatic brain injury	CLINICAL ENDOCRINOLOGY			English	Article							DIFFUSE AXONAL INJURY; SUBARACHNOID HEMORRHAGE; HEAD-INJURY; HYPOPITUITARISM; DYSFUNCTION; MULTICENTER; PREVALENCE; SECONDARY; LESIONS; MEN	Background Several studies have reported a high prevalence of hypopituitarism after traumatic brain injury (TBI). Risk stratification is a prerequisite for cost-effective hormonal screening of these patients. However, it is still unclear which risk factors predispose patients to develop anterior hypopituitarism after TBI. Objective To assess clinical and radiological risk factors for post-traumatic hypopituitarism. Patients and methods Seventy-eight consecutive patients (52 men, 26 women; mean age 36.0 years, range 18-65 years) with mild, moderate or severe TBI were studied. Endocrine and clinical parameters were assessed 3 and 12 months after TBI. Results We found diffuse axonal injury, basal skull fracture and older age to be major risk factors of post-traumatic hypopituitarism. Conclusions We have defined specific risk factors for the development of post-traumatic hypopituitarism that are consistent with pathophysiological considerations. These findings might help to identify at-risk patients.	[Schneider, H. J.; Yassouridis, A.; Stalla, G. K.] Max Planck Inst Psychiat, D-80804 Munich, Germany; [Schneider, M.; von Rosen, F.] Neurol Clin Bad Aibling, Bad Aibling, Germany	Schneider, HJ (corresponding author), Max Planck Inst Psychiat Internal Med Endocrinol, Kraepelinstr 10, D-80804 Munich, Germany.	schneider@mpipsykl.mpg.de					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Ceballos R, 1966, Ala J Med Sci, V3, P185; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; Feldman HA, 2002, J CLIN ENDOCR METAB, V87, P589, DOI 10.1210/jc.87.2.589; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; GREENWOOD R, 2002, J NEUROLOGICAL NEURO, V73, P18; Hassan A, 2002, CLIN EXP OPHTHALMOL, V30, P273, DOI 10.1046/j.1442-9071.2002.00534.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; LOSA M, 1983, KLIN WOCHENSCHR, V61, P1249, DOI 10.1007/BF01540473; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Schneider HJ, 2006, ACTA NEUROCHIR, V148, P449, DOI 10.1007/s00701-005-0724-y; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Song JK, 1999, J NEUROSURG, V90, P1141, DOI 10.3171/jns.1999.90.6.1141; Struffert T, 2003, RADIOLOGE, V43, P1001, DOI 10.1007/s00117-003-0962-z; TEASDALE G, 1974, LANCET, V2, P81; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604	32	55	56	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664			CLIN ENDOCRINOL	Clin. Endocrinol.	FEB	2008	68	2					206	212		10.1111/j.1365-2265.2007.03020.x			7	Endocrinology & Metabolism	Endocrinology & Metabolism	250SD	WOS:000252319800007	17803694				2021-06-18	
J	Davis, DP; Hwang, JQ; Dunford, JV				Davis, Daniel P.; Hwang, James Q.; Dunford, James V.			Rate of decline in oxygen saturation at various pulse oximetry values with prehospital rapid sequence intubation	PREHOSPITAL EMERGENCY CARE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-EMS-Physicians	JAN, 2007	Naples, FL	Natl Assoc EMS Phys		rapid sequence intubation; desaturation; hypoxemia; pulse oximetry	CRICOID PRESSURE; HEAD-INJURY; HYPOTENSION; ASPIRATION; INDUCTION; HYPOXIA; PREOXYGENATION; REGURGITATION; DESATURATION; VENTILATION	Background. A high incidence of desaturations has been observed during prehospital rapid sequence intubation (RSI). The rate of decline in oxygen saturation (SpO2) at various pulse oximetry values has not been defined with emergency RSI. Objective. To define the rate of SpO2 decline at various pulse oximetry values and identify a threshold below which active BVM should be performed during prehospital RSI. Methods. Traumatic brain injury (TBI) patients undergoing RSI by prehospital providers were included in this analysis. The time period from the highest to the lowest preintubation SpO2 value was selected for review. The mean rate of SpO2 decline was calculated for each SpO2 value and then used to define a theoretical SpO2 desaturation curve. The rate of desaturation to hypoxemia (SpO2 90%) was defined for intubation attempts initiated at each SpO2 value. Results. A total of 684 SpO2 values from 87 patients were included. Lower SpO2 values were associated with a faster rate of SpO2 decline, with an inflection point occurring at 93%. The rate of desaturation to hypoxemia with intubation attempts initiated with SpO2 <= 93% was much higher than with SpO2 above 93% (100% vs. 6%, p < 0.01). In patients undergoing multiple attempts, SpO2 values with BVM between attempts was consistently higher than the preintubation SpO2 value. Conclusions. The rate of SpO2 decline increases as SpO2 decreases, with an inflection point occurring around 93%. Intubation attempts below this value are almost always associated with subsequent desaturation, suggesting that BVM should be used prior to laryngoscopy in these patients.	[Davis, Daniel P.; Hwang, James Q.; Dunford, James V.] Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA	Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	davismd@cox.net					Apfel CC, 2005, CURR OPIN ANESTHESIO, V18, P157, DOI 10.1097/01.aco.0000162834.33474.e0; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; BAILLARD C, 2006, AM J RESP CRIT CARE, P1; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Benumof JL, 1997, ANESTHESIOLOGY, V87, P979, DOI 10.1097/00000542-199710000-00034; Benumof JL, 1999, ANESTHESIOLOGY, V91, P603, DOI 10.1097/00000542-199909000-00006; Brimacombe JR, 1997, CAN J ANAESTH, V44, P414, DOI 10.1007/BF03014464; Butler J, 2005, EMERG MED J, V22, P815, DOI 10.1136/emj.2005.030205; Chassard D, 1996, CAN J ANAESTH, V43, P414, DOI 10.1007/BF03011724; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DAVIS DP, 2004, UNPUB J TRAUMA; DRUMMOND GB, 1984, BRIT J ANAESTH, V56, P987, DOI 10.1093/bja/56.9.987; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Edmark L, 2003, ANESTHESIOLOGY, V98, P28, DOI 10.1097/00000542-200301000-00008; Engelhardt T, 1999, BRIT J ANAESTH, V83, P453; Falcone R E, 1996, Air Med J, V15, P163, DOI 10.1016/S1067-991X(96)90024-3; FANNING GL, 1970, ANESTHESIOLOGY, V32, P553, DOI 10.1097/00000542-197006000-00019; Farmery AD, 1996, BRIT J ANAESTH, V76, P284; Garrard A, 2004, ANAESTHESIA, V59, P435, DOI 10.1111/j.1365-2044.2004.03682.x; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Ho-Tai LM, 1998, CAN J ANAESTH, V45, P206, DOI 10.1007/BF03012903; JENSE HG, 1991, ANESTH ANALG, V72, P89; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Levitan RM, 2006, ANN EMERG MED, V47, P548, DOI 10.1016/j.annemergmed.2006.01.013; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RALPH SJ, 1991, ANAESTHESIA, V46, P40, DOI 10.1111/j.1365-2044.1991.tb09314.x; ROBERTS RB, 1974, ANESTH ANALG, V53, P859, DOI 10.1213/00000539-197453060-00010; Safdar Nasia, 2005, Respir Care, V50, P725; Salem MR, 2000, ANESTHESIOLOGY, V92, P1845, DOI 10.1097/00000542-200006000-00054; SELLICK BA, 1961, LANCET, V2, P404; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Smith KJ, 2003, ANESTHESIOLOGY, V99, P60, DOI 10.1097/00000542-200307000-00013; Smith KJ, 2002, CAN J ANAESTH, V49, P503, DOI 10.1007/BF03017931; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; SYVERUD SA, 1988, ANN EMERG MED, V17, P236, DOI 10.1016/S0196-0644(88)80114-8; Tournadre JP, 1997, ANESTHESIOLOGY, V86, P7, DOI 10.1097/00000542-199701000-00003; VADEBONCOEUR TF, 2004, J EMERG MED; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wenzel V, 2001, RESUSCITATION, V49, P123, DOI 10.1016/S0300-9572(00)00349-X	45	55	55	1	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care		2008	12	1					46	51		10.1080/10903120701710470			6	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	251CB	WOS:000252347100008	18189177				2021-06-18	
J	Pieracci, FM; Eachempati, SR; Shou, J; Hydo, LJ; Barie, PS				Pieracci, Fredric M.; Eachempati, Soumitra R.; Shou, Jian; Hydo, Lynn J.; Barie, Philip S.			Use of long-term anticoagulation is associated with traumatic intracranial hemorrhage and subsequent mortality in elderly patients hospitalized after falls: Analysis of the New York state administrative database	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-20, 2007	Ft Myers, FL	Eastern Assoc Surg Trauma		anticoagulation; intracranial hemorrhage; traumatic brain injury; geriatrics; falls	PREINJURY WARFARIN USE; NONVALVULAR ATRIAL-FIBRILLATION; RISK-FACTORS; STROKE PREVENTION; INJURY; PREVALENCE; REVERSAL; IMPACT	Background: Previous studies addressing the relationship between anticoagulation and risk of traumatic intracranial hemorrhage (ICH) have provided conflicting results, and have examined infrequently elderly patients after falls. We used a statewide hospital discharge database to test the hypothesis that long-term anticoagulation (LTA) increases the likelihood of traumatic ICH and subsequent mortality in this patient population. Methods: Patients aged 65 years or older and hospitalized as the result of a fall were extracted from the New York State Statewide Planning and Cooperative Systems Database for the year 2004. LTA, ICH, and additional injuries including skull fracture, vertebral fracture, rib fracture, lower extremity fracture, thoracic visceral injury, and abdominal visceral injury were defined using corresponding International Classification for Disease, Ninth Edition coding. Covariates included age, gender, and comorbidity. Additional outcomes included length of stay and mortality. Multivariable logistic regression was used to identify independent predictors of traumatic ICH and subsequent mortality. Results: A total of 47,717 patients met the inclusion criteria. Falls were associated with a traumatic ICH in 2,517 patients (5.1%), and the mortality rate of patients with a fall-related, traumatic ICH was 15.5% (n = 394). A total of 1,511 (3.2%) patients hospitalized after a fall used LTA. Based on univariate analysis, ICH was the only injury that occurred more commonly in patients who used LTA, when compared with those who did not (8.0% vs. 5.3%, respectively, p < 0.0001). Furthermore, although overall mortality did not differ by use of LTA, mortality after ICH was significantly higher in patients who used LTA when compared with those who did not (21.9% vs. 15.2%, respectively, p = 0.04). Controlling for age, gender, and comorbidity, patients on LTA were 50% more likely to sustain a traumatic ICH after a fall (odds ratio = 1.50; 95% confidence interval, 1.23-1.81; p < 0.0001). Furthermore, among patients who sustained an ICH, mortality was 1.57-fold greater in patients on LTA (odds ratio = 1.57; 95% confidence interval, 1.02-2.45; p = 0.04). Conclusions: These data indicate that use of LTA is independently associated with traumatic ICH and subsequent mortality in elderly patients hospitalized after a fall.	Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA	Pieracci, FM (corresponding author), Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA.	frp9005@med.cornell.edu	Barie, Philip/AAN-8811-2020				Arboix A, 2000, DIABETES CARE, V23, P1527, DOI 10.2337/diacare.23.10.1527; Arnason T, 2006, THROMB RES, V118, P253, DOI 10.1016/j.thromres.2005.06.015; Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Coimbra R, 2005, J TRAUMA, V59, P374, DOI 10.1097/01.ta.000174728.46883.a4; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2006, ARCH INTERN MED, V166, P241, DOI 10.1001/archinte.166.2.241; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Gage BF, 1992, J NEUROL NEUROSUR PS, V55, P653; Garvin R, 2006, J FAM PRACTICE, V55, P157; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Go AS, 1999, ANN INTERN MED, V131, P927, DOI 10.7326/0003-4819-131-12-199912210-00004; Hemphill JC, 2001, STROKE, V32, P891, DOI 10.1161/01.STR.32.4.891; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jensen J, 2002, ANN INTERN MED, V136, P733, DOI 10.7326/0003-4819-136-10-200205210-00008; Johnston JA, 2003, ARCH INTERN MED, V163, P1705, DOI 10.1001/archinte.163.14.1705; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch MJ, 2004, J TRAUMA, V57, P1230, DOI 10.1097/01.TA.0000150839.69648.17; Lankshmirarayan K, 2006, STROKE, V37, P1969; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Man-Son-Hing M, 1999, ARCH INTERN MED, V159, P677, DOI 10.1001/archinte.159.7.677; McCormick D, 2001, ARCH INTERN MED, V161, P2458, DOI 10.1001/archinte.161.20.2458; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Monette J, 1997, J AM GERIATR SOC, V45, P1060, DOI 10.1111/j.1532-5415.1997.tb05967.x; *NAT TRAUM DAT, 2005, AM COLL SURG; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Punthakee X, 2002, THROMB RES, V108, P31, DOI 10.1016/S0049-3848(02)00398-5; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; SINGER D, 2004, CHEST, V16, pS4239; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1990, GERIATRIC MED, P528; van Walraven C, 2002, JAMA-J AM MED ASSOC, V288, P2441, DOI 10.1001/jama.288.19.2441; Weisbord SD, 2001, J GEN INTERN MED, V16, P743, DOI 10.1046/j.1525-1497.2001.10432.x; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Wong KS, 1999, STROKE, V30, P2326, DOI 10.1161/01.STR.30.11.2326	41	55	56	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2007	63	3					519	524		10.1097/TA.0b013e31812e519b			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	211DA	WOS:000249503300007	18073595				2021-06-18	
J	Obenaus, A; Robbins, M; Blanco, G; Galloway, NR; Snissarenko, E; Gillard, E; Lee, S; Curras-Collazo, M				Obenaus, Andre; Robbins, Michael; Blanco, Glen; Galloway, Nicholas R.; Snissarenko, Eugene; Gillard, Elizabeth; Lee, Stefan; Curras-Collazo, Margarita			Multi-modal magnetic resonance imaging alterations in two rat models of mild neurotrauma	JOURNAL OF NEUROTRAUMA			English	Article						immunohistochemistry; apparent diffusion coefficient; T2 weighted imaging; fluid percussion; controlled cortical impact; traumatic brain injury; microglia; astrocytes	TRAUMATIC BRAIN-INJURY; LATERAL FLUID PERCUSSION; CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; TIME-COURSE; DIFFUSION; EDEMA; HISTOLOGY; HIPPOCAMPUS; PERFUSION	Magnetic resonance imaging (MRI) is increasingly used in the assessment of the severity and progression of neurotrauma. We evaluated temporal and regional changes after mild fluid percussion (FPI) and controlled cortical impact (CCI) injury using T2-weighted-imaging (T2WI) and diffusion-weighted imaging (DWI) MRI over 7 days. Region of interest analysis of brain areas distant to the injury site (such as the hippocampus, retrosplenial and piriform cortices, and the thalamus) was undertaken. In the hippocampus of CCI animals, we found a slow increase (51%) in apparent diffusion coefficients (ADC) over 72 h, which returned to control values. The hippocampal T2 values in the CCI animals were elevated by 18% over the 7-day time course compared to control, indicative of edema formation. Histological analysis supported the lack of overt cellular loss in most brain regions after mild CCI injury. FPI animals showed a generalized decrease in hippocampal ADC values over the first 72 h, which then returned to sham levels, with decreased T2 values over the same period, which remained depressed at 7 days. Histological assessment of FPI animals revealed numerous shrunken cells in the hippocampus and thalamus, but other regions showed little damage. Increased immunohistochemical staining for microglia and astroglia at 7 days post-injury was greater in FPI animals within the affected brain regions. In summary, traumatic brain injury is less severe in mild CCI than FPI, based on the temporal events assessed with MRI.	Loma Linda Univ, Dept Radiat Med, Radiobiol Program, Loma Linda, CA 92354 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA USA; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA USA	Obenaus, A (corresponding author), Loma Linda Univ, Dept Radiat Med, Radiobiol Program, 11175 Campus St,CSP A1010, Loma Linda, CA 92354 USA.	aobenaus@dominion.llumc.edu					Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Faden AI, 2005, NEUROPHARMACOLOGY, V49, P410, DOI 10.1016/j.neuropharm.2005.04.001; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Kadri Munaf, 2003, J Perinatol, V23, P181, DOI 10.1038/sj.jp.7210913; Kato H, 1986, No To Shinkei, V38, P295; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Pirko Istvan, 2005, NeuroRx, V2, P250, DOI 10.1602/neurorx.2.2.250; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stroop R, 1998, ACT NEUR S, V71, P303; Thomas DL, 2000, PHYS MED BIOL, V45, pR97, DOI 10.1088/0031-9155/45/8/201; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Pul C, 2005, AM J NEURORADIOL, V26, P469; Van Putten HP, 2005, J NEUROTRAUM, V22, P857; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Wall CJ, 2000, AM J NEURORADIOL, V21, P1841; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	36	55	55	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1147	1160		10.1089/neu.2006.0211			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200006	17610354				2021-06-18	
J	Hillman, J; Aneman, O; Persson, M; Andersson, C; Dabrosin, C; Mellergard, P				Hillman, Jan; Aneman, Oscar; Persson, Mikael; Andersson, Chris; Dabrosin, Charlotte; Mellergard, Pekka			Variations in the response of interleukins in neurosurgical intensive care patients monitored using intracerebral microdialysis	JOURNAL OF NEUROSURGERY			English	Article						intensive care; microdialysis; interleukin; vascular endothelial growth factor; cathepsin-D	TRAUMATIC BRAIN-INJURY; MOLECULAR DIAGNOSTICS; INFLAMMATION; CONTUSION	Object The aim of this study was to make a preliminary evaluation of whether microdialysis monitoring of cytokines and other proteins in severely diseased neurosurgical patients has the potential of adding significant information to optimize care, thus broadening the understanding of the function of these molecules in brain injury. Methods. Paired intracerebral microdialysis catheters with high-cutoff membranes were inserted in 14 comatose patients who had been treated in a neurosurgical intensive care unit following subarachnoidal hemorrhage or traumatic brain injury. Samples were collected every 6 hours (for up to 7 days) and were analyzed at bedside for routine metabolites and later in the laboratory for interleukin (IL)-1 and IL-6; in two patients, vascular endothelial growth factor and cathepsin-D were also checked. Aggregated microprobe data gave rough estimations of profound focal cytokine responses related to morphological tissue injury and to anaerobic metabolism that were not evident from the concomitantly collected cerebrospinal fluid data. Data regarding tissue with no macroscopic evidence of injury demonstrated that IL release not only is elicited in severely compromised tissue but also may be a general phenomenon in brains subjected to stress. Macroscopic tissue injury was strongly linked to IL-6 but not IL-1b activation. Furthermore, IL release seems to be stimulated by local ischemia. The basal tissue concentration level of IL-1b was estimated in the range of 10 to 150 pg/ml; for IL-6, the corresponding figure was 1000 to 20,000 pg/ml. Conclusions. Data in the present study indicate that catheters with high-cutoff membranes have the potential of expanding microdialysis to the study of protein chemistry as a routine bedside method in neurointensive care.	Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden; Univ Hosp, Dept Dermatol, Linkoping, Sweden; Univ Hosp, Dept Gynecol, Linkoping, Sweden	Hillman, J (corresponding author), Univ Hosp, Dept Neurosurg, S-58185 Linkoping, Sweden.	pekka.mellergard@lio.se					Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; BENVENISTE H, 1990, PROG NEUROBIOL, V35, P195, DOI 10.1016/0301-0082(90)90027-E; Ferrari M, 2003, CLIN CHEM LAB MED, V41, P462, DOI 10.1515/CCLM.2003.069; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hillman J, 2006, ACTA NEUROCHIR, V148, P319, DOI 10.1007/s00701-005-0670-8; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; McGlennen RC, 2001, CLIN CHEM, V47, P393; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Perry VH, 2004, BRAIN BEHAV IMMUN, V18, P407, DOI 10.1016/j.bbi.2004.01.004; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sjogren S, 2002, BRIT J DERMATOL, V146, P375, DOI 10.1046/j.1365-2133.2002.04621.x; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039	19	55	55	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2007	106	5					820	825		10.3171/jns.2007.106.5.820			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	161WQ	WOS:000246047800003	17542525				2021-06-18	
J	Wood, RL; Williams, C				Wood, Rodger Ll.; Williams, Claire			Neuropsychological correlates of organic alexithymia	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; emotional perception; executive function; affective disorder; cognitive function; TAS 20	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; FACTORIAL STRUCTURE; FACIAL EXPRESSIONS; COHERENCE ANALYSIS; SOCIAL-PERCEPTION; SPLIT BRAIN; SCALE; EMOTION; RECOGNITION	Deficits in emotional recognition and perception following traumatic brain injury (TBI) have been associated with alexithymia (Henry et al., 2006; Williams et al., 2001). This study examined the prevalence of alexithymia in a TBI population, and its relationship to injury severity, neuropsychological ability and affective disorder. A total of 121 patients completed the Toronto Alexithymia Scale-20 (TAS-20), a measure that addresses 3 distinct characteristics of the alexithymia concept; difficulty identifying feelings, difficulty describing feelings, and externally oriented thinking. Patients also completed a neuropsychological assessment and measures of depression and anxiety. Results confirm a high prevalence of alexithymia after TBI, relative to the general population and an orthopedic control group. There was no relationship between injury severity and the presence of alexithymia. A negative relationship was found between alexithymia and verbal and sequencing abilities, but there was no relationship with executive dysfunction or any other cognitive domain. Moderate correlations were obtained between alexithymia and affective disorder; regression analyses indicated that alexithymia, depression, and anxiety should be considered distinct, but overlapping constructs. The results of this study suggest that increased neuropsychological attention should be directed towards emotional change after head injury and its relationship with cognition and psychosocial outcome.	Univ Coll Swansea, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Swansea SA2 8PP, W Glam, Wales	Wood, RL (corresponding author), Univ Coll Swansea, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X			Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 1996, J NEUROSCI, V16, P7678; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Borod J. C, 2000, NEUROPSYCHOLOGY EMOT; Brooks D. N, 1990, REHABILITATION ADULT, P163; Burgess PW, 2004, CLIN NEUROPSYCHOLOGY; HENDRYX MS, 1991, J PERS ASSESS, V56, P227, DOI 10.1207/s15327752jpa5602_4; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; HOPPE KD, 1977, PSYCHOTHER PSYCHOSOM, V28, P148, DOI 10.1159/000287057; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Houtveen JH, 1997, J PSYCHOPHYSIOL, V11, P147; Jessimer M, 1997, BRAIN COGNITION, V34, P246, DOI 10.1006/brcg.1997.0900; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KANDEL ER, 1991, PRINCIPLES NEURAL SC; Kooiman CG, 2002, J PSYCHOSOM RES, V53, P1083, DOI 10.1016/S0022-3999(02)00348-3; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; LAMBERTY GJ, 1995, J NEUROPSYCH CLIN N, V7, P320; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Loas G, 2001, J PSYCHOSOM RES, V50, P255, DOI 10.1016/S0022-3999(01)00197-0; Mandal MK, 1999, J NERV MENT DIS, V187, P603, DOI 10.1097/00005053-199910000-00003; Marchesi C, 2000, J PSYCHOSOM RES, V49, P43, DOI 10.1016/S0022-3999(00)00084-2; Mayes L C, 1992, Psychoanal Study Child, V47, P23; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; McDonald S, 2004, NEUROPSYCHOL REHABIL, V14, P285, DOI 10.1080/09602010343000237; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Muller J, 2003, J PSYCHOSOM RES, V55, P561, DOI 10.1016/S0022-3999(03)00033-3; Nelson HE, 1982, NATL ADULT READING T; PARKER JDA, 1991, COMPR PSYCHIAT, V32, P387, DOI 10.1016/0010-440X(91)90015-5; PARKER RM, 1992, 20 ITEM TORONTO ALEX; PASINI A, 1992, COMPR PSYCHIAT, V33, P42, DOI 10.1016/0010-440X(92)90078-5; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; SCHLOSSER D, 1989, J CLIN EXP NEUROPSYC, V11, P785, DOI 10.1080/01688638908400935; Shallice, 1997, HAYLING BRIXTON TEST; Smith SD, 2004, BRAIN COGNITION, V55, P452, DOI 10.1016/j.bandc.2004.02.064; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Taylor G. J., 1997, DISORDERS AFFECT REG; TAYLOR GJ, 1985, PSYCHOTHER PSYCHOSOM, V44, P191, DOI 10.1159/000287912; TENHOUTEN WD, 1987, PSYCHOTHER PSYCHOSOM, V47, P1; TENHOUTEN WD, 1985, PSYCHOTHER PSYCHOSOM, V44, P89, DOI 10.1159/000287898; TULSKY D, 1997, WAIS 2 WMS 3 TECHNIC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; Wilson BA, 1996, BEHAV ASSESSMENT DYS; WOOD RL, IN PRESS J NEUROPSYC; WOOD RL, 2006, BRAIN INJURY, V20, P1; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	54	55	57	1	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2007	13	3					471	479		10.1017/S1355617707070518			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	162WZ	WOS:000246121500012	17445296				2021-06-18	
J	Choi, YS; Lin, SL; Lee, B; Kurup, P; Cho, HY; Naegele, JR; Lombroso, PJ; Obrietan, K				Choi, Yun-Sik; Lin, Stanley L.; Lee, Boyoung; Kurup, Pradeep; Cho, Hee-Yeon; Naegele, Janice R.; Lombroso, Paul J.; Obrietan, Karl			Status epilepticus-induced somatostatinergic hilar interneuron degeneration is regulated by striatal enriched protein tyrosine phosphatase	JOURNAL OF NEUROSCIENCE			English	Article						STEP; ERK/MAPK; cell death; apoptosis; hippocampus; seizure; somatostatin	TEMPORAL-LOBE EPILEPSY; DENTATE GRANULE CELLS; TRAUMATIC BRAIN-INJURY; ADULT-RAT HIPPOCAMPUS; MOLECULAR CHARACTERIZATION; NEUROTROPHIC FACTOR; PILOCARPINE MODEL; INDUCED SEIZURES; KINASE PATHWAYS; SELECTIVE LOSS	Excitotoxic cell death is one of the precipitating events in the development of temporal lobe epilepsy. Of particular prominence is the loss of GABAergic hilar neurons. Although the molecular mechanisms responsible for the selective vulnerability of these cells are not well understood, activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway has been implicated in neuroprotective responses to excitotoxicity in other neuronal populations. Here, we report that high levels of the striatal-enriched protein tyrosine phosphatase (STEP), a key regulator of ERK/MAPK signaling, are found in vulnerable somatostatin-immunoreactive hilar interneurons. Under both control conditions and after pilocarpine-induced status epilepticus (SE), ERK/MAPK activation was repressed in STEP-immunoreactive hilar neurons. This contrasts with robust SE-induced ERK/MAPK activation in the granule cell layer of the dentate gyrus, a cell region that does not express STEP. During pilocarpine-induced SE, in vivo disruption of STEP activity allowed activation of the MAPK pathway, leading to immediate-early gene expression and significant rescue from cell death. Thus, STEP increases the sensitivity of neurons to SE-induced excitotoxicity by specifically blocking a latent neuroprotective response initiated by the MAPK pathway. These findings identify a key set of signaling events that render somatostat-inergic hilar interneurons vulnerable to SE-induced cell death.	Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Wesleyan Univ, Dept Biol, Middletown, CT 06459 USA; Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06520 USA	Obrietan, K (corresponding author), Ohio State Univ, Dept Neurosci, Graves Hall,Room 4118,333 W 10th Ave, Columbus, OH 43210 USA.	obrietan.1@osu.edu	Kurup, Pradeep/F-1291-2010	Naegele, Janice/0000-0001-5151-0543	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH01527, K02 MH001527-08, MH62335, R01 MH052711, MH52711, K02 MH001527, R01 MH052711-13, R01 MH062335] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS47176, R01 NS042826, 5P30NS045758, R01 NS042826-05, R01 NS047176, P30 NS045758, NS42826] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K02MH001527, R01MH062335, R01MH052711, R29MH052711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758, R01NS042826, R01NS047176] Funding Source: NIH RePORTER		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; Acsady L, 1998, J NEUROSCI, V18, P3386; Borges K, 2003, EXP NEUROL, V182, P21, DOI 10.1016/S0014-4886(03)00086-4; BOULANGER LM, 1995, J NEUROSCI, V15, P1532; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, EPILEPSY RES, V48, P43, DOI 10.1016/S0920-1211(01)00318-7; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; BUCKMASTER PS, 1995, EUR J NEUROSCI, V7, P1393, DOI 10.1111/j.1460-9568.1995.tb01131.x; Butcher SP, 1997, J NEUROSCI, V17, P6939; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COFFER P, 1994, ONCOGENE, V9, P911; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; El Bahh B, 1999, EPILEPSIA, V40, P1393; ESCLAPEZ M, 1995, NEUROSCIENCE, V64, P339, DOI 10.1016/0306-4522(94)00406-U; Ford Sr, 1998, METH MOL B, V102, P3; Furuichi Y, 2003, BRAIN RES, V965, P137, DOI 10.1016/S0006-8993(02)04151-3; Goodman LJ, 1996, MOL CELL NEUROSCI, V7, P222, DOI 10.1006/mcne.1996.0017; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Haas KZ, 1996, J NEUROSCI, V16, P4250; HAGLUND L, 1984, J COMP NEUROL, V229, P171, DOI 10.1002/cne.902290204; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hetman M, 2000, ACTA NEUROBIOL EXP, V60, P531; Houser CR, 1996, EPILEPSY RES, V26, P207, DOI 10.1016/S0920-1211(96)00054-X; Howard EM, 1998, BRAIN RES, V798, P109, DOI 10.1016/S0006-8993(98)00403-X; Inoue D, 2004, J BIOL CHEM, V279, P49795, DOI 10.1074/jbc.M404096200; Jeon SH, 2000, EXP MOL MED, V32, P227, DOI 10.1038/emm.2000.37; Jiang W, 2005, J NEUROSCI RES, V81, P581, DOI 10.1002/jnr.20566; Kobayashi M, 2003, J NEUROSCI, V23, P2440; KOHLER C, 1985, NEUROSCIENCE, V16, P85, DOI 10.1016/0306-4522(85)90049-1; Kondratyev A, 2001, NEUROSCI LETT, V310, P13, DOI 10.1016/S0304-3940(01)02055-9; Lee B, 2005, J NEUROSCI, V25, P1137, DOI 10.1523/JNEUROSCI.4288-04.2005; Lein ES, 2004, J NEUROSCI, V24, P3879, DOI 10.1523/JNEUROSCI.4710-03.2004; LERANTH C, 1990, J COMP NEUROL, V295, P111, DOI 10.1002/cne.902950110; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P229, DOI 10.1038/jcbfm.1993.28; McDonald DR, 1998, J NEUROSCI, V18, P4451; Moriwaki A, 1998, NEUROSCIENCE, V86, P855, DOI 10.1016/S0306-4522(98)00071-2; Noto T, 2004, MOL BRAIN RES, V128, P30, DOI 10.1016/j.molbrainres.2004.06.003; OBENAUS A, 1993, J NEUROSCI, V13, P4470; Ochiishi T, 1999, NEUROSCIENCE, V93, P955, DOI 10.1016/S0306-4522(99)00179-7; Paul S, 2003, NAT NEUROSCI, V6, P34, DOI 10.1038/nn989; PAUL S, 2007, IN PRESS BIOL PSYCHI; Pelkey KA, 2002, NEURON, V34, P127, DOI 10.1016/S0896-6273(02)00633-5; Prendergast MA, 2002, BRAIN RES, V954, P300, DOI 10.1016/S0006-8993(02)03360-7; QUIRK GJ, 1992, J NEUROSCI, V12, P1945; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ribak C.E., 2005, PROG BRAIN RES, V136, P319; ROBBINS RJ, 1991, ANN NEUROL, V29, P325, DOI 10.1002/ana.410290316; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Scharfman HE, 2000, ANN NY ACAD SCI, V911, P305; Schwartzkroin PA, 1997, EPILEPSIA, V38, P853, DOI 10.1111/j.1528-1157.1997.tb01250.x; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TUCKER MS, 1993, BRAIN RES, V631, P65, DOI 10.1016/0006-8993(93)91187-W; TUFF LP, 1983, BRAIN RES, V277, P79, DOI 10.1016/0006-8993(83)90909-5; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Vogt KE, 2001, J NEUROSCI, V21, P75, DOI 10.1523/JNEUROSCI.21-01-00075.2001; Williamson A, 1999, ANN NEUROL, V45, P92, DOI 10.1002/1531-8249(199901)45:1<92::AID-ART15>3.0.CO;2-N; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x	71	55	58	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 14	2007	27	11					2999	3009		10.1523/JNEUROSCI.4913-06.2007			11	Neurosciences	Neurosciences & Neurology	148VB	WOS:000245103600030	17360923	Green Accepted, Green Published, Bronze			2021-06-18	
J	Dixon, G; Thornton, EW; Young, CA				Dixon, Guy; Thornton, Everard W.; Young, Carolyn A.			Perceptions of self-efficacy and rehabilitation among neurologically disabled adults	CLINICAL REHABILITATION			English	Article; Proceedings Paper	15th Meeting of the European-Neurological-Society	JUN 18-22, 2005	Vienna, AUSTRIA	European Neurol Soc			QUALITATIVE-ANALYSIS; MULTIPLE-SCLEROSIS; PATIENT MOTIVATION; FOLLOW-UP; VALIDATION; PEOPLE; STROKE; PARTICIPATION; SCALE; LIFE	Objective: To explore constructs relevant to self-efficacy in neurological rehabilitation. Design: Qualitative methods using semi-structured interviews. Setting: Specialist neurological rehabilitation unit, Liverpool, UK. Subjects: Twenty-four patients (12 male) with experience of inpatient rehabilitation, aged 17-59 (mean 38.1) years at onset, with diagnoses of stroke (n = 8), traumatic brain injury (n = 6) or other monophasic neurological impairment (n = 10). Results: Eleven themes emerged from the data that reflect self-efficacy beliefs: self-reliance and independence were deemed important and many patients recognized the importance of determination, making time to take an active role and working in partnership with the multidisciplinary team. Patients had complex information needs but were able to use goal setting and the vicarious experiences of other inpatients to map out the stages of their own recovery. It was important for patients to be able to recognize for themselves that they were making progress and they valued external reassurance on this from other patients, staff and visitors. A number of difficulties were identified that interfered with their developing self-efficacy in rehabilitation, such as structuring their time. Two different models for rehabilitation emerged from the data, 'recovery' and 'adaptation'. Conclusions: Patients consistently identified 11 factors falling in the supraordinate themes of self, others and process, and these influenced their self-efficacy to participate in neurological rehabilitation. Patients consider rehabilitation in terms of either an 'adaptation' or 'recovery' model.	Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England; Univ Liverpool, Dept Psychol, Liverpool L69 3BX, Merseyside, England; Univ Liverpool, Div Neurol Sci, Liverpool L69 3BX, Merseyside, England	Young, CA (corresponding author), Walton Ctr Neurol & Neurosurg, Lower Lane, Liverpool L9 7LJ, Merseyside, England.	Carolyn.young@thewaltoncentre.nhs.uk		Young, Carolyn/0000-0003-1745-7720			Airlie J, 2001, CLIN REHABIL, V15, P259, DOI 10.1191/026921501668362643; Bandura A, 1998, PSYCHOL HEALTH, V13, P623, DOI 10.1080/08870449808407422; Bandura A., 1997, SELF EFFICACY EXERCI; Barnes MP, 2003, J NEUROL NEUROSUR PS, V74, P3; Bowling A, 2002, RES METHODS HLTH, V2nd; Burns Robert, 2000, INTRO RES METHODS; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; De Vellis R. F., 2003, SCALE DEVELOPMENT TH; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; Grahn B, 2000, DISABIL REHABIL, V22, P639, DOI 10.1080/096382800445443; Hewlett S, 2001, RHEUMATOLOGY, V40, P1221, DOI 10.1093/rheumatology/40.11.1221; Kobau R, 2003, EPILEPSY BEHAV, V4, P217, DOI 10.1016/S1525-5050(03)00057-X; Lenze EJ, 2004, ARCH PHYS MED REHAB, V85, P1599, DOI 10.1016/j.apmr.2004.03.027; Lenze EJ, 2004, ARCH PHYS MED REHAB, V85, P380, DOI 10.1016/j.apmr.2003.06.001; Maclean N, 2000, SOC SCI MED, V50, P495; Maclean N, 2000, BMJ-BRIT MED J, V321, P1051, DOI 10.1136/bmj.321.7268.1051; Maclean N, 2002, STROKE, V33, P444, DOI 10.1161/hs0202.102367; O'Connell B, 2001, J Qual Clin Pract, V21, P120, DOI 10.1046/j.1440-1762.2001.00426.x; PAJARES F, 1997, ADV MOTIVATION ACHIE, V10; Rigby SA, 2003, MULT SCLER J, V9, P73, DOI 10.1191/1352458503ms870oa; SALMON P, 2000, PSYCHOL MED SURG; Schwartz CE, 1996, ARCH PHYS MED REHAB, V77, P394, DOI 10.1016/S0003-9993(96)90091-X; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Weinman J., 1995, MEASURES HLTH PSYCHO; Wiles R, 2002, DISABIL REHABIL, V24, P841, DOI 10.1080/09638280210142158; Wottrich AW, 2004, DISABIL REHABIL, V26, P1198, DOI 10.1080/09638280410001724889	27	55	56	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	MAR	2007	21	3					230	240		10.1177/0269215506071784			11	Rehabilitation	Rehabilitation	149QO	WOS:000245161900004	17329280				2021-06-18	
J	Holtslag, HR; Post, MW; Lindeman, E; Van der Werken, C				Holtslag, H. R.; Post, M. W.; Lindeman, E.; Van der Werken, Chr.			Long-term functional health status of severely injured patients	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						functional health status; long-term consequences; polytrauma; severely injured patients; sickness impact profile; SIP-136; co-morbidity; major trauma	SICKNESS IMPACT PROFILE; QUALITY-OF-LIFE; LOWER-EXTREMITY FRACTURE; TRAUMA RECOVERY PROJECT; SHORT GENERIC VERSION; MAJOR TRAUMA; MULTIPLE TRAUMA; HEAD-INJURY; WORK STATUS; DETERMINANTS	Background: Studies of the consequences of major trauma have traditionally focused on mortality rates. The aims of this study were, firstly, to investigate the long-term functional health status in a large, unselected group of severely injured patients and to compare this with normative data, and secondly, to explore relations between functional health status and personal and injury characteristics. Methods: A prospective cohort study was performed at the University Medical Centre Utrecht (a level-1 trauma centre) in The Netherlands. Consecutive survivors of major trauma (ISS >= 16; > 16 years of age) were included from January 1999 until December 2000. After an average of 15 months (range 12-18 months), 335 of the 359 eligible persons (response rate 93%) participated. Demographic and injury characteristics were retrieved from a hospital-based registration system. Functional health status was measured using the 136-item Sickness impact profile (SIP). Co-morbidity was assessed at the follow-up examination using a standard list of 26 conditions. Results: Subjects were 249 men and 86 women, mean age 37.7 years, mean ISS was 24.9 (S.D. = 10.6). Almost, three quarters were traffic victims. Mean hospital stay was 25 days (S. D. = 23.4). Discharge destination was home in 70% of all subjects. At follow-up, the mean overall SIP score was 9.3 (S.D. = 10.1), which means mild to moderate disability. The mean score on the physical function dimension was 7.2 (S.D. = 9.8) and that on psychosocial function was 8.7 (S.D. = 12.0). Most problems were experienced in the categories of Work, Ambulation, Home Management, Recreation and Pastimes, and Alertness Behaviour. Scores of younger subjects deviated more strongly from the norm scores than those of elderly patients. Type of injury, especially lesions of traumatic brain and spinal cord and extremity injuries, was a predictor of both psychosocial and physical functioning after more than 1 year. The most important predictors, however, were age and co-morbidity. (C) 2006 Elsevier Ltd. All rights reserved.	Rehabil Ctr Hoogstr, Utrecht, Netherlands; Univ Med Ctr, Dept Rehabil, Rudolf Magnus Inst Neurosci, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr, Dept Surg, NL-3508 GA Utrecht, Netherlands	Holtslag, HR (corresponding author), Univ Med Ctr, Dept Rehabil, Rudolf Magnus Inst Neurosci, POB 85500,HP F00-810, NL-3508 GA Utrecht, Netherlands.	h.r.holtslag@umcutrecht.nl; m.post@dehoogstraat.nl; e.lindeman@umcutrecht.nl; c.werken@chir.umcutrecht.nl					Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; Butcher JL, 1996, J TRAUMA, V41, P4, DOI 10.1097/00005373-199607000-00002; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P863, DOI 10.1016/0895-4356(94)90189-9; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; DEBRUIN AF, 1992, SOC SCI MED, V35, P1003, DOI 10.1016/0277-9536(92)90240-Q; DePalma Judith A, 2003, AACN Clin Issues, V14, P54; Erli HJ, 2000, CHIRURG, V71, P1132, DOI 10.1007/s001040051190; Faergemann C, 1998, J TRAUMA, V45, P123, DOI 10.1097/00005373-199807000-00026; GERETY MB, 1994, J GERONTOL, V49, pM2, DOI 10.1093/geronj/49.1.M2; GRUEN GS, 1995, J TRAUMA, V39, P838, DOI 10.1097/00005373-199511000-00006; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; HOLBROOK TL, 1994, J TRAUMA, V36, P74, DOI 10.1097/00005373-199401000-00011; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Jacobs H M, 1990, Ned Tijdschr Geneeskd, V134, P1950; JURKOVICH G, 1995, J TRAUMA, V39, P625, DOI 10.1097/00005373-199510000-00001; Lew HL, 2002, AM J PHYS MED REHAB, V81, P830, DOI 10.1097/00002060-200211000-00005; Lipsett PA, 2000, J TRAUMA, V49, P737, DOI 10.1097/00005373-200010000-00024; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; MACKENZIE EJ, 1993, J TRAUMA, V34, P528, DOI 10.1097/00005373-199304000-00009; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MacKenzie EJ, 2002, QUAL LIFE RES, V11, P797, DOI 10.1023/A:1020820017658; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meerding WJ, 2004, J TRAUMA, V56, P150, DOI 10.1097/01.TA.0000062969.65847.8B; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Mock C, 2000, J TRAUMA, V49, P1002, DOI 10.1097/00005373-200012000-00005; Morris S, 2000, J TRAUMA, V49, P461, DOI 10.1097/00005373-200009000-00013; Post MWM, 1996, ARCH PHYS MED REHAB, V77, P440, DOI 10.1016/S0003-9993(96)90031-3; Riemsma R P, 2001, Health Technol Assess, V5, P1; SACCO WJ, 1993, J TRAUMA, V35, P538, DOI 10.1097/00005373-199310000-00007; Smith JJ, 2005, J ORTHOP TRAUMA, V19, P249, DOI 10.1097/01.bot.0000151813.10046.e4; Stalp M, 2002, J TRAUMA, V52, P1160, DOI 10.1097/00005373-200206000-00023; SULLIVAN M, 1993, J RHEUMATOL, V20, P1500; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; Van de Port IGL, 2004, DISABIL REHABIL, V26, P635, DOI 10.1080/09638280410001672481; VANDERSLUIS CK, 1995, J TRAUMA, V38, P681, DOI 10.1097/00005373-199505000-00001; vanRoijen L, 1996, INT J TECHNOL ASSESS, V12, P405, DOI 10.1017/S0266462300009764; vanStraten A, 1997, STROKE, V28, P2155, DOI 10.1161/01.STR.28.11.2155; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Zahavi A, 2004, J NEUROL NEUROSUR PS, V75, P1553, DOI 10.1136/jnnp.2003.014282	46	55	55	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAR	2007	38	3					280	289		10.1016/j.injury.2006.10.026			10	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	147CA	WOS:000244979800004	17250834				2021-06-18	
J	Cothren, CC; Smith, WR; Moore, EE; Morgan, SJ				Cothren, C. Clay; Smith, Wade R.; Moore, Ernest E.; Morgan, Steven J.			Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients	WORLD JOURNAL OF SURGERY			English	Article							INTERMITTENT PNEUMATIC COMPRESSION; VENA-CAVAL FILTERS; HIGH-RISK; MAJOR TRAUMA; PULMONARY-EMBOLISM; CLINICAL-TRIAL; PROPHYLAXIS; ENOXAPARIN; THROMBOSIS; INJURY	Introduction: Venous thromboembolism is a preventable cause of death in the severely injured patient. Low-molecular-Weight heparins (LMWHs) have been recommended as effective, safe prophylactic agents. However, LMWH use remains controversial in patients at risk for bleeding, those with traumatic brain injury, and those undergoing multiple invasive or operative procedures. We hypothesized that a protocol utilizing once-daily LMWH prophylaxis in high-risk trauma patients, regardless of the need for invasive procedures, is feasible, safe, and effective. Methods: From August 1998 to August 2000, all patients admitted to our American College of Surgeons-verified Level I trauma facility following injury were evaluated for deep venous thrombosis (DVT) risk and prospectively followed. Patients at high risk for DVT, including those with stable intracranial injuries, were placed on our institutional protocol and prospectively followed. Patients on the protocol received daily injections of the LMWH, dalteparin; DVT screening was performed with duplex ultrasonography within 48 hours of admission and after 7 to 10 days after injury. Regimen compliance, bleeding complications, DVT rates, and pulmonary embolus (PE) rates were analyzed. Results: During the 2-year study period, 6247 trauma patients were admitted; 743 were considered at high risk for DVT. Most of the patients were men (72%), with a mean age of 38.7 years (range 15-89 years) and a mean injury severity score (ISS) of 19.5. Compliance with the daily regimen was maintained in 74% of patients. DVT was detected in 3.9% and PE in 0.8%. The wound complications rate was 2.7%, and the need for unexplained transfusions was 3%. There were no exacerbations of head injury following dalteparin initiation due to bleeding. There were 16 patient deaths; none was caused by PE or late hemorrhage. Conclusions: Once-daily dosing of prophylactic LMWH dalteparin is feasible, safe, and effective in high-risk trauma patients. Our protocol allows one to "operate through" systemic prophylaxis and ensures timely prophylaxis for brain-injured and multisystem trauma patients.	Univ Colorado, Hlth Sci Ctr, Dept Gen Surg, Trauma Serv,Denver Hlth Med Ctr, Denver, CO 80204 USA; Univ Colorado, Hlth Sci Ctr, Dept Orthoped Surg, Denver Hlth Med Ctr, Denver, CO 80204 USA	Cothren, CC (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Gen Surg, Trauma Serv,Denver Hlth Med Ctr, 777 Bannock St,MC 0206, Denver, CO 80204 USA.	clay.cothren@dhha.org					Allen TL, 2005, AM J SURG, V189, P656, DOI 10.1016/j.amjsurg.2005.03.003; Cipolle MD, 2002, J TRAUMA, V52, P453, DOI 10.1097/00005373-200203000-00007; COLWELL CW, 1994, J BONE JOINT SURG AM, V76A, P3, DOI 10.2106/00004623-199401000-00002; Deitcher SR, 2000, AM J MANAG CARE, V6, pS1026; FISHER CG, 1995, J ORTHOP TRAUMA, V9, P1, DOI 10.1097/00005131-199502000-00001; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GRANIT V, 2004, WORLD J SURG, V28, P807; Greenfield LJ, 1997, J TRAUMA, V42, P100, DOI 10.1097/00005373-199701000-00017; Hak D J, 2001, Curr Opin Pulm Med, V7, P338, DOI 10.1097/00063198-200109000-00015; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hill AB, 2002, CAN J SURG, V45, P282; Kelsey LJ, 2000, HEMATOL ONCOL CLIN N, V14, P417, DOI 10.1016/S0889-8588(05)70142-8; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; Langan EM, 1999, J VASC SURG, V30, P484, DOI 10.1016/S0741-5214(99)70075-3; Merli G, 2003, J TRAUMA, V54, P1116, DOI 10.1097/01.TA.0000066385.10596.71; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; Nurmohamed MT, 1996, THROMB HAEMOSTASIS, V75, P233; O'Shea SI, 2002, SEMIN HEMATOL, V39, P172, DOI 10.1053/shem.2002.34090; Olson S, 2002, J CLIN NEUROSCI, V9, P256, DOI 10.1054/jocn.2001.0982; Paiement GD, 1997, ORTHOPEDICS, V20, P7; Pasquale M, 1998, J TRAUMA, V44, P941, DOI 10.1097/00005373-199806000-00001; Pineo G F, 2001, Expert Opin Pharmacother, V2, P1325; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; Schwarcz TH, 2001, J VASC SURG, V34, P447, DOI 10.1067/mva.2001.117146; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; SMITH WR, 2002, THROMBOPROPHYLAXIS E; Tapson VF, 2005, ARCH INTERN MED, V165, P1458, DOI 10.1001/archinte.165.13.1458; Turpie Alexander G G, 2002, Expert Opin Pharmacother, V3, P575, DOI 10.1517/14656566.3.5.575; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Wenzl ME, 2004, CLIN APPL THROMB-HEM, V10, P1, DOI 10.1177/107602960401000101	33	55	57	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JAN	2007	31	1					98	104		10.1007/s00268-006-0304-1			7	Surgery	Surgery	124JW	WOS:000243365100017	17180563				2021-06-18	
J	Jackson, JC; Obremskey, W; Bauer, R; Greevy, R; Cotton, BA; Anderson, V; Song, YN; Ely, EW				Jackson, James C.; Obremskey, William; Bauer, Rebecca; Greevy, Robert; Cotton, Bryan A.; Anderson, Venice; Song, Yanna; Ely, E. Wesley			Long-term cognitive, emotional, and functional outcomes in trauma intensive care unit survivors without intracranial hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						cognitive impairment; critical care; depression; neuropsychological assessment; PTSD; trauma	POSTTRAUMATIC-STRESS-DISORDER; MINI-MENTAL-STATE; BRAIN-INJURY; IMPAIRMENT; DEPRESSION; SEQUELAE; ANXIETY; QUESTIONNAIRE; DEFICITS; DISEASE	Background: Trauma patients without intracranial hemorrhage or focal neurologic deficits are typically considered low risk for lasting neuropsychological and emotional deficits, and such sequela may be overlooked, especially in those with skull fractures and concussions. We undertook this study to determine the prevalence of and risk factors for persistent cognitive impairment and emotional and functional difficulties in a sample of adult trauma intensive care unit survivors without intracranial hemorrhage. Methods: We queried the Vander-bilt University Trauma Registry for all patients admitted during 2003 with an Injury Severity Score > 25 and a head computed tomography scan showing no intracranial hemorrhage. Of the 97 patients identified, 58 were evaluated, in person between 12 to 24 months after hospital discharge, with a comprehensive battery of cognitive, emotional, and functional instruments. The Informant Questionnaire of Cognitive Decline in the Elderly-Short Form (IQCODE-SF) was used to evaluate for pre-existing cognitive deficits in patients suspected of having cognitive impairment before their trauma. Results: A total of 33 (57%) patients were determined to have cognitive impairment, which was most pronounced in the domains of attention and executive functioning/verbal fluency. Of these patients, one (3%) was determined by the IQCODE-SF to be cognitively impaired before trauma intensive care unit hospitalization. Of the 58 patients studied, 21 (36.2%) had a concussion or skull fracture and 37 (63.8%) had neither. Cognitive impairment was significantly more likely to occur in patients who sustained a concussion or skull fracture than in trauma patients who did not (81% versus 43%; p = 0.006). Patients reported significant depressive symptoms (56%), significant symptoms of posttraumatic stress disorder (38%), and significant symptoms of anxiety (29%). Quality of life scores were lower than in the general United States population and employment difficulties were widespread. A total of 34% of patients reported being unemployed at follow-up, and cognitive impairment was more common among these patients compared with patients in the workforce (p = 0.03). Neither cognitive impairment nor emotional dysfunction was associated with age, sex, race, Injury Severity Score, blood loss, ventilatory days, or intramedullary nailing of long-bone fractures. Conclusions: The majority of trauma survivors without intracranial hemorrhage display persistent cognitive impairment, which is nearly twice as likely in those with skull fractures or concussions. This cognitive impairment was associated with functional defects, poor quality of life, and an inability to return to work. Future research must delineate modifiable risk factors for these poor outcomes, especially in patients with skull fractures and concussions, to help improve long-term cognitive and functional status.	Vanderbilt Univ, Med Ctr, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res,Dept Psychiat,Sch Med, Nashville, TN USA; Vanderbilt Univ, Sch Med, Dept Biostat, Div Trauma & Surg Crit Care, Nashville, TN USA; VA Tennessee Valley Hlth Care Syst, Clin Res Ctr Excellence, Nashville, TN USA; Middle Tennessee VA Med Ctr, GRECC, Nashville, TN USA; Trevecca Nazarene Univ, Grad Psychol Dept, Nashville, TN USA	Jackson, JC (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res,Dept Psychiat,Sch Med, 6th Floor,Med Ctr 6109, Nashville, TN USA.	james.c.jackson@vanderbilt.edu	Cotton, Bryan/A-7107-2009; Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027472] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG027472-01A1] Funding Source: Medline		Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; AVIDSON JRT, 1996, DAVIDSON TRAUMS SCAL, P1; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P81; Bromet E, 1998, AM J EPIDEMIOL, V147, P353; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; DISCHINGER PC, 1993, J TRAUMA, V35, P454, DOI 10.1097/00005373-199309000-00020; ECK AT, 1996, BDI 2 DEPRESSION INV; Feinstein A, 2000, BRAIN COGNITION, V44, P78; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Heaton RK, 2004, GRANT 1 REVISED COMP; Hedayati SS, 2004, AM J KIDNEY DIS, V44, P207, DOI 10.1053/j.ajkd.2004.04.025; Hilsabeck RC, 2002, HEPATOLOGY, V35, P440, DOI 10.1053/jhep.2002.31257; Hitzl M, 2001, PHARMACOGENETICS, V11, P293, DOI 10.1097/00008571-200106000-00003; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Laforce R, 2001, PERCEPT MOTOR SKILL, V93, P281, DOI 10.2466/PMS.93.5.281-288; Mamelak M, 2000, NEUROPSY NEUROPSY BE, V13, P125; MARQUIS K, 2000, AM J RESP CRIT CARE, V161, pA383; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Mathiesen HK, 2006, ARCH NEUROL-CHICAGO, V63, P533, DOI 10.1001/archneur.63.4.533; Mikkelsen RL, 2004, NORD J PSYCHIAT, V58, P65, DOI 10.1080/08039480310000824; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; *NAT CTR INJ PREV, 2005, CDC AC INJ CAR RES A; Nirula R, 2003, ACCIDENT ANAL PREV, V35, P201, DOI 10.1016/S0001-4575(01)00104-X; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Patten SB, 2003, NEUROLOGY, V61, P1524, DOI 10.1212/01.WNL.0000095964.34294.B4; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; POKORNY AD, 1972, AM J PSYCHIAT, V129, P118; Reitan RM., 1985, HALSTEAD REITAN NEUR; Rey A., 1958, LEXAMEN CLINIQUE PSY; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Spreen O, 1969, NEUROSENSORY CTR COM; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; VARDY J, 2006, IN PRESS SUPPORT CAR; Ware JE., 1994, SF 36 PHYS MENTAL HL, V1st; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weinert C, 2005, CURR OPIN CRIT CARE, V11, P376, DOI 10.1097/01.ccx.0000168529.23078.64	55	55	58	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2007	62	1					80	88		10.1097/TA.0b013e31802ce9bd			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	126CP	WOS:000243490100018	17215737				2021-06-18	
J	Salehi, F; Kovacs, K; Scheithauer, BW; Pfeifer, EA; Cusimano, M				Salehi, Fateme; Kovacs, Kalman; Scheithauer, Bernd W.; Pfeifer, Eric A.; Cusimano, Michael			Histologic study of the human pituitary gland in acute traumatic brain injury	BRAIN INJURY			English	Article						histology; hypopituitarism; necrosis; pituitary; traumatic brain injury	ANTERIOR-PITUITARY; HEAD-INJURY; HYPOPITUITARISM; ABNORMALITIES; NECROSIS; LESIONS	Purpose: Approximately 25% of patients with traumatic brain injury (TBI) may develop partial or complete hypopituitarism. The causative mechanisms involved in its development are not clear. To the authors' knowledge, there have been no recent morphologic studies of the pituitary following TBI. Methods: To characterize the resultant histologic changes, this study investigated the pituitaries of 42 patients who died following a motor vehicle accident, all from the Mayo Tissue Registry. Twelve patients died instantly at the scene of the accident (Group I) whereas 30 survived between 3 hours and 7 days (Group II). All pituitary specimens were obtained at autopsy, formalin- fixed and paraffin-embedded. Hematoxylin-eosin sections cut in horizontal or sagittal plane were examined light- microscopically. Results: No infarction was noted in the pituitary specimens from group I. In group II, 13 of 30 43%) showed acute infarcts of varying size. The extent of infarction in group II ranged from focal to sub-total necrosis involving 90% of the adenohypophysis. Conclusions: Underlying adenohypophysial pathology in patients dying after TBI is acute infarction. Loss of large numbers of adenohypophysial cells causes reduced secretion of adenohypophysial hormones and may contribute to post- traumatic hypopituitarism.	Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Toronto, St Michaels Hosp, Dept Lab Med, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Dept Neurosurg, Toronto, ON M5B 1W8, Canada	Scheithauer, BW (corresponding author), Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, 200 1st St SW, Rochester, MN 55905 USA.	scheithauer.bernd@mayo.edu	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650			Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2005, THESCIENTIFICWORLDJO, V5, P777, DOI 10.1100/tsw.2005.100; Baldelli Roberto, 2005, Pituitary, V8, P255, DOI 10.1007/s11102-006-6050-4; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Benvenga Salvatore, 2005, Pituitary, V8, P193, DOI 10.1007/s11102-006-6040-6; BEVILACQUA G, 1975, ACTA NEUROPATHOL, V31, P171, DOI 10.1007/BF00688151; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Casanueva FF, 2005, J ENDOCRINOL INVEST, V28, P299; Ceballos R, 1966, Ala J Med Sci, V3, P185; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; DANIEL PM, 1959, LANCET, V2, P927; DANIEL PM, 1958, LANCET, V1, P1101; Daniel PM, 1961, MOD TRENDS ENDOCR, P55; Estes Susie M, 2005, Pituitary, V8, P267, DOI 10.1007/s11102-006-6053-1; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lorenzo Monica, 2005, Pituitary, V8, P233, DOI 10.1007/s11102-006-6046-0; Masel Brent E, 2005, Pituitary, V8, P263, DOI 10.1007/s11102-006-6052-2; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Schneider M, 2005, J NEUROTRAUM, V22, P937, DOI 10.1089/neu.2005.22.937; Sheehan HL, 1937, J PATHOL BACTERIOL, V45, P189, DOI 10.1002/path.1700450118; TREIP CS, 1970, J NEUROL NEUROSUR PS, V33, P715, DOI 10.1136/jnnp.33.5.715-a; Urban RJ, 2005, BRAIN INJURY, V19, P349, DOI 10.1080/02699050400004807; WOLMAN L, 1956, J PATHOL BACTERIOL, V72, P575, DOI 10.1002/path.1700720225	31	55	60	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	6					651	656		10.1080/02699050701426956			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	192LU	WOS:000248204100012	17577716				2021-06-18	
J	Lau, A; Arundine, M; Sun, HS; Jones, M; Tymianski, M				Lau, Anthony; Arundine, Mark; Sun, Hong-Shuo; Jones, Michael; Tymianski, Michael			Inhibition of caspase-mediated apoptosis by peroxynitrite in traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						peroxynitrite; traumatic brain injury; caspase-3; apoptosis; nitric oxide; reactive oxygen species	FLUID-PERCUSSION MODEL; CYTOCHROME-C RELEASE; SPINAL-CORD-INJURY; NITRIC-OXIDE; CELL-DEATH; NEURONAL APOPTOSIS; TYROSINE-NITRATION; IN-VITRO; POLY(ADP-RIBOSE) POLYMERASE; DNA FRAGMENTATION	In traumatic brain injury (TBI), neurons surviving the primary insult may succumb through poorly understood secondary mechanisms. In vitro, cortical neurons exposed to stretch injury exhibited enhanced vulnerability to NMDA, apoptotic-like DNA fragmentation, peroxynitrite (PN)formation, and cytoplasmic cytochrome c accumulation. Surprisingly, caspase-3 activity was undetectable by both immunoblotting and fluorogenic activity assays. Therefore, we hypothesized that PN directly inhibits caspases in these neurons. Consistent with this, stretch injury in cultured neurons elicited tyrosine nitration of procaspase-3, but not caspase-9 or Apaf-1, suggesting a direct interaction of PN with caspase-3. In an ex vivo system, PN inhibited the activity of caspase-3, and this inhibition was reversible with the addition of the sulfhydryl reducing agent dithiothreitol, indicating that PN inhibits caspases by cysteinyl oxidation. Moreover, in cultures, the PN donor 3-morpholinosydnonimine (SIN-1) blocked staurosporine-induced caspase-3 activation and its downstream effects including PARP-1 [poly-(ADP-ribose)polymerase-1] cleavage and phosphotidylserine inversion, suggesting that peroxynitrite can inhibit caspase-3-mediated apoptosis. To examine these mechanisms in vivo, rats were exposed to a lateral fluid percussion injury (FPI). FPI caused increased neuronal protein nitration that colocalized with TUNEL staining, indicating that PN was associated with neurodegeneration. Caspase-3 activity was inhibited in brain lysates harvested after FPI and was restored by adding dithiothreitol. Our data show that caspase-mediated apoptosis is inhibited in neurons subjected to stretch in vitro and to TBI in vivo, mostly because of cysteinyl oxidation of caspase-3 by PN. However, this is insufficient to prevent cell death, indicating that the TBI therapy may, at a minimum, require a combination of both anti-apoptotic and anti-oxidant strategies.	Toronto Western Res Inst, Div Appl & Intervent Res, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Neurosurg, Toronto, ON M5S 1A8, Canada		mike.tymianski@uhn.on.ca		Tymianski, Mike/0000-0002-6311-9565	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS048956] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048956] Funding Source: NIH RePORTER		Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; Conti AC, 1998, J NEUROSCI, V18, P5663; David JC, 1996, J NEUROSCI, V16, P200; Dawson VL, 2004, J BIOENERG BIOMEMBR, V36, P287, DOI 10.1023/B:JOBB.0000041755.22613.8d; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Estevez AG, 1998, J NEUROSCI, V18, P923; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gahm C, 2005, NEUROSURGERY, V57, P1272, DOI 10.1227/01.NEU.0000187317.32529.06; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hill IE, 2000, EXP NEUROL, V162, P73, DOI 10.1006/exnr.2000.7322; Hortobagyi T, 2003, NEUROSCIENCE, V121, P983, DOI 10.1016/S0306-4522(03)00482-2; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Joshi CN, 2004, BRAIN RES PROTOC, V13, P11, DOI 10.1016/j.brainresprot.2003.12.001; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; KOH JY, 1995, EXP NEUROL, V135, P153, DOI 10.1006/exnr.1995.1074; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; Marcum JL, 2005, BIOCHEM BIOPH RES CO, V334, P342, DOI 10.1016/j.bbrc.2005.06.089; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marsan MA, 2000, J SYST ARCHITECT, V46, P105, DOI 10.1016/S1383-7621(98)00064-2; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKee JA, 2005, NEUROCRIT CARE, V2, P342, DOI 10.1385/NCC:2:3:342; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mohr S, 1997, BIOCHEM BIOPH RES CO, V238, P387, DOI 10.1006/bbrc.1997.7304; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; RADI R, 1991, J BIOL CHEM, V266, P4244; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; Sosin DM, 1996, BRAIN INJURY, V10, P47; Spear N, 1998, ARCH BIOCHEM BIOPHYS, V356, P41, DOI 10.1006/abbi.1998.0741; Stefanis L, 2005, NEUROSCIENTIST, V11, P50, DOI 10.1177/1073858404271087; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Sun HS, 2006, J NEUROPHYSIOL, V95, P2590, DOI 10.1152/jn.00970.2005; Szabo C, 1997, NITRIC OXIDE-BIOL CH, V1, P373, DOI 10.1006/niox.1997.0143; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Ueta E, 2003, INT J CANCER, V103, P717, DOI 10.1002/ijc.10832; Virag L, 1998, FREE RADICAL BIO MED, V25, P1075, DOI 10.1016/S0891-5849(98)00139-7; Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Ye YZ, 1996, METHOD ENZYMOL, V269, P201; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	78	55	58	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 8	2006	26	45					11540	11553		10.1523/JNEUROSCI.3507-06.2006			14	Neurosciences	Neurosciences & Neurology	103NE	WOS:000241892700005	17093075	Green Published, Bronze			2021-06-18	
J	Brown, CVR; Rhee, P; Neville, AL; Sangthong, B; Salim, A; Demetriades, D				Brown, Carlos V. R.; Rhee, Peter; Neville, Angela L.; Sangthong, Burapat; Salim, Ali; Demetriades, Demetrios			Obesity and traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						obesity; traumatic brain injury; head injury; blunt trauma	NECROSIS-FACTOR-ALPHA; BLUNT TRAUMA; HEAD-INJURY; INSULIN-RESISTANCE; ADIPOSE-TISSUE; MORTALITY; OUTCOMES; IMPACT; RISK	Background: As obesity continues to run rampant in our society, an understanding of its adverse effect after traumatic injury is starting to unfold. We hypothesize that obesity negatively impacts head-injured patients, and the current study intends to compare obese and lean patients with traumatic brain injury (TBI). Methods: This is a retrospective study evaluating all blunt trauma patients with TBI admitted to the intensive care unit (ICU) in our urban, Level I trauma center from 1998 until 2003. Body mass index (BMI) was used to categorize patients as either lean (BMI < 30 kg/m(2)) or obese (BMI >= 30 kg/m(2)). Admission demographics, type and severity of head injury, and associated injuries were recorded for each patient. Primary outcome was mortality, while secondary outcomes were cause of death, complications, and for survivors, days of mechanical ventilation, ICU length of stay, and hospital length of stay. Obese and lean patients were compared using univariate analysis and multivariate stepwise logistic regression. In addition, a subgroup analysis of patients with isolated head injury was performed. Results:There were 690 patients with TBI admitted to the ICU during the study period, with 129 (19%) obese patients (BMI = 34 +/- 5 kg/m(2)) and 561 (81%) lean patients (BMI = 24 +/- 4 kg/m(2)). The two groups were similar with the exceptions that obese patients were older (46 +/- 20 years versus 39 years, p < 0.01), had lower admission systolic blood pressure (125 +/- 38 mm Hg versus 134 +/- 30 mm Hg,p = 0.01), and more often sustained an associated chest injury (46% versus 35%, p = 0.03). Obese patients with TBI had a trend toward more complications (34% versus 28%, p = 0.17) and a higher mortality (36% versus 25%, p = 0.02). However, stepwise logistic regression failed to identify obesity as an independent risk factor for either morbidity or mortality. In addition, obese patients with isolated head injury had no increase in complications or death. Conclusions: Although obese patients suffer more complications and higher mortality than lean patients after TBI, this adverse effect seems to be due to age, lower admission blood pressure, and more associated chest injury, rather than a direct result of the obese state.	Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90033 USA	Brown, CVR (corresponding author), Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Div Trauma & Crit Care, 1200 N State St 6341, Los Angeles, CA 90033 USA.	carlosbr@usc.edu					BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BOULANGER BR, 1994, CRIT CARE CLIN, V10, P613; BOULANGER BR, 1992, J TRAUMA, V33, P228, DOI 10.1097/00005373-199208000-00011; BOWERS SA, 1980, NEUROSURGERY, V6, P237; Brown CVR, 2005, J TRAUMA, V59, P1048, DOI 10.1097/01.ta.0000189047.65630.c5; BULLOCK MR, 2000, GUIDELINES MANAGEMEN; Das UN, 2001, NUTRITION, V17, P953, DOI 10.1016/S0899-9007(01)00672-4; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Engstrom G, 2003, DIABETES, V52, P2097, DOI 10.2337/diabetes.52.8.2097; Festa A, 2001, INT J OBESITY, V25, P1407, DOI 10.1038/sj.ijo.0801792; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; HORAN TC, 2004, HOSP EPIDEMIOLOGY IN, P1659; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650; Neville AL, 2004, ARCH SURG-CHICAGO, V139, P983, DOI 10.1001/archsurg.139.9.983; SMITHCHOBAN P, 1991, J TRAUMA, V31, P1253; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Yudkin JS, 1999, ARTERIOSCL THROM VAS, V19, P972, DOI 10.1161/01.ATV.19.4.972	20	55	56	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2006	61	3					572	576		10.1097/01.ta.0000200842.19740.38			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	084YL	WOS:000240570200014	16966989				2021-06-18	
J	Watts, AJ; Douglas, JM				Watts, Amy J.; Douglas, Jacinta M.			Interpreting facial expression and communication competence following severe traumatic brain injury	APHASIOLOGY			English	Article							DISCOURSE; RECOGNITION; PERCEPTION; ABILITY; SKILLS	Background: Facial expression is generally understood as playing a crucial role in communication, conveying both information and emotion. This study explored the nexus between the ability to interpret facial expression and communication competence for individuals with traumatic brain injury (TBI). Aims: Three research questions were addressed. The first two questions involved a comparison of TBI and control participants on perceived communication competence, and ability to interpret facial expression. The third research question addressed whether a relationship exists between ability to interpret facial expression and perceived communication competence, in individuals with TBI. Methods & Procedures: Participants included 12 individuals with severe TBI ( PTA. 7 days), and a group of matched controls. A measure of perceived communication competence ( the La Trobe Communication Questionnaire, LCQ) and a measure related to the interpretation of facial expression ( the Emotion Evaluation Test) were administered to TBI and control participants All participants nominated a ''close-other'' who completed the close-other form of the LCQ. Outcomes & Results: Results revealed that TBI participants were perceived to have significantly more difficulties with communication than control participants ( p = .002). Similarly, results also revealed that TBI participants had significantly more difficulty interpreting facial expression than control participants (p < .001). Pearson's Correlation Coefficient ( r) calculations demonstrated a significant relationship between ability to interpret facial expression and close-other perception of communication competence ( r = 5.532). Conclusions: Results are consistent with previous research, and suggest that ability to interpret facial expression is closely related to perceived communication competence, in individuals with TBI. This understanding has implications for rehabilitation and may inform the development of treatment strategies specifically targeting impairment in the ability to read facial expression.	La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3083, Australia	Douglas, JM (corresponding author), La Trobe Univ, Sch Human Commun Sci, Bundoora, Vic 3083, Australia.	J.Douglas@latrobe.edu.au	Douglas, Jacinta M/C-2380-2009	Douglas, Jacinta/0000-0003-0940-6624; Watts, Amy/0000-0001-8790-5678			Bracy C. A., 2005, BRAIN IMPAIR, V6, P1, DOI [10.1375/brim.6.1.1.65476., DOI 10.1375/BRIM.6.1.1.65476, DOI 10.1375/brim.6.1.1.65476]; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Damico JS, 1985, COMMUNICATION SKILLS, P165; DOUGLAS J, 2004, EVIDENCE BASED PRACT; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Frattali CM, 1995, ASHA FUNCTIONAL ASSE; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Karow Colleen M., 2003, Seminars in Speech and Language, V24, P69, DOI 10.1055/s-2003-38900; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; McDonald S., 2005, BRAIN IMPAIR, V6, P56, DOI DOI 10.1375/BRIM.6.1.56.65481; MCDONALD S, 1999, BRAIN DAM B, P19; MCDONALD S, 2002, TVTC AWARENESS SOCIA; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Murdoch BE., 2001, TRAUMATIC BRAIN INJU; NOWICKI S, 1993, J SOC PSYCHOL, V133, P749, DOI 10.1080/00224545.1993.9713934; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; SNOW P, 1999, BRAIN DAM B, P271; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745	34	55	56	0	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	AUG	2006	20	8					707	722		10.1080/02687030500489953			16	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	077MM	WOS:000240033500001					2021-06-18	
J	Schofield, PW; Butler, TG; Hollis, SJ; Smith, NE; Lee, SJ; Kelso, WM				Schofield, Peter W.; Butler, Tony G.; Hollis, Stephanie J.; Smith, Nadine E.; Lee, Stephen J.; Kelso, Wendy M.			Traumatic brain injury among Australian prisoners: Rates, recurrence and sequelae	BRAIN INJURY			English	Article						prisoners; traumatic brain injury; head injury; forensic; criminal justice system	HEAD-INJURY; PSYCHIATRIC-DISORDERS; POPULATION; PREVALENCE; BEHAVIOR; VIOLENCE; COUNTY	Primary objective: To establish the prevalence, severity, recurrence and sequelae of past traumatic brain injury (TBI) among individuals recently received into custody. Research design: Cross-sectional random sample of men recently received into the New South Wales' ( NSW) criminal justice system. Procedures: Participants were screened for a history of TBI including the injury setting, severity, treatment and sequelae of up to five separate TBI episodes. Outcomes and results: Of 200 study participants, 82% endorsed a history of at least one TBI of any severity and 65% a history of TBI with a loss of consciousness (LOC). Multiple past TBIs were common, as were ongoing sequelae. Treatment for the TBI was more common among those TBIs with a LOC compared with no LOC (66% vs .39%). Conclusions: Among individuals entering the criminal justice system, past TBI is common and often associated with ongoing neuropsychiatric and social sequelae. Screening for TBI at the point of reception may be warranted to better understand and treat those with ongoing neuropsychiatric sequelae arising from the TBI.	Ctr Hlth Res Criminal Justice, Eastgardens, NSW 2036, Australia; Univ Newcastle, Ctr Mental Hlth Studies, Newcastle, NSW 2308, Australia; Univ New S Wales, Sch Publ Hlth & Community Med, Kensington, NSW 2033, Australia	Butler, TG (corresponding author), Ctr Hlth Res Criminal Justice, Suite 302,Westfield Off Tower,152 Bunnerong Rd, Eastgardens, NSW 2036, Australia.	tbutler2@optusnet.com.au	Butler, Tony/F-4614-2012; Hollis, Stephanie J/B-5977-2011; Schofield, Peter/J-7133-2013	Butler, Tony/0000-0002-2679-2769; Schofield, Peter/0000-0001-8298-8590			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BACHYRITA G, 1974, AM J PSYCHIAT, V131, P1015; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; BRAGG WD, 1992, SOUTHERN MED J, V85, P365, DOI 10.1097/00007611-199204000-00007; Butler T, 2003, 2001 INMATE HLTH SUR; Butler T., 2004, AUSTR J HLTH PROMOTI, V15, P146; Butterworth P, 2004, J CLIN EPIDEMIOL, V57, P742, DOI 10.1016/j.jclinepi.2003.10.015; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CORBEN S, 2004, STAT PUBLICATION, V25; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; GRONWALL D, 1975, LANCET, V995, P997; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; Miller E, 1999, J FORENSIC PSYCHIATR, V10, P157, DOI 10.1080/09585189908402146; MILLER L, 1998, J COGNITIVE REHABILI, V22, P12; *NSW DEP JUV JUST, 2003, YOUNG PEOPL CUST HLT; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; *SAS I, 1999, SAS STAT SOFTW VERS; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; *SPSS INC, 2004, SPSS VERS 12 COMP PR; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; UALTIERI O, 1991, BRAIN INJURY, V5, P219; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	27	55	55	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2006	20	5					499	506		10.1080/02699050600664749			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	045GO	WOS:000237730800006	16716996				2021-06-18	
J	Boes, M; Kain, M; Kakar, S; Nicholls, F; Cullinane, D; Gerstenfeld, L; Einhorn, TA; Torneta, P				Boes, M; Kain, M; Kakar, S; Nicholls, F; Cullinane, D; Gerstenfeld, L; Einhorn, TA; Torneta, P			Osteogenic effects of traumatic brain injury on experimental fracture-healing	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							HEAD-INJURY; ENHANCED OSTEOGENESIS; HETEROTOPIC OSSIFICATION; GROWTH-FACTOR; FEMORAL FRACTURES; GENE-EXPRESSION; BONE-FORMATION; SPINAL-CORD; CELLS; ADULTS	Background: Heterotopic bone formation has been observed in patients with traumatic brain injury; however, an association between such an injury and enhanced fracture-healing remains unclear. To test the hypothesis that traumatic brain injury causes a systemic response that enhances fracture-healing, we established a reproducible model of traumatic brain injury in association with a standard closed fracture and measured the osteogenic response with an in vitro cell assay and assessed bone-healing with biomechanical testing. Methods: A standard closed femoral fracture was produced in forty-three Sprague-Dawley rats. Twenty-three of the rats were subjected to additional closed head trauma that produced diffuse axonal injury similar to that observed in patients with a traumatic brain injury. Twenty-one days after the procedure, all animals were killed and fracture-healing was assessed by measuring callus size and by mechanical testing. Sera from the animals were used in subsequent in vitro experiments to measure mitogenic effects on established cell lines of committed osteoblasts, fibroblasts, and mesenchymal stem cells. Results: Biomechanical assessment demonstrated that the brain-injury group had increased stiffness (p = 0.02) compared with the fracture-only group. There was no significant difference in torsional strength between the two groups. Cell culture studies showed a significant increase in the proliferative response of mesenchymal stem cells after exposure to sera from the brain-injury group compared with the response after exposure to sera from the fracture-only group (p = 0.0002). This effect was not observed in fibroblasts or committed osteoblasts. Conclusions: These results support data from previous studies that have suggested an increased osteogenic potential and an enhancement of fracture-healing secondary to traumatic brain injury. Our results further suggest that the mechanism for this enhancement is related to the presence of factors in the serum that have a mitogenic effect on undifferentiated mesenchymal stem cells. Clinical Relevance: Fracture-healing may be enhanced by an associated traumatic brain injury. Further understanding of this systemic response could lead to important insights about systemic therapeutic strategies for the enhancement of skeletal repair.	Boston Univ, Med Ctr, Dept Orthopaed, Boston, MA 02118 USA; Boston Univ, Sch Med, Orthopaed Res Lab, Boston, MA 02118 USA	Boes, M (corresponding author), Boston Univ, Med Ctr, Dept Orthopaed, Dowling 2 N,850 Harrison Ave, Boston, MA 02118 USA.	mattboes@hotmail.com; mikain@bmc.org; sanjeev.kakar@bmc.org; thomas.einhorn@bmc.org; ptornetta@pol.net		Tornetta, Paul/0000-0002-6448-8864; Einhorn, Thomas/0000-0002-5075-4885; /0000-0002-0477-1211			Alkhiary YM, 2005, J BONE JOINT SURG AM, V87A, P731, DOI 10.2106/JBJS.D.02115; Asaumi K, 2000, BONE, V26, P625, DOI 10.1016/S8756-3282(00)00281-7; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; CALANDRIELLO B, 1964, Bull Hosp Joint Dis, V25, P170; Einhorn TA, 2003, J BONE JOINT SURG AM, V85A, P1425, DOI 10.2106/00004623-200308000-00002; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GARLAND DE, 1980, CLIN ORTHOP RELAT R, P198; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; GARLAND DE, 1982, CLIN ORTHOP RELAT R, V166, P219; Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736-0266(03)00003-2; Kawamoto K, 2004, PROG BRAIN RES, V146, P369; Khare G N, 1995, Indian J Med Sci, V49, P281; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Kushwaha V P, 1998, J Am Acad Orthop Surg, V6, P298; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/S0092-8674(04)01054-2; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; RENFREE KJ, 1994, SPINE, V19, P740, DOI 10.1097/00007632-199404000-00002; Shea CM, 2003, J CELL BIOCHEM, V90, P1112, DOI 10.1002/jcb.10734; Siwek B, 1997, J BONE MINER RES, V12, P552, DOI 10.1359/jbmr.1997.12.4.552; SPENCER RF, 1990, S AFR J SURG, V28, P51; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; WHITE AA, 1977, J BONE JOINT SURG AM, V59, P189, DOI 10.2106/00004623-197759020-00009; WILDBURGER R, 1995, EUR J CLIN CHEM CLIN, V33, P693; WILDBURGER R, 1994, BONE MINER, V27, P183, DOI 10.1016/S0169-6009(08)80192-4; WILDBURGER R, 1994, RES EXP MED, V194, P247, DOI 10.1007/BF02576386; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Yamashiro T, 2001, BONE, V28, P404, DOI 10.1016/S8756-3282(01)00405-7	32	55	70	0	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	APR	2006	88A	4					738	743		10.2106/JBJS.D.02648			6	Orthopedics; Surgery	Orthopedics; Surgery	029KF	WOS:000236560500008	16595463				2021-06-18	
J	Alexander, MP				Alexander, MP			Impairments of procedures for implementing complex language are due to disruption of frontal attention processes	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						discourse; executive function; attention; aphasia; cerebellum; caudate	SUPPLEMENTARY MOTOR AREA; TRAUMATIC BRAIN-INJURY; NARRATIVE DISCOURSE; DYNAMIC APHASIA; BASAL GANGLIA; LOBE DAMAGE; LESIONS; ANTERIOR; CHILDREN; CORTEX	Production of complex discourse-lengthy, open-ended utterances and narratives-requires intact basic language operations, but it also requires a series of learned procedures for construction of complex, goal-directed communications. The progression of clinical disorders from transcortical motor aphasia to dynamic aphasia to discourse impairments represents it progression of procedural deficits from basic morpho-syntax to complex grammatical structures to narrative and a progression of lesions from posterior frontal to polar and/or lateral frontal to medial frontal. Two cases of impaired utilization of language exemplify the range of impairments from clearly agrammatic. nonfluency to less and less "aphasic" and more and more executive impairments from aphasic a. transcortical motor aphasia to dynamic aphasia to narrative discourse disorder. The clinical phenomenology of these disorders gradually comes to be more accurately defined in the terminology of executive deficits than that of aphasia. The executive deficits are, in turn, based on impairments in various components of attention. Specific impairments in energizing attention and setting response criteria associated, respectively, with lesions in superior medial and left ventrolateral frontal regions may cause defective recruitment of the procedures of complex language assembly.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Behav Neurol Unit, Boston, MA 02215 USA	Alexander, MP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Behav Neurol Unit, KS 253,330 Brookline Ave, Boston, MA 02215 USA.	malexand@bidmc.harvard.edu					ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Alexander MP, 2005, NEUROLOGY, V65, P572, DOI 10.1212/01.wnl.0000172912.07640.92; ALEXANDER MP, 1990, NEUROLOGY, V40, P353, DOI 10.1212/WNL.40.2.353; Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; BURGESS PW, 2005, SPEED CONTROL AGE HO; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2003, PEDIATR NEUROL, V29, P34, DOI 10.1016/S0887-8994(03)00012-2; CHAPMAN SB, 1989, BRAIN LANG, V36, P651, DOI 10.1016/0093-934X(89)90092-8; Chatterjee A, 1997, CORTEX, V33, P419, DOI 10.1016/S0010-9452(08)70228-4; COSTELLO AD, 1989, CORTEX, V25, P103; Crosson B, 2001, J COGNITIVE NEUROSCI, V13, P272, DOI 10.1162/089892901564225; Crozier S, 1999, NEUROPSYCHOLOGIA, V37, P1469, DOI 10.1016/S0028-3932(99)00054-8; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Davis GA, 1997, BRAIN LANG, V56, P183; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; FREEDMAN M, 1984, NEUROLOGY, V34, P409, DOI 10.1212/WNL.34.4.409; FREEMON FR, 1971, J NEUROL NEUROSUR PS, V34, P693, DOI 10.1136/jnnp.34.6.693; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Gasparini M, 1999, EUR J NEUROL, V6, P353, DOI 10.1046/j.1468-1331.1999.630353.x; GELMERS HJ, 1983, J NEUROL NEUROSUR PS, V46, P1052, DOI 10.1136/jnnp.46.11.1052; GODEFROY O, 1992, ARCH NEUROL-CHICAGO, V49, P1285, DOI 10.1001/archneur.1992.00530360087023; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; Goodglass H., 1983, ASSESSMENT APHASIA R; Grindrod CM, 2005, BRAIN COGNITION, V57, P70, DOI 10.1016/j.bandc.2004.08.023; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; Kaplan E., 1983, BOSTON NAMING TEST; Luria A R, 1967, Acta Neurol Psychiatr Belg, V67, P1045; Mackenzie C, 2000, INT J LANG COMM DIS, V35, P269, DOI 10.1080/136828200247188; Marien P, 2001, BRAIN LANG, V79, P580, DOI 10.1006/brln.2001.2569; Marien P, 1996, J NEUROL SCI, V144, P34, DOI 10.1016/S0022-510X(96)00059-7; MASDEU JC, 1978, NEUROLOGY, V28, P1220, DOI 10.1212/WNL.28.12.1220; MEGA MS, 1994, NEUROLOGY, V44, P1824, DOI 10.1212/WNL.44.10.1824; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; MOHR JP, 1978, NEUROLOGY, V28, P311, DOI 10.1212/WNL.28.4.311; NADEAU SE, 1988, BRAIN, V111, P1111, DOI 10.1093/brain/111.5.1111; NOVOA OP, 1987, BRAIN LANG, V30, P206, DOI 10.1016/0093-934X(87)90099-X; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; PINKER S, 1991, SCIENCE, V253, P530, DOI 10.1126/science.1857983; Reilly JS, 1998, BRAIN LANG, V61, P335, DOI 10.1006/brln.1997.1882; Robinson G, 1998, BRAIN, V121, P77, DOI 10.1093/brain/121.1.77; RUBENS AB, 1976, STUDIES NEUROLINGUIS, V1, P293; Schmahmann JD, 1998, BRAIN, V121, P561, DOI 10.1093/brain/121.4.561; SCHWARTZ MF, 1991, COGN NEUROPSYCHOL, V8, P381, DOI 10.1080/02643299108253379; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SILVERI MC, 1994, NEUROLOGY, V44, P2047, DOI 10.1212/WNL.44.11.2047; Sirigu A, 1998, CORTEX, V34, P771, DOI 10.1016/S0010-9452(08)70780-9; Sowell ER, 1999, NEUROIMAGE, V9, P587, DOI 10.1006/nimg.1999.0436; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Stuss D.T., 1994, NEUROPSYCHOLOGY, V8, P355, DOI [DOI 10.1037/0894-4105.8.3.355, 10.1037/0894-4105.8.3.355]; Stuss DT, 2005, NEUROPSYCHOLOGIA, V43, P396, DOI 10.1016/j.neuropsychologia.2004.06.010; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 2002, NEUROPSYCHOLOGY, V16, P500, DOI 10.1037//0894-4105.16.4.500; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; ULATOWSKA HK, 1983, BRAIN LANG, V19, P317, DOI 10.1016/0093-934X(83)90074-3; Ullman MT, 1997, J COGNITIVE NEUROSCI, V9, P266, DOI 10.1162/jocn.1997.9.2.266; VANDONGEN HR, 1985, ANN NEUROL, V17, P306, DOI 10.1002/ana.410170316; Von Stockert T. R, 1974, BRAIN LANG, V1, P277; YAKOVLEV PI, 1961, ARCH NEUROL-CHICAGO, V5, P364, DOI 10.1001/archneur.1961.00450160014002	63	55	58	0	13	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2006	12	2					236	247		10.1017/S1355617706060309			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	031CC	WOS:000236680700009	16573857				2021-06-18	
J	Garcia, M; Bondada, V; Geddes, JW				Garcia, M; Bondada, V; Geddes, JW			Mitochondrial localization of mu-calpain	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						apoptosis; apoptosis inducing factor; Bax; calcium; cell death; cortex; necrosis; neuroblastoma; permeability transition; protease	ACTIVATED NEUTRAL PROTEINASE; APOPTOTIC CELL-DEATH; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; CALPAIN/CALPASTATIN NETWORK; PLATELET CALPAIN; AXONAL DAMAGE; CYTOCHROME-C; BAX-CLEAVAGE; BID CLEAVAGE	Calcium-dependent cysteine proteases, calpains, have physiological roles in cell motility and differentiation but also play a pathological role following insult or disease. The ubiquitous calpains are widely considered to be cytosolic enzymes, although there has been speculation of a mitochondrial calpain. Within a highly enriched fraction of mitochondria obtained from rat cortex and SH-SY5Y human neuroblastoma cells, immunoblotting demonstrated enrichment of the 80 kDa mu-calpain large subunit and 28 kDa small subunit. In rat cortex, antibodies against domains II and III of the large mu-calpain subunit also detected a 40 kDa fragment, similar to the autolytic fragment generated following incubation of human erythrocyte mu-calpain with Ca2+. Mitochondrial proteins including apoptosis inducing factor and mitochondrial Bax are calpain substrates, but the mechanism by which calpains gain access to these proteins is uncertain. Mitochondrial localization of mu-calpain places the enzyme in proximity to its mitochondrial substrates and to Ca2+ released from mitochondrial stores. (c) 2005 Elsevier Inc. All rights reserved.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Geddes, JW (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA.	jgeddes@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045726] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045726] Funding Source: Medline		Aki T, 2002, J BIOCHEM, V132, P921, DOI 10.1093/oxfordjournals.jbchem.a003305; Annis MG, 2005, EMBO J, V24, P2096, DOI 10.1038/sj.emboj.7600675; ARIYOSHI H, 1993, BIOCHEM MOL BIOL INT, V30, P63; BANIK NL, 1991, J NEUROSCI RES, V29, P346, DOI 10.1002/jnr.490290310; Bianchi L, 2004, NAT NEUROSCI, V7, P1337, DOI 10.1038/nn1347; Branca D, 2004, BIOCHEM BIOPH RES CO, V322, P1098, DOI 10.1016/j.bbrc.2004.07.126; Brini M, 2003, CELL CALCIUM, V34, P399, DOI 10.1016/S0143-4160(03)00145-3; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Caro AA, 2002, ARCH BIOCHEM BIOPHYS, V408, P162, DOI 10.1016/S0003-9861(02)00544-1; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; CHAKRABARTI AK, 1988, J NEUROSCI RES, V20, P351, DOI 10.1002/jnr.490200309; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Croall DE, 2000, METH MOL B, V144, P33; Daniel KG, 2003, INT J MOL MED, V12, P247; Ding WX, 2002, BIOCHEM BIOPH RES CO, V291, P321, DOI 10.1006/bbrc.2002.6453; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Gabrijelcic-Geiger D, 2001, BIOL CHEM, V382, P1733, DOI 10.1515/BC.2001.209; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gil-Parrado S, 2002, J BIOL CHEM, V277, P27217, DOI 10.1074/jbc.M202945200; Gil-Parrado S, 2003, J BIOL CHEM, V278, P16336, DOI 10.1074/jbc.M208657200; Glading A, 2002, TRENDS CELL BIOL, V12, P46, DOI 10.1016/S0962-8924(01)02179-1; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gunter TE, 2004, FEBS LETT, V567, P96, DOI 10.1016/j.febslet.2004.03.071; Hewitt KE, 1998, J NEUROSCI RES, V54, P223, DOI 10.1002/(SICI)1097-4547(19981015)54:2<223::AID-JNR10>3.0.CO;2-5; Hood JL, 2004, J BIOL CHEM, V279, P43126, DOI 10.1074/jbc.M408100200; Hood JL, 2003, BIOCHEM BIOPH RES CO, V310, P1200, DOI 10.1016/j.bbrc.2003.09.142; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; KUMAMOTO T, 1995, ACTA NEUROPATHOL, V89, P399; LANE RD, 1992, EXP CELL RES, V203, P5, DOI 10.1016/0014-4827(92)90033-5; Lankiewicz S, 2000, J BIOL CHEM, V275, P17064, DOI 10.1074/jbc.275.22.17064; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Oh SH, 2004, BIOCHEM PHARMACOL, V68, P1845, DOI 10.1016/j.bcp.2004.06.021; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Rutledge TW, 2002, J BIOL CHEM, V277, P37009, DOI 10.1074/jbc.M204526200; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Saris NEL, 2005, BIOCHEMISTRY-MOSCOW+, V70, P187, DOI 10.1007/s10541-005-0100-9; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; SCHWAB C, 1994, HIPPOCAMPUS, V4, P210, DOI 10.1002/hipo.450040212; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Tagliarino C, 2003, CANCER BIOL THER, V2, P141, DOI 10.4161/cbt.2.2.237; TAKEUCHI KH, 1992, J NEUROCHEM, V58, P1526, DOI 10.1111/j.1471-4159.1992.tb11374.x; TAYLOR RG, 1991, BIOMED BIOCHIM ACTA, V50, P491; Thompson VF, 2000, METH MOL B, V144, P3; Toyota H, 2003, CANCER LETT, V189, P221, DOI 10.1016/S0304-3835(02)00552-9; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wood DE, 2000, EXP CELL RES, V256, P375, DOI 10.1006/excr.2000.4859; Yadavalli R, 2004, J BIOL CHEM, V279, P21948, DOI 10.1074/jbc.M400793200; Zalewska T, 1998, MOL CHEM NEUROPATHOL, V33, P185, DOI 10.1007/BF02815181	57	55	58	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	DEC 16	2005	338	2					1241	1247		10.1016/j.bbrc.2005.10.081			7	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	986LM	WOS:000233451100076	16259951				2021-06-18	
J	Quintana, A; Giralt, M; Rojas, S; Penkowa, M; Campbell, IL; Hidalgo, J; Molinero, A				Quintana, A; Giralt, M; Rojas, S; Penkowa, M; Campbell, IL; Hidalgo, J; Molinero, A			Differential role of tumor necrosis factor receptors in mouse brain inflammatory responses in cryolesion brain injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; knockout type-1 TNF receptor; knockout type-2 TNF receptor; gene expression; apoptosis	ASTROCYTE-TARGETED EXPRESSION; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; KAPPA-B ACTIVATION; TRANSGENIC MICE; NERVOUS-SYSTEM; FACTOR-ALPHA; TISSUE INHIBITOR; GENE-EXPRESSION; COLD INJURY	Tumor necrosis factor-alpha (TNF-alpha) is one of the mediators dramatically increased after traumatic brain injury that leads to the activation, proliferation, and hypertrophy of mononuclear, phagocytic cells and gliosis. Eventually, TNF-alpha can induce both apoptosis and necrosis via intracellular signaling. This cytokine exerts its functions via interaction with two receptors: type-1 receptor (TNFR1) and type-2 receptor (TNFR2). In this work, the inflammatory response after a freeze injury (cryolesion) in the cortex was studied in wild-type (WT) animals and in mice lacking TNFR1 (TNFR1 KO) or TNFR2 (TNFR2 KO). Lack of TNFR1, but not of TNFR2, significantly decreased the inflammatory response and tissue damage elicited by the cryolesion at both 3 and 7 days postlesion, with decreased gliosis, lower IL-1 beta immunostaining, and a reduction of apoptosis markers. Cryolesion produced a clear induction of the proinflammatory cytokines interleukin (IL)-1 alpha, IL-1 beta, IL-6, and TNF-alpha; this induction was significantly lower in the TNFR1 KO mice. Host response genes (ICAM-1, A20, EB22/5, and GFAP) were also induced by the cryolesion, but to a lesser extent in TNFR1 KO mice. Lack of TNIFR1 signaling also affected the expression of apoptosis/cell death-related genes (Fas, Rip, p53), matrix metalloproteinases (MMP3, MMP9, MMP12), and their inhibitors (TIMP1), suggesting a role of TNFR1 in extracellular matrix remodeling after injury. However, GDNF, NGF, and BDNF expression were not affected by TNFR1 deficiency. Overall, these results suggest that TNFR1 is involved in the early establishment of the inflammatory response and that its deficiency causes a decreased inflammatory response and tissue damage following brain injury. (c) 2005 Wiley-Liss, Inc.	Autonomous Univ Barcelona, Fac Sci, Inst Neurosci, E-08193 Barcelona, Spain; Autonomous Univ Barcelona, Dept Cellular Biol Physiol & Immunol, Anim Physiol Unit, E-08193 Barcelona, Spain; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	Molinero, A (corresponding author), Autonomous Univ Barcelona, Fac Sci, Inst Neurosci, E-08193 Barcelona, Spain.	amalia.molinero@uab.es	Quintana, Albert/N-5544-2015; Giralt, Mercedes/K-1626-2014; Hidalgo, Juan/C-9082-2011; molinero, amalia/K-2147-2014	Quintana, Albert/0000-0003-1674-7160; Giralt, Mercedes/0000-0002-1806-1528; Hidalgo, Juan/0000-0003-0921-1122; molinero, amalia/0000-0001-8661-8570	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH062231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036979] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH62231] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36979] Funding Source: Medline		Akassoglou K, 2003, P NATL ACAD SCI USA, V100, P709, DOI 10.1073/pnas.0236046100; Aloe L, 1999, BRAIN RES, V840, P125, DOI 10.1016/S0006-8993(99)01748-5; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; BLUETHMANN H, 1994, J LEUKOCYTE BIOL, V56, P565; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CAMPBELL IL, 1994, J IMMUNOL, V153, P3622; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; Carrasco J, 2003, NEUROBIOL DIS, V13, P22, DOI 10.1016/S0969-9961(03)00015-9; Carrasco J, 2000, EXP NEUROL, V163, P46, DOI 10.1006/exnr.1999.7335; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cook JL, 1998, BRAIN RES PROTOC, V3, P1, DOI 10.1016/S1385-299X(98)00012-9; Culpan D, 2003, NEUROSCI LETT, V350, P61, DOI 10.1016/S0304-3940(03)00854-1; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; Debatin KM, 2004, CANCER IMMUNOL IMMUN, V53, P153, DOI 10.1007/s00262-003-0474-8; Dopp JM, 1997, J NEUROIMMUNOL, V75, P104, DOI 10.1016/S0165-5728(97)00009-X; Eissner G, 2004, CYTOKINE GROWTH F R, V15, P353, DOI 10.1016/j.cytogfr.2004.03.011; Ethell DW, 2003, J CLIN IMMUNOL, V23, P439, DOI 10.1023/B:JOCI.0000010420.96419.a8; Eugster HP, 1999, EUR J IMMUNOL, V29, P626, DOI 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.3.CO;2-1; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Hansson E, 2003, FASEB J, V17, P341, DOI 10.1096/fj.02-0429rev; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; HOBBS MV, 1993, J IMMUNOL, V150, P3602; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim GM, 2001, J NEUROSCI, V21, P6617; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Lambertsen KL, 2005, J CEREBR BLOOD F MET, V25, P119, DOI 10.1038/sj.jcbfm.9600014; Lee SJ, 1999, J NEUROIMMUNOL, V98, P77, DOI 10.1016/S0165-5728(99)00084-3; Lee SJ, 2000, J IMMUNOL, V164, P1277, DOI 10.4049/jimmunol.164.3.1277; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; Lucas R, 1997, EUR J IMMUNOL, V27, P1719, DOI 10.1002/eji.1830270719; MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; McGeer EG, 2003, PROG NEURO-PSYCHOPH, V27, P741, DOI 10.1016/S0278-5846(03)00124-6; Molinero A, 2003, J NEUROPATH EXP NEUR, V62, P315, DOI 10.1093/jnen/62.3.315; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Muir EM, 2002, MOL BRAIN RES, V100, P103, DOI 10.1016/S0169-328X(02)00132-8; Munoz-Fernandez MA, 1998, PROG NEUROBIOL, V56, P307; Murakami K, 1999, PROG NEUROBIOL, V57, P289, DOI 10.1016/S0301-0082(98)00047-1; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; Pagenstecher A, 1997, J IMMUNOL METHODS, V206, P1, DOI 10.1016/S0022-1759(97)00077-X; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2003, GLIA, V42, P287, DOI 10.1002/glia.10208; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Poulsen CB, 2005, J NEUROCHEM, V92, P417, DOI 10.1111/j.1471-4159.2004.02877.x; Price DL, 1998, SCIENCE, V282, P1079, DOI 10.1126/science.282.5391.1079; Probert L, 2000, BRAIN, V123, P2005, DOI 10.1093/brain/123.10.2005; Probert L, 2001, GLIA, V36, P212, DOI 10.1002/glia.1110; Raivich G, 2003, J NEUROSCI RES, V72, P726, DOI 10.1002/jnr.10621; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sayer FT, 2002, EXP NEUROL, V175, P282, DOI 10.1006/exnr.2002.7901; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Stalder A K, 1999, Methods Mol Med, V22, P53, DOI 10.1385/0-89603-612-X:53; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Suvannavejh GC, 2000, CELL IMMUNOL, V205, P24, DOI 10.1006/cimm.2000.1706; Trembovler V, 2003, NEUROSCI LETT, V353, P115, DOI 10.1016/j.neulet.2003.09.023; Wang QX, 2000, CHINESE MED J-PEKING, V113, P281; Wetzel M, 2003, EUR J NEUROSCI, V18, P1050, DOI 10.1046/j.1460-9568.2003.02838.x; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	76	55	60	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	DEC 1	2005	82	5					701	716		10.1002/jnr.20680			16	Neurosciences	Neurosciences & Neurology	994BN	WOS:000234004900012	16267827				2021-06-18	
J	Hudak, AM; Caesar, RR; Frol, AB; Krueger, K; Harper, CR; Temkin, NR; Dikmen, SS; Carlile, M; Madden, C; Diaz-Arrastia, R				Hudak, AM; Caesar, RR; Frol, AB; Krueger, K; Harper, CR; Temkin, NR; Dikmen, SS; Carlile, M; Madden, C; Diaz-Arrastia, R			Functional outcome scales in traumatic brain injury: A comparison, of the Glasgow Outcome Scale (extended) and the Functional Status Examination	JOURNAL OF NEUROTRAUMA			English	Article						Abbreviated Injury Scale; Functional Status Examination; Glasgow Outcome Scale; Injury Severity Score; traumatic brain injury	HEAD-INJURY; STRUCTURED INTERVIEWS; CLASSIFICATION; RELIABILITY; DISABILITY; COMMUNITY; VALIDITY; MODERATE	Clinical trials aimed at developing therapies for traumatic brain injury (TBI) require outcome measures that are reliable, validated, and easily administered. The most widely used of these measures, the Glasgow Outcome Scale (GOS) and the GOS-Extended (GOS-E), have been criticized as suffering from ceiling effects. In an attempt to develop a more useful and dynamic outcome measure, the Functional Status Examination (FSE) was developed, which grades outcome across 10 functional domains. The FSE has been demonstrated to be reliable and sensitive in monitoring recovery after TBI. This manuscript compares FSE with GOS-E in a cohort of patients with a wide range of injury severities. 177 individuals who survived at least 6 months after TBI were studied. The FSE and GOS-E were administered 6-12 months after injury. FSE and GOS-E scores correlated well with each other. FSE scores were distributed throughout the range, indicating that ceiling and floor effects were not present. Physiologic measures of injury severity (Glasgow Coma Score [GCS]) did not correlate with anatomic measures (Abbreviated Injury Scale [AIS] and Injury Severity Score [ISS]). GCS correlated weakly with both outcome measures, but AIS/ISS did not. We conclude that FSE and GOS-E are reliable outcome measures for TBI survivors, and FSE may offer some advantages over GOS-E due its ability to provide a more detailed description of deficits. The majority of the variance in outcome is not accounted for by currently available measures of injury severity.	Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Phys Med & Rehabil, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurosurg, Dallas, TX 75390 USA; Baylor Inst Rehabil, Dallas, TX USA; Univ Washington, Dept Neurol Surg & Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Phys Med & Rehabil, Seattle, WA 98195 USA	Hudak, AM (corresponding author), Univ Texas, SW Med Ctr, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Anne.Hudak@UTSouthwestem.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD 48179, U01 HD 42652] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER		Bohac DL, 1997, BRAIN INJURY, V11, P469, DOI 10.1080/713802185; CDC, 1999, TRAUM BRAIN INJ US R; *COMM INJ SCAL, 1990, ABBR INJ SCAL; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; JENNETT B, 1975, LANCET, V1, P480; Kirkness Catherine J, 2002, J Neurosci Nurs, V34, P134; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; World Health Organization, 2001, INT CLASS FUNCT DIS	22	55	57	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2005	22	11					1319	1326		10.1089/neu.2005.22.1319			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	989OI	WOS:000233683000006	16305320				2021-06-18	
J	Shein, NA; Horowitz, M; Alexandrovich, AG; Tsenter, J; Shohami, E				Shein, NA; Horowitz, M; Alexandrovich, AG; Tsenter, J; Shohami, E			Heat acclimation increases hypoxia-inducible factor 1 alpha and erythropoietin receptor expression: implication for neuroprotection after closed head injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						erythropoietin; heat acclimation; hypoxia-inducible factor 1; neuroprotection; traumatic brain injury	RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERMANENT CEREBRAL-ISCHEMIA; TARGET GENES; BRAIN; RAT; TOLERANCE; NEURONS; ASSOCIATION; PROTECTS; RECOVERY	Experimental evidence indicates that long-term exposure to moderately high ambient temperature (heat acclimation, HA) mediates cross-tolerance to various types of subsequently applied stress. The transcriptional activator hypoxia-inducible factor 1 (HIF-1) has been implicated in playing a critical role in HA. It also regulates the expression of Erythropoietin (Epo), whose neuroprotective effects have been shown in a variety of brain injuries. The aim of the present study was to examine whether HA exerts a beneficial effect on the outcome of closed head injury (CHI) in mice and to explore the possible involvement of HIF-1 and Epo in this process. Heat acclimated mice and matched normothermic controls were subjected to CHI or sham surgery. Postinjury motor and cognitive parameters of acclimated mice were compared with those of controls. Mice were killed at various time points after injury or sham surgery and brain levels of HIF-1 alpha, the inducible subunit of HIF-1 alpha Epo, and the specific erythropoietin receptor (EpoR) were analyzed by Western immunoblotting. Motor and cognitive functions of acclimated mice were significantly better than those of controls. Heat acclimation was found to induce a significant increase in expression of nuclear HIF-1 alpha and EpoR. The EpoR/Epo ratio was also significantly higher in acclimated mice as compared with controls. Nuclear HIF-1 alpha and EpoR were higher in the acclimated group at 4 h after injury as well. The improved outcome of acclimated mice taken together with the basal and postinjury upregulation of. the examined proteins suggests the involvement of this pathway in HA-induced neuroprotection.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Fac Med Dent, Environm Physiol Lab, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Physiol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Rehabil Ctr, IL-91120 Jerusalem, Israel	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	horowitz@cc.huji.ac.il; esty@cc.huji.ac.il					Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Arieli Y, 2003, BRAIN RES, V962, P15, DOI 10.1016/S0006-8993(02)03681-8; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bromberg Z, 2004, P 1 INT M PHYS PHARM, P198; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Eynan M, 2002, J APPL PHYSIOL, V93, P2095, DOI 10.1152/japplphysiol.00304.2002; Genc S, 2004, RESTOR NEUROL NEUROS, V22, P105; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Glantz L, 2005, EXP NEUROL, V192, P117, DOI 10.1016/j.expneurol.2004.11.012; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Horowitz M, 2004, J APPL PHYSIOL, V97, P1496, DOI 10.1152/japplphysiol.00306.2004; Horowitz M, 2002, COMP BIOCHEM PHYS A, V131, P475, DOI 10.1016/S1095-6433(01)00500-1; Horowitz M, 2001, J THERM BIOL, V26, P357, DOI 10.1016/S0306-4565(01)00044-4; HOROWITZ M, 2005, EXP BIOL 35 INT C PH; Iwasaki Y, 2002, NEUROL RES, V24, P643, DOI 10.1179/016164102101200681; Jones NM, 2001, J CEREBR BLOOD F MET, V21, P1105, DOI 10.1097/00004647-200109000-00008; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; LEVI E, 1993, J APPL PHYSIOL, V75, P833; Maloyan A, 2001, J MOL CELL CARDIOL, V33, pA72, DOI 10.1016/S0022-2828(01)90285-8; MALOYAN A, 1999, AM J PHYSIOL, V26, pR1506; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; SCHMIDTNIELSEN K, 1964, ANIMAL PHYSL, P13; Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1994, RESTOR NEUROL NEUROS, V6, P107, DOI 10.3233/RNN-1994-6204; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092; Treinin M, 2003, PHYSIOL GENOMICS, V14, P17, DOI 10.1152/physiolgenomics.00179.2002; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; YATSIV I, 2002, NEURAL PLAST, V9, P119	48	55	56	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2005	25	11					1456	1465		10.1038/sj.jcbfm.9600142			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	977PF	WOS:000232815000006	15902197	Bronze			2021-06-18	
J	Jafarian-Tehrani, M; Louin, G; Royo, NC; Besson, VC; Bohme, GA; Plotkine, M; Marchand-Verrecchia, CM				Jafarian-Tehrani, M; Louin, G; Royo, NC; Besson, VC; Bohme, GA; Plotkine, M; Marchand-Verrecchia, CM			1400W, a potent selective inducible NOS inhibitor, improves hi stop atholo gical outcome following traumatic brain injury in rats	NITRIC OXIDE-BIOLOGY AND CHEMISTRY			English	Article						nitric oxide synthases; fluid percussion brain injury; 1400W; RT-PCR; western blots; brain lesion volumes; neuroprotection rat	NITRIC-OXIDE SYNTHASE; FOCAL CEREBRAL-ISCHEMIA; AMINOGUANIDINE TREATMENT; PROTEIN INHIBITOR; L-ARGININE; EXPRESSION; BINDING; MICE; PHOSPHORYLATION; NEUROPROTECTION	There are conflicting data regarding the role of nitric oxide (NO) produced by inducible NO synthase (iNOS) in the pathophysiology of traumatic brain injury (TBI). In this report, we evaluated the effect of a potent selective (iNOS) inhibitor, 1400W, on histopathological outcome following TBI in a rat model of lateral fluid percussion brain injury. First, to design an appropriate treatment protocol, the parallel time courses of iNOS and neuronal NOS (nNOS) gene expression, protein synthesis, and activity were investigated. Early induction of iNOS gene was observed in the cortex of injured rats, from 6 to 72 h with a peak at 24 H. Similarly, iNOS protein was detected from 24 to 72 h and de novo synthesized iNOS was functionally active, as measured by Ca2+ -independent NOS activity. The kinetic studies of nNOS showed discrepancies, since nNOS gene expression and protein synthesis were constant in the cortex of injured rats from 24 to 72 h, while Ca2+ -dependent constitutive NOS activity was markedly decreased at 24 11, persisting up to 72 h. Second, treatment with 1400W, started as a bolus of 20 mg kg(-1) (s.c.) at 18 h post-TBI, followed by s.c.-infusion at a rate of 2.2 mg kg(-1) h(-1) between 18 and 72 h, reduced by 64% the brain lesion volume at 72 h. However, THE same treatment paradigm initiated 24 It post-TBI did not have any effect. In conclusion, administration of a selective iNOS inhibitor, 1400W, even delayed by 18 It improves histopathological outcome Supporting a detrimental role for iNOS induction after TBI. (c) 2004 Elsevier Inc. All rights reserved.	Univ Paris 05, Pharmacol Lab, UPRES EA 2510, F-75270 Paris, France; Aventis Pharma SA, Ctr Rech Paris, Vitry Sur Seine, France	Jafarian-Tehrani, M (corresponding author), Univ Paris 05, Pharmacol Lab, UPRES EA 2510, 4 Ave Obser, F-75270 Paris, France.	mehranz.jafarian@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; besson, valerie C/L-7388-2017; BESSON, VALERIE/AAZ-9989-2020	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; besson, valerie C/0000-0002-1491-2380; BESSON, VALERIE/0000-0002-1491-2380; Jafarian-Tehrani, Mehrnaz/0000-0001-6895-5856			Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Armengou A, 2003, J CEREBR BLOOD F MET, V23, P978, DOI 10.1097/01.WCB.0000080651.64357.C6; Bagetta G, 2004, NEUROSCI LETT, V356, P183, DOI 10.1016/j.neulet.2003.11.065; Bal-Price A, 2001, J NEUROSCI, V21, P6480; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cardenas A, 1998, EUR J PHARMACOL, V354, P161, DOI 10.1016/S0014-2999(98)00458-0; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2002, J NEUROTRAUM, V19, P639, DOI 10.1089/089771502753754109; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Colasanti M, 1999, J BIOL CHEM, V274, P9915, DOI 10.1074/jbc.274.15.9915; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Grandati M, 1997, BRIT J PHARMACOL, V122, P625, DOI 10.1038/sj.bjp.0701427; Greenwood MT, 1997, BIOCHEM BIOPH RES CO, V238, P617, DOI 10.1006/bbrc.1997.7361; Hayashi Y, 1999, J BIOL CHEM, V274, P20597, DOI 10.1074/jbc.274.29.20597; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Law A, 2001, BRIT J PHARMACOL, V133, P1114, DOI 10.1038/sj.bjp.0704179; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Louin G, 2004, J NEUROSCI METH, V138, P73, DOI 10.1016/j.jneumeth.2004.03.010; Lu J, 2003, NEUROPHARMACOLOGY, V44, P253, DOI 10.1016/S0028-3908(02)00380-5; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Madrigal JLM, 2002, BRAIN RES, V938, P87, DOI 10.1016/S0006-8993(02)02467-8; Mattson DL, 2000, HYPERTENSION, V35, P337, DOI 10.1161/01.HYP.35.1.337; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH FS, 1998, DETECTION NOS ISOFOR; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3	50	55	59	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1089-8603	1089-8611		NITRIC OXIDE-BIOL CH	Nitric Oxide-Biol. Chem.	MAR	2005	12	2					61	69		10.1016/j.niox.2004.12.001			9	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	906DO	WOS:000227620900001	15740979				2021-06-18	
J	Amantini, A; Grippo, A; Fossi, S; Cesaretti, C; Piccioli, A; Peris, A; Ragazzoni, A; Pinto, F				Amantini, A; Grippo, A; Fossi, S; Cesaretti, C; Piccioli, A; Peris, A; Ragazzoni, A; Pinto, F			Prediction of 'awakening' and outcome in prolonged acute coma from severe traumatic brain injury: evidence for validity of short latency SEPs	CLINICAL NEUROPHYSIOLOGY			English	Article						somatosensory evoked potentials; coma; traumatic brain injury; outcome prediction; EEG; GCS	SOMATOSENSORY-EVOKED-POTENTIALS; SEVERE HEAD-INJURY; EVENT-RELATED POTENTIALS; PROGNOSTIC VALUE; COMPONENTS; RESPONSES; DAMAGE; EEG	Objective: To evaluate the prognostic value of somatosensory evoked potentials (SEP's) in severe traumatic brain injury (TBI) considering both 'awakening' and disability. Methods: SEPs were recorded in 60 severe TBI with duration of acute coma> 7 days. N20-P25 amplitudes, their side-to-side asymmetry and CCT were measured. SEPs on each hemisphere were classified as normal (N), pathological (P) or absent (A). 'Awakening' and disability were assessed after at least 12 months using Glasgow Outcome Scale (GOS). SEP predictive value was compared with GCS and EEG reactivity. Results: Seventy-five percent regained consciousness. 29/60 had a good outcome (GOS 4-5) and 31/60 had a bad outcome (GOS 1-3). According to the ROC curve, SEP findings were classified in 3 grades. Grade I (NN, NP) had PPV of 93.1% for 'awakening' and 86.2% for good outcome. Grade III (AA) had PPV of 100% forbad outcome and 72.7 % for 'awakening'. Grade II (PP, NA, PA) was associated with the wider range of outcome. A multivariate analysis including SEP grading, GCS and EEG reactivity did not increase the percentage of cases prognosticated by SEP alone. Conclusions: We confirm the high predictive value of SEPs in TBI, which is greater than GCS and EEG reactivity. Indeed, SEP grades I and III were able to predict the correct prognosis in more than 80% of severe TBI. Therefore, SEPs should be used more widely in the prognosis of severe TBI. Significance: Differently from post-anoxic, in post-traumatic coma the presence of normal SEPs has a favourable predictive value both for 'awakening' and disability. We think that in literature enough attention has still not been paid to this finding. (C) 2004 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Univ Florence, Dept Neurol & Psychiat Sci, Az Osped Careggi, I-50134 Florence, Italy; Az Osped Careggi, Intens Care Unit 1, Florence, Italy; Osped S Giovanni di Dio, Serv Neurol, Florence, Italy	Amantini, A (corresponding author), Univ Florence, Dept Neurol & Psychiat Sci, Az Osped Careggi, Vle Morgagni 85, I-50134 Florence, Italy.	amantini@unifi.it	grippo, antonello/AAP-6926-2020	Grippo, Antonello/0000-0002-9997-8564			ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; Brown JIM, 1998, NEUROSURGERY, V42, P1057, DOI 10.1097/00006123-199805000-00060; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Carter BG, 2001, CRIT CARE MED, V29, P178, DOI 10.1097/00003246-200101000-00036; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; Facco E, 2000, INTENS CARE MED, V26, P998, DOI 10.1007/s001340051294; FACCO E, 1990, ELECTROEN CLIN NEURO, P330; FACCO E, 2002, EPIDEMIOLOGIA GESTIO; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; FSICHER C, 2002, NEUROPHYSIOL DATA AN, V45, P448; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Guerit JM, 1999, NEUROPHYSIOL CLIN, V29, P301, DOI 10.1016/S0987-7053(99)90044-8; GUTLING E, 1994, ELECTROEN CLIN NEURO, V92, P568, DOI 10.1016/0168-5597(94)90141-4; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; RUMPL E, 1983, ELECTROEN CLIN NEURO, V56, P583, DOI 10.1016/0013-4694(83)90026-3; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; Soldner F, 2001, ACTA NEUROCHIR, V143, P873, DOI 10.1007/s007010170017; Tozzi F, 1990, Minerva Anestesiol, V56, P1311; Wagner E.H., 1996, CLIN EPIDEMIOLOGY ES	32	55	65	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2005	116	1					229	235		10.1016/j.clinph.2004.07.008			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	885KW	WOS:000226156500026	15589201				2021-06-18	
J	Ramos, AJ; Rubio, MD; Defagot, C; Hischberg, L; Villar, MJ; Brusco, A				Ramos, AJ; Rubio, MD; Defagot, C; Hischberg, L; Villar, MJ; Brusco, A			The 5HT(1A) receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization	BRAIN RESEARCH			English	Article						ischemia; cortical devascularization; 5HT(1A) receptor; 8-OH-DPAT; S100B; astrocyte	BAY X 3702; TRANSIENT FOREBRAIN ISCHEMIA; FIBRILLARY ACIDIC PROTEIN; GLOBAL CEREBRAL-ISCHEMIA; FIBROBLAST-GROWTH-FACTOR; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; 5-HT1A RECEPTOR; NUCLEUS BASALIS; CHOLINERGIC NEURONS	Serotonin 1A (5HT(1A)) receptor agonists have shown neuroprotective properties in different models of central nervous system injury. Activation of neuronal 5HT(1A) receptors appears to be involved in the neuroprotective effects. It remains to be elucidated if astroglial cells are responsive to the 5HT(1A) neuroprotective effects. The participation of astroglial S100B trophic factor has been proposed since 5HT(1A) activation leads to S100B release and nanomolar concentration level of this molecule showed pro-survival activity in neuronal cultures. Using the cortical devascularization model (CD; unilateral pial disruption), a procedure that results in localized ischemia without producing direct physical damage to brain tissue, we tested the effects of a full 511TIA agonist, 8-OH-DPAT, or the antagonist WAY-100635 on cortical neuronal survival, astroglial cell response and S 10013 expression. Wistar rats were subjected to CD lesion which consisted of a craniotomy followed by physical damage to the underlying pial blood vessels. Two and twenty-four hours after the CD lesion, animals received intraperitoneally 8-OH-DPAT (1 mg/kg), WAY-100635 (1 mg/kg) or vehicle (sterile saline). At 3, 7 or 14 days post-lesion, animals were sacrificed and their brains processed for immunohistochemistry to detect GFAP, vimentin, MAP-2, S100B and nuclear Hoechst staining. S100B level in the brain cortex and serum was quantified by an ELISA assay. Serum S100B was considered an index of S100B release. 8-OH-DPAT treatment reduced neuronal death, dendrite loss, astroglial hypertrophy and hyperplasia. In contrast, WAY-100635 treatment increased these parameters of damage. S100B intracellular immunoreactivity in astrocytes and total S100B level showed long-lasting changes after the CD lesion and subsequent treatments depending on the 5HT(1A) activity. The level of serum S100B was increased in 8-OH-DPAT-treated animals. Increased damage observed in WAY-100635-treated animals supports the hypothesis that the protective 8-OH-DPAT action may be mediated by specific 5HT(1A) receptors. The reduction in astroglial hypertrophy and hyperplasia as well as long-term changes in S100B immunoreactivity and increased S100B release that we observed allows us to hypothesize that astroglial cells may play an important role in 5HT(1A)-mediated neuroprotection. (C) 2004 Elsevier B.V. All rights reserved.	Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencia, RA-1121 Buenos Aires, DF, Argentina; Univ Austral, Fac Ciencias Biomed, Buenos Aires, DF, Argentina; Sangtec Med AB, S-16102 Bromma, Sweden	Ramos, AJ (corresponding author), Montreal Neurol Inst, Ctr Neuronal Survival, 3801 Univ St Room MP038, Montreal, PQ H3A 2B4, Canada.	alberto.ramos@mcgill.ca	Ramos, Alberto Javier/AAR-7796-2020	Ramos, Alberto Javier/0000-0003-4009-6337			Adayev T, 2003, BBA-MOL CELL RES, V1640, P85, DOI 10.1016/S0167-4889(03)00023-5; Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahlemeyer B, 1999, EUR J PHARMACOL, V370, P211, DOI 10.1016/S0014-2999(99)00136-3; Ahlemeyer B, 1997, BRAIN RES, V777, P179; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; Azmitia EC, 1996, NEUROPSYCHOPHARMACOL, V14, P35, DOI 10.1016/S0893-133X(96)80057-1; AZMITIA EC, 1995, BRAIN RES, V677, P181, DOI 10.1016/0006-8993(95)00051-Q; Azmitia EC, 2001, BRAIN RES BULL, V56, P413, DOI 10.1016/S0361-9230(01)00614-1; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; Conner JM, 1998, NEUROSCIENCE, V83, P1003, DOI 10.1016/S0306-4522(97)00449-1; Davey GE, 2001, J BIOL CHEM, V276, P30819, DOI 10.1074/jbc.M103541200; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; Deumens R, 2004, NEUROSCIENCE, V125, P591, DOI 10.1016/j.neuroscience.2004.02.010; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Douglas R, 1998, SYNAPTIC ORG BRAIN, P459; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Eriksen JL, 2002, DEV BRAIN RES, V139, P97, DOI 10.1016/S0165-3806(02)00510-2; Eriksen JL, 2001, DEV BRAIN RES, V128, P157, DOI 10.1016/S0165-3806(01)00172-9; Evrard SG, 2003, DEV BRAIN RES, V147, P119, DOI 10.1016/j.devbrainres.2003.09.004; FAGES C, 1994, BRAIN RES, V639, P161, DOI 10.1016/0006-8993(94)91777-9; FIGUEIREDO BC, 1995, MOL BRAIN RES, V33, P1, DOI 10.1016/0169-328X(95)00099-E; FIGUEIREDO BC, 1993, NEUROSCIENCE, V56, P955; Ganat Y, 2002, NEUROSCIENCE, V112, P977, DOI 10.1016/S0306-4522(02)00060-X; Glass JD, 1999, NEUROSCIENCE, V94, P1253, DOI 10.1016/S0306-4522(99)00369-3; HARING JH, 1993, BRAIN RES, V631, P119, DOI 10.1016/0006-8993(93)91195-X; HERRERA DG, 1989, BRAIN RES, V503, P205, DOI 10.1016/0006-8993(89)91665-X; HERRERA DG, 1992, NEUROSCIENCE, V49, P781, DOI 10.1016/0306-4522(92)90356-7; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hu JR, 1996, BBA-MOL CELL RES, V1313, P239, DOI 10.1016/0167-4889(96)00095-X; Hu JR, 1997, J NEUROCHEM, V69, P2294; Huang J, 1997, NEUROCHEM RES, V22, P1329, DOI 10.1023/A:1022062921438; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Joosten EAJ, 1997, PROG NEUROBIOL, V53, P1, DOI 10.1016/S0301-0082(97)00024-5; Kleindienst A, 2004, J NEUROTRAUM, V21, P541, DOI 10.1089/089771504774129874; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Klisch J, 2003, NEUROSCI LETT, V342, P25, DOI 10.1016/S0304-3940(03)00222-2; Koppal T, 2001, NEUROCHEM INT, V39, P401, DOI 10.1016/S0197-0186(01)00047-X; Kruger H, 1999, NEUROREPORT, V10, P2651; Kukley M, 2001, NEUROSCIENCE, V107, P405, DOI 10.1016/S0306-4522(01)00369-4; Lam AGM, 2001, NEUROBIOL AGING, V22, P765, DOI 10.1016/S0197-4580(01)00233-0; Levison SW, 1997, J NEUROSCI RES, V48, P83, DOI 10.1002/(SICI)1097-4547(19970415)48:2<83::AID-JNR1>3.3.CO;2-4; LIBERINI P, 1994, BRAIN RES, V648, P1, DOI 10.1016/0006-8993(94)91897-X; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSTEP HL, 2002, CURR OPIN INVESTIG D, V3, P924; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; Menet V, 2000, GLIA, V31, P267, DOI 10.1002/1098-1136(200009)31:3<267::AID-GLIA80>3.0.CO;2-N; Menet V, 2001, J NEUROSCI, V21, P6147; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Nishi M, 1997, NEUROSCI LETT, V229, P212, DOI 10.1016/S0304-3940(97)00443-6; Nishi M, 1996, SYNAPSE, V23, P1, DOI 10.1002/(SICI)1098-2396(199605)23:1<1::AID-SYN1>3.0.CO;2-E; OBERHAMMER F, 1993, J CELL SCI, V104, P317; Oosterink BJ, 1998, EUR J PHARMACOL, V358, P147, DOI 10.1016/S0014-2999(98)00614-1; Oosterink BJ, 2003, NEUROREPORT, V14, P57, DOI 10.1097/00001756-200301200-00011; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; PIERA MJ, 1995, ARCH INT PHARMACOD T, V329, P347; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; Privat A, 2003, GLIA, V43, P91, DOI 10.1002/glia.10249; Ramos AJ, 2000, BRAIN RES, V883, P1, DOI 10.1016/S0006-8993(00)02862-6; Ramos AJ, 2002, BRAIN RES, V958, P112, DOI 10.1016/S0006-8993(02)03489-3; Ramos AJ, 2002, ANN NY ACAD SCI, V965, P343; RAMOS AJ, 2002, J NEUROCHEM S1, V81, pAP1; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Schaper C, 2000, BRAIN RES, V883, P41, DOI 10.1016/S0006-8993(00)02876-6; Schiffer D, 1996, J NEUROL SCI, V139, P27, DOI 10.1016/0022-510X(96)00073-1; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; Souza TME, 2000, PHYSIOL BEHAV, V71, P29, DOI 10.1016/S0031-9384(00)00299-7; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; Tagliaferro P, 1997, MOL CHEM NEUROPATHOL, V32, P195, DOI 10.1007/BF02815176; Tajrine D, 1997, J NEUROSCI RES, V50, P627; Torup L, 2000, EUR J PHARMACOL, V395, P137, DOI 10.1016/S0014-2999(00)00175-8; WHITAKERAZMITIA PM, 1994, PERSPECT DEV NEUROBI, V2, P233; WHITAKERAZMITIA PM, 1990, BRAIN RES, V528, P155, DOI 10.1016/0006-8993(90)90210-3; Wilson CC, 1998, BRAIN RES, V782, P235, DOI 10.1016/S0006-8993(97)01284-5; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Zhu Y, 1998, J CEREBR BLOOD F MET, V18, P1032	84	55	56	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 31	2004	1030	2					201	220		10.1016/j.brainres.2004.10.019			20	Neurosciences	Neurosciences & Neurology	880FW	WOS:000225775400005	15571670				2021-06-18	
J	O'Keeffe, FM; Dockree, PM; Robertson, IH				O'Keeffe, FM; Dockree, PM; Robertson, IH			Poor insight in traumatic brain injury mediated by impaired error processing? Evidence from electrodermal activity	COGNITIVE BRAIN RESEARCH			English	Article						error awareness; electrodermal activity; traumatic brain injury; no-go task	SUSTAINED ATTENTION; EXECUTIVE FUNCTIONS; FRONTAL DAMAGE; NEURAL SYSTEM; PERFORMANCE; AWARENESS; LESIONS; DYSFUNCTION; FAILURES; BEHAVIOR	Impaired deficit awareness is common following traumatic brain injury (TBI) and is a major obstacle to rehabilitation. We have previously confirmed the presence of impaired error awareness in TBI using a highly discriminating go/no-go procedure. In the present study, we extend this work to try to identify more closely the nature of the error awareness deficit using measures of electrodermal activity (EDA). Sixteen participants with TBI and sixteen age-, sex-, and education-matched controls performed the Sustained Attention to Response Task(SART), while EDA was recorded. TBI detected significantly fewer errors compared to controls. EDA was significantly attenuated for TBI participants even to errors of which they were aware: error detection rates and EDA amplitude were also correlated. These findings suggest that poor insight following TBI may result, in part, from impaired error processing abilities. (C) 2004 Elsevier B.V. All rights reserved.	Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland; Univ Dublin Trinity Coll, Inst Neurosci, Dublin 2, Ireland	Robertson, IH (corresponding author), Univ Dublin Trinity Coll, Dept Psychol, Dublin 2, Ireland.	Ian.Robertson@tcd.ie		Robertson, Ian H/0000-0001-8637-561X			ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks N., 1984, CLOSED HEAD INJURY P; Brunia C. H. M., 1990, PSYCHOPHYSIOLOGICAL, P192; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; COOKE DL, 1995, J CLIN EXP NEUROPSYC, V17, P90, DOI 10.1080/13803399508406585; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAMASIO AR, 1994, DESCARTES ERROR EMOT, P211; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Fassbender C, 2004, COGNITIVE BRAIN RES, V20, P132, DOI 10.1016/j.cogbrainres.2004.02.007; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Gehring WJ, 2000, NAT NEUROSCI, V3, P516, DOI 10.1038/74899; Goldberg E., 1991, AWARENESS DEFICIT BR, P152; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; LEHRER PM, 1989, PSYCHOPHYSIOLOGY, V26, P668, DOI 10.1111/j.1469-8986.1989.tb03169.x; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; MATTHEWS G, 1990, BRIT J PSYCHOL, V81, P17, DOI 10.1111/j.2044-8295.1990.tb02343.x; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCAVINUE L, IN PRESS NEUROPSYCHO; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; O'Connor C, 2004, BRAIN COGNITION, V54, P133, DOI 10.1016/S0278-2626(03)00268-9; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1999, COGNITIVE NEUROREHAB, P240; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rodriguez-Fornells A, 2002, J NEUROSCI, V22, P9990; Rollnik JD, 2004, CLIN NEUROPHYSIOL, V115, P145, DOI 10.1016/j.clinph.2003.05.001; Scheffers MK, 2000, J EXP PSYCHOL HUMAN, V26, P141, DOI 10.1037/0096-1523.26.1.141; Scheffers MK, 1996, PSYCHOPHYSIOLOGY, V33, P42, DOI 10.1111/j.1469-8986.1996.tb02107.x; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Stemmer B, 2004, NEUROPSYCHOLOGIA, V42, P118, DOI 10.1016/S0028-3932(03)00121-0; STERN R, 2001, PSYCHOPHYSIOLOGICAL, P206; STUSS D, 2001, FRONTAL LOBES NEUROP; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; TRANEL D, 1994, PSYCHOPHYSIOLOGY, V31, P427, DOI 10.1111/j.1469-8986.1994.tb01046.x; Ullsperger M, 2002, NEUROPSYCHOLOGY, V16, P548, DOI 10.1037//0894-4105.16.4.548; Umilta C, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, P37; Vidal F, 2000, BIOL PSYCHOL, V51, P109, DOI 10.1016/S0301-0511(99)00032-0; VILKKI J, 1992, NEUROPSYCHOLOGIA, V30, P807, DOI 10.1016/0028-3932(92)90084-Y; Zahn TP, 1999, INT J PSYCHOPHYSIOL, V33, P113, DOI 10.1016/S0167-8760(99)00030-6; Zahn TP, 1999, NEUROPSYCHOLOGIA, V37, P1227, DOI 10.1016/S0028-3932(99)00020-2; ZAIDEL E, 1987, DUALITY UNITY BRAIN; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zimmer H, 2000, Z EXP PSYCHOL, V47, P129	58	55	55	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0926-6410			COGNITIVE BRAIN RES	Cognit. Brain Res.	DEC	2004	22	1					101	112		10.1016/j.cogbrainres.2004.07.012			12	Computer Science, Artificial Intelligence; Neurosciences; Neuroimaging	Computer Science; Neurosciences & Neurology	881VU	WOS:000225898300012	15561506				2021-06-18	
J	Massucci, JL; Kline, AE; Ma, XC; Zafonte, RD; Dixon, CE				Massucci, JL; Kline, AE; Ma, XC; Zafonte, RD; Dixon, CE			Time dependent alterations in dopamine tissue levels and metabolism after experimental traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						catecholamine; CCI; DOPAC; dopamine; TBI	WATER MAZE PERFORMANCE; METHYLPHENIDATE TREATMENT; TYROSINE-HYDROXYLASE; PREFRONTAL CORTEX; WORKING-MEMORY; FRONTAL-CORTEX; TRANSPORTER; EXPRESSION; AGONIST	Several studies have demonstrated alterations in the dopamine (DA) system after traumatic brain injury (TBI). The present study investigated the temporal changes in DA tissue levels and metabolism at 1-h or 1, 7, 14, and 28 days after cortical impact or sham injury in rats. DA and DOPAC levels were measured by HPLC in the frontal cortex (FC) and striatum. DA levels were significantly increased at 1 h in the contralateral FC and at 1 day in the ipsilateral FC versus respective sham groups. DA and DOPAC levels were significantly increased bilaterally at 1 h in the striatum versus sham. These data indicate that TBI induces an early increase in DA and DOPAC, which returns to sham levels over time. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA	Dixon, CE (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA.	dixonec@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD043851] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS303180, NS40125] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD043851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040125] Funding Source: NIH RePORTER		BERGER B, 1991, TRENDS NEUROSCI, V14, P21, DOI 10.1016/0166-2236(91)90179-X; Bjorklund A., 1984, HDB CHEM NEUROANAT 1, P55; BLANCHARD V, 1995, J NEUROCHEM, V64, P1669; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DUNNMEYNELL A, 1994, BRAIN RES, V660, P88, DOI 10.1016/0006-8993(94)90842-7; GAMACHE P, 1993, J CHROMATOGR-BIOMED, V614, P213, DOI 10.1016/0378-4347(93)80311-Q; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Kline AE, 2004, J NEUROTRAUM, V21, P175, DOI 10.1089/089771504322778631; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KLINE AE, IN PRESS J NEUROTRAU; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Phillips JP, 2003, J HEAD TRAUMA REHAB, V18, P342, DOI 10.1097/00001199-200307000-00005; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	23	55	56	0	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 30	2004	372	1-2					127	131		10.1016/j.neulet.2004.09.026			5	Neurosciences	Neurosciences & Neurology	873BT	WOS:000225254500026	15531102				2021-06-18	
J	Hoshizaki, TB; Brien, SE				Hoshizaki, TB; Brien, SE			The science and design of head protection in sport	NEUROSURGERY			English	Article						brain injury criteria; brain trauma; concussion; head protection; helmet; helmet standards; sport; standard testing	FOOTBALL; CONCUSSION; IMPACTS	WE REVIEW THE relationship between science, testing standards, and helmet design to provide an understanding of how helmets protect the brain. Research describing the mechanisms of injury, resulting types of brain injuries, and characteristics of helmet protection are reviewed. The article is designed to describe the state of the relationship between science and helmet performance.	Univ Ottawa, Fac Human Kinet, Ottawa, ON, Canada; Hotel Dieu Grace Hosp, Dept Neurosurg, Windsor, ON, Canada	Hoshizaki, TB (corresponding author), 225 Hemlock Rd, Rockcliffe, ON K1M 1K4, Canada.	bhoshizaki@hotmail.com		Kaye, Andrew Henry/0000-0001-5049-8861			*AM ASS AUT MED, 1980, ABBR INJ SCAL AIS 80; *AM NAT STAND I, 1971, SPEC PROT HEADG VEH; AYA RH, 1965, BOOK MOTORCYCLES TRA; Bennett T., 1977, NFLS OFFICIAL ENCY H; *BRIT STAND I, 1958, 18691960 BS BRIT STA; Cairns H, 1941, BRIT MED J, V1941, P465, DOI 10.1136/bmj.2.4213.465; Cantu R., 2000, NEUROLOGIC ATHLETIC; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P76; CANTU RC, 2000, NEUROLOGIC ATHLETIC, P124; CLEMENT L, 1989, SAFETY HOCKEY, P164; GADD CW, 1966, P 10 STAPP CAR CRASH, P146; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, NEUROSURGERY, P1531; GENNARELLI TA, 1972, P 16 STAPP CAR CRASH, P146; Giza CC, 2000, NEUROLOGIC ATHLETIC, P80; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1955, SURG GYNECOL OBSTET, V101, P680; GURDJIAN ES, 1975, IMPACT HEAD INJURY, P305; HODGSON V, 1973, FINAL REPORT NATL OP; Hodgson V. R., 1972, P 16 STAPP CAR CRASH; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; HODGSON VR, 1968, P 12 STAPP CAR CRASH, P280; HODGSON VR, 1982, ATHLETIC INJURIES HE, P27; HODGSON VR, 1985, UTILITY HEAD INJURY; HODGSON VR, 1983, P 9 C INT SOC BIOM W, P23; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; HOSHIZAKI TB, 1995, IIHF INT S MED SCI I, P90; KING AI, 1975, AIRCRAFT CRASHWORTHI, P83; KING AI, 2003, 2003 INT IRCOBI C BI; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; LOMBARD CHARLES F., 1951, JOUR AVIATION MED, V22, P109; McIntosh A, 1998, ACCIDENT ANAL PREV, V30, P161, DOI 10.1016/S0001-4575(97)00089-4; MERTZ HJ, 1982, P 9 INT TECHN C EXP; Mills NJ., 1996, INT J CRASHWORTHINES, V2, P7; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; *NAT OP COMM STAND, 1982, STAND METH IMP TEST; Newman J, 2000, P 44 STAPP CAR CRASH; Newman JA, 1993, ACCIDENTAL INJURY BI, P292; NEWMAN JA, 1999, P INT IRCOBI C BIOM; Odelgard B., 1989, SAFETY ICE HOCKEY, P220; PATRICK LM, 1970, IMPACT INJURY CRASH, P444; Pearsall DJ, 2000, AM SOC TEST MATER, V1341, P78, DOI 10.1520/STP15229S; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Roper WW, 1927, FOOTBALL TODAY TOMOR, P155; Sano K, 1972, Scand J Rehabil Med, V4, P47; SPYROU E, 2001, MAT SCI SPORTS, P199; Spyrou E, 2000, SPORTS ENG, V3, P25; SWART R, 2003, HIST BICYCLE HELMETS; THIBAULT KL, 1997, 1997 ADV BIOENGINEER, V36, P137; YOGANANDAN N, 1998, FRONTIERS HEAD NECK, P113; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	52	55	55	0	33	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2004	55	4					956	966		10.1227/01.NEU.0000137275.50246.0B			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100052	15458605				2021-06-18	
J	Panerai, RB; Kerins, V; Fan, L; Yeoman, PM; Hope, T; Evans, DH				Panerai, RB; Kerins, V; Fan, L; Yeoman, PM; Hope, T; Evans, DH			Association between dynamic cerebral autoregulation and mortality in severe head injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cerebral autoregulation; cerebral blood flow; Doppler ultrasound; intracranial pressure; severe head injury	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; SPONTANEOUS FLUCTUATIONS; PRESSURE AUTOREGULATION; REACTIVITY; RESPONSES; HUMANS	The objective of the study was to test the hypothesis that dynamic cerebral pressure-autoregulation is associated with the outcome of patients with severe head injury and to derive optimal criteria for future studies on the predictive value of autoregulation indices. Repeated measurements were performed on 32 patients with severe head injury. Arterial blood pressure (ABP) was measured continuously with an intravascular catheter, intracranial pressure (ICP) was recorded with a subdural semiconductor transducer and cerebral blood flow velocity (CBFV) was measured with Doppler ultrasound in the middle cerebral artery. Transfer function analysis was performed on mean beat-to-beat values, using ABP or CBFV as input variables and CBFV or ICP as the output variables. A dynamic index of autoregulation (ARI) ranging between 0 and 9 was extracted from the CBFV step response for a change in ABP. No significant differences between survivors and non-survivors were found due to mean values of ICP, ABP, CPP, CBFV, pCO(2), GCS, age or heart rate. The transfer functions between ABP-ICP and CBFV-ICP did not show any significant differences either. The median [ lower, upper quartiles] ARI was significantly lower for non-survivors compared with survivors [4.8 (0.0, 5.9) v. 6.9 (5.9, 7.4), p = 0.004]. The correlation between ARI and GOS was also significant (r = 0.464, p = 0.011). Cohen's coefficient was optimal for a threshold of ARI = 5.86 (kappa = 0.51, p = 0.0036), leading to a sensitivity for death of 75%, specificity = 76.5%, odds ratio = 9.75 and overall precision = 75.8%. The difference in ARI values between survivors and non-survivors persisted when results were adjusted for GCS (p = 0.028). A similar analysis for the Marshall CT scale did not reach significance (p = 0.072). A logistic regression analysis confirmed that apart from the ARI, no other variables had a significant contribution to predict outcome. In this group of patients, death following severe head injury could not be explained by traditional indices of risk, but was strongly correlated to indices of dynamic cerebral pressure-autoregulation extracted by means of transfer function analysis. Future studies using a prospective design are needed to validate the predictive value of the ARI index, as estimated by transfer function analysis, in relation to death and other unfavourable outcomes.	Univ Leicester, Leicester Royal Infirm, Fac Med, Dept Cardiovasc Sci, Leicester LE1 5WW, Leics, England; Queens Med Ctr, Adult Intens Care Unit, Nottingham NG7 2UH, England; Queens Med Ctr, Dept Neurosurg, Nottingham NG7 2UH, England	Panerai, RB (corresponding author), Univ Leicester, Leicester Royal Infirm, Fac Med, Dept Cardiovasc Sci, Sandringham Bldg Room 126, Leicester LE1 5WW, Leics, England.	rp9@le.ac.uk					AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bendat J.S., 2010, RANDOM DATA ANAL MEA; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Hlatky R, 2002, J NEUROSURG, V97, P1054, DOI 10.3171/jns.2002.97.5.1054; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Minassian A.T., 2002, CRIT CARE MED, V0, P1616; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Muller M, 2003, STROKE, V34, P1197, DOI 10.1161/01.STR.0000068409.81859.C5; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Newell DW, 1996, NEUROSURGERY, V39, P35, DOI 10.1097/00006123-199607000-00008; Panerai RB, 2003, PHYSIOL MEAS, V24, P367, DOI 10.1088/0967-3334/24/2/312; Panerai RB, 1998, MED BIOL ENG COMPUT, V36, P315, DOI 10.1007/BF02522477; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Panerai RB, 2002, PHYSIOL MEAS, V23, P59, DOI 10.1088/0967-3334/23/1/306; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; ROSENTHAL R, 1978, PSYCHOL BULL, V85, P185, DOI 10.1037/0033-2909.85.1.185; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; *STATSOFT INC, 1997, STATISTICA WIND COMP, V3, P3053; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Wagner BP, 2002, CRIT CARE MED, V30, P2014, DOI 10.1097/00003246-200209000-00010; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	35	55	57	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	OCT	2004	18	5					471	479		10.1080/02688690400012343			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	881JL	WOS:000225863000004	15799148				2021-06-18	
J	Hansson, MJ; Mansson, R; Mattiasson, G; Ohlsson, J; Karlsson, J; Keep, MF; Elmer, E				Hansson, MJ; Mansson, R; Mattiasson, G; Ohlsson, J; Karlsson, J; Keep, MF; Elmer, E			Brain-derived respiring mitochondria exhibit homogeneous, complete and cyclosporin-sensitive permeability transition	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; cell death; flow cytometry; ischaemia; neurodegeneration; traumatic brain injury	TRANSIENT FOREBRAIN ISCHEMIA; CYTOCHROME-C RELEASE; IMMUNOSUPPRESSANT FK506; MEMBRANE TRANSITION; HEART-MITOCHONDRIA; DOSE-RESPONSE; AXONAL INJURY; CELL-DEATH; CALCIUM; DAMAGE	The mitochondrial permeability transition (mPT) is increasingly implicated in neuronal cell death. In the present study, isolated respiring brain mitochondria were examined for their ability to undergo calcium-induced mPT and their sensitivity to mPT inhibition by cyclosporin A (CsA). Previous studies have suggested a heterogeneous response to calcium, a limitation of CsA inhibition, and a relative resistance in the ability of respiring brain mitochondria to undergo mPT. Using fluorometric and electron microscopic analyses, we found that virtually the whole population of respiring brain mitochondria readily undergo mPT and swell upon calcium exposure. Further, brain mitochondria were highly sensitive to CsA which potentiated morphological recovery after transient swelling as well as completely blocked mPT induction in the presence of a low concentration of ADP. Using flow cytometry, which allows analysis of individual mitochondria, we demonstrate that both brain and liver mitochondria display homogeneous responses to calcium-induced mPT. We conclude that the mPT is one likely target for the broad in vivo neuroprotective effects displayed by CsA when allowed to penetrate the blood-brain barrier, and that development of compounds inhibiting mPT may prove beneficial for the treatment of severe brain disease.	Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, S-22100 Lund, Sweden; Ryhov Hosp, Dept Internal Med, Jonkoping, Sweden; Malmo Univ Hosp, Dept Neurol, Malmo, Sweden; Univ New Mexico, Hlth Sci Ctr, Dept Internal Med, Community Environm Hlth Program, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Div Neurosurg, Albuquerque, NM 87131 USA	Hansson, MJ (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Expt Brain Res Lab, S-22100 Lund, Sweden.	magnus.hansson@expbr.lu.se	Elmer, Eskil/F-9341-2014; Hansson, Magnus/G-4486-2014	Elmer, Eskil/0000-0001-7901-1826; Hansson, Magnus/0000-0002-0201-0638			Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Anneser JMH, 2001, NEUROREPORT, V12, P2663, DOI 10.1097/00001756-200108280-00015; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Bernardi P, 1999, PHYSIOL REV, V79, P1127; Borel J F, 1996, Adv Pharmacol, V35, P115, DOI 10.1016/S1054-3589(08)60276-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Brustovetsky N, 2000, J NEUROSCI, V20, P8229, DOI 10.1523/JNEUROSCI.20-22-08229.2000; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Butcher SP, 1997, J NEUROSCI, V17, P6939; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; CROMPTON M, 1988, BIOCHEM J, V255, P357; Drake M, 1996, ACTA PHYSIOL SCAND, V158, P155, DOI 10.1046/j.1365-201X.1996.535298000.x; Dubinsky JM, 1998, J NEUROSCI RES, V53, P728, DOI 10.1002/(SICI)1097-4547(19980915)53:6<728::AID-JNR10>3.0.CO;2-U; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; FOLBERGROVA J, 1990, J NEUROCHEM, V55, P1690, DOI 10.1111/j.1471-4159.1990.tb04957.x; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Friberg H, 1998, J NEUROSCI, V18, P5151; Gillessen T, 2002, BIOMED PHARMACOTHER, V56, P186, DOI 10.1016/S0753-3322(02)00184-1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; Keep Marcus F., 2003, P343; Keep Marcus F., 2003, P3; Kristal BS, 2000, DEV NEUROSCI-BASEL, V22, P376, DOI 10.1159/000017463; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 1998, EXP BRAIN RES, V120, P503, DOI 10.1007/s002210050424; Kristian T, 2001, J NEUROTRAUM, V18, P1059, DOI 10.1089/08977150152693755; Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mattiasson G, 2003, J NEUROCHEM, V87, P532, DOI 10.1046/j.1471-4159.2003.02026.x; Mattson MP, 2003, TRENDS MOL MED, V9, P196, DOI 10.1016/S1471-4914(03)00046-7; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Petronilli V, 1998, BIOFACTORS, V8, P263, DOI 10.1002/biof.5520080314; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schinder AF, 1996, J NEUROSCI, V16, P6125; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; VINK R, 1988, J BIOL CHEM, V263, P757; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; White RJ, 1996, J NEUROSCI, V16, P5688; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Yoshimoto T, 2001, BRAIN RES, V899, P148, DOI 10.1016/S0006-8993(01)02220-X; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	77	55	56	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2004	89	3					715	729		10.1111/j.1471-4159.2004.02400.x			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	812QV	WOS:000220854900019	15086528	Bronze			2021-06-18	
J	Petzold, A; Keir, G; Green, AJE; Giovannoni, G; Thompson, EJ				Petzold, A; Keir, G; Green, AJE; Giovannoni, G; Thompson, EJ			An ELISA for glial fibrillary acidic protein	JOURNAL OF IMMUNOLOGICAL METHODS			English	Article						Alzheimer's disease; CSF; ELISA GFAP; GFAP(SM126); normal pressure hydrocephalus; subarachnoid hemorrhage; traumatic brain injury	CEREBROSPINAL-FLUID; MONOCLONAL-ANTIBODIES; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; SENSITIVE ELISA; S-100 PROTEIN; GFAP; CSF; PRESSURE; CHILDREN	Glial fibrillary acidic protein (GFAP) is the major intermediate filament protein of the astrocyte, and body fluid levels of GFAP are an important tool for estimating astrogliosis and astrocytic activation in vivo. This paper presents a new sandwich ELISA allowing quantification of GFAP(SM126) from the cerebrospinal fluid (CSF). The sensitivity of the GFAP(SM126) ELISA is 5 pg/ml with a recovery of 94% and a mean within- and between-batch precision of 6% and 10%, respectively. The upper reference value for CSF GFAP(SM126) levels (9 pg/ml) was defined as the 95% cumulative frequency from 315 CSF samples. Based on this cut-off, a significantly higher proportion of patients with subarachnoid hemorrhage (100%), traumatic brain injury (100%), dementia (76%) and normal pressure hydrocephalus (85%) had pathologically elevated CSF GFAP(SM126) levels compared to patients with peripheral nervous system disorders (0%). In a critical review of the literature, we compare the analytical and clinical sensitivity of previous GFAP ELISA methods with particular reference to patients with dementia. (C) 2004 Elsevier B.V. All rights reserved.	UCL, Neurol Inst, Dept Neuroimmunol, London WC1N 3BG, England	Petzold, A (corresponding author), UCL, Neurol Inst, Dept Neuroimmunol, Queen Sq, London WC1N 3BG, England.	a.petzold@ion.ucl.ac.uk	Petzold, Axel/C-1090-2009; Green, Alison/O-7356-2019	Petzold, Axel/0000-0002-0344-9749; 			AHLSEN G, 1993, BIOL PSYCHIAT, V33, P734, DOI 10.1016/0006-3223(93)90124-V; ALBRECHTSEN M, 1984, PRENATAL DIAG, V4, P405, DOI 10.1002/pd.1970040603; ALBRECHTSEN M, 1984, J NEUROCHEM, V42, P86, DOI 10.1111/j.1471-4159.1984.tb09702.x; ALBRECHTSEN M, 1985, J NEUROIMMUNOL, V8, P301, DOI 10.1016/S0165-5728(85)80069-2; ALBRECHTSEN M, 1985, J NEUROL SCI, V70, P269, DOI 10.1016/0022-510X(85)90168-6; Cody R P, 1997, APPL STAT SAS PROGRA; CROLS R, 1986, J NEUROL, V233, P157, DOI 10.1007/BF00314423; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; EHLERS S, 1994, NEUROPEDIATRICS, V25, P129, DOI 10.1055/s-2008-1071599; Eng F.L., 1970, T AM SOC NEUROCHEM, V1, P42; ENG LF, 1976, ANAL BIOCHEM, V71, P243, DOI 10.1016/0003-2697(76)90033-6; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Fukuyama R, 2001, EUR NEUROL, V46, P35, DOI 10.1159/000050753; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; Jackson RGM, 2001, BRIT J ANAESTH, V86, P601; MCLENDON RE, 1986, J NEUROPATH EXP NEUR, V45, P692, DOI 10.1097/00005072-198611000-00007; MICHETTI F, 1985, CELL TISSUE RES, V240, P137; Missler U, 1999, CLIN CHEM, V45, P138; NOPPE M, 1979, J IMMUNOL METHODS, V27, P75, DOI 10.1016/0022-1759(79)90240-0; PEGRAM CN, 1985, NEUROCHEM PATHOL, V3, P119; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Petzold A, 2002, BRAIN, V125, P1462, DOI 10.1093/brain/awf165; PETZOLD A, 2000, REV NEUROL PARIS, V156, pS140; REEVES SA, 1989, P NATL ACAD SCI USA, V86, P5178, DOI 10.1073/pnas.86.13.5178; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; ROSENGREN LE, 1995, J NEUROL SCI, V133, P61, DOI 10.1016/0022-510X(95)00152-R; ROSENGREN LE, 1985, SCAND J WORK ENV HEA, V11, P447, DOI 10.5271/sjweh.2201; ROSENGREN LE, 1992, J NEUROSCI METH, V44, P113, DOI 10.1016/0165-0270(92)90004-W; TAKAHASHI K, 1984, VIRCHOWS ARCH B, V45, P385, DOI 10.1007/BF02889881; Tullberg M, 1998, NEUROLOGY, V50, P1122, DOI 10.1212/WNL.50.4.1122; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; VICK WW, 1987, ACTA CYTOL, V31, P815; Wallin A, 1996, DEMENTIA, V7, P267, DOI 10.1159/000106891	35	55	59	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-1759	1872-7905		J IMMUNOL METHODS	J. Immunol. Methods	APR	2004	287	1-2					169	177		10.1016/j.jim.2004.01.015			9	Biochemical Research Methods; Immunology	Biochemistry & Molecular Biology; Immunology	816ZW	WOS:000221148800015	15099765				2021-06-18	
J	Gagnon, I; Swaine, B; Friedman, D; Forget, R				Gagnon, I; Swaine, B; Friedman, D; Forget, R			Children show decreased dynamic balance after mild traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	3rd World Congress on Neurological Rehabilitation	APR 02-06, 2002	VENICE, ITALY			brain injuries; equilibrium; pediatrics; rehabilitation	CLOSED-HEAD INJURY; POSTURAL INSTABILITY; MOTOR-PERFORMANCE; CONCUSSION; ADULTS; SWAY; REHABILITATION; RELIABILITY; MANAGEMENT; FEEDBACK	Objective: To compare the balance skills of children after mild traumatic brain injury (TBI) with that of noninjured children matched for age, sex, and premorbid level of physical activity. Design: Cohort study. Setting: Pediatric trauma center. Participants: Thirty-eight children aged 7 to 16 years (mean, 12.2+/-2.8y) were recruited in each group. Children with mild TBI had a mean Glasgow Coma Scale score of 14.8 and were considered normal on a neurologic assessment at hospital discharge. Noninjured children were friends of those with mild TBI. Intervention: Assessments of balance were conducted at 1, 4, and 12 weeks after mild TBI and at corresponding time intervals for the controls. Main Outcome Measures: The balance subtest of the Bruininks-Oseretsky Test of Motor Proficiency (BOTMP), the Pediatric Clinical Test of Sensory Interaction for Balance (P-CTSIB), and the Postural Stress Test (PST) were used. Results: Over the time interval of the study, analyses of variance revealed that children with mild TBI performed significantly worse than the noninjured group on the BOTMP balance subtest (P<.001) and on the PST (P=.031), as well as on the eyes-closed conditions in the P-CTSIB tandem position (P=.05). Conclusions: Children with a mild TBI still showed balance deficits at 12 weeks postinjury. These deficits should be taken into consideration when planning a return to physical activities, particularly to those that require subtle balance skills.	McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Phys Therapy Dept, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; Inst Readaptat Montreal, Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada	Gagnon, I (corresponding author), McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Phys Therapy Dept, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.	Isabelle.gagnon6@sympatico.ca					Bruininks R. H., 1978, BRUININKS OSERETSKY; CHANDLER JM, 1990, PHYS THER, V70, P410, DOI 10.1093/ptj/70.7.410; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; CROWE T K, 1990, Physical and Occupational Therapy in Pediatrics, V10, P1; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FORGET R, 1995, CAN J PHYSIOL PHARM, V73, P285, DOI 10.1139/y95-039; FORGET R, 1990, BRAIN RES, V508, P176, DOI 10.1016/0006-8993(90)91135-4; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gagnon I, 2001, J HEAD TRAUMA REHAB, V16, P595, DOI 10.1097/00001199-200112000-00007; GAGNON I, 2002, NEROREHABIL NEURAL R, V16, P22; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Graham DI, 1996, NEUROTRAUMA, P43; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; HAAS G, 1989, DEV MED CHILD NEUROL, V31, P481; HARBURN KL, 1995, ARCH PHYS MED REHAB, V76, P317, DOI 10.1016/S0003-9993(95)80656-3; Hatzitaki V, 2002, J MOTOR BEHAV, V34, P161, DOI 10.1080/00222890209601938; HIRSCHFELD H, 1991, J NEUROPHYSIOL, V66, P12; HORAK FB, 1986, J NEUROPHYSIOL, V55, P1369; HORAK FB, 1987, PHYS THER, V67, P1881, DOI 10.1093/ptj/67.12.1881; Horak FB, 1997, PHYS THER, V77, P517, DOI 10.1093/ptj/77.5.517; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; Keller M, 2000, J NEUROL NEUROSUR PS, V68, P761, DOI 10.1136/jnnp.68.6.761; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Levin HS, 1989, MILD HEAD INJURY; Levin HS, 1996, NEUROTRAUMA, P749; MOSS NEG, 1994, CLIN REHABIL, V8, P149; Nolin P., 2000, Annales de Readaptation et de Medecine Physique, V43, P236, DOI 10.1016/S0168-6054(00)89087-X; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; Reed ES, 1989, DEV POSTURE GAIT LIF, P3; SALLIS JF, 1988, AM J EPIDEMIOL, V127, P933, DOI 10.1093/oxfordjournals.aje.a114896; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Westcott Sarah L., 1994, Physical and Occupational Therapy in Pediatrics, V14, P1, DOI 10.1300/J006v14n01_01; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; WOLFSON LI, 1986, J AM GERIATR SOC, V34, P845, DOI 10.1111/j.1532-5415.1986.tb07256.x; Woollacott MH, 1996, J AGING PHYS ACTIV, V4, P214, DOI 10.1123/japa.4.3.214	45	55	55	0	13	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2004	85	3					444	452		10.1016/j.apmr.2003.06.014			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	801AC	WOS:000220067800015	15031831				2021-06-18	
J	Wilde, EA; Bigler, ED; Gandhi, PV; Lowry, CM; Blatter, DD; Brooks, J; Ryser, DK				Wilde, EA; Bigler, ED; Gandhi, PV; Lowry, CM; Blatter, DD; Brooks, J; Ryser, DK			Alcohol abuse and traumatic brain injury: Quantitative magnetic resonance imaging and neuropsychological outcome	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; magnetic resonance imaging; neuropsychological outcome; substance abuse; traumatic brain injury	CEREBRAL BLOOD-FLOW; ACUTE ETHANOL INTOXICATION; POSITRON-EMISSION-TOMOGRAPHY; CENTRAL-NERVOUS-SYSTEM; COGNITIVE DEFICITS; HEAD-INJURY; DETOXIFIED ALCOHOLICS; ABSTINENT ALCOHOLICS; GLUCOSE-METABOLISM; HEMORRHAGIC-SHOCK	Prior or concurrent alcohol use at the time of traumatic brain injury (TBI) was examined in terms of post-injury atrophic changes measured by quantitative analysis of magnetic resonance imaging (MRI) and neuropsychological outcome. Two groups of TBI subjects were examined: those with a clinically significant blood alcohol level (BAL) present at the time of injury (TBI+BAL) and those without a significant BAL (TBI-only). To explore the potential impact of both acute and chronic alcohol use, subjects in both groups were further clustered into one of four subgroups (NONE, MILD, MODERATE or HEAVY) based upon available information regarding their pre-injury alcohol use. One-way analysis of covariance (ANCOVA) and multiple analysis of covariance (MANCOVA) were used with subject grouping as the main factor. Age, injury severity as measured by Glasgow Coma Scale (GCS) score, years of education, total intracranial volume (TICV), and the number of days post-injury were included as covariates where appropriate. Increased general atrophy was observed in patients with (a) a positive BAL and/or (b) a history of moderate to heavy pre-injury alcohol use. In addition, performance on neuropsychological outcome variables (WAIS-R and WMS-R Index scores) was generally worse in the subgroups of patients with positive BAL and a history of pre-injury alcohol use, as compared to the other TBI groups though not statistically significant. Implications of alcohol use, at the time of brain injury, are discussed.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; LDS Hosp, Salt Lake City, UT USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Brigham Young Univ, Dept Psychol, Rexburg, ID USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.	erin_bigler@byu.edu					AASLY J, 1993, ACTA NEUROL SCAND, V87, P210; ADAMS KM, 1993, ALCOHOL CLIN EXP RES, V17, P205, DOI 10.1111/j.1530-0277.1993.tb00750.x; ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; *AM PSYCH ASS, 1994, DSM4 DIAGN STAT MAN; BADSBERGJENSEN G, 1990, HISTOL HISTOPATHOL, V5, P349; Baguley IJ, 1997, ARCH PHYS MED REHAB, V78, P1248, DOI 10.1016/S0003-9993(97)90339-7; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Beresford T, 1999, J STUD ALCOHOL, V60, P586, DOI 10.15288/jsa.1999.60.586; BERGLUND M, 1987, ACTA PSYCHIAT SCAND, V75, P202, DOI 10.1111/j.1600-0447.1987.tb02775.x; Bigler E D, 1989, J Neuropsychiatry Clin Neurosci, V1, P341; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Brown SA, 2000, ALCOHOL CLIN EXP RES, V24, P164, DOI 10.1111/j.1530-0277.2000.tb04586.x; BULLOCK R, 1990, ALCOHOL CLIN EXP RES, V24, P164; CASPARI D, 1993, ACTA PSYCHIAT SCAND, V87, P414, DOI 10.1111/j.1600-0447.1993.tb03397.x; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DALLY S, 1988, BRIT J ADDICT, V83, P105; De Bellis MD, 2000, AM J PSYCHIAT, V157, P737, DOI 10.1176/appi.ajp.157.5.737; DEWIT H, 1990, ALCOHOL CLIN EXP RES, V14, P482; Dikmen S. S., 1993, NEUROPSYCHOLOGIA, V7, P296, DOI DOI 10.1037/0894-4105.7.3.296; DISCLAFANI V, 1995, ALCOHOL CLIN EXP RES, V19, P1121; Dupont RM, 1996, PSYCHIAT RES-NEUROIM, V67, P99, DOI 10.1016/0925-4927(96)02769-2; ELMER O, 1984, HAEMOSTASIS, V14, P223; Emsley R, 1996, ALCOHOL ALCOHOLISM, V31, P479; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FULLER MG, 1994, J NEUROPSYCH CLIN N, V6, P143; Gilman S, 1996, ALCOHOL CLIN EXP RES, V20, P1456, DOI 10.1111/j.1530-0277.1996.tb01149.x; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HATA T, 1987, J CEREBR BLOOD F MET, V7, P35, DOI 10.1038/jcbfm.1987.6; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KELLY DF, 1995, CRIT CARE MED, V23, pA245; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Mann K, 1999, ALCOHOL ALCOHOLISM, V34, P567, DOI 10.1093/alcalc/34.4.567; MANN K, 1995, J NEURAL TRANSM-GEN, V99, P145, DOI 10.1007/BF01271475; Masse J, 2000, J NEUROTRAUM, V17, P421, DOI 10.1089/neu.2000.17.421; McCann UD, 1997, NEUROSCIENTIST, V3, P399, DOI 10.1177/107385849700300613; McQueen J D, 1975, Surg Neurol, V4, P375; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; Netrakom P, 1999, PSYCHIAT CLIN N AM, V22, P313, DOI 10.1016/S0193-953X(05)70079-4; Nicolas JM, 1997, ANN NEUROL, V41, P590, DOI 10.1002/ana.410410507; Nutt D, 1999, BRIT J PSYCHIAT, V175, P114, DOI 10.1192/bjp.175.2.114; PARSONS OA, 1993, NEUROL CLIN, V11, P205; PARSONS OA, 1986, ALCOHOL ALCOHOLISM, V21, P137; Parsons OA, 1998, J STUD ALCOHOL, V59, P180, DOI 10.15288/jsa.1998.59.180; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PERSSON LI, 1978, ACTA NEUROL SCAND, V57, P405; Pfefferbaum A, 1998, ARCH GEN PSYCHIAT, V55, P905, DOI 10.1001/archpsyc.55.10.905; Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Robb RA, 2001, IEEE T MED IMAGING, V20, P854, DOI 10.1109/42.952724; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Sabhesan S, 1988, Indian J Psychiatry, V30, P345; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; SCHWARTZ JA, 1993, ALCOHOL CLIN EXP RES, V17, P1119, DOI 10.1111/j.1530-0277.1993.tb05217.x; Selby MJ, 1998, DRUG ALCOHOL DEPEN, V50, P39, DOI 10.1016/S0376-8716(98)00002-7; SHEAR PK, 1992, ALCOHOL, V9, P247, DOI 10.1016/0741-8329(92)90061-E; Shear PK, 1996, ALCOHOL CLIN EXP RES, V20, P1489, DOI 10.1111/j.1530-0277.1996.tb01153.x; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; TEASDALE G, 1974, LANCET, V2, P81; VOLKOW ND, 1990, PSYCHIAT RES-NEUROIM, V35, P39, DOI 10.1016/S0165-1781(06)80006-5; VOLKOW ND, 1994, AM J PSYCHIAT, V151, P178; WANG GJ, 1993, RADIOLOGY, V186, P59, DOI 10.1148/radiology.186.1.8416587; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; White AM, 2000, HIPPOCAMPUS, V10, P88, DOI 10.1002/(SICI)1098-1063(2000)10:1<88::AID-HIPO10>3.0.CO;2-L; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P205, DOI 10.1111/j.1530-0277.1990.tb00473.x; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; ZINK BJ, 1993, J NEUROTRAUM, P3	82	55	55	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					137	147		10.1089/089771504322778604			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200002	15000755				2021-06-18	
J	Mathias, JL; Bigler, ED; Jones, NR; Bowden, SC; Barrett-Woodbridge, M; Brown, GC; Taylor, AJ				Mathias, JL; Bigler, ED; Jones, NR; Bowden, SC; Barrett-Woodbridge, M; Brown, GC; Taylor, AJ			Neuropsychological and information processing performance and its relationship to white matter changes following moderate and severe traumatic brain injury: A preliminary study	APPLIED NEUROPSYCHOLOGY			English	Article; Proceedings Paper	5th World Congress on Traumatic Brain Injury	MAY, 2003	STOCKHOLM, SWEDEN			information processing speed; interhemispheric processing; white matter; traumatic brain injury; neuropsychological performance; corpus callosum	CLOSED-HEAD-INJURY; CORPUS-CALLOSUM; SEX-DIFFERENCES; AXONAL INJURY; REACTION-TIME; MILD; ATTENTION; ATROPHY; DISCONNECTION; INTELLIGENCE	Reductions in information processing speed have frequently been reported following moderate and severe traumatic brain injuries (TBIs), consistent with the effects of diffuse white matter damage. Although the corpus callosum (CC) is a common site for diffuse damage following TBI, the effects of this damage on information processing speed have not been adequately examined. This study assessed a TBI group and a matched control group on tests of attention, memory, fluency, and set shifting ability, together with reaction time (RT) tasks requiring the inter- and intrahemispheric processing of visual and tactile information. The RT tasks were designed to target the cognitive functions that are likely to be affected by diffuse white matter damage, including damage to the CC. The TBI group demonstrated deficits in verbal and visual fluency and verbal memory. They were also slower on the visual and tactile RT tasks, were more affected by task complexity, and slower on RT tasks requiring the interhemispheric transfer of information. In fact, one of the interhemispheric tactile RT tasks proved to be the most discriminating of all the cognitive and RT measures. MRIs completed on a subset of TBI participants indicated that the mean CC measurements were 5% to 19% smaller than a normative control group, with the most atrophied areas being the isthmus and anterior midbody. Although white matter atrophy was moderately related to visual and tactile RT performance, and total hippocampal volume related to memory performance, CC area was not related to many of the tasks that were designed to tap interhemispheric processing. None of the standard cognitive tests correlated with outcome in the TBI group, but 1 of the tactile RT measures was significantly related to 2 measures of outcome.	Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Univ Utah, Dept Psychiat & Radiol, Salt Lake City, UT USA; Univ Adelaide, Dept Neurosurg, Adelaide, SA 5005, Australia; Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; Royal Adelaide Hosp, Dept Radiol, Adelaide, SA, Australia	Mathias, JL (corresponding author), Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia.	jane.mathias@psychology.adelaide.edu.au	Brown, Gregory/D-3983-2013; Mathias, J L/L-6295-2013	Brown, Gregory/0000-0001-7994-2743; Mathias, Jane/0000-0001-8957-8594			ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; ANDERSON DR, 1982, TESTING FIELD VISION; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bagley LJ, 1999, AM J NEURORADIOL, V20, P977; Banich M. T, 1997, NEUROPSYCHOLOGY NEUR; BANICH MT, 1992, J EXP PSYCHOL HUMAN, V18, P763, DOI 10.1037/0096-1523.18.3.763; Banich MT, 1994, NEUROPSYCHOLOGY, V8, P263; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BERGESON AG, IN PRESS CLIN NEUROP; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BRAUNSTEIN P, 1989, STEREOCHEMISTRY ORGA, V3, P1; CECH KM, 1998, J NEUROSURG, V88, P795; CLARKE JM, 1994, BEHAV BRAIN RES, V64, P185, DOI 10.1016/0166-4328(94)90131-7; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Corballis MC, 2002, NEUROPSYCHOLOGIA, V40, P423, DOI 10.1016/S0028-3932(01)00097-5; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; CURRY LM, 1991, PHILADELPHIA HEAD IN; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; Deloche Gerard, 1993, Brain Injury, V7, P363, DOI 10.3109/02699059309034963; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; EVANS RW, 1985, PERCEPT MOTOR SKILL, V61, P699, DOI 10.2466/pms.1985.61.3.699; Freeman J, 2000, BRIT J CLIN PSYCHOL, V39, P95, DOI 10.1348/014466500163130; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gean A, 1994, IMAGING HEAD TRAUMA; GEFFEN G, 1985, NEUROPSYCHOLOGIA, V23, P497, DOI 10.1016/0028-3932(85)90004-1; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V2, P823; Heaton R., 1993, WISCONSIN CARD SORTI; Hillier SL, 1997, BRAIN INJURY, V11, P649; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holden C, 2003, SCIENCE, V299, P192, DOI 10.1126/science.299.5604.192; HOPKINS RO, 2003, J INT NEUROPSYCH SOC, V9, P234; IACOBONI M, 1995, BRAIN, V118, P779, DOI 10.1093/brain/118.3.779; JENNETT B, 1975, LANCET, V1, P480; Johnson SC, 1996, NEUROPSYCHOLOGY, V10, P408, DOI 10.1037/0894-4105.10.3.408; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Klaas PA, 1999, J CLIN EXP NEUROPSYC, V21, P837, DOI 10.1076/jcen.21.6.837.851; Levander MB, 1998, BRAIN INJURY, V12, P165, DOI 10.1080/026990598122791; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Milders M, 1999, J CLIN EXP NEUROPSYC, V21, P171, DOI 10.1076/jcen.21.2.171.932; OTOOLE BI, 1990, ACCIDENT ANAL PREV, V22, P211, DOI 10.1016/0001-4575(90)90013-B; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; QUINN K, 1986, NEUROPSYCHOLOGIA, V24, P793, DOI 10.1016/0028-3932(86)90078-3; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; Robertson I. H., 1994, TEST EVERYDAY ATTENT; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schmidt M., 1996, REY AUDITORY VERBAL; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VUILLEUMIER P, 1995, CLIN NEUROL NEUROSUR, V97, P39, DOI 10.1016/0303-8467(94)00056-C; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Wilson, 1991, NATL ADULT READING T; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	88	55	56	1	8	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2004	11	3					134	152		10.1207/s15324826an1103_2			19	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	883SL	WOS:000226035900002	15590348				2021-06-18	
J	Sarrafzadeh, AS; Kiening, KL; Callsen, TA; Unterberg, AW				Sarrafzadeh, AS; Kiening, KL; Callsen, TA; Unterberg, AW			Metabolic changes during impending and manifest cerebral hypoxia in traumatic brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						brain tissue-PO2; cerebral metabolism; cerebral oxygenation; hypoxia; ischaemia; microdialysis; multimodal monitoring; severe head injury	SEVERE HEAD-INJURY; SUBSTRATE DELIVERY; TISSUE PO2; BLOOD-FLOW; MICRODIALYSIS; HYPERVENTILATION; RELEASE; LACTATE	The objective was to measure metabolic changes monitored by bedside microdialysis during impending and manifest hypoxia in traumatic brain injury. In 41 patients, a PtiO(2)-catheter (Licox; 1/min) was placed into non-lesioned frontal white matter together with a microdialysis catheter (CMA, hourly). Data were analysed for identification of episodes of impending (PtiO(2) <10 - 15 mmHg >5 min) and manifest cerebral hypoxia (PtiO(2) <10 mmHg, >5 min). In 69% of patients hypoxic episodes occurred, most frequently associated with hyperventilation ( p<0.001). During impending hypoxia, glutamate was increased ( p = 0.03), while the energy metabolites remained stable. Manifest hypoxia was reflected by significant increases of glutamate ( p = 0.007) and lactate ( p = 0.044), but normal lactate-pyruvate ratios. We conclude that hyperventilation had a potential adverse effect on cerebral metabolism and was most frequently associated with cerebral hypoxia. A PtiO(2) <10 mmHg can induce metabolic changes with increase of glutamate and lactate. The presence of anaerobic cerebral metabolism probably depends on duration and severity of the hypoxic episode.	Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, D-13353 Berlin, Germany; Heidelberg Univ, Dept Neurosurg, D-6900 Heidelberg, Germany	Sarrafzadeh, AS (corresponding author), Humboldt Univ, Virchow Med Ctr, Charite, Dept Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Magistretti PJ, 2000, BRAIN RES, V886, P108, DOI 10.1016/S0006-8993(00)02945-0; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MEIXENSBERGER J, 1993, ACTA NEUROCHIR, P58; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CS, 1998, NEUROL RES, V20, pS91; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Schneider GH, 1998, ACT NEUR S, V71, P62; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; UNGERSTEDT U, 1987, LIFE SCI, V41, P861, DOI 10.1016/0024-3205(87)90181-0; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011; Zauner A, 1996, ACT NEUR S, V67, P40	25	55	55	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	AUG	2003	17	4					340	346		10.1080/02688690310001601234			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	722FC	WOS:000185363900007	14579900				2021-06-18	
J	Meythaler, JM; Roper, JF; Brunner, RC				Meythaler, JM; Roper, JF; Brunner, RC			Cyproheptadine for intrathecal baclofen withdrawal	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						baclofen; cyproheptadine; hyperpyrexia; malignant; infusion pumps; implantable; muscle spasticity; neuroleptic malignant syndrome; receptors, GABA-B; rehabilitation; serotonin; serotonin syndrome; withdrawal symptoms	TRAUMATIC BRAIN INJURY; SPASTIC HYPERTONIA; SEROTONIN SYNDROME; SPINAL ORIGIN; MANAGEMENT; ECSTASY; DEATH	Objective: To evaluate the efficacy of cyproheptadine in the management of acute intrathecal baclofen (ITB) withdrawal. Design: Descriptive case series. Setting: University hospital with a comprehensive in- and outpatient rehabilitation center. Participants: Four patients (3 with spinal cord injury, 1 with cerebral palsy) with implanted ITB infusion pumps for treatment of severe spasticity, who had ITB withdrawal syndrome because of interruption of ITB infusion. Interventions: Patients were treated with 4 to 8mg of cyproheptadine by mouth every 6 to 8 hours, 5 to 10mg of diazeparn by mouth every 6 to 12 hours, 10 to 20mg of baclofen by mouth every 6 hours, and ITB boluses in some cases. Main Outcome Measures:' Clinical signs and symptoms of ITB withdrawal of varying severity were assessed by vital signs (temperature, heart rate), physical examination (reflexes, tone, clonus), and patient report of symptoms (itching, nausea, headache, malaise). Results: The patients in our series improved significantly when the serotonin antagonist cyproheptadine was added to their regimens. Fever dropped at least 1.5degreesC, and heart rate dropped from rates of 120 to 140 to less than 100bpm. Reflexes, tone, and myoclonus also decreased. Patients reported dramatic reduction in itching after cyproheptadine. These changes were associated temporally with cyproheptadine dosing. Discussion: Acute ITB withdrawal syndrome occurs frequently in cases of malfunctioning intrathecal infusion pumps or catheters. The syndrome commonly presents with pruritus and increased muscle tone. It can progress rapidly to high fever, altered mental status, seizures, profound muscle rigidity, rhabdomyolysis, brain injury, and death. Current therapy with oral baclofen and benzodiazepines is, useful but has variable success, particularly in severe cases. We note that ITB withdrawal is similar to serotonergic syndromes, such as in overdoses of selective serotonin reuptake inhibitors or the popular drug of abuse 3,4-methylenedioxymethamphetamine (Ecstasy). We postulate that ITB withdrawal may be a form of serotonergic syndrome that occurs from loss of gamma-aminobutyric acid B receptor-mediated presynaptic inhibition of serotonin. Conclusion: Cyproheptadine may be a useful adjunct to baclofen and benzodiazepines in the management of acute ITB withdrawal syndrome.	Univ Alabama, Sch Med, Dept Phys Med & Rehabil, Birmingham, AL 35249 USA; Univ Alabama, Spain Rehabil Ctr, Birmingham, AL 35249 USA	Meythaler, JM (corresponding author), Univ Alabama, Sch Med, Dept Phys Med & Rehabil, R157,619 6th Ave S, Birmingham, AL 35249 USA.						Al-Khodairy AT, 1999, AM J PHYS MED REHAB, V78, P272, DOI 10.1097/00002060-199905000-00018; ASHWORTH B, 1964, PRACTITIONER, V192, P540; BARKER I, 1982, LANCET, V2, P556; BOSE P, 2002, J NEUROTRAUM, V19, P1305; Burns AS, 2001, SPINAL CORD, V39, P413, DOI 10.1038/sj.sc.3101178; Carbone JR, 2000, EMERG MED CLIN N AM, V18, P317, DOI 10.1016/S0733-8627(05)70127-9; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; Coffey RJ, 2001, NEUROMODULATION, V4, P142, DOI 10.1046/j.1525-1403.2001.00142.x; Coffey RJ, 2002, ARCH PHYS MED REHAB, V83, P735, DOI 10.1053/apmr.2002.32820; David WS, 2000, NEUROL CLIN, V18, P215, DOI 10.1016/S0733-8619(05)70187-0; GARABEDIANRUFFALO SM, 1985, DRUG INTEL CLIN PHAR, V19, P304; Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; Grenier B, 1996, ANN FR ANESTH, V15, P659, DOI 10.1016/0750-7658(96)82130-7; HARRISON SA, 1985, DRUG INTEL CLIN PHAR, V19, P747, DOI 10.1177/106002808501901012; McRae AL, 2001, MED CLIN N AM, V85, P779, DOI 10.1016/S0025-7125(05)70340-0; *MED EC, 2001, PHYS DESK REF, P1993; Meythaler J M, 2001, Phys Med Rehabil Clin N Am, V12, P725; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; MEYTHALER JM, 1992, AM J PHYS MED REHAB, V71, P321, DOI 10.1097/00002060-199212000-00003; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P155, DOI 10.1053/apmr.2001.19246; Meythaler JM, 1999, SPINAL DRUG DELIVERY, P513; Meythaler JM, 2001, STROKE, V32, P2099, DOI 10.1161/hs0901.095682; Mills KC, 1997, CRIT CARE CLIN, V13, P763, DOI 10.1016/S0749-0704(05)70368-7; Mueller PD, 1998, ANN EMERG MED, V32, P377, DOI 10.1016/S0196-0644(98)70018-6; Nance P, 1999, Phys Med Rehabil Clin N Am, V10, P385; Nance P W, 2001, Phys Med Rehabil Clin N Am, V12, P889; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Ramcharan S, 1998, J TOXICOL-CLIN TOXIC, V36, P727, DOI 10.3109/15563659809162623; Wilkinson R, 1999, BRAIN INJURY, V13, P1025	31	55	56	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2003	84	5					638	642		10.1016/S0003-9993(03)00105-9			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	675NF	WOS:000182700900003	12736874				2021-06-18	
J	Malessy, MJA; Bakker, D; Dekker, J; Van Dijk, JG; Thomeer, RTWM				Malessy, MJA; Bakker, D; Dekker, J; Van Dijk, JG; Thomeer, RTWM			Functional magnetic resonance imaging and control over the biceps muscle after intercostal-musculocutaneous nerve transfer	JOURNAL OF NEUROSURGERY			English	Article						brachial plexus; functional magnetic resonance imaging; intercostal nerve; motor cortex; nerve transfer; plasticity	BRACHIAL-PLEXUS INJURY; PRIMARY MOTOR CORTEX; HUMAN BRAIN; MRI; FMRI; REORGANIZATION; STIMULATION; ACTIVATION; RECOVERY; REPAIR	Object. Recent progress in the understanding of cerebral plastic changes that occur after an intercostal nerve (ICN)musculocutaneous nerve (MCN) transfer motivated a study with functional magnetic resonance (fMR) imaging to map reorganization in the primary motor cortex. Methods. Eleven patients with traumatic root avulsions of the brachial plexus were studied. Nine patients underwent ICN-MCN transfer to restore biceps function and two patients were studied prior to surgery. The biceps muscle recovered well in seven patients who had undergone surgery and remained paralytic in the other two patients. Maps of neural activity within the motor cortex were generated for both arms in each patient by using fMR imaging, and the active pixels were counted. The motor task consisted of biceps muscle contraction. Patients with a paralytic biceps were asked to contract this muscle virtually. The location and intensity of motor activation of the seven surgically treated arms that required good biceps muscle function were compared with those of the four arms with a paralytic biceps and with activity obtained in the contralateral hemisphere regulating the control arms. Activity could be induced in the seven surgically treated patients whose biceps muscles had regained function and was localized within the primary motor area. In contrast, activity could not be induced in the four patients whose biceps muscles were paralytic. Neither the number of active pixels nor the mean value of their activations differed between the seven arms with good biceps function and control arms. The weighted center of gravity of the distribution of activity also did not appear to differ. Conclusions. Reactivation of the neural input activity for volitional biceps control after ICN-MCN transfer, as reflected on fMR images, is induced by successful biceps muscle reinnervation. In addition, the restored input activity does not differ from the normal activity regulating biceps contraction and, therefore, has MCN acceptor qualities. After ICN-MCN transfer, cerebral activity cannot reach the biceps muscle following the normal nervous system pathway. The presence of a common input response between corticospinal neurons of the ICN donor and the MCN acceptor seems crucial to obtain a functional result after transfer. It may even be the case that a common input response between donor and acceptor needs to be present in all types of nerve transfer to become functionally effective.	Leiden Univ, Med Ctr, Dept Neurosurg, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Radiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Neurol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Neurophysiol, NL-2300 RC Leiden, Netherlands	Malessy, MJA (corresponding author), Leiden Univ, Med Ctr, Dept Neurosurg, POB 9600, NL-2300 RC Leiden, Netherlands.	M.J.A.Malessy@lumc.nl					Bakay RAE, 2001, NEUROSURGERY, V49, P367; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Cheng H, 1997, J COMP NEUROL, V380, P155, DOI 10.1002/(SICI)1096-9861(19970407)380:2<155::AID-CNE1>3.0.CO;2-2; Dai TH, 2001, EXP BRAIN RES, V140, P290, DOI 10.1007/s002210100815; Dale AM, 1997, HUM BRAIN MAPP, V5, P329, DOI 10.1002/(SICI)1097-0193(1997)5:5<329::AID-HBM1>3.0.CO;2-5; Dettmers C, 1999, NEUROSCI LETT, V263, P41, DOI 10.1016/S0304-3940(99)00105-6; Evans KC, 1999, J PHYSIOL-LONDON, V520, P383, DOI 10.1111/j.1469-7793.1999.00383.x; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Giraux P, 2001, NAT NEUROSCI, V4, P691, DOI 10.1038/89472; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; KAWAI H, 1994, J BONE JOINT SURG BR, V76B, P666; Kawai H, 2000, BRACHIAL PLEXUS PALS, P161; KAWASHIMA R, 1995, NEUROREPORT, V6, P238, DOI 10.1097/00001756-199501000-00003; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Krings T, 1997, NEUROLOGY, V48, P1406, DOI 10.1212/WNL.48.5.1406; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Malessy MJA, 1998, J NEUROSURG, V88, P266, DOI 10.3171/jns.1998.88.2.0266; Malessy MJA, 1999, J NEUROSURG, V91, P601, DOI 10.3171/jns.1999.91.4.0601; MALESSY MJA, 1993, CLIN NEUROL NEUROSUR, V95, pS95; Malessy MJA, 1998, NEUROSURGERY, V42, P787, DOI 10.1097/00006123-199804000-00062; Malessy MJA, 1999, J NEUROSURG, V91, P636, DOI 10.3171/jns.1999.91.4.0636; Malessy MJA, 1998, J NEUROSURG, V89, P568, DOI 10.3171/jns.1998.89.4.0568; MANO Y, 1995, ANN NEUROL, V38, P15, DOI 10.1002/ana.410380106; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; PENFIELD W, 1954, EPILEPSY FUNCTIONAL, P52; RAO SM, 1995, NEUROLOGY, V45, P919, DOI 10.1212/WNL.45.5.919; Rees G, 2000, NAT NEUROSCI, V3, P716, DOI 10.1038/76673; Rosen BR, 1998, P NATL ACAD SCI USA, V95, P773, DOI 10.1073/pnas.95.3.773; Roth R, 1996, NEUROREPORT, V7, P1280, DOI 10.1097/00001756-199605170-00012; Seddon HJ, 1954, PERIPHERAL NERVE INJ; THOMEER RTWM, 1993, CLIN NEUROL NEUROSUR, V95, pS65; WASSERMANN EM, 1992, ELECTROEN CLIN NEURO, V85, P1, DOI 10.1016/0168-5597(92)90094-R; XUE M, 1996, P SOC MAGN RES, P447	34	55	59	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2003	98	2					261	268		10.3171/jns.2003.98.2.0261			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	643RB	WOS:000180873300001	12593609				2021-06-18	
J	Forducey, PG; Ruwe, WD; Dawson, SJ; Scheideman-Miller, C; McDonald, NB; Hantla, MR				Forducey, PG; Ruwe, WD; Dawson, SJ; Scheideman-Miller, C; McDonald, NB; Hantla, MR			Using telerehabilitation to promote TBI recovery and transfer of knowledge	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; DISABILITIES; STROKE; URBAN; STATE	Advances in the design and delivery of trauma care and acute medical management have increased the number of survivors of traumatic brain injury (TBI), producing societal consequences and medical challenges. Although access to health care for rural patients remains a critical challenge, teletherapy may represent a viable means for the delivery of therapeutic services to such patients. A case study is presented in which teletherapy was successfully utilized to improve the functional outcomes, both physical and cognitive, of a patient with a severe TBI. A physical therapist from a metropolitan rehabilitation center employed teletherapy to provide Neuro Developmental Treatment for a patient and to mentor staff in a nursing home located over 100 miles from the metro area. The patient, who participated in 48 physical teletherapy sessions over a 24-week period, demonstrated improvements in physical functioning and neuropsychological status. During the course of therapy, goals were adjusted upward to match the patient's improvements. This case study provides confirmatory evidence that teletherapy represents an effective and efficient means for providing rehabilitation services for patients in rural communities, as well as for facilitating mentoring relationships between seasoned professionals and trainees located in rural settings.	INTEGRIS Jim Thorpe Rehabil Ctr, Oklahoma City, OK USA	Forducey, PG (corresponding author), INTEGRIS Jim Thorpe Rehabil Ctr, 4219 S Westerna Ave, Oklahoma City, OK USA.						Artunian J, 1997, Rehab Manag, V10, P54; ARTUNIAN J, 1997, REHAB MANAGEMENT, V10, P58; ARTUNIAN J, 1997, REHAB MANAGEMENT, V10, P56; Auchincloss AH, 2002, J RURAL HEALTH, V18, P319, DOI 10.1111/j.1748-0361.2002.tb00894.x; Bobath B., 1990, ADULT HEMIPLEGIA EVA; BORSTAD AL, 2001, P STAT SCI C TEL APP, P3; Bull CN, 2001, J RURAL HEALTH, V17, P356, DOI 10.1111/j.1748-0361.2001.tb00288.x; Burns RB, 1998, ASSIST TECHNOL, V10, P126, DOI 10.1080/10400435.1998.10131970; *CDC, TRAUM BRAIN INJ US R; CLARK PG, 2002, NEUROLOGY REPORT, V26, P86; Conner K, 1999, Rehab Manag, V12, P72; CONNER K, 1999, REHAB MANAGEMENT, V12, P74; DAWSON SJ, 1999, PHYSICAL THERAPY CAS, V3, P84; Eldar R, 2001, J RURAL HEALTH, V17, P341, DOI 10.1111/j.1748-0361.2001.tb00285.x; Gabella B, 1997, ANN EPIDEMIOL, V7, P207, DOI 10.1016/S1047-2797(96)00150-0; Glueckauf RL, 2002, REHABIL PSYCHOL, V47, P3, DOI 10.1037/0090-5550.47.1.3; Keren O, 2001, BRAIN INJURY, V15, P633, DOI 10.1080/02699050010009568; Kopp B, 1999, NEUROREPORT, V10, P807, DOI 10.1097/00001756-199903170-00026; Liepert J, 2000, STROKE, V31, P1210, DOI 10.1161/01.STR.31.6.1210; Nudo RJ, 1999, CURR OPIN NEUROBIOL, V9, P740, DOI 10.1016/S0959-4388(99)00027-6; Ogden R, 1917, PSYCHOBIOLOGY, V1, P33, DOI [10.1037/h0074814, DOI 10.1037/H0074814]; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Rogers FB, 1999, J TRAUMA, V47, P802, DOI 10.1097/00005373-199910000-00038; Rogers FB, 2001, J TRAUMA, V50, P604, DOI 10.1097/00005373-200104000-00003; SCHEIDEMANMILLE.CL, 2002, UNPUB RURAL POST ACU; Schopp LH, 2000, J TELEMED TELECARE, V6, P146, DOI 10.1258/1357633001934474; Snow C, 1996, Mod Healthc, V26, P102; SNOW C, 1996, MODERN HEALTHCARE, V26, P102; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vesmarovich S, 1999, Adv Wound Care, V12, P264; 1998, NIH CONSENSUS STATEM, V16, P1	31	55	57	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2003	18	2					103	111					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	743ZU	WOS:000186604100003	12867673				2021-06-18	
J	Schatz, P; Zillmer, EA				Schatz, P; Zillmer, EA			Computer-based assessment of sports-related concussion	APPLIED NEUROPSYCHOLOGY			English	Article						sports-related concussion; mild traumatic brain injury; neuropsychology; computerized neuropsychological assessment	COGNITIVE ASSESSMENT; RELIABILITY; PERFORMANCE; MACINTOSH; TESTS	Sports-related concussion has received considerable attention from neuropsychologists, athletic trainers, team coaches, physicians, families, and athletes. In this context, researchers have recently developed computer programs for the assessment of sports-related concussion. Computer-based assessment of sports-related concussion saves time, allows for team baseline testing, and can be easily incorporated into the sports medicine environment. This article reviews the advantages and limitations of computer-based assessment of sports-related concussion. Within a well-coordinated concussion management program that includes input from a neuropsychologist, computer-based assessment of sports-related concussion will soon be the most common approach for assessing concussion in athletes.	St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; Drexel Univ, Dept Athlet, Philadelphia, PA 19104 USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, Post Hall 222, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			American Psychological Association, 1986, GUID COMP BAS TEST I; Barak A, 1999, APPL PREV PSYCHOL, V8, P231, DOI 10.1016/S0962-1849(05)80038-1; Barth JT., 1989, MILD HEAD INJURY, P257; Bennett R. E., 1999, ED MEASUREMENT ISSUE, V18, P5, DOI DOI 10.1111/J.1745-3992.1999.TB00266.X; BROOKS J, 1998, EPIREMIOLOGY PREVENT; Campbell KA, 1999, ASSESSMENT, V6, P21, DOI 10.1177/107319119900600103; *COGSTATE, 1999, COGSPORT COMP SOFTW; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLINS M, 2001, 21 ANN C NAT AC NEUR; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ECHEMENDIA RJ, 2001, 21 C NAT AC NEUR SAN; ELWOOD DL, 1972, J CONSULT CLIN PSYCH, V38, P9, DOI 10.1037/h0032416; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, IN PRESS ARCH CLIN N; Erlanger DM, 1999, CONCUSSION RESOLUTIO; FRENCH CC, 1987, BRIT J CLIN PSYCHOL, V26, P267, DOI 10.1111/j.2044-8260.1987.tb01360.x; Gur RC, 2001, NEUROPSYCHOPHARMACOL, V25, P766, DOI 10.1016/S0893-133X(01)00278-0; Gur RC, 2000, BRAIN LANG, V74, P157, DOI 10.1006/brln.2000.2325; HONAKER LM, 1988, CLIN PSYCHOL REV, V8, P561, DOI 10.1016/0272-7358(88)90081-5; Kane R. L., 1997, NEUROPSYCHOLOGY HDB, V1, P423; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR., 2000, IMPACT IMMEDIATE POS; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; MARION DW, R01HD42386; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; MEAD AD, 1993, PSYCHOL BULL, V114, P449, DOI 10.1037/0033-2909.114.3.449; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; REED AV, 1979, BEHAV RES METH INSTR, V11, P572, DOI 10.3758/BF03201384; SPACE LG, 1981, BEHAV RES METH INSTR, V13, P595, DOI 10.3758/BF03202072; WESTALL R, 1986, BEHAV RES METH INSTR, V18, P307, DOI 10.3758/BF03204405; WESTALL RF, 1989, BEHAV RES METH INSTR, V21, P540, DOI 10.3758/BF03202886; WILSON SL, 1991, MICROCOMPUTERS CLIN, P79; ZILLMER EA, 1991, J PERS ASSESS, V57, P381, DOI 10.1207/s15327752jpa5702_15; ZILLMER EA, 1987, J FAMILY MED, V115, P107; ZILLMER ES, 2001, PRINCIPLES CLIN NEUR	39	55	55	1	10	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	1					42	47		10.1207/S15324826AN1001_6			6	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	780NF	WOS:000189386900006	12734074				2021-06-18	
J	Van Laere, KJ; Warwick, J; Versijpt, J; Goethals, I; Audenaert, K; Van Heerden, B; Dierckx, R				Van Laere, KJ; Warwick, J; Versijpt, J; Goethals, I; Audenaert, K; Van Heerden, B; Dierckx, R			Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: An ROC-based comparison of visual, semiquantitative, and voxel-based methods	JOURNAL OF NUCLEAR MEDICINE			English	Article						SPECT; statistical parametric mapping; traumatic brain injury; cognitive impairment; anatomic standardization	F-18 FDG PET; OBSERVER-PERFORMANCE; VALIDATION; IMAGES; INJURY; ACTIVATION; DESIGN; FMRI; MRI; SPM	The technique of anatomic standardization and comparison with normal templates is increasingly used in clinical brain SPECT practice and allows automated, operator-in dependent volume-of-interest (VOI) or voxel-based analysis of whole-brain data. In 2 distinct clinical populations with severe traumatic brain Injury and cognitive impairment, this study compared 3 widely available approaches that use normal templates to evaluate SPECT brain perfusion deficits. Methods: In total, 74 subjects were studied. These included 14 patients with severe, traumatic brain injury (group 1; 10 males, 4 females; mean age +/- SD, 27.6 +/- 8.2 y) and 15 patients with cognitive impairment (group 2; 7 males, 8 females; mean age, 75.8 +/- 8.6 y). These data were compared with those from, respectively, 25 and 20 age- and sex-adjusted healthy volunteers. All data were analyzed in 4 ways. Three semiquantitative statistical algorithms were used: statistical parametric mapping (SPM) using SPM99, brain registration and analysis of SPECT studies (BRASS) using a voxelwise region-growing technique, and a predefined VOI approach. These results were compared with visual analysis based on consensus reading by 3 experienced nuclear medicine physicians. Receiver operating characteristic (ROC) analysis was performed at various statistical cutoffs. Moreover, as a measure of regional agreement, relative regional agreement between methods was assessed. Results: In both study groups, BRASS voxel-based analysis was most accurate, as defined by the area under the ROC curve (0.97 for group 1 and 0.96 for group 2). VOI assessment was slightly more accurate than visual consensus analysis, whereas SPM showed, overall, a lower area under the ROC curve. SPM analysis was also significantly less sensitive at thresholds corresponding to low false-positive fractions. Regional analysis showed 83%-92% agreement between ail methods. Conclusion: Under clinical conditions, classification of brain SPECT studies can greatly be aided by anatomic standardization techniques and reference to normal data. Under the investigated circumstances, SPM was found to have a lower sensitivity than VOI or voxelwise region-growing techniques, especially at low false-positive fractions.	State Univ Ghent Hosp, Div Nucl Med, B-9000 Ghent, Belgium; Univ Stellenbosch, Tygerberg Hosp, Dept Nucl Med, ZA-7600 Matieland, South Africa; State Univ Ghent Hosp, Dept Psychiat, B-9000 Ghent, Belgium	Van Laere, KJ (corresponding author), State Univ Ghent Hosp, Div Nucl Med, P7,De Pintelaan 185, B-9000 Ghent, Belgium.		Versijpt, Jan/F-5531-2013	Versijpt, Jan/0000-0002-8710-5715; Warwick, James/0000-0002-2810-0543			Acton PD, 1998, EUR J NUCL MED, V25, P663; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Burdette JH, 1996, RADIOLOGY, V198, P837, DOI 10.1148/radiology.198.3.8628880; CHAKRABORTY DP, 1990, RADIOLOGY, V174, P873, DOI 10.1148/radiology.174.3.2305073; Drzezga A, 1999, J NUCL MED, V40, P737; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; FRISTON KJ, 1995, HUM BRAIN MAPP, V0003, P00165, DOI DOI 10.1002/HBM.460030303; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Hendel RC, 1999, CIRCULATION, V99, P2742, DOI 10.1161/01.CIR.99.21.2742; ICHISE M, 1994, J NUCL MED, V35, P217; Ishii K, 2001, J NUCL MED, V42, P548; Jagust W, 2001, NEUROLOGY, V56, P950, DOI 10.1212/WNL.56.7.950; Lahorte P, 2000, NEUROIMAGE, V12, P757, DOI 10.1006/nimg.2000.0658; Liow JS, 2000, J NUCL MED, V41, P612; MASDEU JC, 1995, J NEUROIMAGING, V5, pS53; Metz CE, 1998, STAT MED, V17, P1033, DOI 10.1002/(SICI)1097-0258(19980515)17:9<1033::AID-SIM784>3.0.CO;2-Z; METZ CE, 1989, INVEST RADIOL, V24, P234, DOI 10.1097/00004424-198903000-00012; MILLER JW, 1992, PROG NEUROBIOL, V39, P155, DOI 10.1016/0301-0082(92)90009-4; MINOSHIMA S, 1994, J NUCL MED, V35, P1528; Pickut BA, 1997, J NUCL MED, V38, P929; Radau PE, 2000, J NUCL MED, V41, P220; Senda M, 1998, NEUROIMAGE, V8, P283, DOI 10.1006/nimg.1998.0370; Shiina G, 1998, AM J NEURORADIOL, V19, P297; Signorini M, 1999, NEUROIMAGE, V9, P63, DOI 10.1006/nimg.1998.0381; Stamatakis EA, 1999, NEUROIMAGE, V10, P397, DOI 10.1006/nimg.1999.0477; Sugiura M, 1999, J NUCL MED, V40, P317; Swensson RG, 1996, MED PHYS, V23, P1709, DOI 10.1118/1.597758; Talairach J., 1988, COPLANAR STEREOTACTI; Van Laere K, 2001, J NUCL MED, V42, P361; Van Laere K, 2001, EUR J NUCL MED, V28, P873, DOI 10.1007/s002590100549; Van Laere K, 2000, J NUCL MED, V41, P2051; Van Laere K, 2001, EUR J NUCL MED, V28, P435, DOI 10.1007/s002590000461; Van Laere K, 2001, EUR J NUCL MED, V28, P90, DOI 10.1007/s002590000407; VANLAERE K, 2002, IN PRESS NEUROIMAGE; Waldemar G, 1997, Int Psychogeriatr, V9 Suppl 1, P223, DOI 10.1017/S1041610297004924; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004	39	55	55	0	1	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505			J NUCL MED	J. Nucl. Med.	APR	2002	43	4					458	469					12	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	540BA	WOS:000174907300011	11937588				2021-06-18	
J	Grossmann, R; Stence, N; Carr, J; Fuller, L; Waite, M; Dailey, ME				Grossmann, R; Stence, N; Carr, J; Fuller, L; Waite, M; Dailey, ME			Juxtavascular microglia migrate along brain microvessels following activation during early postnatal development	GLIA			English	Article						microglial activation; brain slice; blood vessel; time-lapse imaging; cell motility	HIPPOCAMPAL SLICE CULTURES; PERIVASCULAR CELLS; NERVOUS-SYSTEM; T-LYMPHOCYTES; RAT-BRAIN; LECTIN; MACROPHAGES; NUCLEUS; IMMUNOREACTIVITY; DEGENERATION	Some parenchymal microglia in mammalian brain tissues, termed ''juxtavascular microglia,'' directly contact the basal lamina of blood vessels; however, the functional consequences of this unique structural relationship are unknown. Here we used a rat brain slice model of traumatic brain injury to investigate the dynamic behavior of juxtavascular microglia following activation. Juxtavascular microglia were identified by confocal 3D reconstruction in tissue slices stained with a fluorescent lectin (FITC-IB4) that labels both microglia and blood vessel endothelial cells. Immunolabeling confirmed that juxtavascular cells were true parenchymal microglia (OX42(+), ED2(-)) and not perivascular cells or pericytes. Time-lapse imaging in live tissue slices revealed that activating juxtavascular microglia withdraw most extant branches but often maintain contact with blood vessels, usually moving to the surface of a vessel within 1-4 h. Subsequently, some microglia migrate along the parenchymal surface of vessels, moving at rates up to 40 mum/h. Activated juxtavascular microglia sometimes repeatedly extend veil-like protrusions into the surrounding tissue, consistent with a role in tissue surveillance. Juxtavascular cells were twice as likely as nonjuxtavascular cells to be locomotory by 10 h in vitro, suggesting an enhanced activation response. Moreover, 38% of all juxtavascular cells migrated along a vessel, whereas this was never observed for a nonjuxtavascular cell. These observations identify a mobile subpopulation (10%-30%) of parenchymal microglia that activate rapidly and are preferentially recruited to the surfaces of blood vessels following brain tissue injury. The dynamic and sustained interaction of microglia with brain microvessels may facilitate signaling between injured brain parenchyma and components of the blood-brain barrier or circulating immune cells of the blood in vivo. (C) 2002 Wiley-Liss, Inc.	Univ Iowa, Dept Sci Biol, Iowa City, IA 52242 USA	Dailey, ME (corresponding author), Univ Iowa, Dept Sci Biol, Iowa City, IA 52242 USA.			Grossmann, Ruth/0000-0001-6725-2008	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS043468] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS043468] Funding Source: NIH RePORTER		BOYA J, 1991, J ANAT, V175, P229; Brockhaus J, 1996, GLIA, V16, P81, DOI 10.1002/(SICI)1098-1136(199601)16:1<81::AID-GLIA9>3.0.CO;2-E; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Calvo CF, 1996, EUR J NEUROSCI, V8, P1725, DOI 10.1111/j.1460-9568.1996.tb01316.x; Coltman BW, 1996, INT J DEV NEUROSCI, V14, P707, DOI 10.1016/S0736-5748(96)00071-8; COYLE P, 1978, EXP NEUROL, V58, P549, DOI 10.1016/0014-4886(78)90108-5; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.3.CO;2-0; Dailey ME, 1999, METHODS, V18, P222, DOI 10.1006/meth.1999.0775; DAILEY ME, 1999, IMAGING LIVING CELLS; Dalmau I, 1998, HIPPOCAMPUS, V8, P458, DOI 10.1002/(SICI)1098-1063(1998)8:5<458::AID-HIPO6>3.3.CO;2-E; GEHRMANN J, 1993, GLIA, V7, P50, DOI 10.1002/glia.440070110; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; GRAEBER MB, 1989, J NEUROSCI RES, V22, P103, DOI 10.1002/jnr.490220114; GRAEBER MB, 1990, TRENDS NEUROSCI, V13, P366, DOI 10.1016/0166-2236(90)90020-B; Hailer NP, 1997, EUR J NEUROSCI, V9, P863, DOI 10.1111/j.1460-9568.1997.tb01436.x; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; KIDA SY, 1993, ACTA NEUROPATHOL, V85, P646, DOI 10.1007/BF00334675; Kulla A, 2000, MODERN PATHOL, V13, P56, DOI 10.1038/modpathol.3880010; LASSMANN H, 1991, J NEUROSCI RES, V28, P236, DOI 10.1002/jnr.490280211; Mato M, 1996, P NATL ACAD SCI USA, V93, P3269, DOI 10.1073/pnas.93.8.3269; MATO M, 1986, ACTA NEUROPATHOL, V72, P117, DOI 10.1007/BF00685972; MATSUMOTO Y, 1987, J NEUROL SCI, V77, P35, DOI 10.1016/0022-510X(87)90204-8; Medana IM, 1997, GLIA, V19, P91, DOI 10.1002/(SICI)1098-1136(199702)19:2<91::AID-GLIA1>3.0.CO;2-C; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; Persidsky Y, 1999, AM J PATHOL, V155, P1599, DOI 10.1016/S0002-9440(10)65476-4; Raivich G, 1998, J NEUROSCI, V18, P5804; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Schiefer J, 1999, J NEUROCYTOL, V28, P439, DOI 10.1023/A:1007048903862; Skibo GG, 2000, NEUROSCIENCE, V96, P427, DOI 10.1016/S0306-4522(99)00562-X; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; STREIT WJ, 1993, GLIA, V7, P68, DOI 10.1002/glia.440070112; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Thomas WE, 1999, BRAIN RES REV, V31, P42, DOI 10.1016/S0165-0173(99)00024-7; Watanabe T, 1998, J NEUROIMMUNOL, V81, P90, DOI 10.1016/S0165-5728(97)00163-X; WHITELAND JL, 1995, J HISTOCHEM CYTOCHEM, V43, P313, DOI 10.1177/43.3.7868861; Wu CH, 1997, NEUROSCI RES, V27, P133, DOI 10.1016/S0168-0102(96)01140-6	43	55	60	1	5	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	MAR 1	2002	37	3					229	240		10.1002/glia.10031			12	Neurosciences	Neurosciences & Neurology	533FH	WOS:000174518400004	11857681				2021-06-18	
J	Aradi, I; Soltesz, I				Aradi, I; Soltesz, I			Modulation of network behaviour by changes in variance in interneuronal properties	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							HIPPOCAMPUS IN-VITRO; TRAUMATIC BRAIN INJURY; DENTATE BASKET CELLS; RAT HIPPOCAMPUS; PYRAMIDAL NEURONS; FEBRILE SEIZURES; CA1 INTERNEURONS; GRANULE CELLS; LONG-TERM; INHIBITORY INTERNEURONS	Interneurones are important regulators of neuronal networks. The conventional approach to interneurones is to focus on the mean values of various parameters. Here we tested the hypothesis that changes in the variance of interneuronal properties (e.g. in the degree of scattering of parameter values of individual cells around the population mean) may modify the behaviour of networks. Biophysically based multicompartmental models of principal cells and interneurones showed that changes in the variance in the electrophysiological and anatomical properties of interneurones significantly alter the input-output functions, rhythmicity and synchrony of principal cells, even if the mean values were unchanged. In most cases, increased heterogeneity in interneurones resulted in stronger inhibition of principal cell firing; however, there were parameter ranges where increased interneuronal variance decreased the inhibition of principal cells. Electrophysiological recordings showed that the variance in the resting membrane potential of CA1 stratum oriens interneurones persistently increased following experimental complex febrile seizures in developing rats, without a change in the mean resting membrane potential, indicating that lasting alterations in interneuronal heterogeneity can take place in real neuronal systems. These computational and experimental data demonstrate that modifications in interneuronal population variance influence the behaviour of neuronal networks, and suggest a physiological role for interneuronal diversity. Furthermore, the results indicate that interneuronal heterogeneity can change in neurological diseases, and raise the possibility that neuromodulators may act by regulating the variance of key parameters in interneuronal populations.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA	Soltesz, I (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.	isoltesz@uci.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035951] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35951] Funding Source: Medline		Ali AB, 1999, EUR J NEUROSCI, V11, P1741, DOI 10.1046/j.1460-9568.1999.00592.x; Aradi I, 1999, NEUROCOMPUTING, V26-7, P45, DOI 10.1016/S0925-2312(99)00087-9; Aradi I, 1999, J COMPUT NEUROSCI, V6, P215, DOI 10.1023/A:1008801821784; Banks MI, 2000, NEURON, V25, P449, DOI 10.1016/S0896-6273(00)80907-1; Baram TZ, 1997, DEV BRAIN RES, V98, P265, DOI 10.1016/S0165-3806(96)00190-3; Bergles DE, 1996, J NEUROSCI, V16, P572; Buckmaster PS, 1996, HIPPOCAMPUS, V6, P330, DOI 10.1002/(SICI)1098-1063(1996)6:3<330::AID-HIPO9>3.0.CO;2-Q; BUHL EH, 1994, J NEUROPHYSIOL, V71, P1289; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; BUHL EH, 1995, EUR J NEUROSCI, V7, P1989, DOI 10.1111/j.1460-9568.1995.tb00721.x; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; Caillard O, 1999, J NEUROSCI, V19, P7568, DOI 10.1523/JNEUROSCI.19-17-07568.1999; CAJAL SRY, 1911, HIST SYSTEME NERVEAU, V2; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dube C, 2000, ANN NEUROL, V47, P336, DOI 10.1002/1531-8249(200003)47:3<336::AID-ANA9>3.0.CO;2-W; Fisahn A, 1998, NATURE, V394, P186, DOI 10.1038/28179; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GOLOMB D, 1993, PHYS REV E, V48, P4810, DOI 10.1103/PhysRevE.48.4810; GULYAS AI, 1993, EUR J NEUROSCI, V5, P1729, DOI 10.1111/j.1460-9568.1993.tb00240.x; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Hajos N, 1997, J NEUROSCI, V17, P8427; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; Halasy K, 1996, HIPPOCAMPUS, V6, P306, DOI 10.1002/(SICI)1098-1063(1996)6:3<306::AID-HIPO8>3.0.CO;2-K; HAN ZS, 1993, EUR J NEUROSCI, V5, P395, DOI 10.1111/j.1460-9568.1993.tb00507.x; Hines M, 1995, HDB BRAIN THEORY NEU, P226; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Hollrigel GS, 1998, NEUROSCIENCE, V84, P71, DOI 10.1016/S0306-4522(97)00499-5; JAFFE DB, 1994, J NEUROPHYSIOL, V71, P1065; Jones MV, 1997, J NEUROSCI, V17, P7626; KNEISLER TB, 1995, J PHYSIOL-LONDON, V487, P125, DOI 10.1113/jphysiol.1995.sp020866; KNEISLER TB, 1995, HIPPOCAMPUS, V5, P151, DOI 10.1002/hipo.450050302; LACAILLE JC, 1988, J NEUROSCI, V8, P1400; LI XG, 1992, EXP BRAIN RES, V90, P519; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059; Maccaferri G, 2000, J PHYSIOL-LONDON, V524, P91, DOI 10.1111/j.1469-7793.2000.t01-3-00091.x; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Mainen ZF, 1996, NATURE, V382, P363, DOI 10.1038/382363a0; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; MCBAIN CJ, 1993, J PHYSIOL-LONDON, V462, P373, DOI 10.1113/jphysiol.1993.sp019560; MCBAIN CJ, 1994, J NEUROSCI, V14, P4433; MCCORMICK DA, 1993, CEREB CORTEX, V3, P387, DOI 10.1093/cercor/3.5.387; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McMahon LL, 1997, J NEUROPHYSIOL, V78, P2493; McQuiston AR, 1999, J NEUROSCI, V19, P5693, DOI 10.1523/JNEUROSCI.19-14-05693.1999; Miles R, 2000, SCIENCE, V287, P244, DOI 10.1126/science.287.5451.244; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; Miller KK, 1997, J NEUROSCI, V17, P4994; Morales M, 1997, J NEUROSCI, V17, P3157; MOTT DD, 1997, J NEUROSCI, V17, P3390; Nusser Z, 1997, NEURON, V19, P697, DOI 10.1016/S0896-6273(00)80382-7; Parra P, 1998, NEURON, V20, P983, DOI 10.1016/S0896-6273(00)80479-1; Ross ST, 2001, P NATL ACAD SCI USA, V98, P8874, DOI 10.1073/pnas.141042398; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; SCHARFMAN HE, 1995, HIPPOCAMPUS, V5, P287, DOI 10.1002/hipo.450050403; SIK A, 1995, J NEUROSCI, V15, P6651; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97; Sprent P, 2001, APPL NONPARAMETRIC S; SPRUSTON N, 1992, J NEUROPHYSIOL, V67, P508; Spruston N, 1997, J COMP NEUROL, V385, P427; STALEY KJ, 1992, J NEUROPHYSIOL, V67, P1346; Svoboda KR, 1999, J NEUROSCI, V19, P85; Thomson AM, 2000, EUR J NEUROSCI, V12, P425, DOI 10.1046/j.1460-9568.2000.00915.x; Tiesinga PHE, 2000, NETWORK-COMP NEURAL, V11, P1, DOI 10.1088/0954-898X/11/1/301; Toth Z, 1997, J NEUROSCI, V17, P8106; Traub R. D., 1999, FAST OSCILLATIONS CO; TRAUB RD, 1991, J NEUROPHYSIOL, V66, P635; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; Van Vreeswijk C, 1994, J Comput Neurosci, V1, P313; WANG XJ, 1993, NEUROSCIENCE, V53, P899, DOI 10.1016/0306-4522(93)90474-T; Wang XJ, 1996, J NEUROSCI, V16, P6402; White JA, 2000, P NATL ACAD SCI USA, V97, P8128, DOI 10.1073/pnas.100124097; White JA, 1998, J COMPUT NEUROSCI, V5, P5, DOI 10.1023/A:1008841325921; YLINEN A, 1995, HIPPOCAMPUS, V5, P78, DOI 10.1002/hipo.450050110; YUEN GLF, 1991, NEUROSCIENCE, V41, P411, DOI 10.1016/0306-4522(91)90337-N; ZAR J.H., 1999, BIOSTATISTICAL ANAL	84	55	55	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3751	1469-7793		J PHYSIOL-LONDON	J. Physiol.-London	JAN 1	2002	538	1					227	251		10.1113/jphysiol.2001.013054			25	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	517XT	WOS:000173636300022	11773331	Green Published			2021-06-18	
J	Maas, AIR				Maas, AIR			Neuroprotective agents in traumatic brain injury	EXPERT OPINION ON INVESTIGATIONAL DRUGS			English	Article						clinical trials; head injury; neuroprotection; traumatic brain injury	SEVERE HEAD-INJURY; NERVOUS-SYSTEM TRAUMA; RANDOMIZED CONTROLLED TRIALS; B-2 RECEPTOR ANTAGONIST; FLUID-PERCUSSION INJURY; CORTICAL IMPACT INJURY; CEREBRAL-ISCHEMIA; RAT-BRAIN; SUBARACHNOID HEMORRHAGE; LIPID-PEROXIDATION	The role of neuroprotection in traumatic brain injury (TBI) is reviewed. Basic research and experimental investigations have identified many different compounds with potential neuroprotective effect. However, none of the Phase III trials performed in TBI have been successful in convincingly demonstrating efficacy in the overall population. A common misconception is that consequently these agents are ineffective. The negative results as reported in the overall population may in part be caused by specific aspects of the head injury population as well as by aspects of clinical trial design and analysis. The heterogeneity of the TBI population causes specific problems, such as a risk of imbalances between placebo and treated groups but also causes problems m;hen a possible treatment effect is evaluated in relation to the prognostic effect present. Trials of neuroprotective agents should be targeted first of all to a population in which the mechanism at which the agent is directed is likely to be present and secondly to a population in which the chances of demonstrating efficacy are realistic, e.g., to patients with an intermediate prognosis. The possibilities for concomitant or sequential administration of different neuroprotective agents at different times deserve consideration. The potential for neuroprotection in TBI remains high and we should not be discouraged by recent failures obtained up until now. Rather, prior to initiating new trials, careful consideration of experimental evidence is required in order to optimise chances for mechanistic targeting and lessons learned from previous experience need to be taken to heart in the design of future studies.	Erasmus Univ, Med Ctr, Dept Neurosurg, NL-3015 GD Rotterdam, Netherlands	Maas, AIR (corresponding author), Erasmus Univ, Med Ctr, Dept Neurosurg, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	maas@neur.azr.nl	Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Alexiou T, 2000, NEUROSCI RES COMMUN, V26, P1, DOI 10.1002/(SICI)1520-6769(200001/02)26:1<1::AID-NRC1>3.0.CO;2-Q; ALLESSANDRI B, 1999, J NEUROTRAUM, V16, P981; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P103, DOI 10.1111/j.1399-6576.1995.tb04285.x; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Barzo P, 1997, ACT NEUR S, V70, P119; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; BENTZER P, 1999, J NEUROTRAUM, V16, P979; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CARON MH, 1996, NEUROTRAUMA, P163; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Clark RSB, 1996, CRIT CARE MED, V24, P1243, DOI 10.1097/00003246-199607000-00030; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; FAN L, 1995, MOL BRAIN RES, V30, P125; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P695, DOI 10.1517/13543784.9.4.695; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Jolkkonen J, 1999, EUR J PHARMACOL, V372, P31, DOI 10.1016/S0014-2999(99)00186-7; KAKARIEKA A, 1994, J NEURAL TRANSM-SUPP, P13; KAKARIEKA A, 1997, TRAUMATIC SUBARACHNO; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Katayama Y, 1998, ACT NEUR S, V71, P289; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; Kawamata T, 1997, ACT NEUR S, V70, P191; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; LANG DA, 1991, ACTA NEUROCHIR, V109, P5, DOI 10.1007/BF01405689; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2000, CNS DRUGS, V13, P139, DOI 10.2165/00023210-200013020-00007; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MAHMOOD A, IN PRESS J NEUROSURG; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; PRUNEAU D, 1999, IMMUNOPHARMACOLOGY, P1285; REILLY PL, 1975, LANCET, V2, P375; REISS P, 1999, J NEUROTRAUM, V16, P1016; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHAPIRA Y, 1989, Neurological Research, V11, P169; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Soares HD, 1995, J NEUROSCI, V15, P8223; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Teasdale GM, 1999, ACT NEUR S, V73, P111; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Uenishi H, 1999, ANN NY ACAD SCI, V890, P385, DOI 10.1111/j.1749-6632.1999.tb08018.x; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; YAMASAKI Y, 1994, ACTA NEUROCHIR, P300; Yates D, 2000, BRIT MED J, V321, P128, DOI 10.1136/bmj.321.7254.128; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Young Byron, 1998, Journal of Neurotrauma, V15, P48; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	98	55	58	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1354-3784	1744-7658		EXPERT OPIN INV DRUG	Expert Opin. Investig. Drugs	APR	2001	10	4					753	767		10.1517/13543784.10.4.753			15	Pharmacology & Pharmacy	Pharmacology & Pharmacy	419ZP	WOS:000167979700014	11281824				2021-06-18	
J	Verger, K; Junque, C; Levin, HS; Jurado, MA; Perez-Gomez, M; Bartres-Faz, D; Barrios, M; Alvarez, A; Bartumeus, F; Mercader, JM				Verger, K; Junque, C; Levin, HS; Jurado, MA; Perez-Gomez, M; Bartres-Faz, D; Barrios, M; Alvarez, A; Bartumeus, F; Mercader, JM			Correlation of atrophy measures on MRI with neuropsychological sequelae in children and adolescents with traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; DIFFUSE AXONAL INJURY; CORPUS-CALLOSUM; DEGENERATIVE CHANGES; CLINICAL-FEATURES; CT; COMA; MORPHOLOGY; DAMAGE; INDEX	To examine the relationship between neuropsychological sequelae and atrophy parameters from magnetic resonance imaging (MRI) following paediatric moderate- to- severe traumatic brain injury (TBI), 19 head- injured children and adolescents were studied at least 6 years after injury. Three-dimensional MRI scans were obtained. A semi- automatic computerized method was used to estimate ventricular volumes and the corpus callosum area. Tests of intellectual, memory, visuospatial, frontal lobe, and motor speed functioning were administered to all patients and to 19 matched normal control subjects. Patients' performance significantly differed from controls in general intellectual function, visual memory, visuospatial and frontal lobe tests. The corpus callosum area correlated strongly with several measures involving processing speed and visuospatial function. Ventricular enlargement was less related to neuropsychological outcome. In conclusion, quantitative measurement of the corpus callosum on MRI reflects neuropsychological outcome better than ventricular dilation in paediatric patients.	Univ Barcelona, Dept Psychiat & Clin Psychobiol, Barcelona 08035, Spain; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Barcelona, Dept Methodol Behav Sci, Barcelona, Spain; Hosp Santa Creu & Sant Pau, Dept Neurosurg, E-08025 Barcelona, Spain; Hosp Clin Barcelona, Dept Radiol, Barcelona, Spain	Junque, C (corresponding author), Univ Barcelona, Dept Psychiat & Clin Psychobiol, Passeig Vall Hebron 171, Barcelona 08035, Spain.	cjun-que@psi.ub.es	Barrios, Maite/J-5738-2013; Bartres-Faz, David/C-8997-2011; JURADO, MARIA ANGELES/E-1745-2011; Junque, Carme/B-4400-2011	Barrios, Maite/0000-0003-1979-0818; Bartres-Faz, David/0000-0001-6020-4118; JURADO, MARIA ANGELES/0000-0002-9403-1670; Junque, Carme/0000-0002-6381-3063			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BENTON A L, 1978, Archives of Neurology, V35, P364; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1992, ARCH CLIN NEUROPSYCH, V7, P449, DOI 10.1016/0887-6177(92)90158-J; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; BIGLER ED, 1996, NEUROIMAGING, V2; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; EDWINGCOBBS L, 1987, J CLIN EXPT NEUROPSY, V9, P575; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; Giedd JN, 1996, DEV BRAIN RES, V91, P274; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Heaton R. K, 1981, WISCONSIN CARD SORTI; ICHISE M, 1994, J NUCL MED, V35, P217; JACK CR, 1989, RADIOLOGY, V172, P549, DOI 10.1148/radiology.172.2.2748838; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1992, NEUROSURGERY, V31, P1117, DOI 10.1227/00006123-199212000-00021; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; REY A, 1987, TEST COPIA UNA FIGUR; Rey A, 1964, EXAMEN CLIN PSYCHOL; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Verger K, 2000, BRAIN INJURY, V14, P495; WECHSLER D, 1976, ESCALA INTELIGENCIA	41	55	56	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2001	15	3					211	221					11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	407ZM	WOS:000167302100002	11260770				2021-06-18	
J	Webster, JB; Bell, KR; Hussey, JD; Natale, TK; Lakshminarayan, S				Webster, JB; Bell, KR; Hussey, JD; Natale, TK; Lakshminarayan, S			Sleep apnea in adults with traumatic brain injury: A preliminary investigation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	59th Annual Assembly of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 13-16, 1997	ATLANTA, GEORGIA	Amer Acad Phys Med & Rehabil		brain injuries; sleep apnea syndromes; rehabilitation	EXCESSIVE DAYTIME SLEEPINESS; PREVALENCE; EPIDEMIOLOGY; DISTURBANCES; COMPLAINTS; STROKE; MEN	Objective: To determine the occurrence and nature of sleep-related breathing disorders in adults with traumatic brain injury (TBI). Design: Prospective, observational, consecutive sample en rollment of subjects admitted for rehabilitation after TBT. Setting: Inpatient rehabilitation and subacute rehabilitation units of a tertiary care university medical system. Participants: Subjects (n = 28) included adults with TBI and a Rancho Los Amigos Scale level of 3 or greater who were less than 3 months postinjury and admitted for comprehensive inpatient rehabilitation. Interventions: Overnight sleep study using portable 6-channel monitoring system. Main Outcome Measure: Respiratory disturbance index (RDI), which is the number of apneic and hypopneic episodes per hour of sleep. Results: Evidence of sleep apnea was found in 10 of 28 (36%) subjects as measured by a RDI level of 5 or greater and in 3 of 28 (11%) subjects as measured by a RDI level of 10 or greater. This rate of sleep apnea is significantly (p = .002) higher than would be predicted based on population norms. No correlation was found between the occurrence of significant sleep apnea and measures of TBI severity or other demographic variables. Sleep-related breathing disorders were primarily central though obstructive apneas were also noted. Conclusion: In this preliminary investigation, sleep-related breathing disorders as defined by a respiratory disturbance index of 5 or greater appears to be common in adult subjects with TBI.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; VA Puget Sound Hlth Care Syst, Dept Resp Therapy, Seattle, WA USA; VA Puget Sound Hlth Care Syst, Dept Pulm Med, Seattle, WA USA	Webster, JB (corresponding author), E Carolina Univ, Dept PM&R, Moye Blvd, Greenville, NC 27858 USA.		Sanguansri, Luz/B-6630-2011; Lang, Steven/AAE-8102-2021	Sanguansri, Luz/0000-0003-1908-7604; Lang, Steven/0000-0003-1669-9146; Bell, Kathleen/0000-0002-0928-2046			American Sleep Disorders Association, 1990, INT CLASS SLEEP DIS; ASKENASY JM, 1988, STROKE, V9, P637; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; Bixler EO, 1998, AM J RESP CRIT CARE, V157, P144, DOI 10.1164/ajrccm.157.1.9706079; BONNET MH, 1993, SLEEP, V16, P65; BRESNITZ EA, 1994, EPIDEMIOL REV, V16, P210, DOI 10.1093/oxfordjournals.epirev.a036151; CIRIGNOTTA F, 1989, ACTA NEUROL SCAND, V79, P366, DOI 10.1111/j.1600-0404.1989.tb03802.x; CLINCHOT DM, 1996, ARCH PHYS MED REHAB, V77, P947; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; EMESELLEM HA, 1990, S MED J, V83, P748; FINDLEY LJ, 1986, CHEST, V90, P686, DOI 10.1378/chest.90.5.686; Good DC, 1996, STROKE, V27, P252, DOI 10.1161/01.STR.27.2.252; GREENBERG GD, 1987, SLEEP, V10, P259; GUILLEMINAULT C, 1992, NEUROLOGY, V42, P53; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; HEYMAN A, 1958, NEUROLOGY, V8, P694, DOI 10.1212/WNL.8.9.694; Hudgel DW, 1996, CHEST, V109, P1346, DOI 10.1378/chest.109.5.1346; JENNUM P, 1993, INT J EPIDEMIOL, V22, P439, DOI 10.1093/ije/22.3.439; KANESMART SL, 1996, ARCH PHYS MED REHAB, V77, P943; KAPEN S, 1991, Neurology, V41, P125; Kraus JF, 1993, HEAD INJURY, P1; LANGEVIN B, 1992, SLEEP S6, V15, P525; MANN NR, 1997, ARCH PHYS MED REHAB, V78, P1055; MARTIN JM, 1997, INT J EPIDEMIOL, V26, P381; MOHSENIN V, 1995, ARCH PHYS MED REHAB, V76, P71, DOI 10.1016/S0003-9993(95)80046-8; Neven AK, 1998, THORAX, V53, P638, DOI 10.1136/thx.53.8.638; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; REDLINE S, 1991, CHEST, V100, P1281, DOI 10.1378/chest.100.5.1281; ROEHRS T, 1983, SLEEP, V6, P319, DOI 10.1093/sleep/6.4.319; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; STRADLING JR, 1995, THORAX, V50, P683, DOI 10.1136/thx.50.6.683; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	33	55	55	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2001	82	3					316	321		10.1053/apmr.2001.20840			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	407RG	WOS:000167284100005	11245752				2021-06-18	
J	Saatman, KE; Bareyre, FM; Grady, MS; McIntosh, TK				Saatman, KE; Bareyre, FM; Grady, MS; McIntosh, TK			Acute cytoskeletal alterations and cell death induced by experimental brain injury are attenuated by magnesium treatment and exacerbated by magnesium deficiency	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						calpain; cytoskeleton; head injury; histology; microtubule-associated protein-2; MAP-2; spectrin	MICROTUBULE-ASSOCIATED PROTEIN-2; FOCAL CEREBRAL-ISCHEMIA; CLOSED-HEAD INJURY; RAT HIPPOCAMPUS; NEURONAL INJURY; MAGNETIC-RESONANCE; TRAUMA; ACID; NEURODEGENERATION; PROTECTS	Traumatic brain injury results in a profound decline in intracellular magnesium ion levels that may jeopardize critical cellular functions. We examined the consequences of preinjury magnesium deficiency and post-traumatic magnesium treatment on injury-induced cytoskeletal damage and cell death at 24 h after injury. Adult male rats were fed either a normal (n = 24) or magnesium-deficient diet (n = 16) for 2 wk prior to anesthesia and lateral fluid percussion brain injury (n = 31) or sham injury (n = 9). Normally fed animals were then randomized to receive magnesium chloride (125 mu mol, i.v., n = 10) or vehicle solution (n = 11) at 10 min postinjury. Magnesium treatment reduced cortical cell loss (p < 0.05), cortical alterations in microtubule-associated protein-2 (MAP-2) (p < 0.05), and both cortical and hippocampal calpain mediated spectrin breakdown (p < 0.05 for each region) when compared to vehicle treatment. Conversely, magnesium deficiency prior to brain injury led to a greater area of cortical cell loss (p < 0.05 compared to vehicle treatment). Moreover, brain injury to magnesium-deficient rats resulted in cytoskeletal alterations within the cortex and hippocampus that were not observed in vehicle- or magnesium-treated animals. These data suggest that cortical cell death and cytoskeletal disruptions in cortical and hippocampal neurons may be sensitive to magnesium status after experimental brain injury, and may be mediated in part through modulation of calpains.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Saatman, KE (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P50-NS08803] Funding Source: Medline		Altura B T, 1984, Magnesium, V3, P195; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; CLARK GD, 1987, NEUROSCIENCE, V21, P665, DOI 10.1016/0306-4522(87)90027-3; Conti AC, 1998, J NEUROSCI, V18, P5663; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Eguchi Y, 1997, J NEUROTRAUM, V14, P109, DOI 10.1089/neu.1997.14.109; Emery DL, 2000, J COMP NEUROL, V424, P521; FAVARON M, 1985, FEBS LETT, V183, P260, DOI 10.1016/0014-5793(85)80789-4; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FISCHER S, 1993, EUR J PHARMACOL, V232, P121, DOI 10.1016/0014-2999(93)90736-2; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KASS IS, 1988, ANESTHESIOLOGY, V69, P710, DOI 10.1097/00000542-198811000-00012; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; KOSTYUK FG, 1981, BIOCHIM BIOPHYS ACTA, V650, P128; Kristal BS, 1997, J NEUROCHEM, V69, P524; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marinov MB, 1996, J NEUROSURG, V85, P117, DOI 10.3171/jns.1996.85.1.0117; MATESIC DF, 1994, J NEUROCHEM, V63, P1012; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; National Research Council, 1996, GUIDE CARE USE LAB A, P1; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; POLLARD H, 1994, NEUROSCIENCE, V61, P773, DOI 10.1016/0306-4522(94)90401-4; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; PRESCOTT AR, 1988, J CELL SCI, V89, P321; Regan RF, 1998, J NEUROCHEM, V70, P77; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; SEELIG JM, 1983, AM J PHYSIOL, V202, pH22; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; SMITH DH, 1993, J NEUROSCI, V13, P5383; Suzuki M, 1997, GEN PHARMACOL, V28, P119, DOI 10.1016/S0306-3623(96)00148-6; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tang P, 1998, EPILEPSIA, V39, P577, DOI 10.1111/j.1528-1157.1998.tb01424.x; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; VINK R, 1989, BRAIN RES, V490, P144, DOI 10.1016/0006-8993(89)90440-X; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1991, Magnesium and Trace Elements, V10, P1; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Volpe Pompeo, 1993, Magnesium Research, V6, P267; WOLF G, 1991, NEUROSCIENCE, V43, P31, DOI 10.1016/0306-4522(91)90413-I; WOLF G, 1990, NEUROSCI LETT, V117, P207, DOI 10.1016/0304-3940(90)90145-Y; Zhang AM, 1996, BRAIN RES, V728, P204, DOI 10.1016/0006-8993(96)00401-5; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang ZG, 1999, J CEREBR BLOOD F MET, V19, P68, DOI 10.1097/00004647-199901000-00008	79	55	56	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	2001	60	2					183	194		10.1093/jnen/60.2.183			12	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	402VD	WOS:000167008100008	11273006	Bronze			2021-06-18	
J	Riess, P; Bareyre, FM; Saatman, KE; Cheney, JA; Lifshitz, J; Raghupathi, R; Grady, MS; Neugebauer, E; McIntosh, TK				Riess, P; Bareyre, FM; Saatman, KE; Cheney, JA; Lifshitz, J; Raghupathi, R; Grady, MS; Neugebauer, E; McIntosh, TK			Effects of chronic, post-injury Cyclosporin A administration on motor and sensorimotor function following severe, experimental traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						head injury; immunosuppressant; CsA; behavior	TRANSIENT FOREBRAIN ISCHEMIA; PERMEABILITY TRANSITION; COGNITIVE IMPAIRMENT; AXONAL DAMAGE; RAT; DYSFUNCTION; PROTECTS; DEFICITS; THERAPY; NEURONS	Purpose: Cyclosporin A (CsA) is widely used in clinical situations to attenuate graft rejection following organ and central nervous system transplantation. Previous studies demonstrated that CsA administration is neuroprotective in models of traumatic brain injury (TBI). However, no studies, to date, have evaluated the influence of post-injury CsA administration on behavioral recovery after TBI. Methods: Rats (n = 33) were anesthetized and subjected to severe, lateral fluid percussion brain injury. Fifteen minutes thereafter, animals were randomized to receive the first of 28 daily injections of either CsA (10 mg/kg, ip) or saline. Sham-operated animals (n = 14) were anesthetized and surgically prepared without injury and treated daily either with CsA or saline. Motor and sensorimotor functions were assessed at one day before and two days after injury, and weekly thereafter up to 4 wks post-injury. Cognition was assessed at 1 and 4 wks post-injury using a Morris Water Maze test. Results: Injured animals showed significant impairments in motor, sensorimotor and cognitive function over the 4-week post-injury period. Injured animals treated with CsA showed a significant improvement in motor function assessed using a composite neuroscore (at day 28) and in sensorimotor function assessed using a sticky paper test (at days 2, 14, and 28) (p < 0.05, when compared to vehicle treated, injured animals). No beneficial effects on cognitive function were observed following CsA administration. Conclusion: These data suggest that daily post-injury treatment with CsA improves certain aspects of motor and sensorimotor function following experimental TBI.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Cologne, Dept Surg 2, Biochem & Expt Div, D-51109 Cologne, Germany	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803] Funding Source: NIH RePORTER		AIHARA N, 1994, J COMP NEUROL, V342, P481, DOI 10.1002/cne.903420402; Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BRUNDIN P, 1989, EXP BRAIN RES, V75, P195; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Cheney JA, 2000, J NEUROTRAUM, V17, P83, DOI 10.1089/neu.2000.17.83; CHRISTIANS U, 1993, PHARMACOL THERAPEUT, V57, P291, DOI 10.1016/0163-7258(93)90059-M; Czech KA, 1997, EXP NEUROL, V147, P66, DOI 10.1006/exnr.1997.6589; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Drachman DB, 1996, MUSCLE NERVE, V19, P1239; ELLIOTT JF, 1984, SCIENCE, V226, P1439, DOI 10.1126/science.6334364; Friberg H, 1998, J NEUROSCI, V18, P5151; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; HEWITT CW, 1990, J CLIN LAB IMMUNOL, V31, P23; Jiang HS, 1999, TRANSPLANT INT, V12, P92, DOI 10.1111/j.1432-2277.1999.tb00587.x; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kuroda S, 1999, BRAIN RES, V835, P148, DOI 10.1016/S0006-8993(99)01535-8; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU SL, 1994, J NEUROTRAUM, V11, P73, DOI 10.1089/neu.1994.11.73; LopezLozano JJ, 1997, TRANSPL P, V29, P977, DOI 10.1016/S0041-1345(96)00333-8; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MIDHA R, 1992, MICROSURG, V13, P273, DOI 10.1002/micr.1920130516; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; MOVSOWITZ C, 1990, J ORTHOPAED RES, V8, P635, DOI 10.1002/jor.1100080503; National Research Council, 1996, GUIDE CARE USE LAB A, P1; O'Dell DM, 2000, RESTOR NEUROL NEUROS, V16, P127; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; REEM GH, 1983, SCIENCE, V221, P63, DOI 10.1126/science.6407112; RYFFEL B, 1983, ARCH TOXICOL, V53, P107; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sunio A, 1997, EXP NEUROL, V146, P46, DOI 10.1006/exnr.1997.6484; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tao R, 1998, RESTOR NEUROL NEUROS, V12, P239; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; THOMSON AW, 1983, IMMUNOLOGY, V48, P291; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0	57	55	56	0	0	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2001	18	1					1	8					8	Neurosciences	Neurosciences & Neurology	491RR	WOS:000172123100001	11673665				2021-06-18	
J	Azouvi, P				Azouvi, P			Neuroimaging correlates of cognitive and functional outcome after traumatic brain injury	CURRENT OPINION IN NEUROLOGY			English	Article							CLOSED-HEAD-INJURY; MILD; MRI; SPECT; ADOLESCENTS; PERFORMANCE; ATTENTION; CHILDREN; MEMORY	Magnetic resonance imaging (MRI) may provide an estimate of the severity of diffuse axonal injury by quantitative measurements of atrophy of white matter tracts (such as corpus callosum) and of ventricular enlargement (particularly the third ventricle). However, most MRI studies failed to reveal consistent relationships between the pattern of neuropsychological impairments and the site and extent of focal structural lesions after traumatic brain injury. Functional neuroimaging techniques, such as positron emission tomography or functional MRI, may reveal areas of cerebral dysfunction in regions that look structurally intact on MRI. Studies using these techniques have suggested that the cognitive and behavioural disturbances of traumatic brain injury could be related to a defective activation of a prefrontal-cingulate network. Curr Opin Neurol 13:665-669. (C) 2000 Lippincott Williams & Wilkins.	Univ Paris 05, Dept Neurol Rehabil, Raymond Poincare Hosp, F-92380 Garches, France	Azouvi, P (corresponding author), Univ Paris 05, Dept Neurol Rehabil, Raymond Poincare Hosp, F-92380 Garches, France.						Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; CAZALIS F, 2000, J INT NEUROPSYCH SOC, V6, P379; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gerring J, 2000, BRAIN INJURY, V14, P205; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Plum F, 1998, PHILOS T ROY SOC B, V353, P1929, DOI 10.1098/rstb.1998.0345; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214	20	55	58	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2000	13	6					665	669		10.1097/00019052-200012000-00009			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	425HG	WOS:000168284700009	11148667				2021-06-18	
J	Wagner, AK; Hammond, FM; Sasser, HC; Wiercisiewski, D; Norton, HJ				Wagner, AK; Hammond, FM; Sasser, HC; Wiercisiewski, D; Norton, HJ			Use of injury severity variables in determining disability and community integration after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; outcome; disability; community integration; trauma scores; injury severity	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; SCORE SYSTEMS; RATING-SCALE; CHILDREN; REHABILITATION; VALIDATION; PREDICTION; VIOLENCE; SURVIVAL	Background: Long-term outcome is important in managing traumatic brain injury (TBI), an epidemic in the United States. Many injury severity variables have been shown to predict major morbidity and mortality. Less is known about their relationship with specific long-term outcomes. Methods: Glasgow Coma Scale, Revised Trauma Score, Injury Severity Score, and Trauma and Injury Severity Score, along with other demographic and premorbid values, were obtained for 378 consecutive patients hospitalized after TBI at a Level I trauma center between September 1997 and May 1998, Of this cohort, 120 patients were contacted for 1-year follow-up assessment with the Disability Rating Scale, Community Integration Questionnaire, and employment data. Results: Univariate analyses showed these to be significant single predictors of 1-year outcome. Multivariate analyses revealed that the Revised Trauma Score and Glasgow Coma Scale had significant additive value in predicting injury variables Disability Rating Scale scores when combined with other demographic and premorbid variables studied. Predictive models of 1-year outcome were developed. Conclusion: Injury severity variables are significant single outcome predictors and, in combination with premorbid and demographic variables, help predict long-term disability and community integration for individuals hospitalized with TBI.	Charlotte Inst Rehabil, Charlotte, NC USA; Carolinas Hlth Care Syst, Charlotte, NC USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Kaufmann Bldg,Suite 901, Pittsburgh, PA 15213 USA.						Ashley MJ, 1997, BRAIN INJURY, V11, P677; BONTKE CF, 1996, PHYS MED REHABILITAT, P1027; Bouillon B, 1997, J TRAUMA, V42, P652, DOI 10.1097/00005373-199704000-00012; BOUILLON B, 1993, UNFALLCHIRURG, V96, P55; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHEADLE WG, 1989, ANN SURG, V209, P541, DOI 10.1097/00000658-198905000-00005; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1999, J HEAD TRAUMA REHAB, V14, P176, DOI 10.1097/00001199-199904000-00007; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; MACIVER IN, 1958, LANCET, V1, P390; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MCGONIGAL MD, 1993, J TRAUMA, V34, P863, DOI 10.1097/00005373-199306000-00018; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Zafonte RD, 1997, BRAIN INJURY, V11, P403; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	37	55	57	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2000	49	3					411	419		10.1097/00005373-200009000-00005			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	355DA	WOS:000089369300004	11003316				2021-06-18	
J	Petrov, T; Page, AB; Owen, CR; Rafols, JA				Petrov, T; Page, AB; Owen, CR; Rafols, JA			Expression of the inducible nitric oxide synthase in distinct cellular types after traumatic brain injury: an in situ hybridization anal immunocytochemical study	ACTA NEUROPATHOLOGICA			English	Article						endothelial cells; macrophages; neurons; cytoprotection; cytotoxicity	CENTRAL-NERVOUS-SYSTEM; IN-VIVO EXPRESSION; SPINAL-CORD INJURY; RAT; ACTIVATION; NEURONS; CELLS; PATHOPHYSIOLOGY; PERMEABILITY; INVOLVEMENT	The Marmarou's acceleration traumatic brain injury (TBI) model, in situ hybridization and immunocytochemistry were utilized to study the temporal expression of the inducible form of nitric oxide synthase (iNOS) mRNA and protein in different cellular compartments of the rat brain. Four hours following TBI, expression of iNOS was observed in the endothelial cells of cerebral blood vessels, macrophages and many cortical and hippocampal neurons. In the cortex labeled neuronal and nonneuronal cells were primarily found in the superficial layers. In the hippocampus the strongest neuronal labeling was observed in the CA1 and CA3 (lateral part) regions. By 24 h post TBI endothelial cells no longer expressed iNOS mRNA, and the macrophage and neuronal INOS expression was reduced by 30-50%. The reduction was assessed by automated quantitation of the silver grains that occupy individual cellular profiles using an image analysis system. Immunocytochemistry revealed de novo iNOS synthesis in non-neuronal cells at the different time points, thus paralleling the changes in iNOS mRNA expression. In contrast, iNOS immunoreactivity in neurons was not observed before 24 h post TBI, suggesting failure of iNOS protein translation at 4 h after trauma. The results demonstrate complex spatial and temporal patterns of iNOS expression in discrete cellular populations, indicating different times of nitric oxide synthesis (and release) following TBI. Uncoupling of iNOS mRNA and protein synthesis in neurons suggests differential synthesis of nitric oxide in these cells as compared to non-neuronal cellular populations after trauma.	Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Rafols, JA (corresponding author), Wayne State Univ, Sch Med, Dept Anat & Cell Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.						Aono K, 1997, J CELL BIOCHEM, V65, P349, DOI 10.1002/(SICI)1097-4644(19970601)65:3<349::AID-JCB5>3.3.CO;2-X; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833, DOI 10.1111/j.1476-5381.1993.tb12886.x; AVELLINO AM, 1995, EXP NEUROL, V136, P183, DOI 10.1006/exnr.1995.1095; Bethea JR, 1998, J NEUROSCI, V18, P3251; BLIGHT AR, 1995, BRAIN, V118, P735, DOI 10.1093/brain/118.3.735; Blight AR, 1997, J NEUROTRAUM, V14, P89, DOI 10.1089/neu.1997.14.89; BOULDIN TW, 1990, NEUROTOXICOLOGY, V11, P23; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CAZABON SM, 1998, INTRO BLOOD BRAIN BA, P338; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DEGRACIA DJ, 1997, CEREB BLOOD FLOW MET, V17, P1291; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; Heneka MT, 1998, J NEUROCHEM, V71, P88; Jhamandas JH, 1996, NEUROREPORT, V7, P2843, DOI 10.1097/00001756-199611250-00006; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KRAUSE GS, 1993, STROKE, V24, P747, DOI 10.1161/01.STR.24.5.747; LASKIN DL, 1994, J LEUKOCYTE BIOL, V56, P751; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MincGolomb D, 1996, J NEUROCHEM, V66, P1504; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Oda H, 1997, J NEUROCHEM, V69, P669; PETROV T, 1995, NEUROPHARMACOLOGY, V34, P509, DOI 10.1016/0028-3908(95)00002-N; Petrov T., 1999, Society for Neuroscience Abstracts, V25, P822; PETROV T, 1996, CAN J PHYSL PHARM, V7, pRA21; POGUN S, 1994, SYNAPSE, V18, P21, DOI 10.1002/syn.890180104; POPOVICH PG, 1994, BRAIN RES, V633, P348, DOI 10.1016/0006-8993(94)91560-1; POSTMANTUR RM, 1996, J NEUROPATHOL EXP NE, V55, P68; RADOMSKI MW, 1995, ANN MED, V27, P321, DOI 10.3109/07853899509002585; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Sharma AC, 1998, NEUROL RES, V20, P632; SHUKLA A, 1995, NEUROREPORT, V6, P1629, DOI 10.1097/00001756-199508000-00010; Strijbos PJLM, 1996, J NEUROSCI, V16, P5004; Suzuki N, 1999, ARCH ORAL BIOL, V44, P67, DOI 10.1016/S0003-9969(98)00089-2; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; Tamatani M, 1998, J NEUROCHEM, V71, P1588; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WHITTLE BJR, 1995, HISTOCHEM J, V27, P727; You SJ, 1997, GLIA, V20, P87, DOI 10.1002/(SICI)1098-1136(199706)20:2<87::AID-GLIA1>3.0.CO;2-1	45	55	57	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	AUG	2000	100	2					196	204		10.1007/s004019900167			9	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	336MV	WOS:000088307600013	10963368				2021-06-18	
J	Vanier, M; Mazaux, JM; Lambert, J; Dassa, C; Levin, HS				Vanier, M; Mazaux, JM; Lambert, J; Dassa, C; Levin, HS			Assessment of neuropsychologic impairments after head injury: Interrater reliability and factorial and criterion validity of the neurobehavioral rating scale-revised	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	25th Meeting of the International-Neuropsychological-Society	FEB 05-08, 1997	ORLANDO, FL	Int Neuropsychol Soc		factorial validity; Neurobehavioral Rating Scale-Revised (NRS-R); traumatic brain injuries; screening measure; neuropsychologic dimensions; rehabilitation	TRAUMATIC BRAIN INJURY; BEHAVIORAL SEQUELAE; MEMORY; DYSFUNCTION; VALIDATION; DEPRESSION; RELATIVES; SEVERITY; DEFICITS; AUTONOMY	Objective: To study interrater reliability and factorial and criterion validity of the Neurobehavioral Rating Scale-Revised (NRS-R). Design: Validity study on persons with traumatic brain injury (TBI) and test-retest reliability study on a randomly selected subset of patients. Factor analyses, kappa statistics, intraclass correlation coefficients, and Cronbach's alphas were used. Setting: Inpatients from 15 French hospitals, mainly rehabilitation units. Other recruitment sites included a neurology hospital unit and a psychiatry hospital specifically devoted to TBI rehabilitation. Patients: Two hundred eighty-six TBI patients ages 16 to 70 years (convenience sample). Results: For the reliability study, the average of percentages of agreement among the items was 74.3% and the average of kappa statistics was .40. Factor analyses disclosed a maximum likelihood extraction of 5 correlated factors (F), explaining 42.2% of total variance: (F1) deficits in intentional behavior and in memory, (F2) lowering of emotional state, (F3) emotional and behavioral hyperactivation, (F4) lowering of arousal state and of attention, and (F5) language and speech problems. Results support the criterion validity of the factors. Reliability of the factor scores and internal consistencies of factors were very good. Conclusions: Results describe some important properties of the NRS-R and, through an understanding of its underlying structure and relationships with the patients' clinical characteristics, contribute to the conceptual framework of neuropsychologic impairments after TBI.	Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Social & Prevent Med, Montreal, PQ H3C 3J7, Canada; CHU Bordeaux, Serv Reeduc Fonctionelle Neurol, Bordeaux, France; Baylor Coll Med, Houston, TX 77030 USA	Vanier, M (corresponding author), Univ Montreal, Fac Med, Ecole Readaptat, CP 6128 Succ Centreville, Montreal, PQ H3C 3J7, Canada.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		Alaoui P., 1998, Annales de Readaptation et de Medecine Physique, V41, P171, DOI 10.1016/S0168-6054(98)80001-9; ALEXANDER MP, 1987, NEUROBEHAVIORAL RECO; American Psychological Association American Educational Research Association & National Council on Measurement in Education, 1985, STAND ED PSYCH TEST; AZOUVI P, 1991, TRAUMATISME CRANIEN, P179; BADDELEY A, 1987, NEUROBEHAVIORAL RECO, P295; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; BROOKS DN, 1990, TRAUMATIC BRAIN INJU, P77; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; Dahlstrom W. G., 1972, MMPI HDB, V1; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; Epstein Richard S., 1994, P285; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Feldt L.S., 1989, ED MEASUREMENT, V3rd ed., P105; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; FREEDMAN PE, 1987, J NEUROL NEUROSUR PS, V50, P398, DOI 10.1136/jnnp.50.4.398; Gerbing DW, 1996, STRUCT EQU MODELING, V3, P62, DOI 10.1080/10705519609540030; GIROIRE JM, 1988, NEUROPSYCHOLOGIE MEM, P70; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; GOLDSTEIN FC, 1989, INTEGRATING THEORY P, P217; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; HAMILTON JM, 1995, BRAIN INJURY, V9, P479, DOI 10.3109/02699059509008207; HARTLEY L, 1989, J SPEECH LANGUAGE PA, V13, P51; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Heilman K. M., 1991, FRONTAL LOBE FUNCTIO; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEVIN H S, 1990, Annales de Readaptation et de Medecine Physique, V33, P35; Levin H. S., 1991, FRONTAL LOBE FUNCTIO; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1976, CORTEX, V12, P175, DOI 10.1016/S0010-9452(76)80021-4; LEVIN HS, 1977, CORTEX, V13, P119, DOI 10.1016/S0010-9452(77)80003-8; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LHERMITTE F, 1986, ANN NEUROL, V19, P335, DOI 10.1002/ana.410190405; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A. R, 1973, WORKING BRAIN; LURIA AR, 1967, TROUBLES RESOLUTION; Marsh H.W., 1999, STAT STRATEGIES SMAL, V1, P251; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MAZAUX JM, 1991, TRAUMATISME CRANIEN, P185; MORRISON J, 1995, DSM 4 MADE EASY CLIN; NEARY D, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P304; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Pollens RD, 1988, COGNITIVE REHABILITA, V6, P26; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Silver Jonathan M., 1994, P313; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Tabachnick BG, 2013, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; TRUELLE JL, 1994, BRAIN INJURY NEUROPS, P281; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANIER M, 1991, TRAUMATISME CRANIEN, P166; VANZOMEREN AH, 1990, TRAUMATIC BRAIN INJU, P33; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wiig E. H., 1988, NEUROPSYCHOLOGICAL S, P186; Wood R. L. L., 1984, CLOSED HEAD INJURY P	74	55	58	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2000	81	6					796	806		10.1053/apmr.2000.4436			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	320EN	WOS:000087389000020	10857527				2021-06-18	
J	Kanaki, T; Bujo, H; Hirayama, S; Ishii, I; Morisaki, N; Schneider, WJ; Saito, Y				Kanaki, T; Bujo, H; Hirayama, S; Ishii, I; Morisaki, N; Schneider, WJ; Saito, Y			Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						LDL receptor; atherosclerosis; smooth muscle cell; THP-1	DENSITY-LIPOPROTEIN RECEPTOR; PROTEIN ALPHA(2)-MACROGLOBULIN RECEPTOR; SMOOTH-MUSCLE PHENOTYPE; HEAD-ACTIVATOR; DECREASED EXPRESSION; ENDOCYTIC RECEPTOR; SCAVENGER RECEPTOR; SORTING RECEPTOR; VLDL RECEPTOR; CELLS	Receptors belonging to the LDL receptor (LDLR) family are thought to play key roles in lipoprotein metabolism in a variety of tissues, including the arterial wall. Here, we report that the expression of a 250-kDa mosaic LDLR family member, which we called LR11 for the presence of 11 ligand-binding repeats, is markedly induced during the process of atherogenesis in 2 animal models. Analysis by reverse transcription-polymerase chain reaction and RNase protection assays revealed that LR11 transcript levels rise in rabbit aortas displaying atheromatous lesions after the rabbits have been fed a high-cholesterol diet. Immunohistochemistry demonstrated that the highest induction of LR11 occurs in intimal smooth muscle cells (SMCs), followed by medial SMCs close to the intimal border of the atheromatous lesions. Experimental intimal hyperplasia by endothelial denudation showed that LR11 mRNA levels were also increased in the arteries after balloon injury, with the transcripts localized primarily in the hyperplastic intimal layer. In agreement with the correlation of LR11 induction during increased cell, proliferation, cultured SMCs showed an increase in LR11 expression in the proliferative phase. Furthermore, Northern and Western blot analyses showed that medium conditioned by the monocyte-macrophage cell line THP-1 enhanced LR11 expression in cultured SMCs. These findings suggest that upregulation of LR11 might be contributing to the pathological roles of intimal and medial SMCs during arteriosclerotic lesion development and provide the first insight into the as yet unknown functional significance of this intriguing LDLR family member.	Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, Chiba 260, Japan; Chiba Univ, Fac Pharmaceut Sci, Lab Clin Pharmacol, Chiba 260, Japan; Bioctr, Dept Mol Genet, Vienna, Austria; Univ Vienna, Vienna, Austria	Bujo, H (corresponding author), Chiba Univ, Sch Med, Dept Internal Med 2, Chuo Ku, 1-8-1 Inohana, Chiba 260, Japan.						Bochaton-Piallat ML, 1998, CIRC RES, V82, P1086, DOI 10.1161/01.RES.82.10.1086; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CAMPBELL JH, 1992, EXP CELL RES, V200, P156, DOI 10.1016/S0014-4827(05)80084-9; deVries TJ, 1996, CANCER RES, V56, P1432; Franke I, 1997, EUR J BIOCHEM, V244, P940, DOI 10.1111/j.1432-1033.1997.00940.x; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; Hajjar DP, 1997, J BIOL CHEM, V272, P22975, DOI 10.1074/jbc.272.37.22975; HASEL KW, 1991, MOL CELL BIOL, V11, P3484, DOI 10.1128/MCB.11.7.3484; Hermans-Borgmeyer I, 1998, MECH DEVELOP, V70, P65, DOI 10.1016/S0925-4773(97)00177-9; Hiltunen TP, 1998, CIRCULATION, V97, P1079, DOI 10.1161/01.CIR.97.11.1079; Ishikawa Y, 1998, ARTERIOSCL THROM VAS, V18, P665, DOI 10.1161/01.ATV.18.4.665; Jacobsen L, 1996, J BIOL CHEM, V271, P31379, DOI 10.1074/jbc.271.49.31379; Kanaki T, 1998, DNA CELL BIOL, V17, P647, DOI 10.1089/dna.1998.17.647; KANCHA RK, 1994, ONCOL RES, V6, P365; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Li YH, 1997, BIOCHEM BIOPH RES CO, V240, P122, DOI 10.1006/bbrc.1997.7619; LOPES MBS, 1994, FEBS LETT, V338, P301, DOI 10.1016/0014-5793(94)80288-2; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOERWALD S, 1997, ARTERIOSCLER THROMB, V17, P996; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; Multhaupt HAB, 1996, AM J PATHOL, V148, P1985; Nakazato K, 1996, AM J PATHOL, V149, P1831; Niemann S, 1996, NEUROSCI LETT, V207, P49, DOI 10.1016/0304-3940(96)12485-X; ORLANDI A, 1994, ARTERIOSCLER THROMB, V14, P982, DOI 10.1161/01.ATV.14.6.982; QUACH TT, 1992, DEV BRAIN RES, V68, P97; Raines EW, 1996, BIOESSAYS, V18, P271, DOI 10.1002/bies.950180405; RENNICK RE, 1988, ATHEROSCLEROSIS, V71, P35, DOI 10.1016/0021-9150(88)90300-0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sambrook J., 1989, MOL CLONING LAB; Schneider WJ, 1997, CURR OPIN LIPIDOL, V8, P315, DOI 10.1097/00041433-199710000-00011; Schneider Wolfgang J., 1995, Current Opinion in Lipidology, V6, P92, DOI 10.1097/00041433-199504000-00006; STRICKLAND DK, 1995, FASEB J, V9, P890; SUZUKI J, 1995, BIOCHEM BIOPH RES CO, V206, P835, DOI 10.1006/bbrc.1995.1119; TAKAHASHI K, 1993, J CLIN INVEST, V92, P2060, DOI 10.1172/JCI116802; TAMURA K, 1993, ONCOGENE, V8, P2113; Ueno H, 1997, CIRCULATION, V96, P2272; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Wei GL, 1997, CIRC RES, V80, P418, DOI 10.1161/01.res.0000435858.35902.ea; Wyne KL, 1996, ARTERIOSCL THROM VAS, V16, P407, DOI 10.1161/01.ATV.16.3.407; Yamamoto M, 1997, CANCER RES, V57, P2799; Yamamoto T, 1996, CURR OPIN LIPIDOL, V7, P298, DOI 10.1097/00041433-199610000-00007; Yamazaki H, 1996, J BIOL CHEM, V271, P24761, DOI 10.1074/jbc.271.40.24761; YlaHerttuala S, 1996, CURR OPIN LIPIDOL, V7, P292, DOI 10.1097/00041433-199610000-00006	49	55	55	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-5642			ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	NOV	1999	19	11					2687	2695		10.1161/01.ATV.19.11.2687			9	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	256LA	WOS:000083725700015	10559012	Bronze			2021-06-18	
J	Van Leer, E; Turkstra, L				Van Leer, E; Turkstra, L			The effect of elicitation task on discourse coherence and cohesion in adolescents with brain injury	JOURNAL OF COMMUNICATION DISORDERS			English	Article						narrative structure; discourse analysis; head injury; communication assessment	CLOSED HEAD-INJURY; ADULTS; SKILLS; PERFORMANCE; CHILDREN; DEFICITS	Six adolescents with traumatic brain injury and six adolescents who had been hospitalized for an illness or injury not affecting the brain were administered two narrative tasks designed to vary in their demand for spontaneous organization of information and minimize the requirement for new learning. The discourse topics-a description of each subject's injury and hospitalization, and a re-telling of a current event-were chosen to be representative of discourse in adolescent daily living. Narratives produced by subjects in each group were compared between the two tasks on measures of coherence and cohesion. Subjects in both groups produced significantly more coherent and cohesive narratives in the personal event task than in the current event task, and there was no significant difference between groups. The results are discussed in relation to face validity of language tasks for adolescents, and the multiple factors contributing to adolescent social discourse. (C) 1999 by Elsevier Science Inc.	Univ Arizona, Tucson, AZ 85721 USA	Turkstra, L (corresponding author), Case Western Reserve Univ, Dept Commun Sci, 11206 Euclid Ave, Cleveland, OH 44106 USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC 01409] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P60DC001409] Funding Source: NIH RePORTER		Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; CSIKSZENTMIHALY.M, 1984, BEING ADOLESCENT CON; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Frederiksen C.H., 1990, DISCOURSE ABILITY BR, P69, DOI 10.1007/978-1-4612-3262-9_4; GLOSSER G, 1987, UNPUB GUIDELINES RAT; Glosser G., 1990, BRAIN LANG, V40, P67; Halliday Michael A. K., 1976, COHESION ENGLISH; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HOLLAND A, 1982, CLIN APH C P MINN; JENNETT B, 1975, LANCET, V1, P480; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Patry R., 1990, DISCOURSE ABILITY BR, P3, DOI 10.1007/978-1-4612-3262-9_1; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; Scott C. M., 1988, LATER LANGUAGE DEV A, P49; SEMEL W, 1995, CLIN EVALUATION LANG; Turkstra LS, 1998, J SPEECH LANG HEAR R, V41, P137, DOI 10.1044/jslhr.4101.137	27	55	55	0	6	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0021-9924			J COMMUN DISORD	J. Commun. Disord.	SEP-OCT	1999	32	5					327	349		10.1016/S0021-9924(99)00008-8			23	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	234DD	WOS:000082468500004	10498013				2021-06-18	
J	Levi, RB; Drotar, D; Yeates, KO; Taylor, HG				Levi, RB; Drotar, D; Yeates, KO; Taylor, HG			Posttraumatic stress symptoms in children following orthopedic or traumatic brain injury	JOURNAL OF CLINICAL CHILD PSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; SEVERITY; DISASTER; SEQUELAE; DISORDER; ADOLESCENTS; SUPPORT; AMNESIA; SCALE	Examined posttraumatic stress (PTS) symptoms in children following pediatric traumatic brain injury (TBI). Children (ages 6-12) with TBI (n = 81) and orthopedic injury (OI; n = 59) were assessed 6 and 12 months postinjury. Parents of children with severe TBI reported higher levels of child PTS symptoms than did parents of children with moderate TBI or OI at the 6- and 12-month follow-ups. Group differences in child-reported PTS symptoms emerged at the 12-month follow-up with higher symptom levels reported by children with severe TBI than by those with moderate TBI or OI. At both follow-ups, rates of clinically significant symptom levels were higher in the severe TBI group than in the moderate TBI or OI groups. The group differences in parent and child reports were significant even after taking ethnicity, social disadvantage, and age at injury into account. Parent and child reports of child PTS symptoms were related to family socioeconomic status. Implications for clinical intervention with children and families following pediatric TBI are discussed.	Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Ohio State Univ, Coll Med, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA	Levi, RB (corresponding author), Case Western Reserve Univ, Dept Psychol, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [18830, MCJ-390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; BENEDEK ED, 1985, PSYCHIAT ANN, V15, P168, DOI 10.3928/0048-5713-19850301-08; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Bruce D. A., 1995, TRAUMATIC HEAD INJUR, P40; BURKE JD, 1982, AM J PSYCHIAT, V139, P1010; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Cohen J., 1983, APPL MULTIPLE REGRES; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037/0033-2909.98.2.310; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; EARLS F, 1988, J AM ACAD CHILD PSY, V27, P90, DOI 10.1097/00004583-198801000-00014; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fletcher JM, 1995, HDB PEDIAT PSYCHOL, P362; Frederick C, 1992, CHILD POSTTRAUMATIC; Frederick C., 1985, POSTTRAUMATIC STRESS, P71; GREEN BL, 1991, PSYCHOL ASSESS J CON, V3, P538; Hobfoll S. E., 1991, ANXIETY RES, V4, P187, DOI [10.1080/08917779108248773, DOI 10.1080/08917779108248773]; Hobfoll S.E., 1988, ECOLOGY STRESS; JACOBSON MS, 1986, PEDIATRICS, V77, P236; Keppel-Benson J. M., 1993, CHILDREN DISASTERS, P29; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LaGreca AM, 1996, J CONSULT CLIN PSYCH, V64, P712, DOI 10.1037/0022-006X.66.6.883; LEE ML, 1994, J PSYCHOSOC ONCOL, V12, P43; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LYONS JA, 1987, J DEV BEHAV PEDIATR, V8, P349; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MCCAFFREY RJ, 1985, BEHAV THER, V16, P406, DOI 10.1016/S0005-7894(85)80007-1; McNally R. J., 1991, PSYCHOL ASSESSMENT, V3, P531, DOI [DOI 10.1037/1040-3590.3.4.531, 10.1037/1040-3590.3.4.531]; MOOS R, 1988, LIFE STRESSORS SOCIA; *NAT HEAD INJ FDN, 1985, ED MAN ED NEED KNOW; PYNOOS R, 1986, J AM ACAD CHILD ADOL, V44, P1057; Pynoos Robert S., 1996, P331; PYNOOS RS, 1987, ARCH GEN PSYCHIAT, V44, P1057; PYNOOS RS, 1993, BRIT J PSYCHIAT, V163, P239, DOI 10.1192/bjp.163.2.239; PYNOOS RS, 1990, PSYCHIAT DISORDERS C, P48; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; ROSENBAUM PL, 1996, QUALITY LIFE PHARMAC, P785; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SHAFFER D, 1995, TRAUMATIC HEAD INJUR, P55; SILVER JM, 1992, AM PSYCHIAT PRESS TX, P363; SNOW JH, 1994, PEDIATRIC TRAUMATIC; Sparrow S., 1984, VINELAND ADAPTIVE BE; STALLARD P, 1994, CHILDREN SOC, V8, P89; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Stuber ML, 1996, PSYCHOSOMATICS, V37, P254, DOI 10.1016/S0033-3182(96)71564-5; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TERR LC, 1991, AM J PSYCHIAT, V148, P10; Van Der Kolk Bessel A., 1996, P279; VOGEL JM, 1993, J CLIN CHILD PSYCHOL, V22, P464, DOI 10.1207/s15374424jccp2204_7; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WETHINGTON E, 1986, J HEALTH SOC BEHAV, V27, P78, DOI 10.2307/2136504; WOLFE J, 1991, PSYCHOL ASSESSMENT J, V3, P573, DOI DOI 10.1037/1040-3590.3.4.573; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; YULE W, 1993, CHILDREN DISASTERS, P105	69	55	55	0	4	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	0047-228X			J CLIN CHILD PSYCHOL	J. Clin. Child Psychol.	JUN	1999	28	2					232	243		10.1207/s15374424jccp2802_10			12	Psychology, Clinical; Psychology, Developmental	Psychology	197TW	WOS:000080382600010	10353082				2021-06-18	
J	Tarantino, CA; Dowd, MD; Murdock, TC				Tarantino, CA; Dowd, MD; Murdock, TC			Short vertical falls in infants	PEDIATRIC EMERGENCY CARE			English	Article						pediatric emergency medicine; emergency medicine; accidental falls; injuries; infants	CHILDREN FALL; INJURIES; BED	Objective: To define injuries from short vertical falls (SVF) in infants, and to compare those with minor or no injuries to those with significant injury. Design: Descriptive, retrospective chart review. Setting: Pediatric emergency department (PED) of an urban teaching hospital. Subjects: Infants less than or equal to 10 months treated between January 1990 and December 1992 presenting with a SVF (less than or equal to 4 feet). Results: 167 patients met the definition. The mean age was 5.2 months; 56% were male. The mechanisms of injury included rolling off a bed (55%), being dropped from a caretaker's arms (20%), rolling off a couch (16%), and falling from other objects (10%). The majority of patients (85%) had minor or no injury. Significant injuries were sustained by 15% (n = 25), including 16 with a closed head injury (12 with skull fractures), two with intracranial bleed, and seven with a long bone fracture. Subsequently, the two patients with intracranial hemorrhages were confirmed as being from child abuse. After excluding cases of suspected abuse, the only characteristic found to be independently associated with significant injury was being dropped by the caretaker (odds ratio: 6.4 vs rolling or falling from furniture, 95% CI: 2.0, 21.5). Conclusion: The most common mechanism of a SVF was rolling off a bed. Most patients sustained minor or no injury. No child sustained an intracranial hemorrhage from a SVF, The child with intracranial injury and/or multiple injuries warrants an investigation. Being dropped appears to be a greater risk for significant injury than rolling off or falling from furniture.	Childrens Mercy Hosp, Div Emergency Med, Dept Pediat, Kansas City, MO 64108 USA	Tarantino, CA (corresponding author), Childrens Mercy Hosp, Div Emergency Med, Dept Pediat, 2401 Gillham Rd, Kansas City, MO 64108 USA.						*CDC, 1994, EP INF VERS 6; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; CHIAVIELLO CT, 1994, PEDIATRICS, V94, P679; DUHAIME AC, 1992, PEDIATRICS, V90, P179; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HALL JR, 1989, J TRAUMA, V29, P12723; HELFER RE, 1977, PEDIATRICS, V60, P533; JOFFE M, 1988, PEDIATRICS, V82, P457; LYONS TJ, 1993, PEDIATRICS, V92, P125; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; *STAT EP RES CORP, 1993, EGRET REV 4; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005	13	55	56	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	1999	15	1					5	8		10.1097/00006565-199902000-00002			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	168XJ	WOS:000078718200002	10069302				2021-06-18	
J	Azkue, JJ; Zimmermann, M; Hsieh, TF; Herdegen, T				Azkue, JJ; Zimmermann, M; Hsieh, TF; Herdegen, T			Peripheral nerve insult induces NMDA receptor-mediated, delayed degeneration in spinal neurons	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						rat; neurodegeneration; excitotoxicity; glutamate receptors	TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; CORD DORSAL HORN; CEREBRAL-ISCHEMIA; APOPTOSIS; RAT; GLUTAMATE; NEURECTOMY; ASPARTATE; NECROSIS	Injury of a peripheral nerve gives rise to adaptive functional and structural alterations in spinal neurons. We report that the rearrangement of the spinal circuitry in response to sciatic nerve transection in adult rats involves a delayed mode of degeneration of lumbar spinal cord neurons. Nuclear fragmentation was detected by the TUNEL technique 7 days after sciatic neurectomy but not after 3 or 14 days. Dying cells were preferentially located in the ipsilateral superficial dorsal horn and expressed the neuronal cytoskeletal marker SMI-31, Degeneration was prevented by continous systemic treatment with the NMDA receptor-antagonist MK-801. These data are supportive that apoptosis is induced in spinal neurons in a transsynaptic manner by an early signal from injured afferent fibres via activation of spinal NMDA receptors.	Univ Heidelberg, Inst Physiol 2, Abt Physiol Zent Nervensyst, D-69120 Heidelberg, Germany; Univ Kiel Klinikum, Inst Pharmakol, D-24105 Kiel, Germany	Azkue, JJ (corresponding author), Univ Basque Country, Sch Med & Dent, Dept Neurosci, POB 699, Bilbao 48080, Spain.	ONBAZBAJ@lg.ehu.es					ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Capurso SA, 1997, J NEUROSCI, V17, P7372; CASTROLOPES JM, 1995, BRAIN RES, V679, P289, DOI 10.1016/0006-8993(95)00262-O; CASTROLOPES JM, 1993, BRAIN RES, V620, P287, DOI 10.1016/0006-8993(93)90167-L; DEVOR M, 1981, J NEUROSCI, V1, P679; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gass P, 1995, PROG NEUROBIOL, V47, P257, DOI 10.1016/0301-0082(95)00022-4; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; Larm JA, 1997, J NEUROCHEM, V69, P617; Li YQ, 1996, CANCER RES, V56, P5417; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; RINK A, 1995, AM J PATHOL, V147, P1575; WOOLF CJ, 1992, NATURE, V355, P75, DOI 10.1038/355075a0; ZHANG X, 1995, J NEUROSCI, V15, P2733	21	55	59	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUN	1998	10	6					2204	2206		10.1046/j.1460-9568.1998.00260.x			3	Neurosciences	Neurosciences & Neurology	ZR740	WOS:000074009000028	9753107				2021-06-18	
J	Yehuda, R; Resnick, HS; Schmeidler, J; Yang, RK; Pitman, RK				Yehuda, R; Resnick, HS; Schmeidler, J; Yang, RK; Pitman, RK			Predictors of cortisol and 3-methoxy-4-hydroxyphenylglycol responses in the acute aftermath of rape	BIOLOGICAL PSYCHIATRY			English	Article						posttraumatic stress disorder; rape; cortisol; catecholamines; 3-methoxy-4-hydroxyphenylglycol; prior history; risk factors	POSTTRAUMATIC-STRESS-DISORDER; VIETNAM COMBAT VETERANS; URINARY CORTISOL; CATECHOLAMINE EXCRETION; PLASMA-CORTISOL; BRAIN-REGIONS; NOREPINEPHRINE; SUPPRESSION; SECRETION; RAT	Background: Prospective studies of trauma survivors can provide information about the relationship between rape characteristics and the development of subsequent symptoms. Methods: The present study examined the relationship of prior assault, rape severity, posttraumatic stress disorder (PTSD) symptoms following rape, and subsequent PTSD diagnosis, to the acute cortisol and 3-methoxy,-4-hydroxyphenylglycol (MHPG) response to this traumatic event in 20 women. Results: Women with a history of prior physical or sexual assault showed a significantly attenuated cortisol response to the acute stress of rape compared to women without such a history. MHPG appeared to be associated with injury-related rape characteristics, and symptoms of active avoidance, but not prior history. PTSD status at the 3-month follow-up was predicted by both a prior history of assault and high injury rape, but was not directly predicted by either cortisol or MHPG levels. MHPG and cortisol were nor correlated in the sample as a whole, but were correlated among individuals who did not subsequently develop PTSD (p = .04). Conclusions: The results suggest that different neuroendocrine systems may mediate different components of the response to traumatic stress. Published 1998 Society of Biological Psychiatry.	CUNY Mt Sinai Sch Med, Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY 10468 USA; Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; VA Med Ctr, Res Serv, Manchester, NH USA; Harvard Univ, Sch Med, Boston, MA USA	Yehuda, R (corresponding author), CUNY Mt Sinai Sch Med, Vet Affairs Med Ctr, Dept Psychiat, 130 W Kingsbridge Rd, Bronx, NY 10468 USA.				NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH048559, R01MH049555, R03MH049536] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49536, MH-48559, MH49555] Funding Source: Medline		ANISMAN H, 1991, PSYCHOPHARMACOLOGY B, V44, P775; ANTELMAN SM, 1992, PSYCHOPHARMACOLOGY, V107, P331, DOI 10.1007/BF02245157; BOHUS B, 1984, ADV SERIES NEUROSCIE, P337; BROWN MR, 1986, LIFE SCI, V39, P1003, DOI 10.1016/0024-3205(86)90289-4; CHARNEY DS, 1993, ARCH GEN PSYCHIAT, V50, P294; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; GANONG WF, 1980, FED PROC, V39, P2923; GLAVIN GB, 1985, NEUROSCI BIOBEHAV R, V9, P233, DOI 10.1016/0149-7634(85)90048-X; Goenjian AK, 1996, AM J PSYCHIAT, V153, P929; HARFSTRAND A, 1986, P NATL ACAD SCI USA, V83, P9779, DOI 10.1073/pnas.83.24.9779; IRWIN J, 1986, BRAIN RES, V379, P98, DOI 10.1016/0006-8993(86)90260-X; JONES MT, 1976, J ENDOCRINOL, V69, P1, DOI 10.1677/joe.0.0690001; KOSTEN TR, 1987, PSYCHONEUROENDOCRINO, V12, P13, DOI 10.1016/0306-4530(87)90017-5; KVETNANSKY R, 1978, ENDOCRINOLOGY, V103, P1861; LEMIEUX AM, 1995, PSYCHOSOM MED, V57, P105, DOI 10.1097/00006842-199503000-00002; MASON JW, 1986, J NERV MENT DIS, V174, P145, DOI 10.1097/00005053-198603000-00003; MASON JW, 1988, J NERV MENT DIS, V176, P498, DOI 10.1097/00005053-198808000-00008; MCFALL ME, 1990, BIOL PSYCHIAT, V27, P1165, DOI 10.1016/0006-3223(90)90053-5; MEANEY MJ, 1989, NEUROENDOCRINOLOGY, V50, P597, DOI 10.1159/000125287; MEANEY MJ, 1985, BEHAV NEUROSCI, V99, P765, DOI 10.1037/0735-7044.99.4.765; MELLMAN TA, 1995, BIOL PSYCHIAT, V38, P174, DOI 10.1016/0006-3223(94)00238-X; MUNCK A, 1984, ENDOCR REV, V93, P9783; Murburg MM, 1995, BIOL PSYCHIAT, V38, P819, DOI 10.1016/0006-3223(95)00044-5; Pitman R. K., 1989, BIOL PSYCHIAT, V26, P645; PITMAN RK, 1990, BIOL PSYCHIAT, V27, P245, DOI 10.1016/0006-3223(90)90654-K; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; Saunders B. E., 1989, J INTERPERS VIOLENCE, V4, P267, DOI DOI 10.1177/088626089004003001; SOUTHWICK SM, 1993, ARCH GEN PSYCHIAT, V50, P266; Spitzer RL, 1990, STRUCTURED CLIN INTE; STANFORD SC, 1993, STRESS SYNAPSE SYNDR, P281; TSUDA A, 1982, PHYSIOL BEHAV, V29, P337, DOI 10.1016/0031-9384(82)90023-3; WEINER RI, 1978, PHYSIOL REV, V58, P905; YANG RK, 1988, J LIQ CHROMATOGR, V11, P3223, DOI 10.1080/01483918808076791; Yatham LN, 1996, PSYCHIAT RES, V63, P1, DOI 10.1016/0165-1781(96)02896-X; YEHUDA R, 1990, J NERV MENT DIS, V178, P366, DOI 10.1097/00005053-199006000-00004; YEHUDA R, 1992, J NERV MENT DIS, V180, P321, DOI 10.1097/00005053-199205000-00006; YEHUDA R, 1991, AM J PSYCHIAT, V148, P499; YEHUDA R, 1993, BIOL PSYCHIAT, V34, P18, DOI 10.1016/0006-3223(93)90252-9; Yehuda R, 1996, PSYCHONEUROENDOCRINO, V21, P1, DOI 10.1016/0306-4530(95)00055-0; Yehuda R, 1996, BIOL PSYCHIAT, V40, P79, DOI 10.1016/0006-3223(95)00451-3; YEHUDA R, 1995, AM J PSYCHIAT, V152, P982; YEHUDA R, 1995, ARCH GEN PSYCHIAT, V52, P583; Yehuda R, 1997, NATO ADV SCI I A-LIF, V291, P221; YEHUDA R, 1993, AM J PSYCHIAT, V150, P83; YEHUDA R, IN PRESS BIOL PSYCHI	45	55	56	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	JUN 1	1998	43	11					855	859		10.1016/S0006-3223(97)00554-4			5	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	ZP304	WOS:000073738900012	9611677				2021-06-18	
J	Armstead, WM				Armstead, WM			Brain injury impairs ATP-sensitive K+ channel function in piglet cerebral arteries	STROKE			English	Article						newborn; cerebral circulation; pigs; nucleotides, nitric oxide	GENE-RELATED PEPTIDE; SMOOTH-MUSCLE CELLS; POTASSIUM CHANNELS; NITRIC-OXIDE; MESENTERIC-ARTERIES; BASILAR ARTERY; BLOOD-VESSELS; ACTIVATION; RESPONSES; DILATION	Background and Purpose Traumatic injury is the leading cause of death for infants and children, and mortality is increased with head injury. Previous studies have shown that pial arteries constricted and that responses to several nitric oxide (NO)-dependent dilator stimuli were blunted after fluid percussion injury (FPI) in newborn pigs. Membrane potential of vascular muscle is a major determinant of vascular tone, and activity of K+ channels is a major regulator of membrane potential. Recent data show that the NO releasers sodium nitroprusside (SNP) and S-nitroso-N-acetylpenicillamine (SNAP) and 8-bromo-cGMP elicit dilation via ATP-sensitive K+ channel (K-ATP) activation. The present study was designed to investigate the effect of FPI on K-ATP channel function. Methods Chloralose-anesthetized newborn pigs equipped with a closed cranial window were connected to a percussion device that consisted of a saline-filled cylindrical reservoir and a metal pendulum. Brain injury of moderate severity (1.9 to 2.1 atm) was produced by allowing the pendulum to strike a piston on the cylinder. Pial artery diameter was measured with a video microscaler. Data were analyzed by repeated measures ANOVA. An alpha level of P<.05 was considered significant. Results FPI blunted dilation to cromakalim (10(-8), 10(-6) mol/L), a K-ATP agonist (10+/-1% and 27+/-2% versus 3+/-1% and 7+/-2% before and after FPI, respectively, n=8). Similarly, FPI blunted dilation to calcitonin gene-related peptide, an endogenous K-ATP activator. FPI also blunted dilator responses to SNP, S-nitroso-N-acetylpenicillamine, and 8-bromo-cGMP (10(-6) to 10(-8) mol/L) (10+/-1% and 20+/-1% versus 2+/-1% and 8+/-2% for SNP before and after FPI; 9+/-1% and 16+/-1% versus 2+/-1% and 4+/-1% for 8-bromo-cGMP before and after FPI, respectively, n=8). In contrast, responses to papaverine and brain natriuretic peptide were unchanged after FPI. Conclusions These data show that K-ATP channel function is impaired after FPI. Furthermore, these data suggest that impaired function of mechanisms distal to NO synthase contribute to altered cerebral hemodynamics after FPI.	UNIV PENN, DEPT PHARMACOL, CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA	Armstead, WM (corresponding author), UNIV PENN, DEPT ANESTHESIA, CHILDRENS HOSP PHILADELPHIA, 34TH & CIV CTR BLVD, PHILADELPHIA, PA 19104 USA.						Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1997, AM J PHYSIOL-HEART C, V272, pH1785; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423; ASANO M, 1993, J PHARMACOL EXP THER, V267, P1277; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; Bari F, 1996, J CEREBR BLOOD F MET, V16, P1158, DOI 10.1097/00004647-199611000-00010; BONNET P, 1991, PFLUG ARCH EUR J PHY, V418, P292, DOI 10.1007/BF00370529; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; COLOMBANI PM, 1985, J PEDIATR SURG, V20, P8, DOI 10.1016/S0022-3468(85)80382-1; DEVINE JO, 1995, BRAIN RES, V675, P257, DOI 10.1016/0006-8993(95)00081-Z; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; FARACI FM, 1994, STROKE, V25, P1679, DOI 10.1161/01.STR.25.8.1679; FREDRICKS KT, 1994, AM J PHYSIOL, V267, pH580; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; KITAZONO T, 1993, HYPERTENSION, V22, P677, DOI 10.1161/01.HYP.22.5.677; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; KITAZONO T, 1993, AM J PHYSIOL, V265, pH581; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498; KUBO M, 1994, CIRC RES, V74, P471, DOI 10.1161/01.RES.74.3.471; LEE WS, 1993, LIFE SCI, V52, P1527; Louis TM, 1996, STROKE, V27, P134, DOI 10.1161/01.STR.27.1.134; MAYHAN WG, 1993, AM J PHYSIOL, V265, pH152; MCCARRON JG, 1991, AM J PHYSIOL, V261, pH287; MIYOSHI Y, 1992, CIRC RES, V70, P612, DOI 10.1161/01.RES.70.3.612; NAGAO T, 1991, STROKE, V22, P221, DOI 10.1161/01.STR.22.2.221; NELSON MT, 1995, AM J PHYSIOL-CELL PH, V268, pC799; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; SAITO A, 1989, J PHARMACOL EXP THER, V248, P455; SHANKAR V, 1995, AM J PHYSIOL-HEART C, V269, pH997; Sobey CG, 1996, AM J PHYSIOL-HEART C, V271, pH126; TAGUCHI H, 1995, CIRC RES, V76, P1057, DOI 10.1161/01.RES.76.6.1057; Thorogood MC, 1996, ANESTHESIOLOGY, V84, P614, DOI 10.1097/00000542-199603000-00017; THOROGOOD MC, 1995, AM J PHYSIOL-HEART C, V269, pH1776; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Wilderman MJ, 1996, AM J PHYSIOL-HEART C, V270, pH869	38	55	55	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	NOV	1997	28	11					2273	2279		10.1161/01.STR.28.11.2273			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	YE841	WOS:A1997YE84100033	9368576				2021-06-18	
J	Seel, RT; Kreutzer, JS; Sander, AM				Seel, RT; Kreutzer, JS; Sander, AM			Concordance of patients' and family members' ratings of neurobehavioral functioning after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; FOLLOW-UP; SOCIAL-ADJUSTMENT; RELATIVES; RECOVERY; ADULTS	Objective: To examine differences in family and patient evaluation of neurobehavioral functioning in adults with traumatic brain injury (TBI). Design: Differences were examined by conducting 70 paired sample t tests on scale items and 6 paired sample t tests on scale scores from a neurobehavioral inventory. Setting: Medical center outpatient clinic. Participants: Three hundred one consecutive adult patients with TBI and 301 informants, primarily family members, completed the neurobehavioral inventory. Main Outcome Measure: Neurobehavioral Functioning Inventory (NFI) comprised of six scales with items describing symptoms and daily living problems. Results: Paired t test analyses of the six scales indicated that patients reported a significantly greater level of communication problems than did their matched family members. No differences were found for the other five scales. Paired t test analyses of the 70 scale items revealed significant differences in patient and family ratings for only 13 items. In all 13 instances, patients reported greater levels of dysfunction than were reported by their family members. Analysis of variance (ANOVA) indicated a main effect of injury severity for only the Communication and Memory/Attention scales. Conclusions: Findings indicate general agreement between family members and patients regarding patients' everyday problems. Results do not support contentions that patients tend to underestimate difficulties. Agreement levels appear related to injury severity, item specificity, and item content. More research is needed to identify other variables relating to agreement levels, including age, injury severity, and amount of contact between patients and family members. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, RICHMOND, VA 23298 USA							Barco P.P., 1991, COGNITIVE REHABILITA, P129; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; *COMM ACCR REH FAC, 1996, STAND MED REH; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; KAY T, 1988, ADM MANUAL NYU HEAD; KEPPEL G, 1991, DEISGN ANAL RES HDB; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Sherer M., 1995, J INT NEUROPSYCH SOC, V1, P163; SHERER M, 1996, J INT NEUROPSYCH SOC, V2, P17; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	24	55	56	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	1997	78	11					1254	1259		10.1016/S0003-9993(97)90340-3			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	YE945	WOS:A1997YE94500015	9365357				2021-06-18	
J	Fugate, LP; Spacek, LA; Kresty, LA; Levy, CE; Johnson, JC; Mysiw, WJ				Fugate, LP; Spacek, LA; Kresty, LA; Levy, CE; Johnson, JC; Mysiw, WJ			Measurement and treatment of agitation following traumatic brain injury .2. A Survey of the Brain Injury Special Interest Group of the American Academy of Physical Medicine and Rehabilitation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							HALOPERIDOL; SCALE	Objective: Determine national patterns of measuring and treating agitation after traumatic brain injury (TBI) by physiatrists with expressed interest in treating TBI survivors. Design: A 70% random sample of members of the Brain Injury Special interest Group of the American Academy of Physical Medicine and Rehabilitation was surveyed by telephone. Main Outcome Measure: The survey instrument was designed to determine the most common pharmacologic interventions for agitation and, where possible, match each drug with the target behavioral and cognitive characteristics for which it is prescribed. Data were also collected on the manner in which participants measured agitation and judged treatment efficacy. Results: One hundred twenty-nine of 157 responded, yielding an 82% response rate. The majority of respondents were not measuring agitation in a standard fashion. The five most frequently prescribed drugs by the expert stratum were carbamazepine, tricyclic antidepressants (TCAs), trazodone, amantadine, and beta-blockers. In comparison, the nonexperts most often reported prescribing carbamazepine, beta-blockers, haloperidol, TCAs, and benzodiazepines. Desyrel (p = .06) and amantadine (p = .001) were significantly mon likely to be chosen by experts than by nonexperts. Experts chose haloperidol significantly less often than nonexperts (p = .01). Prescription of sedating drugs such as haloperidol or benzodiazepines was not found to be associated with the acuity of injury of TBI patients in the respondent's practice, practice setting, or years of practice since completing residency. Choice of haloperidol to treat agitation was not significantly associated with the degree to which explosive anger, verbal aggression, or physical aggression were considered important to the respondent's definition of agitation. Conclusions: The majority of physiatrists surveyed did not formally measure agitation. Treatment strategies differ significantly between general physiatrists and those who specialize in the treatment of patients with TBI. The breadth of pharmacologic agents and strategies identified in this survey probably reflects the lack of research specific to the pathophysiology of the disorder of posttraumatic agitation. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	OHIO STATE UNIV,DEPT PREVENT MED,COLUMBUS,OH 43210; UNIV MISSOURI,MED INFORMAT GRP,COLUMBIA,MO	Fugate, LP (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,1018 DODD HALL,480 W 9TH AVE,COLUMBUS,OH 43210, USA.		Mysiw, Walter/E-3724-2011; Levy, Carlos/AAN-7226-2020	Johnson, Jane/0000-0002-8825-5926	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32 HD07892-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [F32HD007892] Funding Source: NIH RePORTER		CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P273; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; DILLMAN DA, 1978, MAIL TELEPHONE SURVE, P173; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	7	55	56	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	SEP	1997	78	9					924	928		10.1016/S0003-9993(97)90051-4			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	XV776	WOS:A1997XV77600002	9305262				2021-06-18	
J	Yundt, KD; Grubb, RL; Diringer, MN; Powers, WJ				Yundt, KD; Grubb, RL; Diringer, MN; Powers, WJ			Cerebral hemodynamic and metabolic changes caused by brain retraction after aneurysmal subarachnoid hemorrhage	NEUROSURGERY			English	Article						brain retraction; cerebral aneurysm; cerebral blood flow; subarachnoid hemorrhage; vasospasm	POSITRON EMISSION TOMOGRAPHY; BLOOD-FLOW; INTRAVENTRICULAR PRESSURE; INTRAVENOUS (H2O)-O-15; OXYGEN UTILIZATION; PATHO-PHYSIOLOGY; ISCHEMIA; VASOSPASM; INJURY; RAT	OBJECTIVE: The cerebral hemodynamic and metabolic effects of aneurysmal subarachnoid hemorrhage are complex. To investigate the impact of surgical retraction, we analyzed positron emission tomography (PET) studies that measured the regional cerebral metabolic rate for oxygen, regional oxygen extraction fraction, and regional cerebral blood flow in four patients before and after right frontotemporal craniotomies for clipping of ruptured anterior circulation aneurysms. METHODS: Preoperative studies were conducted 1 day before surgery and postoperative studies 6 to 17 days after surgery. No patient had hydrocephalus or intracerebral hematoma. At the time of the second PET study, none of the patients had signs of clinical vasospasm. Regional measurements were obtained from the right ventrolateral frontal and anterior temporal regions corresponding to the area of retraction and compared to the same regions in the opposite hemisphere. To establish a quantitative means to differentiate between hemodynamic and metabolic changes related to arterial vasospasm and those caused by brain retraction, we studied a second group of preoperative patients, who had undergone PET during angiographic and clinical vasospasm. RESULTS: There was a 45% reduction in regional cerebral metabolic rate for oxygen (1.87 +/- 0.22 to 1.04 +/- 0.28 mi 100 g(-1) min(-1)) and 32% reduction in regional oxygen extraction fraction (0.41 +/- 0.04 to 0.28 +/- 0.03) in the region of retraction but no change in the opposite hemisphere (paired t test; P = 0.042 and 0.003, respectively). There was no change in regional cerebral blood flow in any region. Brain retraction produced a focal area of tissue injury at the site of retractor blade placement, as compared to more diffuse vascular territory changes produced by vasospasm. CONCLUSION: This reduction in the cerebral metabolic rate of oxygen and the oxygen extraction fraction indicates a primary reduction in metabolism and uncoupling of flow and metabolism (luxury perfusion). Similar findings of luxury perfusion have been reported after ischemic stroke and traumatic brain injury. Further studies will be necessary to fully understand the clinical and pathophysiological significance of these observations.	WASHINGTON UNIV, SCH MED, DEPT NEUROL & NEUROL SURG, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT RADIOL, ST LOUIS, MO 63110 USA; JEWISH HOSP ST LOUIS, LILLIAN STRAUSS INST NEUROSCI, ST LOUIS, MO 63110 USA			Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-13851] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-06833] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL013851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS006833, P50NS006833] Funding Source: NIH RePORTER		AHN CS, 1994, J CEREBR BLOOD F MET, V14, P324, DOI 10.1038/jcbfm.1994.39; ALBIN MS, 1977, ACTA NEUROL SCAND, V56, P522; ANDREWS RJ, 1993, NEUROSURGERY, V33, P1052; BARON JC, 1985, NEURORADIOLOGY, V27, P509, DOI 10.1007/BF00340846; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CARPENTER DA, 1991, J CEREBR BLOOD F MET, V11, P837, DOI 10.1038/jcbfm.1991.143; FARRAR JK, 1981, J NEUROSURG, V55, P857; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; FOX PT, 1985, J COMPUT ASSIST TOMO, V9, P141, DOI 10.1097/00004728-198501000-00025; FRACKOWIAK RSJ, 1985, Q J MED, V57, P713; FUKAMACHI A, 1985, SURG NEUROL, V23, P575, DOI 10.1016/0090-3019(85)90006-0; GRUBB RL, 1977, J NEUROSURG, V46, P446, DOI 10.3171/jns.1977.46.4.0446; HAHN FJY, 1976, AM J ROENTGENOL, V126, P593, DOI 10.2214/ajr.126.3.593; HARADA S, 1994, ACTA NEUROCHIR, P449; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HINO A, 1989, STROKE, V20, P1504, DOI 10.1161/01.STR.20.11.1504; Ishikawa M, 1989, Neurol Med Chir (Tokyo), V29, P382, DOI 10.2176/nmc.29.382; JAKOBSEN M, 1987, J CEREB BLOOD FLO S1, V7, pS650; JAKOBSEN M, 1987, J CEREB BLOOD FLO S1, V7, pS660; KALFAS IH, 1988, NEUROSURGERY, V23, P343, DOI 10.1227/00006123-198809000-00010; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; MARTIN WRW, 1987, J CEREBR BLOOD F MET, V7, P421, DOI 10.1038/jcbfm.1987.85; MINTUN MA, 1984, J NUCL MED, V25, P177; NAZZARO JM, 1992, J NEUROSURG, V76, P746, DOI 10.3171/jns.1992.76.5.0746; OBRIEN PC, 1988, MAYO CLIN PROC, V63, P1140, DOI 10.1016/S0025-6196(12)65511-6; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; POWERS WJ, 1992, NEUROL CLIN, V10, P31; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; POWERS WJ, 1985, J NEUROSURG, V62, P539, DOI 10.3171/jns.1985.62.4.0539; RAICHLE ME, 1983, J NUCL MED, V24, P790; RICE BJ, 1990, J NEUROSURG, V73, P165, DOI 10.3171/jns.1990.73.2.0165; ROSEN JM, 1994, CLIN NUCL MED, V19, P595, DOI 10.1097/00003072-199407000-00006; ROSENORN J, 1985, J NEUROSURG, V63, P608, DOI 10.3171/jns.1985.63.4.0608; ROSENORN J, 1982, J NEUROSURG, V56, P826, DOI 10.3171/jns.1982.56.6.0826; ROSENORN J, 1987, ACTA NEUROCHIR, V87, P140, DOI 10.1007/BF01476065; ROUSSEAUX M, 1994, STROKE, V25, P135, DOI 10.1161/01.STR.25.1.135; TERPOGOSSIAN MM, 1982, J COMPUT ASSIST TOMO, V6, P125, DOI 10.1097/00004728-198202000-00021; UEMURA K, 1987, J CEREB BLOOD FLO S1, V7, pS32; VOLDBY B, 1985, J NEUROSURG, V62, P48, DOI 10.3171/jns.1985.62.1.0048; WELCH MJ, 1985, J LABELLED COMPD RAD, V22, P1193, DOI 10.1002/jlcr.2580221114; WISE RJS, 1983, BRAIN, V106, P197, DOI 10.1093/brain/106.1.197; YOKOH A, 1987, ACTA NEUROCHIR, V87, P134, DOI 10.1007/BF01476064; ZAR JH, 1984, BIOSTAT ANAL, V2, P185	45	55	56	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	1997	40	3					442	450		10.1097/00006123-199703000-00003			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WJ763	WOS:A1997WJ76300009	9055282				2021-06-18	
J	Strebel, S; Lam, AM; Matta, BF; Newell, DW				Strebel, S; Lam, AM; Matta, BF; Newell, DW			Impaired cerebral autoregulation after mild brain injury	SURGICAL NEUROLOGY			English	Article						brain; head injury; autoregulation; cerebral blood flow velocity; equipment; transcranial Doppler ultrasonography; sympathetic nervous system; pharmacology; phenylephrine	SEVERE HEAD-INJURY; BLOOD-FLOW; ANESTHESIA	BACKGROUND Severe head injury may impair cerebral autoregulation, which can increase the risk of secondary neuronal injury. The likelihood of impairment in autoregulation is assumed to be low with mild head injury. We report here the absence of cerebral autoregulation in a patient who suffered a concussion from an automobile accident 6 days earlier. METHODS The patient participated in a clinical study approved by the institutional human subjects review committee, investigating the dose-effect relationship of anesthetics on cerebral autoregulation. The patient was scheduled to undergo repair of a knee injury suffered during a motor vehicle accident, during which she had a concussion. The screening evaluation revealed no evidence of neurologic disease. The test was to be performed three times in each patient: baseline autoregulation measurements during stable fentanyl-nitrous oxide anesthesia, second and third measurements during low dose and high dose of the anesthetic to which the patient was assigned. Autoregulation was tested by increasing the mean systemic blood pressure from 80 mm Hg-100 mm Hg using a phenylephrine infusion while simultaneously recording flow velocity from a middle cerebral artery using transcranial Doppler ultrasonography. RESULTS Static autoregulation testing during baseline testing demonstrated complete absence of this homeostatic mechanism and the study was canceled. Repeated testing in the recovery unit after the patient awoke showed identical results. CONCLUSIONS Trivial mild head injury may result in loss of cerebral autoregulation. A clinical study of a larger series to document the incidence is warranted. (C) 1997 by Elsevier Science Inc.	UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT ANESTHESIOL,SCH MED,SEATTLE,WA 98104; UNIV WASHINGTON,HARBORVIEW MED CTR,DEPT NEUROL SURG,SCH MED,SEATTLE,WA 98104							AGNOLI A, 1968, CIRCULATION, V38, P800, DOI 10.1161/01.CIR.38.4.800; ANDERSON DW, 1980, NEUROSURGERY, V53, P1; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GORDON E, 1973, ACTA ANAESTH SCAND, V17, P63, DOI 10.1111/j.1399-6576.1973.tb00799.x; KASOFF SS, 1972, J NEUROSURG, V36, P463, DOI 10.3171/jns.1972.36.4.0463; LANGFITT TW, 1982, CLIN NEUR, V29, P353; MCPHERSON RW, 1985, BRIT J ANAESTH, V57, P1232, DOI 10.1093/bja/57.12.1232; PAULSON OB, 1970, NEUROLOGY, V20, P63, DOI 10.1212/WNL.20.1.63; SMITH AL, 1970, J APPL PHYSIOL, V29, P665; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008	12	55	55	0	2	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0090-3019			SURG NEUROL	Surg. Neurol.	FEB	1997	47	2					128	131		10.1016/S0090-3019(96)00459-4			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WJ477	WOS:A1997WJ47700014	9040813				2021-06-18	
J	Ingebrigtsen, T; Romner, B; Trumpy, JH				Ingebrigtsen, T; Romner, B; Trumpy, JH			Management of minor head injury: The value of early computed tomography and serum protein S-100 measurements	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						minor head injury; computed tomography; brain injury; protein S-100	NEURON-SPECIFIC ENOLASE; TRAUMATIC INTRACRANIAL HEMATOMA; CENTRAL NERVOUS-SYSTEM; CEREBROSPINAL-FLUID; DAMAGE; MILD; ADMISSION	Computed tomography (CT) scan was performed within 6 h in 91 patients with minor head injury (MHI). Eight patients (9%) demonstrated intracranial lesions on CT scan (6 brain contusions, 1 brain edema and 1 extradural hematoma), No patient required craniotomy, In patients with normal CT scan, no complications to the head injury were observed, Patients with intracranial lesions were hospitalized significantly longer (mean 9.4 days) than patients without (mean 1.6 days), In a subgroup of 50 patients with normal CT scan, serum S-100 protein was measured on admission, Elevated S-100 levels were seen in 10 of 50 patients (0.5-2.4 mu g/L, mean 1.1), These patients were hospitalized significantly longer (mean 3.4 days) compared to patients with normal CT scan and normal S-100 levels (mean 1.1 days), MHI patients with GCS 14-15 without neurological deficits can safely be discharged when CT scan is normal, Serum protein S-100 measurements appear to provide information about diffuse brain injury after MHI. (C) Pearson Professional Ltd 1997		Ingebrigtsen, T (corresponding author), UNIV TROMSO HOSP,DEPT NEUROSURG,N-9038 TROMSO,NORWAY.			Ingebrigtsen, Tor/0000-0001-5966-9786			AURELL A, 1991, STROKE, V22, P1254, DOI 10.1161/01.STR.22.10.1254; Edna T H, 1987, J Oslo City Hosp, V37, P41; Eide Per Kristian, 1993, Tidsskrift for den Norske Laegeforening, V113, P1227; FAGNART OC, 1988, CLIN CHEM, V34, P1387; GALBRAIHT S, 1981, LANCET, V2, P791; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; JENKINS A, 1986, LANCET, V2, P445; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; KATO K, 1982, BIOMED RES-TOKYO, V3, P24; KELLY R, 1981, J ROY SOC MED, V74, P242; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KVARNES TL, 1978, ACTA NEUROCHIR, V41, P223, DOI 10.1007/BF01809151; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; MICHETTI F, 1980, J NEUROL SCI, V44, P259, DOI 10.1016/0022-510X(80)90133-1; MICHETTI F, 1979, NEUROSCI LETT, V11, P247; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MOKUNO K, 1983, J NEUROL SCI, V60, P443, DOI 10.1016/0022-510X(83)90155-7; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; PERSSON L, 1988, ACTA NEUROCHIR, V93, P116, DOI 10.1007/BF01402892; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RABOW L, 1985, ACTA NEUROCHIR, V76, P137, DOI 10.1007/BF01418476; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SABERS A, 1988, Ugeskrift for Laeger, V150, P1161; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; SINDIC CJM, 1982, J NEUROL NEUROSUR PS, V45, P1130, DOI 10.1136/jnnp.45.12.1130; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363	34	55	57	0	1	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	JAN	1997	4	1					29	33		10.1016/S0967-5868(97)90007-2			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	WE662	WOS:A1997WE66200007	18638920				2021-06-18	
J	Yundt, KD; Diringer, MN				Yundt, KD; Diringer, MN			The use of hyperventilation and its impact on cerebral ischemia in the treatment of traumatic brain injury	CRITICAL CARE CLINICS			English	Article							SEVERE HEAD-INJURY; VENOUS OXYGEN-SATURATION; BLOOD-FLOW; CEREBROVASCULAR-DISEASE; COMATOSE PATIENTS; PROLONGED HYPERVENTILATION; INTRAVENTRICULAR PRESSURE; INTRACRANIAL-PRESSURE; POSITRON TOMOGRAPHY; PERFUSION-PRESSURE	Traumatic brain injury is a common occurrence in the United States, leading to approximately 190,000 deaths or long-term disabilities. Following the primary insult, secondary disturbances in cerebral blood now (CBF) and metabolism may have deleterious effects on potentially viable neurons. Recent studies evaluating CBF immediately following head injury have revealed flows low enough to produce cerebral ischemia. Hyperventilation is used routinely to lower suspected increased intracranial pressure (ICP). Aggressive hyperventilation produces a marked reduction in CBF, which may give rise to or exacerbate cerebral ischemia, thus enhancing rather than reducing secondary injury. This article reviews the role of hyperventilation in the treatment of increased ICP and its impact on cerebral ischemia following traumatic brain injury.		Yundt, KD (corresponding author), WASHINGTON UNIV, SCH MED, DEPT NEUROL SURG, 660 S EUCLID AVE, BOX 8057, ST LOUIS, MO 63110 USA.		Diringer, Michael N/C-1165-2008	Diringer, Michael N/0000-0003-2337-5537			ADAMS JH, 1972, SCI FDN NEUROLOGY, P488; ALBRECHT RF, 1987, STROKE, V18, P649, DOI 10.1161/01.STR.18.3.649; ALTMAN DI, 1993, PEDIATRICS, V92, P99; ALTMAN DI, 1991, J NUCL MED, V32, P1738; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BARON JC, 1985, NEURORADIOLOGY, V27, P509, DOI 10.1007/BF00340846; BARON JC, 1989, J CEREBR BLOOD F MET, V9, P723, DOI 10.1038/jcbfm.1989.105; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BULLOCK R, 1995, GUIDELINES MANAGEMEN; CARPENTER DA, 1991, J CEREBR BLOOD F MET, V11, P837, DOI 10.1038/jcbfm.1991.143; CARPENTER DA, 1990, NEUROLOGY, V40, P1587, DOI 10.1212/WNL.40.10.1587; Christensen MS, 1973, STROKE, V4, P568, DOI 10.1161/01.STR.4.4.568; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; CROCKARD HA, 1973, BMJ-BRIT MED J, V4, P634, DOI 10.1136/bmj.4.5893.634; CRUZ J, 1994, CRIT CARE MED, V22, P1465, DOI 10.1097/00003246-199409000-00018; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; CRUZ J, 1992, J NEUROSURG, V77, P162; CRUZ J, 1992, J NEUROSURG, V77, P975; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FARRAR JK, 1991, J CEREB BLOOD FLOW M, V11, pS553; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; FINNERTY FA, 1954, J CLIN INVEST, V33, P1227, DOI 10.1172/JCI102997; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; FRACKOWIAK RSJ, 1985, Q J MED, V57, P713; FRACKOWIAK RSJ, 1985, BRAIN IMAGING BRAIN, P139; FREWEN TC, 1989, CRIT CARE MED, V17, P912, DOI 10.1097/00003246-198909000-00015; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Gibbs EL, 1942, J BIOL CHEM, V144, P325; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GOTOH F, 1965, ARCH NEUROL-CHICAGO, V12, P410, DOI 10.1001/archneur.1965.00460280080008; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HOFF JT, 1975, STROKE, V6, P28, DOI 10.1161/01.STR.6.1.28; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KEE DB, 1984, NEUROSURGERY, V15, P125, DOI 10.1227/00006123-198407000-00026; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LASSEN NA, 1976, BRIT J ANAESTH, V48, P719, DOI 10.1093/bja/48.8.719; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; *NAT HEAD INJ FDN, 1995, FACTS TRAUM BRAIN IN; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OVERGAARD J, 1981, J NEUROSURG, V55, P63, DOI 10.3171/jns.1981.55.1.0063; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; PLUM F, 1967, AM J PHYSIOL, V212, P864; POWERS WJ, 1992, NEUROL CLIN, V10, P31; POWERS WJ, 1991, ANN NEUROL, V29, P231, DOI 10.1002/ana.410290302; POWERS WJ, 1984, ANN NEUROL, V16, P546, DOI 10.1002/ana.410160504; POWERS WJ, 1987, ANN INTERN MED, V106, P27, DOI 10.7326/0003-4819-106-1-27; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; POWERS WJ, 1987, CEREBROVASC DIS, P273; RAICHLE ME, 1970, ARCH NEUROL-CHICAGO, V23, P394, DOI 10.1001/archneur.1970.00480290014002; RAICHLE ME, 1976, ARCH NEUROL-CHICAGO, V33, P523, DOI 10.1001/archneur.1976.00500080001001; REIVICH M, 1964, AM J PHYSIOL, V206, P25; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROPPER AH, 1988, NEUROLOGICAL NEUROSU, P9; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SCHEINBERG P, 1949, J CLIN INVEST, V28, P1163, DOI 10.1172/JCI102150; SHARAN M, 1989, ANN BIOMED ENG, V17, P13, DOI 10.1007/BF02364271; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; SUTTON LN, 1990, J NEUROSURG, V73, P927, DOI 10.3171/jns.1990.73.6.0927; VANRIJEN PC, 1989, MAGN RESON MED, V10, P182, DOI 10.1002/mrm.1910100204; WILSON DF, 1992, ADV EXP MED BIOL, V316, P341; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; YE GF, 1994, ADV EXP MED BIOL, V361, P7; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; ZIVIN JA, 1988, ARCH NEUROL-CHICAGO, V45, P387, DOI 10.1001/archneur.1988.00520280033012	85	55	58	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	JAN	1997	13	1					163	+		10.1016/S0749-0704(05)70300-6			1	Critical Care Medicine	General & Internal Medicine	WE065	WOS:A1997WE06500009	9012580				2021-06-18	
J	Krauss, JK; Trankle, R; Kopp, KH				Krauss, JK; Trankle, R; Kopp, KH			Post-traumatic movement disorders in survivors of severe head injury	NEUROLOGY			English	Article							POSTTRAUMATIC TREMOR; STEREOTAXIC SURGERY; BRAIN INJURY; DYSTONIA; PARKINSONISM; CHILDREN; MIDBRAIN	The present study investigates the occurrence of post-traumatic movement disorders in survivors of severe head injury. We studied a series of 398 consecutive patients who were admitted to the hospital with a Glasgow Coma Score of 8 or less after they sustained a head trauma. One hundred thirty-four out of 398 patients (34%) died after they were admitted to the hospital or in the further course. A recent follow-up was obtained in 221 of the 264 remaining patients (84%). Follow-up consisted of a three-level assessment, including questionnaires, telephone interviews, and personal examinations. Fifty out of 221 patients (22.6%) had developed movement disorders secondary to the head trauma, which were transient in 23 patients (10.4%) and persistent in 27 patients (12.2%). Forty-two patients (19%) had tremors, nine (4.1%) had dystonia, and seven (3.2%) had other movement disorders. Twelve patients (5.4%) had disabling tow-frequency kinetic tremors (2.5 to 4 Hz) or dystonia, or both. Low-frequency kinetic tremors developed with a latency from 2 weeks to 6 months after trauma, and dystonia with a latency from 2 months to 2 years. When compared with patients without movement disorders, this subgroup was characterized by a different distribution profile of Glasgow Coma Scores with a higher proportion of lower scores on admission (p < 0.05). When we compared the initial CT findings, there were highly significant associations between generalized brain edema and the occurrence of any movement disorders, between generalized brain edema and the occurrence of persistent movement disorders, and between generalized brain edema and the occurrence of kinetic tremors and dystonia. We detected similar associations for focal cerebral lesions, but not for subdural and epidural hematomas. In conclusion, transient or persistent movement disorders are common sequelae in survivors of severe head injury. Disabling movement disorders such as kinetic tremors and dystonia, however, occur only in a small group of patients.	UNIV FREIBURG,DEPT NEUROSURG,FREIBURG,GERMANY; UNIV FREIBURG,DEPT ANESTHESIOL & INTENS CARE MED,FREIBURG,GERMANY	Krauss, JK (corresponding author), BAYLOR COLL MED,DEPT NEUROSURG,6560 FANNIN,SUITE 944,HOUSTON,TX 77030, USA.						ANDREW J, 1982, J NEUROL NEUROSUR PS, V45, P815, DOI 10.1136/jnnp.45.9.815; BAIN P, 1993, J NEUROL NEUROSUR PS, V69, P839; BIARY N, 1989, NEUROLOGY, V39, P103, DOI 10.1212/WNL.39.1.103; BULLARD DE, 1984, J NEUROSURG, V61, P316, DOI 10.3171/jns.1984.61.2.0316; BURKE RE, 1980, J NEUROL NEUROSUR PS, V43, P789, DOI 10.1136/jnnp.43.9.789; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; DE MORSIER G., 1960, PSYCHIAT ET NEUROL, V139, P60; FACTOR SA, 1991, MOV DISORD, V3, P30; FACTOR SA, 1993, PARKINSONIAN SYNDROM, P95; Fahn S, 1982, Adv Neurol, V35, P349; Fahn S., 1988, ADV NEUROL, P1; GOETZ CG, 1992, NEUROL CLIN, V10, P907; GOETZ CG, 1991, ANN NEUROL, V29, P191, DOI 10.1002/ana.410290213; Grimberg L, 1934, J NERV MENT DIS, V79, P14, DOI 10.1097/00005053-193401000-00002; JANKOVIC J, 1980, ANN INTERN MED, V93, P460, DOI 10.7326/0003-4819-93-3-460; JANKOVIC J, 1994, NEUROLOGY, V44, P2006, DOI 10.1212/WNL.44.11.2006; JOHNSON SLJ, 1992, ARCH DIS CHILD, V67, P227, DOI 10.1136/adc.67.2.227; KOLLER WC, 1989, MOVEMENT DISORD, V4, P20, DOI 10.1002/mds.870040106; Kono M, 1993, P 10 INT C NEUR SURG; Krauss J K, 1996, Parkinsonism Relat Disord, V2, P35, DOI 10.1016/1353-8020(95)00018-6; KRAUSS JK, 1994, J NEUROSURG, V80, P810, DOI 10.3171/jns.1994.80.5.0810; KRAUSS JK, 1992, MOVEMENT DISORD, V7, P263, DOI 10.1002/mds.870070313; KRAUSS JK, 1995, NEUROL RES, V17, P409, DOI 10.1080/01616412.1995.11740353; KREMER M, 1947, J NEUROL NEUROSUR PS, V10, P49, DOI 10.1136/jnnp.10.2.49; LAKKE JPWF, 1981, J NEUROL SCI, V51, P311, DOI 10.1016/0022-510X(81)90109-X; LEE MS, 1994, NEUROLOGY, V44, P1374, DOI 10.1212/WNL.44.8.1374; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; MAKI Y, 1980, CHILD BRAIN, V7, P113; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1992, BRIT J SURG, V79, P60, DOI 10.1002/bjs.1800790122; MONCKTON S, 1863, BRIT MED J, P382; Munoz JE, 1996, MOVEMENT DISORD, V11, P96, DOI 10.1002/mds.870110119; Narayan RK, 1991, PRINCIPLES NEUROSURG, P235; NAYERNOURI T, 1985, SURG NEUROL, V24, P263, DOI 10.1016/0090-3019(85)90035-7; PETTIGREW LC, 1985, J NEUROL NEUROSUR PS, V48, P650, DOI 10.1136/jnnp.48.7.650; REMY P, 1995, NEUROLOGY, V45, P472, DOI 10.1212/WNL.45.3.472; RONDOT P, 1994, J NEUROL NEUROSUR PS, V57, P658, DOI 10.1136/jnnp.57.5.658; SAMIE MR, 1990, NEUROLOGY, V40, P62, DOI 10.1212/WNL.40.1.62; Scott BL, 1996, NEUROLOGY, V46, P68, DOI 10.1212/WNL.46.1.68; STAROSTARUBINSTEIN S, 1983, SURG NEUROL, V20, P131, DOI 10.1016/0090-3019(83)90463-9; STEWART J, 1989, J NEUROL NEUROSUR PS, V52, P1200, DOI 10.1136/jnnp.52.10.1200; Szelozynska K, 1974, Neurol Neurochir Pol, V8, P167; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	46	55	58	0	8	LITTLE BROWN CO	BOSTON	34 BEACON STREET, BOSTON, MA 02108-1493	0028-3878			NEUROLOGY	Neurology	DEC	1996	47	6					1488	1492		10.1212/WNL.47.6.1488			5	Clinical Neurology	Neurosciences & Neurology	VX507	WOS:A1996VX50700024	8960732				2021-06-18	
J	Cruz, J				Cruz, J			Adverse effects of pentobarbital on cerebral venous oxygenation of comatose patients with acute traumatic brain swelling: Relationship to outcome	JOURNAL OF NEUROSURGERY			English	Article						head injury; coma; intracranial pressure; jugular oxyhemoglobin saturation; barbiturate therapy; outcome	SEVERE HEAD-INJURY; BLOOD-FLOW; PERFUSION-PRESSURE; HYPERVENTILATION; CONSUMPTION; MANAGEMENT; TRIAL	Global cerebrovenous oxygenation was evaluated before and after intravenous administration of pentobarbital sodium for the management of refractory intracranial hypertension in 151 comatose patients who had acute traumatic brain swelling. Two groups of patients were identified: a group in which the jugular oxyhemoglobin saturation (SjO(2)) remained at or above 45% after pentobarbital bolus, and a group in which the SjO(2) dropped below 45%. The two groups were matched by predominant findings on computerized tomography scans of the head, as well as age, postresuscitation Glasgow Coma Scale scores, levels of total hemoglobin content, SjO(2), intracranial pressure (ICP), and cerebral perfusion pressure (CPP) prior to pentobarbital bolus. Outcomes were significantly worse (p < 0.0001) in patients who developed decreases in SjO(2) to levels below 45% than in those whose SjO(2) remained at or above 45%, despite the fact that there were no significant differences between the two groups with regard to ICP and CPP after an intravenous bolus of pentobarbital.		Cruz, J (corresponding author), ALLEGHENY UNIV HLTH SCI,DEPT NEUROSURG,MAIL STOP 455,PHILADELPHIA,PA 19102, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR303687] Funding Source: Medline		CRUZ J, 1993, CRIT CARE MED, V21, P1218, DOI 10.1097/00003246-199308000-00024; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; CRUZ J, 1995, J NEUROSURG, V82, P379, DOI 10.3171/jns.1995.82.3.0379; CRUZ J, 1993, CRIT CARE MED, V21, P1225, DOI 10.1097/00003246-199308000-00025; CRUZ J, 1990, J NEUROSURG, V73, P725, DOI 10.3171/jns.1990.73.5.0725; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; JENNETT B, 1975, LANCET, V1, P480; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; TEASDALE G, 1974, LANCET, V2, P81	16	55	58	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					758	761		10.3171/jns.1996.85.5.0758			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900003	8893711				2021-06-18	
J	Turkstra, LS; McDonald, S; Kaufmann, PM				Turkstra, LS; McDonald, S; Kaufmann, PM			Assessment of pragmatic communication skills in adolescents after traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; LANGUAGE-SKILLS; CHILDREN; ABILITY; DISCOURSE; REQUESTS	Deficits in pragmatic communication ability have a significant impact on functional outcome from traumatic brain injury (TBI), particularly during adolescence, when sophisticated social communication skills are developing. There are few published tests designed to assess pragmatic skills in this age group. In the present study, four tasks designed to tap various aspects of pragmatic communication ability were administered to three brain-injured adolescents and 36 of their uninjured peers aged 15-18 years. The tasks evaluated the ability to negotiate, hint, describe a simple procedure, and understand sarcasm. The four tasks were found to tap distinct aspects of pragmatic ability in control subjects. Further, within the control group, task performance was related more to non-verbal reasoning ability than vocabulary skills. Scores for two of the three TBI subjects were poorer than chose of their peers, while a third mildly injured subject performed within normal limits. Pragmatic task scores were consistent with the results of neuropsychological testing in the three TBI subjects. Implications for clinical management and recommendations for future research are discussed.	NATL CTR NEUROGEN COMMUN DISORDERS,TUCSON,AZ; UNIV NEW S WALES,DEPT PSYCHOL,KENSINGTON,NSW 2033,AUSTRALIA; UNIV ARIZONA,DEPT PEDIAT,TUCSON,AZ 85721			McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P60DC001409] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-01409] Funding Source: Medline		ABBEDUTO L, 1989, SCHOOL PSYCHOL REV, V18, P502; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BURKE W H, 1990, Brain Injury, V4, P371, DOI 10.3109/02699059009026190; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DEATON AV, 1987, J LEARN DISABIL, V20, P581, DOI 10.1177/002221948702001003; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DONDERS J, 1993, BRAIN INJURY, V7, P431, DOI 10.3109/02699059309029686; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1985, SPEECH LANGUAGE EVAL, P71; FLAVELL JH, 1968, DEV ROLE TAKING COMM; FRANCIK EP, 1985, J MEM LANG, V24, P560, DOI 10.1016/0749-596X(85)90046-4; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; Goldman PS, 1974, PLASTICITY RECOVERY; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; HADI AS, 1994, J ROY STAT SOC B MET, V56, P393; Hartley L. L., 1995, COGNITIVE COMMUNICAT; ISAACSON RL, 1975, ABERRANT DEV INFANCY, P1; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; KENNARD M, 1942, ARCH NEUROL PSYCHIAT, V47, P227; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LENNEBERG EH, 1967, BIOL F LANGUAGE; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; MCDONALD S, 1995, IN PRESS BRAIN INJUR; MILTON SB, 1987, CLIN APHASIOLOGY, V14, P114; Nippold M. A., 1993, LANG SPEECH HEAR SER, V24, P21; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; Phelps-Terasaki D., 1992, TEST PRAGMATIC LANGU; Prutting C., 1983, PRAGMATIC ASSESSMENT, P29; REITER S, 1990, CAN J PSYCHIAT, V35, P669, DOI 10.1177/070674379003500804; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; SMITH A, 1984, EARLY BRAIN DAMAGE, V1, P229; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; TAYLOR HG, 1984, EARLY BRAIN DAMAGE, V1, P325; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TIMMERMAN S, 1991, COGNITIVE REHABILITA, P26; TOWNE RL, 1993, LANG SPEECH HEAR SER, V24, P100; WIIG EH, 1988, TEST LANGUAGE COMPET; Ylvisaker M., 1989, MILD MODERATE HEAD I, P203	44	55	55	0	11	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY	1996	10	5					329	345		10.1080/026990596124359			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UL742	WOS:A1996UL74200002	8735664				2021-06-18	
J	Mansfield, RT; Schiding, JK; Hamilton, RL; Kochanek, PM				Mansfield, RT; Schiding, JK; Hamilton, RL; Kochanek, PM			Effects of hypothermia on traumatic brain injury in immature rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						edema; head injury; hypothermia; immature rat; traumatic brain injury	METHYL-D-ASPARTATE; CEREBRAL BLOOD-FLOW; H-3 MK-801 BINDING; MODERATE HYPOTHERMIA; INTRACRANIAL HYPERTENSION; RECEPTOR COMPLEX; MILD HYPOTHERMIA; HEAD-INJURIES; CHILDREN; CORTEX	Hypothermia is beneficial in adult models of traumatic brain injury (TBI), but it has not been evaluated in an immature animal model. We hypothesized that brief hypothermia applied after TBI would reduce cerebral edema and lesion volume in immature rats. Male Wistar rats (3-4 weeks of age, 90-140 g) were anesthetized, intubated, mechanically ventilated, and subjected to TBI by a weight drop onto the exposed right parietal cortex. Hypothermic rats were then cooled to a brain temperature of 32.0 +/- 0.5 degrees C for 4 h, and control rats were maintained at a brain temperature of 37.0 +/- 0.5 degrees C. Cerebral edema(wet - dry weight method) was assessed at 4 and 24 h, and lesion volume was assessed at 5 days, At 4 h, a reduction of percent brain water in the traumatized hemisphere was observed in hypothermic versus normothermic rats (81.75 +/- 0.60 vs. 82.53 +/- 0.67%; p < 0.05), but by 24 h posttrauma, the groups were similar (p = 0.82). Total lesion volume (47.2 +/- 8.5 vs. 44.4 +/- 10.0 mm(3); p = 0.51) and necrotic volume (20.2 +/- 6.3 vs. 20.0 +/- 7.9 mm(3); p = 0.95) were similar in the hypothermic and normothermic groups. We conclude that in this model, a transient (4-h) application of moderate (32 degrees C) hypothermia reduces the cerebral edema characteristically seen in immature rats at 4 h, but this reduction is not sustained at 24 h. Attenuating or delaying the development of cerebral edema could have important therapeutic relevance after TBI. Transient hypothermia, however, did not reduce lesion volume at 5 days posttrauma.	UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, DEPT PATHOL, PITTSBURGH, PA 15260 USA			Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X			ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Biagas K. V., 1992, Society for Neuroscience Abstracts, V18, P1088; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CARSON F, 1980, THEORY PRACTICE HIST, P252; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DSOUZA SW, 1992, LANCET, V339, P1240, DOI 10.1016/0140-6736(92)91188-E; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; LANGFITT TW, 1977, ANN SURG, V186, P411, DOI 10.1097/00000658-197710000-00002; LIN B, 1994, STROKE, V25, P254; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MAGNUSSON KR, 1993, BRAIN RES, V604, P334, DOI 10.1016/0006-8993(93)90386-2; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCDONALD JW, 1992, BRAIN RES, V583, P54, DOI 10.1016/S0006-8993(10)80009-5; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PIGGOTT MA, 1992, BRAIN RES, V588, P277, DOI 10.1016/0006-8993(92)91586-4; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; REAM AK, 1982, ANESTHESIOLOGY, V56, P41, DOI 10.1097/00000542-198201000-00009; ROSOMOFF HL, 1959, J NEUROSURG, V16, P177, DOI 10.3171/jns.1959.16.2.0177; ROSOMOFF HL, 1955, AM J PHYSIOL, V183, P19; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SHULMAN K, 1959, AM J SURG, V98, P704, DOI 10.1016/0002-9610(59)90495-7; SLATER P, 1993, BRIT J PHARMACOL, V108, P1143, DOI 10.1111/j.1476-5381.1993.tb13518.x; STEEN PA, 1980, ANESTHESIOLOGY, V52, P224, DOI 10.1097/00000542-198003000-00007; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAMARU M, 1991, BRAIN RES, V542, P83, DOI 10.1016/0006-8993(91)91001-H; VERHEUL HB, 1993, BRAIN RES, V618, P203, DOI 10.1016/0006-8993(93)91267-V; YAGER J, 1993, PEDIATR RES, V34, P525, DOI 10.1203/00006450-199310000-00029; YOUNG RSK, 1983, STROKE, V14, P622, DOI 10.1161/01.STR.14.4.622; YOUNG RSK, 1980, JAMA-J AM MED ASSOC, V244, P1233, DOI 10.1001/jama.244.11.1233	37	55	56	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1996	16	2					244	252		10.1097/00004647-199603000-00009			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	TW393	WOS:A1996TW39300009	8594056	Bronze			2021-06-18	
J	Collins, LF; Long, CJ				Collins, LF; Long, CJ			Visual reaction time and its relationship to neuropsychological test performance	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; CEREBRAL-DYSFUNCTION; RECOVERY	The purpose of this study was to investigate the relationship between simple and choice reaction time (RT) measures and neuropsychological test performance (as assessed by the Impairment Index of the Halstead-Reitan Neuropsychological Test Battery). Both median RT scores and intraindividual variability of RT scores were evaluated in three groups: impaired TBI, nonimpaired TBI, and normal controls. In all three groups, there was a statistically significant correlation between both reaction time measures and level of cognitive functioning. In addition, SRT speed of information processing (as measured by CRT), and intraindividual variability of RT scores continued to be impaired in many brain-damaged individuals who, according to the Impairment Index, had fully recovered from their cognitive deficits. Median RT scores were better able to discriminate between impaired TBI patients and normal controls; bur intraindividual variability of RT scores was better able to discriminate between nonimpaired TBI patients and normal controls. It was concluded that, by adding the two short RT tests to the neuropsychological test battery, more accurate predictions can be made about a patient's level of cognitive functioning and the nature of treatment needed for continued recovery. Copyright (C) 1996 National Academy of Neuropsychology		Collins, LF (corresponding author), UNIV MEMPHIS,DEPT PSYCHOL,MEMPHIS,TN 38152, USA.						BENTON AL, 1958, CONFIN NEUROL, V19, P247; BLACKBURN H L, 1955, Confin Neurol, V15, P327; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; BRUHN P, 1971, CORTEX, V7, P279; DERENZI E, 1965, CORTEX, V1, P410; ELSASS P, 1986, ACTA NEUROL SCAND, V73, P225; ELSASS P, 1985, ACTA NEUROL SCAND, V71, P11; GOLDSTEIN G, 1990, HDB PSYCHOL ASSESSME, P197; GRONWALL D, 1974, LANCET, V2, P605; Halstead WC, 1985, HALSTEAD REITAN NEUR; HICKS LH, 1970, PSYCHOL BULL, V74, P377, DOI 10.1037/h0033064; JENSEN AR, 1992, PERS INDIV DIFFER, V13, P869, DOI 10.1016/0191-8869(92)90004-9; MARGOLIN DI, 1992, COGNITIVE NEUROPSYCH, P18; MARGOLIN DI, 1992, COGNITIVE NEUROPSYCH, P9; Miller E, 1970, Cortex, V6, P121; ODONNELL WE, 1984, J CLIN PSYCHOL, V21, P553; POSNER MI, 1982, ANNU REV PSYCHOL, V33, P477, DOI 10.1146/annurev.ps.33.020182.002401; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WESTERN SL, IN PRESS ARCH CLIN N; WILLANGER R, 1970, INTELLECTUAL IMPAIRM	21	55	55	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.		1996	11	7					613	623		10.1016/0887-6177(97)81255-3			11	Psychology, Clinical; Psychology	Psychology	VT623	WOS:A1996VT62300006	14588445	Bronze			2021-06-18	
J	WATSON, MR; FENTON, GW; MCCLELLAND, RJ; LUMSDEN, J; HEADLEY, M; RUTHERFORD, WH				WATSON, MR; FENTON, GW; MCCLELLAND, RJ; LUMSDEN, J; HEADLEY, M; RUTHERFORD, WH			THE POST-CONCUSSIONAL STATE - NEUROPHYSIOLOGICAL ASPECTS	BRITISH JOURNAL OF PSYCHIATRY			English	Article							MINOR HEAD-INJURY; SEQUELAE	Background. Twenty-six young men admitted to an Accident and Emergency Department for observation following a minor closed head injury (post-traumatic amnesia (PTA) less than 12 hours) were investigated within 24 hours of admission (day 0) and followed up at 10 days, 6 weeks and 1 year after the trauma. Method. Investigations at day 0 included physical examination, completion of post-concussional symptom and stress-arousal checklists, computerised EEG (CEEG) and auditory brainstem evoked potential (BAEP) recordings. These were repeated at ten days and six weeks. At 12 months follow-up. the Present State Examination (PSE) was carried out and a further post-concussional symptom checklist completed. Results. Post-concussional symptomatology declined progressively from day 0 but half had residual symptoms at 1 year. Seventy-two per cent ran an acute course with recovery by 6 weeks, 8% a chronic unremitting course and 20% initially improved but had an exacerbation of symptoms between 6 weeks and 12 months. The CEEG alpha-theta ratios decreased significantly between days 0 and 10, reaching a baseline thereafter. Measures of CEEG recovery from all channels correlated with symptom counts at six weeks; the slower the recovery the greater the symptoms. A relative delay in left temporal recovery was associated with residual psychiatric morbidity (PSE ID scores) at 12 months. Prolonged central brainstem conduction times occurred in 27% of patients at day 0. These correlated positively with PTA and degree of psychiatric morbidity (PSE ID scores) at 12 months. Conclusions. Symptom chronicity was accompanied by continuing brainstem dysfunction, while the degree of transient cortical dysfunction appeared to have a direct influence in the intensity of early organic symptom reaction to the trauma. Levels of perceived stress at the time of the injury, or afterwards, were not related to symptom formation.	HOLYWELL HOSP,BELFAST,ANTRIM,NORTH IRELAND; UNIV DUNDEE,DUNDEE,SCOTLAND; QUEENS UNIV BELFAST,BELFAST,ANTRIM,NORTH IRELAND; BROADMOOR HOSP,DEPT NEUROPHYSIOL,CROWTHORNE,BERKS,ENGLAND; ST LUKES HOSP,ARMAGH,NORTH IRELAND; CRAIGAVON AREA HOSP,ARMAGH,NORTH IRELAND; ROYAL VICTORIA HOSP,DEPT ACCID & EMERGENCY,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND							Cartlidge N E, 1981, HEAD INJURY; COOPER R, 1965, ELECTROEN CLIN NEURO, V18, P217, DOI 10.1016/0013-4694(65)90088-X; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; GRONWALL D, 1974, LANCET, V2, P605; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MACKAY C, 1978, BRIT J SOC CLIN PSYC, V17, P283, DOI 10.1111/j.2044-8260.1978.tb00280.x; McAllister H G, 1983, Br J Audiol, V17, P275, DOI 10.3109/03005368309081489; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; RUTHERFORD WH, 1977, LANCET, V1, P1; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; Trimble MR, 1981, POSTTRAUMATIC NEUROS; World Health Organization (WHO), 1978, MENT DIS GLOSS GUID	20	55	57	0	2	ROYAL COLLEGE OF PSYCHIATRISTS	LONDON	BRITISH JOURNAL OF PSYCHIATRY 17 BELGRAVE SQUARE, LONDON, ENGLAND SW1X 8PG	0007-1250			BRIT J PSYCHIAT	Br. J. Psychiatry	OCT	1995	167						514	521		10.1192/bjp.167.4.514			8	Psychiatry	Psychiatry	TA964	WOS:A1995TA96400017	8829722				2021-06-18	
J	CORRIGAN, JD; RUST, E; LAMBHART, GL				CORRIGAN, JD; RUST, E; LAMBHART, GL			THE NATURE AND EXTENT OF SUBSTANCE-ABUSE PROBLEMS IN PERSONS WITH TRAUMATIC BRAIN INJURY	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							ALCOHOL; TESTS	Objective: Describe the pre- and postinjury patterns of alcohol and other drug use among persons who have incurred traumatic brain injury (TBI). Injury-related characteristics and negative consequences are also reported, as well as preliminary outcomes of treatment. Design: Descriptive analysis of a consecutive sample of persons referred during an 18-month period to a treatment program for substance abuse after TBI. Setting: A community-based demonstration project affiliated with an acute rehabilitation hospital in a large midwestern academic medical center. Patients: The first 211 persons screened by the program, including all 97 receiving comprehensive assessments and 68 who dropped out prior to assessment. Preliminary outcomes were based on the first 37 clients monitored 6 months after entering into treatment. Intervention: Screening for appropriateness of referral; comprehensive, holistic assessment; and resource and service coordination provided by an interdisciplinary staff that facilitates treatment by local providers. Main Outcome Measures: Alcohol use measured by the Quantity-Frequency-Variability Index, completed by client and significant other; productivity measured by the Employability Rating Scale; multiple sociodemographic indicators. Results: More than 60% of injuries were use related; this included 71% of assaults. Alcohol was the preferred drug for 83%, and more than half used some marijuana. Prior to injury, the study sample consumed significantly greater amounts of alcohol than national averages; after injury, consumption was consistent with national averages. Approximately 20% of individuals who abstained or were light drinkers before injury showed high volume use after injury. Conclusions: There are multiple reasons why the harmful effects of alcohol and other drug use after TBI are underestimated, including cultural acceptance of beer and the subtle sequelae of marijuana use. It is recommended that the extent of use of same-aged peers not be used as the criterion for acceptable use by persons who have experienced TBI. Further study is needed regarding the utility of assessment devices, the effectiveness of referrals made during rehabilitation, and the efficacy of intervention techniques.		CORRIGAN, JD (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,TBI SA,COLUMBUS,OH 43210, USA.		Corrigan, John D./E-2921-2011				BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; CALLAHAN D, 1968, Q J STUD ALCOHOL, V29, P130; Cervantes, 1994, Assessment, V1, P23, DOI 10.1177/1073191194001001004; CHARNESS ME, 1993, NIH933549 NAT I ALC; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; CORRIGAN JD, IN PRESS ARCH PHYS M; CORRIGAN JD, 1994, 102ND ANN CONV AM PS; CORRIGAN JD, IN PRESS BRAIN INJUR; Drubach D A, 1993, Md Med J, V42, P989; Dunlop T W, 1991, J Neuropsychiatry Clin Neurosci, V3, P150; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P27; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; GUALTIERI T, 1990, J HEAD TRAUMA REHAB, V5, P32; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; JENSEN GB, 1993, LANCET, V342, P1201; Jones G.A., 1992, NEUROREHABILITATION, V2, P27; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1991, J HEAD TRAUMA REHAB, V6, P12; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LANGLEY MJ, 1994, MAY INT SUBST AB INT; MILLER JD, 1983, DHHS ADM831263 PUBL; *OH REH SERV COMM, 1992, OH HEAD INJ PROGR NE; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SKINNER HA, 1984, ANN INTERN MED, V101, P847, DOI 10.7326/0003-4819-101-6-847; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; VERMA NP, 1992, CLIN ELECTROENCEPHAL, V23, P147, DOI 10.1177/155005949202300310; WILLIAMS GD, 1992, BRIT J ADDICT, V87, P643; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955	32	55	55	0	6	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1995	10	3					29	46					18	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	RC717	WOS:A1995RC71700004					2021-06-18	
J	MCDONALD, CM; JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; LIAO, SQ; RIVARA, JB				MCDONALD, CM; JAFFE, KM; FAY, GC; POLISSAR, NL; MARTIN, KM; LIAO, SQ; RIVARA, JB			COMPARISON OF INDEXES OF TRAUMATIC BRAIN INJURY SEVERITY AS PREDICTORS OF NEUROBEHAVIORAL OUTCOME IN CHILDREN	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; INTELLECTUAL ABILITY; COMPUTED-TOMOGRAPHY; PRACTICAL SCALE; AMNESIA TEST; RECOVERY; ADOLESCENTS; SEQUELAE; MEMORY; COMA		CHILDRENS HOSP & MED CTR,DEPT REHABIL MED,SEATTLE,WA; CHILDRENS HOSP & MED CTR,DEPT NEUROL,SEATTLE,WA; UNIV WASHINGTON,DEPT REHABIL MED,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,CTR QUANTITAT SCI,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PUBL HLTH,SEATTLE,WA 98195	MCDONALD, CM (corresponding author), UNIV CALIF DAVIS,SACRAMENTO MED CTR,MED CTR,DEPT PHYS MED & REHABIL,4301 X ST,SACRAMENTO,CA 95817, USA.			McDonald, Craig/0000-0002-8779-3220	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR02299] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Achenbach TM, 1986, MANUAL TEACHERS REPO; BIJUR PE, 1990, PEDIATRICS, V86, P337; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; BRUCE DA, 1979, CHILD BRAIN, V5, P174; BRUDE DA, 1986, CLIN PEDIATR, V19, P719; Bruininks R.H., 1984, SCALES INDEPENDENT B; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Conover W.J., 1980, PRACTICAL NONPARAMET; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; DELIS DC, 1989, CALIFORNIA VERBAL LE; DRAPER NR, 1981, APPLIED REGRESSION A; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; Humphreys RP, 1983, CONCEPTS PEDIATRIC N, V3, P191; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Jastak S, 1984, WIDE RANGE ACHIEVEME; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; POLISSAR NL, IN PRESS BRAIN INJUR; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RIVARA F, 1987, PEDIATRICS, V80, P579; RUIJS MBM, 1992, DEV MED CHILD NEUROL, V34, P885; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; TEASDALE G, 1974, LANCET, V2, P81; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; ZIMMERMAN RA, 1981, J NEURORADIOLOGY, V8, P257; 1980, ABBREVIATED INJURY S	50	55	56	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	1994	75	3					328	337		10.1016/0003-9993(94)90038-8			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	NA130	WOS:A1994NA13000018	8129588				2021-06-18	
J	MARTIN, RC; BOLTER, JF; TODD, ME; GOUVIER, WD; NICCOLLS, R				MARTIN, RC; BOLTER, JF; TODD, ME; GOUVIER, WD; NICCOLLS, R			EFFECTS OF SOPHISTICATION AND MOTIVATION ON THE DETECTION OF MALINGERED MEMORY PERFORMANCE USING A COMPUTERIZED FORCED-CHOICE TASK	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FAKING; PROSPECTS; DEFICITS; AMNESIA	The present study employed a computerized forced-choice recognition memory task, the Multi-Digit Memory Test (MDMT), to examine the effects of instructional set (i.e., dissimulation information provided subjects) and motivation (i.e., monetary incentive) on simulated malingering behavior in a group of 119 university undergraduate students and 33 patients sustaining varying severity of closed-head injury. For the nonpatient groups, a significant effect of instructional set was revealed. Motivational incentive, however did not affect forced-choice performance. Overall, significant performance differences emerged between all groups with nonmalingering students performing nearly perfectly, the brain-injured patients performing well above chance levels, sophisticated student malingers performing at chance, and naive student malingers performing well below chance levels. These results suggest the MDMT may offer a clinically useful and convenient addition to a neuropsychological assessment when there is suspicion of feigned memory problems. These data also support the use of naive and sophisticated malingering subjects in further analog studies addressing this topic.		MARTIN, RC (corresponding author), LOUISIANA STATE UNIV,DEPT PSYCHOL,BATON ROUGE,LA 70803, USA.						American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BRANDT J, 1985, ANN NY ACAD SCI, V444, P502, DOI 10.1111/j.1749-6632.1985.tb37625.x; BRANDT J, 1988, CLIN ASSESSMENT MALI; DULANEY EF, 1982, HUM COMMUN RES, V9, P75, DOI 10.1111/j.1468-2958.1982.tb00684.x; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; HEILVEIL I, 1981, PSYCHOTHER-THEOR RES, V18, P329, DOI 10.1037/h0088382; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Jennett B, 1981, MANAGEMENT HEAD INJU; KERR KL, 1990, J CLIN EXPT NEUROPSY, V11, P57; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Niccolls R., 1991, MULTIDIGIT MEMORY TE; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1988, CLIN ASSESSMENT MALI; ROGERS R, 1988, CLIN ASSESSMENT MALI; Sax D. S., 1984, ADV CLIN NEUROPSYCHO, P127; SCHACTER DL, 1986, BEHAVIORAL SCI LAW, V4, P47, DOI DOI 10.1002/BSL.2370040104; SMITH A, 1961, DIS NERV SYST, V22, P69; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	23	55	55	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV	1993	15	6					867	880		10.1080/01688639308402604			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	MM923	WOS:A1993MM92300003	8120124				2021-06-18	
J	CARPENTIERI, SC; MULHERN, RK; DOUGLAS, S; HANNA, S; FAIRCLOUGH, DL				CARPENTIERI, SC; MULHERN, RK; DOUGLAS, S; HANNA, S; FAIRCLOUGH, DL			BEHAVIORAL RESILIENCY AMONG CHILDREN SURVIVING BRAIN-TUMORS - A LONGITUDINAL-STUDY	JOURNAL OF CLINICAL CHILD PSYCHOLOGY			English	Article							CLOSED HEAD-INJURY; VENTRICULAR ENLARGEMENT; CHRONIC ILLNESS; LEUKEMIA; QUALITY; ADJUSTMENT; CHECKLIST; SEQUELAE; AUTISM; CANCER	Compared the social and behavioral adjustment of 40 long-term survivors of childhood brain tumors to a matched control group of children surviving cancers that did not involve the central nervous system. Both groups exhibited significant elevations on the Behavior Problems scales of the Child Behavior Checklist (CBCL) relative to nonclinical norms, although approximately 50% of the children in both groups did not have significantly elevated scores on the CBCL. Contrary to expectations, the brain tumor group did not have significantly more signs of psychopathology than did the cancer control group and examination of serial evaluations suggested a significant decrease in symptoms of emotional disturbance since diagnosis in most children treated for brain tumors. Children in the brain tumor group did display more problems in the Social Competence scales than did children in the cancer control group, especially those related to inhibition of activities and school performance.	MEMPHIS STATE UNIV, MEMPHIS, TN 38152 USA; UNIV TENNESSEE, SCH MED, DEPT PEDIAT, KNOXVILLE, TN 37996 USA; ST JUDE CHILDRENS RES HOSP, DIV BIOSTAT, MEMPHIS, TN 38101 USA; ST JUDE CHILDRENS RES HOSP, DIV DIAGNOST IMAGING, MEMPHIS, TN 38101 USA	CARPENTIERI, SC (corresponding author), ST JUDE CHILDRENS RES HOSP, DIV PSYCHOL, POB 318, 332 N LAUDERDALE, MEMPHIS, TN 38101 USA.						ACHENBACH TM, 1983, CHILD BEHAVIOR CHECK; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BARON D, 1986, MANUAL APPLE 2E CBCL; CARPENTIERI SC, IN PRESS ARCH CLIN N; COURCHESNE E, 1988, NEW ENGL J MED, V318, P1349, DOI 10.1056/NEJM198805263182102; DANOFF BF, 1982, CANCER, V48, P1580, DOI 10.1002/1097-0142(19820415)49:8<1580::AID-CNCR2820490810>3.0.CO;2-7; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GORTMAKER SL, 1990, PEDIATRICS, V85, P267; GREENBERG HS, 1989, J PEDIATR-US, V114, P488, DOI 10.1016/S0022-3476(89)80581-5; HENDREN RL, 1991, J AM ACAD CHILD PSY, V30, P466, DOI 10.1097/00004583-199105000-00018; Hollingshead A.B., 1957, 2 FACTOR INDEX SOCIA; KORNHUBER HH, 1985, EUR ARCH PSY CLIN N, V235, P129, DOI 10.1007/BF00380981; KUN LE, 1983, J NEUROSURG, V58, P1, DOI 10.3171/jns.1983.58.1.0001; KUPST MJ, 1988, J PEDIATR PSYCHOL, V13, P7, DOI 10.1093/jpepsy/13.1.7; LANNERING B, 1990, MED PEDIATR ONCOL, V18, P304, DOI 10.1002/mpo.2950180410; LEBARON S, 1988, CANCER, V62, P1215, DOI 10.1002/1097-0142(19880915)62:6<1215::AID-CNCR2820620629>3.0.CO;2-C; MALEY JE, 1980, AM J PSYCHIAT, V137, P94; MEADOWS A T, 1986, Cancer, V58, P524, DOI 10.1002/1097-0142(19860715)58:2+<524::AID-CNCR2820581319>3.0.CO;2-C; MULHERN RK, 1992, MED PEDIATR ONCOL, V20, P181, DOI 10.1002/mpo.2950200302; MULHERN RK, 1988, J CHILD NEUROL, V3, P47, DOI 10.1177/088307388800300111; MULHERN RK, 1989, PEDIATRICS, V83, P18; MULHERN RK, IN PRESS J PEDIATRIC; MULHERN RK, 1990, CHILD ADOLESCENT DIS, P267; PERRIN EC, 1991, J PEDIATR PSYCHOL, V16, P411, DOI 10.1093/jpepsy/16.4.411; PLESS IB, 1991, J CHILD PSYCHOL PSYC, V32, P347, DOI 10.1111/j.1469-7610.1991.tb00312.x; PRIOR MR, 1984, ARCH NEUROL-CHICAGO, V41, P482, DOI 10.1001/archneur.1984.04050170028010; REISS D, 1983, AM J PSYCHIAT, V140, P453; Rutter M., 1970, CLIN DEV MED, V35; SANDBERG DE, 1991, J AM ACAD CHILD PSY, V30, P124, DOI 10.1097/00004583-199101000-00019; SAWYER M, 1986, AM J PEDIAT HEMATOL, V8, P200; SCHULZ SC, 1983, AM J PSYCHIAT, V140, P1592; SOLLEE ND, 1987, J ABNORM CHILD PSYCH, V15, P479, DOI 10.1007/BF00917235; TATUM WO, 1989, ANN NEUROL, V25, P196, DOI 10.1002/ana.410250216; TAYLOR HG, 1990, NEW ENGL J MED, V323, P1657, DOI 10.1056/NEJM199012133232403; Wechsler D., 1974, MANUAL WECHSLER INTE; WILLIAMS JM, 1986, CANCER TREAT REV, V13, P113	36	55	56	0	5	LAWRENCE ERLBAUM ASSOC INC-TAYLOR & FRANCIS	PHILADELPHIA	325 CHESTNUT STREET, STE 800, PHILADELPHIA, PA 19106 USA	0047-228X			J CLIN CHILD PSYCHOL	J. Clin. Child Psychol.	JUN	1993	22	2					236	246		10.1207/s15374424jccp2202_10			11	Psychology, Clinical; Psychology, Developmental	Psychology	LT894	WOS:A1993LT89400010					2021-06-18	
J	RUGG, MD; PICKLES, CD; POTTER, DD; DOYLE, MC; PENTLAND, B; ROBERTS, RC				RUGG, MD; PICKLES, CD; POTTER, DD; DOYLE, MC; PENTLAND, B; ROBERTS, RC			COGNITIVE BRAIN POTENTIALS IN A 3-STIMULUS AUDITORY ODDBALL TASK AFTER CLOSED HEAD-INJURY	NEUROPSYCHOLOGIA			English	Article							EVENT-RELATED POTENTIALS; PERFORMANCE; DYSFUNCTION; STIMULI; P300	Event-related potentials (ERPs) were recorded in a three stimulus oddball task from 16 patients who had sustained a severe closed head injury at least 6 months before testing, and from 16 control subjects. The stimuli comprised a random sequence of frequent non-target tones (P = 0.70), rare target tones (P = 0.15), and rare novel sounds (P = 0.15). The task requirement was to respond promptly to each target tone. From a latency of 200 msec onwards, the ERPs evoked by frequent nontargets were substantially more negative-going in the head-injured than in the control group. When this difference in the ERPs to the frequent tones was taken into account, there was no evidence to suggest that either the latency or the amplitude of the target-evoked N2 and P3b components differed between the groups. The novel stimuli evoked a prominent P3a component. The amplitude and scalp distribution of this component differed little between the groups, but its peak latency was reliably longer in the head-injured subjects. The findings in respect of the N2 and P3b components suggest that impairments in early processing of task-relevant stimuli are not an invariant feature of closed head injury. The findings regarding P3a suggest that, in the majority of patients, head injury has only a limited effect on the neural systems underlying involuntary shifts of attention.	ASTLEY AINSLIE HOSP,DEPT REHABIL MED,EDINBURGH,SCOTLAND; UNIV DUNDEE,DEPT MED,DUNDEE DD1 4HN,SCOTLAND; DUNDEE ROYAL INFIRM,DEPT NEUROL,DUNDEE,SCOTLAND	RUGG, MD (corresponding author), UNIV ST ANDREWS,DEPT PSYCHOL,WELLCOME BRAIN RES GRP,ST ANDREWS KY16 9JU,FIFE,SCOTLAND.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		BROOKS N, 1984, CLOSED HEAD INJURY P, P44; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; COURCHESNE E, 1975, ELECTROEN CLIN NEURO, V39, P131, DOI 10.1016/0013-4694(75)90003-6; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DEACON D, 1991, ELECTROEN CLIN NEURO, V78, P133, DOI 10.1016/0013-4694(91)90113-I; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; FITZGERALD PG, 1983, BIOL PSYCHOL, V17, P241, DOI 10.1016/0301-0511(83)90003-0; GARCIALARREA L, 1992, NEUROPSYCHOLOGIA, V30, P723, DOI 10.1016/0028-3932(92)90042-K; GRAHAM FK, 1991, HDB COGNITIVE PSYCHO, P253; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HOLDSTOCK JH, IN PRESS NEW DEV EVE; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KNIGHT RT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P139; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCCARTHY G, 1985, ELECTROEN CLIN NEURO, V62, P203, DOI 10.1016/0168-5597(85)90015-2; Miller E, 1970, Cortex, V6, P121; *MIN STAT SOFTW, 1988, REF MAN REL 6 1; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; Naatanen R., 1983, ADV PSYCHOL, VVolume 10, P119; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; RUGG MD, 1992, HDB NEUROPSYCHOLOGIC, P393; SCABINI D, 1989, Society for Neuroscience Abstracts, V15, P477; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; STEPHENSON WA, 1951, ELECTROEN CLIN NEURO, V3, P237, DOI 10.1016/0013-4694(51)90017-X; STOKX LC, 1986, J CLIN EXP NEUROPSYC, V8, P421, DOI 10.1080/01688638608401332; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; Woods DL., 1990, EVENT RELATED BRAIN, P178	38	55	57	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	APR	1993	31	4					373	393		10.1016/0028-3932(93)90161-R			21	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	LB263	WOS:A1993LB26300007	8502373				2021-06-18	
J	LEE, ST; LUI, TN				LEE, ST; LUI, TN			EARLY SEIZURES AFTER MILD CLOSED HEAD-INJURY	JOURNAL OF NEUROSURGERY			English	Article						POSTTRAUMATIC SEIZURE; EARLY SEIZURE; CLOSED HEAD INJURY	COMPUTED TOMOGRAPHIC SCANS; TRAUMA; EPILEPSY; CHILDREN; POPULATION; ADMISSION; COUNTY; RISK	The authors review the seizure incidence in 4232 adult patients with mild closed head injury who did not receive prophylactic anticonvulsant agents. One hundred patients (2.36%) experienced seizures within 1 week after head injury; 43 of these (1.02% of the series) had seizures within 24 hours after trauma. Most of the seizures (84%) that developed during the 1st week after injury were of the generalized tonic-clonic type. The incidence of generalized tonic-clonic seizures was higher than that of partial seizures with motor symptoms both within 24 hours (91% vs. 9%) and during the Day 2 to 7 period (79% vs. 21%). No definite intracranial pathological findings were detected by computerized tomography (CT) in 53% of patients with early posttraumatic seizures; six patients had intracranial hemorrhage without intracranial parenchymal damage (three with epidural hematoma and three with subarachnoid hemorrhage). The most common positive CT findings in the early posttraumatic-seizure group were intracerebral hemorrhage (24%), followed by acute subdural hematoma with intracerebral hemorrhage (17%). Intracerebral parenchymal damage could be identified on CT scans in 41 (48.8%) of 84 patients with generalized tonic-clonic seizures and five (31%) of 16 patients with partial seizures with motor symptoms. The intracerebral parenchymal damage was most commonly detected in the frontal lobe (21%) and the temporal lobe (19%). Seven patients with early posttraumatic seizures received emergency craniotomy to remove an intracranial hematoma (epidural in three, subdural and intracerebral in four) because the mass effect resulted in significant midline shift as seen on CT scans. This review suggests that early posttraumatic seizures after mild closed head injury have a high incidence (53%) in patients with normal CT scan findings. Although the possibility of surgically correctable intracranial hemorrhage is low (7%), the condition may be devastating if not treated properly.	CHANG GUNG MEM HOSP,DEPT SURG,DIV NEUROSURG,TAIPEI,TAIWAN	LEE, ST (corresponding author), TAIPEI MUNICIPAL CHUNG HSIAO HOSP,DEPT NEUROSURG,87 TUNGTEH RD,TAIPEI,TAIWAN.						ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CAVENESS WF, 1961, EPILEPSIA, V2, P123; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; ELVIDGE AR, 1960, INJURIES BRAIN SPINA, P285; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; JAMISON DL, 1974, ARCH DIS CHILD, V49, P376, DOI 10.1136/adc.49.5.376; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, J NEUROL NEUROSUR PS, V38, P378, DOI 10.1136/jnnp.38.4.378; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT B, 1981, MANAGEMENT HEAD INJU, P301; Jennett B, 1975, EPILEPSY NONMISSILE; JONES JJ, 1981, LANCET, V2, P850; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KARPMAN RR, 1980, ARIZ MED, V37, P772; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KLONOFF H, 1969, CAN MED ASSOC J, V100, P235; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; MENDELOW AD, 1990, BRIT MED J, V285, P1530; MISES J, 1976, EPILEPSIA, V11, P37; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; RIVARA F, 1987, PEDIATRICS, V80, P579; ROS S P, 1989, Pediatric Emergency Care, V5, P216, DOI 10.1097/00006565-198912000-00003; SAINSBURY CPQ, 1984, ARCH DIS CHILD, V59, P856, DOI 10.1136/adc.59.9.856; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TEASDALE G, 1974, LANCET, V2, P81; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	34	55	57	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	1992	76	3					435	439		10.3171/jns.1992.76.3.0435			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HF274	WOS:A1992HF27400007	1738023				2021-06-18	
